PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Chen, QM; Merrett, JB; Dilley, T; Purdom, S				Chen, QM; Merrett, JB; Dilley, T; Purdom, S			Down regulation of p53 with HPV E6 delays and modifies cell death in oxidant response of human diploid fibroblasts: an apoptosis-like cell death associated with mitosis	ONCOGENE			English	Article						cell cycle; historic kinase; caspases; bcl-2; morphology	HUMAN PAPILLOMAVIRUS TYPE-16; CYCLIN-DEPENDENT KINASES; CYTOCHROME-C RELEASE; HYDROGEN-PEROXIDE; CASPASE ACTIVATION; EPITHELIAL-CELLS; GROWTH ARREST; BCL-2 FAMILY; GENERATION; PROTEIN	The tumor suppressor p53 protein is known to play a critical role in apoptosis. In normal human diploid fibroblasts (HDFs), expression of the human papillomaviral (HPV) E6 gene results in a reduction of p53 protein and an inhibition of oxidant induced apoptosis within 24 h. In comparison, expression of the HPV E7 gene causes down-regulation of Rb protein without inhibiting apoptosis. Here we determine whether HDFs expressing E6 undergo cell death with a delayed time course following H2O2 exposure. Appearances of caspase-3 activity, cell detachment, trypan blue uptake and aberrant nuclei were all delayed in E6 cells compared to wild type (wt) or E7 cells. A mutant E6 gene that failed to reduce p53 could not delay cell death. Morphological examination revealed nuclear condensation in dying wt or E7 cells but nuclear fragmentation in E6 cells. Flow cytometry analysis indicated an S phase distribution of dying wt or E7 cells but a G2/M phase distribution of dying E6 cells. An elevation of cyclin B was observed in dying E6 cells but not in apoptotic E7 cells. Dying E6 cells also had elevated levels of cdc-2 protein and histone kinase activity, suggesting that the cells died at mitosis. Electron microscopy studies showed that E6 cells may die at prophase or prometaphase. Overexpression of bcl-2 resulted in an inhibition of both caspase-3 and death of E7 or E6 cells. Inactivating caspases with zVAD-fmk also reduced the death rate of E7 and E6 cells. Our data indicate that expression of HPV E6 causes a delay and morphological modification of cell death induced by oxidants. E6 cells die at mitosis, which can be inhibited by bcl-2 overexpression or caspase inhibition.	Univ Arizona, Coll Med, Dept Pharmacol, Tucson, AZ 85724 USA	University of Arizona	Chen, QM (corresponding author), Univ Arizona, Coll Med, Dept Pharmacol, 1501 N Campbell Ave, Tucson, AZ 85724 USA.				NIA NIH HHS [AG17688] Funding Source: Medline; NIEHS NIH HHS [ES010826] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010826] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG017688] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Chen QM, 2000, BIOCHEM J, V347, P543, DOI 10.1042/0264-6021:3470543; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Chen QM, 2000, J CELL SCI, V113, P4087; Clarke DJ, 2000, BIOESSAYS, V22, P351, DOI 10.1002/(SICI)1521-1878(200004)22:4<351::AID-BIES5>3.0.CO;2-W; Dalal S, 1996, J VIROL, V70, P683, DOI 10.1128/JVI.70.2.683-688.1996; Ding HF, 1998, J BIOL CHEM, V273, P28378, DOI 10.1074/jbc.273.43.28378; EARNSHAW WC, 1994, BIOESSAYS, V16, P639, DOI 10.1002/bies.950160908; Endlich B, 2000, RADIAT RES, V153, P36, DOI 10.1667/0033-7587(2000)153[0036:CVTLMS]2.0.CO;2; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; Huang CS, 2000, J BIOL CHEM, V275, P32516, DOI 10.1074/jbc.M005366200; Huang SC, 2000, BIOCHEM PHARMACOL, V60, P771, DOI 10.1016/S0006-2952(00)00397-X; Lee JM, 1998, ONCOGENE, V17, P1653, DOI 10.1038/sj.onc.1202102; Levin S, 1999, TOXICOL PATHOL, V27, P484, DOI 10.1177/019262339902700419; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MAJNO G, 1995, AM J PATHOL, V146, P3; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; Moll UM, 2001, FEBS LETT, V493, P65, DOI 10.1016/S0014-5793(01)02284-0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; Tada-Oikawa S, 1999, FEBS LETT, V442, P65, DOI 10.1016/S0014-5793(98)01618-4; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zachariae W, 1999, CURR OPIN CELL BIOL, V11, P708, DOI 10.1016/S0955-0674(99)00041-1	40	16	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2002	21	34					5313	5324		10.1038/sj.onc.1205644	http://dx.doi.org/10.1038/sj.onc.1205644			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149652				2022-12-17	WOS:000177193900012
J	Wu, CH; Gordon, J; Rastegar, M; Ogretmen, B; Safa, AR				Wu, CH; Gordon, J; Rastegar, M; Ogretmen, B; Safa, AR			Proteinase-3, a serine protease which mediates doxorubicin-induced apoptosis in the HL-60 leukemia cell line, is downregulated in its doxorubicin-resistant variant	ONCOGENE			English	Article						multidrug resistance; caspases; apoptosis; proteinase-3; leukemia; doxorubicin	FLOW-CYTOMETRIC DETECTION; CYTOCHROME-C; REACTIVE OXYGEN; MITOCHONDRIAL RELEASE; CPP32-LIKE PROTEASES; MULTIDRUG RESISTANCE; GROWTH ARREST; TUMOR-CELLS; BCR-ABL; ACTIVATION	We report here that expression or proteinase 3 (PR3), a serine protease, is down-regulated in the HL60/ADR multidrug resistant variant of the human myelogenous leukemia cell line HL-60, and that down-regulation of PR3 is associated with doxorubicin (DOX) resistance in these cells. To determine whether PR3 is involved in DOX-induced apoptosis in HL-60 cells, and whether its loss causes resistance to DOX, we inhibited PR3 expression by an anti-sense PR3 oligodeoxynucleotide and showed that inhibition of PR3 expression results in a significant reduction in DOX-induced DNA fragmentation and increased resistance to DOX-induced apoptosis. Our results revealed that PR3-mediated DOX-induced apoptosis in HL-60 cells is independent of the loss of mitochondrial membrane potential (AT) and activation of the caspase-8 and -9 pathways. Moreover, while PR3 is involved in the cleavage of caspase-3, PR3-mediated DOX-induced DNA fragmentation and apoptosis were not prevented by a specific inhibitor of caspase-3. These data suggest that activation of caspase-3 alone is not sufficient to trigger PR3-mediated DOX-induced apoptosis. Treatment with an anti-PR3 oligomer significantly decreased reactive oxygen species (ROS) generation in cells treated with low concentrations of DOX, revealing a role for PR3 in enhancing production of DOX-induced ROS. Moreover, DOX-induced apoptosis at 0.001 - 0.01 muM was only inhibited in HL-60 cells pre-treated with the antioxidant N-acetyl-cysteine in the absence of anti-PR3, revealing that DOX-induced apoptosis in these cells is PR3- and ROS-dependent. Our results show that Ill is involved in DOX-induced ROS-dependent apoptosis and that its loss is associated with resistance to DOX in HL-60 cells.	Indiana Univ, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; Indiana Univ, Ctr Canc, Indianapolis, IN 46202 USA; Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Medical University of South Carolina	Safa, AR (corresponding author), Indiana Univ, Dept Pharmacol & Toxicol, 1044 W Walnut R4-119, Indianapolis, IN 46202 USA.	asafa@iupui.edu	Rastegar, Mojgan/T-9394-2019	Rastegar, Mojgan/0000-0003-3619-6116; Gordon, John/0000-0002-9781-9842	NATIONAL CANCER INSTITUTE [R01CA080734, R01CA056078, R01CA090878] Funding Source: NIH RePORTER; NCI NIH HHS [CA 56078, CA 80734, CA 90878] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Arrigo AP, 1998, BIOL CHEM, V379, P19; Bank U, 1999, FEBS LETT, V461, P235, DOI 10.1016/S0014-5793(99)01466-0; Bauer G, 2000, ANTICANCER RES, V20, P4115; Bauer V, 1999, GEN PHYSIOL BIOPHYS, V18, P7; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; BORREGAARD N, 1993, EUR J HAEMATOL, V51, P187; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; CAMPOS L, 1993, BLOOD, V81, P3091; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cellbio.4.1.155; CHEN T, 1994, BIOCHEM BIOPH RES CO, V200, P1130, DOI 10.1006/bbrc.1994.1568; Decaudin D, 1997, CANCER RES, V57, P62; Decker P, 2000, J BIOL CHEM, V275, P9043, DOI 10.1074/jbc.275.12.9043; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; DENGLER R, 1995, BRIT J HAEMATOL, V89, P250, DOI 10.1111/j.1365-2141.1995.tb03297.x; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Finucane DM, 1999, EXP CELL RES, V251, P166, DOI 10.1006/excr.1999.4527; FLEMING GF, 1992, CANCER CHEMOTH PHARM, V29, P445, DOI 10.1007/BF00684845; Gamen S, 2000, EXP CELL RES, V258, P223, DOI 10.1006/excr.2000.4924; GULLBERG U, 1995, J BIOL CHEM, V270, P12912, DOI 10.1074/jbc.270.21.12912; Harper L, 2001, KIDNEY INT, V59, P1729, DOI 10.1046/j.1523-1755.2001.0590051729.x; Herrera B, 2001, FASEB J, V15, P741, DOI 10.1096/fj.00-0267com; Hirsch T, 1998, J IMMUNOL, V161, P35; Hishita T, 2001, CANCER RES, V61, P2878; HOIDAL JR, 1994, METHOD ENZYMOL, V244, P61; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; Horman S, 2000, CELL PROLIFERAT, V33, P331, DOI 10.1046/j.1365-2184.2000.00188.x; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; Kunstle G, 1997, IMMUNOL LETT, V55, P5, DOI 10.1016/S0165-2478(96)02642-9; LABBAYE C, 1993, BLOOD, V81, P475; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li X, 2000, EXP CELL RES, V257, P290, DOI 10.1006/excr.2000.4901; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutz PG, 2000, P NATL ACAD SCI USA, V97, P1601, DOI 10.1073/pnas.97.4.1601; Mayet WJ, 1997, EUR J CLIN INVEST, V27, P893, DOI 10.1046/j.1365-2362.1997.2160771.x; MCGRATH T, 1989, BIOCHEM PHARMACOL, V38, P3611, DOI 10.1016/0006-2952(89)90134-2; Molldrem JJ, 1997, BLOOD, V90, P2529, DOI 10.1182/blood.V90.7.2529.2529_2529_2534; Morano KA, 1999, GENE EXPRESSION, V7, P271; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Ogretmen B, 1997, ONCOGENE, V14, P499, DOI 10.1038/sj.onc.1200855; Ogretmen B, 1998, BIOCHEMISTRY-US, V37, P11679, DOI 10.1021/bi980573c; OGRETMEN B, 1995, BIOTECHNIQUES, V19, P374; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; Rao J, 1998, J CELL PHYSIOL, V175, P121, DOI 10.1002/(SICI)1097-4652(199805)175:2<121::AID-JCP1>3.0.CO;2-Q; RAO NV, 1991, J BIOL CHEM, V266, P9540; Rodriguez I, 1996, J EXP MED, V184, P2067, DOI 10.1084/jem.184.5.2067; Safa AR, 1998, METHOD ENZYMOL, V292, P289; Schwarting A, 2000, KIDNEY INT, V57, P2412, DOI 10.1046/j.1523-1755.2000.00100.x; SHENONG GLC, 1987, P NATL ACAD SCI USA, V84, P199, DOI 10.1073/pnas.84.1.199; SLAPERCORTENBACH ICM, 1988, BLOOD, V72, P1639; SPECTOR NL, 1995, J BIOL CHEM, V270, P1003, DOI 10.1074/jbc.270.3.1003; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; Stennicke HR, 1999, CELL DEATH DIFFER, V6, P1054, DOI 10.1038/sj.cdd.4400599; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Sturrock A, 1996, J BIOL CHEM, V271, P32392, DOI 10.1074/jbc.271.50.32392; Sun JY, 1998, J IMMUNOL METHODS, V211, P111, DOI 10.1016/S0022-1759(97)00203-2; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Taekema-Roelvink MEJ, 1998, SCAND J IMMUNOL, V48, P37; Tammariello SP, 2000, J NEUROSCI, V20; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Wong TWL, 2000, LIFE SCI, V67, pPL1111; Wright SC, 1997, J EXP MED, V186, P1107, DOI 10.1084/jem.186.7.1107; WRIGHT SC, 1994, J EXP MED, V180, P2113, DOI 10.1084/jem.180.6.2113; Wu CH, 2001, ONCOGENE, V20, P7006, DOI 10.1038/sj.onc.1204893; Yang JJ, 2001, AM J PATHOL, V158, P581, DOI 10.1016/S0002-9440(10)64000-X; Yang JJ, 1996, AM J PATHOL, V149, P1617; Zimber A, 2000, CANCER RES, V60, P672	75	16	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2002	21	33					5160	5174		10.1038/sj.onc.1205639	http://dx.doi.org/10.1038/sj.onc.1205639			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140766				2022-12-17	WOS:000176975900014
J	Hansen, M; Rusyn, EV; Hughes, PE; Ginsberg, MH; Cox, AD; Willumsen, BM				Hansen, M; Rusyn, EV; Hughes, PE; Ginsberg, MH; Cox, AD; Willumsen, BM			R-Ras C-terminal sequences are sufficient to confer R-Ras specificity to H-Ras	ONCOGENE			English	Article						H-Ras; R-Ras; structure-function; transformation; integrin affinity modulation	NUCLEOTIDE DISSOCIATION STIMULATOR; INTEGRIN CYTOPLASMIC DOMAINS; OUT SIGNAL-TRANSDUCTION; CELLULAR-TRANSFORMATION; PLASMA-MEMBRANE; EFFECTOR LOOP; ACTIVATION; CELLS; PATHWAY; PROTEIN	Activated versions of the similar GTPases, H-Ras and R-Ras, have differing effects on biological phenotypes: Activated H-Ras strongly transforms many fibroblast cell lines causing dramatic changes in cell shape and cytoskeletal organization. In contrast, R-Ras transforms fewer cell lines and the transformed cells display only some of the morphological changes associated with H-Ras transformation. H-Ras cells can survive in the absence of serum whereas R-Ras cells seem to die by an apoptotic-like mechanism in response to removal Of serum. H-Ras can suppress integrin activation and R-Ras specifically antagonizes this effect. To map sequences responsible for these differences we have generated and investigated a panel of H-Ras and R-Ras chimeras. We found that the C-terminal 53 amino acids of R-Ras were necessary and sufficient to specify the contrasting biological properties of R-Ras with respect to focus morphology, reactive oxygen species (ROS) production and reversal of H-Ras-induced integrin suppression. Surprisingly, we found chimeras in which the focus formation and integrin-mediated phenotypes were separated, suggesting that different effectors could be involved in mediating these responses. An integrin profile of H-Ras and R-Ras cell pools showed no significant differences; both activated H-Ras and R-Ras expressing cells were found to have reduced beta(1) activity, suggesting that the activity state of the beta(1) subunit is not sufficient to direct an H-Ras transformed cell morphology.	Univ Copenhagen, Inst Mol Biol, Dept Mol Cell Biol, DK-1353 Copenhagen K, Denmark; Univ N Carolina, Lineberger Canc Ctr, Dept Radiat Oncol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	University of Copenhagen; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Scripps Research Institute	Willumsen, BM (corresponding author), Univ Copenhagen, Inst Mol Biol, Dept Mol Cell Biol, Oster Farimagsgade 2A, DK-1353 Copenhagen K, Denmark.		Willumsen, Berthe M/H-1903-2012	Willumsen, Berthe M/0000-0002-2277-6999; Cox, Adrienne D./0000-0002-4901-2454	NCI NIH HHS [CA 61951, CA 76092] Funding Source: Medline; NHLBI NIH HHS [HL 31950, HL 48728] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076092, R29CA061951] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728, P01HL031950] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALIG L, 1992, J MED CHEM, V35, P4393, DOI 10.1021/jm00101a017; Baker EK, 1997, P NATL ACAD SCI USA, V94, P1973, DOI 10.1073/pnas.94.5.1973; Brenner KA, 2000, ONCOGENE, V19, P3156, DOI 10.1038/sj.onc.1203626; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; CHEN YP, 1994, J BIOL CHEM, V269, P18307; Chou CC, 1997, N-S ARCH PHARMACOL, V355, P177, DOI 10.1007/PL00004929; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; COX AD, 1994, ONCOGENE, V9, P3281; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; HUGHES PE, 2002, IN PRESS MOL CELL BI; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1990, FIBRONECTINS; Jasiulionis MG, 1996, CANCER RES, V56, P1682; JHAPPAN C, 1986, J VIROL, V60, P750, DOI 10.1128/JVI.60.2.750-753.1986; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kinashi T, 2000, J BIOL CHEM, V275, P22590, DOI 10.1074/jbc.M000633200; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LIN CS, 1993, CANCER RES, V53, P2950; LOWE DG, 1988, P NATL ACAD SCI USA, V85, P1015, DOI 10.1073/pnas.85.4.1015; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Oertli B, 2000, ONCOGENE, V19, P4961, DOI 10.1038/sj.onc.1203876; Osada M, 1999, MOL CELL BIOL, V19, P6333; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Ramos JW, 1996, J CELL BIOL, V134, P227, DOI 10.1083/jcb.134.1.227; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SAEZ R, 1994, ONCOGENE, V9, P2977; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Self AJ, 2001, J CELL SCI, V114, P1357; Sethi T, 1999, MOL BIOL CELL, V10, P1799, DOI 10.1091/mbc.10.6.1799; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Wang YC, 1999, CLIN CANCER RES, V5, P129; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILLIAMS G, 1999, DISCOVERY, V1, P11; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILLUMSEN BM, 1995, METHOD ENZYMOL, V250, P269; Woods D, 2001, MOL CELL BIOL, V21, P3192, DOI 10.1128/MCB.21.9.3192-3205.2001; Wyllie AH, 1997, BRIT MED BULL, V53, P451; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813	62	16	17	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 27	2002	21	28					4448	4461		10.1038/sj.onc.1205538	http://dx.doi.org/10.1038/sj.onc.1205538			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080475				2022-12-17	WOS:000176317100010
J	Iijima, Y; Okuda, K; Tojo, A; Tri, NK; Setoyama, M; Sakaki, Y; Asano, S; Tokunaga, K; Kruh, GD; Sato, Y				Iijima, Y; Okuda, K; Tojo, A; Tri, NK; Setoyama, M; Sakaki, Y; Asano, S; Tokunaga, K; Kruh, GD; Sato, Y			Transformation of Ba/F3 cells and rat-1 cells by ETV6/ARG	ONCOGENE			English	Article						translocation; tyrosine kinase; ETV6/ARG; transforming activity	CHRONIC MYELOMONOCYTIC LEUKEMIA; PROTEIN-TYROSINE KINASE; ETV6-NTRK3 GENE FUSION; ABL-RELATED GENE; ENCODES; TEL; OLIGOMERIZATION; DOMAIN; BETA; BCR	ETV6/ARG, a novel fusion gene composed of the ETV6 HLH oligomerization domain and most of sequences of the ARG protein tyrosine, was recently identified in human leukemia cells. The presence of the ETV6/ARG translocation raises the possibility that the resulting fusion protein functions as an oncogene. However, the transforming activity of the ETV6/ARG protein has not been determined and its contribution to leukemogenesis is therefore unknown. Here we address this question by analysing the oncogenic activity of ETV6/ARG in hematopoietic and fibroblast cells. It is demonstrated that expression of ETV6/ARG confers IL3-independent growth to Ba/F3 cells and anchorage independent growth to Rat-1 fibroblasts. It is also shown that multiple signaling molecules, including PI3K, SHC, ras-GAP and CRK-L, are tyrosine phosphorylated in Ba/F3 cells that express ETV6/ARG. Analysis of four different types of ETV6/ARG transcripts previously identified in the AML-M3 leukemia cell line HT93A suggest that ETV6 HLH domain is required for oncogenic activity. Based upon these results it is concluded that ARG can be activated as an oncogene in human malignancy and that the ETV6/ARG oncoprotein triggers some of the same signaling pathways associated with activated ABL oncogenes.	Int Med Ctr Japan, Res Inst, Dept Clin Pathol, Div Mol Cytogenet,Shinjuku Ku, Tokyo 1620052, Japan; Kyoto Prefectural Univ Med, Dept Hyg, Kyoto 6020841, Japan; Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Mol Therapy, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Funct Genomics, Tokyo 1088639, Japan; Univ Tokyo, Grad Sch Med, Sch Int Hlth, Dept Human Genet, Tokyo 1130033, Japan; Fox Chase Canc Ctr, Div Med Sci, Philadelphia, PA 19111 USA	National Center for Global Health & Medicine - Japan; Kyoto Prefectural University of Medicine; University of Tokyo; University of Tokyo; University of Tokyo; Fox Chase Cancer Center	Sato, Y (corresponding author), Int Med Ctr Japan, Res Inst, Dept Clin Pathol, Div Mol Cytogenet,Shinjuku Ku, Toyama 1-21-1, Tokyo 1620052, Japan.	ysato@ri.imcj.go.jp			NCI NIH HHS [CA57273] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057273, R55CA057273] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreasson P, 1997, GENE CHROMOSOME CANC, V20, P299; Baskaran R, 1997, J BIOL CHEM, V272, P18905, DOI 10.1074/jbc.272.30.18905; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Cazzaniga G, 1999, BLOOD, V94, P4370, DOI 10.1182/blood.V94.12.4370.424k34_4370_4373; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Iijima Y, 2000, BLOOD, V95, P2126; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Mysliwiec T, 1996, ONCOGENE, V12, P631; Odero MD, 2001, GENE CHROMOSOME CANC, V31, P134, DOI 10.1002/gcc.1127; Okuda K, 1996, ONCOGENE, V13, P1147; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PEREGO R, 1991, ONCOGENE, V6, P1899; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Wai DH, 2000, ONCOGENE, V19, P906, DOI 10.1038/sj.onc.1203396; Wang BL, 1996, ONCOGENE, V13, P193; Wang BL, 1996, ONCOGENE, V13, P1379; WANG N, 1993, FOCUS, V3, P3	23	16	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2002	21	28					4374	4383		10.1038/sj.onc.1205544	http://dx.doi.org/10.1038/sj.onc.1205544			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080468				2022-12-17	WOS:000176317100003
J	Hsieh, SC; Lo, PK; Wang, FF				Hsieh, SC; Lo, PK; Wang, FF			Mouse DDA3 gene is a direct transcriptional target of p53 and p73	ONCOGENE			English	Article						DDA3; p53; p73; intronic response element	CELL-CYCLE ARREST; KINASE C-ABL; APOPTOTIC RESPONSE; CANDIDATE MEDIATOR; PROTEIN; DNA; INHIBITOR; FAMILY; IDENTIFICATION; ACCUMULATION	The p53 tumor suppressor is a transcription factor that activates the expression of many target genes. We hake previously reported the identification of a p53-regulated mouse gene DDA3. The 5' upstream genomic region of the mouse DDA3 was cloned, and sequence analysis revealed the presence of a potential p53 response element (RE2) residing at nucleotides +390similar to +409 relative to the first translation start site. When fused upstream to a luciferase reporter gene, 5' genomic regions of the DDA3 gene containing RE2 were shown to be responsive to the wild-type, but not mutant p53, in a transient transfection assay. RE2 was sufficient to confer the transactivation responsiveness to p53. Furthermore, gel mobility shift analysis showed that RE2 formed specific complexes with wild-type p53. Induction of DDA3 was found in adriamycin treated normal mouse embryonic fibroblast cells (MEF), but not in p53 knockout (p53(-/-)) MEF. Overexpression of p73 induced DDA3 mRNA expression, and luciferase reporter analysis indicated that RE2 was responsive to transactivation by members of the p73 family proteins. Consistent with these findings, elevated expression of p73 protein and DDA3 mRNA were observed concomitantly in the p53(-/-) MEF cells treated with cisplatin. These results together demonstrated that DDA3 is a transcriptional target gene of p53 and its related-protein p73.	Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan	National Yang Ming Chiao Tung University	Wang, FF (corresponding author), Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan.	ffwang@ym.edu.tw		HSIEH, SHU-CHEN/0000-0002-0844-7435				Agami R, 1999, NATURE, V399, P809; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Gong JG, 1999, NATURE, V399, P806; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Irwin MS, 2001, APOPTOSIS, V6, P17, DOI 10.1023/A:1009663809458; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Lo PK, 1999, ONCOGENE, V18, P7765, DOI 10.1038/sj.onc.1203167; Lohrum MAE, 2000, TRENDS CELL BIOL, V10, P197, DOI 10.1016/S0962-8924(00)01736-0; Marin MC, 2000, BBA-REV CANCER, V1470, pM93, DOI 10.1016/S0304-419X(00)00010-X; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; MIYASHITA T, 1995, CELL, V80, P293; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ohki R, 2000, J BIOL CHEM, V275, P22627, DOI 10.1074/jbc.C000235200; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; STEWART N, 1995, ONCOGENE, V10, P109; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Tang PP, 2000, LEUKEMIA, V14, P1292, DOI 10.1038/sj.leu.2401823; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000; Zhu JH, 1998, CANCER RES, V58, P5061	47	16	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3050	3057		10.1038/sj.onc.1205417	http://dx.doi.org/10.1038/sj.onc.1205417			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082536				2022-12-17	WOS:000175262700013
J	Barda-Saad, M; Shav-Tal, Y; Rozenszajn, AL; Cohen, M; Zauberman, A; Karmazyn, A; Parameswaran, R; Schori, H; Ashush, H; Ben-Nun, A; Zipori, D				Barda-Saad, M; Shav-Tal, Y; Rozenszajn, AL; Cohen, M; Zauberman, A; Karmazyn, A; Parameswaran, R; Schori, H; Ashush, H; Ben-Nun, A; Zipori, D			The mesenchyme expresses T cell receptor mRNAs: relevance to cell growth control	ONCOGENE			English	Article						mesenchyme; stroma; TCR; cell growth; tumors	D-MU PROTEIN; STEM-CELLS; GENE; TRANSCRIPTS; MATURATION; SEQUENCE; LACKING; SURFACE; STROMA	The mesenchyme plays a crucial regulatory role in organ formation and maintenance. However, comprehensive molecular characterization of these cells is lacking. We found unexpectedly that primary mesenchyme, as well as mesenchymal cell clones, express T cell receptor (TCR)chibeta mRNAs, lacking the variable region. Immunological and genetic evidence support the expression of a corresponding TCRbeta protein. Additionally, mRNAs encoding TCR complex components including CD3 and chain are present. A relatively higher expression of the mesenchymal TCRbeta mRNA by cultured mesenchymal cell clones correlates with fast growth, whereas poorly expressing cells are slow growers and are contact inhibited. The clones that express relatively higher amount of the TCR mRNA exhibit an increased capacity to form tumors in nude mice. However, the expression of this mRNA in the mesenchyme is not per se leading to tumorigenesis, as demonstrated by primary mesenchyme that does not form tumors in mice while expressing moderate amounts of the TCR transcripts. The expression of mesencymal TCRbeta was confined to the G2/M phases of the cell cycle in the MBA-13 mesenchymal cell line. This cell cycle dependent expression, considered together with the correlation between growth properties and the level of TCR expression by cell clones, implies association of mesenchymal TCR with cell growth control.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Bar Ilan Univ, Dept Life Sci, Ramat Gan, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Bar Ilan University	Zipori, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	dov.zipori@weizmann.ac.il		Shav-Tal, Yaron/0000-0002-8017-948X				Barda-Saad M, 1999, EXP HEMATOL, V27, P834, DOI 10.1016/S0301-472X(99)00010-7; CALMAN AF, 1986, J EXP MED, V164, P1940, DOI 10.1084/jem.164.6.1940; Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471-4914(01)02016-0; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; EISEMANN A, 1991, ONCOGENE, V6, P1195; Essand M, 1999, P NATL ACAD SCI USA, V96, P9287, DOI 10.1073/pnas.96.16.9287; FAGIOLI M, 1991, EUR J IMMUNOL, V21, P1529, DOI 10.1002/eji.1830210629; GU H, 1991, CELL, V65, P47, DOI 10.1016/0092-8674(91)90406-O; Hilyard Katherine L., 1995, P403; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Hwang A, 1998, J BIOL CHEM, V273, P31505, DOI 10.1074/jbc.273.47.31505; HWANG A, 1995, J BIOL CHEM, V270, P28419; Jacobs H, 1996, ONCOGENE, V12, P2089; Lee BC, 1996, BLOOD, V87, P2283, DOI 10.1182/blood.V87.6.2283.bloodjournal8762283; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; MADRENAS J, 1994, MOL IMMUNOL, V31, P993, DOI 10.1016/0161-5890(94)90094-9; MADRENAS J, 1991, TRANSPLANT P, V23, P837; MADRENAS J, 1992, J IMMUNOL, V148, P612; OSSENDORP F, 1992, J IMMUNOL, V148, P3714; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; QIAN L, 1993, J IMMUNOL, V151, P6801; RETH MG, 1984, NATURE, V312, P418, DOI 10.1038/312418a0; Sciortino S, 2001, EMBO REP, V2, P1018, DOI 10.1093/embo-reports/kve223; Shav-Tal Y, 2000, EXP HEMATOL, V28, P1029, DOI 10.1016/S0301-472X(00)00510-5; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; Shoham T, 2001, LEUKEMIA, V15, P1102, DOI 10.1038/sj.leu.2402145; Snell R.S., 2000, CLIN ANATOMY MED STU; Sutton KA, 1998, IMMUNOLOGY, V93, P213, DOI 10.1046/j.1365-2567.1998.00410.x; Tremain N, 2001, STEM CELLS, V19, P408, DOI 10.1634/stemcells.19-5-408; TSUBATA T, 1991, EUR J IMMUNOL, V21, P1359, DOI 10.1002/eji.1830210605; VANDENHOOFF A, 1988, ADV CANCER RES, V50, P159, DOI 10.1016/S0065-230X(08)60437-6; VANNESS BG, 1981, CELL, V27, P593, DOI 10.1016/0092-8674(81)90401-3; Wallace, 1981, VERTEBRATE LIMB REGE; Wolfgang CD, 2000, P NATL ACAD SCI USA, V97, P9437, DOI 10.1073/pnas.160270597; YOSHIKAI Y, 1984, NATURE, V312, P521, DOI 10.1038/312521a0; ZIPORI D, 1988, BLOOD, V71, P586; ZIPORI D, 1989, HDB HEMOPOIETIC MICR, P287	37	16	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2029	2036		10.1038/sj.onc.1205269	http://dx.doi.org/10.1038/sj.onc.1205269			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960375				2022-12-17	WOS:000174827000009
J	Djelloul, S; Tarunina, M; Barnouin, K; Mackay, A; Jat, PS				Djelloul, S; Tarunina, M; Barnouin, K; Mackay, A; Jat, PS			Differential protein expression, DNA binding and interaction with SV40 large tumour antigen implicate the p63-family of proteins in replicative senescence	ONCOGENE			English	Article						p63; p53; replicative senescence; DNA binding; SV40 T-antigen	LARGE-T-ANTIGEN; RAT EMBRYO FIBROBLASTS; P53 HOMOLOG; CELLULAR SENESCENCE; HUMAN-CELLS; LIFE-SPAN; P63; ANTIBODIES; DIVISION; DISTINCT	P53 activity plays a key role in mammalian cells when they undergo replicative senescence at their Hayflick limit. To determine whether p63 proteins, members of the family of p53-related genes, are also involved in this process, we examined their expression in serially passaged rat embryo fibroblasts. Upon senescence, two truncated DeltaNp63 proteins decreased in abundance whereas two TAp63 isoforms accumulated. 2-D get analysis showed that the DeltaNp63 proteins underwent post-translational modifications in both proliferating and senescent cells. Direct binding of DeltaNp63 proteins to a p53 consensus motif was greater in proliferating cells than senescent cells. In contrast p63alpha isoforms bound to DNA in a p53 dependent manner and this was higher in senescent cells than proliferating cells. An interaction of p63alpha proteins with SV40 large tumour antigen was also detected and ectopic expression of DeltaNp63alpha can extend the lifespan of rat embryo fibroblasts. Taken together the results indicate that p63 proteins may play a role in replicative senescence either by competition for p53 DNA binding sites or by direct interaction with p53 protein bound to DNA.	Royal Free & Univ Coll Sch Med, Ludwig Inst Canc Res, London W1W 7BS, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Royal Free & Univ Coll Sch Med, Dept Surg, LICR UCL Breast Canc Lab, London W1P 7LD, England	Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London; University of London; University College London	Jat, PS (corresponding author), Royal Free & Univ Coll Sch Med, Ludwig Inst Canc Res, Courtauld Bldg,91 Riding House St, London W1W 7BS, England.	parmjit@ludwig.ucl.ac.uk						Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Gonos ES, 1996, MOL CELL BIOL, V16, P5127; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hall PA, 2000, CARCINOGENESIS, V21, P153, DOI 10.1093/carcin/21.2.153; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Harlow E LD, 1988, ANTIBODIES LAB MANUA; Hayflick L, 1985, Clin Geriatr Med, V1, P15; IKRAM Z, 1994, P NATL ACAD SCI USA, V91, P6448, DOI 10.1073/pnas.91.14.6448; Ishida S, 2000, JPN J CANCER RES, V91, P174, DOI 10.1111/j.1349-7006.2000.tb00929.x; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; Katoh I, 2000, ONCOGENE, V19, P3126, DOI 10.1038/sj.onc.1203644; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; PEACOCKE M, 1991, J CELL BIOCHEM, V45, P147, DOI 10.1002/jcb.240450205; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; PEREIRASMITH OM, 1990, J CELL PHYSIOL, V144, P546, DOI 10.1002/jcp.1041440324; Powell AJ, 1999, ONCOGENE, V18, P7343, DOI 10.1038/sj.onc.1203154; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Roth J, 1999, J GEN VIROL, V80, P3251, DOI 10.1099/0022-1317-80-12-3251; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086; Stulik J, 1997, ELECTROPHORESIS, V18, P625, DOI 10.1002/elps.1150180347; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	33	16	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2002	21	7					981	989		10.1038/sj.onc.1205253	http://dx.doi.org/10.1038/sj.onc.1205253			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850815				2022-12-17	WOS:000173580100001
J	Neary, CL; Cho-Chung, YS				Neary, CL; Cho-Chung, YS			Nuclear translocation of the catalytic subunit of protein kinase A induced by an antisense oligonucleotide directed against the RI alpha regulatory subunit	ONCOGENE			English	Article						cAMP; protein kinase A; antisense; immunocytochemistry; nuclear localization	CYCLIC-AMP; SOMATOSTATIN GENE; RESPONSE ELEMENT; OVARIAN-CANCER; FACTOR CREB; CAMP; GROWTH; DIFFERENTIATION; BINDING; CELLS	The regulatory (R) subunits of cAMP-dependent protein kinase (PKA) are implicated in the regulation of cell proliferation and differentiation. There are two isoforms of PKA that are distinguished by two types of R subunit, RI and RII Evidence suggests that RI is associated with proliferation and RII is associated with cell differentiation. Previous work in this laboratory has demonstrated that depletion of the RI alpha subunit by treatment with an antisense oligonucleotide (ODN) induces differentiation in leukemia cells and growth arrest and apoptosis in epithelial cancer cells. Using the prostate cancer cell line PC3M as a model system, we have developed a cell line that overexpresses a retroviral vector construct containing the RI alpha antisense gene. This cell tine has been characterized and the effectiveness of the construct determined. In the work presented here, we demonstrate by immunocytochemistry that treatment with RI alpha antisense ODN induces translocation of the C alpha subunit of PKA to the nucleus of PC3M prostate cancer cells. The translocation of Ca triggered by exogenous antisense ODN treatment mirrors that observed in cells endogenously overexpressing the antisense gene. Triggering the nuclear translocation of the C alpha subunit of PKA in the cell may be an important mechanism of action of RIa antisense that regulates cell growth independent of adenylate cyclase and cellular cAMP levels. The nuclear localization of the Ca subunit of PKA may be an essential step in revealing the mechanism whereby this critical kinase regulates cell growth.	NCI, Cellular Biochem Sect, Basic Res Labs, Ctr Canc Res,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cho-Chung, YS (corresponding author), Bldg 10,Room 5B05, Bethesda, MD 20892 USA.				NCI NIH HHS [N02-BC-76212] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BEEBE SJ, 1986, ENZYMES CONTROL PHOS; BOLD RJ, 1994, REGUL PEPTIDES, V53, P61, DOI 10.1016/0167-0115(94)90159-7; BRADBURY AW, 1994, BRIT J CANCER, V69, P738, DOI 10.1038/bjc.1994.139; BUDILLON A, 1995, P NATL ACAD SCI USA, V92, P10634, DOI 10.1073/pnas.92.23.10634; Chen HX, 2000, CLIN CANCER RES, V6, P1259; Cho YS, 2001, P NATL ACAD SCI USA, V98, P9819, DOI 10.1073/pnas.171314398; CHOCHUNG YS, 1989, CANCER INVEST, V7, P161, DOI 10.3109/07357908909038282; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; CHOCHUNG YS, 1998, APPL ANTISENSE OLIGO; Constantinescu A, 1999, J BIOL CHEM, V274, P26985, DOI 10.1074/jbc.274.38.26985; Dohrman DP, 1996, P NATL ACAD SCI USA, V93, P10217, DOI 10.1073/pnas.93.19.10217; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Levin AA, 1999, BBA-GENE STRUCT EXPR, V1489, P69, DOI 10.1016/S0167-4781(99)00140-2; McDaid HM, 1999, BRIT J CANCER, V79, P933, DOI 10.1038/sj.bjc.6690149; MCGEADY ML, 1989, ONCOGENE, V4, P1375; MILLER WR, 1993, EUR J CANCER, V29A, P989, DOI 10.1016/S0959-8049(05)80207-2; MILLER WR, 1993, BREAST CANCER RES TR, V26, P89, DOI 10.1007/BF00682703; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Nesterova M, 2000, CLIN CANCER RES, V6, P3434; Nesterova M, 2000, ANTISENSE NUCLEIC A, V10, P423, DOI 10.1089/oli.1.2000.10.423; Schiavone N, 2000, BIOCHEM BIOPH RES CO, V270, P406, DOI 10.1006/bbrc.2000.2433; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; Simpson BJB, 1996, CLIN CANCER RES, V2, P201; Srivastava RK, 1998, P NATL ACAD SCI USA, V95, P6687, DOI 10.1073/pnas.95.12.6687; TORTORA G, 1991, P NATL ACAD SCI USA, V88, P2011, DOI 10.1073/pnas.88.5.2011; TORTORA G, 1990, J BIOL CHEM, V265, P18067; Wang H, 1999, P NATL ACAD SCI USA, V96, P13989, DOI 10.1073/pnas.96.24.13989; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOUNG MRI, 1995, INT J CANCER, V61, P104, DOI 10.1002/ijc.2910610118; Zhao QY, 1999, BIOORG MED CHEM LETT, V9, P3453	33	16	17	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2001	20	55					8019	8024		10.1038/sj.onc.1204992	http://dx.doi.org/10.1038/sj.onc.1204992			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	494NL	11753685				2022-12-17	WOS:000172288700011
J	Blesofsky, WA; Mowen, K; Arduini, RM; Baker, DP; Murphy, MA; Bowtell, DDL; David, M				Blesofsky, WA; Mowen, K; Arduini, RM; Baker, DP; Murphy, MA; Bowtell, DDL; David, M			Regulation of STAT protein synthesis by c-Cbl	ONCOGENE			English	Article						interferon; c-Cbl; STAT; translation	EPIDERMAL GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; TRANSCRIPTION FACTOR; FACTOR RECEPTOR; INTERFERON ACTIVATION; SIGNALING PROTEINS; NEGATIVE REGULATOR; CSF-1 RECEPTOR; V-CBL	Many cytokines and growth factors induce transcription of immediate early response genes by activating members of the Signal Transducers and Activators of Transcription (STAT) family. Although significant progress has been made in understanding the events that lead to the activation of STAT proteins, less, is known about the regulation of their expression. Here we report that murine embryonic fibroblasts derived from c-Cbl-deficient mice display significantly increased levels of STAT1 and STAT5 protein. In contrast, STAT2 and STAT3 expression, as well as the levels of the tyrosine kinases Jak1 and Tyk2, appear to be regulated independently of c-Cbl. Interestingly, the half-life of STAT1 was, unaffected by the presence of c-Cbl, indicating that c-Cbl acts independently of STAT1 degradation. Further analysis revealed similar levels of STAT1 mRNA, however, a dramatically increased rate of STAT1 protein synthesis was observed in c-Cbl-deficient cells. Thus, our findings, demonstrate an additional control mechanism over STAT1 function, and also provide a novel biological effect of the Chl protein family.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Peter MacCallum Canc Inst, Trescowthick Res Labs, Melbourne, Vic 3000, Australia; Biogen Inc, Cambridge, MA 02142 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Peter Maccallum Cancer Center; Biogen	David, M (corresponding author), Univ Calif San Diego, Dept Biol, Bonner Hall 3138,9500 Gilman Dr, La Jolla, CA 92093 USA.		Bowtell, David/H-1007-2016	Bowtell, David/0000-0001-9089-7525	NATIONAL CANCER INSTITUTE [R01CA080105] Funding Source: NIH RePORTER; NCI NIH HHS [CA80105] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; BLAKE TJ, 1991, ONCOGENE, V6, P653; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1993, J BIOL CHEM, V268, P6593; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kawata T, 1997, CELL, V89, P909, DOI 10.1016/S0092-8674(00)80276-7; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; LAMER AC, 1993, SCIENCE, V261, P1730; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; LOKVIST WE, 2001, BIOCHEM J, V356, P627; Luca ME, 1999, J NEUROIMMUNOL, V100, P190, DOI 10.1016/S0165-5728(99)00198-8; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Mowen K, 1998, J BIOL CHEM, V273, P30073, DOI 10.1074/jbc.273.46.30073; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Thien CBF, 1999, J IMMUNOL, V162, P7133; Uddin S, 1996, BIOCHEM BIOPH RES CO, V225, P833, DOI 10.1006/bbrc.1996.1259; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; Wang Y, 1999, J CELL BIOCHEM, V72, P119; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	42	16	17	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2001	20	50					7326	7333		10.1038/sj.onc.1204919	http://dx.doi.org/10.1038/sj.onc.1204919			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704862	Green Published			2022-12-17	WOS:000171894200005
J	Stoppler, H; Malerczyk, C; Block, K; Aigner, A; Czubayko, F				Stoppler, H; Malerczyk, C; Block, K; Aigner, A; Czubayko, F			The human papillomavirus (HPV) 16 E6 oncoprotein leads to an increase in gene expression of the angiogenic switch molecule FGF-BP in non-immortalized human keratinocytes	ONCOGENE			English	Article						fibroblast growth factor binding protein; HPV16; E6 oncogene; E7 oncogene; promoter	FIBROBLAST GROWTH-FACTOR; K14-HPV16 TRANSGENIC MICE; TUMOR-SUPPRESSOR PROTEIN; FACTOR-BINDING PROTEIN; TYPE-16 E6; HISTONE DEACETYLASE; TELOMERASE ACTIVITY; E7 ONCOPROTEIN; WILD-TYPE; P53	Fibroblast growth, factor binding protein (FGF-BP) is a secreted protein that binds, FGF-1 and FGF-2 and is involved in mobilization and activation of FGFs from the extracellular matrix. FGF-BP overexpression as, well as ribozyme-mediated reduction of endogenous FGF-BP revealed that FGF-BP can be rate-limiting for tumor growth and angiogenesis. Recent studies showed that FGF-BP expression is up-regulated during early phases of tumorigenesis, indicating that the role of FGF-BP in angiogenesis is a critical early step in the development and progression of tumors.. Human papillomavirus type, 16 (HPV 16) is highly associated with the development of anogenital cancers. Here we demonstrate that the stable expression of the E6 oncogene of HPV 16 leads to an activation of the FGF-BP promoter in primary human foreskin keratinocytes (one of the natural host cells of these viruses). This is associated with, an increase in the steady state levels, of FGF-BP mRNA and FGF-BP protein in cells stably expressing E6. Transient E6 expression revealed that the observed activation of the FGF-BP promoter by the viral oncogene is, an early process which is. independent from immortalization/transformation, events in the cells.	Univ Marburg, Dept Pharmacol, D-35033 Marburg, Germany	Philipps University Marburg	Czubayko, F (corresponding author), Univ Marburg, Dept Pharmacol, Karl Von Frisch Str 1, D-35033 Marburg, Germany.	czubayko@mailer.uni-marburg.de	Aigner, Achim/R-4429-2017	Aigner, Achim/0000-0002-2778-6256				Aigner A, 2001, INT J CANCER, V92, P510, DOI 10.1002/1097-0215(20010515)92:4<510::AID-IJC1227>3.0.CO;2-H; Arbeit JM, 1996, ONCOGENE, V13, P1847; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Coussens LM, 1996, AM J PATHOL, V149, P1899; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DEMERS GW, 1994, VIROLOGY, V198, P169, DOI 10.1006/viro.1994.1019; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ETSCHEID BG, 1994, VIROLOGY, V205, P583, DOI 10.1006/viro.1994.1684; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harris VK, 2000, J BIOL CHEM, V275, P10802, DOI 10.1074/jbc.275.15.10802; Harris VK, 1998, J BIOL CHEM, V273, P19130, DOI 10.1074/jbc.273.30.19130; Harris VK, 2001, ONCOGENE, V20, P1730, DOI 10.1038/sj.onc.1204249; Harris VK, 2000, J BIOL CHEM, V275, P39801; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; IMAI Y, 1991, J VIROL, V65, P4966, DOI 10.1128/JVI.65.9.4966-4972.1991; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kinoshita T, 1997, VIROLOGY, V232, P53, DOI 10.1006/viro.1997.8536; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Kurtz A, 1997, ONCOGENE, V14, P2671, DOI 10.1038/sj.onc.1201117; Lopez-Ocejo O, 2000, ONCOGENE, V19, P4611, DOI 10.1038/sj.onc.1203817; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Mork J, 2001, NEW ENGL J MED, V344, P1125, DOI 10.1056/NEJM200104123441503; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; Nair P, 1999, PATHOL RES PRACT, V195, P163, DOI 10.1016/S0344-0338(99)80029-6; Park JS, 2000, J BIOL CHEM, V275, P6764, DOI 10.1074/jbc.275.10.6764; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; Shino Y, 1997, J VIROL, V71, P4310, DOI 10.1128/JVI.71.6.4310-4318.1997; STOPPLER H, 1994, INTERVIROLOGY, V37, P168; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; Stoppler H, 1997, J BIOL CHEM, V272, P13332, DOI 10.1074/jbc.272.20.13332; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WU DQ, 1991, J BIOL CHEM, V266, P16778; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999	53	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2001	20	50					7430	7436		10.1038/sj.onc.1204957	http://dx.doi.org/10.1038/sj.onc.1204957			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704874				2022-12-17	WOS:000171894200017
J	Bhandari, P; Shashidhara, LS				Bhandari, P; Shashidhara, LS			Studies on human colon cancer gene APC by targeted expression in Drosophila	ONCOGENE			English	Article						colorectal cancer; APC; beta-catenin; drug screening; transgenic Drosophila	LONG-RANGE ACTION; BETA-CATENIN; ADENOMATOUS POLYPOSIS; MORPHOGENETIC FURROW; ADULT ABDOMEN; CELL FATES; WINGLESS; EYE; PROTEIN; ARMADILLO	Mutations in human Adenomatous Polyposis Coli (APC) gene are associated with both familial and sporadic colorectal tumors. APC is known to down regulate beta -catenin levels, a transducer of Wnt signaling. The aim of this study is to provide transgenic Drosophila expressing either full-length or truncated forms of human APC (hAPC) protein and methods for using them in functional,genomics and drug screening. Consistent with its biochemical properties, targeted expression of either full-length hAPC or its beta -catenin binding domain alone negatively regulated the function of the beta -catenin homologue, Armadillo (Arm) and thereby, inhibited Wnt/Wg signaling during fly development. hAPC inhibited Arm function even in the absence of GSK-3 beta activity, although the latter was required to mediate the degradation of Arm. Consistent with this, hAPC suppressed the phenotypes induced by the over-expression of degradation-resistant forms of Arm. Subsequently, using hAPC-induced eye phenotypes as the assay in a suppressor-enhancer screen, we have identified two new loci in Drosophila, which modulate Wnt/Wg signaling. In addition, an anti-colon cancer drug, indomethacin, specifically enhanced hAPC-induced phenotypes.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Shashidhara, LS (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	shashi@gene.ccmbindia.org						Ahmed Y, 1998, CELL, V93, P1171, DOI 10.1016/S0092-8674(00)81461-0; Bienz M, 1999, CURR OPIN GENET DEV, V9, P595, DOI 10.1016/S0959-437X(99)00016-7; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brook WJ, 1996, SCIENCE, V273, P1373, DOI 10.1126/science.273.5280.1373; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; Deshpande N, 1997, J BIOL CHEM, V272, P10664; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Fossgreen A, 1998, P NATL ACAD SCI USA, V95, P13703, DOI 10.1073/pnas.95.23.13703; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; Friedl W, 1996, HUM GENET, V97, P579; GHYSEN A, 1989, DEVELOPMENT, V105, P35; Hayashi S, 1997, P NATL ACAD SCI USA, V94, P242, DOI 10.1073/pnas.94.1.242; Hazelett DJ, 1998, DEVELOPMENT, V125, P3741; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; HELD LI, 1994, ROUX ARCH DEV BIOL, V203, P310, DOI 10.1007/BF00457802; HOOPER JE, 1994, NATURE, V372, P461, DOI 10.1038/372461a0; Jackson GR, 1998, NEURON, V21, P633, DOI 10.1016/S0896-6273(00)80573-5; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kopp A, 1999, DEVELOPMENT, V126, P3495; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MARDON G, 1994, DEVELOPMENT, V120, P3473; Morimura S, 1996, DEV BIOL, V177, P136, DOI 10.1006/dbio.1996.0151; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; Neumann CJ, 1997, DEVELOPMENT, V124, P871; Pai LM, 1997, DEVELOPMENT, V124, P2255; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; Pignoni F, 1997, DEVELOPMENT, V124, P271; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; POLAKIS P, 1997, BIOCHIM BIOPHYS ACTA, V1332, P127; Rao Y, 1998, P NATL ACAD SCI USA, V95, P2077, DOI 10.1073/pnas.95.5.2077; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Scott RJ, 1996, HUM MOL GENET, V5, P1921, DOI 10.1093/hmg/5.12.1921; Shashidhara LS, 1999, DEV BIOL, V212, P491, DOI 10.1006/dbio.1999.9341; Shih IM, 2000, CANCER RES, V60, P1671; Shirras AD, 1996, DEV BIOL, V175, P24, DOI 10.1006/dbio.1996.0092; SIMMONDS AJ, 1995, NATURE, V376, P424, DOI 10.1038/376424a0; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Steitz MC, 1998, DEV BIOL, V197, P218, DOI 10.1006/dbio.1998.8884; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Thomas BI, 1999, TRENDS GENET, V15, P184, DOI 10.1016/S0168-9525(99)01720-5; TREISMAN JE, 1995, DEVELOPMENT, V121, P3519; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; von Kries JP, 2000, NAT STRUCT BIOL, V7, P800; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Wu J, 1999, DEVELOPMENT, V126, P109; Yamaguchi M, 1999, ONCOGENE, V18, P6767, DOI 10.1038/sj.onc.1203113; YOFFE KB, 1995, DEV BIOL, V170, P636, DOI 10.1006/dbio.1995.1243; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	57	16	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2001	20	47					6871	6880		10.1038/sj.onc.1204849	http://dx.doi.org/10.1038/sj.onc.1204849			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687966				2022-12-17	WOS:000171641000008
J	Zhang, SL; Lloyd, R; Bowden, G; Glickman, BW; de Boer, JG				Zhang, SL; Lloyd, R; Bowden, G; Glickman, BW; de Boer, JG			Msh2 DNA mismatch repair gene deficiency and the food-borne mutagen 2-amino-1-methyl-6-phenolimidazo [4,5-b] pyridine (PhIP) synergistically affect mutagenesis in mouse colon	ONCOGENE			English	Article						mismatch repair; dietary mutagen; mutational spectra; lacI; cancer	NONPOLYPOSIS COLORECTAL-CANCER; HETEROCYCLIC AMINES; TRANSGENIC MICE; 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; MAMMALIAN-CELLS; MUTATION; LACI; RATS; SPECIFICITY; RODENTS	Msh2 deficiency and food-borne carcinogen PhIP have been implicated as genetic and environmental factors, respectively, in human colon carcinogenesis. It is not clear whether loss of one or both alleles of Msh2 gene increases the mutational sensitivity in colon when exposed to environmental carcinogens. In the current study, Msh2(+/-)/lacI and Msh2(-/-)/lacI double transgenic mice were treated with PhIP and mutations in the lacI gene were studied in the colon. The spontaneous mutation frequency (MF) is approximately eightfold higher in Msh2(-/-) mice than in Msh2(+/+) mice, while Msh2(+/-) mice display similar levels of spontaneous mutation as the Msh2 wild type mice. PhIP induced a significant increase in MF in all genotypes of mice. However, induced MF is much higher in Msh2-/- mice compared to Msh2(+/+) and Msh2(+/-) mice. Msh2(+/-) mice ;displayed an increased level of G:C >T:A transversions and -1 frameshifts upon PhIP treatment. In contrast, loss of both Msh2 alleles mainly results in increased frequency of G:C >A:T transitions when exposed to PhIP. These results suggest that a defect in mismatch repair may result in an enhanced sensitivity from exposure to a dietary carcinogen. It also provides insight into interaction between genetic and environmental factors in human carcinogenesis.	Univ Victoria, Dept Biol, Ctr Environm Hlth, Victoria, BC V8W 3N5, Canada	University of Victoria	de Boer, JG (corresponding author), Univ Victoria, Dept Biol, Ctr Environm Hlth, POB 1700, Victoria, BC V8W 3N5, Canada.							Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Andrew SE, 1996, MUTAT RES-FUND MOL M, V357, P57, DOI 10.1016/0027-5107(96)00080-2; Andrew SE, 1998, P NATL ACAD SCI USA, V95, P1126, DOI 10.1073/pnas.95.3.1126; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Cariello NF, 1996, ENVIRON MOL MUTAGEN, V28, P397, DOI 10.1002/(SICI)1098-2280(1996)28:4<397::AID-EM14>3.0.CO;2-A; CAROTHRS AM, 1994, CHEM RES TOXICOL, V7, P209, DOI 10.1021/tx00038a015; de Boer JG, 1998, GENETICS, V148, P1441; DOHET C, 1986, P NATL ACAD SCI USA, V83, P3395, DOI 10.1073/pnas.83.10.3395; DYCAICO MJ, 1994, MUTAT RES, V307, P461, DOI 10.1016/0027-5107(94)90257-7; ENDO H, 1994, CANCER RES, V54, P3745; Erfle HL, 1996, ENVIRON MOL MUTAGEN, V28, P393; Eshleman JR, 1996, HUM MOL GENET, V5, P1489, DOI 10.1093/hmg/5.Supplement_1.1489; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FELTON JS, 1986, CARCINOGENESIS, V7, P1081, DOI 10.1093/carcin/7.7.1081; Felton JS, 1997, MUTAT RES-FUND MOL M, V376, P37, DOI 10.1016/S0027-5107(97)00023-7; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; FISHEL R, 1994, CELL, V77, P167; Fornasarig M, 2000, ONCOL REP, V7, P39; FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Glaab WE, 2000, CANCER RES, V60, P4921; Glaab WE, 1999, CARCINOGENESIS, V20, P391, DOI 10.1093/carcin/20.3.391; Godard V, 1999, ANN DERMATOL VENER, V126, P600; Gooderham NJ, 1997, MUTAT RES-FUND MOL M, V376, P53, DOI 10.1016/S0027-5107(97)00025-0; ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LOEB LA, 1991, CANCER RES, V51, P3075; LYNCH HT, 1985, CANCER, V56, P939, DOI 10.1002/1097-0142(19850815)56:4<939::AID-CNCR2820560440>3.0.CO;2-T; Marra G, 1996, GASTROENTEROL CLIN N, V25, P755, DOI 10.1016/S0889-8553(05)70273-9; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; Okonogi H, 1997, CARCINOGENESIS, V18, P745, DOI 10.1093/carcin/18.4.745; Okonogi H, 1997, MUTAT RES-GEN TOX EN, V395, P93, DOI 10.1016/S1383-5718(97)00146-0; Planck M, 2000, GENE CHROMOSOME CANC, V29, P33, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1004>3.0.CO;2-R; RADMAN M, 1985, BIOCHIMIE, V67, P745, DOI 10.1016/S0300-9084(85)80162-0; ROGERS BJ, 1995, MUTAT RES-FUND MOL M, V327, P57, DOI 10.1016/0027-5107(94)00081-F; Sorensen IK, 1997, CARCINOGENESIS, V18, P777, DOI 10.1093/carcin/18.4.777; Stuart GR, 2000, MUTAT RES-FUND MOL M, V452, P101, DOI 10.1016/S0027-5107(00)00058-0; Suri A, 1996, MUTAT RES-FUND MOL M, V372, P23, DOI 10.1016/S0027-5107(96)00105-4; TAKAHASHI S, 1991, JPN J CANCER RES, V82, P135, DOI 10.1111/j.1349-7006.1991.tb01819.x; Toft NJ, 1998, J PATHOL, V185, P123; TUDEK B, 1989, CANCER RES, V49, P1236; TURTELTAUB KW, 1989, FOOD CHEM TOXICOL, V27, P667, DOI 10.1016/0278-6915(89)90121-X; Zhang XB, 1996, CARCINOGENESIS, V17, P2259, DOI 10.1093/carcin/17.10.2259	47	16	16	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					6066	6072		10.1038/sj.onc.1204730	http://dx.doi.org/10.1038/sj.onc.1204730			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593414				2022-12-17	WOS:000171056300014
J	Langa, F; Lafon, I; Vandormael-Pournin, S; Vidaud, M; Babinet, C; Morello, D				Langa, F; Lafon, I; Vandormael-Pournin, S; Vidaud, M; Babinet, C; Morello, D			Healthy mice with an altered c-myc gene: role of the 3 ' untranslated region revisited	ONCOGENE			English	Article						ARE; Cre/loxP; ES cells; mRNA stability; neomycin; targeted mutagenesis	MESSENGER-RNA STABILITY; MOUSE-LIVER REGENERATION; AU-RICH ELEMENTS; POSTTRANSCRIPTIONAL REGULATION; 3'-UNTRANSLATED REGION; PROTEIN-SYNTHESIS; BINDING PROTEIN; TRANSGENIC MICE; HALF-LIFE; DEGRADATION	c-Myc is a protooncogene involved in the control of cellular proliferation, differentiation and apoptosis, Like many other early response genes, regulation of c-myc expression is mainly controlled at the level of mRNA stability. Multiple cls-acting destabilizing elements have been described that are located both in the protein-coding region and in the 3 ' untranslated region (3 ' UTR), However, it is not known when they function during development and whether they act as partly redundant or independent elements to regulate c-myc mRNA level of expression, To begin to address these questions, we created a series of c-myc alleles modified in the 3 ' UTR, using homologous recombination and the Cre/loxP system, and analysed the consequences of these modifications in ES cells and transgenic animals. We found that deletion of the complete 3 ' UTR, including runs of Us and AU-rich elements proposed, on the basis of cell-culture assays, to be involved in the control of c-myc mRNA stability, did not alter the steady-state level of c-myc mRNA in any of the various situations analysed in vivo. Moreover, mice homozygous for the 3 ' UTR-deleted gene were perfectly healthy and fertile, Our results therefore strongly suggest that the 3 ' UTR of c-myc mRNA does not play a major role in the developmental control of c-myc expression.	Univ Toulouse 3, UMR5547, CNRS, Ctr Dev Biol, F-31062 Toulouse 04, France; Inst Pasteur, URA 1960, CNRS, Dev Biol Unit, F-75724 Paris, France; Univ Paris 05, Fac Sci Pharmaceut & Biol, Genet Mol Lab, UPRESS JE 2195, F-75006 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Morello, D (corresponding author), Univ Toulouse 3, UMR5547, CNRS, Ctr Dev Biol, Batiment 4R3,118 Route Narbonne, F-31062 Toulouse 04, France.		Vidaud, Michel/O-7346-2017					AGHIB DF, 1990, ONCOGENE, V5, P707; ALBERTA JA, 1994, J BIOL CHEM, V269, P4532; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P901; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; Bieche I, 2000, CLIN CANCER RES, V6, P452; BONNIEU A, 1990, ONCOGENE, V5, P1585; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; Brewer G, 1998, J BIOL CHEM, V273, P34770, DOI 10.1074/jbc.273.52.34770; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; COLE MD, 1990, ENZYME, V44, P167, DOI 10.1159/000468755; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; Doyle GAR, 1998, NUCLEIC ACIDS RES, V26, P5036, DOI 10.1093/nar/26.22.5036; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; GIBSON CW, 1986, MOL CELL BIOCHEM, V71, P61; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Kress C, 1998, MAMM GENOME, V9, P998, DOI 10.1007/s003359900914; LAIRDOFFRINGA IA, 1991, NUCLEIC ACIDS RES, V19, P2387, DOI 10.1093/nar/19.9.2387; LAIRDOFFRINGA IA, 1992, BIOESSAYS, V14, P119, DOI 10.1002/bies.950140209; LAIRDOFFRINGA IA, 1989, NUCLEIC ACIDS RES, V17, P6499, DOI 10.1093/nar/17.16.6499; Lallemand Y, 1998, TRANSGENIC RES, V7, P105, DOI 10.1023/A:1008868325009; LAVENU A, 1995, MOL CELL BIOL, V15, P4410; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; MAKINO R, 1984, NATURE, V310, P697, DOI 10.1038/310697a0; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; MORELLO D, 1985, IMMUNOGENETICS, V22, P441, DOI 10.1007/BF00418090; MORELLO D, 1993, ONCOGENE, V8, P1921; MORELLO D, 1986, EMBO J, V5, P1877, DOI 10.1002/j.1460-2075.1986.tb04439.x; MORELLO D, 1990, MOL CELL BIOL, V10, P3185, DOI 10.1128/MCB.10.6.3185; MORELLO D, 1990, ONCOGENE, V5, P1511; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; Pistoi S, 1996, MOL CELL BIOL, V16, P5107; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SAUER B, 1990, New Biologist, V2, P441; SOBCZAK J, 1989, ONCOGENE, V4, P1503; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; Yeilding NM, 1997, MOL CELL BIOL, V17, P2698, DOI 10.1128/MCB.17.5.2698; Yeilding NM, 1996, MOL CELL BIOL, V16, P3511; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	45	16	17	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4344	4353		10.1038/sj.onc.1204482	http://dx.doi.org/10.1038/sj.onc.1204482			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466615				2022-12-17	WOS:000169912600008
J	Xi, HK; Goodwin, B; Shepherd, AT; Blanck, G				Xi, HK; Goodwin, B; Shepherd, AT; Blanck, G			Impaired class II transactivator expression in mice lacking interferon regulatory factor-2	ONCOGENE			English	Article						IRF; CIITA; MHC class II; IFN-gamma; mice	BARE LYMPHOCYTE SYNDROME; CREB BINDING-PROTEIN; MHC GENE-EXPRESSION; IFN-GAMMA; DERMAL FIBROBLASTS; CIITA INTERACTS; CHAIN GENE; INDUCTION; ACTIVATION; PROMOTER	Class II transactivator (CIITA) is required for both constitutive and inducible expression of MHC class II genes. IFN-gamma induced expression of CIITA in various cell types is directed by CIITA type IV promoter. The two transactivators, STAT1 and IRF-1, mediate the IFN-gamma activation of the type IV promoter by binding to the GAS and IRF-E of the promoter, respectively. In addition to IRF-1, IRF-2, another member of the IRF family, also activates the human CIITA type IV promoter, and IRF-2 cooperates with IRF-1 to activate the promoter in transient transfection assays, IRF-1 and IRF-2 can co-occupy the IRF-E of the human CIITA type IV promoter. To understand the effect of loss of IRF-2 on the endogenous CIITA expression, we assayed for CIITA expression in IRF-2 knock-out mice. Both basal and IFN-gamma induced CIITA expression were reduced in IRF-2 knock-out mice. At least half of the amount of inducible CIITA mRNA depends on IRF-2, The reduction of IFN-gamma induced CIITA mRNA in IRF-2: knock-out mice was due to the reduction of the type IV CIITA mRNA induction. The reduction of basal CIITA mRNA was apparently due to the reduction of CIITA mRNA originating from other promoters. These data indicate that IRF-2, like IRF-1, plays a critical role in the regulation of the endogenous CIITA gene. The implications in understanding the previously described phenotypes of IRF-2 defective mice are discussed.	Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Program Immunol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Blanck, G (corresponding author), Univ S Florida, Coll Med, Dept Biochem & Mol Biol, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.		Blanck, George/A-5365-2012		NCI NIH HHS [R01CA81497-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081497] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASTA PV, 1987, J IMMUNOL, V138, P1275; BLANCK G, 1990, HUM IMMUNOL, V29, P150, DOI 10.1016/0198-8859(90)90078-4; Bradley MB, 1997, J IMMUNOL, V159, P1086; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367; Chang CH, 1996, IMMUNITY, V4, P167, DOI 10.1016/S1074-7613(00)80681-0; CHIN KC, 1994, IMMUNITY, V1, P687, DOI 10.1016/1074-7613(94)90039-6; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; Fontes JD, 1997, NUCLEIC ACIDS RES, V25, P2522, DOI 10.1093/nar/25.12.2522; Fontes JD, 1996, J EXP MED, V183, P2517, DOI 10.1084/jem.183.6.2517; Fontes JD, 1999, MOL CELL BIOL, V19, P941; Fujii Y, 1999, EMBO J, V18, P5028, DOI 10.1093/emboj/18.18.5028; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GOES N, 1995, J IMMUNOL, V155, P4559; Grieder FB, 1999, VIROLOGY, V257, P106, DOI 10.1006/viro.1999.9662; Harada H, 1998, BIOCHIMIE, V80, P641, DOI 10.1016/S0300-9084(99)80017-0; Hobart M, 1997, J IMMUNOL, V158, P4260; Kretsovali A, 1998, MOL CELL BIOL, V18, P6777, DOI 10.1128/MCB.18.11.6777; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; Lu YM, 1996, J IMMUNOL, V156, P2495; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; Mahanta SK, 1997, P NATL ACAD SCI USA, V94, P6324, DOI 10.1073/pnas.94.12.6324; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; Merediz SAK, 2000, NUCLEIC ACIDS RES, V28, P4219, DOI 10.1093/nar/28.21.4219; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Nikcevich KM, 1999, J NEUROIMMUNOL, V99, P195, DOI 10.1016/S0165-5728(99)00117-4; O'Keefe GM, 1999, EUR J IMMUNOL, V29, P1275, DOI 10.1002/(SICI)1521-4141(199904)29:04<1275::AID-IMMU1275>3.0.CO;2-T; Otten LA, 1998, EUR J IMMUNOL, V28, P473, DOI 10.1002/(SICI)1521-4141(199802)28:02<473::AID-IMMU473>3.0.CO;2-E; Piskurich JF, 1998, J IMMUNOL, V160, P233; Piskurich JF, 1999, MOL CELL BIOL, V19, P431; RILEY JL, 1995, IMMUNITY, V2, P533, DOI 10.1016/1074-7613(95)90033-0; Rohn WM, 1996, CRIT REV IMMUNOL, V16, P311, DOI 10.1615/CritRevImmunol.v16.i3.40; Scholl T, 1997, P NATL ACAD SCI USA, V94, P6330, DOI 10.1073/pnas.94.12.6330; Schoneboom BA, 2000, J INTERF CYTOK RES, V20, P205, DOI 10.1089/107999000312621; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; TING JPY, 1993, CURR OPIN IMMUNOL, V5, P8, DOI 10.1016/0952-7915(93)90074-3; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; Xi HK, 1999, ONCOGENE, V18, P5889, DOI 10.1038/sj.onc.1202969; Zhu XS, 2000, MOL CELL BIOL, V20, P6051, DOI 10.1128/MCB.20.16.6051-6061.2000	44	16	16	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4219	4227		10.1038/sj.onc.1204556	http://dx.doi.org/10.1038/sj.onc.1204556			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464288				2022-12-17	WOS:000169857200012
J	Gu, JJ; Rubin, RM; Yuan, ZM				Gu, JJ; Rubin, RM; Yuan, ZM			A sequence element of p53 that determines its susceptibility to viral oncoprotein-targeted degradation	ONCOGENE			English	Article						p53 degradation; HPV16 E6; E1B55k/E4 34k; p73; p53; chimeras	HUMAN PAPILLOMAVIRUS TYPE-16; E6 ONCOPROTEIN; P73; MDM2; PROTEIN; INACTIVATION; ASSOCIATION; APOPTOSIS; PROMOTES; CANCER	The molecular basis that the viral oncoproteins, including HPV16 E6 and E1B55k/E4 34k complex, differentially target p53 but not its homolog p73 for degradation remains elusive, Using a series of p53/p73 chimeras, we demonstrated that despite binding to the different regions of p53, both HPV16 E6 and E1B55k/E4 34k required a very same p53 sequence, amino acid residues 92 to 112 [p53(aa.92-112)], previously identified as a necessity for Mdm2-mediated degradation, to target p53 for degradation. Removal of the p53(aa.92-112) by either substitution or deletion resulted in a p53 protein that was no longer degradable hy the viral proteins. More significantly, swapping the oncoprotein-binding motif and the p53(aa.92-112) rendered p73 susceptible to oncoprotein-mediated degradation. Collectively, our data supports a model in which the p53(aa.92-112) functions as a determinant for p53 stability while the binding of the oncoproteins directs p53 into the specific pathway for proteolysis.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Yuan, ZM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave,Bldg 1,Room 209, Boston, MA 02115 USA.							ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Crook T, 1996, VIROLOGY, V217, P285, DOI 10.1006/viro.1996.0115; Dobbelstein M, 1998, J GEN VIROL, V79, P3079, DOI 10.1099/0022-1317-79-12-3079; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; Li XQ, 1996, J BIOL CHEM, V271, P4447; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; MARSTON NJ, 1995, ONCOGENE, V10, P1709; Prabhu NS, 1998, INT J ONCOL, V13, P5; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	27	16	16	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3519	3527		10.1038/sj.onc.1204454	http://dx.doi.org/10.1038/sj.onc.1204454			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429698				2022-12-17	WOS:000169478300007
J	Szutorisz, H; Palmqvist, R; Roos, G; Stenling, R; Schorderet, DF; Reddell, R; Lingner, J; Nabholz, M				Szutorisz, H; Palmqvist, R; Roos, G; Stenling, R; Schorderet, DF; Reddell, R; Lingner, J; Nabholz, M			Rearrangements of minisatellites in the human telomerase reverse transcriptase gene are not correlated with its expression in colon carcinomas	ONCOGENE			English	Article						hTERT; minisatellites; rearrangements; colon carcinoma	CATALYTIC SUBUNIT HTERT; SOMATIC MUTATIONS; SUSCEPTIBILITY LOCUS; VARIABLE NUMBER; INSULIN GENE; HUMAN THYMUS; ALLELIC LOSS; LIFE-SPAN; C-MYC; ACTIVATION	Telomerase activation is crucial in human carcinogenesis. The limiting component of telomerase, the catalytic subunit (hTERT), is undetectable in normal somatic cells but present in most tumor cells, including the earliest stages of colon carcinoma, The mechanisms involved in the differential expression in normal and tumor cells are not understood. In normal cells hTERT expression is shut down by a repressor, and upregulation could be a consequence of cis-acting changes in the hTERT gene, making it resistant to repression, We have identified a polymorphic and a monomorphic minisatellite in the second intron of the hTERT gene, and polymorphic one in intron 6, The polymorphic minisatellite in intron 2 contains binding sites for c-Myc, which has been shown to upregulate hTERT transcription, Screening colon carcinoma DNAs for rearrangements of hTERT minisatellites we detected no changes in 33 samples from tumors, most of which express hTERT, This indicates that size rearrangements of the hTERT minisatellites are not required for telomerase expression in colon carcinomas, Minor changes and one LOH were seen in five tumors.	Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; Umea Univ, Dept Med Biosci, SE-90187 Umea, Sweden; CHU Vaudois, Div Med Genet, CH-1011 Lausanne, Switzerland; Childrens Med Res Inst, Westmead, NSW 2145, Australia	Umea University; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Children's Medical Research Institute - Australia	Nabholz, M (corresponding author), Inst Expt Canc Res, CH-1066 Epalinges, Switzerland.		Reddel, Roger R/A-6635-2014	Reddel, Roger R/0000-0002-6302-6107; Lingner, Joachim/0000-0002-2853-5803				Alakurtti K, 2000, GENE, V242, P65, DOI 10.1016/S0378-1119(99)00550-8; ARMOUR JAL, 1989, GENOMICS, V4, P328, DOI 10.1016/0888-7543(89)90338-8; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryce LA, 2000, NEOPLASIA, V2, P197, DOI 10.1038/sj.neo.7900092; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Cuthbert AP, 1999, JNCI-J NATL CANCER I, V91, P37, DOI 10.1093/jnci/91.1.37; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fennelly J, 1997, LEUKEMIA, V11, P807, DOI 10.1038/sj.leu.2400674; Fiskerstrand CE, 1999, FEBS LETT, V458, P171, DOI 10.1016/S0014-5793(99)01150-3; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Gutierrez B, 1998, HUM GENET, V103, P319, DOI 10.1007/s004390050823; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; HOFFOLSEN P, 1995, HUM MUTAT, V5, P329, DOI 10.1002/humu.1380050410; Horikawa I, 1999, CANCER RES, V59, P826; HORN GT, 1989, NUCLEIC ACIDS RES, V17, P2140, DOI 10.1093/nar/17.5.2140; JEFFREYS AJ, 1994, NAT GENET, V6, P136, DOI 10.1038/ng0294-136; Jeffreys AJ, 1997, HUM MOL GENET, V6, P129, DOI 10.1093/hmg/6.1.129; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Kaplanski C, 1997, INT J CANCER, V72, P248, DOI 10.1002/(SICI)1097-0215(19970717)72:2<248::AID-IJC8>3.0.CO;2-R; KENNEDY GC, 1995, NAT GENET, V9, P293, DOI 10.1038/ng0395-293; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kominato Y, 1997, J BIOL CHEM, V272, P25890, DOI 10.1074/jbc.272.41.25890; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Kyo S, 1999, CANCER RES, V59, P5917; Larson GP, 1999, HUM MOL GENET, V8, P1985, DOI 10.1093/hmg/8.11.1985; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Migliaccio M, 2000, J IMMUNOL, V165, P4978, DOI 10.4049/jimmunol.165.9.4978; Murray J, 1999, GENOME RES, V9, P130; NAGEL S, 1995, CANCER RES, V55, P2866; Nakabayashi K, 1999, EXP CELL RES, V252, P376, DOI 10.1006/excr.1999.4619; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5707, DOI 10.1093/nar/16.12.5707; Nikiforov YE, 1998, ONCOGENE, V17, P1983, DOI 10.1038/sj.onc.1202120; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Oh S, 1999, J BIOL CHEM, V274, P37473, DOI 10.1074/jbc.274.52.37473; Palmqvist R, 1998, BRIT J CANCER, V77, P917, DOI 10.1038/bjc.1998.152; Paquette J, 1998, J BIOL CHEM, V273, P14158, DOI 10.1074/jbc.273.23.14158; Phelan CM, 1996, NAT GENET, V12, P309, DOI 10.1038/ng0396-309; PHILLIPS N, 1993, INT J CANCER, V54, P85, DOI 10.1002/ijc.2910540115; Phillips NJ, 1996, CANCER RES, V56, P606; Prokhortchouk EB, 1998, J MOL BIOL, V280, P227, DOI 10.1006/jmbi.1998.1857; Pugliese A, 1997, NAT GENET, V15, P293, DOI 10.1038/ng0397-293; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shipman R, 1996, EUR J CANCER, V32A, P335, DOI 10.1016/0959-8049(95)00535-8; Takakura M, 1999, CANCER RES, V59, P551; Tanaka H, 1998, GENE CHROMOSOME CANC, V23, P123, DOI 10.1002/(SICI)1098-2264(199810)23:2<123::AID-GCC5>3.0.CO;2-4; TREPICCHIO WL, 1992, NUCLEIC ACIDS RES, V20, P2427, DOI 10.1093/nar/20.10.2427; TREPICCHIO WL, 1993, NUCLEIC ACIDS RES, V21, P977, DOI 10.1093/nar/21.4.977; Ulaner GA, 2000, INT J CANCER, V85, P330, DOI 10.1002/(SICI)1097-0215(20000201)85:3<330::AID-IJC6>3.0.CO;2-U; Vafiadis P, 1997, NAT GENET, V15, P289, DOI 10.1038/ng0397-289; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Weitzel JN, 2000, CANCER RES, V60, P259; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Yan P, 1999, J PATHOL, V189, P207, DOI 10.1002/(SICI)1096-9896(199910)189:2<207::AID-PATH424>3.0.CO;2-H; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Yoshida R, 1999, ANTICANCER RES, V19, P2167	61	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2001	20	20					2600	2605		10.1038/sj.onc.1204346	http://dx.doi.org/10.1038/sj.onc.1204346			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420670				2022-12-17	WOS:000168652500011
J	Teckchandani, AM; Feshchenko, EA; Tsygankov, AY				Teckchandani, AM; Feshchenko, EA; Tsygankov, AY			c-Cbl facilitates fibronectin matrix production by v-Abl-transformed NIH3T3 cells via activation of small GTPases	ONCOGENE			English	Article						c-Cbl; fibronectin; adhesion; morphology; tyrosine phosphorylation; ubiquitination	NUCLEOTIDE-RELEASING FACTOR; INTEGRIN SIGNALING PATHWAY; GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; T-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTOONCOGENE PRODUCT; ADAPTER PROTEIN; DEPENDENT ACTIVATION; NEGATIVE REGULATOR	The protooncogenic protein c-Cbl has been shown to act as a multivalent adaptor and a negative regulator of protein tyrosine kinase-mediated signaling, Recent studies have implicated it in the regulation of cell adhesion-related events. We have previously shown that c-Cbl facilitates adhesion and spreading of v-Abl-transformed fibroblasts, and that these effects are dependent on its tyrosine phosphorylation, However, the mechanisms mediating effects of c-Cbl on fibroblast adhesion remain poorly understood. In this study we demonstrate that the tyrosine phosphorylation-dependent effect of c-Cbl on adhesion of v-Abl-transformed fibroblasts is primarily mediated by an increase in fibronectin matrix deposition by these cells. This increase in fibronectin matrix deposition and, hence, in cell adhesion is dependent on cytoskeletal rearrangements induced by RhoA, Rad and, possibly, Rapt activation caused by c-Cbl, The observed activation of these GTPases is mediated by the recruitment of phosphatidylinositol-3' kinase, CrkL and Vav2 to the C-terminal tyrosine residues of c-Cbl, The results of this study also demonstrate that ubiquitination is essential for the observed effects of c-Cbl on fibronectin matrix production and cell adhesion.	Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Tsygankov, AY (corresponding author), Temple Univ, Sch Med, Dept Microbiol & Immunol, Rm 506,3400 N Broad St, Philadelphia, PA 19140 USA.		Tsygankov, Alexander Y/K-6205-2017	Teckchandani, Anjali/0000-0002-2237-9598	NCI NIH HHS [CA78499] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078499] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akamatsu H, 1996, CANCER RES, V56, P4541; Akiyama S K, 1996, Hum Cell, V9, P181; Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; Andoniou CE, 1996, ONCOGENE, V12, P1981; Arai A, 1999, BLOOD, V93, P3713, DOI 10.1182/blood.V93.11.3713.411a36_3713_3722; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Christopher RA, 1997, J CELL SCI, V110, P569; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; Feshchenko EA, 1999, ONCOGENE, V18, P3703, DOI 10.1038/sj.onc.1202672; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HENSKE EP, 1995, ANN HUM GENET, V59, P25, DOI 10.1111/j.1469-1809.1995.tb01603.x; Herzhoff K, 1999, BRIT J DERMATOL, V141, P218; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Jascur T, 1997, J BIOL CHEM, V272, P14483, DOI 10.1074/jbc.272.22.14483; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; KAWATA M, 1988, J BIOL CHEM, V263, P18965; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Klein S, 1996, J BIOL CHEM, V271, P22583, DOI 10.1074/jbc.271.37.22583; Kumar CC, 1999, ANN NY ACAD SCI, V886, P122, DOI 10.1111/j.1749-6632.1999.tb09407.x; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Liu KS, 1999, TERR ATMOS OCEAN SCI, V10, P377, DOI 10.3319/TAO.1999.10.2.377(T); Liu YC, 1997, J BIOL CHEM, V272, P168; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Marengere LEM, 1997, J IMMUNOL, V159, P70; MCKILLOP DFA, 1994, J MUSCLE RES CELL M, V15, P309; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Merlo JJ, 1998, ANTICANCER RES, V18, P2389; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; RAJARAMAN R, 1983, EXP CELL BIOL, V51, P9; Reedquist KA, 1998, J BIOL CHEM, V273, P4944, DOI 10.1074/jbc.273.9.4944; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; RIDLEY AJ, 1992, COLD SPRING HARB SYM, V57, P661, DOI 10.1101/SQB.1992.057.01.072; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Scardigli R, 1996, EXP CELL RES, V227, P223, DOI 10.1006/excr.1996.0271; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Thien CBF, 1998, IMMUNOL CELL BIOL, V76, P473, DOI 10.1046/j.1440-1711.1998.00768.x; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; TSYGANKOV AY, 1994, J BIOL CHEM, V269, P7792; TSYGANKOV AY, 1992, CELL IMMUNOL, V140, P97, DOI 10.1016/0008-8749(92)90179-S; VAHERI A, 1978, BIOCHIM BIOPHYS ACTA, V516, P1, DOI 10.1016/0304-419X(78)90002-1; Vaheri A, 1978, Ann N Y Acad Sci, V312, P343, DOI 10.1111/j.1749-6632.1978.tb16812.x; VOLBERG T, 1994, CELL MOTIL CYTOSKEL, V29, P321, DOI 10.1002/cm.970290405; vonWillebrand M, 1996, EUR J BIOCHEM, V235, P828; WALSH A, 1997, ONCOGENE, V16, P2553; Wang Y, 1999, J CELL BIOCHEM, V72, P119; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Wilde C, 2000, J BIOL CHEM, V275, P16478, DOI 10.1074/jbc.M910362199; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; Zell T, 1998, CURR BIOL, V8, P814, DOI 10.1016/S0960-9822(98)70323-9; Zhang QH, 1997, MOL BIOL CELL, V8, P1415, DOI 10.1091/mbc.8.8.1415; Zhong CL, 1998, J CELL BIOL, V141, P539, DOI 10.1083/jcb.141.2.539	73	16	17	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1739	1755		10.1038/sj.onc.1204246	http://dx.doi.org/10.1038/sj.onc.1204246			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313921				2022-12-17	WOS:000167750900007
J	Palacios, C; del Arroyo, AG; Silva, A; Collins, MKL				Palacios, C; del Arroyo, AG; Silva, A; Collins, MKL			The role of p53 in death of IL-3-dependent cells in response to cytotoxic drugs	ONCOGENE			English	Article						p53; apoptosis; IL-3	DNA-DAMAGING AGENTS; P53-DEPENDENT APOPTOSIS; ANTICANCER AGENTS; C-ABL; LINE; INTERLEUKIN-3; CISPLATIN; PATHWAYS; PROTECTS; STRESS	This report examines the cytotoxicity of chemotherapeutic agents to primary bone marrow-derived IL-3-dependent cells. Such cells derived from p53-null mice were resistant to almost 100-fold higher concentrations of the inhibitors of deoxyribonucleotide synthesis FUdR, methotrexate and hydroxyurea than cells with wild-type p53, In contrast, the cytotoxicity of the DNA damaging agents X-irradiation, cisplatin or bleomycin was p53-independent. The topoisomerase II inhibitor etoposide induced p53-dependent death, which suggests that DNA damage may not be its primary mechanism of cytotoxicity in this cell type. An IL3-dependent cell line which expresses wild-type p53 was used to demonstrate that the ability of cytotoxic drugs to increase p53 expression level does not control their ability to induce p53-dependent loss of clonigenicity. Finally, comparison with a p53-null IL3-dependent cell line was used to show that absence of p53 delays the rate of entry into apoptosis following treatment with either DNA damaging agents or inhibitors of deoxyribonucleotide synthesis. This distinguishes short-term effects of p53 on rate of entry into apoptosis from its role in controlling ultimate cell survival.	Windeyer Inst Med Sci, Dept Immunol, London W1P 6DB, England; CSIC, Ctr Invest Biol, Madrid, Spain	University of London; University College London; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Collins, MKL (corresponding author), Windeyer Inst Med Sci, Dept Immunol, 46 Cleveland St, London W1P 6DB, England.		Palacios, Carmen/G-7422-2015	Palacios, Carmen/0000-0002-1267-2619				Agami R, 1999, NATURE, V399, P809; Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; ASCASO R, 1994, EUR J IMMUNOL, V24, P537, DOI 10.1002/eji.1830240307; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EASTMAN A, 1987, PHARMACOL THERAPEUT, V34, P155, DOI 10.1016/0163-7258(87)90009-X; Frenkel J, 1999, ONCOGENE, V18, P2901, DOI 10.1038/sj.onc.1202518; Gong JG, 1999, NATURE, V399, P806; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; Griffiths SD, 1997, ONCOGENE, V14, P523, DOI 10.1038/sj.onc.1200871; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; INGRAHAM HA, 1986, BIOCHEMISTRY-US, V25, P3225, DOI 10.1021/bi00359a022; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; Lamb JR, 1997, NAT MED, V3, P962, DOI 10.1038/nm0997-962; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LOIKE JD, 1976, BIOCHEMISTRY-US, V15, P5443, DOI 10.1021/bi00670a004; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OConnor PM, 1997, CANCER RES, V57, P4285; Oliver FJ, 1997, J BIOL CHEM, V272, P10624; OLIVER FJ, 1993, BIOCHEM BIOPH RES CO, V194, P126, DOI 10.1006/bbrc.1993.1794; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Pritchard DM, 1998, CANCER RES, V58, P5453; Silva A, 1997, BLOOD, V89, P2717, DOI 10.1182/blood.V89.8.2717; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TANIZAWA A, 1989, EXP CELL RES, V185, P237, DOI 10.1016/0014-4827(89)90052-9; TISHLER RB, 1993, CANCER RES, V53, P2212; Wlodarski P, 1998, BLOOD, V91, P2998, DOI 10.1182/blood.V91.8.2998.2998_2998_3006; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163	31	16	17	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3556	3559		10.1038/sj.onc.1203683	http://dx.doi.org/10.1038/sj.onc.1203683			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918614				2022-12-17	WOS:000088346500012
J	Suzuki, J; Kaziro, Y; Koide, H				Suzuki, J; Kaziro, Y; Koide, H			Positive regulation of skeletal myogenesis by R-Ras	ONCOGENE			English	Article						R-Ras; apoptosis; myogenesis; Ras; motility	GTP-BINDING PROTEINS; H-RAS; MUSCLE-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; MYOBLAST DIFFERENTIATION; MYOCYTE DIFFERENTIATION; ACTIVATED RAS; BAF3 CELLS; IN-VITRO; EXPRESSION	Most of the proteins in the Ras-family proteins, including Pas, Rap and TC21, have been reported to be strong inhibitors of skeletal myogenesis. Here we show that R-Ras, another member of this family, promotes terminal differentiation of C2C12 skeletal myoblasts, In contrast to Pas, which induced markedly transformed phenotype of C2C12 cells, an activated mutant of R-Ras (R-Ras(Q87L)) did not exhibit any inhibitory effect on the differentiation of C2C12 cells, but enhanced the formation of multinucleated myotubes, Although R-Ras(Q87L) showed little effect on induction of two muscle-specific proteins, creatine kinase and myogenin, it prevented cell death during myoblast differentiation, probably through Akt activation and Bcl-x(L) induction. Motility of C2C12 cells, which may be involved in fusion of myoblasts, was also stimulated by R-Ras(Q87L). Furthermore, we observed a transient activation of endogenous R-Ras during differentiation of C2C12 cells. The ectopic expression of R-Ras GAP inhibited the differentiation. These results suggest that R-Ras has a positive effect on the terminal differentiation of myoblasts and may be involved in the program of skeletal myogenesis.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 226, Japan	Tokyo Institute of Technology	Koide, H (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 226, Japan.		Koide, Hiroshi/E-9000-2011	Koide, Hiroshi/0000-0001-5916-3179				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Crawley S, 1997, EXP CELL RES, V235, P274, DOI 10.1006/excr.1997.3671; Dominov JA, 1998, J CELL BIOL, V142, P537, DOI 10.1083/jcb.142.2.537; Edamatsu H, 1998, FEBS LETT, V440, P231, DOI 10.1016/S0014-5793(98)01457-4; Fimia GM, 1996, J BIOL CHEM, V271, P15575, DOI 10.1074/jbc.271.26.15575; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/er.17.5.481; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Graham SM, 1999, ONCOGENE, V18, P2107, DOI 10.1038/sj.onc.1202517; GUTMANN DH, 1994, J NEUROSCI RES, V37, P398, DOI 10.1002/jnr.490370312; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Itoh N, 1996, DEVELOPMENT, V122, P291; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Kishida S, 1997, ONCOGENE, V15, P2899, DOI 10.1038/sj.onc.1201473; KONIECZNY SF, 1989, ONCOGENE, V4, P473; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; MCCLEARN D, 1995, DEV DYNAM, V202, P365, DOI 10.1002/aja.1002020406; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; Nancy V, 1999, J BIOL CHEM, V274, P8737, DOI 10.1074/jbc.274.13.8737; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Olson E N, 1992, Semin Cell Biol, V3, P127; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PAYNE PA, 1987, P NATL ACAD SCI USA, V84, P8956, DOI 10.1073/pnas.84.24.8956; Pizon V, 1999, EXP CELL RES, V246, P56, DOI 10.1006/excr.1998.4284; Ramocki MB, 1998, J BIOL CHEM, V273, P17696, DOI 10.1074/jbc.273.28.17696; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; REY I, 1994, ONCOGENE, V9, P685; Rohwedel J, 1998, DEV BIOL, V201, P167, DOI 10.1006/dbio.1998.9002; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; SAEZ R, 1994, ONCOGENE, V9, P2977; STOCKDALE FE, 1992, DEV BIOL, V154, P284, DOI 10.1016/0012-1606(92)90068-R; Suzuki J, 1998, FEBS LETT, V437, P112, DOI 10.1016/S0014-5793(98)01213-7; Suzuki J, 1997, ONCOGENE, V15, P1689, DOI 10.1038/sj.onc.1201333; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang J, 1997, CANCER RES, V57, P351; Yamamoto T, 1995, J BIOL CHEM, V270, P30557, DOI 10.1074/jbc.270.51.30557; Yao CC, 1996, J CELL SCI, V109, P3139; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	52	16	18	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 24	2000	19	9					1138	1146		10.1038/sj.onc.1203402	http://dx.doi.org/10.1038/sj.onc.1203402			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MX	10713701				2022-12-17	WOS:000085567800003
J	Dickson, C; Creer, A; Fantl, V				Dickson, C; Creer, A; Fantl, V			Mammary gland oncogenes as indicators of pathways important in mammary gland development	ONCOGENE			English	Article						mammary gland; cyclin D1; fibroblast growth factor; dominant negative Fgf-receptor	GROWTH-FACTOR FAMILY; TRANSGENIC MICE; TUMOR VIRUS; CYCLIN D1; BREAST-CANCER; EXPRESSION; MOUSE; INT-2; GENE; ACTIVATION	The identification of dominant acting proto-oncogenes in mammary tumors from mice and humans has highlighted a number of signal transduction pathways that have subsequently been shown to have a role in normal mammary growth and differentiation. Here we describe the use of two different transgenic mouse strategies to investigate the function of two of these signalling pathways in the normal growth and differentiation of the mouse mammary gland during pregnancy.	Imperial Canc Res Fund, London WC2A 3PX, England	Cancer Research UK	Dickson, C (corresponding author), Imperial Canc Res Fund, 44 Lincolns Inn Fields, London WC2A 3PX, England.							BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; COLEMANKRNACIK S, 1994, MOL ENDOCRINOL, V8, P218, DOI 10.1210/me.8.2.218; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DICKSON C, 1991, ANN NY ACAD SCI, V638, P18, DOI 10.1111/j.1749-6632.1991.tb49014.x; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fantl V, 1999, DEV BIOL, V212, P1, DOI 10.1006/dbio.1999.9329; Gallahan D, 1996, CANCER RES, V56, P1775; GILLETT C, 1994, CANCER RES, V54, P1812; Jackson D, 1997, J CELL SCI, V110, P1261; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; LAMMIE GA, 1991, ONCOGENE, V6, P439; LAMMIE GA, 1991, CANCER CELL, V3, P1; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MATHIEU M, 1995, J BIOL CHEM, V270, P24197, DOI 10.1074/jbc.270.41.24197; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; NUSSE R, 1991, CURR TOP MICROBIOL, V171, P44; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; PETERS G, 1991, SEMIN VIROL, V2, P319; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; STAMP G, 1992, CELL GROWTH DIFFER, V3, P929; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x	33	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1097	1101		10.1038/sj.onc.1203267	http://dx.doi.org/10.1038/sj.onc.1203267			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713696				2022-12-17	WOS:000085796400018
J	Gavine, PR; Neil, JC; Crouch, DH				Gavine, PR; Neil, JC; Crouch, DH			Protein stabilization: a common consequence of mutations in independently derived v-Myc alleles	ONCOGENE			English	Article						Myc; viral mutations; stabilization	ALPHA IN-VIVO; C-MYC; TRANSFORMING ACTIVITY; INDUCED DEGRADATION; PROTEASOME PATHWAY; TERMINAL REGION; PHOSPHORYLATION; DOMAIN; MYOD; FOS	Myc is overexpressed in many cancers as a result of gene rearrangement or amplification, but coding sequence changes which cluster in the N-terminal transactivation domain also appear to play a role in tumour progression. The prototypic v-Myc gene of MC29 virus differs from avian c-Myc by a series of mutations, including a change at a regulatory phosphorylation site within the mutational hotspot (thr-61) which is known to potentiate transformation in vitro. We now show that the mutation at thr-61 stabilizes the v-Myc protein (turnover difference) and that this single mutation is both necessary and sufficient for the phenotype. A major involvement of the proteasome in Myc degradation was confirmed, but surprisingly, a dilysine motif adjacent to thr-61 proved not to be the ubiquitin target. Two other v-Myc genes which carry a mutation at thr-61 (avian MH2) or a large deletion encompassing this domain (feline T17) were found to be stabilized to a similar extent as MC29, showing that stabilization is a common feature of independently derived Myc oncogenes, These results suggest a common selective process in the genesis of these three viral oncoproteins and a mechanistic link with Jun, Fos and Myb oncoproteins which are also stabilized relative to their cellular counterparts.	Univ Dundee, Ninewells Hosp & Med Sch, Ctr Biomed Res, Dundee DD1 9SY, Scotland; Univ Glasgow, Sch Vet, Dept Vet Pathol, Glasgow G61 1QH, Lanark, Scotland	University of Dundee; University of Glasgow	Crouch, DH (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Ctr Biomed Res, Dundee DD1 9SY, Scotland.							Bies J, 1997, ONCOGENE, V14, P203, DOI 10.1038/sj.onc.1200828; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Chen RH, 1996, ONCOGENE, V12, P1493; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; COLL J, 1983, EMBO J, V12, P2189; Colman MS, 1996, NUCLEIC ACIDS RES, V24, P1971, DOI 10.1093/nar/24.10.1971; CROUCH DH, 1990, ONCOGENE, V5, P683; CROUCH DH, 1993, ONCOGENE, V8, P1849; CURRAN T, 1984, CELL, V36, P259; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; FULTON R, 1996, J VIROL, V170, P1154; GILLESPIE DAF, 1991, SEMINARS VIROLOGY, V2, P329; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; ISAKSSON A, 1996, BIOCHIM BIOPHYS ACTA, V1288, P21; Kilbey A, 1996, ONCOGENE, V12, P2409; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; LAROCCA SA, 1994, ONCOGENE, V9, P3499; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; May GHW, 1998, CURR BIOL, V8, P117, DOI 10.1016/S0960-9822(98)70043-0; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nakajima T, 1998, J BIOL CHEM, V273, P20036, DOI 10.1074/jbc.273.32.20036; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; PULVERER BJ, 1994, ONCOGENE, V9, P59; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; SmithSorensen B, 1996, J BIOL CHEM, V271, P5513, DOI 10.1074/jbc.271.10.5513; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WALTHER N, 1986, VIROLOGY, V154, P219, DOI 10.1016/0042-6822(86)90444-7	37	16	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7552	7558		10.1038/sj.onc.1203102	http://dx.doi.org/10.1038/sj.onc.1203102			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602514				2022-12-17	WOS:000084119600016
J	Lee, AWM; Nambirajan, S; Moffat, JG				Lee, AWM; Nambirajan, S; Moffat, JG			CSF-1 activates MAPK-dependent and p53-independent pathways to induce growth arrest of hormone-dependent human breast cancer cells	ONCOGENE			English	Article						colony-stimulating factor-1 receptor; p31Waf1/Cip1; cyclin D1; MAP kinase; breast cancer; estrogen	COLONY-STIMULATING FACTOR; CYCLIN D1 EXPRESSION; FACTOR-I; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; CDK INHIBITORS; INDEPENDENT GROWTH; CARCINOMA CELLS; GENE-EXPRESSION; DNA-DAMAGE	The CSF-1 receptor (CSF-1R) is expressed in >50% of human breast cancers. To investigate the consequence of CSF-1R expression, hormone-dependent human breast cancer cell lines, MCF-7 and T-47D, were transfected with CSF-1R, Unexpectedly, CSF-1 substantially inhibited estradiol (E-2) and insulin-dependent proliferation of MCF-7 transfectants (MCF-7fms) and prevented cyclin E/cdk2 and cyclin A/cdk2 activation, consistent with a G(1) arrest. In contrast, CSF-1 increased DNA synthesis in T-47D transfectants (T-47Dfms) alone and with E-2 or insulin. In response to CSF-1, there was a marked and sustained upregulation of the cyclin-dependent kinase inhibitor, p21(Waf1/Cip1), in MCF-7fms but not T-47Dfms, CSF-1 also markedly upregulated cyclin D1 in MCF-7fms, The coordinate increase in cyclin D1 and p21 had the effect of decreasing the specific but not absolute activity of cyclin D1/cdk4, p53 was not involved since CSF-I induction of p21 was unaffected by dominant-negative p53 expression. ERK activation by CSF-1 was robust and sustained in MCF-7fms and to a much lesser extent in T-47Dfms. Using pharmacological and transient transfection approaches, we showed that ERK activation was necessary and sufficient for p21 induction in MCF-7fms, Moreover, activated MEK inhibited E-2-stimulated cdk2 activity. Our findings indicate that the consequence of CSF-1R-mediated signals in human breast cancer cells is dependent on the genetic background of the particular tumor.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Lee, AWM (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.				NIDDK NIH HHS [R01 DK48929] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048929] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; Bacus SS, 1996, ONCOGENE, V12, P2535; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; CASEY G, 1991, ONCOGENE, V6, P1791; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FILDERMAN AE, 1992, CANCER RES, V52, P3661; Flick MB, 1997, ONCOGENE, V14, P2553, DOI 10.1038/sj.onc.1201092; Giani C, 1998, ONCOGENE, V17, P425, DOI 10.1038/sj.onc.1201954; Gorospe M, 1996, MOL CELL BIOL, V16, P762; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hamilton JA, 1997, J LEUKOCYTE BIOL, V62, P145, DOI 10.1002/jlb.62.2.145; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Iavarone A, 1997, NATURE, V387, P417; JIANG HP, 1994, ONCOGENE, V9, P3397; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; KACINSKI BM, 1991, ONCOGENE, V6, P941; KATO JY, 1989, MOL CELL BIOL, V9, P4069, DOI 10.1128/MCB.9.9.4069; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lange CA, 1998, J BIOL CHEM, V273, P31308, DOI 10.1074/jbc.273.47.31308; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee AW, 1999, BLOOD, V93, P537, DOI 10.1182/blood.V93.2.537.402k30_537_553; LEE AW, 1990, P NATL ACAD SCI USA, V87, P7270, DOI 10.1073/pnas.87.18.7270; LEE AWM, 1992, CURR TOP CELL REGUL, V32, P73; LI Y, 1994, ONCOGENE, V9, P2261; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mandal M, 1998, ONCOGENE, V16, P217, DOI 10.1038/sj.onc.1201529; MUSGROVE EA, 1993, EUR J CANCER, V29A, P2273, DOI 10.1016/0959-8049(93)90221-Z; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; MUSGROVE EA, 1995, INT J CANCER, V63, P584, DOI 10.1002/ijc.2910630420; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Parry D, 1999, MOL CELL BIOL, V19, P1775; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; POLLARD JW, 1994, P NATL ACAD SCI USA, V91, P9312, DOI 10.1073/pnas.91.20.9312; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; Roth P, 1992, Curr Top Microbiol Immunol, V181, P141; ROUSSEL MF, 1994, J CELL SCI, P105; RUDEN TV, 1991, LEUKEMIA, V5, P3; Sapi E, 1998, CANCER RES, V58, P1027; SCHOLL SM, 1994, JNCI-J NATL CANCER I, V86, P120, DOI 10.1093/jnci/86.2.120; Sekiguchi T, 1998, ONCOGENE, V16, P369, DOI 10.1038/sj.onc.1201539; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STANLEY E, 1981, J IMMUNOL METHODS, V264, P1694; TANG RP, 1992, J CELL BIOCHEM, V50, P350, DOI 10.1002/jcb.240500403; Tombes RM, 1998, BIOCHEM J, V330, P1451; Wang HS, 1997, CANCER RES, V57, P1750; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YAN GZ, 1995, J NEUROSCI, V15, P6200; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	70	16	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	1999	18	52					7477	7494		10.1038/sj.onc.1203123	http://dx.doi.org/10.1038/sj.onc.1203123			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602507				2022-12-17	WOS:000084119600009
J	Yin, XY; Gupta, K; Han, WP; Levitan, ES; Prochownik, EV				Yin, XY; Gupta, K; Han, WP; Levitan, ES; Prochownik, EV			Mmip-2, a novel RING finger protein that interacts with mad members of the Myc oncoprotein network	ONCOGENE			English	Article						RING finger proteins; zinc finger proteins; helix-loop-helix; leucine zipper proteins; mad; mxi1; max; myc	C-MYC; TRANSCRIPTIONAL REPRESSION; DNA-BINDING; CELL-GROWTH; EPIDERMAL DIFFERENTIATION; GENE-EXPRESSION; ZIPPER PROTEIN; IN-VITRO; DOMAIN; COMPLEX	Mad proteins are basic-helix-loop - helix -leucine zipper (bHLH-ZIP)-containing members of the myc oncoprotein network. They interact with the bHLH-ZIP protein max, compete for the same DNA binding sites as myc-max heterodimers and down-regulate myc-responsive genes. Using the bHLH-ZIP domain of mad1 as a yeast two-hybrid 'bait', we identified Mmip-2, a novel RING finger protein that interacts with all mad members, but weakly or not at all with c-myc, max or unrelated bHLH or bZIP proteins. The mad1-Mmip-2 interaction is mediated by the ZIP domain in the former protein and by at least two regions in the latter which do not include the RING finger. Mmip-2 can disrupt max-mad DNA binding and can reverse the suppressive effects of mad proteins on c-myc-responsive target genes and on c-myc+ras-mediated focus formation in fibroblasts. Tagging with spectral variants of green fluorescent protein showed that Mmip-2 and mad proteins reside in separate cytoplasmic and nuclear compartments, respectively. When co-expressed, however, the proteins interact and translocate to the cellular compartment occupied by the more abundant protein. These observations suggest a novel way by which Mmip-2 can modulate the transcriptional activity of myc oncoproteins.	Univ Pittsburgh, Inst Canc, Childrens Hosp Pittsburgh, Hematol Oncol Sect, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Med Ctr, Dept Pharmacol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Univ Pittsburgh, Inst Canc, Childrens Hosp Pittsburgh, Hematol Oncol Sect, 3705 5th Ave, Pittsburgh, PA 15213 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032385] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33741] Funding Source: Medline; NINDS NIH HHS [NS32385] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anand G, 1997, J BIOL CHEM, V272, P19140, DOI 10.1074/jbc.272.31.19140; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BARRETT J, 1992, MOL CELL BIOL, V12, P3130, DOI 10.1128/MCB.12.7.3130; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; Bellon SF, 1997, NAT STRUCT BIOL, V4, P586, DOI 10.1038/nsb0797-586; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; Dang CV, 1999, MOL CELL BIOL, V19, P1; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FINKEL T, 1993, J BIOL CHEM, V268, P5; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; Gupta K, 1998, ONCOGENE, V16, P1149, DOI 10.1038/sj.onc.1201634; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hemenway CS, 1998, ONCOGENE, V16, P2541, DOI 10.1038/sj.onc.1202042; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HU HM, 1994, J BIOL CHEM, V269, P30069; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; Langlands K, 1997, ANAL BIOCHEM, V249, P250, DOI 10.1006/abio.1997.2184; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; LARSSON LG, 1994, ONCOGENE, V9, P1247; LEU TMJ, 1995, MOL CELL BIOL, V15, P5657; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; MA A, 1993, ONCOGENE, V8, P1093; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; STARNAUD R, 1988, ONCOGENE, V3, P553; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yin XY, 1998, ONCOGENE, V16, P2629, DOI 10.1038/sj.onc.1201777; ZERVOS, 1994, CELL, V79, P389; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	67	16	25	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	1999	18	48					6621	6634		10.1038/sj.onc.1203097	http://dx.doi.org/10.1038/sj.onc.1203097			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597267				2022-12-17	WOS:000083792000001
J	Takahama, Y; Ochiya, T; Tanooka, H; Yamamoto, H; Sakamoto, H; Nakano, H; Terada, M				Takahama, Y; Ochiya, T; Tanooka, H; Yamamoto, H; Sakamoto, H; Nakano, H; Terada, M			Adenovirus-mediated transfer of HST-1/FGF-4 gene protects mice from lethal irradiation	ONCOGENE			English	Article						HST-/FGF-4; radiation; adenovirus; gene therapy	INTESTINAL STEM-CELLS; GROWTH-FACTOR; TRANSFORMING GENE; LIMB DEVELOPMENT; IN-VIVO; RADIATION; EXPRESSION; INTERLEUKIN-11; PROLIFERATION; CHEMOTHERAPY	Intraperitoneal injection of a replication-deficient adenovirus containing the HST-1 (FGF-4) gene (Adex1HST-1) increased peripheral platelet counts in mice, and also effectively prevented experimentally induced thrombocytopenia. Here, we report the therapeutic potential of Adex1HST-1 on severely injured mice after exposure to otherffise lethal irradiation. Eighteen out of 20 mice that received Adex1HST-1 prior to gamma-irradiation (9 Gy) survived, while all the 20 mice with prior administration of control adenoviruses died after irradiation (P<0.0001). Hematological and histopathological analyses revealed that Adex1HST-1 acts as a potent protector against lethal irradiation, which causes injury of intestinal tract as well as myelosuppression in the bone marrow and spleen. These data demonstrate that the protective effects of administration of Adex1HST-1 against irradiation are superior to any other protective effects of cytokines against a lethal dose of irradiation, and that the pre-administration of Adex1NST-1 may be useful for lessening the side effects of currently used chemo- and radio-therapy against cancer.	Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 1040045, Japan; Nara Med Univ, Dept Surg 1, Nara 6348522, Japan	National Cancer Center - Japan; Nara Medical University	Terada, M (corresponding author), Natl Canc Ctr, Res Inst, Chuo Ku, 1-1 Tsukiji,5 Chome, Tokyo 1040045, Japan.		Ochiya, Takahiro/AAH-7585-2019					AINSWORTH EJ, 1988, PHARMACOL THERAPEUT, V39, P223; BLUMENTHAL RD, 1995, EXP HEMATOL, V23, P1088; Booth C, 1995, CELL PROLIFERAT, V28, P581, DOI 10.1111/j.1365-2184.1995.tb00046.x; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; Deroanne CF, 1997, CANCER RES, V57, P5590; DU XX, 1994, BLOOD, V83, P33; Farrell CL, 1998, CANCER RES, V58, P933; Galzie Z, 1997, BIOCHEM CELL BIOL, V75, P669, DOI 10.1139/bcb-75-6-669; HANSON WR, 1983, RADIAT RES, V96, P393, DOI 10.2307/3576222; Hu MCT, 1998, MOL CELL BIOL, V18, P6063, DOI 10.1128/MCB.18.10.6063; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; KATOH O, 1992, BIOCHEM BIOPH RES CO, V183, P83, DOI 10.1016/0006-291X(92)91612-T; KONISHI H, 1995, J CLIN INVEST, V96, P1125, DOI 10.1172/JCI118099; Konishi H, 1996, ONCOGENE, V13, P9; Lamb K, 1996, MOL REPROD DEV, V44, P460; Maisin JR, 1998, INT J RADIAT BIOL, V73, P443, DOI 10.1080/095530098142284; NETA R, 1988, PHARMACOL THERAPEUT, V39, P261, DOI 10.1016/0163-7258(88)90070-8; NISWANDER L, 1992, DEVELOPMENT, V114, P755; OCHIYA T, 1995, J CELL BIOL, V130, P997, DOI 10.1083/jcb.130.4.997; POTTEN CS, 1995, INT J CANCER, V62, P356, DOI 10.1002/ijc.2910620321; Potten CS, 1997, BRIT J CANCER, V75, P1454, DOI 10.1038/bjc.1997.249; Quito FL, 1996, BLOOD, V87, P1282, DOI 10.1182/blood.V87.4.1282.bloodjournal8741282; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P12368, DOI 10.1073/pnas.91.26.12368; Sonis ST, 1998, ORAL ONCOL, V34, P39, DOI 10.1016/S1368-8375(97)00053-5; SUZUKI HR, 1992, DEV BIOL, V150, P219, DOI 10.1016/0012-1606(92)90020-H; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; VanBuul PPW, 1997, INT J RADIAT BIOL, V71, P259; Verrees JF, 1996, INT J COLORECTAL DIS, V11, P211, DOI 10.1007/s003840050049; Wambersie A, 1996, Rev Med Brux, V17, P27; WILSON EL, 1991, BLOOD, V77, P954; Wright JA, 1996, HISTOL HISTOPATHOL, V11, P521; YOSHIDA T, 1994, CANCER LETT, V83, P261, DOI 10.1016/0304-3835(94)90328-X	34	16	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	1999	18	43					5943	5947		10.1038/sj.onc.1203171	http://dx.doi.org/10.1038/sj.onc.1203171			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557081				2022-12-17	WOS:000083270700011
J	Batsche, E; Cremisi, C				Batsche, E; Cremisi, C			Opposite transcriptional activity between the wild type c-myc gene coding for c-Myc1 and c-Myc2 proteins and c-Myc1 and c-Myc2 separately	ONCOGENE			English	Article						wild type; e-myc; c-myc1; c-myc2 activation; repression	FACTOR AP-2; DNA-BINDING; TRANSLATIONAL INITIATION; FUNCTIONAL-ANALYSIS; EPITHELIAL-CELLS; EXPRESSION; ONCOGENE; DIFFERENTIATION; PROMOTER; ELEMENT	E-cadherin expression nas previously shown to be activated by RE and c-myc specifically in epithelial cells, through interaction with the AP-2 transcription factor. Here we show that only a wild type c-myc gene, coding for the two c-Myc proteins c-Myc2 and c-Myc1, was able to transactivate the E-cadherin promoter, in contrast to c-Myc2 or c-Myc1 alone which strongly repressed E-cadherin in both epithelial cells and fibroblasts, In addition, overexpression of c-myc2 or c-myc1 inhibited c-myc and RE-mediated activation in a dose-dependent manner, suggesting that the ratio of the two C-myc proteins is essential for transactivation. We also showed by using several mutants of the E-cadherin promoter, that the AP-2 binding sites were the main target of c-myc2- and c-myc1-mediated repression. AP-2-mediated inhibition was cell-type specific, as was the activation. Nevertheless, when high amounts of c-myc2 and c-myc1 were used, a second c-myc-mediated repression was observed, possibly mediated by the Inr sequence of the E-cadherin promoter. Hone,er, this repression was independent of cell type, Our results suggest a new way to regulate c-myc transcriptional activity by interfering with the ratio of the two c-myc proteins, which has already been found to be disrupted in vivo in several tumor types.	Univ Paris 05, INSERM, CJF 94 02, F-75270 Paris 06, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Cremisi, C (corresponding author), Univ Paris 05, INSERM, CJF 94 02, 45 Rue Saints Peres, F-75270 Paris 06, France.			Batsche, Eric/0000-0002-5145-5270				Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1994, MOL BIOL CELL, V5, P597, DOI 10.1091/mbc.5.5.597; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CREMISI C, 1989, MECH B CELL NEOPLASI, P314; DOSAKAAKITA H, 1991, ONCOGENE, V6, P371; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; HANN SR, 1992, GENE DEV, V6, P1229, DOI 10.1101/gad.6.7.1229; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HANN SR, 1994, BIOCHIMIE, V76, P880, DOI 10.1016/0300-9084(94)90190-2; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; Jiang MS, 1998, P NATL ACAD SCI USA, V95, P3467, DOI 10.1073/pnas.95.7.3467; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; MARTEL C, 1995, ONCOGENE, V10, P2195; MUCHARDT C, 1992, EMBO J, V11, P2573, DOI 10.1002/j.1460-2075.1992.tb05322.x; ONCLERCQ R, 1989, NUCLEIC ACIDS RES, V17, P735, DOI 10.1093/nar/17.2.735; ONCLERCQ R, 1988, J VIROL, V62, P4533, DOI 10.1128/JVI.62.12.4533-4537.1988; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; SHRIVASTAVA A, 1993, SCIENCE, V262, P24796; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TRONCHE F, 1989, MOL CELL BIOL, V9, P4759, DOI 10.1128/MCB.9.11.4759; VERSTEEG R, 1988, EMBO J, V7, P1023, DOI 10.1002/j.1460-2075.1988.tb02909.x; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; YANG BS, 1991, MOL CELL BIOL, V11, P2291, DOI 10.1128/MCB.11.4.2291	37	16	16	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	1999	18	41					5662	5671		10.1038/sj.onc.1202927	http://dx.doi.org/10.1038/sj.onc.1202927			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523846				2022-12-17	WOS:000083016500007
J	Barbeau, B; Barat, C; Bergeron, D; Rassart, E				Barbeau, B; Barat, C; Bergeron, D; Rassart, E			The GATA-1 and Spi-1 transcriptional factors bind to a GATA/EBS dual element in the Fli-1 exon 1	ONCOGENE			English	Article						Fli-1; Ets binding site EBS; Spi-1; GATA-1; Ets-2	MURINE LEUKEMIA-VIRUS; NON-T-CELL; ETS GENE FAMILY; DNA-BINDING; ACTIVATION DOMAINS; HEMATOPOIETIC-CELLS; PUTATIVE ONCOGENE; TRANSGENIC MICE; FACTOR PU.1; EXPRESSION	Fli-1 is a proto-oncogene which is rearranged in tumors induced by three different retroviruses, Cas-Br-E, F-MuLV, and 10A1. This gene is a member of the Ets gene family, a class of transcription factors that recognize and bind to a DNA motif known as the Ets binding site (EBS). Our laboratory has previously cloned and characterized the promoter region of both human and mouse Fli-1 genes. We had then identified several regulatory elements conserved between the two species. Two of them, an exon 1 GATA/EBS dual element and an EBS element located in the 5' end of intron 1, were analysed in the present study. EMSA analysis performed with nuclear extracts from different cell lines showed that the EBS element in intron 1 (EBSi) was bound by one potential Ets-related ubiquitous factor. The GATA/ EBS element was bound by several factors that seemed Ets-related, one of which was found to be specifically expressed in hematopoietic cells. the GATA/EBS dual element was thus chosen for further analysis. A human Fli-1-derived genomic fragment containing the GATA/ EBS led to enhanced transcription when positioned upstream of the SV40 promoter in the erythroleukemic HEL cell line. In addition, an increasing number of GATA/EBS oligonucleotides upstream of this same promoter resulted in a copy number-dependent increase in luciferase activity which was greatly reduced when the EBS consensus sequence was mutated. One of the factors binding to the GATA/EBS region was identified to be Spi-1 by supershift analysis and was also shown to bind to the EBS element of the human Ets-2 gene. Supershift analysis also demonstrated the binding of the GATA-1 factor to the GATA/EBS dual element. Our results suggest that Spi-1 and GATA-1 might play a key role in the regulation of Fli-1.	Univ Quebec, Dept Sci Biol, Mol Biol Lab, Montreal, PQ H3C 3P8, Canada	University of Quebec; University of Quebec Montreal	Rassart, E (corresponding author), Univ Quebec, Dept Sci Biol, Mol Biol Lab, CP 8888, Montreal, PQ H3C 3P8, Canada.		Barbeau, Benoit/A-1174-2010	Barbeau, Benoit/0000-0002-4108-8155				AUMONT FL, 1993, DIFFERENTIATION, V52, P169, DOI 10.1111/j.1432-0436.1993.tb00627.x; Barbeau B, 1996, BBA-GENE STRUCT EXPR, V1307, P220, DOI 10.1016/0167-4781(96)00060-7; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BERGERON D, 1993, LEUKEMIA, V7, P954; BERGERON D, 1992, VIROLOGY, V191, P661, DOI 10.1016/0042-6822(92)90241-G; BERGERON D, 1991, J VIROL, V65, P7, DOI 10.1128/JVI.65.1.7-15.1991; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BHATTACHARYA G, 1993, ONCOGENE, V8, P3459; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CARVALHO M, 1993, J VIROL, V67, P3885, DOI 10.1128/JVI.67.7.3885-3890.1993; CARVALHO M, 1993, 9 ANN M ONC FRED MAR, P224; CHEN HM, 1995, ONCOGENE, V11, P1549; CHEN JH, 1993, ONCOGENE, V8, P3375; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; EICHBAUM QG, 1994, J EXP MED, V179, P1985, DOI 10.1084/jem.179.6.1985; FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLDBERG Y, 1994, J BIOL CHEM, V269, P16566; HAHN SL, 1994, ONCOGENE, V9, P2499; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HENKEL G, 1994, P NATL ACAD SCI USA, V91, P7737, DOI 10.1073/pnas.91.16.7737; HROMAS R, 1993, BLOOD, V82, P2998; HROMAS R, 1993, BIOCHIM BIOPHYS ACTA, V1172, P155, DOI 10.1016/0167-4781(93)90283-J; JORCYK CL, 1991, ONCOGENE, V6, P523; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; MAJERUS MA, 1992, NUCLEIC ACIDS RES, V20, P2699, DOI 10.1093/nar/20.11.2699; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; MAVROTHALASSITIS GJ, 1991, CELL GROWTH DIFFER, V2, P215; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Melet F, 1996, MOL CELL BIOL, V16, P2708; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; OKA T, 1991, ONCOGENE, V6, P2077; ORKIN SH, 1992, BLOOD, V80, P575; OTT DE, 1994, VIROLOGY, V205, P563, DOI 10.1006/viro.1994.1680; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRASAD DDK, 1998, ONCOGENE, V17, P1149; RAO VN, 1993, CANCER RES, V53, P215; REDDY MA, 1994, J EXP MED, V180, P2309, DOI 10.1084/jem.180.6.2309; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SETH A, 1993, ONCOGENE, V8, P1783; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; ZHANG LQ, 1993, ONCOGENE, V8, P1621; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961	61	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	1999	18	40					5535	5545		10.1038/sj.onc.1202913	http://dx.doi.org/10.1038/sj.onc.1202913			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523830				2022-12-17	WOS:000082894700006
J	Wang, G; Miskimins, R; Miskimins, WK				Wang, G; Miskimins, R; Miskimins, WK			The cyclin-dependent kinase inhibitor p27(Kip1) is localized to the cytosol in Swiss/3T3 cells	ONCOGENE			English	Article						p27(Kip1); Cdk2; cyclin E; cell cycle	MESSENGER-RNA; GROWTH-FACTOR; BREAST-CANCER; EXPRESSION; P27; ACCUMULATION; FIBROBLASTS; ACTIVATION; PROTEIN; ARREST	p27(Kip1) plays an important role in cell cycle progression by negatively regulating the activity of cyclin-Cdk complexes. To understand how p27(Kip1) functions, the level and subcellular location of p27(Kip1) in Swiss/3T3 cells following serum stimulation of quiescent cells was examined. Surprisingly, p27(Kip1) was observed exclusively in the cytosol throughout G1 and into early S phase. However, as expected, p27(Kip1) in the cytosolic fraction was greatly reduced following serum stimulation and reached very low levels hy late G1, The decline in the level of p27(Kip1) corresponded in time to an increase in the nuclear level of both Cdk2 and cyclin E. In quiescent 3T3 cells Cdk2 was inactive and co-precipitated with p27(Kip1). After serum stimulation, both nuclear and cytosolic Cdk2 was activated and this corresponded to the decline in p27(Kip1). Overexpression of p27(Kip1) allowed accumulation of the inhibitor in the nucleus but inhibited entry of Cdk2 into the nucleus following serum stimulation. The subcellular localization of p27(Kip1) was also examined in a,variety of other mammalian cells. In all the cell lines examined the preponderance of p27(Kip1) was found in the cytosolic fraction. However, a substantial level of nuclear p27(Kip1) was observed for several cell lines. In a primary mixed glial cell culture p27(Kip1) localized to the nucleus. The results suggest that cytosolic p27(Kip1) has a functional role in regulating cell cycle progression, possibly through inhibiting transport of cyclin E-Cdk 2 complexes into the nucleus.	Univ S Dakota, Sch Med, Div Basic Biomed Sci, Biochem & Mol Biol Grp, Vermillion, SD 57069 USA	University of South Dakota	Miskimins, WK (corresponding author), Univ S Dakota, Sch Med, Div Basic Biomed Sci, Biochem & Mol Biol Grp, Vermillion, SD 57069 USA.				NINDS NIH HHS [R01-NS36164] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036164] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Friessen AJ, 1997, J NEUROSCI RES, V50, P373; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Johnson D, 1998, ONCOGENE, V16, P2017, DOI 10.1038/sj.onc.1201727; Kamesaki H, 1998, J IMMUNOL, V160, P770; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; MISKIMINS WK, 1982, J CELL BIOCHEM, V20, P41, DOI 10.1002/jcb.240200105; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; Moro A, 1998, BIOCHEM BIOPH RES CO, V245, P752, DOI 10.1006/bbrc.1998.8512; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; OUYANG Q, 1993, MOL CELL BIOL, V13, P1796, DOI 10.1128/MCB.13.3.1796; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, GENE DEV, V98, P9; RAVITZ MJ, 1995, CANCER RES, V55, P1413; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Shiyanov P, 1997, MOL BIOL CELL, V8, P1815, DOI 10.1091/mbc.8.9.1815; Singh SP, 1998, CANCER RES, V58, P1730; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253	26	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 16	1999	18	37					5204	5210		10.1038/sj.onc.1202912	http://dx.doi.org/10.1038/sj.onc.1202912			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498870				2022-12-17	WOS:000082555700009
J	Rosenberger, SF; Gupta, A; Bowden, GT				Rosenberger, SF; Gupta, A; Bowden, GT			Inhibition of p38 MAP kinase increases okadaic acid mediated AP-1 expression and DNA binding but has no effect on TRE dependent transcription	ONCOGENE			English	Article						okadaic acid; p38 MAPK; SB 203580; AP-1	ACTIVATED PROTEIN-KINASE; PROMOTER-INDUCED TRANSFORMATION; EPIDERMAL-CELL LINES; MOUSE JB6 CELLS; TUMOR PROMOTER; C-JUN; SUBSTRATE-SPECIFICITY; RESPONSE ELEMENT; RETINOIC ACID; PHOSPHORYLATION	By performing in vitro kinase assays we found in papilloma producing 308 mouse keratinocytes that okadaic acid elevated activities of extracellular signal-regulated kinase (ERK) 1/2, c-Jun N-terminal kinases (JNKs) and p38 mitogen-activated protein kinases (MAPKs). This okadaic acid mediated activation of MAP kinases correlated with increased AP-1 binding to a consensus TPA responsive element (TRE) and elevated TRE dependent transcription. To determine the role of p38 MAP kinases in these processes we employed the specific p38 MAP kinase inhibitor SB 203580. Using orthophosphate labeling we showed a decrease in phosphorylation of MAPK activated protein kinase-2 (MAPKAP-K2) indicating reduced activity of p38 MAPKs utilizing this kinase as substrate. In contrast, we found the SB 203580 raised activities of ERK-1/2 and JNKs. Electrophoretic mobility shift assays revealed an increase in TRE binding activity in response to SB 203580 most likely resulting from increased expression of the major TRE binding components JunD and FosB as indicated by Western blot analyses. Increased TRE DNA binding failed to lead to increased transactivation correlating with the inability of SB 203580 to increase phosphorylation of these AP-1 proteins. These data indicate that SB 203580 sensitive p38 MAP kinases are not involved in okadaic acid mediated increases in TRE DNA binding and transactivation.	Univ Arizona, Hlth Sci Ctr, Dept Radiat Oncol, Tucson, AZ 85724 USA	University of Arizona; University of Arizona Health Sciences	Bowden, GT (corresponding author), Univ Arizona, Hlth Sci Ctr, Dept Radiat Oncol, Tucson, AZ 85724 USA.				NCI NIH HHS [CA 23074, CA 40584] Funding Source: Medline; NIEHS NIH HHS [P30-ESO 6694] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040584, P30CA023074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Daum G, 1998, FEBS LETT, V427, P271, DOI 10.1016/S0014-5793(98)00448-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DONG ZG, 1995, INT J ONCOL, V7, P359; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; Dong ZG, 1997, J BIOL CHEM, V272, P9962; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; Dong ZG, 1997, CANCER RES, V57, P4414; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; Hazzalin CA, 1997, ONCOGENE, V15, P2321, DOI 10.1038/sj.onc.1201403; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; HONKANEN RE, 1991, J BIOL CHEM, V266, P6614; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li JJ, 1996, CANCER RES, V56, P483; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MURATA M, 1982, B JPN SOC SCI FISH, V48, P549; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; Rosenberger SF, 1999, J BIOL CHEM, V274, P1124, DOI 10.1074/jbc.274.2.1124; Rosenberger SF, 1996, ONCOGENE, V12, P2301; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSA T, 1989, BIOCHEM BIOPH RES CO, V159, P939, DOI 10.1016/0006-291X(89)92199-2; Schliess F, 1998, ARCH BIOCHEM BIOPHYS, V351, P35, DOI 10.1006/abbi.1997.0517; Sheikh-Hamad D, 1998, J BIOL CHEM, V273, P1832, DOI 10.1074/jbc.273.3.1832; Skinner M, 1997, MOL CELL BIOL, V17, P2372, DOI 10.1128/MCB.17.5.2372; STRICKLAND JE, 1988, CANCER RES, V48, P165; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Wang HL, 1996, ONCOGENE, V13, P2639; WATTS RG, 1995, MOL CARCINOGEN, V13, P27, DOI 10.1002/mc.2940130106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6	44	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	1999	18	24					3626	3632		10.1038/sj.onc.1202695	http://dx.doi.org/10.1038/sj.onc.1202695			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380884				2022-12-17	WOS:000080891700008
J	Liu, H; Vuyyuru, VB; Pham, CD; Yang, YD; Singh, B				Liu, H; Vuyyuru, VB; Pham, CD; Yang, YD; Singh, B			Evidence of an interaction between Mos and Hsp70: a role of the Mos residue serine 3 in mediating Hsp70 association	ONCOGENE			English	Article						mos oncogene; cytostatic factor; molecular chaperone; protein phosphorylation; enzyme regulation	MURINE SARCOMA-VIRUS; PROTEIN-KINASE ACTIVITY; V-MOS; C-MOS; XENOPUS-OOCYTES; MOLECULAR CHAPERONES; CYTOSTATIC FACTOR; ONCOGENE PRODUCT; CELL-CYCLE; MAP KINASE	c-Mos is a germ cell-specific MAP kinase kinase kinase (;MAPKKK) that plays an essential role during meiotic divisions of oocytes, c-Mos is a key component of an activity, cytostatic factor, required for metaphase II arrest of unfertilized eggs in vertebrates. To understand the regulation of c-Mos, we are investigating c-Mos-interacting proteins, We provide evidence that mouse c-Mos binds to Hsp70, a molecular chaperone. Hsp70 was found to associate with Mos ectopically expressed in COS-1 cells. Mos-Hsp70 complexes could be immunoprecipitated with both Mos and Hsp70 antibodies. Despite a low-abundance of Mos, the Hsp70 antibody immunoprecipitated Mos as the major protein. Of importance, the Mos protein present in anti-Hsp70 immunoprecipitates functioned as an active MAPKKK indicating that it is not grossly misfolded, It is known that c-Mos protein kinase activity in cell extracts of transfected COS-1 or NIH3T3 cells is labile, We found that the inclusion of adenosine triphosphate (ATP) in cell extracts protected against the loss of Mos kinase activity, In the absence of ATP from cell extracts, protein kinase activity of Mos was lost within 6 h on ice even though the Mos protein was not degraded and remained bound to Hsp70. Based on our identification of c-Mos-Hsp70 interaction, one of the roles of ATP may be to assist the regulation of c-Mos via ATP involvement in the protein-folding function of Hsp70 and possibly other molecular chaperones. We also detected by coimmunoprecipitation a physical association between endogenous c-Mos and Hsp70 in Xenopus eggs, To provide further evidence for the functional significance of Hsp70 interaction to Mos function, we show that the residue serine 3 in Mos, which is important for the regulation of protein kinase activity of Mos is also important for Hsp70 association.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Singh, B (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Box 172,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA045125, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, R01 CA45125] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; BAI W, 1992, ONCOGENE, V7, P493; BAI WL, 1993, ONCOGENE, V8, P2207; BAI WL, 1992, ONCOGENE, V7, P1757; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; Bukau B, 1996, TRENDS CELL BIOL, V6, P480, DOI 10.1016/0962-8924(96)84946-4; Chen MZ, 1997, MOL CELL BIOL, V17, P1904, DOI 10.1128/MCB.17.4.1904; CHEN MZ, 1995, MOL CELL BIOL, V15, P4727; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; Dix DJ, 1996, P NATL ACAD SCI USA, V93, P3264, DOI 10.1073/pnas.93.8.3264; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; FREEMAN RS, 1992, J CELL BIOL, V116, P725, DOI 10.1083/jcb.116.3.725; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; MAXWELL SA, 1985, J GEN VIROL, V66, P2135, DOI 10.1099/0022-1317-66-10-2135; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; Pennisi E, 1996, SCIENCE, V274, P1613, DOI 10.1126/science.274.5293.1613; Pham CD, 1997, INT J GYNECOL CANCER, V7, P314, DOI 10.1046/j.1525-1438.1997.00461.x; PHAM CD, 1995, ONCOGENE, V10, P1683; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; Rassow J, 1997, TRENDS CELL BIOL, V7, P129, DOI 10.1016/S0962-8924(96)10056-8; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; Sambrook J, 1989, MOL CLONING LAB MANU; SCHULTE TW, 1995, J BIOL CHEM, V270, P585; SHIBUYA EK, 1989, DEVELOPMENT, V106, P799; SHIBUYA EK, 1988, DEV BIOL, V129, P253, DOI 10.1016/0012-1606(88)90179-0; SINGH B, 1990, VIROLOGY, V178, P535, DOI 10.1016/0042-6822(90)90351-Q; SINGH B, 1988, ONCOGENE, V3, P79; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; Singh RK, 1997, B MATER SCI, V20, P259, DOI 10.1007/BF02744896; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; UZAWA M, 1995, DEV BIOL, V171, P512; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; WANG XM, 1994, P NATL ACAD SCI USA, V91, P8329, DOI 10.1073/pnas.91.18.8329; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; Yang YD, 1996, MOL CELL BIOL, V16, P800; Yang YD, 1998, J BIOL CHEM, V273, P15946, DOI 10.1074/jbc.273.26.15946; ZHOU R, 1991, CELL GROWTH DIFFER, V2, P257; ZHOU RP, 1992, MOL CELL BIOL, V12, P3583, DOI 10.1128/MCB.12.8.3583; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	47	16	16	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 10	1999	18	23					3461	3470		10.1038/sj.onc.1202699	http://dx.doi.org/10.1038/sj.onc.1202699			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376524				2022-12-17	WOS:000080850600004
J	Lecointe, N; Meerabux, J; Ebihara, M; Hill, A; Young, BD				Lecointe, N; Meerabux, J; Ebihara, M; Hill, A; Young, BD			Molecular analysis of an unstable genomic region at chromosome band 11q23 reveals a disruption of the gene encoding the alpha 2 subunit of platelet-activating factor acetylhydrolase (Pafah1a2) in human lymphoma	ONCOGENE			English	Article						11q23; mediastinal large cell lymphoma with; sclerosis (MLCLS); lymphoma proprotein convertase (LPC); alpha 2 subunit of platelet activating factor; acetylhydrolase (Pafah1a2); gene duplication; LINEI element	ACUTE MYELOID-LEUKEMIA; NONLYMPHOID HEMATOLOGIC MALIGNANCIES; DIEKER LISSENCEPHALY GENE; BETA-SUBUNIT; TRANSLOCATION BREAKPOINT; HOMOLOGOUS RECOMBINATION; TANDEM DUPLICATION; EXPRESSION; PROTEIN; CLONING	A region of 150 kb has been analysed around a previously isolated, lymphoma associated, translocation breakpoint located at chromosome band 11q23. This balanced and reciprocal translocation, t(11;14)(q32;q23), has been shown to result in the fusion between chromosome 11 specific sequence and the switch gamma 4 region of the IGH locus, The LPC gene, encoding a novel proprotein convertase belonging to the furin family, has been identified in this region. In order to characterize further the region surrounding the translocation, we have determined the detailed structure of LPC, Here we show that LPC consists of at least 16 exons covering 25 kb, and that there is a partial duplication, involving mobile genetic elements and containing LPC exons 13-17 in a tail-tail configuration at 65 kb downstream. Since the chromosomal breakpoint lay between these two structures, the intervening region was further analysed and shown to contain at least two unrelated genes, The previously known SM22 gene was localized close to the 3' tail of LPC, Furthermore,,ve identified the gene encoding the alpha 2 subunit of platelet-activating factor acetylhydrolase (Pafah1a2) at the chromosomal breakpoint, The position of another previously identified breakpoint was also located to within the first intron of this gene, Altogether, our results give evidence of a genomic instability of this area of 11q23 and show that Pafah1a2 and not LPC is the gene disrupted by the translocation, suggesting that deregulated Pafah1a2 may have a role in lymphomagenesis.	Univ London St Bartholomews Hosp Med Coll, Dept Med Oncol, Imperial Canc Res Fund, London EC1M 6BQ, England	Cancer Research UK; University of London; Queen Mary University London	Young, BD (corresponding author), Univ London St Bartholomews Hosp Med Coll, Dept Med Oncol, Imperial Canc Res Fund, Charterhouse Sq, London EC1M 6BQ, England.							Adachi H, 1997, BIOCHEM BIOPH RES CO, V233, P10, DOI 10.1006/bbrc.1997.6383; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; AKAO Y, 1993, GENE CHROMOSOME CANC, V8, P167, DOI 10.1002/gcc.2870080305; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BAZAN NG, 1995, NATURE, V374, P501, DOI 10.1038/374501a0; Bennett SAL, 1997, MOL CARCINOGEN, V20, P366, DOI 10.1002/(SICI)1098-2744(199712)20:4<366::AID-MC6>3.0.CO;2-H; BENNETT SAL, 1993, CARCINOGENESIS, V14, P1289, DOI 10.1093/carcin/14.7.1289; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; BLANK ML, 1981, LIFE SCI, V29, P769, DOI 10.1016/0024-3205(81)90031-X; Boeke JD, 1997, NAT GENET, V16, P6, DOI 10.1038/ng0597-6; Brown MA, 1996, ONCOGENE, V12, P2507; Camoretti-Mercado B, 1998, GENOMICS, V49, P452, DOI 10.1006/geno.1998.5267; Chong SS, 1997, HUM MOL GENET, V6, P147, DOI 10.1093/hmg/6.2.147; CROSSEN PE, 1993, GENE CHROMOSOME CANC, V8, P60, DOI 10.1002/gcc.2870080110; DENIZOT Y, 1995, LEUKEMIA, V9, P1982; DENIZOT Y, 1995, BLOOD, V85, P2992, DOI 10.1182/blood.V85.10.2992.bloodjournal85102992; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; Hallenberger S, 1997, J VIROL, V71, P1036, DOI 10.1128/JVI.71.2.1036-1045.1997; Hattori M, 1995, J BIOL CHEM, V270, P31345, DOI 10.1074/jbc.270.52.31345; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; Hirotsune S, 1998, NAT GENET, V19, P333, DOI 10.1038/1221; Ho YS, 1997, NATURE, V385, P89, DOI 10.1038/385089a0; Jurka J, 1997, P NATL ACAD SCI USA, V94, P1872, DOI 10.1073/pnas.94.5.1872; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; Kurahashi H, 1998, HUM GENET, V103, P189, DOI 10.1007/s004390050805; LEHRACH H., 1990, GENOME ANAL, P39; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; Li WH, 1996, MOL PHYLOGENET EVOL, V5, P182, DOI 10.1006/mpev.1996.0012; MAEDA N, 1986, ANNU REV GENET, V20, P81; Meerabux J, 1996, CANCER RES, V56, P448; MEERABUX JM, 1994, ONCOGENE, V9, P893; MIKI Y, 1992, CANCER RES, V52, P643; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Moro F, 1998, GENOMICS, V51, P157, DOI 10.1006/geno.1998.5322; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; Roth M, 1996, J EXP MED, V184, P191, DOI 10.1084/jem.184.1.191; Sambrook J, 1989, MOL CLONING LAB MANU; Sapir T, 1997, EMBO J, V16, P6977, DOI 10.1093/emboj/16.23.6977; Sassaman DM, 1997, NAT GENET, V16, P37, DOI 10.1038/ng0597-37; SCHICHMAN SA, 1994, CANCER RES, V54, P4277; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; Shimada A, 1998, J INVEST DERMATOL, V110, P889, DOI 10.1046/j.1523-1747.1998.00202.x; Strout MP, 1998, P NATL ACAD SCI USA, V95, P2390, DOI 10.1073/pnas.95.5.2390; Toriello HV, 1996, NAT GENET, V13, P361, DOI 10.1038/ng0796-361; VONLINDERN M, 1992, GENE CHROMOSOME CANC, V5, P227, DOI 10.1002/gcc.2870050309; WARD CJ, 1994, CELL, V77, P881; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YOUNG BD, 1992, BAILLIERE CLIN HAEM, V5, P881, DOI 10.1016/S0950-3536(11)80050-8	48	16	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	1999	18	18					2852	2859		10.1038/sj.onc.1202645	http://dx.doi.org/10.1038/sj.onc.1202645			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362256				2022-12-17	WOS:000080125100008
J	Hu, MCT; Wang, YP; Qiu, WR				Hu, MCT; Wang, YP; Qiu, WR			Human fibroblast growth factor-18 stimulates fibroblast cell proliferation and is mapped to chromosome 14p11	ONCOGENE			English	Article						FGF; growth factor; cell proliferation; chromosome mapping	INSITU HYBRIDIZATION; MOLECULAR-CLONING; FACTOR FAMILY; GENES; MESODERM; INVIVO; MEMBER	The fibroblast growth factors (FGFs) play crucial roles in controlling embryonic development, cell growth, morphogenesis, and tissue repair in animals. Furthermore, FGFs may have a role in angiogenesis and may be involved in tumor invasion and metastasis, Here, we present the cloning and sequence of human FGF-18, a novel member of the FGF family. Sequence comparison indicates that FGF-18 is conserved with the other FGFs and most homologous to FGF-8 among the FGF family members. We showed that human FGF-18 was expressed primarily in the heart, skeletal muscle, and pancreas, and at lower levels in the other tissues. FGP-18 was also expressed at low levels in certain cancer cell lines. FGF-18 contains a typical signal peptide and was secreted when it was transfected into mammalian cells, Recombinant FGF-18 protein stimulated proliferation in the fibroblast cell line NIH3T3 in a dose-dependent manner, suggesting that FGF-18 is a functional growth factor. Finally, the FGF-18 gene was evolutionarily conserved, and localized to human chromosome 14p11.	Amgen Inc, Dept Cell Biol & Funct Genom, Thousand Oaks, CA 91320 USA	Amgen	Hu, MCT (corresponding author), Amgen Inc, Dept Cell Biol & Funct Genom, 14-1 D, Thousand Oaks, CA 91320 USA.							BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CLARKE MSF, 1993, J CELL SCI, V106, P121; CUEVAS P, 1988, BIOCHEM BIOPH RES CO, V156, P611, DOI 10.1016/S0006-291X(88)80887-8; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOSPODAROWICZ D, 1978, IN VITRO CELL DEV B, V14, P85; GOSPODAROWICZ D, 1986, CELL DIFFER DEV, V19, P1, DOI 10.1016/0045-6039(86)90021-7; GOSPODAROWICZ D, 1974, NATURE, V249, P123, DOI 10.1038/249123a0; GOSPODAROWICZ D, 1991, CELL BIOL REV, V25, P307; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; Hoshikawa M, 1998, BIOCHEM BIOPH RES CO, V244, P187, DOI 10.1006/bbrc.1998.8239; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; MARICS I, 1989, ONCOGENE, V4, P335; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; Sambrook J, 1989, MOL CLONING LAB MANU; SLACK JMW, 1988, DEVELOPMENT, V103, P581; TANAKA A, 1995, FEBS LETT, V363, P226, DOI 10.1016/0014-5793(95)00324-3; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Verdier AS, 1997, GENOMICS, V40, P151, DOI 10.1006/geno.1996.4492; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Zhou M, 1998, NAT MED, V4, P201, DOI 10.1038/nm0298-201	27	16	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	1999	18	16					2635	2642		10.1038/sj.onc.1202616	http://dx.doi.org/10.1038/sj.onc.1202616			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353607				2022-12-17	WOS:000079907100011
J	Cambier, N; Zhang, Y; Vairo, G; Kosmopoulos, K; Metcalf, D; Nicola, NA; Elefanty, AG				Cambier, N; Zhang, Y; Vairo, G; Kosmopoulos, K; Metcalf, D; Nicola, NA; Elefanty, AG			Expression of BCR-ABL in M1 myeloid leukemia cells induces differentiation without arresting proliferation	ONCOGENE			English	Article						BCR-ABL oncogene; M1 cell differentiation	CHRONIC MYELOGENOUS LEUKEMIA; CONSTITUTIVE C-MYC; INHIBITORY FACTOR; TYROSINE KINASE; MONOCLONAL-ANTIBODY; SCAVENGER RECEPTOR; CYCLIN D1; V-ABL; ERYTHROLEUKEMIA-CELLS; ONCOGENE EXPRESSION	The mechanism leading to the expanding population of maturing myeloid cells which characterises chronic myeloid leukemia (CML) remains obscure. Because of its ability to mimic the proliferative and cell survival functions of hematopoietic growth factors, me hypothesized that the oncogene activated in CML, BCR-ABL, might also influence differentiation. To test this hypothesis, nle examined the effects of expressing BCR-ABL on the myeloid differentiation of murine M1 leukemic cells, which cease dividing and differentiate into macrophages in the presence of the cytokines leukemia inhibitory factor (LIF) or interleukin (IL)-6, We found that BCR-ABL induced macrophage differentiation in M1 cells, accompanied by increased expression of macrophage cell surface markers and the acquisition of phagocytic ability. Interestingly, clones of M1 cells which expressed BCR-ABL remained in cell cycle and were refractory to the growth inhibition and apoptosis induced by IL-6 or LIF in parental M1 cells. These cells also expressed inappropriately high levels of c-MYC mRNA for their degree of differentiation, which may have been important in maintaining cellular proliferation. These data suggest that BCR-ABL can stimulate both differentiation and proliferation and that these characterisitics may contribute to the phenotype observed in CML.	PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; PO Royal Melbourne Hosp, Cooperat Res Ctr Cellular Growth Factors, Melbourne, Vic 3050, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital	Elefanty, AG (corresponding author), PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.		Elefanty, Andrew G/A-6066-2008; Nicola, Nicos/D-2989-2011	Nicola, Nicos/0000-0003-1054-7889; Elefanty, Andrew/0000-0001-6448-8314	NATIONAL CANCER INSTITUTE [R37CA022556, R01CA022556] Funding Source: NIH RePORTER; NCI NIH HHS [CA22556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1995, P NATL ACAD SCI USA, V92, P9540, DOI 10.1073/pnas.92.21.9540; AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BRUCE AG, 1992, J IMMUNOL, V149, P1271; Cambier N, 1998, ONCOGENE, V16, P335, DOI 10.1038/sj.onc.1201490; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; Clarkson BD, 1997, LEUKEMIA, V11, P1404, DOI 10.1038/sj.leu.2400751; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; Cortez D, 1996, ONCOGENE, V13, P2589; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; ELEFANTY AG, 1992, MOL CELL BIOL, V12, P1755, DOI 10.1128/MCB.12.4.1755; ELEFANTY AG, 1992, BLOOD, V79, P1271; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; ELEFANTY AG, 1997, MOL HAEMOPOIESIS, P589; FRASER I, 1993, NATURE, V364, P343, DOI 10.1038/364343a0; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GROFFEN J, 1987, CHRONIC MYELOID LEUK, P983; Hariharan I K, 1988, Oncogene Res, V3, P387; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; LANEUVILLE P, 1991, ONCOGENE, V6, P275; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; METCALF D, 1988, LEUKEMIA, V2, P216; Metcalf D, 1984, CLONAL CULTURE HEMOP; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P239; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RESNITZKY D, 1991, CELL GROWTH DIFFER, V2, P33; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHABO Y, 1988, BLOOD, V72, P2070; SIRARD C, 1994, BLOOD, V83, P1575; Skorski T, 1996, P NATL ACAD SCI USA, V93, P13137, DOI 10.1073/pnas.93.23.13137; Smith D, 1997, BRIT TELECOMMUN ENG, V16, P1; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; TANIGAWA T, 1995, BLOOD, V85, P379; TAUCHI T, 1995, INT J HEMATOL, V61, P105; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; Vairo G, 1996, ONCOGENE, V13, P1511; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAFRIRI D, 1993, P NATL ACAD SCI USA, V90, P477, DOI 10.1073/pnas.90.2.477	58	16	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					343	352		10.1038/sj.onc.1202302	http://dx.doi.org/10.1038/sj.onc.1202302			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927191				2022-12-17	WOS:000078166500007
J	Chen, YC; Freund, R; Listerud, M; Wang, Z; Talmage, DA				Chen, YC; Freund, R; Listerud, M; Wang, Z; Talmage, DA			Retinoic acid inhibits transformation by preventing phosphatidylinositol 3-kinase dependent activation of the c-fos promoter	ONCOGENE			English	Article						vitamin A; retinoic acid; Jun kinase; polyoma virus	MIDDLE-T-ANTIGEN; JUN TRANSCRIPTIONAL ACTIVITY; JNK/SAPK SIGNALING PATHWAY; SERUM RESPONSE ELEMENT; POLYOMA-VIRUS MUTANT; SIZED TUMOR-ANTIGEN; PROTEIN-KINASE-C; PP70 S6 KINASE; TYROSINE PHOSPHORYLATION; RAT FIBROBLASTS	Retinoic acid inhibits transformation of cells by polyoma virus middle T oncoprotein. Inhibition of transformation results from a retinoic acid-dependent failure of cells to fully express the c-fos proto-oncogene. Retinoic acid prevents transactivation of the c-fos promoter by disrupting signaling between tyrosine kinases at the plasma membrane and trans-acting factors at the c-fos promoter. We used complementary genetic, biochemical and molecular approaches to demonstrate that: (1) phosphatidylinositol 3-kinase signaling is the principle mechanism of polyoma virus middle T oncoprotein activation of c-fos expression; (2) middle T/phosphatidylinositol 3-kinase transactivation of the c-fos promoter and transformation of cells requires activation of both the small GTP-binding protein Rac and Jun N-terminal kinase; (3) retinoic acid inhibits activation of Jun N- terminal kinase, thereby preventing c-fos transactivation and transformation; and (4) middle T activation of c-fos transcription requires both the serum response element and the promoter proximal cyclic AMP response element. These studies identify a novel target through which retinoids prevent oncogenic transformation.	Columbia Univ, Inst Human Nutr, New York, NY 10032 USA; Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA	Columbia University; University System of Maryland; University of Maryland Baltimore	Talmage, DA (corresponding author), Columbia Univ, Inst Human Nutr, New York, NY 10032 USA.			Talmage, David/0000-0003-4627-3007	NCI NIH HHS [CA63111] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA063111] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTO AS, 1908, CELL, V92, P475; Bronson R, 1997, P NATL ACAD SCI USA, V94, P7954, DOI 10.1073/pnas.94.15.7954; BUSAM KJ, 1992, J BIOL CHEM, V267, P19971; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; CARMICHAEL G, 1984, P NATL ACAD SCI-BIOL, V81, P679, DOI 10.1073/pnas.81.3.679; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; Crespo P, 1996, ONCOGENE, V13, P455; Dahl J, 1996, MOL CELL BIOL, V16, P2728; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Fisher GJ, 1998, J CLIN INVEST, V101, P1432, DOI 10.1172/JCI2153; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franklin CC, 1995, ONCOGENE, V11, P2365; FREUND R, 1992, AM J PATHOL, V141, P1409; FREUND R, 1992, VIROLOGY, V191, P716, DOI 10.1016/0042-6822(92)90247-M; GLENN GM, 1993, J VIROL, V67, P1945, DOI 10.1128/JVI.67.4.1945-1952.1993; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HARVEY R, 1984, MOL CELL BIOL, V4, P1334, DOI 10.1128/MCB.4.7.1334; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JANKNECHT R, 1995, ONCOGENE, V10, P1209; Janknecht R, 1996, ONCOGENE, V12, P1961; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Khuri FR, 1996, CELL GROWTH DIFFER, V7, P595; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LING LE, 1992, J VIROL, V66, P1702, DOI 10.1128/JVI.66.3.1702-1708.1992; Mangelsdorf David J., 1994, P319; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MEANS AL, 1995, ANNU REV BIOCHEM, V64, P201, DOI 10.1146/annurev.bi.64.070195.001221; Meili R, 1998, ONCOGENE, V16, P903, DOI 10.1038/sj.onc.1201605; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; NAGPAL S, 1995, J BIOL CHEM, V270, P923, DOI 10.1074/jbc.270.2.923; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RAMEH LE, 1991, ONCOGENE, V6, P1049; RAPTIS L, 1991, J VIROL, V65, P5203, DOI 10.1128/JVI.65.10.5203-5210.1991; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SCHAFFHAUSEN B, 1981, J VIROL, V40, P184, DOI 10.1128/JVI.40.1.184-196.1981; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; Soprano DR, 1996, ONCOGENE, V12, P577; SRINIVAS S, 1994, P NATL ACAD SCI USA, V91, P10064, DOI 10.1073/pnas.91.21.10064; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TALMAGE DA, 1994, ONCOGENE, V9, P3557; TALMAGE DA, 1992, ONCOGENE, V7, P1837; TALMAGE DA, 1988, MOL CELL BIOL, V8, P2309, DOI 10.1128/MCB.8.6.2309; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; URICH M, 1995, J BIOL CHEM, V270, P29286, DOI 10.1074/jbc.270.49.29286; Urich M, 1997, ONCOGENE, V14, P1235, DOI 10.1038/sj.onc.1200982; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; Xu X, 1996, ONCOGENE, V13, P135; Yi XD, 1997, J VIROL, V71, P6279, DOI 10.1128/JVI.71.9.6279-6286.1997; ZULLO J, 1987, P NATL ACAD SCI USA, V84, P1210, DOI 10.1073/pnas.84.5.1210	68	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					139	148		10.1038/sj.onc.1202272	http://dx.doi.org/10.1038/sj.onc.1202272			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926928				2022-12-17	WOS:000078166000015
J	Dong, ZG; Huang, CS; Ma, WY; Malewicz, B; Baumann, WJ; Kiss, Z				Dong, ZG; Huang, CS; Ma, WY; Malewicz, B; Baumann, WJ; Kiss, Z			Increased synthesis of phosphocholine is required for UV-induced AP-1 activation	ONCOGENE			English	Article						AP-1; UV irradiation; phosphocholine phosphatidylcholine; MAP kinase	PROTEIN-KINASE-C; NUCLEAR MAGNETIC-RESONANCE; NIH 3T3 FIBROBLASTS; SIGNAL-TRANSDUCTION; GROWTH-FACTORS; ULTRAVIOLET-LIGHT; CHOLINE-PHOSPHATE; PHOSPHOLIPASE-D; PHORBOL ESTER; DNA-SYNTHESIS	Exposure of mammalian cells to UV irradiation stimulates phosphatidylcholine hydrolysis and activates the transcription factor AP-1. Since phosphocholine (PCho), a phospholipid metabolite, is a potential regulator of mitogenesis and carcinogenesis, we examined the effect of UV exposure on the formation of PCho and the possible mediatory role of PCho in UVB-and UVC-induced activation of AP-1 in mouse JB6 epidermal cells. We found that both UVB and UVC irradiation resulted in increased PCho levels. Hemicholinium-3 (HC-3), an inhibitor of choline kinase, strongly inhibited UV-induced AP-1 activity. By contrast, relatively low levels of PCho (80 mu M) or choline (20 mu M) nearly doubled UV-induced AP-1 activity, while higher (2-20 mM) concentrations of PCho alone stimulated AP-1 activity 6-8-fold. Importantly, HC-3 inhibited only the stimulatory effect of choline, but not of PCho, on AP-1 activity. Of the mitogen-activated protein (MAP) kinases involved in the regulation of AP-1 activity, UVC stimulated the MAP kinase family ERK-1/ERK-2, JNK as well as p38 kinase activity. These UVC effects were all inhibited by HC-3. With UVB, by contrast, only the activation of ERK-1/ERK-2 was inhibited by HC-3. The data suggest that increased formation of PCho is required for UV-induced activation of AP-1 by an ERK-1/ERK-2-dependent mechanism.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16Th Ave NE, Austin, MN 55912 USA.			Huang, Chuanshu/0000-0003-4133-5096	NATIONAL CANCER INSTITUTE [R29CA074916] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004654] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009292] Funding Source: NIH RePORTER; NCI NIH HHS [CA74916] Funding Source: Medline; NCRR NIH HHS [RR04654] Funding Source: Medline; NIAAA NIH HHS [AA09292] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1995, INDUCED GENE EXPRESS, P63; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; CARSBERG CJ, 1995, BIOCHEM J, V305, P471, DOI 10.1042/bj3050471; Chung TW, 1997, J BIOL CHEM, V272, P3064, DOI 10.1074/jbc.272.5.3064; CUADRADO A, 1993, ONCOGENE, V8, P2959; DALY PF, 1987, J BIOL CHEM, V262, P14875; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; DONG ZG, 1995, INT J ONCOL, V7, P359; Dong ZG, 1997, J BIOL CHEM, V272, P9962; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; EVANS FE, 1977, P NATL ACAD SCI USA, V74, P4909, DOI 10.1073/pnas.74.11.4909; HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1997, J BIOL CHEM, V272, P26325, DOI 10.1074/jbc.272.42.26325; Huang CS, 1997, ONCOGENE, V14, P1945, DOI 10.1038/sj.onc.1201056; *IARC, 1992, IARC MON EV CARC RIS, V55; ISHIDATE K, 1980, BIOCHEM BIOPH RES CO, V96, P946, DOI 10.1016/0006-291X(80)91446-1; JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kiss Z, 1996, ARCH BIOCHEM BIOPHYS, V335, P191, DOI 10.1006/abbi.1996.0497; KISS Z, 1995, FEBS LETT, V358, P243, DOI 10.1016/0014-5793(94)01434-3; KISS Z, 1994, BIOCHEM J, V300, P751, DOI 10.1042/bj3000751; Kiss Z, 1997, FEBS LETT, V412, P197, DOI 10.1016/S0014-5793(97)00776-X; KISS Z, 1995, FEBS LETT, V357, P279, DOI 10.1016/0014-5793(94)01371-7; Kiss Z, 1996, BIOCHEM BIOPH RES CO, V218, P505, DOI 10.1006/bbrc.1996.0090; MACARA IG, 1989, MOL CELL BIOL, V9, P325, DOI 10.1128/MCB.9.1.325; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NAVON G, 1977, P NATL ACAD SCI USA, V74, P87, DOI 10.1073/pnas.74.1.87; PAULSON BK, 1989, BIOCHIM BIOPHYS ACTA, V1004, P274, DOI 10.1016/0005-2760(89)90278-6; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RATNAM S, 1995, ARCH BIOCHEM BIOPHYS, V323, P313, DOI 10.1006/abbi.1995.9959; RONAI ZA, 1988, J VIROL, V62, P1057, DOI 10.1128/JVI.62.3.1057-1060.1988; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SHEA CR, 1991, PHYSL BIOCH MOL BIOL, P910; STABERG B, 1983, J INVEST DERMATOL, V81, P517, DOI 10.1111/1523-1747.ep12522855; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STRICKLAND PT, 1986, J INVEST DERMATOL, V87, P272, DOI 10.1111/1523-1747.ep12696669; TOMONO M, 1995, BIOCHEM BIOPH RES CO, V213, P980, DOI 10.1006/bbrc.1995.2225; WARDEN CH, 1985, J BIOL CHEM, V260, P6006	46	16	16	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1845	1853		10.1038/sj.onc.1202084	http://dx.doi.org/10.1038/sj.onc.1202084			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778051				2022-12-17	WOS:000076303300011
J	Bennoun, M; Grimber, G; Couton, D; Seye, A; Molina, T; Briand, P; Joulin, V				Bennoun, M; Grimber, G; Couton, D; Seye, A; Molina, T; Briand, P; Joulin, V			The amino-terminal region of SV40 large T antigen is sufficient to induce hepatic tumours in mice	ONCOGENE			English	Article						pRb; p300; p53; transgenic mice; hepatic tumour; SV40 large T-antigen	SIMIAN-VIRUS-40 LARGE-T; INDUCED TUMORIGENESIS; P53-DEFICIENT MICE; PROTEINS P130; J-DOMAIN; P53; P300; GENE; RETINOBLASTOMA; BINDING	The transforming activity of SV40 large T-antigen (Tag) depends on its binding to cellular proteins involved in the control of the cell cycle (p53, pRb, p300..) and on the J-domain region in the amino-terminus. We established transgenic lines expressing wild-type or Tag mutant proteins lacking one of the three transforming domains, to determine the respective contributions of these domains to hepatic tumour formation. Tag mutants with no pRb-binding domain or N-terminal fragment did not cause neoplastic liver abnormalities. The dl1137 Tag mutant protein, which inhibits pRb function without affecting p53, induced hepatic tumours, These tumours grew significantly faster than those induced by wild-type Tag. Our results demonstrate different requirements for each of the inactivating functions of SV40 Tag in hepatocyte transformation and show that the loss of p53 function has only a moderate effect on hepatic tumour formation.	Inst Cochin Genet Mol, INSERM, U380, F-75014 Paris, France; Lab Univ Rech Histopathol, F-75006 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Joulin, V (corresponding author), Inst Cochin Genet Mol, INSERM, U380, 22 Rue Mechain, F-75014 Paris, France.		Molina, Thierry/ABA-5214-2020	Molina, Thierry/0000-0002-3929-9754; JOULIN, Virginie/0000-0003-1091-7819				Allemand I, 1995, ONCOGENE, V11, P2583; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Bowman T, 1996, GENE DEV, V10, P826, DOI 10.1101/gad.10.7.826; Carbone M, 1997, ONCOGENE, V15, P1877, DOI 10.1038/sj.onc.1201375; CHEN JD, 1992, ONCOGENE, V7, P1167; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUBOIS N, 1991, J HEPATOL, V13, P227, DOI 10.1016/0168-8278(91)90819-W; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Eckner R, 1996, MOL CELL BIOL, V16, P3454; FAN GS, 1995, CELL GROWTH DIFFER, V6, P1463; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; PIPAS JM, 1983, MOL CELL BIOL, V3, P203, DOI 10.1128/MCB.3.2.203; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; Sang NL, 1997, J CELL BIOCHEM, V66, P277, DOI 10.1002/(SICI)1097-4644(19970901)66:3<277::AID-JCB1>3.0.CO;2-M; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; Stubdal H, 1996, J VIROL, V70, P2781, DOI 10.1128/JVI.70.5.2781-2788.1996; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Williams BO, 1996, CURR OPIN GENET DEV, V6, P65; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116	29	16	16	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1253	1259		10.1038/sj.onc.1202047	http://dx.doi.org/10.1038/sj.onc.1202047			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771968				2022-12-17	WOS:000075803300007
J	Cadoret, A; Baron-Delage, S; Bertrand, F; Kornprost, M; Groyer, A; Gespach, C; Capeau, J; Cherqui, G				Cadoret, A; Baron-Delage, S; Bertrand, F; Kornprost, M; Groyer, A; Gespach, C; Capeau, J; Cherqui, G			Oncogene-induced up-regulation of Caco-2 cell proliferation involves IGF-II gene activation through a protein kinase C-mediated pathway	ONCOGENE			English	Article						Ha-ras; polyoma middle T; IGF-II gene; PKC; Spl; Caco-2 cells	GROWTH-FACTOR-I; MIDDLE-T-ONCOGENES; TRANSCRIPTION FACTOR SP1; MOUSE EMBRYO FIBROBLASTS; FACTOR BINDING-PROTEINS; COLON-CARCINOMA CELLS; HUMAN HA-RAS; MESSENGER-RNA; FACTOR (IGF)-II; DOWN-REGULATION	We previously reported that I as and polyoma middle T (PyMT), a constitutive activator of the src protooncogene product, up-regulated Caco-2 cell proliferation along with protein kinase C (PKC) alpha expression and PKC activity. We aimed to investigate whether oncogene-induced up-regulation of Caco-2 cell proliferation involved stimulation of the autocrine IGF-II/IGF-I receptor (IGF1R) loop described in these cells and if so, to analyse the role of overexpressed and activated PKC, Compared with control vector transfected Caco-2 cells, ras- and PyMT-transfected cells exhibited increased expression of the 6.0 and 4.8 kb IGF-II transcripts. This was due to increased activity of the P3 and P4 promoters of the IGF-II gene which correlated with increased expression and DNA-binding activity of Spl, a transcription factor interacting with several specific sites in P3 and P4 promoters. Oncogene-transfected cells displayed enhanced autocrine IGF-II production, which was fully responsible for the oncogene-induced increase in their proliferation since this increase was blunted by anti-human IGF-II and IGF1R (alpha IR3) antibodies. PKC mediated oncogene activation of the IGF-II gene presumably through action on Spl since (i) PKC activation by phorbol 12-myristate 13-acetate increased Spl expression, P3 and P4 activity and IGF-II mRNA in control but not in oncogene-transfected cells; and (ii) PKC inhibition by the PKC inhibitor Go6976 reduced Spl, P3 and P4 activity and IGF-II mRNA in all three cell lines. This is the first evidence that ras- and PyMT/src oncogenes up-regulate Caco-2 cell proliferation through a PKC-mediated pathway which stimulates IGF-II gene transcription and thereby increases autocrine IGF-II production, The mechanisms underlying IGF-II gene activation by PKC most probably involve action on Sp1.	Fac Med St Antoine, Biol Cellulaire Lab, INSERM, U402, F-75571 Paris 12, France; Fac Med Xavier Bichat, INSERM, U327, F-75018 Paris, France; Hop St Antoine, INSERM, U482, F-75571 Paris 12, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Cherqui, G (corresponding author), Fac Med St Antoine, Biol Cellulaire Lab, INSERM, U402, 27 Rue Chaligny, F-75571 Paris 12, France.		Cadoret, Axelle/L-2529-2017	Cadoret, Axelle/0000-0002-4283-6864				ADENIS A, 1995, EUR J CANCER, V31A, P50, DOI 10.1016/0959-8049(94)00368-F; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; BaronDelage S, 1996, AM J PHYSIOL-GASTR L, V270, pG314, DOI 10.1152/ajpgi.1996.270.2.G314; BARONDELAGE S, 1994, J BIOL CHEM, V269, P18686; BASERGA R, 1995, CANCER RES, V55, P249; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; BINOUX M, 1986, J CLIN ENDOCR METAB, V63, P1151, DOI 10.1210/jcem-63-5-1151; BISSONNETTE M, 1994, AM J PHYSIOL, V267, pG465, DOI 10.1152/ajpgi.1994.267.3.G465; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Cadoret A, 1997, ONCOGENE, V14, P1589, DOI 10.1038/sj.onc.1200992; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHASTRE E, 1993, GASTROENTEROLOGY, V105, P1776, DOI 10.1016/0016-5085(93)91076-T; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; CULLEN KJ, 1992, MOL ENDOCRINOL, V6, P91, DOI 10.1210/me.6.1.91; CULOUSCOU JM, 1991, CANCER RES, V51, P2813; DAngelo DD, 1996, J BIOL CHEM, V271, P19696, DOI 10.1074/jbc.271.33.19696; DELAGE S, 1993, CANCER RES, V53, P2762; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GUO YS, 1992, GASTROENTEROLOGY, V102, P1101; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; HOEFLICH A, 1994, MOL CELL ENDOCRINOL, V101, P141, DOI 10.1016/0303-7207(94)90228-3; HOLTHUIZEN P, 1990, BIOCHIM BIOPHYS ACTA, V1087, P341, DOI 10.1016/0167-4781(90)90010-Y; HOLTHUIZEN PE, 1993, REGUL PEPTIDES, V48, P77, DOI 10.1016/0167-0115(93)90337-8; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KULL FC, 1983, J BIOL CHEM, V258, P6561; LAHM H, 1994, INT J CANCER, V58, P452, DOI 10.1002/ijc.2910580325; LAMBERT S, 1990, INT J CANCER, V46, P405, DOI 10.1002/ijc.2910460313; LAMONERIE T, 1995, INT J CANCER, V61, P587, DOI 10.1002/ijc.2910610425; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Levy P, 1996, BRIT J CANCER, V74, P423, DOI 10.1038/bjc.1996.376; Marais R, 1996, CANCER SURV, V27, P101; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Morrione A, 1997, P NATL ACAD SCI USA, V94, P3777, DOI 10.1073/pnas.94.8.3777; MORRIONE A, 1995, J VIROL, V69, P5300, DOI 10.1128/JVI.69.9.5300-5303.1995; NODA M, 1988, J BIOL CHEM, V263, P18574; OBEID LM, 1992, J BIOL CHEM, V267, P20804; Park JHY, 1996, J CELL PHYSIOL, V166, P396, DOI 10.1002/(SICI)1097-4652(199602)166:2<396::AID-JCP18>3.0.CO;2-9; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SUSSENBACH JS, 1991, MODERN CONCEPTS INSU, P639; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; TRICOLI JV, 1986, CANCER RES, V46, P6169; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Ye JP, 1996, MOL CELL BIOL, V16, P6178; Yurochko AD, 1997, J VIROL, V71, P4638, DOI 10.1128/JVI.71.6.4638-4648.1997; ZARRILLI R, 1994, CELL GROWTH DIFFER, V5, P1085; Zarrilli R, 1996, J BIOL CHEM, V271, P8108, DOI 10.1074/jbc.271.14.8108; Zenilman ME, 1997, CANCER INVEST, V15, P1, DOI 10.3109/07357909709018911; ZHANG Y, 1995, AM J PHYSIOL-ENDOC M, V269, pE804, DOI 10.1152/ajpendo.1995.269.5.E804	54	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					877	887		10.1038/sj.onc.1202013	http://dx.doi.org/10.1038/sj.onc.1202013			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780004				2022-12-17	WOS:000075448800009
J	Coppee, F; Depoortere, F; Bartek, J; Ledent, C; Parmentier, M; Dumont, JE				Coppee, F; Depoortere, F; Bartek, J; Ledent, C; Parmentier, M; Dumont, JE			Differential patterns of cell cycle regulatory proteins expression in transgenic models of thyroid tumours	ONCOGENE			English	Review						cyclins; cdk(s); CKI; thyroid; HPV 16 E7; cAMP	PAPILLOMAVIRUS TYPE-16 E7; GROWTH-FACTOR-BETA; 10T1/2 MOUSE FIBROBLASTS; D-CDK COMPLEXES; INHIBITOR P27(KIP1); RETINOBLASTOMA GENE; DEPENDENT KINASES; P53-INDEPENDENT EXPRESSION; SUBCELLULAR-LOCALIZATION; MYOGENIC DIFFERENTIATION	Cell cycle proteins regulate the transitions from G1 to S and G2 to M phases. In higher eukaryotes, their function is controlled by intracellular cascades regulated by extracellular growth factors, We have studied m previously described transgenic mouse models for thyroid proliferative diseases the expression of the key proteins regulating the cell cycle by Western blotting and immunohistochemistry, and have correlated the observations with the known actions of the transgenes on the signal transduction cascades. In the adenosine A(2a) receptor model, the cyclic AMP pathway, upstream of the Rb family cell division block, is constitutively activated. In the model expressing HPV 16 E7 protein, the Rb-like proteins are inhibited, Cyclin-dependent kinases cdk4, cdk2 and cdc2, and the associated cyclins D, E and A have been studied. Cyclin D3 appears as the major cyclin D subtype expressed in mouse thyroid epithelial cells in normal and transgenic mice. In the adenosine A(2a)R model, all cell cycle proteins tested were accumulated. In the E7 model, all cell cycle proteins except for D-type cyclins and cdk4 were also accumulated. A similar pattern was observed in thyroids coexpressing both transgenes, suggesting a dominant effect of E7 over the consequences of the cAMP cascade activation. The cyclin-dependent kinase inhibitors p21(cip1/waf1) and pt27(kip1) were not downregulated in these proliferating thyroids which suggest other roles than the inhibition of the cell cycle progression.	Free Univ Brussels, IRIBHN, B-1070 Brussels, Belgium; Danish Canc Soc, Div Canc Biol, DK-2100 Copenhagen, Denmark	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Danish Cancer Society	Coppee, F (corresponding author), Free Univ Brussels, IRIBHN, 808 Route Lennik,Campus Erasme, B-1070 Brussels, Belgium.		Bartek, Jiri/G-5870-2014	Parmentier, Marc/0000-0001-8081-4685				Akagi M, 1996, JPN J CANCER RES, V87, P377, DOI 10.1111/j.1349-7006.1996.tb00233.x; Akiyama T, 1997, CANCER RES, V57, P1495; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; Baptist M, 1996, J CELL PHYSIOL, V166, P256; Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BATES S, 1994, ONCOGENE, V9, P1633; Botz J, 1996, MOL CELL BIOL, V16, P3401; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CHRISTOPHE D, 1990, TRENDS ENDOCRIN MET, V1, P351, DOI 10.1016/1043-2760(90)90083-F; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Coppee F, 1996, ONCOGENE, V13, P1471; Coulonval K, 1997, EXP CELL RES, V233, P395, DOI 10.1006/excr.1997.3582; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; Depoortere F, 1996, J CELL SCI, V109, P1759; DEPOORTERE F, 1998, J CELL SCI, V140, P1; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; Duttaroy A, 1997, J CELL BIOCHEM, V64, P434; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; GRANA X, 1995, ONCOGENE, V11, P211; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; Ishida A, 1997, J BIOL CHEM, V272, P10050; JARKUS J, 1996, ONCOGENE, V12, P2369; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KIESS M, 1995, ONCOGENE, V10, P159; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOTANI S, 1995, ONCOGENE, V10, P663; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; LEDENT C, 1995, ONCOGENE, V10, P1789; LEDENT C, 1990, P NATL ACAD SCI USA, V87, P6176, DOI 10.1073/pnas.87.16.6176; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Lloyd RV, 1997, AM J PATHOL, V150, P401; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1995, ONCOGENE, V10, P2125; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAENHAUT C, 1990, BIOCHEM BIOPH RES CO, V173, P1169, DOI 10.1016/S0006-291X(05)80909-X; Marchetti A, 1996, ONCOGENE, V12, P1319; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; NADEL A, 1997, J PATHOL, V183, P156; NEVINS JR, 1992, SCIENCE, V258, P424; OTHANI K, 1995, P NATL ACAD SCI USA, V92, P12146; OTHSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Palmero I, 1996, CANCER SURV, V27, P351; PALMERO I, 1993, ONCOGENE, V8, P1049; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Pei XF, 1996, CARCINOGENESIS, V17, P1395, DOI 10.1093/carcin/17.7.1395; Pirson I, 1996, J CELL PHYSIOL, V168, P59, DOI 10.1002/(SICI)1097-4652(199607)168:1<59::AID-JCP8>3.0.CO;2-7; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Qian X, 1996, ENDOCRINOLOGY, V137, P3051, DOI 10.1210/en.137.7.3051; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; Ravitz MJ, 1996, J CELL PHYSIOL, V168, P510, DOI 10.1002/(SICI)1097-4652(199609)168:3<510::AID-JCP3>3.0.CO;2-S; RAVITZ MJ, 1995, CANCER RES, V55, P1413; ROGER PP, 1985, EUR J BIOCHEM, V152, P239, DOI 10.1111/j.1432-1033.1985.tb09189.x; ROGER PP, 1984, MOL CELL ENDOCRINOL, V36, P79, DOI 10.1016/0303-7207(84)90087-X; ROGER PP, 1982, MOL CELL ENDOCRINOL, V26, P165, DOI 10.1016/0303-7207(82)90014-4; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; STRAUSS M, 1995, NAT MED, V1, P1245, DOI 10.1038/nm1295-1245; SUAREZ HG, 1991, ONCOGENE, V6, P677; Sweeney KJ, 1997, ONCOGENE, V14, P1329, DOI 10.1038/sj.onc.1200951; TAM SW, 1994, ONCOGENE, V9, P2663; Tiainen M, 1996, MOL CELL BIOL, V16, P5302; Tikoo R, 1997, J BIOL CHEM, V272, P442; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Tron VA, 1996, AM J PATHOL, V149, P1139; Usuda H, 1996, VIRCHOWS ARCH, V428, P159; Vassart G, 1996, ANN ENDOCRINOL-PARIS, V57, P50; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wang ZY, 1996, GENOMICS, V35, P156, DOI 10.1006/geno.1996.0334; Ward AC, 1996, BIOCHEM BIOPH RES CO, V224, P10, DOI 10.1006/bbrc.1996.0976; WynfordThomas D, 1997, HORM RES, V47, P145, DOI 10.1159/000185458; Xiong Y, 1996, J VIROL, V70, P999, DOI 10.1128/JVI.70.2.999-1008.1996; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZerfassThome K, 1996, ONCOGENE, V13, P2323	104	16	16	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					631	641		10.1038/sj.onc.1201966	http://dx.doi.org/10.1038/sj.onc.1201966			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704929				2022-12-17	WOS:000075195300011
J	Sorokin, A; Reed, E; Nnkemere, N; Dulin, NO; Schlessinger, J				Sorokin, A; Reed, E; Nnkemere, N; Dulin, NO; Schlessinger, J			Crk protein binds to PDGF receptor and insulin receptor substrate-1 with different modulating effects on PDGF- and insulin-dependent signaling pathways	ONCOGENE			English	Article						Crk; PDGF receptor; IRS-1; ERK cascade	EPIDERMAL-GROWTH-FACTOR; MEDIATED CELL-ADHESION; STIMULATES TYROSINE PHOSPHORYLATION; GUANINE-NUCLEOTIDE EXCHANGE; GTPASE-ACTIVATING PROTEIN; SH3 DOMAINS; C-CRK; V-CRK; FACTOR-I; BETA-SUBUNIT	We have studied the involvement of murine c-Crk, an SH2/SH3 containing adaptor protein, in signaling pathways stimulated by different receptor tyrosine kinases. We show here that c-Crk is associated with components of insulin-and PDGF-dependent signaling pathways. Insulin treatment of murine myoblast cells induces the formation of stable complex of endogenous c-Crk with insulin receptor substrate-1 (IRS-1) mediated via the SH2 domain of Crk. The ligand dependent physical association of c-Crk with IRS-1 is direct. However IRS-1 is also co-precipitated with c-Crk from quiescent L6 cells. The association of IRS-1 with c-Crk in quiescent cells is probably not direct since Far Western blot analysis did not reveal the binding of neither SH2 domain nor amino-terminal SH3 domain of c-Crk to IRS-1 from unstimulated cells. We also show that PDGF treatment of murine myoblast cells induces association of c-Crk with the PDGF receptor and tyrosine phosphorylation of c-Crk. Overexpression of c-Crk enhanced insulin-but not PDGF-induced activation of MAP kinases when compared to parental cell lines. Thus, the formation of the direct IRS-1/Crk complex appears to be crucial for Crk-mediated insulin-induced activation of MAP kinase, whereas Crk is probably involved in other PDGF-induced responses. These data provide support to the hypothesis that insulin and PDGF employ different mechanisms for activation of MAP kinase cascade.	Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; NYU, Med Ctr, Dept Pharmacol, New York, NY 10016 USA	Medical College of Wisconsin; Case Western Reserve University; New York University	Sorokin, A (corresponding author), Med Coll Wisconsin, Dept Med, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.			Sorokin, Andrey/0000-0002-5660-0190	NHLBI NIH HHS [HL22563] Funding Source: Medline; NIDDK NIH HHS [DK41684] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022563, R01HL022563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041684] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BeitnerJohnson D, 1996, J BIOL CHEM, V271, P9287, DOI 10.1074/jbc.271.16.9287; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; CASE RD, 1994, J BIOL CHEM, V269, P10467; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAJARDO JE, 1993, MOL CELL BIOL, V13, P7295, DOI 10.1128/MCB.13.12.7295; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Hansen K, 1997, FEBS LETT, V409, P195, DOI 10.1016/S0014-5793(97)00495-X; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; HERRERA R, 1986, J BIOL CHEM, V261, P1980; Hoeve J.T., 1993, ONCOGENE, V8, P2469; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; Khwaja A, 1996, ONCOGENE, V12, P2491; KLARLUND JK, 1995, J BIOL CHEM, V270, P23421, DOI 10.1074/jbc.270.40.23421; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MARUTA H, 1994, BIOESSAYS, V16, P489, DOI 10.1002/bies.950160708; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; MYERS MG, 1994, J BIOL CHEM, V269, P28783; NANBERG E, 1993, J BIOL CHEM, V268, P18187; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; ODA T, 1994, J BIOL CHEM, V269, P22925; OGAWA S, 1994, ONCOGENE, V9, P1669; OSTEROP APRM, 1993, EUR J BIOCHEM, V212, P477, DOI 10.1111/j.1432-1033.1993.tb17684.x; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; QUON MJ, 1994, J BIOL CHEM, V269, P27920; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; RICE KM, 1994, BIOCHEM BIOPH RES CO, V198, P523, DOI 10.1006/bbrc.1994.1077; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SCHLESINGER J, 1994, CURR BIOL, V7, P25; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SmithHall J, 1997, BIOCHEMISTRY-US, V36, P8304, DOI 10.1021/bi9630974; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P24058; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VRIESSMITS AMM, 1992, NATURE, V357, P602; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1994, J BIOL CHEM, V269, P1	94	16	16	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 14	1998	16	19					2425	2434		10.1038/sj.onc.1201781	http://dx.doi.org/10.1038/sj.onc.1201781			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627109				2022-12-17	WOS:000073672300001
J	Jefferson, AB; Klippel, A; Williams, LT				Jefferson, AB; Klippel, A; Williams, LT			Inhibition of mSOS-activity by binding of phosphatidylinositol 4,5-P-2 to the mSOS pleckstrin homology domain	ONCOGENE			English	Article						SOS; Ras; pleckstrin homology domain; phosphatidylinositol 4,5P(2)	NUCLEOTIDE EXCHANGE FACTOR; BRUTON TYROSINE KINASE; PH DOMAIN; G(BETA-GAMMA) SUBUNITS; SIGNAL-TRANSDUCTION; FACTOR SOS; RAS; PROTEINS; RECEPTOR; GRB2	There are several recently reported examples of inositol phospholipids binding to pleckstrin homology (PH) domains of proteins. The PH domain of SOS, a guanine nucleotide exchange factor for Ras, binds to phosphatidylinositol 4,5 bisphosphate (PtdIns4,5P(2)). We found that binding of PtdIns4,5P(2) to 6-his-tagged recombinant mSOS in vitro inhibits the ability of SOS to catalyze the association of GTP on p21(RAS). This inhibition was specific for PtdIns4,5P(2): a number of other phosphatidylinositols and phosphatidylserine failed to inhibit Ras GTP-association. We confirmed that the specificity of binding of PtdIns's to recombinant GST-SOS-PH domain is the same as the specificity of PtdIns's for inhibition of SOS activity: namely, that only Ptdins4,5P(2) binds significantly to the SOS-PH domain. In addition, the inhibition of Ras GTP-binding is not blocked by excess free inositols suggesting that SOS binds to PtdIns4,5P(2) with higher affinity than it binds to free inositols. Addition of SOS-PH domain protein prevented the inhibition of SOS by PtdIns4,5P(2) as did addition of the high affinity PtdIns4,5P(2)-binding drug neomycin. This confirmed that SOS inhibition is mediated by the SOS-PH domain binding to the inositol moiety of PtdIns4,5P(2). Binding of Grb2 to SOS did not prevent the inhibition of SOS by Ptdins4,5P(2) suggesting that there must be another mechanism for regulating this inhibition. These findings show that the phospholipid PtdIns4,5P(2) can suppress the activity of an enzyme involved in signal transduction and suggest that this inhibitory effect must be relieved when SOS is activated.	Chiron Corp, Emeryville, CA 94608 USA	Novartis	Jefferson, AB (corresponding author), Chiron Corp, 4560 Horton St, Emeryville, CA 94608 USA.							ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Byrne JL, 1996, ONCOGENE, V13, P2055; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; deMora JF, 1996, J BIOL CHEM, V271, P18272, DOI 10.1074/jbc.271.30.18272; FERGUSON KM, 1995, NAT STRUCT BIOL, V2, P715, DOI 10.1038/nsb0995-715; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HARLEY WB, 1994, INFECT DIS CLIN PRAC, V3, P168, DOI 10.1097/00019048-199405000-00004; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; INGLEY E, 1994, J CELL BIOCHEM, V56, P436, DOI 10.1002/jcb.240560403; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LODHI S, 1979, BIOCHIM BIOPHYS ACTA, V557, P1, DOI 10.1016/0005-2736(79)90084-1; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P9111, DOI 10.1021/bi00028a021; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; Wang DS, 1996, J ORG CHEM, V61, P5905, DOI 10.1021/jo960602u; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	41	16	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2303	2310		10.1038/sj.onc.1201891	http://dx.doi.org/10.1038/sj.onc.1201891			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620547				2022-12-17	WOS:000073428000002
J	Flores, AM; Kassatly, RF; Cress, WD				Flores, AM; Kassatly, RF; Cress, WD			E2F-3 accumulation is regulated by polypeptide stability	ONCOGENE			English	Article						cell cycle; E2F; protein stability; Rb	TRANSCRIPTION FACTOR E2F; B-MYB TRANSCRIPTION; UBIQUITIN-PROTEASOME PATHWAY; RETINOBLASTOMA GENE-PRODUCT; BINDING PROTEIN; IN-VIVO; FAMILY; P107; EXPRESSION; PRB	E2F is a complex family of transcription factors which appears to regulate the transcription of genes required for the S phase of the mammalian cell cycle. In the present work, we have examined the mechanisms regulating E2F-3 accumulation in mouse fibroblasts. We have determined that E2F-3 DNA binding activity is restricted to the G(1)/S transition and S phase in both normal BALB/c-3T3 fibroblasts and in an SV40 virus-transformed BALB/c-3T3 derivative. Immunoblot analysis indicates that G(0) and G(1) cells have little or no E2F-3 polypeptide and that the increase in the DNA binding activity of E2F-3 at the G(1)/S boundary is reflected by an increase in total E2F-3 protein. In contrast to the E2F-3 polypeptide, RNAse protection assays demonstrate that the E2F-3 mRNA is clearly present in G(0) and G(1) cells. Finally, pulse/chase experiments indicate that the half-life of E2F-3 is approximately 40-fold greater in cells blocked in S phase relative to asynchronously growing cells. Together, these results indicate that the accumulation E2F-3 at S phase may be regulated, at least in part, at the level of protein stability.	Univ S Florida, H Lee Moffitt Canc Ctr, Mol Oncol Program, Coll Med, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Res Inst, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Cress, WD (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr, Mol Oncol Program, Coll Med, 12902 Magnolia Dr, Tampa, FL 33612 USA.							ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Bennett JD, 1996, ONCOGENE, V13, P1073; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Cress WD, 1996, MOL CELL BIOL, V16, P2119; CRESS WD, 1994, J VIROL, V68, P4212, DOI 10.1128/JVI.68.7.4213-4219.1994; Dagnino L, 1997, CELL GROWTH DIFFER, V8, P553; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Fry CJ, 1997, MOL CELL BIOL, V17, P1966, DOI 10.1128/MCB.17.4.1966; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; HUBER HE, 1994, J BIOL CHEM, V269, P6999; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Moberg K, 1996, MOL CELL BIOL, V16, P1436; OLSON JE, 1993, J CELL PHYSIOL, V154, P333, DOI 10.1002/jcp.1041540217; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; TAO Y, 1997, IN PRESS MOL CEL DEC; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011	43	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 12	1998	16	10					1289	1298		10.1038/sj.onc.1201633	http://dx.doi.org/10.1038/sj.onc.1201633			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546430				2022-12-17	WOS:000072422000007
J	Suminami, Y; Kashii, Y; Law, JC; Lin, WC; Stanson, J; Reichert, TE; Rabinowich, H; Whiteside, TL				Suminami, Y; Kashii, Y; Law, JC; Lin, WC; Stanson, J; Reichert, TE; Rabinowich, H; Whiteside, TL			Molecular analysis of the IL-2 receptor beta chain gene expressed in human tumor cells	ONCOGENE			English	Article						IL-2R; IL-2; tumor cells; IL-2R on carcinomas; tumor growth	INTERLEUKIN-2 RECEPTOR; GAMMA-CHAIN; MONOCLONAL-ANTIBODIES; SIGNAL TRANSDUCTION; LIGAND-BINDING; GROWTH; CARCINOMA; CYTOKINES; CANCER; SYSTEM	Interleukin-2 (IL-2) is recognized as a T cell growth factor. We have previously reported that human carcinoma cell lines are inhibited in growth by exogenous IL-2, which binds to the IL-2 receptor beta (IL-2R beta) chain ubiquitously expressed on the surface of tumor cells. A possibility was considered that IL-2R beta on carcinomas responsible for negative signaling was different from that expressed on hematopoietic cells. To investigate this possibility, mRNA for the IL-2R beta chain was amplified and compared in carcinoma and lymphoid cells. Using RT-PCR with pairs of sense-antisense oligonucleotide primers specific for the various regions of extracellular, transmembrane and intracellular domains of the IL-2R beta chain, we amplified mRNA obtained from three human carcinoma cell lines and human lymphoid cells as controls. The identity of the amplicons was confirmed by Southern analysis with the P-32-labeled cDNA probe coding for the entire span of the IL-2R beta chain. In addition, genomic DNA obtained from the tumor cell lines was sequenced to examine the possibility that a mutation is present in the gene coding for the intracellular IL-2R beta chain domain. No mutations or deletions were detected. The message for all three domains of the beta chain was identical in tumor cells and in normal lymphoid cells used as controls. Also, by Western blot and northern analyses no differences between IL-2R beta chain in tumors vs that expressed in lymphoid cells were demonstrable. The IL-2R gamma chain, which participates in IL-2/IL-2R signaling pathway, was expressed in tumor cells. Expression of JAK1 transcripts in these cells was comparable to that in lymphocytes. However, RT-PCR analysis identified differences in expression of JAK3 splice variants (B and M) in tumor cells. These differences may be responsible for altered downstream signaling by IL-2. Overall, our data indicate that the same IL-2/IL-2R pathway is operative in human carcinomas and in normal epithelial or lymphoid cells.	Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Human Genet Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Whiteside, TL (corresponding author), Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA.		Lin, Wen-chang/ABH-7976-2020; Lin, Wen-chang/B-3100-2011	Lin, Wen-chang/0000-0003-0194-1745; Lin, Wen-chang/0000-0003-0194-1745	NCI NIH HHS [R0-1 CA63513] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063513] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAMFORD RN, 1997, IMMUNOLOGIST, V5, P52; CHEN K, 1987, LAB INVEST, V56, P114; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HEO DS, 1990, CANCER RES, V50, P3681; Johnston JA, 1996, J LEUKOCYTE BIOL, V60, P441, DOI 10.1002/jlb.60.4.441; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LAI KS, 1995, J BIOL CHEM, V270, P25028, DOI 10.1074/jbc.270.42.25028; LIN WC, 1995, J IMMUNOL, V155, P4805; LIN WC, 1993, ARCH OTOLARYNGOL, V119, P1229; McCombie W R, 1992, DNA Seq, V2, P289, DOI 10.3109/10425179209030961; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; RABINOWICH H, 1992, J IMMUNOL, V149, P340; REICHERT T, 1997, UNPUB ROLE ENDOGENOU; ROBB RJ, 1981, J EXP MED, V154, P1455, DOI 10.1084/jem.154.5.1455; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBUYA H, 1990, NUCLEIC ACIDS RES, V18, P3697, DOI 10.1093/nar/18.13.3697; SIEGEL JP, 1987, SCIENCE, V238, P75, DOI 10.1126/science.3116668; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TANIGUCHI T, 1986, IMMUNOL REV, V92, P121, DOI 10.1111/j.1600-065X.1986.tb01497.x; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TSUDO M, 1989, P NATL ACAD SCI USA, V86, P1982, DOI 10.1073/pnas.86.6.1982; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WEIDMANN E, 1992, CANCER RES, V52, P5963; YASUMURA S, 1994, INT J CANCER, V59, P225, DOI 10.1002/ijc.2910590215	30	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 12	1998	16	10					1309	1317		10.1038/sj.onc.1201640	http://dx.doi.org/10.1038/sj.onc.1201640			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546432				2022-12-17	WOS:000072422000009
J	deMora, JF; Uren, A; Heidaran, M; Santos, E				deMora, JF; Uren, A; Heidaran, M; Santos, E			Biological activity of p27(kip1) and its amino- and carboxy-terminal domains in G2/M transition of Xenopus oocytes	ONCOGENE			English	Article						p27(kip1); Xenopus oocytes; cell cycle; cdc2 kinase; MPF; GVBD	DEPENDENT-KINASE INHIBITOR; P34CDC2 PROTEIN-KINASE; FIBROBLAST CELL-CYCLE; PHOSPHORYLATION SITES; TYROSINE PHOSPHATASE; ACTIVATING KINASE; CDK6 INHIBITOR; CDC2; P27; CLONING	p27(kip1) is a general inhibitor of Cdks that preferentially accumulates and functions during G1 phase, before the restriction point of the mammalian cell cycle. We observed that injection of purified p27(kip1) into Xenopus oocytes potently inhibits the G2/M transition and activation/dephosphorylation of the maturation promoting factor (MPF, p34(cdc2)/cyclin B complex) kinase associated with germinal vesicle breakdown (GVBD) induced by progesterone or insulin. Addition of exogenous p27(kip1) in vitro to lysates of hormonally matured oocytes blocked the enzymatic activity of the activated MPF kinase present in those extracts. Interestingly, the isolated amino-terminal region of p27(kip1) (p27N), encompassing only the Cdk binding site, exhibited a similar inhibitory behavior in vitro and a weaker inhibitory effect in vivo than the complete p27(kip1) protein. Surprisingly, the remaining carboxy-terminal region of p27(kip1) (p27C) actually induced GVBD when injected alone into the oocytes, and also accelerated the kinetics of insulin-or progesterone-induced GVBD. Consistent with the in vivo observations, p27C formed a complex with, and activated, the MPF kinase in lysates of immature oocytes, although this activation was blocked by simultaneous addition of p27N or complete p27(kip1). Active MPF was able to phosphorylate p27C only in the absence of p27N or whole p27(kip1), suggesting that the inhibitory activity associated with the amino terminus is dominant over the activation produced by p27C. These results demonstrate the functional interaction of p27(kip1) with cyclin B/p34(cdc2) complexes during G2/M progression in oocytes, and suggest that the amino and carboxy terminal portions of this protein may play opposite regulatory roles, reminiscent of the corresponding N- and C-terminal portions of p21(waf). We speculate that accumulation of a truncated, C-terminal p27 fragment may play a physiological regulatory role in progression through G2 and later stages of the cell cycle.			deMora, JF (corresponding author), NCI, MOL & CELLULAR BIOL LAB, DBS, BETHESDA, MD 20892 USA.		de Mora, Jaime Font/H-6304-2015; de Mora, Jaime Font/AAK-7591-2021	de Mora, Jaime Font/0000-0002-6816-2095; de Mora, Jaime Font/0000-0002-6816-2095				APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; deMora JF, 1996, J BIOL CHEM, V271, P18272, DOI 10.1074/jbc.271.30.18272; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; Draetta Giulio, 1993, Trends in Cell Biology, V3, P287, DOI 10.1016/0962-8924(93)90001-H; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; GRIGORESCU F, 1994, HORM RES, V42, P5; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALL M, 1995, ONCOGENE, V11, P1581; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lee TH, 1996, P NATL ACAD SCI USA, V93, P352, DOI 10.1073/pnas.93.1.352; LOUNDGREN K, 1991, CELL, V64, P1111; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MALLER JL, 1994, SEMIN DEV BIOL, V5, P138; MARCOTE MJ, 1993, MOL CELL BIOL, V13, P5122, DOI 10.1128/MCB.13.8.5122; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PALEMBELLA VJ, 1994, CELL, V78, P773; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; Patra D, 1996, GENE DEV, V10, P1503, DOI 10.1101/gad.10.12.1503; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SAMIEI M, 1991, J BIOL CHEM, V266, P14889; Shou WY, 1996, MOL BIOL CELL, V7, P457, DOI 10.1091/mbc.7.3.457; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SU JY, 1995, P NATL ACAD SCI USA, V92, P10187, DOI 10.1073/pnas.92.22.10187; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Wang QM, 1996, CANCER RES, V56, P264	55	16	17	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2541	2551		10.1038/sj.onc.1201420	http://dx.doi.org/10.1038/sj.onc.1201420			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399642				2022-12-17	WOS:A1997YG73200004
J	Allay, E; Reese, JS; McGuire, EA; Koc, ON; Sedransk, N; Gerson, SL				Allay, E; Reese, JS; McGuire, EA; Koc, ON; Sedransk, N; Gerson, SL			Potentiation of lymphomagenesis by methylnitrosourea in mice transgenic for LMO1 is blocked by O-6-alkylguanine DNA-alkyltransferase	ONCOGENE			English	Article						DNA repair; LMO1; lymphomagenesis; O-6-alkylguanine; DNA-alkyltransferase; carcinogenesis	INDUCED THYMIC LYMPHOMAS; N-METHYLNITROSOUREA; ESCHERICHIA-COLI; EXPRESSION; GENE; RAS; METHYLTRANSFERASE; PROTECTS; REPAIR; LEUKEMIA	We evaluated induction of lymphomas by the methylating carcinogen, N-methylnitrosourea [MNU], in transgenic mice expressing both LMO1 and the DNA repair gene, MGMT, in the thymus, The goal was to determine whether environmental mutagens shorten the latency or increase the incidence of LMO1+lymphomas and whether mice transgenic for both LMO1 and MGMT, and thereby able to repair O-6-methylguanine DNA adducts induced by MNU, would be protected, Mice heterozygous for LMO1 or MGMT were crossed and offspring treated with MNU at 6 weeks of age, MNU induced lymphoma incidence was highest in the LMO1 mice, 91% and lowest in the hMGMT+mice, 15%, MNU induced K-ras mutations in codon 12 in non-MGMT transgenics resulted in a shorter latency of tumors and accounting for half of the early lymphomas in LMO1 mice, The effect of MNU was abrogated in the LMO1/hMGMT transgenic mice, indicating the ability of MGMT expression to block the carcinogenic effect of MNU even in cancer prone mice, Thus, methylating agents potentiate lymphomagenesis of LMO1, in part through activation of K-ras and the MAPK pathway, a process which appear to synergize with LMO1 mediated transcription activation, O-6-alkylguanine DNA-alkyltransferase mediated DNA repair effectively blocks chemical carcinogenesis in mice carrying the LMO1 oncogene.	CASE WESTERN RESERVE UNIV,SCH MED,DIV HEMATOL ONCOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,CWRU IRELAND CANC CTR,CLEVELAND,OH 44106; UNIV HOSP CLEVELAND,CLEVELAND,OH 44106; UNIV PITTSBURGH,DIV HEMATOL,INST CANC,PITTSBURGH,PA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL CANCER INSTITUTE [R01CA063193, P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006288] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA43703, R01CA63193] Funding Source: Medline; NIEHS NIH HHS [R01ES06288] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANGEL JM, 1993, MOL CARCINOGEN, V7, P151, DOI 10.1002/mc.2940070305; Becker K, 1996, CANCER RES, V56, P3244; BOEHM T, 1990, ONCOGENE, V5, P1103; BREUER M, 1991, CANCER RES, V51, P958; COROMINAS M, 1991, CANCER RES, V51, P5129; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; ELSON A, 1995, ONCOGENE, V11, P181; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; Gerson Stanton L., 1993, Current Opinion in Oncology, V5, P136; HAQQI TM, 1992, P NATL ACAD SCI USA, V89, P1253, DOI 10.1073/pnas.89.4.1253; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; KANEKO Y, 1989, LEUKEMIA, V3, P886; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Knudson AG, 1995, ADV CANCER RES, V67, P1, DOI 10.1016/S0065-230X(08)60708-3; LINDEMAN G, 1994, ONCOGENE, V10, P1013; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; LIU LL, 1994, CANCER RES, V54, P4648; MACKAY WJ, 1994, J BACTERIOL, V176, P3224, DOI 10.1128/jb.176.11.3224-3230.1994; MANGUES R, 1994, CANCER RES, V54, P6395; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; NAKATSURU Y, 1993, P NATL ACAD SCI USA, V90, P6468, DOI 10.1073/pnas.90.14.6468; NEALE GAM, 1995, BLOOD, V86, P3060; NEWCOMB EW, 1988, CANCER RES, V48, P5514; PAULY GT, 1994, BIOCHEMISTRY-US, V33, P9169, DOI 10.1021/bi00197a020; REBECK GW, 1991, J BACTERIOL, V173, P2068, DOI 10.1128/jb.173.6.2068-2076.1991; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; XIAO W, 1995, MUTAT RES-DNA REPAIR, V336, P133, DOI 10.1016/0921-8777(94)00048-B; ZAIDI NH, 1995, CARCINOGENESIS, V16, P451, DOI 10.1093/carcin/16.3.451; ZAIDI NH, 1995, CARCINOGENESIS, V16, P1047, DOI 10.1093/carcin/16.5.1047	31	16	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 23	1997	15	17					2127	2132		10.1038/sj.onc.1201384	http://dx.doi.org/10.1038/sj.onc.1201384			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366529	Bronze			2022-12-17	WOS:A1997YC28400013
J	Barsky, SH; Sternlicht, MD; Safarians, S; Nguyen, M; Chin, K; Stewart, SD; Hiti, AL; Gray, JW				Barsky, SH; Sternlicht, MD; Safarians, S; Nguyen, M; Chin, K; Stewart, SD; Hiti, AL; Gray, JW			Evidence of a dominant transcriptional pathway which regulates an undifferentiated and complete metastatic phenotype	ONCOGENE			English	Article						somatic cell hybridization; spontaneous metastasis; human-human fusions	COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN-MALIGNANT-MELANOMA; GROWTH-FACTOR RECEPTOR; SOMATIC-CELL HYBRIDS; HUMAN LUNG-CANCER; DNA METHYLTRANSFERASE; MONOCLONAL-ANTIBODY; EPITHELIAL-CELLS; PROSTATE-CANCER; SOLID TUMORS	The highly metastatic amelanotic C8161 human melanoma line was found to exhibit complete dominance of its undifferentiated and metastatic phenotype in multiple somatic cell hybridization studies designed to bypass the presence of potential tumor suppressor genes. In a three armed approach involving somatic cell fusions of C8161 with recipient lines of greater differentiation, different lineage, and different tumorigenicity status, the metastatic and undifferentiated phenotype of C8161 was promiscuously dominant. In somatic cell hybrids produced between the C8161 and a group of non-metastatic human melanoma lines which exhibited melanocyte differentiation markers including S100, HMB-45, NKI/ C3, and melanin, the fusions were uniformly metastatic and undifferentiated. In somatic cell hybrids of C8161 and MCF-7 the fusions exhibited an estrogen independent and unresponsive, estrogen receptor (ER) negative, and highly metastatic phenotype. In fusions between C8161 and HMS-1, an immortalized 'benign' human myoepithelial line which produced an abundant extracellular matrix (ECM) and high levels of protease and angiogenic inhibitors including maspin, tissue inhibitor of metalloproteinase-1 (TIMP-1), alpha 1-antitrypsin (alpha 1-AT), protease nexin II (PN-II), thrombospondin-l and soluble basic fibroblast growth factor (bFGF) receptors, the hybrids showed complete absence of matrix, absent maspin expression, markedly decreased protease inhibitor and angiogenic inhibitor production, high levels of proteases and angiogenic factors, and a highly metastatic phenotype. In our somatic cell fusions, the human-human hybrids represented true and complete fusions and not hybrid clones selected for by loss of dominant-acting growth suppressor genes. This finding was supported by detailed comparative genomic hybridization (CGH) studies, Q-banding karyotype analysis, and autofusions of representative clones. The purposeful creation of inherently unstable human-murine fusions between C8161 and B16-F1 where loss of putative suppressor loci would be expected, resulted in fusions exhibiting decreased growth and non-metastatic behavior with progressive chromosomal loss. Neither p53, nm23, DNA methyltransferase, activated I as, fibroblast growth factor-4 (FGF-4), or epidermal growth factor receptor (EGFR) mediated the acquisition of the metastatic or undifferentiated phenotype within the C8161-human fusions. These studies are the first studies ever to successfully transfer the complete metastatic phenotype by somatic cell fusion and support the presence of a new high level regulatory pathway(s) involving dominant trans-acting factors which act pleiotropically to regulate an undifferentiated and highly metastatic phenotype.	UNIV CALIF LOS ANGELES,SCH MED,DIV SURG ONCOL,LOS ANGELES,CA 90024; UNIV CALIF SAN FRANCISCO,CTR CANC,CANC GENET PROGRAM,SAN FRANCISCO,CA 94143; CEDARS SINAI MED CTR,LAB CYTOGENET,LOS ANGELES,CA 90211; UNIV SO CALIF,DEPT PATHOL,LOS ANGELES,CA 90033	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California San Francisco; Cedars Sinai Medical Center; University of Southern California	Barsky, SH (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90024, USA.				NATIONAL CANCER INSTITUTE [R01CA040225, R01CA056735] Funding Source: NIH RePORTER; NCI NIH HHS [CA01351, CA40225, CA56735] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINI A, 1987, CANCER RES, V47, P3239; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARSKY SH, 1983, LAB INVEST, V49, P140; CAREY TE, 1976, P NATL ACAD SCI USA, V73, P3278, DOI 10.1073/pnas.73.9.3278; CHAMBERS AF, 1992, BIOCHEM CELL BIOL, V70, P817, DOI 10.1139/o92-124; CHENG L, 1988, LAB INVEST, V58, P346; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P165, DOI 10.1007/BF01542629; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; ERICKSON LA, 1984, ANAL BIOCHEM, V137, P454, DOI 10.1016/0003-2697(84)90113-1; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; FIDLER IJ, 1990, J NATL CANCER I, V82, P166, DOI 10.1093/jnci/82.3.166; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FUJIWARA T, 1993, CANCER RES, V53, P4129; GEISER AG, 1986, P NATL ACAD SCI USA, V83, P5209, DOI 10.1073/pnas.83.14.5209; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; GOPALAKRISHNA R, 1988, P NATL ACAD SCI USA, V85, P612, DOI 10.1073/pnas.85.2.612; GOWN AM, 1984, AM J PATHOL, V114, P309; HARRIS H, 1988, CANCER RES, V48, P3302; HARRIS H, 1969, NATURE, V223, P363, DOI 10.1038/223363a0; HERRON GS, 1986, J BIOL CHEM, V261, P2814; ICHIKAWA T, 1994, CANCER RES, V54, P2299; ITO M, 1994, CANCER LETT, V78, P33, DOI 10.1016/0304-3835(94)90028-0; JOHNSON JP, 1991, CANCER METAST REV, V10, P11, DOI 10.1007/BF00046840; KAIGHN ME, 1990, CANCER RES, V50, P1890; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KOZLOWSKI JM, 1984, CANCER RES, V44, P3522; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LOCKSHIN A, 1985, CANCER RES, V45, P345; MACDOUGALL JR, 1995, CANCER RES, V55, P4174; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MCLESKEY SW, 1993, CANCER RES, V53, P2168; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MUELLER BM, 1991, CANCER RES, V51, P2193; NEVINS JR, 1987, METHODS ENZYMOLOGY G, P234; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PIPER J, 1995, CYTOMETRY, V19, P10, DOI 10.1002/cyto.990190104; QUINLAN DC, 1992, CANCER RES, V52, P4828; RINKERSCHAEFFER CW, 1994, CANCER RES, V54, P6249; RODER JC, 1978, J IMMUNOL, V121, P2509; SIDEBOTTOM E, 1983, BRIT J CANCER, V47, P399, DOI 10.1038/bjc.1983.60; SOMMERS CL, 1990, CANCER RES, V50, P67; SPRUCK CH, 1993, CANCER RES, V53, P1162; STAROSELSKY AH, 1991, CANCER RES, V51, P6292; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; Sternlicht MD, 1996, IN VITRO CELL DEV-AN, V32, P550; TAKAHASHI K, 1984, VIRCHOWS ARCH B, V45, P385, DOI 10.1007/BF02889881; TSUCHIDA T, 1987, J NATL CANCER I, V78, P55, DOI 10.1093/jnci/78.1.55; VENNEGOOR C, 1985, INT J CANCER, V35, P287, DOI 10.1002/ijc.2910350302; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211; WELCH DR, 1994, ONCOGENE, V9, P255; XU YH, 1984, NATURE, V309, P806, DOI 10.1038/309806a0; YAMANISHI DT, 1991, CARCINOGENESIS, V12, P105, DOI 10.1093/carcin/12.1.105; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287; ZAJCHOWSKI DA, 1990, P NATL ACAD SCI USA, V87, P2314, DOI 10.1073/pnas.87.6.2314	58	16	18	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 23	1997	15	17					2077	2091		10.1038/sj.onc.1201379	http://dx.doi.org/10.1038/sj.onc.1201379			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366525				2022-12-17	WOS:A1997YC28400009
J	Wan, HS; Dawson, MI; Hong, WK; Lotan, R				Wan, HS; Dawson, MI; Hong, WK; Lotan, R			Enhancement of Calu-1 human lung carcinoma cell growth in serum-free medium by retinoids: Dependence on AP-1 activation, but not on retinoid response element activation	ONCOGENE			English	Article						retinoids; AP-1; lung cancer; nuclear receptors; growth stimulation	ACID RECEPTOR-GAMMA; PROTEIN-KINASE-C; BRONCHIAL EPITHELIAL-CELLS; BREAST-CANCER CELLS; BETA-CAROTENE; ESTROGEN-RECEPTOR; MAMMARY-CARCINOMA; NUCLEAR RECEPTORS; RIBONUCLEIC-ACID; GENE-EXPRESSION	Many lung cancer cell lines are resistant to the growth inhibitory effects of retinoids, However, some small-cell lung cancer cell lines were inhibited by all trans-retinoic acid (ATRA) in serum-free medium, We compared the responses of seven non-small cell lung cancer (NSCLC) cell lines to ATRA in serum-free medium and in medium supplemented with delipidized serum, Whereas the growth of four cell lines was inhibited more in serum-free medium, the growth of the Calu-1 cell line was stimulated by ATRA in a dose-dependent fashion with a maximum at 10(-8) M. Delipidized serum (>2.5%) but not bovine serum albumin (0.15%) suppressed growth stimulation by ATRA, Transcripts of RA receptors RAR alpha and RAR gamma but not of RAR beta were detected in Calu-1 cells, Receptor expression, the formation of a complex among receptors and a RA-responsive element (RARE), and the transcriptional activation RARE were not suppressed by serum, Natural retinoids and synthetic receptor class-or subtype-selective retinoid agonists, which activated RARs and RXRs for gene transcription from a RARE, and a RAR antagonist (CD2366), which was unable to do so, stimulated the growth of Calu-1 cells in serum-free medium but not in serum-containing medium, Both ATRA and CD2366 enhanced the transcriptional activation of an Activator Protein-1 (AP-1)-luciferase reporter construct in serum-free medium but not in delipidized serum, Transcriptional activation of the RARE by ATRA occurred both in the presence or absence of delipidized serum, These results demonstrate that retinoid-induced growth stimulation of Calu-1 cells is associated with enhanced AP-1 transactivation but not with RARE transactivation.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT TUMOR BIOL, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT THORAC HEAD & NECK MED ONCOL, HOUSTON, TX 77030 USA; SRI INT, RETINOID PROGRAM, MENLO PK, CA 94025 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; SRI International					NATIONAL CANCER INSTITUTE [U19CA068437] Funding Source: NIH RePORTER; NCI NIH HHS [U19 CA68437] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; AMOS B, 1990, METHOD ENZYMOL, V190, P217; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AVIS I, 1995, CELL GROWTH DIFFER, V6, P485; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; BOEHM MF, 1994, J MED CHEM, V37, P2930, DOI 10.1021/jm00044a014; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; DAWSON MI, 1983, J MED CHEM, V26, P1653, DOI 10.1021/jm00365a021; DAWSON MI, 1995, CANCER RES, V55, P4446; DAWSON MI, 1995, J MED CHEM, V38, P3368, DOI 10.1021/jm00017a021; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Duester G, 1996, BIOCHEMISTRY-US, V35, P12221, DOI 10.1021/bi961176+; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; Fanjul AN, 1996, J BIOL CHEM, V271, P22441, DOI 10.1074/jbc.271.37.22441; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; GITTER BD, 1991, CLIN IMMUNOL IMMUNOP, V61, P191, DOI 10.1016/S0090-1229(05)80023-6; Gottardis MM, 1996, CANCER RES, V56, P5566; Gudas Lorraine J., 1994, P443; Haq R, 1991, Biochem Biophys Res Commun, V180, P1137; Hodam JR, 1996, BBA-MOL CELL RES, V1311, P102, DOI 10.1016/0167-4889(95)00203-0; Hong WK, 1995, CLIN CANCER RES, V1, P677; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; Jetten A M, 1992, J Natl Cancer Inst Monogr, P93; JIANG XL, 1992, INT J IMMUNOPHARMACO, V14, P195, DOI 10.1016/0192-0561(92)90031-F; KAGECHIKA H, 1989, J MED CHEM, V32, P1098, DOI 10.1021/jm00125a027; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kazmi SMI, 1996, CANCER RES, V56, P1056; KITABAYASHI I, 1994, IN VITRO CELL DEV-AN, V30A, P761; KOJIMA R, 1994, J BIOL CHEM, V269, P32700; KURIE JM, 1993, BIOCHIM BIOPHYS ACTA, V1179, P203, DOI 10.1016/0167-4889(93)90142-C; KURLANDSKY SB, 1994, J BIOL CHEM, V269, P32821; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LECHNER JF, 1982, IN VITRO CELL DEV B, V18, P633; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; LOTAN R, 1995, RETINOIDS ONCOLOGY, P1031; Mangelsdorf David J., 1994, P319; MOASSER MM, 1995, ONCOGENE, V10, P1537; NAPOLI JL, 1988, J BIOL CHEM, V263, P17372; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; Oridate N, 1996, ONCOGENE, V12, P2019; PENG YM, 1987, J NATL CANCER I, V78, P95, DOI 10.1093/jnci/78.1.95; PFAHL M, 1994, VITAM HORM, V49, P327; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; RIAZULHAQ, 1991, P NATL ACAD SCI USA, V88, P8272, DOI 10.1073/pnas.88.18.8272; ROBERTSON KA, 1992, MOL CELL BIOL, V12, P3743, DOI 10.1128/MCB.12.9.3743; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROCHETTEEGLY C, 1992, MOL ENDOCRINOL, V6, P2197, DOI 10.1210/me.6.12.2197; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SANCHEZ JH, 1987, TOXICOL IN VITRO, V1, P183, DOI 10.1016/0887-2333(87)90019-1; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SHAO ZM, 1995, ONCOGENE, V11, P493; SHARIF M, 1992, ONCOGENE, V7, P953; SHEIKH MS, 1995, CARCINOGENESIS, V16, P2477, DOI 10.1093/carcin/16.10.2477; Soprano DR, 1996, ONCOGENE, V12, P577; VERMA AK, 1992, J NUTR, V122, P2144, DOI 10.1093/jn/122.11.2144; WANG XD, 1991, ARCH BIOCHEM BIOPHYS, V285, P8, DOI 10.1016/0003-9861(91)90322-A; WU R, 1990, AM J RESP CELL MOL, V3, P467, DOI 10.1165/ajrcmb/3.5.467; YANG PC, 1992, AM J RESP CELL MOL, V7, P161, DOI 10.1165/ajrcmb/7.2.161; ZHANG QY, 1992, J IMMUNOL, V149, P1402; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016; ZOU CP, 1994, CANCER RES, V54, P5479; ZYLBERKATZ E, 1986, LEUKEMIA RES, V10, P1425, DOI 10.1016/0145-2126(86)90009-3	72	16	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	1997	15	17					2109	2118		10.1038/sj.onc.1201381	http://dx.doi.org/10.1038/sj.onc.1201381			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366527				2022-12-17	WOS:A1997YC28400011
J	Petrenko, O; Ischenko, I; Enrietto, PJ				Petrenko, O; Ischenko, I; Enrietto, PJ			Characterization of changes in gene expression associated with malignant transformation by the NF-kappa B family member, v-Rel	ONCOGENE			English	Article						v-Rel; NF-kappa B; oncogene; transformation	RECEPTOR FUSION PROTEIN; BONE-MARROW CELLS; C-REL; TRANSCRIPTIONAL REGULATION; HEMATOPOIETIC-CELLS; TARGETED DISRUPTION; HOMOLOGY DOMAIN; LYMPHOID-CELLS; GROWTH-FACTOR; MICE LACKING	In this study, alterations in gene expression patterns have been examined in v-Rel-transformed avian bone marrow cells, Using a conditional v-Rel estrogen receptor chimera (v-RelER) which transforms cells in an estrogen-dependent manner, we constructed subtraction cDNA libraries from v-RelER-transformed bone marrow cells, Several different sequences were identified whose expression was altered upon hormone activation of v-RelER. These include two genes related to the MIP-I chemokine family (mip-1 beta and a tca3 homologue), a cell surface antigen sca-2 and the transcription factor nfkb1. The expression of each gene was assayed in a number of wild-type and mutant v-Rel-expressing fibroblast and hematopoietic cells, All v-Rel-transformed hematopoietic cells tested express high levels of nfkb1 and sca-2. In fibroblasts, wild-type v-Rel induced expression of mip-1 beta and nfkb1, while nontransforming mutants of v-Rel failed to do so, suggesting a role for these two genes in v-Rel mediated transformation, Finally, these genes are expressed at high levels in cells overexpressing wild-type and truncated forms of c-Rel, implying that v-Rel transforms, in part, by induction of c-Rel target genes.			Petrenko, O (corresponding author), SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794, USA.				NCI NIH HHS [CA51792] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; ADAMS DH, 1994, P NATL ACAD SCI USA, V91, P7144, DOI 10.1073/pnas.91.15.7144; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; BARTH CF, 1988, J EXP MED, V167, P89, DOI 10.1084/jem.167.1.89; BARTH CF, 1990, J VIROL, V64, P6054, DOI 10.1128/JVI.64.12.6054-6062.1990; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BOEHMELT G, 1995, CELL, V80, P341, DOI 10.1016/0092-8674(95)90417-4; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BURD PR, 1987, J IMMUNOL, V139, P3126; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; ERNST H, 1987, J BIOL CHEM, V262, P1206; FRANKEL S, 1994, J MOL BIOL, V235, P1351, DOI 10.1006/jmbi.1994.1090; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; Gilmore TD, 1996, ONCOGENE, V13, P1367; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; HODGSON J, 1995, J VIROL, V69, P1971, DOI 10.1128/JVI.69.3.1971-1979.1995; HRDLICKOVA R, 1995, J VIROL, V69, P403; HRDLICKOVA R, 1994, J VIROL, V68, P2371; KABRUN N, 1990, MOL CELL BIOL, V10, P4788, DOI 10.1128/MCB.10.9.4788; Klement JF, 1996, MOL CELL BIOL, V16, P2341; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; LARSEN J, 1993, ONCOGENE, V8, P3221; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; LIPTAY S, 1992, GENOMICS, V13, P287, DOI 10.1016/0888-7543(92)90244-M; Lloyd AR, 1996, J IMMUNOL, V156, P932; LU D, 1991, ONCOGENE, V6, P1235; METZ T, 1991, EMBO J, V10, P837, DOI 10.1002/j.1460-2075.1991.tb08016.x; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; MORRISON LE, 1991, ONCOGENE, V6, P1657; MORRISON LE, 1992, ONCOGENE, V7, P1137; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MUKHOPADHYAY T, 1995, ONCOGENE, V11, P999; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Noda S, 1996, J EXP MED, V183, P2355, DOI 10.1084/jem.183.5.2355; OHNO H, 1993, LEUKEMIA, V7, P2057; SAITOH SI, 1995, J IMMUNOL, V155, P5574; SARKAR S, 1993, ONCOGENE, V8, P2245; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SCHWEINFEST CW, 1990, GENET ANAL-BIOMOL E, V7, P64, DOI 10.1016/0735-0651(90)90042-E; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SMARDOVA J, 1995, ONCOGENE, V10, P2017; SPRANGRUDE GJ, 1989, J IMMUNOL, V142, P425; TAUB DD, 1995, J IMMUNOL, V155, P3877; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Walker AK, 1996, ONCOGENE, V12, P2515; WALTER PP, 1995, MOL CELL BIOL, V15, P6178; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; White DW, 1996, MOL CELL BIOL, V16, P1169; WIDMER F, 1990, J CELL BIOL, V111, P3035, DOI 10.1083/jcb.111.6.3035; Zhang GQ, 1996, ONCOGENE, V12, P1153; ZHANG GQ, 1995, MOL CELL BIOL, V15, P1806	65	16	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1671	1680		10.1038/sj.onc.1201334	http://dx.doi.org/10.1038/sj.onc.1201334			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349500				2022-12-17	WOS:A1997XY63100006
J	Kogerman, P; Sy, MS; Culp, LA				Kogerman, P; Sy, MS; Culp, LA			Counter-selection for over-expressed human CD44s in primary tumors versus lung metastases in a mouse fibrosarcoma model	ONCOGENE			English	Article						CD44; metastasis; nude mice; 3T3; sis	SPLICE VARIANTS; 3T3 CELLS; PROGRESSION; DEGRADATION; ONCOGENE; CANCER; GROWTH; HYALURONAN; CARCINOMAS; ISOFORMS	Human CD44 standard isoform cDNA (hCD44s) was transfected into sis-transformed Balb/c 3T3 cells and into ras-revertant IIIA4 cells (both tumorigenic but nonmetastatic). Transfectants were injected subcutaneously into athymic nude mice to elucidate the functional role of hCD44s over-expression in progression and metastasis. The transfectants (but not parental cells) vr ere capable of lung micrometastasis and of binding exogenously-added hyaluronan. hCD44s protein expression was conserved in lung micrometastases suggesting that it may have been necessary for their formation. In contrast, no hCD44s protein was detected in large subcutaneous (s.c.) tumors but normal levels of murine CD44 were detected. A second round of tumor development, using these two tumor cell classes, demonstrated that hCD44s-nonexpressing s.c. tumor cells re-expressed it in lung micrometastases. Conversely, hCD44s-expressing lung micrometastatic cells, when injected into a second group of mice, downregulated hCD44s expression in order to grow sizable s.c. tumors. S.c. tumor cells still contained the hCD44s gene but its expression was inhibited by epigenetic mechanisms, one of which was shown to be methylation of the hCD44s gene. These studies demonstrate (a) opposing selective pressures on CD44s over-expression for s.c. tumor growth and for metastatic spread to the lung and (b) further credence for the significance of CD44 for metastatic spread of fibrosarcomas. Therefore, CD44s may he a critical component of the metastatic phenotype induced by specific oncogenes.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOL BIOL & MICROBIOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PATHOL,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University			Kogerman, Priit/B-6333-2008		NCI NIH HHS [CA27755, CA60469] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA060469, R01CA027755] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CULTY M, 1994, J CELL PHYSIOL, V160, P275, DOI 10.1002/jcp.1041600209; CULTY M, 1992, J CELL BIOL, V116, P1055, DOI 10.1083/jcb.116.4.1055; DeGrendele HC, 1996, J EXP MED, V183, P1119, DOI 10.1084/jem.183.3.1119; FIDLER IJ, 1994, CANCER METAST REV, V13, P209, DOI 10.1007/BF00689637; FOX SB, 1994, CANCER RES, V54, P4539; GOROWSKI JJ, 1995, J BIOL CHEM, V270, P26940; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; GUO YJ, 1994, CANCER RES, V54, P1561; GUO YJ, 1993, CELL IMMUNOL, V152, P186, DOI 10.1006/cimm.1993.1278; HEIDER KH, 1993, CANCER RES, V53, P4197; HOUCHENS DP, 1978, P S USE ATHYMIC NUDE, P267; Jackson PA, 1995, J CLIN PATHOL, V48, P1098, DOI 10.1136/jcp.48.12.1098; Kogerman P, 1996, CLIN EXP METASTAS, V14, P73, DOI 10.1007/BF00157688; Kogerman P, 1996, J CELL PHYSIOL, V169, P341, DOI 10.1002/(SICI)1097-4652(199611)169:2<341::AID-JCP13>3.3.CO;2-M; Kogerman P, 1997, INT J ONCOL, V10, P553; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LEWIN DI, 1996, J NIH RES, V8, P24; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; NICOLSON GL, 1993, EXP CELL RES, V204, P171, DOI 10.1006/excr.1993.1022; RADINSKY R, 1992, In Vivo (Attiki), V6, P325; RADINSKY R, 1987, P NATL ACAD SCI USA, V84, P5143, DOI 10.1073/pnas.84.15.5143; RADINSKY R, 1991, INT J CANCER, V48, P148; RUDY W, 1993, CANCER RES, V53, P1262; Sambrook J, 1989, MOL CLONING LAB MANU; Sinn Hans-Peter, 1995, Breast Cancer Research and Treatment, V36, P307, DOI 10.1007/BF00713402; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; Weiss L, 1990, Adv Cancer Res, V54, P159, DOI 10.1016/S0065-230X(08)60811-8; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; WIELENGA VJM, 1993, CANCER RES, V53, P4754	31	16	16	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1407	1416		10.1038/sj.onc.1201306	http://dx.doi.org/10.1038/sj.onc.1201306			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333016				2022-12-17	WOS:A1997XW41100004
J	Kimura, Y; Furuhata, T; Shiratsuchi, T; Nishimori, H; Hirata, K; Nakamura, Y; Tokino, T				Kimura, Y; Furuhata, T; Shiratsuchi, T; Nishimori, H; Hirata, K; Nakamura, Y; Tokino, T			GML sensitizes cancer cells to Taxol by induction of apoptosis	ONCOGENE			English	Article						p53; gml; apoptosis; chemosensitivity	ANTICANCER AGENTS; THYMOCYTE APOPTOSIS; OVARIAN-CANCER; P53; CYTOTOXICITY; EXPRESSION; RADIATION; INCREASE; DRUG	Recently we identified a novel gene, gml, whose expression is regulated in a p53-dependent manner and found that gml expression was correlated with the sensitivity of esophageal cancer cells to anticancer drugs. To further investigate the biological mechanism of gml in determining the chemosensitivity of cancer cells to clinically useful agents, we introduced gml cDNA into TE10, an esophageal cancer cell line that lacks endogenous gml expression. In two resulting stable cell lines which expressed gml cDNA in the absence of wild-type p53, cell death occurred within 6 h after treatment with Taxol. TE10 parent cells or TE10 cells transfected with vector alone displayed relative resistance for 36 h. Induction of gml did not by itself affect viability. Morphological analysis confirmed that the increased chemosensitivity to Taxol conferred by gml was due to apoptosis. These data suggest that reduced expression of gml is likely to be associated with poor response rates to chemotherapy, and that an assay for gml expression might serve a clinical purpose as a predictor of chemotherapeutic sensitivity.	SAPPORO MED UNIV,DEPT SURG 1,SAPPORO,HOKKAIDO,JAPAN	Sapporo Medical University	Kimura, Y (corresponding author), UNIV TOKYO,INST MED SCI,MOL MED LAB,4-6-1 SHIROKANEDAI,TOKYO,JAPAN.		Tokino, Takashi/AAI-9887-2021	Kimura, Yasutoshi/0000-0002-7790-9250				CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Delia D, 1996, NAT MED, V2, P724, DOI 10.1038/nm0796-724; DONALDSON KL, 1994, INT J CANCER, V57, P847, DOI 10.1002/ijc.2910570614; Furuhata T, 1996, ONCOGENE, V13, P1965; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREGORY RE, 1993, CLIN PHARMACY, V12, P401; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SIRE EAG, 1995, ANN ONCOL, V6, P589, DOI 10.1093/oxfordjournals.annonc.a059249; SLICHENMYER WJ, 1991, ANTI-CANCER DRUG, V2, P519, DOI 10.1097/00001813-199112000-00002; TISHLER RB, 1995, CANCER RES, V55, P6021; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Wu GS, 1996, NAT MED, V2, P255, DOI 10.1038/nm0396-255a; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	18	16	17	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1369	1374		10.1038/sj.onc.1201255	http://dx.doi.org/10.1038/sj.onc.1201255			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315106				2022-12-17	WOS:A1997XV84500016
J	Porcellini, A; Ruggiano, G; Pannain, S; Ciullo, I; Amabile, G; Fenzi, G; Avvedimento, EV				Porcellini, A; Ruggiano, G; Pannain, S; Ciullo, I; Amabile, G; Fenzi, G; Avvedimento, EV			Mutations of thyrotropin receptor isolated from thyroid autonomous functioning adenomas confer TSH-independent growth to thyroid cells	ONCOGENE			English	Article						thyrotropin receptor; mutations; cAMP signaling; neoplasm, genetics	SOMATIC MUTATIONS; THYROGLOBULIN GENE; FRTL5 CELLS; EXPRESSION; ADENOSINE-3',5'-MONOPHOSPHATE; ACTIVATION; TRANSFORMATION; IDENTIFICATION; CLONING; HORMONE	TSH receptor mutants in the VI transmembrane segment, found in thyroid autonomously functioning adeonomas, have been expressed in differentiated thyroid cells, All mutant receptors constitutively stimulated adenylyl cyclase, The biological activity, measured as cAMP production relative to the wild type receptor, was specific for each mutant in transient and stable transfection assays. Cells expressing these mutants proliferated in the absence of TSH, The rate of growth in the absence of TSH paralleled basal cAMP production for each mutant receptor, Low TSH concentrations stimulated of mutant receptor-expressing growth of the cells expressing the wild type receptor, Also, the entry in the cell cycle and the plating efficiency were markedly stimulated by the expression of the mutant receptors, These data provide a molecular link between the occurrence of TSH receptor mutations and thyroid autonomously functioning adenomas.	UNIV REGGIO CALABRIA,FAC MED,DIPARTIMENTO MED SPERIMENTALE,I-88100 CATANZARO,ITALY; FDN G PASCALE,SERV ONCOL SPERIMENTALE E,IST NAZL TUMORI,I-80131 NAPLES,ITALY; UNIV NAPLES FEDERICO II,FAC MED,CTR ENDOCRINOL & ONCOL SPERIMENTALE,I-80131 NAPLES,ITALY; UNIV NAPLES FEDERICO II,FAC MED,DIPARTIMENTO BIOL & PATOL MOL & CELLULARE L CALIF,I-80131 NAPLES,ITALY; UNIV NAPLES FEDERICO II,FAC MED,DEPT ENDOCRINOL,I-80131 NAPLES,ITALY	Universita Mediterranea di Reggio Calabria; IRCCS Fondazione Pascale; University of Naples Federico II; University of Naples Federico II; University of Naples Federico II			Porcellini, Antonio/AAC-6097-2019; Porcellini, Antonio/E-1900-2011	Porcellini, Antonio/0000-0001-6882-9518				AKAMIZU T, 1990, P NATL ACAD SCI USA, V87, P5677, DOI 10.1073/pnas.87.15.5677; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; AVVEDIMENTO EV, 1989, CELL, V58, P1135, DOI 10.1016/0092-8674(89)90511-4; AVVEDIMENTO VE, 1984, BIOCHEM BIOPH RES CO, V122, P472; AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; AVVEDIMENTO VE, 1988, P NATL ACAD SCI USA, V85, P1744, DOI 10.1073/pnas.85.6.1744; BIDEY SP, 1988, J ENDOCRINOL, V119, P365, DOI 10.1677/joe.0.1190365; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; JIN S, 1986, ENDOCRINOLOGY, V119, P802, DOI 10.1210/endo-119-2-802; KOPP P, 1995, NEW ENGL J MED, V332, P150, DOI 10.1056/NEJM199501193320304; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAENHAUT C, 1991, BIOCHIMIE, V73, P29, DOI 10.1016/0300-9084(91)90070-H; OSULLIVAN C, 1991, MOL CARCINOGEN, V4, P345, DOI 10.1002/mc.2940040503; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PASCHKE R, 1994, J CLIN ENDOCR METAB, V79, P1785, DOI 10.1210/jc.79.6.1785; PORCELLINI A, 1995, ONCOGENE, V11, P1089; PORCELLINI A, 1994, J CLIN ENDOCR METAB, V79, P567; SAJI M, 1992, ENDOCRINOLOGY, V130, P520, DOI 10.1210/en.130.1.520; Sambrook J, 1989, MOL CLONING LAB MANU; SETTE C, 1994, J BIOL CHEM, V269, P9245; SUAREZ HG, 1991, ONCOGENE, V6, P677; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P127, DOI 10.1210/endo-122-1-127; TRAMONTANO D, 1986, ENDOCRINOLOGY, V118, P1945, DOI 10.1210/endo-118-5-1945; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1099, DOI 10.1210/endo-114-4-1099	32	16	16	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					781	789		10.1038/sj.onc.1201240	http://dx.doi.org/10.1038/sj.onc.1201240			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266964				2022-12-17	WOS:A1997XQ11700004
J	Ganter, B; Lipsick, JS				Ganter, B; Lipsick, JS			Myb binding sites within the N-ras promoter repress transcription	ONCOGENE			English	Article						Myb; N-ras; promoter; transcription	AVIAN-MYELOBLASTOSIS VIRUS; AMINO-TERMINAL REGION; C-MYB; DNA-BINDING; V-MYB; MAMMALIAN-CELLS; TRANSFORMING GENES; SARCOMA-VIRUSES; RECEPTOR GENE; HUMAN BLADDER	In vitro and in vivo methods were combined to determine the function of the three Myb binding sites (NrasI, NrasII and NrasIII) within the promoter region of the mouse N-ras gene. We found that the c-Myb DNA-binding domain can bind with high affinity to NrasI and NrasII, but with a reduced affinity to NrasIII: In contrast, the full length v-Myb protein from BM2 cells only bound to the middle one of the three sites, NrasII. Both c-Myb and v-Myb functioned as repressors and reduce the basal activity of the N-ras promoter by 60%, as determined by transient transfection experiments using different regions of the N-ras promoter. This repression required a functional Myb DNA-binding domain and could not be overcome by fusion to the potent VP16 activation domain. In electrophoretic mobility shift assays, the v-Myb protein is shown to be present in different conformations depending on its binding to the NrasII or the mim-1A site. The v-Myb conformation is thus suggested to play a critical role in the regulation of v-Myb activity.	STANFORD UNIV,SCH MED,DEPT PATHOL,STANFORD,CA 94305	Stanford University					NCI NIH HHS [R01 CA43592] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043592] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; AUSUBEL FM, 1987, CURR PROTO MOL BIOL; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOHRMANN D, 1987, NATURE, V325, P268; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; DONIGER J, 1988, NUCLEIC ACIDS RES, V16, P969, DOI 10.1093/nar/16.3.969; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; GARCIA A, 1991, ONCOGENE, V6, P265; GEROSA MA, 1989, J NATL CANCER I, V81, P63, DOI 10.1093/jnci/81.1.63; GUERRERO I, 1986, J CELL PHYSIOL, V129, P71, DOI 10.1002/jcp.1041290111; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INOUE T, 1994, J BIOL CHEM, V269, P32451; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; JEFFERS M, 1994, BBA-GENE STRUCT EXPR, V1219, P623, DOI 10.1016/0167-4781(94)90221-6; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KU DH, 1993, J BIOL CHEM, V268, P2255; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; Lipsick JS, 1996, ONCOGENE, V13, P223; MELOTTI P, 1994, J EXP MED, V179, P1023, DOI 10.1084/jem.179.3.1023; MIZUGUCHI G, 1995, J BIOL CHEM, V270, P9384, DOI 10.1074/jbc.270.16.9384; MOSCOVICI C, 1982, EXPRESSION DIFFERENT, P325; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; PACIUCCI R, 1991, MOL CELL BIOL, V11, P1334, DOI 10.1128/MCB.11.3.1334; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sambrook J, 1989, J SAMBROOK MOL CLONI; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; THORN JT, 1991, ONCOGENE, V6, P1843; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; YAMAMOTO K, 1993, JPN J CANCER RES, V84, P1136, DOI 10.1111/j.1349-7006.1993.tb02813.x	56	16	18	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 10	1997	15	2					193	202		10.1038/sj.onc.1201173	http://dx.doi.org/10.1038/sj.onc.1201173			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244354				2022-12-17	WOS:A1997XK37200007
J	BalcerKubiczek, EK; Meltzer, SJ; Han, LH; Zhang, XF; Shi, ZM; Harrison, GH; Abraham, JM				BalcerKubiczek, EK; Meltzer, SJ; Han, LH; Zhang, XF; Shi, ZM; Harrison, GH; Abraham, JM			Csa-19, a radiation-responsive human gene, identified by an unbiased two-gel cDNA library screening method in human cancer cells	ONCOGENE			English	Article						Csa-19; X-ray; fission neutron; gene transcription; DNA damage; signal transduction	PROTEIN-KINASE-C; CARDIAC ACTIN GENE; IONIZING-RADIATION; MESSENGER-RNA; CYCLOSPORINE-A; LEUKEMIA-CELLS; INDUCTION; ACTIVATION; EXPOSURE; APOPTOSIS	A novel polymerase chain reaction (PCR)-based method was used to identify candidate genes whose expression is altered in cancer cells by ionizing radiation, Transcriptional induction of randomly selected genes in control versus irradiated human HL60 cells was compared, Among several complementary DNA (cDNA) clones recovered by this approach, one cDNA clone (CL68-5) was downregulated in X-irradiated HL60 cells but unaffected by 12-O-tetradecanoyl phorbol-13-atetate, forskolin, or cyclosporin-A. DNA sequencing of the CL68-5 cDNA revealed 100% nucleotide sequence homology to the reported human Csa-19 gene, Northern blot analysis of RNA from control and irradiated cells revealed the expression of a single 0.7-kilobase (kb) messenger RNA (mRNA) transcript, This 0.7-kb Csa-19 mRNA transcript was also expressed in a variety of human adult and corresponding fetal normal tissues, Moreover, when the effect of X- or fission neutron-irradiation on Csa-19 mRNA was compared in cultured human cells differing in p53 gene status (p53(-/-) ver sus p53(+/+)), downregulation of Csa-19 by X-rays or fission neutrons was similar in p53-wild type and p53-null cell lines, Our results provide the first known example of a radiation-responsive gene in human cancer cells whose expression is not-associated with p53, adenylate cyclase or protein kinase C.	UNIV MARYLAND,DEPT MED,DIV GASTROENTEROL,SCH MED,BALTIMORE,MD 21201; UNIV MARYLAND,VET AFFAIRS HOSP,BALTIMORE,MD 21201; UNIV MARYLAND,GRAD SCH,PROGRAM MOL & CELL BIOL,BALTIMORE,MD 21201; UNIV MARYLAND,CTR CANC,PROGRAM ONCOL,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	BalcerKubiczek, EK (corresponding author), UNIV MARYLAND,DEPT RADIAT ONCOL,DIV RADIAT RES,BALTIMORE,MD 21201, USA.				NATIONAL CANCER INSTITUTE [R01CA067497] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047717] Funding Source: NIH RePORTER; NCI NIH HHS [CA67497] Funding Source: Medline; NIDDK NIH HHS [DK47717] Funding Source: Medline; NIEHS NIH HHS [ES07120] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABEND M, 1995, INT J RADIAT BIOL, V67, P315, DOI 10.1080/09553009514550371; Abraham JM, 1996, CELL GROWTH DIFFER, V7, P855; BAE IS, 1995, CANCER RES, V55, P2387; BalcerKubiczek EK, 1996, ENVIRON HEALTH PERSP, V104, P1188, DOI 10.2307/3432912; BALCERKUBICZEK EK, 1995, RADIAT RES, V142, P256, DOI 10.2307/3579133; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COHEN P, 1985, CURR TOP CELL REGUL, V17, P23; COLLEDGE WH, 1990, BIOCHIM BIOPHYS ACTA, V1087, P39, DOI 10.1016/0167-4781(90)90118-L; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; EINAT P, 1990, DIFFERENTIATION, V44, P36, DOI 10.1111/j.1432-0436.1990.tb00534.x; ELDEIRY WS, 1994, CANCER RES, V54, P1169; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FISICARO N, 1995, MOL IMMUNOL, V32, P565, DOI 10.1016/0161-5890(95)00032-A; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FUKS Z, 1993, RADIAT ONCOL INVEST, V1, P81; FUTREAL PA, 1991, NUCLEIC ACIDS RES, V19, P6977, DOI 10.1093/nar/19.24.6977; Hall EJ, 1994, RADIOBIOLOGY RADIOLO, V1994, P153; HARRISON GH, 1997, IN PRESS BIOELECTROC; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOLLANDER MC, 1989, CANCER RES, V49, P1687; Hopcia KL, 1996, RADIAT RES, V145, P315, DOI 10.2307/3578987; HULTSCH T, 1990, J IMMUNOL, V144, P2659; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JUNG M, 1994, CANCER RES, V54, P2541; Kondratyev AD, 1996, CANCER RES, V56, P1498; LEWIN B, 1994, GENES, V5, P271; Makepeace CM, 1996, RADIAT RES, V146, P116, DOI 10.2307/3579405; MANIATIS T, 1982, MOL CLONING LAB MANU, P70; MELTZER SJ, 1994, CANCER RES, V54, P3379; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PRICE BD, 1994, CANCER RES, V54, P896; RAO A, 1995, J LEUKOCYTE BIOL, V57, P536, DOI 10.1002/jlb.57.4.536; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SHENA M, 1996, P NATL ACAD SCI USA, V93, P10614; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; STARZL TE, 1991, TRANSPLANTATION, V51, P67, DOI 10.1097/00007890-199101000-00010; THOMAS MG, 1994, BIOTECHNIQUES, V16, P229; TSANG P, 1995, HUM MOL GENET, V4, P1499, DOI 10.1093/hmg/4.9.1499; WEICHSELBAUM RR, 1991, J NATL CANCER I, V83, P480, DOI 10.1093/jnci/83.7.480; WILSON RE, 1993, ONCOGENE, V8, P3229; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; WRESCHNER DH, 1988, EUR J BIOCHEM, V172, P333, DOI 10.1111/j.1432-1033.1988.tb13891.x; YADANBAKHSH K, 1995, P NATL ACAD SCI USA, V92, P437; Yan J, 1996, INT J RADIAT BIOL, V69, P539, DOI 10.1080/095530096145544; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	49	16	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					3051	3057		10.1038/sj.onc.1201151	http://dx.doi.org/10.1038/sj.onc.1201151			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223668				2022-12-17	WOS:A1997XG10000007
J	Shridhar, V; Rivard, S; Wang, XH; Shridhar, R; Paisley, C; Mullins, C; Beirnat, L; Dugan, M; Sarkar, F; Miller, OJ; Vaitkevicius, VK; Smith, DI				Shridhar, V; Rivard, S; Wang, XH; Shridhar, R; Paisley, C; Mullins, C; Beirnat, L; Dugan, M; Sarkar, F; Miller, OJ; Vaitkevicius, VK; Smith, DI			Mutations in the arginine-rich protein gene (ARP) in pancreatic cancer	ONCOGENE			English	Article						pancreatic adenocarcinoma; ARP gene; recurring mutations	RENAL-CELL CARCINOMA; LUNG-CANCER; ADENOCARCINOMA; CHROMOSOME-3; ALLELOTYPE; DELETION; HETEROZYGOSITY	The ARP gene encodes a highly conserved arginine-rich protein from chromosomal band 3p21.1. At the cytogenetic level this region is frequently deleted in a variety of different solid tumors, although not in pancreatic cancer. We have reported the presence of a specific mutation (ATG(50)-->AGG) or deletion of codon 50 of the ARP gene in different tumor types (Shridhar et al., 1996, 1996a). In the present study, we have observed mutations involving codon 50 in II of 37 pancreatic tumors. The frequency of codon 50 mutation is roughly the same in pancreatic tumors as in the other types of tumors previously examined, In addition, we have detected mutations at codon 51 in multiple PCR subclones in two other pancreatic tumors, Mutations in the ARP gene are thus commonly observed in pancreatic cancer, as web as many other cancers.	WAYNE STATE UNIV,SCH MED,DEPT INTERNAL MED,DIV HEMATOL ONCOL,KARMANOS CANC INST,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,DEPT PATHOL,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,CTR MOL MED & GENET,DETROIT,MI 48201	Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University; Wayne State University					NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [CA48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; GRIFFIN CA, 1995, CANCER RES, V55, P2394; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HAHN SA, 1995, CANCER RES, V55, P4670; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1991, P NATL ACAD SCI USA, V88, P194, DOI 10.1073/pnas.88.1.194; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; MILLER YE, 1989, J CLIN INVEST, V83, P2120, DOI 10.1172/JCI114125; MORITA R, 1991, CANCER RES, V51, P820; MUIRA I, 1990, GENES CHROM CANC, V2, P328; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; SCHRIDHAR R, 1996, CANCER RES, V56, P4475; SCHRIDHAR V, 1996, ONCOGENE, V12, P1931; SEYMOUR AB, 1994, CANCER RES, V54, P2761; Shridhar R, 1996, CANCER RES, V56, P5576; YAMAKAWA K, 1991, CANCER RES, V51, P4707; YOKOYAMA S, 1992, CANCER RES, V52, P873; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	22	16	21	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 8	1997	14	18					2213	2216		10.1038/sj.onc.1201054	http://dx.doi.org/10.1038/sj.onc.1201054			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WX938	9174057				2022-12-17	WOS:A1997WX93800010
J	Defilippi, P; Olivo, C; Tarone, G; Mancini, P; Torrisi, MR; Eva, A				Defilippi, P; Olivo, C; Tarone, G; Mancini, P; Torrisi, MR; Eva, A			Actin cytoskeleton polymerization in Dbl-transformed NIH3T3 fibroblasts is dependent on cell adhesion to specific extracellular matrix proteins	ONCOGENE			English	Article						Dbl; integrins; stress fibers	GUANINE-NUCLEOTIDE EXCHANGE; GTP-BINDING PROTEIN; RHO GENE-PRODUCT; ONCOGENE PRODUCT; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; ESCHERICHIA-COLI; LAMININ RECEPTOR; STRESS FIBERS; INTEGRIN	The Dbl oncogene is the putative exchange factor for two small GTP-binding proteins, RhoA and CDC42 which are involved in the polymerization of actin to produce stress fibers and filopodia, respectively. We report here that Dbl oncogene-transformed NIH3T3 cells show actin stress fibers only when cells are plated on fibronectin, Plating of cells on collagen I and IV as well as on poly-D-lysine and gelatin induces polymerization of actin to form filopodia, lamellipodia and membrane ruffles but not stress fibers, The putative collagen receptors, alpha 1/beta 1 and alpha 2/beta 1 integrins are expressed at reduced level in Dbl-transformed cells compared to untransformed NIH3T3 fibroblasts, Nevertheless, adhesion to collagens is not altered, Inhibitory monoclonal antibody to mouse integrin beta 1 subunit blocked adhesion of both Dbl-transformed and untransformed NIH3T3 cells, demonstrating that adhesion to collagen I and TV is mediated by the beta 1 family of integrins. Dbl product rapidly induces the depolymerization of actin stress fibers, rounding up of the cells, and formation of filopodia and lamellipodia when microinjected in NIH3T3 cells plated on gelatin, Thus, Dbl may exert its effect on actin cytoskeleton organization in response to extracellular proteins by altering integrin-mediated signalling pathways.	IST GIANNINA GASLINI,MOL BIOL LAB,I-16148 GENOA,ITALY; UNIV ROMA LA SAPIENZA,DIPARTIMENT MED SPERIMENTALE & PATOL,I-00161 ROME,ITALY; UNIV ROMA LA SAPIENZA,DIPARTIMENTO PSICOL,I-00161 ROME,ITALY; UNIV TURIN,DIPARTIMENTO GENET BIOL & CHIM MED,I-10126 TURIN,ITALY	University of Genoa; IRCCS Istituto Giannina Gaslini; Sapienza University Rome; Sapienza University Rome; University of Turin			Eva, Alessandra/J-8268-2016; DEFILIPPI, Paola/L-2232-2014	Eva, Alessandra/0000-0003-2949-078X; Tarone, Guido/0000-0003-4805-086X; Defilippi, Paola/0000-0001-6427-4906; mancini, patrizia/0000-0003-0556-2056	NCI NIH HHS [CA63111] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA063111] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; DEFILIPPI P, 1991, J CELL BIOL, V114, P855, DOI 10.1083/jcb.114.4.855; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; GEHLSEN KR, 1988, SCIENCE, V241, P1228, DOI 10.1126/science.2970671; GRAZIANI G, 1989, ONCOGENE, V4, P823; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNATIUS MJ, 1988, NEURON, V1, P713, DOI 10.1016/0896-6273(88)90170-5; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KOLAND JG, 1990, BIOCHEM BIOPH RES CO, V166, P90, DOI 10.1016/0006-291X(90)91915-F; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KRAMER RH, 1989, J BIOL CHEM, V264, P4686; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RON D, 1991, NEW BIOL, V3, P372; RON D, 1989, ONCOGENE, V4, P1067; ROSSINO P, 1991, CELL REGUL, V2, P1021, DOI 10.1091/mbc.2.12.1021; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; TARONE G, 1982, J CELL BIOL, V94, P179, DOI 10.1083/jcb.94.1.179; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; ZANGRILLI D, 1995, METHOD ENZYMOL, V256, P347; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	40	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 24	1997	14	16					1933	1943		10.1038/sj.onc.1201027	http://dx.doi.org/10.1038/sj.onc.1201027			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WV804	9150360				2022-12-17	WOS:A1997WV80400006
J	Carrozza, ML; Jacobs, H; Acton, D; Verma, I; Berns, A				Carrozza, ML; Jacobs, H; Acton, D; Verma, I; Berns, A			Overexpression of the FosB2 gene in thymocytes causes aberrant development of T cells and thymic epithelial cells	ONCOGENE			English	Article						oncogene; thymus; development	C-FOS; TRANSGENIC MICE; PROTO-ONCOGENE; STEM-CELLS; JUN; TRANSCRIPTION; DIFFERENTIATION; ACTIVATION; EXPRESSION; INTERACTS	We have examined the role of the AP-1 transcription factor on thymocyte maturation and thymus architecture by overexpressing FosB2 in transgenic mice. FosB2 is a naturally occurring splice variant of the FosB2 gene, encoding a truncated protein which lacks two domains necessary for transcriptional activation. The expression of FosB2 in the thymocytes severely affected their maturation and the structure of the whole thymus: the phenotype developed slowly during the first months of life, resulting in a progressive expansion of the medulla and concomitant reduction of the cortex. CD4(+) thymocytes represented the major thymocyte population, whereas the CD4(+)8(+) thymocytes were virtually absent. This phenotype appeared to be an intrinsic property of bone marrow derived cells, as it could be reproduced in bone marrow chimaeric mice, This pathology was very reminiscent to that observed in mice overexpressing c-Fos in thymic epithelium: also in that case the thymus underwent with age a progressive expansion of the epithelium and major changes in the ratio of thymocyte subsets, but the phenotype appeared to be an intrinsic property of the epithelial cells since it could not be reproduced by transgenic bone marrow transplantation. We speculate that both overexpression of FosB2 in thymocytes and overexpression of c-Fos in thymic epithelium results in aberrant signaling between thymocytes and stroma, that ultimately alters the thymic micromilieu, leading to this severe pathology.	NETHERLANDS CANC INST, DIV MOL GENET, NL-1066 CX AMSTERDAM, NETHERLANDS; SALK INST BIOL STUDIES, LA JOLLA, CA 92037 USA	Netherlands Cancer Institute; Salk Institute				Jacobs, Heinz/0000-0001-6227-9850				BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BOYD RL, 1991, IMMUNOL TODAY, V12, P71, DOI 10.1016/0167-5699(91)90161-L; BOYD RL, 1993, IMMUNOL TODAY, V14, P445, DOI 10.1016/0167-5699(93)90248-J; COUTURE C, 1992, EUR J IMMUNOL, V22, P2579, DOI 10.1002/eji.1830221017; CRISPE IN, 1987, NATURE, V329, P336, DOI 10.1038/329336a0; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207, DOI 10.1016/S0065-2776(08)60643-4; GALY AHM, 1992, J IMMUNOL, V149, P775; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; KRIMPENFORT P, 1988, EMBO J, V7, P745, DOI 10.1002/j.1460-2075.1988.tb02871.x; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; METZ R, 1994, EMBO J, V13, P3832, DOI 10.1002/j.1460-2075.1994.tb06694.x; MORGAN JI, 1991, REV NEUROSCI, V14, P421; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; MULLER R, 1985, BIOCHIM BIOPHYS ACTA, V823, P207; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; OKADA S, 1994, MOL CELL BIOL, V14, P382, DOI 10.1128/MCB.14.1.382; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; RAMARLI D, 1987, P NATL ACAD SCI USA, V84, P8598, DOI 10.1073/pnas.84.23.8598; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RITTER MA, 1993, IMMUNOL TODAY, V14, P462, DOI 10.1016/0167-5699(93)90250-O; RUTHER U, 1988, CELL, V53, P847, DOI 10.1016/S0092-8674(88)90289-9; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHORES EW, 1991, EUR J IMMUNOL, V21, P1657, DOI 10.1002/eji.1830210711; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SURH CD, 1992, J EXP MED, V176, P495, DOI 10.1084/jem.176.2.495; VANEWIJK W, 1994, IMMUNOL TODAY, V15, P214, DOI 10.1016/0167-5699(94)90246-1; VUKMANOVIC S, 1992, NATURE, V359, P729, DOI 10.1038/359729a0; WISDOM R, 1992, GENE DEV, V6, P667, DOI 10.1101/gad.6.4.667; WOLF SS, 1992, IMMUNOLOGY, V77, P362; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZUGIC JN, 1991, IMMUNOL TODAY, V12, P65	39	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	1997	14	9					1083	1091		10.1038/sj.onc.1200921	http://dx.doi.org/10.1038/sj.onc.1200921			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070657				2022-12-17	WOS:A1997WM07000010
J	Leonardsen, L; DeClue, JE; Lybaek, H; Lowy, DR; Willumsen, BM				Leonardsen, L; DeClue, JE; Lybaek, H; Lowy, DR; Willumsen, BM			Rasp21 sequences opposite the nucleotide binding pocket are required for GRF-mediated nucleotide release	ONCOGENE			English	Article						Rasp21-mutants; GRF; GNEF; Ras-loop 7; nucleotide-exchange	MURINE SARCOMA-VIRUS; GTPASE-ACTIVATING PROTEIN; SWITCH-II REGION; GUANINE-NUCLEOTIDE; SACCHAROMYCES-CEREVISIAE; EXCHANGE FACTOR; CATALYTIC DOMAIN; SIGNAL TRANSDUCTION; TERMINAL DOMAIN; TYROSINE KINASE	The substrate requirements for the catalytic activity of the mouse Cdc25 homolog Guanine nucleotide Release Factor, GRF, were determined using the catalytic domain of GRF expressed in insect cells and E. coli expressed H-Ras mutants. We found a requirement for the loop 7 residues in Ras (amino acids 102 to 105) for stimulation of guanine nucleotide release. The dependence on the switch I and II regions of Rasp21 (encompassing the residues that shift position in the GTP- versus GDP-bound protein), which had been seen with Sdc25-mediated exchange, was also found for GRF. In addition, the sensitivity of H-Ras to GRF was abolished when residues 130-139 were replaced by proline-aspartic acid-glutamine, whereas substitution of the entire loop 8 (residues 123-130 replaced by leucine-isoleucine-arginine) had no effect on the stimulation of guanine nucleotide release by GRF. Substrate activity of Ras proteins were independent of their post-translational processing, GDP release was stimulated threefold more effectively by GRF than was GTP release, and no major differences were found between the mammalian N-, H- and K-Ras proteins. Examining the responsiveness of the Ras protein from S. pombe and the human Ras like proteins RhoA, Rap1A, Rad and G25K revealed a strict Ras specificity; of these only S. pombe Ras was GRF sensitive.	UNIV COPENHAGEN, DEPT MOL CELL BIOL, DK-1353 COPENHAGEN, DENMARK; NCI, CELLULAR ONCOL LAB, BETHESDA, MD 20892 USA	University of Copenhagen; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Willumsen, Berthe M/H-1903-2012	Willumsen, Berthe M/0000-0002-2277-6999				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEVALLIERMULTON MC, 1993, J BIOL CHEM, V268, P11113; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DECLUE JE, 1991, MOL CELL BIOL, V11, P3132, DOI 10.1128/MCB.11.6.3132; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DHAR R, 1982, SCIENCE, V217, P934, DOI 10.1126/science.6287572; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; HANEY SA, 1994, J BIOL CHEM, V269, P16541; HOWE LR, 1993, ONCOGENE, V8, P2583; HWANG YW, 1993, J BIOL CHEM, V268, P24692; JACQUET E, 1992, J BIOL CHEM, V267, P24181; JACQUET E, 1995, BIOCHEMISTRY-US, V34, P12347, DOI 10.1021/bi00038a031; JACQUET E, 1994, BIOCHEM BIOPH RES CO, V199, P497, DOI 10.1006/bbrc.1994.1256; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; LACAL JC, 1986, MOL CELL BIOL, V6, P4214, DOI 10.1128/MCB.6.12.4214; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MIRISOLA MG, 1994, J BIOL CHEM, V269, P15740; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MOODIE SA, 1995, ONCOGENE, V11, P447; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; PAGE MJ, 1989, J BIOL CHEM, V264, P19147; PAPAGEORGE AG, 1989, J VIROL, V44, P509; POULLET P, 1995, EUR J BIOCHEM, V227, P537, DOI 10.1111/j.1432-1033.1995.tb20421.x; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; REDDY EP, 1985, J VIROL, V53, P984, DOI 10.1128/JVI.53.3.984-987.1985; RUTA M, 1986, MOL CELL BIOL, V6, P1706, DOI 10.1128/MCB.6.5.1706; SEGAL M, 1995, EUR J BIOCHEM, V228, P96, DOI 10.1111/j.1432-1033.1995.tb20235.x; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; STONE JC, 1988, MOL CELL BIOL, V8, P3565, DOI 10.1128/MCB.8.8.3565; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VELU TJ, 1989, J VIROL, V63, P1384, DOI 10.1128/JVI.63.3.1384-1392.1989; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; WANG XZ, 1991, GENE, V100, P131, DOI 10.1016/0378-1119(91)90358-I; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; WILLUMSEN BM, 1989, NATO ADV SCI I A-LIF, V165, P165; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILLUMSEN BM, 1991, MOL CELL BIOL, V11, P6026, DOI 10.1128/MCB.11.12.6026; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WILLUMSEN BM, 1995, METHOD ENZYMOL, V250, P269	54	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2177	2187						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950985				2022-12-17	WOS:A1996VV14500015
J	Kumar, A; Toscani, A; Rane, S; Reddy, EP				Kumar, A; Toscani, A; Rane, S; Reddy, EP			Structural organization and chromosomal mapping of JAK3 locus	ONCOGENE			English	Article						JAK3 genomic sequence; chromosome 19; intron exon organization	PROTEIN-TYROSINE KINASE; GAMMA SIGNAL-TRANSDUCTION; MICE LACKING JAK3; INSITU HYBRIDIZATION; TRANSCRIPTION FACTOR; LYMPHOID DEVELOPMENT; RECEPTOR; ACTIVATION; CELLS; PHOSPHORYLATION	In this study, we have isolated the genomic DNA clone encoding the murine JAK3 gene and determined its sequence. Partial genomic clones of the JAK1 and JAK2 genes encoding the tyrosine kinase domain were also isolated and compared with JAK3. The genomic structure of JAK3 consists of 23 exons. The exon/intron boundaries and the distribution of coding sequences within the exons of each of the three JAK genes were found to follow a similar pattern suggesting that various members of the JAK family have originated from a single primordial gene by duplication and the structure has been closely maintained through evolution. Using in situ hybridization and FISH analysis, we have mapped the JAK3 gene to human chromosome 19p13.1-p13.2.	TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOL BIOL, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NCI NIH HHS [CA68239] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068239] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; HARPUR AG, 1992, ONCOGENE, V7, P1347; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HENG HHQ, 1994, HUM MOL GENET, V3, P61, DOI 10.1093/hmg/3.1.61; HUNTER T, 1993, NATURE, V366, P114, DOI 10.1038/366114a0; INOUE M, 1991, P NATL ACAD SCI USA, V88, P2278, DOI 10.1073/pnas.88.6.2278; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kono DH, 1996, MAMM GENOME, V7, P476, DOI 10.1007/s003359900145; LAI KS, 1995, J BIOL CHEM, V270, P25028, DOI 10.1074/jbc.270.42.25028; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MUSSO T, 1995, J EXP MED, V181, P1425, DOI 10.1084/jem.181.4.1425; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.biochem.55.1.1119; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; RANE SG, 1994, ONCOGENE, V9, P2415; RUI H, 1994, J BIOL CHEM, V269, P5364; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLINDER C, 1995, ANNU REV BIOCHEM, V64, P621; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	32	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	1996	13	9					2009	2014						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934548				2022-12-17	WOS:A1996VR79500021
J	Martincic, D; Whitlock, JA				Martincic, D; Whitlock, JA			Improved detection of p53 point mutations by dideoxyfingerprinting (ddF)	ONCOGENE			English	Article						p53; point mutations; single strand conformational polymorphism; dideoxyfingerprinting	SINGLE BASE SUBSTITUTIONS; CONFORMATION POLYMORPHISM ANALYSIS; POTENTIAL GROWTH-REGULATORS; POLYMERASE CHAIN-REACTION; AUTOCRINE HYPOTHESIS; MALIGNANT GLIOMAS; SENSITIVE METHOD; GENOMIC DNA; PCR-SSCP; GENE	Two screening techniques for identifying point mutations (single-strand conformational polymorphism (SSCP) and dideoxyfingerprinting (ddF)) were compared to sequencing to determine their efficiency in detecting mutations in exons 5-8 of the p53 tumor suppressor gene. Twelve human glioblastoma cell Lines were studied by each of the three methods, Ten mutations were identified by sequencing; of these, 10/10 were detected by ddF, while SSCP detected 6/10 true mutations and falsely identified two presumed mutations not confirmed by sequencing. We examined the impact of parameters which influence DNA conformation (gel temperature, gel composition, and PCR product size) on the ability of SSCP and ddF to detect mutations. The sensitivity of SSCP varied with both gel temperature and the size of the PCR product; in contrast, ddF was not influenced by either gel temperature or product length (up to 460 nucleotides), We conclude that the increased sensitivity of ddF, together with its greater ease of application due to the lack of need for optimization, provides significant advantages over SSCP in screening DNA sequences for the presence of point mutations, Our results also suggest that the incidence of p53 mutations may be underestimated in studies of human cancers which utilize SSCP as the method of mutational screening.	VANDERBILT UNIV,SCH MED,DEPT PEDIAT,DIV PEDIAT HEMATOL ONCOL,NASHVILLE,TN 37232	Vanderbilt University				Whitlock, James/0000-0002-7887-0634	NICHD NIH HHS [HD28819] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028819] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BLAZYK H, 1995, BIOTECHNIQUES, V18, P256; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; FEARON ER, 1992, FASEB J, V6, P2783, DOI 10.1096/fasebj.6.10.1321771; FRANKEL RH, 1992, CANCER RES, V52, P1427; FULTS D, 1992, CANCER RES, V52, P674; GLAVAC D, 1993, HUM MUTAT, V2, P404, DOI 10.1002/humu.1380020513; GROMPE M, 1993, NAT GENET, V5, P111, DOI 10.1038/ng1093-111; HAYASHI K, 1993, HUM MUTAT, V2, P338, DOI 10.1002/humu.1380020503; Hayashi K, 1991, PCR Methods Appl, V1, P34; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HONGYO T, 1993, NUCLEIC ACIDS RES, V21, P3637, DOI 10.1093/nar/21.16.3637; JENNINGS MT, 1991, INT J CANCER, V49, P129, DOI 10.1002/ijc.2910490124; JENNINGS MT, 1994, HUM PATHOL, V25, P464, DOI 10.1016/0046-8177(94)90118-X; Latchman DS, 1996, NEW ENGL J MED, V334, P28, DOI 10.1056/NEJM199601043340108; LIU Q, 1995, BIOTECHNIQUES, V18, P470; Liu Q, 1994, PCR Methods Appl, V4, P97; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MOHABEER AJ, 1991, NUCLEIC ACIDS RES, V19, P3154, DOI 10.1093/nar/19.11.3154; MYERS RM, 1985, NATURE, V313, P495, DOI 10.1038/313495a0; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1992, NUCLEIC ACIDS RES, V20, P871, DOI 10.1093/nar/20.4.871; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; Scriver C.R., 1995, METABOLIC MOL BASES, P1; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; Sjogren S, 1996, J NATL CANCER I, V88, P173, DOI 10.1093/jnci/88.3-4.173; STRAUSS WM, 1991, CURRENT PROTOCOLS MO; VIDALPUIG A, 1994, BIOTECHNIQUES, V17, P490; VONDEIMLING A, 1992, CANCER RES, V52, P2987; WHITE MB, 1992, GENOMICS, V12, P301, DOI 10.1016/0888-7543(92)90377-5	33	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					2039	2044						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934553				2022-12-17	WOS:A1996VR79500026
J	Chen, Y; Knudsen, ES; Wang, JYJ				Chen, Y; Knudsen, ES; Wang, JYJ			The RB/p107/p130 phosphorylation pathway is not inhibited in rapamycin-induced G(1)-prolongation of NIH3T3 cells	ONCOGENE			English	Article						cdk2; cyclin A; cyclin E; p27(kip1)	ABL TYROSINE KINASE; HUMAN CYCLIN-E; S-PHASE ENTRY; RETINOBLASTOMA PROTEIN; MAMMALIAN FIBROBLASTS; GROWTH SUPPRESSION; TGF-BETA; EXPRESSION; G(1); ARREST	The immunosuppressant rapamycin has previously been shown to inhibit G(1)/S transition in several cell types. In Swiss-3T3 cells, rapamycin prolongs G(1) through the inhibition of the S6-kinase. In T-lymphocytes, rapamycin blocks the mitogen-induced down regulation of p27(Kip1), an inhibitor of the cdk/cyclin complexes. We show here that an NIH3T3 line (N-3T3) is also sensitive to the G(1)/S inhibitory effect of rapamycin. Unlike lymphocytes, rapamycin does not affect p27(Kip1) in these immortalized fibroblasts, nor does rapamycin affect the activity of cyclin D- or cyclin E-dependent kinases. As a result, rapamycin does not inhibit the phosphorylation of the retinoblastoma protein (RB) or two RB-related proteins, p107 and p130. Despite the phosphorylation of RB/p107/p130, the expression of cyclin A and its associated kinase activity is delayed in rapamycin-treated N-3T3 cells. Ectopic expression of cyclin A, but not cyclins D and E or E2F-1 and -4, can overcome the effect of rapamycin. Taken together, these results suggest that entry into S-phase is likely to involve rapamycin-sensitive pathways other than the phosphorylation of the pocket proteins.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR GENET MOL,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [R01CA058320] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA058320, CA58320, CA5028] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERS MW, 1993, J BIOL CHEM, V268, P22825; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DOU QP, 1993, CANCER RES, V53, P1493; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUANG TS, 1995, P NATL ACAD SCI USA, V92, P4793, DOI 10.1073/pnas.92.11.4793; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; MARX SO, 1995, CIRC RES, V76, P412, DOI 10.1161/01.RES.76.3.412; MORICE WG, 1993, J BIOL CHEM, V268, P22737; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NAKAMURA T, 1995, EXP CELL RES, V216, P422, DOI 10.1006/excr.1995.1053; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Pines Jonathon, 1994, Seminars in Cell Biology, V5, P399, DOI 10.1006/scel.1994.1047; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x	47	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1765	1771						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895523				2022-12-17	WOS:A1996VM88700022
J	Huang, K; Sommers, CL; Grinberg, A; Kozak, CA; Love, PE				Huang, K; Sommers, CL; Grinberg, A; Kozak, CA; Love, PE			Cloning and characterization of PTP-K1, a novel nonreceptor protein tyrosine phosphatase highly expressed in bone marrow	ONCOGENE			English	Article						protein tyrosine phosphatase; cDNA cloning; signal transduction	NUCLEAR-LOCALIZATION; SIGNAL-TRANSDUCTION; SEQUENCE HOMOLOGY; RICH SEQUENCES; PROLINE-RICH; RECEPTOR; FAMILY; CDNA; IDENTIFICATION; DOMAINS	A novel nonreceptor protein tyrosine phosphatase (PTP), PTP-K1, was identified using a consensus polymerase chain reaction-based approach, The full length cDNA encompasses an open reading frame of 1362 base pairs, predicting a protein of 453 amino acid residues with a molecular mass of 54 kDa, The PTP domain is located in the N-terminal portion of the molecule and shares similar to 50% amino acid identify with two other nonreceptor PTPs: PEP and PTP-PEST, PTP-K1 is preferentially expressed in mouse bone marrow with transcripts of 1.7 kb, 1.9 kb and 3.5 kb, The 1.7 kb transcript was also detected in kidney, lung and ovary, The PTP domain of PTP-K1 was expressed as a fusion protein in bacteria and had intrinsic PTP catalytic activity, Indirect immunofluorescence microscopy in COS-7 cells showed that PTP-K1 was localized to the cytoplasm, Ptp-k1 was mapped to mouse chromosome 1, and was closely linked to the interleukin-1 receptor gene, The high level expression of PTP-K1 mRNA in bone marrow suggests that PTP-K1 may be involved in signal transduction in growth and differentiation of hematopoietic cells.	NICHHD,NIH,LAB MAMMALIAN GENES & DEV,BETHESDA,MD 20892; NIAID,MOL MICROBIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								Adachi M, 1996, CELL, V85, P15; ADAMSON MC, 1991, VIROLOGY, V183, P778, DOI 10.1016/0042-6822(91)91010-E; ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; CHANG HL, 1991, J IMMUNOL, V147, P1687; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; DENHERTOG J, 1992, BIOCHEM BIOPH RES CO, V184, P1241, DOI 10.1016/S0006-291X(05)80015-4; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FLORES E, 1994, MOL CELL BIOL, V14, P4938, DOI 10.1128/MCB.14.7.4938; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; Green EL, 1981, GENETICS PROBABILITY, P77; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HIGASHITSUJI H, 1995, ONCOGENE, V10, P407; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; KOZAK CA, 1994, GENOMICS, V21, P659, DOI 10.1006/geno.1994.1331; KOZAK CA, 1990, GENOMICS, V8, P519, DOI 10.1016/0888-7543(90)90039-W; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MIYASAKA H, 1992, BIOCHEM BIOPH RES CO, V185, P818, DOI 10.1016/0006-291X(92)91700-Z; MIZUNO K, 1993, MOL CELL BIOL, V13, P5513, DOI 10.1128/MCB.13.9.5513; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; MOUREY RJ, 1994, CURR OPIN GENET DEV, V4, P31, DOI 10.1016/0959-437X(94)90088-4; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAGA Y, 1986, P NATL ACAD SCI USA, V83, P6940, DOI 10.1073/pnas.83.18.6940; SCHEPENS J, 1992, MOL BIOL REP, V16, P241, DOI 10.1007/BF00419663; SELDIN MF, 1994, MAMM GENOME, V5, pS1; SOMMERS CL, 1995, ONCOGENE, V11, P245; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TONKS NK, 1992, COLD SPRING HARB SYM, V57, P87, DOI 10.1101/SQB.1992.057.01.012; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; ZANKE B, 1992, EUR J IMMUNOL, V22, P235, DOI 10.1002/eji.1830220134	41	16	19	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1567	1573						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875997				2022-12-17	WOS:A1996VL38400024
J	Konishi, H; Ochiya, T; Yasuda, Y; Sakamoto, H; Muto, T; Sugimura, T; Terada, M				Konishi, H; Ochiya, T; Yasuda, Y; Sakamoto, H; Muto, T; Sugimura, T; Terada, M			HST-1/FGF-4 stimulates proliferation of megakaryocyte progenitors synergistically and promotes megakaryocyte maturation	ONCOGENE			English	Article						FGF-4 (fibroblast growth factor 4); adenovirus-mediated gene transfer; megakaryocytopoiesis; maturation; proliferation	C-KIT LIGAND; BINDING GROWTH-FACTOR; HUMAN BONE-MARROW; TRANSFORMING GENE; FGF RECEPTOR; CELL-LINE; K-FGF; EXPRESSION; INVITRO; HST	Megakaryocyte (MK) development is dependent on the complex interaction of MK progenitors, various cytokines and stromal elements, We previously reported that an injection of replication-deficient adenovirus containing HST-1/FGF-4 cDNA (Adex1HST-1) into mice caused a twofold increase in peripheral platelet count for 30 days without any other hematological or histological abnormality, In the present study using Adex1HST-1-infected human megakaryocytic Dami cells, we demonstrated for the first time that HST-1/FGF-4 promoted MK maturation, inducing increases in DNA ploidy, cytoplasmic and membrane maturation, and platelet-like particle release, Moreover, HST-1/FGF-4 acted on megakaryocytic cells to induce secretion of IL-6 and TNF-alpha, and increased adhesion of megakaryocytic cells to human endothelial cells primarily via VLA-4 and LFA-1 molecules; both mechanisms have been shown to lead to MK maturation, We also showed that HST-1/FGF-4 stimulates the proliferation of MK progenitors not alone but synergistically with IL-3 via IL-6 and with c-mpl ligand (thrombopoietin) not via IL-6, This result supports the hypothesis of the presence of two distinct populations of MK progenitors: IL-3-dependent and Tpo-dependent. All these results suggest that HST-1/FGF-4 can regulate MK development not only as an MK potentiating factor, but also as an inducer of cytokine secretion from MK, and as a modulator of adhesive interations with endothelial cells.	NATL CANC CTR, RES INST, DIV GENET, CHUO KU, TOKYO 104, JAPAN; UNIV TOKYO, SCH MED, DEPT SURG 1, BUNKYO KU, TOKYO 113, JAPAN; INST PASTEUR KYOTO, SAKYO KU, KYOTO 606, JAPAN	National Cancer Center - Japan; University of Tokyo			Ochiya, Takahiro/AAH-7585-2019					ADELAIDE J, 1988, ONCOGENE, V2, P413; AVRAHAM H, 1992, BLOOD, V79, P365; AVRAHAM H, 1992, BLOOD, V80, P1679; AVRAHAM H, 1993, J CLIN INVEST, V91, P2378, DOI 10.1172/JCI116470; AVRAHAM H, 1994, BLOOD, V83, P2126; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BIKFALVI A, 1992, BLOOD, V80, P1905; BLAM SB, 1988, ONCOGENE, V3, P129; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BRANDT JE, 1994, BLOOD, V83, P1507; BRIDDELL RA, 1991, BLOOD, V78, P2854; BROUDY VC, 1995, BLOOD, V85, P1719, DOI 10.1182/blood.V85.7.1719.bloodjournal8571719; BRUNNER G, 1993, BLOOD, V81, P631; BRUNO E, 1993, BLOOD, V82, P430, DOI 10.1182/blood.V82.2.430.bloodjournal822430; BURSTEIN SA, 1992, J CELL PHYSIOL, V153, P305, DOI 10.1002/jcp.1041530210; DEGABRIELE G, 1967, BRIT J HAEMATOL, V13, P202; GONSKY R, 1991, MOL ENDOCRINOL, V5, P1687, DOI 10.1210/mend-5-11-1687; GREENBERG SM, 1988, BLOOD, V72, P1968; GURNEY AL, 1994, SCIENCE, V265, P1445, DOI 10.1126/science.8073287; HOFFMAN R, 1989, BLOOD, V74, P1196; ISHIBASHI T, 1989, P NATL ACAD SCI USA, V86, P5953, DOI 10.1073/pnas.86.15.5953; JACKSON CW, 1973, BLOOD, V42, P413, DOI 10.1182/blood.V42.3.413.413; KATOH O, 1992, BIOCHEM BIOPH RES CO, V183, P83, DOI 10.1016/0006-291X(92)91612-T; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; KAUSHANSKY K, 1995, P NATL ACAD SCI USA, V92, P3234, DOI 10.1073/pnas.92.8.3234; KISHI T, 1994, BIOCHEM BIOPH RES CO, V202, P1387, DOI 10.1006/bbrc.1994.2084; KONISHI H, 1995, J CLIN INVEST, V96, P1125, DOI 10.1172/JCI118099; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; METCALF D, 1992, TRENDS BIOCHEM SCI, V17, P286, DOI 10.1016/0968-0004(92)90436-D; MIYAGAWA K, 1988, ONCOGENE, V3, P383; NAVARRO S, 1991, BLOOD, V77, P461; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; OCHIYA T, 1995, J CELL BIOL, V130, P997, DOI 10.1083/jcb.130.4.997; OGAWA M, 1993, BLOOD, V81, P2844; PAUL CC, 1993, BLOOD, V81, P1193; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; QUARTO N, 1989, ONCOGENE RES, V5, P101; QUESENBERRY PJ, 1991, EXP HEMATOL, V19, P35; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P12368, DOI 10.1073/pnas.91.26.12368; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SUZUKI HR, 1992, DEV BIOL, V150, P219, DOI 10.1016/0012-1606(92)90020-H; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TERAMURA M, 1992, BLOOD, V79, P327; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELCICH A, 1989, ONCOGENE RES, V5, P31; WICKENHAUSER C, 1995, BLOOD, V85, P685, DOI 10.1182/blood.V85.3.685.bloodjournal853685; YANAI N, 1994, BLOOD, V83, P2844, DOI 10.1182/blood.V83.10.2844.2844; YOSHIDA MC, 1988, P NATL ACAD SCI USA, V85, P4861, DOI 10.1073/pnas.85.13.4861; YOSHIDA T, 1991, METHOD ENZYMOL, V198, P124; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V155, P1324, DOI 10.1016/S0006-291X(88)81286-5	54	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	1996	13	1					9	19						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700558				2022-12-17	WOS:A1996UX31900002
J	Lee, JE; Beck, TW; Wojnowski, L; Rapp, UR				Lee, JE; Beck, TW; Wojnowski, L; Rapp, UR			Regulation of A-raf expression	ONCOGENE			English	Article						A-raf; steroid hormones; glucocorticoid receptor; transcription	MAMMARY-TUMOR VIRUS; DNA-BINDING DOMAIN; ESTROGEN-RESPONSIVE ELEMENT; STEROID-HORMONE RECEPTORS; GLUCOCORTICOID RECEPTOR; GENE-EXPRESSION; TRANSCRIPTION FACTORS; MMTV PROMOTER; GROWTH-FACTOR; AMINO-ACIDS	The Raf family proto-oncogenes encode cytoplasmic protein serine/threonine kinases which play a critical role in cell growth and development, A-raf shares several functional properties with Raf-1 including transforming activity, stimulation of the Raf/MAPK pathway and the ability of dominant negative versions to functionally block Ras signalling, A-raf transcripts are predominantly expressed in the mouse urogenital tissues, Interestingly, the human A-raf promoter region contains three potential glucocorticoid response elements GRE-1, GRE-2 and GRE-3, at positions -17, -34 and -168 respectively from the transcriptional start site, DNA sequence analysis of the mouse A-raf promoter region demonstrated that GRE-1 and -2 were conserved evolutionarily, To determine whether the human A-raf GREs represent functional motifs, an expression vector for the glucocorticoid receptor was cotransfected with A-raf promoter/reporter constructs into HeLa cells, A fivefold dexamethasone-dependent induction of A-raf promoter activity was observed using constructs containing all three GRE motifs whereas point mutations in the GREs either diminished or abolished dexamethasone induction, Electrophoretic mobility shift assays (EMSAs) using purified glucocorticoid receptor DNA binding domain (DBD) demonstrated that both GRE-2 and -3 motifs interact with DBD and oligonucleotide competition experiments established that these have different affinities for DBD, Using nuclear extracts from human and rodent cell lines in EMSAs, a specific protein-DNA complex was observed with GRE-1 which displayed binding properties unlike that of glucocorticoid receptor, These results demonstrate that the A-raf promoter is regulated in part by members of the glucocorticoid family of steroid hormone receptors and suggest a model for the regulation of A-raf expression in urogenital tissues.	NCI,FREDERICK CANC RES & DEV CTR,BIOL CARCINOGENESIS & DEV PROGRAM,DYN CORP,PROGRAM RESOURCES,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,VIRAL PATHOL SECT,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick								AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEATO M, 1991, Critical Reviews in Oncogenesis, V2, P195; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; BUETTI E, 1989, NUCLEIC ACIDS RES, V17, P3065, DOI 10.1093/nar/17.8.3065; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; GOWLAND PL, 1989, MOL CELL BIOL, V9, P3999, DOI 10.1128/MCB.9.9.3999; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; LANGER SJ, 1988, MOL CELL BIOL, V8, P3872, DOI 10.1128/MCB.8.9.3872; LEE JE, 1994, GENOMICS, V20, P43, DOI 10.1006/geno.1994.1125; LU XY, 1994, EMBO J, V13, P2592, DOI 10.1002/j.1460-2075.1994.tb06549.x; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MAGNUSON NS, 1994, SEMIN CANCER BIOL, V5, P247; MIKSICEK R, 1987, EMBO J, V6, P1355, DOI 10.1002/j.1460-2075.1987.tb02375.x; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; MORLEY KL, 1987, NUCLEIC ACIDS RES, V15, P6973, DOI 10.1093/nar/15.17.6973; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NOWOCK J, 1985, NUCLEIC ACIDS RES, V13, P2045, DOI 10.1093/nar/13.6.2045; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; RAPP UR, 1991, ONCOGENE, V6, P495; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SLATER EP, 1990, MOL ENDOCRINOL, V4, P604, DOI 10.1210/mend-4-4-604; STORM SM, 1990, ONCOGENE, V5, P345; TOOHEY MG, 1990, J VIROL, V64, P4477, DOI 10.1128/JVI.64.9.4477-4488.1990; TRUSS M, 1992, J STEROID BIOCHEM, V43, P365, DOI 10.1016/0960-0760(92)90071-P; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WADEWITZ AG, 1993, ONCOGENE, V8, P1055; WINER MA, 1993, MOL REPROD DEV, V35, P16, DOI 10.1002/mrd.1080350104	41	16	18	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1669	1677						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622887				2022-12-17	WOS:A1996UG45800009
J	Helftenbein, G; Krusekopf, K; Just, U; Cross, M; Ostertag, W; Niemann, H; Tamura, T				Helftenbein, G; Krusekopf, K; Just, U; Cross, M; Ostertag, W; Niemann, H; Tamura, T			Transcriptional regulation of the c-fms proto-oncogene mediated by granulocyte macrophage colony-stimulating factor (GM-CSF) in murine cell lines	ONCOGENE			English	Article						transreceptor control; c-fms proto-oncogene; M-CSF receptor; GM-CSF mediated signal transduction	RECEPTOR GENE FAMILY; FACTOR-I RECEPTOR; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; MESSENGER-RNA; BETA-SUBUNIT; EXPRESSION; INTERLEUKIN-3; CLONING	Differentiation of blood cells is paralleled by a timely ordered expression of cytokine receptor genes. We show here that the expression of the c-fms gene which encodes the lineage-specific receptor for macrophage colony-stimulating factor (M-CSF or CSF-1) is directly linked to ligand-mediated activation of the receptor for the granulocyte/macrophage colony-stimulating factor (GMCSF). In interleukin-3 (IL-3) dependent multipotent progenitor cells, FDC-Pmix GMV#2 cells, GM-CSF treatment results in the rapid formation of full-length c-fms transcripts. Surprisingly, this upregulation of c-fms transcripts is also observed in mouse NIH3T3 fibroblasts stably transfected with genes coding for the alpha- and beta-subunits of the GM-CSF receptor. These results indicate a direct control by the GM-CSF receptor that takes place regardless of cell differentiation. Furthermore, a 2.1 kb genomic fragment containing the c-fins proximal promoter directs GM-CSF-inducible expression of a reporter gene, suggesting a regulation of c-fms gene expression on the transcriptional level.	UNIV GIESSEN, INST VIROL, D-35392 GIESSEN, GERMANY; UNIV HAMBURG, HEINRICH PETTE INST EXPTL VIROL & IMMUNOL, D-20251 HAMBURG, GERMANY; CHRISTIE HOSP NATL HLTH SERV TRUST, PATERSON INST CANC RES, CANC RES CAMPAIGN DEPT EXPTL HAEMATOL, MANCHESTER M20 8BX, LANCS, ENGLAND; BUNDESFORSCH ANSTALT VIRUSKRANKHEITEN TIERE, D-72076 TUBINGEN, GERMANY	Justus Liebig University Giessen; Heinrich Pette Institute; University of Hamburg; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research			Just, Ursula/E-6992-2010	Cross, Michael/0000-0002-8815-7621				ADUNYAH SE, 1991, J BIOL CHEM, V266, P5670; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; EDER M, 1993, EMBO J, V12, P1647, DOI 10.1002/j.1460-2075.1993.tb05810.x; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; JUST U, 1993, GROWTH FACTORS, V9, P291, DOI 10.3109/08977199308991589; JUST U, 1991, CELL, V64, P1163, DOI 10.1016/0092-8674(91)90271-Y; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIYAJIMA A, 1992, TRENDS BIOCHEM SCI, V17, P378, DOI 10.1016/0968-0004(92)90004-S; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NIENHUIS AW, 1985, CELL, V42, P421, DOI 10.1016/0092-8674(85)90099-6; OKUDA K, 1992, BLOOD, V79, P2880; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; REDDY MA, 1992, MOL ENDOCRINOL, V6, P1051, DOI 10.1210/me.6.7.1051; REDDY MA, 1994, J EXP MED, V180, P2309, DOI 10.1084/jem.180.6.2309; ROBERTS WM, 1992, BLOOD, V79, P586; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHATZMUNDING M, 1992, EUR J BIOCHEM, V204, P705, DOI 10.1111/j.1432-1033.1992.tb16685.x; SHERR CJ, 1990, BLOOD, V75, P1; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; TAMURA T, 1986, MOL CELL BIOL, V6, P4745, DOI 10.1128/MCB.6.12.4745; WATANABE S, 1993, MOL CELL BIOL, V13, P1440, DOI 10.1128/MCB.13.3.1440; WEBER B, 1989, MOL CELL BIOL, V9, P769, DOI 10.1128/MCB.9.2.769; WOOLFORD J, 1985, MOL CELL BIOL, V5, P3458, DOI 10.1128/MCB.5.12.3458; YUE X, 1993, MOL CELL BIOL, V13, P3191, DOI 10.1128/MCB.13.6.3191; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	35	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	1996	12	4					931	935						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632916				2022-12-17	WOS:A1996TW68600025
J	Makela, TP; Hellsten, E; Vesa, J; Hirvonen, H; Palotie, A; Peltonen, L; Alitalo, K				Makela, TP; Hellsten, E; Vesa, J; Hirvonen, H; Palotie, A; Peltonen, L; Alitalo, K			The rearranged L-myc fusion gene (RLF) encodes a Zn-15 related zinc finger protein	ONCOGENE			English	Article						RLF-L-myc rearrangement; small-cell lung carcinoma; zinc finger; transcription factor	CELL LUNG-CANCER; EXPRESSION; AMPLIFICATION; DROSOPHILA; BINDING; COMMON; MAX	We have previously characterized intrachromosomal rearrangements at 1p32 fusing the first exon of the RLF gene with L-myc, Here we present the full-length cDNA sequence of the 6251 bp RLH mRNA, The predicted 1914 amino acid Rlf protein contains sixteen widely spaced zinc finger motifs, and is related to the Zn-15 transcription factor, RLF is widely expressed in fetal and adult tissues, suggesting that it has a general role in transcriptional regulation. The zinc fingers are not contained in the 79 amino acid N-terminal region of RLP involved in the RLF-L-myc fusions, and the transforming ability of the RLF-L-myc and the normal L-myc proteins is indistinguishable. These findings suggest that the role of the rearrangements fusing RLF and L-myc is to the tightly controlled deregulate expression of the L-myc gene.	HELSINKI UNIV, HAARTMAN INST, MOLEC CANC BIOL LAB, SF-00014 HELSINKI, FINLAND; WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; NATL PUBL HLTH INST, DEPT HUMAN MOLEC GENET, SF-00300 HELSINKI, FINLAND; UNIV TURKU, DEPT BIOCHEM MED, SF-20520 TURKU, FINLAND; HELSINKI UNIV, CENT HOSP, DEPT CLIN CHEM, SF-00290 HELSINKI, FINLAND	University of Helsinki; Massachusetts Institute of Technology (MIT); Whitehead Institute; Finland National Institute for Health & Welfare; University of Turku; University of Helsinki; Helsinki University Central Hospital			Alitalo, Kari K/J-5013-2014; makela, tomi/B-3734-2009	Alitalo, Kari K/0000-0002-7331-0902; makela, tomi/0000-0002-4869-8044; Palotie, Aarno/0000-0002-2527-5874				ALITALO K, 1992, GENE AMPLIFICATION M, P371; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; FASANO L, 1991, CELL, V64, P63, DOI 10.1016/0092-8674(91)90209-H; HELLSTEN E, 1995, GENOMICS, V25, P404, DOI 10.1016/0888-7543(95)80040-S; HIRVONEN H, 1991, BLOOD, V78, P3012; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIPKIN SM, 1993, GENE DEV, V7, P1674, DOI 10.1101/gad.7.9.1674; MACLEANHUNTER S, 1994, ONCOGENE, V9, P3509; MAKELA TP, 1992, ONCOGENE, V7, P405; MAKELA TP, 1991, MOL CELL BIOL, V11, P4015; MAKELA TP, 1992, GENE, V118, P293, DOI 10.1016/0378-1119(92)90203-2; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MAKELA TP, 1991, EMBO J, V10, P1331, DOI 10.1002/j.1460-2075.1991.tb07652.x; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; REUTER G, 1990, NATURE, V344, P219, DOI 10.1038/344219a0; RHODES D, 1993, SCI AM, V268, P56, DOI 10.1038/scientificamerican0293-56; SEKIDO Y, 1992, MOL CELL BIOL, V12, P1747, DOI 10.1128/MCB.12.4.1747	18	16	17	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2699	2704						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545128				2022-12-17	WOS:A1995TP18800027
J	PAN, MG; WANG, YH; HIRSCH, DD; LABUDDA, K; STORK, PJS				PAN, MG; WANG, YH; HIRSCH, DD; LABUDDA, K; STORK, PJS			THE WNT-1 PROTOONCOGENE REGULATES MAP KINASE ACTIVATION BY MULTIPLE GROWTH-FACTORS IN PC12 CELLS	ONCOGENE			English	Article						WNT-1; GROWTH FACTORS; MAP KINASE; PC12 CELLS	DROSOPHILA HOMOLOG; XENOPUS EMBRYOS; PROTOONCOGENE; MESODERM; GENE; RAF; PHOSPHORYLATION; PLAKOGLOBIN; EXPRESSION; INHIBITION	PC12/Wnt-1 cells display morphological changes in response to stimulation by select growth factors but do not respond to NGF. Furthermore, stimulation by EGF can induce neuronal differentiation in these cells but not in wild type cells. We have found that in these cells, compared to wild type PC12 cells, FGF and EGF stimulation of MAP kinase activity is enhanced, while NGF stimulation of MAP kinase in diminished, Finally, in cells expressing Wnt-1, the effect of cyclic adenosine monophosphate (cAMP) on MAP kinase activation is reversed; cAMP stimulates MAP kinase in wild type PC12 cells but inhibits MAP kinase in PC12/Wnt-1 cells. These data suggest that Wnt-1 expression alters the specificity of growth factor signaling in neuronal cells.	OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,DEPT CELL BIOL & ANAT,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DIV CARDIOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BIOCHEM,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University								AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; COHEN SM, 1990, NATURE, V343, P173, DOI 10.1038/343173a0; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1993, CELL, V73, P215; Forrester LM, 1992, CURR OPIN GENET DEV, V2, P38, DOI 10.1016/S0959-437X(05)80319-3; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HO PL, 1992, J CELL PHYSIOL, V150, P647, DOI 10.1002/jcp.1041500326; HOOPER JE, 1994, NATURE, V372, P461, DOI 10.1038/372461a0; ISONO F, 1994, J NEUROCHEM, V63, P1235; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; KEIFER P, 1991, MOL CELL BIOL, V11, P5929; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MACHIDA CM, 1991, J CELL BIOL, V114, P1037, DOI 10.1083/jcb.114.5.1037; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PARKIN NT, 1993, GENE DEV, V7, P2181, DOI 10.1101/gad.7.11.2181; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; RAMAKRISHNA NR, 1993, DEVELOPMENT S, V119, P95; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHACKLEFORD GM, 1993, NEURON, V11, P865, DOI 10.1016/0896-6273(93)90116-9; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SKALHEGG BS, 1992, J BIOL CHEM, V267, P15707; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHENG CF, 1994, BIOCHEMISTRY-US, V33, P5595, DOI 10.1021/bi00184a031	58	16	16	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2005	2012						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478519				2022-12-17	WOS:A1995TF29700010
J	MILLER, ME; ENGEL, DA; SMITH, MM				MILLER, ME; ENGEL, DA; SMITH, MM			CYCLIC-AMP SIGNALING IS REQUIRED FOR FUNCTION OF THE N-TERMINAL AND CR-1 DOMAINS OF ADENOVIRUS E1A IN SACCHAROMYCES-CEREVISIAE	ONCOGENE			English	Article						GENE REGULATION; TRANSCRIPTION; YEAST; GENETICS	EARLY REGION-1A POLYPEPTIDES; RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; DNA-BINDING ACTIVITY; FOS MESSENGER-RNA; ADENYLATE-CYCLASE; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; CDC28 MUTATION; 1A PROTEINS	We have constructed yeast vectors in which derivatives of the adenovirus E1A gene are expressed from the GAL1 promoter. Cells expressing E1A(289) grow poorly and accumulate cells with a 1C DNA content. Using a series of E1A deletion mutants, we have identified three regions within the E1A protein that are necessary for the G(1) growth phenotype; each deletion partially relieves the growth defect. These deletions span residues 4-25, 38-60 and 140-186, which fall within the N-terminal, CR1 and CR3 domains of E1A respectively. Expression of the first 82 residues of E1A, spanning just the N-terminal and CR1 domains, strongly inhibits yeast cell growth in G(1) showing that these domains can function independently of other domains of E1A. Using this strong growth inhibition, we isolated a yeast mutant in the net1 gene that conferred resistance to the expression of E1A(1-82). The mutant was insensitive to expression of both E1A(1-82) and full length E1A, but remained sensitive to the toxicity caused by over-expression of a Ga14p-VP16 fusion. Finally, we found that the function of E1A in yeast depends on the cyclic AMP signaling pathway, providing a striking parallel with the action of E1A at the c-fos promoter in mammalian cells. These results suggest that a genetic analysis of the yeast model system will provide relevant new insights into mechanisms of gene regulation by E1A proteins.	UNIV VIRGINIA, SCH MED, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, SCH MED, CTR CANC, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028920] Funding Source: NIH RePORTER; NCI NIH HHS [5T3 CA09109] Funding Source: Medline; NIGMS NIH HHS [GM28920] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BARTLETT R, 1990, BIOESSAYS, V12, P457, DOI 10.1002/bies.950121002; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BROACH JR, 1991, TRENDS GENET, V7, P28, DOI 10.1016/0168-9525(91)90018-L; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHINNADURAI G, 1992, ONCOGENE, V7, P1255; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Coulombe Benoit, 1992, Gene Expression, V2, P99; DYSON N, 1992, CANCER SURV, V12, P161; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ENGEL DA, 1991, P NATL ACAD SCI USA, V88, P3957, DOI 10.1073/pnas.88.9.3957; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GEDRICH RW, 1992, J VIROL, V66, P5849, DOI 10.1128/JVI.66.10.5849-5859.1992; GEDRICH RW, 1995, J VIROL, V69, P2333, DOI 10.1128/JVI.69.4.2333-2340.1995; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P2488, DOI 10.1073/pnas.91.7.2488; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HANDA H, 1987, GENE, V58, P127; HANEY SA, 1994, J BIOL CHEM, V269, P16541; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARLOW E, 1988, ANTIBODIES LABORATOR; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HOWE JA, 1992, VIROLOGY, V186, P15, DOI 10.1016/0042-6822(92)90057-V; JANASWAMI PM, 1992, J BIOL CHEM, V267, P24886; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KALVAKOLANU DVR, 1992, J BIOL CHEM, V267, P2530; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; KLEIN C, 1994, MOL CELL BIOL, V14, P1920, DOI 10.1128/MCB.14.3.1920; KORNUC M, 1988, MOL CELL BIOL, V8, P3717, DOI 10.1128/MCB.8.9.3717; KRAUS VB, 1994, P NATL ACAD SCI USA, V91, P6279, DOI 10.1073/pnas.91.14.6279; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MAI B, 1993, FEBS LETT, V321, P153, DOI 10.1016/0014-5793(93)80098-F; MALHOTRA P, 1993, J BIOL CHEM, V268, P20392; Matsumoto K, 1985, Yeast, V1, P15, DOI 10.1002/yea.320010103; NEVINS JR, 1992, SCIENCE, V258, P424; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; REED SI, 1992, CIBA F SYMP, V170, P7; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; ROWE DT, 1983, VIROLOGY, V127, P253, DOI 10.1016/0042-6822(83)90142-3; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RYMOND BC, 1983, GENE, V25, P249, DOI 10.1016/0378-1119(83)90229-9; Sambrook J., 1989, MOL CLONING LAB MANU; SELLERS JW, 1990, MOL CELL BIOL, V10, P5077, DOI 10.1128/MCB.10.10.5077; Sherman F., 1982, METHODS YEAST GENETI; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH MM, 1991, METHOD CELL BIOL, V35, P485; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; TATCHELL K, 1986, J BACTERIOL, V166, P364, DOI 10.1128/jb.166.2.364-367.1986; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; VANDENELSEN P, 1983, VIROLOGY, V128, P377; VINCENT AC, 1992, MOL CELL BIOL, V12, P5394, DOI 10.1128/MCB.12.12.5394; WADA T, 1990, BIOCHEM BIOPH RES CO, V170, P470, DOI 10.1016/0006-291X(90)92115-G; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE SP, 1983, J VIROL, V46, P1003, DOI 10.1128/JVI.46.3.1003-1013.1983; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; ZHOU QJ, 1995, J VIROL, V69, P4323, DOI 10.1128/JVI.69.7.4323-4330.1995; ZIELER HA, 1995, MOL CELL BIOL, V15, P3227	79	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	1995	11	8					1623	1630						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478587				2022-12-17	WOS:A1995TC53500021
J	MATSUGI, T; KREIDER, BL; DELWEL, R; CLEVELAND, JL; ASKEW, DS; IHLE, JN				MATSUGI, T; KREIDER, BL; DELWEL, R; CLEVELAND, JL; ASKEW, DS; IHLE, JN			THE EVI-1 ZINC-FINGER MYELOID TRANSFORMING PROTEIN BINDS TO GENOMIC FRAGMENTS CONTAINING (GATA)(N) SEQUENCES	ONCOGENE			English	Article						EVI-1; BINDING; GATA ELEMENTS	COLONY-STIMULATING FACTOR; RETROVIRAL INSERTIONS; VIRAL INTEGRATION; GENE; DNA; EXPRESSION; IDENTIFICATION; TRANSCRIPTION; DIFFERENTIATION; SPECIFICITY	The EVI1 gene is activated by chromosomal translocations and inversions in approximately 5% of human acute myeloid leukemia (AML) and by retroviral insertion in approximately 20% of murine myeloid leukemias, EVI1 encodes a nuclear DNA-binding protein having 10 zinc finger motifs in two noncontiguous domains consisting of an amino-terminal domain of seven fingers and a carboxyl domain containing three fingers, To evaluate the sequence specificity of Evi-1 binding and potentially identify genomic targets, whole-genome PCR was utilized to isolate multiple Sau3A fragments which specifically bind to the amino-terminal zinc finger domain, The majority of these clones represented single copy sequences and virtually all contained variable numbers of repeats of the GATA motif, the target sequence for the erythroid-specific transcription factor GATA-1, GST/Evi-1 fusion proteins containing the amino-terminal domain of zinc fingers bound the GATA motif in these clones as well as to those present in the human gamma-globin promoter, similar to the binding of purified GATA-1 protein, By obtaining corresponding large genomic clones for eight of these fragments, transcription units were found associated with two. One corresponded to the glyceraldehyde-3-phosphate dehydrogenase gene and its expression was not affected by Evi-1, The second is a novel gene whose expression is repressed in murine myeloid cell lines that express Evi-1.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; UNIV CINCINNATI, DEPT PATHOL, CINCINNATI, OH USA; ERASMUS UNIV ROTTERDAM, ROTTERDAM, NETHERLANDS; HUMAN GENOME SCI, ROCKVILLE, MD 20859 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University System of Ohio; University of Cincinnati; Erasmus University Rotterdam; GlaxoSmithKline; Human Genome Sciences Inc				Askew, David/0000-0002-6477-2515	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline; NIDDK NIH HHS [DK 42932, DK 44150] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASKEW DS, 1991, ONCOGENE, V6, P2041; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; BELLOMO MJ, 1992, CANCER GENET CYTOGEN, V59, P138, DOI 10.1016/0165-4608(92)90208-P; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; DESJARLAIS JR, 1992, PROTEINS, V12, P101, DOI 10.1002/prot.340120202; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7344; DURBIN EJ, 1989, CHROMOSOMA, V97, P301, DOI 10.1007/BF00371970; FICHELSON S, 1992, LEUKEMIA, V6, P93; FUNABIKI T, 1994, ONCOGENE, V9, P1575; KELLER AD, 1991, NUCLEIC ACIDS RES, V19, P4675, DOI 10.1093/nar/19.17.4675; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1989, NUCLEIC ACIDS RES, V17, P3645, DOI 10.1093/nar/17.10.3645; KREIDER BL, 1990, MOL CELL BIOL, V10, P4846, DOI 10.1128/MCB.10.9.4846; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PERKINS AS, 1991, MOL CELL BIOL, V11, P2665, DOI 10.1128/MCB.11.5.2665; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; SINGH L, 1984, CELL, V36, P111, DOI 10.1016/0092-8674(84)90079-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOMPAYRAC L, 1990, P NATL ACAD SCI USA, V87, P3274, DOI 10.1073/pnas.87.9.3274	27	16	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					191	198						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624127				2022-12-17	WOS:A1995RJ29500022
J	WONG, KK; HARDIN, JD; BOAST, S; COOPER, CL; MERRELL, KT; DOYLE, TG; GOFF, SP; CALAME, KL				WONG, KK; HARDIN, JD; BOAST, S; COOPER, CL; MERRELL, KT; DOYLE, TG; GOFF, SP; CALAME, KL			A ROLE FOR C-ABL IN C-MYC REGULATION	ONCOGENE			English	Article						C-ABL; C-MYC; TRANSCRIPTION TYROSINE KINASE; ABL(ML) MOUSE	NF-KAPPA-B; TYROSINE KINASE; CELL-CYCLE; V-ABL; MESSENGER-RNA; GENE; BINDING; TRANSFORMATION; PROTEIN; PROMOTER	c-Abl, a nonreceptor tyrosine kinase, appears to play a role in cell cycle progression, cell proliferation and differentiation. Mice homozygous for a mutation in c-abl (abl(ml)), show pleiotropic abnormalities, including neonatal death, developmental defects, susceptibility to infection and dehydration (Schwartzberg et al., 1991). However, the exact substrates of c-Abl and the signal transduction pathways it might initiate are not known. We have examined how c-Abl affects c-myc expression by studying abl(ml) mice. Quantitative riboprobe analyses demonstrated that in the heart, liver, thymus, brain, testes, intestines and lung, there were no differences in the-steady-state level of c-myc RNA between the abl(ml) mice and Littermate controls. However, in adrenal glands, kidneys and splenic B cells, c-myc RNA levels were decreased approximately 50% compared to littermate controls. Induction of c-myc mRNA following activation of splenic B cells with LPS is also defective in abl(ml) splenocytes. Finally, me show that c-Abl can directly transactivate c-myc transcription. These results suggest that c-Abl is involved in the normal transcription regulation of c-myc in selected tissues and that decreased c-myc RNA could be one cause of abnormalities in the abl(ml) mice.	COLUMBIA UNIV, COLL PHYS & SURG, INTEGRATED PROGRAM CELLULAR MOLEC & BIOPHYS STUDI, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT MICROBIOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA; HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Columbia University; Howard Hughes Medical Institute			Goff, Stephen P/K-6337-2014	Goff, Stephen P/0000-0003-0693-5547				BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHEN YY, 1994, GENE DEV, V8, P688, DOI 10.1101/gad.8.6.688; CHEN YY, 1992, P NATL ACAD SCI USA, V89, P6683, DOI 10.1073/pnas.89.15.6683; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; DUYAO MP, 1990, CURR TOP MICROBIOL, V166, P211; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HARDIN JD, 1994, UNPUB; JACKSON P, 1993, EMBO J, V12, P2809, DOI 10.1002/j.1460-2075.1993.tb05942.x; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KESSLER DJ, 1992, ONCOGENE, V7, P2447; KESSLER DJ, 1992, J EXP MED, V176, P787, DOI 10.1084/jem.176.3.787; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KLUG CA, 1994, GENE DEV, V8, P678, DOI 10.1101/gad.8.6.678; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MONROE JG, 1983, J IMMUNOL, V130, P626; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; Robertson E, 1987, TERATOCARCINOMAS EMB; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN R, 1993, ONCOGENES TUMOR SUPP, P167; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E	47	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	1995	10	4					705	711						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862448				2022-12-17	WOS:A1995QH61200010
J	DREBIN, JA; HARTZELL, SW; GRIFFIN, C; CAMPBELL, MJ; NIEDERHUBER, JE				DREBIN, JA; HARTZELL, SW; GRIFFIN, C; CAMPBELL, MJ; NIEDERHUBER, JE			MOLECULAR-CLONING AND CHROMOSOMAL LOCALIZATION OF THE HUMAN HOMOLOG OF A B-LYMPHOCYTE SPECIFIC PROTEIN-TYROSINE KINASE (BLK)	ONCOGENE			English	Article						BLK; PROTEIN TYROSINE KINASE; B LYMPHOCYTE	CELL ANTIGEN RECEPTOR; TUMOR-SUPPRESSOR GENE; GROWTH-FACTOR; TRANSFORMING PROTEIN; CONSERVED FEATURES; BINDING SITE; SH3 DOMAINS; SRC FAMILY; PHOSPHORYLATION; CARCINOMA	A cDNA encoding the human homologue of the murine protein tyrosine kinase, blk, has been cloned from a human B-lymphocyte cDNA library by cross-species hybridization using the murine blk cDNA as a probe. The sequence of the 2608 bp human blk cDNA clone contains an open reading frame encoding a predicted 505 amino acid protein with SH3, SH2 and catalytic domains that contain consensus sequences of the src protein tyrosine kinase family. Comparison of human and murine blk sequences indicated that they share 86% amino acid identity, the most conserved region being the catalytic domain (93% identity). Like the murine blk gene, human blk is expressed only in B lymphocytes. The human blk gene was mapped to chromosome 8 at p22-23.	STANFORD UNIV, SCH MED, DEPT SURG, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT SURG, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT ONCOL, BALTIMORE, MD 21205 USA	Stanford University; Stanford University; Johns Hopkins University; Johns Hopkins University					NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P01HG000373] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00373] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CANNIZZARO LA, 1984, CYTOGENET CELL GENET, V38, P308, DOI 10.1159/000132079; CARLOCK LR, 1986, SOMAT CELL MOLEC GEN, V12, P163, DOI 10.1007/BF01560663; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; CUNNINGHAM C, 1993, ONCOGENE, V8, P1391; DECKER SJ, 1984, MOL CELL BIOL, V4, P571, DOI 10.1128/MCB.4.4.571; DEFRANCO AL, 1987, ANNU REV CELL BIOL, V3, P143; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; EK B, 1982, NATURE, V295, P419, DOI 10.1038/295419a0; EMI M, 1993, GENE CHROMOSOME CANC, V7, P152, DOI 10.1002/gcc.2870070307; EMI M, 1993, J BIOL CHEM, V268, P2120; FAGAN K, 1988, HUM GENET, V79, P365; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; FONG D, 1992, HUM GENET, V89, P10, DOI 10.1007/BF00207033; FUJIWARA Y, 1993, CANCER RES, V53, P1172; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GORDON JI, 1991, J BIOL CHEM, V266, P8647; GRIFFIN CA, 1987, P NATL ACAD SCI USA, V84, P512, DOI 10.1073/pnas.84.2.512; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HICKMAN D, 1994, BICH J, P441; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KNOWLES MA, 1993, ONCOGENE, V8, P1357; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LIN JJ, 1992, J IMMUNOL, V149, P1548; LINDBLOM A, 1993, CANCER RES, V53, P4356; MACOSKA JA, 1994, CANCER RES, V54, P3824; Marshall CJ, 1985, RNA TUMOR VIRUSES MO, P487; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; OHATA H, 1993, GENE CHROMOSOME CANC, V7, P85, DOI 10.1002/gcc.2870070204; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RESH MD, 1990, ONCOGENE, V5, P1437; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; SHECHTER I, 1994, GENOMICS, V20, P116, DOI 10.1006/geno.1994.1135; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; SPARKES R S, 1987, Genomics, V1, P138, DOI 10.1016/0888-7543(87)90005-X; SPARKES RS, 1989, GENOMICS, V5, P240, DOI 10.1016/0888-7543(89)90052-9; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WASYLYSHYN ML, 1991, SURGERY, V110, P265; WONG WW, 1985, P NATL ACAD SCI USA, V82, P7711, DOI 10.1073/pnas.82.22.7711; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310	59	16	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	1995	10	3					477	486						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845672				2022-12-17	WOS:A1995QF64800008
J	VOELKERDING, KV; STEFFEN, DW; ZAIDI, SHE; MALTER, JS				VOELKERDING, KV; STEFFEN, DW; ZAIDI, SHE; MALTER, JS			POSTTRANSCRIPTIONAL REGULATION OF THE P53 TUMOR-SUPPRESSOR GENE DURING GROWTH-INDUCTION OF HUMAN PERIPHERAL-BLOOD MONONUCLEAR-CELLS	ONCOGENE			English	Article						P53; POSTTRANSCRIPTIONAL REGULATION	MESSENGER-RNA DEGRADATION; 3' UNTRANSLATED REGION; C-FOS; PHORBOL ESTER; PROTEIN; EXPRESSION; MYC; ACTIVATION; STABILITY; DIFFERENTIATION	Regulation of p53 gene expression at the posttranscriptional level was investigated during growth induction of human peripheral blood mononuclear cells (PBMCs). Freshly isolated PBMCs, which are in the G(0) phase of the cell cycle, were shown to express low levels of p53 mRNA that was rapidly degraded with a half life of Ih. The rapid decay of p53 mRNA in quiescent PBMCs was dependent on global protein synthesis as treatment with cycloheximide resulted in stabilization of the p53 message. PBMCs were stimulated to enter the cell cycle by treatment with a combination of the mitogenic lectin phytohemagglutinin (PHA) and phorbol ester (TPA). Progressive stabilization of the p53 message occurred in PBMCs during growth induction. By 24 h of incubation in the presence of PHA and TPA, the half life of p53 mRNA was 6 h and p53 mRNA steady state levels were increased 4.5 to 5.0-fold. p53 protein was not detected in quiescent PBMCs, but was readily detected in PBMCs stimulated for 24 h with PHA and TPA. Stabilization of p53 mRNA was observed in PBMCs treated with either PHA or TPA, but to a lesser degree than when PKA and TPA were used as co-stimulants. These results indicate that differential degradation of p53 messenger RNA occurs in quiescent vs mitogen stimulated PBMCs and suggest that post-transcriptional regulation importantly contributes to increased p53 mRNA steady state levels as PBMCs enter the cell cycle.	UNIV WISCONSIN,CTR COMPREHENS CANC,MADISON,WI 53792	University of Wisconsin System; University of Wisconsin Madison	VOELKERDING, KV (corresponding author), UNIV WISCONSIN,DEPT PATHOL,MADISON,WI 53792, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045213] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK45213] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTMAN A, 1992, IMMUNOLOGY, V76, P465; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BONNIEU A, 1988, ONCOGENE RES, V3, P155; CALABRETTA B, 1986, CANCER RES, V46, P5738; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; HASSAPOGLIDOU S, 1993, ONCOGENE, V8, P1501; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KINZLER KW, 1992, CELL, V70, P523; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3172; MERCER WE, 1985, EXP CELL RES, V100, P31; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; OSIPOVICH OA, 1992, ONCOGENE, V7, P549; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; Peltz Stuart W., 1992, Current Opinion in Cell Biology, V4, P979, DOI 10.1016/0955-0674(92)90129-Z; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777	32	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					515	521						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845676				2022-12-17	WOS:A1995QF64800012
J	AGOFF, SN; WU, B				AGOFF, SN; WU, B			CBF MEDIATES ADENOVIRUS ELA TRANSACTIVATION BY INTERACTION AT THE C-TERMINAL PROMOTER TARGETING DOMAIN OF CONSERVED REGION-3	ONCOGENE			English	Note							E2F TRANSCRIPTION FACTOR; HUMAN HSP70 PROMOTER; E1A GENE-PRODUCTS; PROTEIN; TRANSACTIVATION; TRANSFORMATION; COMPLEXES; MUTANTS; FAMILY; BINDS	Genetic and biochemical evidence suggest that conserved region 3 (CR3) of the adenovirus Ela polypeptide can provide two distinct and separable functions: an N-terminal transcriptional activation region and a C-terminal promoter targeting region. It is thought that the promoter targeting region of Ela CR3 interacts with promoter-specific transcription factors, thereby bringing the activation region of Ela CR3 in proximity of the promoter. Here we report that CBP, a CCAAT-box-binding factor that regulates hsp70 gene expression and mediates Ela trans-activation in vivo, interacts with the promoter targeting region of Ela CR3 in vitro. Point mutations in Ela CR3 that are defective in stimulating transcription from the hsp70 promoter are also defective in stimulating transcription directed by a synthetic activator, GAL-CBF, composed of the DNA-binding domain of yeast GAL4 fused to CBF. These mutations fall into two classes with respect to their abilities to interact with CBF in vitro. Mutations in the transcriptional activation region of Ela CR3 do not affect binding to CBF, but mutation of the promoter targeting region of Ela CR3 prevents association with CBF in vitro.	NORTHWESTERN UNIV, DEPT BIOCHEM MOLEC BIOL & CELL BIOL, EVANSTON, IL 60208 USA	Northwestern University								BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; CHATTERJEE P, 1988, EMBO J, V5, P835; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P2488, DOI 10.1073/pnas.91.7.2488; GLENN GM, 1987, MOL CELL BIOL, V7, P1004, DOI 10.1128/MCB.7.3.1004; HALEY KP, 1984, P NATL ACAD SCI-BIOL, V81, P5734, DOI 10.1073/pnas.81.18.5734; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LILLIE JW, 1987, CELL, V61, P1217; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LUM LSY, 1992, MOL CELL BIOL, V12, P2599, DOI 10.1128/MCB.12.6.2599; LUM LSY, 1990, MOL CELL BIOL, V10, P6709, DOI 10.1128/MCB.10.12.6709; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MONTELL C, 1982, NATURE, V295, P380, DOI 10.1038/295380a0; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; SIMON MC, 1987, MOL CELL BIOL, V7, P2884, DOI 10.1128/MCB.7.8.2884; WEBSTER LC, 1991, MOL CELL BIOL, V11, P4287, DOI 10.1128/MCB.11.9.4287; WINBERG G, 1984, EMBO J, V3, P1907, DOI 10.1002/j.1460-2075.1984.tb02066.x; WU BJ, 1986, MOL CELL BIOL, V6, P2994, DOI 10.1128/MCB.6.8.2994; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629	28	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3707	3711						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970730				2022-12-17	WOS:A1994PT39200036
J	ALBAGLI, O; SOUDANT, N; FERREIRA, E; DHORDAIN, P; DEWITTE, F; BEGUE, A; FLOURENS, A; STEHELIN, D; LEPRINCE, D				ALBAGLI, O; SOUDANT, N; FERREIRA, E; DHORDAIN, P; DEWITTE, F; BEGUE, A; FLOURENS, A; STEHELIN, D; LEPRINCE, D			A MODEL FOR GENE EVOLUTION OF THE ETS-1 ETS-2 TRANSCRIPTION FACTORS BASED ON STRUCTURAL AND FUNCTIONAL HOMOLOGIES	ONCOGENE			English	Article							PU.1 REGULATES EXPRESSION; ETS PROTO-ONCOGENE; DNA-BINDING; ACTIVATION DOMAINS; V-ETS; C-ETS-1 LOCUS; PROTEINS; FAMILY; PROMOTER; CELLS	The chicken c-ets-l locus encodes two transcription factors, p54(c-ets-1) and p68(c-ets-1) that differ in their N-termini, encoded respectively by the I-54 and alpha beta exons. p68(c-ets-1) equivalents are only found in birds and reptiles while p54(c-ets-1) is widely conserved in vertebrates, from amphibians to mammals. Thus, the classical view concerning the evolution of the c-ets-1 gene has been to consider that I-54 is of ancient origin whereas alpha and beta, which provide an additional activating domain in p68(c-ets-1), would have been acquired much more recently. Sequencing the alpha and beta exons in various species pinpointed a highly conserved region of 13 amino acids which is rich in acidic and hydrophobic residues, a feature of some other transactivating domains. Strikingly, this subdomain is also present in the otherwise unrelated N-terminal activating region of p58(c-ets-2) and was thus named BEC for Ets-1-Beta/Ets-2-Conserved sequence. Moreover, the two N-termini share the BEC sequence at a homologous position in their highly similar genomic organization indicating a common origin. This structural homology underlies a functional similarity since fusion of the heterologous GAL4 DNA-binding domain with either of the two isolated domains demonstrates that BEC is essential in both cases for the transactivating activity. The function of the alpha beta domain in the context of p68(c-ets-1) also strictly depends on the presence of the BEC sequence. Finally, the whole N-terminus of p58(c-ets-2) can functionally substitute for its counterpart in p68(c-ets-1) further demonstrating that p68(c-ets-1) and p58(c-ets-2) are structurally and functionally more closely related than previously thought. Besides, we also found BEC in the N-terminus of the Drosophila pointed gene which may be considered as closely related to the uncommitted 'ets1/2' common ancestor. These data demonstrate that the alpha and beta exons are not a recent and specific acquisition but stem, like the p58(c-ets-2) N-terminus, from the invertebrate unduplicated 'ets 1/2' gene. This work unravels a new model for the ets-1/ets-2 gene's evolution, based for the first time on both structural and functional evidences. Accordingly, p68(c-ets-1) and p58(c-ets-2) are the direct descendants of the ancestral 'ets1/2' gene whereas I-54 may have been acquired as a second promoter in the c-ets-1 gene after the duplication. Indeed, I-54 is not found in the Drosophila pointed gene. The high degree of similarity, and hence of functional redundancy, between p68(c-ets-1) and p58(c-ets-2) may have led to the rapid divergence (and even loss in mammals) of alpha and beta during evolution whereas I-54, which provided a novel function unique to c-ets-1, was maintained within the presently widespread p54(c-ets-1) version.	INST PASTEUR,CNRS,URA 1160,F-59019 LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				Leprince, Dominique/0000-0002-1999-0775				ALBAGLI O, 1992, ONCOGENE, V7, P1435; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BHATTACHARYA G, 1993, ONCOGENE, V8, P3459; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; CHUMAKOV AM, 1993, J VIROL, V67, P2421, DOI 10.1128/JVI.67.4.2421-2425.1993; COFFER P, 1994, ONCOGENE, V9, P911; Crepieux Pascale, 1993, Gene Expression, V3, P215; DEGNAN BM, 1993, NUCLEIC ACIDS RES, V21, P3479, DOI 10.1093/nar/21.15.3479; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GEGONNE A, 1992, NEW BIOL, V4, P512; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HARDWICK JM, 1992, J VIROL, V66, P5500, DOI 10.1128/JVI.66.9.5500-5508.1992; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HOPP TP, 1983, MOL IMMUNOL, V20, P483, DOI 10.1016/0161-5890(83)90029-9; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JAWORSKI CJ, 1989, NATURE, V337, P752, DOI 10.1038/337752a0; JENNINGS CGB, 1992, DEV BIOL, V150, P121, DOI 10.1016/0012-1606(92)90012-6; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAGET MP, 1993, NUCLEIC ACIDS RES, V21, P5987, DOI 10.1093/nar/21.25.5987; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1990, ONCOGENE RES, V5, P255; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; LI X, 1993, NATURE, V367, P83; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PAHL HL, 1993, J BIOL CHEM, V268, P5014; QUEVA C, 1993, ONCOGENE, V8, P2511; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RAO VN, 1993, ONCOGENE, V8, P2167; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VENKATESH LK, 1993, J VIROL, V67, P3868, DOI 10.1128/JVI.67.7.3868-3876.1993; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1990, ONCOGENE, V5, P1521; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; WOLFF CM, 1991, CELL GROWTH DIFFER, V2, P447; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	59	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3259	3271						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936650				2022-12-17	WOS:A1994PM65800019
J	HAMAGUCHI, I; IWAMA, A; YAMAGUCHI, N; SAKANO, S; MATSUDA, Y; SUDA, T				HAMAGUCHI, I; IWAMA, A; YAMAGUCHI, N; SAKANO, S; MATSUDA, Y; SUDA, T			CHARACTERIZATION OF MOUSE NONRECEPTOR TYROSINE KINASE GENE, HYL	ONCOGENE			English	Note							RAT-BRAIN; PROTEIN; MICE; FYN; LOCALIZATION; FAMILY; CSK	We previously reported a novel human non-receptor tyrosine kinase gene, HYL (hematopoietic consensus tyrosine-lacking kinase) (Sakano et al., 1994), which consists of each of the SH2 (src homology 2), SH3 and tyrosine kinase catalytic domains. HYL has unique structural features shared with CSK (C-terminal Src kinase). Recently it has also been reported that matk (Bennett et al., 1994) and Ctk (Klages et al., 1994) are isolated as novel kinases with structural similarity to CSK. Comparisons of cDNA sequence indicate the HYL, matk and Ctk are the same gene. We further characterized the mouse HYL genomic structure and HYL mRNA expression in mouse brain. The mouse HYL gene is distributed over 5.8 kb and is composed of 12 exons; The exon-intron organization is almost identical with that of human CSK. The mouse HYL gene was assigned to the R-positive C1 band of chromosome 10 by fluorescent in situ hybridization. RNA in situ hybridization demonstrated the broad distribution of HYL mRNA expression in various neuronal cells. Especially, strong signals were detected in Purkinje cells, pyramidal cells in the hippocampus, granule cells in the dentate gyrus, and mitral cells in the olfactory bulb, indicating that mRNA expression of HYL in brain is very similar to that of SRC-family kinases. These findings establish close relationship between the HYL and CSK genes and also suggest that HYL may play an important role in signal transduction through SRC-family kinases in the central nervous system.	KUMAMOTO UNIV,SCH MED,INST MOLEC EMBRYOL & GENET,DEPT CELL DIFFERENTIAT,KUMAMOTO 860,JAPAN; ASAHI CHEM IND CO LTD,FUNDAMENTAL RES LAB LIFE SCI,FUJI 416,SHIZUOKA,JAPAN; NATL INST RADIOL SCI,DIV GENET,CHIBA 263,JAPAN	Kumamoto University; National Institutes for Quantum Science & Technology			Suda, Toshio/H-6761-2013	Suda, Toshio/0000-0001-7540-1771				BENNETT BD, 1994, J BIOL CHEM, V269, P1068; BOLEN JB, 1993, ONCOGENE, V8, P2025; BRAUNINGER A, 1993, ONCOGENE, V8, P1365; CARTWRIGHT CA, 1988, P NATL ACAD SCI USA, V85, P3348, DOI 10.1073/pnas.85.10.3348; COOKE M P, 1989, New Biologist, V1, P66; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; MATSUDA Y, 1992, CYTOGENET CELL GENET, V61, P282, DOI 10.1159/000133423; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; ROSS CA, 1988, P NATL ACAD SCI USA, V85, P9831, DOI 10.1073/pnas.85.24.9831; SAKANO S, 1994, ONCOGENE, V9, P1115; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SOMSSICH IE, 1989, GENETIC VARIANTS STR, P580; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; TAYLOR BA, 1993, MAMM GENOME, V4, pS154, DOI 10.1007/BF00360836; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; YAGI T, 1993, NATURE, V366, P742, DOI 10.1038/366742a0; YAGI T, 1993, ONCOGENE, V8, P3343; ZHAO YH, 1991, ONCOGENE, V6, P1725	25	16	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3371	3374						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936664				2022-12-17	WOS:A1994PM65800033
J	PRICE, TNC; MOORWOOD, K; JAMES, MR; BURKE, JF; MAYNE, LV				PRICE, TNC; MOORWOOD, K; JAMES, MR; BURKE, JF; MAYNE, LV			CELL-CYCLE PROGRESSION, MORPHOLOGY AND CONTACT INHIBITION ARE REGULATED BY THE AMOUNT OF SV40 T-ANTIGEN IN IMMORTAL HUMAN-CELLS	ONCOGENE			English	Article							HUMAN-FIBROBLASTS	Expression of Simian Virus 40 (SV40) T antigen in human dermal fibroblasts over-rides the normal controls on cell division leading to changes in cellular proliferation and life span. These changes are accompanied by other changes in cell morphology, expression of cell specific functions, and altered cell-cell interactions. In this study, we have examined the effects of different amounts of T antigen on cell cycle progression, life span and morphology in human dermal fibroblasts and demonstrated T antigen to be a concentration dependent regulator of the cell cycle. Using a novel, metal inducible episomal expression vector (p735.6) which produces low basal levels of protein but high (greater than 100-fold) levels of induction, we have compared the effects of low and high levels of T antigen expression in a precrisis and immortalised human line (1BRMT1). The presence of inducing agent led to maximal levels of T antigen expression and resulted in cultures with a high rate of proliferation, an extended in vitro life span, a loss of contact inhibition of growth and a morphology characteristic of SV40-transformed cells. In the absence of inducing agent, read-through of the T antigen gene resulted in low but detectable levels of protein. The reduction in T antigen levels was accompanied by a 50% or greater reduction in the proliferative rate and restoration of cell morphology and contact inhibition similar to that found in non-transfected cells. The results presented here demonstrate that low amounts of T antigen are sufficient to maintain cell viability and prevent the re-expression of the senescent phenotype seen in the absence of T antigen. Similarly, the ability of T antigen to extend the in vitro life span is not dependent on high level expression of T antigen. In contrast, the rate of proliferation of human cells as well as the cell morphology and contact inhibition are dependent on the amount of T antigen present. Many of the cellular effects can be minimised or reversed by reducing T antigen expression.	UNIV SUSSEX,TRAFFORD CTR MED RES,DIV BIOL SCI,BRIGHTON BN1 9RY,E SUSSEX,ENGLAND	University of Brighton; University of Sussex								MAYNE LV, 1986, EXP CELL RES, V162, P530, DOI 10.1016/0014-4827(86)90356-3; OGRIS E, 1993, ONCOGENE, V8, P1277; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; Sambrook J., 1989, MOL CLONING LAB MANU; SHAY JW, 1992, EXP GERONTOL, V27, P477, DOI 10.1016/0531-5565(92)90003-I; SLADEK TL, 1992, ONCOGENE, V7, P1305; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088	7	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2897	2904						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084594				2022-12-17	WOS:A1994PG82200015
J	STOLZENBERG, MC; BRUGIERES, L; GARDES, M; DESSARPSFREICHEY, F; CHOMPRET, A; BRESSAC, B; LENOIR, G; BONAITIPELLIE, C; LEMERLE, J; FEUNTEUN, J				STOLZENBERG, MC; BRUGIERES, L; GARDES, M; DESSARPSFREICHEY, F; CHOMPRET, A; BRESSAC, B; LENOIR, G; BONAITIPELLIE, C; LEMERLE, J; FEUNTEUN, J			GERM-LINE EXCLUSION OF A SINGLE P53 ALLELE BY PREMATURE TERMINATION OF TRANSLATION IN A LI-FRAUMENI SYNDROME FAMILY	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENE; MESSENGER-RNA; NONSENSE MUTATIONS; BREAST-CANCER; DEFICIENT; NEOPLASMS; CHILDREN; MICE	Germline p53 mutations have been detected in approximately half of the families affected by the Li-Fraumeni syndrome (LFS), in which they are believed to represent the genetic status predisposing to multiple cancers. Failure to detect mutations in the other half of LFS families suggests that sequence analysis, which has been limited to the p53 gene coding region, have overlooked other genetic events lying outside of this region or/and that alterations in other gene(s) than p53 may also lead to the syndrome. In this report, we present the evidence that a single base pair deletion in the p53 coding sequence, leading to premature signal termination of translation, generates a null allele by preventing transport of mutant allele mRNAs into the cytoplasm. This allelic exclusion which confers a status of unizygote vis-a-vis the wild-type p53 gene to individuals who carry the mutant allele, leads to predisposition to multiple cancers in a Li-Fraumeni family. Thus, the loss of the wild-type p53 allele appears as the rate limiting step in tumor induction.	INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,URA 1158,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,DEPT PEDIAT ONCOL,F-94805 VILLEJUIF,FRANCE; INSERM,U155,UNITE RECH EPIDEMIOL GENET,F-75016 PARIS,FRANCE; INST GUSTAVE ROUSSY,UNITE DIAGNOST MOLEC,F-94805 VILLEJUIF,FRANCE; INT AGCY RES CANC,F-69372 LYON 08,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; World Health Organization; International Agency for Research on Cancer (IARC)			Feunteun, Jean/AAZ-1267-2020; Paillerets, Brigitte Bressac-de/D-8954-2018; Stolzenberg, Marie-Claude/I-6281-2017	Paillerets, Brigitte Bressac-de/0000-0003-0245-8608; Stolzenberg, Marie-Claude/0000-0001-8026-0360; Feunteun, Jean/0000-0003-1212-9189				BASERGA SJ, 1992, P NATL ACAD SCI USA, V89, P2935, DOI 10.1073/pnas.89.7.2935; BIRCH JM, 1994, CANCER RES, V54, P1298; BORRESEN AL, 1992, CANCER RES, V52, P3234; BRUGIERES L, 1993, CANCER RES, V53, P452; CHENG J, 1990, Molecular and Cellular Biology, V10, P5215; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ENSSLE J, 1993, P NATL ACAD SCI USA, V90, P10091, DOI 10.1073/pnas.90.21.10091; FELIX CA, 1993, ONCOGENE, V8, P1203; FREBOURG T, 1992, CANCER RES, V52, P6976; FREBOURG T, 1994, CANCER RES, V54, P878; FREBOURG T, 1992, J CLIN INVEST, V90, P1637, DOI 10.1172/JCI116034; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HORIO Y, 1994, ONCOGENE, V9, P1231; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; JOLLY KW, 1994, ONCOGENE, V9, P97; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LI FP, 1988, CANCER RES, V48, P5358; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MAQUAT LE, 1981, CELL, V27, P543, DOI 10.1016/0092-8674(81)90396-2; MCINTOSH I, 1993, NAT GENET, V4, P219, DOI 10.1038/ng0793-219; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SIDRANSKY D, 1992, CANCER RES, V52, P2984; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868	33	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2799	2804						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084585				2022-12-17	WOS:A1994PG82200005
J	XU, NZ; MCCORMICK, F; GUTKIND, JS				XU, NZ; MCCORMICK, F; GUTKIND, JS			THE NONCATALYTIC DOMAIN OF RAS-GAP INHIBITS TRANSFORMATION-INDUCED BY G-PROTEIN COUPLED RECEPTORS	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; TYROSINE PHOSPHORYLATION; OVEREXPRESSION; CELLS; DNA	We have studied the relationship between vas-GAP and G protein coupled receptors in a proliferative setting comprised of NIH3T3 expressing transfected muscarinic receptors (mAChRs). GAP expression plasmids were engineered to encode wild-type GAP, its carboxyl-terminal catalytic domain, a mutant lacking a portion of the catalytic domain, and an amino-terminal domain which contained the hydrophobic region as well as SH2-SH3 domains. Cotransfection of each GAP expression plasmid into NIH3T3 cells did not affect the transforming ability of the v-mos oncogene, but plasmids encoding wild-type GAP or the mutant consisting of an intact catalytic domain inhibited transformation induced by normal c-ras. Wild-type GAP also prevented transformation by mi mAChRs, whereas the mutant consisting of only its catalytic domain lacked any demonstrable effect. In contrast, the N-terminal non-catalytic domain of GAP effectively prevented m1-induced focus-formation. Cell lines coexpressing m1 receptors and each of the GAP constructs revealed that GAP proteins do not affect mi receptor density, receptor ligand binding characteristics or coupling to the PI-PLC signal transduction pathway. Thus, our findings suggest a role for the N-terminal non-catalytic domain of GAP in regulating biological functions mediated by G protein-coupled receptors.	NIDR,CELLULAR DEV & ONCOL LAB,MOLEC SIGNALING UNIT,BETHESDA,MD 20892; ONYX PHARMACEUT,RICHMOND,CA 94806	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; 				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BLAIR DG, 1980, P NATL ACAD SCI-BIOL, V77, P3504, DOI 10.1073/pnas.77.6.3504; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOMINGUEZ I, 1991, EMBO J, V10, P3215, DOI 10.1002/j.1460-2075.1991.tb04884.x; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUIDEON P, 1992, MOL CELL BIOL, V12, P2050; GUTKIND JS, 1992, BIOCHEM BIOPH RES CO, V188, P155; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	23	16	16	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					597	601						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290270				2022-12-17	WOS:A1994MW24800027
J	SEHGAL, PB; MARGULIES, L				SEHGAL, PB; MARGULIES, L			CELL-TYPE-DEPENDENT AND PROMOTER-DEPENDENT TS PHENOTYPE OF P53 VAL(135)	ONCOGENE			English	Note							WILD-TYPE P53; INTERLEUKIN-6 PROMOTER; RESPONSIVE ELEMENT; GENE-PRODUCT; ENHANCER; INHIBITION; REPRESSION; EXPRESSION; PROTEIN; MUTANT	The p53 mutant Val(135) is widely considered to have a wild-type (wt) phenotype at 32.5 degrees C, but not at 37 degrees C. The ability of wt murine p53 and its Val(135) mutant to modulate transcription from the muscle-specific creatine kinase promoter (- 3.3 kb pMCK), from a reporter construct containing two copies of the p53-binding DNA element from within MCK (p50-2), and from the interleukin-6 (IL-6) promoter (pTC225) was evaluated in transient transfection experiments in CV1 and HeLa cells. In CV1 cells, wt p53 was confirmed to activate the pMCK and p50-2 reporters, but to repress the IL-6 promoter. However, although in these cells p53 Val(135) had the expected wt-like phenotype with respect to activation of the p50-2 reporter at 32.5 degrees C (32.5 degrees C) 37 degrees C), this mutant had little effect on expression from pMCK at either temperature, and activated rather than repressed the IL-6 promoter at 32.5 degrees C. In HeLa cells, although wt p53 activated p50-2 but repressed the MCK and IL-6 promoters, p53 Val(135) activated all three reporters. Unexpectedly, in these cells the upregulation of p50-2 and pIC225 was basically temperature-independent, and that of pMCK was inversely ts (37 degrees C>32.5 degrees C). The novel ts properties of p53 Val(135) show that this mutant is not always wt-like at 32.5 degrees C but exhibits strong cell-type and promoter-dependent differences in its ts phenotype for transcriptional modulation.	NEW YORK MED COLL, DEPT MED, VALHALLA, NY 10595 USA	New York Medical College	SEHGAL, PB (corresponding author), NEW YORK MED COLL, DEPT MICROBIOL & IMMUNOL, VALHALLA, NY 10595 USA.							BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; MARGULIES L, 1993, J BIOL CHEM, V268, P15096; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	20	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3417	3419						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247545				2022-12-17	WOS:A1993MG78200027
J	ZHANG, N; GONG, ZZ; MINDEN, M; LU, M				ZHANG, N; GONG, ZZ; MINDEN, M; LU, M			THE HOX-11 (TCL-3) HOMEOBOX PROTOONCOGENE ENCODES A NUCLEAR-PROTEIN THAT UNDERGOES CELL CYCLE-DEPENDENT REGULATION	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; ACUTE LYMPHOBLASTIC-LEUKEMIA; E2F TRANSCRIPTION FACTOR; SACCHAROMYCES-CEREVISIAE; G1-SPECIFIC CYCLINS; BINDING PROTEIN; EXPRESSION; PHOSPHORYLATION; PROLIFERATION; YEAST	Molecular analysis of the t(10;14) chromosomal translocation found in pediatric patients with T-cell acute lymphoblastic leukemia has led to the identification of the HOX-11 (TCL-3) protooncogene. The HOX-11 cDNA contains an open reading frame encoding a homeoprotein with features of DNA-binding. The majority of the t(10;14) chromosomal translocation breakpoints have been mapped to the 5' end of the HOX-11 gene, supporting the notion that deregulation of the HOX-11 gene by the t(10;14) chromosomal translocation contributed importantly to leukemia formation. To further define the role of the HOX-11 homeoprotein, we have prepared rabbit antiserum against a trpE-HOX-11 fusion protein. The purified anti-HOX-11 IgG immunoprecipitated a protein with apparent relative molecular mass of 40 kD. Biochemical fractionation demonstrated that the protein is localized in the nucleus. Furthermore, the HOX-11 RNA and protein appeared to be modulated during the cell cycle, with the highest level of expression at G(1)/S phase boundary. Taken together, these data suggest that the HOX-11 gene product may function as a transcription factor for G(1) progression in the cell cycle.	UNIV OTTAWA, NE ONTARIO REG CANC CTR, SUDBURY P3E 5J1, ON, CANADA; UNIV OTTAWA, DEPT MED, SUDBURY P3E 5J1, ON, CANADA; UNIV TORONTO, ONTARIO CANC INST, TORONTO M4X 1K9, ON, CANADA; UNIV TORONTO, DEPT MED BIOPHYS, TORONTO M4X 1K9, ON, CANADA	University of Ottawa; University of Ottawa; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto								AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; ANDREWS BJ, 1990, J BIOL CHEM, V265, P14057; ANDREWS BJ, 1992, NATURE, V355, P393, DOI 10.1038/355393a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CASTRILLO JL, 1991, SCIENCE, V253, P197, DOI 10.1126/science.1677216; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; DUBE ID, 1991, BLOOD, V78, P2996; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; GEHRING WJ, 1992, TRENDS BIOCHEM SCI, V17, P277, DOI 10.1016/0968-0004(92)90434-B; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HATANO M, 1992, BLOOD S, V80, pA355; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAGAN J, 1989, P NATL ACAD SCI USA, V86, P4161, DOI 10.1073/pnas.86.11.4161; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KONGSUWAN K, 1988, EMBO J, V7, P2131, DOI 10.1002/j.1460-2075.1988.tb03052.x; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LU M, 1992, NUCLEIC ACIDS RES, V20, P263, DOI 10.1093/nar/20.2.263; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; LU M, 1990, GENE CHROMOSOME CANC, V2, P217, DOI 10.1002/gcc.2870020309; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MING L, 1992, ONCOGENE, V7, P1325; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NASMYTH KA, 1990, CELL, V63, P1117, DOI 10.1016/0092-8674(90)90404-3; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHEN WF, 1989, P NATL ACAD SCI USA, V86, P8536, DOI 10.1073/pnas.86.21.8536; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; ZUTTER M, 1990, P NATL ACAD SCI USA, V87, P3161, DOI 10.1073/pnas.87.8.3161	41	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3265	3270						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	7902555				2022-12-17	WOS:A1993MG78200009
J	MICHELIN, S; DAYAGROSJEAN, L; SUREAU, F; SAID, S; SARASIN, A; SUAREZ, HG				MICHELIN, S; DAYAGROSJEAN, L; SUREAU, F; SAID, S; SARASIN, A; SUAREZ, HG			CHARACTERIZATION OF A C-MET PROTOONCOGENE ACTIVATED IN HUMAN XERODERMA-PIGMENTOSUM CELLS AFTER TREATMENT WITH N-METHYL-N'-NITRO-N-NITROSOGUANIDINE (MNNG)	ONCOGENE			English	Article							TYROSINE KINASE FAMILY; DNA; GENE; LINE; TRANSFORMATION; REARRANGEMENTS; ABNORMALITIES; RECEPTOR; PRODUCT; REPEATS	Human xeroderma pigmentosum (XP) fibroblasts were transformed with N-methyl-N'-nitro-N-nitrosoguanidine (MNNG). The transformed cells, called ASKMN, were immortalized, grew in agar and were tumorigenic in nude mice. A trp-met oncogene was identified in ASKMN cells, after transfection of high molecular weight DNA on 3T3 mouse cells. The ASKMN cells and the 3T3 transformants expressed the 5-kb mRNA transcribed by the tpr-met oncogene and its p65tpr-met phosphorylated protein. Using the polymerase chain reaction (PCR) technique followed by hybridization with synthetic probes or direct sequencing, we showed that the sequence encompassing the 'rearranged breakpoint' was the same as that previously described in the tpr-met oncogene present in the MNNG-HOS cells. However, G to A transitions found in the tpr or met sequences of the ASKMN oncogene, probably the result of the specific mutagenic activity of MNNG, were absent in the MNNG-HOS gene. Apparently normal chromosomes 1 and 7 were identified in the ASKMN cell metaphases using several cytogenetic techniques.	INST RECH SCI CANC,GENET MOLEC LAB,CNRS,UPR 42,BOITE POSTALE 8,F-94801 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS)								ALLARD MW, 1991, BIOTECHNIQUES, V10, P24; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BERNHEIM A, 1981, HUM GENET, V57, P432, DOI 10.1007/BF00281699; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BROOKES P, 1964, NATURE, V202, P781, DOI 10.1038/202781a0; CARIELLO NF, 1990, MUTAT RES, V231, P165, DOI 10.1016/0027-5107(90)90023-W; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; Deininger PL, 1989, MOBILE DNA, P619; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRECO A, 1992, ONCOGENE, V7, P237; HANAWALT PC, 1986, TRENDS GENET, V2, P124, DOI 10.1016/0168-9525(86)90201-5; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HYRIEN O, 1987, EMBO J, V6, P2401, DOI 10.1002/j.1460-2075.1987.tb02518.x; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; KRAEMER KH, 1987, ARCH DERMATOL, V123, P241, DOI 10.1001/archderm.123.2.241; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MICHELIN S, 1991, EXP CELL RES, V196, P314, DOI 10.1016/0014-4827(91)90266-W; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; NALDINI L, 1991, ONCOGENE, V6, P501; NARDEUX PC, 1987, BIOCHEM BIOPH RES CO, V146, P395, DOI 10.1016/0006-291X(87)90542-0; PARK M, 1986, COLD SPRING HARB SYM, V51, P967, DOI 10.1101/SQB.1986.051.01.110; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; RHIM JS, 1975, NATURE, V256, P751, DOI 10.1038/256751a0; STARY A, 1992, NUCLEIC ACIDS RES, V20, P4269, DOI 10.1093/nar/20.16.4269; STOPPALYONNET D, 1990, P NATL ACAD SCI USA, V87, P1551, DOI 10.1073/pnas.87.4.1551; SUAREZ H, 1988, BIOCHIMIE, V70, P969, DOI 10.1016/0300-9084(88)90239-8; SUAREZ HG, 1989, ANTICANCER RES, V9, P1331; SUAREZ HG, 1991, ONCOGENE, V6, P677; TESTA JR, 1990, ONCOGENE, V5, P1565; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1973; YOSIDA TH, 1983, CANCER GENET CYTOGEN, V8, P153, DOI 10.1016/0165-4608(83)90047-X; YUNIS JJ, 1978, CYTOGENET CELL GENET, V22, P679, DOI 10.1159/000131052	36	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1983	1991						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510940				2022-12-17	WOS:A1993LG68200031
J	SCHUUR, ER; DASGUPTA, P; REDDY, EP; RABINOVICH, JM; BALUDA, MA				SCHUUR, ER; DASGUPTA, P; REDDY, EP; RABINOVICH, JM; BALUDA, MA			ALTERNATIVE SPLICING OF THE CHICKEN C-MYB EXON-9A	ONCOGENE			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; GENE V-MYB; TRANSFORMING GENE; PROTO-ONCOGENE; MESSENGER-RNA; DIFFERENTIAL EXPRESSION; HEMATOPOIETIC-CELLS; NUCLEOTIDE-SEQUENCE; MYELOID-LEUKEMIA; DOWN-REGULATION	The c-myb gene products are thought to be regulators of cellular replication and of differentiation and heterogeneity may underlie their multiple functions. To investigate the possible existence of heterogeneity we have examined the chicken c-myb mRNAs by Northern blot analysis and polymerase chain reaction amplification of cDNAs (RT-PCR). Northern blot analysis with the c-myb cDNA clone pSG3, which contains the entire open reading frame (ORF) plus 500 base pairs of 3' untranslated sequences (Gerondakis & Bishop, 1986), and genomic probes revealed c-myb RNA species of 4.3 kb in addition to the major 4.0 kb species. The 4.3 kb c-myb RNA contained the alternatively spliced exon 9A which is highly conserved and has also been detected in a minor 4.3 kb alternatively spliced c-myb mRNA in murine and human cells. Sequencing of the avian exon 9A revealed 360 bp exon homologous to that found in murine and human mRNAs, which contains three highly conserved sequence regions shared by all three species. RT-PCR demonstrated usage of exon 9A in five hematopoietic tissues and revealed an additional splicing variant which used the 3' portion of exon 9A. Northern blot analysis using splice site-specific oligonucleotide probes spanning the two splice junctions between exon 9 and 9A revealed four additional c-myb RNAs of 4.4 kb, 2.2 kb, 2.0 kb and 1.4 kb.	UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90033; UNIV CALIF LOS ANGELES,SCH MED,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024; TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL & LAB MED,LOS ANGELES,CA 90024	University of Southern California; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [R01CA010197] Funding Source: NIH RePORTER; NCI NIH HHS [CA 10197] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BALUDA MA, 1990, ONCOGENESIS ONCOGENE, P131; BENDER TP, 1987, J IMMUNOL, V139, P3822; BERGER SL, 1987, METHOD ENZYMOL, V152, P227; BORTNER DM, 1991, NUCLEIC ACIDS RES, V19, P1533, DOI 10.1093/nar/19.7.1533; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; CHEN JH, 1980, J VIROL, V36, P162, DOI 10.1128/JVI.36.1.162-170.1980; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; DASGUPTA P, 1989, ONCOGENE, V4, P1419; DUDEK H, 1989, ONCOGENE, V4, P1061; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARCIA A, 1991, ONCOGENE, V6, P265; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GONDA TJ, 1983, J VIROL, V46, P212, DOI 10.1128/JVI.46.1.212-220.1983; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRASSER FA, 1992, ONCOGENE, V7, P1005; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; HAHN SL, 1989, MOL CELL BIOL, V9, P837, DOI 10.1128/MCB.9.2.837; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KIM WK, 1989, MOL CELL BIOL, V9, P3771, DOI 10.1128/MCB.9.9.3771; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; Lipsick J S, 1986, Gene Amplif Anal, V4, P73; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MANIATIS T, 1982, MOL CLONING LABORATO, P280; Moscovici C., 1973, Methods Cell Biol, V7, P313; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PERBAL B, 1983, J VIROL, V45, P925, DOI 10.1128/JVI.45.3.925-940.1983; PERBAL B, 1982, J VIROL, V44, P586, DOI 10.1128/JVI.44.2.586-594.1982; PERBAL B, 1982, J VIROL, V41, P250, DOI 10.1128/JVI.41.1.250-257.1982; PUNYAMMALEE B, 1991, ONCOGENE, V6, P11; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHUUR ER, 1991, ONCOGENE, V6, P1923; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHENONG GLC, 1989, MOL CELL BIOL, V9, P5456, DOI 10.1128/MCB.9.12.5456; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SORET J, 1990, FEBS LETT, V263, P254, DOI 10.1016/0014-5793(90)81387-4; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; VELLARD M, 1991, ONCOGENE, V6, P505; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WATSON RJ, 1987, EMBO J, V6, P1643, DOI 10.1002/j.1460-2075.1987.tb02413.x; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WESTIN EH, 1990, ONCOGENE, V5, P1117; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	57	16	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1839	1847						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510928				2022-12-17	WOS:A1993LG68200016
J	ALT, M; GRASSMANN, R				ALT, M; GRASSMANN, R			RESISTANCE OF HUMAN FIBROBLASTS TO C-FOS MEDIATED TRANSFORMATION	ONCOGENE			English	Article							OSTEO-SARCOMA VIRUS; HERPESVIRUS-SAIMIRI; MAMMALIAN-CELLS; NUCLEOTIDE-SEQUENCE; DELETION MUTANTS; GENE-EXPRESSION; TRANSGENIC MICE; PROTEIN; TRANSCRIPTION; AP-1	Overexpression of the proto-oncogene c-fos induces transformation of primary avian and established rodent mesenchymal cells and tumor development in transgenic mice. As overexpression of Fos was also found in several human tumors of mesenchymal origin, we were interested whether c-fos is a transforming protein for human cells. Since fos genes transduced by infection competent vectors were most efficient in cellular transformation, expression cassettes of the human c-fos were introduced into a replication competent herpesvirus saimiri vector. Infection of human neonatal fibroblasts, cells of mesenchymal origin, resulted in episomal persistence of the recombinant viral genome and expression of c-fos in high excess. However careful examination for transformed phenotype failed to detect any changes in morphology, serum dependence, anchorage dependence, and life span, suggesting resistance of human mesechymal cells against c-fos mediated transformation.	UNIV ERLANGEN NURNBERG,INST KLIN & MOLEK VIROL,LOSCHGESTR 7,W-8520 ERLANGEN,GERMANY	University of Erlangen Nuremberg								ALT M, 1991, GENE, V102, P265, DOI 10.1016/0378-1119(91)90088-S; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; CELANDER D, 1984, NATURE, V312, P159, DOI 10.1038/312159a0; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; CURRAN T, 1984, CELL, V36, P259; Curran T, 1988, ONCOGENE HDB, P307; DESROSIERS RC, 1984, J VIROL, V49, P343, DOI 10.1128/JVI.49.2.343-348.1984; DESROSIERS RC, 1986, J VIROL, V57, P701, DOI 10.1128/JVI.57.2.701-705.1986; DESROSIERS RC, 1985, SCIENCE, V228, P184, DOI 10.1126/science.2983431; FAHRER C, 1989, INT J CANCER, V44, P652, DOI 10.1002/ijc.2910440416; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINKEL MP, 1966, SCIENCE, V151, P698, DOI 10.1126/science.151.3711.698; FINKEL MP, 1975, FRONTIERS RADIATION, V10, P28; FLECKENSTEIN B, 1975, J VIROL, V15, P398, DOI 10.1128/JVI.15.2.398-406.1975; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GARDELLA T, 1984, J VIROL, V50, P248, DOI 10.1128/JVI.50.1.248-254.1984; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRASSMANN R, 1989, J VIROL, V63, P1818, DOI 10.1128/JVI.63.4.1818-1821.1989; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; IBA H, 1988, ONCOGENE RES, V2, P121; LEE WMF, 1988, MOL CELL BIOL, V8, P5521, DOI 10.1128/MCB.8.12.5521; LUCIBELLO FC, 1988, ONCOGENE, V3, P43; MILLER AD, 1984, CELL, V36, P51; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SIMMER B, 1991, J GEN VIROL, V72, P1953, DOI 10.1099/0022-1317-72-8-1953; STAMMINGER T, 1990, J GEN VIROL, V71, P105, DOI 10.1099/0022-1317-71-1-105; TSAI LH, 1991, ONCOGENE, V6, P81; VANBEVEREN C, 1984, VIROLOGY, V135, P229, DOI 10.1016/0042-6822(84)90133-8; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VERMA I, 1968, TRENDS GENET, V2, P93; WARD JM, 1976, CANCER RES, V36, P3985; WISOM R, 1990, MOL CELL BIOL, V10, P5626; WU JX, 1990, ONCOGENE, V5, P989; YU SF, 1986, P NATL ACAD SCI USA, V83, P3194, DOI 10.1073/pnas.83.10.3194	42	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1421	1427						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8389028				2022-12-17	WOS:A1993LE06400004
J	LEE, EB; BEUG, H; HAYMAN, MJ				LEE, EB; BEUG, H; HAYMAN, MJ			MUTATIONAL ANALYSIS OF THE ROLE OF THE CARBOXY-TERMINAL REGION OF THE V-ERBB PROTEIN IN ERYTHROID CELL-TRANSFORMATION	ONCOGENE			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; GROWTH-FACTOR RECEPTOR; SINGLE POINT MUTATION; EGF RECEPTOR; TYROSINE KINASES; GENE-PRODUCT; C-ERBB; IDENTIFICATION; EXPRESSION; MUTANTS	The v-erbB protein encoded by the avian erythroblastosis virus AEV-H is responsible for the transformation of fibroblasts and erythroblasts by this virus. Deletion of amino acids 961-1102, which lie carboxy terminal to the kinase domain of the v-erbB protein, destroys the ability of the virus to transform erythroid cells without severely affecting fibroblast transformation. This region is termed the E-domain and has been postulated to contain a region important for erythroid cell transformation. In-frame deletions of approximately 23 amino acids were introduced throughout the E-domain in an attempt to locate a specific region that was essential for erythroid cell transformation. Several of the deletions gave rise to a partial transformed phenotype, although no single deletion that completely abolished erythroid cell transformation was found. Interestingly, deletion of amino acids 1031-1055 resulted in a superactivated v-erbB protein that was more active for erythroid cell transformation than the wild-type AEV-H v-erbB protein. This indicates that there is a negative regulatory region located within this region that normally partially suppresses the transforming activity of the v-erbB protein for erythroid cells. These data suggest that the E-domain contains both negative and positive regulatory regions that function in erythroid cells, and complete deletion of the region is necessary to abolish erythroid cell transformation.	SUNY STONY BROOK, DEPT IRON STEEL & OTHER MET, STONY BROOK, NY 11794 USA; INST MOLEC PATHOL, A-1030 VIENNA, AUSTRIA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)					NATIONAL CANCER INSTITUTE [R01CA042573, P01CA028146] Funding Source: NIH RePORTER; NCI NIH HHS [CA42573, CA28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1986, J VIROL, V57, P1127, DOI 10.1128/JVI.57.3.1127-1138.1986; BEUG H, 1984, CELL, V36, P963, DOI 10.1016/0092-8674(84)90046-1; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GILMORE T, 1985, CELL, V40, P609, DOI 10.1016/0092-8674(85)90209-0; GRAF T, 1973, VIROLOGY, V54, P398, DOI 10.1016/0042-6822(73)90152-9; HAYMAN MJ, 1986, VIROLOGY, V150, P270, DOI 10.1016/0042-6822(86)90287-4; HAYMAN MJ, 1984, NATURE, V309, P460, DOI 10.1038/309460a0; HAYMAN MJ, 1983, CELL, V32, P579, DOI 10.1016/0092-8674(83)90477-4; HAYMAN MJ, 1992, CANCER SURV, V15, P53; HAYMAN MJ, 1991, CANCER CELL-MON REV, V3, P302; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JANSSON M, 1987, ONCOGENE, V1, P167; KAMPS MP, 1988, ONCOGENE, V2, P305; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOWENZ E, 1987, MODERN TRENDS HUMA 7, V31, P199; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARSEN J, 1992, ONCOGENE, V7, P1903; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LEE EB, 1990, ONCOGENE, V5, P1165; MAIHLE NJ, 1989, BIOCHIM BIOPHYS ACTA, V948, P287, DOI 10.1016/0304-419X(89)90003-6; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PELLEY RJ, 1988, J VIROL, V62, P1840, DOI 10.1128/JVI.62.5.1840-1844.1988; RAINES MA, 1988, J VIROL, V62, P2444, DOI 10.1128/JVI.62.7.2444-2452.1988; ROBINSON HL, 1992, ONCOGENE, V7, P2025; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROYERPOKORA B, 1979, NATURE, V282, P750, DOI 10.1038/282750a0; SCHROEDER C, 1990, ONCOGENE, V5, P1445; SHU HKG, 1991, J VIROL, V65, P6173, DOI 10.1128/JVI.65.11.6173-6180.1991; SHU HKG, 1990, P NATL ACAD SCI USA, V87, P9103, DOI 10.1073/pnas.87.23.9103; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; THEROUX SJ, 1992, IN PRESS J BIOL CHEM; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YAMAMOTO T, 1983, CELL, V34, P225, DOI 10.1016/0092-8674(83)90153-8; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	43	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1317	1327						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8097581				2022-12-17	WOS:A1993KY32800025
J	OHMORI, Y; TANABE, J; TAKADA, S; LEE, WMF; OBINATA, M				OHMORI, Y; TANABE, J; TAKADA, S; LEE, WMF; OBINATA, M			FUNCTIONAL DOMAINS OF C-MYC INVOLVED IN THE COMMITMENT AND DIFFERENTIATION OF MURINE ERYTHROLEUKEMIA-CELLS	ONCOGENE			English	Article							DNA-BINDING; LEUCINE ZIPPER; ERYTHROID DIFFERENTIATION; NUCLEAR-LOCALIZATION; PROTEIN; GENE; SEQUENCE; TRANSLOCATION; EXPRESSION; TRANSFORMATION	In the early event of the induction of mouse erythroleukemia (MEL) cell differentiation, c-myc mRNA levels show a drastic change. The elevated expression of a transfected c-myc gene inhibits the commitment and differentiation of MEL cell transformants. In the present work, we have introduced human c-myc mutants into MEL cells under the inducible promoter to define the functional domains of c-Myc involved in erythroid differentiation. The c-Myc domains necessary for commitment and differentiation are not co-localized; almost entire regions are required for inhibition of commitment, whereas domains II and IV that are essential for co-tranforming activity with ras are required for inhibition of differentiation. Interestingly, mutants that delete domains for c-Myc dimerization motifs enhanced differentiation. These results suggest that c-Myc may regulate commitment and differentiation by interacting with proteins through different domains.	TOHOKU UNIV,TUBERCULOSIS & CANC RES INST,DEPT CELL BIOL,SEIRYOMACHI 4-1,SENDAI,MIYAGI 980,JAPAN; UNIV PENN,DEPT MED,ONCOL SECT,PHILADELPHIA,PA 19104; UNIV PENN,CTR CANC,PHILADELPHIA,PA 19104	Tohoku University; University of Pennsylvania; University of Pennsylvania				Takada, Shinji/0000-0003-4125-6056				ALONSO MC, 1988, EMBO J, V7, P2583; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BEIMLING P, 1985, BIOCHEMISTRY-US, V24, P6349, DOI 10.1021/bi00344a005; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; COPPOLA JA, 1986, NATURE, V320, P761; CROUCH DH, 1990, ONCOGENE, V5, P683; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DANG CV, 1989, MOL CELL BIOL, V9, P2477, DOI 10.1128/MCB.9.6.2477; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GUSELLA J, 1976, CELL, V9, P221, DOI 10.1016/0092-8674(76)90113-6; KLAEMBT C, 1989, EMBO J, V8, P203; KUME TU, 1988, J MOL BIOL, V202, P779, DOI 10.1016/0022-2836(88)90558-X; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; RUSTGI AK, 1991, NATURE, V352, P540; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAKADA S, 1992, JPN J CANCER RES, V83, P61, DOI 10.1111/j.1349-7006.1992.tb02352.x; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAMAMOTO T, 1989, CELL DIFFER DEV, V28, P129, DOI 10.1016/0922-3371(89)90049-X	34	16	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					379	386						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426744				2022-12-17	WOS:A1993KN00600017
J	BARLAT, I; SCHWEIGHOFFER, F; CHEVALLIERMULTON, MC; DUCHESNE, M; FATH, I; LANDAIS, D; JACQUET, M; TOCQUE, B				BARLAT, I; SCHWEIGHOFFER, F; CHEVALLIERMULTON, MC; DUCHESNE, M; FATH, I; LANDAIS, D; JACQUET, M; TOCQUE, B			THE SACCHAROMYCES-CEREVISIAE GENE-PRODUCT SDC25 C-DOMAIN FUNCTIONS AS AN ONCOPROTEIN IN NIH3T3 CELLS	ONCOGENE			English	Note							GUANINE-NUCLEOTIDE EXCHANGE; GDP-GTP EXCHANGE; RAS PROTEINS; P21RAS; ACTIVATION; STIMULATION; SCD25	Ras proteins in mammalian cells cycle between a GTP-bound 'on' state and a GDP-bound 'off' state. Activation of Ras p21 results from the dissociation of tightly bound GDP and the exchange of bound GDP for GTP. A guanine nucleotide exchange factor is required for this activation. Activation promotes interaction with effector molecules and allows the signal to be transduced. In Saccharomyces cerevisiae, the function of guanine nucleotide exchange has been ascribed to the product of the CDC25 gene. The C-terminus domain of SDC25, a homologue of CDC25, can substitute for the CDC25 protein in yeast. We have demonstrated that the SDC25 C-terminus domain promotes GTP binding to Ras p21 in CHO cells. In the present study, we found that the stable expression of the SDC25 C-terminus domain induced transformation of NIH3T3 cells. Ras proteins in these tumorigenic cells were GTP bound. In addition, the coexpression of wild-type Ha-Ras protein with the SDC25 C-terminus was found to enhance the tumorigenic properties of the NIH3T3 cells. These results imply that, in subsets of human tumours, cellular Ras p21 might be found in its GTP-bound active form as a consequence of an oncogenic activation of a mammalian Ras guanine nucleotide exchange factor.	RHONE POULENC RORER,13 QUAI JULES GUESDE,BP 14,F-94403 VITRY,FRANCE; UNIV PARIS 11,INFORMAT GENET & DEV GRP CNRS,URA 1354,F-91405 ORSAY,FRANCE	Sanofi-Aventis; UDICE-French Research Universities; Universite Paris Saclay								BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOYMARCOTTE E, 1989, GENE, V77, P21, DOI 10.1016/0378-1119(89)90355-7; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; FUJIOKA H, 1992, J BIOL CHEM, V267, P926; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; REY I, 1991, ONCOGENE, V6, P347; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667	16	16	17	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					215	218						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	7999142				2022-12-17	WOS:A1993KN00500027
J	BERGSAGEL, PL; TIMBLIN, CR; ECKHARDT, L; LASKOV, R; KUEHL, WM				BERGSAGEL, PL; TIMBLIN, CR; ECKHARDT, L; LASKOV, R; KUEHL, WM			SEQUENCE AND EXPRESSION OF A MURINE CDNA-ENCODING PC326, A NOVEL GENE EXPRESSED IN PLASMACYTOMAS BUT NOT NORMAL PLASMA-CELLS	ONCOGENE			English	Article							TRANSLOCATED MYC GENE; C-MOS; SACCHAROMYCES-CEREVISIAE; MOUSE MYELOMA; BETA-SUBUNIT; G-PROTEIN; EXTINCTION; ONCOGENE; ENHANCER; HYBRIDS	Using a subtractive cDNA approach we have identified a gene, PC326, expressed in 13 of 14 murine plasmacytoma cell lines, but not in any B- or pre-B-lymphoma cell lines. It expresses 4.6-kb and 5.2-kb mRNAs that encode a 747 amino acid protein containing two highly acidic domains flanking a novel, moderately acidic 20 amino acid sequence that is repeated 7.5 times. Sequence comparison identifies an additional 43 amino acid domain that is homologous to a repeated sequence found in the members of the beta-transducin gene family. The PC326 mRNA is detectable in testis but in no other murine tissues, including plasma cells induced by lipopolysaccharide stimulation of splenocytes. Somatic cell hybrids derived from plasmacytomas and fibroblast or T-cell lines have a fibroblastic or T-cell phenotype respectively. Unlike B-cell-specific genes (e.g. immunoglobulin), the expression of which is extinguished in these hybrids, PC326 mRNA appears to be irreversibly turned on in these hybrids. Since PC326 is not expressed in normal plasma cells, it appears that its expression is a cause or consequence of the tumorigenic process that generates murine plasmacytomas.	NCI, USN, MED ONCOL BRANCH, BLDG 8, ROOM 5101, BETHESDA, MD 20889 USA; COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA; HEBREW UNIV JERUSALEM, HADASSAH MED SCH, HUBERT H HUMPHREY CTR EXPTL MED & CANC RES, IL-91010 JERUSALEM, ISRAEL	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy; Columbia University; Hebrew University of Jerusalem			Bergsagel, Peter Leif/A-7842-2011	Bergsagel, Peter Leif/0000-0003-1523-7388				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BANROQUES J, 1989, MOL CELL BIOL, V9, P3710, DOI 10.1128/MCB.9.9.3710; Battey, 1986, BASIC METHODS MOL BI; BERGMAN Y, 1990, EMBO J, V9, P849, DOI 10.1002/j.1460-2075.1990.tb08182.x; BERGSAGEL PL, 1992, J IMMUNOL, V148, P590; BRANDT SJ, 1990, J CLIN INVEST, V86, P592, DOI 10.1172/JCI114749; CANAANI E, 1983, P NATL ACAD SCI-BIOL, V80, P7118, DOI 10.1073/pnas.80.23.7118; COHEN JB, 1983, NATURE, V306, P797, DOI 10.1038/306797a0; DELIDAKIS C, 1991, GENETICS, V129, P803; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DURONIO RJ, 1992, PROTEINS, V13, P41, DOI 10.1002/prot.340130105; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; GATTONICELLI S, 1983, NATURE, V306, P795, DOI 10.1038/306795a0; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; GREENBERG A, 1987, MOL CELL BIOL, V7, P936, DOI 10.1128/MCB.7.2.936; GREENBERG A, 1989, INT J CANCER, V43, P87, DOI 10.1002/ijc.2910430118; HARTLEY DA, 1988, CELL, V55, P785, DOI 10.1016/0092-8674(88)90134-1; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; ICHO T, 1988, J BIOL CHEM, V263, P1467; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KOSHLAND ME, 1985, ANNU REV IMMUNOL, V3, P425; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAYEV AS, 1980, NUCLEIC ACIDS RES, V8, P1201, DOI 10.1093/nar/8.6.1201; LASKOV R, 1991, INT J CANCER, V48, P574, DOI 10.1002/ijc.2910480416; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; PONZETTO C, 1985, MOL CELL BIOL, V5, P1791, DOI 10.1128/MCB.5.7.1791; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SETHI N, 1991, MOL CELL BIOL, V11, P5592, DOI 10.1128/MCB.11.11.5592; TIMBLIN C, 1990, CURR TOP MICROBIOL, V166, P141; TIMBLIN C, 1990, NUCLEIC ACIDS RES, V18, P1587, DOI 10.1093/nar/18.6.1587; WEISSINGER EM, 1991, P NATL ACAD SCI USA, V88, P8735, DOI 10.1073/pnas.88.19.8735; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WILLIAMS FE, 1990, MOL CELL BIOL, V10, P6500, DOI 10.1128/MCB.10.12.6500; YOCHEM J, 1987, J MOL BIOL, V195, P233, DOI 10.1016/0022-2836(87)90646-2; YU H, 1989, CELL, V58, P441, DOI 10.1016/0092-8674(89)90425-X; ZALLER DM, 1988, MOL CELL BIOL, V8, P1932, DOI 10.1128/MCB.8.5.1932	39	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1992	7	10					2059	2064						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408147				2022-12-17	WOS:A1992JP42400021
J	ROBINSON, HL; TRACY, SE; NAIR, N; TAGLIENTISIAN, C; GAMETT, DC				ROBINSON, HL; TRACY, SE; NAIR, N; TAGLIENTISIAN, C; GAMETT, DC			CHARACTERIZATION FO AN ANGIOSARCOMA-INDUCING MUTATION IN THE ERBB ONCOGENE	ONCOGENE			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; GROWTH-FACTOR RECEPTOR; TISSUE-SPECIFIC TRANSFORMATION; C-ERBB; V-ERBB; TYROSINE KINASE; EGF RECEPTOR; CELLS; GENE; DOMAIN	The erbB oncogenes of two transducing viruses that arose in chicken 5005 have been molecularly characterized. One of these viruses, AEV-5005, caused erythroblastosis. The other, AAV-5005, caused angiosarcoma. Both viruses had identical 5' junctions of viral and host sequences, indicating that both arose from the same proviral insertion. The erbB oncogenes of both viruses encoded transmembrane, kinase and C-terminal domains of the chicken epidermal growth factor receptor. The C-terminal domain of the AEV-5005 erbB was complete, whereas that of AAV-5005 contained a 59 amino acid internal deletion (amino acids 993-1051 of the chicken epidermal growth factor receptor). Oncogenicity tests using retroviral constructs containing the erbB sequences from AEV-5005 and AAV-5005 demonstrated that both erbB genes caused erythroblastosis and that the 59 amino acid deletion conferred the ability to induce angiosarcoma. The 59 amino acid deletion also caused increased levels of erbB autophosphorylation in cells grown in the presence of sodium orthovanadate.	UNIV MASSACHUSETTS,MED CTR,DEPT MOLEC GENET & MICROBIOL,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester	ROBINSON, HL (corresponding author), UNIV MASSACHUSETTS,MED CTR,DEPT PATHOL,55 LAKE AVE N,WORCESTER,MA 01655, USA.			Tracy, Sharon/0000-0002-5731-5228	NATIONAL CANCER INSTITUTE [R01CA023086] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 23772, R01 CA 23086] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEUG H, 1986, J VIROL, V57, P1127, DOI 10.1128/JVI.57.3.1127-1138.1986; BRUSKIN A, 1990, ONCOGENE, V5, P15; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CHOI OR, 1986, MOL CELL BIOL, V6, P1751, DOI 10.1128/MCB.6.5.1751; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; DEBUIRE B, 1984, SCIENCE, V224, P1456, DOI 10.1126/science.6328658; Enzinger FM, 1983, SOFT TISSUE TUMORS, V1, P422; GAMETT DC, 1986, P NATL ACAD SCI USA, V83, P6053, DOI 10.1073/pnas.83.16.6053; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; HIHARA H, 1983, J NATL CANCER I, V70, P891; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JANSSON M, 1987, ONCOGENE, V1, P167; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; MAIHLE N J, 1988, Biochimica et Biophysica Acta, V948, P287; MILES BD, 1985, J VIROL, V54, P295, DOI 10.1128/JVI.54.2.295-303.1985; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NAIR N, 1992, MOL CELL BIOL, V12, P2010, DOI 10.1128/MCB.12.5.2010; NILSEN TW, 1985, CELL, V41, P719, DOI 10.1016/S0092-8674(85)80052-0; PELLEY RJ, 1989, P NATL ACAD SCI USA, V86, P7164, DOI 10.1073/pnas.86.18.7164; PELLEY RJ, 1988, J VIROL, V62, P1840, DOI 10.1128/JVI.62.5.1840-1844.1988; RAINES MA, 1985, P NATL ACAD SCI USA, V82, P2287, DOI 10.1073/pnas.82.8.2287; RAINES MA, 1988, J VIROL, V62, P2444, DOI 10.1128/JVI.62.7.2444-2452.1988; ROBINSON HL, 1985, J VIROL, V55, P617, DOI 10.1128/JVI.55.3.617-622.1985; SASAKI T, 1984, J BIOL CHEM, V259, P2489; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SHU HKG, 1991, J VIROL, V65, P6173, DOI 10.1128/JVI.65.11.6173-6180.1991; SHU HKG, 1990, P NATL ACAD SCI USA, V87, P9103, DOI 10.1073/pnas.87.23.9103; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; THEROUX SJ, 1992, J BIOL CHEM, V267, P7967; TRACY SE, 1985, J VIROL, V54, P304, DOI 10.1128/JVI.54.2.304-310.1985; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VIJAYA S, 1986, J VIROL, V60, P683, DOI 10.1128/JVI.60.2.683-692.1986; WALTON GM, 1990, J BIOL CHEM, V265, P1750; YAMAMOTO T, 1983, CELL, V34, P225, DOI 10.1016/0092-8674(83)90153-8; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X; YONEMOTO W, 1987, MOL CELL BIOL, V7, P905, DOI 10.1128/MCB.7.2.905	37	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2025	2030						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408143				2022-12-17	WOS:A1992JP42400017
J	PLET, A; TOURKINE, N; MECHTI, N; JEANTEUR, P; BLANCHARD, JM				PLET, A; TOURKINE, N; MECHTI, N; JEANTEUR, P; BLANCHARD, JM			INVIVO FOOTPRINTS BETWEEN THE MURINE C-MYC P1 AND P2 PROMOTERS	ONCOGENE			English	Article							E2F TRANSCRIPTION FACTOR; TRANS-ACTIVATION; GENE-REGULATION; PROTEIN; ELEMENT; INVITRO; TRANSACTIVATION; INITIATION; EXPRESSION; ACCURATE	Assuming that when transcription starts at the P2 promoter of the c-myc gene sites located immediately upstream from P2 are occupied whereas in the absence of initiation they are not, the polymerase chain reaction (PCR)-based method of Mueller & Wold 1(1989). Science, 246, 780-7861 was used to map in vivo footprints upstream from the P2 promoter in various mouse cell lines. In cultured Friend erythroleukemic cells induced to differentiate with dimethysulfoxide (DMSO), a clear protection corresponding to ME1a2 and E2F sites was observed, consistent with in vitro band-shift and footprint data. However, in cell lines in which the gene was either silent or truncated the footprints were no longer visible. Friend c-myc transcripts decreased to a barely detectable level after 3 h of DMSO treatment. Transcription, as measured by in vitro run-on, was turned off at the level of RNA polymerase elongation rather than initiation [Mechti N., Piechaczyk, M. Blanchard, J.-M., Marty, L., Bonnieu, A., Jeanteur. Ph. & Lebler, B. (1986). Nucleic Acids Res., 24, 9653-96661. The state of occupancy of the sites did not vary from the first hours up to 9 days of DMSO treatment, suggesting that DNA occupancy per se cannot explain premature termination, which rather would involve a more complex phenomenon.			PLET, A (corresponding author), CNRS, URA 1191, 2 PL EUGENE BATAILLON, F-34095 MONTPELLIER 5, FRANCE.							ASSELIN C, 1989, ONCOGENE, V4, P549; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BLANCHARD JM, 1988, BIOCHIMIE, V70, P877, DOI 10.1016/0300-9084(88)90228-3; BRAITHWAITE AW, 1991, NEW BIOL, V3, P18; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAHRLANDER PD, 1985, EMBO J, V4, P3195, DOI 10.1002/j.1460-2075.1985.tb04065.x; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; HALL DJ, 1990, ONCOGENE, V5, P47; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; KERPPOLA TK, 1988, MOL CELL BIOL, V8, P4389, DOI 10.1128/MCB.8.10.4389; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; MOBERG KH, 1991, J CELL PHYSIOL, V148, P75, DOI 10.1002/jcp.1041480110; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NISHIKURA K, 1986, MOL CELL BIOL, V6, P4093, DOI 10.1128/MCB.6.11.4093; PIECHACZYK M, 1987, TRENDS GENET, V3, P47, DOI 10.1016/0168-9525(87)90166-1; SACCA R, 1990, ONCOGENE, V5, P1499; SOBCZAK J, 1989, ONCOGENE, V4, P1503; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; SPENCER CA, 1991, ADV CANCER RES, V56, P1; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; TOURKINE N, 1989, ONCOGENE, V4, P973; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938	32	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1992	7	9					1847	1851						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501892				2022-12-17	WOS:A1992JJ37600021
J	ALMOUSTAFA, AE; QUATANNENS, B; DIETERLENLIEVRE, F; SAULE, S				ALMOUSTAFA, AE; QUATANNENS, B; DIETERLENLIEVRE, F; SAULE, S			TUMORIGENIC EFFECTS MEDIATED IN THE AVIAN EMBRYO BY ONE OR MORE ONCOGENES ASSOCIATED WITH V-MYC	ONCOGENE			English	Note							C-MYC; CELLS; TRANSFORMATION; E26; EXPRESSION; RETROVIRUS; DOMAINS; INVIVO; QUAIL; ERBA	We have previously shown that introduction of the v-myc oncogene in chick or quail embryos at E3 induces rapidly growing heart rhabdomyomas. We now report that a retrovirus containing one or two other oncogenes induces additional pathologies specified by the v-myc-associated oncogene. The v-mil/myc combination introduced at E3 induces, in addition to heart rhabdomyomas, tumors of proliferating celts aggregated onto the luminal aspect of vessels in both chick and quail embryos. In the quail these cells react positively with the quail-specific mAb QH1, which recognizes endothelial and most hemopoietic cells, while chick intravascular cells do not react with the chick-specific mAb VIA2 that recognizes hemopoietic cells. Thus the v-mil/myc tumors appear to be of endothelial origin. The v-myb-ets/myc combination injected at E3 induces cardiorhabdomyomas and aggressive VIA2-positive hemopoietic tumors in chick embryos, but only the v-myc-induced cardiorhabdomyomas in quail embryos. When injected into hatched animals, v-myc alone transforms hemopoietic and perhaps endothelial cells, but not cardiac cells. Thus the developmental stage at which a cell type can be transformed by v-myc and another associated oncogene depends on as yet undefined species-specific factors. More importantly, several examples of oncogene cooperation in vivo are adduced by these experiments. The type of cell transformed is specified by the viral oncogene combination.	CNRS,INST EMBRYOL CELLULAIRE & MOLEC,49BIS AV BELLE GABRIELLE,F-94130 NOGENT SUR MARNE,FRANCE; COLL FRANCE,F-75231 PARIS 05,FRANCE; INST PASTEUR,CNRS,URA 1160,F-59019 LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; College de France; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								ALEXANDER RW, 1979, J NATL CANCER I, V62, P359; ALMOUSTAFA AE, 1988, CELL DIFFER DEV, V25, P119, DOI 10.1016/0922-3371(88)90005-6; AMOUYEL P, 1989, J VIROL, V63, P3382, DOI 10.1128/JVI.63.8.3382-3388.1989; BACHNOU N, 1991, ONCOGENE, V6, P1041; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BECHADE C, 1988, J VIROL, V62, P1211; Begg AM, 1927, LANCET, V1, P912; BIEGALKE BJ, 1987, J VIROL, V61, P2139; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; FERRE F, 1986, CR ACAD SCI III-VIE, V303, P633; GEGONNE A, 1987, MOL CELL BIOL, V7, P806, DOI 10.1128/MCB.7.2.806; GRAF T, 1979, VIROLOGY, V99, P431, DOI 10.1016/0042-6822(79)90024-2; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; JAFFREDO T, 1989, DEVELOPMENT, V105, P679; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MARTIN P, 1986, J VIROL, V57, P1191, DOI 10.1128/JVI.57.3.1191-1194.1986; MARTIN P, 1986, VIROLOGY, V153, P272, DOI 10.1016/0042-6822(86)90030-9; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; MURRAY JA, 1930, SCI REP CANCER RES F, V9, P1; PARDANAUD L, 1987, DEVELOPMENT, V100, P339; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RONG PM, 1987, DEV BIOL, V122, P338, DOI 10.1016/0012-1606(87)90299-5; SAULE S, 1987, P NATL ACAD SCI USA, V84, P7982, DOI 10.1073/pnas.84.22.7982; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917	27	16	16	2	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1667	1670						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630827				2022-12-17	WOS:A1992JE81300027
J	PRONK, GJ; POLAKIS, P; WONG, G; DEVRIESSMITS, AMM; BOS, JL; MCCORMICK, F				PRONK, GJ; POLAKIS, P; WONG, G; DEVRIESSMITS, AMM; BOS, JL; MCCORMICK, F			ASSOCIATION OF A TYROSINE KINASE-ACTIVITY WITH GAP COMPLEXES IN V-SRC TRANSFORMED FIBROBLASTS	ONCOGENE			English	Note							GTPASE-ACTIVATING PROTEIN; RAS P21 GTPASE; PHOSPHOLIPASE-C; GENE-PRODUCT; VIRAL ONCOGENE; DOMAIN; PHOSPHORYLATION; RECEPTORS; BINDING; IDENTIFICATION	p21ras GAP is phosphorylated on tyrosine residues and associates with 62 kDa and 190 kDa tyrosine phosphorylated proteins in v-src-transformed fibroblasts. We were interested in identifying the tyrosine kinase responsible for phosphorylation of GAP and the two associated proteins. Here, we report that GAP-immunoprecipitates from v-src transformed cells contain a tyrosine kinase activity that phosphorylates GAP, p62 and p190. Tryptic peptide analysis indicated that the sites phosphorylated in vitro and in vivo are indistinguishable, suggesting that the precipitated kinase could be responsible for tyrosine phosphorylation of GAP in vivo. The GAP-associated kinase activity might be due to v-src itself, because pp60v-src is able to associate with GAP in vitro and GAP can be phosphorylated by pp60v-src immunecomplexes.	UNIV UTRECHT,PHYSIOL CHEM LAB,VONDELLAAN 24,3521 GG UTRECHT,NETHERLANDS; CETUS CORP,DEPT MOLEC BIOL,EMERYVILLE,CA 94608	Utrecht University								ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BOYLE WJ, 1991, IN PRESS METHODS ENZ; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; EMORI Y, 1989, J BIOL CHEM, V264, P21885; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2991, DOI 10.1128/MCB.10.6.2991; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	33	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					389	394						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1549356				2022-12-17	WOS:A1992HG98200026
J	SACCHI, N; WENDTNER, CM; THIELE, CJ				SACCHI, N; WENDTNER, CM; THIELE, CJ			SINGLE-CELL DETECTION OF ETS-1 TRANSCRIPTS IN HUMAN NEUROECTODERMAL CELLS	ONCOGENE			English	Note							EWINGS-SARCOMA; DNA-BINDING; PROTOONCOGENE EXPRESSION; TRANSFORMING GENE; PROTO-ONCOGENES; SEQUENCE; PROTEINS; ERYTHROBLASTOSIS; LINES; NEUROEPITHELIOMA	The genes of the ets family are thought to code for a novel class of transcriptional factors. These proteins have a specific DNA-binding domain different from the basic domain of both the helix-loop-helix and leucine zipper families of DNA-binding proteins. The ets-1 gene product has been shown to bind to the enhancer region of the human T-cell receptor alpha-gene during thymocyte ontogeny. This finding explains the high expression of ets-1 observed in T cells and the correlation between ets-1 expression and the expression of the T-cell receptor gene during fetal development. The ets-1 gene is also possibly biologically active in neural cells. By using RNA in situ hybridization analysis, we demonstrate the presence of ets-1 transcripts in cells of peripheral embryonal neuroectodermal tumors, specifically neuroepithelioma and neuroblastoma. In addition, the gene is found transcribed in Ewing's sarcoma, postulated to be ontogenetically related to tumors derived from the neural crest.	NCI, PEDIAT ONCOL BRANCH, MOLEC GENET LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	SACCHI, N (corresponding author), NCI, MOLEC ONCOL LAB, FREDERICK, MD 21702 USA.							AMOUYEL P, 1988, BRAIN RES, V447, P149, DOI 10.1016/0006-8993(88)90976-6; BHAT NK, 1989, J IMMUNOL, V142, P672; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BIEDLER JL, 1989, CANCER RES, V41, P4678; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BRESSER J, 1987, GENE ANAL TECH, V4, P89, DOI 10.1016/0735-0651(87)90002-1; CAVAZZANA AO, 1987, AM J PATHOL, V127, P507; DONNER L, 1985, ADV NEUROBLASTOMA RE, P347; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; ISRAEL MA, 1989, PRINCIPLES PRACTICE, P623; JORCYK CL, 1991, ONCOGENE, V6, P523; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOIZUMI S, 1990, ONCOGENE, V5, P675; KOVAR H, 1990, ONCOGENE, V5, P1067; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIPINSKI M, 1987, CANCER RES, V47, P183; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; MAVROTHALASSITIS GJ, 1991, CELL GROWTH DIFFER, V2, P215; MCKEON C, 1988, CANCER RES, V48, P4307; MUJOO K, 1987, CANCER RES, V47, P1098; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; PAPAS TS, 1990, AM J MED GENET, P251; PRIBYL LJ, 1988, DEV BIOL, V127, P45, DOI 10.1016/0012-1606(88)90187-X; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; SACCHI N, 1988, LEUKEMIA, V2, P12; SETH A, 1990, ONCOGENESIS, P207; SHYAM E, 1990, CANCER RES, V50, P5013; THIELE CJ, 1988, ONCOGENE, V3, P281; THIELE CJ, 1987, J CLIN INVEST, V80, P804, DOI 10.1172/JCI113137; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WHANGPENG J, 1984, NEW ENGL J MED, V311, P584, DOI 10.1056/NEJM198408303110907	45	16	16	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1991	6	11					2149	2154						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1945417				2022-12-17	WOS:A1991GX11900028
J	COLLETTA, G; CIRAFICI, AM; DICARLO, A; CIARDIELLO, F; SALOMON, DS; VECCHIO, G				COLLETTA, G; CIRAFICI, AM; DICARLO, A; CIARDIELLO, F; SALOMON, DS; VECCHIO, G			CONSTITUTIVE EXPRESSION OF TRANSFORMING GROWTH FACTOR-ALPHA DOES NOT TRANSFORM RAT-THYROID EPITHELIAL-CELLS	ONCOGENE			English	Note							MURINE SARCOMA-VIRUS; ACCOMPANIES VIRAL TRANSFORMATION; TGF-ALPHA; INDUCTION; PHENOTYPE; BETA; RESPONSIVENESS; PROTOONCOGENE; KERATINOCYTES; FIBROBLASTS	To evaluate the role of transforming growth factor-alpha (TGF-alpha) in transformed rat thyroid epithelial cells, expression and production of TGF-alpha were measured in a normal rat thyroid epithelial cell line, FRTL-5, and in the same cells transformed by the Ki-ras oncogene. FRTL-5 cells transformed with Ki-ras exhibit a 5- to 7-fold increase in the levels of TGF-alpha-specific mRNA and a 3- to 4-fold enhancement of the amounts of TGF-alpha protein in the conditioned medium, as compared with the normal thyroid cells. Although conditioned medium from the Ki-ras transformed FRTL-5 cells or authentic epidermal growth factor or TGF-alpha are able to stimulate the anchorage-dependent growth of nontransformed FRTL-5 cells, neither conditioned medium nor the growth factors are able to induce the anchorage-independent growth of these cells in soft agar. FRTL-5 cells were then transfected with an expression vector plasmid containing the human TGF-alpha cDNA to directly ascertain if overexpression of this growth factor is able to induce transformation in these cells. The TGF-alpha-transfected FRTL-5 clones constitutively produced high amounts of TGF-alpha at a level equivalent to or greater than the level found in the conditioned medium from the Ki-ras transformed FRTL-5 clones. Moreover, in contrast to the Ki-ras transformed cells, the TGF-alpha transfectants were unable to grow in soft agar, did not form tumors in nude mice, and showed no reduction in the secretion of thyroglobulin. These data demonstrate that unlike Ki-ras, the constitutive expression of biologically active TGF-alpha is not entirely sufficient to elicit a transformed phenotype in these cells.	NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	COLLETTA, G (corresponding author), FAC MED & CHIRURG NAPLES,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,CNR,I-80121 NAPLES,ITALY.			Ciardiello, Fortunato/0000-0002-3369-4841				AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; ANZANO MA, 1985, MOL CELL BIOL, V5, P242, DOI 10.1128/MCB.5.1.242; BUICK RN, 1987, EXP CELL RES, V170, P300, DOI 10.1016/0014-4827(87)90308-9; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; CIARDIELLO F, 1988, MOL ENDOCRINOL, V2, P1202, DOI 10.1210/mend-2-12-1202; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; COLLETTA G, 1988, FEBS LETT, V228, P37, DOI 10.1016/0014-5793(88)80579-9; COLLETTA G, 1983, MOL CELL BIOL, V3, P2099, DOI 10.1128/MCB.3.11.2099; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DERYNCK R, 1986, J CELL BIOCHEM, V32, P293, DOI 10.1002/jcb.240320406; DICKSON RB, 1987, P NATL ACAD SCI USA, V84, P837, DOI 10.1073/pnas.84.3.837; DIMARCO E, 1989, ONCOGENE, V4, P831; FREIBERGER R, 1989, FRTL5 TODAY, P177; FUSCO A, 1981, INT J CANCER, V28, P655, DOI 10.1002/ijc.2910280519; FUSCO A, 1982, CANCER RES, V42, P618; FUSCO A, 1987, MOL CELL BIOL, V2, P337; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; IBERG N, 1989, J BIOL CHEM, V264, P19951; JAKOWLEW SB, 1988, ONCOGENE RES, V2, P135; KAPLAN PL, 1983, CELL, V33, P931, DOI 10.1016/0092-8674(83)90036-3; MCGEADY ML, 1989, ONCOGENE, V4, P1375; RIZZINO A, 1986, CANCER RES, V46, P2816; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SHANKAR V, 1989, MOL CARCINOGEN, V2, P1, DOI 10.1002/mc.2940020102; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; TRAMONTANO D, 1989, FRTL5 TODAY, P177; WEISSMAN B, 1985, MOL CELL BIOL, V5, P3386, DOI 10.1128/MCB.5.12.3386	29	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					583	587						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1709483				2022-12-17	WOS:A1991FR93900012
J	MIGNOTTE, B; LARCHER, JC; ZHENG, DQ; ESNAULT, C; COULAUD, D; FEUNTEUN, J				MIGNOTTE, B; LARCHER, JC; ZHENG, DQ; ESNAULT, C; COULAUD, D; FEUNTEUN, J			SV40 INDUCED CELLULAR IMMORTALIZATION - PHENOTYPIC CHANGES ASSOCIATED WITH THE LOSS OF PROLIFERATIVE CAPACITY IN A CONDITIONALLY IMMORTALIZED CELL-LINE	ONCOGENE			English	Article									INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,F-94805 VILLEJUIF,FRANCE; COLL FRANCE,BIOCHIM CELLULAIRE,F-75231 PARIS,FRANCE; INST GUSTAVE ROUSSY,MICROSCOPIE CELLULAIRE & MOLEC LAB,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,BIOCHIM & ENZYMOL LAB,F-94805 VILLEJUIF,FRANCE	UNICANCER; Gustave Roussy; UDICE-French Research Universities; PSL Research University Paris; College de France; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy			Feunteun, Jean/AAZ-1267-2020; Mignotte, Bernard/A-3499-2009	Mignotte, Bernard/0000-0002-8512-8518; Feunteun, Jean/0000-0003-1212-9189				ANDERSON L, 1981, P NATL ACAD SCI-BIOL, V78, P2407, DOI 10.1073/pnas.78.4.2407; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; CORRAL M, 1989, EXP CELL RES, V184, P158, DOI 10.1016/0014-4827(89)90374-1; DEAN PN, 1974, J CELL BIOL, V60, P523, DOI 10.1083/jcb.60.2.523; EHRHART JC, 1988, ONCOGENE, V3, P595; ESNAULT C, 1984, CANCER RES, V44, P4355; GLAICHENHAUS N, 1986, EMBO J, V5, P1261, DOI 10.1002/j.1460-2075.1986.tb04355.x; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; JACQUEMINSABLON H, 1990, BIOL CELL, V68, P227, DOI 10.1016/0248-4900(90)90312-Q; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; KAO HT, 1983, MOL CELL BIOL, V3, P2058, DOI 10.1128/MCB.3.11.2058; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LOWE DG, 1986, J BIOL CHEM, V261, P2102; MIZZEN LA, 1989, J BIOL CHEM, V264, P20664; MODICANAPOLITANO JS, 1989, CANCER RES, V49, P3369; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; NASS MMK, 1983, EXP CELL RES, V148, P47; OBERLEY LW, 1989, MOL CELL BIOCHEM, V84, P147; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PETIT CA, 1983, VIROLOGY, V127, P74, DOI 10.1016/0042-6822(83)90372-0; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SAWAI ET, 1989, J VIROL, V63, P3961, DOI 10.1128/JVI.63.9.3961-3973.1989; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; TAYLOR ICA, 1989, J BIOL CHEM, V264, P16160; VAYSSIERE JL, 1987, BIOCHEM BIOPH RES CO, V145, P443, DOI 10.1016/0006-291X(87)91341-6; WALDINGER D, 1989, EUR J CELL BIOL, V50, P435; WEINBERG RA, 1989, CANCER RES, V49, P3713; WU BJ, 1986, MOL CELL BIOL, V6, P2994, DOI 10.1128/MCB.6.8.2994; ZUCKERMAN SH, 1984, BIOCHIM BIOPHYS ACTA, V804, P285, DOI 10.1016/0167-4889(84)90131-9	33	16	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1990	5	10					1529	1533						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK502	2174526				2022-12-17	WOS:A1990EK50200012
J	HSIAO, WLW; PAI, HLH; MATSUI, MS; WEINSTEIN, IB				HSIAO, WLW; PAI, HLH; MATSUI, MS; WEINSTEIN, IB			EFFECTS OF SPECIFIC FATTY-ACIDS ON CELL-TRANSFORMATION INDUCED BY AN ACTIVATED C-H-RAS ONCOGENE	ONCOGENE			English	Article									COLUMBIA UNIV HLTH SCI,SCH PUBL HLTH,CTR COMPREHENS CANC,NEW YORK,NY 10032; COLUMBIA UNIV HLTH SCI,SCH PUBL HLTH,INST CANC RES,NEW YORK,NY 10032; COLUMBIA UNIV HLTH SCI,SCH PUBL HLTH,DIV ENVIRONM SCI,NEW YORK,NY 10032; COLUMBIA UNIV HLTH SCI,DEPT DERMATOL,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University; Columbia University					NCI NIH HHS [CA 02656] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AYLSWORTH CF, 1987, LIPIDS, V22, P445, DOI 10.1007/BF02537277; BACCHETTI S, 1977, P NATL ACAD SCI USA, V74, P1590, DOI 10.1073/pnas.74.4.1590; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.biochem.56.1.159; BUSS JE, 1986, MOL CELL BIOL, V6, P116, DOI 10.1128/MCB.6.1.116; CORREA P, 1981, CANCER RES, V41, P3685; FIELD CJ, 1984, NUTR RES, V4, P743, DOI 10.1016/S0271-5317(84)80050-0; FOLCH J, 1957, J BIOL CHEM, V226, P497; FREEMAN AE, 1970, J NATL CANCER I, V44, P65; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; HSIAO WLW, 1987, MOL CELL BIOL, V7, P3380, DOI 10.1128/MCB.7.10.3380; HSIAO WLW, 1984, SCIENCE, V226, P552, DOI 10.1126/science.6436974; HSIAO WLW, 1986, MOL CELL BIOL, V6, P1087; Kalamegham R, 1984, Nutr Cancer, V6, P22, DOI 10.1080/01635588509513803; LEVINE L, 1981, ADV CANCER RES, V35, P49, DOI 10.1016/S0065-230X(08)60908-2; LOPES CA, 1989, IN PRESS MOL CARCINO; MATSUI MS, 1987, CANCER RES, V47, P2385; MCGEE R, 1981, BIOCHIM BIOPHYS ACTA, V663, P314, DOI 10.1016/0005-2760(81)90217-4; MERRILL AH, 1989, NUTR REV, V47, P161; MORRISON WR, 1964, J LIPID RES, V5, P600; MURAKAMI K, 1985, FEBS LETT, V192, P189, DOI 10.1016/0014-5793(85)80105-8; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; REDDY BS, 1981, CANCER RES, V41, P3700; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WEINSTEIN IB, 1978, CARCINOGENESIS, V2, P313; WELSCH CW, 1983, J NATL CANCER I, V70, P215; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WYNDER EL, 1979, CANCER, V43, P1955, DOI 10.1002/1097-0142(197905)43:5+<1955::AID-CNCR2820430702>3.0.CO;2-K	30	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1990	5	3					417	421						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	2107493				2022-12-17	WOS:A1990CW41500021
J	KING, FJ; COLE, MD				KING, FJ; COLE, MD			MOLECULAR-CLONING AND SEQUENCING OF THE MURINE C-FGR GENE	ONCOGENE			English	Article											KING, FJ (corresponding author), PRINCETON UNIV,DEPT BIOL,LEWIS THOMAS LAB,PRINCETON,NJ 08544, USA.							ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BAUMBACH WR, 1987, MOL CELL BIOL, V7, P664, DOI 10.1128/MCB.7.2.664; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; BUSS JE, 1984, MOL CELL BIOL, V4, P2697, DOI 10.1128/MCB.4.12.2697; CHEAH MSC, 1986, NATURE, V319, P238, DOI 10.1038/319238a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FOSTER DA, 1986, MOL CELL BIOL, V6, P325, DOI 10.1128/MCB.6.1.325; GARBER EA, 1985, MOL CELL BIOL, V5, P2781, DOI 10.1128/MCB.5.10.2781; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KAPPES B, 1989, ONCOGENE, V4, P363; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KEATH EJ, 1984, CELL, V37, P521, DOI 10.1016/0092-8674(84)90382-9; KOREN HS, 1975, J IMMUNOL, V114, P894; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; Maniatis T., 1982, MOL CLONING; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; METCALF D, 1969, J NATL CANCER I, V43, P983; METCALF D, 1982, INT J CANCER, V30, P773, DOI 10.1002/ijc.2910300616; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; NAHARRO G, 1983, J VIROL, V47, P611, DOI 10.1128/JVI.47.3.611-619.1983; NAHARRO G, 1983, VIROLOGY, V125, P502, DOI 10.1016/0042-6822(83)90223-4; NICOLA NA, 1982, J CELL PHYSIOL, V112, P257, DOI 10.1002/jcp.1041120215; PERLMUTTER R M, 1988, Biochimica et Biophysica Acta, V948, P245; PERRICAUDET M, 1980, P NATL ACAD SCI-BIOL, V77, P3778, DOI 10.1073/pnas.77.7.3778; Potts W M, 1988, Oncogene Res, V3, P343; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; RASHEED S, 1982, VIROLOGY, V117, P238, DOI 10.1016/0042-6822(82)90522-0; RAVE N, 1979, NUCLEIC ACIDS RES, V6, P3559, DOI 10.1093/nar/6.11.3559; RESH MD, 1988, MOL CELL BIOL, V8, P1896, DOI 10.1128/MCB.8.5.1896; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; YI TL, 1989, ONCOGENE, V4, P1081; ZELLER MJ, 1983, J BIOL CHEM, V256, P10837	49	16	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1990	5	3					337	344						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	2179817				2022-12-17	WOS:A1990CW41500011
J	VANROY, F; LIEBAUT, G; MAREEL, M; FIERS, W				VANROY, F; LIEBAUT, G; MAREEL, M; FIERS, W			PARTIAL TRANSFORMATION OF HUMAN TUMOR-CELL LINES SHOWING DEFECTIVE INTERACTION BETWEEN UNUSUAL P53 GENE-PRODUCT AND SV40 LARGE-T ANTIGEN	ONCOGENE			English	Article									STATE UNIV GHENT,EXPTL CANCEROL LAB,B-9000 GHENT,BELGIUM	Ghent University	VANROY, F (corresponding author), STATE UNIV GHENT,MOLEC BIOL LAB,B-9000 GHENT,BELGIUM.		van Roy, Frans M/C-6123-2009	van Roy, Frans M/0000-0003-4358-1039				AZZARONE B, 1985, RETROVIRUSES HUMAN P, P473; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BENCHIMOL S, 1982, EMBO J, V1, P1055, DOI 10.1002/j.1460-2075.1982.tb01296.x; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; CHANG S E, 1986, Biochimica et Biophysica Acta, V823, P161, DOI 10.1016/0304-419X(86)90001-6; CHO HY, 1976, SCIENCE, V194, P951, DOI 10.1126/science.62397; CRAWFORD L, 1985, BIOESSAYS, V3, P117, DOI 10.1002/bies.950030307; CRAWFORD L, 1982, J VIROL, V42, P612, DOI 10.1128/JVI.42.2.612-620.1982; CRAWFORD L, 1983, INT REV EXP PATHOL, V25, P1; CRAWFORD LV, 1981, P NATL ACAD SCI-BIOL, V78, P41, DOI 10.1073/pnas.78.1.41; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; EHRHART JC, 1988, ONCOGENE, V3, P595; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1988, ONCOGENE, V3, P313; FANNING E, 1981, J GEN VIROL, V55, P367, DOI 10.1099/0022-1317-55-2-367; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Gluzman Y, 1980, Cold Spring Harb Symp Quant Biol, V44 Pt 1,, P293; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KLEIN G, 1982, ADV VIRAL ONCOLOGY, V2; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; MAREEL M, 1979, VIRCHOWS ARCH B, V30, P95; Mareel M M, 1987, J Cell Sci Suppl, V8, P141; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MCALLISTER RM, 1971, CANCER-AM CANCER SOC, V27, P397, DOI 10.1002/1097-0142(197102)27:2<397::AID-CNCR2820270224>3.0.CO;2-X; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; OHARA BM, 1988, ONCOGENE, V3, P295; OREILLY DR, 1986, BIOL CELL, V57, P187, DOI 10.1111/j.1768-322X.1986.tb00475.x; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; POHL J, 1988, MOL CELL BIOL, V8, P2078, DOI 10.1128/MCB.8.5.2078; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; RHIM JS, 1977, INT J CANCER, V19, P505, DOI 10.1002/ijc.2910190411; RHIM JS, 1975, INT J CANCER, V16, P840, DOI 10.1002/ijc.2910160516; ROVINSKI B, 1988, ONCOGENE, V2, P445; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; STURZBECHER HW, 1987, ONCOGENE, V1, P201; TAINSKY MA, 1987, MOL CELL BIOL, V7, P1280, DOI 10.1128/MCB.7.3.1280; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; THATHAMANGALAM U, 1986, VIROLOGY, V155, P132, DOI 10.1016/0042-6822(86)90174-1; TODARO GJ, 1974, J NATL CANCER I, V52, P167, DOI 10.1093/jnci/52.1.167; VANROY F, 1983, J VIROL, V45, P315, DOI 10.1128/JVI.45.1.315-331.1983; VANROY F, 1981, J VIROL, V40, P28, DOI 10.1128/JVI.40.1.28-44.1981; VANROY FM, 1986, CANCER RES, V46, P4787; VILCEK J, 1973, P NATL ACAD SCI USA, V70, P3909, DOI 10.1073/pnas.70.12.3909; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4	62	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1990	5	2					207	218						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU029	2157184				2022-12-17	WOS:A1990CU02900007
J	SULLIVAN, NF; WILLIS, AE; MOORE, JP; LINDAHL, T				SULLIVAN, NF; WILLIS, AE; MOORE, JP; LINDAHL, T			HIGH-LEVELS OF THE C-MYC PROTEIN IN CELL-LINES OF BLOOM SYNDROME ORIGIN	ONCOGENE			English	Note									CHESTER BEATTY INST CANC RES,LONDON SW3 6JB,ENGLAND	University of London; Institute of Cancer Research - UK	SULLIVAN, NF (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.			Willis, Anne/0000-0002-1470-8531				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; CHAN JYH, 1987, NATURE, V325, P357, DOI 10.1038/325357a0; DETHE G, 1978, NATURE, V274, P756, DOI 10.1038/274756a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; EVANS HJ, 1982, SISTER CHROMATID EXC, P184; GERMAN J, 1989, CLIN GENET, V35, P57; German J., 1983, CHROMOSOME MUTATION, P97; HENDERSON EE, 1980, CHEM-BIOL INTERACT, V33, P63, DOI 10.1016/0009-2797(80)90044-7; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LANGLOIS RG, 1989, P NATL ACAD SCI USA, V86, P670, DOI 10.1073/pnas.86.2.670; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MOORE JP, 1987, ONCOGENE RES, V2, P65; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; RUNGER TM, 1989, EMBO J, V8, P1419, DOI 10.1002/j.1460-2075.1989.tb03523.x; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SHIRAISHI Y, 1986, P NATL ACAD SCI USA, V82, P5102; SULLIVAN NF, 1989, ONCOGENE, V4, P1497; VILPO JA, 1989, MUTAT RES, V210, P59, DOI 10.1016/0027-5107(89)90044-4; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448; WEKSBERG R, 1988, AM J HUM GENET, V42, P816; WILLIS AE, 1989, CARCINOGENESIS, V10, P217, DOI 10.1093/carcin/10.1.217; WILLIS AE, 1987, NATURE, V325, P355, DOI 10.1038/325355a0; WILLIS AE, 1987, P NATL ACAD SCI USA, V84, P8016, DOI 10.1073/pnas.84.22.8016	23	16	16	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1989	4	12					1509	1511						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659	2687770				2022-12-17	WOS:A1989CB65900014
J	LIU, E; SANTOS, G; LEE, WMF; OSBORNE, CK; BENZ, CC				LIU, E; SANTOS, G; LEE, WMF; OSBORNE, CK; BENZ, CC			EFFECTS OF C-MYC OVEREXPRESSION ON THE GROWTH-CHARACTERISTICS OF MCF-7 HUMAN-BREAST CANCER-CELLS	ONCOGENE			English	Article									UNIV N CAROLINA,CURRICULUM GENET,CHAPEL HILL,NC 27599; UNIV CALIF SAN FRANCISCO,CANC RES INST,SAN FRANCISCO,CA 94143; UNIV TEXAS,HLTH SCI CTR,DEPT MED,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,DIV ONCOL,SAN ANTONIO,TX 78284	University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California San Francisco; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	LIU, E (corresponding author), UNIV N CAROLINA,LINEBERGER CANC RES CTR,DEPT MED,CB 7295,ROOM 227,CHAPEL HILL,NC 27599, USA.		Liu, Edison/C-4141-2008		NATIONAL CANCER INSTITUTE [K08CA001036, P01CA044768, R01CA036773] Funding Source: NIH RePORTER; NCI NIH HHS [CA-44768, 7-K08-CA01036-03, CA 36773] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BENZ C, 1986, CANCER RES, V46, P2276; BENZ C, 1987, MOL PHARMACOL, V32, P13; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CARLONI G, 1988, FEBS LETT, V233, P269; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; EVANS GI, 1985, MOL CELL BIOL, V6, P3610; EVANS JL, 1987, J IMMUNOL, V139, P3497; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; FRIEDMAN MA, 1981, CANCER, V47, P134, DOI 10.1002/1097-0142(19810101)47:1<134::AID-CNCR2820470122>3.0.CO;2-M; HOFFMAN PG, 1980, CANCER, V46, P2801, DOI 10.1002/1097-0142(19801215)46:12+<2801::AID-CNCR2820461412>3.0.CO;2-W; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LAVIALLE C, 1988, ONCOGENE, V3, P335; LEE WMF, 1985, MOL CELL BIOL, V5, P3345, DOI 10.1128/MCB.5.12.3345; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; LIU E, 1988, P NATL ACAD SCI USA, V85, P1952, DOI 10.1073/pnas.85.6.1952; LOKE SL, 1988, AM J PATHOL, V131, P29; Maniatis T., 1982, MOL CLONING; OSBORNE CK, 1985, CANCER RES, V45, P584; SCHWAB M, 1986, MOL CELL BIOL, V6, P2752, DOI 10.1128/MCB.6.7.2752; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAUB R, 1982, P NATL ACAD SCI USA, V79, P7824; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VARLEY JM, 1987, ONCOGENE, V1, P423; VARLEY JM, 1988, ONCOGENE, V3, P87; YOKOTA S, 1987, J IMMUNOL, V139, P2810; ZERLIN M, 1987, ONCOGENE, V1, P19	39	16	16	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1989	4	8					979	984						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AJ297	2668848				2022-12-17	WOS:A1989AJ29700005
J	PULLANO, TG; SINN, E; CARNEY, WP				PULLANO, TG; SINN, E; CARNEY, WP			CHARACTERIZATION OF MONOCLONAL-ANTIBODY R256, SPECIFIC FOR ACTIVATED RAS P21 WITH ARGININE AT 12, AND ANALYSIS OF BREAST-CARCINOMA OF V-HARVEY-RAS TRANSGENIC MOUSE	ONCOGENE			English	Article									HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School	PULLANO, TG (corresponding author), DUPONT CO,ONCOGENE RES GRP,DEPT MED PROD,N BILLERICA,MA 01862, USA.							ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; CARNEY WP, 1986, P NATL ACAD SCI USA, V83, P7485, DOI 10.1073/pnas.83.19.7485; CARNEY WP, 1988, HUMAN TUMOR ANTIGENS, P53; CLARK R, 1985, P NATL ACAD SCI USA, V82, P5280, DOI 10.1073/pnas.82.16.5280; Cooper G M, 1984, Biochim Biophys Acta, V738, P9, DOI 10.1016/0304-419X(84)90017-9; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; DER CJ, 1983, CELL, V32, P201, DOI 10.1016/0092-8674(83)90510-X; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FEIG LA, 1987, MOL ENDOCRINOL, V1, P127, DOI 10.1210/mend-1-2-127; FINKEL T, 1984, CELL, V37, P151, DOI 10.1016/0092-8674(84)90310-6; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GALFRE G, 1979, NATURE, V277, P131, DOI 10.1038/277131a0; GUERRERO I, 1986, J CELL PHYSIOL, V129, P71, DOI 10.1002/jcp.1041290111; GUERRERO I, 1984, P NATL ACAD SCI-BIOL, V81, P202, DOI 10.1073/pnas.81.1.202; KAGAN A, 1979, METHOD HORM RADIOIMM, P327; KRAUS MH, 1984, P NATL ACAD SCI-BIOL, V81, P5384, DOI 10.1073/pnas.81.17.5384; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PAPAGEORGE AG, 1986, MOL CELL BIOL, V6, P1843, DOI 10.1128/MCB.6.5.1843; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RODENHUIS S, 1988, CANCER RES, V48, P5738; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SRIVASTAVA SK, 1985, P NATL ACAD SCI USA, V82, P38, DOI 10.1073/pnas.82.1.38; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YUASA Y, 1983, NATURE, V303, P775, DOI 10.1038/303775a0	32	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1989	4	8					1003	1008						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AJ297	2474786				2022-12-17	WOS:A1989AJ29700009
J	MITSUNOBU, F; FUKUI, M; ODA, T; YAMAMOTO, T; TOYOSHIMA, K				MITSUNOBU, F; FUKUI, M; ODA, T; YAMAMOTO, T; TOYOSHIMA, K			A MECHANISM OF C-RAF-1 ACTIVATION - FUSION OF THE LIPOCORTIN-II AMINO-TERMINAL SEQUENCE WITH THE C-RAF-1 KINASE DOMAIN	ONCOGENE			English	Article									UNIV TOKYO,INST MED SCI,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN; OKAYAMA UNIV,SCH MED,OKAYAMA 700,JAPAN	University of Tokyo; Okayama University			MITSUNOBU, Fumihiro/B-1983-2011					BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P4743; COOPER JA, 1983, CURR TOP MICROBIOL, V107, P125; DAVIS RW, 1982, ADV BACTERIAL GENET, P109; ERIKSON E, 1980, CELL, V21, P829, DOI 10.1016/0092-8674(80)90446-8; FUKUI M, 1985, P NATL ACAD SCI USA, V82, P5954, DOI 10.1073/pnas.82.17.5954; FUKUI M, 1987, MOL CELL BIOL, V7, P1776, DOI 10.1128/MCB.7.5.1776; GLENNEY J, 1986, P NATL ACAD SCI USA, V83, P4258, DOI 10.1073/pnas.83.12.4258; GLENNEY JR, 1985, P NATL ACAD SCI USA, V82, P7884, DOI 10.1073/pnas.82.23.7884; GLENNEY JR, 1986, J BIOL CHEM, V261, P485; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HUANG KS, 1986, CELL, V46, P191, DOI 10.1016/0092-8674(86)90736-1; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; ISHIKAWA F, 1986, P NATL ACAD SCI USA, V83, P3209, DOI 10.1073/pnas.83.10.3209; JOHNSSON N, 1986, FEBS LETT, V198, P361, DOI 10.1016/0014-5793(86)80437-9; KAWAI S, 1980, J VIROL, V34, P772, DOI 10.1128/JVI.34.3.772-776.1980; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MANIATIS T, 1975, P NATL ACAD SCI USA, V72, P1184, DOI 10.1073/pnas.72.3.1184; MOLDERS H, 1985, EMBO J, V4, P693, DOI 10.1002/j.1460-2075.1985.tb03685.x; OHASHI M, 1980, EXP GERONTOL, V15, P121, DOI 10.1016/0531-5565(80)90083-2; PEPINSKY RB, 1986, J BIOL CHEM, V261, P4239; RADKE K, 1980, CELL, V21, P821, DOI 10.1016/0092-8674(80)90445-6; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIS CJM, 1986, CELL, V46, P201, DOI 10.1016/0092-8674(86)90737-3; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHIMIZU K, 1985, P NATL ACAD SCI USA, V82, P5641, DOI 10.1073/pnas.82.17.5641; SUTRAVE P, 1984, NATURE, V309, P85, DOI 10.1038/309085a0; TAHIRA T, 1987, NUCLEIC ACIDS RES, V15, P4809, DOI 10.1093/nar/15.12.4809; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	39	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1989	4	4					437	442						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5677	2524024				2022-12-17	WOS:A1989U567700007
J	KHANDJIAN, EW; GAUCHAT, JF				KHANDJIAN, EW; GAUCHAT, JF			ONE SINGLE BURST OF SV40-GENE EXPRESSION INDUCES CELL-PROLIFERATION IN TRANSFORMING INFECTION OF MOUSE CELLS	ONCOGENE			English	Article									QUAI ERNEST ANSERMET,DEPT MOLEC BIOL 30,CH-1211 GENEVA 4,SWITZERLAND									ACHESON NH, 1980, MOL BIOL TUMOR VIR 2, P125; Anderson CW., 1986, CANC CELLS, V4, P395; CARROLL RB, 1974, P NATL ACAD SCI USA, V71, P3754, DOI 10.1073/pnas.71.9.3754; CHIA W, 1981, P NATL ACAD SCI-BIOL, V78, P6638, DOI 10.1073/pnas.78.11.6638; CRAWFORD L, 1983, INT REV EXP PATHOL, V25, P1; DARLIX JL, 1984, P NATL ACAD SCI-BIOL, V81, P5425, DOI 10.1073/pnas.81.17.5425; DEFROMENTEL CC, 1986, EXP CELL RES, V164, P35, DOI 10.1016/0014-4827(86)90452-0; DENHARDT DT, 1986, BIOCHIM BIOPHYS ACTA, V865, P83, DOI 10.1016/0304-419X(86)90024-7; DUTHU A, 1985, VIROLOGY, V147, P275, DOI 10.1016/0042-6822(85)90130-8; ERNOULTLANGE M, 1984, J VIROL, V50, P163, DOI 10.1128/JVI.50.1.163-173.1984; FUKS P, 1967, ISRAEL J MED SCI, V3, P912; FYRBERG EA, 1980, CELL, V19, P365, DOI 10.1016/0092-8674(80)90511-5; GARIGLIO P, 1981, NUCLEIC ACIDS RES, V9, P2589, DOI 10.1093/nar/9.11.2589; GAUCHAT JF, 1986, NUCLEIC ACIDS RES, V14, P9339, DOI 10.1093/nar/14.23.9339; GAUCHAT JF, 1985, THESIS U GENEVA SWIT; GILDEN RV, 1965, P NATL ACAD SCI USA, V53, P684, DOI 10.1073/pnas.53.3.684; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HANDA H, 1980, J VIROL, V34, P592, DOI 10.1128/JVI.34.3.592-597.1980; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P504, DOI 10.1016/0006-291X(73)90740-7; HISCOTT JB, 1981, J VIROL, V37, P802, DOI 10.1128/JVI.37.2.802-812.1981; KHANDJIAN EW, 1982, P NATL ACAD SCI-BIOL, V79, P1139, DOI 10.1073/pnas.79.4.1139; KHANDJIAN EW, 1986, MOL BIOL REP, V11, P107, DOI 10.1007/BF00364822; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1985, PROC R SOC SER B-BIO, V226, P25, DOI 10.1098/rspb.1985.0077; LANGE M, 1981, J VIROL, V38, P940, DOI 10.1128/JVI.38.3.940-951.1981; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MANIATIS T, 1982, MOL CLONING LABORATO; MATTER JM, 1983, NUCLEIC ACIDS RES, V11, P1039, DOI 10.1093/nar/11.4.1039; MAY E, 1973, P NATL ACAD SCI USA, V70, P1654, DOI 10.1073/pnas.70.6.1654; MAY E, 1971, P NATL ACAD SCI USA, V68, P1208, DOI 10.1073/pnas.68.6.1208; Monier R., 1986, PAPOVAVIRIDAE, V1, P247; MUELLER C, 1978, CELL, V15, P579, DOI 10.1016/0092-8674(78)90026-0; OMILLI F, 1986, MOL CELL BIOL, V6, P1875, DOI 10.1128/MCB.6.6.1875; PUVION E, 1988, IN PRESS EXP CELL RE; RIGBY PWJ, 1985, PROC R SOC SER B-BIO, V226, P15, DOI 10.1098/rspb.1985.0076; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SCHWYZER M, 1980, J BIOL CHEM, V255, P5627; SEILERTUYNS A, 1981, J MOL BIOL, V151, P607, DOI 10.1016/0022-2836(81)90426-5; SETZER DR, 1980, CELL, V22, P361, DOI 10.1016/0092-8674(80)90346-3; SPECTOR DL, 1987, ONCOGENE, V1, P5; STOKER M, 1968, NATURE, V218, P234, DOI 10.1038/218234a0; TJIAN R, 1978, P NATL ACAD SCI USA, V75, P1279, DOI 10.1073/pnas.75.3.1279; TOPP WC, 1980, MOL BIOL TUMOR VIR 2, P205; WEIL R, 1978, BIOCHIM BIOPHYS ACTA, V516, P301, DOI 10.1016/0304-419X(78)90012-4; WINOCOUR E, 1963, VIROLOGY, V19, P158, DOI 10.1016/0042-6822(63)90005-9	47	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1988	3	2					195	200						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	2842716				2022-12-17	WOS:A1988Q053400010
J	JANSSEN, JWG; STEENVOORDEN, ACM; LOSEKOOT, M; BARTRAM, CR				JANSSEN, JWG; STEENVOORDEN, ACM; LOSEKOOT, M; BARTRAM, CR			NOVEL TRANSFORMING SEQUENCES IN HUMAN ACUTE MYELOCYTIC-LEUKEMIA CELL-LINES	ONCOGENE			English	Article									UNIV ULM, DEPT PEDIAT 2, MOLEC BIOL SECT, D-7900 ULM, GERMANY; NETHERLANDS CANC INST, DIV MOLEC BIOL, 1066 CX AMSTERDAM, NETHERLANDS	Ulm University; Netherlands Cancer Institute			Losekoot, Monique/AAC-2182-2022					BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BRADLEY TR, 1982, BRIT J HAEMATOL, V51, P595, DOI 10.1111/j.1365-2141.1982.tb02823.x; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; COOPER GM, 1983, BIOCHIM BIOPHYS ACTA, V738, P9; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; DETAISNE C, 1984, NATURE, V310, P581, DOI 10.1038/310581a0; DIAMOND A, 1983, NATURE, V305, P112, DOI 10.1038/305112a0; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FRANCHINI G, 1981, NATURE, V290, P154, DOI 10.1038/290154a0; FUKUI M, 1985, P NATL ACAD SCI USA, V82, P5954, DOI 10.1073/pnas.82.17.5954; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GROFFEN J, 1983, J EXP MED, V158, P9, DOI 10.1084/jem.158.1.9; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; HEISTERKAMP N, 1983, Journal of Molecular and Applied Genetics, V2, P57; HEISTERKAMP N, 1983, VIROLOGY, V126, P248, DOI 10.1016/0042-6822(83)90476-2; HERRMANN R, 1980, CANCER-AM CANCER SOC, V46, P1383, DOI 10.1002/1097-0142(19800915)46:6<1383::AID-CNCR2820460616>3.0.CO;2-Y; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; JANSSEN JWG, 1985, CANCER RES, V45, P3262; JONES M, 1980, P NATL ACAD SCI-BIOL, V77, P2651, DOI 10.1073/pnas.77.5.2651; KOEFFLER HP, 1978, SCIENCE, V200, P1153, DOI 10.1126/science.306682; LEPRINCE D, 1983, EMBO J, V2, P1073, DOI 10.1002/j.1460-2075.1983.tb01548.x; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MCCOY MS, 1983, NATURE, V302, P79, DOI 10.1038/302079a0; MOLDERS H, 1985, EMBO J, V4, P693, DOI 10.1002/j.1460-2075.1985.tb03685.x; NEEDLEMAN SW, 1986, BLOOD, V67, P753; OCHIYA T, 1986, P NATL ACAD SCI USA, V83, P4993, DOI 10.1073/pnas.83.14.4993; PADUA RA, 1984, NATURE, V311, P671, DOI 10.1038/311671a0; PARKER RC, 1985, MOL CELL BIOL, V5, P831, DOI 10.1128/MCB.5.4.831; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RUBIN CM, 1980, NATURE, V284, P372, DOI 10.1038/284372a0; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SHIMIZU K, 1985, P NATL ACAD SCI USA, V82, P5641, DOI 10.1073/pnas.82.17.5641; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; WOLF D, 1985, MOL CELL BIOL, V5, P1887, DOI 10.1128/MCB.5.8.1887; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	46	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1987	1	2					175	179						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J6352	3325881				2022-12-17	WOS:A1987J635200010
J	KUROSAWA, H; YAMADA, M; NAKAGOME, Y				KUROSAWA, H; YAMADA, M; NAKAGOME, Y			RESTRICTION FRAGMENT LENGTH POLYMORPHISMS OF THE HUMAN N-MYC GENE - RELATIONSHIP TO GENE AMPLIFICATION	ONCOGENE			English	Article									NATL CHILDRENS MED RES CTR,3-35-31 TAISHIDO,SETAGAYA KU,TOKYO 154,JAPAN; DOKKYO UNIV,SCH MED,DEPT PEDIAT 2,MIBU,TOCHIGI 32102,JAPAN	National Center for Child Health & Development - Japan; Dokkyo Medical University								BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; BRODEUR G M, 1986, Cancer, V58, P541, DOI 10.1002/1097-0142(19860715)58:2+<541::AID-CNCR2820581322>3.0.CO;2-2; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; GARSON JA, 1986, LANCET, V1, P1496; GERHARD DS, 1987, NATURE, V325, P73, DOI 10.1038/325073a0; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; ISHIKAWA S, 1977, ACTA PATHOL JAPON, V27, P697; JULIER C, 1985, CYTOGENET CELL GENET, V40, P664; KINZLER KW, 1986, P NATL ACAD SCI USA, V83, P1031, DOI 10.1073/pnas.83.4.1031; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; KOUFOS A, 1985, NATURE, V316, P330, DOI 10.1038/316330a0; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; KRONTIRIS TG, 1985, NATURE, V313, P369, DOI 10.1038/313369a0; KUGA N, 1975, GANN, V66, P547; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; LIDEREAU R, 1985, P NATL ACAD SCI USA, V82, P7068, DOI 10.1073/pnas.82.20.7068; MANITATIS T, 1982, MOL CLONING LABORATO; MATHIEUMAHUL D, 1985, HUM GENET, V71, P41, DOI 10.1007/BF00295666; MITANI K, 1986, JPN J CANCER RES, V77, P1062; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; SCHWAB M, 1984, NATURE, V308, P288, DOI 10.1038/308288a0; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SLAMON DJ, 1986, SCIENCE, V232, P768, DOI 10.1126/science.3008339; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; THEIN SL, 1986, NATURE, V321, P84, DOI 10.1038/321084a0; TSUI LC, 1985, SCIENCE, V230, P1054, DOI 10.1126/science.2997931; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WAINSCOAT JS, 1986, NATURE, V319, P491, DOI 10.1038/319491a0; XU DQ, 1985, P NATL ACAD SCI USA, V82, P2862, DOI 10.1073/pnas.82.9.2862; XU DQ, 1986, P NATL ACAD SCI USA, V83, P3447, DOI 10.1073/pnas.83.10.3447; YAMADA M, 1985, P NATL ACAD SCI USA, V82, P3567, DOI 10.1073/pnas.82.11.3567; YAMADA M, 1982, GENE, V18, P309; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	41	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	2	1					85	90						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	L4813	2894002				2022-12-17	WOS:A1987L481300013
J	Mazziotta, C; Rotondo, JC; Lanzillotti, C; Campione, G; Martini, F; Tognon, M				Mazziotta, Chiara; Rotondo, John Charles; Lanzillotti, Carmen; Campione, Giulia; Martini, Fernanda; Tognon, Mauro			Cancer biology and molecular genetics of A(3) adenosine receptor	ONCOGENE			English	Review							CELL-CYCLE ARREST; CL-IB-MECA; PROMOTER HYPERMETHYLATION; SEMEN SAMPLES; AGONIST; PROLIFERATION; EXPRESSION; TARGET; GROWTH; PHOSPHORYLATION	A(3) adenosine receptor (A(3)AR) is a cell membrane protein, which has been found to be overexpressed in a large number of cancer types. This receptor plays an important role in cancer by interacting with adenosine. Specifically, A(3)AR has a dual nature in different pathophysiological conditions, as it is expressed according to tissue type and stimulated by an adenosine dose-dependent manner. A(3)AR activation leads to tumor growth, cell proliferation and survival in some cases, while triggering cytostatic and apoptotic pathways in others. This review aims to describe the most relevant aspects of A(3)AR activation and its ligands whereas it summarizes A(3)AR activities in cancer. Progress in the field of A(3)AR modulators, with a potential therapeutic role in cancer treatment are reported, as well.	[Mazziotta, Chiara; Rotondo, John Charles; Lanzillotti, Carmen; Campione, Giulia; Martini, Fernanda; Tognon, Mauro] Univ Ferrara, Sch Med, Dept Med Sci, Labs Cell Biol & Mol Genet,Sect Expt Med, 64-B Fossato Mortara St, I-44121 Ferrara, Italy; [Mazziotta, Chiara; Rotondo, John Charles; Lanzillotti, Carmen] Univ Ferrara, Ctr Studies Gender Med, Dept Med Sci, 64-B Fossato Mortara St, I-44121 Ferrara, Italy; [Martini, Fernanda] Univ Ferrara, Lab Technol Adv Therapies LTTA, I-44121 Ferrara, Italy	University of Ferrara; University of Ferrara; University of Ferrara	Martini, F; Tognon, M (corresponding author), Univ Ferrara, Sch Med, Dept Med Sci, Labs Cell Biol & Mol Genet,Sect Expt Med, 64-B Fossato Mortara St, I-44121 Ferrara, Italy.; Martini, F (corresponding author), Univ Ferrara, Lab Technol Adv Therapies LTTA, I-44121 Ferrara, Italy.	mrf@unife.it; tgm@unife.it		Mazziotta, Chiara/0000-0002-5091-0497; Tognon, Mauro/0000-0001-8269-7937	Associazione Italiana per la Ricerca sul Cancro (AIRC) [MFAG 21956, IG 21617]; International Association for the Study of Lung Cancer (IASLC)	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); International Association for the Study of Lung Cancer (IASLC)	The works of JCR and MT have been supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), grants MFAG 21956 and IG 21617, respectively. JCR was also supported by The International Association for the Study of Lung Cancer (IASLC).	Abedi H, 2014, TUMOR BIOL, V35, P11027, DOI 10.1007/s13277-014-2396-9; Aghaei M, 2011, J CANCER RES CLIN, V137, P1511, DOI 10.1007/s00432-011-1031-z; Ahmad A, 2010, EXTRACELLULAR ATP AND ADENOSINE AS REGULATORS OF ENDOTHELIAL CELL FUNCTION, P113, DOI 10.1007/978-90-481-3435-9_7; Allard B, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1601481; Bar-Yehuda S, 2008, INT J ONCOL, V33, P287, DOI 10.3892/ijo_00000008; Bar-Yehuda S, 2007, EXPERT OPIN INV DRUG, V16, P1601, DOI 10.1517/13543784.16.10.1601; Borea PA, 2018, PHYSIOL REV, V98, P1591, DOI 10.1152/physrev.00049.2017; Borea PA, 2015, PHARMACOL REV, V67, P74, DOI 10.1124/pr.113.008540; Borea PA, 2016, TRENDS PHARMACOL SCI, V37, P419, DOI 10.1016/j.tips.2016.02.006; Cohen S, 2011, J CELL PHYSIOL, V226, P2438, DOI 10.1002/jcp.22593; Contini C, 2019, J CELL PHYSIOL, V234, P100, DOI 10.1002/jcp.26952; Di Bonaventura MVM, 2019, J PSYCHOPHARMACOL, V33, P1550, DOI 10.1177/0269881119845798; Di Virgilio F, 2017, ONCOGENE, V36, P293, DOI 10.1038/onc.2016.206; Effendi WI, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030785; Ezeamuzie CI, 1999, BRIT J PHARMACOL, V127, P188, DOI 10.1038/sj.bjp.0702476; Fishman, 2007, J RHEUMATOL; Fishman P, 2004, ONCOGENE, V23, P2465, DOI 10.1038/sj.onc.1207355; Fishman P, 2009, Handb Exp Pharmacol, P399, DOI 10.1007/978-3-540-89615-9_14; Fishman P, 2001, EXP CELL RES, V269, P230, DOI 10.1006/excr.2001.5327; Fishman P, 2000, EUR J CANCER, V36, P1452, DOI 10.1016/S0959-8049(00)00130-1; Fishman P, 2016, CLIN RHEUMATOL, V35, P2359, DOI 10.1007/s10067-016-3202-4; Fishman P, 2012, DRUG DISCOV TODAY, V17, P359, DOI 10.1016/j.drudis.2011.10.007; Gessi S, 2004, CLIN CANCER RES, V10, P5895, DOI 10.1158/1078-0432.CCR-1134-03; Gessi S, 2008, PHARMACOL THERAPEUT, V117, P123, DOI 10.1016/j.pharmthera.2007.09.002; Gessi S, 2007, J CELL PHYSIOL, V211, P826, DOI 10.1002/jcp.20994; Gessi S, 2011, BBA-BIOMEMBRANES, V1808, P1400, DOI 10.1016/j.bbamem.2010.09.020; Gessi S, 2010, BIOCHEM PHARMACOL, V79, P1483, DOI 10.1016/j.bcp.2010.01.009; Gorain B, 2019, CURR PHARM DESIGN, V25, P2828, DOI 10.2174/1381612825666190716102037; Gorlach A, 2005, CIRC RES, V97, P1, DOI 10.1161/01.RES.0000174112.36064.77; Gorzalczany Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102603; Hajizadeh F, 2020, INT IMMUNOPHARMACOL, V87, DOI 10.1016/j.intimp.2020.106853; Hammarberg C, 2003, J NEUROCHEM, V86, P1051, DOI 10.1046/j.1471-4159.2003.01919.x; HERSHFIELD MS, 1976, J BIOL CHEM, V251, P7348; Jacobson KA, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00124; Jacobson KA, 2018, MED RES REV, V38, P1031, DOI 10.1002/med.21456; Jajoo S, 2009, NEOPLASIA, V11, P1132, DOI 10.1593/neo.09744; Joshaghani HR, 2017, J CANCER RES THER, V13, P107, DOI 10.4103/0973-1482.199381; Joyce JA, 2015, SCIENCE, V348, P74, DOI 10.1126/science.aaa6204; Karakashev SV, 2015, CANCER MANAG RES, V7, P253, DOI 10.2147/CMAR.S58285; Kazemi MH, 2018, J CELL PHYSIOL, V233, P2032, DOI 10.1002/jcp.25873; Kim SJ, 2008, CANCER LETT, V264, P309, DOI 10.1016/j.canlet.2008.01.037; Kim TH, 2012, NEUROCHEM RES, V37, P2667, DOI 10.1007/s11064-012-0855-5; Klaasse EC, 2008, PURINERG SIGNAL, V4, P21, DOI 10.1007/s11302-007-9086-7; Koscso B, 2011, EXPERT OPIN INV DRUG, V20, P757, DOI 10.1517/13543784.2011.573785; Koszalka P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151420; Lanzillotti C, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.646032; Ledderose C, 2016, PURINERG SIGNAL, V12, P673, DOI 10.1007/s11302-016-9531-6; Lee HS, 2011, IMMUNOBIOLOGY, V216, P997, DOI 10.1016/j.imbio.2011.03.008; Lee JY, 2006, NEUROSCI LETT, V396, P1, DOI 10.1016/j.neulet.2005.11.004; Liu Z., 2020, CANCER CELL INT, V24, DOI [DOI 10.1186/S12935-019-1086-5, 10.1186/s12935-019-1086-5]; Lofgren L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205707; Mailavaram RP, 2019, CURR PHARM DESIGN, V25, P2772, DOI 10.2174/1381612825666190716114056; Marwein S, 2019, CURR PHARM DESIGN, V25, P2842, DOI 10.2174/1381612825666190716141851; Maugeri G, 2019, J MOL NEUROSCI, V69, P166, DOI 10.1007/s12031-019-01346-4; Mazziotta C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.676627; Mazzoni E, 2020, J INFECTION, V80, P563, DOI 10.1016/j.jinf.2020.02.006; Merighi S, 2005, NEOPLASIA, V7, P894, DOI 10.1593/neo.05334; Merighi S, 2005, J BIOL CHEM, V280, P19516, DOI 10.1074/jbc.M413772200; Merighi S, 2002, J INVEST DERMATOL, V119, P923, DOI 10.1046/j.1523-1747.2002.00111.x; Merighi S, 2007, MOL PHARMACOL, V72, P162, DOI 10.1124/mol.106.031849; Merighi S, 2006, BIOCHEM PHARMACOL, V72, P19, DOI 10.1016/j.bcp.2006.03.020; Merighi Stefania, 2006, Purinergic Signal, V2, P627, DOI 10.1007/s11302-006-9020-4; Mlejnek P, 2013, J PHYSIOL BIOCHEM, V69, P405, DOI 10.1007/s13105-012-0222-7; Montinaro A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045401; Morello S, 2008, CANCER BIOL THER, V7, P278, DOI 10.4161/cbt.7.2.5301; Nigim F, 2015, J NEUROPATH EXP NEUR, V74, P710, DOI 10.1097/NEN.0000000000000210; Pastor-Anglada M, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00627; PHILLIS JW, 1992, LIFE SCI, V51, pPL149, DOI 10.1016/0024-3205(92)90363-T; Preti M, 2020, INFECT AGENTS CANCER, V15, DOI 10.1186/s13027-020-00286-8; Przybyla T, 2018, ACTA BIOCHIM POL, V65, P1, DOI 10.18388/abp.2017_1588; Ren TH, 2015, SCI REP-UK, V5, DOI 10.1038/srep09047; Ren TH, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/818251; ROSE FR, 1988, J EXP MED, V167, P1186, DOI 10.1084/jem.167.3.1186; Roth S, 2019, EBIOMEDICINE, V48, P20, DOI 10.1016/j.ebiom.2019.09.030; Rotondo JC, 2012, HUM REPROD, V27, P3632, DOI 10.1093/humrep/des319; Rotondo JC, 2013, EPIGENETICS-US, V8, P990, DOI 10.4161/epi.25798; Rotondo JC, 2021, FRONT CELL DEV BIOL, V09, DOI 10.3389/fcell.2021.689624; Rotondo JC, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.591452; Rotondo JC, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.550543; Rotondo JC, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00670; Rotondo JC, 2018, ENVIRON TOXICOL CHEM, V37, P942, DOI 10.1002/etc.4029; Rotondo JC, 2016, JAMA DERMATOL, V152, P928, DOI 10.1001/jamadermatol.2016.1336; Salvatore CA, 2000, J BIOL CHEM, V275, P4429, DOI 10.1074/jbc.275.6.4429; Santos, 2014, PHARMACOL THERAPEUT, DOI [10.5772/57206, DOI 10.5772/57206]; Schulte G, 2000, MOL PHARMACOL, V58, P477, DOI 10.1124/mol.58.3.477; Stemmer SM, 2012, J HEPATOL, V56, pS555, DOI 10.1016/S0168-8278(12)61422-6; Stomper J, 2021, LEUKEMIA, V35, P1873, DOI 10.1038/s41375-021-01218-0; Suresh RR, 2020, PURINERG SIGNAL, V16, P367, DOI 10.1007/s11302-020-09715-0; Taliani S, 2010, J MED CHEM, V53, P3954, DOI 10.1021/jm901785w; Tognon M, 2015, CANCER-AM CANCER SOC, V121, P2618, DOI 10.1002/cncr.29404; Tsuchiya A, 2015, WORLD J GASTROENTERO, V21, P10931, DOI 10.3748/wjg.v21.i39.10931; Vaisitti T, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041167; Varani K, 2010, BRIT J PHARMACOL, V160, P101, DOI 10.1111/j.1476-5381.2010.00667.x; Varani K, 2013, EUR J CANCER, V49, P482, DOI 10.1016/j.ejca.2012.06.005; Varani K, 2011, AM J RESP CRIT CARE, V183, P522, DOI 10.1164/rccm.201006-0980OC; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510	96	15	15	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2022	41	3					301	308		10.1038/s41388-021-02090-z	http://dx.doi.org/10.1038/s41388-021-02090-z		NOV 2021	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YF8LK	34750517	hybrid, Green Published			2022-12-17	WOS:000715670800002
J	Nehme, Z; Pasquereau, S; Ahmad, SH; Coaquette, A; Molimard, C; Monnien, F; Algros, MP; Adotevi, O; Assaf, MD; Feugeas, JP; Herbein, G				Nehme, Zeina; Pasquereau, Sebastien; Haidar Ahmad, Sandy; Coaquette, Alain; Molimard, Chloe; Monnien, Franck; Algros, Marie-Paule; Adotevi, Olivier; Diab Assaf, Mona; Feugeas, Jean-Paul; Herbein, Georges			Polyploid giant cancer cells, stemness and epithelial-mesenchymal plasticity elicited by human cytomegalovirus	ONCOGENE			English	Article								A growing body of evidence is recognizing human cytomegalovirus (HCMV) as a potential oncogenic virus. We hereby provide the first experimental in vitro evidence for HCMV as a reprogramming vector, through the induction of dedifferentiation of mature human mammary epithelial cells (HMECs), generation of a polyploid giant cancer cell (PGCC) phenotype characterized by sustained growth of blastomere-like cells, in concordance with the acquisition of embryonic stem cells characteristics and epithelial-mesenchymal plasticity. HCMV presence parallels the succession of the observed cellular and molecular events potentially ensuing the transformation process. Correlation between PGCCs detection and HCMV presence in breast cancer tissue further validates our hypothesis in vivo. Our study indicates that some clinical HCMV strains conserve the potential to transform HMECs and fit with a "blastomere-like" model of oncogenesis, which may be relevant in the pathophysiology of breast cancer and other adenocarcinoma, especially of poor prognosis.	[Nehme, Zeina; Pasquereau, Sebastien; Haidar Ahmad, Sandy; Herbein, Georges] Univ Bourgogne France Comte, Dept Pathogens & Inflammat, EPILAB, EA4266, Besancon, France; [Nehme, Zeina; Haidar Ahmad, Sandy; Diab Assaf, Mona] Lebanese Univ, Beirut, Lebanon; [Coaquette, Alain; Herbein, Georges] CHRU Besancon, Dept Virol, Besancon, France; [Molimard, Chloe; Monnien, Franck; Algros, Marie-Paule] CHRU Besancon, Dept Pathol, Besancon, France; [Adotevi, Olivier; Feugeas, Jean-Paul] Univ Bourgogne Franche Comte, Interact Greffon Hote Tumeur Ingn Cellulaire & Ge, INSERM, EFS BFC,UMR1098,RIGHT, Besancon, France	Universite de Franche-Comte; Lebanese University; Universite de Franche-Comte; CHU Besancon; Universite de Franche-Comte; CHU Besancon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Franche-Comte	Herbein, G (corresponding author), Univ Bourgogne France Comte, Dept Pathogens & Inflammat, EPILAB, EA4266, Besancon, France.; Herbein, G (corresponding author), CHRU Besancon, Dept Virol, Besancon, France.	georges.herbein@univ-fcomte.fr	Adotevi, Olivier/AAX-8290-2021	Pasquereau, Sebastien/0000-0002-9291-797X; adotevi, olivier/0000-0002-7742-136X; Nehme, Zeina/0000-0002-4750-6389; Haidar Ahmad, sandy/0000-0001-5375-0874	University of Franche-Comte; Region Franche-Comte; municipality of Habbouch	University of Franche-Comte; Region Franche-Comte(Region Bourgogne-Franche-Comte); municipality of Habbouch	This work was supported by grants from the University of Franche-Comte, and the Region Franche-Comte. Z.N. is a recipient of a doctoral scholarship from the municipality of Habbouch. The funders had no role in the data collection, analysis, patient recruitment, or decision to publish. We thank DImaCell Imaging Ressource Center, University of Bourgogne Franche-Comte, Faculty of Health Sciences, 25000 Besancon, France for technical support.	Al Moussawi F, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30109-1; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Aloia A, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0652-6; Belzile JP, 2014, J VIROL, V88, P4021, DOI 10.1128/JVI.03492-13; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chuang PK, 2019, P NATL ACAD SCI USA, V116, P3518, DOI 10.1073/pnas.1816946116; Coaquette A, 2004, CLIN INFECT DIS, V39, P155, DOI 10.1086/421496; Cobbs CS, 2002, CANCER RES, V62, P3347; Cojohari O, 2016, J VIROL, V90, P6443, DOI 10.1128/JVI.00214-16; Collins-McMillen D, 2019, P NATL ACAD SCI USA, V116, P17492, DOI 10.1073/pnas.1900783116; Coronel R, 2015, J VIROL, V89, P5615, DOI 10.1128/JVI.00305-15; Dai XF, 2015, AM J CANCER RES, V5, P2929; Dimri G, 2005, BREAST CANCER RES, V7, P171, DOI 10.1186/bcr1275; Fei F, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0277-8; Fornara O, 2016, CELL DEATH DIFFER, V23, P261, DOI 10.1038/cdd.2015.91; FURUKAWA T, 1984, VIROLOGY, V137, P191, DOI 10.1016/0042-6822(84)90023-0; Ganem D, 2010, J CLIN INVEST, V120, P939, DOI 10.1172/JCI40567; GEDER L, 1976, SCIENCE, V192, P1134, DOI 10.1126/science.179143; HEIEREN MH, 1988, TRANSPLANTATION, V46, P426, DOI 10.1097/00007890-198809000-00018; Hein SM, 2016, ONCOGENE, V35, P1461, DOI 10.1038/onc.2015.206; Herbein G, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.567116; Hoffding MK, 2015, STEM CELL RES, V14, P39, DOI 10.1016/j.scr.2014.11.003; Huang YH, 2014, HISTOPATHOLOGY, V64, P494, DOI 10.1111/his.12257; Huesing A, 2012, J MED GENET, V49, P601, DOI 10.1136/jmedgenet-2011-100716; Jha HC, 2016, PATHOGENS, V5, DOI 10.3390/pathogens5010018; Khan KA, 2009, J IMMUNOL, V182, P7784, DOI 10.4049/jimmunol.0803800; Knudsen ES, 2015, CELL CYCLE, V14, P109, DOI 10.4161/15384101.2014.967118; Kumar A, 2018, EBIOMEDICINE, V30, P167, DOI 10.1016/j.ebiom.2018.03.015; Lawson DA, 2015, NATURE, V526, P131, DOI 10.1038/nature15260; Lee EYHP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003236; Lepiller Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059591; Ling GQ, 2012, ONCOL LETT, V4, P1264, DOI 10.3892/ol.2012.916; Liu JS, 2020, SEMIN CANCER BIOL, V60, P380, DOI 10.1016/j.semcancer.2019.09.005; Liu JS, 2018, SEMIN CANCER BIOL, V53, P1, DOI 10.1016/j.semcancer.2018.07.004; Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009; Lopez-Sanchez LM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099143; Lu X, 2014, ONCOGENE, V33, P2655, DOI 10.1038/onc.2013.209; Luo JF, 2017, AM J TRANSL RES, V9, P5671; Luo MH, 2010, J VIROL, V84, P3528, DOI 10.1128/JVI.02161-09; Manners O, 2018, CURR OPIN VIROL, V32, P60, DOI 10.1016/j.coviro.2018.08.014; McFarlane S, 2011, VIROLOGY, V414, P83, DOI 10.1016/j.virol.2011.03.005; Michaelis M, 2009, NEOPLASIA, V11, P1, DOI 10.1593/neo.81178; Morales-Sanchez A, 2014, VIRUSES-BASEL, V6, P4047, DOI 10.3390/v6104047; Munz C, 2019, NAT REV MICROBIOL, V17, P691, DOI 10.1038/s41579-019-0249-7; Newbold RF, 2002, MUTAGENESIS, V17, P539, DOI 10.1093/mutage/17.6.539; Niu N, 2017, ONCOGENE, V36, P4887, DOI 10.1038/onc.2017.72; Niu N, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.75; Oberstein A, 2017, P NATL ACAD SCI USA, V114, pE8244, DOI 10.1073/pnas.1710799114; Odeberg J, 2006, J VIROL, V80, P8929, DOI 10.1128/JVI.00676-06; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Polyak K, 2011, J CLIN INVEST, V121, P3786, DOI 10.1172/JCI60534; Prichard MN, 2008, J VIROL, V82, P5054, DOI 10.1128/JVI.02174-07; Rodilla V, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6040103; Romaniuk A, 2019, MOL BIOL REP, V46, P1401, DOI 10.1007/s11033-018-4496-x; Sinzger C, 2008, CURR TOP MICROBIOL, V325, P63; Soroceanu L, 2015, CANCER RES, V75, P3065, DOI 10.1158/0008-5472.CAN-14-3307; Straat K, 2009, JNCI-J NATL CANCER I, V101, P488, DOI 10.1093/jnci/djp031; Taher C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056795; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tanabe K, 2013, P NATL ACAD SCI USA, V110, P12172, DOI 10.1073/pnas.1310291110; Tata PR, 2013, NATURE, V503, P218, DOI 10.1038/nature12777; Tsai HL, 1996, J BIOL CHEM, V271, P3534; Wang D, 2014, ONCOTARGET, V5, P10803, DOI 10.18632/oncotarget.2506; Wang MH, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0013-8; Weljie AM, 2011, INT J BIOCHEM CELL B, V43, P981, DOI 10.1016/j.biocel.2010.08.009; White E, 2006, CELL DEATH DIFFER, V13, P1371, DOI 10.1038/sj.cdd.4401941; Xiong SM, 2019, TRENDS CELL BIOL, V29, P623, DOI 10.1016/j.tcb.2019.05.001; Yamashita N, 2018, CLIN BREAST CANCER, V18, pE1003, DOI 10.1016/j.clbc.2018.02.002; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410; Yu KR, 2012, STEM CELLS, V30, P876, DOI 10.1002/stem.1052; Yu W, 2017, STEM CELL RES, V19, P139, DOI 10.1016/j.scr.2017.01.011; Yu YJ, 2011, TRENDS MICROBIOL, V19, P360, DOI 10.1016/j.tim.2011.04.002; Zhang S, 2014, ONCOGENE, V33, P116, DOI 10.1038/onc.2013.96; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6; Zheng L, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1825	76	15	16	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2021	40	17					3030	3046		10.1038/s41388-021-01715-7	http://dx.doi.org/10.1038/s41388-021-01715-7		MAR 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RV2NJ	33767437				2022-12-17	WOS:000632820300001
J	Jalalirad, M; Haddad, TC; Salisbury, JL; Radisky, D; Zhang, MZ; Schroeder, M; Tuma, A; Leof, E; Carter, JM; Degnim, AC; Boughey, JC; Sarkaria, J; Yu, J; Wang, LW; Liu, MC; Zammataro, L; Malatino, L; Galanis, E; Ingle, JN; Goetz, MP; D'Assoro, AB				Jalalirad, Mohammad; Haddad, Tufia C.; Salisbury, Jeffrey L.; Radisky, Derek; Zhang, Minzhi; Schroeder, Mark; Tuma, Ann; Leof, Eduard; Carter, Jodi M.; Degnim, Amy C.; Boughey, Judy C.; Sarkaria, Jann; Yu, Jia; Wang, Liewei; Liu, Minetta C.; Zammataro, Luca; Malatino, Lorenzo; Galanis, Evanthia; Ingle, James N.; Goetz, Matthew P.; D'Assoro, Antonino B.			Aurora-A kinase oncogenic signaling mediates TGF-beta-induced triple-negative breast cancer plasticity and chemoresistance	ONCOGENE			English	Article								Triple-negative breast cancer (TNBCs) account for 15-20% of all breast cancers and represent the most aggressive subtype of this malignancy. Early tumor relapse and progression are linked to the enrichment of a sub-fraction of cancer cells, termed breast tumor-initiating cells (BTICs), that undergo epithelial to mesenchymal transition (EMT) and typically exhibit a basal-like CD44(high)/CD24(low) and/or ALDH1(high) phenotype with critical cancer stem-like features such as high self-renewal capacity and intrinsic (de novo) resistance to standard of care chemotherapy. One of the major mechanisms responsible for the intrinsic drug resistance of BTICs is their high ALDH1 activity leading to inhibition of chemotherapy-induced apoptosis. In this study, we demonstrated that aurora-A kinase (AURKA) is required to mediate TGF-beta-induced expression of the SNAI1 gene, enrichment of ALDH1(high) BTICs, self-renewal capacity, and chemoresistance in TNBC experimental models. Significantly, the combination of docetaxel (DTX) with dual TGF-beta and AURKA pharmacologic targeting impaired tumor relapse and the emergence of distant metastasis. We also showed in unique chemoresistant TNBC cells isolated from patient-derived TNBC brain metastasis that dual TGF-beta and AURKA pharmacologic targeting reversed cancer plasticity and enhanced the sensitivity of TNBC cells to DTX-based-chemotherapy. Taken together, these findings reveal for the first time the critical role of AURKA oncogenic signaling in mediating TGF-beta-induced TNBC plasticity, chemoresistance, and tumor progression.	[Jalalirad, Mohammad; Haddad, Tufia C.; Zhang, Minzhi; Yu, Jia; Wang, Liewei; Liu, Minetta C.; Galanis, Evanthia; Ingle, James N.; Goetz, Matthew P.; D'Assoro, Antonino B.] Mayo Clin, Dept Oncol, Coll Med, Rochester, MN 55905 USA; [Salisbury, Jeffrey L.; Radisky, Derek; Leof, Eduard] Mayo Clin, Dept Biochem & Mol Biol, Coll Med, Rochester, MN USA; [Schroeder, Mark; Tuma, Ann; Sarkaria, Jann] Mayo Clin, Dept Radiat Oncol, Coll Med, Rochester, MN USA; [Carter, Jodi M.; Liu, Minetta C.] Mayo Clin, Dept Lab Med & Pathol, Coll Med, Rochester, MN USA; [Degnim, Amy C.; Boughey, Judy C.] Mayo Clin, Dept Surg, Coll Med, Rochester, MN USA; [Zammataro, Luca] Yale Univ, Dept Oncol, New Heaven, CT USA; [Malatino, Lorenzo] Univ Catania, Dept Clin & Expt Med, Catania, Italy; [Galanis, Evanthia] Mayo Clin, Dept Mol Med, Coll Med, Rochester, MN USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Yale University; University of Catania; Mayo Clinic	D'Assoro, AB (corresponding author), Mayo Clin, Dept Oncol, Coll Med, Rochester, MN 55905 USA.	dassoro.antonio@mayo.edu	Malatino, Lorenzo/I-7319-2018	Malatino, Lorenzo/0000-0003-2944-2729; Carter, Jodi/0000-0002-5973-0732	Intramural RECDA; Nan Sawyer Award; Randy Shaver Cancer Research and Community Fund; Mayo Clinic Breast Cancer Specialized Program of Research Excellence (SPORE) NIH [CA116201]; Mayo Clinic Breast Cancer SPORE NIH [CA116201]; Prospect Creek Foundation; Mayo Clinic Comprehensive Cancer Center;  [NCI-CA214893];  [NCI-CA72836]	Intramural RECDA; Nan Sawyer Award; Randy Shaver Cancer Research and Community Fund; Mayo Clinic Breast Cancer Specialized Program of Research Excellence (SPORE) NIH; Mayo Clinic Breast Cancer SPORE NIH; Prospect Creek Foundation; Mayo Clinic Comprehensive Cancer Center; ; 	This study was supported by Intramural RECDA, The Nan Sawyer Award, the Randy Shaver Cancer Research and Community Fund, the Mayo Clinic Breast Cancer Specialized Program of Research Excellence (SPORE) NIH CA116201 Developmental Research Program, and NCI-CA214893 to ABD, NCI-CA72836 to JLS, the Mayo Clinic Breast Cancer SPORE NIH CA116201 to JI and MG, the Prospect Creek Foundation to EG, and the Mayo Clinic Comprehensive Cancer Center.	Ahmad A, 2019, ADV EXP MED BIOL, V1152, P1, DOI 10.1007/978-3-030-20301-6_1; Alamgeer M, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3648; Ascolani G, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004199; Bhola NE, 2013, J CLIN INVEST, V123, P1348, DOI 10.1172/JCI65416; Bierie B, 2008, CANCER RES, V68, P1809, DOI 10.1158/0008-5472.CAN-07-5597; Boss DS, 2009, ONCOLOGIST, V14, P780, DOI 10.1634/theoncologist.2009-0019; Cammareri P, 2010, CANCER RES, V70, P4655, DOI 10.1158/0008-5472.CAN-09-3953; Chiorean R, 2013, BREAST, V22, P1026, DOI 10.1016/j.breast.2013.08.007; Chou CH, 2013, CANCER RES, V73, P953, DOI [10.1158/0008-5472.CAN-12-2397, 10.1158/1538-7445.AM2012-4651]; Connolly EC, 2011, CANCER RES, V71, P2339, DOI 10.1158/0008-5472.CAN-10-2941; D'Assoro AB, 2014, ONCOGENE, V33, P599, DOI 10.1038/onc.2012.628; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; D'Assoro AB, 2016, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00295; Daly AC, 2008, MOL CELL BIOL, V28, P6889, DOI 10.1128/MCB.01192-08; de Carcer G, 2014, NAT CELL BIOL, V16, P504, DOI 10.1038/ncb2978; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Dutertre S, 2002, ONCOGENE, V21, P6175, DOI 10.1038/sj.onc.1205775; Goepfert TM, 2007, INT J CANCER, V120, P985, DOI 10.1002/ijc.22420; Haddad TC, 2018, BREAST CANCER RES TR, V168, P639, DOI 10.1007/s10549-017-4616-7; Huddle BC, 2018, J MED CHEM, V61, P8754, DOI 10.1021/acs.jmedchem.8b00930; Hwang-Verslues WW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008377; Jiang HL, 2015, ONCOTARGET, V6, P16352, DOI 10.18632/oncotarget.3877; Karicheva O, 2016, ONCOTARGET, V7, P64109, DOI 10.18632/oncotarget.11627; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Leontovich AA, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-1020-0; Leontovich AA, 2013, ONCOL REP, V29, P1785, DOI 10.3892/or.2013.2313; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Lyons TG, 2019, ADV EXP MED BIOL, V1152, P377, DOI 10.1007/978-3-030-20301-6_20; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Moreira MP, 2018, EXP CELL RES, V363, P283, DOI 10.1016/j.yexcr.2018.01.018; Motomura H, 2020, ANTICANCER RES, V40, P35, DOI 10.21873/anticanres.13924; Ohmine S, 2018, ONCOL REP, V39, P1725, DOI 10.3892/or.2018.6239; Opyrchal M, 2017, ONCOTARGET, V8, P91803, DOI 10.18632/oncotarget.20610; Opyrchal M, 2014, INT J ONCOL, V45, P1193, DOI 10.3892/ijo.2014.2523; Pandy JGP, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6253-5; Perera M., 2010, Cancer Genomics & Proteomics, V7, P217; Shionome Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055457; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Siggelkow W, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-562; Smith AL, 2012, CLIN CANCER RES, V18, P4514, DOI 10.1158/1078-0432.CCR-11-3224; Sridharan S, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01311; Staff S, 2010, ONCOL REP, V23, P307, DOI 10.3892/or_00000637; Szasz AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056707; Tan AR, 2009, BREAST CANCER RES TR, V115, P453, DOI 10.1007/s10549-008-0184-1; Taylor MA, 2011, GENE EXPRESSION, V15, P117, DOI 10.3727/105221611X13176664479322; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; Wahdan-Alaswad R, 2016, CELL CYCLE, V15, P1046, DOI 10.1080/15384101.2016.1152432; Yagata H, 2011, BREAST CANCER-TOKYO, V18, P165, DOI 10.1007/s12282-011-0254-9; Yang G, 2013, INT J CANCER, V133, P275, DOI 10.1002/ijc.28032; Zhang L, 2013, MOL CELL, V51, P559, DOI 10.1016/j.molcel.2013.07.014; Zheng FM, 2014, MOL CANCER THER, V13, P1991, DOI 10.1158/1535-7163.MCT-13-1029	52	15	15	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2021	40	14					2509	2523		10.1038/s41388-021-01711-x	http://dx.doi.org/10.1038/s41388-021-01711-x		MAR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK3YE	33674749	hybrid, Green Published			2022-12-17	WOS:000625607100005
J	Wang, M; Zhao, XX; Qiu, R; Gong, Z; Huang, F; Yu, WJ; Shen, B; Sha, X; Dong, HB; Huang, JY; Wang, L; Zhu, W; Xu, WR				Wang, Mei; Zhao, Xinxin; Qiu, Rong; Gong, Zheng; Huang, Feng; Yu, Wanjun; Shen, Bo; Sha, Xin; Dong, Haibo; Huang, Jiaying; Wang, Lin; Zhu, Wei; Xu, Wenrong			Lymph node metastasis-derived gastric cancer cells educate bone marrow-derived mesenchymal stem cells via YAP signaling activation by exosomal Wnt5a	ONCOGENE			English	Article							BLOOD-VESSELS; IN-VIVO; INVASION; EXIT	Lymph node metastasis (LNM), a common metastatic gastric-cancer (GC) route, is closely related to poor prognosis in GC patients. Bone marrow-derived mesenchymal stem cells (BM-MSCs) preferentially engraft at metastatic lesions. Whether BM-MSCs are specifically reprogrammed by LNM-derived GC cells (LNM-GCs) and incorporated into metastatic LN microenvironment to prompt GC malignant progression remains unknown. Herein, we found that LNM-GCs specifically educated BM-MSCs via secretory exosomes. Exosomal Wnt5a was identified as key protein mediating LNM-GCs education of BM-MSCs, which was verified by analysis of serum exosomes collected from GC patients with LNM. Wnt5a-enriched exosomes induced YAP dephosphorylation in BM-MSCs, whereas Wnt5a-deficient exosomes exerted the opposite effect. Inhibition of YAP signaling by verteporfin blocked LNM-GC exosome- and serum exosome-mediated reprogramming in BM-MSCs. Analysis of MSC-like cells obtained from metastatic LN tissues of GC patients (GLN-MSCs) confirmed that BM-MSCs incorporated into metastatic LN microenvironment, and that YAP activation participated in maintaining their tumor-promoting phenotype and function. Collectively, our results show that LNM-GCs specifically educated BM-MSCs via exosomal Wnt5a-elicited activation of YAP signaling. This study provides new insights into the mechanisms of LNM in GC and BM-MSC reprogramming, and will provide potential therapeutic targets and detection indicators for GC patients with LNM.	[Wang, Mei; Zhao, Xinxin; Qiu, Rong; Gong, Zheng; Huang, Feng; Yu, Wanjun; Huang, Jiaying; Wang, Lin; Zhu, Wei; Xu, Wenrong] Jiangsu Univ, Sch Med, Key Lab Med Sci & Lab Med Jiangsu Prov, Zhenjiang, Jiangsu, Peoples R China; [Shen, Bo] Nanjing Med Univ, Affiliated Canc Hosp, Dept Oncol, Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China; [Shen, Bo] Nanjing Med Univ, Jiangsu Inst Canc Res, Affiliated Canc Hosp, Nanjing, Jiangsu, Peoples R China; [Sha, Xin] Jiangsu Univ, Affiliated Hosp Jiangsu Univ, Dept Surg, Zhenjiang, Jiangsu, Peoples R China; [Dong, Haibo] Jiangsu Univ, Dept Hematol, Nanjing Drum Tower Hosp, Affiliated Hosp, Nanjing, Jiangsu, Peoples R China	Jiangsu University; Nanjing Medical University; Nanjing Medical University; Jiangsu University; Jiangsu University; Nanjing University	Wang, M (corresponding author), Jiangsu Univ, Sch Med, Key Lab Med Sci & Lab Med Jiangsu Prov, Zhenjiang, Jiangsu, Peoples R China.	wangmei8417@163.com			National Natural Science Foundation of China [81772641, 81902510, 81302119, 81972313, 81972822]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China [grant numbers 81772641, 81902510, 81302119, 81972313, and 81972822].	Astudillo P, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00110; Baglio SR, 2017, CLIN CANCER RES, V23, P3721, DOI 10.1158/1078-0432.CCR-16-2726; Barcellos-de-Souza P, 2013, BBA-REV CANCER, V1836, P321, DOI 10.1016/j.bbcan.2013.10.004; Blache U, 2019, LIFE SCI ALLIANCE, V2, DOI 10.26508/lsa.201900304; Blogowski W, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1099798; Brown M, 2018, SCIENCE, V359, P1408, DOI 10.1126/science.aal3662; Canesin G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184418; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Deng JY, 2014, WORLD J GASTROENTERO, V20, P3967, DOI 10.3748/wjg.v20.i14.3967; Flanagan DJ, 2019, CANCER RES, V79, P970, DOI 10.1158/0008-5472.CAN-18-2095; Gangoda L, 2017, PROTEOMICS, V17, DOI 10.1002/pmic.201600370; Gonzalez ME, 2017, CELL REP, V18, P1215, DOI 10.1016/j.celrep.2016.12.079; Gross JC, 2012, NAT CELL BIOL, V14, P1036, DOI 10.1038/ncb2574; Hanaki H, 2012, MOL CANCER THER, V11, P298, DOI 10.1158/1535-7163.MCT-11-0682; Ji H, 2013, PROTEOMICS, V13, P1672, DOI 10.1002/pmic.201200562; Kasashima H, 2016, AM J PATHOL, V186, P3028, DOI 10.1016/j.ajpath.2016.07.024; Lazar I, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12380; Li XX, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0269-y; Lin LY, 2016, ONCOGENE, V35, P6038, DOI 10.1038/onc.2016.131; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; Luo C, 2020, J CLIN INVEST, V130, P853, DOI 10.1172/JCI130038; Meade Kayla J, 2019, Oncotarget, V10, P3027, DOI 10.18632/oncotarget.26903; Nam S, 2017, CELL PHYSIOL BIOCHEM, V41, P33, DOI 10.1159/000455934; Pan ZJ, 2017, INT J ONCOL, V51, P1055, DOI 10.3892/ijo.2017.4101; Park HW, 2015, CELL, V162, P780, DOI 10.1016/j.cell.2015.07.013; Pellino A, 2019, WORLD J GASTROENTERO, V25, P5773, DOI 10.3748/wjg.v25.i38.5773; Pereira ER, 2018, SCIENCE, V359, P1403, DOI 10.1126/science.aal3622; Ridge SM, 2018, INT J CANCER, V142, P2056, DOI 10.1002/ijc.31226; Ridge SM, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0597-8; Safholm A, 2008, CLIN CANCER RES, V14, P6556, DOI 10.1158/1078-0432.CCR-08-0711; Shen YM, 2019, STEM CELLS DEV, V28, P464, DOI 10.1089/scd.2018.0125; Shi YF, 2017, NAT REV DRUG DISCOV, V16, P35, DOI 10.1038/nrd.2016.193; Sleeman JP, 2015, J MOL MED, V93, P1173, DOI 10.1007/s00109-015-1351-6; Tao SC, 2017, THERANOSTICS, V7, P180, DOI 10.7150/thno.17133; Wang M, 2014, BRIT J CANCER, V110, P1199, DOI 10.1038/bjc.2014.14; Xie CY, 2017, STEM CELL TRANSL MED, V6, P1120, DOI 10.1002/sctm.16-0204; Yamamoto H, 2009, GASTROENTEROLOGY, V137, P242, DOI 10.1053/j.gastro.2009.02.003; Zheng YG, 2019, DEV CELL, V50, P264, DOI 10.1016/j.devcel.2019.06.003; Zhu HY, 2016, INT J BIOL SCI, V12, P389, DOI 10.7150/ijbs.13688; Zhu T, 2018, ONCOL LETT, V15, P3409, DOI 10.3892/ol.2018.7813	40	15	15	8	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2021	40	12					2296	2308		10.1038/s41388-021-01722-8	http://dx.doi.org/10.1038/s41388-021-01722-8		MAR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL8NI	33654199	hybrid, Green Published			2022-12-17	WOS:000624398900004
J	Varone, E; Decio, A; Chernorudskiy, A; Minoli, L; Brunelli, L; Ioli, F; Piotti, A; Pastorelli, R; Fratelli, M; Gobbi, M; Giavazzi, R; Zito, E				Varone, Ersilia; Decio, Alessandra; Chernorudskiy, Alexander; Minoli, Lucia; Brunelli, Laura; Ioli, Federica; Piotti, Arianna; Pastorelli, Roberta; Fratelli, Maddalena; Gobbi, Marco; Giavazzi, Raffaella; Zito, Ester			The ER stress response mediator ERO1 triggers cancer metastasis by favoring the angiogenic switch in hypoxic conditions	ONCOGENE			English	Article								Solid tumors are often characterized by a hypoxic microenvironment which contributes, through the hypoxia-inducible factor HIF-1, to the invasion-metastasis cascade. Endoplasmic reticulum (ER) stress also leads tumor cells to thrive and spread by inducing a transcriptional and translational program, the Unfolded Protein Response (UPR), aimed at restoring ER homeostasis. We studied ERO1 alpha (henceforth ERO1), a protein disulfide oxidase with the tumor-relevant characteristic of being positively regulated by both ER stress and hypoxia. Analysis of the redox secretome indicated that pro-angiogenic HIF-1 targets, were blunted in ERO1-devoid breast cancer cells under hypoxic conditions. ERO1 deficiency reduced tumor cell migration and lung metastases by impinging on tumor angiogenesis, negatively regulating the upstream ATF4/CHOP branch of the UPR and selectively impeding oxidative folding of angiogenic factors, among which VEGF-A. Thus, ERO1 deficiency acted synergistically with the otherwise feeble curative effects of anti-angiogenic therapy in aggressive breast cancer murine models and it might be exploited to treat cancers with pathological HIF-1-dependent angiogenesis. Furthermore, ERO1 levels are higher in the more aggressive basal breast tumors and correlate inversely with the disease- and metastasis-free interval of breast cancer patients. Thus, taking advantage of our in vitro data on ERO1-regulated gene products we identified a gene set associated with ERO1 expression in basal tumors and related to UPR, hypoxia, and angiogenesis, whose levels might be investigated in patients as a hallmark of tumor aggressiveness and orient those with lower levels toward an effective anti-angiogenic therapy.	[Varone, Ersilia; Decio, Alessandra; Chernorudskiy, Alexander; Brunelli, Laura; Ioli, Federica; Piotti, Arianna; Pastorelli, Roberta; Fratelli, Maddalena; Gobbi, Marco; Giavazzi, Raffaella; Zito, Ester] Ist Ric Farmacol Mario Negri IRCCS, Milan, Italy; [Minoli, Lucia] Univ Milan, Dept Vet Med, Mouse & Anim Pathol Lab, Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Milan	Zito, E (corresponding author), Ist Ric Farmacol Mario Negri IRCCS, Milan, Italy.	ester.zito@marionegri.it	Chernorudskiy, Alexander/ABE-4390-2021; Minoli, Lucia/AAB-8777-2022; Varone, Ersilia/ABE-4711-2021; Brunelli, Laura/J-8664-2018; Gobbi, Marco/J-2638-2016; Decio, Alessandra/J-5250-2018	Chernorudskiy, Alexander/0000-0002-8175-5688; Minoli, Lucia/0000-0001-8938-4319; Varone, Ersilia/0000-0002-1537-3358; Brunelli, Laura/0000-0002-5465-9586; Gobbi, Marco/0000-0003-1014-6225; Decio, Alessandra/0000-0002-1845-7063; Piotti, Arianna/0000-0003-3614-8202	AIRC [MFAG 20018, IG 23520]; Cariplo Grant [2017-0896]	AIRC(Fondazione AIRC per la ricerca sul cancro); Cariplo Grant(Fondazione Cariplo)	We are indebted to David Ron, in whose lab some of the reagents were developed, to Enrico Garattini for providing breast tumor cell lines and Nica Borgese for the critical reading of the paper. This study was supported by AIRC MFAG 20018 grant to EZ, Cariplo Grant 2017-0896 to AD and AIRC IG 23520 to RG.	Abcouwer SF, 2002, INVEST OPHTH VIS SCI, V43, P2791; Blais JD, 2010, J BIOL CHEM, V285, P20993, DOI 10.1074/jbc.M110.126599; Canovi M, 2014, SENSORS-BASEL, V14, P10864, DOI 10.3390/s140610864; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chin KT, 2011, FASEB J, V25, P2583, DOI 10.1096/fj.11-184622; Claesson-Welsh L, 2013, J INTERN MED, V273, P114, DOI 10.1111/joim.12019; Cruz-Munoz W, 2008, CANCER RES, V68, P4500, DOI 10.1158/0008-5472.CAN-08-0041; Cubillos-Ruiz JR, 2017, CELL, V168, P692, DOI 10.1016/j.cell.2016.12.004; Dey S, 2015, J CLIN INVEST, V125, P2592, DOI 10.1172/JCI78031; Dore-Savard L, 2016, SCI REP-UK, V6, DOI 10.1038/srep39460; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Ghosh R, 2010, PLOS ONE, V5, pA104, DOI 10.1371/journal.pone.0009575; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Iyer S, 2011, FEBS J, V278, P4304, DOI 10.1111/j.1742-4658.2011.08350.x; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Mandal K, 2011, ANGEW CHEM INT EDIT, V50, P8029, DOI 10.1002/anie.201103237; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; May D, 2005, ONCOGENE, V24, P1011, DOI 10.1038/sj.onc.1208325; Nakatsu MN, 2003, LAB INVEST, V83, P1873, DOI 10.1097/01.LAB.0000107160.81875.33; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; Pozzer D, 2019, REDOX BIOL, V20, P354, DOI 10.1016/j.redox.2018.10.017; Rutkevich LA, 2012, MOL BIOL CELL, V23, P2017, DOI 10.1091/mbc.E12-02-0102; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Sitohy B, 2012, CANCER RES, V72, P1909, DOI 10.1158/0008-5472.CAN-11-3406; Tanaka T, 2016, BRIT J CANCER, V114, P1227, DOI 10.1038/bjc.2016.105; Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007; VARTANIAN RK, 1994, AM J PATHOL, V144, P1188; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Wang YG, 2012, CANCER RES, V72, P5396, DOI 10.1158/0008-5472.CAN-12-0474; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Wong CCL, 2011, P NATL ACAD SCI USA, V108, P16369, DOI 10.1073/pnas.1113483108; Workman P, 2010, BRIT J CANCER, V102, P1555, DOI 10.1038/sj.bjc.6605642; Yang SK, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1134-4; Zhang YN, 2019, EBIOMEDICINE, V41, P408, DOI 10.1016/j.ebiom.2019.02.041; Zito E, 2015, FREE RADICAL BIO MED, V83, P299, DOI 10.1016/j.freeradbiomed.2015.01.011; Zito E, 2013, ANTIOXID REDOX SIGN, V18, P1666, DOI 10.1089/ars.2012.4966; Zito E, 2012, MOL CELL, V48, P39, DOI 10.1016/j.molcel.2012.08.010; Zito E, 2010, MOL CELL, V40, P787, DOI 10.1016/j.molcel.2010.11.010; Zito E, 2010, J CELL BIOL, V188, P821, DOI 10.1083/jcb.200911086	45	15	15	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1721	1736		10.1038/s41388-021-01659-y	http://dx.doi.org/10.1038/s41388-021-01659-y		FEB 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33531624	Green Published, hybrid			2022-12-17	WOS:000613991700001
J	Yin, LJ; Li, JJ; Wang, J; Pu, TJ; Wei, J; Li, QL; Wu, BJ				Yin, Lijuan; Li, Jingjing; Wang, Jing; Pu, Tianjie; Wei, Jing; Li, Qinlong; Wu, Boyang Jason			MAOA promotes prostate cancer cell perineural invasion through SEMA3C/PlexinA2/NRP1-cMET signaling	ONCOGENE			English	Article							MONOAMINE-OXIDASE; RECEPTOR; METASTASIS; EXPRESSION; GROWTH; NEUROGENESIS; ACTIVATION; MECHANISMS; REGULATOR; SURVIVAL	Perineural invasion (PNI), a pathologic feature defined as cancer cell invasion in, around, and through nerves, is an indicator of poor prognosis and survival in prostate cancer (PC). Despite widespread recognition of the clinical significance of PNI, the molecular mechanisms are largely unknown. Here, we report that monoamine oxidase A (MAOA) is a clinically and functionally important mediator of PNI in PC. MAOA promotes PNI of PC cells in vitro and tumor innervation in an orthotopic xenograft model. Mechanistically, MAOA activates SEMA3C in a Twist1-dependent transcriptional manner, which in turn stimulates cMET to facilitate PNI via autocrine or paracrine interaction with coactivated PlexinA2 and NRP1. Furthermore, MAOA inhibitor treatment effectively reduces PNI of PC cells in vitro and tumor-infiltrating nerve fiber density along with suppressed xenograft tumor growth and progression in mice. Collectively, these findings characterize the contribution of MAOA to the pathogenesis of PNI and provide a rationale for using MAOA inhibitors as a targeted treatment for PNI in PC.	[Yin, Lijuan; Li, Qinlong] Cedars Sinai Med Ctr, Dept Med, Samuel Oschin Comprehens Canc Inst, Urooncol Res Program, Los Angeles, CA 90048 USA; [Li, Jingjing; Wang, Jing; Pu, Tianjie; Wei, Jing; Wu, Boyang Jason] Washington State Univ, Coll Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Spokane, WA 99202 USA; [Yin, Lijuan] Sichuan Univ, West China Hosp, Dept Pathol, Chengdu 610041, Sichuan, Peoples R China; [Li, Jingjing] Shanghai Jiao Tong Univ, Sch Pharm, Lab Regener, Shanghai 200240, Peoples R China	Cedars Sinai Medical Center; Washington State University; Sichuan University; Shanghai Jiao Tong University	Wu, BJ (corresponding author), Washington State Univ, Coll Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Spokane, WA 99202 USA.	boyang.wu@wsu.edu	Pu, Tianjie/AFD-8574-2022; Pu, Tianjie/AAE-9454-2022	Li, Jingjing/0000-0002-0661-5642	DOD Prostate Cancer Research Program [W81XWH-15-1-0493, W81XWH-19-1-0279]; NIH/NCI [R37CA233658]; WSU startup fund	DOD Prostate Cancer Research Program; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); WSU startup fund	We thank Gina Chu (Cedars-Sinai Medical Center) for technical help, Leland W.K. Chung (Cedars-Sinai Medical Center) for comprehensive support of this study, and Gary Mawyer for editorial assistance. This work was supported by DOD Prostate Cancer Research Program grants W81XWH-15-1-0493 and W81XWH-19-1-0279, NIH/NCI grant R37CA233658, and the WSU startup fund to BJW.	Ayala GE, 2008, CLIN CANCER RES, V14, P7593, DOI 10.1158/1078-0432.CCR-08-1164; Bakst RL, 2016, J NEUROL SURG PART B, V77, P96, DOI 10.1055/s-0036-1571835; Binmadi NO, 2012, AM J PATHOL, V180, P1232, DOI 10.1016/j.ajpath.2011.12.009; Bortolato M, 2008, ADV DRUG DELIVER REV, V60, P1527, DOI 10.1016/j.addr.2008.06.002; CARDEN MJ, 1987, J NEUROSCI, V7, P3489; Chauvet S, 2007, NEURON, V56, P807, DOI 10.1016/j.neuron.2007.10.019; Chen WR, 2007, J PERIPHER NERV SYST, V12, P121, DOI 10.1111/j.1529-8027.2007.00131.x; Chilton JK, 2006, DEV BIOL, V292, P13, DOI 10.1016/j.ydbio.2005.12.048; Ciftci S, 2015, PROSTATE, V75, P1783, DOI 10.1002/pros.23067; DeLancey JO, 2013, UROLOGY, V81, P354, DOI 10.1016/j.urology.2012.09.034; Deng XY, 2014, CANCER TREAT REV, V40, P730, DOI 10.1016/j.ctrv.2014.04.003; Ding Y, 2013, CLIN CANCER RES, V19, P6101, DOI 10.1158/1078-0432.CCR-12-3669; Eide T, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-4; Flamand V, 2010, J CANCER RES CLIN, V136, P1761, DOI 10.1007/s00432-010-0835-6; Gaur S, 2019, PROSTATE, V79, P667, DOI 10.1002/pros.23774; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; He SB, 2014, P NATL ACAD SCI USA, V111, pE2008, DOI 10.1073/pnas.1402944111; Herman JG, 2007, INT J ONCOL, V30, P1231; Huyett P, 2017, JOVE-J VIS EXP, DOI 10.3791/55043; Jobling P, 2015, CANCER RES, V75, P1777, DOI 10.1158/0008-5472.CAN-14-3180; Khatiwada P, 2020, PEERJ, V8, DOI 10.7717/peerj.8921; Knudsen BS, 2002, UROLOGY, V60, P1113, DOI 10.1016/S0090-4295(02)01954-4; KO KR, 2018, SCI REP UK, V8; Kraus RD, 2019, ADV RADIAT ONCOL, V4, P96, DOI 10.1016/j.adro.2018.09.006; Kruger RR, 2005, NAT REV MOL CELL BIO, V6, P789, DOI 10.1038/nrm1740; Li JJ, 2020, ONCOGENE, V39, P3305, DOI 10.1038/s41388-020-1217-4; Liebig C, 2009, CANCER-AM CANCER SOC, V115, P3379, DOI 10.1002/cncr.24396; Magnon C, 2013, SCIENCE, V341, P143, DOI 10.1126/science.1236361; Maru N, 2001, HUM PATHOL, V32, P828, DOI 10.1053/hupa.2001.26456; Parra LM, 2010, NAT NEUROSCI, V13, P29, DOI 10.1038/nn.2457; Peacock JW, 2018, EMBO MOL MED, V10, P219, DOI 10.15252/emmm.201707689; Pundavela J, 2014, AM J PATHOL, V184, P3156, DOI 10.1016/j.ajpath.2014.08.009; Saloman JL, 2016, TRENDS NEUROSCI, V39, P880, DOI 10.1016/j.tins.2016.10.002; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Swiercz JM, 2004, J CELL BIOL, V165, P869, DOI 10.1083/jcb.200312094; Tam KJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11914-6; Tam KJ, 2017, ONCOTARGET, V8, P9617, DOI 10.18632/oncotarget.14168; True L, 2006, P NATL ACAD SCI USA, V103, P10991, DOI 10.1073/pnas.0603678103; VILLERS A, 1989, J UROLOGY, V142, P763, DOI 10.1016/S0022-5347(17)38881-X; Westerink RHS, 2008, ACTA PHYSIOL, V192, P273, DOI 10.1111/j.1748-1716.2007.01805.x; Wong VV, 1997, J BIOL CHEM, V272, P5187, DOI 10.1074/jbc.272.8.5187; Wu JB, 2017, CANCER CELL, V31, P368, DOI 10.1016/j.ccell.2017.02.003; Wu JB, 2014, J CLIN INVEST, V124, P2891, DOI 10.1172/JCI70982; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zhang DX, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10798	47	15	15	6	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2021	40	7					1362	1374		10.1038/s41388-020-01615-2	http://dx.doi.org/10.1038/s41388-020-01615-2		JAN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QK0LS	33420365	Green Accepted			2022-12-17	WOS:000607346000001
J	Swoboda, A; Soukup, R; Eckel, O; Kinslechner, K; Wingelhofer, B; Schorghofer, D; Sternberg, C; Pham, HTT; Vallianou, M; Horvath, J; Stoiber, D; Kenner, L; Larue, L; Poli, V; Beermann, F; Yokota, T; Kubicek, S; Krausgruber, T; Rendeiro, AF; Bock, C; Zenz, R; Kovacic, B; Aberger, F; Hengstschlager, M; Petzelbauer, P; Mikula, M; Moriggl, R				Swoboda, Alexander; Soukup, Robert; Eckel, Oliver; Kinslechner, Katharina; Wingelhofer, Bettina; Schoerghofer, David; Sternberg, Christina; Pham, Ha T. T.; Vallianou, Maria; Horvath, Jaqueline; Stoiber, Dagmar; Kenner, Lukas; Larue, Lionel; Poli, Valeria; Beermann, Friedrich; Yokota, Takashi; Kubicek, Stefan; Krausgruber, Thomas; Rendeiro, Andre F.; Bock, Christoph; Zenz, Rainer; Kovacic, Boris; Aberger, Fritz; Hengstschlaeger, Markus; Petzelbauer, Peter; Mikula, Mario; Moriggl, Richard			STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pathway	ONCOGENE			English	Article							MICROPHTHALMIA TRANSCRIPTION FACTOR; STEM-CELLS; EXPRESSION; GENE; RESISTANCE; CANCER; SUPPRESSION; MELANOCYTES; PROGRESSION; ACTIVATION	Metastatic melanoma is hallmarked by its ability of phenotype switching to more slowly proliferating, but highly invasive cells. Here, we tested the impact of signal transducer and activator of transcription 3 (STAT3) on melanoma progression in association with melanocyte inducing transcription factor (MITF) expression levels. We established a mouse melanoma model for deleting Stat3 in melanocytes with specific expression of human hyperactive NRAS(Q61K) in an Ink4a-deficient background, two frequent driver mutations in human melanoma. Mice devoid of Stat3 showed early disease onset with higher proliferation in primary tumors, but displayed significantly diminished lung, brain, and liver metastases. Whole-genome expression profiling of tumor-derived cells also showed a reduced invasion phenotype, which was further corroborated by 3D melanoma model analysis. Notably, loss or knockdown of STAT3 in mouse or human cells resulted in the upregulation of MITF and induction of cell proliferation. Mechanistically we show that STAT3-induced CAAT Box Enhancer Binding Protein (CEBP) expression was sufficient to suppress MITF transcription. Epigenetic analysis by ATAC-seq confirmed that CEBPa/b binding to the MITF enhancer region silenced the MITF locus. Finally, by classification of patient-derived melanoma samples, we show that STAT3 and MITF act antagonistically and hence contribute differentially to melanoma progression. We conclude that STAT3 is a driver of the metastatic process in melanoma and able to antagonize MITF via direct induction of CEBP family member transcription.	[Swoboda, Alexander; Wingelhofer, Bettina; Pham, Ha T. T.; Horvath, Jaqueline; Stoiber, Dagmar; Kenner, Lukas; Moriggl, Richard] Ludwig Boltzmann Inst Canc Res, Vienna, Austria; [Swoboda, Alexander; Eckel, Oliver; Wingelhofer, Bettina; Pham, Ha T. T.; Moriggl, Richard] Univ Vet Med, Inst Anim Breeding & Genet, Vienna, Austria; [Soukup, Robert; Eckel, Oliver; Kinslechner, Katharina; Schoerghofer, David; Vallianou, Maria; Kovacic, Boris; Hengstschlaeger, Markus; Mikula, Mario] Med Univ Vienna, Inst Med Genet, Ctr Pathobiochem & Genet, Vienna, Austria; [Sternberg, Christina; Aberger, Fritz] Univ Salzburg, Canc Cluster Salzburg, Dept Biosci, Salzburg, Austria; [Horvath, Jaqueline; Stoiber, Dagmar] Med Univ Vienna, Ctr Physiol & Pharmacol, Inst Pharmacol, Vienna, Austria; [Kenner, Lukas] Med Univ Vienna, Inst Clin Pathol, Vienna, Austria; [Kenner, Lukas] Univ Vet Med, Unit Pathol Lab Anim, Vienna, Austria; [Kenner, Lukas] Med Univ Vienna, CBMed Core Lab2, Vienna, Austria; [Larue, Lionel] Inst Curie Normal & Pathol Dev Melanocytes, CNRS, INSERM, UMR3347,U1021 Equipe Labellisee, Orsay, France; [Poli, Valeria] Univ Torino, Dept Mol Biotechnol & Hlth Sci, Turin, Italy; [Beermann, Friedrich] Swiss Fed Inst Technol Lausanne, ISREC, Lausanne, Switzerland; [Yokota, Takashi] Kanazawa Univ, Grad Sch Med Sci, Dept Stem Cell Biol, Kanazawa, Ishikawa, Japan; [Kubicek, Stefan; Krausgruber, Thomas; Rendeiro, Andre F.; Bock, Christoph] Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria; [Bock, Christoph] Med Univ Vienna, Dept Lab Med, Vienna, Austria; [Bock, Christoph] Max Planck Inst Informat, Saarland Informat Campus, Saarbrucken, Germany; [Zenz, Rainer] Med Univ Vienna, Inst Canc Res, Vienna, Austria; [Petzelbauer, Peter] Med Univ Vienna, Dept Dermatol, Skin & Endothelium Res Div SERD, Vienna, Austria	Ludwig Boltzmann Institute; University of Veterinary Medicine Vienna; Medical University of Vienna; Salzburg University; Medical University of Vienna; Medical University of Vienna; University of Veterinary Medicine Vienna; Medical University of Vienna; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Saclay; University of Turin; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute Experimental Cancer Research; Kanazawa University; Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; Medical University of Vienna; Max Planck Society; Medical University of Vienna; Medical University of Vienna	Moriggl, R (corresponding author), Ludwig Boltzmann Inst Canc Res, Vienna, Austria.; Moriggl, R (corresponding author), Univ Vet Med, Inst Anim Breeding & Genet, Vienna, Austria.; Mikula, M (corresponding author), Med Univ Vienna, Inst Med Genet, Ctr Pathobiochem & Genet, Vienna, Austria.	mario.mikula@meduniwien.ac.at; richard.moriggl@vetmeduni.ac.at	Bock, Christoph/AAE-7618-2019; Krausgruber, Thomas/H-8490-2018; petzelbauer, peter/GLU-3941-2022; Kubicek, Stefan/C-2089-2017; Rendeiro, André F./AAC-4747-2019; Yokota, Takashi/J-8483-2015	Bock, Christoph/0000-0001-6091-3088; Krausgruber, Thomas/0000-0002-1374-0329; Kubicek, Stefan/0000-0003-0855-8343; Rendeiro, André F./0000-0001-9362-5373; Aberger, Fritz/0000-0003-2009-6305; Moriggl, Richard/0000-0003-0918-9463; Petzelbauer, Peter/0000-0001-7080-5259; Kenner, Lukas/0000-0003-2184-1338	Austrian Science Fund (FWF) [AIRC IG16930, SFB-F061, SFB-F047, P 25336-B13]	Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	We thank Safia Zahma, Birgit Schutz, Eva Bauer, Michaela Schlederer, and Karin Neumuller for excellent technical assistance. We also thank the Biomedical Sequencing Facility at CeMM for assistance with next-generation sequencing. VP was supported by the grant AIRC IG16930, AS, OE, RZ, and RM were supported by a private melanoma research donation from Liechtenstein, RM was further supported by two network grants SFB-F061 and SFB-F047, and RS, KK, MV, and MM were supported by P 25336-B13, all from the Austrian Science Fund (FWF).	Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250; Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Alonzi T, 2001, MOL CELL BIOL, V21, P1621, DOI 10.1128/MCB.21.5.1621-1632.2001; Anastas JN, 2014, J CLIN INVEST, V124, P2877, DOI 10.1172/JCI70156; Bu X, 2016, TRENDS MOL MED, V22, P448, DOI 10.1016/j.molmed.2016.04.008; Cao HH, 2016, SCI REP-UK, V6, DOI 10.1038/srep21731; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Delmas V, 2003, GENESIS, V36, P73, DOI 10.1002/gene.10197; Fofaria NM, 2014, ONCOTARGET, V5, P7051, DOI 10.18632/oncotarget.2251; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Goding CR, 2019, GENE DEV, V33, P983, DOI 10.1101/gad.324657.119; Gong AH, 2015, CANCER RES, V75, P2337, DOI 10.1158/0008-5472.CAN-14-2800; Goodall J, 2008, CANCER RES, V68, P7788, DOI 10.1158/0008-5472.CAN-08-1053; Grabner B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7285; He WZ, 2018, CANCER RES, V78, P3293, DOI 10.1158/0008-5472.CAN-17-3131; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Huser L, 2018, INT J CANCER, V143, P3131, DOI 10.1002/ijc.31609; Igelmann S, 2019, CANCERS, V11, DOI 10.3390/cancers11101428; Jeffs AR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008461; Ji ZY, 2015, J INVEST DERMATOL, V135, P1863, DOI 10.1038/jid.2015.105; Kemper K, 2014, CANCER RES, V74, P5937, DOI 10.1158/0008-5472.CAN-14-1174; Kinslechner K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051063; Kortylewski M, 2005, CANCER METAST REV, V24, P315, DOI 10.1007/s10555-005-1580-1; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Kudo-Saito C, 2009, CANCER CELL, V15, P195, DOI 10.1016/j.ccr.2009.01.023; Kulesza DW, 2019, CELL BIOL INT, V43, P613, DOI 10.1002/cbin.11134; Lacreusette A, 2007, ONCOGENE, V26, P881, DOI 10.1038/sj.onc.1209844; Ladstein RG, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-140; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lee JW, 2019, NATURE, V567, P249, DOI 10.1038/s41586-019-1004-y; Lee M, 2000, J BIOL CHEM, V275, P37978, DOI 10.1074/jbc.M003816200; Li FZ, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00031; Luciani F, 2011, DEVELOPMENT, V138, P3943, DOI 10.1242/dev.067447; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Mirea MA, 2020, CANCERS, V12, DOI 10.3390/cancers12092508; Musteanu M, 2010, GASTROENTEROLOGY, V138, P1003, DOI 10.1053/j.gastro.2009.11.049; Niu GL, 1999, CANCER RES, V59, P5059; Ohanna M, 2013, ONCOTARGET, V4, P2212, DOI 10.18632/oncotarget.1143; Pencik J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8736; Qi XP, 2013, IMMUNITY, V39, P97, DOI 10.1016/j.immuni.2013.06.012; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shenoy AK, 2016, J CLIN INVEST, V126, P4174, DOI 10.1172/JCI86623; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Steder M, 2013, CANCER CELL, V24, P512, DOI 10.1016/j.ccr.2013.08.023; Steingrimsson E, 2004, ANNU REV GENET, V38, P365, DOI 10.1146/annurev.genet.38.072902.092717; Strub T, 2011, ONCOGENE, V30, P2319, DOI 10.1038/onc.2010.612; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tang Y, 2008, P NATL ACAD SCI USA, V105, P2445, DOI 10.1073/pnas.0705395105; Tang Y, 2012, STEM CELLS, V30, P2645, DOI 10.1002/stem.1225; Tu TJ, 2011, ONCOLOGY-BASEL, V80, P181, DOI 10.1159/000328518; Verastegui C, 2000, J BIOL CHEM, V275, P30757, DOI 10.1074/jbc.C000445200; Verfaillie A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7683; Weidenfeld K, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00381; Yamada T, 1997, J BIOCHEM-TOKYO, V121, P731; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; Yokoyama S, 2008, PIGM CELL MELANOMA R, V21, P457, DOI 10.1111/j.1755-148X.2008.00480.x	58	15	16	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2021	40	6					1091	1105		10.1038/s41388-020-01584-6	http://dx.doi.org/10.1038/s41388-020-01584-6		DEC 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QG0OL	33323974	Green Accepted			2022-12-17	WOS:000599126500003
J	Chen, LF; Yuan, RF; Wen, CY; Liu, TD; Feng, Q; Deng, XQ; Du, YY; Peng, XG				Chen, Leifeng; Yuan, Rongfa; Wen, Chongyu; Liu, Tiande; Feng, Qian; Deng, Xueqiang; Du, Yunyan; Peng, Xiaogang			E3 ubiquitin ligase UBR5 promotes pancreatic cancer growth and aerobic glycolysis by downregulating FBP1 via destabilization of C/EBP alpha	ONCOGENE			English	Article							PROTEIN; METASTASIS; SUPPRESSES; CELLS	Pancreatic cancer is one of the most fatal cancers in humans. While it thrives in a state of malnutrition, the mechanism by which pancreatic cancer cells adapt to metabolic stress through metabolic reprogramming remains unclear. Here, we showed that UBR5, an E3 ubiquitin ligase, was significantly upregulated in pancreatic cancer patient samples compared to the levels in adjacent normal tissues. Levels of UBR5 were closely related to a malignant phenotype and shorter survival among pancreatic cancer patients. Multivariate analyses also revealed that UBR5 overexpression was an independent predictor of poor outcomes among patients with pancreatic cancer. Functional assays revealed that UBR5 contributes to the growth of pancreatic cancer cells by inducing aerobic glycolysis. Furthermore, we demonstrated that UBR5 knockdown increased levels of fructose-1,6-bisphosphatase (FBP1), an important negative regulator in the process of aerobic glycolysis in many cancers. We found a significant negative correlation between levels of UBR5 and FBP1, further demonstrating that UBR5-induced aerobic glycolysis is dependent on FBP1 in pancreatic cancer cells. Mechanistically, UBR5 regulates FBP1 expression by modulating C/EBP alpha, directly binding to C/EBP alpha, and promoting its ubiquitination and degradation. Together, these results identify a mechanism used by pancreatic cancer cells to survive the nutrient-poor tumour microenvironment and also provide insight regarding the role of UBR5 in pancreatic cancer cell adaptation to metabolic stresses.	[Chen, Leifeng] Jiangxi Prov Clin Res Ctr Gen Surg Dis, Nanchang, Jiangxi, Peoples R China; [Chen, Leifeng; Yuan, Rongfa; Wen, Chongyu; Liu, Tiande; Feng, Qian; Deng, Xueqiang] Nanchang Univ, Affiliated Hosp 2, Dept Gen Surg, Nanchang, Jiangxi, Peoples R China; [Du, Yunyan] Nanchang Univ, Jiangxi Prov Peoples Hosp, Dept Med, Nanchang, Jiangxi, Peoples R China; [Peng, Xiaogang] Nanchang Univ, Affiliated Hosp 2, Jiangxi Prov Key Lab Mol Med, Nanchang, Jiangxi, Peoples R China	Nanchang University; Nanchang University; Nanchang University	Du, YY (corresponding author), Nanchang Univ, Jiangxi Prov Peoples Hosp, Dept Med, Nanchang, Jiangxi, Peoples R China.; Peng, XG (corresponding author), Nanchang Univ, Affiliated Hosp 2, Jiangxi Prov Key Lab Mol Med, Nanchang, Jiangxi, Peoples R China.	695728274@qq.com; pxg8205@163.com		Peng, Xiaogang/0000-0002-8173-5118	National Natural Science Foundation of China [81760523, 81560117, 32060166, 81960436, 81560396]; Project of the Jiangxi Provincial Department of Science and Technology [20171BAB215024, 20192BCB23023]; Project of the Jiangxi Provincial Department of Education [GJJ160251]; Project of the Jiangxi Provincial Health Commission [2017A264]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Project of the Jiangxi Provincial Department of Science and Technology; Project of the Jiangxi Provincial Department of Education; Project of the Jiangxi Provincial Health Commission	This study was supported by grants from the National Natural Science Foundation of China (nos. 81760523, 81560117, 32060166, 81960436 and 81560396), the Project of the Jiangxi Provincial Department of Science and Technology (nos. 20171BAB215024 and 20192BCB23023), the Project of the Jiangxi Provincial Department of Education (no. GJJ160251) and the Project of the Jiangxi Provincial Health Commission (no. 2017A264).	Bengoechea-Alonso MT, 2010, P NATL ACAD SCI USA, V107, P11817, DOI 10.1073/pnas.0913367107; Bolt MJ, 2015, ONCOGENE, V34, P154, DOI 10.1038/onc.2013.550; Breaux M, 2015, MOL CELL BIOL, V35, P3005, DOI 10.1128/MCB.00421-15; Callaghan MJ, 1998, ONCOGENE, V17, P3479, DOI 10.1038/sj.onc.1202249; Cong JJ, 2018, CELL METAB, V28, P243, DOI 10.1016/j.cmet.2018.06.021; Flint TR, 2017, TRENDS MOL MED, V23, P451, DOI 10.1016/j.molmed.2017.03.001; Gonzalez D, 2017, J BIOL CHEM, V292, P18924, DOI 10.1074/jbc.M117.811109; Habrook CJ, 2017, CANCER CELL, V31, P5, DOI 10.1016/j.ccell.2016.12.006; Henderson MJ, 2002, J BIOL CHEM, V277, P26468, DOI 10.1074/jbc.M203527200; Hu MY, 2019, J CANCER, V10, P1870, DOI 10.7150/jca.28299; Ilic M, 2016, WORLD J GASTROENTERO, V22, P9694, DOI 10.3748/wjg.v22.i44.9694; Liao LQ, 2017, CANCER RES, V77, P2090, DOI 10.1158/0008-5472.CAN-16-2409; Lin SC, 2017, J PATHOL, V241, P638, DOI 10.1002/path.4868; Liu GM, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1165-x; Liu TD, 2012, EXP CELL RES, V318, P1994, DOI 10.1016/j.yexcr.2012.04.017; Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237; Maisonneuve P, 2019, PRESSE MED, V48, pE113, DOI 10.1016/j.lpm.2019.02.030; Matsuura K, 2017, ONCOGENE, V36, P1698, DOI 10.1038/onc.2016.336; Min HY, 2018, BIOMOL THER, V26, P45, DOI 10.4062/biomolther.2017.211; Pedersen TA, 2007, EMBO J, V26, P1081, DOI 10.1038/sj.emboj.7601563; Qin YY, 2014, ONCOL REP, V31, P2635, DOI 10.3892/or.2014.3145; Shearer RF, 2015, MOL CANCER RES, V13, P1523, DOI 10.1158/1541-7786.MCR-15-0383; Shi DB, 2015, CANCER LETT, V369, P376, DOI 10.1016/j.canlet.2015.08.029; Subbaiah VK, 2016, ONCOGENE, V35, P2062, DOI 10.1038/onc.2015.268; Tao YM, 2014, P NATL ACAD SCI USA, V111, pE4429, DOI 10.1073/pnas.1407139111; Wang B, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0888-y; Wang J, 2017, DIGEST DIS SCI, V62, P2781, DOI 10.1007/s10620-017-4732-6; Wattanavanitchakorn S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194252; Weng WH, 2014, ONCOL REP, V31, P1921, DOI 10.3892/or.2014.3005; Xie H, 2017, J BIOL CHEM, V292, P16825, DOI 10.1074/jbc.R117.799973; Yang J, 2017, CARCINOGENESIS, V38, P134, DOI 10.1093/carcin/bgw109; Yang M, 2016, BIOCHEM BIOPH RES CO, V478, P1624, DOI 10.1016/j.bbrc.2016.08.170; Yang Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08759-0; Zhang TY, 2014, P NATL ACAD SCI USA, V111, P12091, DOI 10.1073/pnas.1400230111	34	15	17	1	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					262	276		10.1038/s41388-020-01527-1	http://dx.doi.org/10.1038/s41388-020-01527-1		OCT 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33122826				2022-12-17	WOS:000582827800003
J	Zheng, XC; Lu, ST; He, ZX; Huang, HH; Yao, ZC; Miao, YT; Cai, CQ; Zou, F				Zheng, Xianchong; Lu, Sitong; He, Zhanxin; Huang, Hehai; Yao, Zhuocheng; Miao, Yutian; Cai, Chunqing; Zou, Fei			MCU-dependent negative sorting of miR-4488 to extracellular vesicles enhances angiogenesis and promotes breast cancer metastatic colonization	ONCOGENE			English	Article							MICROENVIRONMENTAL REGULATION; NICHE FORMATION; EXOSOMES; UNIPORTER; FRACTALKINE; COMPONENT; PROTEIN	Based on Stephen Paget's well-established theory, both cell-autonomous and non-cell-autonomous mechanisms are crucial for metastasis. Although the mitochondrial calcium uniporter (MCU) has been suggested to be involved in breast cancer (BC) progression via cell-autonomous mechanisms, whether it assists the metastasis of BC cells through non-cell-autonomous mechanisms remains unclear. This study aimed to demonstrate that the MCU regulates BC metastatic colonization via non-cell-autonomous mechanisms. The results suggested that extracellular vesicles (EVs) derived from MCU-downregulated MDA-MB-231 cells suppressed angiogenesis in the metastatic niche in a nude mouse model, thereby hindering the colonization of BC cells. Mechanistically, we revealed that the MCU negatively correlated with miR-4488 in EVs derived from BC cells. Significantly, miR-4488 was determined to suppress angiogenesis of vascular endothelial cells by directly targeting angiogenic CX3CL1. Furthermore, we identified miR-4488 as being significantly downregulated in serum EVs from patients with triple-negative BC. Hence, this study suggests that MCU-dependent negative sorting of miR-4488 to EVs enhances angiogenesis in the metastatic niche and, thus, favors the metastatic colonization of BC cells.	[Zheng, Xianchong; Lu, Sitong; He, Zhanxin; Huang, Hehai; Yao, Zhuocheng; Miao, Yutian; Cai, Chunqing; Zou, Fei] Southern Med Univ, Sch Publ Hlth, Dept Occupat Hlth & Occupat Med, Guangzhou 510515, Peoples R China; [Zheng, Xianchong] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China	Southern Medical University - China; State Key Lab Oncology South China; Sun Yat Sen University	Cai, CQ; Zou, F (corresponding author), Southern Med Univ, Sch Publ Hlth, Dept Occupat Hlth & Occupat Med, Guangzhou 510515, Peoples R China.	h_zcn@126.com; zfei@smu.edu.cn			National Natural Science Foundation of China [81671860, 81741131]; Natural Science Foundation of Guangdong Province [2015A030310100]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province)	We thank Prof. Tiebang Kang and Prof. Hailin Tang from Sun Yat-Sen University Cancer Center for providing us BC clinical samples. We thank Dr. Sihua Qin from Clinical Laboratory, Nanfang Hospital of Southern Medical University for helping us on NTA. This work was supported by the National Natural Science Foundation of China under Grant 81671860 and 81741131; the Natural Science Foundation of Guangdong Province under Grant 2015A030310100.	Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Baughman JM, 2011, NATURE, V476, P341, DOI 10.1038/nature10234; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; Bianchini G, 2016, NAT REV CLIN ONCOL, V13, P674, DOI 10.1038/nrclinonc.2016.66; Bielenberg DR, 2015, CANCER J, V21, P267, DOI 10.1097/PPO.0000000000000138; Cha DJ, 2015, ELIFE, V4, DOI 10.7554/eLife.07197; Cheng L, 2014, KIDNEY INT, V86, P433, DOI 10.1038/ki.2013.502; Corrigan L, 2014, J CELL BIOL, V206, P671, DOI 10.1083/jcb.201401072; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Curry MC, 2013, BIOCHEM BIOPH RES CO, V434, P695, DOI 10.1016/j.bbrc.2013.04.015; de Palma M, 2017, NAT REV CANCER, V17, P457, DOI 10.1038/nrc.2017.51; De Stefani D, 2011, NATURE, V476, P336, DOI 10.1038/nature10230; Dweep H, 2015, NAT METHODS, V12, P697, DOI 10.1038/nmeth.3485; Fan GC, 2014, BLOOD, V124, P3669, DOI 10.1182/blood-2014-10-607846; Fang T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02583-0; Fong MY, 2015, NAT CELL BIOL, V17, P183, DOI 10.1038/ncb3094; Garcia-Silva S, 2016, NAT CELL BIOL, V18, P911, DOI 10.1038/ncb3404; Hall DD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096866; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harbeck N, 2017, LANCET, V389, P1134, DOI [10.1016/S0140-6736(16)31891-8, 10.1016/s0140-6736(16)31891-8]; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Janas T, 2015, FEBS LETT, V589, P1391, DOI 10.1016/j.febslet.2015.04.036; Kavanagh EL, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.82; Kornilov R, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2017.1422674; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Liu YF, 2016, CANCER CELL, V30, P243, DOI 10.1016/j.ccell.2016.06.021; Liu Y, 2016, CANCER CELL, V30, P668, DOI 10.1016/j.ccell.2016.09.011; Matamala N, 2015, CLIN CHEM, V61, P1098, DOI 10.1373/clinchem.2015.238691; Ozawa PMM, 2018, BREAST CANCER RES TR, V172, P713, DOI 10.1007/s10549-018-4925-5; O'Brien K, 2013, EUR J CANCER, V49, P1845, DOI 10.1016/j.ejca.2013.01.017; Tosar JP, 2015, NUCLEIC ACIDS RES, V43, P5601, DOI 10.1093/nar/gkv432; Ribatti D, 2006, CLIN EXP MED, V6, P145, DOI 10.1007/s10238-006-0117-4; Ribatti D, 2016, TRANSL ONCOL, V9, P453, DOI 10.1016/j.tranon.2016.07.002; Santangelo L, 2016, CELL REP, V17, P799, DOI 10.1016/j.celrep.2016.09.031; Szukiewicz D, 2013, MEDIAT INFLAMM, V2013, DOI [DOI 10.1155/2013/437576, 10.1155/2013/437576]; Takemoto-Kimura S, 2017, J NEUROCHEM, V141, P808, DOI 10.1111/jnc.14020; Tang SH, 2015, BIOCHEM BIOPH RES CO, V458, P186, DOI 10.1016/j.bbrc.2015.01.092; Thery C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750; Tosatto A, 2016, EMBO MOL MED, V8, P569, DOI 10.15252/emmm.201606255; Villarroya-Beltri C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3980; Volin MV, 2010, PATHOBIOLOGY, V77, P7, DOI 10.1159/000272949; Whiteside TL, 2016, J CLIN INVEST, V126, P1216, DOI 10.1172/JCI81136; Xu R, 2018, NAT REV CLIN ONCOL, V15, P617, DOI 10.1038/s41571-018-0036-9; You JJ, 2007, INVEST OPHTH VIS SCI, V48, P5290, DOI 10.1167/iovs.07-0187; Zhang Y, 2014, TRENDS CELL BIOL, V24, P153, DOI 10.1016/j.tcb.2013.09.007; Zhou WY, 2014, CANCER CELL, V25, P501, DOI 10.1016/j.ccr.2014.03.007	46	15	16	2	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2020	39	46					6975	6989		10.1038/s41388-020-01514-6	http://dx.doi.org/10.1038/s41388-020-01514-6		OCT 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OQ9FF	33067576				2022-12-17	WOS:000578435000001
J	Bhagirath, D; Liston, M; Patel, N; Akoto, T; Lui, B; Yang, TL; To, DM; Majid, S; Dahiya, R; Tabatabai, ZL; Saini, S				Bhagirath, Divya; Liston, Michael; Patel, Nikhil; Akoto, Theresa; Lui, Byron; Yang, Thao Ly; To, Dat My; Majid, Shahana; Dahiya, Rajvir; Tabatabai, Z. Laura; Saini, Sharanjot			MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer	ONCOGENE			English	Article							INCREASED SURVIVAL; ENZALUTAMIDE; ABIRATERONE; CELLS; IDENTIFICATION; COMMON; MEN; AR	Therapy-induced neuroendocrine prostate cancer (NEPC), an extremely aggressive variant of castration-resistant prostate cancer (CRPC), is increasing in incidence with the widespread use of highly potent androgen receptor (AR)-pathway inhibitors (APIs) such as Enzalutamide (ENZ) and Abiraterone and arises via a reversible trans-differentiation process, referred to as neuroendocrine differentiation (NED). The molecular basis of NED is not completely understood leading to a lack of effective molecular markers for its diagnosis. Here, we demonstrate for the first time, that lineage switching to NE states is accompanied by key miRNA alterations including downregulation of miR-106a similar to 363 cluster and upregulation of miR-301a and miR-375. To systematically investigate the key miRNAs alterations driving therapy-induced NED, we performed small RNA-NGS in a retrospective cohort of human metastatic CRPC clinical samples + PDX models with adenocarcinoma features (CRPC-adeno) vs those with neuroendocrine features (CRPC-NE). Further, with the application of machine learning algorithms to sequencing data, we trained a 'miRNA classifier' that could robustly classify 'CRPC-NE' from 'CRPC-Adeno' cases. The performance of classifier was validated in an additional cohort of mCRPC patients and publicly available PCa cohorts. Importantly, we demonstrate that miR-106a similar to 363 cluster pleiotropically regulate cardinal nodal proteins instrumental in driving NEPC including Aurora Kinase A, N-Myc, E2F1 and STAT3. Our study has important clinical implications and transformative potential as our 'miRNA classifier' can be used as a molecular tool to stratify mCRPC patients into those with/without NED and guide treatment decisions. Further, we identify novel miRNA NED drivers that can be exploited for NEPC therapeutic targeting.	[Bhagirath, Divya; Akoto, Theresa; Saini, Sharanjot] Augusta Univ, Dept Biochem & Mol Biol, Augusta, GA USA; [Liston, Michael; Lui, Byron; Yang, Thao Ly; To, Dat My; Majid, Shahana; Dahiya, Rajvir; Tabatabai, Z. Laura] Vet Affairs Med Ctr, San Francisco, CA 94121 USA; [Liston, Michael; Lui, Byron; Yang, Thao Ly; To, Dat My; Majid, Shahana; Dahiya, Rajvir; Tabatabai, Z. Laura] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Patel, Nikhil] Augusta Univ, Dept Pathol, Augusta, GA USA	University System of Georgia; Augusta University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University System of Georgia; Augusta University	Saini, S (corresponding author), Augusta Univ, Dept Biochem & Mol Biol, Augusta, GA USA.	ssaini@augusta.edu	Patel, Nikhil/O-6072-2018	Patel, Nikhil/0000-0001-9335-0082	US Army Medical Research Acquisition Activity (USAMRAA) through the Idea Development Award [W81XWH-18-1-0303]; National Cancer Institute at the National Institutes of Health [RO1CA177984]; Prostate Cancer Biorepository Network (PCBN) [W81XWH-18-2-0013, W81XWH-18-2-0015, W81XWH-18-2-0016, W81XWH-18-2-0017, W81XWH-18-2-0018, W81XWH-18-2-0019]	US Army Medical Research Acquisition Activity (USAMRAA) through the Idea Development Award; National Cancer Institute at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Prostate Cancer Biorepository Network (PCBN)	We sincerely thank Dr. Paul Jedlicka at University of Colorado, Denver for miR-106a-363 sponge and control constructs and Dr. Felix Feng at UCSF for LNCaP-AR-Enzalutamide resistant cell line. This work is supported by the US Army Medical Research Acquisition Activity (USAMRAA) through the Idea Development Award under Award No. W81XWH-18-1-0303. Additionally, supported by Award no. W81XWH-18-2-0013, W81XWH-18-2-0015, W81XWH-18-2-0016, W81XWH-18-2-0017, W81XWH-18-2-0018, and W81XWH-18-2-0019 Prostate Cancer Biorepository Network (PCBN). Funding support by the National Cancer Institute at the National Institutes of Health (Grant Number RO1CA177984) is also acknowledged. Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the Department of Defense or the U.S. Army.	Aggarwal R, 2018, J CLIN ONCOL, V36, P2492, DOI 10.1200/JCO.2017.77.6880; Aggarwal R, 2014, J NATL COMPR CANC NE, V12, P719, DOI 10.6004/jnccn.2014.0073; Aggarwal RR, 2014, ONCOLOGY-NY, V28, P838; Alshalalfa M, 2019, INT J CANCER, V145, P3453, DOI 10.1002/ijc.32430; Antonarakis ES, 2017, J CLIN ONCOL, V35, P2149, DOI 10.1200/JCO.2016.70.1961; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Beltran H, 2019, CLIN CANCER RES, V25, P43, DOI 10.1158/1078-0432.CCR-18-1912; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Berger A, 2019, J CLIN INVEST, V129, P3924, DOI 10.1172/JCI127961; Bhagirath D, 2019, CLIN CANCER RES, V25, P6532, DOI 10.1158/1078-0432.CCR-19-0498; Bishop JL, 2017, CANCER DISCOV, V7, P54, DOI 10.1158/2159-8290.CD-15-1263; Chen SY, 2019, AM J CLIN EXP UROL, V7, P327; Damodaran C, 2016, UROL ONCOL-SEMIN ORI, V34, DOI 10.1016/j.urolonc.2016.03.009; Dang Q, 2015, MOL ONCOL, V9, P1241, DOI 10.1016/j.molonc.2015.02.010; Dankert JT, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200472; Dardenne E, 2016, CANCER CELL, V30, P563, DOI 10.1016/j.ccell.2016.09.005; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Ding M, 2015, ONCOTARGET, V6, P7686, DOI 10.18632/oncotarget.3480; Dylla L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063032; Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079; Fernandes RC, 2019, ENDOCR-RELAT CANCER, V26, pR237, DOI 10.1530/ERC-18-0571; Gupta K, 2017, TRANSL CANCER RES, V6, pS104, DOI 10.21037/tcr.2017.01.20; HAYWARD SW, 1995, IN VITRO CELL DEV-AN, V31, P14; Hu CD, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00090; Hussain M, 2018, NEW ENGL J MED, V379, P1381, DOI 10.1056/NEJMc1810065; Hussain M, 2018, NEW ENGL J MED, V378, P2465, DOI 10.1056/NEJMoa1800536; Knudsen KE, 2009, CLIN CANCER RES, V15, P4792, DOI 10.1158/1078-0432.CCR-08-2660; Kojima S, 2017, J HUM GENET, V62, P25, DOI 10.1038/jhg.2016.69; Labrecque MP, 2019, J CLIN INVEST, V129, P4492, DOI 10.1172/JCI128212; LAI SL, 1995, ANTICANCER RES, V15, P225; Lee JK, 2016, CANCER CELL, V29, P536, DOI 10.1016/j.ccell.2016.03.001; Li Z, 2015, MOL CANCER RES, V13, P584, DOI 10.1158/1541-7786.MCR-14-0277-T; Liu B, 2019, CLIN CANCER RES, V25, P6839, DOI 10.1158/1078-0432.CCR-19-0317; Lotan TL, 2011, MODERN PATHOL, V24, P820, DOI 10.1038/modpathol.2011.7; Maina PK, 2016, ONCOTARGET, V7, P75585, DOI 10.18632/oncotarget.12310; Nam Robert K, 2018, Oncotarget, V9, P19159, DOI 10.18632/oncotarget.24937; Nam RK, 2016, PROSTATE, V76, P869, DOI 10.1002/pros.23177; Nam RK, 2015, J CANCER, V6, P1160, DOI 10.7150/jca.13397; Nguyen HM, 2017, PROSTATE, V77, P654, DOI 10.1002/pros.23313; Park JW, 2018, SCIENCE, V362, P91, DOI 10.1126/science.aat5749; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Sasaki T, 2005, EUR UROL, V48, P224, DOI 10.1016/j.eururo.2005.03.017; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Schlomm T, 2016, EUR UROL, V69, P1157, DOI 10.1016/j.eururo.2016.02.024; Selth LA, 2017, ONCOGENE, V36, P24, DOI 10.1038/onc.2016.185; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; TAKAYAMA K, 2017, CANCERS, V9; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thieu W, 2014, UROL ONCOL-SEMIN ORI, V32, P517, DOI 10.1016/j.urolonc.2013.11.004; WANG Y, 2016, MOL CANCER, V15	51	15	15	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2020	39	49					7209	7223		10.1038/s41388-020-01493-8	http://dx.doi.org/10.1038/s41388-020-01493-8		OCT 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PB0GA	33037409	Green Accepted, Green Submitted			2022-12-17	WOS:000578440800003
J	Peng, KS; Zhuo, MH; Li, M; Chen, Q; Mo, PL; Yu, CD				Peng, Kesong; Zhuo, Minghui; Li, Ming; Chen, Qiang; Mo, Pingli; Yu, Chundong			Histone demethylase JMJD2D activates HIF1 signaling pathway via multiple mechanisms to promote colorectal cancer glycolysis and progression	ONCOGENE			English	Article							HYPOXIA; MTOR; HIF-1-ALPHA; ALPHA	Hypoxia-inducible factor 1 (HIF1) signaling pathway plays a key role in cancer progression by enhancing glycolysis through activating the transcription of glycolytic genes. JMJD2D, a histone demethylase that specifically demethylates H3K9me2/3, can promote colorectal cancer (CRC) progression. However, it is unknown whether JMJD2D could promote CRC progression by enhancing glycolysis through activating HIF1 signaling pathway. In this study, we found that downregulation of JMJD2D inhibited the glycolysis in CRC cells through suppressing HIF1 signaling pathway to downregulate glycolytic gene expression. Restoring HIF1 signaling by enforced expression of HIF1 alpha in JMJD2D-knockdown CRC cells partially recovered CRC cell glycolysis, proliferation, migration, invasion, xenograft growth, and metastasis, suggesting that JMJD2D promotes CRC progression by enhancing glycolysis through activating HIF1 signaling pathway. JMJD2D activated HIF1 signaling pathway through three different mechanisms: JMJD2D cooperated with the transcription factor SOX9 to enhance mTOR expression and then to promote HIF1 alpha translation; JMJD2D cooperated with the transcription factor c-Fos to enhance HIF1 beta transcription; JMJD2D interacted and cooperated with HIF1 alpha to enhance the expression of glycolytic gene. The demethylase-defective mutant of JMJD2D could not induce the expression of mTOR, HIF1 alpha, HIF1 beta, and glycolytic genes, suggesting that the demethylase activity of JMJD2D is important for glycolysis through activating HIF1 signaling. Clinically, a highly positive correlation between the expression of JMJD2D and mTOR, HIF1 beta, and several glycolytic genes in human CRC specimens was identified. Collectively, our study reveals an important role of JMJD2D in CRC progression by enhancing glycolysis through activating HIF1 signaling pathway.	[Peng, Kesong; Zhuo, Minghui; Chen, Qiang; Mo, Pingli; Yu, Chundong] Xiamen Univ, Sch Life Sci, Innovat Ctr Cell Biol, State Key Lab Cellular Stress Biol, Xiamen, Peoples R China; [Peng, Kesong] Fudan Univ, Sch Basic Med Sci, Dept Cellular & Genet Med, Shanghai, Peoples R China; [Li, Ming] Xiamen Univ, Sch Med, Xiangan Hosp, Dept Hepatobiliary Surg, Xiamen, Peoples R China	Xiamen University; Fudan University; Xiamen University	Mo, PL; Yu, CD (corresponding author), Xiamen Univ, Sch Life Sci, Innovat Ctr Cell Biol, State Key Lab Cellular Stress Biol, Xiamen, Peoples R China.	mop@xmu.edu.cn; cdyu@xmu.edu.cn		Li, Ming/0000-0002-9700-1282; Peng, Kesong/0000-0001-9035-3421	National Natural Science Foundation of China [81970485, 81772942]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by grants from the National Natural Science Foundation of China (No. 81970485 and No. 81772942 to CY). We thank Dr Mingxia Zhu and Shuhai Lin (Xiamen University) for the technical support and reagents.	Berry WL, 2013, CANCER RES, V73, P2936, DOI 10.1158/0008-5472.CAN-12-4300; Dancey J, 2010, NAT REV CLIN ONCOL, V7, P209, DOI 10.1038/nrclinonc.2010.21; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Dong FY, 2019, EBIOMEDICINE, V39, P472, DOI 10.1016/j.ebiom.2018.11.055; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hu FQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0861-6; Iadevaia V, 2012, METHODS MOL BIOL, V821, P171, DOI 10.1007/978-1-61779-430-8_10; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kim AL, 2018, J INVEST DERMATOL, V138, P1716, DOI 10.1016/j.jid.2018.01.040; Koh MY, 2008, TRENDS BIOCHEM SCI, V33, P526, DOI 10.1016/j.tibs.2008.08.002; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007; Mi CL, 2017, J ETHNOPHARMACOL, V203, P27, DOI 10.1016/j.jep.2017.03.033; Peng KS, 2019, GASTROENTEROLOGY, V156, P1112, DOI 10.1053/j.gastro.2018.11.036; San-Millan I, 2017, CARCINOGENESIS, V38, P119, DOI 10.1093/carcin/bgw127; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Wan W, 2017, ONCOGENE, V36, P3868, DOI 10.1038/onc.2017.13; Wouters BG, 2008, NAT REV CANCER, V8, P851, DOI 10.1038/nrc2501; Zhong H, 1999, CANCER RES, V59, P5830; Zhuo MH, 2020, ONCOGENE, V39, P3336, DOI 10.1038/s41388-020-1219-2	25	15	15	7	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2020	39	47					7076	7091		10.1038/s41388-020-01483-w	http://dx.doi.org/10.1038/s41388-020-01483-w		SEP 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OT7KA	32989255				2022-12-17	WOS:000573446900001
J	Lin, SR; Wen, YC; Yeh, HL; Jiang, KC; Chen, WH; Mokgautsi, N; Huang, J; Chen, WY; Liu, YN				Lin, Shian-Ren; Wen, Yu-Ching; Yeh, Hsiu-Lien; Jiang, Kuo-Ching; Chen, Wei-Hao; Mokgautsi, Ntlotlang; Huang, Jiaoti; Chen, Wei-Yu; Liu, Yen-Nien			EGFR-upregulated LIFR promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; MITOCHONDRIAL-DNA CONTENT; ANDROGEN RECEPTOR; STEM-CELLS; EXPRESSION; ACTIVATION; MECHANISMS; STAT3; ADENOCARCINOMAS; LOCALIZATION	Neuroendocrine (NE) differentiation is a well-recognized phenotypic change of prostate cancer after androgen deprivation therapy (ADT), and it ultimately develops into an aggressive subset of this disease. However, the contribution of signaling pathways that lead to metabolic disorders and NE differentiation of prostate cancer remains unclear. In this study, we identified that ADT induced upregulation of the succinate-CoA ligase GDP-forming beta subunit (SUCLG2), which regulates succinate metabolism and NE differentiation of prostate cancer. We demonstrated a connection that upregulation of epidermal growth factor receptor (EGFR)-leukemia inhibitory factor receptor (LIFR) signaling induced SUCLG2 expression in prostate cancer cells. The LIFR is upregulated by nuclear EGFR, which acts as a transcriptional regulator, directly binds to theLIFRpromoter, and drives NE differentiation and glycolysis of prostate cancer. LIFR upregulation is associated with SUCLG2, which increased succinate synthesis and enzymatic activities of mitochondrial nucleoside diphosphate kinase (NDPK) in prostate cancer cells. Knockdown of SUCLG2 suppressed NE differentiation in cultured cells and reduced prostate tumor growth in a xenograft model. Analysis of prostate tissue samples showed increased intensity of nuclear EGFR associated with the LIFR and SUCLG2 in castration-resistant prostate cancer tumors. Our study provides a mechanism whereby ADT upregulates EGFR-LIFR signaling that activates SUCLG2, which subsequently stimulates the metabolic changes associated with NE differentiation and aggressive prostate cancer phenotype.	[Lin, Shian-Ren; Jiang, Kuo-Ching; Chen, Wei-Hao; Mokgautsi, Ntlotlang; Liu, Yen-Nien] Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Coll Med Sci & Technol, Taipei, Taiwan; [Wen, Yu-Ching] Taipei Med Univ, Wan Fang Hosp, Dept Urol, Taipei, Taiwan; [Wen, Yu-Ching] Taipei Med Univ, Sch Med, Dept Urol, Coll Med, Taipei, Taiwan; [Yeh, Hsiu-Lien] Natl Tsing Hua Univ, Inst Informat Syst & Applicat, Hsinchu, Taiwan; [Huang, Jiaoti; Liu, Yen-Nien] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; [Chen, Wei-Yu] Taipei Med Univ, Wan Fang Hosp, Dept Pathol, Taipei, Taiwan; [Chen, Wei-Yu] Taipei Med Univ, Sch Med, Dept Pathol, Coll Med, Taipei, Taiwan	Taipei Medical University; Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University; National Tsing Hua University; Duke University; Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University	Liu, YN (corresponding author), Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Coll Med Sci & Technol, Taipei, Taiwan.; Liu, YN (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.; Chen, WY (corresponding author), Taipei Med Univ, Wan Fang Hosp, Dept Pathol, Taipei, Taiwan.; Chen, WY (corresponding author), Taipei Med Univ, Sch Med, Dept Pathol, Coll Med, Taipei, Taiwan.	1047@tmu.edu.tw; liuy@tmu.edu.tw	Liu, Yen-Nien/AAW-4698-2021; Lin, Shian-Ren/AAR-6238-2020	Lin, Shian-Ren/0000-0002-4160-2361	Ministry of Science and Technology of Taiwan [MOST108-2320-B-038-047, MOST 109-2314-B-038-105, MOST109-2326-B-038-001-MY3]; Taipei Medical University-Wan Fang Hospital [109TMU-WFH-01]; National Health Research Institute of Taiwan [NHRI-EX109-10702BI]	Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan); Taipei Medical University-Wan Fang Hospital; National Health Research Institute of Taiwan(National Health Research Institutes - Taiwan)	This work was jointly supported by grants from the Ministry of Science and Technology of Taiwan (MOST108-2320-B-038-047) to WYC, (MOST 109-2314-B-038-105) to YCW, and (MOST109-2326-B-038-001-MY3) to YNL, Taipei Medical University-Wan Fang Hospital (109TMU-WFH-01) to WYC, and the National Health Research Institute of Taiwan (NHRI-EX109-10702BI) to YNL.	Aggarwal R, 2018, J CLIN ONCOL, V36, P2492, DOI 10.1200/JCO.2017.77.6880; Cortes MA, 2012, CARCINOGENESIS, V33, P1169, DOI 10.1093/carcin/bgs139; Angelescu R, 2013, ENDOSC ULTRASOUND, V2, P86, DOI [10.4103/2303-9027.117692, 10.7178/eus.05.005]; Beltran H, 2019, CLIN CANCER RES, V25, P6916, DOI 10.1158/1078-0432.CCR-19-1423; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Brand TM, 2013, RADIOTHER ONCOL, V108, P370, DOI 10.1016/j.radonc.2013.06.010; Brand TM, 2011, DISCOV MED, V12, P419; Bressy C, 2018, CANCER RES, V78, P909, DOI 10.1158/0008-5472.CAN-15-2790; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Cai CM, 2009, CANCER RES, V69, P5202, DOI 10.1158/0008-5472.CAN-09-0026; Chang YS, 2015, CANCER RES, V75, P3077, DOI 10.1158/0008-5472.CAN-14-3380; Chen L, 2020, GUT, V69, P630, DOI 10.1136/gutjnl-2019-318325; Chiarugi P, 2014, SEMIN ONCOL, V41, P267, DOI 10.1053/j.seminoncol.2014.03.004; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Choueiri TK, 2009, CANCER, V115, P981, DOI 10.1002/cncr.24064; Chua CY, 2016, ONCOGENE, V35, P738, DOI 10.1038/onc.2015.131; Dai C, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a030452; Day KC, 2017, CANCER RES, V77, P74, DOI 10.1158/0008-5472.CAN-16-1656; DISANTAGNESE PA, 1992, HUM PATHOL, V23, P287; Dobolyi A, 2015, J BIOENERG BIOMEMBR, V47, P33, DOI 10.1007/s10863-014-9586-4; Dobolyi A, 2015, BRAIN STRUCT FUNCT, V220, P135, DOI 10.1007/s00429-013-0643-2; Dziennis S, 2008, REV NEUROSCIENCE, V19, P341; Egan Kathryn, 2010, J Clin Med Res, V2, P225, DOI 10.4021/jocmr443w; Faraco CCF, 2018, J STRUCT BIOL, V202, P61, DOI 10.1016/j.jsb.2017.12.007; Gagliano-Juca T, 2018, J CLIN ENDOCR METAB, V103, P3900, DOI 10.1210/jc.2018-01068; Heidenreich A, 2014, EUR UROL, V65, P467, DOI 10.1016/j.eururo.2013.11.002; Hoshino M, 2007, PATHOBIOLOGY, V74, P15, DOI 10.1159/000101047; Hsing AW, 2007, AM J CLIN NUTR, V86, p843S, DOI 10.1093/ajcn/86.3.843S; Huang JT, 2006, PROSTATE, V66, P1399, DOI 10.1002/pros.20434; Humez S, 2006, ENDOCR-RELAT CANCER, V13, P181, DOI 10.1677/erc.1.01079; Kharmate G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154967; Kim J, 2019, CELL METAB, V30, P434, DOI 10.1016/j.cmet.2019.08.013; Kim MM, 2004, CLIN CANCER RES, V10, P8512, DOI 10.1158/1078-0432.CCR-04-0734; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; Li QH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06067-7; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Liu YN, 2019, CLIN CANCER RES, V25, P4128, DOI 10.1158/1078-0432.CCR-18-3239; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Madshus IH, 2009, J CELL SCI, V122, P3433, DOI 10.1242/jcs.050260; Mahdavi A, 2007, PLOS COMPUT BIOL, V3, P1257, DOI 10.1371/journal.pcbi.0030130; Marcoux N, 2019, J CLIN ONCOL, V37, P278, DOI 10.1200/JCO.18.01585; Martin-Orozco RM, 2007, NEOPLASIA, V9, P614, DOI 10.1593/neo.07337; Miller C, 2011, BBA-MOL BASIS DIS, V1812, P625, DOI 10.1016/j.bbadis.2011.01.013; Mizumachi T, 2008, PROSTATE, V68, P408, DOI 10.1002/pros.20697; Mosquera JM, 2013, NEOPLASIA, V15, P1, DOI 10.1593/neo.121550; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Nicola NA, 2015, CYTOKINE GROWTH F R, V26, P533, DOI 10.1016/j.cytogfr.2015.07.001; Onishi K, 2015, DEVELOPMENT, V142, P2230, DOI 10.1242/dev.117598; Papouchado B, 2005, MODERN PATHOL, V18, P1329, DOI 10.1038/modpathol.3800427; Peraldo-Neia C, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-31; Read J, 2017, EUR J CANCER, V70, P62, DOI 10.1016/j.ejca.2016.10.017; Rimawi MF, 2010, CANCER-AM CANCER SOC, V116, P1234, DOI 10.1002/cncr.24816; Rooney JP, 2015, METHODS MOL BIOL, V1241, P23, DOI 10.1007/978-1-4939-1875-1_3; Sasaki T, 2018, J CLIN MED, V7, DOI 10.3390/jcm7120565; Scaltriti M, 2006, CLIN CANCER RES, V12, P5268, DOI 10.1158/1078-0432.CCR-05-1554; Schindelin J, 2015, MOL REPROD DEV, V82, P518, DOI 10.1002/mrd.22489; Shah T, 2006, J NEUROENDOCRINOL, V18, P355, DOI 10.1111/j.1365-2826.2006.01425.x; Shao JL, 2019, CANCER LETT, V451, P110, DOI 10.1016/j.canlet.2019.02.042; Spiotto MT, 2000, PROSTATE, V42, P88, DOI 10.1002/(SICI)1097-0045(20000201)42:2<88::AID-PROS2>3.0.CO;2-P; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295; Thomas R, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00800; Timofeeva OA, 2012, J BIOL CHEM, V287, P14192, DOI 10.1074/jbc.M111.323899; Traish AM, 2009, BRIT J CANCER, V101, P1949, DOI 10.1038/sj.bjc.6605376; Tsai YC, 2017, CANCER LETT, V384, P1, DOI 10.1016/j.canlet.2016.10.014; Vlachostergios PJ, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00006; Wang G, 2006, ONCOGENE, V25, P7311, DOI 10.1038/sj.onc.1209715; Wang Y, 2006, BRIT J CANCER, V95, P1087, DOI 10.1038/sj.bjc.6603377; Williamson SR, 2011, MODERN PATHOL, V24, P1120, DOI 10.1038/modpathol.2011.56; Wu HX, 2018, BBA-MOL BASIS DIS, V1864, P2769, DOI 10.1016/j.bbadis.2018.05.004; Xu RH, 2005, CANCER RES, V65, P613; Xue Y, 1997, AM J PATHOL, V151, P1759; Zhang XQ, 2003, ONCOGENE, V22, P6704, DOI 10.1038/sj.onc.1206764	73	15	15	1	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2020	39	44					6757	6775		10.1038/s41388-020-01468-9	http://dx.doi.org/10.1038/s41388-020-01468-9		SEP 2020	19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OH9QS	32963351				2022-12-17	WOS:000572030400001
J	Liu, Y; Yang, L; Liao, F; Wang, W; Wang, ZF				Liu, Yu; Yang, Liang; Liao, Fan; Wang, Wei; Wang, Zhi-Fei			MiR-450a-5p strengthens the drug sensitivity of gefitinib in glioma chemotherapy via regulating autophagy by targeting EGFR	ONCOGENE			English	Article							CELL LUNG-CANCER; KINASE INHIBITORS; WIPI PROTEINS; RESISTANCE; GROWTH; TEMOZOLOMIDE; MUTANT; CHEMORESISTANCE; IDENTIFICATION; CONTRIBUTES	Glioma reported to be refractory to EGFR tyrosine kinase inhibitor is the most common malignant tumor in central nervous system. Our research showed the low expression of miR-450a-5p and high expression of EGFR in glioma tissues. MiR-450a-5p was also observed to synergize with gefitinib to inhibit the proliferation, migration and invasion and induce the apoptosis and autophagy of glioma cells. Furthermore, miR-450a-5p was demonstrated to target 3 ' UTR of EGFR, and regulated EGFR-induced PI3K/AKT/mTOR signaling pathway. Moreover, the above effects induced by miR-450a-5p in glioma cells were reversed by WIPI1 silencing. The inhibition role of miR-450a-5p on glioma growth was also confirmed in vivo by subcutaneous and intracranial tumor xenografts. Therefore, we conclude that miR-450a-5p synergizes with gefitinib to inhibit the glioma tumorigenesis through inducing autophagy by regulating the EGFR-induced PI3K/AKT/mTOR signaling pathway, thereby enhancing the drug sensitivity of gefitinib.	[Liu, Yu; Yang, Liang; Liao, Fan; Wang, Zhi-Fei] Cent South Univ, Xiangya Hosp 3, Dept Neurosurg, Changsha 410013, Peoples R China; [Wang, Wei] Cent South Univ, Xiangya Hosp 2, Dept Neurol, Changsha 410011, Peoples R China	Central South University; Central South University	Wang, ZF (corresponding author), Cent South Univ, Xiangya Hosp 3, Dept Neurosurg, Changsha 410013, Peoples R China.	doctorwangzhifei@163.com			New Xiangya Talent Project of the Third Xiangya Hospital of Central South University [JY201711]	New Xiangya Talent Project of the Third Xiangya Hospital of Central South University	This work was supported by the New Xiangya Talent Project of the Third Xiangya Hospital of Central South University (No. JY201711).	Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Chang CY, 2014, EXP CELL RES, V327, P102, DOI 10.1016/j.yexcr.2014.05.011; Chen XR, 2017, CANCER RES, V77, P4998, DOI 10.1158/0008-5472.CAN-17-1139; Chistiakov DA, 2017, EUR J PHARMACOL, V810, P70, DOI 10.1016/j.ejphar.2017.05.064; Cho YH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58237-7; Davis ME, 2016, CLIN J ONCOL NURS, V20, P2, DOI 10.1188/16.CJON.S1.2-8; Detassis S, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00086; Dhillon S, 2015, TARGET ONCOL, V10, P153, DOI 10.1007/s11523-015-0358-9; Gharwan H, 2016, NAT REV CLIN ONCOL, V13, P209, DOI 10.1038/nrclinonc.2015.213; Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697; Gump JM, 2011, TRENDS CELL BIOL, V21, P387, DOI 10.1016/j.tcb.2011.03.007; Han J, 2016, INT J ONCOL, V48, P1855, DOI 10.3892/ijo.2016.3401; Han J, 2015, INT J CLIN EXP PATHO, V8, P12698; Hassan B, 2013, SURG ONCOL CLIN N AM, V22, P641, DOI 10.1016/j.soc.2013.06.008; Jendrossek V, 2003, EXPERT OPIN INV DRUG, V12, P1899, DOI 10.1517/13543784.12.12.1899; Jutten B, 2014, CELL CYCLE, V13, P42, DOI 10.4161/cc.27518; Koperski L, 2017, ONCOTARGET, V8, P49191, DOI 10.18632/oncotarget.16788; Lan FM, 2015, J NEUROCHEM, V134, P811, DOI 10.1111/jnc.13174; Learn CA, 2004, CLIN CANCER RES, V10, P3216, DOI 10.1158/1078-0432.CCR-03-0521; Li H, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0618-0; Li YH, 2014, INT J MOL MED, V34, P491, DOI 10.3892/ijmm.2014.1813; Ma W, 2017, EXP THER MED, V14, P2853, DOI 10.3892/etm.2017.4847; Ma YH, 2017, ONCOTARGET, V8, P88529, DOI 10.18632/oncotarget.19874; Muller AJ, 2015, FEBS LETT, V589, P1546, DOI 10.1016/j.febslet.2015.05.008; Nakada M, 2014, BRAIN TUMOR PATHOL, V31, P198, DOI 10.1007/s10014-013-0174-9; Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P896, DOI 10.1093/neuonc/nou087; Paquette M, 2018, CANCERS, V10, DOI 10.3390/cancers10010018; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pedersen MW, 2005, BRIT J CANCER, V93, P915, DOI 10.1038/sj.bjc.6602793; Peng Y, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2015.4; Proikas-Cezanne T, 2015, J CELL SCI, V128, P207, DOI 10.1242/jcs.146258; Rich JN, 2004, J CLIN ONCOL, V22, P133, DOI 10.1200/JCO.2004.08.110; Sarkaria JN, 2008, CLIN CANCER RES, V14, P2900, DOI 10.1158/1078-0432.CCR-07-1719; Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350; Touat M, 2017, ANN ONCOL, V28, P1457, DOI 10.1093/annonc/mdx106; Wang SH, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0210-9; Wu H, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0173-0; Yamaoka T, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112420; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; YUN SH, 2018, COCHRANE DB SYST REV, V16, DOI DOI 10.3390/MD16040123; Zhou KC, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00046	41	15	15	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2020	39	39					6190	6202		10.1038/s41388-020-01422-9	http://dx.doi.org/10.1038/s41388-020-01422-9		AUG 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NS8XO	32820249	hybrid, Green Published			2022-12-17	WOS:000561253800005
J	Bartolome, RA; Pintado-Berninches, L; Jaen, M; de los Rios, V; Imbaud, JI; Casal, JI				Bartolome, Ruben A.; Pintado-Berninches, Laura; Jaen, Marta; de los Rios, Vivian; Imbaud, Juan Ignacio; Casal, J. Ignacio			SOSTDC1 promotes invasion and liver metastasis in colorectal cancer via interaction with ALCAM/CD166	ONCOGENE			English	Article							CELL-ADHESION MOLECULE; MORPHOGENETIC PROTEIN ANTAGONIST; STEM-CELLS; ACTIN CYTOSKELETON; PANCREATIC-CANCER; PROGNOSTIC MARKER; POOR SURVIVAL; EXPRESSION; MIGRATION; CD166	The mechanistic basis of liver metastasis in colorectal cancer remains poorly understood. We previously reported that the sclerostin domain containing-1 (SOSTDC1) protein is overexpressed in the secretome of metastatic colorectal cancer cells and can inhibit liver homing. Here, we investigated the mechanisms of SOSTDC1 for promoting invasiveness and progression of colorectal cancer liver metastasis. SOSTDC1 inhibition of BMP4 maintains the expression of cancer stem cell traits, including SOX2 and NANOG. Immunoprecipitation and mass spectrometry analyses reveal the association of SOSTDC1 with ALCAM/CD166, which was confirmed by confocal microscopy and competition ELISA. Interaction with ALCAM is mediated by the N-terminal region of SOSTDC1, which contains a sequence similar to the ALCAM-binding motif used by CD6. Knocking down either SOSTDC1 or ALCAM expression, or using blocking antibodies, reduces the invasive activity by inhibiting Src and PI3K/AKT signaling pathways. In addition, ALCAM interacts with the alpha 2ss1 and alpha 1ss1 integrins, providing a possible link to Src activation. Finally, inoculation of SOSTDC1-silenced metastatic cells increases mouse survival by inhibiting liver metastasis. In conclusion, SOSTDC1 promotes invasion and liver metastasis in colorectal cancer, by overcoming BMP4-specific antimetastatic signals and inducing ALCAM-mediated Src and PI3K/AKT activation. These experiments underscore the potential of SOSTDC1 as a therapeutic target in metastatic colorectal cancer.	[Bartolome, Ruben A.; Pintado-Berninches, Laura; Jaen, Marta; de los Rios, Vivian; Casal, J. Ignacio] CSIC, Ctr Invest Biol, Dept Mol Biomed, Ramiro de Maeztu 9, Madrid 28039, Spain; [Imbaud, Juan Ignacio] Prot Alternat SL, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Bartolome, RA; Casal, JI (corresponding author), CSIC, Ctr Invest Biol, Dept Mol Biomed, Ramiro de Maeztu 9, Madrid 28039, Spain.	rubenabc@cib.csic.es; icasal@cib.csic.es	Imbaud, Juan Ignacio/AAP-2121-2021; Casal, J. Ignacio/M-2312-2014; Bartolome, Ruben A/M-1873-2014	Imbaud, Juan Ignacio/0000-0002-6026-4265; Casal, J. Ignacio/0000-0003-1085-2840; Bartolome, Ruben A/0000-0002-3292-1491	Ministerio de Ciencia e Innovacion [BIO2015-66489-R, RTI2018-095055-B100]; Foundation Ramon Areces; PRB3 [ISCIII-SGEFI/FEDER-PT17/0019/0008]	Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Foundation Ramon Areces; PRB3	We thank Diego Laxalde, Alejandro Diaz, Jose Ramon Gutierrez, Marcos Rodriguez, Eva Calvino, and Gema Elvira for their contributions to the paper. This research was supported by grants from the Ministerio de Ciencia e Innovacion (BIO2015-66489-R, RTI2018-095055-B100), Foundation Ramon Areces and PRB3 (ISCIII-SGEFI/FEDER-PT17/0019/0008).	Barderas R, 2013, MOL CELL PROTEOMICS, V12, P1602, DOI 10.1074/mcp.M112.022848; Bartolome RA, 2014, ONCOGENE, V33, P1658, DOI 10.1038/onc.2013.117; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Blish KR, 2008, MOL BIOL CELL, V19, P457, DOI 10.1091/mbc.E07-05-0433; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Chappell PE, 2015, STRUCTURE, V23, P1426, DOI 10.1016/j.str.2015.05.019; Chen GH, 2018, INT J MOL MED, V42, P3424, DOI 10.3892/ijmm.2018.3926; Clausen KA, 2011, BREAST CANCER RES TR, V129, P737, DOI 10.1007/s10549-010-1261-9; Cui YZ, 2019, AM J CANCER RES, V9, P2331; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Devis L, 2017, J PATHOL, V241, P475, DOI 10.1002/path.4851; Donizy P, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0331-z; Gao H, 2012, CELL, V150, P764, DOI 10.1016/j.cell.2012.06.035; Gilsanz A, 2013, CELL MOL LIFE SCI, V70, P475, DOI 10.1007/s00018-012-1132-0; Gopal G, 2013, CANCER GENET-NY, V206, P174, DOI 10.1016/j.cancergen.2013.04.005; Horst D, 2009, CANCER INVEST, V27, P844, DOI 10.1080/07357900902744502; Inaguma S, 2018, HUM PATHOL, V71, P1, DOI 10.1016/j.humpath.2017.04.032; Kahlert C, 2009, BRIT J CANCER, V101, P457, DOI 10.1038/sj.bjc.6605136; Kholmanskikh SS, 2003, J NEUROSCI, V23, P8673; Kim GR, 2015, ONCOL LETT, V9, P1641, DOI 10.3892/ol.2015.2918; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lintern KB, 2009, J BIOL CHEM, V284, P23159, DOI 10.1074/jbc.M109.025478; Liu L, 2016, CELL BIOSCI, V6, DOI 10.1186/s13578-016-0091-9; Lo FY, 2012, LUNG CANCER, V77, P585, DOI 10.1016/j.lungcan.2012.05.105; Lunter PC, 2005, CANCER RES, V65, P8801, DOI 10.1158/0008-5472.CAN-05-0378; MORIKAWA K, 1988, CANCER RES, V48, P1943; Nolan K, 2014, PROTEIN SCI, V23, P999, DOI 10.1002/pro.2485; Oskarsson T, 2014, CELL STEM CELL, V14, P306, DOI 10.1016/j.stem.2014.02.002; Piazza T, 2005, J CELL SCI, V118, P1515, DOI 10.1242/jcs.02280; Rauhala HE, 2013, ANTICANCER RES, V33, P45; Rawat A, 2014, CELL ONCOL, V37, P409, DOI 10.1007/s13402-014-0204-6; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Secondini C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016078; Tesfay L, 2015, CANCER RES, V75, P2254, DOI 10.1158/0008-5472.CAN-14-2465; Torres S, 2015, CLIN CANCER RES, V21, P4892, DOI 10.1158/1078-0432.CCR-14-3096; Tudor C, 2014, J BIOL CHEM, V289, P13445, DOI 10.1074/jbc.M113.546754; van Kilsdonk JWJ, 2008, CANCER RES, V68, P3671, DOI 10.1158/0008-5472.CAN-07-5767; von Lersner A, 2019, CLIN EXP METASTAS, V36, P87, DOI 10.1007/s10585-019-09957-2; Weichert W, 2004, J CLIN PATHOL, V57, P1160, DOI 10.1136/jcp.2004.016238; Weidle Ulrich H., 2010, Cancer Genomics & Proteomics, V7, P231; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Yan K, 2014, GENE DEV, V28, P1085, DOI 10.1101/gad.235515.113; Yanagita M, 2005, CYTOKINE GROWTH F R, V16, P309, DOI 10.1016/j.cytogfr.2005.02.007; Yanagita M, 2004, BIOCHEM BIOPH RES CO, V316, P490, DOI 10.1016/j.bbrc.2004.02.075; Young RA, 2011, CELL, V144, P940, DOI 10.1016/j.cell.2011.01.032; Zhou QY, 2017, MOL CELL BIOCHEM, V435, P87, DOI 10.1007/s11010-017-3059-0	46	15	15	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2020	39	38					6085	6098		10.1038/s41388-020-01419-4	http://dx.doi.org/10.1038/s41388-020-01419-4		AUG 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NQ9JF	32801337	Green Submitted			2022-12-17	WOS:000559940500001
J	Ko, CJ; Hsu, TW; Wu, SR; Lan, SW; Hsiao, TF; Lin, HY; Lin, HH; Tu, HF; Lee, CF; Huang, CC; Chen, MJM; Hsiao, PW; Huang, HP; Lee, MS				Ko, Chun-Jung; Hsu, Ting-Wei; Wu, Shang-Ru; Lan, Shao-Wei; Hsiao, Ting-Feng; Lin, Hsin-Ying; Lin, Hsin-Hsien; Tu, Hsin-Fang; Lee, Cheng-Fan; Huang, Cheng-Chung; Chen, Mei-Ju May; Hsiao, Pei-Wen; Huang, Hsiang-Po; Lee, Ming-Shyue			Inhibition of TMPRSS2 by HAI-2 reduces prostate cancer cell invasion and metastasis	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; FACTOR ACTIVATOR INHIBITOR; ANCHORED SERINE-PROTEASE; PERICELLULAR PROTEOLYSIS; SWISS-MODEL; MATRIPTASE; EXPRESSION; CLUSPRO; TISSUE; MET	TMPRSS2 is an important membrane-anchored serine protease involved in human prostate cancer progression and metastasis. A serine protease physiologically often comes together with a cognate inhibitor for execution of proteolytically biologic function; however, TMPRSS2's cognate inhibitor is still elusive. To identify the cognate inhibitor of TMPRSS2, in this study, we applied co-immunoprecipitation and LC/MS/MS analysis and isolated hepatocyte growth factor activator inhibitors (HAIs) to be potential inhibitor candidates for TMPRSS2. Moreover, the recombinant HAI-2 proteins exhibited a better inhibitory effect on TMPRSS2 proteolytic activity than HAI-1, and recombinant HAI-2 proteins had a high affinity to form a complex with TMPRSS2. The immunofluorescence images further showed that TMPRSS2 was co-localized to HAI-2. Both KD1 and KD2 domain of HAI-2 showed comparable inhibitory effects on TMPRSS2 proteolytic activity. In addition, HAI-2 overexpression could suppress the induction effect of TMPRSS2 on pro-HGF activation, extracellular matrix degradation and prostate cancer cell invasion. We further determined that the expression levels of TMPRSS2 were inversely correlated with HAI-2 levels during prostate cancer progression. In orthotopic xenograft animal model, TMPRSS2 overexpression promoted prostate cancer metastasis, and HAI-2 overexpression efficiently blocked TMPRSS2-induced metastasis. In summary, the results together indicate that HAI-2 can function as a cognate inhibitor for TMPRSS2 in human prostate cancer cells and may serve as a potential factor to suppress TMPRSS2-mediated malignancy.	[Ko, Chun-Jung; Hsu, Ting-Wei; Wu, Shang-Ru; Lan, Shao-Wei; Lin, Hsin-Ying; Lin, Hsin-Hsien; Tu, Hsin-Fang; Lee, Cheng-Fan; Huang, Cheng-Chung; Lee, Ming-Shyue] Natl Taiwan Univ, Coll Med, Dept Biochem & Mol Biol, Taipei, Taiwan; [Ko, Chun-Jung] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Hsiao, Ting-Feng] Chang Gung Univ, Coll Med, Grad Inst Biomed Sci, Taoyuan, Taiwan; [Hsiao, Ting-Feng] Chang Gung Univ, Mol Med Res Ctr, Taoyuan, Taiwan; [Chen, Mei-Ju May] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Hsiao, Pei-Wen] Acad Sinica, Agr Biotechnol Res Ctr, Taipei, Taiwan; [Huang, Hsiang-Po] Natl Taiwan Univ, Coll Med, Grad Inst Med Genom & Prote, Taipei, Taiwan	National Taiwan University; University of Texas System; UTMD Anderson Cancer Center; Chang Gung University; Chang Gung University; University of Texas System; UTMD Anderson Cancer Center; Academia Sinica - Taiwan; National Taiwan University	Lee, MS (corresponding author), Natl Taiwan Univ, Coll Med, Dept Biochem & Mol Biol, Taipei, Taiwan.	mslee2006@ntu.edu.tw	Ko, Chun-Jung/AAA-6187-2022; Tu, Hsin-Fang/HGA-9284-2022	Hsiao, Ting-Feng/0000-0003-4074-9019; HUANG, HSIANG-PO/0000-0002-3382-305X; Ko, Chun-Jung/0000-0001-6565-7060	Ministry of Science and Technology [MOST 104-2320-B-002-044-MY3, MOST 105-2911-I-002-521, MOST 106-2320-B-002-046-MY3, MOST 108-2320-B-002-024-MY3]; National Health Research Institutes Grant [NHRI-EX106-10401BI, NHRI-EX109-10725BI]; National Taiwan University [NTU-CESRP-104R7602C4, NTU105R89612, NYU107L890504]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); National Health Research Institutes Grant; National Taiwan University(National Taiwan University)	This study was supported by Ministry of Science and Technology Grants MOST 104-2320-B-002-044-MY3, MOST 105-2911-I-002-521, MOST 106-2320-B-002-046-MY3 and MOST 108-2320-B-002-024-MY3, National Health Research Institutes Grant NHRI-EX106-10401BI and NHRI-EX109-10725BI, and National Taiwan University Grant NTU-CESRP-104R7602C4, NTU105R89612 and NYU107L890504 to M.S. Lee. We appreciate the service of the First Core Laboratory of National Taiwan University College of Medicine. We thank Dr. Chen-Yong Lin at the Georgetown University for his gifts of antibodies. We would like to acknowledge Dr. Chia-Jung Yu (Chang Gung University, Taoyuan, Taiwan; Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan) and the Proteomics Core Laboratory of Chang Gung University for providing proteomics technical support.	Aalinkeel R, 2004, CANCER RES, V64, P5311, DOI 10.1158/0008-5472.CAN-2506-2; Benaud CM, 2002, CLIN EXP METASTAS, V19, P639, DOI 10.1023/A:1020985632550; Biasini Marco, 2014, Nucleic Acids Res, V42, pW252, DOI 10.1093/nar/gku340; Bugge TH, 2009, J BIOL CHEM, V284, P23177, DOI 10.1074/jbc.R109.021006; Chen YW, 2010, AM J PATHOL, V176, P2986, DOI 10.2353/ajpath.2010.090665; Chou FP, 2013, AM J PATHOL, V183, P1306, DOI 10.1016/j.ajpath.2013.06.024; Comeau SR, 2004, BIOINFORMATICS, V20, P45, DOI 10.1093/bioinformatics/btg371; Comeau SR, 2004, NUCLEIC ACIDS RES, V32, pW96, DOI 10.1093/nar/gkh354; Debes JD, 2004, NEW ENGL J MED, V351, P1488, DOI 10.1056/NEJMp048178; Delaria KA, 1997, J BIOL CHEM, V272, P12209, DOI 10.1074/jbc.272.18.12209; Dozmorov MG, 2009, PROSTATE, V69, P1077, DOI 10.1002/pros.20960; Eder T, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091458; Fan B, 2005, J BIOL CHEM, V280, P34513, DOI 10.1074/jbc.M502119200; Garten W, 2015, EUR J CELL BIOL, V94, P375, DOI 10.1016/j.ejcb.2015.05.013; Herter S, 2005, BIOCHEM J, V390, P125, DOI 10.1042/BJ20041955; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Humphrey PA, 2006, CLIN GENITOURIN CANC, V4, P269, DOI 10.3816/CGC.2006.n.006; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jin JS, 2007, HISTOL HISTOPATHOL, V22, P305, DOI 10.14670/HH-22.305; Kang JY, 2003, CANCER RES, V63, P1101; Kawaguchi M, 2014, CANCERS, V6, P1890, DOI 10.3390/cancers6041890; Kawaguchi T, 1997, J BIOL CHEM, V272, P27558, DOI 10.1074/jbc.272.44.27558; Kirchhofer D, 2005, FEBS LETT, V579, P1945, DOI 10.1016/j.febslet.2005.01.085; Ko CJ, 2015, CANCER RES, V75, P2949, DOI 10.1158/0008-5472.CAN-14-3297; Kozakov D, 2006, PROTEINS, V65, P392, DOI 10.1002/prot.21117; Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169; Kozakov D, 2013, PROTEINS, V81, P2159, DOI 10.1002/prot.24403; Kumar D, 2018, CANCER RES, V78, P3769, DOI 10.1158/0008-5472.CAN-17-1076; Lai YS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127293; Lam DK, 2015, PAIN, V156, P923, DOI 10.1097/j.pain.0000000000000130; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; Lopez-Otin C, 2008, J BIOL CHEM, V283, P30433, DOI 10.1074/jbc.R800035200; Lucas J, 2008, J PATHOL, V215, P118, DOI 10.1002/path.2330; Lucas JM, 2014, CANCER DISCOV, V4, P1310, DOI 10.1158/2159-8290.CD-13-1010; Maurer E, 2013, BIOCHEM J, V450, P583, DOI 10.1042/BJ20121518; Mestres J, 2008, NAT BIOTECHNOL, V26, P983, DOI 10.1038/nbt0908-983; Mierke CT, 2013, EUR J CELL BIOL, V92, P89, DOI 10.1016/j.ejcb.2012.12.002; Miyazawa K, 2010, FEBS J, V277, P2208, DOI 10.1111/j.1742-4658.2010.07637.x; Oberst MD, 2005, AM J PHYSIOL-CELL PH, V289, pC462, DOI 10.1152/ajpcell.00076.2005; Pietras K, 2010, EXP CELL RES, V316, P1324, DOI 10.1016/j.yexcr.2010.02.045; PISTERS LL, 1995, J UROLOGY, V154, P293, DOI 10.1016/S0022-5347(01)67297-5; Qin L, 1998, FEBS LETT, V436, P111, DOI 10.1016/S0014-5793(98)01105-3; Roversi FM, 2018, BIOMED PHARMACOTHER, V101, P278, DOI 10.1016/j.biopha.2018.02.100; Russo AL, 2009, CLIN CANCER RES, V15, P4292, DOI 10.1158/1078-0432.CCR-09-0599; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; Sevenich L, 2014, GENE DEV, V28, P2331, DOI 10.1101/gad.250647.114; Shen CA-SaMM, 2000, GENE DEV, V14, P26; Shimomura T, 1997, J BIOL CHEM, V272, P6370, DOI 10.1074/jbc.272.10.6370; Stowell SR, 2015, ANNU REV PATHOL-MECH, V10, P473, DOI 10.1146/annurev-pathol-012414-040438; Tao LL, 2017, ONCOL LETT, V14, P2611, DOI 10.3892/ol.2017.6497; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tsai CH, 2014, ONCOGENE, V33, P4643, DOI 10.1038/onc.2013.412; Vogel LK, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-176; Wilson S, 2005, BIOCHEM J, V388, P967, DOI 10.1042/BJ20041066; Wu SR, 2019, BRIT J CANCER, V120, P499, DOI 10.1038/s41416-019-0400-2	58	15	15	5	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2020	39	37					5950	5963		10.1038/s41388-020-01413-w	http://dx.doi.org/10.1038/s41388-020-01413-w		AUG 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NM2OY	32778768	Bronze, Green Published			2022-12-17	WOS:000558201400002
J	Buschhaus, JM; Humphries, BA; Eckley, SS; Robison, TH; Cutter, AC; Rajendran, S; Haley, HR; Bevoor, AS; Luker, KE; Luker, GD				Buschhaus, Johanna M.; Humphries, Brock A.; Eckley, Samantha S.; Robison, Tanner H.; Cutter, Alyssa C.; Rajendran, Shrila; Haley, Henry R.; Bevoor, Avinash S.; Luker, Kathryn E.; Luker, Gary D.			Targeting disseminated estrogen-receptor-positive breast cancer cells in bone marrow	ONCOGENE			English	Article							SIGNALING PATHWAY; AKT INHIBITOR; IN-VITRO; THIOREDOXIN; METASTASIS; CYCLE; OPPORTUNITIES; SENSITIVITY; SURVIVAL; FACILE	Estrogen receptor-positive (ER+) breast cancer can recur up to 20 years after initial diagnosis. Delayed recurrences arise from disseminated tumors cells (DTCs) in sites such as bone marrow that remain quiescent during endocrine therapy and subsequently proliferate to produce clinically detectable metastases. Identifying therapies that eliminate DTCs and/or effectively target cells transitioning to proliferation promises to reduce risk of recurrence. To tackle this problem, we utilized a 3D co-culture model incorporating ER+ breast cancer cells and bone marrow mesenchymal stem cells to represent DTCs in a bone marrow niche. 3D co-cultures maintained cancer cells in a quiescent, viable state as measured by both single-cell and population-scale imaging. Single-cell imaging methods for metabolism by fluorescence lifetime (FLIM) of NADH and signaling by kinases Akt and ERK revealed that breast cancer cells utilized oxidative phosphorylation and signaling by Akt to a greater extent both in 3D co-cultures and a mouse model of ER+ breast cancer cells in bone marrow. Using our 3D co-culture model, we discovered that combination therapies targeting oxidative phosphorylation via the thioredoxin reductase (TrxR) inhibitor, D9, and the Akt inhibitor, MK-2206, preferentially eliminated breast cancer cells without altering viability of bone marrow stromal cells. Treatment of mice with disseminated ER+ human breast cancer showed that D9 plus MK-2206 blocked formation of new metastases more effectively than tamoxifen. These data establish an integrated experimental system to investigate DTCs in bone marrow and identify combination therapy against metabolic and kinase targets as a promising approach to effectively target these cells and reduce risk of recurrence in breast cancer.	[Buschhaus, Johanna M.; Robison, Tanner H.; Luker, Gary D.] Univ Michigan, Dept Biomed Engn, 2200 Bonisteel Blvd, Ann Arbor, MI 48109 USA; [Buschhaus, Johanna M.; Humphries, Brock A.; Robison, Tanner H.; Cutter, Alyssa C.; Rajendran, Shrila; Haley, Henry R.; Bevoor, Avinash S.; Luker, Kathryn E.; Luker, Gary D.] Univ Michigan, Dept Radiol, Ctr Mol Imaging, 109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA; [Eckley, Samantha S.] Univ Michigan, Unit Lab Anim Med, 412 Victor Vaughan, Ann Arbor, MI 48109 USA; [Luker, Gary D.] Univ Michigan, Dept Microbiol & Immunol, 109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA; [Eckley, Samantha S.] Univ Iowa, Off Anim Resources, Iowa City, IA USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Iowa	Luker, GD (corresponding author), Univ Michigan, Dept Biomed Engn, 2200 Bonisteel Blvd, Ann Arbor, MI 48109 USA.; Luker, GD (corresponding author), Univ Michigan, Dept Radiol, Ctr Mol Imaging, 109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.; Luker, GD (corresponding author), Univ Michigan, Dept Microbiol & Immunol, 109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	gluker@med.umich.edu		Humphries, Brock/0000-0002-6992-3394; Robison, Tanner/0000-0001-6407-6475; luker, gary/0000-0001-6832-2581; Buschhaus, Johanna/0000-0002-4181-0953	United States National Institutes of Health [R01CA238042, R01CA196018, U01CA210152, R01CA238023, R33CA225549, R50CA221807, R37CA222563]; American Cancer Society - Michigan Cancer Research Fund Postdoctoral Fellowship [PF-18-236-01-CCG]; University of Michigan Rogel Cancer Center through National Institutes of Health [P30CA046592]; National Science Foundation Graduate Research Fellowship [DGE 1256260]	United States National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society - Michigan Cancer Research Fund Postdoctoral Fellowship; University of Michigan Rogel Cancer Center through National Institutes of Health; National Science Foundation Graduate Research Fellowship(National Science Foundation (NSF))	We thank Aye J. Muniz and Max Wicha for paper feedback. We thank Michael Pihalja for assistance with flow cytometry. We acknowledge funding from United States National Institutes of Health grants R01CA238042, R01CA196018, U01CA210152, R01CA238023, R33CA225549, R50CA221807, and R37CA222563. Brock Humphries, Ph.D., was supported by an American Cancer Society - Michigan Cancer Research Fund Postdoctoral Fellowship, PF-18-236-01-CCG. We acknowledge support to the University of Michigan Rogel Cancer Center through National Institutes of Health grant P30CA046592 for flow cytometry and animal imaging studies. This material is based upon work supported by the National Science Foundation Graduate Research Fellowship under Grant No. DGE 1256260 to Johanna Buschhaus.	Abu-Eid R, 2014, CANCER IMMUNOL RES, V2, P1080, DOI 10.1158/2326-6066.CIR-14-0095; Aka JA, 2012, PLOS ONE, P7; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Bartkowiak K, 2012, CANCER MICROENVIRON, V5, P59, DOI 10.1007/s12307-011-0067-6; Buschhaus JM, 2018, METHODS MOL BIOL, V1686, P201, DOI 10.1007/978-1-4939-7371-2_15; Cavnar SP, 2016, TOMOGRAPHY, V2, P146, DOI 10.18383/j.tom.2016.00157; Cavnar SP, 2015, NEOPLASIA, V17, P625, DOI 10.1016/j.neo.2015.08.001; Cavnar SP, 2014, JALA-J LAB AUTOM, V19, P208, DOI 10.1177/2211068213504296; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Ding W, 2014, BRIT J HAEMATOL, V164, P146, DOI 10.1111/bjh.12564; Eckley SS, 2019, TOMOGRAPHY, V5, P346, DOI 10.18383/j.tom.2019.00019; Grabinski N, 2011, CELL SIGNAL, V23, P1952, DOI 10.1016/j.cellsig.2011.07.003; Gross S, 2015, J CLIN INVEST, V125, P1780, DOI 10.1172/JCI76094; Haley HR, 2018, TOMOGRAPHY, V4, P84, DOI 10.18383/j.tom.2018.00010; Heinz S, 2017, SCI REP-UK, V7, DOI 10.1038/srep45465; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; Holen I, 2016, CLIN EXP METASTAS, V33, P211, DOI 10.1007/s10585-015-9770-x; Humphries BA, 2019, MOL CANCER RES, V17, P1142, DOI 10.1158/1541-7786.MCR-18-0836; Iwata M, 2014, STEM CELLS DEV, V23, P729, DOI 10.1089/scd.2013.0300; Kaboli PJ, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.10480; Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820; Kohno M, 2006, ANN MED, V38, P200, DOI 10.1080/07853890600551037; LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039; Lu X, 2011, CANCER CELL, V20, P701, DOI 10.1016/j.ccr.2011.11.002; Luengo A, 2017, CELL CHEM BIOL, V24, P1161, DOI 10.1016/j.chembiol.2017.08.028; Luo M, 2018, CELL METAB, V28, P69, DOI 10.1016/j.cmet.2018.06.006; Ma G, 2015, INT J BIOL SCI, V11, P618, DOI 10.7150/ijbs.11380; Martini M, 2014, ANN MED, V46, P372, DOI 10.3109/07853890.2014.912836; Maryu G, 2016, CELL STRUCT FUNCT, V41, P81, DOI 10.1247/csf.16007; Mehta G, 2012, J CONTROL RELEASE, V164, P192, DOI 10.1016/j.jconrel.2012.04.045; Melzer C, 2016, CELL COMMUN SIGNAL, V14, DOI 10.1186/s12964-016-0143-0; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Ogba N, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0489-4; Ottewell PD, 2014, CLIN CANCER RES, V20, P2922, DOI 10.1158/1078-0432.CCR-13-1246; Ozdemir B, 2018, ENDOCR RELAT CANC, V25; Pan HC, 2017, NEW ENGL J MED, V377, P1836, DOI 10.1056/NEJMoa1701830; Pantel Klaus, 2014, Bonekey Rep, V3, P584, DOI 10.1038/bonekey.2014.79; Patel CH, 2019, NAT REV DRUG DISCOV, V18, P669, DOI 10.1038/s41573-019-0032-5; Phansalkar Neerad, 2011, 2011 International Conference on Communications and Signal Processing (ICCSP), P218, DOI 10.1109/ICCSP.2011.5739305; Plava J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0960-z; Pozarowski Piotr, 2004, Methods Mol Biol, V281, P301; Pradhan S, 2018, J BIOL ENG, V12, DOI 10.1186/s13036-018-0120-9; Regot S, 2014, CELL, V157, P1724, DOI 10.1016/j.cell.2014.04.039; Sakaue-Sawano A, 2008, CELL, V132, P487, DOI 10.1016/j.cell.2007.12.033; Scalcon V, 2018, FREE RADICAL BIO MED, V127, P62, DOI 10.1016/j.freeradbiomed.2018.03.043; Shi Junlin, 2018, Oncotarget, V9, P9206, DOI 10.18632/oncotarget.24104; Sosa MS, 2011, CLIN CANCER RES, V17, P5850, DOI 10.1158/1078-0432.CCR-10-2574; Spinosa PC, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aaw4204; Stringari C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048014; Thakur S, 2018, CLIN CANCER RES, V24, P4030, DOI 10.1158/1078-0432.CCR-17-3167; TRIPATHY D, 2015, J CLIN ONCOL S, V33; Vallabhaneni KC, 2015, ONCOTARGET, V6, P4953, DOI 10.18632/oncotarget.3211; Walsh AJ, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.11.116015; Wang H, 2015, CANCER CELL, V27, P193, DOI 10.1016/j.ccell.2014.11.017; Weinberg SE, 2015, NAT CHEM BIOL, V11, P9, DOI 10.1038/nchembio.1712; Widner DB, 2018, CURR OSTEOPOROS REP, V16, P596, DOI 10.1007/s11914-018-0471-7; Xue G., 2015, JNCI-J NATL CANCER I, V107, P171; Yarosz EL, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e14; Yin ZP, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1409-3; Zhang D, 2014, J MED CHEM, V57, P8132, DOI 10.1021/jm5012098; Zhang XHF, 2013, CLIN CANCER RES, DOI [10.1158/078-0432.CCR-13-838, DOI 10.1158/078-0432.CCR-13-838]; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017; Zhang Y, 2013, CLIN CANCER RES, V19, P4196, DOI 10.1158/1078-0432.CCR-13-0804; Zhong W, 2017, ONCOTARGET, V8, P73693, DOI 10.18632/oncotarget.17793	64	15	16	3	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2020	39	34					5649	5662		10.1038/s41388-020-01391-z	http://dx.doi.org/10.1038/s41388-020-01391-z		JUL 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NE9FK	32678295	Green Accepted			2022-12-17	WOS:000557627400001
J	Nair, J; Huang, TT; Murai, J; Haynes, B; Steeg, PS; Pommier, Y; Lee, JM				Nair, Jayakumar; Huang, Tzu-Ting; Murai, Junko; Haynes, Brittany; Steeg, Patricia S.; Pommier, Yves; Lee, Jung-Min			Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer	ONCOGENE			English	Article							CHECKPOINT KINASE 1; CYCLIN B1; DNA-DAMAGE; PHOSPHORYLATION; REPLICATION; GEMCITABINE; ACTIVATION; PATHWAYS; PROTEINS; CELLS	High grade serous ovarian cancer (HGSOC) is a fatal gynecologic malignancy in the U.S. with limited treatment options. New therapeutic strategies include targeting of the cell cycle checkpoints, e.g., ATR and CHK1. We recently reported a promising clinical activity of the CHK1 inhibitor (CHK1i) prexasertib monotherapy inBRCAwild-type (BRCAwt) HGSOC patients. In this study, biopsies of treated patients and cell line models were used to investigate possible mechanisms of resistance to CHK1i. We report that BRCAwt HGSOC develops resistance to prexasertib monotherapy via a prolonged G2 delay induced by lower CDK1/CyclinB1 activity, thus preventing cells from mitotic catastrophe and cell death. On the other hand, we noted CHK1's regulation on RAD51-mediated homologous recombination (HR) repair was not altered in CHK1i-resistant cells. Therefore, CHK1i sensitizes CHK1i-resistant cells to DNA damaging agents such as gemcitabine or hydroxyurea by inhibition of HR. In summary, our results demonstrate new mechanistic insights of functionally distinct CHK1 activities and highlight a potential combination treatment approach to overcome CHK1i resistance in BRCAwt HGSOC.	[Nair, Jayakumar; Huang, Tzu-Ting; Haynes, Brittany; Steeg, Patricia S.; Lee, Jung-Min] NIH, Womens Malignancies Branch, Bldg 10, Bethesda, MD 20892 USA; [Murai, Junko; Pommier, Yves] NCI, Dev Therapeut Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Murai, Junko; Pommier, Yves] NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Nair, J (corresponding author), NIH, Womens Malignancies Branch, Bldg 10, Bethesda, MD 20892 USA.	jayakumar.nair@nih.gov	Murai, Junko/AAU-9516-2021	Nair, Jayakumar/0000-0002-4478-4607	Intramural Research Program of NCI, CCR [ZIA BC011525, Z01 BC01006150]	Intramural Research Program of NCI, CCR	We thank Dr. Chen X, Mrs. Bao T, and Mrs. Shetty J at the Sequencing Facility, National Cancer Institute (NCI) at Frederick; Dr. Cam M, Lack J, and Abdalla A, at the Center for Cancer Research (CCR) Collaborative Bioinformatics Resource, NCI for their expertise in generating the RNA-seq datasets and help with data analysis. This research was supported by the Intramural Research Program of NCI, CCR (JML, #ZIA BC011525 and JM, YP Z01 BC01006150).	Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Barnard D, 2016, INVEST NEW DRUG, V34, P49, DOI 10.1007/s10637-015-0310-y; Belanger F, 2018, CANCER RES, V78, P5561, DOI 10.1158/0008-5472.CAN-18-0618; Biswas K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03020-6; Booth L, 2013, CANCER BIOL THER, V14, P458, DOI 10.4161/cbt.24424; Brill E, 2017, ONCOTARGET, V8, P111026, DOI 10.18632/oncotarget.22195; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; DARZYNKIEWICZ Z, 2001, CURRENT PROTOCOLS CY, V7, P7; Edelman MJ, 2007, CLIN CANCER RES, V13, P2667, DOI 10.1158/1078-0432.CCR-06-1832; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; Gomez LA, 2007, MOL CANCER THER, V6, P1534, DOI 10.1158/1535-7163.MCT-06-0727; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Haynes B, 2018, CANCER TREAT REV, V71, P1, DOI 10.1016/j.ctrv.2018.09.003; Kao GD, 1997, CANCER RES, V57, P753; Kim H, 2017, CLIN CANCER RES, V23, P3097, DOI 10.1158/1078-0432.CCR-16-2273; King C, 2015, MOL CANCER THER, V14, P2004, DOI 10.1158/1535-7163.MCT-14-1037; Kurman RJ, 2008, INT J GYNECOL PATHOL, V27, P151, DOI 10.1097/PGP.0b013e318161e4f5; Lee JM, 2014, ANN ONCOL, V25, P32, DOI 10.1093/annonc/mdt384; Lee JM, 2018, LANCET ONCOL, V19, P207, DOI 10.1016/S1470-2045(18)30009-3; Lowery CD, 2019, CLIN CANCER RES, V25, P2278, DOI 10.1158/1078-0432.CCR-18-2728; Ma CX, 2011, TRENDS MOL MED, V17, P88, DOI 10.1016/j.molmed.2010.10.009; MCKENNA WG, 1991, RADIAT RES, V125, P283, DOI 10.2307/3578111; Mimitou EP, 2009, DNA REPAIR, V8, P983, DOI 10.1016/j.dnarep.2009.04.017; Montano R, 2012, MOL CANCER THER, V11, P427, DOI 10.1158/1535-7163.MCT-11-0406; Murai J, 2018, MOL CELL, V69, P371, DOI 10.1016/j.molcel.2018.01.012; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Parsels LA, 2009, MOL CANCER THER, V8, P45, DOI 10.1158/1535-7163.MCT-08-0662; Patch AM, 2015, NATURE, V521, P489, DOI 10.1038/nature14410; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; ROEHM NW, 1991, J IMMUNOL METHODS, V142, P257, DOI 10.1016/0022-1759(91)90114-U; Ruff P, 2016, CELL REP, V17, P3359, DOI 10.1016/j.celrep.2016.12.003; Ruiz S, 2016, MOL CELL, V62, P307, DOI 10.1016/j.molcel.2016.03.006; Sabbaghi MA, 2017, CLIN CANCER RES, V23, P7006, DOI 10.1158/1078-0432.CCR-17-0696; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Smith J, 2010, ADV CANCER RES, V108, P73, DOI 10.1016/S0065.230X(10)08002.4; Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Van Horn RD, 2010, J BIOL CHEM, V285, P21849, DOI 10.1074/jbc.M110.141010; Wang Y, 2000, GENE DEV, V14, P927; Young LA, 2019, CANCER RES, V79, P3762, DOI 10.1158/0008-5472.CAN-18-2480; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	41	15	16	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2020	39	33					5520	5535		10.1038/s41388-020-1383-4	http://dx.doi.org/10.1038/s41388-020-1383-4		JUL 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NB0QV	32647134	Green Published, hybrid			2022-12-17	WOS:000546858900001
J	Helbing, DL; Schulz, A; Morrison, H				Helbing, Dario-Lucas; Schulz, Alexander; Morrison, Helen			Pathomechanisms in schwannoma development and progression	ONCOGENE			English	Review							VESTIBULAR SCHWANNOMA; NEUROFIBROMATOSIS TYPE-2; WALLERIAN DEGENERATION; CELL PROLIFERATION; PLASMA-MEMBRANE; PHASE-II; GROWTH; NEUREGULIN-1; MERLIN; REGENERATION	Schwannomas are tumors of the peripheral nervous system, consisting of different cell types. These include tumorigenic Schwann cells, axons, macrophages, T cells, fibroblasts, blood vessels, and an extracellular matrix. All cell types involved constitute an intricate "tumor microenvironment" and play relevant roles in the development and progression of schwannomas. AlthoughNf2tumor suppressor gene-deficient Schwann cells are the primary tumorigenic element and principle focus of current research efforts, evidence is accumulating regarding the contributory roles of other cell types in schwannoma pathology. In this review, we aim to provide an overview of intra- and intercellular mechanisms contributing to schwannoma formation.	[Helbing, Dario-Lucas; Schulz, Alexander; Morrison, Helen] Fritz Lipmann Inst, Leibniz Inst Aging, D-07745 Jena, Germany; [Helbing, Dario-Lucas] Friedrich Schiller Univ Jena, Inst Mol Cell Biol, Jena Univ Hosp, D-07745 Jena, Germany; [Schulz, Alexander] MVZ Human Genet, D-99084 Erfurt, Germany	Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); Friedrich Schiller University of Jena	Morrison, H (corresponding author), Fritz Lipmann Inst, Leibniz Inst Aging, D-07745 Jena, Germany.	Helen.Morrison@leibniz-fli.de	Helbing, Dario/GYU-0930-2022; Morrison, Helen/F-9748-2014	Morrison, Helen/0000-0003-4938-1409; Helbing, Dario Lucas/0000-0001-6051-559X	Projekt DEAL	Projekt DEAL	We would like to thank Prof. Steffen Rosahl, Helios Clinic Erfurt, Department of Neurosurgery and Dr. Michael Brodhun, Helios Clinic Erfurt, Department of Pathology for providing tumor samples and performing histochemical stainings. Furthermore, we would like to thank Birgit Perner for help in setting up an imaging protocol for the Axio Scan.Z1 device and Leonie Karoline Stabenow for critical reading and editing of the manuscript. Open access funding provided by Projekt DEAL.	Abe M, 2000, Brain Tumor Pathol, V17, P35, DOI 10.1007/BF02478916; Alanin MC, 2015, EUR ARCH OTO-RHINO-L, V272, P3627, DOI 10.1007/s00405-014-3398-3; Ammoun S, 2014, ONCOGENE, V33, P336, DOI 10.1038/onc.2012.587; Arthur-Farraj PJ, 2012, NEURON, V75, P633, DOI 10.1016/j.neuron.2012.06.021; Asthagiri AR, 2009, LANCET, V373, P1974, DOI 10.1016/S0140-6736(09)60259-2; Baumer P, 2013, J NEUROL, V260, P38, DOI 10.1007/s00415-012-6581-8; Birchmeier C, 2008, GLIA, V56, P1491, DOI 10.1002/glia.20753; Cattin AL, 2015, CELL, V162, P1127, DOI 10.1016/j.cell.2015.07.021; Caye-Thomasen P, 2005, OTOL NEUROTOL, V26, P98, DOI 10.1097/00129492-200501000-00017; Chen PW, 2015, ACTA NEUROPATHOL, V130, P605, DOI 10.1007/s00401-015-1482-4; Cui Y, 2019, ONCOGENE, V38, P6370, DOI 10.1038/s41388-019-0883-6; de Vries M, 2013, OTOL NEUROTOL, V34, P347, DOI 10.1097/MAO.0b013e31827c9fbf; de Vries M, 2012, VIRCHOWS ARCH, V460, P629, DOI 10.1007/s00428-012-1236-9; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Fricker FR, 2011, FUTUR NEUROL, V6, P809, DOI 10.2217/FNL.11.45; Fry EJ, 2007, NEURON, V53, P649, DOI 10.1016/j.neuron.2007.02.009; Fuse MA, 2019, NEURO-ONCOLOGY, V21, P486, DOI 10.1093/neuonc/noz002; Gao RL, 2010, J AM COLL CARDIOL, V55, P1907, DOI 10.1016/j.jacc.2009.12.044; Giovannini M, 2014, NEURO-ONCOLOGY, V16, P493, DOI 10.1093/neuonc/not242; Gomez-Sanchez JA, 2015, J CELL BIOL, V210, P153, DOI 10.1083/jcb.201503019; Gorzelany JA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005007; Gosk J, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/547926; Hilton DA, 2014, BRAIN PATHOL, V24, P205, DOI 10.1111/bpa.12125; Hobson MI, 2000, J ANAT, V197, P591, DOI 10.1046/j.1469-7580.2000.19740591.x; Hochart A, 2015, J NEURO-ONCOL, V124, P229, DOI 10.1007/s11060-015-1828-8; Hours M, 2009, OCCUP ENVIRON MED, V66, P480, DOI 10.1136/oem.2008.042101; Italiani P, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00514; Kandathil CK, 2014, OTOL NEUROTOL, V35, P353, DOI 10.1097/MAO.0000000000000189; Karajannis MA, 2012, NEURO-ONCOLOGY, V14, P1163, DOI 10.1093/neuonc/nos146; Lallemand D, 2009, ONCOGENE, V28, P854, DOI 10.1038/onc.2008.427; Lewis D, 2019, NEURO-ONCOLOGY, V21, P314, DOI 10.1093/neuonc/noy177; Li W, 2010, CELL, V140, P477, DOI 10.1016/j.cell.2010.01.029; Lutz AB, 2017, P NATL ACAD SCI USA, V114, pE8072, DOI 10.1073/pnas.1710566114; Mautner VF, 1996, NEUROSURGERY, V38, P880, DOI 10.1097/00006123-199605000-00004; Mendes-Ferreira P, 2013, DRUG DISCOV TODAY, V18, P836, DOI 10.1016/j.drudis.2013.01.010; Michailov GV, 2004, SCIENCE, V304, P700, DOI 10.1126/science.1095862; Mindos T, 2017, J CELL BIOL, V216, P495, DOI 10.1083/jcb.201606052; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Morrison H, 2007, CANCER RES, V67, P520, DOI 10.1158/0008-5472.CAN-06-1608; Neff BA, 2012, LARYNGOSCOPE, V122, P2269, DOI 10.1002/lary.23472; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Papiez J, 2014, INT J CLIN EXP PATHO, V7, P4032; Pathmanaban ON, 2020, NEUROONCOL ADV, P2; Petrilli AM, 2016, ONCOGENE, V35, P537, DOI 10.1038/onc.2015.125; Plotkin SR, 2012, OTOL NEUROTOL, V33, P1046, DOI 10.1097/MAO.0b013e31825e73f5; SALZER JL, 1980, J CELL BIOL, V84, P739, DOI 10.1083/jcb.84.3.739; SAMII M, 1995, J NEUROSURG, V82, P711, DOI 10.3171/jns.1995.82.5.0711; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]; Schlehofer B, 2007, EUR J CANCER, V43, P1741, DOI 10.1016/j.ejca.2007.05.008; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Schulte E, 2018, PROMETHEUS KOPF HALS; Schulz A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159718; Schulz A, 2016, ACTA NEUROPATHOL, V132, P289, DOI 10.1007/s00401-016-1583-8; Schulz A, 2014, BRAIN, V137, P420, DOI 10.1093/brain/awt327; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; SIAN CS, 1981, HUM PATHOL, V12, P145, DOI 10.1016/S0046-8177(81)80102-5; Stassart RM, 2013, NAT NEUROSCI, V16, P48, DOI 10.1038/nn.3281; Svennigsen AF, 2013, BRAIN SCI, V3, P1182, DOI 10.3390/brainsci3031182; Tagoe T, 2014, J NEUROSCI, V34, P2684, DOI 10.1523/JNEUROSCI.3977-13.2014; Tamaskovic R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11672; Tikoo R, 2000, J NEUROSCI, V20, P4627, DOI 10.1523/JNEUROSCI.20-12-04627.2000; Truong K, 2018, NEUROSCIENCE, V374, P205, DOI 10.1016/j.neuroscience.2018.01.054; Vargas ME, 2007, ANNU REV NEUROSCI, V30, P153, DOI 10.1146/annurev.neuro.30.051606.094354; Wang SY, 2018, J NEURO-ONCOL, V138, P183, DOI 10.1007/s11060-018-2788-6; Wippold FJ, 2007, AM J NEURORADIOL, V28, P1633, DOI 10.3174/ajnr.A0682; Yin F, 2013, CELL, V154, P1342, DOI 10.1016/j.cell.2013.08.025; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Zhang LW, 2009, CLIN NEUROL NEUROSUR, V111, P261, DOI 10.1016/j.clineuro.2008.10.014	68	15	17	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2020	39	32					5421	5429		10.1038/s41388-020-1374-5	http://dx.doi.org/10.1038/s41388-020-1374-5		JUL 2020	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW4DS	32616891	Green Published, hybrid			2022-12-17	WOS:000545059900004
J	Borges, KS; Pignatti, E; Leng, S; Kariyawasam, D; Ruiz-Babot, G; Ramalho, FS; Taketo, MM; Carlone, DL; Breault, DT				Borges, Kleiton Silva; Pignatti, Emanuele; Leng, Sining; Kariyawasam, Dulanjalee; Ruiz-Babot, Gerard; Ramalho, Fernando Silva; Taketo, Makoto Mark; Carlone, Diana L.; Breault, David T.			Wnt/beta-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice	ONCOGENE			English	Article							BETA-CATENIN; GENOMIC CHARACTERIZATION; MOUSE MODELS; FACTOR-I; CANCER; TUMORS; MUTATIONS; EXPRESSION; PATHWAY; CELLS	Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with limited therapeutic options. The lack of mouse models that recapitulate the genetics of ACC has hampered progress in the field. We analyzed The Cancer Genome Atlas (TCGA) dataset for ACC and found that patients harboring alterations in both p53/Rb and Wnt/beta-catenin signaling pathways show a worse prognosis compared with patients that harbored alterations in only one. To model this, we utilized theCyp11b2(AS)(Cre)mouse line to generate mice with adrenocortical-specific Wnt/beta-catenin activation,Trp53deletion, or the combination of both. Mice with targeted Wnt/beta-catenin activation orTrp53deletion showed no changes associated with tumor formation. In contrast, alterations in both pathways led to ACC with pulmonary metastases. Similar to ACCs in humans, these tumors produced increased levels of corticosterone and aldosterone and showed a high proliferation index. Gene expression analysis revealed that mouse tumors exhibited downregulation ofStarandCyp11b1and upregulation ofEzh2, similar to ACC patients with a poor prognosis. Altogether, these data show that altering both Wnt/beta-catenin and p53/Rb signaling is sufficient to drive ACC in mouse. This autochthonous model of ACC represents a new tool to investigate the biology of ACC and to identify new treatment strategies.	[Borges, Kleiton Silva; Pignatti, Emanuele; Leng, Sining; Kariyawasam, Dulanjalee; Ruiz-Babot, Gerard; Carlone, Diana L.; Breault, David T.] Boston Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA; [Borges, Kleiton Silva; Pignatti, Emanuele; Kariyawasam, Dulanjalee; Ruiz-Babot, Gerard; Carlone, Diana L.; Breault, David T.] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA; [Borges, Kleiton Silva] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, Ribeirao Preto, Brazil; [Leng, Sining] Harvard Med Sch, Div Med Sci, Boston, MA 02115 USA; [Ramalho, Fernando Silva] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pathol, Ribeirao Preto, Brazil; [Taketo, Makoto Mark] Kyoto Univ, Grad Sch Med, Div Expt Therapeut, Kyoto 6068506, Japan; [Carlone, Diana L.; Breault, David T.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP); Harvard University; Harvard Medical School; Universidade de Sao Paulo; Kyoto University; Harvard University	Breault, DT (corresponding author), Boston Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA.; Breault, DT (corresponding author), Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA.; Breault, DT (corresponding author), Harvard Stem Cell Inst, Cambridge, MA 02138 USA.	david.breault@childrens.harvard.edu	Borges, Kleiton/AAT-7336-2020; Pignatti, Emanuele/AAF-2743-2021; Borges, Kleiton Silva/C-7214-2012; Breault, David/HDN-6048-2022; Ramalho, Fernando Silva/G-3817-2012; kariyawasam, dulanjalee/AAH-1867-2021	Borges, Kleiton/0000-0003-0356-922X; Borges, Kleiton Silva/0000-0003-0356-922X; Ramalho, Fernando Silva/0000-0002-7529-466X; breault, David/0000-0002-0402-4857; Pignatti, Emanuele/0000-0002-5372-5692	National Institutes of Health (NIH) [RO1 DK100653, R01 DK123694]; FundacAo de Amparo a Pesquisa do Estado de SAo Paulo scholarship [16/00862-0]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [409711/2018-7, 151760/2018-7]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); FundacAo de Amparo a Pesquisa do Estado de SAo Paulo scholarship; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by National Institutes of Health (NIH) grants RO1 DK100653 and R01 DK123694 (D.T.B.). K.S.B. was supported by FundacAo de Amparo a Pesquisa do Estado de SAo Paulo scholarship 16/00862-0, Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), scholarship 409711/2018-7 and Grant 151760/2018-7. We thank Graziella Ribeiro Sousa for her technical assistance with IHC experiments.	Abiven G, 2006, J CLIN ENDOCR METAB, V91, P2650, DOI 10.1210/jc.2005-2730; Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; Assie G, 2014, NAT GENET, V46, P607, DOI 10.1038/ng.2953; Basham KJ, 2019, GENE DEV, V33, P209, DOI 10.1101/gad.317412.118; Basham KJ, 2016, MOL CELL ENDOCRINOL, V421, P82, DOI 10.1016/j.mce.2015.11.031; Batisse-Lignier M, 2017, ONCOGENE, V36, P4445, DOI 10.1038/onc.2017.54; Berthon A, 2010, HUM MOL GENET, V19, P1561, DOI 10.1093/hmg/ddq029; Bonnet-Serrano F, 2018, ENDOCR-RELAT CANCER, V25, pR131, DOI 10.1530/ERC-17-0361; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Drelon C, 2016, HUM MOL GENET, V25, P2789, DOI 10.1093/hmg/ddw136; Drelon C, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12751; Drelon C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044171; Else T, 2014, ENDOCR REV, V35, P282, DOI 10.1210/er.2013-1029; Else T, 2014, J CLIN ENDOCR METAB, V99, P455, DOI 10.1210/jc.2013-2856; Else T, 2012, MOL CELL ENDOCRINOL, V351, P66, DOI 10.1016/j.mce.2011.12.008; Fassnacht M, 2018, EUR J ENDOCRINOL, V179, pG1, DOI 10.1530/EJE-18-0608; Fassnacht M, 2013, J CLIN ENDOCR METAB, V98, P4551, DOI 10.1210/jc.2013-3020; Freedman BD, 2013, DEV CELL, V26, P666, DOI 10.1016/j.devcel.2013.07.016; Haluska P, 2010, CANCER CHEMOTH PHARM, V65, P765, DOI 10.1007/s00280-009-1083-9; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Heaton JH, 2012, AM J PATHOL, V181, P1017, DOI 10.1016/j.ajpath.2012.05.026; Jones RL, 2015, CLIN CANCER RES, V21, P693, DOI 10.1158/1078-0432.CCR-14-0265; Kastenhuber ER, 2017, CELL, V170, P1062, DOI 10.1016/j.cell.2017.08.028; Kim AC, 2008, DEVELOPMENT, V135, P2593, DOI 10.1242/dev.021493; Leal LF, 2011, J CLIN ENDOCR METAB, V96, P3106, DOI 10.1210/jc.2011-0363; Leccia F, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00093; Liang SH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15295-9; Lippert J, 2018, J CLIN ENDOCR METAB, V103, P4511, DOI 10.1210/jc.2018-01348; Mai PL, 2016, CANCER-AM CANCER SOC, V122, P3673, DOI 10.1002/cncr.30248; Marino S, 2000, GENE DEV, V14, P994; Mohan Dipika R, 2019, Curr Opin Endocr Metab Res, V8, P72, DOI 10.1016/j.coemr.2019.07.006; Mohan DR, 2018, J ENDOCR SOC, V2, P1259, DOI 10.1210/js.2018-00197; Mouat IC, 2019, ENDOCR-RELAT CANCER, V26, P217, DOI 10.1530/ERC-18-0385; Park JH, 2018, CANCER RES, V78, P5375, DOI 10.1158/0008-5472.CAN-18-0016; Pereira SS, 2018, EUR J ENDOCRINOL, V179, pR95, DOI 10.1530/EJE-17-0976; Pignatti E, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107524; Pinto EM, 2017, J CLIN ONCOL, V35, P3956, DOI 10.1200/JCO.2017.74.2460; Ragazzon B, 2010, CANCER RES, V70, P8276, DOI 10.1158/0008-5472.CAN-10-2014; Ribeiro RC, 2001, P NATL ACAD SCI USA, V98, P9330, DOI 10.1073/pnas.161479898; Sbiera S, 2010, J CLIN ENDOCR METAB, V95, pE161, DOI 10.1210/jc.2010-0653; Terzolo M, 2001, UROLOGY, V57, P176, DOI 10.1016/S0090-4295(00)00852-9; Tissier F, 2005, CANCER RES, V65, P7622, DOI 10.1158/0008-5472.CAN-05-0593; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; WALDMAN T, 1995, CANCER RES, V55, P5187; Wasserman JD, 2012, MOL CELL ENDOCRINOL, V351, P101, DOI 10.1016/j.mce.2011.09.010; WEISS LM, 1984, AM J SURG PATHOL, V8, P163, DOI 10.1097/00000478-198403000-00001; Zheng SY, 2016, CANCER CELL, V29, P723, DOI 10.1016/j.ccell.2016.04.002; Zsippai A, 2011, AM J CANCER RES, V1, P618	49	15	15	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 23	2020	39	30					5282	5291		10.1038/s41388-020-1358-5	http://dx.doi.org/10.1038/s41388-020-1358-5		JUN 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MO5BV	32561853	hybrid, Green Published			2022-12-17	WOS:000541308400002
J	Shepard, A; Kissil, JL				Shepard, Alyssa; Kissil, Joseph L.			The use of non-traditional models in the study of cancer resistance-the case of the naked mole rat	ONCOGENE			English	Review							LONGEST-LIVING RODENT; HEAT-SHOCK PROTEINS; AGE-RELATED-CHANGES; TUMOR-SUPPRESSOR; HETEROCEPHALUS-GLABER; OXIDATIVE STRESS; DNA-REPAIR; NEGLIGIBLE SENESCENCE; CONTACT INHIBITION; RIBOSOMAL-RNA	Non-traditional model organisms are typically defined as any model the deviates from the typical laboratory animals, such as mouse, rat, and worm. These models are becoming increasingly important in human disease research, such as cancer, as they often display unusual biological features. Naked mole rats (NMRs) are currently one of the most popular non-traditional model, particularly in the longevity and cancer research fields. NMRs display an exceptionally long lifespan (similar to 30 years), yet have been observed to display a low incidence of cancer, making them excellent candidates for understanding endogenous cancer resistance mechanisms. Over the past decade, many potential resistance mechanisms have been characterized. These include unique biological mechanisms involved in genome stability, protein stability, oxidative metabolism, and other cellular mechanisms such as cell cycle regulation and senescence. This review aims to summarize the many identified cancer resistance mechanisms to understand some of the main hypotheses that have thus far been generated. Many of these proposed mechanisms remain to be fully characterized or confirmed in vivo, giving the field a direction to grow and further understand the complex biology displayed by the NMR.	[Shepard, Alyssa; Kissil, Joseph L.] Scripps Res Inst, Dept Mol Med, Jupiter, FL 33458 USA	Scripps Research Institute	Kissil, JL (corresponding author), Scripps Res Inst, Dept Mol Med, Jupiter, FL 33458 USA.	jkissil@scripps.edu						ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Anastasiou D, 2012, NAT CHEM BIOL, V8, P839, DOI 10.1038/NCHEMBIO.1060; Andziak B, 2005, MECH AGEING DEV, V126, P1206, DOI 10.1016/j.mad.2005.06.009; Andziak B, 2006, AGING CELL, V5, P463, DOI 10.1111/j.1474-9726.2006.00237.x; Azpurua J, 2013, P NATL ACAD SCI USA, V110, P17350, DOI 10.1073/pnas.1313473110; Bailey KL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176096; Ballal RD, 2009, J BIOL CHEM, V284, P36083, DOI 10.1074/jbc.M109.025825; Ben-David U, 2011, NAT REV CANCER, V11, P268, DOI 10.1038/nrc3034; Bens M, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-015-2349-8; Bleeker FE, 2010, ACTA NEUROPATHOL, V119, P487, DOI 10.1007/s00401-010-0645-6; Bowers LW, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00077; Brites P, 2004, BBA-MOL CELL BIOL L, V1636, P219, DOI 10.1016/j.bbalip.2003.12.010; Buffenstein R, 2005, J GERONTOL A-BIOL, V60, P1369, DOI 10.1093/gerona/60.11.1369; BUFFENSTEIN R, 1991, J ENDOCRINOL, V129, P21, DOI 10.1677/joe.0.1290021; Buffenstein R, 2008, J COMP PHYSIOL B, V178, P439, DOI 10.1007/s00360-007-0237-5; Buffenstein Rochelle, 2002, Sci Aging Knowledge Environ, V2002, ppe7, DOI 10.1126/sageke.2002.21.pe7; Cellarier E, 2003, CANCER TREAT REV, V29, P489, DOI 10.1016/S0305-7372(03)00118-X; Cheng JS, 2017, ONCOTARGET, V8, P96924, DOI 10.18632/oncotarget.19661; Cole JE, 2020, J VET DIAGN INVEST, V32, P132, DOI 10.1177/1040638719894985; Cong W, 2018, BMC MICROBIOL, V18, DOI 10.1186/s12866-018-1226-4; Cvijovic I, 2018, GENETICS, V209, P1235, DOI 10.1534/genetics.118.301058; Davies KTJ, 2015, MOL BIOL EVOL, V32, P3089, DOI 10.1093/molbev/msv175; De Waal EM, 2013, BIOCHEM BIOPH RES CO, V434, P815, DOI 10.1016/j.bbrc.2013.04.019; Debebe T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10287-0; Debebe T, 2016, GUT PATHOG, V8, DOI 10.1186/s13099-016-0107-3; Delaney MA, 2016, VET PATHOL, V53, P691, DOI 10.1177/0300985816630796; Delaney MA, 2013, VET PATHOL, V50, P607, DOI 10.1177/0300985812471543; Deuker MM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64009-0; Djojosubroto MW, 2003, MOL CELLS, V15, P164; Du W, 2013, ONCOGENE, V32, P3319, DOI 10.1038/onc.2012.359; Evdokimov A, 2018, AGING-US, V10, P1454, DOI 10.18632/aging.101482; Evfratov SA, 2014, ACTA NATURAE, V6, P41, DOI 10.32607/20758251-2014-6-2-41-47; Fang XD, 2014, CELL REP, V8, P1354, DOI 10.1016/j.celrep.2014.07.030; FAULKES CG, 1990, J REPROD FERTIL, V89, P317; Faulkes CG, 2015, BIOL LETTERS, V11, DOI 10.1098/rsbl.2015.0185; Gelfond JA, 2015, STAT APPL GENET MOL, V14, P507, DOI 10.1515/sagmb-2014-0056; Gorbunova V, 2012, P NATL ACAD SCI USA, V109, P19392, DOI 10.1073/pnas.1217211109; Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173; Guan CQ, 2013, J CELL BIOCHEM, V114, P1343, DOI 10.1002/jcb.24475; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Heinze I, 2018, BMC BIOL, V16, DOI 10.1186/s12915-018-0547-y; Hensen SMM, 2013, BIOCHIMIE, V95, P1245, DOI 10.1016/j.biochi.2013.01.017; Hetz C, 2015, NAT CELL BIOL, V17, P829, DOI 10.1038/ncb3184; HILL W. C., 1957, PROC ZOOL SOC LONDON, V128, P455; Hilton HG, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000528; Hulbert AJ, 2007, PHYSIOL REV, V87, P1175, DOI 10.1152/physrev.00047.2006; Hulbert AJ, 2006, J GERONTOL A-BIOL, V61, P1009, DOI 10.1093/gerona/61.10.1009; JARVIS JUM, 1981, SCIENCE, V212, P571, DOI 10.1126/science.7209555; Jiang JJ, 2016, EPIGENET CHROMATIN, V9, DOI 10.1186/s13072-016-0101-5; KANUI TI, 1990, COMP BIOCHEM PHYS C, V96, P131, DOI 10.1016/0742-8413(90)90057-G; Keane M, 2014, BIOINFORMATICS, V30, P3558, DOI 10.1093/bioinformatics/btu579; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; Kim EB, 2011, NATURE, V479, P223, DOI 10.1038/nature10533; Kosova AA, 2019, AGING-US, V11, P2852, DOI 10.18632/aging.101959; Kowalczyk A, 2020, ELIFE, V9, DOI 10.7554/eLife.51089; Kurz S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189514; Lambert MJ, 2017, AGING-US, V9, P573, DOI 10.18632/aging.101180; Lee BP, 2020, GEROSCIENCE, V42, P633, DOI 10.1007/s11357-019-00150-7; Lee SG, 2017, STEM CELL REP, V9, P1706, DOI 10.1016/j.stemcr.2017.09.013; Lee S, 2019, NAT CELL BIOL, V21, P94, DOI 10.1038/s41556-018-0249-2; Lewis KN, 2018, GEROSCIENCE, V40, P105, DOI 10.1007/s11357-018-0014-2; Lewis KN, 2015, P NATL ACAD SCI USA, V112, P3722, DOI 10.1073/pnas.1417566112; Lewis KN, 2012, GERONTOLOGY, V58, P453, DOI 10.1159/000335966; Lewis KN, 2010, INTEGR COMP BIOL, V50, P829, DOI 10.1093/icb/icq034; Liang ST, 2010, AGING CELL, V9, P626, DOI 10.1111/j.1474-9726.2010.00588.x; Lindner I, 2010, CANCER RES, V70, P277, DOI 10.1158/0008-5472.CAN-09-1462; Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320; MacRae SL, 2015, AGING-US, V7, P1171, DOI 10.18632/aging.100866; MacRae SL, 2015, AGING CELL, V14, P288, DOI 10.1111/acel.12314; Manov I, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-91; Mao ZY, 2011, SCIENCE, V332, P1443, DOI 10.1126/science.1202723; Melen GJ, 1999, EMBO J, V18, P3107, DOI 10.1093/emboj/18.11.3107; Millet C, 2007, CRIT REV EUKAR GENE, V17, P281, DOI 10.1615/CritRevEukarGeneExpr.v17.i4.30; Mitchell TW, 2007, EXP GERONTOL, V42, P1053, DOI 10.1016/j.exger.2007.09.004; Miyawaki S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11471; Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207; Morgan CC, 2013, BMC EVOL BIOL, V13, DOI 10.1186/1471-2148-13-251; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Munro D, 2019, AGING CELL, V18, DOI 10.1111/acel.12916; Nevo Y, 2012, NUCLEIC ACIDS RES, V40, P10980, DOI 10.1093/nar/gks834; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; O'Connor TP, 2002, COMP BIOCHEM PHYS A, V133, P835, DOI 10.1016/S1095-6433(02)00198-8; Ozenne P, 2010, INT J CANCER, V127, P2239, DOI 10.1002/ijc.25511; Pace C N, 1986, Methods Enzymol, V131, P266; Pawaria S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050365; Perez VI, 2009, P NATL ACAD SCI USA, V106, P3059, DOI 10.1073/pnas.0809620106; Populo H, 2012, INT J MOL SCI, V13, P1886, DOI 10.3390/ijms13021886; Pride H, 2015, BIOCHEM BIOPH RES CO, V457, P669, DOI 10.1016/j.bbrc.2015.01.046; Rodriguez KA, 2016, CELL STRESS CHAPERON, V21, P453, DOI 10.1007/s12192-016-0672-x; Rodriguez KA, 2014, BBA-MOL BASIS DIS, V1842, P2060, DOI 10.1016/j.bbadis.2014.07.005; Ruby JG, 2018, ELIFE, V7, DOI 10.7554/eLife.31157; Ruppell E, 1845, RUPPELL MUS SENCKENB, V3, P99; Sabeti PC, 2006, SCIENCE, V312, P1614, DOI 10.1126/science.1124309; Sahm A, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007272; Salmon AB, 2008, J GERONTOL A-BIOL, V63, P232, DOI 10.1093/gerona/63.3.232; Seim I, 2014, AGING-US, V6, P879, DOI 10.18632/aging.100699; Seluanov A, 2007, AGING CELL, V6, P45, DOI 10.1111/j.1474-9726.2006.00262.x; Seluanov A, 2009, P NATL ACAD SCI USA, V106, P19352, DOI 10.1073/pnas.0905252106; Seluanov A, 2008, AGING CELL, V7, P813, DOI 10.1111/j.1474-9726.2008.00431.x; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; Shebzukhov Y, 2019, EUR J IMMUNOL, V49, P2103, DOI 10.1002/eji.201948124; Stewart DJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt356; Stocker S, 2018, NAT CHEM BIOL, V14, P148, DOI 10.1038/nchembio.2536; Sulak M, 2016, ELIFE, V5, DOI [10.7554/eLife.11994, 10.7554/eLife.24307]; Takahashi K, 2003, NATURE, V423, P541, DOI 10.1038/nature01646; Takai KK, 2011, MOL CELL, V44, P647, DOI 10.1016/j.molcel.2011.08.043; Tan L, 2017, STEM CELL REP, V9, P1721, DOI 10.1016/j.stemcr.2017.10.001; Tang JS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167851; Tang PMK, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14677; Taylor KR, 2017, J GERONTOL A-BIOL, V72, P38, DOI 10.1093/gerona/glw047; Thieme R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130470; Tian X, 2019, CELL, V177, P622, DOI 10.1016/j.cell.2019.03.043; Tian X, 2015, P NATL ACAD SCI USA, V112, P1053, DOI 10.1073/pnas.1418203112; Tian X, 2013, NATURE, V499, P346, DOI 10.1038/nature12234; Triplett JC, 2015, BBA-MOL BASIS DIS, V1852, P2213, DOI 10.1016/j.bbadis.2015.08.002; Triplett JC, 2015, J NEUROCHEM, V134, P538, DOI 10.1111/jnc.13149; Viltard M, 2019, AGING-US, V11, P4783, DOI 10.18632/aging.102116; Vina J, 2013, ANTIOXID REDOX SIGN, V19, P779, DOI 10.1089/ars.2012.5111; Vyssokikh MY, 2020, P NATL ACAD SCI USA, V117, P6491, DOI 10.1073/pnas.1916414117; Wada H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54442-1; Wei HT, 2016, GENOM PROTEOM BIOINF, V14, P131, DOI 10.1016/j.gpb.2016.05.001; Went P, 2006, BRIT J CANCER, V94, P128, DOI 10.1038/sj.bjc.6602924; Whitley D, 1999, J VASC SURG, V29, P748, DOI 10.1016/S0741-5214(99)70329-0; Wu JM, 2017, TRENDS PHARMACOL SCI, V38, P226, DOI 10.1016/j.tips.2016.11.009; Yang ZY, 2015, GENE, V572, P101, DOI 10.1016/j.gene.2015.07.004; Yang ZY, 2013, BMC SYST BIOL, V7, DOI 10.1186/1752-0509-7-S2-S5; Yu CF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026729; YUAN PM, 1981, MECH AGEING DEV, V17, P151, DOI 10.1016/0047-6374(81)90081-6; Zhao SM, 2016, ONCOTARGET, V7, P84839, DOI 10.18632/oncotarget.13321; Zhao SM, 2014, CELL PHYSIOL BIOCHEM, V34, P463, DOI 10.1159/000363015; Zhao SM, 2014, CELL PHYSIOL BIOCHEM, V33, P321, DOI 10.1159/000356672; Zhao Y, 2018, P NATL ACAD SCI USA, V115, P1801, DOI 10.1073/pnas.1721160115; Zhao YF, 2019, ONCOGENE, V38, P4297, DOI 10.1038/s41388-019-0719-4	133	15	15	2	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2020	39	28					5083	5097		10.1038/s41388-020-1355-8	http://dx.doi.org/10.1038/s41388-020-1355-8		JUN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MH4RK	32535616				2022-12-17	WOS:000539953300002
J	Liu, C; Liu, L; Wang, K; Li, XF; Ge, LY; Ma, RZ; Fan, YD; Li, LC; Liu, ZF; Qiu, M; Hao, YC; Shi, ZF; Xia, CY; Straat, K; Huang, Y; Ma, LL; Xu, DW				Liu, Cheng; Liu, Li; Wang, Kun; Li, Xiao-Feng; Ge, Li-Yuan; Ma, Run-Zhuo; Fan, Yi-Dong; Li, Lu-Chao; Liu, Zheng-Fang; Qiu, Min; Hao, Yi-Chang; Shi, Zhen-Feng; Xia, Chuan-You; Straat, Klas; Huang, Yi; Ma, Lu-Lin; Xu, Dawei			VHL-HIF-2 alpha axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR	ONCOGENE			English	Article							FACTOR RECEPTOR PROTEIN; GROWTH; CANCER; EXPRESSION; PROMOTES; PROLIFERATION; TRANSCRIPTION; INHIBITION; SUPPRESSES; ACTIVATION	It has been well established that the von Hippel-Lindau/hypoxia-inducible factor alpha (VHL-HIF alpha) axis and epidermal growth factor receptor (EGFR) signaling pathway play a critical role in the pathogenesis and progression of renal cell carcinoma (RCC). However, few studies have addressed the relationship between the two oncogenic drivers in RCC. SET and MYND domain-containing protein 3 (SMYD3) is a histone methyltransferase involved in gene transcription and oncogenesis, but its expression and function in RCC remain unclear. In the present study, we found that SMYD3 expression was significantly elevated in RCC tumors and correlated with advanced tumor stage, histological and nuclear grade, and shorter survival. Depletion of SMYD3 inhibited RCC cell proliferation, colony numbers, and xenograft tumor formation, while promoted apoptosis. Mechanistically, SMYD3 cooperates with SP1 to transcriptionally promote EGFR expression, amplifying its downstream signaling activity. TCGA data analyses revealed a significantly increased SMYD3 expression in primary RCC tumors carrying the loss-of-function VHL mutations. We further showed that HIF-2 alpha can directly bind to the SMYD3 promoter and subsequently induced SMYD3 transcription and expression. Taken together, we identify the VHL/HIF-2 alpha/SMYD3 signaling cascade-mediated EGFR hyperactivity through which SMYD3 promotes RCC progression. Our study suggests that SMYD3 is a potential therapeutic target and prognostic factor in RCC.	[Liu, Cheng; Ge, Li-Yuan; Ma, Run-Zhuo; Qiu, Min; Hao, Yi-Chang; Huang, Yi; Ma, Lu-Lin] Peking Univ, Hosp 3, Dept Urol, Beijing, Peoples R China; [Liu, Li] Beijing Univ Chinese Med, Sch Nursing, Beijing, Peoples R China; [Wang, Kun] Tianjin Med Univ Canc Inst & Hosp, Dept Urol, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China; [Li, Xiao-Feng; Fan, Yi-Dong; Li, Lu-Chao; Liu, Zheng-Fang] Shandong Univ, Qilu Hosp, Dept Urol, Jinan, Peoples R China; [Ge, Li-Yuan; Shi, Zhen-Feng] Peoples Hosp Xinjiang Uyghur Autonomous Region, Dept Urol, Xinjiang, Peoples R China; [Xia, Chuan-You; Straat, Klas; Xu, Dawei] Karolinska Univ Hosp Solna, Karolinska Inst, Bioclinicum, Dept Med,Div Hematol, Stockholm, Sweden; [Xia, Chuan-You; Straat, Klas; Xu, Dawei] Karolinska Univ Hosp Solna, Karolinska Inst, Ctr Mol Med, Stockholm, Sweden; [Xu, Dawei] Shandong Univ, Karolinska Inst, Collaborat Lab Canc & Stem Cell Res, Jinan, Peoples R China	Peking University; Beijing University of Chinese Medicine; Tianjin Medical University; Shandong University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Shandong University	Liu, C; Ma, LL (corresponding author), Peking Univ, Hosp 3, Dept Urol, Beijing, Peoples R China.	chengliu@bjmu.edu.cn; malulin@bjmu.edu.cn	Ma, Runzhuo/Y-3043-2019; Ma, Runzhuo/GXM-4966-2022; Ge, Li/T-3955-2018	Ge, Li/0000-0002-1824-8034; Xu, Dawei/0000-0003-3141-4524	Peking University Medicine Fund of Fostering Young Scholars' Scientific and Technological Innovation [BMU2018PY003]; National Natural Science Foundation of China [81711530048, 81572515, 81672522, 81972381]; Peking University Third Hospital Clinical Research Fund [BYSY2018062, BYSY2018012]; Fundamental Research funds for the Central Universities [2020-JYB-XJSJJ-031]; Swedish Cancer Society; Swedish Research Council; Cancer Society in Stockholm	Peking University Medicine Fund of Fostering Young Scholars' Scientific and Technological Innovation; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Peking University Third Hospital Clinical Research Fund; Fundamental Research funds for the Central Universities(Fundamental Research Funds for the Central Universities); Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Cancer Society in Stockholm	The study was funded by Peking University Medicine Fund of Fostering Young Scholars' Scientific and Technological Innovation BMU2018PY003; the National Natural Science Foundation of China (Nos: 81711530048, 81572515, 81672522, and 81972381); Peking University Third Hospital Clinical Research Fund BYSY2018062 and BYSY2018012; the Fundamental Research funds for the Central Universities (No. 2020-JYB-XJSJJ-031); the Swedish Cancer Society, the Swedish Research Council, and Cancer Society in Stockholm.	An JB, 2007, MOL CANCER THER, V6, P61, DOI 10.1158/1535-7163.MCT-06-0255; Bheda A, 2008, ONCOGENE, V27, P4315, DOI 10.1038/onc.2008.65; Chakraborty AA, 2017, SCI TRANSL MED, V36, P3533; Chappell JC, 2019, J CLIN INVEST, V129, P442, DOI 10.1172/JCI120855; CHEN F, 2015, TRANSL PSYCHIAT, V5, DOI DOI 10.1038/srep13470; Chu CL, 2018, J BUON, V23, P1097; Cohen D, 2007, CLIN GENITOURIN CANC, V5, P264, DOI 10.3816/CGC.2007.n.002; Coppin C, 2011, BJU INT, V108, P1556, DOI 10.1111/j.1464-410X.2011.10629.x; Cossu-Rocca P, 2016, AM J CANCER RES, V6, P71; Dehghani Mehdi, 2018, Oncotarget, V9, P26737, DOI 10.18632/oncotarget.25481; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Erfani P, 2015, EPIGENETICS-US, V10, P496, DOI 10.1080/15592294.2015.1042645; Feng ZH, 2017, CANCER SCI, V108, P1620, DOI 10.1111/cas.13297; Fenizia C, 2019, NUCLEIC ACIDS RES, V47, P1278, DOI 10.1093/nar/gky1221; Giakountis A, 2017, SEMIN CANCER BIOL, V42, P70, DOI 10.1016/j.semcancer.2016.08.008; Gong XH, 2018, CELL PHYSIOL BIOCHEM, V45, P523, DOI 10.1159/000487030; Guo JL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20431-z; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; Hsieh JJ, 2018, J CLIN ONCOL, V36, P3533, DOI 10.1200/JCO.2018.79.2549; Huang L, 2017, AM J TRANSL RES, V9, P1; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Johnson AC, 1996, J BIOL CHEM, V271, P3033; Kassouf Wassim, 2008, Eur Urol, V54, P853, DOI 10.1016/j.eururo.2008.01.011; Kim H, 2009, J BIOL CHEM, V284, P19867, DOI 10.1074/jbc.M109.021485; Kim JM, 2015, NUCLEIC ACIDS RES, V43, P8868, DOI 10.1093/nar/gkv874; Lin FJ, 2019, INFLAMM RES, V68, P739, DOI 10.1007/s00011-019-01257-5; Liu C, 2007, CANCER RES, V67, P2626, DOI 10.1158/0008-5472.CAN-06-4126; Liu C, 2013, JNCI-J NATL CANCER I, V105, P1719, DOI 10.1093/jnci/djt304; Liu F, 2018, ONCOTARGETS THER, V11, P6209, DOI 10.2147/OTT.S172803; Liu L, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317705337; Mazur PK, 2014, NATURE, V510, P283, DOI 10.1038/nature13320; Merseburger AS, 2005, ANTICANCER RES, V25, P1901; Minner S, 2012, CANCER-AM CANCER SOC, V118, P1268, DOI 10.1002/cncr.26436; Mizumoto A, 2015, J PHARMACOL EXP THER, V355, P152, DOI 10.1124/jpet.115.226639; Ravaud A, 2008, J CLIN ONCOL, V26, P2285, DOI 10.1200/JCO.2007.14.5029; Ricketts CJ, 2017, CANCER DISCOV, V7, P1221, DOI 10.1158/2159-8290.CD-17-0971; Sarris ME, 2016, CANCER CELL, V29, P354, DOI 10.1016/j.ccell.2016.01.013; Schodel J, 2016, EUR UROL, V69, P646, DOI 10.1016/j.eururo.2015.08.007; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21601, 10.3322/caac.21590]; Smith K, 2005, CANCER RES, V65, P5221, DOI 10.1158/0008-5472.CAN-05-0169; Thomasson Marcus, 2012, BMC Res Notes, V5, P216, DOI 10.1186/1756-0500-5-216; Tsuge M, 2005, NAT GENET, V37, P1104, DOI 10.1038/ng1638; Turajlic S, 2018, CELL, V173, P595, DOI 10.1016/j.cell.2018.03.043; Van Aller GS, 2012, EPIGENETICS-US, V7, P340, DOI 10.4161/epi.19506; Wang AB, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1331-9; Wang GL, 2020, AGING-US, V12, P2030, DOI 10.18632/aging.102718; Yuan XT, 2019, ONCOGENE, V38, P6172, DOI 10.1038/s41388-019-0872-9; Zhang F, 2018, INT J CANCER, V142, P2543, DOI 10.1002/ijc.31278	48	15	15	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	21					4286	4298		10.1038/s41388-020-1291-7	http://dx.doi.org/10.1038/s41388-020-1291-7		APR 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LQ2DH	32291411				2022-12-17	WOS:000526237900003
J	Grassi, ES; Pantazopoulou, V; Pietras, A				Grassi, Elisa Stellaria; Pantazopoulou, Vasiliki; Pietras, Alexander			Hypoxia-induced release, nuclear translocation, and signaling activity of a DLK1 intracellular fragment in glioma	ONCOGENE			English	Article							STEM-CELLS; TUMOR; INTERACTS; PREF-1; AKT; HIF-2-ALPHA; INHIBITION; ACTIVATION; EXPRESSION; PHENOTYPE	Glioblastoma multiforme is characterized in part by severe hypoxia associated with tumor necrosis. The cellular response to hypoxia can influence several properties of tumor cells associated with aggressive tumor growth, including metabolic adaptations and tumor cell migration and invasion. Here, we found that Delta Like Non-Canonical Notch Ligand 1 (DLK1) expression was elevated as compared with normal brain in a genetically engineered mouse model of glioma, and that DLK1 expression increased with tumor grade in human glioma samples. DLK1 expression was highest in hypoxic and perivascular tumor areas, and we found that hypoxia induced the release and nuclear translocation of an intracellular fragment of DLK1 in murine glioma as well as in human glioma cultures. Release of the intracellular fragment was dependent on ADAM17 and Hypoxia-inducible Factor 1alpha and 2alpha (HIF-1alpha/HIF-2alpha), as ADAM17 inhibitors and HIF1A/HIF2A siRNA blocked DLK1 cleavage. Expression of a cleavable form of DLK1 amplified several hypoxia-induced traits of glioma cells such as colony formation, stem cell marker gene expression, a PI3K-pathway-mediated metabolic shift, and enhanced invasiveness. Effects of DLK1 were dependent on DLK1-cleavage by ADAM17, as expression of non-cleavable DLK1 could not replicate the DLK1-induced hypoxic phenotype. Finally, forced expression of DLK1 resulted in more invasive tumor growth in a PDGFB-induced glioma mouse model without affecting overall survival. Together, our findings suggest a previously undescribed role for DLK1 as an intracellular signaling molecule.	[Grassi, Elisa Stellaria; Pantazopoulou, Vasiliki; Pietras, Alexander] Lund Univ, Div Translat Canc Res, Dept Lab Med, Lund, Sweden; [Grassi, Elisa Stellaria] Univ Milan, Dept Clin Sci & Community Hlth DISCCO, Milan, Italy	Lund University; University of Milan	Pietras, A (corresponding author), Lund Univ, Div Translat Canc Res, Dept Lab Med, Lund, Sweden.	Alexander.Pietras@med.lu.se	; Grassi, Elisa Stellaria/K-4402-2016	Pietras, Alexander/0000-0002-5783-9347; Grassi, Elisa Stellaria/0000-0002-0410-1277; Pantazopoulou, Vasiliki/0000-0002-5965-5795	Ragnar Soderberg Foundation; Swedish Cancer Society; Swedish Research Council; Swedish Childhood Cancer Fund; Ollie & Elof Ericssons foundation; Jeanssons stiftelser; Crafoord foundation; Gosta Miltons donationsfond; Stiftelsen Cancera	Ragnar Soderberg Foundation; Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Childhood Cancer Fund; Ollie & Elof Ericssons foundation; Jeanssons stiftelser; Crafoord foundation; Gosta Miltons donationsfond; Stiftelsen Cancera	The authors thank Christina Moller for skillful technical assistance and A HGCC (www.hgcc.se) (Lene Uhrbom, Bengt Westermark, Karin Forsberg Nilsson and Sven Nelander, Uppsala University, Sweden) for human GBM cultures. This work was supported by grants from the Ragnar Soderberg Foundation, the Swedish Cancer Society, the Swedish Research Council, the Swedish Childhood Cancer Fund, Ollie & Elof Ericssons foundation, Jeanssons stiftelser, the Crafoord foundation, Gosta Miltons donationsfond, and Stiftelsen Cancera.	Baladron V, 2005, EXP CELL RES, V303, P343, DOI 10.1016/j.yexcr.2004.10.001; Bernstock JD, 2020, J NEUROSURG, V133, P655, DOI 10.3171/2019.5.JNS19364; Bleau AM, 2009, CELL STEM CELL, V4, P226, DOI 10.1016/j.stem.2009.01.007; Bowman RL, 2017, NEURO-ONCOLOGY, V19, P139, DOI 10.1093/neuonc/now247; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Ceccarelli M, 2016, CELL, V164, P550, DOI 10.1016/j.cell.2015.12.028; Ceder JA, 2008, EUR UROL, V54, P1344, DOI 10.1016/j.eururo.2008.03.006; Cho SJ, 2008, MOL MED REP, V1, P83; Dekel B, 2006, CANCER RES, V66, P6040, DOI 10.1158/0008-5472.CAN-05-4528; Dyczynska E, 2007, J BIOL CHEM, V282, P436, DOI 10.1074/jbc.M605451200; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Falix FA, 2012, BBA-MOL BASIS DIS, V1822, P988, DOI 10.1016/j.bbadis.2012.02.003; Ferron SR, 2011, NATURE, V475, P381, DOI 10.1038/nature10229; Gulyaeva O, 2018, CELL REP, V25, P1002, DOI 10.1016/j.celrep.2018.09.086; Hambardzumyan D, 2015, TRENDS CANCER, V1, P252, DOI 10.1016/j.trecan.2015.10.009; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Huang CC, 2019, ONCOGENE, V38, P3201, DOI 10.1038/s41388-018-0658-5; Hudak Carolyn S, 2013, Front Endocrinol (Lausanne), V4, P79, DOI 10.3389/fendo.2013.00079; Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818; Jawhari S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.318; Johansson E, 2017, CELL REP, V20, P1641, DOI 10.1016/j.celrep.2017.07.049; Kim Y, 2009, CANCER RES, V69, P9271, DOI 10.1158/0008-5472.CAN-09-1605; Li L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099222; Ma JC, 2009, MOL CELL BIOCHEM, V331, P161, DOI 10.1007/s11010-009-0154-x; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Masui K, 2015, BRAIN PATHOL, V25, P755, DOI 10.1111/bpa.12307; Nagano O, 2004, J CELL BIOL, V165, P893, DOI 10.1083/jcb.200310024; Pelullo M, 2019, CANCER RES, V79, P5575, DOI 10.1158/0008-5472.CAN-19-0145; Pietras A, 2008, J PATHOL, V214, P482, DOI 10.1002/path.2304; Pietras A, 2014, CELL STEM CELL, V14, P357, DOI 10.1016/j.stem.2014.01.005; Puchalski RB, 2018, SCIENCE, V360, P660, DOI 10.1126/science.aaf2666; Strickland M, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00043; Tong B, 2018, EXP CELL RES, V371, P122, DOI 10.1016/j.yexcr.2018.08.002; Traustadottir GA, 2019, CYTOKINE GROWTH F R, V46, P17, DOI 10.1016/j.cytogfr.2019.03.006; Traustadottir GA, 2017, INT J BIOL MACROMOL, V97, P460, DOI 10.1016/j.ijbiomac.2017.01.067; Villanueva C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036134; Wang YH, 2006, MOL CELL BIOL, V26, P5421, DOI 10.1128/MCB.02437-05; Wang YH, 2010, MOL CELL BIOL, V30, P3480, DOI 10.1128/MCB.00057-10; Wang YH, 2009, CELL METAB, V9, P287, DOI 10.1016/j.cmet.2009.01.013; Weskamp G, 2004, J BIOL CHEM, V279, P4241, DOI 10.1074/jbc.M307974200; Xie Y, 2015, EBIOMEDICINE, V2, P1351, DOI 10.1016/j.ebiom.2015.08.026; Yin D, 2006, ONCOGENE, V25, P1852, DOI 10.1038/sj.onc.1209219; Yun Z, 2015, J CLIN INVEST, V125, P2264, DOI 10.1172/JCI82058; Zhang Z, 2018, MOL MED REP, V18, P3547, DOI 10.3892/mmr.2018.9375; Zhao Z, 2020, BIORXIV, DOI [10.1101/2020.01.20.911982, DOI 10.1101/2020.01.20.911982]; Zheng XG, 2007, CANCER SCI, V98, P674, DOI 10.1111/j.1349-7006.2007.00440.x	47	15	15	4	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	20					4028	4044		10.1038/s41388-020-1273-9	http://dx.doi.org/10.1038/s41388-020-1273-9		MAR 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LN3GC	32205867	Green Published, hybrid			2022-12-17	WOS:000521527400001
J	Brummer, G; Fang, W; Smart, C; Zinda, B; Alissa, N; Berkland, C; Miller, D; Cheng, N				Brummer, Gage; Fang, Wei; Smart, Curtis; Zinda, Brandon; Alissa, Nadia; Berkland, Cory; Miller, David; Cheng, Nikki			CCR2 signaling in breast carcinoma cells promotes tumor growth and invasion by promoting CCL2 and suppressing CD154 effects on the angiogenic and immune microenvironments	ONCOGENE			English	Article							NF-KAPPA-B; MONOCYTE CHEMOATTRACTANT PROTEIN-1; CANCER PROGRESSION; NUCLEAR FACTOR; CYCLOSPORINE-A; ACTIVATION; EXPRESSION; CHEMOKINE; RECEPTOR; IMMUNOTHERAPY	Breast cancer is the second leading cause of cancer-related deaths for women, due mainly to metastatic disease. Invasive tumors exhibit aberrations in recruitment and activity of immune cells, including decreased cytotoxic T cells. Restoring the levels and activity of cytotoxic T cells is a promising anticancer strategy; but its success is tumor type dependent. The mechanisms that coordinate recruitment and activity of immune cells and other stromal cells in breast cancer remain poorly understood. Using the MMTV-PyVmT/FVB mammary tumor model, we demonstrate a novel role for CCL2/CCR2 chemokine signaling in tumor progression by altering the microenvironment. Selective targeting of CCR2 in the PyVmT mammary epithelium inhibited tumor growth and invasion, elevated CD8+ T cells, decreased M2 macrophages and decreased angiogenesis. Co-culture models demonstrated these stromal cell responses were mediated by tumor-derived CCL2 and CCR2-mediated suppression of the T-cell activating cytokine, CD154. Coculture analysis indicated that CCR2-induced stromal reactivity was important for tumor cell proliferation and invasion. In breast tumor tissues, CD154 expression inversely correlated with CCR2 expression and correlated with relapse free survival. Targeting the CCL2/CCR2 signaling pathway may reprogram the immune angiogenic and microenvironments and enhance effectiveness of targeted and immunotherapies.	[Brummer, Gage; Fang, Wei; Smart, Curtis; Zinda, Brandon; Cheng, Nikki] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66160 USA; [Alissa, Nadia; Cheng, Nikki] Univ Kansas, Dept Canc Biol, Med Ctr, Kansas City, KS 66160 USA; [Berkland, Cory] Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66045 USA; [Miller, David] Pittsburg State Univ, Dept Engn Technol, Pittsburg, KS 66762 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; Pittsburg State University	Cheng, N (corresponding author), Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66160 USA.; Cheng, N (corresponding author), Univ Kansas, Dept Canc Biol, Med Ctr, Kansas City, KS 66160 USA.	ncheng@kumc.edu			NCI NIH HHS [R01 CA207445, R01 CA172764] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Saleh K, 2017, ONCOL LETT, V14, P337, DOI 10.3892/ol.2017.6144; Aras S, 2017, BRIT J CANCER, V117, P1583, DOI 10.1038/bjc.2017.356; Arasanz H, 2017, MELANOMA MANAG, V4, P39, DOI 10.2217/mmt-2016-0019; Artym Vira V, 2010, Curr Protoc Cell Biol, VChapter 10, DOI 10.1002/0471143030.cb1018s48; Balkwill FR, 2012, J PATHOL, V226, P148, DOI 10.1002/path.3029; Baoum A, 2009, PHARM RES-DORDR, V26, P2619, DOI 10.1007/s11095-009-9976-1; Barnhart B, 2000, J IMMUNOL, V165, P4478, DOI 10.4049/jimmunol.165.8.4478; Behbod F, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2358; Blum S, 2017, LEUKEMIA RES, V60, P63, DOI 10.1016/j.leukres.2017.06.011; Borsig L, 2014, ONCOGENE, V33, P3217, DOI 10.1038/onc.2013.272; Boss V, 1998, J BIOL CHEM, V273, P19664, DOI 10.1074/jbc.273.31.19664; Brandvold KR, 2012, ACS CHEM BIOL, V7, P1393, DOI 10.1021/cb300172e; Brantley-Sieders DM, 2011, CANCER RES, V71, P976, DOI 10.1158/0008-5472.CAN-10-3396; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brodmerkel CM, 2005, J IMMUNOL, V175, P5370, DOI 10.4049/jimmunol.175.8.5370; Brummer G, 2018, MOL CANCER RES, V16, P296, DOI 10.1158/1541-7786.MCR-17-0308; Clawson GA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134320; Connor CS, 2015, J SURG ONCOL, V111, P198, DOI 10.1002/jso.23790; Crist SA, 2008, BLOOD, V111, P3553, DOI 10.1182/blood-2007-05-088161; Du LL, 2017, HEMATOL ONCOL CLIN N, V31, P131, DOI 10.1016/j.hoc.2016.08.004; Dusaban SS, 2013, P NATL ACAD SCI USA, V110, P3609, DOI 10.1073/pnas.1217355110; Fang WB, 2016, ONCOTARGET, V7, P49349, DOI 10.18632/oncotarget.9885; Fang WB, 2015, BREAST CANCER RES TR, V150, P309, DOI 10.1007/s10549-015-3324-4; Fang WB, 2012, J BIOL CHEM, V287, P36593, DOI 10.1074/jbc.M112.365999; Fang WB, 2011, CLIN EXP METASTAS, V28, P351, DOI 10.1007/s10585-011-9373-0; Ford GS, 1999, J IMMUNOL, V162, P4037; Franca TT, 2019, EXPERT REV CLIN IMMU, V15, P529, DOI 10.1080/1744666X.2019.1573674; Georganaki M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03081; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hamilton BJ, 2003, MOL CELL BIOL, V23, P510, DOI 10.1128/MCB.23.2.510-525.2003; Hassan GS, 2015, CANCER TREAT REV, V41, P431, DOI 10.1016/j.ctrv.2015.03.007; Hembruff SL, 2010, NEOPLASIA, V12, P425, DOI 10.1593/neo.10200; Hida K, 2016, INT J CLIN ONCOL, V21, P206, DOI 10.1007/s10147-016-0957-1; Huang DR, 2001, J EXP MED, V193, P713, DOI 10.1084/jem.193.6.713; Khondee S, 2011, MOL PHARMACEUT, V8, P788, DOI 10.1021/mp100393j; Kim JH, 2010, J BIOL CHEM, V285, P5224, DOI 10.1074/jbc.M109.042812; Kurihara T, 1996, J BIOL CHEM, V271, P11603, DOI 10.1074/jbc.271.20.11603; Law AMK, 2017, ENDOCR-RELAT CANCER, V24, pR123, DOI [10.1530/ERC-16-0404, 10.1530/ERC-16-0404e]; Lee EG, 2013, J IMMUNOTOXICOL, V10, P192, DOI 10.3109/1547691X.2012.707700; Lefebvre E, 2016, CTS-CLIN TRANSL SCI, V9, P139, DOI 10.1111/cts.12397; Li TL, 2018, ONCOL LETT, V16, P687, DOI 10.3892/ol.2018.8733; Lim SY, 2016, ONCOTARGET, V7, P28697, DOI 10.18632/oncotarget.7376; Linehan D, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.5_suppl.92; Liu SZ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3148; MartinezMartinez S, 1997, MOL CELL BIOL, V17, P6437, DOI 10.1128/MCB.17.11.6437; Meyer S, 1997, FEBS LETT, V413, P354, DOI 10.1016/S0014-5793(97)00930-7; Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182/blood-2002-01-0151; Moscat J, 2003, EMBO REP, V4, P31, DOI 10.1038/sj.embor.embor704; Pearson LL, 2001, INT IMMUNOL, V13, P273, DOI 10.1093/intimm/13.3.273; Pfeifhofer C, 2003, J EXP MED, V197, P1525, DOI 10.1084/jem.20020234; Pickel L, 2010, CANCER BIOL THER, V9, P277, DOI 10.4161/cbt.9.4.10643; Qian YC, 2002, P NATL ACAD SCI USA, V99, P9386, DOI 10.1073/pnas.142294499; Rakhmilevich AL, 2012, INT REV IMMUNOL, V31, P267, DOI 10.3109/08830185.2012.698337; Ribatti D, 2017, ONCOTARGET, V8, P7175, DOI 10.18632/oncotarget.12739; Richardsen E, 2015, ANTICANCER RES, V35, P865; Ridiandries A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103217; ROLLINS BJ, 1990, AM J PATHOL, V136, P1229; Schaaf MB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0061-0; Scribner KC, 2013, ONCOGENE, V32, P2631, DOI 10.1038/onc.2012.286; Seo AN, 2013, BRIT J CANCER, V109, P2705, DOI 10.1038/bjc.2013.634; Slone S, 2016, CELL SIGNAL, V28, P1735, DOI 10.1016/j.cellsig.2016.08.005; Srahna M, 2001, CLIN EXP IMMUNOL, V125, P229, DOI 10.1046/j.1365-2249.2001.01601.x; Stuelten CH, 2018, NAT REV CANCER, V18, P296, DOI 10.1038/nrc.2018.15; Palomino DCT, 2015, EINSTEIN-SAO PAULO, V13, P469, DOI 10.1590/S1679-45082015RB3438; Tylaska LA, 2002, CYTOKINE, V18, P184, DOI 10.1006/cyto.2002.1031; Valdez KE, 2011, J PATHOL, V225, P565, DOI 10.1002/path.2969; Vonderheide RH, 2010, CLIN CANCER RES, V16, P3485, DOI 10.1158/1078-0432.CCR-10-0505; Wyckoff JB, 2007, CANCER RES, V67, P2649, DOI 10.1158/0008-5472.CAN-06-1823; Xue CB, 2011, ACS MED CHEM LETT, V2, P450, DOI 10.1021/ml200030q; Yang M, 2009, BIOCHEM J, V417, P287, DOI 10.1042/BJ20081561; Yao M, 2016, ADV CANCER RES, V132, P265, DOI 10.1016/bs.acr.2016.05.005; Yao M, 2019, MOL CANCER RES, V17, P604, DOI 10.1158/1541-7786.MCR-18-0750; Yao M, 2017, TRANSL ONCOL, V10, P734, DOI 10.1016/j.tranon.2017.06.009; Yao M, 2016, MODERN PATHOL, V29, P810, DOI 10.1038/modpathol.2016.78; Yoshimura T, 2017, CYTOKINE, V98, P71, DOI 10.1016/j.cyto.2017.02.001; Youngblood V, 2015, MOL CANCER RES, V13, P524, DOI 10.1158/1541-7786.MCR-14-0142; Zhao XX, 2017, ONCOTARGET, V8, P30576, DOI 10.18632/oncotarget.15736	79	15	15	3	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2275	2289		10.1038/s41388-019-1141-7	http://dx.doi.org/10.1038/s41388-019-1141-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31827233	Green Accepted			2022-12-17	WOS:000519440400004
J	Herrmann, A; Lahtz, C; Song, J; Aftabizadeh, M; Cherryholmes, GA; Xin, H; Adamus, T; Lee, HY; Grunert, D; Armstrong, B; Chu, PG; Brown, C; Lim, M; Forman, S; Yu, H				Herrmann, Andreas; Lahtz, Christoph; Song, Jieun; Aftabizadeh, Maryam; Cherryholmes, Gregory A.; Xin, Hong; Adamus, Tomasz; Lee, Heehyoung; Grunert, David; Armstrong, Brian; Chu, Peiguo; Brown, Christine; Lim, Michael; Forman, Stephen; Yu, Hua			Integrin alpha 6 signaling induces STAT3-TET3-mediated hydroxymethylation of genes critical for maintenance of glioma stem cells	ONCOGENE			English	Article							EXTRACELLULAR-MATRIX; TET PROTEINS; CANCER; 5-HYDROXYMETHYLCYTOSINE; DNA; 5-METHYLCYTOSINE; GLIOBLASTOMA; PLURIPOTENT; EPIGENETICS; RESISTANCE	Both the extracellular matrix (ECM) and DNA epigenetic regulation are critical for maintaining stem cell phenotype and cancer progression. Whether and how ECM regulates epigenetic alterations to influence cancer stem cells (CSCs) remain to be explored. Here we report that ECM through laminin-integrin alpha 6 upregulates ten-eleven translocation enzyme 3 (TET3) dioxygenase. TET3 in turn mediates DNA cytosine 5 '-hydroxymethylation (5hmC) and upregulates genes critical for maintenance of glioma stem cells (GSCs). Activating integrin alpha 6-FAK pathway increases STAT3 activity, TET3 expression and 5hmC levels in GSCs. Moreover, targeting STAT3 disrupts integrin alpha 6-FAK signaling and inhibits TET3(+) GSC maturation in vivo. STAT3 directly regulates TET3 expression and the two proteins are co-localized with 5hmC in GSC clusters. 5hmC is upregulated by STAT3 at the promoters of several tumorigenic genes, including c-Myc, known to be critical for GSCs. In vivo silencing of TET3 in GSC-enriched tumors reduces 5hmC accumulation and expression of the GSC critical genes, leading to tumor growth inhibition. TET3 expression and 5hmC accumulation also co-segregate with integrin alpha 6 in patient malignant glioma. Thus, ECM- integrin alpha 6-STAT3-TET3 axis regulates hydroxymethylation of genes important for GSCs, thereby increasing GSC tumorigenicity and resistance to therapies.	[Herrmann, Andreas; Lahtz, Christoph; Song, Jieun; Aftabizadeh, Maryam; Cherryholmes, Gregory A.; Xin, Hong; Adamus, Tomasz; Lee, Heehyoung; Grunert, David; Yu, Hua] City Hope Comprehens Canc Ctr, Dept Immunooncol, Beckman Res Inst, Duarte, CA 91010 USA; [Herrmann, Andreas; Lahtz, Christoph; Adamus, Tomasz] Sorrento Therapeut, San Diego, CA 92121 USA; [Armstrong, Brian] City Hope Comprehens Canc Ctr, Dept Neurosci, Beckman Res Inst, Duarte, CA 91010 USA; [Chu, Peiguo] City Hope Comprehens Canc Ctr, Dept Pathol, Duarte, CA 91010 USA; [Brown, Christine; Forman, Stephen] City Hope Comprehens Canc Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA 91010 USA; [Lim, Michael] Johns Hopkins Univ, Dept Neurosurg, Baltimore, MD 21287 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope; City of Hope; Johns Hopkins University	Herrmann, A; Yu, H (corresponding author), City Hope Comprehens Canc Ctr, Dept Immunooncol, Beckman Res Inst, Duarte, CA 91010 USA.; Herrmann, A (corresponding author), Sorrento Therapeut, San Diego, CA 92121 USA.	aherrmann@sorrentotherapeutics.com; hyu@coh.org	; Song, Ji Eun/A-3567-2013	Lim, Michael/0000-0003-0523-3076; YU, Hua/0000-0003-0931-1000; Song, Ji Eun/0000-0001-7886-1765	Billy and Audrey Wilder Endowment; National Cancer Institute of the National Institutes of Health [P30CA033572];  [R01CA122976];  [R01CA146092]	Billy and Audrey Wilder Endowment; National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; 	This work is funded in part by R01CA122976 and R01CA146092 (to HY), as well as the Billy and Audrey Wilder Endowment (to HY). Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under grant number P30CA033572 (to City of Hope Comprehensive Cancer Center). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Acerbi I, 2015, INTEGR BIOL-UK, V7, P1120, DOI 10.1039/c5ib00040h; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Baylin SB, 2011, NAT MED, V17, P288, DOI 10.1038/nm0311-288; Branco MR, 2012, NAT REV GENET, V13, P7, DOI 10.1038/nrg3080; Brown CE, 2012, CLIN CANCER RES, V18, P2199, DOI 10.1158/1078-0432.CCR-11-1669; Brown CE, 2009, CANCER RES, V69, P8886, DOI 10.1158/0008-5472.CAN-09-2687; Cimmino L, 2015, NAT IMMUNOL, V16, P653, DOI 10.1038/ni.3148; Cui Q, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10637; Frantz C, 2010, J CELL SCI, V123, P4195, DOI 10.1242/jcs.023820; Guo JU, 2011, CELL, V145, P423, DOI 10.1016/j.cell.2011.03.022; Herrmann A, 2015, J CLIN INVEST, V125, P2547, DOI 10.1172/JCI82555; Herrmann A, 2014, CANCER RES, V74, P5218, DOI 10.1158/0008-5472.CAN-14-1151; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Huang H, 2013, P NATL ACAD SCI USA, V110, P11994, DOI 10.1073/pnas.1310656110; Huang Y, 2014, P NATL ACAD SCI USA, V111, P1361, DOI 10.1073/pnas.1322921111; Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303; Jiang X, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02290-w; Jin F, 2008, NEUROSCIENCE, V154, P541, DOI 10.1016/j.neuroscience.2008.03.054; Johnson KC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13177; Koh KP, 2011, CELL STEM CELL, V8, P200, DOI 10.1016/j.stem.2011.01.008; Lathia JD, 2010, CELL STEM CELL, V6, P421, DOI 10.1016/j.stem.2010.02.018; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003; Mathieu J, 2011, CANCER RES, V71, P4640, DOI 10.1158/0008-5472.CAN-10-3320; Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107; Meissner A, 2010, NAT BIOTECHNOL, V28, P1079, DOI 10.1038/nbt.1684; Pickup MW, 2014, EMBO REP, V15, P1243, DOI 10.15252/embr.201439246; Prasad P, 2017, STEM CELLS, V35, P1468, DOI 10.1002/stem.2621; Schroeder A, 2014, CANCER RES, V74, P1227, DOI 10.1158/0008-5472.CAN-13-0594; Singh SK, 2003, CANCER RES, V63, P5821; Sun YB, 2012, ANNU REV BIOPHYS, V41, P519, DOI 10.1146/annurev-biophys-042910-155306; Tagscherer KE, 2008, ONCOGENE, V27, P6646, DOI 10.1038/onc.2008.259; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Takai H, 2014, CELL REP, V9, P48, DOI 10.1016/j.celrep.2014.08.071; Veron N, 2011, NATURE, V473, P293, DOI 10.1038/473293a; Wang JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003769; Weaver VM, 1997, TRENDS CELL BIOL, V7, P40, DOI 10.1016/S0962-8924(97)30078-6; Wu MZ, 2015, CANCER RES, V75, P3912, DOI 10.1158/0008-5472.CAN-14-3208; Yang L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133896; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Zhang F, 2016, SCI REP-UK, V6, DOI 10.1038/srep20882	42	15	16	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2156	2169		10.1038/s41388-019-1134-6	http://dx.doi.org/10.1038/s41388-019-1134-6			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31819166	Green Accepted			2022-12-17	WOS:000518584000010
J	Sarac, H; Morova, T; Pires, E; McCullagh, J; Kaplan, A; Cingoz, A; Bagci-Onder, T; Onder, T; Kawamura, A; Lack, NA				Sarac, Hilal; Morova, Tunc; Pires, Elisabete; McCullagh, James; Kaplan, Anil; Cingoz, Ahmet; Bagci-Onder, Tugba; onder, Tamer; Kawamura, Akane; Lack, Nathan A.			Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer	ONCOGENE			English	Article							CARCINOMA-CELL LINE; ANDROGEN-RECEPTOR; H3K9 METHYLATION; TUMOR-GROWTH; DEMETHYLASE; PROGRESSION; PROLIFERATION; TRANSCRIPTION; EXPRESSION; PROTEIN	Androgen deprivation therapy (ADT) is the standard care for prostate cancer (PCa) patients who fail surgery or radiotherapy. While initially effective, the cancer almost always recurs as a more aggressive castration resistant prostate cancer (CRPC). Previous studies have demonstrated that chromatin modifying enzymes can play a critical role in the conversion to CRPC. However, only a handful of these potential pharmacological targets have been tested. Therefore, in this study, we conducted a focused shRNA screen of chromatin modifying enzymes previously shown to be involved in cellular differentiation. We found that altering the balance between histone methylation and demethylation impacted growth and proliferation. Of all genes tested, KDM3B, a histone H3K9 demethylase, was found to have the most antiproliferative effect. These results were phenocopied with a KDM3B CRISPR/Cas9 knockout. When tested in several PCa cell lines, the decrease in proliferation was remarkably specific to androgen-independent cells. Genetic rescue experiments showed that only the enzymatically active KDM3B could recover the phenotype. Surprisingly, despite the decreased proliferation of androgen-independent cell no alterations in the cell cycle distribution were observed following KDM3B knockdown. Whole transcriptome analyses revealed changes in the gene expression profile following loss of KDM3B, including downregulation of metabolic enzymes such as ARG2 and RDH11. Metabolomic analysis of KDM3B knockout showed a decrease in several critical amino acids. Overall, our work reveals, for the first time, the specificity and the dependence of KDM3B in CRPC proliferation.	[Sarac, Hilal; Morova, Tunc; Kaplan, Anil; Cingoz, Ahmet; Bagci-Onder, Tugba; onder, Tamer; Lack, Nathan A.] Koc Univ, Sch Med, TR-34450 Istanbul, Turkey; [Sarac, Hilal; Pires, Elisabete; McCullagh, James; Kawamura, Akane] Univ Oxford, Dept Chem, Chem Res Lab, Oxford OX1 3TA, England; [Sarac, Hilal; Kawamura, Akane] Univ Oxford, Wellcome Ctr Human Genet, Radcliffe Dept Med, Oxford OX3 7BN, England; [Morova, Tunc; Lack, Nathan A.] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC V6H 3Z6, Canada	Koc University; University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; University of British Columbia	Lack, NA (corresponding author), Koc Univ, Sch Med, TR-34450 Istanbul, Turkey.	nlack@ku.edu.tr	Onder, Tamer T/H-3330-2013; Onder, Tamer/O-3669-2019; Cingoz, Ahmet/AAG-4228-2019; McCullagh, James/AAD-2669-2022; KAPLAN, ANIL/AAT-2829-2020; Onder, Tugba Bagci/AAN-1392-2021; Kawamura, Akane/I-4047-2018	Onder, Tamer T/0000-0002-2372-9158; Onder, Tamer/0000-0002-2372-9158; Cingoz, Ahmet/0000-0002-1111-7752; McCullagh, James/0000-0003-4733-1205; Bagci Onder, Tugba/0000-0003-3646-2613; Pires, Elisabete/0000-0001-8646-062X; Kawamura, Akane/0000-0003-1169-5082	TUBITAK 1001 [114Z997]; Royal Society Newton Advanced Fellowship [NA150165]; Wellcome Trust [203141/Z/16/Z]; Royal Society Dorothy Hodgkin Fellowship [DH120028]; Cancer Research UK Programme Grant [C8717/A18245]; BBSRC [BB/R013829/1] Funding Source: UKRI; EPSRC [EP/L003376/1] Funding Source: UKRI	TUBITAK 1001(Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)); Royal Society Newton Advanced Fellowship; Wellcome Trust(Wellcome Trust); Royal Society Dorothy Hodgkin Fellowship(Royal Society of London); Cancer Research UK Programme Grant(Cancer Research UK); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	This work was primarily supported by TUBITAK 1001 (114Z997) and the Royal Society Newton Advanced Fellowship (NA150165 to NAL and AK). We thank Zeynep Kahya for helping with shRNA library packaging. We also gratefully acknowledge the services and facilities of the Koc University Research Centre for Translational Medicine and Wellcome Trust Core Award Grant number 203141/Z/16/Z. AK gratefully acknowledges the Royal Society Dorothy Hodgkin Fellowship (DH120028), the Cancer Research UK Programme Grant (C8717/A18245).	Acar O, 2013, SCI WORLD J, DOI 10.1155/2013/379641; Albany C, 2011, PROSTATE CANCER, V2011, DOI 10.1155/2011/580318; [Anonymous], P NATL ACAD SCI US, V102, P15545, DOI [10.1073/pnas.0506580102, DOI 10.1073/PNAS.0506580102, DOI 10.1073/pnas.0506580102]; Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215; Braadland PR, 2019, ENDOCR-RELAT CANCER, V26, pR211, DOI 10.1530/ERC-18-0579; Brauchle M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060549; Caldwell RB, 2015, TRENDS PHARMACOL SCI, V36, P395, DOI 10.1016/j.tips.2015.03.006; Carlberg C., 2018, HUMAN EPIGENOMICS, DOI DOI 10.4330/wjc.v8.i9.504; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen Y, 2008, CURR OPIN PHARMACOL, V8, P440, DOI 10.1016/j.coph.2008.07.005; Coffey K, 2013, NUCLEIC ACIDS RES, V41, P4433, DOI 10.1093/nar/gkt106; Cohet N, 2010, J CELL PHYSIOL, V223, P667, DOI 10.1002/jcp.22072; Crea F, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-52; Culig Z, 1999, BRIT J CANCER, V81, P242, DOI 10.1038/sj.bjc.6690684; Duan LL, 2015, CHEM BIOL, V22, P1185, DOI 10.1016/j.chembiol.2015.08.007; Fagerberg L, 2014, MOL CELL PROTEOMICS, V13, P397, DOI 10.1074/mcp.M113.035600; Gannon PO, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012107; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giskeodegard GF, 2015, BRIT J CANCER, V113, P1712, DOI 10.1038/bjc.2015.411; Goda S, 2013, J BIOL CHEM, V288, P36948, DOI 10.1074/jbc.M113.492595; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Gravina GL, 2013, ONCOL REP, V29, P1189, DOI 10.3892/or.2012.2192; Han A, 2015, BMB REP, V48, P401, DOI 10.5483/BMBRep.2015.48.7.188; Hatch SB, 2017, EPIGENET CHROMATIN, V10, DOI 10.1186/s13072-017-0116-6; Hausinger R, 2015, SERIES RSCM 2 OXOGLU, DOI [10.1039/9781782621959, DOI 10.1039/9781782621959]; Heck D, 2014, NAT BIOTECHNOL, V32, P941, DOI 10.1038/nbt.2951; Helsen C, 2014, ENDOCR-RELAT CANCER, V21, pT105, DOI 10.1530/ERC-13-0545; Hopkinson RJ, 2013, CHEM SCI, V4, P3110, DOI [10.1039/C3SC51122G, 10.1039/c3sc51122g]; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Hu ZB, 2001, ONCOGENE, V20, P6946, DOI 10.1038/sj.onc.1204850; Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092; Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206; Kim JY, 2012, MOL CELL BIOL, V32, P2917, DOI 10.1128/MCB.00133-12; Kim TD, 2016, J CLIN INVEST, V126, P706, DOI 10.1172/JCI78132; King ONF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015535; Korenchuk S, 2001, IN VIVO, V15, P163; Kummalue T, 2015, EXP HEMATOL, V43, P414, DOI 10.1016/j.exphem.2015.01.006; Kurien BT, 2006, METHODS, V38, P283, DOI 10.1016/j.ymeth.2005.11.007; Kurt IC, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.288; Li J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15146; Li SH, 2018, CELL REP, V23, P389, DOI 10.1016/j.celrep.2018.03.051; Liu YX, 2013, GUT, V62, P571, DOI 10.1136/gutjnl-2011-301059; Liu ZL, 2015, INT J BIOL SCI, V11, P1447, DOI 10.7150/ijbs.13795; MacKinnon RN, 2011, CANCER GENET-NY, V204, P187, DOI 10.1016/j.cancergen.2011.02.001; Maina PK, 2016, ONCOTARGET, V7, P75585, DOI 10.18632/oncotarget.12310; McAllister TE, 2016, J MED CHEM, V59, P1308, DOI 10.1021/acs.jmedchem.5b01758; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249; Okada Y, 2007, NATURE, V450, P119, DOI 10.1038/nature06236; Onder TT, 2012, NATURE, V483, P598, DOI 10.1038/nature10953; Paolicchi E, 2013, CRIT REV ONCOL HEMAT, V86, P97, DOI 10.1016/j.critrevonc.2012.11.008; Papp B, 2013, CELL, V152, P1324, DOI 10.1016/j.cell.2013.02.043; Pauler FM, 2009, GENOME RES, V19, P221, DOI 10.1101/gr.080861.108; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Rotili D, 2014, J MED CHEM, V57, P42, DOI 10.1021/jm4012802; Shen Y, 2017, COATINGS, V7, DOI 10.3390/coatings7120212; SHEPPARD D, 1994, AM J RESP CELL MOL, V11, P1; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Tai S, 2011, PROSTATE, V71, P1668, DOI 10.1002/pros.21383; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Teng T, 2013, MOL CELL BIOL, V33, P4660, DOI 10.1128/MCB.01174-13; Tong D, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.74; Urbanucci A, 2017, CELL REP, V19, P2045, DOI 10.1016/j.celrep.2017.05.049; Waddington CH, 2012, INT J EPIDEMIOL, V41, P10, DOI 10.1093/ije/dyr184; Wang L, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3035; Wei CG, 2018, MOL MED REP, V17, P2901, DOI 10.3892/mmr.2017.8257; Wilson S, 2017, ONCOTARGET, V8, P30328, DOI 10.18632/oncotarget.15681; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Wu LZ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153556; Xiang Y, 2007, P NATL ACAD SCI USA, V104, P19226, DOI 10.1073/pnas.0700735104; Xin L, 2006, P NATL ACAD SCI USA, V103, P7789, DOI 10.1073/pnas.0602567103; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027; Zhang JW, 2016, EXP CELL RES, V349, P77, DOI 10.1016/j.yexcr.2016.09.023; Zhang QJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07173-2; Zong Y, 2013, NAT REV UROL, V10, P90, DOI [10.1038/nrurol.2012.237, 10.1038/nruro1.2012.237]	79	15	15	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2187	2201		10.1038/s41388-019-1116-8	http://dx.doi.org/10.1038/s41388-019-1116-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31822799	Green Published, hybrid			2022-12-17	WOS:000518584000012
J	Li, F; Li, ZM; Han, Q; Cheng, YR; Ji, WX; Yang, Y; Lu, S; Xia, WL				Li, Fan; Li, Ziming; Han, Qing; Cheng, Yirui; Ji, Wenxiang; Yang, Ying; Lu, Shun; Xia, Weiliang			Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104	ONCOGENE			English	Article							TUMOR PROGRESSION; FGF19 CONTRIBUTES; BETA-KLOTHO; CANCER; GROWTH; FGFR4; PROMOTES; TARGET; IDENTIFICATION; EXPRESSION	Lung cancer occurrence and associated mortality ranks top in all countries. Despite the rapid development of targeted and immune therapies, many patients experience relapse within a few years. It is urgent to uncover the mechanisms that drive lung cancer progression and identify novel molecular targets. Our group has previously identified FGF19 as a prognostic marker and potential driver gene of lung squamous cell carcinomas (LSQ) in Chinese smoking patients. However, the underlying mechanism of how FGF19 promotes the progression of LSQ remains unclear. In this study, we characterized and confirmed that FGF19 serves as an oncogenic driver in LSQ development and progression, and reported that the amplification and high expression of FGF19 in LSQ was significantly associated with poor overall and progression-free survival. A higher serum level of FGF19 was found in lung cancer patients, which could also serve as a novel diagnostic index to screen lung cancer. Overproduction of FGF19 in LSQ cells markedly promoted cell growth, progression and metastasis, while downregulating FGF19 effectively inhibited LSQ progression in vitro and in vivo. Moreover, downregulating the receptor FGFR4 was also effective to suppress the growth and migration of LSQ cells. Since FGF19 could be induced by smoking or endoplasmic reticulum stress, to tackle the more malignant FGF19-overproducing LSQ, we reported for the first time that inhibiting mTOR pathway by using AZD2014 was effective and feasible. These findings have offered a new strategy by using anti-FGF19/FGFR4 therapy or mTOR-based therapy in FGF19-driven LSQ.	[Li, Fan; Han, Qing; Cheng, Yirui; Xia, Weiliang] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Renji Med Clin Stem Cell Res Ctr 10, Ren Ji Hosp,Sch Med, Shanghai, Peoples R China; [Li, Fan; Han, Qing; Cheng, Yirui; Xia, Weiliang] Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai, Peoples R China; [Li, Ziming; Ji, Wenxiang; Yang, Ying; Lu, Shun] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Xia, WL (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Renji Med Clin Stem Cell Res Ctr 10, Ren Ji Hosp,Sch Med, Shanghai, Peoples R China.; Xia, WL (corresponding author), Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai, Peoples R China.	wlxia@sjtu.edu.cn	XIA, WEILIANG/AEA-0835-2022; li, fan/AAY-5915-2020; Lu, Shun/ABF-8341-2021; Li, Fan/GRX-7461-2022	XIA, WEILIANG/0000-0002-0256-4219; 	National Natural Science Foundation of China [81773115]; National Key Grant of China [2016YFC0906400]; Medical-Engineering Joint Funds from Shanghai Jiao Tong University [YG2017MS52, YG2017MS81]; Shanghai Science and Technology Commission guidance projects [18411968200]; Shanghai Chest Hospital Project of Collaborative Innovation [YJXT20190209]; Shanghai Youth Top Talent Project	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Grant of China; Medical-Engineering Joint Funds from Shanghai Jiao Tong University; Shanghai Science and Technology Commission guidance projects; Shanghai Chest Hospital Project of Collaborative Innovation; Shanghai Youth Top Talent Project	This work is financially supported, in whole or in part, by National Natural Science Foundation of China (81773115), National Key Grant of China (2016YFC0906400) and Medical-Engineering Joint Funds from Shanghai Jiao Tong University (YG2017MS52, YG2017MS81), Shanghai Science and Technology Commission guidance projects (18411968200), Shanghai Chest Hospital Project of Collaborative Innovation (YJXT20190209) and Shanghai Youth Top Talent Project.	Aldhahrani Adil, 2017, ERJ Open Res, V3, DOI 10.1183/23120541.00107-2016; Beck JT, 2014, CANCER TREAT REV, V40, P980, DOI 10.1016/j.ctrv.2014.06.006; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Desnoyers L, 2008, ONCOGENE, V27, P85, DOI 10.1038/sj.onc.1210623; Feng S, 2013, CANCER RES, V73, P2551, DOI 10.1158/0008-5472.CAN-12-4108; Gao LX, 2019, ONCOGENE, V38, P2394, DOI 10.1038/s41388-018-0591-7; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Guichard SM, 2015, MOL CANCER THER, V14, P2508, DOI 10.1158/1535-7163.MCT-15-0365; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hagel M, 2015, CANCER DISCOV, V5, P424, DOI 10.1158/2159-8290.CD-14-1029; Ji WX, 2016, ONCOTARGET, V7, P15118, DOI 10.18632/oncotarget.7701; Joshi JJ, 2017, CANCER RES, V77, P6999, DOI 10.1158/0008-5472.CAN-17-1865; Koole K, 2015, PATHOBIOLOGY, V82, P280, DOI 10.1159/000439536; Lang LW, 2019, CURR CANCER DRUG TAR, V19, P17, DOI 10.2174/1568009618666180319091731; Lewis DR, 2014, CANCER-AM CANCER SOC, V120, P2883, DOI 10.1002/cncr.28749; Li F, 2019, THERANOSTICS, V9, P7474, DOI 10.7150/thno.35582; Lin BC, 2007, J BIOL CHEM, V282, P27277, DOI 10.1074/jbc.M704244200; Lin YN, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109249; Luo YD, 2010, J BIOL CHEM, V285, P30069, DOI 10.1074/jbc.M110.148288; Massafra V, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171185; Nagamatsu H, 2015, PROSTATE, V75, P1092, DOI 10.1002/pros.22994; Pelaez-Garcia A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063695; Piotrowska Z, 2018, CANCER DISCOV, V8, P1529, DOI 10.1158/2159-8290.CD-18-1022; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Raja A, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060536; Sawey ET, 2011, CANCER CELL, V19, P347, DOI 10.1016/j.ccr.2011.01.040; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Singleton KR, 2015, CANCER RES, V75, P4398, DOI 10.1158/0008-5472.CAN-15-0509; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tan Q, 2016, ONCOTARGET, V7, P18394, DOI 10.18632/oncotarget.7817; Teng Y, 2017, CANCER RES, V77, P6215, DOI 10.1158/0008-5472.CAN-17-2039; Tiong KH, 2016, ONCOTARGET, V7, P57633, DOI 10.18632/oncotarget.9328; Turunen SP, 2019, CELL DEATH DIFFER, V26, P2577, DOI 10.1038/s41418-019-0321-x; Wan ZY, 2016, HEPATOLOGY, V64, P1289, DOI 10.1002/hep.28639; Wang S, 2016, ONCOL RES, V23, P197, DOI 10.3727/096504016X14537290676919; Yoo C, 2017, ONCOTARGET, V8, P38592, DOI 10.18632/oncotarget.16951; Zhang XC, 2017, THORAC CANCER, V8, P655, DOI 10.1111/1759-7714.12504; Zhang XL, 2016, OTOLARYNG HEAD NECK, V154, P52, DOI 10.1177/0194599815609534; Zhao HK, 2016, ONCOTARGET, V7, P13575, DOI 10.18632/oncotarget.6185; Zhou M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15433	40	15	15	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	17					3507	3521		10.1038/s41388-020-1227-2	http://dx.doi.org/10.1038/s41388-020-1227-2		FEB 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LH1YK	32111983	Green Published, hybrid			2022-12-17	WOS:000517049100002
J	Orsolic, I; Bursac, S; Jurada, D; Hofman, ID; Dembic, Z; Bartek, J; Mihalek, I; Volarevic, S				Orsolic, Ines; Bursac, Sladana; Jurada, Deana; Drmic Hofman, Irena; Dembic, Zlatko; Bartek, Jiri; Mihalek, Ivana; Volarevic, Sinisa			Cancer-associated mutations in the ribosomal protein L5 gene dysregulate the HDM2/p53-mediated ribosome biogenesis checkpoint	ONCOGENE			English	Article							DIAMOND-BLACKFAN ANEMIA; RPL11 GENES; P53; L11; RNA; INHIBITION; IDENTIFICATION; CONSERVATION; DEGRADATION; ACTIVATION	Perturbations in ribosome biogenesis have been associated with cancer. Such aberrations activate p53 through the RPL5/RPL11/5S rRNA complex-mediated inhibition of HDM2. Studies using animal models have suggested that this signaling pathway might constitute an important anticancer barrier. To gain a deeper insight into this issue in humans, here we analyze somatic mutations in RPL5 and RPL11 coding regions, reported in The Cancer Genome Atlas and International Cancer Genome Consortium databases. Using a combined computational and statistical approach, complemented by a range of biochemical and functional analyses in human cancer cell models, we demonstrate the existence of several mechanisms by which RPL5 mutations may impair wild-type p53 upregulation and ribosome biogenesis. Unexpectedly, the same approach provides only modest evidence for a similar role of RPL11, suggesting that RPL5 represents a preferred target during human tumorigenesis in cancers with wild-type p53. Furthermore, we find that several functional cancer-associated RPL5 somatic mutations occur as rare germline variants in general population. Our results shed light on the so-far enigmatic role of cancer-associated mutations in genes encoding ribosomal proteins, with implications for our understanding of the tumor suppressive role of the RPL5/RPL11/5S rRNA complex in human malignancies.	[Orsolic, Ines; Bursac, Sladana; Jurada, Deana; Mihalek, Ivana; Volarevic, Sinisa] Univ Rijeka, Fac Med, Dept Mol Med & Biotechnol, Rijeka 51000, Croatia; [Drmic Hofman, Irena] Univ Split, Sch Med, Dept Med Chem & Biochem, Split 21000, Croatia; [Dembic, Zlatko] Univ Oslo, Fac Dent, Inst Oral Biol, PB 1052 Blindern, N-0316 Oslo, Norway; [Bartek, Jiri] Karolinska Inst, Dept Med Biochem & Biophys, Div Genome Biol, S-17176 Stockholm, Sweden; [Bartek, Jiri] Danish Canc Soc Res, DK-2100 Copenhagen, Denmark	University of Rijeka; University of Split; University of Oslo; Karolinska Institutet; Danish Cancer Society	Mihalek, I; Volarevic, S (corresponding author), Univ Rijeka, Fac Med, Dept Mol Med & Biotechnol, Rijeka 51000, Croatia.; Bartek, J (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Genome Biol, S-17176 Stockholm, Sweden.; Bartek, J (corresponding author), Danish Canc Soc Res, DK-2100 Copenhagen, Denmark.	jb@cancer.dk; ivana.mihalek@medri.uniri.hr; sinisa.volarevic@medri.uniri.hr	Bursać, Slađana/Q-7894-2018; Volarevic, Sinisa/O-4349-2018; Oršolić, Ines/AGE-5929-2022; Dembic, Zlatko/A-1833-2008	Bursać, Slađana/0000-0002-6478-3409; Volarevic, Sinisa/0000-0003-4893-389X; Oršolić, Ines/0000-0003-4517-7187; Dembic, Zlatko/0000-0002-9970-6497	Croatian Science Foundation [09.01/220, 2079]; Scientific Center of Excellence for Reproductive and Regenerative Medicine [KK.01.1.1.01.0008]; University of Rijeka [uniri-biomed-18-206]; Swedish Cancer Society [170176]; Swedish Research Council [VR-MH 2014-46602-117891-30]; Novo Nordisk Foundation [16854]; Danish National Research Foundation (project CARD) [DNRF125]; Danish Cancer Society [R204-A12617]; Lundbeck Foundation	Croatian Science Foundation; Scientific Center of Excellence for Reproductive and Regenerative Medicine; University of Rijeka; Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Danish National Research Foundation (project CARD); Danish Cancer Society(Danish Cancer Society); Lundbeck Foundation(Lundbeckfonden)	We are grateful to Drs George Thomas and Jonathan Ashwell for critical review of the manuscript and helpful suggestions. We would also like to thank Davor Mihalek for his expert assistance in preparing the supplementary movie as well as Miljana Uzelac and Ivana Matui for their technical help. The authors sincerely thank Dr. Moshe Oren (Weizmann Institute of Science) for providing the pCMV-HA3-HDM1B expression plasmid. The pCHDM1A-HDM2 expression plasmid was kindly provided by Dr. Karen Vousden (Francis Crick Institute). SV laboratory was supported with grants from the Croatian Science Foundation (09.01/220 and 2079 to SV), the Scientific Center of Excellence for Reproductive and Regenerative Medicine (KK.01.1.1.01.0008 to SV), the University of Rijeka (uniri-biomed-18-206 to SV). JB laboratory is funded by grants from the Swedish Cancer Society (grant number: 170176) and the Swedish Research Council (VR-MH 2014-46602-117891-30), the Novo Nordisk Foundation (no. 16854), the Danish National Research Foundation (project CARD: no. DNRF125), the Danish Cancer Society (R204-A12617), and the Lundbeck Foundation.	Ajore R, 2017, EMBO MOL MED, V9, P498, DOI 10.15252/emmm.201606660; ANDERSON DE, 1990, BIOCHEMISTRY-US, V29, P2403, DOI 10.1021/bi00461a025; Anslyn E.V., 2006, MODERN PHYS ORGANIC; Arena G, 2018, CELL DEATH DIFFER, V25, P1533, DOI 10.1038/s41418-018-0156-x; Aspesi A, 2019, NAT REV CANCER, V19, P228, DOI 10.1038/s41568-019-0105-0; Badertscher L, 2015, CELL REP, V13, P2879, DOI 10.1016/j.celrep.2015.11.061; Ben-Shem A, 2011, SCIENCE, V334, P1524, DOI 10.1126/science.1212642; Berman H. M., 2006, INT TABLES CRYSTALLO, P675, DOI DOI 10.1107/97809553602060000722; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Bohlman Stephen, 2014, Subcell Biochem, V85, P235, DOI 10.1007/978-94-017-9211-0_13; Boria I, 2010, HUM MUTAT, V31, P1269, DOI 10.1002/humu.21383; Bursac S, 2012, P NATL ACAD SCI USA, V109, P20467, DOI 10.1073/pnas.1218535109; Bywater MJ, 2012, CANCER CELL, V22, P51, DOI 10.1016/j.ccr.2012.05.019; Cancer Genome Atlas Research Network, 2013, Nat Genet, V45, P1113, DOI 10.1038/ng.2764; Cmejla R, 2009, HUM MUTAT, V30, P321, DOI 10.1002/humu.20874; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; De Keersmaecker K, 2013, NAT GENET, V45, P186, DOI 10.1038/ng.2508; Delaporta P, 2014, PEDIATR BLOOD CANCER, V61, P2249, DOI 10.1002/pbc.25183; Donati G, 2013, CELL REP, V4, P87, DOI 10.1016/j.celrep.2013.05.045; Ebert BL, 2008, NATURE, V451, P335, DOI 10.1038/nature06494; Errichiello E, 2017, BLOOD CELL MOL DIS, V64, P38, DOI 10.1016/j.bcmd.2017.03.002; Fancello L, 2017, ONCOTARGET, V8, P14462, DOI 10.18632/oncotarget.14895; Fersht AR, 2002, CELL, V108, P573, DOI 10.1016/S0092-8674(02)00620-7; Ballester EF, 2015, CLIN CASE REP, V3, P392, DOI 10.1002/ccr3.240; Gao J, 2017, RETHINK ASIA INT REL, P1; Gazda HT, 2008, AM J HUM GENET, V83, P769, DOI 10.1016/j.ajhg.2008.11.004; Golomb L, 2014, FEBS LETT, V588, P2571, DOI 10.1016/j.febslet.2014.04.014; Greenman C, 2006, GENETICS, V173, P2187, DOI 10.1534/genetics.105.044677; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hofman IJF, 2017, LEUKEMIA, V31, P1706, DOI 10.1038/leu.2016.370; Hofman IJF, 2017, HAEMATOLOGICA, V102, pE317, DOI 10.3324/haematol.2016.162198; Horn HF, 2008, ONCOGENE, V27, P5774, DOI 10.1038/onc.2008.189; Hunter JD, 2007, COMPUT SCI ENG, V9, P90, DOI 10.1109/MCSE.2007.55; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; Kamburov A, 2015, P NATL ACAD SCI USA, V112, pE5486, DOI 10.1073/pnas.1516373112; Karlin S, 1996, J BACTERIOL, V178, P1881, DOI 10.1128/jb.178.7.1881-1894.1996; Kazerounian S, 2016, J CANCER, V7, P32, DOI 10.7150/jca.13292; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Lindstrom MS, 2018, ONCOGENE, V37, P2351, DOI 10.1038/s41388-017-0121-z; Liu S, 2017, ONCOGENE, V36, P1374, DOI 10.1038/onc.2016.301; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Lykke-Andersen S, 2015, NAT REV MOL CELL BIO, V16, P665, DOI 10.1038/nrm4063; Macias E, 2010, CANCER CELL, V18, P231, DOI 10.1016/j.ccr.2010.08.007; Mihalek I, 2003, J MOL BIOL, V331, P263, DOI 10.1016/S0022-2836(03)00663-6; Morgado-Palacin L, 2015, CELL REP, V13, P712, DOI 10.1016/j.celrep.2015.09.038; Narla A, 2010, BLOOD, V115, P3196, DOI 10.1182/blood-2009-10-178129; Nicolas E, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11390; Nishimura K, 2015, CELL REP, V10, P1310, DOI 10.1016/j.celrep.2015.01.055; Noller HF, 2012, CSH PERSPECT BIOL, V4, P1, DOI 10.1101/cshperspect.a003681; Orsolic I, 2016, SEMIN CANCER BIOL, V37-38, P36, DOI 10.1016/j.semcancer.2015.12.004; Pelletier J, 2018, NAT REV CANCER, V18, P51, DOI 10.1038/nrc.2017.104; Pon JR, 2015, ANNU REV PATHOL-MECH, V10, P25, DOI 10.1146/annurev-pathol-012414-040312; Quarello P, 2010, HAEMATOL-HEMATOL J, V95, P206, DOI 10.3324/haematol.2009.011783; Rahman N, 2014, NATURE, V505, P302, DOI 10.1038/nature12981; Sivley RM, 2018, AM J HUM GENET, V102, P415, DOI 10.1016/j.ajhg.2018.01.017; Sloan KE, 2013, CELL REP, V5, P237, DOI 10.1016/j.celrep.2013.08.049; Tafforeau L, 2013, MOL CELL, V51, P539, DOI 10.1016/j.molcel.2013.08.011; Tahmasebi S, 2018, NAT REV MOL CELL BIO, V19, P791, DOI 10.1038/s41580-018-0034-x; Tzoneva G, 2013, NAT MED, V19, P368, DOI 10.1038/nm.3078; Velimezi G, 2013, NAT CELL BIOL, V15, P967, DOI 10.1038/ncb2795; Vlachos A, 2012, BLOOD, V119, P3815, DOI 10.1182/blood-2011-08-375972; Voorhees RM, 2014, CELL, V157, P1632, DOI 10.1016/j.cell.2014.05.024; Zhang JY, 2007, GENE DEV, V21, P2580, DOI 10.1101/gad.1569307; Zhang JJ, 2011, DATABASE-OXFORD, DOI [10.1093/database/bar026, 10.1155/2011/958381]; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zheng JG, 2015, GENE DEV, V29, P1524, DOI 10.1101/gad.261792.115	67	15	15	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	17					3443	3457		10.1038/s41388-020-1231-6	http://dx.doi.org/10.1038/s41388-020-1231-6		FEB 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LH1YK	32108164				2022-12-17	WOS:000516891300004
J	Wang, Y; Liu, Y; Bailey, C; Zhang, HX; He, M; Sun, DX; Zhang, P; Parkin, B; Baer, MR; Zheng, P; Malek, SN; Liu, Y				Wang, Yin; Liu, Yan; Bailey, Christopher; Zhang, Huixia; He, Miao; Sun, Duxin; Zhang, Peng; Parkin, Brian; Baer, Maria R.; Zheng, Pan; Malek, Sami N.; Liu, Yang			Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1 alpha with echinomycin	ONCOGENE			English	Article							MYELODYSPLASTIC SYNDROMES; P53 MUTATIONS; STEM-CELLS; TP53 GENE; SURVIVAL; PERMEABILITY; HIF1-ALPHA	TP53 mutation in acute myeloid leukemia (AML) is associated with poor prognosis. Since no targeted therapy is available to restore p53 function, it is of great interest to test whether other pathways activated by TP53 mutations can be therapeutically targeted. Here, we showed HIF-1 alpha target genes are enriched in TP53-mutated versus TP53-wild-type AML. To determine the role of this activation, we tested efficacy of HIF-1 alpha inhibitor echinomycin in TP53-mutated AML samples in vitro and in vivo. Echinomycin was broadly effective against a panel of primary AML blast cells, with low nanomolar IC(50)s and, based on colony-forming unit assay, was tenfold more effective in eliminating AML stem cells. Echinomycin selectively eliminated CD34(+)CD38(-) AML cells. To test the therapeutic efficacy of echinomycin, we established a xenograft model of TP53-mutated AML. Echinomycin was broadly effective against xenografts from multiple AML samples in vivo, and more effective than cytarabine + daunorubicin chemotherapy. Importantly, while cytarabine + daunorubicin enriched for AML stem cells, echinomycin nearly eliminated this population. Using TP53-mutated AML cell line THP1 and patient-derived AML cells, we tested a new echinomycin formulation with longer half-life and significantly improved therapeutic effect. Our data suggest a novel approach to treat AML with TP53 mutations.	[Wang, Yin; Liu, Yan; Bailey, Christopher; Zhang, Peng; Zheng, Pan; Liu, Yang] Univ Maryland, Sch Med, Dept Surg, Div Immunotherapy,Inst Human Virol, Baltimore, MD 21201 USA; [Wang, Yin; Liu, Yan; Bailey, Christopher; Zhang, Peng; Zheng, Pan; Liu, Yang] Univ Maryland, Sch Med, Ctr Comprehens Canc, Baltimore, MD 21201 USA; [Bailey, Christopher] George Washington Univ, Sch Med, Grad Program Integrated Biomed Res, Washington, DC 20052 USA; [Zhang, Huixia; He, Miao; Sun, Duxin] Univ Michigan, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA; [Parkin, Brian; Malek, Sami N.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Baer, Maria R.] Univ Maryland, Dept Med, Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA; [Zheng, Pan; Liu, Yang] OncoImmune Inc, Rockville, MD 20853 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; George Washington University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University System of Maryland; University of Maryland Baltimore	Wang, Y; Liu, Y (corresponding author), Univ Maryland, Sch Med, Dept Surg, Div Immunotherapy,Inst Human Virol, Baltimore, MD 21201 USA.; Wang, Y; Liu, Y (corresponding author), Univ Maryland, Sch Med, Ctr Comprehens Canc, Baltimore, MD 21201 USA.; Liu, Y (corresponding author), OncoImmune Inc, Rockville, MD 20853 USA.	yin.wang@ihv.umaryland.edu; yaliu@ihv.umaryland.edu	Sun, Duxin/AAA-1774-2022	Zhang, Peng/0000-0002-6218-1885	National Institutes of Health National Cancer Institute [CA171972, CA183030, CA164469]; OncoImmune, Inc.	National Institutes of Health National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OncoImmune, Inc.	This study was supported by grants from the National Institutes of Health National Cancer Institute [CA171972, CA183030 (YL) and CA164469 (YW)] and a grant from OncoImmune, Inc. Some of the studies were performed when the authors were at the Children's National Medical Center in Washington, DC.	Bally C, 2014, LEUKEMIA RES, V38, P751, DOI 10.1016/j.leukres.2014.03.012; Bejar R, 2014, J CLIN ONCOL, V32, P2691, DOI 10.1200/JCO.2013.52.3381; BenYehuda D, 1996, BLOOD, V88, P4296; Birner P, 2001, CLIN CANCER RES, V7, P1661; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Cerqueira BBS, 2015, EUR J PHARM BIOPHARM, V97, P140, DOI 10.1016/j.ejpb.2015.10.007; Cheloni G, 2017, BLOOD, V130, P655, DOI 10.1182/blood-2016-10-745588; CORBAZ R, 1957, HELV CHIM ACTA, V40, P199, DOI 10.1002/hlca.19570400124; Haferlach C, 2008, LEUKEMIA, V22, P1539, DOI 10.1038/leu.2008.143; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hou HA, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.59; Huang J, 2009, J CLIN INVEST, V119, P3519, DOI 10.1172/JCI40572; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; Iyer AK, 2006, DRUG DISCOV TODAY, V11, P812, DOI 10.1016/j.drudis.2006.07.005; Kong DH, 2005, CANCER RES, V65, P9047, DOI 10.1158/0008-5472.CAN-05-1235; Kumar P, 2012, CRIT REV THER DRUG, V29, P355, DOI 10.1615/CritRevTherDrugCarrierSyst.v29.i5.10; Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5; Ok CY, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0139-z; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Parkin B, 2010, BLOOD, V116, P4958, DOI 10.1182/blood-2010-01-266999; Ruckner FG, 2012, BLOOD, V119, P2114, DOI 10.1182/blood-2011-08-375758; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Shih AH, 2013, HAEMATOLOGICA, V98, P908, DOI 10.3324/haematol.2012.076729; Silverman JA, 2013, CANCER CHEMOTH PHARM, V71, P555, DOI 10.1007/s00280-012-2042-4; SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Tyner JW, 2018, NATURE, V562, P526, DOI 10.1038/s41586-018-0623-z; Wang Y, 2014, BLOOD, V124, P1127, DOI 10.1182/blood-2013-12-544221; Wang Y, 2011, CELL STEM CELL, V8, P399, DOI 10.1016/j.stem.2011.02.006; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; Welch JS, 2016, NEW ENGL J MED, V375, P2023, DOI 10.1056/NEJMoa1605949; Zhang HJ, 2012, BLOOD, V119, P2595, DOI 10.1182/blood-2011-10-387381	32	15	16	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	14					3015	3027		10.1038/s41388-020-1201-z	http://dx.doi.org/10.1038/s41388-020-1201-z		FEB 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KZ2VB	32060420	Green Accepted			2022-12-17	WOS:000513384400001
J	Luiken, S; Fraas, A; Bieg, M; Sugiyanto, R; Goeppert, B; Singer, S; Ploeger, C; Warsow, G; Marquardt, JU; Sticht, C; De La Torre, C; Pusch, S; Mehrabi, A; Gretz, N; Schlesner, M; Eils, R; Schirmacher, P; Longerich, T; Roessler, S				Luiken, Sarah; Fraas, Angelika; Bieg, Matthias; Sugiyanto, Raisatun; Goeppert, Benjamin; Singer, Stephan; Ploeger, Carolin; Warsow, Gregor; Marquardt, Jens U.; Sticht, Carsten; De La Torre, Carolina; Pusch, Stefan; Mehrabi, Arianeb; Gretz, Norbert; Schlesner, Matthias; Eils, Roland; Schirmacher, Peter; Longerich, Thomas; Roessler, Stephanie			NOTCH target gene HES5 mediates oncogenic and tumor suppressive functions in hepatocarcinogenesis	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; ORNITHINE-DECARBOXYLASE; MYC; SURVEILLANCE; HEPATOCYTES; MUTATIONS; PATHWAY; ROLES; FATE; SOX2	NOTCH receptor signaling plays a pivotal role in liver homeostasis and hepatocarcinogenesis. However, the role of NOTCH pathway mutations and the NOTCH target gene HES5 in liver tumorigenesis are poorly understood. Here we performed whole-exome sequencing of 54 human HCC specimens and compared the prevalence of NOTCH pathway component mutations with the TCGA-LIHC cohort (N = 364). In addition, we functionally characterized the NOTCH target HES5 and the patient-derived HES5-R31G mutation in vitro and in an orthotopic mouse model applying different oncogenic backgrounds, to dissect the role of HES5 in different tumor subgroups in vivo. We identified nonsynonymous mutations in 14 immediate NOTCH pathway genes affecting 24.1% and 16.8% of HCC patients in the two independent cohorts, respectively. Among these, the HES5-R31G mutation was predicted in silico to have high biological relevance. Functional analyses in cell culture showed that HES5 reduced cell migration and clonogenicity. Further analyses revealed that the patient-derived HES5-R31G mutant protein was non-functional due to loss of DNA binding and greatly reduced nuclear localization. Furthermore, HES5 exhibited a negative feedback loop by directly inhibiting the NOTCH target HES1 and downregulated the pro-proliferative MYC targets ODC1 and LDHA. Interestingly, HES5 inhibited MYC-dependent hepatocarcinogenesis, whereas it promoted AKT-dependent liver tumor formation and stem cell features in a murine model. Thus, NOTCH pathway component mutations are commonly observed in HCC. Furthermore, the NOTCH target gene HES5 has both pro- and anti-tumorigenic functions in liver cancer proposing a driver gene dependency and it promotes tumorigenesis with its interaction partner AKT.	[Luiken, Sarah; Fraas, Angelika; Sugiyanto, Raisatun; Goeppert, Benjamin; Singer, Stephan; Ploeger, Carolin; Schirmacher, Peter; Longerich, Thomas; Roessler, Stephanie] Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany; [Bieg, Matthias; Eils, Roland] Berlin Inst Hlth, Ctr Digital Hlth, Berlin, Germany; [Bieg, Matthias; Eils, Roland] Charite Univ Med Berlin, Berlin, Germany; [Bieg, Matthias; Eils, Roland] Heidelberg Ctr Personalized Oncol DKFZ HIPO, Heidelberg, Germany; [Warsow, Gregor; Schlesner, Matthias] German Canc Res Ctr, Bioinformat & Omics Data Analyt, Heidelberg, Germany; [Marquardt, Jens U.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Med 1, Mainz, Germany; [Sticht, Carsten; De La Torre, Carolina; Gretz, Norbert] Heidelberg Univ, Med Res Ctr, Mannheim, Germany; [Pusch, Stefan] Univ Hosp Heidelberg, Dept Neuropathol, Heidelberg, Germany; [Pusch, Stefan] German Canc Res Ctr, Clin Cooperat Unit Neuropathol, Heidelberg, Germany; [Mehrabi, Arianeb] Univ Hosp Heidelberg, Dept Gen Visceral & Transplantat Surg, Heidelberg, Germany; [Eils, Roland] Univ Hosp Heidelberg, Hlth Data Sci Unit, Heidelberg, Germany; [Eils, Roland] Heidelberg Univ, German Ctr Lung Res DZL, Translat Lung Res Ctr Heidelberg TLRC, Heidelberg, Germany	Ruprecht Karls University Heidelberg; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; German Cancer Research Center (DKFZ); Johannes Gutenberg University of Mainz; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Roessler, S (corresponding author), Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany.	Stephanie.Roessler@med.uni-heidelberg.de	Roessler, Stephanie/J-8432-2019; Goeppert, Benjamin/AAC-2303-2022; Eils, Roland/B-6121-2009	Roessler, Stephanie/0000-0002-5333-5942; Eils, Roland/0000-0002-0034-4036; Fritzsche, Sarah/0000-0003-4621-1391	German Research Foundation (DFG) CRC SFB/TR 209 Liver Cancer; European Union [667273]; HIPO project [H014]; Projekt DEAL	German Research Foundation (DFG) CRC SFB/TR 209 Liver Cancer(German Research Foundation (DFG)); European Union(European Commission); HIPO project; Projekt DEAL	We thank Darjus F. Tschaharganeh (University Hospital Heidelberg) for providing vectors used for hydrodynamic tail vein injection. Tissue samples were provided by the tissue bank of the National Center for Tumor Diseases (NCT; Heidelberg, Germany) in accordance with the regulations of the tissue bank and the approval of the Ethics Committee of Heidelberg University. We thank Veronika Geissler (NCT tissue bank, Heidelberg), the Center for Model System and Comparative Pathology (CMCP) of the Institute of Pathology Heidelberg and Leon Schwab for technical assistance. We thank the Nikon Imaging Center Heidelberg for help with image acquisition and Dr Carlo Beretta from MATH-Clinic (University Heidelberg) for help with Fiji Macro. This work was supported by German Research Foundation (DFG) CRC SFB/TR 209 Liver Cancer (B01 to SR, B04 to SS, B08 to TL and Z01 to PS) and the European Union's Horizon 2020 research and innovation program under grant agreement number 667273 (HEP-CAR) to PS and SR. We thank the Genomics and Proteomics Core Facility (GPCF) of DKFZ for Whole Genome Sequencing and the DKFZ-Heidelberg Center for Personalized Oncology (DKFZ-HIPO) for technical support and funding through HIPO project H014. Open access funding provided by Projekt DEAL.	Abitbol S, 2018, J HEPATOL, V68, P1203, DOI 10.1016/j.jhep.2017.12.018; Ally A, 2017, CELL, V169, P1327, DOI 10.1016/j.cell.2017.05.046; Aster JC, 2017, ANNU REV PATHOL-MECH, V12, P245, DOI 10.1146/annurev-pathol-052016-100127; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Boulter L, 2012, NAT MED, V18, P572, DOI 10.1038/nm.2667; Braccioli L, 2018, STEM CELL RES, V33, P110, DOI 10.1016/j.scr.2018.10.005; Bray SJ, 2016, NAT REV MOL CELL BIO, V17, P722, DOI 10.1038/nrm.2016.94; Calvisi DF, 2011, GASTROENTEROLOGY, V140, P1071, DOI 10.1053/j.gastro.2010.12.006; Chen X, 2014, AM J PATHOL, V184, P912, DOI 10.1016/j.ajpath.2013.12.002; Chen ZZ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12598; Dill MT, 2013, HEPATOLOGY, V57, P1607, DOI 10.1002/hep.26165; Ding L, 2018, CELL, V173, P305, DOI 10.1016/j.cell.2018.03.033; Dugger SA, 2018, NAT REV DRUG DISCOV, V17, P183, DOI 10.1038/nrd.2017.226; Eggert T, 2016, CANCER CELL, V30, P533, DOI 10.1016/j.ccell.2016.09.003; Evert M, 2013, HEPATOLOGY, V58, P1857, DOI 10.1002/hep.26411; Fan B, 2012, J CLIN INVEST, V122, P2911, DOI 10.1172/JCI63212; Fu WY, 2019, CLIN CANCER RES, V25, P2835, DOI 10.1158/1078-0432.CCR-18-2732; Fujimoto A, 2012, NAT GENET, V44, P760, DOI 10.1038/ng.2291; Geisler F, 2015, HEPATOLOGY, V61, P382, DOI 10.1002/hep.27268; Giachino C, 2015, CANCER CELL, V28, P730, DOI 10.1016/j.ccell.2015.10.008; Gramantieri L, 2007, LIVER INT, V27, P997, DOI 10.1111/j.1478-3231.2007.01544.x; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Hoare M, 2016, NAT CELL BIOL, V18, P979, DOI 10.1038/ncb3397; Huang J, 2012, NAT GENET, V44, P1117, DOI 10.1038/ng.2391; Imayoshi I, 2013, SCIENCE, V342, P1203, DOI 10.1126/science.1242366; Jiang WD, 2010, INT J CANCER, V127, P1011, DOI 10.1002/ijc.25118; Kageyama R, 2007, DEVELOPMENT, V134, P1243, DOI 10.1242/dev.000786; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; Kim JW, 2004, MOL CELL BIOL, V24, P5923, DOI 10.1128/MCB.24.13.5923-5936.2004; Kuang SQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061807; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Lachenmayer A, 2012, CLIN CANCER RES, V18, P4997, DOI 10.1158/1078-0432.CCR-11-2322; Le A, 2010, P NATL ACAD SCI USA, V107, P2037, DOI 10.1073/pnas.0914433107; Liu HY, 2015, NAT CELL BIOL, V17, P1036, DOI 10.1038/ncb3210; Liu LM, 2016, HEPATOLOGY, V64, P814, DOI 10.1002/hep.28690; Llovet JM, 2015, NAT REV CLIN ONCOL, V12, P408, DOI [10.1038/nrclinonc.2015.103, 10.1038/nrclinonc.2015.121]; Mittal S, 2013, J CLIN GASTROENTEROL, V47, pS2, DOI 10.1097/MCG.0b013e3182872f29; Morell CM, 2014, J HEPATOL, V60, P885, DOI 10.1016/j.jhep.2013.11.028; Nilsson JA, 2005, CANCER CELL, V7, P433, DOI 10.1016/j.ccr.2005.03.036; Ploeger C, 2016, HEPATOLOGY, V64, P828, DOI 10.1002/hep.28684; Roessler S, 2012, GASTROENTEROLOGY, V142, P957, DOI 10.1053/j.gastro.2011.12.039; Rudin CM, 2012, NAT GENET, V44, P1111, DOI 10.1038/ng.2405; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Sun LC, 2015, ANTI-CANCER AGENT ME, V15, P809, DOI 10.2174/1871520615666150202102809; Totoki Y, 2014, NAT GENET, V46, P1267, DOI 10.1038/ng.3126; Tschaharganeh DF, 2014, CELL, V158, P579, DOI 10.1016/j.cell.2014.05.051; Tschaharganeh DF, 2013, GASTROENTEROLOGY, V144, P1530, DOI 10.1053/j.gastro.2013.02.009; Viatour P, 2011, J EXP MED, V208, P1963, DOI 10.1084/jem.20110198; Villanueva A, 2012, GASTROENTEROLOGY, V143, P1660, DOI 10.1053/j.gastro.2012.09.002; Zender S, 2013, CANCER CELL, V23, P784, DOI 10.1016/j.ccr.2013.04.019; Zhou L, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0073724, 10.1371/journal.pone.0057382]	52	15	15	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	15					3128	3144		10.1038/s41388-020-1198-3	http://dx.doi.org/10.1038/s41388-020-1198-3		FEB 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LB8NS	32055024	hybrid, Green Published			2022-12-17	WOS:000513314100002
J	Chan, YC; Chang, YC; Chuang, HH; Yang, YC; Lin, YF; Huang, MS; Hsiao, M; Yang, CJ; Hua, KT				Chan, Yung-Chieh; Chang, Yu-Chan; Chuang, Hsiang-Hao; Yang, Yi-Chieh; Lin, Yuan-Feng; Huang, Ming-Shyan; Hsiao, Michael; Yang, Chih-Jen; Hua, Kuo-Tai			Overexpression of PSAT1 promotes metastasis of lung adenocarcinoma by suppressing the IRF1-IFN gamma axis	ONCOGENE			English	Article							L-SERINE BIOSYNTHESIS; NEU-LAXOVA SYNDROME; PYRUVATE-KINASE M2; PHOSPHOSERINE AMINOTRANSFERASE; PHOSPHORYLATED PATHWAY; DNA METHYLATION; BREAST; EXPRESSION; DEFICIENCY; CELLS	An increasing number of enzymes involved in serine biosynthesis have been identified and correlated with malignant evolution in various types of cancer. Here we showed that the overexpression of phosphoserine aminotransferase 1 (PSAT1) is widely found in lung cancer tissues compared with nontumor tissues and predicts a poorer prognosis in patients with lung adenocarcinoma. PSAT1 expression was examined in a tissue microarray by immunohistochemistry. The data show that the knockdown of PSAT1 dramatically inhibits the in vitro and in vivo metastatic potential of highly metastatic lung cancer cells; conversely, the enforced expression of exogenous PSAT1 predominantly enhances the metastatic potential of lung cancer cells. Importantly, manipulating PSAT1 expression regulates the in vivo tumor metastatic abilities in lung cancer cells. Adjusting the glucose and glutamine concentrations did not alter the PSAT1-driven cell invasion properties, indicating that this process might not rely on the activation of its enzymatic function. RNA microarray analysis of transcriptional profiling from PSAT1 alternation in CL1-5 and CL1-0 cells demonstrated that interferon regulatory factor 1 (IRF1) acts as a crucial regulator of PSAT1-induced gene expression upon metastatic progression. Decreasing the IRF1-IFIH1 axis compromised the PSAT1-prompted transcriptional reprogramming in cancer cells. Our results identify PSAT1 as a key regulator by a novel PSAT1/IRF1 axis in lung cancer progression, which may serve as a potential biomarker and therapeutic target for the treatment of lung cancer patients.	[Chan, Yung-Chieh] Show Chwan Mem Hosp, Innovat Ctr, Changhua, Taiwan; [Chang, Yu-Chan; Hsiao, Michael] Acad Sinica, Genom Res Ctr, Taipei, Taiwan; [Chuang, Hsiang-Hao; Yang, Chih-Jen] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Kaohsiung, Taiwan; [Yang, Yi-Chieh] Tungs Taichung MetroHarbor Hosp, Dept Med Res, Taichung, Taiwan; [Yang, Yi-Chieh; Lin, Yuan-Feng] Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan; [Huang, Ming-Shyan] E DA Canc Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Kaohsiung, Taiwan; [Huang, Ming-Shyan] I Shou Univ, Sch Med, Kaohsiung, Taiwan; [Hsiao, Michael] Kaohsiung Med Univ, Coll Med, Dept Biochem, Kaohsiung, Taiwan; [Yang, Chih-Jen] Kaohsiung Med Univ, Kaohsiung Municipal Ta Tung Hosp, Dept Internal Med, Kaohsiung, Taiwan; [Hua, Kuo-Tai] Natl Taiwan Univ, Coll Med, Grad Inst Toxicol, Taipei, Taiwan	Show Chwan Memorial Hospital; Academia Sinica - Taiwan; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Tungs' Taichung MetroHarbor Hospital; Taipei Medical University; E-Da Hospital; I Shou University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Municipal Ta-Tung Hospital; National Taiwan University	Yang, CJ (corresponding author), Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Kaohsiung, Taiwan.; Yang, CJ (corresponding author), Kaohsiung Med Univ, Kaohsiung Municipal Ta Tung Hosp, Dept Internal Med, Kaohsiung, Taiwan.; Hua, KT (corresponding author), Natl Taiwan Univ, Coll Med, Grad Inst Toxicol, Taipei, Taiwan.	chjeya@cc.kmu.edu.tw; kthua@ntu.edu.tw	Hsiao, Michael/U-6238-2019; Chuang, Hsiang-Hao/AFR-5829-2022; Chang, Yu-Chan/W-3582-2019; Chan, yung-chieh/E-4091-2012	Hsiao, Michael/0000-0001-8529-9213; Chuang, Hsiang-Hao/0000-0002-3590-5622; Chang, Yu-Chan/0000-0003-0474-9935; Hua, Kuo-Tai/0000-0002-8468-4977	Ministry of Science and Technology [MOST 104-0210-01-09-02, MOST 105-0210-01-13-01, MOST 106-0210-01-15-02, MOST 108-2628-B-002-014]; Academia Sinica	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Academia Sinica(Academia Sinica - Taiwan)	This study is supported by grants from Academia Sinica and Ministry of Science and Technology grants (MOST 104-0210-01-09-02, MOST 105-0210-01-13-01, MOST 106-0210-01-15-02, and MOST 108-2628-B-002-014). We like to thank Miss Tracy Tsai for her assists in immunohistochemistry works. And also like to thank the GRC Instrument Core Facilities for their support for the Affymetrix microarray, IVIS spectrum, and Aperio digital pathology analyses.	Acuna-Hidalgo R, 2014, AM J HUM GENET, V95, P285, DOI 10.1016/j.ajhg.2014.07.012; Anastasiou D, 2011, SCIENCE, V334, P1278, DOI 10.1126/science.1211485; Bachmann SB, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-125; Baek JY, 2003, BIOCHEM J, V373, P191, DOI 10.1042/BJ20030144; Basurko MJ, 1999, IUBMB LIFE, V48, P525, DOI 10.1080/713803557; Bouker KB, 2005, CARCINOGENESIS, V26, P1527, DOI 10.1093/carcin/bgi113; Bu DW, 2013, CANCER EPIDEM BIOMAR, V22, P2212, DOI 10.1158/1055-9965.EPI-13-0208; Chen FF, 2013, ONCOL LETT, V5, P417, DOI 10.3892/ol.2012.1051; Cheng TY, 2018, ONCOGENE, V37, P1730, DOI 10.1038/s41388-017-0086-y; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; De Koning TJ, 2003, BIOCHEM J, V371, P653, DOI 10.1042/BJ20021785; Gromova I, 2015, MOL ONCOL, V9, P1636, DOI 10.1016/j.molonc.2015.05.003; Hanley Matthew P, 2015, Curr Pharmacol Rep, V1, P197; Harrison C, 2012, THER ADV HEMATOL, V3, P341, DOI 10.1177/2040620712459746; Hart CE, 2007, AM J HUM GENET, V80, P931, DOI 10.1086/517888; Hu Y, 2014, APOPTOSIS, V19, P1627, DOI 10.1007/s10495-014-1030-z; Jaeken J, 1996, J INHERIT METAB DIS, V19, P223, DOI 10.1007/BF01799435; KNOX WE, 1969, ARCH BIOCHEM BIOPHYS, V132, P397, DOI 10.1016/0003-9861(69)90381-6; Ksienzyk A, 2012, ONCOIMMUNOLOGY, V1, DOI 10.4161/onci.19405; Ksienzyk A, 2011, CANCER RES, V71, P6410, DOI 10.1158/0008-5472.CAN-11-1565; Kwon JE, 2014, NEOPLASMA, V61, P566, DOI 10.4149/neo_2014_069; LEE YC, 1985, JPN J CLIN ONCOL, V15, P637; Liu JL, 2013, J NEURO-ONCOL, V111, P245, DOI 10.1007/s11060-012-1018-x; Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890; LUND K, 1985, ARCH BIOCHEM BIOPHYS, V237, P186, DOI 10.1016/0003-9861(85)90268-1; Ma B, 2016, SCI REP-UK, V6, DOI 10.1038/srep26299; Ma L, 2013, CELL, V152, P599, DOI 10.1016/j.cell.2012.12.028; Maddocks ODK, 2013, NATURE, V493, P542, DOI 10.1038/nature11743; Martens JWM, 2005, CANCER RES, V65, P4101, DOI 10.1158/0008-5472.CAN-05-0064; Mehrmohamadi M, 2014, CELL REP, V9, P1507, DOI 10.1016/j.celrep.2014.10.026; Mizuno H, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-18; Nilsson R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4128; Noh S, 2014, TUMOR BIOL, V35, P4457, DOI 10.1007/s13277-013-1588-z; Pamment J, 2002, ONCOGENE, V21, P7776, DOI 10.1038/sj.onc.1205981; Pollari S, 2011, BREAST CANCER RES TR, V125, P421, DOI 10.1007/s10549-010-0848-5; Quezada SA, 2014, NAT IMMUNOL, V15, P703, DOI 10.1038/ni.2945; Ranoa DRE, 2016, ONCOTARGET, V7, P26496, DOI 10.18632/oncotarget.8420; Shaheen R, 2014, AM J HUM GENET, V94, P898, DOI 10.1016/j.ajhg.2014.04.015; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Tabatabaie L, 2010, MOL GENET METAB, V99, P256, DOI 10.1016/j.ymgme.2009.10.012; Tisserand J, 2011, J BIOL CHEM, V286, P33369, DOI 10.1074/jbc.M111.225680; Vie N, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-14; Wang N, 2015, MOL CANCER THER, V14, P982, DOI 10.1158/1535-7163.MCT-14-0751; Yang Y, 2015, INT J CANCER, V136, pE39, DOI 10.1002/ijc.29150; Ye JB, 2012, P NATL ACAD SCI USA, V109, P6904, DOI 10.1073/pnas.1204176109; Yin K, 2015, ONCOTARGETS THER, V8, P1069, DOI 10.2147/OTT.S82433; Yu XF, 2016, CANCER RES, V76, P2166, DOI 10.1158/0008-5472.CAN-15-2142; Yuan L, 2015, CANCER LETT, V359, P136, DOI 10.1016/j.canlet.2015.01.003; Zhang WC, 2012, CELL, V148, P259, DOI 10.1016/j.cell.2011.11.050	49	15	17	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	12					2509	2522		10.1038/s41388-020-1160-4	http://dx.doi.org/10.1038/s41388-020-1160-4		JAN 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KW4HU	31988456				2022-12-17	WOS:000509655100005
J	Ouahoud, S; Voorneveld, PW; van der Burg, LRA; de Jonge-Muller, ESM; Schoonderwoerd, MJA; Paauwe, M; de Vos, T; de Wit, S; van Pelt, GW; Mesker, WE; Hawinkels, LJAC; Hardwick, JCH				Ouahoud, Sarah; Voorneveld, Philip W.; van der Burg, Lennart R. A.; de Jonge-Muller, Eveline S. M.; Schoonderwoerd, Mark J. A.; Paauwe, Madelon; de Vos, Thijs; de Wit, Sophie; van Pelt, Gabi W.; Mesker, Wilma E.; Hawinkels, Lukas J. A. C.; Hardwick, James C. H.			Bidirectional tumor/stroma crosstalk promotes metastasis in mesenchymal colorectal cancer	ONCOGENE			English	Article							BONE MORPHOGENETIC PROTEIN; APOPTOSIS-INDUCING LIGAND; TUMOR-STROMA RATIO; CONSENSUS MOLECULAR SUBTYPES; INDEPENDENT PREDICTOR; PANCREATIC-CANCER; POOR-PROGNOSIS; CELLS; SMAD4; SURVIVAL	Patients with the mesenchymal subtype colorectal cancer (CRC) have a poor prognosis, in particular patients with stroma-rich tumors and aberrant SMAD4 expression. We hypothesized that interactions between SMAD4-deficient CRC cells and cancer-associated fibroblasts provide a biological explanation. In transwell invasion assays, fibroblasts increased the invasive capacity of SMAD4-deficient HT29 CRC cells, but not isogenic SMAD4-proficient HT29 cells. A TGF-beta/BMP-specific array showed BMP2 upregulation by fibroblasts upon stimulation with conditioned medium from SMAD4-deficient CRC cells, while also stimulating their invasion. In a mouse model for experimental liver metastasis, the co-injection of fibroblasts increased metastasis formation of SMAD4-deficient CRC cells (p = 0.02) but not that of SMAD4-proficient CRC cells. Significantly less metastases were seen in mice co-injected with BMP2 knocked-down fibroblasts. Fibroblast BMP2 expression seemed to be regulated by TRAIL, a factor overexpressed in SMAD4-deficient CRC cells. In a cohort of 146 stage III CRC patients, we showed that patients with a combination of high stromal BMP2 expression and the loss of tumor SMAD4 expression had a significantly poorer overall survival (HR 2.88, p = 0.04). Our results suggest the existence of a reciprocal loop in which TRAIL from SMAD4-deficient CRC cells induces BMP2 in fibroblasts, which enhances CRC invasiveness and metastasis.	[Ouahoud, Sarah; Voorneveld, Philip W.; van der Burg, Lennart R. A.; de Jonge-Muller, Eveline S. M.; Schoonderwoerd, Mark J. A.; Paauwe, Madelon; de Vos, Thijs; de Wit, Sophie; Hawinkels, Lukas J. A. C.; Hardwick, James C. H.] Leiden Univ, Dept Gastroenterol & Hepatol, Med Ctr, Leiden, Netherlands; [van Pelt, Gabi W.; Mesker, Wilma E.] Leiden Univ, Dept Surg, Med Ctr, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Hardwick, JCH (corresponding author), Leiden Univ, Dept Gastroenterol & Hepatol, Med Ctr, Leiden, Netherlands.	J.C.H.Hardwick@LUMC.nl	Hawinkels, Lukas/Q-5098-2019; Hardwick, James/J-4862-2013	Hawinkels, Lukas/0000-0002-2274-9325; Hardwick, James/0000-0002-9575-5099; Voorneveld, Philip/0000-0002-3881-4435				Alazzouzi H, 2005, CLIN CANCER RES, V11, P2606, DOI 10.1158/1078-0432.CCR-04-1458; Alhopuro P, 2005, CLIN CANCER RES, V11, P6311, DOI 10.1158/1078-0432.CCR-05-0244; Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Chen SX, 2014, J PROTEOMICS, V110, P155, DOI 10.1016/j.jprot.2014.07.031; Cortez VS, 2017, NAT IMMUNOL, V18, P995, DOI 10.1038/ni.3809; Dekker TJA, 2013, BREAST CANCER RES TR, V139, P371, DOI 10.1007/s10549-013-2571-5; Dienstmann R, 2017, NAT REV CANCER, V17, P79, DOI 10.1038/nrc.2016.126; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Hardwick JC, 2008, NAT REV CANCER, V8, P806, DOI 10.1038/nrc2467; Hardwick JCH, 2004, GASTROENTEROLOGY, V126, P111, DOI 10.1053/j.gastro.2003.10.067; Hawinkels LJAC, 2011, GROWTH FACTORS, V29, P140, DOI 10.3109/08977194.2011.595411; Herzer K, 2008, MOL CANCER RES, V6, P1169, DOI 10.1158/1541-7786.MCR-08-0073; Huijbers A, 2013, ANN ONCOL, V24, P179, DOI 10.1093/annonc/mds246; Irshad S, 2017, J PATHOL, V242, P178, DOI 10.1002/path.4891; Jin H, 2012, APPL MICROBIOL BIOT, V93, P1715, DOI 10.1007/s00253-011-3865-3; Jiramongkolchai P, 2016, BIOCHEM SOC T, V44, P1117, DOI 10.1042/BST20160069; Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465; Kang MH, 2011, EXP CELL RES, V317, P1746, DOI 10.1016/j.yexcr.2011.04.006; Karagiannis GS, 2013, MOL ONCOL, V7, P826, DOI 10.1016/j.molonc.2013.04.002; Katsuno Y, 2008, ONCOGENE, V27, P6322, DOI 10.1038/onc.2008.232; Kleeff J, 1999, GASTROENTEROLOGY, V116, P1202, DOI 10.1016/S0016-5085(99)70024-7; Koch PS, 2017, BLOOD, V129, P415, DOI 10.1182/blood-2016-07-729822; Kodach LL, 2008, GASTROENTEROLOGY, V134, P1332, DOI 10.1053/j.gastro.2008.02.059; Kodach LL, 2008, CANCER, V112, P300, DOI 10.1002/cncr.23160; Koornstra JJ, 2003, J PATHOL, V200, P327, DOI 10.1002/path.1364; Lane D, 2004, GYNECOL ONCOL, V93, P594, DOI 10.1016/j.ygyno.2004.03.029; Lee TJ, 2006, BIOCHEM BIOPH RES CO, V351, P1024, DOI 10.1016/j.bbrc.2006.10.163; Lemke J, 2014, CELL DEATH DIFFER, V21, P1350, DOI 10.1038/cdd.2014.81; Liu J, 2014, GYNECOL ONCOL, V132, P81, DOI 10.1016/j.ygyno.2013.11.003; Lv Z, 2015, SURGERY, V158, P142, DOI 10.1016/j.surg.2015.02.013; Mesker WE, 2007, CELL ONCOL, V29, P387; Mesker WE, 2009, CELL ONCOL, V31, P169, DOI 10.3233/CLO-2009-0478; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Paauwe M, 2018, CLIN CANCER RES, V24, P6331, DOI 10.1158/1078-0432.CCR-18-0329; Papageorgis P, 2011, CANCER RES, V71, P998, DOI 10.1158/0008-5472.CAN-09-3269; Song JH, 2007, CANCER RES, V67, P6946, DOI 10.1158/0008-5472.CAN-06-3896; Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492; Voorneveld PW, 2015, BRIT J CANCER, V112, P122, DOI 10.1038/bjc.2014.560; Voorneveld PW, 2013, BRIT J CANCER, V109, P1805, DOI 10.1038/bjc.2013.486; Voorneveld PW, 2014, GASTROENTEROLOGY, V147, P196, DOI 10.1053/j.gastro.2014.03.052; Wakefield LM, 2013, NAT REV CANCER, V13, P328, DOI 10.1038/nrc3500; Wang K, 2012, J THORAC ONCOL, V7, P1457, DOI 10.1097/JTO.0b013e318260dfe8; Wenger T, 2006, CELL DEATH DIFFER, V13, P1740, DOI 10.1038/sj.cdd.4401867; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792	45	15	15	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	12					2453	2466		10.1038/s41388-020-1157-z	http://dx.doi.org/10.1038/s41388-020-1157-z		JAN 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KW4HU	31974473	Green Published			2022-12-17	WOS:000509037000001
J	Dias, MM; Adamoski, D; dos Reis, LM; Ascencao, CFR; de Oliveira, KRS; Mafra, ACP; Bastos, ACD; Quintero, M; Cassago, CD; Ferreira, IM; Fidelis, CHV; Rocco, SA; Bajgelman, MC; Stine, Z; Berindan-Neagoe, I; Calin, GA; Ambrosio, ALB; Dias, SMG				Dias, Marilia M.; Adamoski, Douglas; dos Reis, Larissa M.; Ascencao, Carolline F. R.; de Oliveira, Krishina R. S.; Paschoalini Mafra, Ana Carolina; da Silva Bastos, Alliny Cristiny; Quintero, Melissa; Cassago, Carolina de G.; Ferreira, Igor M.; Fidelis, Carlos H., V; Rocco, Silvana A.; Bajgelman, Marcio Chaim; Stine, Zachary; Berindan-Neagoe, Ioana; Calin, George A.; Berteli Ambrosio, Andre Luis; Gomes Dias, Sandra Martha			GLS2 is protumorigenic in breast cancers	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; ASPARAGINE SYNTHETASE; GLUTAMINE-METABOLISM; GROWTH; ROLES; ACTIVATION; PATHWAY; CELLS; TRANSFORMATION; CONTRIBUTES	Many types of cancers have a well-established dependence on glutamine metabolism to support survival and growth, a process linked to glutaminase 1 (GLS) isoforms. Conversely, GLS2 variants often have tumor-suppressing activity. Triple-negative (TN) breast cancer (testing negative for estrogen, progesterone, and Her2 receptors) has elevated GLS protein levels and reportedly depends on exogenous glutamine and GLS activity for survival. Despite having high GLS levels, we verified that several breast cancer cells (including TN cells) express endogenous GLS2, defying its role as a bona fide tumor suppressor. Moreover, ectopic GLS2 expression rescued cell proliferation, TCA anaplerosis, redox balance, and mitochondrial function after GLS inhibition by the small molecule currently in clinical trials CB-839 or GLS knockdown of GLS-dependent cell lines. In several cell lines, GLS2 knockdown decreased cell proliferation and glutamine-linked metabolic phenotypes. Strikingly, long-term treatment of TN cells with another GLS-exclusive inhibitor bis-2 '-(5-phenylacetamide-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES) selected for a drug-resistant population with increased endogenous GLS2 and restored proliferative capacity. GLS2 was linked to enhanced in vitro cell migration and invasion, mesenchymal markers (through the ERK-ZEB1-vimentin axis under certain conditions) and in vivo lung metastasis. Of concern, GLS2 amplification or overexpression is linked to an overall, disease-free and distant metastasis-free worse survival prognosis in breast cancer. Altogether, these data establish an unforeseen role of GLS2 in sustaining tumor proliferation and underlying metastasis in breast cancer and provide an initial framework for exploring GLS2 as a novel therapeutic target.	[Dias, Marilia M.; Adamoski, Douglas; dos Reis, Larissa M.; Ascencao, Carolline F. R.; de Oliveira, Krishina R. S.; Paschoalini Mafra, Ana Carolina; da Silva Bastos, Alliny Cristiny; Quintero, Melissa; Cassago, Carolina de G.; Ferreira, Igor M.; Rocco, Silvana A.; Bajgelman, Marcio Chaim; Berteli Ambrosio, Andre Luis; Gomes Dias, Sandra Martha] Brazilian Ctr Res Energy & Mat CNPEM, Brazilian Biosci Natl Lab LNBio, BR-13083970 Campinas, SP, Brazil; [Dias, Marilia M.; Adamoski, Douglas; dos Reis, Larissa M.; Ascencao, Carolline F. R.; de Oliveira, Krishina R. S.; Paschoalini Mafra, Ana Carolina; da Silva Bastos, Alliny Cristiny] Univ Estadual Campinas, Grad Program Genet & Mol Biol, Inst Biol, UNICAMP, Campinas, SP, Brazil; [Fidelis, Carlos H., V] Univ Estadual Campinas, Inst Chem, ThoMSon Mass Spectrometry Lab, BR-13083970 Campinas, SP, Brazil; [Stine, Zachary] Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA; [Berindan-Neagoe, Ioana] Univ Med & Pharm Iuliu Hatieganu, Res Ctr Funct Genom Biomed & Translat Med, Cluj Napoca 400337, Romania; [Berindan-Neagoe, Ioana] Univ Med & Pharm Iuliu Hatieganu, MedFuture Res Ctr Adv Med, Cluj Napoca 400349, Romania; [Berindan-Neagoe, Ioana] Oncol Inst Prof Dr Ion Chiricuta, Dept Funct Genom & Expt Pathol, Cluj Napoca 400015, Romania; [Calin, George A.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Unit 1950, Houston, TX 77030 USA; [Calin, George A.] Univ Texas MD Anderson Canc Ctr, Ctr RNA Inference & Noncoding RNAs, 1515 Holcombe Blvd,Unit 1950, Houston, TX 77030 USA; [Berteli Ambrosio, Andre Luis] Univ Sao Paulo, Sao Carlos Inst Phys IFSC, BR-13563120 Sao Carlos, SP, Brazil	Universidade de Sao Paulo; Universidade Estadual de Campinas; Universidade Estadual de Campinas; The Wistar Institute; Iuliu Hatieganu University of Medicine & Pharmacy; Iuliu Hatieganu University of Medicine & Pharmacy; Oncology Institute Prof. Dr. Ion Chiricuta; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Universidade de Sao Paulo	Ambrosio, ALB; Dias, SMG (corresponding author), Brazilian Ctr Res Energy & Mat CNPEM, Brazilian Biosci Natl Lab LNBio, BR-13083970 Campinas, SP, Brazil.; Ambrosio, ALB (corresponding author), Univ Sao Paulo, Sao Carlos Inst Phys IFSC, BR-13563120 Sao Carlos, SP, Brazil.	andre@ifsc.usp.br; sandra.dias@lnbio.cnpem.br	Dias, Marília M/C-3014-2012; Bajgelman, Marcio Chaim/A-8146-2019; Rocco, Silvana Aparecida/Q-3828-2019; Reis, Larissa Menezes dos/T-9867-2019; Ambrosio, Andre/AAB-1178-2020; Escobar, Melissa Quintero/AAN-8999-2021; Rocco, Silvana Aparecida/H-6300-2014; Fidelis, Carlos HV/B-9696-2012; Adamoski, Douglas/J-8570-2014	Bajgelman, Marcio Chaim/0000-0003-3371-1143; Rocco, Silvana Aparecida/0000-0003-4551-3443; Escobar, Melissa Quintero/0000-0002-2645-7418; Rocco, Silvana Aparecida/0000-0003-4551-3443; Adamoski, Douglas/0000-0001-5062-2586; Mafra, Ana Carolina/0000-0002-2547-9033; Menezes dos Reis, Larissa/0000-0003-1597-0176; Dias, Marilia/0000-0003-1415-9023; Calin, George/0000-0001-6704-5615	Sao Paulo State Research Foundation, FAPESP [2012/14298-9, 2014/20673-2, 2014/15968-3, 2015/25832-4, 2013/05668-0, 2013/23510-4, 2012/11577-4, 2014/18061-9, 2014/17820-3, 2016/06625-0, 2014/06512-6, 2011/10127-2, 2012/09452-9]; LNBio; National Institutes of Health (NIH/NCATS) grant through the NIH Common Fund, Office of Strategic Coordination (OSC) [UH3TR00943-01]; NCI [1R01 CA182905-01, 1R01CA222007-01A1]; NIGMS [1R01GM122775-01]; U54 grant UPR/MDACC Partnership for Excellence in Cancer Research 2016 Pilot Project [CA096297/CA096300]; DOD [CA160445P1]; Chronic Lymphocytic Leukemia Moonshot Flagship project; Sister Institution Network Fund (SINF) 2017 grant; Estate of C. G. Johnson, Jr	Sao Paulo State Research Foundation, FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); LNBio; National Institutes of Health (NIH/NCATS) grant through the NIH Common Fund, Office of Strategic Coordination (OSC)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); U54 grant UPR/MDACC Partnership for Excellence in Cancer Research 2016 Pilot Project; DOD(United States Department of Defense); Chronic Lymphocytic Leukemia Moonshot Flagship project; Sister Institution Network Fund (SINF) 2017 grant; Estate of C. G. Johnson, Jr	This work was supported by the Sao Paulo State Research Foundation, FAPESP, under grants 2012/14298-9 (ALBA) and 2014/20673-2 (ALBA), 2014/15968-3 (SMGD), 2015/25832-4 (SMGD) and fellowships 2013/05668-0 (IMF) 2013/23510-4 (CFRA), 2012/11577-4 (MMD), 2014/18061-9 (LMR), 2014/17820-3 (DAM), 2016/06625-0 (ACPM), 2014/06512-6 (KRSO), 2011/10127-2 (CAGC), and 2012/09452-9 (MQE). We thank LNBio for financial support and access to all facilities (PBQT, LCCMI, LPP, LEC, LVV, and LIB). Data used in this publication were generated by the National Cancer Institute Clinical Proteomic Tumor Analysis Consortium (CPTAC). The results published here are in whole or part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/. We thank Dr Alessandra Girasole for expert technical support. GAC is the Felix L. Haas Endowed Professor in Basic Science. Work in GAC's laboratory is supported by National Institutes of Health (NIH/NCATS) grant UH3TR00943-01 through the NIH Common Fund, Office of Strategic Coordination (OSC), the NCI grants 1R01 CA182905-01 and 1R01CA222007-01A1, an NIGMS 1R01GM122775-01 grant, a U54 grant #CA096297/CA096300 UPR/MDACC Partnership for Excellence in Cancer Research 2016 Pilot Project, a Team DOD (CA160445P1) grant, a Chronic Lymphocytic Leukemia Moonshot Flagship project, a Sister Institution Network Fund (SINF) 2017 grant, and the Estate of C. G. Johnson, Jr.	Bastide C, 2002, PROSTATE CANCER P D, V5, P311, DOI 10.1038/sj.pcan.4500606; Billin AN, 2000, MOL CELL BIOL, V20, P8845, DOI 10.1128/MCB.20.23.8845-8854.2000; Cassago A, 2012, P NATL ACAD SCI USA, V109, P1092, DOI 10.1073/pnas.1112495109; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Davis FM, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-76; de Guzzi Cassago CA, 2018, BIOCHEMISTRY-US; Elgadi KM, 1999, PHYSIOL GENOMICS, V1, P51, DOI 10.1152/physiolgenomics.1999.1.2.51; Gameiro PA, 2013, CELL METAB, V17, P372, DOI 10.1016/j.cmet.2013.02.002; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Gross MI, 2014, MOL CANCER THER, V13, P890, DOI 10.1158/1535-7163.MCT-13-0870; Hollestelle A, 2007, MOL CANCER RES, V5, P195, DOI 10.1158/1541-7786.MCR-06-0263; Hu WW, 2010, P NATL ACAD SCI USA, V107, P7455, DOI 10.1073/pnas.1001006107; Jang MH, 2015, HUM PATHOL, V46, P1267, DOI 10.1016/j.humpath.2015.05.010; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Katt WP, 2017, FUTURE MED CHEM, V9, P223, DOI 10.4155/fmc-2016-0190; Kim J, 2016, ONCOTARGET, V7, P85021, DOI 10.18632/oncotarget.13116; Kim RK, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.99; Koh LWH, 2013, ANTIOXID REDOX SIGN, V19, P2261, DOI 10.1089/ars.2012.4999; Kung HN, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002229; Kuo T, 2016, CANC LETT, V383, P1; Lampa M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185092; Lee SY, 2016, ONCOTARGET, V7, P7925, DOI 10.18632/oncotarget.6879; Lee YZ, 2014, ONCOTARGET, V5, P6087, DOI 10.18632/oncotarget.2173; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Liu CY, 2015, ONCOTARGET, V6, P15966, DOI 10.18632/oncotarget.3862; Liu J, 2014, ONCOTARGET, V5, P2635, DOI 10.18632/oncotarget.1862; Liu W, 2012, P NATL ACAD SCI USA, V109, P8983, DOI 10.1073/pnas.1203244109; Lorenzi PL, 2008, MOL CANCER THER, V7, P3123, DOI 10.1158/1535-7163.MCT-08-0589; Martin-Rufian M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038380; McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001; Nitta M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010767; Panosyan EH, 2014, MOL CANCER RES, V12, P694, DOI 10.1158/1541-7786.MCR-13-0576; Pavlova NN, 2018, CELL METAB, V27, P428, DOI 10.1016/j.cmet.2017.12.006; Pieter A, 2012, CANCER BIOL THER, V13, P1185, DOI 10.4161/cbt.21348; Sanchez-Tillo E, 2011, AM J CANCER RES, V1, P897; Seltzer MJ, 2010, CANCER RES, V70, P8981, DOI 10.1158/0008-5472.CAN-10-1666; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Shirakihara T, 2007, MOL BIOL CELL, V18, P3533, DOI 10.1091/mbc.E07-03-0249; Sircar K, 2012, AM J PATHOL, V180, P895, DOI 10.1016/j.ajpath.2011.11.030; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Suzuki S, 2010, P NATL ACAD SCI USA, V107, P7461, DOI 10.1073/pnas.1002459107; Szeliga M, 2015, NEUROCHEM INT, V88, P6, DOI 10.1016/j.neuint.2014.11.004; Timmerman LA, 2013, CANCER CELL, V24, P450, DOI 10.1016/j.ccr.2013.08.020; UBUKA T, 1971, J NATL CANCER I, V46, P291; Wang BG, 2016, ONCOTARGET, V7, P20357, DOI 10.18632/oncotarget.7952; Wang JB, 2010, CANCER CELL, V18, P207, DOI 10.1016/j.ccr.2010.08.009; Wellen KE, 2010, GENE DEV, V24, P2784, DOI 10.1101/gad.1985910; Xiao DB, 2015, ONCOTARGET, V6, P40655, DOI 10.18632/oncotarget.5821; Xu D, 2011, J CELL BIOL, V193, P409, DOI 10.1083/jcb.201010100; Yuneva MO, 2012, CELL METAB, V15, P157, DOI 10.1016/j.cmet.2011.12.015; Zacharias NM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16327-z; Zhang C.J., 2016, BIOENERG OPEN ACCESS, V5, P1	53	15	17	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					690	702		10.1038/s41388-019-1007-z	http://dx.doi.org/10.1038/s41388-019-1007-z			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31541193				2022-12-17	WOS:000509718300015
J	Lin, SC; Lin, CH; Shih, NC; Liu, HL; Wang, WC; Lin, KY; Liu, ZY; Tseng, YJ; Chang, HK; Lin, YC; Yeh, YC; Minato, H; Fujii, T; Wu, YC; Chen, MY; Chou, TY				Lin, Shin-Chih; Lin, Chia-Hung; Shih, Nien-Chu; Liu, Hsin-Ling; Wang, Wen-Chao; Lin, Kun-Yang; Liu, Zih-Yu; Tseng, Yu-Jhen; Chang, Hsueh-Kai; Lin, Yi-Cheng; Yeh, Yi-Chen; Minato, Hiroshi; Fujii, Takeshi; Wu, Yu-Chung; Chen, Mei-Yu; Chou, Teh-Ying			Cellular prion protein transcriptionally regulated by NFIL3 enhances lung cancer cell lamellipodium formation and migration through JNK signaling	ONCOGENE			English	Article							GENE-EXPRESSION; MAP KINASES; RESISTANCE; SURVIVAL; INVASION; COLON; METASTASIS; STATISTICS; APOPTOSIS; FAMILY	Tumor invasion and metastasis are the major causes of treatment failure and mortality in lung cancer patients. In this study, we identified a group of genes with differential expression in in situ and invasive lung adenocarcinoma tissues by expression profiling; among these genes we further characterized the association of the upregulation of PRNP, the gene encoding cellular Prion protein (PrPc), with lung adenocarcinoma invasiveness. Immunohistochemistry on clinical specimens showed an association of PrPc expression with invasive but not in situ lung adenocarcinoma. Consistently, the expression of PrPc was higher in the highly invasive than in the lowly invasive lung adenocarcinoma cell lines. Knockdown of PrPc expression in cultured lung adenocarcinoma cells decreased their lamellipodium formation, in vitro migration and invasion, and in vivo experimental lung metastasis. Phosphorylation of JNKs was found to correlate with PrPc expression and the inhibition of JNKs suppressed the PrPc-induced up-regulation of lamellipodium formation, cell migration, and invasion. Moreover, we identified the nuclear factor, interleukin 3 regulated (NFIL3) protein as a transcriptional activator of the PRNP promoter. Accordingly, NFIL3 promoted lung cancer cell migration and invasion in a PrPc-dependent manner. High NFIL3 expression in clinical specimens of lung adenocarcinoma was also associated with tumor invasiveness. Overall, our observations suggest that the NFIL3/PrPc axis, through regulating lamellipodium formation and cell mobility via JNK signaling, plays a critical role in lung cancer invasiveness and metastasis.	[Lin, Shin-Chih; Chen, Mei-Yu; Chou, Teh-Ying] Natl Yang Ming Univ, Program Mol Med, Taipei 11221, Taiwan; [Lin, Shin-Chih; Chen, Mei-Yu; Chou, Teh-Ying] Acad Sinica, Taipei 11221, Taiwan; [Lin, Shin-Chih; Liu, Hsin-Ling; Lin, Kun-Yang; Chen, Mei-Yu; Chou, Teh-Ying] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 11221, Taiwan; [Lin, Chia-Hung; Lin, Yi-Cheng; Yeh, Yi-Chen; Chou, Teh-Ying] Taipei Vet Gen Hosp, Dept Pathol & Lab Med, Div Mol Pathol, Taipei 11221, Taiwan; [Shih, Nien-Chu; Wang, Wen-Chao; Liu, Zih-Yu; Tseng, Yu-Jhen; Chang, Hsueh-Kai; Chou, Teh-Ying] Natl Yang Ming Univ, Inst Clin Med, Taipei 11221, Taiwan; [Minato, Hiroshi] Kanazawa Med Univ, Dept Pathol & Lab Med, 1-1 Daigaku, Kahoku, Ishikawa 9200293, Japan; [Fujii, Takeshi] Toranomon Gen Hosp, Dept Pathol, Minato Ku, 2-2-2 Toranomon, Tokyo 1058470, Japan; [Wu, Yu-Chung] Taipei Vet Gen Hosp, Dept Surg, Div Thorac Surg, Taipei 11221, Taiwan	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; Kanazawa Medical University; Toranomon Hospital; Taipei Veterans General Hospital	Chen, MY; Chou, TY (corresponding author), Natl Yang Ming Univ, Program Mol Med, Taipei 11221, Taiwan.; Chen, MY; Chou, TY (corresponding author), Acad Sinica, Taipei 11221, Taiwan.; Chen, MY; Chou, TY (corresponding author), Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 11221, Taiwan.; Chou, TY (corresponding author), Taipei Vet Gen Hosp, Dept Pathol & Lab Med, Div Mol Pathol, Taipei 11221, Taiwan.; Chou, TY (corresponding author), Natl Yang Ming Univ, Inst Clin Med, Taipei 11221, Taiwan.	meychen@ym.edu.tw; tychou@vghtpe.gov.tw	Fujii, Takeshi/D-5877-2014	Fujii, Takeshi/0000-0001-7237-1183; CHEN, MEI-YU/0000-0002-5765-9178; Lin, Kun-Yang/0000-0002-6197-3995; Lin, Chia-Hung/0000-0002-1819-7310	Ministry of Science and Technology [102-2320-B-010-005-MY3]; Taipei Veterans General Hospital, Taiwan [VGH94-286, V98C1-102, V99C1-187, V100C-082, V101C-009]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Taipei Veterans General Hospital, Taiwan(Taipei Veterans General Hospital)	This work was supported by grant 102-2320-B-010-005-MY3 from the Ministry of Science and Technology and grants VGH94-286, V98C1-102, V99C1-187, V100C-082 and V101C-009 from Taipei Veterans General Hospital, Taiwan.	Bellingham SA, 2009, J BIOL CHEM, V284, P1291, DOI 10.1074/jbc.M804755200; Bos JL, 2007, CELL, V129, P865, DOI 10.1016/j.cell.2007.05.018; Bounhar Y, 2001, J BIOL CHEM, V276, P39145, DOI 10.1074/jbc.C100443200; Burgess STG, 2009, J BIOL CHEM, V284, P6716, DOI 10.1074/jbc.M807065200; Carulla P, 2011, MOL BIOL CELL, V22, P3041, DOI 10.1091/mbc.E11-04-0321; Chen JJW, 2001, CANCER RES, V61, P5223; Cheng YY, 2014, MOL CARCINOGEN, V53, P686, DOI 10.1002/mc.22021; Chieng CKL, 2015, TUMOR BIOL, V36, P8107, DOI 10.1007/s13277-015-3530-z; Chou TY, 2009, CELL SIGNAL, V21, P704, DOI 10.1016/j.cellsig.2009.01.008; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Cichon AC, 2014, MOL CELL NEUROSCI, V63, P31, DOI 10.1016/j.mcn.2014.09.001; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; Danson CM, 2007, J CELL SCI, V120, P4144, DOI 10.1242/jcs.013714; Dery MA, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3398; Dovas A, 2005, BIOCHEM J, V390, P1, DOI 10.1042/BJ20050104; Du L, 2013, CANCER RES, V73, P2682, DOI 10.1158/0008-5472.CAN-12-3759; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; Gil M, 2016, BIOCHEM BIOPH RES CO, V470, P213, DOI 10.1016/j.bbrc.2016.01.038; Goswami CP, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-970; Herms J, 1999, J NEUROSCI, V19, P8866, DOI 10.1523/JNEUROSCI.19-20-08866.1999; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Ikushima S, 1997, P NATL ACAD SCI USA, V94, P2609, DOI 10.1073/pnas.94.6.2609; Kamizono S, 2009, J EXP MED, V206, P2977, DOI 10.1084/jem.20092176; Keniry M, 2013, GENE DEV, V27, P916, DOI 10.1101/gad.214049.113; Kim HJ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.37; Kuribara R, 1999, MOL CELL BIOL, V19, P2754; Li QQ, 2011, CANCER SCI, V102, P400, DOI 10.1111/j.1349-7006.2010.01811.x; Lin JZ, 2011, PROTEIN SCI, V20, P216, DOI 10.1002/pro.548; Liu T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071896; Lopes MH, 2005, J NEUROSCI, V25, P11330, DOI 10.1523/JNEUROSCI.2313-05.2005; Martins VR, 2002, FEBS LETT, V512, P25, DOI 10.1016/S0014-5793(02)02291-3; Mattei V, 2004, FEBS LETT, V560, P14, DOI 10.1016/S0014-5793(04)00029-8; Mehrpour M, 2010, CANCER LETT, V290, P1, DOI 10.1016/j.canlet.2009.07.009; Misiewicz M, 2013, J BIOL CHEM, V288, P20378, DOI 10.1074/jbc.M113.457242; Morel E, 2004, J BIOL CHEM, V279, P1499, DOI 10.1074/jbc.M308578200; Ohno T, 2007, NUCLEIC ACIDS RES, V35, P648, DOI 10.1093/nar/gkl868; Pan YL, 2006, FASEB J, V20, P1886, DOI 10.1096/fj.06-6138fje; Qi JJ, 2016, GUT, V65, P1690, DOI 10.1136/gutjnl-2014-307900; Santuccione A, 2005, J CELL BIOL, V169, P341, DOI 10.1083/jcb.200409127; Satoh J, 2009, NEUROPATH APPL NEURO, V35, P16, DOI 10.1111/j.1365-2990.2008.00947.x; Seillet C, 2014, J IMMUNOL, V192, P2667, DOI 10.4049/jimmunol.1302605; Shaul YD, 2016, NUCLEIC ACIDS RES, V44, pD560, DOI 10.1093/nar/gkv1337; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Solis GP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070327; Takabayashi T, 2010, J BIOL CHEM, V285, P16155, DOI 10.1074/jbc.M109.081901; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Wang JH, 2011, WORLD J GASTROENTERO, V17, P3986, DOI 10.3748/wjg.v17.i35.3986; Yap YHY, 2012, CELL BIOL INT, V36, P273, DOI 10.1042/CBI20110088; Yap YHY, 2011, CANCER LETT, V306, P111, DOI 10.1016/j.canlet.2011.02.040; ZHANG W, 1995, MOL CELL BIOL, V15, P6055	51	15	16	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					385	398		10.1038/s41388-019-0994-0	http://dx.doi.org/10.1038/s41388-019-0994-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31477838				2022-12-17	WOS:000507766400010
J	McAuley, JR; Bailey, KM; Ekambaram, P; Klei, LR; Kang, H; Hu, D; Freeman, TJ; Concel, VJ; Hubel, NE; Lee, JY; Klei, HB; Cheng, J; Sekar, P; Bridwell, RE; Covic, L; Lucas, PC; McAllister-Lucas, LM				McAuley, J. Randall; Bailey, Kelly M.; Ekambaram, Prasanna; Klei, Linda R.; Kang, Heejae; Hu, Dong; Freeman, Tanner J.; Concel, Vincent J.; Hubel, Nathaniel E.; Lee, Jia-Ying (Lloyd); Klei, Hanna B.; Cheng, Jing; Sekar, Preethiya; Bridwell, Rachel E.; Covic, Lidija; Lucas, Peter C.; McAllister-Lucas, Linda M.			MALT1 is a critical mediator of PAR1-driven NF-kappa B activation and metastasis in multiple tumor types	ONCOGENE			English	Article							BREAST-CANCER; PARACASPASE MALT1; IN-VITRO; THROMBIN; RECEPTOR; PROTEASE; PAR1; OSTEOSARCOMA; TUMORIGENESIS; INFLAMMATION	Protease-activated receptor 1 (PAR1), a thrombin-responsive G protein-coupled receptor (GPCR), is implicated in promoting metastasis in multiple tumor types, including both sarcomas and carcinomas, but the molecular mechanisms responsible remain largely unknown. We previously discovered that PAR1 stimulation in endothelial cells leads to activation of NF-kappa B, mediated by a protein complex comprised of CARMA3, Bc110, and the MALT1 effector protein (CBM complex). Given the strong association between NF-kappa B and metastasis, we hypothesized that this CBM complex could play a critical role in the PAR1-driven metastatic progression of specific solid tumors. In support of our hypothesis, we demonstrate that PAR1 stimulation results in NF-kappa B activation in both osteosarcoma and breast cancer, which is suppressed by siRNA-mediated MALT1 knockdown, suggesting that an intact CBM complex is required for the response in both tumor cell types. We identify several metastasis-associated genes that are upregulated in a MALT1-dependent manner after PAR1 stimulation in cancer cells, including those encoding the matrix remodeling protein, MMP9, and the cytokines, IL-1 beta and IL-8. Further, exogenous expression of PAR1 in MCF7 breast cancer cells confers highly invasive and metastatic behavior which can be blocked by CRISPR/Cas9-mediated MALT1 knockout. Importantly, we find that PAR1 stimulation induces MALT1 protease activity in both osteosarcoma and breast cancer cells, an activity that is mechanistically linked to NF-kappa B activation and potentially other responses associated with aggressive phenotype. Several small molecule MALT1 protease inhibitors have recently been described that could therefore represent promising new therapeutics for the prevention and/or treatment of PAR1-driven tumor metastasis.	[McAuley, J. Randall; Klei, Linda R.; Kang, Heejae; Hu, Dong; Freeman, Tanner J.; Hubel, Nathaniel E.; Lee, Jia-Ying (Lloyd); Lucas, Peter C.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA; [Bailey, Kelly M.; Ekambaram, Prasanna; Concel, Vincent J.; Hubel, Nathaniel E.; Klei, Hanna B.; Cheng, Jing; Sekar, Preethiya; Bridwell, Rachel E.; Lucas, Peter C.; McAllister-Lucas, Linda M.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; [Covic, Lidija] Tufts Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Tufts Medical Center	McAllister-Lucas, LM (corresponding author), Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA.	linda.mcallister@chp.edu	Cheng, Jing/AGR-7527-2022; Nuñez, Gabriel/A-7160-2014	Bailey, Kelly/0000-0003-3925-3243; Lucas, Peter/0000-0003-4880-7172; Lee, Jia-Ying/0000-0001-9012-766X	NIH [5F30CA196095]; Hyundai Scholar's Hope Grant [91499PA]; University of Pittsburgh Medical Scientist Training Program (MSTP) [T32GM008208]; NIH career development award [K12HD052892]; Alex's Lemonade Stand Foundation Young Investigator Award; John G. Rangos Senior Research Scholar Fund; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD052892] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008208] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Hyundai Scholar's Hope Grant; University of Pittsburgh Medical Scientist Training Program (MSTP); NIH career development award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alex's Lemonade Stand Foundation Young Investigator Award; John G. Rangos Senior Research Scholar Fund; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors wish to thank Celia Paris for her support and Katrina O'Halloran, Emily Elliott, Yijen Wu, Amir Borhani, and Nathan Salamacha for their technical assistance. In addition, we thank Dr Ed Prochownik for use of his laboratory equipment. This work was supported by NIH Grant 5F30CA196095 to JRM and a Hyundai Scholar's Hope Grant #91499PA to LMM-L. JRM also received support from The University of Pittsburgh Medical Scientist Training Program (MSTP) T32GM008208. KMB received support from an NIH career development award, K12HD052892, an Alex's Lemonade Stand Foundation Young Investigator Award, and the John G. Rangos Senior Research Scholar Fund.	Afonina IS, 2015, FEBS J, V282, P3286, DOI 10.1111/febs.13325; Bacci G, 2005, ACTA ONCOL, V44, P748, DOI 10.1080/02841860500327503; Bagati A, 2015, JOVE-J VIS EXP, DOI 10.3791/51480; Bardet M, 2018, IMMUNOL CELL BIOL, V96, P81, DOI 10.1111/imcb.1018; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781; Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101; Bohers E, 2015, LEUKEMIA LYMPHOMA, V56, P1213, DOI 10.3109/10428194.2014.941836; Bohers E, 2014, GENE CHROMOSOME CANC, V53, P144, DOI 10.1002/gcc.22126; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; Borensztajn K, 2009, BRIT J HAEMATOL, V145, P548, DOI 10.1111/j.1365-2141.2009.07643.x; Chay CH, 2002, UROLOGY, V60, P760, DOI 10.1016/S0090-4295(02)01969-6; Chen HT, 2010, J CELL PHYSIOL, V223, P737, DOI 10.1002/jcp.22083; Cisowski J, 2011, AM J PATHOL, V179, P513, DOI 10.1016/j.ajpath.2011.03.025; Coornaert B, 2008, NAT IMMUNOL, V9, P263, DOI 10.1038/ni1561; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Dai BY, 2017, BLOOD, V129, P333, DOI 10.1182/blood-2016-05-718775; Delekta PC, 2010, J BIOL CHEM, V285, P41432, DOI 10.1074/jbc.M110.158949; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Ekambaram P, 2018, CANCER RES, V78, P1225, DOI 10.1158/0008-5472.CAN-17-1089; Foley CJ, 2012, J BIOL CHEM, V287, P24330, DOI 10.1074/jbc.M112.356303; Fontan L, 2018, J CLIN INVEST, V128, P4397, DOI 10.1172/JCI99436; Fontan L, 2012, CANCER CELL, V22, P812, DOI 10.1016/j.ccr.2012.11.003; Hailfinger S, 2011, P NATL ACAD SCI USA, V108, P14596, DOI 10.1073/pnas.1105020108; Han N, 2011, ONCOL LETT, V2, P599, DOI 10.3892/ol.2011.291; Hernandez NA, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-47; Hernandez-Rodriguez NA, 2002, INT J BIOL MARKER, V17, P189, DOI 10.1177/172460080201700308; Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Ichikawa J, 2012, CANCER-AM CANCER SOC, V118, P2494, DOI 10.1002/cncr.26518; Jaworski M, 2016, CELL MOL LIFE SCI, V73, P459, DOI 10.1007/s00018-015-2059-z; Justus CR, 2014, JOVE-J VIS EXP, DOI 10.3791/51046; Kelly AD, 2013, GENOME MED, V5, DOI 10.1186/gm406; Lenz G, 2008, SCIENCE, V319, P1676, DOI 10.1126/science.1153629; Liao D, 2015, CLIN CANCER RES, V21, P5349, DOI 10.1158/1078-0432.CCR-15-0198; Lim SM, 2015, J MED CHEM, V58, P8491, DOI 10.1021/acs.jmedchem.5b01415; Lin C, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3081-3; Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23; Ludeman MJ, 2004, J BIOL CHEM, V279, P18592, DOI 10.1074/jbc.M310836200; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; Mahanivong C, 2008, ONCOGENE, V27, P1273, DOI 10.1038/sj.onc.1210746; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; McAllister-Lucas LM, 2007, P NATL ACAD SCI USA, V104, P139, DOI 10.1073/pnas.0601947103; McAllister-Lucas LM, 2010, J BIOL CHEM, V285, P25880, DOI 10.1074/jbc.C110.109421; McAuley JR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01887; Meloni L, 2018, MOLECULES, V23, DOI 10.3390/molecules23123144; Nagel D, 2012, CANCER CELL, V22, P825, DOI 10.1016/j.ccr.2012.11.002; Pagani O, 2010, JNCI-J NATL CANCER I, V102, P456, DOI 10.1093/jnci/djq029; Pires BRB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169622; Queiroz KCS, 2014, INT J CANCER, V135, P2294, DOI 10.1002/ijc.28726; Radjabi AR, 2008, J BIOL CHEM, V283, P2822, DOI 10.1074/jbc.M704855200; Rebeaud F, 2008, NAT IMMUNOL, V9, P272, DOI 10.1038/ni1568; Rehman AO, 2009, INT J ORAL SCI, V1, P105, DOI 10.4248/IJOS.09059; Sano T, 1999, INT J ONCOL, V15, P1197; Shi XL, 2004, MOL CANCER RES, V2, P395; Smith SM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106966; Staal J, 2011, EMBO J, V30, P1742, DOI 10.1038/emboj.2011.85; Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25; Sun XQ, 2010, CANCER METAST REV, V29, P709, DOI 10.1007/s10555-010-9256-x; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Tang QL, 2012, JNCI-J NATL CANCER I, V104, P749, DOI 10.1093/jnci/djs210; Taniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142; Tantivejkul K, 2005, J CELL BIOCHEM, V96, P641, DOI 10.1002/jcb.20533; Toruner M, 2006, J BIOL CHEM, V281, P8686, DOI 10.1074/jbc.M512178200; Villares GJ, 2011, ONCOTARGET, V2, P8; Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016; Xia YF, 2014, CANCER IMMUNOL RES, V2, P823, DOI 10.1158/2326-6066.CIR-14-0112; Yang E, 2016, ONCOGENE, V35, P1529, DOI 10.1038/onc.2015.217; Yuan Ta-Chun, 2004, Clin Prostate Cancer, V3, P189, DOI 10.3816/CGC.2004.n.030; Zhang SL, 2017, PROTEIN CELL, V8, P856, DOI 10.1007/s13238-017-0441-3; Zigler M, 2011, CANCER RES, V71, P6561, DOI 10.1158/0008-5472.CAN-11-1432	71	15	15	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2019	38	49					7384	7398		10.1038/s41388-019-0958-4	http://dx.doi.org/10.1038/s41388-019-0958-4			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JT4BN	31420608				2022-12-17	WOS:000500936600002
J	Secker, KA; Keppeler, H; Duerr-Stoerzer, S; Schmid, H; Schneidawind, D; Hentrich, T; Schulze-Hentrich, JM; Mankel, B; Fend, F; Schneidawind, C				Secker, Kathy-Ann; Keppeler, Hildegard; Duerr-Stoerzer, Silke; Schmid, Hannes; Schneidawind, Dominik; Hentrich, Thomas; Schulze-Hentrich, Julia M.; Mankel, Barbara; Fend, Falko; Schneidawind, Corina			Inhibition of DOT1L and PRMT5 promote synergistic anti-tumor activity in a human MLL leukemia model induced by CRISPR/Cas9	ONCOGENE			English	Article							HEMATOPOIETIC PROGENITOR CELLS; GENE-EXPRESSION PROFILE; ACUTE MYELOID-LEUKEMIA; STEM-CELLS; ARGININE METHYLATION; PROTEIN; TRANSLOCATIONS; MURINE; IDENTIFICATION; MAINTENANCE	MLL rearrangements play a crucial role in leukemogenesis and comprise a poor prognosis. Therefore, new treatment strategies are urgently needed. We used the CRISPR/Cas9 system to generate an innovative leukemia model based on 100% pure MLL-AF4 or -AF9 rearranged cells derived from umbilical cord blood with indefinite growth in cell culture systems. Our model shared phenotypical, morphological and molecular features of patient cells faithfully mimicking the nature of the disease. Thus, it serves as a fundamental basis for pharmacological studies: inhibition of histone methyltransferase disruptor of telomeric silencing 1-like (DOT1L) is one specific therapeutic approach currently tested in clinical trials. However, success was limited by restricted response warranting further investigation of drug combinations. Recently, it has been shown that the inhibition of protein arginine methyltransferase 5 (PRMT5) exhibits anti-tumoral activity against human cell lines and in MLL mouse models. Here, we used DOT1L and PRMT5 inhibitors in our human MLL-rearranged model demonstrating dose-dependent reduced proliferation, impairment of cell cycle, increasing differentiation, apoptosis, downregulation of target genes and sensitization to chemotherapy. Strikingly, the combination of both compounds led to synergistic anti-tumoral effects. Our study provides a strong rationale for novel targeted combination therapies to improve the outcome of MLL-rearranged leukemias.	[Secker, Kathy-Ann; Keppeler, Hildegard; Duerr-Stoerzer, Silke; Schmid, Hannes; Schneidawind, Dominik; Schneidawind, Corina] Univ Hosp Tuebingen, Dept Hematol & Oncol, Tubingen, Germany; [Hentrich, Thomas; Schulze-Hentrich, Julia M.] Univ Tubingen, Inst Med Genet & Appl Genom, Tubingen, Germany; [Mankel, Barbara; Fend, Falko] Univ Tubingen, Inst Pathol & Neuropathol, Tubingen, Germany; [Mankel, Barbara; Fend, Falko] Univ Hosp Tuebingen, Ctr Comprehens Canc, Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Schneidawind, C (corresponding author), Univ Hosp Tuebingen, Dept Hematol & Oncol, Tubingen, Germany.	corina.schneidawind@med.uni-tuebingen.de	Schulze-Hentrich, Julia M./C-1830-2017; Schneidawind, Dominik/AAR-4509-2020; Hentrich, Thomas/N-9336-2019	Schulze-Hentrich, Julia M./0000-0002-9242-2096; Hentrich, Thomas/0000-0002-1488-9096; Fend, Falko/0000-0002-5496-293X	Junior Research Group Grant of the Interdisciplinary Centre for Clinical Research (IZKF) [2383-0-0, 2386-0-0, 2316-0-0]; Wuerttembergischer Krebspreis; Clinician Scientist Program of the Faculty of Medicine Tuebingen; Max Eder Junior Research Group Grant from the Deutsche Krebshilfe; American Society for Blood and Marrow Transplantation (ASBMT); Margarete-von-Wrangell fellowship through the Ministry of Science, Research and the Arts Baden-Wuerttemberg; decipherPD transnational consortium on Epigenomics of Complex Diseases (BMBF) [01KU1503]	Junior Research Group Grant of the Interdisciplinary Centre for Clinical Research (IZKF); Wuerttembergischer Krebspreis; Clinician Scientist Program of the Faculty of Medicine Tuebingen; Max Eder Junior Research Group Grant from the Deutsche Krebshilfe; American Society for Blood and Marrow Transplantation (ASBMT); Margarete-von-Wrangell fellowship through the Ministry of Science, Research and the Arts Baden-Wuerttemberg; decipherPD transnational consortium on Epigenomics of Complex Diseases (BMBF)(Federal Ministry of Education & Research (BMBF))	We thank the Flow Cytometry Core Facility Berg of the University Hospital Tuebingen for their excellent technical support. Likewise, we would like to thank the Department of Obstetrics and Gynecology of the University Hospital Tuebingen for providing human cord blood, and the core facility c.ATG of the University Hospital Tuebingen for preparing the RNA-seq libraries, sequencing the samples and data quality control. Furthermore, we thank Dr. Johan Jeong for his technical support in the analysis of the RNA-seq data. CS was supported by a Junior Research Group Grant of the Interdisciplinary Centre for Clinical Research (IZKF, 2383-0-0), the Wuerttembergischer Krebspreis and the Clinician Scientist Program of the Faculty of Medicine Tuebingen. DS was supported by a Max Eder Junior Research Group Grant from the Deutsche Krebshilfe, a New Investigator Award of the American Society for Blood and Marrow Transplantation (ASBMT), a Junior Research Group Grant of the Interdisciplinary Centre for Clinical Research (IZKF, 2316-0-0) and the Clinician Scientist Program of the Faculty of Medicine Tuebingen. JMSH was supported by a Margarete-von-Wrangell fellowship through the Ministry of Science, Research and the Arts Baden-Wuerttemberg, a Junior Research Group Grant of the Interdisciplinary Centre for Clinical Research (IZKF, 2386-0-0) and, together with TH, received funding from the decipherPD transnational consortium on Epigenomics of Complex Diseases (BMBF grant number 01KU1503).	Andersson AK, 2015, NAT GENET, V47, P330, DOI 10.1038/ng.3230; Andrews S., 2010, FASTQC QUALITY CONTR; Aoki Y, 2015, BLOOD, V125, P967, DOI 10.1182/blood-2014-03-563304; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Baer MR, 1998, LEUKEMIA, V12, P317, DOI 10.1038/sj.leu.2400933; Barabe F, 2007, SCIENCE, V316, P600, DOI 10.1126/science.1139851; Bouchlaka MN, 2013, J EXP MED, V210, P2223, DOI 10.1084/jem.20131219; Breese EH, 2013, BLOOD, V122, P3722; Breese EH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136644; Brinkmann KO, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13938; Buechele C, 2015, BLOOD, V126, P1683, DOI 10.1182/blood-2015-05-646398; Bueno C, 2012, CELL RES, V22, P986, DOI 10.1038/cr.2012.4; Bursen A, 2010, BLOOD, V115, P3570, DOI 10.1182/blood-2009-06-229542; Chen W, 2008, CANCER CELL, V13, P432, DOI 10.1016/j.ccr.2008.03.005; Chen W, 2011, BLOOD, V117, P3474, DOI 10.1182/blood-2010-11-317529; Choi PS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4728; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Daigle SR, 2013, BLOOD, V122, P1017, DOI 10.1182/blood-2013-04-497644; Daigle SR, 2011, CANCER CELL, V20, P53, DOI 10.1016/j.ccr.2011.06.009; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Gundry MC, 2016, CELL REP, V17, P1453, DOI 10.1016/j.celrep.2016.09.092; Jansson M, 2008, NAT CELL BIOL, V10, P1431, DOI 10.1038/ncb1802; Kaushik S, 2018, LEUKEMIA, V32, P499, DOI 10.1038/leu.2017.206; Kerbel RS, 2003, CANCER BIOL THER, V2, pS134; Krivtsov AV, 2008, CANCER CELL, V14, P355, DOI 10.1016/j.ccr.2008.10.001; Langer T, 2003, GENE CHROMOSOME CANC, V36, P393, DOI 10.1002/gcc.10167; Lavallee VP, 2015, NAT GENET, V47, P1030, DOI 10.1038/ng.3371; Leek JT, 2012, BIOINFORMATICS, V28, P882, DOI 10.1093/bioinformatics/bts034; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lin S, 2016, CANCER CELL, V30, P737, DOI 10.1016/j.ccell.2016.10.008; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Meyer C, 2018, LEUKEMIA, V32, P273, DOI 10.1038/leu.2017.213; Meyer C, 2013, LEUKEMIA, V27, P2165, DOI 10.1038/leu.2013.135; Mongiardi MP, 2015, SCI REP-UK, V5, DOI 10.1038/srep15494; Montes R, 2011, BLOOD, V117, P4746, DOI 10.1182/blood-2010-12-322230; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Moreno-Mateos MA, 2015, NAT METHODS, V12, P982, DOI [10.1038/NMETH.3543, 10.1038/nmeth.3543]; Moriya K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037892; Mullighan CG, 2007, LEUKEMIA, V21, P2000, DOI 10.1038/sj.leu.2404808; Muntean AG, 2012, ANNU REV PATHOL-MECH, V7, P283, DOI 10.1146/annurev-pathol-011811-132434; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Piganeau M, 2013, GENOME RES, V23, P1182, DOI 10.1101/gr.147314.112; Reichel M, 2001, ONCOGENE, V20, P2900, DOI 10.1038/sj.onc.1204401; Reimer J, 2017, HAEMATOLOGICA, V102, P1558, DOI 10.3324/haematol.2017.164046; Schneidawind C, 2018, BLOOD ADV, V2, P832, DOI 10.1182/bloodadvances.2017013748; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Serio J, 2018, ONCOGENE, V37, P450, DOI 10.1038/onc.2017.337; Shi JW, 2015, NAT BIOTECHNOL, V33, P661, DOI 10.1038/nbt.3235; Slany RK, 2009, HAEMATOL-HEMATOL J, V94, P984, DOI 10.3324/haematol.2008.002436; Somervaille TCP, 2006, CANCER CELL, V10, P257, DOI 10.1016/j.ccr.2006.08.020; Somervaille TCP, 2009, CELL STEM CELL, V4, P129, DOI 10.1016/j.stem.2008.11.015; Srinivasan K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11295; Stam RW, 2010, BLOOD, V115, P2835, DOI 10.1182/blood-2009-07-233049; Stein EM, 2018, BLOOD, V131, P2661, DOI 10.1182/blood-2017-12-818948; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Torres R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4964; Wei J, 2008, CANCER CELL, V13, P483, DOI 10.1016/j.ccr.2008.04.020; Yang YZ, 2013, NAT REV CANCER, V13, P37, DOI 10.1038/nrc3409; Zhang BL, 2015, ONCOTARGET, V6, P22799, DOI 10.18632/oncotarget.4332	59	15	17	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2019	38	46					7181	7195		10.1038/s41388-019-0937-9	http://dx.doi.org/10.1038/s41388-019-0937-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JN5HX	31417187				2022-12-17	WOS:000496930500005
J	Thakur, VS; Aguila, B; Brett-Morris, A; Creighton, CJ; Welford, SM				Thakur, Vijay S.; Aguila, Brittany; Brett-Morris, Adina; Creighton, Chad J.; Welford, Scott M.			Spermidine/spermine N1-acetyltransferase 1 is a gene-specific transcriptional regulator that drives brain tumor aggressiveness	ONCOGENE			English	Article							CELL-MIGRATION; PROLIFERATION; GLIOBLASTOMA; EXPRESSION; BINDING; GROWTH	Spermidine/spermine N1-acetyltransferase 1 (SAT1), the rate-limiting enzyme in polyamine catabolism, has broad regulatory roles due to near ubiquitous polyamine binding. We describe a novel function of SAT1 as a gene-specific transcriptional regulator through local polyamine acetylation. SAT1 expression is elevated in aggressive brain tumors and promotes resistance to radiotherapy. Expression profiling in glioma cells identified SAT1 target genes that distinguish high-and low-grade tumors, in support of the prognostic utility of SAT1 expression. We further discovered mechanisms of SAT1-driven tumor aggressiveness through promotion of expression of both DNA damage response pathways as well as cell cycle regulatory genes. Mechanistically, SAT1 associates specifically with the promoter of the MELK gene, which functionally controls other SAT1 targets, and leads biologically to maintenance of neurosphere stemness in conjunction with FOXM1 and EZH2. CRISPR knockin mutants demonstrate the essentiality of the polyamine acetyltransferase activity of SAT1 for its function as a transcriptional regulator. Together, the data demonstrate that gene-specific polyamine removal is a major transcriptional regulatory mechanism active in high-grade gliomas that drives poor outcomes.	[Thakur, Vijay S.; Welford, Scott M.] Univ Miami, Miller Sch Med, Dept Radiat Oncol, Miami, FL 33136 USA; [Aguila, Brittany] Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; [Brett-Morris, Adina] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; [Creighton, Chad J.] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA; [Creighton, Chad J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Welford, Scott M.] Univ Miami, Sylvester Comprehens Canc Ctr, Miller Sch Med, Miami, FL 33136 USA	University of Miami; Case Western Reserve University; Case Western Reserve University; Baylor College of Medicine; Baylor College of Medicine; University of Miami	Welford, SM (corresponding author), Univ Miami, Miller Sch Med, Dept Radiat Oncol, Miami, FL 33136 USA.; Welford, SM (corresponding author), Univ Miami, Sylvester Comprehens Canc Ctr, Miller Sch Med, Miami, FL 33136 USA.	scott.welford@med.miami.edu			 [P30CA125123];  [R01CA187053]; NATIONAL CANCER INSTITUTE [P30CA125123, R01CA187053] Funding Source: NIH RePORTER	; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by P30CA125123 (CJC); and R01CA187053 (SMW).	Baek JH, 2007, J BIOL CHEM, V282, P33358, DOI 10.1074/jbc.M705627200; Brett-Morris A, 2014, CANCER RES, V74, P6925, DOI 10.1158/0008-5472.CAN-14-1249; Ceccarelli M, 2016, CELL, V164, P550, DOI 10.1016/j.cell.2015.12.028; Chen X, 2013, MOL CELL BIOL, V33, P227, DOI 10.1128/MCB.00881-12; Coleman CS, 1996, BIOCHEM J, V316, P697, DOI 10.1042/bj3160697; Dehart GW, 2008, P NATL ACAD SCI USA, V105, P7188, DOI 10.1073/pnas.0708044105; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Holst CM, 2008, CELL BIOL INT, V32, P39, DOI 10.1016/j.cellbi.2007.08.008; Huang L, 2017, BIOCHEM BIOPH RES CO, V490, P707, DOI 10.1016/j.bbrc.2017.06.105; Joshi K, 2013, STEM CELLS, V31, P1051, DOI 10.1002/stem.1358; Kim SH, 2015, STEM CELL REP, V4, P226, DOI 10.1016/j.stemcr.2014.12.006; Krieg AJ, 2006, MOL CELL BIOL, V26, P7030, DOI 10.1128/MCB.00322-06; Lee SB, 2011, BIOCHEM J, V433, P205, DOI 10.1042/BJ20101322; Pegg AE, 2008, AM J PHYSIOL-ENDOC M, V294, pE995, DOI 10.1152/ajpendo.90217.2008; Pegg AE, 2011, METHODS MOL BIOL, V720, P3, DOI 10.1007/978-1-61779-034-8_1; Santos JS, 2010, DEV DYNAM, V239, P1010, DOI 10.1002/dvdy.22228; Sharma V, 2017, CARCINOGENESIS, V38, P152, DOI 10.1093/carcin/bgw126; Takeuchi H, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006441; Uemura T, 2008, J BIOL CHEM, V283, P26428, DOI 10.1074/jbc.M804714200; Veeravalli KK, 2012, CELL SIGNAL, V24, P272, DOI 10.1016/j.cellsig.2011.09.011; Wang J, 2017, J CLIN INVEST, V127, P3075, DOI 10.1172/JCI89092; Yoo J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11045	22	15	15	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2019	38	41					6794	6800		10.1038/s41388-019-0917-0	http://dx.doi.org/10.1038/s41388-019-0917-0			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JC8UZ	31399646	Green Accepted			2022-12-17	WOS:000489552900007
J	Kleinschmidt, EG; Miller, NLG; Ozmadenci, D; Tancioni, I; Osterman, CD; Barrie, AM; Taylor, KN; Ye, A; Jiang, SL; Connolly, DC; Stupack, DG; Schlaepfer, DD				Kleinschmidt, Elizabeth G.; Miller, Nichol L. G.; Ozmadenci, Duygu; Tancioni, Isabelle; Osterman, Carlos Diaz; Barrie, Allison M.; Taylor, Kristin N.; Ye, Aaron; Jiang, Shulin; Connolly, Denise C.; Stupack, Dwayne G.; Schlaepfer, David D.			Rgnef promotes ovarian tumor progression and confers protection from oxidative stress	ONCOGENE			English	Article							NUCLEOTIDE EXCHANGE FACTOR; SET ENRICHMENT ANALYSIS; NF-KAPPA-B; ADHESION; CELL; EXPRESSION; P190RHOGEF; GENE; ANTIOXIDANT	Ovarian cancer is the fifth-leading cause of cancer death among women. The dissemination of ovarian tumors and growth as spheroids accompanies late-stage disease. In cell culture, ovarian tumor cell spheroids can exhibit elevated resistance to environmental stressors, such as reactive oxygen species. Homeostatic balance of the antioxidant response is a protective mechanism that prevents anoikis, a form of programmed cell death. Signaling pathways activated by integrin receptors suppress anoikis. Rgnef (ARHGEF28/p190RhoGEF) is a guanine nucleotide exchange factor that is activated downstream of integrins. We find that Rgnef protein levels are elevated in late-stage serous ovarian cancer, high Rgnef mRNA levels are associated with decreased progression-free and overall survival, and genomic ARHGEF28 loss is associated with increased patient survival. Using transgenic and transplantable Rgnef knockout mouse models, we find that Rgnef is essential for supporting three-dimensional ovarian spheroid formation in vitro and tumor growth in mice. Using RNA-sequencing and bioinformatic analyses, we identify a conserved Rgnef-supported anti-oxidant gene signature including Gpx4, Nqo1, and Gsta4; common targets of the NF-kB transcription factor. Antioxidant treatment enhanced growth of Rgnef-knockout spheroids and Rgnef re-expression facilitated NF-kappa B-dependent tumorsphere survival. These studies reveal a new role for Rgnef in ovarian cancer to facilitate NF-kappa B-mediated gene expression protecting cells from oxidative stress.	[Kleinschmidt, Elizabeth G.; Miller, Nichol L. G.; Ozmadenci, Duygu; Tancioni, Isabelle; Osterman, Carlos Diaz; Barrie, Allison M.; Taylor, Kristin N.; Ye, Aaron; Jiang, Shulin; Stupack, Dwayne G.; Schlaepfer, David D.] UC San Diego Hlth, Dept Obstet Gynecol & Reprod Sci, Moores Canc Ctr, La Jolla, CA 92093 USA; [Kleinschmidt, Elizabeth G.] UC San Diego Hlth, Biomed Sci Grad Program, La Jolla, CA 92093 USA; [Connolly, Denise C.] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Miller, Nichol L. G.] Pfizer Inc, La Jolla, CA 92121 USA	Fox Chase Cancer Center; Pfizer	Schlaepfer, DD (corresponding author), UC San Diego Hlth, Dept Obstet Gynecol & Reprod Sci, Moores Canc Ctr, La Jolla, CA 92093 USA.	dschlaepfer@ucsd.edu		Diaz Osterman, Carlos/0000-0002-7003-1115	NIH [RO1CA107263, T32-CA121938]; Gaines Family fellowship; NCI [P30 CA006927, CA195723]; DOD [W81XWH-16-1-0142]; UCSD Cancer Center Support grant [P30CA023100]; UCSD Altman Clinical and Translational Research grant [NIH UL1TR001442];  [RO1CA180769];  [RO1CA102310]; NATIONAL CANCER INSTITUTE [P30CA006927, P30CA023100, T32CA121938, R01CA180769, R01CA102310] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001442] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Gaines Family fellowship; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD(United States Department of Defense); UCSD Cancer Center Support grant; UCSD Altman Clinical and Translational Research grant; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Supported by grants RO1CA180769, RO1CA102310, and UCSD Cancer Center Support grant P30CA023100, from UCSD Altman Clinical and Translational Research grant NIH UL1TR001442, and from charitable donations from Nine Girls Ask. DGS was supported by NIH RO1CA107263. KNT and AMB are fellows of the UCSD Reproductive Medicine Gynecologic Oncology Program and were supported by the Gaines Family fellowship. CDO was supported by NIH training grant (T32-CA121938). DCC was supported by NCI P30 CA006927, NCI CA195723, DOD W81XWH-16-1-0142 and charitable donations from The Roberta Dubrow Fund.	Al Habyan S, 2018, ONCOGENE, V37, P5127, DOI 10.1038/s41388-018-0317-x; Anders Simon, 2010, Genome Biol, V11, pR106, DOI 10.1186/gb-2010-11-10-r106; Baccam M, 2003, J IMMUNOL, V170, P3099, DOI 10.4049/jimmunol.170.6.3099; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cheung K, 2017, MOL CELL NEUROSCI, V82, P88, DOI 10.1016/j.mcn.2017.05.003; Connolly DC, 2003, CANCER RES, V63, P1389; de la Vega MR, 2018, CANCER CELL, V34, P21, DOI 10.1016/j.ccell.2018.03.022; Diviani D, 2016, CELL CHEM BIOL, V23, P1135, DOI 10.1016/j.chembiol.2016.07.015; Gabbasov R, 2018, ONCOGENE, V37, P4854, DOI 10.1038/s41388-018-0296-y; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Harris IS, 2015, CANCER CELL, V27, P211, DOI 10.1016/j.ccell.2014.11.019; Hellner K, 2016, EBIOMEDICINE, V10, P137, DOI 10.1016/j.ebiom.2016.06.048; Kenny HA, 2009, CANCER TREAT RES, V149, P335, DOI 10.1007/978-0-387-98094-2_16; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Konstantinopoulos PA, 2009, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-59; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Lachmann A, 2010, BIOINFORMATICS, V26, P2438, DOI 10.1093/bioinformatics/btq466; Lanczky A, 2016, BREAST CANCER RES TR, V160, P439, DOI 10.1007/s10549-016-4013-7; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Lee JR, 2003, J IMMUNOL, V170, P19, DOI 10.4049/jimmunol.170.1.19; Lim Y, 2008, J CELL BIOL, V180, P187, DOI 10.1083/jcb.200708194; Masia-Balague M, 2015, J BIOL CHEM, V290, P15197, DOI 10.1074/jbc.M114.628164; Michael J Morgan, 2011, Cell Research, V21, P103; Miller NLG, 2014, CURR MOL MED, V14, P221, DOI 10.2174/1566524014666140128110339; Miller NLG, 2013, J CELL SCI, V126, P5074, DOI 10.1242/jcs.135509; Miller NLG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037830; Quinn BA, 2010, J OVARIAN RES, V3, DOI 10.1186/1757-2215-3-24; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Reddig PJ, 2005, CANCER METAST REV, V24, P425, DOI 10.1007/s10555-005-5134-3; Roy L, 2018, CANCERS, V10, DOI 10.3390/cancers10080241; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Shield K, 2009, GYNECOL ONCOL, V113, P143, DOI 10.1016/j.ygyno.2008.11.032; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tancioni I, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0551-x; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; van der Wijst MGP, 2014, BBA-REV CANCER, V1846, P494, DOI 10.1016/j.bbcan.2014.09.004; Ward KK, 2013, CLIN EXP METASTAS, V30, P579, DOI 10.1007/s10585-012-9562-5; Wu JH, 2003, MOL BRAIN RES, V117, P27, DOI 10.1016/S0169-328X(03)00263-8; Yu HG, 2011, CANCER RES, V71, P360, DOI 10.1158/0008-5472.CAN-10-2894; Zhang H, 2016, CELL, V166, P755, DOI 10.1016/j.cell.2016.05.069	47	15	15	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2019	38	36					6323	6337		10.1038/s41388-019-0881-8	http://dx.doi.org/10.1038/s41388-019-0881-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IX6EX	31308489	Green Accepted, Green Submitted			2022-12-17	WOS:000485776800001
J	Ohsug, T; Yamaguchi, K; Zhu, C; Ikenoue, T; Takane, K; Shinozaki, M; Tsurita, G; Yano, H; Furukawa, Y				Ohsug, Tomoyuki; Yamaguchi, Kiyoshi; Zhu, Chi; Ikenoue, Tsuneo; Takane, Kiyoko; Shinozaki, Masaru; Tsurita, Giichiro; Yano, Hideaki; Furukawa, Yoichi			Anti-apoptotic effect by the suppression of IRF1 as a downstream of Wnt/beta-catenin signaling in colorectal cancer cells	ONCOGENE			English	Article							REGULATORY FACTOR-I; TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR; INTERFERON-GAMMA; GROWTH-FACTOR; STEM-CELLS; GENE; UBIQUITINATION; EXPRESSION; COLON	Impaired Wnt signaling pathway plays a crucial role in the development of colorectal cancer through activation of the beta-catenin/TCF7L2 complex. Although genes upregulated by Wnt/beta-catenin signaling have been intensively studied, the roles of downregulated genes are poorly understood. Previously, we reported that interferon-induced proteins with tetratricopeptide repeats 2 (IFIT2) was downregulated by the Wnt/beta-catenin signaling, and that the suppressed expression of IFIT2 conferred antiapoptotic property to colorectal cancer (CRC) cells. However, the mechanisms underlying how Wnt/beta-catenin signaling regulates IFIT2 remain to be elucidated. In this study, we have uncovered that the expression of IFIT2 is induced by IRF1, which is negatively regulated by the Wnt/beta-catenin signaling. In addition, we found that downregulation of IRF1 is mediated by its degradation through the ubiquitination-proteasome pathway, and that decreased activity of a deubiquitinase complex containing USP1 and UAF1 is involved in the degradation of IRF1 by Wnt/beta-catenin signaling. These data should provide better understanding of the Wnt signaling pathway and human carcinogenesis.	[Ohsug, Tomoyuki; Yamaguchi, Kiyoshi; Zhu, Chi; Ikenoue, Tsuneo; Takane, Kiyoko; Furukawa, Yoichi] Univ Tokyo, Adv Clin Res Ctr, Inst Med Sci, Div Clin Genome Res, Tokyo 1088639, Japan; [Shinozaki, Masaru; Tsurita, Giichiro] Univ Tokyo, IMSUT Hosp, Inst Med Sci, Dept Surg, Tokyo 1088639, Japan; [Yano, Hideaki] Natl Ctr Global Hlth & Med, Dept Surg, Ctr Hosp, Tokyo 1628655, Japan	University of Tokyo; University of Tokyo; National Center for Global Health & Medicine - Japan	Furukawa, Y (corresponding author), Univ Tokyo, Adv Clin Res Ctr, Inst Med Sci, Div Clin Genome Res, Tokyo 1088639, Japan.	furukawa@ims.u-tokyo.ac.jp		ZHU, CHI/0000-0001-9529-7000	JSPS KAKENHI [JP17H03575]; Sasakawa Scientific Research Grant from the Japan Science Society [29-435]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Sasakawa Scientific Research Grant from the Japan Science Society	This work was supported in part by JSPS KAKENHI Grant numbers JP17H03575 (Y. F.) and the Sasakawa Scientific Research Grant (Grant numbers 29-435, T. O.) from the Japan Science Society.	[Anonymous], 2017, J EXP MED, V214, P3553; Au J Sancea, 2000, ONCOGENE, V19, P3372; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; Breuhahn K, 2006, ONCOGENE, V25, P3787, DOI 10.1038/sj.onc.1209556; Chen JJ, 2011, CHEM BIOL, V18, P1390, DOI 10.1016/j.chembiol.2011.08.014; Clarke N, 2004, EMBO J, V23, P3051, DOI 10.1038/sj.emboj.7600302; Cohn MA, 2007, MOL CELL, V28, P786, DOI 10.1016/j.molcel.2007.09.031; Cohn MA, 2009, J BIOL CHEM, V284, P5343, DOI 10.1074/jbc.M808430200; Connett JM, 2005, J INTERF CYTOK RES, V25, P587, DOI 10.1089/jir.2005.25.587; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Gao J, 2010, CELL DEATH DIFFER, V17, P699, DOI 10.1038/cdd.2009.156; Giatromanolaki A, 2004, CYTOKINE, V26, P164, DOI 10.1016/j.cyto.2004.03.001; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; HARADA H, 1994, ONCOGENE, V9, P3313; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; Hoeller D, 2009, NATURE, V458, P438, DOI 10.1038/nature07960; Huang TT, 2006, NAT CELL BIOL, V8, P339, DOI 10.1038/ncb1378; Kano A, 1999, BIOCHEM BIOPH RES CO, V257, P672, DOI 10.1006/bbrc.1999.0276; Kim EJ, 2002, J CELL BIOCHEM, V85, P369, DOI 10.1002/jcb.10142; Kim JH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081604; Kim PKM, 2004, ONCOGENE, V23, P1125, DOI 10.1038/sj.onc.1207023; Kroger A, 2003, ONCOGENE, V22, P1045, DOI 10.1038/sj.onc.1206260; Landre V, 2013, BIOCHEM J, V449, P707, DOI 10.1042/BJ20121076; Lebwohl D, 1998, EUR J CANCER, V34, P1522, DOI 10.1016/S0959-8049(98)00224-X; Lecona E, 2016, NAT STRUCT MOL BIOL, V23, P270, DOI 10.1038/nsmb.3185; Lee KY, 2010, J BIOL CHEM, V285, P10362, DOI 10.1074/jbc.M109.092544; Li X, 2013, ONCOGENE, V32, P471, DOI 10.1038/onc.2012.66; Liang FS, 2016, CELL REP, V15, P2118, DOI 10.1016/j.celrep.2016.05.007; Lien WH, 2014, GENE DEV, V28, P1517, DOI 10.1101/gad.244772.114; Lowney JK, 1999, ANN SURG ONCOL, V6, P604, DOI 10.1007/s10434-999-0604-4; Mannick EE, 2005, J GASTROEN HEPATOL, V20, P371, DOI 10.1111/j.1440-1746.2005.03573.x; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; Mistry H, 2013, MOL CANCER THER, V12, P2651, DOI 10.1158/1535-7163.MCT-13-0103-T; Moretti J, 2012, J BIOL CHEM, V287, P29429, DOI 10.1074/jbc.M112.366807; Moriyama Y, 2001, CLIN CANCER RES, V7, P1293; Murai J, 2011, MOL CELL BIOL, V31, P2462, DOI 10.1128/MCB.05058-11; Murtas D, 2013, BRIT J CANCER, V109, P76, DOI 10.1038/bjc.2013.335; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Narayan V, 2011, J BIOL CHEM, V286, P607, DOI 10.1074/jbc.M110.153122; Nozawa H, 1998, INT J CANCER, V77, P522, DOI 10.1002/(SICI)1097-0215(19980812)77:4<522::AID-IJC8>3.0.CO;2-W; Nozawa H, 1999, GENE DEV, V13, P1240, DOI 10.1101/gad.13.10.1240; Oestergaard VH, 2007, MOL CELL, V28, P798, DOI 10.1016/j.molcel.2007.09.020; Ohsugi T, 2017, ONCOTARGET, V8, P100176, DOI 10.18632/oncotarget.22122; Palacios J, 1998, CANCER RES, V58, P1344; Pamment J, 2002, ONCOGENE, V21, P7776, DOI 10.1038/sj.onc.1205981; Penninger JM, 1997, IMMUNITY, V7, P243, DOI 10.1016/S1074-7613(00)80527-0; Pettersson S, 2009, BIOCHEM J, V418, P575, DOI 10.1042/BJ20082087; Ritorto MS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5763; Ruiz-Ruiz C, 2004, J BIOL CHEM, V279, P19712, DOI 10.1074/jbc.M313023200; Sakai T, 2014, PANCREAS, V43, P909, DOI 10.1097/MPA.0000000000000116; Salahshor S, 2005, J CLIN PATHOL, V58, P225, DOI 10.1136/jcp.2003.009506; Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schwartz JL, 2011, INT J BREAST CANCER, V2011, DOI 10.4061/2011/912102; Tada S, 1998, INT J ONCOL, V13, P1207; Tamura G, 1996, CANCER RES, V56, P612; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tan RSP, 1996, CANCER RES, V56, P2417; TANAKA N, 1994, CANCER LETT, V83, P191, DOI 10.1016/0304-3835(94)90318-2; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tomita Y, 2003, INT J CANCER, V104, P400, DOI 10.1002/ijc.10956; van Twest S, 2017, MOL CELL, V65, P247, DOI 10.1016/j.molcel.2016.11.005; Wang Y, 2007, CANCER RES, V67, P2535, DOI 10.1158/0008-5472.CAN-06-3530; Xie D, 2001, CANCER RES, V61, P8917; Yanai H, 2012, ONCOIMMUNOLOGY, V1, P1376, DOI 10.4161/onci.22475; Yin JP, 2015, STRUCTURE, V23, P2043, DOI 10.1016/j.str.2015.08.010; Yuan L, 2015, CANCER LETT, V359, P136, DOI 10.1016/j.canlet.2015.01.003; Zeng G, 2007, NEOPLASIA, V9, P951, DOI 10.1593/neo.07469; Zurawel RH, 1998, CANCER RES, V58, P896	70	15	16	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2019	38	32					6051	6064		10.1038/s41388-019-0856-9	http://dx.doi.org/10.1038/s41388-019-0856-9			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IP8XH	31292489				2022-12-17	WOS:000480329900004
J	Xu, ZL; Li, LC; Qian, YY; Song, Y; Qin, LP; Duan, YY; Wang, ML; Li, PS; Jiang, BC; Ma, CH; Shao, CS; Gong, YQ				Xu, Zhiliang; Li, Linchuan; Qian, Yanyan; Song, Yu; Qin, Liping; Duan, Yuyao; Wang, Molin; Li, Peishan; Jiang, Baichun; Ma, Chunhong; Shao, Changshun; Gong, Yaoqin			Upregulation of IL-6 in CUL4B-deficient myeloid-derived suppressive cells increases the aggressiveness of cancer cells	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; TUMOR PROGRESSION; METHYLATION; TUMORIGENESIS; INTERLEUKIN-6; DYSREGULATION; PROMOTER; PATHWAY; CUL4A; STAT3	Cancer progression depends on a tumor-supportive microenvironment. Myeloid-derived suppressor cells (MDSCs) represent key cellular components in tumor microenvironment and have been demonstrated to facilitate tumor progression by restricting host immune responses and by sustaining the malignancy of cancer cells. CUL4B, which assembles the CUL4B-RING E3 ligase complex (CRL4B), possesses a potent oncogenic property in cancer cells by epigenetically inactivating many tumor suppressors. However, CUL4B in hematopoietic cells exerts tumor-suppressive effect by restricting the accumulation and function of MDSCs. How CUL4B regulates the function of MDSCs is not fully characterized. In the present study, we demonstrate that the enhanced growth and metastasis of transplanted tumor cells in hematopoietic or myeloid cell-specific Cul4b knockout recipient mice is mediated by increased production of IL-6 in MDSCs. CUL4B complex epigenetically represses IL-6 transcription in myeloid cells. The IL-6 produced by MDSCs renders cancer cells stem cell-like properties by activating IL-6/STAT3 signaling. This crosstalk was effectively blocked either by blocking IL-6 in MDSCs or by inhibition of STAT3 activation in tumor cells. These findings provide a new mechanistic insight into the cancer-promoting property of MDSCs.	[Xu, Zhiliang; Li, Linchuan; Qian, Yanyan; Song, Yu; Qin, Liping; Duan, Yuyao; Wang, Molin; Li, Peishan; Jiang, Baichun; Gong, Yaoqin] Shandong Univ, Key Lab Expt Teratol, Inst Mol Med & Genet, Minist Educ,Sch Basic Med Sci, Jinan, Shandong, Peoples R China; [Ma, Chunhong] Shandong Univ, Key Lab Expt Teratol, Minist Educ, Dept Immunol,Sch Basic Med Sci, Jinan, Shandong, Peoples R China; [Shao, Changshun] Soochow Univ, Inst Translat Med, State Key Lab Radiat Med & Protect, Suzhou, Jiangsu, Peoples R China	Shandong University; Shandong University; Soochow University - China	Gong, YQ (corresponding author), Shandong Univ, Key Lab Expt Teratol, Inst Mol Med & Genet, Minist Educ,Sch Basic Med Sci, Jinan, Shandong, Peoples R China.	yxg8@sdu.edu.cn	Shao, Changshun/AAD-8977-2022; ma, chunhong/C-6043-2008	Shao, Changshun/0000-0003-2618-9342; ma, chunhong/0000-0002-8121-4718; Qian, Yanyan/0000-0002-1759-5835	National Natural Science Foundation of China [81330050, 81571523]; Natural Science Foundation of Shandong Province [ZR2016HZ01]; Key Research and Development Program of Shandong Province [2016ZDJS07A08]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); Key Research and Development Program of Shandong Province	This work was supported by the National Natural Science Foundation of China (81330050 and 81571523), the Natural Science Foundation of Shandong Province (ZR2016HZ01), and the Key Research and Development Program of Shandong Province (2016ZDJS07A08).	Albini A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00527; Chen Z, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01344-9; Chin AR, 2014, MOL CELL ENDOCRINOL, V382, P598, DOI 10.1016/j.mce.2013.03.024; Dandrea M, 2009, NUCLEIC ACIDS RES, V37, P6681, DOI 10.1093/nar/gkp723; Gabrilovich DI, 2017, CANCER IMMUNOL RES, V5, P3, DOI 10.1158/2326-6066.CIR-16-0297; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Hannah J, 2015, GENE, V573, P33, DOI 10.1016/j.gene.2015.08.064; He YM, 2018, J CELL BIOCHEM, V119, P5308, DOI 10.1002/jcb.26643; Hu HL, 2012, CANCER CELL, V22, P781, DOI 10.1016/j.ccr.2012.10.024; Ishida K, 2012, J PERIODONTOL, V83, P917, DOI 10.1902/jop.2011.110356; Ji QH, 2014, J CELL SCI, V127, P4679, DOI 10.1242/jcs.154245; Jia L, 2017, J BIOL CHEM, V292, P2966, DOI 10.1074/jbc.M116.765230; Jiang BC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037070; Jiang T, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0534-7; Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8; Khoshbin AP, 2019, ARCH IMMUNOL THER EX, V67, P89, DOI 10.1007/s00005-018-0531-9; Kishimoto T, 2005, ANNU REV IMMUNOL, V23, P1, DOI 10.1146/annurev.immunol.23.021704.115806; Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Mi J, 2017, MOL ONCOL, V11, P305, DOI 10.1002/1878-0261.12038; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; Nile CJ, 2008, ARTHRITIS RHEUM, V58, P2686, DOI 10.1002/art.23758; Peng DJ, 2016, CANCER RES, V76, P3156, DOI 10.1158/0008-5472.CAN-15-2528; Qian YY, 2015, CANCER RES, V75, P5070, DOI 10.1158/0008-5472.CAN-15-0898; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Safarzadeh E, 2018, J CELL PHYSIOL, V233, P3024, DOI 10.1002/jcp.26075; Tang BK, 2011, MOL IMMUNOL, V48, P1001, DOI 10.1016/j.molimm.2011.01.003; Umansky V, 2013, CANCER MICROENVIRON, V6, P169, DOI 10.1007/s12307-012-0126-7; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Wang SW, 2014, INT J ONCOL, V44, P1032, DOI 10.3892/ijo.2014.2259; Xiong S, 2018, AM J CANCER RES, V8, P302; Yang Y, 2015, ONCOGENE, V34, P104, DOI 10.1038/onc.2013.522; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Yuan JP, 2015, J PATHOL, V235, P784, DOI 10.1002/path.4492	35	15	16	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2019	38	30					5860	5872		10.1038/s41388-019-0847-x	http://dx.doi.org/10.1038/s41388-019-0847-x			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IT3FY	31235785				2022-12-17	WOS:000482739300002
J	Coleman, DJ; Gao, L; King, CJ; Schwartzman, J; Urrutia, J; Sehrawat, A; Tayou, J; Balter, A; Burchard, J; Chiotti, KE; Derrick, DS; Sun, DC; Xia, Z; Heiser, LM; Alumkal, JJ				Coleman, Daniel J.; Gao, Lina; King, Carly J.; Schwartzman, Jacob; Urrutia, Joshua; Sehrawat, Archana; Tayou, Junior; Balter, Ariel; Burchard, Julja; Chiotti, Kami E.; Derrick, Daniel S.; Sun, Duanchen; Xia, Zheng; Heiser, Laura M.; Alumkal, Joshi J.			BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer	ONCOGENE			English	Article							CASTRATION-RESISTANT; ANDROGEN RECEPTOR; MCM PROTEINS; EXPRESSION; VARIANTS	BET bromodomain inhibitors block prostate cancer cell growth at least in part through c-Myc and androgen receptor (AR) suppression. However, little is known about other transcriptional regulators whose suppression contributes to BET bromodomain inhibitor anti-tumor activity. Moreover, the anti-tumor activity of BET bromodomain inhibition in AR-independent castration-resistant prostate cancers (CRPC), whose frequency is increasing, is also unknown. Herein, we demonstrate that BET bromodomain inhibition blocks growth of a diverse set of CRPC cell models, including those that are AR-independent or in which c-Myc is not suppressed. To identify transcriptional regulators whose suppression accounts for these effects, we treated multiple CRPC cell lines with the BET bromodomain inhibitor JQ1 and then performed RNA-sequencing followed by Master Regulator computational analysis. This approach identified several previously unappreciated transcriptional regulators that are highly expressed in CRPC and whose suppression, via both transcriptional or post-translational mechanisms, contributes to the anti-tumor activity of BET bromodomain inhibitors.	[Coleman, Daniel J.; Gao, Lina; King, Carly J.; Schwartzman, Jacob; Urrutia, Joshua; Sehrawat, Archana; Tayou, Junior; Chiotti, Kami E.; Derrick, Daniel S.; Heiser, Laura M.; Alumkal, Joshi J.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97239 USA; [King, Carly J.; Derrick, Daniel S.; Sun, Duanchen; Xia, Zheng; Heiser, Laura M.] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97239 USA; [Balter, Ariel; Burchard, Julja] Oregon Hlth & Sci Univ, Computat Biol Program, Portland, OR 97239 USA; [Chiotti, Kami E.; Alumkal, Joshi J.] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Heiser, LM; Alumkal, JJ (corresponding author), Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97239 USA.; Heiser, LM (corresponding author), Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97239 USA.; Alumkal, JJ (corresponding author), Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA.	heiserl@ohsu.edu; alumkalj@ohsu.edu	Xia, Zheng/AAC-5360-2022	Xia, Zheng/0000-0003-3364-8324; Coleman, Daniel/0000-0002-3414-3160; Urrutia, Joshua/0000-0003-2171-0936; Schwartzman, Jacob/0000-0002-2640-8181	National Institutes of Health (NIH)/National Cancer Institute (NCI) R01 award [CA178610]; Pacific Northwest Prostate Cancer SPORE/NCI [P50 CA097186]; Cancer Center Support Grant (CCSG) [P30 CA069533]; Oregon Clinical and Translational Research Institute (OCTRI) from the National Center for Advancing Translational Sciences (NCATS), NIH [UL1TR000128]; Department of Defense Synergistic Idea Award [W81XWH-13-1-0420]; Department of Defense Impact Awards [W81XWH-16-1-0597, W81XWH-16-1-1601]; Prospect Creek Foundation; Hope Foundation Award; Stand Up to Cancer-Prostate Cancer Foundation-Prostate Dream Team Translational Cancer Research Grant [SU2C-AACR-DT0409]; Movember Foundation; Wayne D. Kuni and Joan E. Kuni Foundation; Stand Up To Cancer is a program of the Entertainment Industry Foundation [7465sc]; NATIONAL CANCER INSTITUTE [P30CA069533, P50CA097186, R01CA178610] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [K01LM012877] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Cancer Institute (NCI) R01 award; Pacific Northwest Prostate Cancer SPORE/NCI; Cancer Center Support Grant (CCSG); Oregon Clinical and Translational Research Institute (OCTRI) from the National Center for Advancing Translational Sciences (NCATS), NIH; Department of Defense Synergistic Idea Award; Department of Defense Impact Awards; Prospect Creek Foundation; Hope Foundation Award; Stand Up to Cancer-Prostate Cancer Foundation-Prostate Dream Team Translational Cancer Research Grant; Movember Foundation; Wayne D. Kuni and Joan E. Kuni Foundation; Stand Up To Cancer is a program of the Entertainment Industry Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	This research was supported by: National Institutes of Health (NIH)/National Cancer Institute (NCI) R01 award CA178610; the Pacific Northwest Prostate Cancer SPORE/NCI (P50 CA097186); Cancer Center Support Grant (CCSG) (P30 CA069533); the Oregon Clinical and Translational Research Institute (OCTRI) (UL1TR000128) from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH; Department of Defense Synergistic Idea Award (W81XWH-13-1-0420); Department of Defense Impact Awards (W81XWH-16-1-0597 and W81XWH-16-1-1601). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or DOD. Other support includes: Wayne D. Kuni and Joan E. Kuni Foundation, Prospect Creek Foundation, a Hope Foundation Award, and a Stand Up to Cancer-Prostate Cancer Foundation-Prostate Dream Team Translational Cancer Research Grant (SU2C-AACR-DT0409); this research grant is made possible by the generous support of the Movember Foundation. Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research (7465sc). We thank Dr. James Bradner at Dana-Farber Cancer Institute for providing the JQ1 compound used in in vivo studies.	Aggarwal R, 2018, J CLIN ONCOL, V36, P2492, DOI 10.1200/JCO.2017.77.6880; Alvarez MJ, 2016, NAT GENET, V48, P838, DOI 10.1038/ng.3593; Alvarez MJ, 2014, BIOCONDUCTOR, P1; Alvarez MJ, 2013, BIOCONDUCTOR; American Cancer Society, 2019, CANC FACTS FIG 2019; Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Aytes A, 2014, CANCER CELL, V25, P638, DOI 10.1016/j.ccr.2014.03.017; Bandopadhayay P, 2014, CLIN CANCER RES, V20, P912, DOI 10.1158/1078-0432.CCR-13-2281; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Bishop JL, 2015, ONCOTARGET, V6, P234, DOI 10.18632/oncotarget.2703; Bluemn EG, 2017, CANCER CELL, V32, P474, DOI 10.1016/j.ccell.2017.09.003; Chan SC, 2015, NUCLEIC ACIDS RES, V43, P5880, DOI 10.1093/nar/gkv262; Coleman DJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40518-5; Coleman DJ, 2016, ONCOTARGET, V7, P40690, DOI 10.18632/oncotarget.9816; Culig Z, 1999, BRIT J CANCER, V81, P242, DOI 10.1038/sj.bjc.6690684; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; Gao LB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070739; Gertz J, 2013, MOL CELL, V52, P25, DOI 10.1016/j.molcel.2013.08.037; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; Hafner M, 2016, NAT METHODS, V13, P521, DOI [10.1038/NMETH.3853, 10.1038/nmeth.3853]; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Ibarra A, 2008, P NATL ACAD SCI USA, V105, P8956, DOI 10.1073/pnas.0803978105; Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027; Kuruma H, 2013, MOL CANCER THER, V12, P567, DOI 10.1158/1535-7163.MCT-12-0798; Lefebvre C, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.31; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Pruitt SC, 2007, STEM CELLS, V25, P3121, DOI 10.1634/stemcells.2007-0483; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Rathert P, 2015, NATURE, V525, P543, DOI 10.1038/nature14898; Shima N, 2007, NAT GENET, V39, P93, DOI 10.1038/ng1936; Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508; Smallwood A, 2012, GENOME RES, V22, P1426, DOI 10.1101/gr.124818.111; Snoek R, 2009, CLIN CANCER RES, V15, P39, DOI 10.1158/1078-0432.CCR-08-1726; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Valensin S, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-196; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Wyce A, 2013, ONCOTARGET, V4, P2419, DOI 10.18632/oncotarget.1572; Yankulov K, 1999, MOL CELL BIOL, V19, P6154; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963	46	15	15	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5658	5669		10.1038/s41388-019-0815-5	http://dx.doi.org/10.1038/s41388-019-0815-5			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	30996246	Green Accepted			2022-12-17	WOS:000474845100008
J	Torres-Hernandez, A; Wang, W; Nikiforov, Y; Tejada, K; Torres, L; Kalabin, A; Wu, Y; Ul Haq, MI; Khan, MY; Zhao, Z; Su, WY; Camargo, J; Hundeyin, M; Diskin, B; Adam, S; Rossi, JAK; Kurz, E; Aykut, B; Shadaloey, SAA; Leinwand, J; Miller, G				Torres-Hernandez, Alejandro; Wang, Wei; Nikiforov, Yuri; Tejada, Karla; Torres, Luisana; Kalabin, Aleksandr; Wu, Yue; Ul Haq, Muhammad Israr; Khan, Mohammed Y.; Zhao, Zhen; Su, Wenyu; Camargo, Jimmy; Hundeyin, Mautin; Diskin, Brian; Adam, Salma; Rossi, Juan A. Kochen; Kurz, Emma; Aykut, Berk; Shadaloey, Sorin A. A.; Leinwand, Joshua; Miller, George			Targeting SYK signaling in myeloid cells protects against liver fibrosis and hepatocarcinogenesis	ONCOGENE			English	Article							HEPATIC STELLATE CELLS; TYROSINE KINASE; RECEPTOR 4; INFLAMMATION; INHIBITION; INJURY; NK	Liver fibrosis and fibrosis-associated hepatocarcinogenesis are driven by chronic inflammation and are leading causes of morbidity and death worldwide. SYK signaling regulates critical processes in innate and adaptive immunity, as well as parenchymal cells. We discovered high SYK expression in the parenchymal hepatocyte, hepatic stellate cell (HSC), and the inflammatory compartments in the fibrotic liver. We postulated that targeting SYK would mitigate hepatic fibrosis and oncogenic progression. We found that inhibition of SYK with the selective small molecule inhibitors Piceatannol and PRT062607 markedly protected against toxin-induced hepatic fibrosis, associated hepatocellular injury and intra-hepatic inflammation, and hepatocarcinogenesis. SYK inhibition resulted in increased intra-tumoral expression of the p16 and p53 but decreased expression of Bcl-xL and SMAD4. Further, hepatic expression of genes regulating angiogenesis, apoptosis, cell cycle regulation, and cellular senescence were affected by targeting SYK. We found that SYK inhibition mitigated both HSC trans-differentiation and acquisition of an inflammatory phenotype in T cells, B cells, and myeloid cells. However, in vivo experiments employing selective targeted deletion of SYK indicated that only SYK deletion in the myeloid compartment was sufficient to confer protection against fibrogenic progression. Targeting SYK promoted myeloid cell differentiation into hepato-protective TNF alpha(low) CD206(hi) phenotype downregulating mTOR, IL-8 signaling and oxidative phosphorylation. Collectively, these data suggest that SYK is an attractive target for experimental therapeutics in treating hepatic fibrosis and oncogenesis.	[Torres-Hernandez, Alejandro; Wang, Wei; Nikiforov, Yuri; Tejada, Karla; Torres, Luisana; Kalabin, Aleksandr; Wu, Yue; Ul Haq, Muhammad Israr; Khan, Mohammed Y.; Zhao, Zhen; Su, Wenyu; Camargo, Jimmy; Hundeyin, Mautin; Diskin, Brian; Adam, Salma; Rossi, Juan A. Kochen; Kurz, Emma; Aykut, Berk; Shadaloey, Sorin A. A.; Leinwand, Joshua; Miller, George] NYU, Sch Med, Dept Surg, SA Localio Lab, 450 East 29th St, New York, NY 10016 USA; [Miller, George] NYU, Sch Med, Dept Cell Biol, 450 East 29th St, New York, NY 10016 USA	New York University; New York University	Miller, G (corresponding author), NYU, Sch Med, Dept Surg, SA Localio Lab, 450 East 29th St, New York, NY 10016 USA.; Miller, G (corresponding author), NYU, Sch Med, Dept Cell Biol, 450 East 29th St, New York, NY 10016 USA.	george.miller@nyumc.org	Hundeyin, Mautin/AAU-6792-2020	Kalabin, Aleksandr/0000-0003-4133-6267	Cancer Center Support Grant at the Laura and Isaac Perlmutter Cancer Center [P30CA016087]; NYU Cancer Institute Center Support Grant [NIH/NCI 5 P30CA16087]; NCI [CA168611, CA155649, CA193111]; Society of University Surgeons-Ethicon Resident Research Award; American Liver Foundation-Thomas F. Nealon, III Postdoctoral Research Fellowship Honoring Zachery Rue; American Liver Foundation Postdoctoral Research Fellowship; NYU Physician-Scientist Training Program; NATIONAL CANCER INSTITUTE [P30CA016087] Funding Source: NIH RePORTER	Cancer Center Support Grant at the Laura and Isaac Perlmutter Cancer Center; NYU Cancer Institute Center Support Grant; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Society of University Surgeons-Ethicon Resident Research Award; American Liver Foundation-Thomas F. Nealon, III Postdoctoral Research Fellowship Honoring Zachery Rue; American Liver Foundation Postdoctoral Research Fellowship; NYU Physician-Scientist Training Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the NYU Langone Health Genome Technology Center (GTC) for expert library preparation and sequencing; the GTC is partially supported by the Cancer Center Support Grant P30CA016087 at the Laura and Isaac Perlmutter Cancer Center. We thank the NYU Langone Health Experimental Pathology Research Laboratory, which is partially funded by NYU Cancer Institute Center Support Grant NIH/NCI 5 P30CA16087, for expert tissue processing and equipment support. This work was supported by NCI CA168611 (GM), CA155649 (GM), CA193111 (ATH, BD), Society of University Surgeons-Ethicon Resident Research Award (ATH), American Liver Foundation-Thomas F. Nealon, III Postdoctoral Research Fellowship Honoring Zachery Rue (ATH), American Liver Foundation Postdoctoral Research Fellowship (WW), NYU Physician-Scientist Training Program (ATH).	Anderson Robert N, 2005, Natl Vital Stat Rep, V53, P1; Coffey G, 2017, J CLIN PHARMACOL, V57, P194, DOI 10.1002/jcph.794; Cornall RJ, 2000, P NATL ACAD SCI USA, V97, P1713, DOI 10.1073/pnas.97.4.1713; Daley D, 2017, J EXP MED, V214, P1711, DOI 10.1084/jem.20161707; Dapito DH, 2012, CANCER CELL, V21, P504, DOI 10.1016/j.ccr.2012.02.007; de Rosamel L, 2017, EXPERT OPIN EMERG DR, V22, P175, DOI 10.1080/14728214.2017.1336538; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Guo JS, 2010, FIBROGENESIS TISSUE, V3, DOI 10.1186/1755-1536-3-21; Hellerbrand C, 1999, J HEPATOL, V30, P77, DOI 10.1016/S0168-8278(99)80010-5; Inarrairaegui M, 2018, CLIN CANCER RES, V24, P1518, DOI 10.1158/1078-0432.CCR-17-0289; Kant R, 2014, J MED MICROBIOL, V63, P293, DOI 10.1099/jmm.0.064220-0; Koyama Y, 2017, J CLIN INVEST, V127, P55, DOI 10.1172/JCI88881; Kurniawan DW, 2018, J CONTROL RELEASE, V288, P227, DOI 10.1016/j.jconrel.2018.09.004; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Marcus A, 2014, ADV IMMUNOL, V122, P91, DOI 10.1016/B978-0-12-800267-4.00003-1; Melhem A, 2006, J HEPATOL, V45, P60, DOI 10.1016/j.jhep.2005.12.025; Miller YI, 2012, BRIT J PHARMACOL, V167, P990, DOI 10.1111/j.1476-5381.2012.02097.x; Mocsai A, 2010, NAT REV IMMUNOL, V10, P387, DOI 10.1038/nri2765; Moreira RK, 2007, ARCH PATHOL LAB MED, V131, P1728; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Notas G, 2009, CLIN IMMUNOL, V130, P16, DOI 10.1016/j.clim.2008.08.008; Novobrantseva TI, 2005, J CLIN INVEST, V115, P3072, DOI 10.1172/JCI24798; O'Neill LAJ, 2016, CELL REP, V17, P625, DOI 10.1016/j.celrep.2016.09.085; Ochi A, 2012, J EXP MED, V209, P1671, DOI 10.1084/jem.20111706; Poynard T, 2003, J HEPATOL, V38, P257, DOI 10.1016/S0168-8278(02)00413-0; Pradere JP, 2013, HEPATOLOGY, V58, P1461, DOI 10.1002/hep.26429; Pradere JP, 2010, SEMIN LIVER DIS, V30, P232, DOI 10.1055/s-0030-1255353; Qu C, 2018, HEPATOLOGY, V68, P1125, DOI 10.1002/hep.29881; Seifert L, 2015, CELL REP, V13, P1909, DOI 10.1016/j.celrep.2015.10.058; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Thapa M, 2015, HEPATOLOGY, V61, P2067, DOI 10.1002/hep.27761; Uehara T., 2014, CURR PROTOC PHARM, V66, P11; Wang W, 2017, HEPATOLOGY, V66, P108, DOI 10.1002/hep.29129; Weiskirchen Ralf, 2014, Hepatobiliary Surg Nutr, V3, P344, DOI 10.3978/j.issn.2304-3881.2014.11.03; Wick G, 2010, TRENDS IMMUNOL, V31, P110, DOI 10.1016/j.it.2009.12.001; Yang J, 2015, J HEPATOCELL CARCINO, V2, P11, DOI 10.2147/JHC.S44515; Yang L, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00138; Zambirinis CP, 2015, J EXP MED, V212, P2077, DOI 10.1084/jem.20142162; Zhou Z, 2018, CELL MOL GASTROENTER, V5, P399, DOI 10.1016/j.jcmgh.2018.01.003	41	15	16	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4512	4526		10.1038/s41388-019-0734-5	http://dx.doi.org/10.1038/s41388-019-0734-5			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30742098				2022-12-17	WOS:000470240300006
J	Li, ZP; Jiao, XM; Di Sante, G; Ertel, A; Casimiro, MC; Wang, M; Katiyar, S; Ju, XM; Klopfenstein, DV; Tozeren, A; Dampier, W; Chepelev, I; Jeltsch, A; Pestell, RG				Li, Zhiping; Jiao, Xuanmao; Di Sante, Gabriele; Ertel, Adam; Casimiro, Mathew C.; Wang, Min; Katiyar, Sanjay; Ju, Xiaoming; Klopfenstein, D., V; Tozeren, Aydin; Dampier, William; Chepelev, Iouri; Jeltsch, Albert; Pestell, Richard G.			Cyclin D1 integrates G9a-mediated histone methylation	ONCOGENE			English	Article							NUCLEAR LAMINA INTERACTIONS; METHYLTRANSFERASE G9A; LYSINE METHYLTRANSFERASE; CHROMOSOMAL INSTABILITY; NEGATIVE REGULATION; CHROMATIN DYNAMICS; PROTEIN FAMILIES; DI-METHYLATION; CELLS; CANCER	Lysine methylation of histones and non-histone substrates by the SET domain containing protein lysine methyltransferase (KMT) G9a/EHMT2 governs transcription contributing to apoptosis, aberrant cell growth, and pluripotency. The positioning of chromosomes within the nuclear three-dimensional space involves interactions between nuclear lamina (NL) and the lamina-associated domains (LAD). Contact of individual LADs with the NL are dependent upon H3K9me2 introduced by G9a. The mechanisms governing the recruitment of G9a to distinct subcellular sites, into chromatin or to LAD, is not known. The cyclin D1 gene product encodes the regulatory subunit of the holoenzyme that phosphorylates pRB and NRF1 thereby governing cell-cycle progression and mitochondrial metabolism. Herein, we show that cyclin D1 enhanced H3K9 dimethylation though direct association with G9a. Endogenous cyclin D1 was required for the recruitment of G9a to target genes in chromatin, for G9a-induced H3K9me2 of histones, and for NL-LAD interaction. The finding that cyclin D1 is required for recruitment of G9a to target genes in chromatin and for H3K9 dimethylation, identifies a novel mechanism coordinating protein methylation.	[Li, Zhiping; Jiao, Xuanmao; Di Sante, Gabriele; Casimiro, Mathew C.; Wang, Min; Katiyar, Sanjay; Pestell, Richard G.] Penn Biotechnol Ctr, Baruch S Blumberg Inst, Penn Canc & Regenerat Med Res Ctr, 3805 Old Easton Rd, Doylestown, PA 18902 USA; [Ertel, Adam; Ju, Xiaoming] Thomas Jefferson Univ, Dept Canc Biol, 233 South 10th St, Philadelphia, PA 19107 USA; [Klopfenstein, D., V; Tozeren, Aydin] Drexel Univ, Ctr Integrated Bioinformat, Sch Biomed Engn, Philadelphia, PA 19104 USA; [Dampier, William] Drexel Univ, Dept Microbiol & Immunol, Coll Med, Philadelphia, PA 19104 USA; [Chepelev, Iouri] Cincinnati Childrens Hosp Med Ctr, Ctr Autoimmune Genom & Etiol, Cincinnati, OH 45229 USA; [Chepelev, Iouri] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45267 USA; [Jeltsch, Albert] Univ Stuttgart, Inst Biochem & Tech Biochem, Dept Biochem, Allmandring 31, D-70569 Stuttgart, Germany; [Pestell, Richard G.] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore 637551, Singapore	Jefferson University; Drexel University; Drexel University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Stuttgart; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Pestell, RG (corresponding author), Penn Biotechnol Ctr, Baruch S Blumberg Inst, Penn Canc & Regenerat Med Res Ctr, 3805 Old Easton Rd, Doylestown, PA 18902 USA.; Pestell, RG (corresponding author), Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore 637551, Singapore.	richard.pestell@bblumberg.org	Jeltsch, Albert/O-7404-2014	Jeltsch, Albert/0000-0001-6113-9290; Klopfenstein, DV/0000-0003-0161-7603; Chepelev, Iouri/0000-0002-2121-8805	Breast Cancer Research Foundation; Pennsylvania Department of Health; Dr. Ralph and Marian C. Falk Medical Research Trust;  [R01CA70896];  [R01CA75503];  [R01CA86072]	Breast Cancer Research Foundation; Pennsylvania Department of Health; Dr. Ralph and Marian C. Falk Medical Research Trust; ; ; 	This work was supported in part by R01CA70896, R01CA75503, and R01CA86072 (RGP). This project was funded in part from the Dr. Ralph and Marian C. Falk Medical Research Trust (RGP), a grant from the Breast Cancer Research Foundation (RGP), and a grant from the Pennsylvania Department of Health (RGP).	Aggarwal P, 2010, CANCER CELL, V18, P329, DOI 10.1016/j.ccr.2010.08.012; Amendola M, 2015, EMBO REP, V16, P610, DOI 10.15252/embr.201439789; Banaszynski LA, 2006, CELL, V126, P995, DOI 10.1016/j.cell.2006.07.025; Bizen N, 2014, STEM CELLS, V32, P1602, DOI 10.1002/stem.1613; Casimiro MC, 2015, ONCOTARGET, V6, P8525, DOI 10.18632/oncotarget.3267; Casimiro MC, 2013, MOL ENDOCRINOL, V27, P1415, DOI 10.1210/me.2013-1065; Casimiro MC, 2012, J CLIN INVEST, V122, P833, DOI 10.1172/JCI60256; Chen WL, 2017, CURR CANCER DRUG TAR, V17, P555, DOI 10.2174/1568009616666160512145303; Cho HS, 2011, NEOPLASIA, V13, P676, DOI 10.1593/neo.11512; Collins RE, 2005, J BIOL CHEM, V280, P5563, DOI 10.1074/jbc.M410483200; Collins R, 2010, NUCLEIC ACIDS RES, V38, P3503, DOI 10.1093/nar/gkq081; Czimmerer Z, 2018, IMMUNITY, V48, P75, DOI 10.1016/j.immuni.2017.12.010; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; Deimling S.J., 2017, NEUROGENESIS AUSTIN, V4; Ding J, 2013, CELL METAB, V18, P896, DOI 10.1016/j.cmet.2013.11.004; Esteve PO, 2006, GENE DEV, V20, P3089, DOI 10.1101/gad.1463706; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fang TC, 2012, J EXP MED, V209, P661, DOI 10.1084/jem.20112343; Fu MF, 2005, J BIOL CHEM, V280, P16934, DOI 10.1074/jbc.M500403200; Fu MF, 2005, J BIOL CHEM, V280, P29728, DOI 10.1074/jbc.M503188200; Gong Z, 2018, GENET MOL BIOL, V41, P488, DOI [10.1590/1678-4685-GMB-2017-0164, 10.1590/1678-4685-gmb-2017-0164]; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huang J, 2010, J BIOL CHEM, V285, P9636, DOI 10.1074/jbc.M109.062588; Huang TH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.65; Hulit J, 2004, MOL CELL BIOL, V24, P7598, DOI 10.1128/MCB.24.17.7598-7611.2004; Ju XM, 2014, CANCER RES, V74, P508, DOI 10.1158/0008-5472.CAN-13-1313; Kind J, 2015, CELL, V163, P134, DOI 10.1016/j.cell.2015.08.040; Kind J, 2013, CELL, V153, P178, DOI 10.1016/j.cell.2013.02.028; Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017; Lee JS, 2010, MOL CELL, V39, P71, DOI 10.1016/j.molcel.2010.06.008; Li Y, 2016, NUCLEIC ACIDS RES, V44, P7173, DOI 10.1093/nar/gkw327; Li ZP, 2006, MOL CELL BIOL, V26, P4240, DOI 10.1128/MCB.02124-05; Li ZP, 2010, CANCER RES, V70, P8802, DOI 10.1158/0008-5472.CAN-10-0312; Lindsay J, 2008, CTS-CLIN TRANSL SCI, V1, P107, DOI 10.1111/j.1752-8062.2008.00041.x; Lukaszewicz AI, 2011, P NATL ACAD SCI USA, V108, P11632, DOI 10.1073/pnas.1106230108; Marampon F, 2008, MOL BIOL CELL, V19, P2566, DOI 10.1091/mbc.E06-12-1110; Mi HY, 2005, NUCLEIC ACIDS RES, V33, pD284, DOI 10.1093/nar/gki078; Mozzetta C, 2014, MOL CELL, V53, P277, DOI 10.1016/j.molcel.2013.12.005; Nishio H, 2004, P NATL ACAD SCI USA, V101, P11257, DOI 10.1073/pnas.0401343101; Nozawa RS, 2010, NAT CELL BIOL, V12, P719, DOI 10.1038/ncb2075; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Peric-Hupkes D, 2010, COLD SH Q B, V75, P517, DOI 10.1101/sqb.2010.75.014; Peric-Hupkes D, 2010, MOL CELL, V38, P603, DOI 10.1016/j.molcel.2010.03.016; Pestell RG, 2013, AM J PATHOL, V183, P3, DOI 10.1016/j.ajpath.2013.03.001; Plaisier SB, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq636; Prokocimer M, 2009, J CELL MOL MED, V13, P1059, DOI [10.1111/j.1582-4934.2009.00676.x, 10.1111/j.1582-4934.2008.00676.x]; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Ramagopalan SV, 2010, GENOME RES, V20, P1352, DOI 10.1101/gr.107920.110; Rathert P, 2008, NAT CHEM BIOL, V4, P344, DOI 10.1038/nchembio.88; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797; Roopra A, 2004, MOL CELL, V14, P727, DOI 10.1016/j.molcel.2004.05.026; Sakamaki T, 2006, MOL CELL BIOL, V26, P5449, DOI 10.1128/MCB.02074-05; Sampath SC, 2007, MOL CELL, V27, P596, DOI 10.1016/j.molcel.2007.06.026; Shambaugh GE, 1996, J NEUROPATH EXP NEUR, V55, P1009, DOI 10.1097/00005072-199609000-00008; Shinkai Y, 2011, GENE DEV, V25, P781, DOI 10.1101/gad.2027411; Stahl M, 2006, CANCER RES, V66, P7562, DOI 10.1158/0008-5472.CAN-06-0974; Strickfaden H, 2010, NUCLEUS-PHILA, V1, P284, DOI 10.4161/nucl.1.3.11969; Tachibana M, 2005, GENE DEV, V19, P815, DOI 10.1101/gad.1284005; Takahashi A, 2012, MOL CELL, V45, P123, DOI 10.1016/j.molcel.2011.10.018; Takawa M, 2011, CANCER SCI, V102, P1298, DOI 10.1111/j.1349-7006.2011.01958.x; Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403; Towbin BD, 2012, CELL, V150, P934, DOI 10.1016/j.cell.2012.06.051; Walter J, 2003, J CELL BIOL, V160, P685, DOI 10.1083/jcb.200211103; Wang CG, 2003, MOL CELL BIOL, V23, P6159, DOI 10.1128/MCB.23.17.6159-6173.2003; Wang CG, 2006, P NATL ACAD SCI USA, V103, P11567, DOI 10.1073/pnas.0603363103; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wozniak RJ, 2007, ONCOGENE, V26, P77, DOI 10.1038/sj.onc.1209763; Zullo JM, 2012, CELL, V149, P1474, DOI 10.1016/j.cell.2012.04.035; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	71	15	16	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4232	4249		10.1038/s41388-019-0723-8	http://dx.doi.org/10.1038/s41388-019-0723-8			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30718920	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000469339100003
J	Dai, W; Xu, XH; Wang, DY; Wu, J; Wang, JK				Dai, Wei; Xu, Xinhui; Wang, Danyang; Wu, Jian; Wang, Jinke			Cancer therapy with a CRISPR-assisted telomerase-activating gene expression system	ONCOGENE			English	Article							GENOME; RNA; MAINTENANCE; IMETELSTAT; INHIBITOR; SEQUENCE; TOOL	Cancer is caused by a series of alterations in genome and epigenome and exists in multiple complex forms, making it difficult to be prevented and/or treated. Telomerase, an enzyme responsible for the maintenance of telomere, is silent in most normal somatic cells but activated in 90% of cancer cells, making it an excellent target for cancer therapy. Therefore, various telomerase activity inhibitors have been developed to treat cancer but all failed due to side effects. Here we acted oppositely to develop a cancer gene therapy named telomerase-activating gene expression (Tage) system by utilizing the telomerase activity in cancer cells. The Tage system consisted of an effector gene expression vector that carried a 3' telomerase-recognizable stick end and an artificial transcription factor expression vector that could express dCas9-VP64 and an sgRNA targeting telomere repeat sequences. By using Cas9 as an effector gene, the Tage system effectively killed various cancer cells, including HepG2, HeLa, PANC-1, MDA-MB-453, A549, HT-29, SKOV-3, Hepa1-6, and RAW264.7, without affecting normal cells MRC-5, HL7702, and bone marrow mesenchymal stem cell (BMSC). More importantly, a four-base 3' stick end produced by the homothallic switching endonuclease in cells could be recognized by telomerase, allowing the Tage system to effectively kill cancer cells in vivo. The Tage system could effectively and safely realize its in vivo application by using adeno-associated virus (AAV) as gene vector. The virus-loaded Tage system could significantly and specifically kill cancer cells in mice by intravenous drug administration without side effects or toxicity.	[Dai, Wei; Xu, Xinhui; Wang, Danyang; Wu, Jian; Wang, Jinke] Southeast Univ, State Key Lab Bioelect, Nanjing 210096, Jiangsu, Peoples R China	Southeast University - China	Wang, JK (corresponding author), Southeast Univ, State Key Lab Bioelect, Nanjing 210096, Jiangsu, Peoples R China.	wangjinke@seu.edu.cn	Wang, Jinke/AAT-7832-2021	Wang, Jinke/0000-0002-3352-4690	National Natural Science Foundation of China [61571119]; National Key Research and Development Program of China [2017YFA0205502]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China	This work was supported by the National Natural Science Foundation of China (61571119) and the National Key Research and Development Program of China (2017YFA0205502).	Aschacher T, 2016, ONCOGENE, V35, P94, DOI 10.1038/onc.2015.65; Banerjee Budhaditya, 2017, Curr Opin Syst Biol, V1, P1, DOI 10.1016/j.coisb.2016.12.016; Bikard D, 2014, NAT BIOTECHNOL, V32, P1146, DOI 10.1038/nbt.3043; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLACKBURN EH, 1984, CELL, V37, P7, DOI 10.1016/0092-8674(84)90295-2; Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47; Chavez A, 2016, NAT METHODS, V13, P563, DOI [10.1038/nmeth.3871, 10.1038/NMETH.3871]; Colgin LM, 1999, CURR OPIN GENET DEV, V9, P97, DOI 10.1016/S0959-437X(99)80014-8; Colgin LM, 2003, CURR BIOL, V13, P942, DOI 10.1016/S0960-9822(03)00339-7; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Deltcheva E, 2011, NATURE, V471, P602, DOI 10.1038/nature09886; Deng YB, 2007, LAB INVEST, V87, P1071, DOI 10.1038/labinvest.3700673; Diede SJ, 1999, CELL, V99, P723, DOI 10.1016/S0092-8674(00)81670-0; Doudna JA, 2014, SCIENCE, V346, P1077, DOI 10.1126/science.1258096; Dunbar CE, 2018, SCIENCE, V359, P175, DOI 10.1126/science.aan4672; Gasiunas G, 2012, P NATL ACAD SCI USA, V109, pE2579, DOI 10.1073/pnas.1208507109; George LA, 2017, BLOOD ADV, V1, P2591, DOI 10.1182/bloodadvances.2017009878; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; Horvath P, 2010, SCIENCE, V327, P167, DOI 10.1126/science.1179555; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Jafri MA, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0324-x; Jinek M, 2013, ELIFE, V2, DOI 10.7554/eLife.00471; Khan FA, 2016, ONCOTARGET, V7, P52541, DOI 10.18632/oncotarget.9646; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Maciejowski J, 2017, NAT REV MOL CELL BIO, V18, P175, DOI 10.1038/nrm.2016.171; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; Martinez P, 2010, AGING CELL, V9, P653, DOI 10.1111/j.1474-9726.2010.00596.x; Mendell JR, 2017, NEW ENGL J MED, V377, P1713, DOI 10.1056/NEJMoa1706198; Mosoyan G, 2017, LEUKEMIA, V31, P2458, DOI 10.1038/leu.2017.78; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; Nissim L, 2017, CELL, V171, P1138, DOI 10.1016/j.cell.2017.09.049; Niu YY, 2014, CELL, V156, P836, DOI 10.1016/j.cell.2014.01.027; Platt RJ, 2014, CELL, V159, P440, DOI 10.1016/j.cell.2014.09.014; Sachdeva M, 2015, CANCER GENE THER, V22, P509, DOI 10.1038/cgt.2015.54; Samanta MK, 2016, TRANSGENIC RES, V25, P561, DOI 10.1007/s11248-016-9953-5; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; Shay JW, 2011, SEMIN CANCER BIOL, V21, P349, DOI 10.1016/j.semcancer.2011.10.001; Stewart SA, 2010, CANCER RES, V70, P7365, DOI 10.1158/0008-5472.CAN-10-1373; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Tefferi A, 2015, NEW ENGL J MED, V373, P908, DOI 10.1056/NEJMoa1310523; Valdmanis PN, 2017, HUM GENE THER, V28, P361, DOI 10.1089/hum.2016.171; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Williams TL, 2010, J BIOL CHEM, V285, P35814, DOI 10.1074/jbc.M110.170167; Wright WE, 1996, DEV GENET, V18, P173; Wright WE, 2002, NAT BIOTECHNOL, V20, P682, DOI 10.1038/nbt0702-682; Xue W, 2014, NATURE, V514, P380, DOI 10.1038/nature13589	46	15	15	2	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					4110	4124		10.1038/s41388-019-0707-8	http://dx.doi.org/10.1038/s41388-019-0707-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30696954	Green Submitted			2022-12-17	WOS:000468740200010
J	Rosenfeld, YBZ; Krumbein, M; Yeffet, A; Schiffmann, N; Mishalian, I; Pikarsky, E; Oberman, F; Fridlender, Z; Yisraeli, JK				Rosenfeld, Yifat Bar-Zakay; Krumbein, Miriam; Yeffet, Avner; Schiffmann, Nathan; Mishalian, Inbal; Pikarsky, Eli; Oberman, Froma; Fridlender, Zvi; Yisraeli, Joel K.			VICKZ1 enhances tumor progression and metastasis in lung adenocarcinomas in mice	ONCOGENE			English	Article							BREAST-CANCER CELLS; MESSENGER-RNA; BINDING-PROTEIN; PANCREATIC-CANCER; STEM-CELLS; CRD-BP; EXPRESSION; PROMOTE; GROWTH; IGF2BP1	The VICKZ (Igf2bp) family of RNA binding proteins regulate RNA function at many levels, including intracellular RNA localization, RNA stability, and translational control. One or more of the three VICKZ paralogs are upregulated in many different types of cancers. Here, we show how VICKZ1 enhances, and dominant negative VICKZ1 inhibits, cell migration, growth in soft agar, and wound healing in a mouse lung adenocarcinoma cell line containing a constitutively active, mutant Kras. Similarly, modulation of VICKZ1 activity promotes or inhibits metastases upon implantation of these cells into syngeneic mice. To test these effects in a genetic model system, we generated a mouse with an inducible VICKZ1 transgene and found that isolated overexpression of VICKZ1 in the lungs had no noticeable effect on morphology. Although directed overexpression of mutant Kras in the lungs led to the formation of small adenomas, concurrent overexpression of VICKZ1 remarkably accelerated tumor growth and formation of pulmonary adenocarcinomas. VICKZ1-containing ribonucleoprotein complexes are highly enriched in Kras mRNA in lung adenocarcinoma cells, and Kras signaling is enhanced in these cells by overexpression of VICKZ1. Analysis of lung carcinoma patients reveals that elevated VICKZ1 expression correlates with lower overall survival; this reduction is dramatically enhanced in those patients bearing a mutant Kras gene. Our study reveals that RNA binding proteins of the VICKZ family can synergize with Kras to influence signaling and oncogenic activity.	[Rosenfeld, Yifat Bar-Zakay; Krumbein, Miriam; Yeffet, Avner; Schiffmann, Nathan; Oberman, Froma; Yisraeli, Joel K.] Hebrew Univ Hadassah Med Sch, Inst Med Res Israel Canada, Dept Dev Biol & Canc Res, IL-91120 Jerusalem, Israel; [Mishalian, Inbal; Fridlender, Zvi] Hadassah Hebrew Univ Med Ctr, Inst Pulm Med, POB 12000, IL-91120 Jerusalem, Israel; [Pikarsky, Eli] Hebrew Univ Hadassah Med Sch, Inst Med Res Israel Canada, Lautenberg Ctr Immunol & Canc Res, Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Yisraeli, JK (corresponding author), Hebrew Univ Hadassah Med Sch, Inst Med Res Israel Canada, Dept Dev Biol & Canc Res, IL-91120 Jerusalem, Israel.	joely@ekmd.huji.ac.il	pikarsky, eli/GXV-7099-2022; Yisraeli, Joel/S-2031-2019	Yisraeli, Joel/0000-0001-6538-6686; pikarsky, eli/0000-0003-4186-7105	Israel Science Foundation; Israel Cancer Research Fund; Eliahu Penn Foundation (JKY)	Israel Science Foundation(Israel Science Foundation); Israel Cancer Research Fund; Eliahu Penn Foundation (JKY)	This research was supported by the Israel Science Foundation, the Israel Cancer Research Fund, and the Eliahu Penn Foundation (JKY).	Barghash A, 2016, ONCOTARGET, V7, P49743, DOI 10.18632/oncotarget.10439; Bell JL, 2013, CELL MOL LIFE SCI, V70, P2657, DOI 10.1007/s00018-012-1186-z; Boyerinas B, 2012, INT J CANCER, V130, P1787, DOI 10.1002/ijc.26190; Busch B, 2016, NUCLEIC ACIDS RES, V44, P3845, DOI 10.1093/nar/gkw099; Carmel MS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136408; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Chen CL, 2013, J CLIN INVEST, V123, P2832, DOI 10.1172/JCI65859; Conway AE, 2016, CELL REP, V15, P666, DOI 10.1016/j.celrep.2016.03.052; Dai N, 2015, CELL METAB, V21, P609, DOI 10.1016/j.cmet.2015.03.006; Dai N, 2013, GENE DEV, V27, P301, DOI 10.1101/gad.209130.112; Dai N, 2011, GENE DEV, V25, P1159, DOI 10.1101/gad.2042311; Davidson B, 2014, HUM PATHOL, V45, P1520, DOI 10.1016/j.humpath.2014.03.005; Degrauwe N, 2016, GENE DEV, V30, P2459, DOI 10.1101/gad.287540.116; Degrauwe N, 2016, CELL REP, V15, P1634, DOI 10.1016/j.celrep.2016.04.086; Doyle GAR, 1998, NUCLEIC ACIDS RES, V26, P5036, DOI 10.1093/nar/26.22.5036; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Fridlender ZG, 2011, AM J RESP CELL MOL, V44, P230, DOI 10.1165/rcmb.2010-0080OC; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gong Y, 2014, ADV ANAT PATHOL, V21, P191, DOI 10.1097/PAP.0000000000000021; Goswami S, 2010, J BIOL CHEM, V285, P20532, DOI 10.1074/jbc.M110.109298; Gu W, 2012, J CELL SCI, V125, P81, DOI 10.1242/jcs.086132; Gu W, 2009, J CELL SCI, V122, P1895, DOI 10.1242/jcs.045278; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Hamilton KE, 2013, CARCINOGENESIS, V34, P2647, DOI 10.1093/carcin/bgt217; Ioannidis P, 2004, CANCER LETT, V209, P245, DOI 10.1016/j.canlet.2003.12.015; Janiszewska M, 2012, GENE DEV, V26, P1926, DOI 10.1101/gad.188292.112; JnBaptiste CK, 2017, GENE DEV, V31, P674, DOI 10.1101/gad.296301.117; Kalous A, 2014, DEV NEUROBIOL, V74, P303, DOI 10.1002/dneu.22110; Kato T, 2007, CLIN CANCER RES, V13, P434, DOI 10.1158/1078-0432.CCR-06-1297; Khan P, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2078-7; Kim HY, 2018, CANCER LETT, V415, P30, DOI 10.1016/j.canlet.2017.11.039; Kugel S, 2016, CELL, V165, P1401, DOI 10.1016/j.cell.2016.04.033; Laggai S, 2014, J LIPID RES, V55, P1087, DOI 10.1194/jlr.M045500; LEADER M, 1986, HISTOPATHOLOGY, V10, P1315, DOI 10.1111/j.1365-2559.1986.tb02574.x; Maizels Y, 2015, J CELL SCI, V128, P1922, DOI 10.1242/jcs.163972; Mongroo PS, 2011, CANCER RES, V71, P2172, DOI 10.1158/0008-5472.CAN-10-3295; Mueller S, 2018, NATURE, V554, P62, DOI 10.1038/nature25459; Muller S, 2018, NUCLEIC ACIDS RES, V46, P6285, DOI 10.1093/nar/gky229; Noubissi FK, 2006, NATURE, V441, P898, DOI 10.1038/nature04839; Noubissi Felicite K, 2010, Genes Cancer, V1, P1074, DOI 10.1177/1947601910395581; Noubissi FK, 2009, CANCER RES, V69, P8572, DOI 10.1158/0008-5472.CAN-09-1500; Nwokafor CU, 2016, ONCOTARGET, V7, P72662, DOI 10.18632/oncotarget.12083; Oberman F, 2007, RNA, V13, P1558, DOI 10.1261/rna.559507; Samanta S, 2013, J BIOL CHEM, V288, P12569, DOI 10.1074/jbc.C112.442319; Stohr N, 2012, GENE DEV, V26, P176, DOI 10.1101/gad.177642.111; Stoskus M, 2016, BLOOD CELL MOL DIS, V57, P30, DOI 10.1016/j.bcmd.2015.11.006; Tessier CR, 2004, CANCER RES, V64, P209, DOI 10.1158/0008-5472.CAN-03-2927; Timar J, 2014, CURR OPIN ONCOL, V26, P138, DOI 10.1097/CCO.0000000000000051; Uekita T, 2014, MOL CANCER RES, V12, P1449, DOI 10.1158/1541-7786.MCR-13-0587; Vainer G, 2008, J PATHOL, V215, P445, DOI 10.1002/path.2376; Vikesaa J, 2006, EMBO J, V25, P1456, DOI 10.1038/sj.emboj.7601039; Wang GL, 2016, ONCOTARGET, V7, P15690, DOI 10.18632/oncotarget.7464; Yisraeli JK, 2005, BIOL CELL, V97, P87; Zhang JH, 2015, ONCOL LETT, V9, P1927, DOI 10.3892/ol.2015.2910	55	15	15	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					4169	4181		10.1038/s41388-019-0715-8	http://dx.doi.org/10.1038/s41388-019-0715-8			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30700831				2022-12-17	WOS:000468740200014
J	Avraham, S; Korin, B; Aviram, S; Shechter, D; Shaked, Y; Aronheim, A				Avraham, Shimrit; Korin, Ben; Aviram, Sharon; Shechter, Dvir; Shaked, Yuval; Aronheim, Ami			ATF3 and JDP2 deficiency in cancer associated fibroblasts promotes tumor growth via SDF-1 transcription	ONCOGENE			English	Article							JUN DIMERIZATION PROTEIN-2; ADAPTIVE-RESPONSE; AP-1 REPRESSOR; CELLS; MICROENVIRONMENT; ANGIOGENESIS; SDF-1/CXCL12; FACTOR-3; GENE; BETA	The activating transcription factor 3 (ATF3) and the c-Jun dimerization protein 2 (JDP2) are members of the basic leucine zipper (bZIP) family of transcription factors. These proteins share a high degree of homology and both can activate or repress transcription. Deficiency of either one of them in the non-cancer host cells was shown to reduce metastases. As ATF3 and JDP2 compensate each other's function, we studied the double deficiency of ATF3 and JDP2 in the stromal tumor microenvironment. Here, we show that mice with ATF3 and JDP2 double deficiency (designated thereafter dKO) developed larger tumors with high vascular perfusion and increased cell proliferation rate compared to wild type (WT) mice. We further identify that the underlying mechanism involves tumor associated fibroblasts which secrete high levels of stromal cell-derived factor 1 (SDF-1) in dKO fibroblasts. SDF-1 depletion in dKO fibroblasts dampened tumor growth and blood vessel perfusion. Furthermore, ATF3 and JDP2 were found to regulate SDF-1 transcription and secretion in fibroblasts, a phenomenon that is potentiated in the presence of cancer cells. Collectively, our results suggest that ATF3 and JDP2 regulate the expression of essential tumor promoting factors expressed by fibroblasts within the tumor microenvironment, and thus restrain tumor growth.	[Avraham, Shimrit; Aviram, Sharon; Shechter, Dvir; Shaked, Yuval; Aronheim, Ami] Technion Israel Inst Technol, Dept Cell Biol & Canc Sci, Rappaport Fac Med B, Haifa, Israel; [Korin, Ben] Technion Israel Inst Technol, Dept Immunol, Rappaport Fac Med B, Dept Neurosci, Haifa, Israel	Technion Israel Institute of Technology; Technion Israel Institute of Technology	Shaked, Y; Aronheim, A (corresponding author), Technion Israel Inst Technol, Dept Cell Biol & Canc Sci, Rappaport Fac Med B, Haifa, Israel.	yshaked@technion.ac.il; aronheim@technion.ac.il			Israel Science Foundation [731/17]; European Research Council H2020 [771112]; United States-Israel Binational grant [2015139]	Israel Science Foundation(Israel Science Foundation); European Research Council H2020; United States-Israel Binational grant	This research work was partially supported by the Israel Science Foundation grant #731/17 to A.A, the United States-Israel Binational grant #2015139 to A.A and the European Research Council H2020 (No. 771112) given to YS.	Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Barbarov Y, 2015, ONCOTARGET, V6, P37737, DOI 10.18632/oncotarget.5648; Bastian Seubert, 2015, HEPATOLOG, V61, P238; Bitton-Worms K, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-54; Buganim Y, 2011, CARCINOGENESIS, V32, P1749, DOI 10.1093/carcin/bgr203; Chang YS, 2017, P NATL ACAD SCI USA, V114, pE7159, DOI 10.1073/pnas.1700455114; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; Christopher W, 2003, NAT MED, V9, P8; Darlyuk-Saadon I, 2013, BIOCHIM BIOPHYS ACTA, V10, P54; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; FOLKMAN J, 1986, CANCER RES, V46, P467; Franco M, 2006, CANCER RES, V66, P3639, DOI 10.1158/0008-5472.CAN-05-3295; Franco OE, 2010, SEMIN CELL DEV BIOL, V21, P33, DOI 10.1016/j.semcdb.2009.10.010; Garcia-Moruja C, 2005, J MOL BIOL, V348, P43, DOI 10.1016/j.jmb.2005.02.016; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; Hai T, 2010, GENE EXPRESSION, V15, P1, DOI 10.3727/105221610X12819686555015; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hartman MG, 2004, MOL CELL BIOL, V24, P5721, DOI 10.1128/MCB.24.13.5721-5732.2004; Heinrich R, 2004, J BIOL CHEM, V279, P5708, DOI 10.1074/jbc.M307608200; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Jin CY, 2001, FEBS LETT, V489, P34, DOI 10.1016/S0014-5793(00)02387-5; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kalfon R, 2017, INT J CARDIOL, V249, P357, DOI 10.1016/j.ijcard.2017.08.074; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Katz S, 2001, FEBS LETT, V506, P196, DOI 10.1016/S0014-5793(01)02907-6; Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107; Kryczek I, 2007, AM J PHYSIOL-CELL PH, V292, pC987, DOI 10.1152/ajpcell.00406.2006; Lu D, 2006, J BIOL CHEM, V281, P10473, DOI 10.1074/jbc.M509278200; Ma S, 2014, CELL DEATH DIFFER, V21, P216, DOI 10.1038/cdd.2013.158; Madlambayan GJ, 2009, BLOOD, V114, P4310, DOI 10.1182/blood-2009-03-211342; Mao Y, 2013, CANCER METAST REV, V32, P303, DOI 10.1007/s10555-012-9415-3; Mashima T, 2001, J CELL PHYSIOL, V188, P352, DOI 10.1002/jcp.1130; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pan J, 2010, ONCOGENE, V29, P6245, DOI 10.1038/onc.2010.355; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shaked Y, 2008, CANCER CELL, V14, P263, DOI 10.1016/j.ccr.2008.08.001; Sharon Y, 2013, JOVE-J VIS EXP, DOI 10.3791/4425; Spaeth EL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004992; Timaner M, 2016, CURR PROTOC CELL BIO, V2016; Tsai MH, 2016, GENE, V590, P193, DOI 10.1016/j.gene.2016.03.048; Urruticoechea A, 2005, J CLIN ONCOL, V23, P7212, DOI 10.1200/JCO.2005.07.501; Wardell SE, 2002, MOL CELL BIOL, V22, P5451, DOI 10.1128/MCB.22.15.5451-5466.2002; Weidenfeld-Baranboim K, 2008, NUCLEIC ACIDS RES, V36, P3608, DOI 10.1093/nar/gkn268; Wolford CC, 2013, J CLIN INVEST, V123, P2893, DOI 10.1172/JCI64410; Yin X, 2008, ONCOGENE, V27, P2118, DOI 10.1038/sj.onc.1210861	49	15	15	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3812	3823		10.1038/s41388-019-0692-y	http://dx.doi.org/10.1038/s41388-019-0692-y			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30670778	hybrid, Green Published			2022-12-17	WOS:000468035600004
J	Zhang, SP; Guo, XW; Wu, HG; Sun, Y; Ma, XJ; Li, JK; Xu, Q; Wu, CX; Li, QW; Jiang, CZ; Li, WZ; Ho, MS; Lv, ZW; Xue, L				Zhang, Shiping; Guo, Xiaowei; Wu, Honggui; Sun, Ying; Ma, Xianjue; Li, Jikai; Xu, Qian; Wu, Chenxi; Li, Qiwen; Jiang, Cizhong; Li, Wenzhe; Ho, Margaret S.; Lv, Zhongwei; Xue, Lei			Wingless modulates activator protein-1-mediated tumor invasion	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; LONG-RANGE ACTION; BETA-CATENIN; ONCOGENIC RAS; CELL-DEATH; DROSOPHILA; MIGRATION; GROWTH; CANCER; PROLIFERATION	Metastasis begins with a subset of local tumor cells acquiring the potential to invade into surrounding tissues, and remains to be a major obstacle for cancer treatments. More than 90% of cancer patients died from tumor metastasis, instead of primary tumor growth. The canonical Wnt/beta-catenin pathway plays essential roles in promoting tumor formation, yet its function in regulating tumor metastasis and the underlying mechanisms remain controversial. Here we employed well-established Drosophila tumor models to investigate the regulating mechanism of Wingless (Wg) pathway in tumor invasion. Our results showed that Wg signaling is necessary and sufficient for cell polarity disruption-induced cell migration and molecular changes reminiscent of epithelial-mesenchymal transition (EMT). Moreover, reducing Wg signaling suppressed lgl(-/-)/Ras(V12)-induced tumor invasion, and cooperation between Arm and Ras(V12) is sufficient to induce tumor invasion. Mechanistically, we found that cell polarity disruption activates JNK signaling, which in turn upregulate wg expression through transcription factor activator protein-1 (AP-1). We identified a consensus AP-1 binding site located in the 2nd intron of wg, and confirmed that it is essential for AP-1 induced wg transcription both in vitro and in vivo. Lastly, we confirmed that the transcriptional activation of WNT by AP-1 is conserved in human cancer cells. These evidences reveal a positive role of Wnt/beta-catenin pathway in tumor invasion, and provide a conserved mechanism that connects JNK and Wnt signaling in regulating tumor progression.	[Zhang, Shiping; Guo, Xiaowei; Wu, Honggui; Sun, Ying; Ma, Xianjue; Li, Jikai; Wu, Chenxi; Li, Qiwen; Jiang, Cizhong; Li, Wenzhe; Lv, Zhongwei; Xue, Lei] Tongji Univ, Shanghai Peoples Hosp 10, Shanghai Key Lab Signaling & Dis Res, Inst Intervent Vessel,Sch Life Sci & Technol, 1239 Siping Rd, Shanghai 200092, Peoples R China; [Zhang, Shiping; Ho, Margaret S.] ShanghaiTech Univ, Sch Life Sci & Technol, 393 Middle Huaxia Rd, Shanghai 201210, Peoples R China; [Ma, Xianjue] Yale Univ, Sch Med, Dept Genet, Howard Hughes Med Inst, 295 Congress Ave, New Haven, CT 06519 USA; [Xu, Qian] Fujian Univ Tradit Chinese Med, Inst Integrated Chinese & Western Med, 1 Qiu Yang Rd, Fuzhou 350122, Fujian, Peoples R China; [Wu, Chenxi] North China Univ Sci & Technol, Coll Tradit Chinese Med, 21 Bohai Rd, Tangshan 063210, Peoples R China; [Xue, Lei] Zhuhai Peoples Hosp, Ctr Intervent Radiol, Zhuhai 519000, Peoples R China	Tongji University; ShanghaiTech University; Howard Hughes Medical Institute; Yale University; Fujian University of Traditional Chinese Medicine; North China University of Science & Technology	Xue, L (corresponding author), Tongji Univ, Shanghai Peoples Hosp 10, Shanghai Key Lab Signaling & Dis Res, Inst Intervent Vessel,Sch Life Sci & Technol, 1239 Siping Rd, Shanghai 200092, Peoples R China.; Xue, L (corresponding author), Zhuhai Peoples Hosp, Ctr Intervent Radiol, Zhuhai 519000, Peoples R China.	lei.xue@tongji.edu.cn	Ho, Margaret/K-6310-2017	Ho, Margaret/0000-0002-2387-7564; Ma, Xianjue/0000-0003-4360-3947	National Natural Science Foundation of China [31571516, 31701278, 31771595]; Shanghai Committee of Science and Technology [18430711600, 18140900400, 09DZ2260100]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Committee of Science and Technology(Shanghai Science & Technology Committee)	We thank Bloomington Drosophila Stock Center, Vienna Drosophila RNAi Center, Fly Stocks of National Institute of Genetics, the Core Facility of Drosophila Resource and Technology at SIBCB of CAS, Developmental Studies Hybridoma Bank, Dr. Jose ' Carlos Pastor-Pareja and Dr. Haiyun Song for fly stocks and antibodies. We thank Drs. Zhihua Liu, Ru Zhang, Fan Zhang and Jian Fei for cell lines and plasmids. We thank Dr. Mark Peifer and other lab members for discussion and critical comments. This work is founded by National Natural Science Foundation of China (31571516, 31701278 and 31771595), and Shanghai Committee of Science and Technology (18430711600, 18140900400, 09DZ2260100).	Agnes F, 1999, DEVELOPMENT, V126, P5453; Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Arozarena I, 2011, ONCOGENE, V30, P4531, DOI 10.1038/onc.2011.162; Bachmann IM, 2005, CLIN CANCER RES, V11, P8606, DOI 10.1158/1078-0432.CCR-05-0011; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chien AJ, 2009, P NATL ACAD SCI USA, V106, P1193, DOI 10.1073/pnas.0811902106; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Cordero JB, 2010, DEV CELL, V18, P999, DOI 10.1016/j.devcel.2010.05.014; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Fu L, 2011, GUT, V60, P1635, DOI 10.1136/gut.2011.241638; Gerlitz O, 2002, GENE DEV, V16, P1055, DOI 10.1101/gad.991802; Gonzalez C, 2013, NAT REV CANCER, V13, P172, DOI 10.1038/nrc3461; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hunter Kent W, 2008, Breast Cancer Res, V10 Suppl 1, pS2, DOI 10.1186/bcr1988; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Jung A, 2001, AM J PATHOL, V159, P1613, DOI 10.1016/S0002-9440(10)63007-6; Jung HY, 2015, CLIN CANCER RES, V21, P962, DOI 10.1158/1078-0432.CCR-13-3173; Liu LA, 2010, CLIN CANCER RES, V16, P2740, DOI 10.1158/1078-0432.CCR-09-2610; Ma X, 2016, ONCOGENE, V35, P846, DOI 10.1038/onc.2015.137; Ma X, 2014, CELL DEATH DIFFER, V21, P407, DOI 10.1038/cdd.2013.154; Ma X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.392; Ma XJ, 2017, P NATL ACAD SCI USA, V114, P1934, DOI 10.1073/pnas.1621359114; Ma XJ, 2013, DEV BIOL, V380, P211, DOI 10.1016/j.ydbio.2013.05.013; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Millar JBA, 2002, GENOME BIOL, V3; Morin X, 2001, P NATL ACAD SCI USA, V98, P15050, DOI 10.1073/pnas.261408198; Neumann CJ, 1997, DEVELOPMENT, V124, P871; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Pastor-Pareja JC, 2011, DEV CELL, V21, P245, DOI 10.1016/j.devcel.2011.06.026; Qiang YW, 2005, BLOOD, V106, P1786, DOI 10.1182/blood-2005-01-0049; Rallis A, 2010, DEV BIOL, V339, P65, DOI 10.1016/j.ydbio.2009.12.016; Rubin GM, 2000, SCIENCE, V287, P2216, DOI 10.1126/science.287.5461.2216; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Swarup S, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007930; Uhlirova M, 2006, EMBO J, V25, P5294, DOI 10.1038/sj.emboj.7601401; Ulivieri A, 2008, J PATHOL, V215, P87, DOI 10.1002/path.2331; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; van Amerongen R, 2009, DEVELOPMENT, V136, P3205, DOI 10.1242/dev.033910; Vidal M, 2006, DEV CELL, V10, P33, DOI 10.1016/j.devcel.2005.11.007; Wang AL, 2014, MOL CELL BIOCHEM, V395, P211, DOI 10.1007/s11010-014-2127-y; Wang X, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.196; Weston CR, 2007, CURR OPIN CELL BIOL, V19, P142, DOI 10.1016/j.ceb.2007.02.001; Yamben IF, 2013, DEV BIOL, V384, P41, DOI 10.1016/j.ydbio.2013.09.027; Yang JB, 2015, INT J CLIN EXP PATHO, V8, P11837; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhang S, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.85; Zhang SP, 2016, SCI REP-UK, V6, DOI 10.1038/srep22348; Zhao M, 2008, GENETICS, V178, P1947, DOI 10.1534/genetics.108.086983; Zi XL, 2005, CANCER RES, V65, P9762, DOI 10.1158/0008-5472.CAN-05-0103; Zulehner G, 2010, AM J PATHOL, V176, P472, DOI 10.2353/ajpath.2010.090300	56	15	15	2	29	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3871	3885		10.1038/s41388-018-0629-x	http://dx.doi.org/10.1038/s41388-018-0629-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30683884				2022-12-17	WOS:000468035600008
J	Vitiello, M; Evangelista, M; Di Lascio, N; Kusmic, C; Massa, A; Orso, F; Sarti, S; Marranci, A; Rodzik, K; Germelli, L; Chandra, D; Salvetti, A; Pucci, A; Taverna, D; Faita, F; Gravekamp, C; Poliseno, L				Vitiello, Marianna; Evangelista, Monica; Di Lascio, Nicole; Kusmic, Claudia; Massa, Annamaria; Orso, Francesca; Sarti, Samanta; Marranci, Andrea; Rodzik, Katarzyna; Germelli, Lorenzo; Chandra, Dinesh; Salvetti, Alessandra; Pucci, Angela; Taverna, Daniela; Faita, Francesco; Gravekamp, Claudia; Poliseno, Laura			Antitumoral effects of attenuated Listeria monocytogenes in a genetically engineered mouse model of melanoma	ONCOGENE			English	Article							VACCINE; IMMUNOTHERAPY	Attenuated Listeria monocytogenes (Lm(at)-LLO) represents a valuable anticancer vaccine and drug delivery platform. Here we show that in vitro Lm(at)-LLO causes ROS production and, in turn, apoptotic killing of a wide variety of melanoma cells, irrespectively of their stage, mutational status, sensitivity to BRAF inhibitors or degree of stemness. We also show that, when administered in the therapeutic setting to Braf/Pten genetically engineered mice, Lm(at)-LLO causes a strong decrease in the size and volume of primary melanoma tumors, as well as a reduction of the metastatic burden. At the molecular level, we confirm that the anti-melanoma activity exerted in vivo by Lm(at)-LLO depends also on its ability to potentiate the immune response of the organism against the infected tumor. Our data pave the way to the preclinical testing of listeria-based immunotherapeutic strategies against metastatic melanoma, using a genetically engineered mouse rather than xenograft models.	[Vitiello, Marianna; Evangelista, Monica; Di Lascio, Nicole; Kusmic, Claudia; Sarti, Samanta; Marranci, Andrea; Germelli, Lorenzo; Faita, Francesco; Poliseno, Laura] CNR, Inst Clin Physiol, Pisa, Italy; [Vitiello, Marianna; Sarti, Samanta; Marranci, Andrea; Germelli, Lorenzo; Poliseno, Laura] ISPRO, Core Res Lab, Oncogen Unit, Pisa, Italy; [Massa, Annamaria; Orso, Francesca; Taverna, Daniela] Univ Torino, MBC, Turin, Italy; [Massa, Annamaria; Orso, Francesca; Taverna, Daniela] Univ Torino, Dept Mol Biotechnol & Hlth Sci, Turin, Italy; [Orso, Francesca; Taverna, Daniela] Univ Torino, Ctr Complex Syst Mol Biol & Med, Turin, Italy; [Rodzik, Katarzyna] Ctr Postgrad Med Educ, Dept Biochem & Mol Biol, Warsaw, Poland; [Chandra, Dinesh; Gravekamp, Claudia] Albert Einstein Coll Med, Dept Microbiol & Immunol, New York, NY USA; [Salvetti, Alessandra] Univ Pisa, Dept Clin & Expt Med, Unit Expt Biol & Genet, Pisa, Italy; [Pucci, Angela] Pisa Univ Hosp, Dept Histopathol, Pisa, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); University of Turin; University of Turin; University of Turin; Centre of Postgraduate Medical Education - Poland; Yeshiva University; University of Pisa; University of Pisa; Azienda Ospedaliero Universitaria Pisana	Vitiello, M; Poliseno, L (corresponding author), CNR, Inst Clin Physiol, Pisa, Italy.; Vitiello, M; Poliseno, L (corresponding author), ISPRO, Core Res Lab, Oncogen Unit, Pisa, Italy.	mariannavitiello@live.it; laura.poliseno@cnr.it	Rodzik, Katarzyna/V-1038-2019; Chandra, Dinesh/P-4377-2014; Pucci, Angela/A-6509-2013; Kusmic, Claudia/AGY-5715-2022; Marranci, Andrea/AAA-7874-2019; Orso, Francesca/B-1985-2014; Poliseno, Laura/B-5711-2012; Massa, Annamaria/AAB-9872-2019; Vitiello, Marianna/AAC-3659-2022; Faita, Francesco/K-6681-2016	Chandra, Dinesh/0000-0001-5763-1645; Pucci, Angela/0000-0001-8110-4458; Marranci, Andrea/0000-0002-8334-8795; Massa, Annamaria/0000-0002-8156-3037; Vitiello, Marianna/0000-0001-7443-2728; GERMELLI, LORENZO/0000-0002-7318-7545; Orso, Francesca/0000-0003-4706-6464; Faita, Francesco/0000-0002-6201-1843	MFAG grant - Associazione Italiana per la Ricerca sul Cancro (AIRC) [17095]; ITT-Istituto Toscano Tumori; ISPRO-Istituto per lo Studio, la Prevenzione e la Rete Oncologica; Italian Ministry of Health [GR-2011-02348535]; EMBO short-term fellowship; AIRC fellowship	MFAG grant - Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); ITT-Istituto Toscano Tumori; ISPRO-Istituto per lo Studio, la Prevenzione e la Rete Oncologica; Italian Ministry of Health(Ministry of Health, Italy); EMBO short-term fellowship(European Molecular Biology Organization (EMBO)); AIRC fellowship(Fondazione AIRC per la ricerca sul cancro)	The authors would like to thank all the Poliseno lab members for their insightful discussions; S. Burchielli (FTGM, Pisa) for her assistance with animal procedures; D. Colecchia (IFC-CNR, ISPRO, Siena) for his assistance in preparing the figures; M. La Ferla (Fondazione Pisana per la Scienza, Pisa) for his assistance with the detection of listeria by FACS; G. Pelosi (IFC-CNR, Pisa) for his assistance with light microscopy; A. Ripoli (IFC-CNR, Pisa) for his support with statistical analyses; B. Stecca (ISPRO, Firenze) for providing us with the Aldefluor (TM). This work was supported by MFAG #17095 grant awarded by Associazione Italiana per la Ricerca sul Cancro (AIRC) to LP; start up funding awarded by ITT-Istituto Toscano Tumori and ISPRO-Istituto per lo Studio, la Prevenzione e la Rete Oncologica to LP. It was also supported by GR-2011-02348535 grant awarded by Italian Ministry of Health to LP. MV was supported by an EMBO short-term fellowship and an AIRC fellowship.	Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161; Buonaguro L, 2011, CLIN VACCINE IMMUNOL, V18, P23, DOI 10.1128/CVI.00286-10; Chandra D, 2017, ONCOTARGET, V8, P20729, DOI 10.18632/oncotarget.15117; Damsky WE, 2011, CANCER CELL, V20, P741, DOI 10.1016/j.ccr.2011.10.030; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Deng WW, 2018, P NATL ACAD SCI USA, V115, P8179, DOI 10.1073/pnas.1801910115; Flickinger JC, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030048; Grzywa TM, 2017, TRANSL ONCOL, V10, P956, DOI 10.1016/j.tranon.2017.09.007; Hellmann MD, 2017, IMMUNITY, V47, P221, DOI 10.1016/j.immuni.2017.08.001; Jahangir A, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1342025; Karachaliou N, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.06.47; Kee D, 2017, EJSO-EUR J SURG ONC, V43, P594, DOI 10.1016/j.ejso.2016.07.014; Kim SH, 2008, BRIT J CANCER, V99, P741, DOI 10.1038/sj.bjc.6604526; Kim SH, 2009, CANCER RES, V69, P5860, DOI 10.1158/0008-5472.CAN-08-4855; Klein WM, 2007, MODERN PATHOL, V20, P102, DOI 10.1038/modpathol.3800720; Liao W, 2011, CURR OPIN IMMUNOL, V23, P598, DOI 10.1016/j.coi.2011.08.003; Menzies AM, 2016, JAMA ONCOL, V2, P1259, DOI 10.1001/jamaoncol.2016.3418; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Pan ZK, 1999, CANCER RES, V59, P5264; Quispe-Tintaya W, 2013, P NATL ACAD SCI USA, V110, P8668, DOI 10.1073/pnas.1211287110; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Vitiello M, 2017, ONCOTARGET, V8, P25395, DOI 10.18632/oncotarget.15915; Wood LM, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00051; Xin G, 2017, P NATL ACAD SCI USA, V114, P740, DOI 10.1073/pnas.1614315114; Yuan P, 2013, P NATL ACAD SCI USA, V110, P18226, DOI 10.1073/pnas.1317577110	26	15	16	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3756	3762		10.1038/s41388-019-0681-1	http://dx.doi.org/10.1038/s41388-019-0681-1			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30664692	Green Published, hybrid			2022-12-17	WOS:000467379600014
J	Gianni, M; Terao, M; Kurosaki, M; Paroni, G; Brunelli, L; Pastorelli, R; Zanetti, A; Lupi, M; Acquavita, A; Bolis, M; Fratelli, M; Rochette-Egly, C; Garattini, E				Gianni, Maurizio; Terao, Mineko; Kurosaki, Mami; Paroni, Gabriela; Brunelli, Laura; Pastorelli, Roberta; Zanetti, Adriana; Lupi, Monica; Acquavita, Andrea; Bolis, Marco; Fratelli, Maddalena; Rochette-Egly, Cecile; Garattini, Enrico			S100A3 a partner protein regulating the stability/activity of RAR alpha and PML-RAR alpha in cellular models of breast/lung cancer and acute myeloid leukemia	ONCOGENE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; UNION-OF-PHARMACOLOGY; GROWTH-FACTOR; NUCLEAR; RECEPTOR; CELLS; DEGRADATION; PHOSPHORYLATION; EXPRESSION	All trans-retinoic acid (ATRA) is used in the treatment of acute promyelocytic leukemia (APL) and it is a promising agent also in solid tumors. The pharmacological activity of ATRA is mediated by the ligand-activated RAR and RXR transcription factors. In the present study, we define the basal and ATRA dependent RAR alpha interactome in a RAR alpha-overexpressing breast cancer cellular model, identifying 28 nuclear proteins. We focus our attention on the S100A3 calcium-binding protein, which interacts with RAR alpha constitutively. In ATRA-sensitive breast cancer cells, S100A3 binds to RAR alpha in basal conditions and binding is reduced by the retinoid. The interaction of S100A3 with RAR alpha is direct and in lung cancer, APL and acute-myeloid-leukemia (AML) cells. In APL, S100A3 interacts not only with RAR alpha, but also with PML-RAR alpha. The interaction surface maps to the RAR alpha ligand-binding domain, where the I396 residue plays a crucial role. Binding of S100A3 to RARWPML-RAR alpha controls the constitutive and ATRA-dependent degradation of these receptors. S100A3 knockdown decreases the amounts of RAR alpha in breast- and lung cancer cells, inducing resistance to ATRA-dependent antiproliferative/differentiating effects. Conversely, S100A3 knockdown in PML-RAR alpha(+) APL and PML-RAR alpha(-) AML cells reduces the amounts of RAR alpha/PML-RAR alpha and increases basal and ATRA-induced differentiation. In this cellular context, opposite effects on RAR alpha/PML-RAR alpha levels and ATRA-induced differentiation are observed upon S100A3 overexpression. Our results provide new insights into the molecular mechanisms controlling RARa activity and have practical implications, as S100A3 represents a novel target for rational drug combinations aimed at potentiating the activity of ATRA.	[Gianni, Maurizio; Terao, Mineko; Kurosaki, Mami; Paroni, Gabriela; Zanetti, Adriana; Acquavita, Andrea; Bolis, Marco; Fratelli, Maddalena; Garattini, Enrico] IRCCS, Ist Ric Farmacol Mario Negri, Lab Mol Biol, Via La Masa 19, I-20156 Milan, Italy; [Brunelli, Laura; Pastorelli, Roberta] IRCCS, Ist Ric Farmacol Mario Negri, Lab Mass Spectrometry, Via La Masa 19, I-20156 Milan, Italy; [Lupi, Monica] IRCCS, Ist Ric Farmacol Mario Negri, Lab Canc Pharmacol, Via La Masa 19, I-20156 Milan, Italy; [Rochette-Egly, Cecile] Univ Strasbourg, CNRS, Dept Funct Genom & Canc, IGBMC,INSERM,U964,UMR7104, 1 Rue Laurent Fries,BP 10142, F-67404 Illkirch Graffenstaden, France	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Garattini, E (corresponding author), IRCCS, Ist Ric Farmacol Mario Negri, Lab Mol Biol, Via La Masa 19, I-20156 Milan, Italy.	enrico.garattini@marionegri.it	adriana, zanetti/ABA-1189-2020; terao, mineko/AAU-8089-2020; Paroni, Gabriela/J-4848-2018; Pastorelli, Roberta/AAA-6736-2020; Bolis, Marco/AAC-2379-2019; Terao, Mineko/AAA-6415-2020; Brunelli, Laura/J-8664-2018; Gianni, Maurizio/ABG-6322-2020; Garattini, Enrico/AAI-1998-2019; KUROSAKI, Mami/ABG-2224-2020; Fratelli, Maddalena/AAA-6446-2020; Lupi, Monica/AAH-5704-2019	adriana, zanetti/0000-0002-5825-9707; Paroni, Gabriela/0000-0003-0132-0869; Pastorelli, Roberta/0000-0001-5097-600X; Bolis, Marco/0000-0003-4377-5079; Terao, Mineko/0000-0002-9976-9869; Brunelli, Laura/0000-0002-5465-9586; Gianni, Maurizio/0000-0002-6945-708X; KUROSAKI, Mami/0000-0001-8231-713X; Fratelli, Maddalena/0000-0002-1769-3427; Lupi, Monica/0000-0002-9835-7870; Garattini, Enrico/0000-0001-8983-886X	Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) [to Enrico Garattini] Funding Source: Medline	Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)(Fondazione AIRC per la ricerca sul cancro)		Benbrook DM, 2014, SUBCELL BIOCHEM, V70, P1, DOI 10.1007/978-94-017-9050-5_1; Berry DC, 2007, PPAR RES, V2007, DOI 10.1155/2007/73256; Bolis M, 2017, ANN ONCOL, V28, P611, DOI 10.1093/annonc/mdw660; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; Caccamo D, 2013, AMINO ACIDS, V44, P151, DOI 10.1007/s00726-011-1083-z; Carrier M, 2018, FEBS LETT, V592, P1426, DOI 10.1002/1873-3468.13033; Centritto F, 2015, EMBO MOL MED, V7, P950, DOI 10.15252/emmm.201404670; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; DANIELPOUR D, 1991, J CELL PHYSIOL, V148, P235, DOI 10.1002/jcp.1041480208; de The H, 2018, NAT REV CANCER, V18, P117, DOI 10.1038/nrc.2017.103; de The H, 2017, CANCER CELL, V32, P552, DOI 10.1016/j.ccell.2017.10.002; Eckert RL, 2004, J INVEST DERMATOL, V123, P23, DOI 10.1111/j.0022-202X.2004.22719.x; Gaillard E, 2006, P NATL ACAD SCI USA, V103, P9548, DOI 10.1073/pnas.0509717103; Garattini E, 2007, VITAM HORM, V75, P301, DOI 10.1016/S0083-6729(06)75012-9; Germain P, 2006, PHARMACOL REV, V58, P712, DOI 10.1124/pr.58.4.4; Germain P, 2006, PHARMACOL REV, V58, P760, DOI 10.1124/pr.58.4.7; Gianni M, 2006, EMBO J, V25, P739, DOI 10.1038/sj.emboj.7600981; Gianni M, 2012, LEUKEMIA, V26, P1850, DOI 10.1038/leu.2012.50; Gianni M, 1996, BLOOD, V87, P1520, DOI 10.1182/blood.V87.4.1520.bloodjournal8741520; Gianni' M, 2001, BLOOD, V97, P3234, DOI 10.1182/blood.V97.10.3234; Gianni M, 2017, ONCOTARGET, V8, P37041, DOI 10.18632/oncotarget.10556; Gianni M, 2009, CANCER RES, V69, P1016, DOI 10.1158/0008-5472.CAN-08-2603; Hatakeyama D, 2002, BBA-MOL CELL RES, V1589, P15, DOI 10.1016/S0167-4889(01)00183-5; Heizmann C. W., 2007, V45, P93; Hoedt E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104563; Hu LZ, 2014, J STEROID BIOCHEM, V144, P237, DOI 10.1016/j.jsbmb.2013.11.002; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Huang D, 2017, FRONT MED-PRC, V11, P410, DOI 10.1007/s11684-017-0527-6; Joo K, 2013, P NATL ACAD SCI USA, V110, P5987, DOI 10.1073/pnas.1220927110; Kani K, 2017, METHODS MOL BIOL, V1550, P171, DOI 10.1007/978-1-4939-6747-6_13; Kizawa K, 2013, BBA-MOL CELL RES, V1833, P1712, DOI 10.1016/j.bbamcr.2012.07.009; Kizawa K, 2011, BIOCHIMIE, V93, P2038, DOI 10.1016/j.biochi.2011.05.028; Lalevee S, 2010, METHODS MOL BIOL, V647, P251, DOI 10.1007/978-1-60761-738-9_15; le Maire A, 2010, NAT STRUCT MOL BIOL, V17, P801, DOI 10.1038/nsmb.1855; Levi L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9794; Li XP, 2016, ONCOL LETT, V11, P2839, DOI 10.3892/ol.2016.4294; Luscinskas FW, 2012, EUR J IMMUNOL, V42, P296, DOI 10.1002/eji.201142342; Mark M, 2006, ANNU REV PHARMACOL, V46, P451, DOI 10.1146/annurev.pharmtox.46.120604.141156; O'Connell PA, 2011, BLOOD, V117, P4095, DOI 10.1182/blood-2010-07-298851; Ovcharenko A, 2013, LEUKEMIA RES, V37, P956, DOI 10.1016/j.leukres.2013.03.010; Paroni G, 2012, ONCOGENE, V31, P3431, DOI 10.1038/onc.2011.506; Parrella E, 2004, J BIOL CHEM, V279, P42026, DOI 10.1074/jbc.M406530200; Piskunov A, 2014, SUBCELL BIOCHEM, V70, P103, DOI 10.1007/978-94-017-9050-5_6; Sahin U, 2014, J PATHOL, V234, P289, DOI 10.1002/path.4426; Schug TT, 2007, CELL, V129, P723, DOI 10.1016/j.cell.2007.02.050; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; Steinbach D, 2007, CANCER GENET CYTOGEN, V177, P51, DOI 10.1016/j.cancergencyto.2007.05.011; TAHAYATO A, 1993, MOL ENDOCRINOL, V7, P1642, DOI 10.1210/me.7.12.1642; Wu YZ, 2004, LEUKEMIA RES, V28, P203, DOI 10.1016/S0145-2126(03)00211-X; Yoshida H, 1996, CANCER RES, V56, P2945; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807; Zhu YL, 2017, FRONT MED-PRC, V11, P87, DOI 10.1007/s11684-016-0469-4	52	15	16	5	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2482	2500		10.1038/s41388-018-0599-z	http://dx.doi.org/10.1038/s41388-018-0599-z			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30532072	hybrid, Green Published			2022-12-17	WOS:000463335200004
J	Zhao, H; Martin, E; Matalkah, F; Shah, N; Ivanov, A; Ruppert, JM; Lockman, PR; Agazie, YM				Zhao, Hua; Martin, Elisha; Matalkah, Fatimah; Shah, Neal; Ivanov, Alexey; Ruppert, J. Michael; Lockman, Paul R.; Agazie, Yehenew M.			Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis	ONCOGENE			English	Article							EPIDERMAL-GROWTH-FACTOR; CRYSTAL-STRUCTURE; TYROSINE PHOSPHATASE; MOLECULAR-MECHANISM; BASAL-LIKE; MAMMARY; LEADS; PHOSPHORYLATION; TRANSITION; COMPLEX	Overexpression of the human epidermal growth factor receptor 2 (HER2) is the cause of HER2-positive breast cancer (BC). Although HER2-inactivating therapies have benefited BC patients, development of resistance and disease recurrence have been the major clinical problems, pointing to a need for alternative therapeutic strategies. For that to happen, proteins that play critical roles in the biology of HER2-induced tumorigenesis have to be identified and characterized. Here, we show that the Src homology phosphotyrosyl phosphatase 2 (Shp2) encoded by the Ptpn11 gene is a requisite for ErbB2-induced tumorigenesis. We report that conditional knockout of Shp2 alleles in the ErbB2 BC model mice abrogates mammary tumorigenesis by blocking the expression of the ErbB2 transgene. We also show that inhibition of SHP2 encoded by the PTPN11 gene in the HER2-amplified BC cells induces a normal-like cellular phenotype and suppresses tumorigenesis and metastasis by blocking HER2 overexpression. These findings demonstrate that ErbB2-induced tumors in mice or xenograft tumors induced by transplantation of HER2-amplified BC cells are vulnerable to SHP2 inhibition since it abrogates the expression of the very oncogene that causes of the disease. This report paves the way for developing SHP2-targeting therapies for BC treatment in the future.	[Zhao, Hua; Martin, Elisha; Matalkah, Fatimah; Ivanov, Alexey; Ruppert, J. Michael; Agazie, Yehenew M.] West Virginia Univ, Sch Med, Dept Biochem, Morgantown, WV 26506 USA; [Shah, Neal; Lockman, Paul R.] West Virginia Univ, Sch Med, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA; [Ivanov, Alexey; Ruppert, J. Michael; Agazie, Yehenew M.] West Virginia Univ, Sch Med, WVU Canc Inst, Morgantown, WV 26506 USA	West Virginia University; West Virginia University; West Virginia University	Agazie, YM (corresponding author), West Virginia Univ, Sch Med, Dept Biochem, Morgantown, WV 26506 USA.; Agazie, YM (corresponding author), West Virginia Univ, Sch Med, WVU Canc Inst, Morgantown, WV 26506 USA.	yagazie@hsc.wvu.edu		Ivanov, Alexey/0000-0002-8617-4604; Ruppert, John/0000-0001-6004-6527; Lockman, Paul/0000-0002-6995-9944; Matalkah, Fatimah/0000-0002-0160-3757	National Cancer Institute (NCI), a component of the National Institute of Health (NIH) [CA124940]; NIH [GM103488, GM104842, GM103434, P20RR016440, P30RR032138/P30GM103488]; NATIONAL CANCER INSTITUTE [R01CA124940] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM104942] Funding Source: NIH RePORTER	National Cancer Institute (NCI), a component of the National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by a grant (CA124940) from the National Cancer Institute (NCI), a component of the National Institute of Health (NIH) to YMA. The Flow Core and Imaging facilities are supported by grants from NIH (GM103488, GM104842, GM103434, P20RR016440, and P30RR032138/P30GM103488.). We would like to thank Dr. Benjamin Neel and Dr. Timothy Lane for providing the SHP2-floxed and the MMTV-Cre mice, respectively. Also, we thank Dr. Karen Martin, Dr. Amanda Ammer, and Mrs. Sarah McLaughlin for their support in microscopic and ultrasound imaging and Dr. Katherine Brundage for her support in FACS analyses.	Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; Ahmed Z, 2010, CELL SIGNAL, V22, P23, DOI 10.1016/j.cellsig.2009.08.011; Bentires-Alj M, 2006, NAT MED, V12, P114, DOI 10.1038/nm1341; Brandt BH, 1999, FASEB J, V13, P1939, DOI 10.1096/fasebj.13.14.1939; Burks J, 2006, ONCOGENE, V25, P7166, DOI 10.1038/sj.onc.1209728; Cleghon V, 1998, MOL CELL, V2, P719, DOI 10.1016/S1097-2765(00)80287-7; Deblois G, 2010, CANCER RES, V70, P10277, DOI 10.1158/0008-5472.CAN-10-2840; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dent S, 2013, CANCER TREAT REV, V39, P622, DOI 10.1016/j.ctrv.2013.01.002; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; FENG GS, 1994, ONCOGENE, V9, P1545; Fornaro M, 2006, J CELL BIOL, V175, P87, DOI 10.1083/jcb.200602029; Frearson JA, 1998, J EXP MED, V187, P1417, DOI 10.1084/jem.187.9.1417; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hartman Z, 2013, ONCOGENE, V32, P4169, DOI 10.1038/onc.2012.418; Hartman ZR, 2013, MOL CANCER RES, V11, P651, DOI 10.1158/1541-7786.MCR-12-0578; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Ke YH, 2006, J BIOL CHEM, V281, P34374, DOI 10.1074/jbc.M607325200; Kim YS, 2014, J BREAST CANCER, V17, P121, DOI 10.4048/jbc.2014.17.2.121; Lan LX, 2015, EMBO J, V34, P1493, DOI 10.15252/embj.201489004; Li G, 2002, DEVELOPMENT, V129, P4159; Matalkah F, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-015-0659-z; Muenst S, 2013, HISTOPATHOLOGY, V63, P74, DOI 10.1111/his.12140; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Pegram M D, 2000, Cancer Treat Res, V103, P57; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Verma S, 2012, NEW ENGL J MED, V367, P1783, DOI 10.1056/NEJMoa1209124; Zhao H, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1131-2; Zhou X, 2008, HISTOPATHOLOGY, V53, P389, DOI 10.1111/j.1365-2559.2008.03103.x; Zhou XD, 2008, CELL DEATH DIFFER, V15, P988, DOI 10.1038/cdd.2008.54; Zhou XD, 2009, J BIOL CHEM, V284, P12226, DOI 10.1074/jbc.M900020200	38	15	15	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2275	2290		10.1038/s41388-018-0574-8	http://dx.doi.org/10.1038/s41388-018-0574-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30467378	Green Submitted, Green Accepted			2022-12-17	WOS:000462588000004
J	Torres-Adorno, AM; Vitrac, H; Qi, Y; Tans, L; Levental, KR; Fan, YY; Yang, PY; Chapkin, RS; Eckhardt, BL; Ueno, NT				Torres-Adorno, Angie M.; Vitrac, Heidi; Qi, Yuan; Tans, Lin; Levental, Kandice R.; Fan, Yang-Yi; Yang, Peiying; Chapkin, Robert S.; Eckhardt, Bedrich L.; Ueno, Naoto T.			Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux	ONCOGENE			English	Article							HISTONE DEACETYLASE INHIBITOR; RECEPTOR TYROSINE KINASE; POOR-PROGNOSIS; FISH-OIL; EXPRESSION; OMEGA-3-FATTY-ACIDS; PROGRESSION; CELLS; OVEREXPRESSION; TUMORIGENESIS	Triple-negative breast cancer (TNBC), the most aggressive breast cancer subtype, currently lacks effective targeted therapy options. Eicosapentaenoic acid (EPA), an omega-3 fatty acid and constituent of fish oil, is a common supplement with anti-inflammatory properties. Although it is not a mainstream treatment, several preclinical studies have demonstrated that EPA exerts anti-tumor activity in breast cancer. However, against solid tumors, EPA as a monotherapy is clinically ineffective; thus, we sought to develop a novel targeted drug combination to bolster its therapeutic action against TNBC. Using a high-throughput functional siRNA screen, we identified Ephrin type-A receptor 2 (EPHA2), an oncogenic cell-surface receptor tyrosine kinase, as a therapeutic target that sensitizes TNBC cells to EPA. EPHA2 expression was uniquely elevated in TNBC cell lines and patient tumors. In independent functional expression studies in TNBC models, EPHA2 gene-silencing combined with EPA significantly reduced cell growth and enhanced apoptosis compared with monotherapies, both in vitro and in vivo. EPHA2-specific inhibitors similarly enhanced the therapeutic action of EPA. Finally, we identified that therapy-mediated apoptosis was attributed to a lethal increase in cancer cell membrane polarity due to ABCA1 inhibition and subsequent dysregulation of cholesterol homeostasis. This study provides new molecular and preclinical evidence to support a clinical evaluation of EPA combined with EPHA2 inhibition in patients with TNBC.	[Torres-Adorno, Angie M.] Univ Texas MD Anderson Canc Ctr, UThlth Grad Sch Biomed Sci, Houston, TX 77030 USA; [Torres-Adorno, Angie M.; Eckhardt, Bedrich L.; Ueno, Naoto T.] Univ Texas MD Anderson Canc Ctr, Sect Translat Breast Canc Res, Houston, TX 77030 USA; [Torres-Adorno, Angie M.; Eckhardt, Bedrich L.; Ueno, Naoto T.] Univ Texas MD Anderson Canc Ctr, Morgan Welch Inflammatory Breast Canc Res Program, Dept Breast Med Oncol, Houston, TX 77030 USA; [Vitrac, Heidi] McGovern Med Sch, UThlth, Dept Biochem & Mol Biol, Houston, TX USA; [Qi, Yuan] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Tans, Lin; Yang, Peiying] Univ Texas MD Anderson Canc Ctr, Dept Palliat Rehabil & Integrat Med, Houston, TX 77030 USA; [Levental, Kandice R.] McGovern Med Sch, UThlth, Dept Integrat Biol & Pharmacol, Houston, TX USA; [Fan, Yang-Yi; Chapkin, Robert S.] Texas A&M Univ, Dept Nutr & Food Sci, Program Integrat Nutr & Complex Dis, College Stn, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; Texas A&M University System; Texas A&M University College Station	Eckhardt, BL; Ueno, NT (corresponding author), Univ Texas MD Anderson Canc Ctr, Sect Translat Breast Canc Res, Houston, TX 77030 USA.; Eckhardt, BL; Ueno, NT (corresponding author), Univ Texas MD Anderson Canc Ctr, Morgan Welch Inflammatory Breast Canc Res Program, Dept Breast Med Oncol, Houston, TX 77030 USA.	beckhardt@mdanderson.org; nueno@mdanderson.org	; Vitrac, Heidi/R-7117-2018	Chapkin, Robert/0000-0002-6515-3898; Eckhardt, Bedrich/0000-0002-3402-3900; Vitrac, Heidi/0000-0002-8858-4914	Morgan Welch Inflammatory Breast Cancer Research Program; State of Texas Rare and Aggressive Breast Cancer Research Program; National Institutes of Health/National Cancer Institute [R01CA123318, P30CA016672]; Cancer Prevention and Research Institute of Texas [RP110532-P3]; John Dunn Research Foundation Endowment; NATIONAL CANCER INSTITUTE [R35CA197707, P30CA016672] Funding Source: NIH RePORTER	Morgan Welch Inflammatory Breast Cancer Research Program; State of Texas Rare and Aggressive Breast Cancer Research Program; National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Prevention and Research Institute of Texas; John Dunn Research Foundation Endowment; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Morgan Welch Inflammatory Breast Cancer Research Program, the State of Texas Rare and Aggressive Breast Cancer Research Program, the National Institutes of Health/National Cancer Institute through grants R01CA123318 and P30CA016672 (used the Characterized Cell Line Core, the Flow Cytometry and Cellular Imaging Facility, and the Bioinformatics Shared Resource at MD Anderson Cancer Center), the Cancer Prevention and Research Institute of Texas through grant RP110532-P3 (used MD Anderson's siRNA Screening Service), and the John Dunn Research Foundation Endowment awarded to William Dowhan.	Arnato KR, 2014, J CLIN INVEST, V124, P2037, DOI 10.1172/JCI72522; Bae SY, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1121-4; Brantley-Sieders DM, 2008, J CLIN INVEST, V118, P64, DOI 10.1172/JCI33154; Brinton EA, 2017, LIPIDS HEALTH DIS, V16, DOI 10.1186/s12944-017-0415-8; Chou JL, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-014-0036-2; Ciftci O, 2014, ANDROLOGIA, V46, P1161, DOI 10.1111/and.12209; Corsetto PA, 2012, CELL BIOCHEM BIOPHYS, V64, P45, DOI 10.1007/s12013-012-9365-y; Corsetto PA, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-73; Cortese F, 2016, PHARMACOL RES, V107, P1, DOI 10.1016/j.phrs.2016.02.012; Dunne PD, 2016, CLIN CANCER RES, V22, P230, DOI 10.1158/1078-0432.CCR-15-0603; Fabian CJ, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0571-6; Fan C, 2006, NEW ENGL J MED, V355, P560, DOI 10.1056/NEJMoa052933; Ford NA, 2015, CANCER PREV RES, V8, P796, DOI 10.1158/1940-6207.CAPR-15-0018; Fournier N, 2016, BBA-MOL CELL BIOL L, V1861, P331, DOI 10.1016/j.bbalip.2016.01.002; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Hou H, 2017, NEOPLASMA, V64, P81, DOI 10.4149/neo_2017_110; Hoy SM, 2017, AM J CARDIOVASC DRUG, V17, P157, DOI 10.1007/s40256-017-0213-8; Hu Yan-Wei, 2009, Atherosclerosis, V204, pe35, DOI 10.1016/j.atherosclerosis.2008.11.003; Huang J, 2014, ONCOGENE, V33, P2737, DOI 10.1038/onc.2013.238; Jaureguiberry MS, 2014, ACTA BIOCH BIOPH SIN, V46, P273, DOI 10.1093/abbs/gmt155; Kamat AA, 2009, CANCER-AM CANCER SOC, V115, P2684, DOI 10.1002/cncr.24335; Kinch MS, 2003, CLIN CANCER RES, V9, P613; Laviano A, 2013, CURR OPIN CLIN NUTR, V16, P156, DOI 10.1097/MCO.0b013e32835d2d99; Le Du F, 2015, ONCOTARGET, V6, P12890, DOI 10.18632/oncotarget.3849; Lee AHS, 1996, BRIT J CANCER, V74, P796, DOI 10.1038/bjc.1996.438; Lee J, 2014, BREAST CANCER RES TR, V146, P259, DOI 10.1007/s10549-014-3014-7; Madden SF, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3444; Makarewicz-Wujec M, 2017, KARDIOL POL, V75, P673, DOI 10.5603/KP.a2017.0072; Mandal CC, 2010, BIOCHEM BIOPH RES CO, V402, P602, DOI 10.1016/j.bbrc.2010.10.063; McAuliffe PF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136851; Miao H, 2009, CANCER CELL, V16, P9, DOI 10.1016/j.ccr.2009.04.009; Miserez AR, 2002, ATHEROSCLEROSIS, V164, P15, DOI 10.1016/S0021-9150(01)00762-6; Mudali SV, 2006, CLIN EXP METASTAS, V23, P357, DOI 10.1007/s10585-006-9045-7; Nandi S, 2009, J LIPID RES, V50, P456, DOI 10.1194/jlr.M800345-JLR200; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Park JE, 2013, GENES-BASEL, V4, P334, DOI 10.3390/genes4030334; Pencina MJ, 2014, NEW ENGL J MED, V370, P1422, DOI 10.1056/NEJMoa1315665; Pounds S, 2003, BIOINFORMATICS, V19, P1236, DOI 10.1093/bioinformatics/btg148; Ramos EJB, 2004, J AM COLL SURGEONS, V199, P716, DOI 10.1016/j.jamcollsurg.2004.07.014; Rose DP, 1996, CLIN CANCER RES, V2, P1751; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Song W, 2017, ONCOGENE, V36, P5620, DOI 10.1038/onc.2017.170; Sugiyama N, 2013, CELL CYCLE, V12, P2927, DOI 10.4161/cc.26180; Tandon M, 2011, EXPERT OPIN THER TAR, V15, P31, DOI 10.1517/14728222.2011.538682; Thaker PH, 2004, CLIN CANCER RES, V10, P5145, DOI 10.1158/1078-0432.CCR-03-0589; Torres-Adorno AM, 2017, CLIN CANCER RES, V23, P4780, DOI 10.1158/1078-0432.CCR-16-2622; Wang XP, 2017, ONCOTARGET, V8, P67904, DOI 10.18632/oncotarget.18958; Zelinski DP, 2001, CANCER RES, V61, P2301; Zhao WN, 2016, CANCER RES, V76, P2037, DOI 10.1158/0008-5472.CAN-15-1970	51	15	17	3	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					2135	2150		10.1038/s41388-018-0569-5	http://dx.doi.org/10.1038/s41388-018-0569-5			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30459358	Green Accepted			2022-12-17	WOS:000461822600010
J	Zhou, PJ; Wang, X; An, N; Wei, LZ; Zhang, L; Huang, XX; Zhu, HH; Fang, YX; Gao, WQ				Zhou, Pei-Jie; Wang, Xiao; An, Na; Wei, Lianzi; Zhang, Long; Huang, Xingxu; Zhu, Helen He; Fang, Yu-Xiang; Gao, Wei-Qiang			Loss of Par3 promotes prostatic tumorigenesis by enhancing cell growth and changing cell division modes	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; HIPPO PATHWAY; STEM-CELL; POLARITY PROTEIN; CANCER; CYCLE; COMPLEX; MURINE; BASAL; LINK	Although cell polarity plays an important role in epithelial tumorigenesis, the consequence of polarity protein loss in prostatic tumorigenesis and the underlying mechanisms remain unclear. Using conditional knockout mouse models, we found in the current study that loss of polarity protein Par3 increases prostatic epithelial cell growth, elevates symmetrical cell divisions in basal cells, and randomizes spindle orientation in luminal cells, causing the development of high-grade prostatic intraepithelial neoplasia (PIN). Mechanistically, loss of Par3 dissociates the Par3/merlin/Lats1 complex, consequently inhibiting phosphorylation of Lats1 to attenuate the Hippo pathway. Furthermore, attenuated Hippo pathway enhances nuclear translocation of Yes-associated protein (YAP), which promotes cell proliferation and symmetrical cell divisions through transcriptional activation of Ki-67 and Sox2. In addition, Lats1 dephosphorylation impairs its interaction with G protein signaling modulator 2 (GPSM2, which is also known as LGN) that causes randomization of spindle orientation in luminal cells. Interestingly, co-deletion of Par3 and Lats1 for complete blockade of the Hippo pathway in mice results in prostate tumor initiation, whereas co-deletion of Par3 and YAP for disrupting YAP nuclear translocation reverses the phenotypes to a relatively normal state. Therefore, our findings highlight combination of Par3 loss and blockade of the Hippo pathway as a novel mechanism for prostatic tumorigenesis.	[Zhou, Pei-Jie; Wang, Xiao; An, Na; Wei, Lianzi; Zhu, Helen He; Fang, Yu-Xiang; Gao, Wei-Qiang] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Renji Med X Clin Stern Cell Res Ctr, Ren Ji Hosp,Sch Med, Shanghai 200127, Peoples R China; [Zhang, Long] Zhejiang Univ, Life Sci Inst, Hangzhou 310058, Zhejiang, Peoples R China; [Zhang, Long] Zhejiang Univ, Innovat Ctr Cell Signalling Network, Hangzhou 310058, Zhejiang, Peoples R China; [Huang, Xingxu] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China; [Gao, Wei-Qiang] Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai 200030, Peoples R China; [Gao, Wei-Qiang] Shanghai Jiao Tong Univ, Med X Res Inst, Shanghai 200030, Peoples R China	Shanghai Jiao Tong University; Zhejiang University; Zhejiang University; ShanghaiTech University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Fang, YX; Gao, WQ (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Renji Med X Clin Stern Cell Res Ctr, Ren Ji Hosp,Sch Med, Shanghai 200127, Peoples R China.; Gao, WQ (corresponding author), Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai 200030, Peoples R China.; Gao, WQ (corresponding author), Shanghai Jiao Tong Univ, Med X Res Inst, Shanghai 200030, Peoples R China.	fyx2003108@sina.com; gao.weiqiang@sjtu.edu.cn	Gao, Wei/GXH-0380-2022; Zhang, Long/AAT-6571-2021	Zhang, Long/0000-0001-8139-0474; huang, xingxu/0000-0001-8934-1247	Ministry of Science and Technology of the People's Republic of China [2017YFA0102900, 2016YFA0502500]; National Natural Science Foundation of China [81672543, 81630073, 81372189]; Science and Technology Commission of Shanghai Municipality [16JC1405700]; High Peak IV subject on stem cells and translational medicine from Education Commission of Shanghai Municipality; KC Wong foundation	Ministry of Science and Technology of the People's Republic of China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); High Peak IV subject on stem cells and translational medicine from Education Commission of Shanghai Municipality; KC Wong foundation	This study was supported by funds from the Ministry of Science and Technology of the People's Republic of China (2017YFA0102900 to W-QG, 2016YFA0502500 to LZ), National Natural Science Foundation of China (81672543 to Y-XF, 81630073 and 81372189 to W-QG), Science and Technology Commission of Shanghai Municipality (16JC1405700 to W-QG), High Peak IV subject on stem cells and translational medicine from Education Commission of Shanghai Municipality, and KC Wong foundation (to W-QG).	Abate-Shen C, 2003, CANCER RES, V63, P3886; Basu-Roy U, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7411; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Bultje RS, 2009, NEURON, V63, P189, DOI 10.1016/j.neuron.2009.07.004; Carminati M, 2016, NAT STRUCT MOL BIOL, V23, P155, DOI 10.1038/nsmb.3152; Chang YL, 2015, ONCOTARGET, V6, P24017, DOI 10.18632/oncotarget.4447; Choi N, 2012, CANCER CELL, V21, P253, DOI 10.1016/j.ccr.2012.01.005; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Dikovskaya D, 2004, MOL BIOL CELL, V15, P2978, DOI 10.1091/mbc.E03-08-0613; Gladden AB, 2010, DEV CELL, V19, P727, DOI 10.1016/j.devcel.2010.10.008; Goldstein AS, 2008, P NATL ACAD SCI USA, V105, P20882, DOI 10.1073/pnas.0811411106; Goulas S, 2012, CELL STEM CELL, V11, P529, DOI 10.1016/j.stem.2012.06.017; Iden S, 2012, CANCER CELL, V22, P389, DOI 10.1016/j.ccr.2012.08.004; Ittmann M, 2013, CANCER RES, V73, P2718, DOI 10.1158/0008-5472.CAN-12-4213; Keder A, 2015, CURR BIOL, V25, P2739, DOI 10.1016/j.cub.2015.08.064; Lee YJ, 2014, NATURE, V510, P547, DOI 10.1038/nature13267; Lv XB, 2015, EMBO REP, V16, P975, DOI 10.15252/embr.201439951; Lygerou Z, 2000, SCIENCE, V290, P2271; Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169; McCaffrey LM, 2012, CANCER CELL, V22, P601, DOI 10.1016/j.ccr.2012.10.003; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Surzenko N, 2013, DEVELOPMENT, V140, P1445, DOI 10.1242/dev.071878; Thoma CR, 2009, NAT CELL BIOL, V11, P994, DOI 10.1038/ncb1912; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; von Stein W, 2005, DEVELOPMENT, V132, P1675, DOI 10.1242/dev.01720; Wang JJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4415; Wang X, 2009, NATURE, V461, P495, DOI 10.1038/nature08361; Williams SE, 2014, NAT CELL BIOL, V16, P758, DOI 10.1038/ncb3001; Xie YT, 2002, ONCOGENE, V21, P5791, DOI 10.1038/sj.onc.1205700; Yin F, 2013, CELL, V154, P1342, DOI 10.1016/j.cell.2013.08.025; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhou PJ, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0609-y	35	15	15	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					2192	2205		10.1038/s41388-018-0580-x	http://dx.doi.org/10.1038/s41388-018-0580-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30467379				2022-12-17	WOS:000461822600014
J	Traboulsi, T; El Ezzy, M; Dumeaux, V; Audemard, E; Mader, S				Traboulsi, Tatiana; El Ezzy, Mohamed; Dumeaux, Vanessa; Audemard, Eric; Mader, Sylvie			Role of SUMOylation in differential ER alpha transcriptional repression by tamoxifen and fulvestrant in breast cancer cells	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; SUMO MODIFICATION; POSTMENOPAUSAL WOMEN; HISTONE SUMOYLATION; TISSUE-SPECIFICITY; ANDROGEN RECEPTOR; ENDOCRINE THERAPY; PURE ANTIESTROGEN; ESR1 MUTATIONS; NUCLEAR	Antiestrogens (AEs) are widely used for treatment of estrogen receptor alpha (ER alpha)-positive breast cancer, but display variable degrees of partial agonism in estrogen target tissues and breast cancer (BC) cells. The fact that BC cells resistant to selective ER modulators (SERMs) like tamoxifen (Tam) can still be sensitive to pure AEs, also called selective ER downregulators, suggests different mechanisms of action, some of which may contribute to the more complete suppression of estrogen target genes by pure AEs. We report herein that pure AEs such as fulvestrant induce transient binding of ER alpha to DNA, followed by rapid release after 30-40 min without loss of nuclear localization. Loss of DNA binding preceded receptor degradation and was not prevented by proteasome inhibition. Chromatin was less accessible in the presence of fulvestrant than with estradiol or Tam as early as 20 min following treatment, suggesting that chromatin remodeling by pure AEs at ER alpha target regions prevents transcription in spite of receptor binding. SUMO2/3 marks were detected on chromatin at the peak of ER alpha binding in cells treated with pure AEs, but not SERMs. Furthermore, decreasing SUMOylation by overexpressing the deSUMOylase SENP1 significantly delayed receptor release from DNA and de-repressed expression of estrogen target genes in the presence of fulvestrant, both in ER alpha-expressing MCF-7 cells and in transiently transfected ER-negative SK-BR-3 cells. Finally, mutation V534E, identified in a breast metastasis resistant to hormonal therapies, prevented ER alpha modification and resulted in increased transcriptional activity of estrogen target genes in the presence of fulvestrant in SK-BR-3 cells. Together, our results establish a role for SUMOylation in achieving a more complete transcriptional shut-off of estrogen target genes by pure AEs vs. SERMs in BC cells.	[Traboulsi, Tatiana; El Ezzy, Mohamed; Dumeaux, Vanessa; Audemard, Eric; Mader, Sylvie] Inst Res Immunol & Canc, Montreal, PQ H3C 3J7, Canada; [Traboulsi, Tatiana; Mader, Sylvie] Univ Montreal, Dept Biochem & Mol Med, Montreal, PQ H3C 3J7, Canada; [Dumeaux, Vanessa] Concordia Univ, PERFORM Ctr, Montreal, PQ H4B 1R6, Canada	Universite de Montreal; Universite de Montreal; Concordia University - Canada	Mader, S (corresponding author), Inst Res Immunol & Canc, Montreal, PQ H3C 3J7, Canada.; Mader, S (corresponding author), Univ Montreal, Dept Biochem & Mol Med, Montreal, PQ H3C 3J7, Canada.	sylvie.mader@umontreal.ca		Audemard, Eric/0000-0002-1661-896X; Traboulsi, Tatiana/0000-0001-9769-0340	Canadian Institutes of Health Research [125863]; Canadian Imperial Bank of Commerce (CIBC) breast cancer research chair at Universite de Montreal; Fonds de recherche Quebec-sante (FRQS) scholarship; Universite de Montreal	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Imperial Bank of Commerce (CIBC) breast cancer research chair at Universite de Montreal; Fonds de recherche Quebec-sante (FRQS) scholarship; Universite de Montreal	This work has been funded by the Canadian Institutes of Health Research (grant 125863 to SM) and from the Canadian Imperial Bank of Commerce (CIBC) breast cancer research chair at Universite de Montreal (to SM). TT was the recipient of a Fonds de recherche Quebec-sante (FRQS) scholarship and both TT and MEE were recipients of several scholarships from the Universite de Montreal.	Ali S, 2011, ANNU REV MED, V62, P217, DOI 10.1146/annurev-med-052209-100305; Angus L, 2017, CANCER TREAT REV, V52, P33, DOI 10.1016/j.ctrv.2016.11.001; Bray NL, 2016, NAT BIOTECHNOL, V34, P888, DOI 10.1038/nbt0816-888d; DAUVOIS S, 1993, J CELL SCI, V106, P1377; Flach KD, 2016, J ENDOCRINOL, V229, pR43, DOI 10.1530/JOE-16-0003; Eeckhoute J, 2009, GENOME RES, V19, P372, DOI 10.1101/gr.084582.108; El Khissiin A, 1999, FEBS LETT, V448, P160, DOI 10.1016/S0014-5793(99)00343-9; Frasor J, 2004, CANCER RES, V64, P1522, DOI 10.1158/0008-5472.CAN-03-3326; GALLAGHER A, 1993, ENDOCRINOLOGY, V133, P2787, DOI 10.1210/en.133.6.2787; Garcia-Dominguez M, 2009, BBA-GENE REGUL MECH, V1789, P451, DOI 10.1016/j.bbagrm.2009.07.001; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Gushima M, 2010, MOL CELL ENDOCRINOL, V319, P14, DOI 10.1016/j.mce.2010.01.006; Hall JM, 2005, MOL INTERV, V5, P343, DOI 10.1124/mi.5.6.7; Harrod A, 2017, ONCOGENE, V36, P2286, DOI 10.1038/onc.2016.382; Heideker J, 2009, DNA REPAIR, V8, P517, DOI 10.1016/j.dnarep.2009.01.010; Hilmi K, 2012, MOL CELL BIOL, V32, P3823, DOI 10.1128/MCB.00290-12; Howell A, 2002, J CLIN ONCOL, V20, P3396, DOI 10.1200/JCO.2002.10.057; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; HU XF, 1993, INT J CANCER, V55, P873, DOI 10.1002/ijc.2910550529; Hua GQ, 2016, P NATL ACAD SCI USA, V113, pE635, DOI 10.1073/pnas.1522826113; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Lemieux S, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkx338; Lin DY, 2006, MOL CELL, V24, P341, DOI 10.1016/j.molcel.2006.10.019; Lin DY, 2004, MOL CELL BIOL, V24, P10529, DOI 10.1128/MCB.24.24.10529-10541.2004; Lupien M, 2007, MOL ENDOCRINOL, V21, P797, DOI 10.1210/me.2006-0074; LYKKESFELDT AE, 1994, CANCER RES, V54, P1587; LYKKESFELDT AE, 1995, INT J CANCER, V61, P529, DOI 10.1002/ijc.2910610417; Maison C, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2016.1225546; MARTIN L, 1978, J ENDOCRINOL, V78, P125, DOI 10.1677/joe.0.0780125; Martinkovich S, 2014, CLIN INTERV AGING, V9, P1437, DOI 10.2147/CIA.S66690; McDonnell DP, 2015, J MED CHEM, V58, P4883, DOI 10.1021/acs.jmedchem.5b00760; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579; Nathan D, 2006, GENE DEV, V20, P966, DOI 10.1101/gad.1404206; Neyret-Kahn H, 2013, GENOME RES, V23, P1563, DOI 10.1101/gr.154872.113; Osborne CK, 2002, J CLIN ONCOL, V20, P3386, DOI 10.1200/JCO.2002.10.058; Paakinaho V, 2014, NUCLEIC ACIDS RES, V42, P1575, DOI 10.1093/nar/gkt1033; Pike ACW, 2001, STRUCTURE, V9, P145, DOI 10.1016/S0969-2126(01)00568-8; Pimentel H, 2017, NAT METHODS, V14, P687, DOI 10.1038/nmeth.4324; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Pourcet B, 2010, J BIOL CHEM, V285, P5983, DOI 10.1074/jbc.M109.078311; Rahman S, 2017, NUCLEIC ACIDS RES, V45, P3017, DOI 10.1093/nar/gkw1220; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Robinson DR, 2013, NAT GENET, V45, P1446, DOI 10.1038/ng.2823; Sanchez R, 2002, BIOESSAYS, V24, P244, DOI 10.1002/bies.10066; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shih HM, 2007, BIOCHEM SOC T, V35, P1397, DOI 10.1042/BST0351397; Shilo Y, 2003, P NATL ACAD SCI USA, V100, P13225, DOI 10.1073/pnas.1735528100; Shin JA, 2005, MOL CELL, V19, P817, DOI 10.1016/j.molcel.2005.08.021; Simon JM, 2012, NAT PROTOC, V7, P256, DOI 10.1038/nprot.2011.444; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Stielow B, 2008, EMBO REP, V9, P899, DOI 10.1038/embor.2008.127; Tian S, 2002, BIOCHEM J, V367, P907, DOI 10.1042/BJ20021085; Tiefenbach J, 2006, MOL BIOL CELL, V17, P1643, DOI 10.1091/mbc.E05-07-0610; Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822; Traboulsi T, 2017, J MOL ENDOCRINOL, V58, pR15, DOI 10.1530/JME-16-0024; Uchimura Y, 2006, J BIOL CHEM, V281, P23180, DOI 10.1074/jbc.M602280200; WAKELING AE, 1991, CANCER RES, V51, P3867; WARD RL, 1993, BONE MINER, V22, P87, DOI 10.1016/S0169-6009(08)80220-6; Wardell SE, 2012, MOL ENDOCRINOL, V26, P1235, DOI 10.1210/me.2012-1031; Wardell SE, 2011, BIOCHEM PHARMACOL, V82, P122, DOI 10.1016/j.bcp.2011.03.031; Webb P, 2003, J BIOL CHEM, V278, P6912, DOI 10.1074/jbc.M208501200; Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200	67	15	15	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					1019	1037		10.1038/s41388-018-0468-9	http://dx.doi.org/10.1038/s41388-018-0468-9			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30190545	Green Published, hybrid			2022-12-17	WOS:000458624900007
J	Bao, YH; Guo, YC; Yang, YQ; Wei, XN; Zhang, SS; Zhang, YM; Li, K; Yuan, M; Guo, DL; Macias, V; Zhu, XD; Zhang, W; Yang, WC				Bao, Yonghua; Guo, Yongchen; Yang, Yiqiong; Wei, Xiaonan; Zhang, Shanshan; Zhang, Yongmeng; Li, Kai; Yuan, Ming; Guo, Dongli; Macias, Virgilia; Zhu, Xiangdong; Zhang, Wei; Yang, Wancai			PRSS8 suppresses colorectal carcinogenesis and metastasis	ONCOGENE			English	Article							E-CADHERIN EXPRESSION; BETA-CATENIN; IN-VITRO; CANCER; PROSTASIN; INVASIVENESS; LOCALIZATION; INFLAMMATION; WNT; APC	The serine protease PRSS8 has shown important physiological and pathological functions, but its roles in cancer initiation and progression are unclear. We developed and dynamically characterized a conditional knockout Prss8(fl/fl), p-Villin-Cre(+) mouse model. We found that genetic deficiency of the Prss8 gene caused spontaneous colitis and an inflamed rectum at an early age and caused intestinal tumors at a late age, which were linked to increased intestinal cell proliferation and migration but decreased cell differentiation. Increased PRSS8 expression inhibited cancer cell growth and metastasis in nude mice and inhibited cancer cell migration, invasion, colony formation and tumor sphere formation in vitro, but decreased PRSS8 expression facilitated malignancies in vivo and in vitro. Gene profiling on manipulated cancer cells and intestinal epithelial cells of Prss8 mouse models, gene set enrichment analysis and mechanistic studies revealed that PRSS8 targeted the Wnt/beta-catenin, epithelial-mesenchymal transition, and stem cell signaling pathways, which were further supported by the results from the TCGA data mining and validated by immunohistochemical staining on colorectal cancer tissue microarrays. In conclusion, PRSS8 is a novel tumor suppressor that plays critical roles in the suppression of colorectal carcinogenesis and metastasis.	[Bao, Yonghua; Guo, Yongchen; Yang, Yiqiong; Wei, Xiaonan; Zhu, Xiangdong; Zhang, Wei; Yang, Wancai] Jining Med Univ, Dept Pathol, Jining 272067, Peoples R China; [Bao, Yonghua; Guo, Yongchen; Yang, Yiqiong; Wei, Xiaonan; Zhu, Xiangdong; Zhang, Wei; Yang, Wancai] Jining Med Univ, Inst Precis Med, Jining 272067, Peoples R China; [Zhang, Shanshan; Zhang, Yongmeng; Li, Kai; Yuan, Ming] Xinxiang Med Univ, Dept Pathol, Xinxiang 453003, Peoples R China; [Guo, Dongli] Jining Med Univ, Affiliated Hosp, Dept Gastrointestinal Surg, Jining 272067, Peoples R China; [Macias, Virgilia; Yang, Wancai] Univ Illinois, Dept Pathol, Chicago, IL 60612 USA; [Zhu, Xiangdong] Univ Illinois, Dept Emergency Med, Chicago, IL 60612 USA; [Zhang, Wei] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA	Jining Medical University; Jining Medical University; Xinxiang Medical University; Jining Medical University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Northwestern University	Yang, WC (corresponding author), Jining Med Univ, Dept Pathol, Jining 272067, Peoples R China.; Yang, WC (corresponding author), Jining Med Univ, Inst Precis Med, Jining 272067, Peoples R China.; Yang, WC (corresponding author), Univ Illinois, Dept Pathol, Chicago, IL 60612 USA.	wyang06@uic.edu	Yang, Wancai/O-7655-2019	Yang, Wancai/0000-0001-7437-9197; Zhang, Wei/0000-0003-0875-263X	National Nature Science Foundation of China [81672750, 91229115, 81502105]; Key Laboratory of Higher Education Institutes of Shandong Province; Nature Science Foundation of Shandong Province [2016ZRB14436]; Taishan Scholar Program of Shandong Province, China; Innovation Team of Science and Technology, Henan Province, China; Startup Fund from Jining Medical University; Fostering fund from Jining Medical University	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Laboratory of Higher Education Institutes of Shandong Province; Nature Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); Taishan Scholar Program of Shandong Province, China; Innovation Team of Science and Technology, Henan Province, China; Startup Fund from Jining Medical University; Fostering fund from Jining Medical University	This work was supported in part by grants from the National Nature Science Foundation of China (grants 81672750 and 91229115 to WY, grant 81502105 to YB), a grant from the Key Laboratory of Higher Education Institutes of Shandong Province, the Nature Science Foundation of Shandong Province (grant 2016ZRB14436 to YG) and Taishan Scholar Program of Shandong Province, China, a grant from the Innovation Team of Science and Technology, Henan Province, China, the Startup Fund from Jining Medical University (to YB and YG) and Fostering fund from Jining Medical University (to YG). We would like to thank Prof. Weixing Zhao (Xinxiang Medical University, Xinxiang, China), Prof. Renya Zhang (Jining Medical University, Jining, China) and Prof. Anjia Han (Sun Yat-sen University, Guangzhou, China) for assistance with the histopathology analysis of the mouse models, Prof. Alan Diamond (University of Illinois at Chicago, Chicago, USA) for critical discussion, and Springer Nature Author Services for editing this manuscript. We would also like to thank the Research Histology and Tissue Imaging Core (RHTIC) facility at the University of Illinois at Chicago (Chicago, IL) for their technical assistance.	Aoki K, 2007, J CELL SCI, V120, P3327, DOI 10.1242/jcs.03485; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bao YH, 2016, ONCOTARGET, V7, P28540, DOI 10.18632/oncotarget.8677; Bao YH, 2016, ONCOTARGET, V7, P26780, DOI 10.18632/oncotarget.8511; Bao Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099132; Baranwal S, 2009, BIOCHEM BIOPH RES CO, V384, P6, DOI 10.1016/j.bbrc.2009.04.051; Beck B, 2013, NAT REV CANCER, V13, P727, DOI 10.1038/nrc3597; Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060; Bi XL, 2012, CARCINOGENESIS, V33, P326, DOI 10.1093/carcin/bgr293; Buchanan FG, 2006, CANCER CELL, V9, P6, DOI 10.1016/j.ccr.2005.12.029; Chen LM, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-377; Chen LM, 2004, PROSTATE, V59, P1, DOI 10.1002/pros.10346; Chen LM, 2002, INT J CANCER, V97, P323, DOI 10.1002/ijc.1601; Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013; DOKI Y, 1993, CANCER RES, V53, P3421; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Grivennikov SI, 2013, SEMIN IMMUNOPATHOL, V35, P229, DOI 10.1007/s00281-012-0352-6; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Grivennikov SI, 2010, CYTOKINE GROWTH F R, V21, P11, DOI 10.1016/j.cytogfr.2009.11.005; Hooper JD, 2000, BBA-GENE STRUCT EXPR, V1492, P63, DOI 10.1016/S0167-4781(00)00071-3; Hu D, 2008, CARCINOGENESIS, V29, P2317, DOI 10.1093/carcin/bgn239; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Keppner A, 2016, INFLAMM BOWEL DIS, V22, P2824, DOI 10.1097/MIB.0000000000000940; Lee SY, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0577-4; Liu JC, 2007, CANCER RES, V67, P8671, DOI 10.1158/0008-5472.CAN-07-1486; Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228; Mok SC, 2001, J NATL CANCER I, V93, P1458, DOI 10.1093/jnci/93.19.1458; Mokry M, 2012, NUCLEIC ACIDS RES, V40, P148, DOI 10.1093/nar/gkr720; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; OKA H, 1993, CANCER RES, V53, P1696; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Ordonez-Moran P, 2015, CANCER CELL, V28, P815, DOI 10.1016/j.ccell.2015.11.001; Paoni NF, 2003, PHYSIOL GENOMICS, V15, P228, DOI 10.1152/physiolgenomics.00078.2003; Peters DE, 2014, J BIOL CHEM, V289, P14740, DOI 10.1074/jbc.M113.541318; Rodriguez-Salas N, 2017, CRIT REV ONCOL HEMAT, V109, P9, DOI 10.1016/j.critrevonc.2016.11.007; Sakashita K, 2008, J SURG ONCOL, V98, P559, DOI 10.1002/jso.21158; Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674; Sarojini S, 2012, J ONCOL, V2012, DOI 10.1155/2012/709049; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takahashi S, 2003, PROSTATE, V54, P187, DOI 10.1002/pros.10178; Uchimura K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4428; UMBAS R, 1994, CANCER RES, V54, P3929; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wong NACS, 2002, AM J PATHOL, V160, P389, DOI 10.1016/S0002-9440(10)64856-0; Yang K, 2008, CANCER RES, V68, P7313, DOI 10.1158/0008-5472.CAN-08-0598; Yu JX, 1996, GENOMICS, V32, P334, DOI 10.1006/geno.1996.0127; YU JX, 1994, J BIOL CHEM, V269, P18843	50	15	15	2	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2019	38	4					497	517		10.1038/s41388-018-0453-3	http://dx.doi.org/10.1038/s41388-018-0453-3			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HI6UB	30115975				2022-12-17	WOS:000456589800004
J	Lai, CY; Liu, H; Tin, KX; Huang, Y; Yeh, KH; Peng, HW; Chen, HD; He, JY; Chiang, YJ; Liu, CS; Weng, SY; Tao, MH; Yen, JJY; Yang-Yen, HF				Lai, Ching-Yu; Liu, Hsuan; Tin, Kai Xuan; Huang, Yi; Yeh, Kun-Hai; Peng, Hubert W.; Chen, Huan-Da; He, Jun-Yu; Chiang, Yun-Jung; Liu, Chun-Shan; Weng, Shih-Yen; Tao, Mi-Hua; Yen, Jeffrey Jong-Young; Yang-Yen, Hsin-Fang			Identification of UAP1L1 as a critical factor for protein O-GlcNAcylation and cell proliferation in human hepatoma cells	ONCOGENE			English	Article							GLCNAC TRANSFERASE; C-MYC; CANCER; GLYCOSYLATION; SITE; METABOLISM; PLATFORM; GLYCANS; COMPLEX; DAMAGE	Aged hepatocyte-specific-Mcl-1 knockout (MKO-hep) mice are prone to develop liver tumors mimicking human hepatocellular carcinoma (HCC). Here we reported that a protein named UDP-N-acetylglucosamine pyrophosphorylase-1-like-1 (Uap1l1) is upregulated in the liver of young MKO-hep mice without any macroscopically detectable tumor nodules and is prominently expressed in the hepatic tumors developed in the aged MKO-hep mice. Intriguingly, human UAP1L1 is also significantly upregulated in a distinct subset of HCC tissues and patients with upregulated expression of UAP1L1 appeared to have poor prognosis. Overexpression of UAP1L1 significantly promoted, whereas UAP1L1 knockdown markedly reduced the proliferation of human hepatoma cells both in vitro and in vivo. UAP1L1 shows similar to 59% sequence identity to UDP-N-acetylglucosamine pyrophosphorylase-1 (UAP1), which is directly involved in the synthesis of the sugar donor (UDP-GlcNac) for N-acetylglucosamine modification (O-GlcNAcylation) of proteins. However, unlike UAP1, UAP1L1 harbors very limited UDP-GlcNAc synthesis activity. Moreover, although both UAP1 and UAP1L1 are required for O-GlcNAc transferase (OGT)-mediated protein O-GlcNAcylation, they appear to function distinctly from each other. UAP1L1 directly interacts with OGT, but does not seem to be an OGT substrate. In addition, UAP1L1 alone is not sufficient to activate OGT activity in vitro, suggesting that UAP1L1 may function together with other proteins to modulate OGT activity in vivo. Lastly, UAP1L1 knockdown attenuated c-MYC O-GlcNAcylation and protein stability, and overexpression of c-MYC significantly rescued the proliferation defect of UAP1L1 knockdown HepG2 cells, suggesting that c-MYC is one downstream target of UAP1L1 that contributes to UAP1L1-mediated cell proliferation, at least in HepG2 cells.	[Lai, Ching-Yu; Tin, Kai Xuan; Yeh, Kun-Hai; Peng, Hubert W.; Chen, Huan-Da; He, Jun-Yu; Weng, Shih-Yen; Yang-Yen, Hsin-Fang] Acad Sinica, Inst Mol Biol, Taipei, Taiwan; [Lai, Ching-Yu; Tao, Mi-Hua; Yen, Jeffrey Jong-Young; Yang-Yen, Hsin-Fang] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; [Liu, Hsuan; Huang, Yi] Chang Gung Univ, Mol Med Res Ctr, Taoyuan, Taiwan; [Liu, Hsuan] Chang Gung Univ, Dept Mol & Cellular Biol, Taoyuan, Taiwan; [Huang, Yi] ACT Genom Co LTD, Taipei, Taiwan; [Chiang, Yun-Jung; Liu, Chun-Shan; Tao, Mi-Hua; Yen, Jeffrey Jong-Young] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; [Weng, Shih-Yen] Taipei Med Univ, Wan Fang Hosp, Dept Internal Med, Div Gastroenterol, Taipei, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center; Chang Gung University; Chang Gung University; Academia Sinica - Taiwan; Taipei Medical University; Taipei Municipal WanFang Hospital	Yang-Yen, HF (corresponding author), Acad Sinica, Inst Mol Biol, Taipei, Taiwan.; Yang-Yen, HF (corresponding author), Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan.	imbyy@gate.sinica.edu.tw	Tao, Mi-Hua/S-7020-2018; Yang-Yen, Hsin-Fang/ABA-5808-2021; Yen, Jeffrey Jong-Young/Q-5134-2018	Yang-Yen, Hsin-Fang/0000-0001-9048-4800; Yen, Jeffrey Jong-Young/0000-0001-6299-1995; Chiang, Yun-Jung/0000-0001-5024-8977; Tao, Mi-Hua/0000-0002-4307-5729; Liu, Chun-Shan/0000-0003-0887-0484; Peng, Hubert/0000-0003-4881-1331	Academia Sinica; National Science Council of Taiwan [99-2320-B-001-009-MY3, 102-2320-B-001 -024 -MY3]; Chang Gung Memorial Hospital [CMRPG3D1512]; Ministry of Education of Taiwan [EMRPD1E1581]	Academia Sinica(Academia Sinica - Taiwan); National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); Chang Gung Memorial Hospital(Chang Gung Memorial Hospital); Ministry of Education of Taiwan(Ministry of Education, Taiwan)	We greatly appreciate the gift of mammalian OGT expression vectors from Dr Xiaochun Yu (Beckman Research Institute), the bacterial OGT expression vector from Dr Hsiu-Ming Shih (Academia Sinica), and various hepatoma cell lines from Dr Yuh-Shan Jou (Academia Sinica). We also thank Yi-Ning Chen at the Bioinformatics core at IMB for I-TASSER modeling and the Metabolomics Facilities of the Scientific Instrument Center at Academia Sinica for the analysis of the cellular levels of UDP-GlcNAc. This study was supported in part by an intramural fund from Academia Sinica and by grants (99-2320-B-001-009-MY3; 102-2320-B-001 -024 -MY3) from the National Science Council of Taiwan to H-FY-Y; funding to HL was provided by Chang Gung Memorial Hospital (CMRPG3D1512) and the Ministry of Education of Taiwan (EMRPD1E1581).	Butkinaree C, 2010, BBA-GEN SUBJECTS, V1800, P96, DOI 10.1016/j.bbagen.2009.07.018; Capotosti F, 2011, CELL, V144, P376, DOI 10.1016/j.cell.2010.12.030; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen Q, 2016, NUCLEIC ACIDS RES, V44, P9266, DOI 10.1093/nar/gkw663; Cheung WD, 2008, J BIOL CHEM, V283, P33935, DOI 10.1074/jbc.M806199200; CHOU TY, 1995, P NATL ACAD SCI USA, V92, P4417, DOI 10.1073/pnas.92.10.4417; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; Christiansen MN, 2014, PROTEOMICS, V14, P525, DOI 10.1002/pmic.201300387; Cummings RD, 2014, CHEM BIOL, V21, P1, DOI 10.1016/j.chembiol.2013.12.010; Fuster MM, 2005, NAT REV CANCER, V5, P526, DOI 10.1038/nrc1649; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; Hanover JA, 2012, NAT REV MOL CELL BIO, V13, P312, DOI 10.1038/nrm3334; Hikita H, 2009, HEPATOLOGY, V50, P1217, DOI 10.1002/hep.23126; Hill VK, 2011, CANCER RES, V71, P2988, DOI 10.1158/0008-5472.CAN-10-4026; Itkonen HM, 2013, CANCER RES, V73, P5277, DOI 10.1158/0008-5472.CAN-13-0549; Lau KS, 2008, GLYCOBIOLOGY, V18, P750, DOI 10.1093/glycob/cwn071; Lazarus MB, 2012, NAT CHEM BIOL, V8, P966, DOI [10.1038/NCHEMBIO.1109, 10.1038/nchembio.1109]; Lazarus MB, 2011, NATURE, V469, P564, DOI 10.1038/nature09638; Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527; Mio T, 1998, J BIOL CHEM, V273, P14392, DOI 10.1074/jbc.273.23.14392; Nakajima K, 2010, GLYCOBIOLOGY, V20, P865, DOI 10.1093/glycob/cwq044; Peneff C, 2001, EMBO J, V20, P6191, DOI 10.1093/emboj/20.22.6191; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5; Ruan HB, 2012, CELL METAB, V16, P226, DOI 10.1016/j.cmet.2012.07.006; Shibata T, 2014, NAT REV GASTRO HEPAT, V11, DOI 10.1038/nrgastro.2014.6; Stowell SR, 2015, ANNU REV PATHOL-MECH, V10, P473, DOI 10.1146/annurev-pathol-012414-040438; Terasaka N, 2011, NAT STRUCT MOL BIOL, V18, P1268, DOI 10.1038/nsmb.2121; Vick B, 2009, HEPATOLOGY, V49, P627, DOI 10.1002/hep.22664; Weber A, 2010, HEPATOLOGY, V51, P1226, DOI 10.1002/hep.23479; Wellen KE, 2012, NAT REV MOL CELL BIO, V13, P270, DOI 10.1038/nrm3305; Wellen KE, 2010, GENE DEV, V24, P2784, DOI 10.1101/gad.1985910; Weng SY, 2011, J HEPATOL, V54, P685, DOI 10.1016/j.jhep.2010.07.035; Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213; Yang XY, 2017, NAT REV MOL CELL BIO, V18, P452, DOI 10.1038/nrm.2017.22	36	15	15	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2019	38	3					317	331		10.1038/s41388-018-0442-6	http://dx.doi.org/10.1038/s41388-018-0442-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HH6OP	30097606				2022-12-17	WOS:000455851200002
J	Sbrissa, D; Semaan, L; Govindarajan, B; Li, YF; Caruthers, NJ; Stemmer, PM; Cher, ML; Sethi, S; Vaishampayan, U; Shisheva, A; Chinni, SR				Sbrissa, Diego; Semaan, Louie; Govindarajan, Barani; Li, Yanfeng; Caruthers, Nicholas J.; Stemmer, Paul M.; Cher, Michael L.; Sethi, Seema; Vaishampayan, Ulka; Shisheva, Assia; Chinni, Sreenivasa R.			A novel cross-talk between CXCR4 and PI4KIII alpha in prostate cancer cells	ONCOGENE			English	Article							CHEMOKINE RECEPTOR CXCR4; PLASMA-MEMBRANE; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 4-PHOSPHATE; SIGNALING PATHWAY; EXPRESSION; PROTEIN; MIGRATION; METASTASIS; DIMERIZATION	Chemokine signaling regulates cell migration and tumor metastasis. CXCL12, a member of the chemokine family, and its receptor, CXCR4, a G protein coupled receptor (GPCR), are key mediators of prostate-cancer (PC) bone metastasis. In PC cells androgens activate CXCR4 gene expression and receptor signaling on lipid rafts, which induces protease expression and cancer cell invasion. To identify novel lipid-raft-associated CXCR4 regulators supporting invasion/metastasis, we performed a SILAC-based quantitative proteomic analysis of lipid-rafts derived from PC3 stable cell lines with overexpression or knockdown of CXCR4. This analysis identified the evolutionarily conserved phosphatidylinositol 4-kinase III alpha (PI4KIII alpha), and SAC1 phosphatase that dephosphorylates phosphatidylinositol-4-phosphate as potential candidate CXCR4 regulators. CXCR4 interacted with PI4KIII alpha membrane targeting machinery recruiting them to the plasma membrane for PI4P production. Consistent with this interaction, PI4KIII alpha was found tightly linked to the CXCR4 induced PC cell invasion. Thus, ablation of PI4KIII alpha in CXCR4-expressing PC3 cells reduced cellular invasion in response to a variety of chemokines. Immunofluorescence microscopy in CXCR4-expressing cells revealed localized production of PI4P on the invasive projections. Human tumor studies documented increased PI4KIII alpha expression in metastatic tumors vs. the primary tumor counterparts, further supporting the PI4KIIIa role in tumor metastasis. Furthermore, we also identified an unexpected function of PI4KIII alpha in GPCR signaling where CXCR4 regulates PI4KIII alpha activity and mediate tumor metastasis. Altogether, our study identifies a novel cross-talk between PI4KIII alpha and CXCR4 in promoting tumor metastasis and suggests that PI4KIII alpha pharmacological targeting may have therapeutic benefit for advanced prostate cancer patients.	[Sbrissa, Diego; Semaan, Louie; Li, Yanfeng; Cher, Michael L.; Chinni, Sreenivasa R.] Wayne State Univ, Sch Med, Dept Urol, Detroit, MI 48201 USA; [Sbrissa, Diego; Shisheva, Assia] Wayne State Univ, Sch Med, Dept Physiol, Detroit, MI 48201 USA; [Govindarajan, Barani; Cher, Michael L.; Sethi, Seema; Chinni, Sreenivasa R.] Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; [Caruthers, Nicholas J.; Stemmer, Paul M.] Wayne State Univ, Sch Med, Inst Environm Hlth Sci, Detroit, MI 48201 USA; [Caruthers, Nicholas J.; Stemmer, Paul M.] Wayne State Univ, Sch Med, Prote Core Facil, Detroit, MI 48201 USA; [Cher, Michael L.; Vaishampayan, Ulka; Chinni, Sreenivasa R.] Wayne State Univ, Sch Med, Dept Oncol, Detroit, MI 48201 USA	Wayne State University; Wayne State University; Wayne State University; Wayne State University; Wayne State University; Wayne State University	Chinni, SR (corresponding author), Wayne State Univ, Sch Med, Dept Urol, Detroit, MI 48201 USA.; Chinni, SR (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA.; Chinni, SR (corresponding author), Wayne State Univ, Sch Med, Dept Oncol, Detroit, MI 48201 USA.	schinni@med.wayne.edu		Stemmer, Paul/0000-0003-3315-9846; Vaishampayan, Ulka/0000-0001-5800-4571	U.S. Department of Defense [W81XWH-09-1-0250]; NIH-NCI Grant [CA151557]; Fund for Cancer Research; NATIONAL CANCER INSTITUTE [R01CA151557] Funding Source: NIH RePORTER	U.S. Department of Defense(United States Department of Defense); NIH-NCI Grant; Fund for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Special thanks to Dr. Balla for providing PI4KIII alpha and EFR3B expression constructs, Dr. DeCamilli for TTC7B construct and Dr. Mayinger for anti-Sac1 antibodies. We would like to thank Mr. Ussama A. Khan for technical assistance in preparing data. We also thank Astellas/Medivation for supporting clinical protocol for human tumor biopsy material collection. Supported by U.S. Department of Defense, W81XWH-09-1-0250, NIH-NCI Grant CA151557 and Fund for Cancer Research.	Ao MF, 2007, CANCER RES, V67, P4244, DOI 10.1158/0008-5472.CAN-06-3946; Bachelder RE, 2002, CANCER RES, V62, P7203; Baird D, 2008, J CELL BIOL, V183, P1061, DOI 10.1083/jcb.200804003; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Balla A, 2005, MOL BIOL CELL, V16, P1282, DOI 10.1091/mbc.E04-07-0578; Balla A, 2006, TRENDS CELL BIOL, V16, P351, DOI 10.1016/j.tcb.2006.05.003; Balla A, 2008, MOL BIOL CELL, V19, P711, DOI 10.1091/mbc.E07-07-0713; Baskin JM, 2016, NAT CELL BIOL, V18, P132, DOI 10.1038/ncb3271; Bendall SC, 2008, MOL CELL PROTEOMICS, V7, P1587, DOI 10.1074/mcp.M800113-MCP200; Bojjireddy N, 2015, J CELL SCI, V128, P118, DOI 10.1242/jcs.157495; Bojjireddy N, 2014, J BIOL CHEM, V289, P6120, DOI 10.1074/jbc.M113.531426; Bunney TD, 2010, NAT REV CANCER, V10, P342, DOI 10.1038/nrc2842; Burke JE, 2014, SCIENCE, V344, P1035, DOI 10.1126/science.1253397; Cai JA, 2010, TRANSL ONCOL, V3, P195, DOI 10.1593/tlo.09328; Cao CH, 2008, MOL BIOL CELL, V19, P3334, DOI 10.1091/mbc.E08-04-0367; Castellone MD, 2004, ONCOGENE, V23, P5958, DOI 10.1038/sj.onc.1207790; Chinni SR, 2006, PROSTATE, V66, P32, DOI 10.1002/pros.20318; Chinni SR, 2008, MOL CANCER RES, V6, P446, DOI 10.1158/1541-7786.MCR-07-0117; Chu KME, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.84; Chung JY, 2015, EMBO REP, V16, P312, DOI 10.15252/embr.201439151; Coke CJ, 2016, J BIOL CHEM, V291, P9991, DOI 10.1074/jbc.M115.712661; Conley-LaComb MK, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0552-0; Di Paolo G, 2006, NATURE, V443, P651, DOI 10.1038/nature05185; Dillenburg-Pilla P, 2015, FASEB J, V29, P1056, DOI 10.1096/fj.14-260083; Hammond GRV, 2009, BIOCHEM J, V422, P23, DOI 10.1042/BJ20090428; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Ikonomov OC, 2011, J BIOL CHEM, V286, P13404, DOI 10.1074/jbc.M111.222364; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kukreja P, 2005, CANCER RES, V65, P9891, DOI 10.1158/0008-5472.CAN-05-1293; Lee BC, 2005, CANCER RES, V65, P2840, DOI 10.1158/0008-5472.CAN-04-3309; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nakatsu F, 2012, J CELL BIOL, V199, P1003, DOI 10.1083/jcb.201206095; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Phillips RJ, 2005, J BIOL CHEM, V280, P22473, DOI 10.1074/jbc.M500963200; Sbrissa D, 1999, J BIOL CHEM, V274, P21589, DOI 10.1074/jbc.274.31.21589; Sbrissa D, 2007, J BIOL CHEM, V282, P23878, DOI 10.1074/jbc.M611678200; Schioppa T, 2003, J EXP MED, V198, P1391, DOI 10.1084/jem.20030267; Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414; Singareddy R, 2013, MOL CANCER RES, V11, P1349, DOI 10.1158/1541-7786.MCR-12-0705; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; Wang JH, 2006, MOL CANCER THER, V5, P2474, DOI 10.1158/1535-7163.MCT-05-0261; Wu XD, 2014, DEV CELL, V28, P19, DOI 10.1016/j.devcel.2013.11.012	43	15	16	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2019	38	3					332	344		10.1038/s41388-018-0448-0	http://dx.doi.org/10.1038/s41388-018-0448-0			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HH6OP	30111818	Green Accepted			2022-12-17	WOS:000455851200003
J	Bechard, ME; Word, AE; Tran, AV; Liu, XJ; Locasale, JW; McDonald, OG				Bechard, Matthew E.; Word, Anna E.; Tran, Amanda V.; Liu, Xiaojing; Locasale, Jason W.; McDonald, Oliver G.			Pentose conversions support the tumorigenesis of pancreatic cancer distant metastases	ONCOGENE			English	Article							ANABOLIC GLUCOSE-METABOLISM; RAS-TRANSFORMED CELLS; PROMOTE TUMOR-GROWTH; 6-PHOSPHOGLUCONATE DEHYDROGENASE; DUCTAL ADENOCARCINOMA; PHOSPHATE PATHWAY; KRAS; PATTERNS; PROTEIN; BIOSYNTHESIS	Pancreatic ductal adenocarcinoma (PDAC) adopts several unique metabolic strategies to support primary tumor growth. Whether additional metabolic strategies are adopted to support metastatic tumorigenesis is less clear. This could be particularly relevant for distant metastasis, which often follows a rapidly progressive clinical course. Here we report that PDAC distant metastases evolve a unique series of metabolic reactions to maintain activation of the anabolic glucose enzyme phosphogluconate dehydrogenase (PGD). PGD catalytic activity was recurrently elevated across distant metastases, and modulating PGD activity levels dictated tumorigenic capacity. Metabolomics data raised the possibility that distant metastases evolved a core pentose conversion pathway (PCP) that converted glucose-derived metabolites into PGD substrate, thereby hyperactivating the enzyme. Consistent with this, each individual metabolite in the PCP stimulated PGD catalysis in distant metastases, and knockdown of each individual PCP enzyme selectively impaired tumorigenesis. We propose that the PCP manufactures PGD substrate outside of the rate-limiting oxidative pentose phosphate pathway (oxPPP). This enables PGD-dependent tumorigenesis by providing adequate substrate to fuel high catalytic activity, and raises the possibility that PDAC distant metastases adopt their own unique metabolic strategies to support tumor growth.	[Bechard, Matthew E.; Word, Anna E.; Tran, Amanda V.; McDonald, Oliver G.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, 221 Kirkland Hall, Nashville, TN 37235 USA; [Word, Anna E.] Vanderbilt Univ, Dept Biomed Engn, Nashville, TN 37235 USA; [Liu, Xiaojing; Locasale, Jason W.] Duke Univ, Sch Med, Duke Canc Inst, Durham, NC USA; [Liu, Xiaojing; Locasale, Jason W.] Duke Univ, Sch Med, Duke Mol Physiol Inst, Durham, NC USA; [Liu, Xiaojing; Locasale, Jason W.] Duke Univ, Sch Med, Dept Pharmacol & Canc Biol, Durham, NC USA; [McDonald, Oliver G.] Vanderbilt Univ, Med Ctr, Epithelial Biol Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA; [McDonald, Oliver G.] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA	Vanderbilt University; Vanderbilt University; Duke University; Duke University; Duke University; Vanderbilt University; Vanderbilt University	McDonald, OG (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, 221 Kirkland Hall, Nashville, TN 37235 USA.; McDonald, OG (corresponding author), Vanderbilt Univ, Med Ctr, Epithelial Biol Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA.; McDonald, OG (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA.	oliver.g.mcdonald@vanderbilt.edu	Locasale, Jason W/ABE-6505-2020	Locasale, Jason W/0000-0002-7766-3502; Word, Anna/0000-0002-6088-1781; Liu, Xiaojing/0000-0002-4231-6017	AACR Pancreatic Cancer Action Network Pathway to Leadership grant; Vanderbilt GI SPORE; Vanderbilt Digestive Diseases Research Center; NATIONAL CANCER INSTITUTE [R01CA222594] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [S10OD021630, S10OD018164] Funding Source: NIH RePORTER	AACR Pancreatic Cancer Action Network Pathway to Leadership grant; Vanderbilt GI SPORE; Vanderbilt Digestive Diseases Research Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the AACR Pancreatic Cancer Action Network Pathway to Leadership grant (OGM), the Vanderbilt GI SPORE (OGM), and the Vanderbilt Digestive Diseases Research Center (OGM).	Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Bryant KL, 2014, TRENDS BIOCHEM SCI, V39, P91, DOI 10.1016/j.tibs.2013.12.004; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Carter H, 2010, CANCER BIOL THER, V10, P582, DOI 10.4161/cbt.10.6.12537; Cheung WKC, 2013, CANCER CELL, V23, P725, DOI 10.1016/j.ccr.2013.04.009; Commisso C, 2013, NATURE, V497, P633, DOI 10.1038/nature12138; Davidson SM, 2017, NAT MED, V23, P235, DOI 10.1038/nm.4256; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; DYSON JED, 1971, BIOCHEM BIOPH RES CO, V43, P183, DOI 10.1016/S0006-291X(71)80104-3; Egger S, 2010, BIOCHEM SOC T, V38, P1378, DOI 10.1042/BST0381378; Embuscado EE, 2005, CANCER BIOL THER, V4, P548, DOI 10.4161/cbt.4.5.1663; Habrook CJ, 2017, CANCER CELL, V31, P5, DOI 10.1016/j.ccell.2016.12.006; Haeno H, 2012, CELL, V148, P362, DOI 10.1016/j.cell.2011.11.060; Hanau S, 2013, BBA-PROTEINS PROTEOM, V1834, P2647, DOI 10.1016/j.bbapap.2013.09.018; Hitosugi T, 2012, CANCER CELL, V22, P585, DOI 10.1016/j.ccr.2012.09.020; Iacobuzio-Donahue CA, 2009, J CLIN ONCOL, V27, P1806, DOI 10.1200/JCO.2008.17.7188; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kamphorst JJ, 2015, CANCER RES, V75, P544, DOI 10.1158/0008-5472.CAN-14-2211; Kamphorst JJ, 2013, P NATL ACAD SCI USA, V110, P8882, DOI 10.1073/pnas.1307237110; KOHLER E, 1970, FEBS LETT, V6, P225, DOI 10.1016/0014-5793(70)80063-1; Linster CL, 2007, FEBS J, V274, P1, DOI 10.1111/j.1742-4658.2006.05607.x; Makohon-Moore A, 2016, NAT REV CANCER, V16, P553, DOI 10.1038/nrc.2016.66; Makohon-Moore AP, 2017, NAT GENET, V49, P358, DOI 10.1038/ng.3764; McDonald OG, 2017, NAT GENET, V49, P367, DOI 10.1038/ng.3753; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Mueller S, 2018, NATURE, V554, P62, DOI 10.1038/nature25459; Murphy SJ, 2016, CANCER RES, V76, P749, DOI 10.1158/0008-5472.CAN-15-2198; Murphy SJ, 2013, GASTROENTEROLOGY, V145, P1098, DOI 10.1053/j.gastro.2013.07.049; Notta F, 2016, NATURE, V538, P378, DOI 10.1038/nature19823; Patra KC, 2014, TRENDS BIOCHEM SCI, V39, P347, DOI 10.1016/j.tibs.2014.06.005; Qiu WL, 2011, ONCOTARGET, V2, P862; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Ridky TW, 2010, NAT MED, V16, P1450, DOI 10.1038/nm.2265; Rippa M, 1998, BBA-PROTEIN STRUCT M, V1429, P83, DOI 10.1016/S0167-4838(98)00222-2; Rohatgi N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098760; Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Shan CL, 2014, MOL CELL, V55, P552, DOI 10.1016/j.molcel.2014.06.020; Shi JW, 2015, NAT BIOTECHNOL, V33, P661, DOI 10.1038/nbt.3235; Singh A, 2013, J CLIN INVEST, V123, P2921, DOI 10.1172/JCI66353; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Sousa CM, 2016, NATURE, V536, P479, DOI 10.1038/nature19084; Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Yachida S, 2012, CLIN CANCER RES, V18, P6339, DOI 10.1158/1078-0432.CCR-12-1215; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Yao PB, 2017, J BIOL CHEM, V292, P17113, DOI 10.1074/jbc.M117.810309; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; Zhong Y, 2017, CLIN CANCER RES, V23, P1607, DOI 10.1158/1078-0432.CCR-15-1615	54	15	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2018	37	38					5248	5256		10.1038/s41388-018-0346-5	http://dx.doi.org/10.1038/s41388-018-0346-5			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU2IP	29849117	Green Accepted			2022-12-17	WOS:000445093100008
J	Gabbasov, R; Xiao, F; Howe, CG; Bickel, LE; O'Brien, SW; Benrubi, D; Do, TV; Zhou, Y; Nicolas, E; Cai, KQ; Litwin, S; Seo, S; Golemis, EA; Connolly, DC				Gabbasov, Rashid; Xiao, Fang; Howe, Caitlin G.; Bickel, Laura E.; O'Brien, Shane W.; Benrubi, Daniel; Do, Thuy-Vy; Zhou, Yan; Nicolas, Emmanuelle; Cai, Kathy Q.; Litwin, Samuel; Seo, Sachiko; Golemis, Erica A.; Connolly, Denise C.			NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice	ONCOGENE			English	Article							SUBSTRATE LYMPHOCYTE TYPE; EPITHELIAL-CELL; FALLOPIAN-TUBE; T-CELLS; EXPRESSION; CARCINOMA; KINASE; DIFFERENTIATION; MIGRATION; SURVIVAL	Neural precursor cell expressed, developmentally downregulated 9 (NEDD9) supports oncogenic signaling in a number of solid and hematologic tumors. Little is known about the role of NEDD9 in ovarian carcinoma (OC), but available data suggest elevated mRNA and protein expression in advanced stage high-grade cancers. We used a transgenic MISIIR-TAg mouse OC model combined with genetic ablation of Nedd9 to investigate its action in the development and progression of OC. A Nedd9(-/-)genotype delayed tumor growth rate, reduced incidence of ascites, and reduced expression and activation of signaling proteins including SRC, STAT3, E-cadherin, and AURKA. Cell lines established from MISIIR-TAg; Nedd9(-/-) and MISIIR-TAg; Nedd9(+/+) mice exhibited altered migration and invasion. Growth of these cells in a syngeneic allograft model indicated that systemic Nedd9 loss in the microenvironment had little impact on tumor allograft growth, but in a Nedd9 wildtype background Nedd9(-/-) allografts exhibited significantly reduced growth, dissemination, and oncogenic signaling compared to Nedd9(+/+) allografts. Gene expression analysis revealed that Nedd9(+/+) tumors exhibited more mesenchymal "stem-like" transcriptional program, including increased expression of Aldh1a1 and Aldh1a2. Conversely, loss of Nedd9 resulted in increased expression of differentiation genes, including fallopian tube markers Foxj1, Ovgp1, and Pax8. Collectively, these data suggest that tumor cell-intrinsic Nedd9 expression promotes OC development and progression by broad induction of oncogenic protein signaling and stem/mesenchymal gene expression.	[Gabbasov, Rashid; Xiao, Fang; Howe, Caitlin G.; Bickel, Laura E.; O'Brien, Shane W.; Do, Thuy-Vy; Golemis, Erica A.; Connolly, Denise C.] Fox Chase Canc Ctr, Mol Therapeut Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Gabbasov, Rashid] Kazan Fed Univ, Dept Biochem & Biotechnol, Kazan, Russia; [Benrubi, Daniel] Fox Chase Canc Ctr, Div Gynecol Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Zhou, Yan; Litwin, Samuel] Fox Chase Canc Ctr, Biostat & Bioinformat Facil, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Nicolas, Emmanuelle] Fox Chase Canc Ctr, Genom Facil, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Cai, Kathy Q.] Fox Chase Canc Ctr, Histopathol Facil, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Seo, Sachiko] Natl Canc Res Ctr East, Dept Hematol & Oncol, Kashiwa, Chiba, Japan	Fox Chase Cancer Center; Kazan Federal University; Fox Chase Cancer Center; Fox Chase Cancer Center; Fox Chase Cancer Center; Fox Chase Cancer Center	Connolly, DC (corresponding author), Fox Chase Canc Ctr, Mol Therapeut Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	Denise.Connolly@fccc.edu	Howe, Caitlin/ABF-3709-2020; Gabbasov, Rashid/D-2482-2019	Gabbasov, Rashid/0000-0001-7621-7407; Golemis, Erica/0000-0003-3618-3673; Howe, Caitlin/0000-0002-4935-9298	Ovarian SPORE [P50 CA083638]; FCCC Core Grant [NCI P30 CA006927];  [R01 CA136596];  [R01 CA63366]; NATIONAL CANCER INSTITUTE [P30CA006927, R01CA136596, R01CA063366, P50CA083638] Funding Source: NIH RePORTER	Ovarian SPORE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FCCC Core Grant; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by R01 CA136596 (to DCC); R01 CA63366 (to EAG); Ovarian SPORE P50 CA083638, the FCCC Core Grant NCI P30 CA006927, and charitable donations from the Roberta Dubrow Fund, the Teal Tea Foundation, and the Bucks County Board of Associates (to DCC).	Beck TN, 2014, PHYSIOL GENOMICS, V46, P699, DOI 10.1152/physiolgenomics.00062.2014; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bonome T, 2008, CANCER RES, V68, P5478, DOI 10.1158/0008-5472.CAN-07-6595; Bowen NJ, 2007, GYNECOL ONCOL, V104, P331, DOI 10.1016/j.ygyno.2006.08.052; Bowtell DD, 2015, NAT REV CANCER, V15, P668, DOI 10.1038/nrc4019; Buchheit CL, 2014, NAT REV CANCER, V14, P632, DOI 10.1038/nrc3789; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Colvin EK, 2014, SEMIN CELL DEV BIOL, V27, P61, DOI 10.1016/j.semcdb.2014.02.004; Connolly DC, 2003, CANCER RES, V63, P1389; Connolly DC, 2009, CURR PROTOC PHARM; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Do TV, 2014, ONCOGENE, V33, P539, DOI 10.1038/onc.2012.632; Donninger H, 2004, ONCOGENE, V23, P8065, DOI 10.1038/sj.onc.1207959; Facciabene A, 2012, CANCER RES, V72, P2162, DOI 10.1158/0008-5472.CAN-11-3687; Fuller ES, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00057; Gritsina G, 2015, MOL CANCER THER, V14, P1035, DOI 10.1158/1535-7163.MCT-14-0800; Hensley H, 2007, CANCER BIOL THER, V6, P1717, DOI 10.4161/cbt.6.11.4830; Ice RJ, 2013, CANCER RES, V73, P3168, DOI 10.1158/0008-5472.CAN-12-4008; Izumchenko E, 2009, CANCER RES, V69, P7198, DOI 10.1158/0008-5472.CAN-09-0795; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Kessler M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9989; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Kulbe H, 2012, CANCER RES, V72, P66, DOI 10.1158/0008-5472.CAN-11-2178; Little JL, 2014, ONCOGENE, V33, P411, DOI 10.1038/onc.2012.607; Liu HQ, 2013, CLIN CANCER RES, V19, P5053, DOI 10.1158/1078-0432.CCR-13-1115; Ma Y, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-85; McPherson A, 2016, NAT GENET, V48, P758, DOI 10.1038/ng.3573; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166; Natarajan M, 2006, ONCOGENE, V25, P1721, DOI 10.1038/sj.onc.1209199; Natraj U, 2002, BIOL REPROD, V67, P1897, DOI 10.1095/biolreprod67.6.1897; Nikonova AS, 2014, IUBMB LIFE, V66, P387, DOI 10.1002/iub.1282; Okada A, 2004, J MOL ENDOCRINOL, V32, P615, DOI 10.1677/jme.0.0320615; Paik DY, 2012, STEM CELLS, V30, P2487, DOI 10.1002/stem.1207; Perets R, 2016, CANCER RES, V76, P10, DOI 10.1158/0008-5472.CAN-15-1382; Quinn BA, 2010, J OVARIAN RES, V3, DOI 10.1186/1757-2215-3-24; Ratushny V, 2012, ONCOGENE, V31, P1217, DOI 10.1038/onc.2011.314; Schwede M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057799; Seo S, 2005, J IMMUNOL, V175, P3492, DOI 10.4049/jimmunol.175.6.3492; Seo S, 2011, CANCER SCI, V102, P2109, DOI 10.1111/j.1349-7006.2011.02066.x; Shagisultanova E, 2015, GENE, V567, P1, DOI 10.1016/j.gene.2015.04.086; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Silver DL, 2004, CANCER RES, V64, P3550, DOI 10.1158/0008-5472.CAN-03-3959; Singh MK, 2010, CANCER RES, V70, P8907, DOI 10.1158/0008-5472.CAN-10-0353; Siu MKY, 2013, ONCOGENE, V32, P3500, DOI 10.1038/onc.2012.363; Sivertsen S, 2006, ACTA CYTOL, V50, P603, DOI 10.1159/000326027; Thomas J, 2010, BIOL CELL, V102, P499, DOI 10.1042/BC20100035; Verhaak RGW, 2013, J CLIN INVEST, V123, P517, DOI 10.1172/JCI65833; Wang HX, 2014, HUM PATHOL, V45, P401, DOI 10.1016/j.humpath.2013.10.005; Wang Z, 2016, ONCOTARGET, V8, P1714; Ward KK, 2013, CLIN EXP METASTAS, V30, P579, DOI 10.1007/s10585-012-9562-5; Wiener JR, 2003, GYNECOL ONCOL, V88, P73, DOI 10.1006/gyno.2002.6851; Wu R, 2016, J PATHOL, V240, P341, DOI 10.1002/path.4783; Xu S, 2014, SCI REP-UK, V4, DOI 10.1038/srep05646; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177; Zhong J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035058	56	15	16	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2018	37	35					4854	4870		10.1038/s41388-018-0296-y	http://dx.doi.org/10.1038/s41388-018-0296-y			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS0BA	29773902	Green Accepted			2022-12-17	WOS:000443146000007
J	Madhav, A; Andres, A; Duong, F; Mishra, R; Haldar, S; Liu, ZQ; Angara, B; Gottlieb, R; Zumsteg, ZS; Bhowmick, NA				Madhav, Anisha; Andres, Allen; Duong, Frank; Mishra, Rajeev; Haldar, Subhash; Liu, Zhenqiu; Angara, Bryan; Gottlieb, Roberta; Zumsteg, Zachary S.; Bhowmick, Neil A.			Antagonizing CD105 enhances radiation sensitivity in prostate cancer	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; CELLS IN-VITRO; ENDOGLIN CD105; TGF-BETA; PANCREATIC-CANCER; ENERGY-METABOLISM; GASTRIC-CANCER; PHASE-I; THERAPY; RADIOSENSITIVITY	Radiation therapy is the primary intervention for nearly half of the patients with localized advanced prostate cancer and standard of care for recurrent disease following surgery. The development of radiation-resistant disease is an obstacle for nearly 30-50% of patients undergoing radiotherapy. A better understanding of mechanisms that lead to radiation resistance could aid in the development of sensitizing agents to improve outcome. Here we identified a radiation-resistance pathway mediated by CD105, downstream of BMP and TGF-beta signaling. Antagonizing CD 105-dependent BMP signaling with a partially humanized monoclonal antibody, TRC105, resulted in a significant reduction in clonogenicity when combined with irradiation. In trying to better understand the mechanism for the radio-sensitization, we found that radiation-induced CD 105/ BMP signaling was sufficient and necessary for the upregulation of sirtuin 1 (SIRT1) in contributing to p53 stabilization and PGC-1 alpha activation. Combining TRC105 with irradiation delayed DNA damage repair compared to irradiation alone. However, in the absence of p53 function, combining TRC105 and radiation resulted in no reduction in clonogenicity compared to radiation alone, despite similar reduction of DNA damage repair observed in p53-intact cells. This suggested DNA damage repair was not the sole determinant of CD 105 radio-resistance. As cancer cells undergo an energy deficit following irradiation, due to the demands of DNA and organelle repair, we examined SIRT1's role on p53 and PGC-1 alpha with respect to glycolysis and mitochondrial biogenesis, respectively. Consequently, blocking the CD105-SIRT1 axis was found to deplete the ATP stores of irradiated cells and cause G2 cell cycle arrest. Xenograft models supported these findings that combining TRC105 with irradiation significantly reduces tumor size over irradiation alone (p value = 10(-9)). We identified a novel synthetic lethality strategy of combining radiation and CD 105 targeting to address the DNA repair and metabolic addiction induced by irradiation in p53-functional prostate cancers.	[Madhav, Anisha; Andres, Allen; Bhowmick, Neil A.] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA 90048 USA; [Duong, Frank; Mishra, Rajeev; Haldar, Subhash; Liu, Zhenqiu; Angara, Bryan; Gottlieb, Roberta; Bhowmick, Neil A.] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA; [Zumsteg, Zachary S.] Cedars Sinai Med Ctr, Dept Radiat Oncol, Los Angeles, CA 90048 USA; [Bhowmick, Neil A.] Greater Los Angeles Vet Adm, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center	Bhowmick, NA (corresponding author), Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA 90048 USA.; Bhowmick, NA (corresponding author), Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA.; Bhowmick, NA (corresponding author), Greater Los Angeles Vet Adm, Los Angeles, CA 90048 USA.	bhowmickn@cshs.org	Mishra, Rajeev/AEX-2208-2022; Bhowmick, Neil/AAA-7302-2019	Mishra, Rajeev/0000-0002-7411-4022; Bhowmick, Neil/0000-0001-8747-5989; Haldar, Subhash/0000-0002-1230-1770; Gottlieb, Roberta/0000-0002-1432-006X	Department of Defense [PC161016]; Department of Veterans Affairs [I01BX0011040]; National Cancer Institute (NIH) [CA108646, CA098912]; NATIONAL CANCER INSTITUTE [P01CA098912, R01CA108646] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001040] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); Department of Veterans Affairs(US Department of Veterans Affairs); National Cancer Institute (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	This work was supported by grants from the Department of Defense (PC161016 to AM), Department of Veterans Affairs (I01BX0011040 to NAB), and the National Cancer Institute (NIH, CA108646 and CA098912 to NAB). The metabolic analysis was possible because of help from the Cedars-Sinai Medical Center Metabolism and Mitochondrial Research Core. We also thank Tracon Pharmaceuticals for providing the CD105 antagonist, TRC105.	Andres AM, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89303; Arciuch VGA, 2012, ANTIOXID REDOX SIGN, V16, P1150, DOI 10.1089/ars.2011.4085; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Biswas S, 2007, J CLIN INVEST, V117, P1305, DOI 10.1172/JCI30740; Borno ST, 2012, CANCER DISCOV, V2, P1024, DOI 10.1158/2159-8290.CD-12-0041; Bouquet F, 2011, CLIN CANCER RES, V17, P6754, DOI 10.1158/1078-0432.CCR-11-0544; Canto C, 2012, PHARMACOL REV, V64, P166, DOI 10.1124/pr.110.003905; Canto C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4; Chen L, 2016, CELL CYCLE, V15, P840, DOI 10.1080/15384101.2016.1151582; Deckbar D, 2011, CRIT REV BIOCHEM MOL, V46, P271, DOI 10.3109/10409238.2011.575764; Ewan KB, 2002, CANCER RES, V62, P5627; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Hardee ME, 2012, CANCER RES, V72, P4119, DOI 10.1158/0008-5472.CAN-12-0546; Hoeferlin L Alexis, 2011, Genes Cancer, V2, P889, DOI 10.1177/1947601911432495; Jonker L, 2014, MICROCIRCULATION, V21, P93, DOI 10.1111/micc.12099; Jung-Hynes B, 2009, J BIOL CHEM, V284, P3823, DOI 10.1074/jbc.M807869200; Karzai FH, 2015, BJU INT, V116, P546, DOI 10.1111/bju.12986; Koyama Y, 2010, EXP THER MED, V1, P627, DOI 10.3892/etm_00000098; Kumar S, 2014, ONCOGENE, V33, P3970, DOI 10.1038/onc.2013.386; Lee NY, 2008, J BIOL CHEM, V283, P32527, DOI 10.1074/jbc.M803059200; Lin Zhenghong, 2013, Genes Cancer, V4, P97, DOI 10.1177/1947601912475079; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Miao ZF, 2016, HUM PATHOL, V51, P114, DOI 10.1016/j.humpath.2015.12.023; Moeller BJ, 2004, CELL CYCLE, V3, P1107; Moon DH, 2017, UROL ONCOL-SEMIN ORI, V35, P59, DOI 10.1016/j.urolonc.2016.06.002; Morris WJ, 2017, INT J RADIAT ONCOL, V98, P275, DOI 10.1016/j.ijrobp.2016.11.026; Munoz-Fontela C, 2011, CELL CYCLE, V10, P3701, DOI 10.4161/cc.10.21.17899; Pal K, 2014, MOL CANCER THER, V13, P2264, DOI 10.1158/1535-7163.MCT-14-0291; Placencio VR, 2008, CANCER RES, V68, P4709, DOI 10.1158/0008-5472.CAN-07-6289; Romero D, 2010, CARCINOGENESIS, V31, P359, DOI 10.1093/carcin/bgp217; Rosen LS, 2012, CLIN CANCER RES, V18, P4820, DOI 10.1158/1078-0432.CCR-12-0098; Rukstalis Daniel B, 2002, Rev Urol, V4 Suppl 2, pS12; Sanchez-Elsner T, 2002, J BIOL CHEM, V277, P43799, DOI 10.1074/jbc.M207160200; Shipley WU, 2017, NEW ENGL J MED, V376, P417, DOI 10.1056/NEJMoa1607529; Smith SJ, 2012, ACTA NEUROPATHOL, V124, P99, DOI 10.1007/s00401-012-0952-1; Vo MN, 2010, BREAST CANCER RES TR, V119, P767, DOI 10.1007/s10549-008-0261-5; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Winter Jordan M, 2006, HPB (Oxford), V8, P324, DOI 10.1080/13651820600804203; Yamamori T, 2012, FREE RADICAL BIO MED, V53, P260, DOI 10.1016/j.freeradbiomed.2012.04.033; Yamoah K, 2015, INT J RADIAT ONCOL, V93, P737, DOI 10.1016/j.ijrobp.2015.07.2284; YOUNG VR, 1977, CANCER RES, V37, P2336; Zhang J, 2015, CANCER LETT, V363, P108, DOI 10.1016/j.canlet.2015.04.015; Zhong J, 2013, RADIOTHER ONCOL, V106, P390, DOI 10.1016/j.radonc.2013.02.013; Ziebarth AJ, 2013, CLIN CANCER RES, V19, P170, DOI 10.1158/1078-0432.CCR-12-1045; Zumsteg ZS, 2016, CLIN CANCER RES, V22, P2009, DOI 10.1158/1078-0432.CCR-15-2245; Zumsteg ZS, 2015, J UROLOGY, V194, P1624, DOI 10.1016/j.juro.2015.06.100	46	15	15	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2018	37	32					4385	4397		10.1038/s41388-018-0278-0	http://dx.doi.org/10.1038/s41388-018-0278-0			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP8FA	29717261	hybrid, Green Accepted, Green Published			2022-12-17	WOS:000441144300004
J	AlQarni, S; Al-Sheikh, Y; Campbell, D; Drotar, M; Hannigan, A; Boyle, S; Herzyk, P; Kossenkov, A; Armfield, K; Jamieson, L; Bailo, M; Lieberman, PM; Tsimbouri, P; Wilson, JB				AlQarni, Sana; Al-Sheikh, Yazeed; Campbell, Donald; Drotar, Mark; Hannigan, Adele; Boyle, Shelagh; Herzyk, Pawel; Kossenkov, Andrew; Armfield, Kate; Jamieson, Lauren; Bailo, Mariarca; Lieberman, Paul M.; Tsimbouri, Penelope; Wilson, Joanna B.			Lymphomas driven by Epstein-Barr virus nuclear antigen-1 (EBNA1) are dependant upon Mdm2	ONCOGENE			English	Article							BURKITTS-LYMPHOMA; TRANSGENIC MICE; IN-VITRO; P53; EXPRESSION; SURVIVAL; PROTEIN; IMMORTALIZATION; TUMORIGENESIS; TRANSCRIPTION	Epstein-Barr virus (EBV)-associated Burkitt's lymphoma is characterised by the deregulation of c-Myc expression and a restricted viral gene expression pattern in which the EBV nuclear antigen-1 (EBNA1) is the only viral protein to be consistently expressed. EBNA1 is required for viral genome propagation and segregation during latency. However, it has been much debated whether the protein plays a role in viral-associated tumourigenesis. We show that the lymphomas which arise in E mu EBNA1 transgenic mice are unequivocally linked to EBNA1 expression and that both C-Myc and Mdm2 deregulation are central to this process. Tumour cell survival is supported by IL-2 and there is a skew towards CD8-positive T cells in the tumour environment, while the immune check-point protein PD-L1 is upregulated in the tumours. Additionally, several isoforms of Mdm2 are upregulated in the E mu EBNA1 tumours, with increased phosphorylation at ser166, an expression pattern not seen in E mu c-Myc transgenic tumours. Concomitantly, E2F1, Xiap, Mta1, C-Fos and Stat1 are upregulated in the tumours. Using four independent inhibitors of Mdm2 we demonstrate that the E mu EBNA1 tumour cells are dependant upon Mdm2 for survival (as they are upon c-Myc) and that Mdm2 inhibition is not accompanied by upregulation of p53, instead cell death is linked to loss of E2F1 expression, providing new insight into the underlying tumourigenic mechanism. This opens a new path to combat EBV-associated disease.	[AlQarni, Sana; Al-Sheikh, Yazeed; Campbell, Donald; Drotar, Mark; Hannigan, Adele; Herzyk, Pawel; Armfield, Kate; Jamieson, Lauren; Bailo, Mariarca; Tsimbouri, Penelope; Wilson, Joanna B.] Univ Glasgow, Coll Med Vet & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; [Al-Sheikh, Yazeed] King Saud Univ, Coll Appl Med Sci, Riyadh, Saudi Arabia; [Hannigan, Adele] TCBiopharm, 2 Parklands Way Holtown, Motherwell ML1 4WR, Scotland; [Boyle, Shelagh] Univ Edinburgh, Inst Genet & Mol Med, MRC Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; [Kossenkov, Andrew; Lieberman, Paul M.] Wistar Inst Anat & Biol, Ctr Chem Biol & Translat Med, 3601 Spruce St, Philadelphia, PA 19104 USA	University of Glasgow; King Saud University; University of Edinburgh; The Wistar Institute	Wilson, JB (corresponding author), Univ Glasgow, Coll Med Vet & Life Sci, Glasgow G12 8QQ, Lanark, Scotland.	Joanna.wilson@glasgow.ac.uk			Bloodwise; Wellcome Trust; BBSRC; Saudi Arabian PhD scholarships; NATIONAL CANCER INSTITUTE [P30CA010815, R01CA093606] Funding Source: NIH RePORTER	Bloodwise; Wellcome Trust(Wellcome TrustEuropean Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Saudi Arabian PhD scholarships; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funding contribution to the work includes former LRF (now Bloodwise) grants. AH was supported by a Wellcome Trust PhD studentship while at GU, KA is supported by a PhD BBSRC studentship. SA is, and YA was, supported by Saudi Arabian PhD scholarships.	Achilli F, 2005, AMYOTROPH LATERAL SC, V6, P111, DOI 10.1080/14660820510035351; Bill KLJ, 2016, CLIN CANCER RES, V22, P1150, DOI 10.1158/1078-0432.CCR-15-1522; Boyman O, 2012, NAT REV IMMUNOL, V12, P180, DOI 10.1038/nri3156; Canaan A, 2009, P NATL ACAD SCI USA, V106, P22421, DOI 10.1073/pnas.0911676106; Croft JA, 1999, J CELL BIOL, V145, P1119, DOI 10.1083/jcb.145.6.1119; Deschamps T, 2017, J GEN VIROL, V98, P251, DOI 10.1099/jgv.0.000681; Drotar ME, 2003, INT J CANCER, V106, P388, DOI 10.1002/ijc.11224; Gnanasundram SV, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02282-w; Goodman A, 2017, NAT REV CLIN ONCOL, V14, P203, DOI 10.1038/nrclinonc.2016.168; Gu LB, 2016, CANCER CELL, V30, P623, DOI 10.1016/j.ccell.2016.08.015; Hannigan A, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-184; Kang MS, 2005, P NATL ACAD SCI USA, V102, P820, DOI 10.1073/pnas.0408774102; Kennedy G, 2003, P NATL ACAD SCI USA, V100, P14269, DOI 10.1073/pnas.2336099100; Kojima K, 2010, MOL CANCER THER, V9, P2545, DOI 10.1158/1535-7163.MCT-10-0337; Li DQ, 2009, J BIOL CHEM, V284, P34545, DOI 10.1074/jbc.M109.056499; Malik-Soni N, 2012, J VIROL, V86, P6999, DOI 10.1128/JVI.00194-12; O'Neil JD, 2008, J GEN VIROL, V89, P2833, DOI 10.1099/vir.0.2008/003392-0; Okoro Danielle R, 2012, Genes Cancer, V3, P311, DOI 10.1177/1947601912455323; Owen TJ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-241; Renouf B, 2009, LEUKEMIA, V23, P1557, DOI 10.1038/leu.2009.92; Rosso Melissa, 2014, Subcell Biochem, V85, P247, DOI 10.1007/978-94-017-9211-0_14; Saridakis V, 2005, MOL CELL, V18, P25, DOI 10.1016/j.molcel.2005.02.029; Schuster K, 2007, MOL CANCER RES, V5, P403, DOI 10.1158/1541-7786.MCR-06-0146; Sivachandran N, 2011, J VIROL, V85, P10425, DOI 10.1128/JVI.05293-11; Tempera I, 2016, J VIROL, V90, P345, DOI 10.1128/JVI.02318-15; Tian X, 2011, CELL SIGNAL, V23, P193, DOI 10.1016/j.cellsig.2010.09.003; Tsimbouri P, 2002, ONCOGENE, V21, P5182, DOI 10.1038/sj.onc.1205490; Tsimbourri P, 2008, J GEN VIROL, V89, P2821, DOI 10.1099/vir.0.83296-0; Volk EL, 2009, MOL CANCER RES, V7, P863, DOI 10.1158/1541-7786.MCR-08-0418; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Wilson J B, 1992, Curr Top Microbiol Immunol, V182, P375; Wilson J B, 2001, Methods Mol Biol, V174, P361; Wilson JB, 1996, EMBO J, V15, P3117, DOI 10.1002/j.1460-2075.1996.tb00674.x; Wood VHJ, 2007, ONCOGENE, V26, P4135, DOI 10.1038/sj.onc.1210496; Xie N, 2016, SCI REP-UK, V6, DOI 10.1038/srep36171; Zhang HL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100960; Zhang Z, 2005, ONCOGENE, V24, P7238, DOI 10.1038/sj.onc.1208814; Zheng TS, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3996; Zimber-Strobl U, 1999, CURR TOP MICROBIOL, V246, P315	39	15	16	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2018	37	29					3998	4012		10.1038/s41388-018-0147-x	http://dx.doi.org/10.1038/s41388-018-0147-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GN5LP	29691476	Green Accepted			2022-12-17	WOS:000439101300007
J	Coant, N; Garcia-Barros, M; Zhang, QF; Obeid, LM; Hannun, YA				Coant, Nicolas; Garcia-Barros, Monica; Zhang, Qifeng; Obeid, Lina M.; Hannun, Yusuf A.			AKT as a key target for growth promoting functions of neutral ceramidase in colon cancer cells	ONCOGENE			English	Article							ADJUVANT TREATMENT; PATHWAY; SPHINGOLIPIDS; MECHANISM; LINES; GENE; FLUOROURACIL; SPHINGOSINE; OXALIPLATIN; LEUCOVORIN	Despite advances in the field, colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide. Research into bioactive sphingolipids over the past two decades has played an important role in increasing our understanding of the pathogenesis and therapeutics of CRC. In the complex metabolic network of sphingolipids, ceramidases (CDases) have a key function. These enzymes hydrolyze ceramides into sphingosine (SPH) which in turn is phosphorylated by sphingosine kinases (SK) 1 and 2 to generate sphingosine-1 phosphate (S1P). Importantly, we have recently shown that inhibition of neutral CDase (nCDase) induces an increase of ceramide in colon cancer cells which decreases cellular growth, increases apoptosis and modulates the WNT/beta-catenin pathway. We have also shown that the deletion of nCDase protected mice from the onset and progression of colorectal cancer in the AOM carcinogen model. Here, we demonstrate that AKT is a key target for the growth suppressing functions of ceramide. The results show that inhibition of nCDase activates GSK3 beta through dephosphorylation, and thus is required for the subsequent phosphorylation and degradation of beta-catenin. Our findings show that inhibition of nCDase also inhibits the basal activation status of AKT, and we further establish that a constitutively active AKT (AKT T308D, S473D; AKT(DD)) reverses the effect of nCDase on beta-catenin degradation. Functionally, the AKT(DD) mutant is able to overcome the growth suppressive effects of nCDase inhibition in CRC cells. Moreover, nCDase inhibition induces a growth delay of xenograft tumors from control cells, whereas xenograft tumors from constitutively active AKT cells become resistant to nCDase inhibition. Taken together, these results provide important mechanistic insight into how nCDase regulates cell proliferation. These findings demonstrate a heretofore unappreciated, but critical, role for nCDase in enabling/maintaining basal activation of AKT and also suggest that nCDase is a suitable novel target for colon cancer therapy.	[Coant, Nicolas; Garcia-Barros, Monica; Obeid, Lina M.; Hannun, Yusuf A.] SUNY Stony Brook, Stony Brook Canc Ctr, Stony Brook, NY 11794 USA; [Zhang, Qifeng] Babraham Inst, Signalling Programme, Babraham Res Campus, Cambridge, England; [Obeid, Lina M.; Hannun, Yusuf A.] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA; [Obeid, Lina M.] Northport VA Med Ctr, Northport, NY USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hannun, YA (corresponding author), SUNY Stony Brook, Stony Brook Canc Ctr, Stony Brook, NY 11794 USA.; Hannun, YA (corresponding author), SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA.	Yusuf.Hannun@stonybrookmedicine.edu		COANT, Nicolas/0000-0001-9237-2132	NCI [CA172517, CA97132]; Research Histology Core Laboratory, Department of Pathology, Stony Brook University; NATIONAL CANCER INSTITUTE [P01CA097132, R01CA172517] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000156] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Research Histology Core Laboratory, Department of Pathology, Stony Brook University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	This work was supported by NCI grants CA172517 and CA97132. We acknowledge the support from the "Research Histology Core Laboratory, Department of Pathology, Stony Brook University". We would like to thank Ayanna Lewis, MD for proof reading the manuscript.	Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35; Airola MV, 2015, STRUCTURE, V23, P1482, DOI 10.1016/j.str.2015.06.013; Anderson Karen E., 2016, Advances in Biological Regulation, V62, P18, DOI 10.1016/j.jbior.2015.11.002; Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Andre T, 2009, J CLIN ONCOL, V27, P3109, DOI 10.1200/JCO.2008.20.6771; Berg KCG, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0691-y; Carrato Alfredo, 2008, Gastrointest Cancer Res, V2, pS42; Clark J, 2011, NAT METHODS, V8, P267, DOI 10.1038/NMETH.1564; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; Fakih MG, 2015, J CLIN ONCOL, V33, P1809, DOI 10.1200/JCO.2014.59.7633; Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208; Gandy KAO, 2013, BIOCHEM J, V449, P661, DOI 10.1042/BJ20120213; Garcia-Barros M, 2016, FASEB J, V30, P4159, DOI 10.1096/fj.201600611R; Garcia-Barros M, 2014, BBA-MOL CELL BIOL L, V1841, P773, DOI 10.1016/j.bbalip.2013.09.007; Hafsi S, 2012, INT J ONCOL, V40, P639, DOI 10.3892/ijo.2011.1312; Halder K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091656; Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329; Hannun YA, 2011, J BIOL CHEM, V286, P27855, DOI 10.1074/jbc.R111.254359; Holland WL, 2011, J CLIN INVEST, V121, P1858, DOI 10.1172/JCI43378; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Jiang BH, 2008, CURR CANCER DRUG TAR, V8, P19, DOI 10.2174/156800908783497122; Kawamori T, 2009, FASEB J, V23, P405, DOI 10.1096/fj.08-117572; KIM JH, 1986, CANCER RES, V46, P1120; Kitatani K, 2008, CELL SIGNAL, V20, P1010, DOI 10.1016/j.cellsig.2007.12.006; Knowles MA, 2009, CANCER METAST REV, V28, P305, DOI 10.1007/s10555-009-9198-3; Kono M, 2006, J BIOL CHEM, V281, P7324, DOI 10.1074/jbc.M508382200; Krycer JR, 2010, TRENDS ENDOCRIN MET, V21, P268, DOI 10.1016/j.tem.2010.01.001; Kumar A, 2012, CARCINOGENESIS, V33, P1726, DOI 10.1093/carcin/bgs174; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Mao CG, 2008, BBA-MOL CELL BIOL L, V1781, P424, DOI 10.1016/j.bbalip.2008.06.002; Muller EJ, 2008, J INVEST DERMATOL, V128, P501, DOI 10.1038/sj.jid.5701248; Nelson VM, 2013, J GASTROINTEST ONCOL, V4, P245, DOI 10.3978/j.issn.2078-6891.2013.035; Nikolova-Karakashian MN, 2010, ADV EXP MED BIOL, V688, P86; Oaks J, 2015, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00388; Powell DJ, 2003, MOL CELL BIOL, V23, P7794, DOI 10.1128/MCB.23.21.7794-7808.2003; Rahman A, 2016, FREE RADICAL BIO MED, V96, P273, DOI 10.1016/j.freeradbiomed.2016.05.001; Sasaki AT, 2006, EUR J CELL BIOL, V85, P873, DOI 10.1016/j.ejcb.2006.04.007; Snider AJ, 2012, PROSTAG OTH LIPID M, V99, P124, DOI 10.1016/j.prostaglandins.2012.08.003; Stewart B, 2014, WORLD CANC REPORT 20, P619; Stoica BA, 2003, MOL CELL NEUROSCI, V22, P365, DOI 10.1016/S1044-7431(02)00028-3; Symolon H, 2011, MOL CANCER THER, V10, P648, DOI 10.1158/1535-7163.MCT-10-0754; Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055-9965.EPI-15-0578; Verdaguer H, 2016, THER ADV MED ONCOL, V8, P230, DOI 10.1177/1758834016635888; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wu BX, 2009, BBA-MOL CELL BIOL L, V1791, P730, DOI 10.1016/j.bbalip.2009.03.012; Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002; Yeang CH, 2008, FASEB J, V22, P2605, DOI 10.1096/fj.08-108985; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568	51	15	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2018	37	28					3852	3863		10.1038/s41388-018-0236-x	http://dx.doi.org/10.1038/s41388-018-0236-x			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM8HR	29662189	Green Accepted			2022-12-17	WOS:000438465600007
J	Tomoshige, K; Guo, MZ; Tsuchiya, T; Fukazawa, T; Fink-Baldauf, IM; Stuart, WD; Naomoto, Y; Nagayasu, T; Maeda, Y				Tomoshige, Koichi; Guo, Minzhe; Tsuchiya, Tomoshi; Fukazawa, Takuya; Fink-Baldauf, Iris M.; Stuart, William D.; Naomoto, Yoshio; Nagayasu, Takeshi; Maeda, Yutaka			An EGFR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo	ONCOGENE			English	Article							TRANSFORMING-GROWTH-FACTOR; FACTOR-ALPHA; TRANSGENIC MICE; CONDITIONAL EXPRESSION; KINASE INHIBITORS; EPITHELIAL-CELLS; FACTOR RECEPTOR; STEM-CELLS; TGF-ALPHA; MUTATIONS	EGFR ligands (e.g., EGF and TGFA) have been shown to be clinically associated with poor survival in lung cancer. Since TGFA itself initiates autochthonous tumors in liver, breast, and pancreas but not in the lung in transgenic mice in vivo, it would appear that an EGFR ligand may not initiate but rather promote lung cancer. However, it has not been proven in vivo whether lung cancer is promoted by an EGFR ligand. Using transgenic mouse models conditionally expressing EGFR(L858R) or Kras(G12D) with TGFA (an EGFR ligand) in lung epithelium, we determined that TGFA promoted the growth of EGFR(L858R)-lung tumors in airway regions but not that of Kras(G12D)-lung tumors. Analysis of TCGA datasets identified Delta Np63 and AGR2 as potential key tumor-promoting regulators, which were highly induced in the TGFA-induced EGFR(L858R)-lung tumors. The expression of AGR2 was positively correlated with the expression of TGFA in human EGFR-mutant lung adenocarcinomas. The expression of TGFA in human EGFR-mutant lung adenocarcinomas but not in the EGFR wild-type lung adenocarcinoma was associated with poor survival. These results suggest that targeting EGFR ligands may benefit patients who carry EGFR-mutant lung tumors but will not benefit patients with KRAS-mutant lung tumors.	[Tomoshige, Koichi; Guo, Minzhe; Fink-Baldauf, Iris M.; Stuart, William D.; Maeda, Yutaka] Cincinnati Childrens Hosp Med Ctr, Div Neonatol Perinatal & Pulm Biol, Perinatal Inst, Cincinnati, OH 45229 USA; [Tomoshige, Koichi; Guo, Minzhe; Fink-Baldauf, Iris M.; Stuart, William D.; Maeda, Yutaka] Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA; [Tsuchiya, Tomoshi; Nagayasu, Takeshi] Nagasaki Univ, Grad Sch Biomed Sci, Dept Surg Oncol, Nagasaki 8528501, Japan; [Fukazawa, Takuya; Naomoto, Yoshio] Kawasaki Med Sch, Dept Gen Surg, Okayama 7010192, Japan; [Tomoshige, Koichi] Nagasaki Univ, Grad Sch Biomed Sci, Dept Clin Oncol, Nagasaki 8528501, Japan; [Tomoshige, Koichi] Nagasaki Univ, Grad Sch Biomed Sci, Dept Surg Oncol, Nagasaki 8528501, Japan	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Nagasaki University; Kawasaki Medical School; Nagasaki University; Nagasaki University	Maeda, Y (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Neonatol Perinatal & Pulm Biol, Perinatal Inst, Cincinnati, OH 45229 USA.; Maeda, Y (corresponding author), Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA.	yutaka.maeda@cchmc.org	Fukazawa, Takuya/GLR-7099-2022; Guo, Minzhe/Y-3982-2018	Tomoshige, Koichi/0000-0002-0712-2989; GUO, MINZHE/0000-0002-5502-9172; Tsuchiya, Tomoshi/0000-0002-8419-1478	American Lung Association [RG309608]; CF-RDP Pilot & Feasibility Grant; Cincinnati Children's Hospital Medical Center; Rotary Foundation Global Grant; AMED; Ministry of Education, Science and Culture, Japan	American Lung Association; CF-RDP Pilot & Feasibility Grant; Cincinnati Children's Hospital Medical Center; Rotary Foundation Global Grant; AMED(Japan Agency for Medical Research and Development (AMED)); Ministry of Education, Science and Culture, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This study was supported by the American Lung Association (RG309608), Trustee Award Grant, CF-RDP Pilot & Feasibility Grant, Cincinnati Children's Hospital Medical Center (YM), the Rotary Foundation Global Grant (KT), AMED (TF), and the Ministry of Education, Science and Culture, Japan (TT, TF, YN, and TN)	Ceteci F, 2011, NEOPLASIA, V13, P1005, DOI 10.1593/neo.11652; Chen Z, 2010, CANCER RES, V70, P9827, DOI 10.1158/0008-5472.CAN-10-1671; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337; Dave V, 2008, AM J RESP CELL MOL, V38, P337, DOI 10.1165/rcmb.2007-0182OC; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Fessart D, 2016, ELIFE, V5, DOI 10.7554/eLife.13887; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; Freed DM, 2017, CELL, V171, P683, DOI 10.1016/j.cell.2017.09.017; Gazdar AF, 2008, CANCER PREV RES, V1, P156, DOI 10.1158/1940-6207.CAPR-08-0080; Giannou AD, 2017, EMBO MOL MED, V9, P672, DOI 10.15252/emmm.201606978; Green JA, 2017, J EXP MED, V214, P3565, DOI 10.1084/jem.20170356; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Han XK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4261; Hardie WD, 2004, AM J PHYSIOL-LUNG C, V286, pL741, DOI 10.1152/ajplung.00208.2003; Hogan BLM, 2014, CELL STEM CELL, V15, P123, DOI 10.1016/j.stem.2014.07.012; Huang QL, 2016, MOL CANCER THER, V15, P2521, DOI 10.1158/1535-7163.MCT-16-0258; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Ji HB, 2007, CANCER RES, V67, P4933, DOI 10.1158/0008-5472.CAN-06-4592; Jia Y, 2016, NATURE, V534, P129, DOI 10.1038/nature17960; Klijn C, 2015, NAT BIOTECHNOL, V33, P306, DOI 10.1038/nbt.3080; KORFHAGEN TR, 1994, J CLIN INVEST, V93, P1691, DOI 10.1172/JCI117152; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li DN, 2007, CANCER CELL, V12, P81, DOI 10.1016/j.ccr.2007.06.005; Linardou H, 2009, NAT REV CLIN ONCOL, V6, P352, DOI 10.1038/nrclinonc.2009.62; Liu J, 2015, CELL REP, V10, P1599, DOI 10.1016/j.celrep.2015.02.014; Maeda Y, 2006, J BIOL CHEM, V281, P9600, DOI 10.1074/jbc.M510435200; Maeda Y, 2012, J CLIN INVEST, V122, P4388, DOI 10.1172/JCI64048; Perera SA, 2009, P NATL ACAD SCI USA, V106, P474, DOI 10.1073/pnas.0808930106; Perl AK, 2009, AM J RESP CELL MOL, V40, P1, DOI 10.1165/rcmb.2008-0011ED; Politi K, 2006, GENE DEV, V20, P1496, DOI 10.1101/gad.1417406; Regales L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000810; Rodriguez PC, 2016, CLIN CANCER RES, V22, P3782, DOI 10.1158/1078-0432.CCR-15-0855; Rusch V, 1997, CLIN CANCER RES, V3, P515; Saito M, 2016, CANCER SCI, V107, P713, DOI 10.1111/cas.12941; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; Schneider MR, 2005, ENDOCRINOLOGY, V146, P5237, DOI 10.1210/en.2005-0418; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Siveke JT, 2007, CANCER CELL, V12, P266, DOI 10.1016/j.ccr.2007.08.002; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Tata PR, 2013, NATURE, V503, P218, DOI 10.1038/nature12777; TATEISHI M, 1991, BRIT J CANCER, V63, P130, DOI 10.1038/bjc.1991.26; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; Wagner M, 1998, GASTROENTEROLOGY, V115, P1254, DOI 10.1016/S0016-5085(98)70098-8; Watanabe H, 2014, J CLIN INVEST, V124, P1636, DOI 10.1172/JCI71545; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Xu CX, 2015, MOL CANCER THER, V14, P2382, DOI 10.1158/1535-7163.MCT-15-0077; Yanagi S, 2007, J CLIN INVEST, V117, P2929, DOI 10.1172/JCI31854; Yoh K, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00051; Zhang J, 2008, CANCER PREV RES, V1, P201, DOI 10.1158/1940-6207.CAPR-08-0014; Zhang X, 2017, NAT COMMUN, V8, P1, DOI [10.1038/ncomms14542, 10.1038/s41467-017-01968-5, 10.1038/s41467-017-00321-0]; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao R, 2014, DEV CELL, V30, P151, DOI 10.1016/j.devcel.2014.06.004; Zhou WJ, 2009, NATURE, V462, P1070, DOI 10.1038/nature08622	56	15	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2018	37	28					3894	3908		10.1038/s41388-018-0240-1	http://dx.doi.org/10.1038/s41388-018-0240-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM8HR	29662194				2022-12-17	WOS:000438465600010
J	Yu, Y; Rahmanto, YS; Lee, MH; Wu, PH; Phillip, JM; Huang, CH; Vitolo, MI; Gaillard, S; Martin, SS; Wirtz, D; Shih, IM; Wang, TL				Yu, Yu; Rahmanto, Yohan Suryo; Lee, Meng-Horng; Wu, Pei-Hsun; Phillip, Jude M.; Huang, Chuan-Hsiang; Vitolo, Michele I.; Gaillard, Stephanie; Martin, Stuart S.; Wirtz, Denis; Shih, Ie-Ming; Wang, Tian-Li			Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; NON-HODGKIN-LYMPHOMA; BREAST-CANCER CELLS; RHEUMATOID-ARTHRITIS; PHOSPHOINOSITIDE 3-KINASE; ACTIN CYTOSKELETON; EPITHELIAL-CELLS; PROTEIN; PHOSPHORYLATION; METASTASIS	Cell motility and invasiveness are prerequisites for dissemination, and largely account for cancer mortality. We have identified an actionable kinase, spleen tyrosine kinase (SYK), which is keenly tightly associated with tumor progression in ovarian cancer. Here, we report that active recombinant SYK directly phosphorylates cortactin and cofilin, which are critically involved in assembly and dynamics of actin filament through phosphorylation signaling. Enhancing SYK activity by inducing expression of a constitutively active SYK mutant, SYK130E, increased growth factor-stimulated migration and invasion of ovarian cancer cells, which was abrogated by cortactin knockdown. Similarly, SYK inhibitors significantly decreased invasion of ovarian cancer cells across basement membrane in real-time transwell assays and in 3D tumor spheroid models. SYK inactivation by targeted gene knockout or by small molecule inhibition reduced actin polymerization. Collectively, this study reported a new mechanism by which SYK signaling regulates ovarian cancer cell motility and invasiveness, and suggest a target-based strategy to prevent or suppress the advancement of ovarian malignancies.	[Yu, Yu; Rahmanto, Yohan Suryo; Gaillard, Stephanie; Shih, Ie-Ming; Wang, Tian-Li] Johns Hopkins Med Inst, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA; [Yu, Yu; Rahmanto, Yohan Suryo; Huang, Chuan-Hsiang; Shih, Ie-Ming; Wang, Tian-Li] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21287 USA; [Lee, Meng-Horng; Wu, Pei-Hsun; Phillip, Jude M.; Wirtz, Denis] Johns Hopkins Univ, Dept Chem & Biomol Engn, Phys Sci Oncol Ctr, Baltimore, MD 21218 USA; [Lee, Meng-Horng; Wu, Pei-Hsun; Phillip, Jude M.; Wirtz, Denis] Johns Hopkins Univ, Inst NanoBioTechol, Baltimore, MD 21218 USA; [Vitolo, Michele I.; Martin, Stuart S.] Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; [Vitolo, Michele I.; Martin, Stuart S.] Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Natl Canc Inst, Ctr Canc, Baltimore, MD 21201 USA; [Gaillard, Stephanie; Shih, Ie-Ming; Wang, Tian-Li] Johns Hopkins Med Inst, Dept Gynecol & Obstet, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins Medicine	Shih, IM; Wang, TL (corresponding author), Johns Hopkins Med Inst, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA.; Shih, IM; Wang, TL (corresponding author), Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21287 USA.; Shih, IM; Wang, TL (corresponding author), Johns Hopkins Med Inst, Dept Gynecol & Obstet, Baltimore, MD 21287 USA.	shihie@yahoo.com; tlw@jhmi.edu	Phillip, Jude/AAR-6240-2020; Suryo Rahmanto, Yohan/K-8043-2018; sdsd, shihieih/ABE-6190-2020; Yu, Yu/AAD-7947-2019	Suryo Rahmanto, Yohan/0000-0003-1453-7872; Yu, Yu/0000-0002-0209-0586; Huang, Chuan-Hsiang/0000-0001-9993-8004	NIH/NCI [RO1CA215483, UO1CA200469, RO1CA148826, R21CA187512, K22CA212060, KO1-CA166576]; Richard W. TeLinde Research Program; Ovarian Cancer Research Foundation Alliance (OCRFA) [458972]; Honorable Tina Brozman Foundation; TEAL award; US Department of Defense Ovarian Cancer Consortium [W81XWH-11-2-0230]; NATIONAL CANCER INSTITUTE [R01CA215483, K01CA166576, K22CA212060, R21CA187512, U01CA200469, R01CA174388, R01CA148826] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Richard W. TeLinde Research Program; Ovarian Cancer Research Foundation Alliance (OCRFA); Honorable Tina Brozman Foundation; TEAL award; US Department of Defense Ovarian Cancer Consortium; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NIH/NCI grants, RO1CA215483 (I.M.S.), UO1CA200469 (I.M.S.), RO1CA148826 (T.L.W.), R21CA187512 (T.L.W.), K22CA212060 (C.H.H.), KO1-CA166576 (M.I.V.), Richard W. TeLinde Research Program (www.gynecologycancer.org), Ovarian Cancer Research Foundation Alliance (OCRFA) Grant # 458972 (I.M.S.), The Honorable Tina Brozman Foundation (I.M.S. and T.L.W.), TEAL award (T.L.W.), and US Department of Defense Ovarian Cancer Consortium grant W81XWH-11-2-0230 (I.M.S. and T.L.W.).	Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Beitz LO, 1999, J BIOL CHEM, V274, P32662, DOI 10.1074/jbc.274.46.32662; Bordeleau F, 2014, AM J PHYSIOL-CELL PH, V306, pC110, DOI 10.1152/ajpcell.00283.2013; Cheng SH, 2011, BLOOD, V118, P6342, DOI 10.1182/blood-2011-02-333773; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; Cox D, 1996, J BIOL CHEM, V271, P16597, DOI 10.1074/jbc.271.28.16597; Friedberg JW, 2010, BLOOD, V115, P2578, DOI 10.1182/blood-2009-08-236471; Gagliardi PA, 2015, SCI REP-UK, V5, DOI 10.1038/srep10206; Ghotra VPS, 2015, CANCER RES, V75, P230, DOI 10.1158/0008-5472.CAN-14-0629; Hastie EL, 2016, EUR J CELL BIOL, V95, P441, DOI 10.1016/j.ejcb.2016.06.006; Hatton O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042610; Hoon JL, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5020017; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Inagaki N, 2017, TRENDS CELL BIOL, V27, P515, DOI 10.1016/j.tcb.2017.02.003; Jaumouille V, 2014, DEV CELL, V29, P534, DOI 10.1016/j.devcel.2014.04.031; Kunwar S, 2016, RHEUMATOL INT, V36, P1077, DOI 10.1007/s00296-016-3482-7; Kurman RJ, 2016, AM J PATHOL, V186, P733, DOI 10.1016/j.ajpath.2015.11.011; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; Layton T, 2009, AM J PATHOL, V175, P2625, DOI 10.2353/ajpath.2009.090543; Li Y, 2012, J BIOL CHEM, V287, P31116, DOI 10.1074/jbc.M112.373647; Linder S, 2011, ANNU REV CELL DEV BI, V27, P185, DOI 10.1146/annurev-cellbio-092910-154216; Lu J, 2006, J BIOL CHEM, V281, P8806, DOI 10.1074/jbc.M507305200; Lua BL, 2005, FEBS LETT, V579, P577, DOI 10.1016/j.febslet.2004.12.055; Luangdilok S, 2007, CANCER RES, V67, P7907, DOI 10.1158/0008-5472.CAN-07-0331; Macdonald-Obermann JL, 2014, J BIOL CHEM, V289, P26178, DOI 10.1074/jbc.M114.586826; Mocsai A, 2010, NAT REV IMMUNOL, V10, P387, DOI 10.1038/nri2765; Moon KD, 2005, J BIOL CHEM, V280, P1543, DOI 10.1074/jbc.M407805200; Ocana-Morgner C, 2009, BLOOD, V113, P1474, DOI 10.1182/blood-2008-04-152587; Paz H, 2014, ONCOGENE, V33, P4193, DOI 10.1038/onc.2013.393; Pearce G, 2011, BLOOD, V117, P1574, DOI 10.1182/blood-2010-07-295659; Pohl G, 2005, CANCER RES, V65, P1994, DOI 10.1158/0008-5472.CAN-04-3625; Prinos P, 2011, NAT STRUCT MOL BIOL, V18, P673, DOI 10.1038/nsmb.2040; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Riedl J, 2008, NAT METHODS, V5, P605, DOI 10.1038/nmeth.1220; Ruschel A, 2004, CELL SIGNAL, V16, P1249, DOI 10.1016/j.cellsig.2004.03.007; Sharman J, 2015, BLOOD, V125, P2336, DOI 10.1182/blood-2014-08-595934; Stephens LR, 2001, J BIOL CHEM, V276, P42767, DOI 10.1074/jbc.M107194200; Tsang E, 2008, J BIOL CHEM, V283, P32650, DOI 10.1074/jbc.M806340200; Weinblatt ME, 2008, ARTHRITIS RHEUM-US, V58, P3309, DOI 10.1002/art.23992; Weinblatt ME, 2010, NEW ENGL J MED, V363, P1303, DOI 10.1056/NEJMoa1000500; Wu PH, 2015, SCI REP-UK, V5, DOI 10.1038/srep18437; Xue L, 2012, P NATL ACAD SCI USA, V109, P5615, DOI 10.1073/pnas.1119418109; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Yap KL, 2012, CANCER RES, V72, P4085, DOI 10.1158/0008-5472.CAN-12-0302; Yoo Y, 2010, ONCOGENE, V29, P263, DOI 10.1038/onc.2009.319; Young RM, 2009, BLOOD, V113, P2508, DOI 10.1182/blood-2008-05-158618; Yu L, 2014, INT J GYNECOL CANCER, V24, P1158, DOI 10.1097/IGC.0000000000000179; Yu Y, 2015, CANCER CELL, V28, P82, DOI 10.1016/j.ccell.2015.05.009; Zhang XY, 2009, MOL CANCER RES, V7, P634, DOI 10.1158/1541-7786.MCR-08-0371	49	15	16	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2018	37	28					3778	3789		10.1038/s41388-018-0241-0	http://dx.doi.org/10.1038/s41388-018-0241-0			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM8HR	29643476	Green Accepted			2022-12-17	WOS:000438465600002
J	Li, XM; Ruan, XH; Zhang, PT; Yu, Y; Gao, M; Yuan, SK; Zhao, ZW; Yang, J; Zhao, L				Li, Xiaomeng; Ruan, Xianhui; Zhang, Peitao; Yu, Yang; Gao, Ming; Yuan, Shukai; Zhao, Zewei; Yang, Jie; Zhao, Li			TBX3 promotes proliferation of papillary thyroid carcinoma cells through facilitating PRC2-mediated p57(KIP2) repression	ONCOGENE			English	Article							BECKWITH-WIEDEMANN-SYNDROME; BOX TRANSCRIPTION FACTORS; ULNAR-MAMMARY SYNDROME; BREAST-CANCER; DOWNSTREAM TARGET; CYCLE REGULATORS; E-CADHERIN; C-MYC; EXPRESSION; GENE	The T-box transcription factor TBX3 has been implicated in the patterning and differentiation of a number of tissues during embryonic development, and is overexpressed in a variety of cancers; however, the precise function of TBX3 in papillary thyroid carcinoma (PTC) development remains to be determined. In the current study, we report downregulation of TBX3 in PTC cells delays the G1/S-phase transition, decreases cell growth in vitro, and inhibits tumor formation in vivo. We identified p57(KIP2) as a novel downstream target that serves as the key mediator of TBX3's control over PTC cell proliferation. Reduced expression of TBX3 resulted in increased p57(KIP2) level, while knockdown of p57(KIP2) rescues the cell-cycle arrest phenotype. In clinical PTC specimens, the expression of TBX3 is markedly upregulated and significantly correlated with advanced tumor grade, but negatively correlated with the expression of p57(KIP2). Mechanism investigation revealed that TBX3 directly binds to the CDKN1C gene promoter region, the coding gene of p57(KIP2), and represses its transcription. Furthermore, recruitment of main components of the PRC2 complex as well as class I histone deacetylases, HDAC1 and HDAC2, is required for TBX3 to fulfill the transcriptional repression function. Our findings illustrate the previously unknown function and mechanism in cell proliferation regulation by the TBX3-p57(KIP2) axis and provide evidence for the contribution of the PRC2 complex and HDAC1/2. Targeting of this pathway may present a novel and molecular defined strategy against PTC development.	[Li, Xiaomeng; Zhang, Peitao; Yuan, Shukai; Zhao, Zewei; Yang, Jie; Zhao, Li] Tianjin Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Tianjin 300070, Peoples R China; [Ruan, Xianhui; Yu, Yang; Gao, Ming] Tianjin Med Univ Canc Inst & Hosp, Dept Thyroid & Neck Tumor, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjin 300060, Peoples R China	Tianjin Medical University; Tianjin Medical University	Yang, J; Zhao, L (corresponding author), Tianjin Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Tianjin 300070, Peoples R China.	yangj@tijmu.edu.cn; shzhaoli@tijmu.edu.cn		Yuan, Shukai/0000-0003-0354-5113	National Natural Science Foundation of China [31371329, 81702710, 81472580]; Innovation Team Development Plan of the Ministry of Education [IRT13085]; Tianjin Municipal Science and Technology Commission [13JCYBJC37200, 17JCQNJC11200]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovation Team Development Plan of the Ministry of Education; Tianjin Municipal Science and Technology Commission	This research work was supported by the grants from the National Natural Science Foundation of China (31371329 to L.Z., 81702710 to S.Y., 81472580 to M.G.). Innovation Team Development Plan of the Ministry of Education (IRT13085), The Tianjin Municipal Science and Technology Commission (13JCYBJC37200 to L,Z., 17JCQNJC11200 to S.Y.).	Bamshad M, 1997, NAT GENET, V16, P311, DOI 10.1038/ng0797-311; Borriello A, 2011, MOL CANCER RES, V9, P1269, DOI 10.1158/1541-7786.MCR-11-0220; Boyd SC, 2013, J INVEST DERMATOL, V133, P1269, DOI 10.1038/jid.2012.421; Burgucu D, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-481; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; Douglas NC, 2013, J MAMMARY GLAND BIOL, V18, P143, DOI 10.1007/s10911-013-9282-8; Fagman H, 2011, DEV BIOL, V359, P163, DOI 10.1016/j.ydbio.2011.08.015; Fan WW, 2004, CANCER RES, V64, P5132, DOI 10.1158/0008-5472.CAN-04-0615; Fillmore CM, 2010, P NATL ACAD SCI USA, V107, P21737, DOI 10.1073/pnas.1007863107; Higashimoto K, 2006, CYTOGENET GENOME RES, V113, P306, DOI 10.1159/000090846; Ito Y, 2004, PATHOBIOLOGY, V71, P164, DOI 10.1159/000076472; Ito Y, 2002, INT J MOL MED, V9, P373; Kikuchi T, 2002, ONCOGENE, V21, P2741, DOI 10.1038/sj.onc.1205376; Kobatake T, 2004, ONCOL REP, V12, P1087; Lai SL, 2000, CLIN CANCER RES, V6, P3172; Li J, 2013, MOL BIOL CELL, V24, P3569, DOI 10.1091/mbc.E13-05-0273; Lingbeek ME, 2002, J BIOL CHEM, V277, P26120, DOI 10.1074/jbc.M200403200; Lloyd RV, 2011, HEAD NECK PATHOL, V5, P51, DOI 10.1007/s12105-010-0236-9; Lomnytska M, 2006, INT J CANCER, V118, P412, DOI 10.1002/ijc.21332; Lyng H, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-268; Melck A, 2007, ANN SURG ONCOL, V14, P3403, DOI 10.1245/s10434-007-9572-8; Mesbah K, 2012, HUM MOL GENET, V21, P1217, DOI 10.1093/hmg/ddr553; Perkhofer L, 2016, STEM CELL RES, V17, P367, DOI 10.1016/j.scr.2016.08.007; Platonova N, 2007, CELL TISSUE RES, V328, P301, DOI 10.1007/s00441-006-0364-4; Renard CA, 2007, CANCER RES, V67, P901, DOI 10.1158/0008-5472.CAN-06-2344; Rodriguez M, 2008, CANCER RES, V68, P7872, DOI 10.1158/0008-5472.CAN-08-0301; Sato N, 2005, CLIN CANCER RES, V11, P4681, DOI 10.1158/1078-0432.CCR-04-2471; Shan ZZ, 2015, AM J CANCER RES, V5, P344; Sun CC, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2016.94; Trowe MO, 2013, DEVELOPMENT, V140, P2299, DOI 10.1242/dev.094524; Wansleben S, 2014, BBA-REV CANCER, V1846, P380, DOI 10.1016/j.bbcan.2014.08.004; Willmer T, 2016, CELL DIV, V11, DOI 10.1186/s13008-016-0019-0; Willmer T, 2015, CELL CYCLE, V14, P3173, DOI 10.1080/15384101.2015.1080398; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Yang XJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005011; Yarosh W, 2008, CANCER RES, V68, P693, DOI 10.1158/0008-5472.CAN-07-5012; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0; Zhao L, 2012, DEV CELL, V22, P585, DOI 10.1016/j.devcel.2011.12.023	38	15	15	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	21					2773	2792		10.1038/s41388-017-0090-2	http://dx.doi.org/10.1038/s41388-017-0090-2			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG8EE	29511350				2022-12-17	WOS:000432929800002
J	Pollan, SG; Huang, FJ; Sperger, JM; Lang, JM; Morrissey, C; Cress, AE; Chu, CY; Bhowmick, NA; You, S; Freeman, MR; Spassov, DS; Moasser, MM; Carter, WG; Satapathy, SR; Shah, K; Knudsen, BS				Pollan, Sara G.; Huang, Fangjin; Sperger, Jamie M.; Lang, Joshua M.; Morrissey, Colm; Cress, Anne E.; Chu, C. Y.; Bhowmick, Neil A.; You, Sungyong; Freeman, Michael R.; Spassov, Danislav S.; Moasser, Mark M.; Carter, William G.; Satapathy, Shakti Ranjan; Shah, Kavita; Knudsen, Beatrice S.			Regulation of inside-out beta 1-integrin activation by CDCP1	ONCOGENE			English	Article							DOMAIN-CONTAINING PROTEIN-1; CYCLIN-DEPENDENT KINASE-5; SURFACE GLYCOPROTEIN CDCP1; PROSTATE-CANCER CELLS; PKC-DELTA; C-DELTA; INTEGRIN ACTIVATION; MONOCLONAL-ANTIBODY; ANOIKIS RESISTANCE; ANDROGEN RECEPTOR	Tumor metastasis depends on the dynamic regulation of cell adhesion through beta 1-integrin. The Cub-Domain Containing Protein-1, CDCP1, is a transmembrane glycoprotein which regulates cell adhesion. Overexpression and loss of CDCP1 have been observed in the same cancer types to promote metastatic progression. Here, we demonstrate reduced CDCP1 expression in high-grade, primary prostate cancers, circulating tumor cells and tumor metastases of patients with castrate-resistant prostate cancer. CDCP1 is expressed in epithelial and not mesenchymal cells, and its cell surface and mRNA expression declines upon stimulation with TGF beta 1 and epithelial-to-mesenchymal transition. Silencing of CDCP1 in DU145 and PC3 cells resulted in 3.4-fold higher proliferation of non-adherent cells and 4.4-fold greater anchorage independent growth. CDCP1-silenced tumors grew in 100% of mice, compared to 30% growth of CDCP1-expressing tumors. After CDCP1 silencing, cell adhesion and migration diminished 2.1-fold, caused by loss of inside-out activation of beta 1-integrin. We determined that the loss of CDCP1 reduces CDK5 kinase activity due to the phosphorylation of its regulatory subunit, CDK5R1/p35, by c-SRC on Y234. This generates a binding site for the C2 domain of PKC delta, which in turn phosphorylates CDK5 on T77. The resulting dissociation of the CDK5R1/CDK5 complex abolishes the activity of CDK5. Mutations of CDK5-T77 and CDK5R1-Y234 phosphorylation sites re-establish the CDK5/CDKR1 complex and the inside-out activity of beta 1-integrin. Altogether, we discovered a new mechanism of regulation of CDK5 through loss of CDCP1, which dynamically regulates beta 1-integrin in non-adherent cells and which may promote vascular dissemination in patients with advanced prostate cancer.	[Pollan, Sara G.; Huang, Fangjin; Chu, C. Y.; Bhowmick, Neil A.; You, Sungyong; Freeman, Michael R.; Knudsen, Beatrice S.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; [Sperger, Jamie M.; Lang, Joshua M.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53705 USA; [Morrissey, Colm] Univ Washington, Seattle, WA 98195 USA; [Cress, Anne E.] Univ Arizona, Ctr Canc, Tucson, AZ 85704 USA; [Spassov, Danislav S.; Moasser, Mark M.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Carter, William G.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; [Satapathy, Shakti Ranjan; Shah, Kavita] Purdue Univ, W Lafayette, IN 47907 USA	Cedars Sinai Medical Center; University of Wisconsin System; University of Wisconsin Madison; University of Washington; University of Washington Seattle; University of Arizona; University of California System; University of California San Francisco; Fred Hutchinson Cancer Center; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Knudsen, BS (corresponding author), Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.	Beatrice.Knudsen@cshs.org	Satapathy, Shakti Ranjan/L-3124-2018; Satapathy, Shakti Ranjan/AAB-5787-2021; Bhowmick, Neil/AAA-7302-2019; Cress, Anne/V-6527-2019; You, Sungyong/AAJ-7372-2020; Shah, Kavita/Y-9755-2019; Spassov, Danislav S/GQA-4368-2022	Satapathy, Shakti Ranjan/0000-0002-3212-8960; Satapathy, Shakti Ranjan/0000-0002-3212-8960; Bhowmick, Neil/0000-0001-8747-5989; Cress, Anne/0000-0001-6194-0061; You, Sungyong/0000-0003-3513-1783; Shah, Kavita/0000-0002-0451-1305; Spassov, Danislav S/0000-0002-6680-877X	Pacific Northwest Prostate Cancer SPORE [P50CA97186]; Richard M. LUCAS Foundation; Department of Defense Synergistic Idea Development Award [W81XWH-08-1-0268]; Cedars-Sinai Medical Center; NATIONAL CANCER INSTITUTE [P50CA097186, R01CA159406] Funding Source: NIH RePORTER	Pacific Northwest Prostate Cancer SPORE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Richard M. LUCAS Foundation; Department of Defense Synergistic Idea Development Award(United States Department of Defense); Cedars-Sinai Medical Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We heartily acknowledge Wen-Chin Huang for assistance in animal surgery, L. Chung for support in in vivo experiments, and to C. Pospisil for cloning PKCd mutant with inactive kinase into vector. We thank the patients and their families, Robert Vessella, Eva Corey, Celestia Higano, Bruce Montgomery, Peter Nelson, Paul Lange, Martine Roudier, and Lawrence True for their contributions to the University of Washington Medical Center Prostate Cancer Donor Rapid Autopsy Program supported by funding by the Pacific Northwest Prostate Cancer SPORE (P50CA97186) and the Richard M. LUCAS Foundation. We are thankful to Jennifer Kitchel and the Biobank and Translational Research Core at Cedars-Sinai Medical Center for xenograft embedding, tissue processing, and IHC staining. This work was supported by Department of Defense Synergistic Idea Development Award W81XWH-08-1-0268 and start-up funding from Cedars-Sinai Medical Center.	Alvares SM, 2008, BBA-GEN SUBJECTS, V1780, P486, DOI 10.1016/j.bbagen.2008.01.010; Antal CE, 2015, CELL, V160, P489, DOI 10.1016/j.cell.2015.01.001; Benes CH, 2012, ONCOGENE, V31, P653, DOI 10.1038/onc.2011.262; Benes CH, 2005, CELL, V121, P271, DOI 10.1016/j.cell.2005.02.019; Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; Bosutti A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075538; Calderwood DA, 2013, NAT REV MOL CELL BIO, V14, P503, DOI 10.1038/nrm3624; Cantu E, 2013, AM J TRANSPLANT, V13, P1898, DOI 10.1111/ajt.12283; Casar B, 2014, ONCOGENE, V33, P255, DOI 10.1038/onc.2012.547; Casar B, 2012, ONCOGENE, V31, P3924, DOI 10.1038/onc.2011.555; Chang KH, 2011, MOL BIOL CELL, V22, P1452, DOI 10.1091/mbc.E10-07-0654; Das L, 2017, J CELL BIOCHEM, V118, P1038, DOI 10.1002/jcb.25673; Deryugina EI, 2009, MOL CANCER RES, V7, P1197, DOI 10.1158/1541-7786.MCR-09-0100; DeVries-Seimon TA, 2007, J BIOL CHEM, V282, P22307, DOI 10.1074/jbc.M703661200; Dickreuter E, 2016, ONCOGENE, V35, P1353, DOI 10.1038/onc.2015.212; Dong Y, 2012, J BIOL CHEM, V287, P9792, DOI 10.1074/jbc.M111.335448; Fukuchi K, 2010, MOL PHARMACEUT, V7, P245, DOI 10.1021/mp900236t; Ganguly KK, 2013, CELL ADHES MIGR, V7, P251, DOI 10.4161/cam.23840; Gao C, 2002, MOL CANCER RES, V1, P12; Ginsberg MH, 2014, BMB REP, V47, P655, DOI 10.5483/BMBRep.2014.47.12.241; GLASER KB, 1993, BIOCHEM PHARMACOL, V45, P711, DOI 10.1016/0006-2952(93)90147-O; Hisanaga S, 2003, NEUROSIGNALS, V12, P221, DOI 10.1159/000074624; Hoffmann A, 2017, US Patent, Patent No. 9555110; Hofmann J, 2004, CURR CANCER DRUG TAR, V4, P125, DOI 10.2174/1568009043481579; Hsu FN, 2011, J BIOL CHEM, V286, P33141, DOI 10.1074/jbc.M111.252080; Jin J, 2015, MATH PROBL ENG, V2015, DOI 10.1155/2015/931629; Kato H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046576; Kawauchi T, 2012, INT J MOL SCI, V13, P4564, DOI 10.3390/ijms13044564; Kimura H, 2006, LEUKEMIA, V20, P1551, DOI 10.1038/sj.leu.2404312; Knudsen BS, 2009, APPL IMMUNOHISTO M M, V17, P57, DOI 10.1097/PAI.0b013e3181816ae2; LI WQ, 1995, J BIOL CHEM, V270, P8311, DOI 10.1074/jbc.270.14.8311; Li XY, 2016, ONCOTARGET, V7, P12869, DOI 10.18632/oncotarget.7331; Liu H, 2011, P NATL ACAD SCI USA, V108, P1379, DOI 10.1073/pnas.1017228108; Liu Y, 2006, J BIOL CHEM, V281, P12102, DOI 10.1074/jbc.M600508200; Mamat S, 2010, ONCOL REP, V23, P1221, DOI 10.3892/or_00000753; Minciacchi VR, 2017, PROSTATE CANCER P D, V20, P251, DOI 10.1038/pcan.2017.7; Moser M, 2009, SCIENCE, V324, P895, DOI 10.1126/science.1163865; Nakano N, 2005, BRIT J DERMATOL, V153, P37, DOI 10.1111/j.1365-2133.2005.06583.x; O'Hare MJ, 2005, J NEUROSCI, V25, P8954, DOI 10.1523/JNEUROSCI.2899-05.2005; Ohlsson L, 2012, INT J CANCER, V130, P1833, DOI 10.1002/ijc.26182; Orchard-Webb DJ, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-754; Parvani JG, 2013, MOL BIOL CELL, V24, P3449, DOI 10.1091/mbc.E12-10-0776; Provasi D, 2014, PROTEINS, V82, P3231, DOI 10.1002/prot.24540; Putzke AP, 2011, AM J PATHOL, V179, P400, DOI 10.1016/j.ajpath.2011.03.028; Rai AC, 2014, BIOMETALS, V27, P1231, DOI 10.1007/s10534-014-9785-9; Razorenova OV, 2011, P NATL ACAD SCI USA, V108, P1931, DOI 10.1073/pnas.1011777108; Sachdev S, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-12; Sandvig K, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.012914; Sato K, 2007, J NEUROSCI RES, V85, P3071, DOI 10.1002/jnr.21438; Sawada G, 2014, ANN SURG ONCOL, V21, pS640, DOI 10.1245/s10434-014-3740-4; Schehr JL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159397; Schiewer MJ, 2012, CANCER DISCOV, V2, P1134, DOI 10.1158/2159-8290.CD-12-0120; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shattil SJ, 2010, NAT REV MOL CELL BIO, V11, P288, DOI 10.1038/nrm2871; Siva AC, 2008, CANCER RES, V68, P3759, DOI 10.1158/0008-5472.CAN-07-1657; Siva AC, 2008, J IMMUNOL METHODS, V330, P109, DOI 10.1016/j.jim.2007.11.008; Spassov DS, 2012, ONCOGENE, V31, P419, DOI 10.1038/onc.2011.246; Spassov DS, 2013, CANCER RES, V73, P1168, DOI 10.1158/0008-5472.CAN-12-2496; Spassov DS, 2011, CELL CYCLE, V10, P1225, DOI 10.4161/cc.10.8.15343; Spassov DS, 2011, MOL CELL BIOL, V31, P766, DOI 10.1128/MCB.00841-10; Spassov DS, 2009, AM J PATHOL, V174, P1756, DOI 10.2353/ajpath.2009.080890; Sperger JM, 2016, CLIN CANCER RES, V23, P746; Stahelin RV, 2012, J BIOL CHEM, V287, P30518, DOI 10.1074/jbc.M112.391557; Strock CJ, 2006, CANCER RES, V66, P7509, DOI 10.1158/0008-5472.CAN-05-3048; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Tun HW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010696; Twardowski PW, 2013, ANTI-CANCER DRUG, V24, P743, DOI 10.1097/CAD.0b013e328361feb0; Uekita T, 2008, AM J PATHOL, V172, P1729, DOI 10.2353/ajpath.2008.070981; Uekita T, 2007, MOL CELL BIOL, V27, P7649, DOI 10.1128/MCB.01246-07; Uekita T, 2011, CANCER SCI, V102, P1943, DOI 10.1111/j.1349-7006.2011.02052.x; Wortmann A, 2011, J BIOL CHEM, V286, P42303, DOI 10.1074/jbc.M111.227462; Wortmann A, 2009, IUBMB LIFE, V61, P723, DOI 10.1002/iub.198; Wright HJ, 2016, ONCOGENE, V35, P4762, DOI 10.1038/onc.2016.7; Yang J, 2013, ANAT REC, V296, P1501, DOI 10.1002/ar.22769; Yang LF, 2015, ONCOTARGET, V6, P43743, DOI 10.18632/oncotarget.6193; You SY, 2016, CANCER RES, V76, P4948, DOI 10.1158/0008-5472.CAN-16-0902; Zarif JC, 2015, ONCOTARGET, V6, P6862, DOI 10.18632/oncotarget.3119	78	15	16	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	21					2817	2836		10.1038/s41388-018-0142-2	http://dx.doi.org/10.1038/s41388-018-0142-2			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG8EE	29511352	Green Accepted			2022-12-17	WOS:000432929800005
J	Celik, H; Sciandra, M; Flashner, B; Gelmez, E; Kayrakilogiu, N; Allegakoen, DV; Petro, JR; Conn, EJ; Hour, S; Han, J; Oktay, L; Tiwari, PB; Hayran, M; Harris, BT; Manara, MC; Toretsky, JA; Scotlandi, K; Uren, A				Celik, Haydar; Sciandra, Marika; Flashner, Bess; Gelmez, Elif; Kayrakilogiu, Neslihan; Allegakoen, David V.; Petro, Jeff R.; Conn, Erin J.; Hour, Sarah; Han, Jenny; Oktay, Lalehan; Tiwari, Purushottam B.; Hayran, Mutlu; Harris, Brent T.; Manara, Maria Cristina; Toretsky, Jeffrey A.; Scotlandi, Katia; Uren, Aykut			Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99	ONCOGENE			English	Article							MIC2 EXPRESSION; CELL; TUMORS; GENE; OSTEOSARCOMA; ENGAGEMENT; MIGRATION; CANCER; FAMILY; IDENTIFICATION	Ewing sarcoma (ES) is an aggressive bone and soft tissue malignancy that predominantly affects children and adolescents. CD99 is a cell surface protein that is highly expressed on ES cells and is required to maintain their malignancy. We screened small molecule libraries for binding to extracellular domain of recombinant CD99 and subsequent inhibition of ES cell growth. We identified two structurally similar FDA-approved compounds, clofarabine and cladribine that selectively inhibited the growth of ES cells in a panel of 14 ES vs. 28 non-ES cell lines. Both drugs inhibited CD99 dimerization and its interaction with downstream signaling components. A membrane-impermeable analog of clofarabine showed similar cytotoxicity in culture, suggesting that it can function through inhibiting CD99 independent of DNA metabolism. Both drugs drastically inhibited anchorage-independent growth of ES cells, but clofarabine was more effective in inhibiting growth of three different ES xenografts. Our findings provide a novel molecular mechanism for clofarabine that involves direct binding to a cell surface receptor CD99 and inhibiting its biological activities.	[Celik, Haydar; Flashner, Bess; Gelmez, Elif; Kayrakilogiu, Neslihan; Allegakoen, David V.; Petro, Jeff R.; Conn, Erin J.; Hour, Sarah; Han, Jenny; Oktay, Lalehan; Tiwari, Purushottam B.; Toretsky, Jeffrey A.; Uren, Aykut] Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20007 USA; [Sciandra, Marika; Manara, Maria Cristina; Scotlandi, Katia] Rizzoli Orthopaed Inst, Expt Oncol Lab, CRS Dev Biomol Therapies, Bologna, Italy; [Sciandra, Marika; Manara, Maria Cristina; Scotlandi, Katia] Rizzoli Orthopaed Inst, RIT Dept, STB, PROMETEO Lab, Bologna, Italy; [Hayran, Mutlu] Hacettepe Univ, Canc Inst, Dept Prevent Oncol, Ankara, Turkey; [Harris, Brent T.] Georgetown Univ, Med Ctr, Dept Pathol, Washington, DC 20007 USA	Georgetown University; IRCCS Istituto Ortopedico Rizzoli; IRCCS Istituto Ortopedico Rizzoli; Hacettepe University; Georgetown University	Uren, A (corresponding author), Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20007 USA.; Scotlandi, K (corresponding author), Rizzoli Orthopaed Inst, Expt Oncol Lab, CRS Dev Biomol Therapies, Bologna, Italy.; Scotlandi, K (corresponding author), Rizzoli Orthopaed Inst, RIT Dept, STB, PROMETEO Lab, Bologna, Italy.	katia.scotlandi@ior.it; au26@georgetown.edu	Manara, Maria Cristina/K-3366-2018; Scotlandi, Katia/J-9009-2016; Sciandra, Marika/C-8724-2018	Manara, Maria Cristina/0000-0001-5686-720X; Scotlandi, Katia/0000-0001-6114-9499; Sciandra, Marika/0000-0001-7147-6960; Celik, Haydar/0000-0003-4314-8438	Children's Cancer Foundation; Hyundai Hope on Wheels; Alan B. Slifka Foundation; Italian Association for Cancer Research [AIRC_IG14049]; National Cancer Institute [P30CA51008]	Children's Cancer Foundation; Hyundai Hope on Wheels; Alan B. Slifka Foundation; Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the funds from the Children's Cancer Foundation (to A. Uren), Hyundai Hope on Wheels (to A. Uren), the Alan B. Slifka Foundation (to A. Uren and K. Scotlandi) and the Italian Association for Cancer Research (AIRC_IG14049 to K. Scotlandi). The authors thank the Animal Models Shared Resource, Tissue Culture Shared Resource, Histopathology and Tissue Shared Resource and the Biacore Molecular Interaction Shared Resource at the Lombardi Comprehensive Cancer Center (Georgetown University), which are supported by a grant P30CA51008 from the National Cancer Institute.	AMBROS IM, 1991, CANCER, V67, P1886, DOI 10.1002/1097-0142(19910401)67:7<1886::AID-CNCR2820670712>3.0.CO;2-U; Arndt CAS, 1999, NEW ENGL J MED, V341, P342, DOI 10.1056/NEJM199907293410507; AUBRIT F, 1989, EUR J IMMUNOL, V19, P1431, DOI 10.1002/eji.1830190813; BERNARD A, 1988, J IMMUNOL, V140, P1802; Bixel G, 2004, BLOOD, V104, P3205, DOI 10.1182/blood-2004-03-1184; Bonate PL, 2006, NAT REV DRUG DISCOV, V5, P855, DOI 10.1038/nrd2055; Brohl AS, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004475; CCEDILELIK H, 2015, MOL CELL BIOL, V35, P3145, DOI DOI 10.1128/MCB.00332-15; Choi G, 2007, EXP MOL MED, V39, P746, DOI 10.1038/emm.2007.81; Chung SS, 2014, BLOOD, V124, P3760; Chung SS, 2013, BLOOD, V122; Chung SS, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaj2025; Cox CV, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165210; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dworzak MN, 1999, BRIT J HAEMATOL, V105, P690, DOI 10.1046/j.1365-2141.1999.01426.x; DWORZAK MN, 1994, BLOOD, V83, P415, DOI 10.1182/blood.V83.2.415.bloodjournal832415; ELLIS NA, 1994, NAT GENET, V8, P285, DOI 10.1038/ng1194-285; FELLINGER EJ, 1991, AM J PATHOL, V139, P317; Franzetti GA, 2013, ONCOGENE, V32, P3915, DOI 10.1038/onc.2012.403; Gaspar N, 2015, J CLIN ONCOL, V33, P3036, DOI 10.1200/JCO.2014.59.5256; GELIN C, 1989, EMBO J, V8, P3253, DOI 10.1002/j.1460-2075.1989.tb08485.x; Gellini M, 2013, CURR PHARM BIOTECHNO, V14, P449, DOI 10.2174/1389201011314040011; Giovannoni G, 2010, NEW ENGL J MED, V362, P416, DOI 10.1056/NEJMoa0902533; Gollnest T, 2016, ANGEW CHEM INT EDIT, V55, P5255, DOI 10.1002/anie.201511808; Gollnest T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9716; Guerzoni C, 2015, CLIN CANCER RES, V21, P146, DOI 10.1158/1078-0432.CCR-14-0492; Halliday BE, 1998, DIAGN CYTOPATHOL, V19, P410, DOI 10.1002/(SICI)1097-0339(199812)19:6<410::AID-DC2>3.0.CO;2-Z; Hu-Lieskovan S, 2005, CANCER RES, V65, P4633, DOI 10.1158/0008-5472.CAN-04-2857; Husak Z, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.164; Husak Z, 2010, J LEUKOCYTE BIOL, V88, P405, DOI 10.1189/jlb.0210097; KAWASAKI H, 1993, BLOOD, V81, P597; Khoury JD, 2005, ADV ANAT PATHOL, V12, P212, DOI 10.1097/01.pap.0000175114.55541.52; Kim HJ, 2004, IMMUNOL LETT, V95, P155, DOI 10.1016/j.imlet.2004.07.001; KOVAR H, 1990, ONCOGENE, V5, P1067; Kovar Heinrich, 1998, Current Opinion in Oncology, V10, P334, DOI 10.1097/00001622-199807000-00010; Kovar H, 2016, ONCOTARGET, V7, P8613, DOI 10.18632/oncotarget.6937; Kreppel M, 2006, ONCOGENE, V25, P2795, DOI 10.1038/sj.onc.1209300; Lawlor Elizabeth R., 2015, Critical Reviews in Oncogenesis, V20, P155, DOI 10.1615/CritRevOncog.2015013553; Lee CS, 1996, PEDIATR PATHOL LAB M, V16, P379, DOI 10.1080/15513819609168678; Longhi A, 2012, CANCER-AM CANCER SOC, V118, P5050, DOI 10.1002/cncr.27493; Lucas DR, 2001, AM J CLIN PATHOL, V115, P11; Manara MC, 2006, MOL BIOL CELL, V17, P1910, DOI 10.1091/mbc.E05-10-0971; Mi-Kyung L, 2008, J MICROBIOL BIOTECHN, V18, P472; Miyagawa Y, 2008, MOL CELL BIOL, V28, P2125, DOI 10.1128/MCB.00740-07; Moricoli D, 2016, APPL MICROBIOL BIOT, V100, P3949, DOI 10.1007/s00253-015-7226-5; PERLMAN EJ, 1994, HUM PATHOL, V25, P304, DOI 10.1016/0046-8177(94)90203-8; Rocchi A, 2010, J CLIN INVEST, V120, P668, DOI 10.1172/JCI36667; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Scotlandi K, 2000, CANCER RES, V60, P5134; Scotlandi K, 2006, EUR J CANCER, V42, P91, DOI 10.1016/j.ejca.2005.09.015; Sigal DS, 2010, BLOOD, V116, P2884, DOI 10.1182/blood-2010-02-246140; Sohn HW, 1998, AM J PATHOL, V153, P1937, DOI 10.1016/S0002-9440(10)65707-0; Suh YH, 2003, GENE, V307, P63, DOI 10.1016/S0378-1119(03)00401-3; Ventura S, 2016, ONCOGENE, V35, P3944, DOI 10.1038/onc.2015.463; Watson RL, 2015, J EXP MED, V212, P1021, DOI 10.1084/jem.20150354; WEIDNER N, 1994, AM J SURG PATHOL, V18, P486, DOI 10.1097/00000478-199405000-00008; Winger RC, 2016, J IMMUNOL, V196, P1443, DOI 10.4049/jimmunol.1501634; Zucchini C, 2014, ONCOGENE, V33, P1912, DOI 10.1038/onc.2013.152	59	15	17	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	16					2181	2196		10.1038/s41388-017-0080-4	http://dx.doi.org/10.1038/s41388-017-0080-4			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GD5ZV	29382926				2022-12-17	WOS:000430589000008
J	Abbaci, A; Talbot, H; Saada, S; Gachard, N; Abraham, J; Jaccard, A; Bordessoule, D; Fauchais, AL; Naves, T; Jauberteau, MO				Abbaci, A.; Talbot, H.; Saada, S.; Gachard, N.; Abraham, J.; Jaccard, A.; Bordessoule, D.; Fauchais, A. L.; Naves, T.; Jauberteau, M. O.			Neurotensin receptor type 2 protects B-cell chronic lymphocytic leukemia cells from apoptosis	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; CHEMOKINE RECEPTOR; SIGNALING PATHWAY; COUPLED RECEPTORS; IN-VITRO; EXPRESSION; ACTIVATION; SURVIVAL; BCL-2; OVEREXPRESSION	B-cell chronic lymphocytic leukemia (B-CLL) cells are resistant to apoptosis, and consequently accumulate to the detriment of normal B cells and patient immunity. Because current therapies fail to eradicate these apoptosis-resistant cells, it is essential to identify alternative survival pathways as novel targets for anticancer therapies. Overexpression of cell-surface G protein-coupled receptors drives cell transformation, and thus plays a critical role in malignancies. In this study, we identified neurotensin receptor 2 (NTSR2) as an essential driver of apoptosis resistance in B-CLL. NTSR2 was highly expressed in B-CLL cells, whereas expression of its natural ligand, neurotensin (NTS), was minimal in both B-CLL cells and patient plasma. Surprisingly, NTSR2 remained in a constitutively active phosphorylated state, caused not by a mutation-induced gain-of-function but rather by an interaction with the oncogenic tyrosine kinase receptor TrkB. Functional and biochemical characterization revealed that the NTSR2-TrkB interaction acts as a conditional oncogenic driver requiring the TrkB ligand brain-derived neurotrophic factor (BDNF), which unlike NTS is highly expressed in B-CLL cells. Together, NTSR2, TrkB and BDNF induce autocrine and/or paracrine survival pathways that are independent of mutation status and indolent or progressive disease course. The NTSR2-TrkB interaction activates survival signaling pathways, including the Src and AKT kinase pathways, as well as expression of the anti-apoptotic proteins Bcl-2 and Bcl-xL. When NTSR2 was downregulated, TrkB failed to protect B-CLL cells from a drastic decrease in viability via typical apoptotic cell death, reflected by DNA fragmentation and Annexin V presentation. Together, our findings demonstrate that the NTSR2-TrkB interaction plays a crucial role in B-CLL cell survival, suggesting that inhibition of NTSR2 represents a promising targeted strategy for treating B-CLL malignancy.	[Abbaci, A.; Talbot, H.; Saada, S.; Fauchais, A. L.; Naves, T.; Jauberteau, M. O.] Limoges Univ, Equipe Accueil Cellular Homeostasis & Dis 3842, Fac Med, Limoges, France; [Gachard, N.] Dupuytren Hosp Univ Ctr Limoges, Hematol Lab, Limoges, France; [Gachard, N.; Jaccard, A.; Bordessoule, D.] Limoges Univ, CNRS, UMR 7276, Limoges, France; [Abraham, J.; Jaccard, A.; Bordessoule, D.] Dupuytren Hosp Univ Ctr Limoges, Dept Hematol, Limoges, France; [Fauchais, A. L.] Dupuytren Hosp Univ Ctr Limoges, Dept Internal Med, Limoges, France; [Jauberteau, M. O.] Dupuytren Hosp Univ Ctr Limoges, Dept Immunol, Limoges, France	CHU Limoges; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); CHU Limoges; CHU Limoges; CHU Limoges	Jauberteau, MO (corresponding author), Fac Med Limoges, Lab Homeostasie Cellulaire & Pathol, EA3842, 2 Rue Docteur Marcland, F-87025 Limoges, France.	m-o.jauberteau-marchan@unilim.fr	Naves, Thomas/AAB-5874-2020	Naves, Thomas/0000-0002-5291-5689; Jauberteau, Marie-Odile/0000-0002-8811-8948; SAADA, Sofiane/0000-0003-2057-3159; Talbot, Hugo/0000-0001-9774-8573	Limousin regional council from Limoges; La Ligue Nationale Contre le Cancer (Comite Departemental de La Haute-Vienne) from Limoges; CORC (Comite d'Orientation de la Recherche en Cancerologie) from Limoges	Limousin regional council from Limoges; La Ligue Nationale Contre le Cancer (Comite Departemental de La Haute-Vienne) from Limoges; CORC (Comite d'Orientation de la Recherche en Cancerologie) from Limoges	This work was supported and funded by grants from the Limousin regional council, La Ligue Nationale Contre le Cancer (Comite Departemental de La Haute-Vienne) and CORC (Comite d'Orientation de la Recherche en Cancerologie) from Limoges.	Ai LS, 2013, INT J CANCER, V133, P1074, DOI 10.1002/ijc.28116; Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894; Barragan M, 2002, BLOOD, V99, P2969, DOI 10.1182/blood.V99.8.2969; Bellanger C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027213; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Burkle A, 2007, BLOOD, V110, P3316, DOI 10.1182/blood-2007-05-089409; Burger JA, 1999, BLOOD, V94, P3658, DOI 10.1182/blood.V94.11.3658.423k11_3658_3667; Cattaneo F, 2014, INT J MOL SCI, V15, P19700, DOI 10.3390/ijms151119700; Cazorla M, 2011, J CLIN INVEST, V121, P1846, DOI 10.1172/JCI43992; Chiorazzi N., 2005, NEW ENGL J MED, V352, P804, DOI [10.1002/9781444300857.ch36, DOI 10.1056/NEJMRA041720, 10.1056/NEJMra041720]; Choi SY, 1999, BRIT J PHARMACOL, V126, P1050, DOI 10.1038/sj.bjp.0702378; Cuni S, 2004, LEUKEMIA, V18, P1391, DOI 10.1038/sj.leu.2403398; Dalwadi H, 2003, J IMMUNOL, V170, P1707, DOI 10.4049/jimmunol.170.4.1707; De la Cruz-Morcillo MA, 2016, ONCOTARGET, V7, P34480, DOI 10.18632/oncotarget.8911; Delcourt N, 2007, TRENDS PHARMACOL SCI, V28, P602, DOI 10.1016/j.tips.2007.09.007; Dielschneider RF, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.391; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Drost AC, 2012, LEUKEMIA LYMPHOMA, V53, P665, DOI 10.3109/10428194.2011.625578; Dupouy S, 2014, ONCOTARGET, V5, P8235, DOI 10.18632/oncotarget.1632; Dupouy S, 2011, BIOCHIMIE, V93, P1369, DOI 10.1016/j.biochi.2011.04.024; El-Shewy HM, 2006, J BIOL CHEM, V281, P31399, DOI 10.1074/jbc.M605339200; Fauchais AL, 2008, J IMMUNOL, V181, P3027, DOI 10.4049/jimmunol.181.5.3027; Frade JM, 1996, NATURE, V383, P166; Ghosh AK, 2013, ADV EXP MED BIOL, V792, P215, DOI 10.1007/978-1-4614-8051-8_10; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Kehrl JH, 1998, IMMUNITY, V8, P1, DOI 10.1016/S1074-7613(00)80453-7; Kehrl JH, 2016, BIOCHEM PHARMACOL, V114, P40, DOI 10.1016/j.bcp.2016.04.005; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Kitada S, 2002, ONCOGENE, V21, P3459, DOI 10.1038/sj.onc.1205327; Liu Y, 2016, CANCER LETT, V376, P226, DOI 10.1016/j.canlet.2016.03.031; Longo PG, 2007, LEUKEMIA, V21, P110, DOI 10.1038/sj.leu.2404417; Longo PG, 2008, BLOOD, V111, P846, DOI 10.1182/blood-2007-05-089037; Magazin M, 2004, J INVEST DERMATOL, V122, P111, DOI 10.1046/j.0022-202X.2003.22131.x; Martin S, 2002, J CELL SCI, V115, P165; Mazella J, 1998, J BIOL CHEM, V273, P26273, DOI 10.1074/jbc.273.41.26273; Mira E, 2001, EMBO REP, V2, P151, DOI 10.1093/embo-reports/kve027; Mohle R, 1999, LEUKEMIA, V13, P1954, DOI 10.1038/sj.leu.2401602; Moughal NA, 2004, CELL SIGNAL, V16, P127, DOI 10.1016/j.cellsig.2003.08.004; Moughal NA, 2006, J NEUROCHEM, V98, P1920, DOI 10.1111/j.1471-4159.2006.04009.x; Ohman L, 2002, GUT, V51, P392, DOI 10.1136/gut.51.3.392; Pearse RN, 2005, BLOOD, V105, P4429, DOI 10.1182/blood-2004-08-3096; Raijmakers R, 2010, ANAL CHEM, V82, P824, DOI 10.1021/ac901764g; Rooswinkel RW, 2014, BLOOD, V123, P2806, DOI 10.1182/blood-2013-08-519470; Rosati E, 2009, BLOOD, V113, P856, DOI 10.1182/blood-2008-02-139725; Rossi D, 2013, BLOOD, V121, P1403, DOI 10.1182/blood-2012-09-458265; Saada S, 2012, J IMMUNOL, V189, P5293, DOI 10.4049/jimmunol.1102937; Saiya-Cork K, 2011, CLIN CANCER RES, V17, P2679, DOI 10.1158/1078-0432.CCR-10-2058; Schrottner P, 2010, ANN HEMATOL, V89, P437, DOI 10.1007/s00277-009-0876-6; Somai S, 2002, BIOCHEM BIOPH RES CO, V295, P482, DOI 10.1016/S0006-291X(02)00703-9; Strober Warren, 2015, Curr Protoc Immunol, V111, DOI 10.1002/0471142735.ima03bs111; Sun CY, 2012, INT J CANCER, V130, P827, DOI 10.1002/ijc.26059; Swift SL, 2010, CANCER RES, V70, P347, DOI 10.1158/0008-5472.CAN-09-1252; Thiele CJ, 2009, CLIN CANCER RES, V15, P5962, DOI 10.1158/1078-0432.CCR-08-0651; Ticchioni M, 2007, ONCOGENE, V26, P7081, DOI 10.1038/sj.onc.1210519; Tomasi ML, 2015, ONCOTARGET, V6, P37706, DOI 10.18632/oncotarget.5342; Vita N, 1998, EUR J PHARMACOL, V360, P265, DOI 10.1016/S0014-2999(98)00678-5; Wilson CM, 2014, CNS NEUROL DISORD-DR, V13, P1354, DOI 10.2174/1871527313666141023151642; Wilson CM, 2014, J CELL SCI, V127, P3983, DOI 10.1242/jcs.149336; Woyach JA, 2012, BLOOD, V120, P1175, DOI 10.1182/blood-2012-02-362624; Wu ZR, 2017, CANCER LETT, V388, P73, DOI 10.1016/j.canlet.2016.11.032; Yaktapour N, 2013, BLOOD, V122, P1621, DOI 10.1182/blood-2013-02-484386; Younes M, 2014, ONCOTARGET, V5, P8252, DOI 10.18632/oncotarget.1633	62	15	15	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2018	37	6					756	767		10.1038/onc.2017.365	http://dx.doi.org/10.1038/onc.2017.365			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FV5ND	29059151	Green Published, hybrid			2022-12-17	WOS:000424628100007
J	Chen, YR; Chou, HC; Yang, CH; Chen, HY; Liu, YW; Lin, TY; Yeh, CL; Chao, WT; Tsou, HH; Chuang, HC; Tan, TH				Chen, Y-R; Chou, H-C; Yang, C-H; Chen, H-Y; Liu, Y-W; Lin, T-Y; Yeh, C-L; Chao, W-T; Tsou, H-H; Chuang, H-C; Tan, T-H			Deficiency in VHR/DUSP3, a suppressor of focal adhesion kinase, reveals its role in regulating cell adhesion and migration	ONCOGENE			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; DUAL-SPECIFICITY PHOSPHATASE; SRC FAMILY KINASES; DOWN-REGULATION; CANCER CELLS; VHR; ACTIVATION; EXPRESSION; JNK; MAP	Vaccinia H1-related phosphatase (VHR/DUSP3) is a member of the dual-specificity phosphatase family. Deregulation of VHR is observed in various malignant diseases. We identified focal adhesion kinase (FAK) as a VHR-interacting molecule. Over-expression of VHR decreased tyrosine phosphorylation of FAK and decreasing VHR promoted FAK tyrosine phosphorylation. In vitro assays proved that recombinant VHR directly dephosphorylated FAK and paxillin. VHR-knockout mice did not have obvious abnormality; however, VHR-knockout cells showed decreased expression of integrins and FAK but stronger FAK and paxillin phosphorylation upon attachment to fibronectin. Additionally, VHR-knockout fibroblast and lung epithelial cells had elevated ligand-induced epidermal growth factor receptor (EGFR) phosphorylation. Inducible expression of VHR suppressed directional cell migration, and VHR deficiency resulted in a higher cell migratory ability. VHR-knockout cells have stronger FAK phosphorylation in cell adhesions, long-lasting trailing ends and slower turnover of focal adhesions. These collective data indicate that VHR is a FAK phosphatase and participates in regulating the formation and disassembly of focal adhesions.	[Chen, Y-R; Chou, H-C; Yang, C-H; Chen, H-Y; Liu, Y-W; Lin, T-Y; Yeh, C-L] Natl Hlth Res Inst, Inst Mol & Genom Med, Zhunan 35053, Taiwan; [Chen, H-Y; Chao, W-T] Tunghai Univ, Dept Life Sci, Taichung, Taiwan; [Tsou, H-H] Natl Hlth Res Inst, Inst Populat Hlth Sci, Div Biostat & Bioinformat, Zhunan, Taiwan; [Chao, W-T] China Med Univ, Coll Publ Hlth, Grad Inst Biostat, Taichung, Taiwan; [Chuang, H-C; Tan, T-H] Natl Hlth Res Inst, Immunol Res Ctr, Zhunan 35053, Taiwan; [Tan, T-H] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX USA	National Health Research Institutes - Taiwan; Tunghai University; National Health Research Institutes - Taiwan; China Medical University Taiwan; National Health Research Institutes - Taiwan; Baylor College of Medicine	Chen, YR (corresponding author), Natl Hlth Res Inst, Inst Mol & Genom Med, Zhunan 35053, Taiwan.; Tan, TH (corresponding author), Natl Hlth Res Inst, Immunol Res Ctr, Zhunan 35053, Taiwan.	yrchen@nhri.org.tw; ttan@nhri.org.tw	Chuang, Huai-Chia/E-9486-2016; Chen, Yi-Rong/E-3991-2010; Chen, Yi-Rong/CAF-2186-2022; Chen, Yi-Rong/CAH-7991-2022; Tan, Tse-Hua/ABD-7080-2021; Tan, Tse-Hua/E-3983-2010	Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170	National Health Research Institutes, Taiwan [MG-102-PP-03, MG-103-PP-03, 105-IMPP01, 105-IMSP01]; Ministry of Science and Technology, Taiwan [102-2628-B-400-003, 105-2314-B-400-027]	National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan); Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan)	We thank National Health Research Institutes Transgenic Animal Core for assistance in the mouse blastocyst injection and Optical Biology Core for the assistance in confocal microscopy and time-lapsed photography analyses. This work was supported by grants from National Health Research Institutes, Taiwan (MG-102-PP-03 and MG-103-PP-03 to Y-R Chen; 105-IMPP01 and 105-IMSP01 to T-H Tan), and grants from Ministry of Science and Technology, Taiwan (102-2628-B-400-003 to Y-R Chen and 105-2314-B-400-027 to T-H Tan).	Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Alonso A, 2001, J BIOL CHEM, V276, P4766, DOI 10.1074/jbc.M006497200; Amand M, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-108; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Arnoldussen YJ, 2008, CANCER RES, V68, P9255, DOI 10.1158/0008-5472.CAN-08-1224; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chen AJ, 2002, J BIOL CHEM, V277, P36592, DOI 10.1074/jbc.M200453200; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Davidson D, 2001, EMBO J, V20, P3414, DOI 10.1093/emboj/20.13.3414; Fredriksson S, 2002, NAT BIOTECHNOL, V20, P473, DOI 10.1038/nbt0502-473; Gallegos LL, 2016, SCI REP-UK, V6, DOI 10.1038/srep27114; Hao L, 2007, INT J CANCER, V121, P39, DOI 10.1002/ijc.22597; Henkens R, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-147; Hood KL, 2002, BIOCHEM BIOPH RES CO, V298, P545, DOI 10.1016/S0006-291X(02)02488-9; Hoyt R, 2007, J IMMUNOL, V179, P3402, DOI 10.4049/jimmunol.179.6.3402; Huang CY, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-24; ILLC D, 1995, NATURE, V377, P539; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lee J, 2015, SCI REP-UK, V5, DOI 10.1038/srep12296; Li JP, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4618; Li JP, 2010, J BIOL CHEM, V285, P5472, DOI 10.1074/jbc.M109.060186; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Musumeci L, 2015, CIRCULATION, V131, P656, DOI 10.1161/CIRCULATIONAHA.114.010186; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; Pavic K, 2015, FEBS J, V282, P1871, DOI 10.1111/febs.13263; Rahmouni S, 2006, NAT CELL BIOL, V8, P524, DOI 10.1038/ncb1398; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schumacher MA, 2002, BIOCHEMISTRY-US, V41, P3009, DOI 10.1021/bi015799l; Sieg DJ, 1999, J CELL SCI, V112, P2677; Singh P, 2015, J IMMUNOL, V194, P4951, DOI 10.4049/jimmunol.1402431; Todd JL, 2002, ONCOGENE, V21, P2573, DOI 10.1038/sj.onc.1205344; Todd JL, 1999, J BIOL CHEM, V274, P13271, DOI 10.1074/jbc.274.19.13271; Wang JY, 2006, J NEUROCHEM, V98, P89, DOI 10.1111/j.1471-4159.2006.03852.x; Wang JY, 2011, J BIOL CHEM, V286, P10177, DOI 10.1074/jbc.M110.163295; Wang XH, 2012, J BIOL CHEM, V287, P11037, DOI 10.1074/jbc.M111.310946; Xiao Q, 2013, J AM CHEM SOC, V135, P9760, DOI 10.1021/ja401692t; Yang CH, 2015, BBA-MOL BASIS DIS, V1852, P1540, DOI 10.1016/j.bbadis.2015.04.020; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125	40	15	17	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2017	36	47					6509	6517		10.1038/onc.2017.255	http://dx.doi.org/10.1038/onc.2017.255			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FN5LN	28759036				2022-12-17	WOS:000416049200001
J	Garzon, J; Rodriguez, R; Kong, Z; Chabes, A; Rodriguez-Acebes, S; Mendez, J; Moreno, S; Garcia-Higuera, I				Garzon, J.; Rodriguez, R.; Kong, Z.; Chabes, A.; Rodriguez-Acebes, S.; Mendez, J.; Moreno, S.; Garcia-Higuera, I.			Shortage of dNTPs underlies altered replication dynamics and DNA breakage in the absence of the APC/C cofactor Cdh1	ONCOGENE			English	Article							ANAPHASE-PROMOTING COMPLEX; CELL-CYCLE CONTROL; RIBONUCLEOTIDE REDUCTASE; FORK PROGRESSION; GENOMIC INSTABILITY; UBIQUITIN LIGASES; TUMOR SUPPRESSION; MAMMALIAN-CELLS; DORMANT ORIGINS; EXCESS MCM2-7	The APC/C-Cdh1 ubiquitin-ligase complex targets cell cycle regulators for proteosomal degradation and helps prevent tumor development and accumulation of chromosomal aberrations. Replication stress has been proposed to be the main driver of genomic instability in the absence of Cdh1, but the real contribution of APC/C-Cdh1 to efficient replication, especially in normal cells, remains unclear. Here we show that, in primary MEFs, acute depletion or permanent ablation of Cdh1 slowed down replication fork movement and increased origin activity. Partial inhibition of origin firing does not accelerate replication forks, suggesting that fork progression is intrinsically limited in the absence of Cdh1. Moreover, exogenous supply of nucleotide precursors, or ectopic overexpression of RRM2, the regulatory subunit of Ribonucleotide Reductase, restore replication efficiency, indicating that dNTP availability could be impaired upon Cdh1 loss. Indeed, we found reduced dNTP levels in Cdh1-deficient MEFs. Importantly, DNA breakage is also significantly alleviated by increasing intracellular dNTP pools, strongly suggesting that genomic instability is the result of aberrant replication. These observations highlight the relevance of APC/C-Cdh1 activity during G1 to ensure an adequate supply of dNTPs to the replisome, prevent replication stress and the resulting chromosomal breaks and, ultimately, suppress tumorigenesis.	[Garzon, J.; Rodriguez, R.; Moreno, S.; Garcia-Higuera, I.] Univ Salamanca, CSIC, IBFG, C Zacarias Gonzalez 2, Salamanca 37007, Spain; [Kong, Z.; Chabes, A.] Umea Univ, Dept Med Biochem & Biophys, Umea, Sweden; [Rodriguez-Acebes, S.; Mendez, J.] Spanish Natl Canc Res Ctr CNIO, DNA Replicat Grp, Madrid, Spain; [Moreno, S.; Garcia-Higuera, I.] Salamanca Univ, Inst Biomed Res Salamanca IBSAL, Salamanca, Spain; [Garzon, J.] Univ Aberdeen, Inst Med Sci, Aberdeen AB25 2ZD, Scotland	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca; Umea University; Centro Nacional de Investigaciones Oncologicas (CNIO); University of Salamanca; University of Aberdeen	Moreno, S; Garcia-Higuera, I (corresponding author), Univ Salamanca, CSIC, IBFG, C Zacarias Gonzalez 2, Salamanca 37007, Spain.	smo@usal.es; igh@usal.es	Garcia-Higuera, Irene/L-5004-2014; Moreno, Sergio/K-3671-2014; Rodriguez, Sara/AAA-8972-2019; Mendez, Juan/K-8001-2014	Garcia-Higuera, Irene/0000-0001-6331-075X; Moreno, Sergio/0000-0002-8039-1413; Rodriguez, Sara/0000-0002-9867-7591; Mendez, Juan/0000-0002-3235-2559; Chabes, Andrei/0000-0003-1708-8259	Spanish Ministry of Economy and Competitiveness MINECO [CSD2007-0015, BFU2011-28274, BFU2014-55439]; Junta de Castilla y Leon [CSI151U13, CSI084U16]; Swedish Cancer Society; Knut and Alice Wallenberg Foundation; Swedish Research Council; Fundacion Cientifica de la Asociacion Espanola contra el Cancer (AECC); CSIC JAE predoctoral fellowship (MINECO); CSIC FPU predoctoral fellowship (MINECO)	Spanish Ministry of Economy and Competitiveness MINECO(Spanish Government); Junta de Castilla y Leon(Junta de Castilla y Leon); Swedish Cancer Society(Swedish Cancer Society); Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Swedish Research Council(Swedish Research CouncilEuropean Commission); Fundacion Cientifica de la Asociacion Espanola contra el Cancer (AECC); CSIC JAE predoctoral fellowship (MINECO); CSIC FPU predoctoral fellowship (MINECO)	This research was funded by grants from the Spanish Ministry of Economy and Competitiveness MINECO (CSD2007-0015, BFU2011-28274 and BFU2014-55439) and Junta de Castilla y Leon (CSI151U13 and CSI084U16), the Swedish Cancer Society, the Knut and Alice Wallenberg Foundation and the Swedish Research Council (AC). IGH is supported by Fundacion Cientifica de la Asociacion Espanola contra el Cancer (AECC). JG and RR were recipients of CSIC JAE and FPU predoctoral fellowships (MINECO).	Anglana M, 2003, CELL, V114, P385, DOI 10.1016/S0092-8674(03)00569-5; Ayuda-Duran P, 2014, NUCLEIC ACIDS RES, V42, P7057, DOI 10.1093/nar/gku313; Bester AC, 2011, CELL, V145, P435, DOI 10.1016/j.cell.2011.03.044; Chabes AL, 2003, P NATL ACAD SCI USA, V100, P3925, DOI 10.1073/pnas.0330774100; Chang LF, 2014, CURR OPIN STRUC BIOL, V29, P1, DOI 10.1016/j.sbi.2014.08.003; Choudhury R, 2016, CELL REP, V16, P3359, DOI 10.1016/j.celrep.2016.08.058; Craney A, 2013, CURR OPIN CELL BIOL, V25, P704, DOI 10.1016/j.ceb.2013.07.004; D'Angiolella V, 2012, CELL, V149, P1023, DOI 10.1016/j.cell.2012.03.043; Delgado-Esteban M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3879; Eguren M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3880; Eguren M, 2011, SEMIN CELL DEV BIOL, V22, P572, DOI 10.1016/j.semcdb.2011.03.010; Engelbert D, 2008, ONCOGENE, V27, P907, DOI 10.1038/sj.onc.1210703; Fay DS, 2002, GENE DEV, V16, P503, DOI 10.1101/gad.952302; Gaillard H, 2015, NAT REV CANCER, V15, P276, DOI 10.1038/nrc3916; Garcia-Higuera I, 2008, NAT CELL BIOL, V10, P802, DOI 10.1038/ncb1742; Ge XQ, 2007, GENE DEV, V21, P3331, DOI 10.1101/gad.457807; Gelot C, 2015, GENES-BASEL, V6, P267, DOI 10.3390/genes6020267; Greil C, 2016, ONCOGENE, V35, P3062, DOI 10.1038/onc.2015.367; Guarino E, 2014, SEMIN CELL DEV BIOL, V30, P97, DOI 10.1016/j.semcdb.2014.03.030; Hofer A, 2012, CRIT REV BIOCHEM MOL, V47, P50, DOI 10.3109/10409238.2011.630372; Ibarra A, 2008, P NATL ACAD SCI USA, V105, P8956, DOI 10.1073/pnas.0803978105; Ke PY, 2005, GENE DEV, V19, P1920, DOI 10.1101/gad.1322905; Kitamura K, 1998, MOL BIOL CELL, V9, P1065, DOI 10.1091/mbc.9.5.1065; Labib K, 2011, PHILOS T R SOC B, V366, P3554, DOI 10.1098/rstb.2011.0071; Lopez-Contreras AJ, 2015, GENE DEV, V29, P690, DOI 10.1101/gad.256958.114; Lopez-Contreras AJ, 2010, DNA REPAIR, V9, P1249, DOI 10.1016/j.dnarep.2010.09.012; Lukas C, 2011, NAT CELL BIOL, V13, P243, DOI 10.1038/ncb2201; Montagnoli A, 2008, NAT CHEM BIOL, V4, P357, DOI 10.1038/nchembio.90; Mouron S, 2013, NAT STRUCT MOL BIOL, V20, P1383, DOI 10.1038/nsmb.2719; Munoz S, 2017, CHROMOSOMA, V126, P1, DOI 10.1007/s00412-016-0573-x; Pines J, 2011, NAT REV MOL CELL BIO, V12, P427, DOI 10.1038/nrm3132; Poli J, 2012, EMBO J, V31, P883, DOI 10.1038/emboj.2011.470; Pu X, 2015, CURR PROTOC TOXICOL, V65; Ruiz S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9036; Ruzankina Y, 2008, MECH AGEING DEV, V129, P460, DOI 10.1016/j.mad.2008.03.009; Sigl R, 2009, J CELL SCI, V122, P4208, DOI 10.1242/jcs.054197; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Sivakumar S, 2015, NAT REV MOL CELL BIO, V16, P82, DOI 10.1038/nrm3934; Sivaprasad U, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-8; Stillman B, 2013, P NATL ACAD SCI USA, V110, P14120, DOI 10.1073/pnas.1312901110; Teixeira LK, 2015, CURR BIOL, V25, P1327, DOI 10.1016/j.cub.2015.03.022; Teixeira LK, 2013, ANNU REV BIOCHEM, V82, P387, DOI 10.1146/annurev-biochem-060410-105307; Wasch R, 2010, ONCOGENE, V29, P1, DOI 10.1038/onc.2009.325; Wilhelm T, 2014, P NATL ACAD SCI USA, V111, P763, DOI 10.1073/pnas.1311520111; Woodward AM, 2006, J CELL BIOL, V173, P673, DOI 10.1083/jcb.200602108; Yokochi T, 2007, CURR PROTOC CELL BIO, P10; Yuan X, 2014, MOL BIOL CELL, V25, P441, DOI 10.1091/mbc.E13-08-0480; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897; Zhang JF, 2014, BBA-REV CANCER, V1845, P277, DOI 10.1016/j.bbcan.2014.02.001; Zhong Y, 2013, J CELL BIOL, V201, P373, DOI 10.1083/jcb.201208060	50	15	15	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5808	5818		10.1038/onc.2017.186	http://dx.doi.org/10.1038/onc.2017.186			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28604743	Green Submitted			2022-12-17	WOS:000413292900003
J	Pedersen, K; Bilal, F; Morales, CB; Salcedo, MT; Macarulla, T; Masso-Valles, D; Mohan, V; Vivancos, A; Carreras, MJ; Serres, X; Abu-Suboh, M; Balsells, J; Allende, E; Sagi, I; Soucek, L; Tabernero, J; Arribas, J				Pedersen, K.; Bilal, F.; Bernado Morales, C.; Salcedo, M. T.; Macarulla, T.; Masso-Valles, D.; Mohan, V.; Vivancos, A.; Carreras, M-J; Serres, X.; Abu-Suboh, M.; Balsells, J.; Allende, E.; Sagi, I.; Soucek, L.; Tabernero, J.; Arribas, J.			Pancreatic cancer heterogeneity and response to Mek inhibition	ONCOGENE			English	Article							PATIENT-DERIVED XENOGRAFTS; DUCTAL ADENOCARCINOMA; SURVIVAL; MICE; GEMCITABINE; ACTIVATION; PATHWAY	Our increasing knowledge of the mechanisms behind the progression of pancreatic cancer (PC) has not yet translated into effective treatments. Many promising drugs have failed in the clinic, highlighting the need for better preclinical models to assess drug efficacy and characterize mechanisms of resistance. Using different experimental models, including patient-derived xenografts (PDXs), we gauged the efficacy of therapies aimed at two hallmark lesions of PCs: activation of signaling pathways by oncogenic KRAS and inactivation of tumor-suppressor genes. Although the drug targeting inactivation of tumor suppressors by DNA methylation had little effect, the inhibition of Mek, a K-Ras effector, in combination with the standard of care (chemotherapy consisting of gemcitabine/Nab-paclitaxel), reduced the growth of three out of five PC-PDXs and impaired metastasis. The two least responding PC-PDXs were composed of genetically diverse cells, which displayed sensitivities to the Mek inhibitor differing by 410-fold. Unexpectedly, our analysis of this genetic diversity unveiled different KRAS mutations. As mutation in KRAS occurs early during progression, this heterogeneity may reflect the simultaneous appearance of different malignant cellular clones or, alternatively, that cells containing two mutations of KRAS are selected during tumor evolution. In vitro and in vivo analyses indicated that the intratumoral heterogeneity, along with the selective pressure imposed by the Mek inhibitor, resulted in rapid selection of resistant cells. Together with the gemcitabine/Nab-paclitaxel backbone, Mek inhibition could be effective in treatment of PC. However, resistance because of intratumoral heterogeneity is likely to develop frequently, pointing to the necessity of identifying the factors and mechanisms of resistance to further develop this therapy.	[Pedersen, K.; Bilal, F.; Bernado Morales, C.; Masso-Valles, D.; Soucek, L.; Tabernero, J.; Arribas, J.] VHIO, Preclin Res Program, Barcelona, Spain; [Bilal, F.; Bernado Morales, C.; Tabernero, J.; Arribas, J.] CIBER ONC, Barcelona, Spain; [Bilal, F.; Masso-Valles, D.; Soucek, L.; Arribas, J.] Univ Autonoma Barcelona, Dept Biochem & Mol Biol, Campus UAB, Bellaterra, Spain; [Salcedo, M. T.; Macarulla, T.; Carreras, M-J; Serres, X.; Abu-Suboh, M.; Balsells, J.; Allende, E.; Tabernero, J.] Vall Hebron Univ Hosp HUVH, Barcelona, Spain; [Salcedo, M. T.; Macarulla, T.; Tabernero, J.] Univ Autonoma Barcelona, Barcelona, Spain; [Mohan, V.; Sagi, I.] Weizmann Inst Sci, Dept Biol Regulat, Rehovot, Israel; [Vivancos, A.; Tabernero, J.] VHIO, Clin Res Program, Barcelona, Spain; [Soucek, L.; Arribas, J.] ICREA, Barcelona, Spain	Vall d'Hebron Institut d'Oncologia (VHIO); CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Autonomous University of Barcelona; Weizmann Institute of Science; Vall d'Hebron Institut d'Oncologia (VHIO); ICREA	Arribas, J (corresponding author), VHIO, C Natzaret 115-117, Barcelona 08035, Spain.	jarribas@vhio.net	Macarulla, Teresa/AAG-9230-2019; Soucek, Laura/AAG-7393-2019; Soucek, Laura/AAG-8377-2019; Arribas, Joaquin/M-4482-2014; Tabernero, Josep/AAG-5026-2019; Miquel, Josep Maria/AAG-3508-2019; Vivancos, Ana/AAG-8331-2019	Soucek, Laura/0000-0002-4750-7971; Arribas, Joaquin/0000-0002-0504-0664; Tabernero, Josep/0000-0002-2495-8139; Vivancos, Ana/0000-0003-2888-6512; Balsells Valls, Joaquim/0000-0002-1202-4136; Bernado Morales, Cristina/0000-0003-1376-0407; Abu-Suboh Abadia, Monder/0000-0003-2373-6400; Macarulla, Teresa/0000-0002-5856-4082; Masso-Valles, Daniel/0000-0003-4231-0456; Serres-Creixams, Xavier/0000-0001-8642-467X	Instituto de Salud Carlos III [PI16/00253]; AECC; AGAUR-FIDGR predoctoral fellowship; Instituto de Salud Carlos III (CIBER-ONC)	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); AECC; AGAUR-FIDGR predoctoral fellowship; Instituto de Salud Carlos III (CIBER-ONC)(Instituto de Salud Carlos III)	We thank Faye Su from Novartis and Daniel Pierce from Celgene for providing reagents and valuable insights. This work was supported by funds from the Instituto de Salud Carlos III (PI16/00253 and CIBER-ONC). KP was supported by the postdoctoral program from the AECC. FB was supported by the AGAUR-FIDGR-2014 predoctoral fellowship.	Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Borroto A, 2003, J BIOL CHEM, V278, P25933, DOI 10.1074/jbc.M301673200; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Byrne AT, 2017, NAT REV CANCER, V17, P254, DOI 10.1038/nrc.2016.140; Collins MA, 2012, J CLIN INVEST, V122, P639, DOI 10.1172/JCI59227; Collisson EA, 2012, CANCER DISCOV, V2, P685, DOI 10.1158/2159-8290.CD-11-0347; Fisher R, 2013, BRIT J CANCER, V108, P479, DOI 10.1038/bjc.2012.581; Gore J, 2014, CANCER CELL, V25, P711, DOI 10.1016/j.ccr.2014.05.026; Kim MP, 2009, NAT PROTOC, V4, P1670, DOI 10.1038/nprot.2009.171; Kopetz S, 2012, CLIN CANCER RES, V18, P5160, DOI 10.1158/1078-0432.CCR-12-2408; Missiaglia E, 2005, ONCOGENE, V24, P199, DOI 10.1038/sj.onc.1208018; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; VANCUTSEM E, 2015, J CLIN ONCOL S, V33; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Weisenberger DJ, 2014, J CLIN INVEST, V124, P17, DOI 10.1172/JCI69740; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529	19	15	15	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2017	36	40					5639	5647		10.1038/onc.2017.174	http://dx.doi.org/10.1038/onc.2017.174			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI8ZW	28581516				2022-12-17	WOS:000412293600008
J	Raschell, G; Melino, G; Malewicz, M				Raschell, G.; Melino, G.; Malewicz, M.			New factors in mammalian DNA repair-the chromatin connection	ONCOGENE			English	Review							DOUBLE-STRAND BREAKS; PK-MEDIATED PHOSPHORYLATION; DAMAGE RESPONSE; TRANSCRIPTIONAL REGULATION; PROTEIN-KINASE; GENOME INTEGRITY; STRUCTURAL BASIS; ATM; PROMOTES; XLF	In response to DNA damage mammalian cells activate a complex network of stress response pathways collectively termed DNA damage response (DDR). DDR involves a temporary arrest of the cell cycle to allow for the repair of the damage. DDR also attenuates gene expression by silencing global transcription and translation. Main function of DDR is, however, to prevent the fixation of debilitating changes to DNA by activation of various DNA repair pathways. Proper execution of DDR requires careful coordination between these interdependent cellular responses. Deregulation of some aspects of DDR orchestration is potentially pathological and could lead to various undesired outcomes such as DNA translocations, cellular transformation or acute cell death. It is thus critical to understand the regulation of DDR in cells especially in the light of a strong linkage between the DDR impairment and the occurrence of common human diseases such as cancer. In this review we focus on recent advances in understanding of mammalian DNA repair regulation and a on the function of PAXX/c9orf142 and ZNF281 proteins that recently had been discovered to play a role in that process. We focus on regulation of double-strand DNA break (DSB) repair via the non-homologous end joining pathway, as unrepaired DSBs are the primary cause of pathological cellular states after DNA damage. Interestingly these new factors operate at the level of chromatin, which reinforces a notion of a central role of chromatin structure in the regulation of cellular DDR regulation.	[Raschell, G.] ENEA Res Ctr Casaccia, Lab Biosafety & Risk Assessment, Rome, Italy; [Melino, G.] Univ Roma Tor Vergata, Dept Expt Med & Surg, Rome, Italy; [Melino, G.; Malewicz, M.] MRC, Toxicol Unit, Hodgkin Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England	Italian National Agency New Technical Energy & Sustainable Economics Development; University of Rome Tor Vergata; University of Leicester	Malewicz, M (corresponding author), MRC, Toxicol Unit, Hodgkin Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England.	mm531@le.ac.uk			Medical Research Council, UK; Associazione Italiana per la Ricerca contro il Cancro (AIRC) [AIRC 2014 IG15653, AIRC 5xmille MCO9979, AIRC 2011 IG11955]; Fondazione Roma malattie Non trasmissibili Cronico-Degenerative (NCD); MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_UP_A600_1109, MC_U132670600] Funding Source: researchfish	Medical Research Council, UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Associazione Italiana per la Ricerca contro il Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Roma malattie Non trasmissibili Cronico-Degenerative (NCD)(Fondazione Roma); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work has been supported by the Medical Research Council, UK; grants from Associazione Italiana per la Ricerca contro il Cancro (AIRC): AIRC 2014 IG15653 (to GM), AIRC 5xmille MCO9979 (to GM) and AIRC 2011 IG11955 (to GM), Fondazione Roma malattie Non trasmissibili Cronico-Degenerative (NCD) Grant (to GM).	Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Adamowicz M, 2016, CELL REP, V16, P2068, DOI 10.1016/j.celrep.2016.07.038; Ahel D, 2009, SCIENCE, V325, P1240, DOI 10.1126/science.1177321; Ahel I, 2008, NATURE, V451, P81, DOI 10.1038/nature06420; Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031; Alam SK, 2016, CELL DEATH DIFFER, V23, P707, DOI 10.1038/cdd.2015.133; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Balmus G, 2016, GENE DEV, V30, P2152, DOI 10.1101/gad.290510.116; Barroso-Gonzalez J, 2016, CELL DEATH DIFFER, V23, P1448, DOI 10.1038/cdd.2016.23; Beck C, 2014, EXP CELL RES, V329, P18, DOI 10.1016/j.yexcr.2014.07.003; Berkovich E, 2007, NAT CELL BIOL, V9, P683, DOI 10.1038/ncb1599; Biswas AK, 2012, CANCER RES, V72, P13, DOI 10.1158/0008-5472.CAN-11-2196; Boehler C, 2011, METHODS MOL BIOL, V780, P313, DOI 10.1007/978-1-61779-270-0_19; Botuyan MV, 2006, CELL, V127, P1361, DOI 10.1016/j.cell.2006.10.043; Britton S, 2013, J CELL BIOL, V202, P579, DOI 10.1083/jcb.201303073; Brouwer I, 2016, NATURE, V535, P566, DOI 10.1038/nature18643; Bruinsma W, 2016, ONCOGENE; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; Bunch H, 2015, BMC MOL BIOL, V16, DOI 10.1186/s12867-015-0040-x; Callen E, 2012, IMMUNITY, V37, P971, DOI 10.1016/j.immuni.2012.10.007; Caron P, 2015, CELL REP, V13, P1, DOI 10.1016/j.celrep.2015.10.024; Ceccaldi R, 2016, TRENDS CELL BIOL, V26, P52, DOI 10.1016/j.tcb.2015.07.009; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Couto CAM, 2011, J CELL BIOL, V194, P367, DOI 10.1083/jcb.201012132; Craxton A, 2015, CELL DEATH DIFFER, V22, P890, DOI 10.1038/cdd.2015.22; Cuella-Martin R, 2016, MOL CELL, V64, P51, DOI 10.1016/j.molcel.2016.08.002; Dantuma NP, 2016, EMBO J, V35, P6, DOI 10.15252/embj.201592595; Dynlacht BD, 1997, NATURE, V389, P149, DOI 10.1038/38225; El Ghamrasni S, 2016, ONCOGENE, V35, P4836, DOI 10.1038/onc.2016.16; Fattah KR, 2008, DNA REPAIR, V7, P762, DOI 10.1016/j.dnarep.2008.02.008; Fidalgo M, 2016, CELL STEM CELL, V19, P355, DOI 10.1016/j.stem.2016.05.025; Fidalgo M, 2012, P NATL ACAD SCI USA, V109, P16202, DOI 10.1073/pnas.1208533109; Fidalgo M, 2011, STEM CELLS, V29, P1705, DOI 10.1002/stem.736; Fradet-Turcotte A, 2013, NATURE, V499, P50, DOI 10.1038/nature12318; Gibbs-Seymour I, 2016, MOL CELL, V62, P432, DOI 10.1016/j.molcel.2016.03.008; Gibson BA, 2012, NAT REV MOL CELL BIO, V13, P411, DOI 10.1038/nrm3376; Goggolidou P, 2014, DEVELOPMENT, V141, P3966, DOI 10.1242/dev.107755; Goldstein M, 2013, P NATL ACAD SCI USA, V110, P16874, DOI 10.1073/pnas.1306160110; Goodarzi AA, 2013, ADV GENET, V82, P1, DOI 10.1016/B978-0-12-407676-1.00001-9; Goodwin JF, 2015, CANCER CELL, V28, P97, DOI 10.1016/j.ccell.2015.06.004; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grundy GJ, 2013, EMBO J, V32, P112, DOI 10.1038/emboj.2012.304; Gunn AR, 2016, J CELL SCI, V129, P3845, DOI 10.1242/jcs.193375; Haggerty TJ, 2003, P NATL ACAD SCI USA, V100, P5313, DOI 10.1073/pnas.0931346100; Hahn S, 2014, J MOL MED, V92, P571, DOI 10.1007/s00109-014-1160-3; Hahn S, 2013, EMBO J, V32, P3079, DOI 10.1038/emboj.2013.236; Han BY, 2016, GENE DEV, V30, P1509, DOI 10.1101/gad.279406.116; Hedstrom E, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.250; Izhar L, 2015, CELL REP, V11, P1486, DOI 10.1016/j.celrep.2015.04.053; Jang ER, 2010, EXP MOL MED, V42, P195, DOI 10.3858/emm.2010.42.3.020; Kaidi A, 2013, NATURE, V498, DOI 10.1038/nature12201; Kolas NK, 2007, SCIENCE, V318, P1637, DOI 10.1126/science.1150034; Kumar V, 2016, P NATL ACAD SCI USA, V113, P10619, DOI 10.1073/pnas.1611882113; Law DJ, 2006, NUCLEIC ACIDS RES, V34, P1342, DOI 10.1093/nar/gkl022; Law DJ, 1999, BIOCHEM BIOPH RES CO, V262, P113, DOI 10.1006/bbrc.1999.1180; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lescale C, 2016, CELL REP, V16, P2967, DOI 10.1016/j.celrep.2016.08.069; Li G, 2008, MOL CELL, V31, P631, DOI 10.1016/j.molcel.2008.07.017; Li Z, 2016, CELL DEATH DIFFER, V23, P1765, DOI 10.1038/cdd.2016.65; Lieber MR, 2010, ANNU REV BIOCHEM, V79, P181, DOI 10.1146/annurev.biochem.052308.093131; Liu H, 2014, GENOME BIOL EVOL, V6, P510, DOI 10.1093/gbe/evu030; Liu XS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9325; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; Lu G, 2013, SCI WORLD J, DOI 10.1155/2013/424617; Luijsterburg MS, 2016, MOL CELL, V61, P547, DOI 10.1016/j.molcel.2016.01.019; Lukas J, 2011, NAT CELL BIOL, V13, P1161, DOI 10.1038/ncb2344; Luscombe NM, 2000, GENOME BIOL, V1; Malewicz M, 2014, EXP CELL RES, V329, P94, DOI 10.1016/j.yexcr.2014.08.032; Malewicz M, 2011, GENE DEV, V25, P2031, DOI 10.1101/gad.16872411; Mallo M, 2010, DEV BIOL, V344, P7, DOI 10.1016/j.ydbio.2010.04.024; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Mehrotra PV, 2011, MOL CELL, V41, P46, DOI 10.1016/j.molcel.2010.12.008; Messina DN, 2004, GENOME RES, V14, P2041, DOI 10.1101/gr.2584104; Miller KM, 2010, NAT STRUCT MOL BIOL, V17, P1144, DOI 10.1038/nsmb.1899; Moll U, 1999, ONCOGENE, V18, P3114, DOI 10.1038/sj.onc.1202640; Montenegro MF, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.85; Mullan PB, 2006, ONCOGENE, V25, P5854, DOI 10.1038/sj.onc.1209872; Muralidharan SV, 2016, ONCOGENE, V35, P4689, DOI 10.1038/onc.2015.521; Musselman CA, 2012, P NATL ACAD SCI USA, V109, P787, DOI 10.1073/pnas.1113655109; Nakahashi H, 2013, CELL REP, V3, P1678, DOI 10.1016/j.celrep.2013.04.024; Nicolai S, 2015, AGING-US, V7, P1050, DOI 10.18632/aging.100858; Noon AT, 2010, NAT CELL BIOL, V12, P177, DOI 10.1038/ncb2017; Ochi T, 2015, SCIENCE, V347, P185, DOI 10.1126/science.1261971; Ochs F, 2016, NAT STRUCT MOL BIOL, V23, P714, DOI 10.1038/nsmb.3251; Ozes AR, 2016, ONCOGENE, V35, P5350, DOI 10.1038/onc.2016.75; Paiva C, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.161; Panier S, 2014, NAT REV MOL CELL BIO, V15, P7, DOI 10.1038/nrm3719; Pederiva C, 2016, CELL DEATH DIFFER, V23, P1648, DOI 10.1038/cdd.2016.58; Petrus NCM, 2016, CLIN TRANSL ALLERGY, V6, DOI 10.1186/s13601-016-0105-z; Pieraccioli M, 2016, ONCOGENE, V35, P2592, DOI 10.1038/onc.2015.320; Polo SE, 2011, GENE DEV, V25, P409, DOI 10.1101/gad.2021311; Polo SE, 2010, EMBO J, V29, P3130, DOI 10.1038/emboj.2010.188; Prakash R, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016600; Price BD, 2013, CELL, V152, P1344, DOI 10.1016/j.cell.2013.02.011; Roach JC, 2007, P NATL ACAD SCI USA, V104, P16245, DOI 10.1073/pnas.0707757104; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rulten SL, 2011, MOL CELL, V41, P33, DOI 10.1016/j.molcel.2010.12.006; Scharer CD, 2009, CANCER RES, V69, P709, DOI 10.1158/0008-5472.CAN-08-3415; Shah MY, 2016, ONCOGENE, V35, P5905, DOI 10.1038/onc.2016.116; Shiloh Y, 2013, NAT REV MOL CELL BIO, V14, P197, DOI 10.1038/nrm3546; Simon I, 2001, CELL, V106, P697, DOI 10.1016/S0092-8674(01)00494-9; Starnes LM, 2016, GENE DEV, V30, P149, DOI 10.1101/gad.268797.115; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Thacker J, 2004, DNA REPAIR, V3, P1081, DOI 10.1016/j.dnarep.2004.04.012; Thorslund T, 2015, NATURE, V527, P389, DOI 10.1038/nature15401; Tong KI, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.298; Vaquerizas JM, 2009, NAT REV GENET, V10, P252, DOI 10.1038/nrg2538; Viticchie G, 2011, CELL CYCLE, V10, P1121, DOI 10.4161/cc.10.7.15180; Wang JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284; Wang Y, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.198; Wang Y, 2016, NUCLEIC ACIDS RES, V45, P1177; Waters CA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5286; Waters CA, 2014, DNA REPAIR, V17, P39, DOI 10.1016/j.dnarep.2014.02.008; Wilson MD, 2016, NATURE, V536, P100, DOI 10.1038/nature18951; Wu GK, 2006, CELL CYCLE, V5, P1592, DOI 10.4161/cc.5.15.3127; Xing MT, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7233; Xu Y, 2012, MOL CELL, V48, P723, DOI 10.1016/j.molcel.2012.09.026; Yang Q, 2016, CELL DEATH DIFFER, V23, P1406, DOI 10.1038/cdd.2016.29; Zha S, 2011, NATURE, V469, P250, DOI 10.1038/nature09604; Zhang CZY, 2010, BBA-REV CANCER, V1806, P36, DOI 10.1016/j.bbcan.2010.03.002; Zhang YY, 2016, NAT STRUCT MOL BIOL, V23, P522, DOI 10.1038/nsmb.3211; Zuniga A, 2015, DEVELOPMENT, V142, P3810, DOI 10.1242/dev.125757	123	15	15	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4673	4681		10.1038/onc.2017.60	http://dx.doi.org/10.1038/onc.2017.60			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28394347	hybrid, Green Published			2022-12-17	WOS:000407702400001
J	Sumner, ET; Chawla, AT; Cororaton, AD; Koblinski, JE; Kovi, RC; Love, IM; Szomju, BB; Korwar, S; Ellis, KC; Grossman, SR				Sumner, E. T.; Chawla, A. T.; Cororaton, A. D.; Koblinski, J. E.; Kovi, R. C.; Love, I. M.; Szomju, B. B.; Korwar, S.; Ellis, K. C.; Grossman, S. R.			Transforming activity and therapeutic targeting of C-terminal-binding protein 2 in Apc-mutated neoplasia	ONCOGENE			English	Article							P53-INDEPENDENT APOPTOSIS; ADENOMATOUS POLYPOSIS; COLORECTAL TUMORS; GENE-EXPRESSION; CTBP; CANCER; MUTATIONS; COREPRESSOR; INHIBITORS; STABILITY	Overexpression of the transcriptional coregulators C-terminal binding proteins 1 and 2 (CtBP1 and 2) occurs in many human solid tumors and is associated with poor prognosis. CtBP modulates oncogenic gene expression programs and is an emerging drug target, but its oncogenic role is unclear. Consistent with this oncogenic potential, exogenous CtBP2 transformed primary mouse and human cells to anchorage independence similarly to mutant H-Ras. To investigate CtBP's contribution to in vivo tumorigenesis, Apc(min/+) mice, which succumb to massive intestinal polyposis, were bred to Ctbp2(+/-) mice. CtBP interacts with adenomatous polyposis coli (APC) protein, and is stabilized in both APC-mutated human colon cancers and Apc(min/+) intestinal polyps. Ctbp2 heterozygosity increased the median survival of Apc(min/+) mice from 21 to 48 weeks, and reduced polyp formation by 90%, with Ctbp2(+/-) polyps exhibiting reduced levels of beta-catenin and its oncogenic transcriptional target, cyclin D1. CtBP's potential as a therapeutic target was studied by treating Apc(min/+) mice with the CtBP small-molecule inhibitors 4-methylthio-2-oxobutyric acid and 2-hydroxy-imino phenylpyruvic acid, both of which reduced polyposis by more than half compared with vehicle treatment. Phenocopying Ctbp2 deletion, both Ctbp inhibitors caused substantial decreases in the protein level of Ctbp2, as well its oncogenic partner beta-catenin, and the effects of the inhibitors on CtBP and beta-catenin levels could be modeled in an APC-mutated human colon cancer cell line. CtBP2 is thus a druggable transforming oncoprotein critical for the evolution of neoplasia driven by Apc mutation.	[Sumner, E. T.; Grossman, S. R.] Virginia Commonwealth Univ, Dept Pharmacol Toxicol, Richmond, VA 23298 USA; [Chawla, A. T.] Virginia Commonwealth Univ, Wright Ctr Clin & Translat Res, Richmond, VA 23298 USA; [Cororaton, A. D.; Love, I. M.; Szomju, B. B.; Grossman, S. R.] Virginia Commonwealth Univ, Massey Canc Ctr, Dept Internal Med, 1201 East Marshall St,Box 980070, Richmond, VA 23298 USA; [Koblinski, J. E.] Virginia Commonwealth Univ, Dept Pathol, Richmond, VA 23298 USA; [Koblinski, J. E.; Ellis, K. C.; Grossman, S. R.] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA; [Kovi, R. C.] NIEHS, Cellular & Mol Pathol Branch, POB 12233, Res Triangle Pk, NC 27709 USA; [Korwar, S.; Ellis, K. C.] Virginia Commonwealth Univ, Dept Med Chem, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Virginia Commonwealth University	Grossman, SR (corresponding author), Virginia Commonwealth Univ, Massey Canc Ctr, Dept Internal Med, 1201 East Marshall St,Box 980070, Richmond, VA 23298 USA.	steven.grossman@vcuhealth.org	Chawla, Ayesha/AAW-8696-2021	Chawla, Ayesha/0000-0003-4401-2188; Koblinski, Jennifer/0000-0002-7156-2030	NCI [P30CA016059]; ACS; NATIONAL CANCER INSTITUTE [P30CA016059] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ACS(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank LL for kindly donating BJ-blast cells and VSV-g/gag-pol retroviral expression vectors. We also thank SJ for his insight and thoughtful suggestions. SRG was funded by P30CA016059 from NCI and a Research Scholar Grant from ACS.	Barroilhet L, 2013, ONCOGENE, V32, P3896, DOI 10.1038/onc.2012.380; Chinnadurai G, 2009, CANCER RES, V69, P731, DOI 10.1158/0008-5472.CAN-08-3349; Di LJ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2438; GRODEN J, 1993, AM J HUM GENET, V52, P263; Grooteclaes M, 2003, P NATL ACAD SCI USA, V100, P4568, DOI 10.1073/pnas.0830998100; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Hildebrand JD, 2002, MOL CELL BIOL, V22, P5296, DOI 10.1128/MCB.22.15.5296-5307.2002; Korwar S, 2016, BIOORGAN MED CHEM, V24, P2707, DOI 10.1016/j.bmc.2016.04.037; Kovi RC, 2010, CELL DEATH DIFFER, V17, P513, DOI 10.1038/cdd.2009.140; Nadauld LD, 2006, J BIOL CHEM, V281, P37828, DOI 10.1074/jbc.M602119200; Paliwal S, 2006, MOL CELL BIOL, V26, P2360, DOI 10.1128/MCB.26.6.2360-2372.2006; Paliwal S, 2007, CANCER RES, V67, P9322, DOI 10.1158/0008-5472.CAN-07-1743; Paliwal Seema, 2012, Genes Cancer, V3, P481, DOI 10.1177/1947601912463695; Phelps RA, 2009, CELL, V137, P623, DOI 10.1016/j.cell.2009.02.037; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Schneikert J, 2011, HUM MOL GENET, V20, P3554, DOI 10.1093/hmg/ddr273; Straza MW, 2010, CELL CYCLE, V9, P3740, DOI 10.4161/cc.9.18.12936; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; Yekkala K, 2007, MOL CANCER RES, V5, P1296, DOI 10.1158/1541-7786.MCR-07-0232; Zhang CW, 2014, GENE, V546, P73, DOI 10.1016/j.gene.2014.05.032	21	15	15	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4810	4816		10.1038/onc.2017.106	http://dx.doi.org/10.1038/onc.2017.106			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28414304	Green Accepted			2022-12-17	WOS:000407702400013
J	Shin, CH; Robinson, JP; Sonnen, JA; Welker, AE; Yu, DX; VanBrocklin, MW; Holmen, SL				Shin, C. H.; Robinson, J. P.; Sonnen, J. A.; Welker, A. E.; Yu, D. X.; VanBrocklin, M. W.; Holmen, S. L.			HBEGF promotes gliomagenesis in the context of Ink4al Arf and Pten loss	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; HB-EGF; GENE-EXPRESSION; INK4A/ARF LOSS; ACTIVATION; AXL; RESISTANCE; SUBTYPES; GLIOMAS; LOOP	Heparin-binding epidermal growth factor (EGF)-like growth factor (HBEGF) is a ligand for the EGF receptor (EGFR), one of the most commonly amplified receptor tyrosine kinases (RTKs) in glioblastoma (GBM). While HBEGF has been found to be expressed in a subset of malignant gliomas, its sufficiency for glioma initiation has not been evaluated. In this study, we demonstrate that HBEGF can initiate GBM in mice in the context of Ink4a/Arf and Pten loss, and that these tumors are similar to the classical GBM subtype observed in patients. Isogenic astrocytes from these mice showed activation not only of Egfr but also the RTK Axl in response to HBEGF stimulation. Deletion of either Egfr or Axl decreased the tumorigenic properties of HBEGF-transformed cells; however, only EGFR was able to rescue the phenotype in cells lacking both RTKs indicating that Egfr is required for activation of Axl in this context. Silencing of HBEGF in vivo resulted in tumor regression and significantly increased survival, suggesting that HBEGF may be a clinically relevant target.	[Shin, C. H.; Welker, A. E.; Yu, D. X.; VanBrocklin, M. W.; Holmen, S. L.] Univ Utah, Hlth Sci Ctr, Huntsman Canc Inst, 2000 Circle Hope Dr, Salt Lake City, UT 84112 USA; [Shin, C. H.; VanBrocklin, M. W.; Holmen, S. L.] Univ Utah, Hlth Sci Ctr, Dept Oncol Sci, Salt Lake City, UT 84112 USA; [Robinson, J. P.] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA; [Sonnen, J. A.] Univ Utah, Hlth Sci Ctr, Dept Pathol, Salt Lake City, UT 84112 USA; [Sonnen, J. A.] ARUP Labs, Salt Lake City, UT USA; [Yu, D. X.; VanBrocklin, M. W.; Holmen, S. L.] Univ Utah, Hlth Sci Ctr, Dept Surg, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Minnesota System; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; ARUP Laboratories; Utah System of Higher Education; University of Utah	Holmen, SL (corresponding author), Univ Utah, Hlth Sci Ctr, Huntsman Canc Inst, 2000 Circle Hope Dr, Salt Lake City, UT 84112 USA.	sheri.holmen@hci.utah.edu	Sonnen, Joshua/AAT-5788-2021; Sonnen, Joshua/H-3738-2016	Robinson, James/0000-0002-6585-0116; Sonnen, Joshua/0000-0001-9267-8705	HCI from the National Cancer Institute (NCI) [P30CA042014]; National Institute of Neurological Disorders and Stroke [NIH R01NS073870]; NCI [NIH F30CA203096]; NATIONAL CANCER INSTITUTE [F30CA203096, P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS075155, R01NS073870] Funding Source: NIH RePORTER	HCI from the National Cancer Institute (NCI); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank the members of the VanBrocklin, McMahon and Holmen labs, as well as E Holland, R DePinho and M Bosenberg for providing mouse strains, reagents and advice. We thank the Huntsman Cancer Institute (HCI) Vivarium staff for assistance. We thank Tim Parnell for his bioinformatics expertise. We acknowledge the use of the Mutation Generation and Detection Core, the DNA Synthesis Core, the DNA Sequencing Core and the Small Animal Imaging Core supported by P30CA042014 awarded to HCI from the National Cancer Institute (NCI). We also acknowledge use of the HCI Shared Resources for high-throughput genomics and bioinformatics analysis, glass wash and research histology. This work was supported by the National Institute of Neurological Disorders and Stroke (NIH R01NS073870, to SLH) and the NCI (NIH F30CA203096, to CHS).	Acquaviva J, 2011, CANCER RES, V71, P7198, DOI 10.1158/0008-5472.CAN-11-1514; Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cho JH, 2015, CELL REP, V13, P898, DOI 10.1016/j.celrep.2015.09.057; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; He C, 2015, ONCOGENE, V34, P6040, DOI 10.1038/onc.2015.52; Holmen SL, 2005, CANCER RES, V65, P8250, DOI 10.1158/0008-5472.CAN-05-1173; Hu RZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063074; Hutterer M, 2008, CLIN CANCER RES, V14, P130, DOI 10.1158/1078-0432.CCR-07-0862; Jin KL, 2003, AGING CELL, V2, P175, DOI 10.1046/j.1474-9728.2003.00046.x; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Kornblum HI, 1999, EUR J NEUROSCI, V11, P3236, DOI 10.1046/j.1460-9568.1999.00744.x; Li L, 2014, ONCOGENE, V33, P4253, DOI 10.1038/onc.2013.400; Liu L, 2009, CANCER RES, V69, P6871, DOI 10.1158/0008-5472.CAN-08-4490; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Lu FH, 2016, CANCER CELL, V29, P669, DOI 10.1016/j.ccell.2016.03.027; Meyer AS, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004155; Mishima K, 1998, ACTA NEUROPATHOL, V96, P322, DOI 10.1007/s004010050901; Ongusaha PP, 2004, CANCER RES, V64, P5283, DOI 10.1158/0008-5472.CAN-04-0925; Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223; Ozawa T, 2014, CANCER CELL, V26, P288, DOI 10.1016/j.ccr.2014.06.005; Puschmann TB, 2014, J NEUROCHEM, V128, P878, DOI 10.1111/jnc.12519; Ramnarain DB, 2006, CANCER RES, V66, P867, DOI 10.1158/0008-5472.CAN-05-2753; Ray KC, 2013, ONCOGENE, V33, P1; Robinson JP, 2011, ONCOGENE, V30, P1341, DOI 10.1038/onc.2010.513; Robinson JP, 2010, ONCOGENE, V29, P335, DOI 10.1038/onc.2009.333; Robinson JP, 2011, AM J CANCER RES, V1, P155; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Sato S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051964; Shin Clifford H, 2015, Genes Cancer, V6, P9; Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103; VanBrocklin MW, 2012, NEURO-ONCOLOGY, V14, P34, DOI 10.1093/neuonc/nor184; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Yotsumoto F, 2010, INT J CANCER, V127, P2707, DOI 10.1002/ijc.25472; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330; Zheng HW, 2008, NATURE, V455, P1129, DOI 10.1038/nature07443	38	15	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2017	36	32					4610	4618		10.1038/onc.2017.83	http://dx.doi.org/10.1038/onc.2017.83			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD0RK	28368403	Green Accepted			2022-12-17	WOS:000407246200008
J	Wang, LT; Chiou, SS; Chai, CY; Hsi, E; Chiang, CM; Huang, SK; Wang, SN; Yokoyama, KK; Hsu, SH				Wang, L-T; Chiou, S-S; Chai, C-Y; Hsi, E.; Chiang, C-M; Huang, S-K; Wang, S-N; Yokoyama, K. K.; Hsu, S-H			Transcription factor SPZ1 promotes TWIST-mediated epithelial-mesenchymal transition and oncogenesis in human liver cancer	ONCOGENE			English	Article							SAETHRE-CHOTZEN-SYNDROME; HEPATOCELLULAR-CARCINOMA; EXPRESSION; METASTASIS; PROTEIN; CELLS; GENE; TUMORIGENESIS; PROGRESSION; MECHANISMS	The epithelial-mesenchymal transition (EMT) is an important process in the progression of cancer. However, its occurrence and mechanism of regulation are not fully understood. We propose a regulatory pathway in which spermatogenic leucine zipper 1 (SPZ1) promotes EMT through its transactivating ability in increasing TWIST1 expression. We compared the expression of SPZ1 and TWIST1 in specimens of hepatocarcinoma cells (HCCs) and non-HCCs. Expression of SPZ1 exhibited a tumor-specific expression pattern and a high correlation with patients' survival time, tumor size, tumor number and progression stage. Moreover, forced expression and knockdown of SPZ1 in hepatoma cells showed that SPZ1 was able to regulate the cellular proliferation, invasion, and tumorigenic activity in a TWIST1-dependent manner in vitro and in vivo. These data demonstrate that SPZ1, a newly dscribed molecule, transactivates TWIST1 promoters, and that this SPZ1-TWIST axis mediates EMT signaling and exerts significant regulatory effects on tumor oncogenesis.	[Wang, L-T; Yokoyama, K. K.; Hsu, S-H] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung 807, Taiwan; [Chiou, S-S] Kaohsiung Med Univ Hosp, Dept Pediat, Fac Med, Kaohsiung, Taiwan; [Chiou, S-S] Kaohsiung Med Univ Hosp, Div Hematol Oncol, Dept Pediat, Kaohsiung, Taiwan; [Chai, C-Y] Kaohsiung Med Univ Hosp, Dept Pathol, Coll Med, Fac Med, Kaohsiung, Taiwan; [Hsi, E.] Kaohsiung Med Univ Hosp, Dept Genome Med, Coll Med, Kaohsiung, Taiwan; [Chiang, C-M] Univ Texas Southwestern Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA; [Chiang, C-M] Univ Texas Southwestern Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA; [Huang, S-K] Natl Hlth Res Inst, Div Environm Hlth & Occupat Med, Zhunan, Taiwan; [Wang, S-N] Kaohsiung Med Univ Hosp, Div Hepatobiliary Surg, Dept Surg, Kaohsiung 807, Taiwan; [Wang, S-N] Kaohsiung Med Univ Hosp, Dept Surg, Fac Med, Kaohsiung, Taiwan; [Yokoyama, K. K.] Tokushima Bunri Univ, Dept Pharmaceut Sci, Sanuki, Japan; [Yokoyama, K. K.] Univ Tokyo, Grad Sch Med, Dept Mol Prevent Med, Tokyo, Japan; [Yokoyama, K. K.; Hsu, S-H] Kaohsiung Med Univ, Ctr Infect Dis & Canc Res, Kaohsiung, Taiwan; [Yokoyama, K. K.] Kaohsiung Med Univ, Coll Med, Ctr Environm Med, Kaohsiung, Taiwan; [Yokoyama, K. K.] Kaohsiung Med Univ, Ctr Stem Cell Res, Kaohsiung, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; National Health Research Institutes - Taiwan; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Tokushima Bunri University; University of Tokyo; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University	Yokoyama, KK; Hsu, SH (corresponding author), Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung 807, Taiwan.; Wang, SN (corresponding author), Kaohsiung Med Univ Hosp, Div Hepatobiliary Surg, Dept Surg, Kaohsiung 807, Taiwan.	snwang@cc.kmu.edu; kazu@kmu.edu.tw; jackhsu@kmu.edu.tw	Hsu, Shih-Hsien/D-5139-2009	Hsu, Shih Hsien/0000-0003-2102-0505; Chai, Chee-Yin/0000-0003-0486-9742; Wang, Li-Ting/0000-0002-3335-8055	Kaohsiung Medical University Hospital [KMUH 104-4R34, KMUH 105-5R28, 105-5T10]; National Science Council, Taiwan [NSC-102-2320-B-037-032-MY3, MOST 105-2314-B-037-070-MY2]; Ministry of Science and Technology [MOST-104-2314-B-037-043, MOST 104-2320-B-037-033-My2, MOST 104-2314-B-033-002, MOST-105-2314-B-037-049]; National Health Research Institutes [NHRI-Ex102-10109B1, NHRI-Ex104-10416S1]; Kaohsiung Medical University grant [KMU-TP103G00, KMU-TP103G01, KMU-TP103G03, KMU-TP103G04, KMU-TP103G05, KMU-TP103A104, KMU-DT103001, KMU-TP104A04, KMU-TPE23, KMU-DT104001, KMU-TP105PR4, KMU-TP105E00]; NIH [CA103867]; CPRIT [RP110471, RP140367]; Welch Foundation [I-1805]; NATIONAL CANCER INSTITUTE [R01CA103867] Funding Source: NIH RePORTER	Kaohsiung Medical University Hospital; National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); National Health Research Institutes(National Health Research Institutes, Japan); Kaohsiung Medical University grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CPRIT; Welch Foundation(The Welch Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge supports from the Liver Disease Prevention and Treatment Research Foundation in Taiwan. This work was supported in part by research grants KMUH 104-4R34 and KMUH 105-5R28, 105-5T10 from Kaohsiung Medical University Hospital, NSC-102-2320-B-037-032-MY3, MOST 105-2314-B-037-070-MY2 from the National Science Council, Taiwan, MOST-104-2314-B-037-043; MOST 104-2320-B-037-033-My2, MOST 104-2314-B-033-002, and MOST-105-2314-B-037-049 from Ministry of Science and Technology, the National Health Research Institutes (NHRI-Ex102-10109B1; NHRI-Ex104-10416S1), Kaohsiung Medical University grant (KMU-TP103G00, G01, G03, G04, G05, KMU-TP103A104, KMU-DT103001, KMU-TP104A04, KMU-TPE23, KMU-DT104001, KMU-TP105PR4, and KMU-TP105E00), NIH (CA103867), CPRIT (RP110471 and RP140367) and Welch Foundation (I-1805).	[Anonymous], 1989, JPN J SURG, V19, P98; Barnes RM, 2009, INT J DEV BIOL, V53, P909, DOI 10.1387/ijdb.082747rb; Beck B, 2015, CELL STEM CELL, V16, P67, DOI 10.1016/j.stem.2014.12.002; Casas E, 2011, CANCER RES, V71, P245, DOI 10.1158/0008-5472.CAN-10-2330; Che N, 2011, HUM PATHOL, V42, P840, DOI 10.1016/j.humpath.2010.03.010; El Ghouzzi V, 1999, EUR J HUM GENET, V7, P27, DOI 10.1038/sj.ejhg.5200240; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hou Y, 2012, CELL RES, V22, P259, DOI 10.1038/cr.2011.139; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; Hsu SH, 2005, CANCER RES, V65, P4041, DOI 10.1158/0008-5472.CAN-04-3658; Hsu SH, 2004, EXP CELL RES, V294, P185, DOI 10.1016/j.yexcr.2003.10.029; Hsu SH, 2001, MECH DEVELOP, V100, P177, DOI 10.1016/S0925-4773(00)00513-X; Hsu SH, 2013, CANCER RES, V73, P508, DOI 10.1158/0008-5472.CAN-12-2795; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; Kwok WK, 2007, CARCINOGENESIS, V28, P2467, DOI 10.1093/carcin/bgm185; Lei PF, 2015, ONCOL LETT, V10, P417, DOI 10.3892/ol.2015.3246; LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martin A, 2010, NAT CELL BIOL, V12, P924, DOI 10.1038/ncb1010-924; Ohba K, 2014, INT J CLIN EXP PATHO, V7, P3158; PAN DJ, 1991, GENE DEV, V5, P1892, DOI 10.1101/gad.5.10.1892; Piccinin S, 2012, CANCER CELL, V22, P404, DOI 10.1016/j.ccr.2012.08.003; Qin Q, 2012, CELL RES, V22, P90, DOI 10.1038/cr.2011.144; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Vesuna F, 2008, BIOCHEM BIOPH RES CO, V367, P235, DOI 10.1016/j.bbrc.2007.11.151; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yu WL, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00012; Zhou Y, 2015, INT J CLIN EXP MED, V8, P9239; Zhu Z, 2010, INT J CANCER, V126, P2067, DOI 10.1002/ijc.24868	32	15	16	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4405	4414		10.1038/onc.2017.69	http://dx.doi.org/10.1038/onc.2017.69			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28368406	hybrid, Green Published			2022-12-17	WOS:000406806000003
J	Zhang, H; Lu, Y; Chen, E; Li, X; Lv, B; Vikis, HG; Liu, P				Zhang, H.; Lu, Y.; Chen, E.; Li, X.; Lv, B.; Vikis, H. G.; Liu, P.			XRN2 promotes EMT and metastasis through regulating maturation of miR-10a	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; MIR-200 FAMILY; EXPRESSION ANALYSIS; REPRESSORS ZEB1; CANCER; MICRORNA-10A; PLASTICITY; ROLES; PHENOTYPE; MIGRATION	MicroRNAs (miRNAs) have been proposed as critical regulatory molecules in the epithelial-mesenchymal transition (EMT) program. However, the roles of mature miRNA biogenesis during EMT process needs to be defined. Here we determined that increased expression of XRN2 induced EMT and promoted metastasis in vitro and in vivo. Furthermore, we uncovered that XRN2 functions as pro-metastatic gene, which accelerates miR-10a maturation by binding pre-miR-10a in a DICER-independent manner. These findings suggest that XRN2 is a novel regulator of EMT that contributes to the metastatic processes in lung cancer through a novel miRNA regulatory mechanism.	[Zhang, H.] Zhejiang Univ, Sch Med, Dept Pathol, Hangzhou, Zhejiang, Peoples R China; [Lu, Y.; Lv, B.] Zhejiang Univ, Affiliated Womens Hosp, Dept Gynecol Oncol, Hangzhou, Zhejiang, Peoples R China; [Lu, Y.; Lv, B.; Liu, P.] Zhejiang Univ, Inst Translat Med, Sch Med, Hangzhou, Zhejiang, Peoples R China; [Chen, E.; Li, X.; Liu, P.] Zhejiang Univ, Sir Run Run Shaw Hosp, Div Resp Med, Hangzhou, Zhejiang, Peoples R China; [Chen, E.; Li, X.; Liu, P.] Zhejiang Univ, Sch Med, Inst Translat Med, Hangzhou 310058, Zhejiang, Peoples R China; [Vikis, H. G.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA; [Liu, P.] Med Coll Wisconsin, Dept Physiol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA; [Liu, P.] Med Coll Wisconsin, Ctr Canc, Milwaukee, WI 53226 USA	Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin	Liu, P (corresponding author), Zhejiang Univ, Sch Med, Inst Translat Med, Hangzhou 310058, Zhejiang, Peoples R China.; Liu, P (corresponding author), Zhejiang Univ, Sir Run Run Shaw Hosp, Hangzhou 310058, Zhejiang, Peoples R China.	pyliu@zju.edu.cn			National Natural Science Foundation of China [81372514, 81472420, 81572256, 31401125]; National Key Research and Development program [2016YFA0501800, 2016YFC0902700]; Fundamental Research Funds for the Central Universities; 1000 talent Plan of China, Louisiana Hope Research Grant by Free to Breathe	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development program; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); 1000 talent Plan of China, Louisiana Hope Research Grant by Free to Breathe	This work has been support by National Natural Science Foundation of China (no. 81372514, 81472420, 81572256 and 31401125), National Key Research and Development program (2016YFA0501800 and 2016YFC0902700), the Fundamental Research Funds for the Central Universities and 1000 talent Plan of China, Louisiana Hope Research Grant provided by Free to Breathe. We thank Alison Kriegel for reading and commenting on the manuscript.	Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Chang CH, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0257-3; Chatterjee S, 2009, NATURE, V461, P546, DOI 10.1038/nature08349; Couvillion MT, 2012, MOL CELL, V48, P509, DOI 10.1016/j.molcel.2012.09.010; Dip N, 2012, J UROLOGY, V188, P1951, DOI 10.1016/j.juro.2012.07.004; Ebert MS, 2012, CELL, V149, P515, DOI 10.1016/j.cell.2012.04.005; Fang Y, 2010, P NATL ACAD SCI USA, V107, P13450, DOI 10.1073/pnas.1002120107; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Kuner R, 2009, LUNG CANCER, V63, P32, DOI 10.1016/j.lungcan.2008.03.033; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Li HZ, 2004, BIOINFORMATICS, V20, P208, DOI 10.1093/bioinformatics/bth900; Li X, 2013, HAEMATOLOGICA, V98, P414, DOI 10.3324/haematol.2012.071753; Long MJ, 2012, CANCER LETT, V324, P186, DOI 10.1016/j.canlet.2012.05.022; Lu Y, 2010, ONCOGENE, V29, P1041, DOI 10.1038/onc.2009.396; Lu Y, 2006, PLOS MED, V3, P2229, DOI 10.1371/journal.pmed.0030467; Lu Y, 2012, CARCINOGENESIS, V33, P1046, DOI 10.1093/carcin/bgs100; Lund AH, 2010, CELL DEATH DIFFER, V17, P209, DOI 10.1038/cdd.2009.58; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Miki TS, 2014, NUCLEIC ACIDS RES, V42, P4056, DOI 10.1093/nar/gkt1418; Miki TS, 2013, BIOCHEM SOC T, V41, P825, DOI 10.1042/BST20130001; Ohuchida K, 2012, ANN SURG ONCOL, V19, P2394, DOI 10.1245/s10434-012-2252-3; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826; Takahashi H, 2012, NAT IMMUNOL, V13, P587, DOI 10.1038/ni.2286; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tomida S, 2009, J CLIN ONCOL, V27, P2793, DOI 10.1200/JCO.2008.19.7053; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Varnholt H, 2008, HEPATOLOGY, V47, P1223, DOI 10.1002/hep.22158; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wagschal A, 2012, CELL, V150, P1147, DOI 10.1016/j.cell.2012.08.004; Wang MS, 2011, NUCLEIC ACIDS RES, V39, P1811, DOI 10.1093/nar/gkq1050; Weiss FU, 2009, GASTROENTEROLOGY, V137, P2136, DOI 10.1053/j.gastro.2009.08.065; Xiang S, 2009, NATURE, V458, P784, DOI 10.1038/nature07731; Xiao FF, 2009, NUCLEIC ACIDS RES, V37, pD105, DOI 10.1093/nar/gkn851; Yan Y, 2013, HEPATOLOGY, V57, P667, DOI 10.1002/hep.26071; Zakrzewska-Placzek M, 2010, NUCLEIC ACIDS RES, V38, P4487, DOI 10.1093/nar/gkq172; Zhang H, 2010, ONCOGENE, V29, P937, DOI 10.1038/onc.2009.406; Zhang JS, 2012, CANCER METAST REV, V31, P653, DOI 10.1007/s10555-012-9368-6; Zhao M, 2015, SCI REP-UK, V5, DOI 10.1038/srep11459	47	15	16	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2017	36	27					3925	3933		10.1038/onc.2017.39	http://dx.doi.org/10.1038/onc.2017.39			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EZ6SM	28319071				2022-12-17	WOS:000404848200012
J	Guo, A; Lu, P; Lee, J; Zhen, C; Chiosis, G; Wang, YL				Guo, A.; Lu, P.; Lee, J.; Zhen, C.; Chiosis, G.; Wang, Y. L.			HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; IBRUTINIB RESISTANCE; INHIBITOR IBRUTINIB; ANTITUMOR-ACTIVITY; LYMPHOMA; MECHANISMS; MUTATIONS; PROTEINS; TARGETS; BTK	Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of B cells in the hematopoietic system and lymphoid tissues. Although inhibitors targeting the B-cell receptor (BCR) pathway have been successful in the treatment of the disease, the underlying mechanisms leading to BCR over-activity in CLL are not fully understood. In this study, we found that HSP90, a highly conserved molecular chaperone, is overexpressed in CLL compared with resting B cells. HSP90 overexpression is accompanied by the overexpression of several BCR kinases including LYN, spleen tyrosine kinase, Bruton tyrosine kinase and AKT. Chemical and immune-precipitation demonstrated that these BCR constituents are present in a multi-client chaperone complex with HSP90. Inhibition of HSP90 with PU-H71 destabilized the BCR kinases and caused apoptosis of CLL cells through the mitochondrial apoptotic pathway. Further, PU-H71 induced apoptosis in the presence of stromal co-culture or cytoprotective survival signals. Finally, genetic knockdown of HSP90 and its client AKT, but not BTK, reduced CLL viability. Overall, our study suggests that the chaperone function of HSP90 contributes to the over-activity of the BCR signaling in CLL and inhibition of HSP90 has the potential to achieve a multi-targeting effect. Thus, HSP90 inhibition may be explored to prevent or overcome drug resistance to single targeting agents.	[Guo, A.; Lu, P.; Lee, J.; Zhen, C.; Wang, Y. L.] Univ Chicago, Dept Pathol, Div Genom & Mol Pathol, Chicago, IL 60637 USA; [Chiosis, G.] Mem Sloan Kettering Canc Ctr, Program Chem Biol, 1275 York Ave, New York, NY 10021 USA; [Chiosis, G.] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA	University of Chicago; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Wang, YL (corresponding author), Univ Chicago, Dept Pathol, MC1089,N316,5841 South Maryland Ave, Chicago, IL 60637 USA.	ylwang@bsd.uchicago.edu	Wang, Y. Lynn/GRF-6667-2022	Wang, Y. Lynn/0000-0003-0773-1212; Lee, Justine C./0000-0002-8943-0837; Lee, Jimmy/0000-0002-5547-4858	NATIONAL CANCER INSTITUTE [P30CA008748, P50CA192937, R01CA172546, P01CA186866, R21CA158609] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [TL1TR000459] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R03MH076499] Funding Source: NIH RePORTER; NCATS NIH HHS [TL1 TR000459] Funding Source: Medline; NCI NIH HHS [R21 CA158609, P50 CA192937, R01 CA172546, P01 CA186866, P30 CA008748] Funding Source: Medline; NCRR NIH HHS [UL1 RR024996] Funding Source: Medline; NIMH NIH HHS [R03 MH076499] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Advani RH, 2013, J CLIN ONCOL, V31, P88, DOI 10.1200/JCO.2012.42.7906; Andersen OS, 2013, NAT CHEM BIOL, V9, P667, DOI 10.1038/nchembio.1368; Balakrishnan K, 2009, BLOOD, V113, P149, DOI 10.1182/blood-2008-02-138560; Burger JA, 2011, HEMATOL-AM SOC HEMAT, P96, DOI 10.1182/asheducation-2011.1.96; Byrd JC, 2013, NEW ENGL J MED, V369, P32, DOI 10.1056/NEJMoa1215637; Cheng S, 2015, LEUKEMIA, V29, P895, DOI 10.1038/leu.2014.263; Cheng S, 2014, LEUKEMIA, V28, P649, DOI 10.1038/leu.2013.358; Cheng SH, 2011, BLOOD, V118, P6342, DOI 10.1182/blood-2011-02-333773; Chiorazzi N, 2005, NEW ENGL J MED, V352, P804, DOI 10.1056/NEJMra041720; Davis RE, 2010, NATURE, V463, P88, DOI 10.1038/nature08638; Duhren-von Minden M, 2012, NATURE, V489, P309, DOI 10.1038/nature11309; Furman RR, 2014, NEW ENGL J MED, V370, P2352, DOI 10.1056/NEJMc1402716; Furman RR, 2014, NEW ENGL J MED, V370, P997, DOI 10.1056/NEJMoa1315226; Gerecitano JF, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.2537; Goldstein RL, 2015, J CLIN INVEST, V125, P4559, DOI 10.1172/JCI80714; Grzybowska-Izydorczyk O, 2010, EUR J CANCER, V46, P800, DOI 10.1016/j.ejca.2009.11.023; Guo AL, 2016, ONCOTARGET, V7, P4598, DOI 10.18632/oncotarget.6727; Haerzschel A, 2016, ANN HEMATOL, V95, P1979, DOI 10.1007/s00277-016-2788-6; Hayden RE, 2012, LEUKEMIA LYMPHOMA, V53, P537, DOI 10.3109/10428194.2011.610014; Hertlein E, 2010, BLOOD, V116, P45, DOI 10.1182/blood-2010-01-263756; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Landau DA, 2015, NATURE, V526, P525, DOI 10.1038/nature15395; Landau DA, 2013, CELL, V152, P714, DOI 10.1016/j.cell.2013.01.019; Liu TM, 2015, BLOOD, V126, P61, DOI 10.1182/blood-2015-02-626846; Lu P, 2009, LEUKEMIA, V23, P807, DOI 10.1038/leu.2008.304; Ma J, 2015, ONCOTARGET, V6, P43881, DOI 10.18632/oncotarget.6316; Morton LM, 2006, BLOOD, V107, P265, DOI 10.1182/blood-2005-06-2508; Moulick K, 2011, NAT CHEM BIOL, V7, P818, DOI 10.1038/nchembio.670; Puente XS, 2015, NATURE, V526, P519, DOI 10.1038/nature14666; Rai KR, 2016, AM J HEMATOL, V91, P330, DOI 10.1002/ajh.24282; Robertson LE, 1996, LEUKEMIA, V10, P456; Scaltriti M, 2012, CLIN CANCER RES, V18, P4508, DOI 10.1158/1078-0432.CCR-11-2138; Sharman J, 2015, BLOOD, V125, P2336, DOI 10.1182/blood-2014-08-595934; Shrestha L, 2016, CELL CHEM BIOL, V23, P158, DOI 10.1016/j.chembiol.2015.12.006; Song ZB, 2010, CLIN CANCER RES, V16, P587, DOI 10.1158/1078-0432.CCR-09-1519; Taldone T, 2014, TRENDS PHARMACOL SCI, V35, P48, DOI 10.1016/j.tips.2014.09.001; Trentin L, 2008, BLOOD, V112, P4665, DOI 10.1182/blood-2008-02-139139; Walsby E, 2012, ONCOTARGET, V3, P525; Woyach JA, 2014, NEW ENGL J MED, V370, P2286, DOI 10.1056/NEJMoa1400029; Yang C, 2008, LEUKEMIA, V22, P1755, DOI 10.1038/leu.2008.163; Zong HL, 2015, CELL REP, V13, P2159, DOI 10.1016/j.celrep.2015.10.073	41	15	15	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2017	36	24					3441	3449		10.1038/onc.2016.494	http://dx.doi.org/10.1038/onc.2016.494			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EX6GL	28114285	Green Accepted			2022-12-17	WOS:000403340700008
J	Chiche, A; Moumen, M; Romagnoli, M; Petit, V; Lasla, H; Jezequel, P; de la Grange, P; Jonkers, J; Deugnier, MA; Glukhova, MA; Faraldo, MM				Chiche, A.; Moumen, M.; Romagnoli, M.; Petit, V.; Lasla, H.; Jezequel, P.; de la Grange, P.; Jonkers, J.; Deugnier, M-A; Glukhova, M. A.; Faraldo, M. M.			p53 deficiency induces cancer stem cell pool expansion in a mouse model of triple-negative breast tumors	ONCOGENE			English	Article							MAMMARY EPITHELIAL-CELLS; SELF-RENEWAL; WNT/BETA-CATENIN; BASAL; MET; EXPRESSION; GLAND; TUMORIGENESIS; DISTINCT; PROGENITORS	Triple-negative breast cancer is a heterogeneous disease characterized by the expression of basal cell markers, no estrogen or progesterone receptor expression and a lack of HER2 overexpression. Triple-negative tumors often display activated Wnt/beta-catenin signaling and most have impaired p53 function. We studied the interplay between p53 loss and Wnt/beta-catenin signaling in stem cell function and tumorigenesis, by deleting p53 from the mammary epithelium of K5 Delta N beta cat mice displaying a constitutive activation of Wnt/beta-catenin signaling in basal cells. K5 Delta N beta cat transgenic mice present amplification of the basal stem cell pool and develop triple-negative mammary carcinomas. The loss of p53 in K5 Delta N beta cat mice led to an early expansion of mammary stem/progenitor cells and accelerated the formation of triple-negative tumors. In particular, p53-deficient tumors expressed high levels of integrins and extracellular matrix components and were enriched in cancer stem cells. They also overexpressed the tyrosine kinase receptor Met, a feature characteristic of human triple-negative breast tumors. The inhibition of Met kinase activity impaired tumorsphere formation, demonstrating the requirement of Met signaling for cancer stem cell growth in this model. Human basal-like breast cancers with predicted mutated p53 status had higher levels of MET expression than tumors with wild-type p53. These results connect p53 loss and beta-catenin activation to stem cell regulation and tumorigenesis in triple-negative cancer and highlight the role of Met signaling in maintaining cancer stem cell properties, revealing new cues for targeted therapies.	[Chiche, A.; Moumen, M.; Romagnoli, M.; Petit, V.; Deugnier, M-A; Glukhova, M. A.; Faraldo, M. M.] PSL Res Univ, CNRS, UMR144, Inst Curie, 26 Rue Ulm, F-75005 Paris, France; [Lasla, H.; Jezequel, P.] Inst Cancerol Ouest, St Herblain, France; [de la Grange, P.] Hop La Pitie Salpetriere, IPEPS ICM, GenoSplice Technol, Paris, France; [Jonkers, J.] Netherlands Canc Inst, Div Mol Pathol, Amsterdam, Netherlands; [Jonkers, J.] Netherlands Canc Inst, Canc Genom Ctr Netherlands, Amsterdam, Netherlands; [Deugnier, M-A; Glukhova, M. A.; Faraldo, M. M.] Inst Natl Sante & Rech Med, Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Netherlands Cancer Institute; Netherlands Cancer Institute; Institut National de la Sante et de la Recherche Medicale (Inserm)	Faraldo, MM (corresponding author), PSL Res Univ, CNRS, UMR144, Inst Curie, 26 Rue Ulm, F-75005 Paris, France.	maria-luisa.martin-faraldo@curie.fr	Deugnier, Marie-Ange/M-7556-2018; Deugnier, Marie-Ange/AAF-5877-2021; Jonkers, Jos/AAG-3246-2019; Martin-Faraldo, Maria-Luisa/M-5811-2018	Deugnier, Marie-Ange/0000-0002-2199-1099; Jonkers, Jos/0000-0002-9264-9792; Faraldo, Marisa/0000-0001-9497-1171; PETIT, Valerie/0000-0003-1645-9396	La Ligue Nationale Contre le Cancer; Canceropole lle de France [2014-1-SEIN-01-ICR-1]; La Ligue Nationale Contre le Cancer Comites d'Ile de France; Association pour la Recherche sur le Cancer; Institut Curie and Servier Laboratories	La Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Canceropole lle de France; La Ligue Nationale Contre le Cancer Comites d'Ile de France; Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Institut Curie and Servier Laboratories	We are particularly grateful to A Di Cicco, D Gentien, A Rapinat and B Albaud for expert technical assistance, to Dr I Grandjean, S Jannet and the personnel of the animal facilities at Institut Curie for taking care of the mice and to Z Maciorowski, A Viguier and S Grondin for excellent assistance with flow cytometry. We also thank Dr JL Jorcano for providing mouse strains and Dr D Medina for valuable discussions. The work was supported by grants from La Ligue Nationale Contre le Cancer (Equipe Labelisee 2013), Canceropole lle de France (2014-1-SEIN-01-ICR-1) to MAG. and a grant from La Ligue Nationale Contre le Cancer Comites d'Ile de France to MMF. MM and AC received funding from Association pour la Recherche sur le Cancer; AC, from Institut Curie and Servier Laboratories; MAG. is Directeur de Recherche, MMF, MAD and AG are Charge de Recherche at the Institut National de la Sante et de la Recherche Medicale (INSERM).	Ali NA, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0437-3; Arcand SL, 2015, BMC MED GENET, V16, DOI 10.1186/s12881-015-0169-y; Ballard MS, 2015, CELL REP, V13, P290, DOI 10.1016/j.celrep.2015.09.006; Bertheau P, 2013, BREAST, V22, pS27, DOI 10.1016/j.breast.2013.07.005; Bertucci F, 2012, CURR MOL MED, V12, P96, DOI 10.2174/156652412798376134; Bonizzi G, 2012, TRENDS MOL MED, V18, P6, DOI 10.1016/j.molmed.2011.08.002; Cagnet S, 2014, ONCOGENE, V33, P4286, DOI 10.1038/onc.2013.391; Chang C, 2015, GENE DEV, V29, P1, DOI 10.1101/gad.253682.114; Chiche A, 2013, STEM CELLS, V31, P1857, DOI 10.1002/stem.1429; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; de la Grange P, 2005, NUCLEIC ACIDS RES, V33, P4276, DOI 10.1093/nar/gki738; Di-Cicco A, 2015, ELIFE, V4, DOI 10.7554/eLife.06104; Dimeo TA, 2009, CANCER RES, V69, P5364, DOI 10.1158/0008-5472.CAN-08-4135; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Dumay A, 2013, INT J CANCER, V132, P1227, DOI 10.1002/ijc.27767; Faraldo MM, 2015, METHODS MOL BIOL, V1293, P161, DOI 10.1007/978-1-4939-2519-3_9; Farmer P, 2005, ONCOGENE, V24, P4660, DOI 10.1038/sj.onc.1208561; Gastaldi S, 2013, ONCOGENE, V32, P1428, DOI 10.1038/onc.2012.154; Gastaldi S, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2617; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Golubovskaya VM, 2008, MOL CARCINOGEN, V47, P373, DOI 10.1002/mc.20395; Graveel CR, 2009, P NATL ACAD SCI USA, V106, P12909, DOI 10.1073/pnas.0810403106; Gunther EJ, 2003, GENE DEV, V17, P488, DOI 10.1101/gad.1051603; Herschkowitz JI, 2012, P NATL ACAD SCI USA, V109, P2778, DOI 10.1073/pnas.1018862108; Ho-Yen CM, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0547-6; Holland JD, 2013, CELL REP, V5, P1214, DOI 10.1016/j.celrep.2013.11.001; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Jezequel P, 2013, DATABASE-OXFORD, DOI 10.1093/database/bas060; Jin L, 2011, P NATL ACAD SCI USA, V108, P15840, DOI 10.1073/pnas.1019312108; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kataoka H, 2010, FEBS J, V277, P2230, DOI 10.1111/j.1742-4658.2010.07640.x; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Knight JF, 2013, P NATL ACAD SCI USA, V110, pE1301, DOI 10.1073/pnas.1210353110; Korkaya H, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000121; Liao JM, 2014, J MOL CELL BIOL, V6, P206, DOI 10.1093/jmcb/mju018; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Lu X, 2013, ONCOGENE, V32, P2900, DOI 10.1038/onc.2012.299; Maroun CR, 2014, PHARMACOL THERAPEUT, V142, P316, DOI 10.1016/j.pharmthera.2013.12.014; Medina D, 2002, FASEB J, V16, P881, DOI 10.1096/fj.01-0885fje; Meniel V, 2005, CANCER RES, V65, P410; Meyer MJ, 2010, CANCER RES, V70, P4624, DOI 10.1158/0008-5472.CAN-09-3619; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Moumen M, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-132; Moumen M, 2012, STEM CELLS, V30, P1246, DOI 10.1002/stem.1090; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Ponzo MG, 2009, P NATL ACAD SCI USA, V106, P12903, DOI 10.1073/pnas.0810402106; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Prater MD, 2014, NAT CELL BIOL, V16, P942, DOI 10.1038/ncb3025; Ramirez A, 2004, GENESIS, V39, P52, DOI 10.1002/gene.20025; Reis JS, 2011, LANCET, V378, P1812, DOI 10.1016/S0140-6736(11)61539-0; Ridgeway AG, 2006, ONCOGENE, V25, P3518, DOI 10.1038/sj.onc.1209391; Rios AC, 2014, NATURE, V506, P322, DOI 10.1038/nature12948; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shi L, 2013, CIRC RES, V113, P1320, DOI 10.1161/CIRCRESAHA.113.301824; Skibinski A, 2015, ONCOGENE, V34, P5309, DOI 10.1038/onc.2014.475; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Spike Benjamin T, 2011, Genes Cancer, V2, P404, DOI 10.1177/1947601911410224; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Taddei I, 2008, NAT CELL BIOL, V10, P716, DOI 10.1038/ncb1734; Tao LW, 2011, STEM CELLS, V29, P119, DOI 10.1002/stem.552; Teissedre B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004537; Teuliere J, 2005, DEVELOPMENT, V132, P267, DOI 10.1242/dev.01583; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; van Amerongen R, 2012, CELL STEM CELL, V11, P387, DOI 10.1016/j.stem.2012.05.023; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; van Miltenburg MHAM, 2014, BRIT J CANCER, V110, P2747, DOI 10.1038/bjc.2014.219; Vieira AF, 2012, STEM CELLS, V30, P854, DOI 10.1002/stem.1075; Zeng YA, 2010, CELL STEM CELL, V6, P568, DOI 10.1016/j.stem.2010.03.020; Zoratti GL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7776	72	15	16	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2017	36	17					2355	2365		10.1038/onc.2016.396	http://dx.doi.org/10.1038/onc.2016.396			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET4QE	27775073				2022-12-17	WOS:000400268900003
J	Ai, J; Pascal, LE; Wei, L; Zang, Y; Zhou, Y; Yu, X; Gong, Y; Nakajima, S; Nelson, JB; Levine, AS; Lan, L; Wang, Z				Ai, J.; Pascal, L. E.; Wei, L.; Zang, Y.; Zhou, Y.; Yu, X.; Gong, Y.; Nakajima, S.; Nelson, J. B.; Levine, A. S.; Lan, L.; Wang, Z.			EAF2 regulates DNA repair through Ku70/Ku80 in the prostate	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; DAMAGE RESPONSE; ANDROGEN RECEPTOR; CANCER; PROTEIN; RADIATION; SUPPRESSION; POLYMERASE; EXPRESSION; PATHWAYS	Androgens are known to protect prostate cancer cells from DNA damage. Recent studies showed regulation of DNA repair genes by androgen receptor signaling in prostate cancers. ELL-associated factor 2 (EAF2) is an androgen-regulated tumor suppressor and its intracellular localization can be modulated by ultraviolet light, suggesting a potential role for EAF2 in androgen regulation of DNA repair in prostate cancer cells. Here we show that knockdown of EAF2 or its homolog EAF1 sensitized prostate cancer cells to DNA damage and the sensitization did not require p53. EAF2 knockout mouse prostate was also sensitized to gamma-irradiation. Furthermore, EAF2 knockdown blocked androgen repression of LNCaP or C4-2 cells from doxorubicin induction of gamma H2ax, a DNA damage marker. In human prostate cancer specimens, EAF2 expression was inversely correlated with the level of gamma H2ax. Further analysis showed that EAF2 and EAF1 are required for the recruitment and retention of Ku70/Ku80 to DNA damage sites and play a functional role in nonhomologous end-joining DNA repair. These findings provide evidence for EAF2 as a key factor mediating androgen protection of DNA damage via Ku70/Ku80 in prostate cancer cells.	[Ai, J.; Pascal, L. E.; Zang, Y.; Zhou, Y.; Yu, X.; Gong, Y.; Nelson, J. B.; Wang, Z.] Univ Pittsburgh, Sch Med, Dept Urol, 5200 Ctr Ave,Suite G40, Pittsburgh, PA 15232 USA; [Wei, L.; Nakajima, S.; Levine, A. S.; Lan, L.; Wang, Z.] Univ Pittsburgh, Sch Med, Canc Inst, Pittsburgh, PA USA; [Wei, L.; Levine, A. S.; Lan, L.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA USA; [Zang, Y.; Zhou, Y.] Soochow Univ, Affiliated Hosp 2, Dept Urol, Suzhou, Peoples R China; [Yu, X.] Southern Med Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China; [Gong, Y.] Peking Univ, Hosp 1, Dept Urol, Beijing, Peoples R China; [Gong, Y.] Peking Univ, Inst Urol, Beijing, Peoples R China; [Nakajima, S.; Wang, Z.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA; [Wang, Z.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Soochow University - China; Southern Medical University - China; Peking University; Peking University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wang, Z (corresponding author), Univ Pittsburgh, Sch Med, Dept Urol, 5200 Ctr Ave,Suite G40, Pittsburgh, PA 15232 USA.	wangz2@upmc.edu	Pascal, Laura E./AAH-5743-2019; Zang, Yachen/GNW-5928-2022	Pascal, Laura E./0000-0003-3840-1662; 	National Institutes of Health [R01CA186780, 1 P50 CA180995, 1R50CA211242, T32 DK007774]; Tippens Foundation; Flow Cytometry and Tissue and Research Pathology Services (TARPS) [P30CA047904]; NATIONAL CANCER INSTITUTE [P50CA180995, P30CA047904, R50CA211242, R01CA186780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM118833] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Tippens Foundation; Flow Cytometry and Tissue and Research Pathology Services (TARPS); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This investigation was supported in part by the National Institutes of Health Grants R01CA186780, 1 P50 CA180995, 1R50CA211242 and T32 DK007774 and a scholarship from the Tippens Foundation (to LEP). This project used the UPCI Animal Facility, Flow Cytometry and Tissue and Research Pathology Services (TARPS), and was supported in part by award P30CA047904. We thank Dr Leland WK Chung for providing C4-2 cells and Drs Javid Dar, Amy Deng, Tomoko Koya and Xinhui Wang for assistance in generating the EAF1 antibody. We thank Marie Acquafondata, Jon Duboy, Anthony Green, Bratislav Janjic, Marianne Notaro, Aiyuan Zhang and Katie Leschak for technical assistance. We thank Dr Michael Epperly for assistance in designing and performing irradiation experiments. We thank Dr Anil V Parwani for reviewing human prostate specimens and Dr Lora H Rigatti for reviewing mouse prostate specimens. We also thank Drs Weijun Liu, Susanne M Gollin and Dale W Lewis and all members of the Wang laboratory for insightful discussion during this project and critical reading of the manuscript.	Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031; Ai J, 2014, ONCOGENE, V33, P2286, DOI 10.1038/onc.2013.190; Bolla M, 2010, LANCET ONCOL, V11, P1066, DOI 10.1016/S1470-2045(10)70223-0; Bowen C, 2015, CANCER RES, V75, P2686, DOI 10.1158/0008-5472.CAN-14-3387; Chatrchyan S, 2014, PHYS REV LETT, V112, DOI 10.1103/PhysRevLett.112.182001; Chen Z, 2014, MOL CELL BIOL, V34, P1085, DOI 10.1128/MCB.00718-13; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; di Fagagna FD, 2008, NAT REV CANCER, V8, P512, DOI 10.1038/nrc2440; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Dobbs TA, 2010, DNA REPAIR, V9, P1307, DOI 10.1016/j.dnarep.2010.09.019; Erbaykent-Tepedelen B, 2014, J STEROID BIOCHEM, V141, P26, DOI 10.1016/j.jsbmb.2014.01.001; Goodwin JF, 2013, CANCER DISCOV, V3, P1254, DOI 10.1158/2159-8290.CD-13-0108; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; Helleday T, 2007, DNA REPAIR, V6, P923, DOI 10.1016/j.dnarep.2007.02.006; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jiang F, 2003, ENDOCRINOLOGY, V144, P1257, DOI 10.1210/en.2002-220718; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kong SE, 2005, P NATL ACAD SCI USA, V102, P10094, DOI 10.1073/pnas.0503017102; Koontz Bridget F., 2011, Archivos Espanoles de Urologia, V64, P858; Kuo LJ, 2008, IN VIVO, V22, P305; Lan L, 2005, J CELL SCI, V118, P4153, DOI 10.1242/jcs.02544; Lan L, 2010, MOL CELL, V40, P976, DOI 10.1016/j.molcel.2010.12.003; Lawrence MD, 2013, RADIAT RES, V180, P376, DOI 10.1667/RR3381.2; Lieber MR, 2004, DNA REPAIR, V3, P817, DOI 10.1016/j.dnarep.2004.03.015; Liu Jing, 2013, J Toxicol, V2013, P967029, DOI 10.1155/2013/967029; Liu YG, 2001, CARCINOGENESIS, V22, P851, DOI 10.1093/carcin/22.6.851; Mah LJ, 2010, LEUKEMIA, V24, P679, DOI 10.1038/leu.2010.6; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; Ouyang X, 2005, CANCER RES, V65, P6773, DOI 10.1158/0008-5472.CAN-05-1948; Pascal LE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079542; Pascal LE, 2011, ANGIOGENESIS, V14, P331, DOI 10.1007/s10456-011-9217-1; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Polkinghorn WR, 2013, CANCER DISCOV, V3, P1245, DOI 10.1158/2159-8290.CD-13-0172; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Saporita AJ, 2007, PROSTATE, V67, P509, DOI 10.1002/pros.20541; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Su F, 2010, ONCOGENE, V29, P421, DOI 10.1038/onc.2009.326; Ta HQ, 2014, ENDOCR-RELAT CANCER, V21, pR395, DOI 10.1530/ERC-14-0217; Takahashi H, 2011, CELL, V146, P92, DOI 10.1016/j.cell.2011.06.005; Valenzuela MT, 1995, ANTI-CANCER DRUG, V6, P749, DOI 10.1097/00001813-199512000-00006; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wang Z, 1997, P NATL ACAD SCI USA, V94, P12999, DOI 10.1073/pnas.94.24.12999; Xiao F, 2012, INT J OPHTHALMOL-CHI, V5, P570, DOI 10.3980/j.issn.2222-3959.2012.05.05; Xiao W, 2008, ONCOGENE, V27, P1536, DOI 10.1038/sj.onc.1210786; Xiao WH, 2003, CANCER RES, V63, P4698; Xiao WH, 2009, CANCER RES, V69, P2599, DOI 10.1158/0008-5472.CAN-08-2595; Zhang H, 2015, APPL NMR SPECTROSC, V1, P3; Zhang ZW, 2011, CELL CYCLE, V10, P3545, DOI 10.4161/cc.10.20.17841; Zhuang FF, 2008, DNA CELL BIOL, V27, P649, DOI 10.1089/dna.2008.0733	52	15	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2017	36	15					2054	2065		10.1038/onc.2016.373	http://dx.doi.org/10.1038/onc.2016.373			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DK	27721405	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000399782500002
J	De Cian, MC; Pauper, E; Bandiera, R; Vidal, VPI; Sacco, S; Gregoire, EP; Chassot, AA; Panzolini, C; Wilhelm, D; Pailhoux, E; Youssef, SA; de Bruin, A; Teerds, K; Schedl, A; Gillot, I; Chaboissier, MC				De Cian, M-C; Pauper, E.; Bandiera, R.; Vidal, V. P. I.; Sacco, S.; Gregoire, E. P.; Chassot, A-A; Panzolini, C.; Wilhelm, D.; Pailhoux, E.; Youssef, S. A.; de Bruin, A.; Teerds, K.; Schedl, A.; Gillot, I.; Chaboissier, M-C			Amplification of R-spondin1 signaling induces granulosa cell fate defects and cancers in mouse adult ovary	ONCOGENE			English	Article							BETA-CATENIN; FOLLICULAR DEVELOPMENT; SERTOLI-CELLS; DIFFERENTIATION; RSPO1; SPECIFICATION; DISRUPTION; EXPRESSION; CADHERINS; ATRESIA	R-spondin1 is a secreted regulator of WNT signaling, involved in both embryonic development and homeostasis of adult organs. It can have a dual role, acting either as a mitogen or as a tumor suppressor. During ovarian development, Rspo1 is a key factor required for sex determination and differentiation of the follicular cell progenitors, but is downregulated after birth. In human, increased RSPO1 expression is associated with ovarian carcinomas, but it is not clear whether it is a cause or a consequence of the tumorigenic process. To address the role of Rspo1 expression in adult ovaries, we generated an Rspol gain-of-function mouse model. Females were hypofertile and exhibited various ovarian defects, ranging from cysts to ovarian tumors. Detailed phenotypical characterization showed anomalies in the ovulation process. Although follicles responded to initial follicle-stimulating hormone stimulation and developed normally until the pre-ovulatory stage, they did not progress any further. Although non-ovulated oocytes degenerated, the surrounding follicular cells did not begin atresia. RSPO1-induced expression not only promotes canonical WNT signaling but also alters granulosa cell fate decisions by maintaining epithelial-like traits in these cells. This prevents follicle cells from undergoing apoptosis, leading to the accumulation of granulosa cell tumors that reactivates the epithelial program from their progenitors. Taken together, our data demonstrate that activation of RSPO1 is sufficient in promoting ovarian tumors and thus supports a direct involvement of this gene in the commencement of ovarian cancers.	[De Cian, M-C; Pauper, E.; Vidal, V. P. I.; Sacco, S.; Gregoire, E. P.; Chassot, A-A; Panzolini, C.; Schedl, A.; Gillot, I.; Chaboissier, M-C] Univ Nice Sophia Antipolis, iBV, CNRS, INSERM, Nice, France; [De Cian, M-C] Univ Corte, EA 7310, Corte, France; [Bandiera, R.] Univ Cambridge, Wellcome Trust Med Res Council Cambridge Stem Cel, Cambridge CB2 1TN, England; [Wilhelm, D.] Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic, Australia; [Pailhoux, E.] Univ Paris Saclay, INRA, UMR BDR, ENVA, Jouy En Josas, France; [Youssef, S. A.; de Bruin, A.] Univ Utrecht, Fac Vet Med, Dutch Mol Pathol Ctr, Dept Pathobiol, Utrecht, Netherlands; [de Bruin, A.] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat, Div Mol Genet, Groningen, Netherlands; [Teerds, K.] Wageningen Univ, Dept Human & Anim Physiol, Wageningen, Netherlands	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Cambridge; University of Melbourne; Ecole Nationale Veterinaire d'Alfort (ENVA); INRAE; UDICE-French Research Universities; Universite Paris Saclay; Utrecht University; University of Groningen; Wageningen University & Research	Gillot, I; Chaboissier, MC (corresponding author), Univ Nice Sophia Antipolis, iBV, UFR Sci, Parc Valrose,28 Ave Valrose, F-06108 Nice 2, France.	gillot@unice.fr; marie-christine.chaboissier@unice.fr	vidal, valerie/S-2597-2019; Grégoire, Elodie P./CAG-7541-2022; de Bruin, Alain/AAL-9195-2020; CHABOISSIER, Marie-Christine/F-6166-2019; Schedl, Andreas/F-8823-2015; Vidal, Valerie/M-1477-2018; Wilhelm, Dagmar/B-6915-2009; CHABOISSIER, Marie-Christine/AAZ-5905-2021; Schedl, Andreas/GOP-3427-2022; Chassot, Anne-Amandine/O-2102-2016; Teerds, Katja/H-7580-2019	Grégoire, Elodie P./0000-0001-7614-4754; CHABOISSIER, Marie-Christine/0000-0003-0934-8217; Schedl, Andreas/0000-0001-9380-7396; Wilhelm, Dagmar/0000-0002-7757-4075; CHABOISSIER, Marie-Christine/0000-0003-0934-8217; Chassot, Anne-Amandine/0000-0003-1242-9456; Teerds, Katja/0000-0002-0930-1198	Fondation ARC pour la Recherche sur le Cancer [PJA 20131200236]; Agence Nationale de la Recherche [ANR-09-GENM-009-03, ANR-11-LABX-0028-01]; INRA; Ligue Nationale contre le Cancer	Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); Agence Nationale de la Recherche(French National Research Agency (ANR)); INRA; Ligue Nationale contre le Cancer(Ligue nationale contre le cancer)	We thank Mireille Cutajar-Bossert for her work and management of funding and also Fariba Jianmotamedi, Aurelie Charlet and Beatrice Polo for their punctual help in this work. We are thankful to Walter Birchmeier (Berlin, Germany) for the Axin2<SUP>+/LacZ</SUP> mice and Ken Morohashi (Fukuoka, Japan) for the SF1 antibody. We thank Aitana Perea-Gomez for critical reading of the manuscript. This work was supported by grants from the Fondation ARC pour la Recherche sur le Cancer (PJA 20131200236) and Agence Nationale de la Recherche (ANR-09-GENM-009-03 and ANR-11-LABX-0028-01). EP was supported by a fellowship from INRA and Ligue Nationale contre le Cancer.	Ahima RS, 1997, J CLIN INVEST, V99, P391, DOI 10.1172/JCI119172; Albrecht KH, 2001, DEV BIOL, V240, P92, DOI 10.1006/dbio.2001.0438; Auguste A, 2011, SEX DEV, V5, P304, DOI 10.1159/000334517; Bandiera R, 2013, DEV CELL, V27, P5, DOI 10.1016/j.devcel.2013.09.003; Bingham NC, 2006, GENESIS, V44, P419, DOI 10.1002/dvg.20231; Boerboom D, 2006, CANCER RES, V66, P1964, DOI 10.1158/0008-5472.CAN-05-3493; Boerboom D, 2005, CANCER RES, V65, P9206, DOI 10.1158/0008-5472.CAN-05-1024; Chassot AA, 2008, HUM MOL GENET, V17, P1264, DOI 10.1093/hmg/ddn016; Chassot AA, 2012, DEVELOPMENT, V139, P4461, DOI 10.1242/dev.078972; Chidgey M, 2007, BRIT J CANCER, V96, P1783, DOI 10.1038/sj.bjc.6603808; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; de Lau W, 2014, GENE DEV, V28, P305, DOI 10.1101/gad.235473.113; Durlinger ALL, 2002, REPRODUCTION, V124, P601, DOI 10.1530/reprod/124.5.601; Fan HY, 2010, MOL ENDOCRINOL, V24, P1529, DOI 10.1210/me.2010-0141; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Hatano O, 1996, GENES CELLS, V1, P663, DOI 10.1046/j.1365-2443.1996.00254.x; Hirshfield AN, 1997, ENVIRON MOL MUTAGEN, V29, P10; Huang CCJ, 2010, ENDOCRINOLOGY, V151, P1119, DOI 10.1210/en.2009-0814; Jamieson S, 2012, ENDOCR REV, V33, P109, DOI 10.1210/er.2011-0014; Karl J, 1998, DEV BIOL, V203, P323, DOI 10.1006/dbio.1998.9068; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kim AC, 2008, DEVELOPMENT, V135, P2593, DOI 10.1242/dev.021493; Kim KA, 2005, SCIENCE, V309, P1256, DOI 10.1126/science.1112521; Kuchenbaecker KB, 2015, NAT GENET, V47, P164, DOI 10.1038/ng.3185; Liu C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7934; Liu Z. H., 2015, HIGHWAY, V2015, P1, DOI DOI 10.1016/J.FUPR0C.2015.01.025; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Lyashenko N, 2011, NAT CELL BIOL, V13, P753, DOI 10.1038/ncb2260; Maatouk DM, 2008, HUM MOL GENET, V17, P2949, DOI 10.1093/hmg/ddn193; Maatouk DM, 2013, DEV BIOL, V383, P295, DOI 10.1016/j.ydbio.2013.08.026; Maeda O, 2004, ONCOGENE, V23, P964, DOI 10.1038/sj.onc.1207254; Makrigiannakis A, 1999, AM J PATHOL, V154, P1391, DOI 10.1016/S0002-9440(10)65393-X; Mork L, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.111.095208; Mullany LK, 2012, ENDOCRINOLOGY, V153, P1585, DOI 10.1210/en.2011-2121; Ng A, 2014, NAT CELL BIOL, V16, P745, DOI 10.1038/ncb3000; OSMAN P, 1985, J REPROD FERTIL, V73, P261, DOI 10.1530/jrf.0.0730261; Pan HJ, 2014, ENDOCRINOLOGY, V155, P3624, DOI 10.1210/en.2013-2183; Parma P, 2006, NAT GENET, V38, P1304, DOI 10.1038/ng1907; Rastetter RH, 2014, DEV BIOL, V394, P242, DOI 10.1016/j.ydbio.2014.08.013; Rocha AS, 2015, CELL REP, V13, P1757, DOI 10.1016/j.celrep.2015.10.049; Rowlands TM, 2000, REV REPROD, V5, P53; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; Sun XF, 2014, FASEB J, V28, P2380, DOI 10.1096/fj.13-248344; Svingen T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052620; Tomaselli S, 2008, HUM MUTAT, V29, P220, DOI 10.1002/humu.20665; Tomaselli S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016366; Tomizuka K, 2008, HUM MOL GENET, V17, P1278, DOI 10.1093/hmg/ddn036; Zheng WJ, 2014, HUM MOL GENET, V23, P920, DOI 10.1093/hmg/ddt486	48	15	15	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2017	36	2					208	218		10.1038/onc.2016.191	http://dx.doi.org/10.1038/onc.2016.191			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK5AA	27270435	Green Published, hybrid			2022-12-17	WOS:000393938100006
J	Sharma, P; Kuehn, MR				Sharma, P.; Kuehn, M. R.			SENP1-modulated sumoylation regulates retinoblastoma protein (RB) and Lamin A/C interaction and stabilization	ONCOGENE			English	Article							TUMOR-SUPPRESSOR PROTEIN; A-TYPE LAMINS; PROSTATE-CANCER; SUMO; MUTATIONS; SENP1; MECHANISMS; PATHWAY; GENE; PROLIFERATION	The retinoblastoma tumor suppressor protein (RB) plays a critical role in cell proliferation and differentiation and its inactivation is a frequent underlying factor in tumorigenesis. While the regulation of RB function by phosphorylation is well studied, proteasome-mediated RB protein degradation is emerging as an important regulatory mechanism. Although our understanding of RB turnover is currently limited, there is evidence that the nuclear lamina filament protein Lamin A/C protects RB from proteasomal degradation. Here we show that SUMO1 conjugation of RB and Lamin A/C is modulated by the SUMO protease SENP1 and that sumoylation of both proteins is required for their interaction. Importantly, this SUMO1-dependent complex protects both RB and Lamin A/C from proteasomal turnover.	[Sharma, P.; Kuehn, M. R.] NCI, NIH, Frederick, MD 21701 USA; [Sharma, P.] NHGRI, Undiagnosed Dis Program, UDP Translat Lab, Rockville, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Kuehn, MR (corresponding author), NCI, NIH, Frederick, MD 21701 USA.	mkuehn@mail.nih.gov	Sharma, Prashant/ABH-1968-2021		Intramural Research Program of the National Cancer Institute, National Institutes of Health	Intramural Research Program of the National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Stefano Campaner (IIT, Milan) for discussions, and Alessandra Mazzoni (AIRC, Milan), Shyam Sharan (NCI, Frederick), Sushil Rane (NIDDK, Bethesda) and Tom Misteli (NCI, Bethesda) for comments on the manuscript. This work was supported by the Intramural Research Program of the National Cancer Institute, National Institutes of Health.	AHMED SA, 1994, J IMMUNOL METHODS, V170, P211, DOI 10.1016/0022-1759(94)90396-4; Bawa-Khalfe T, 2010, J BIOL CHEM, V285, P25859, DOI 10.1074/jbc.M110.134874; Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; Burdelski C, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1555-8; Butin-Israeli V, 2012, TRENDS GENET, V28, P464, DOI 10.1016/j.tig.2012.06.001; Cao HN, 2003, J HUM GENET, V48, P271, DOI 10.1007/s10038-003-0025-3; De Sandre-Giovannoli A, 2003, SCIENCE, V300, P2055, DOI 10.1126/science.1084125; Dechat T, 2010, COLD SH Q B, V75, P533, DOI 10.1101/sqb.2010.75.018; Dechat T, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000547; Dick FA, 2013, NAT REV MOL CELL BIO, V14, P297, DOI 10.1038/nrm3567; Dittmer T, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-5-222; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; Evdokimov E, 2008, J CELL SCI, V121, P4106, DOI 10.1242/jcs.038570; Ezhevsky SA, 2001, MOL CELL BIOL, V21, P4773, DOI 10.1128/MCB.21.14.4773-4784.2001; Fatkin D, 1999, NEW ENGL J MED, V341, P1715, DOI 10.1056/NEJM199912023412302; Gareau JR, 2010, NAT REV MOL CELL BIO, V11, P861, DOI 10.1038/nrm3011; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Huang W., 2012, EVID-BASED COMPL ALT, V2012, P1, DOI DOI 10.1155/2012/910520; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jiao W, 2006, J BIOL CHEM, V281, P38098, DOI 10.1074/jbc.M605271200; Johnson BR, 2004, P NATL ACAD SCI USA, V101, P9677, DOI 10.1073/pnas.0403250101; Kennedy BK, 2014, ADV EXP MED BIOL, V773, P127, DOI 10.1007/978-1-4899-8032-8_6; Ledl A, 2005, ONCOGENE, V24, P3810, DOI 10.1038/sj.onc.1208539; Li T, 2013, UROL ONCOL-SEMIN ORI, V31, P1539, DOI 10.1016/j.urolonc.2012.03.007; Ma CC, 2014, TUMOR BIOL, V35, P12729, DOI 10.1007/s13277-014-2598-1; Macdonald James I, 2012, Genes Cancer, V3, P619, DOI 10.1177/1947601912473305; Maraldi NM, 2011, J CELL BIOCHEM, V112, P979, DOI 10.1002/jcb.22992; Marji J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011132; Markiewicz E, 2002, MOL BIOL CELL, V13, P4401, DOI 10.1091/mbc.E02-07-0450; Mu JW, 2014, CHINESE MED J-PEKING, V127, P4060, DOI 10.3760/cma.j.issn.0366-6999.20141013; Muchir A, 2000, HUM MOL GENET, V9, P1453, DOI 10.1093/hmg/9.9.1453; Mukhopadhyay D, 2007, TRENDS BIOCHEM SCI, V32, P286, DOI 10.1016/j.tibs.2007.05.002; Narasimha AM, 2014, ELIFE, V3, DOI 10.7554/eLife.02872; Nitta RT, 2006, MOL CELL BIOL, V26, P5360, DOI 10.1128/MCB.02464-05; Pekovic V, 2007, J CELL BIOL, V176, P163, DOI 10.1083/jcb.200606139; Schreiber KH, 2013, CELL, V152, P1365, DOI 10.1016/j.cell.2013.02.015; Sharma P, 2013, CELL REP, V3, P1640, DOI 10.1016/j.celrep.2013.04.016; Sharma P, 2010, J CELL SCI, V123, P1227, DOI 10.1242/jcs.060160; Simon DN, 2013, MOL BIOL CELL, V24, P342, DOI 10.1091/mbc.E12-07-0527; Ulrich HD, 2005, TRENDS CELL BIOL, V15, P525, DOI 10.1016/j.tcb.2005.08.002; Van Berlo JH, 2005, HUM MOL GENET, V14, P2839, DOI 10.1093/hmg/ddi316; Wang C, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/328707; Wang J, 2001, ONCOGENE, V20, P4740, DOI 10.1038/sj.onc.1204655; Wang Q., 2013, POWERTECH POWERTECH, P1; Wilkinson KA, 2010, BIOCHEM J, V428, P133, DOI 10.1042/BJ20100158; Xu Y, 2011, CANCER LETT, V309, P78, DOI 10.1016/j.canlet.2011.05.019; Xu Z, 2009, ANTIOXID REDOX SIGN, V11, P1453, DOI [10.1089/ars.2008.2182, 10.1089/ARS.2008.2182]; Yamaguchi T, 2005, MOL CELL BIOL, V25, P5171, DOI 10.1128/MCB.25.12.5171-5182.2005; Yan XM, 2016, BIOTECHNOL APPL BIOC, V63, P435, DOI 10.1002/bab.1375; Ying HQ, 2006, CELL CYCLE, V5, P506, DOI 10.4161/cc.5.5.2515; Zhang YQ, 2008, J CELL BIOL, V182, P35, DOI 10.1083/jcb.200712124	52	15	16	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2016	35	50					6429	6438		10.1038/onc.2016.177	http://dx.doi.org/10.1038/onc.2016.177			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TP	27270425				2022-12-17	WOS:000390247600007
J	Lu, C; Thoeni, C; Connor, A; Kawabe, H; Gallinger, S; Rotin, D				Lu, C.; Thoeni, C.; Connor, A.; Kawabe, H.; Gallinger, S.; Rotin, D.			Intestinal knockout of Nedd4 enhances growth of Apc(min) tumors	ONCOGENE			English	Article							UBIQUITIN LIGASE NEDD4-1; COLORECTAL-CANCER; BETA-CATENIN; STEM-CELLS; C2 DOMAIN; EXPRESSION; PROTEIN; MOTIF; PHOSPHORYLATION; DEGRADATION	Nedd4 (Nedd4-1) is an E3 ubiquitin ligase that belongs to the HECT family and comprises a C2-WW(n)-HECT domain architecture. Although it has been reported to regulate growth factor receptors and cellular signaling, its role in cancer development has been controversial, with some studies proposing that it promotes cancer while others suggest it inhibits tumor growth. Here, we tested the effect of Nedd4 on intestinal tumor formation and growth using Nedd4-knockout mice (Nedd4 floxed (fl) mice crossed to villin-Cre mice). Although we find that knockout of Nedd4 on its own does not cause tumor growth, its knockout in the context of Apc(+/min)-derived colorectal tumors leads to augmentation of tumor growth, suggesting that Nedd4 normally suppresses intestinal WNT signaling and growth of colonic tumors. WNT signaling microarray, immunoblotting and immunohistochemistry analyses of tumors derived from the Villin-Cre; Nedd4(fl/fl); Apc(+/min) colons demonstrated elevated expression of the WNT upstream effectors LEF1 (full length) and YY1 in these tumors relative to control (Apc(+/min) alone) tumors. Together, these results suggest that Nedd4 suppresses colonic WNT signaling and tumor growth, at least in part, by suppressing the transcription factors LEF1 and YY1.	[Lu, C.; Thoeni, C.; Rotin, D.] Hosp Sick Children, Cell Biol Program, PGCRL 19-9715,686 Bay St, Toronto, ON M5G 0A4, Canada; [Lu, C.; Thoeni, C.; Rotin, D.] Univ Toronto, Dept Biochem, Toronto, ON, Canada; [Connor, A.; Gallinger, S.] Univ Toronto, Univ Hlth Network, Mt Sinai Hosp, Toronto, ON, Canada; [Kawabe, H.] Max Planck Inst Expt Med, Dept Mol Neurobiol, Gottingen, Germany	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University Health Network Toronto; Max Planck Society	Rotin, D (corresponding author), Hosp Sick Children, Cell Biol Program, PGCRL 19-9715,686 Bay St, Toronto, ON M5G 0A4, Canada.	drotin@sickkids.ca	Kawabe, Hiroshi/U-7325-2018; Gallinger, Steven/E-4575-2013	Connor, Ashton/0000-0002-7596-3771; Kawabe, Hiroshi/0000-0001-5650-8696	Canadian Institute of Health Research [MOP-130422]; German Research Foundation [SPP1365/KA3423/1-1]; Fritz Thyssen Foundation; Canada Research Chair form the Canadian Foundation for Innovation (CFI)	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); German Research Foundation(German Research Foundation (DFG)); Fritz Thyssen Foundation; Canada Research Chair form the Canadian Foundation for Innovation (CFI)	We would like to thank Kazuko Hay for technical support and Dr Sylvie Robine for the Vil-Cre<SUP>ERT2</SUP> mice. This grant was supported by the Canadian Institute of Health Research (MOP-130422, to DR), the German Research Foundation SPP1365/KA3423/1-1 (to HK) and the Fritz Thyssen Foundation (to HK). DR is a recipient of a Canada Research Chair form the Canadian Foundation for Innovation (CFI).	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Adegboyega PA, 2004, CLIN CANCER RES, V10, P5870, DOI 10.1158/1078-0432.CCR-0431-03; Arce L, 2006, ONCOGENE, V25, P7492, DOI 10.1038/sj.onc.1210056; Barker N, 2010, CELL STEM CELL, V7, P656, DOI 10.1016/j.stem.2010.11.016; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Buller NVJA, 2015, GASTROENTEROLOGY, V148, P170, DOI 10.1053/j.gastro.2014.10.006; Cadigan KM, 2012, COLD SPRING HARB PER, V4, P6; Chinnappan D, 2009, INT J ONCOL, V34, P1417, DOI 10.3892/ijo_00000270; Eide PW, 2013, CELL SIGNAL, V25, P12, DOI 10.1016/j.cellsig.2012.08.012; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Fouladkou F, 2010, J BIOL CHEM, V285, P6770, DOI 10.1074/jbc.M109.082347; Harty RN, 2000, P NATL ACAD SCI USA, V97, P13871, DOI 10.1073/pnas.250277297; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/ng0501-53; Hsia HE, 2014, P NATL ACAD SCI USA, V111, P13205, DOI 10.1073/pnas.1400737111; Huang Z, 2015, ONCOGENE, V34, P1105, DOI 10.1038/onc.2014.56; Ing B, 2007, MOL CELL BIOL, V27, P481, DOI 10.1128/MCB.00463-06; Isella C, 2015, NAT GENET, V47, P312, DOI 10.1038/ng.3224; Kanelis V, 2001, NAT STRUCT BIOL, V8, P407, DOI 10.1038/87562; Kanelis V, 2006, STRUCTURE, V14, P543, DOI 10.1016/j.str.2005.11.018; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; Kawabe H, 2010, NEURON, V65, P358, DOI 10.1016/j.neuron.2010.01.007; Kim SS, 2008, APMIS, V116, P779, DOI 10.1111/j.1600-0463.2008.00999.x; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Leykauf K, 2006, J CELL SCI, V119, P3634, DOI 10.1242/jcs.03149; Liu Y, 2009, DEV BIOL, V330, P153, DOI 10.1016/j.ydbio.2009.03.023; Lucero OM, 2010, CURR ONCOL REP, V12, P314, DOI 10.1007/s11912-010-0114-3; Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200; March HN, 2011, NAT GENET, V43, P1202, DOI 10.1038/ng.990; Martin ES, 2007, CANCER RES, V67, P10736, DOI 10.1158/0008-5472.CAN-07-2742; MOOLENBEEK C, 1981, LAB ANIM, V15, P57, DOI 10.1258/002367781780958577; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Murdaca J, 2004, J BIOL CHEM, V279, P26754, DOI 10.1074/jbc.M311802200; Najdi Rani, 2011, J Carcinog, V10, P5, DOI 10.4103/1477-3163.78111; Owens BMJ, 2013, MUCOSAL IMMUNOL, V6, P224, DOI 10.1038/mi.2012.125; Pali-Scholl I, 2008, EXP TOXICOL PATHOL, V60, P337, DOI 10.1016/j.etp.2008.03.004; Persaud A, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005290; Persaud A, 2011, EMBO J, V30, P3259, DOI 10.1038/emboj.2011.234; Persaud A, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.85; Pinchuk I V, 2010, Curr Gastroenterol Rep, V12, P310, DOI 10.1007/s11894-010-0135-y; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Porfiri E, 1997, ONCOGENE, V15, P2833, DOI 10.1038/sj.onc.1201462; Rotin D, 2009, NAT REV MOL CELL BIO, V10, P398, DOI 10.1038/nrm2690; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Tanksley JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081514; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Wang J, 2010, J BIOL CHEM, V285, P12279, DOI 10.1074/jbc.M109.086405; Wang WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076596; Wend P, 2010, SEMIN CELL DEV BIOL, V21, P855, DOI 10.1016/j.semcdb.2010.09.004; Wiesner S, 2007, CELL, V130, P651, DOI 10.1016/j.cell.2007.06.050; Yang BL, 2008, NAT IMMUNOL, V9, P1356, DOI 10.1038/ni.1670; Yokoyama NN, 2010, NUCLEIC ACIDS RES, V38, P6375, DOI 10.1093/nar/gkq492; Zaravinos A, 2010, CELL CYCLE, V9, P512, DOI 10.4161/cc.9.3.10588; Zhou PH, 2014, NATURE, V506, P52, DOI 10.1038/nature12988	55	15	16	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2016	35	45					5839	5849		10.1038/onc.2016.125	http://dx.doi.org/10.1038/onc.2016.125			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EB7IR	27086928				2022-12-17	WOS:000387560800003
J	Pant, V; Xiong, S; Chau, G; Tsai, K; Shetty, G; Lozano, G				Pant, V.; Xiong, S.; Chau, G.; Tsai, K.; Shetty, G.; Lozano, G.			Distinct downstream targets manifest p53-dependent pathologies in mice	ONCOGENE			English	Article							EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; P53 INHIBITION; MDM2; EXPRESSION; DIFFERENTIATION; INACTIVATION; ACTIVATION; MUTATIONS; STABILITY	Mdm2, the principal negative regulator of p53, is critical for survival, a fact clearly demonstrated by the p53-dependent death of germline or conditional mice following deletion of Mdm2. On the other hand, Mdm2 hypomorphic (Mdm2(Puro Delta 7-12)) or heterozygous (Mdm2(+/-)) mice that express either 30 or 50% of normal Mdm2 levels, respectively, are viable but present distinct phenotypes because of increased p53 activity. Mdm2 levels are also transcriptionally regulated by p53. We evaluated the significance of this reciprocal relationship in a new hypomorphic mouse model inheriting an aberrant Mdm2 allele with insertion of the neomycin cassette and deletion of 184-bp sequence in intron 3. These mice also carry mutations in the Mdm2 P2-promoter and thus express suboptimal levels of Mdm2 entirely encoded from the P1-promoter. Resulting mice exhibit abnormalities in skin pigmentation and reproductive tissue architecture, and are subfertile. Notably, all these phenotypes are rescued on a p53-null background. Furthermore, these phenotypes depend on distinct p53 downstream activities as genetic ablation of the pro-apoptotic gene Puma reverts the reproductive abnormalities but not skin hyperpigmentation, whereas deletion of cell cycle arrest gene p21 does not rescue either phenotype. Moreover, p53-mediated upregulation of Kitl influences skin pigmentation. Altogether, these data emphasize tissue-specific p53 activities that regulate cell fate.	[Pant, V.; Xiong, S.; Chau, G.; Lozano, G.] Univ Texas MD Anderson Canc Ctr, Dept Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA; [Tsai, K.] Univ Texas MD Anderson Canc Ctr, Dept Dermatol, Houston, TX 77030 USA; [Shetty, G.] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Lozano, G (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.	gglozano@mdanderson.org	Xiong, Shunbin/AAR-5823-2021	Shetty, Gunapala/0000-0001-5786-0667; Pant, Vinod/0000-0002-3286-1804; Chau, Gilda/0000-0002-7907-3290	NCI Cancer Center Support Grant [CA16672]; NIH grant [CA47296]; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA047296] Funding Source: NIH RePORTER	NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Mdm2<SUP>PND/PND</SUP> mice were made by the GEM Facility at the MDACC funded by an NCI Cancer Center Support Grant (CA16672). The studies were supported by NIH grant CA47296 to GL.	ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, COLD SPRING HARB SYM, V59, P225, DOI 10.1101/SQB.1994.059.01.027; Beumer TL, 1998, CELL DEATH DIFFER, V5, P669, DOI 10.1038/sj.cdd.4400396; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Francoz S, 2006, P NATL ACAD SCI USA, V103, P3232, DOI 10.1073/pnas.0508476103; Grier JD, 2006, MOL CELL BIOL, V26, P192, DOI 10.1128/MCB.26.1.192-198.2006; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kunisada T, 1998, DEVELOPMENT, V125, P2915; Liu G, 2007, J PATHOL, V213, P360, DOI 10.1002/path.2238; LUNA RMD, 1995, NATURE, V378, P203; Marino S, 2000, GENE DEV, V14, P994; McGowan KA, 2008, NAT GENET, V40, P963, DOI 10.1038/ng.188; McGowan KA, 2011, BLOOD, V118, P3622, DOI 10.1182/blood-2010-11-318584; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Mendrysa SM, 2000, MOL CELL BIOL, V20, P2023, DOI 10.1128/MCB.20.6.2023-2030.2000; OKURA M, 1995, J INVEST DERMATOL, V105, P322, DOI 10.1111/1523-1747.ep12319939; Pant V, 2014, ONCOTARGET, V5, P1149, DOI 10.18632/oncotarget.1797; Pant V, 2013, GENE DEV, V27, P1857, DOI 10.1101/gad.227249.113; Perry ME, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000968; Post SM, 2010, CANCER CELL, V18, P220, DOI 10.1016/j.ccr.2010.07.010; Shetty G, 2001, ENDOCRINOLOGY, V142, P2789, DOI 10.1210/en.142.7.2789; Steingrimsson E, 2006, DEV DYNAM, V235, P2401, DOI 10.1002/dvdy.20840; Sullivan JM, 2012, RADIAT RES, V177, P307, DOI 10.1667/RR2545.1; Terzian T, 2007, MOL CELL BIOL, V27, P5479, DOI 10.1128/MCB.00555-06; Terzian T, 2011, J PATHOL, V224, P540, DOI 10.1002/path.2891; Vanover JC, 2009, PIGM CELL MELANOMA R, V22, P827, DOI 10.1111/j.1755-148X.2009.00617.x; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xiong SB, 2006, P NATL ACAD SCI USA, V103, P3226, DOI 10.1073/pnas.0508500103; Zeron-Medina J, 2013, CELL, V155, P410, DOI 10.1016/j.cell.2013.09.017; Zhang Y, 2014, J PATHOL, V233, P380, DOI 10.1002/path.4368	37	15	15	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2016	35	44					5713	5721		10.1038/onc.2016.111	http://dx.doi.org/10.1038/onc.2016.111			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XQ	27065327	Green Accepted			2022-12-17	WOS:000386998400003
J	Yang, Y; Huycke, MM; Herman, TS; Wang, X				Yang, Y.; Huycke, M. M.; Herman, T. S.; Wang, X.			Glutathione S-transferase alpha 4 induction by activator protein 1 in colorectal cancer	ONCOGENE			English	Article							FAECALIS-INFECTED MACROPHAGES; TRANSCRIPTION FACTOR; C-JUN; OXIDATIVE STRESS; CELL-LINES; GENETIC-POLYMORPHISM; SIGNALING PATHWAY; EPITHELIAL-CELLS; RESPONSE ELEMENT; HUMAN TISSUES	Glutathione S-transferase alpha 4 (GSTA4) is a phase II detoxifying enzyme that metabolizes electrophiles and carcinogens including 4-hydroxy-2-nonenal (4-HNE), an endogenous carcinogen that contributes to colorectal carcinogenesis. In this study, we investigated GSTA4 expression and regulation in murine primary colonic epithelial cells, microbiome-driven murine colitis and human carcinomas. Exposure of YAMC cells to 4-HNE induced Gsta4 expression. Using an inflammation-associated model of colorectal cancer (CRC), Gsta4 expression increased in vivo in colon macrophages and serum after 2 weeks of colonization of IL-10 deficient (Il10(-/-)) mice with Enterococcus faecalis. Increased expression was noted after 9 months of colonization in colon macrophages and epithelia in areas of inflammation. In human colon biopsies, immunohistochemistry showed no GSTA4 expression in normal epithelial cells, whereas GSTA4 was strongly expressed in the neoplastic epithelia of invasive carcinomas. For tubular adenomas, increased expression was primarily noted in stromal macrophages. Increased GSTA4 was confirmed in established human CRC cell lines and associated with 4-HNE-protein adducts in human colon adenomas and CRC. Next, we showed that 4-HNE induced activation of c-Jun and Nrf2, two components of the oncogenic transcription factor AP-1. AP-1 inhibitors and gene-specific small interfering RNAs partially suppressed GSTA4 expression. Co-immunoprecipitation confirmed interactions between c-Jun and Nrf2 supporting a role for AP-1 in regulating 4-HNE-induced GSTA4 expression. These findings demonstrate GSTA4 activation during 4-HNE-induced neoplastic transformation in colorectal carcinogenesis. GSTA4 is a potential surrogate biomarker for CRC screening and should provide novel approaches for chemoprevention.	[Yang, Y.; Herman, T. S.; Wang, X.] Univ Oklahoma, Hlth Sci Ctr, Dept Radiat Oncol, Oklahoma City, OK USA; [Yang, Y.; Huycke, M. M.; Wang, X.] Oklahoma City VA Hlth Care Syst, Muchmore Labs Infect Dis Res, Oklahoma City, OK USA; [Huycke, M. M.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Wang, X (corresponding author), Univ Oklahoma, Dept Radiat Oncol, Hlth Sci Ctr, VA Med Ctr, 921 NE 13th St,Room 3R-109, Oklahoma City, OK 73104 USA.	xingmin-wang@ouhsc.edu	Huycke, Mark M./AAG-9384-2020; Wang, Xingmin/GOV-6306-2022	Huycke, Mark/0000-0002-6110-5629	Oklahoma Center for the Advancement of Science and Technology [HR10-032]; Francis Duffy Endowment	Oklahoma Center for the Advancement of Science and Technology; Francis Duffy Endowment	We thank Jim Henthorn in the Flow Cytometry and Imaging Laboratory, the Histology and Immunohistochemistry Core in the Peggy and Charles Stephenson Cancer Center (NIH GM103639) at the University of Oklahoma Health Sciences Center for technical assistance. Supported in part by Oklahoma Center for the Advancement of Science and Technology grant HR10-032 (XW) and Francis Duffy Endowment.	Abel EL, 2010, JNCI-J NATL CANCER I, V102, P1663, DOI 10.1093/jnci/djq392; Apidianakis Y, 2012, FASEB J, V26, P730, DOI 10.1096/fj.11-192484; Arlt A, 2013, ONCOGENE, V32, P4825, DOI 10.1038/onc.2012.493; Bakuradze T, 2010, MOL NUTR FOOD RES, V54, P1734, DOI 10.1002/mnfr.201000147; Barrera G, 2004, FREE RADICAL BIO MED, V37, P597, DOI 10.1016/j.freeradbiomed.2004.05.023; Chaudhary P, 2013, J BIOL CHEM, V288, P20532, DOI 10.1074/jbc.M113.467662; Cheng JZ, 2001, BIOCHEM BIOPH RES CO, V282, P1268, DOI 10.1006/bbrc.2001.4707; Coles BF, 2005, METHOD ENZYMOL, V401, P9, DOI 10.1016/S0076-6879(05)01002-5; Dang DT, 2005, CANCER RES, V65, P9485, DOI 10.1158/0008-5472.CAN-05-1930; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Desmots F, 2005, FEBS LETT, V579, P5691, DOI 10.1016/j.febslet.2005.08.088; Desmots F, 2001, J HISTOCHEM CYTOCHEM, V49, P1573, DOI 10.1177/002215540104901211; Diribarne G, 2009, RNA BIOL, V6, P122, DOI 10.4161/rna.6.2.8115; Edalat M, 2004, HISTOCHEM CELL BIOL, V122, P151, DOI 10.1007/s00418-004-0688-7; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Engle MR, 2004, TOXICOL APPL PHARM, V194, P296, DOI 10.1016/j.taap.2003.10.001; Feng ZH, 2004, P NATL ACAD SCI USA, V101, P8598, DOI 10.1073/pnas.0402794101; Fontana MF, 2015, J IMMUNOL, V194, P177, DOI 10.4049/jimmunol.1401595; Giera S, 2010, TOXICOL SCI, V115, P22, DOI 10.1093/toxsci/kfq033; Hasselblatt P, 2008, ONCOGENE, V27, P6102, DOI 10.1038/onc.2008.211; Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Johns LE, 2000, MUTAGENESIS, V15, P399, DOI 10.1093/mutage/15.5.399; Kalinina EV, 2012, B EXP BIOL MED+, V154, P64, DOI 10.1007/s10517-012-1876-4; Kumagai T, 2004, J BIOL CHEM, V279, P48389, DOI 10.1074/jbc.M409935200; Levy S, 2009, FREE RADICAL BIO MED, V47, P1172, DOI 10.1016/j.freeradbiomed.2009.07.036; Matsumura T, 2013, FASEB J, V27, P3198, DOI 10.1096/fj.12-222745; Miller DP, 2003, EPIDEMIOLOGY, V14, P545, DOI 10.1097/01.ede.0000073120.46981.24; Mitrunen K, 2001, CANCER EPIDEM BIOMAR, V10, P229; Miyanishi K, 2001, GASTROENTEROLOGY, V121, P865, DOI 10.1053/gast.2001.27982; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200; Nobuoka A, 2004, GASTROENTEROLOGY, V127, P428, DOI 10.1053/j.gastro.2004.05.021; Nomani H, 2005, CLIN BIOCHEM, V38, P621, DOI 10.1016/j.clinbiochem.2005.04.004; Orom UA, 2013, CELL, V154, P1190, DOI 10.1016/j.cell.2013.08.028; Ritchie KJ, 2009, P NATL ACAD SCI USA, V106, P20859, DOI 10.1073/pnas.0911351106; Sawers L, 2014, BRIT J CANCER, V111, P1150, DOI 10.1038/bjc.2014.386; Schaur R. J., 2003, Molecular Aspects of Medicine, V24, P149, DOI 10.1016/S0098-2997(03)00009-8; Searchfield L, 2011, HISTOPATHOLOGY, V58, P180, DOI 10.1111/j.1365-2559.2010.03733.x; Sharma A, 2008, ARCH BIOCHEM BIOPHYS, V480, P85, DOI 10.1016/j.abb.2008.09.016; Shelton P, 2013, FASEB J, V27, P414, DOI 10.1096/fj.12-217257; Shimizu T, 2010, CANCER SCI, V101, P1093, DOI 10.1111/j.1349-7006.2010.01508.x; Shireman LM, 2010, ARCH BIOCHEM BIOPHYS, V504, P182, DOI 10.1016/j.abb.2010.09.005; Sirota R, 2015, REDOX BIOL, V4, P48, DOI 10.1016/j.redox.2014.11.012; Sweeney C, 2002, TOXICOLOGY, V181, P83, DOI 10.1016/S0300-483X(02)00259-7; Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6; Wang XM, 2015, GUT, V64, P459, DOI 10.1136/gutjnl-2014-307213; Wang XM, 2013, CANCER PREV RES, V6, P206, DOI 10.1158/1940-6207.CAPR-12-0350; Wang XM, 2012, GASTROENTEROLOGY, V142, P543, DOI 10.1053/j.gastro.2011.11.020; Wang XM, 2008, CANCER RES, V68, P9909, DOI 10.1158/0008-5472.CAN-08-1551; West JD, 2005, CHEM RES TOXICOL, V18, P1642, DOI 10.1021/tx050211n; Yang YH, 2013, TRANSL ONCOL, V6, P596, DOI 10.1593/tlo.13412; Zarrouki B, 2007, FEBS LETT, V581, P2394, DOI 10.1016/j.febslet.2007.04.048; ZHONG S, 1993, CARCINOGENESIS, V14, P1821, DOI 10.1093/carcin/14.9.1821	55	15	15	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2016	35	44					5795	5806		10.1038/onc.2016.113	http://dx.doi.org/10.1038/onc.2016.113			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XQ	27065323	Green Accepted			2022-12-17	WOS:000386998400010
J	Nodomi, S; Umeda, K; Saida, S; Kinehara, T; Hamabata, T; Daifu, T; Kato, I; Hiramatsu, H; Watanabe, KI; Kuwahara, Y; Iehara, T; Adachi, S; Konishi, E; Nakahata, T; Hosoi, H; Heike, T				Nodomi, S.; Umeda, K.; Saida, S.; Kinehara, T.; Hamabata, T.; Daifu, T.; Kato, I.; Hiramatsu, H.; Watanabe, K-I; Kuwahara, Y.; Iehara, T.; Adachi, S.; Konishi, E.; Nakahata, T.; Hosoi, H.; Heike, T.			CD146 is a novel marker for highly tumorigenic cells and a potential therapeutic target in malignant rhabdoid tumor	ONCOGENE			English	Article							CANCER STEM-CELLS; ATYPICAL TERATOID/RHABDOID TUMOR; CENTRAL-NERVOUS-SYSTEM; NATIONAL-WILMS-TUMOR; INITIATING CELLS; HUMAN-MELANOMA; BREAST-CANCER; LINE; IDENTIFICATION; EXPRESSION	Malignant rhabdoid tumor (MRT) is a rare, highly aggressive pediatric malignancy that primarily develops during infancy and early childhood. Despite the existing standard of intensive multimodal therapy, the prognosis of patients with MRT is dismal; therefore, a greater understanding of the biology of this disease is required to establish novel therapies. In this study, we identified a highly tumorigenic sub-population in MRT, based on the expression of CD146 (also known as melanoma cell adhesion molecule), a cell adhesion molecule expressed by neural crest cells and various derivatives. CD146(+) cells isolated from four MRT cell lines by cell sorting exhibited enhanced self-renewal and invasive potential in vitro. In a xenograft model using immunodeficient NOD/Shi-scid IL-2R gamma-null mice, purified CD146+ cells obtained from MRT cell lines or a primary tumor exhibited the exclusive ability to form tumors in vivo. Blocking of CD146-related mechanisms, either by short hairpin RNA knockdown or treatment with a polyclonal antibody against CD146, effectively suppressed tumor growth of MRT cells both in vitro and in vivo via induction of apoptosis by inactivating Akt. Furthermore, CD146 positivity in immunohistological analysis of 11 MRT patient samples was associated with poor patient outcomes. These results suggest that CD146 defines a distinct sub-population in MRT with high tumorigenic capacity and that this marker represents a promising therapeutic target.	[Nodomi, S.; Umeda, K.; Saida, S.; Kinehara, T.; Hamabata, T.; Daifu, T.; Kato, I.; Hiramatsu, H.; Watanabe, K-I; Heike, T.] Kyoto Univ, Grad Sch Med, Dept Pediat, Kyoto, Japan; [Kuwahara, Y.; Iehara, T.; Hosoi, H.] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pediat, Kyoto, Japan; [Adachi, S.] Kyoto Univ, Grad Sch Med, Dept Human Hlth Sci, Kyoto, Japan; [Konishi, E.] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Surg Pathol, Kyoto, Japan; [Nakahata, T.] Kyoto Univ, Ctr iPS Cell Res & Applicat, Dept Clin Applicat, Kyoto, Japan	Kyoto University; Kyoto Prefectural University of Medicine; Kyoto University; Kyoto Prefectural University of Medicine; Kyoto University	Umeda, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pediat, Sakyo Ku, 54 Kawahara Cho, Kyoto, Kyoto 6068507, Japan.	umeume@kuhp.kyoto-u.ac.jp		Kuwahara, Yasumichi/0000-0002-0139-8503; Konishi, Eiichi/0000-0002-7122-2271	Takeda Science Foundation;  [24591407];  [25461602]	Takeda Science Foundation(Takeda Science Foundation (TSF)); ; 	We thank all staff for help with histological analysis. We also thank Dr Y Yui and Dr R Nishikomori for providing a critical reading of the manuscript. We are grateful to Dr R Yamada for helpful discussions about statistical analysis of microarray data. This study was supported by grants from the Grant-in-Aid for Scientific Research (C) (24591407 and 25461602) and the Takeda Science Foundation.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Biegel JA, 1999, CANCER RES, V59, P74; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Chen DH, 2013, CANCER RES, V73, P5821, DOI 10.1158/0008-5472.CAN-13-1080; Chiou SH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002090; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Gadd S, 2010, LAB INVEST, V90, P724, DOI 10.1038/labinvest.2010.66; Ginn KF, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00114; Hilden JM, 2004, J CLIN ONCOL, V22, P2877, DOI 10.1200/jco.2004.07.073; Ho DMT, 2000, ACTA NEUROPATHOL, V99, P482, DOI 10.1007/s004010051149; Ito A, 2009, J IMMUNOL, V183, P4782, DOI 10.4049/jimmunol.0900699; Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207; Jiang TX, 2012, BLOOD, V120, P2330, DOI 10.1182/blood-2012-01-406108; Jiang XH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-116; Jouve N, 2013, J BIOL CHEM, V288, P2571, DOI 10.1074/jbc.M112.418848; Katsumi Y, 2008, CLIN CANCER RES, V14, P1192, DOI 10.1158/1078-0432.CCR-07-1661; Kuroda H, 2005, CANCER GENET CYTOGEN, V158, P172, DOI 10.1016/j.cancergencyto.2004.08.032; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Li G, 2003, ONCOGENE, V22, P6891, DOI 10.1038/sj.onc.1206819; Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003; McGary EC, 2003, CLIN CANCER RES, V9, P6560; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Mills L, 2002, CANCER RES, V62, P5106; Misawa A, 2004, J HUM GENET, V49, P586, DOI 10.1007/s10038-004-0191-y; O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824; Okuno K, 2010, ONCOL REP, V23, P485, DOI 10.3892/or_00000659; PARHAM DM, 1994, AM J SURG PATHOL, V18, P1010, DOI 10.1097/00000478-199410000-00005; Pujades C, 2002, INT J DEV BIOL, V46, P263; Rehman J, 2004, CIRCULATION, V109, P1292, DOI 10.1161/01.CIR.0000121425.42966.F1; Sawyers CL, 2008, NATURE, V452, P548, DOI 10.1038/nature06913; Shi IM, 1999, J PATHOL, V189, P4, DOI 10.1002/(SICI)1096-9896(199909)189:1<4::AID-PATH332>3.0.CO;2-P; Shiokawa M, 2010, BIOCHEM BIOPH RES CO, V399, P733, DOI 10.1016/j.bbrc.2010.07.145; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Stewart JM, 2011, P NATL ACAD SCI USA, V108, P6468, DOI 10.1073/pnas.1005529108; Sugimoto T, 1999, INT J CANCER, V82, P678, DOI 10.1002/(SICI)1097-0215(19990827)82:5<678::AID-IJC10>3.0.CO;2-K; Sultan I, 2010, PEDIATR BLOOD CANCER, V54, P35, DOI 10.1002/pbc.22285; Tekautz TM, 2005, J CLIN ONCOL, V23, P1491, DOI 10.1200/JCO.2005.05.187; Tomlinson GE, 2005, J CLIN ONCOL, V23, P7641, DOI 10.1200/JCO.2004.00.8110; Tu T, 2015, CELL RES, V25, P275, DOI 10.1038/cr.2015.15; van den Heuvel-Eibrink MM, 2011, PEDIAT BLOOD CANC, V56, P733; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Wang ZQ, 2013, CANCER LETT, V330, P150, DOI 10.1016/j.canlet.2012.11.049; WEEKS DA, 1989, AM J SURG PATHOL, V13, P439, DOI 10.1097/00000478-198906000-00001; Yan XY, 2003, BLOOD, V102, P184, DOI 10.1182/blood-2002-04-1004; Yanagisawa S, 2009, CLIN CANCER RES, V15, P3014, DOI 10.1158/1078-0432.CCR-08-2237; Yoshimura K, 2006, J CELL PHYSIOL, V208, P64, DOI 10.1002/jcp.20636; Zhang Y, 2008, HYBRIDOMA, V27, P345, DOI 10.1089/hyb.2008.0034; Zhong Y, 2010, CANCER LETT, V299, P150, DOI 10.1016/j.canlet.2010.08.013; Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	52	15	18	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2016	35	40					5317	5327		10.1038/onc.2016.72	http://dx.doi.org/10.1038/onc.2016.72			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DZ7NO	27041577	hybrid, Green Published			2022-12-17	WOS:000386053000010
J	Rajendran, D; Zhang, Y; Berry, DM; McGlade, CJ				Rajendran, D.; Zhang, Y.; Berry, D. M.; McGlade, C. J.			Regulation of Numb isoform expression by activated ERK signaling	ONCOGENE			English	Article							TRACT-BINDING-PROTEIN; PROMOTES NEURONAL DIFFERENTIATION; CELL LUNG-CANCER; MAMMALIAN NUMB; BREAST-CANCER; MULTIPLE ROLES; MOUSE NUMB; NOTCH; KINASE; GROWTH	The endocytic adaptor protein Numb has a major role in development as an intrinsic regulator of cell fate determination and inhibitor of the Notch signaling pathway. In vertebrates, four protein isoforms of Numb are produced through alternative splicing (AS) of two cassette exons (exons 3 and 9). AS of coding exon 9 (E9) produces E9-included (p72/p71) and -excluded (p66/p65) protein products. Expression of Numb isoforms is developmentally regulated and E9-included products are expressed in progenitors, whereas E9-excluded isoforms are dominantly expressed in differentiated cells. Analyses of AS events in multiple cancers previously identified a switch in Numb transcript and protein expression from the E9-excluded to the E9-included isoform, suggesting that misregulation of the mechanisms that control E9 inclusion may have a role in tumorigenesis. Here we identify splicing factors ASF/SF2 and PTBP1 as regulators of E9 splicing and show that activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway promotes E9 inclusion in cancer cells. Our evidence supports a mechanism by which Numb AS is regulated in response to oncogenic signaling pathways, and contributes to activation of downstream pathways to promote tumorigenesis.	[Rajendran, D.; Zhang, Y.; Berry, D. M.; McGlade, C. J.] Hosp Sick Children, Peter Gilgan Ctr Res & Learning, Program Cell Biol, Room 17-9706, Toronto, ON M5G 0A4, Canada; [Rajendran, D.; Zhang, Y.; Berry, D. M.; McGlade, C. J.] Hosp Sick Children, Peter Gilgan Ctr Res & Learning, Arthur & Sonia Labatt Brain Tumour Res Ctr, Room 17-9706, Toronto, ON M5G 0A4, Canada; [Rajendran, D.; Zhang, Y.; McGlade, C. J.] Univ Toronto, Dept Med Biophys, Room 17-9706, Toronto, ON M5G 0A4, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	McGlade, CJ (corresponding author), Hosp Sick Children, Peter Gilgan Ctr Res & Learning, Program Cell Biol, Room 17-9706, Toronto, ON M5G 0A4, Canada.; McGlade, CJ (corresponding author), Hosp Sick Children, Peter Gilgan Ctr Res & Learning, Arthur & Sonia Labatt Brain Tumour Res Ctr, Room 17-9706, Toronto, ON M5G 0A4, Canada.; McGlade, CJ (corresponding author), Univ Toronto, Dept Med Biophys, Room 17-9706, Toronto, ON M5G 0A4, Canada.	jmcglade@sickkids.ca		Zhang, Yangjing/0000-0003-3762-0767	Canadian Institutes of Health Research [MOP-106507]; RESTRACOMP studentship from Garron Family Cancer Centre and Sickkids Research Institute	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); RESTRACOMP studentship from Garron Family Cancer Centre and Sickkids Research Institute	We thank J Woodgett (University of Toronto) for activated MEK and MEKK, V Stambolic (University of Toronto) for Akt constructs, G Zadeh (University of Toronto) for activated RAS, M Moran (University of Toronto) for A549 cells, A Huang (University of Toronto) for YBX1 plasmid, B Blencowe (University of Toronto) for ExonTrap pet01 plasmid, SPARC BioCentre (Hospital for Sick Children, Toronto) for cDNAs and S Dho for comments on the manuscript. This work was supported by an operating grant to CJM from the Canadian Institutes of Health Research (MOP-106507). YZ is supported by a RESTRACOMP studentship from the Garron Family Cancer Centre and Sickkids Research Institute.	Al-Hussaini H, 2011, MOL CANCER THER, V10, P9, DOI 10.1158/1535-7163.MCT-10-0677; Bani-Yaghoub M, 2007, DEV DYNAM, V236, P696, DOI 10.1002/dvdy.21072; Bechara EG, 2013, MOL CELL, V52, P720, DOI 10.1016/j.molcel.2013.11.010; Berezovska O, 1999, NEUROSCIENCE, V93, P433, DOI 10.1016/S0306-4522(99)00157-8; Blissenbach M, 2010, J VIROL, V84, P6598, DOI 10.1128/JVI.02264-09; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Brognard J, 2001, CANCER RES, V61, P3986; Cheung HC, 2006, MODERN PATHOL, V19, P1034, DOI 10.1038/modpathol.3800635; Cheung HC, 2009, BRAIN, V132, P2277, DOI 10.1093/brain/awp153; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Das S, 2012, CELL REP, V1, P110, DOI 10.1016/j.celrep.2011.12.001; Dho SE, 2006, MOL BIOL CELL, V17, P4142, DOI 10.1091/mbc.E06-02-0097; Dho SE, 1999, J BIOL CHEM, V274, P33097, DOI 10.1074/jbc.274.46.33097; Dooley CM, 2003, J NEUROBIOL, V54, P313, DOI 10.1002/neu.10176; French MB, 2002, J IMMUNOL, V168, P3173, DOI 10.4049/jimmunol.168.7.3173; Guo R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062729; Guo SC, 2011, BBA-REV CANCER, V1815, P197, DOI 10.1016/j.bbcan.2010.12.002; He X, 2007, ONCOGENE, V26, P4961, DOI 10.1038/sj.onc.1210307; He X, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2013.47; Ho TH, 2004, EMBO J, V23, P3103, DOI 10.1038/sj.emboj.7600300; Izaguirre DI, 2012, MOL CARCINOGEN, V51, P895, DOI 10.1002/mc.20859; Izrailit J, 2013, P NATL ACAD SCI USA, V110, P1714, DOI 10.1073/pnas.1214014110; Karaczyn A, 2010, NEURAL DEV, V5, DOI 10.1186/1749-8104-5-31; Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209; Kim KK, 2013, J CELL BIOL, V200, P443, DOI 10.1083/jcb.201206146; Langer W, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-676; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Makeyev EV, 2007, MOL CELL, V27, P435, DOI 10.1016/j.molcel.2007.07.015; Maraver A, 2012, CANCER CELL, V22, P222, DOI 10.1016/j.ccr.2012.06.014; McCutcheon IE, 2004, NEURO-ONCOLOGY, V6, P9, DOI 10.1215/S1152851703000279; McGill MA, 2003, J BIOL CHEM, V278, P23196, DOI 10.1074/jbc.M302827200; McGill MA, 2009, J BIOL CHEM, V284, P26427, DOI 10.1074/jbc.M109.014845; Misquitta-Ali CM, 2011, MOL CELL BIOL, V31, P138, DOI 10.1128/MCB.00709-10; Nieber F, 2013, BMC DEV BIOL, V13, DOI 10.1186/1471-213X-13-36; Nishimura T, 2007, DEV CELL, V13, P15, DOI 10.1016/j.devcel.2007.05.003; Ohori M, 2005, BIOCHEM BIOPH RES CO, V336, P357, DOI 10.1016/j.bbrc.2005.08.082; Paz I, 2010, NUCLEIC ACIDS RES, V38, pW281, DOI 10.1093/nar/gkq444; Pece S, 2004, J CELL BIOL, V167, P215, DOI 10.1083/jcb.200406140; Rasin MR, 2007, NAT NEUROSCI, V10, P819, DOI 10.1038/nn1924; Reugels AM, 2006, DEV DYNAM, V235, P934, DOI 10.1002/dvdy.20699; Revil T, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-399; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Santolini E, 2000, J CELL BIOL, V151, P1345, DOI 10.1083/jcb.151.6.1345; Sato K, 2011, MOL BIOL CELL, V22, P3103, DOI 10.1091/mbc.E11-03-0274; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; Stickeler E, 2001, EMBO J, V20, P3821, DOI 10.1093/emboj/20.14.3821; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Teplova M, 2008, NAT STRUCT MOL BIOL, V15, P1343, DOI 10.1038/nsmb.1519; Toriya M, 2006, DEV NEUROSCI-BASEL, V28, P142, DOI 10.1159/000090760; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; Verdi J, 1996, CURR BIOL, V6, P1134, DOI 10.1016/S0960-9822(02)70680-5; Verdi JM, 1999, P NATL ACAD SCI USA, V96, P10472, DOI 10.1073/pnas.96.18.10472; Westhoff B, 2009, P NATL ACAD SCI USA, V106, P22293, DOI 10.1073/pnas.0907781106; Yoshida T, 2003, DIFFERENTIATION, V71, P486, DOI 10.1046/j.1432-0436.2003.7108006.x; Zhang CL, 2010, SCIENCE, V329, P439, DOI 10.1126/science.1191150; Zhang SF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091466; Zhong WM, 2000, P NATL ACAD SCI USA, V97, P6844, DOI 10.1073/pnas.97.12.6844; Zilian O, 2001, CURR BIOL, V11, P494, DOI 10.1016/S0960-9822(01)00149-X; Zong FY, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004289	60	15	18	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2016	35	39					5202	5213		10.1038/onc.2016.69	http://dx.doi.org/10.1038/onc.2016.69			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX5PI	27041567				2022-12-17	WOS:000384433000011
J	Zhang, L; Ma, T; Brozick, J; Babalola, K; Budiu, R; Tseng, G; Vlad, AM				Zhang, L.; Ma, T.; Brozick, J.; Babalola, K.; Budiu, R.; Tseng, G.; Vlad, A. M.			Effects of Kras activation and Pten deletion alone or in combination on MUC1 biology and epithelial-to-mesenchymal transition in ovarian cancer	ONCOGENE			English	Article							K-RAS; DISTANT METASTASES; MOUSE MODEL; CELL-LINES; EXPRESSION; CARCINOMA; IMMUNOBIOLOGY; INHIBITION; MUTATIONS; ONCOGENE	Mucin1 (MUC1) is an epithelial glycoprotein overexpressed in ovarian cancer and actively involved in tumor cell migration and metastasis. Using novel in vitro and in vivo MUC1-expressing conditional (Cre-loxP) ovarian tumor models, we focus here on MUC1 biology and the roles of Kras activation and Pten deletion during cell transformation and epithelial-to-mesenchymal transition (EMT). We generated several novel murine ovarian cancer cell lines derived from the ovarian surface epithelia (OSE) of mice with conditional mutations in Kras, Pten or both. In addition, we also generated several tumor-derived new cell lines that reproduce the original tumor phenotype in vivo and mirror late stage metastatic disease. Our results demonstrate that de novo activation of oncogenic Kras does not trigger increased proliferation, cellular transformation or EMT, and prevents MUC1 upregulation. In contrast, Pten deletion accelerates cell proliferation, triggers cellular transformation in vitro and in vivo, and stimulates MUC1 expression. Ovarian tumor-derived cell lines MKP-Liver and MKP-Lung cells reproduce in vivo EMT and represent the first immune competent mouse model for distant hematogenous spread. Whole genome microarray expression analysis using tumor and OSE-derived cell lines reveal a 121 gene signature associated with EMT and metastasis. When applied to n = 542 cases from The Cancer Genome Atlas (TCGA) ovarian cancer dataset, the gene signature identifies a patient subset with decreased survival (P = 0.04). Using an extensive collection of novel murine cell lines we have identified distinct roles for Kras and Pten on MUC1 and EMT in vivo and in vitro. The data has implications for future design of combination therapies targeting Kras mutations, Pten deletions and MUC1 vaccines.	[Zhang, L.; Babalola, K.; Budiu, R.; Vlad, A. M.] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, B403,204 Craft Ave, Pittsburgh, PA 15213 USA; [Zhang, L.; Brozick, J.; Budiu, R.; Vlad, A. M.] Magee Womens Res Inst, B403,204 Craft Ave, Pittsburgh, PA 15213 USA; [Ma, T.; Tseng, G.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Vlad, AM (corresponding author), Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, B403,204 Craft Ave, Pittsburgh, PA 15213 USA.; Vlad, AM (corresponding author), Magee Womens Res Inst, B403,204 Craft Ave, Pittsburgh, PA 15213 USA.	vladam@upmc.edu	Brozick, Joan/AAA-5785-2019; Ma, Tianzhou/AAC-8221-2021	Ma, Tianzhou/0000-0003-3605-0811	Department of Defense (DOD) Ovarian Cancer Academy Award [W81XWH-10-1-0525]; NIH/NCI [R01 CA163462]; NIH; NATIONAL CANCER INSTITUTE [R01CA163462] Funding Source: NIH RePORTER	Department of Defense (DOD) Ovarian Cancer Academy Award; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was partly supported by the Department of Defense (DOD) Ovarian Cancer Academy Award W81XWH-10-1-0525 and NIH/NCI R01 CA163462 (to AMV). Dr Vlad's work has been funded by the NIH.	Baines AT, 2011, FUTURE MED CHEM, V3, P1787, DOI [10.4155/FMC.11.121, 10.4155/fmc.11.121]; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Besmer DM, 2011, CANCER RES, V71, P4432, DOI 10.1158/0008-5472.CAN-10-4439; Borowicz S, 2014, JOVE-J VIS EXP, DOI 10.3791/51998; Budiu RA, 2013, ONCOGENE, V32, P3664, DOI 10.1038/onc.2012.397; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Carson DD, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.127pe35; Cormio G, 2003, INT J GYNECOL CANCER, V13, P125, DOI 10.1046/j.1525-1438.2003.13054.x; DAUPLAT J, 1987, CANCER-AM CANCER SOC, V60, P1561, DOI 10.1002/1097-0142(19871001)60:7<1561::AID-CNCR2820600725>3.0.CO;2-V; Davidson B, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00033; Deng JL, 2013, CANCER METAST REV, V32, P535, DOI 10.1007/s10555-013-9423-y; Dinulescu DM, 2005, NAT MED, V11, P63, DOI 10.1038/nm1173; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Dong Y, 1997, J PATHOL, V183, P311, DOI 10.1002/(SICI)1096-9896(199711)183:3<311::AID-PATH917>3.0.CO;2-2; Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224; Hasan N, 2015, TRANSL CANCER RES, V4, P14, DOI 10.3978/j.issn.2218-676X.2015.01.02; Horlings HM, 2015, J PATHOL, V236, P397, DOI 10.1002/path.4542; Horlings HM, 2015, JAMA ONCOL, V1, P275, DOI 10.1001/jamaoncol.2015.35; Huang J, 2011, GENE CHROMOSOME CANC, V50, P606, DOI 10.1002/gcc.20883; Ince TA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8419; Iwanaga K, 2008, CANCER RES, V68, P1119, DOI 10.1158/0008-5472.CAN-07-3117; Jain N, 2014, CLIN CANCER RES, V20, P490, DOI 10.1158/1078-0432.CCR-13-1311; Jayson GC, 2014, LANCET, V384, P1376, DOI 10.1016/S0140-6736(13)62146-7; Kandil E, 2013, J SURG RES, V184, P898, DOI 10.1016/j.jss.2013.03.052; KERR VE, 1985, CANCER, V56, P1209, DOI 10.1002/1097-0142(19850901)56:5<1209::AID-CNCR2820560542>3.0.CO;2-Y; Kindelberger DW, 2007, AM J SURG PATHOL, V31, P161, DOI 10.1097/01.pas.0000213335.40358.47; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Lengyel E, 2014, ONCOGENE, V33, P3619, DOI 10.1038/onc.2013.321; Maione P, 2013, REV RECENT CLIN TRIA, V8, P93, DOI 10.2174/15748871113089990047; McDermott KM, 2001, INT J CANCER, V94, P783, DOI 10.1002/ijc.1554; MIZUUCHI H, 1995, CANCER, V76, P86, DOI 10.1002/1097-0142(19950701)76:1<86::AID-CNCR2820760112>3.0.CO;2-L; Nick AM, 2015, NAT REV CLIN ONCOL, V12, P239, DOI 10.1038/nrclinonc.2015.26; Obata K, 1998, CANCER RES, V58, P2095; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585; Roh MH, 2010, MODERN PATHOL, V23, P1316, DOI 10.1038/modpathol.2010.119; Roy LD, 2011, ONCOGENE, V30, P1449, DOI 10.1038/onc.2010.526; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Vlad AM, 2004, ADV IMMUNOL, V82, P249, DOI 10.1016/S0065-2776(04)82006-6; Wang L, 2007, GYNECOL ONCOL, V105, P695, DOI 10.1016/j.ygyno.2007.02.004; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Zhang LX, 2013, CANCER IMMUNOL IMMUN, V62, P423, DOI 10.1007/s00262-012-1325-2	45	15	15	0	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2016	35	38					5010	5020		10.1038/onc.2016.53	http://dx.doi.org/10.1038/onc.2016.53			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW9GT	26973247	Green Accepted			2022-12-17	WOS:000383965300005
J	Lee, JM; Lee, SH; Wang, JH; Oh, SJ; Kim, B; Jung, S; Shim, SH; Lin, PW; Lee, SB; Cho, MY; Koh, YJ; Kim, SY; Ahn, S; Lee, J; Kim, KM; Cheong, KH; Choi, J; Kim, KA				Lee, J. M.; Lee, S. H.; Wang, J-H; Oh, S. J.; Kim, B.; Jung, S.; Shim, S-h; Lin, P. W.; Lee, S. B.; Cho, M-Y; Koh, Y. J.; Kim, S. Y.; Ahn, S.; Lee, J.; Kim, K-m; Cheong, K. H.; Choi, J.; Kim, K-A			Novel strategy for a bispecific antibody: induction of dual target internalization and degradation	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; C-MET ANTIBODY; TYROSINE KINASE INHIBITORS; ACQUIRED-RESISTANCE; RNA INTERFERENCE; IN-VIVO; THERAPY; MECHANISM; CETUXIMAB	Activation of the extensive cross-talk among the receptor tyrosine kinases (RTKs), particularly ErbB family-Met cross-talk, has emerged as a likely source of drug resistance. Notwithstanding brilliant successes were attained while using small-molecule inhibitors or antibody therapeutics against specific RTKs in multiple cancers over recent decades, a high recurrence rate remains unsolved in patients treated with these targeted inhibitors. It is well aligned with multifaceted properties of cancer and cross-talk and convergence of signaling pathways of RTKs. Thereby many therapeutic interventions have been actively developed to overcome inherent or acquired resistance. To date, no bispecific antibody (BsAb) showed complete depletion of dual RTKs from the plasma membrane and efficient dual degradation. In this manuscript, we report the first findings of a target-specific dual internalization and degradation of membrane RTKs induced by designed BsAbs based on the internalizing monoclonal antibodies and the therapeutic values of these BsAbs. Leveraging the anti-Met mAb able to internalize and degrade by a unique mechanism, we generated the BsAbs for Met/epidermal growth factor receptor (EGFR) and Met/HER2 to induce an efficient EGFR or HER2 internalization and degradation in the presence of Met that is frequently overexpressed in the invasive tumors and involved in the resistance against EGFR-or HER2-targeted therapies. We found that Met/EGFR BsAb ME22S induces dissociation of the Met-EGFR complex from Hsp90, followed by significant degradation of Met and EGFR. By employing patient-derived tumor models we demonstrate therapeutic potential of the BsAb-mediated dual degradation in various cancers.	[Lee, J. M.; Oh, S. J.; Kim, B.; Jung, S.; Kim, K-A] Samsung Bioepis Co Ltd, Open Innovat Team, 107 Chomdandaero, Inchon 406840, South Korea; [Lee, S. H.; Shim, S-h; Choi, J.] SAIT, Samsung Biomed Res Inst, Gyeonggi Do, South Korea; [Wang, J-H] Samsung Bioepis Co Ltd, Qual Evaluat Team, Bioassay Grp, Inchon, South Korea; [Lin, P. W.; Lee, S. B.] Samsung Bioepis Co Ltd, Cell Engn Team, Inchon, South Korea; [Cho, M-Y; Koh, Y. J.; Cheong, K. H.] SAIT, Gyeonggi Do, South Korea; [Kim, S. Y.; Lee, J.; Kim, K-m] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul, South Korea; [Ahn, S.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol & Translat Genom, Seoul, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center	Kim, KA (corresponding author), Samsung Bioepis Co Ltd, Open Innovat Team, 107 Chomdandaero, Inchon 406840, South Korea.	ka10.kim@samsung.com	Lee, Jee Yun/C-9646-2011; Lee, Ji Min/ABE-7494-2021	Lee, Ji Min/0000-0003-2978-2440				Adams GP, 2005, NAT BIOTECHNOL, V23, P1147, DOI 10.1038/nbt1137; Annamalai B, 2009, MOL CANCER RES, V7, P1021, DOI 10.1158/1541-7786.MCR-08-0582; Castoldi R, 2013, ONCOGENE, V32, P5593, DOI 10.1038/onc.2013.245; Davidson BL, 2011, NAT REV GENET, V12, P329, DOI 10.1038/nrg2968; Dhomen Nathalie S., 2012, Critical Reviews in Oncogenesis, V17, P31; Doebele RC, 2010, LUNG CANCER, V69, P1, DOI 10.1016/j.lungcan.2009.12.009; Doody JF, 2007, MOL CANCER THER, V6, P2642, DOI 10.1158/1535-7163.MCT-06-0506; Duan Y, 2012, MOL IMMUNOL, V51, P188, DOI 10.1016/j.molimm.2012.03.015; Dulak AM, 2011, ONCOGENE, V30, P3625, DOI 10.1038/onc.2011.84; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Goffin JR, 2013, CLIN THER, V35, P1282, DOI 10.1016/j.clinthera.2013.08.007; Greenall SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034658; Guix M, 2008, J CLIN INVEST, V118, P2609, DOI 10.1172/JCI34588; Gusenbauer S, 2013, ONCOGENE, V32, P3846, DOI 10.1038/onc.2012.396; Ha SY, 2015, INT J CANCER, V136, P1629, DOI 10.1002/ijc.29159; Jin HK, 2008, CANCER RES, V68, P4360, DOI 10.1158/0008-5472.CAN-07-5960; Jo MJ, 2000, J BIOL CHEM, V275, P8806, DOI 10.1074/jbc.275.12.8806; Karamouzis MV, 2009, LANCET ONCOL, V10, P709, DOI 10.1016/S1470-2045(09)70137-8; Kim B, 2015, ONCOGENE, V34, P1083, DOI 10.1038/onc.2014.51; Kim S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111693; Krishnamoorthy GP, 2013, J BIOL CHEM, V288, P17481, DOI 10.1074/jbc.M112.439422; Lee JM, 2014, ONCOGENE, V33, P34, DOI 10.1038/onc.2012.551; Lee JY, 2015, ONCOTARGET, V6, P25619, DOI 10.18632/oncotarget.4627; Lin L., 2012, CHEMOTHER RES PRACT, V2012, DOI DOI 10.1155/2012/817297; Liska D, 2011, CLIN CANCER RES, V17, P472, DOI 10.1158/1078-0432.CCR-10-0568; Mahalingam D, 2009, BRIT J CANCER, V100, P1523, DOI 10.1038/sj.bjc.6605066; Martens T, 2006, CLIN CANCER RES, V12, P6144, DOI 10.1158/1078-0432.CCR-05-1418; McDermott U, 2010, CANCER RES, V70, P1625, DOI 10.1158/0008-5472.CAN-09-3620; Miyata Y, 2013, CURR PHARM DESIGN, V19, P347, DOI 10.2174/138161213804143725; Modjtahedi H, 1996, BRIT J CANCER, V73, P228, DOI 10.1038/bjc.1996.40; Oh YM, 2014, SCI REP-UK, V4, DOI 10.1038/srep04980; Oh YM, 2012, MOL CELLS, V34, P523, DOI 10.1007/s10059-012-0194-z; Pai SI, 2006, GENE THER, V13, P464, DOI 10.1038/sj.gt.3302694; REITER Y, 1994, BIOCHEMISTRY-US, V33, P5451, DOI 10.1021/bi00184a014; Reungwetwattana Thanyanan, 2013, J Carcinog, V12, P22, DOI 10.4103/1477-3163.123972; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sequist LV, 2007, J CLIN ONCOL, V25, P587, DOI 10.1200/JCO.2006.07.3585; Sgambato A, 2012, CURR PHARM DESIGN, V18, P6155, DOI 10.2174/138161212803582478; Sierra J Rafael, 2011, Ther Adv Med Oncol, V3, pS21, DOI 10.1177/1758834011422557; Sliwkowski MX, 2013, SCIENCE, V341, P1192, DOI 10.1126/science.1241145; Spigel DR, 2013, J CLIN ONCOL, V31, P4105, DOI 10.1200/JCO.2012.47.4189; Stevenson M, 2004, NEW ENGL J MED, V351, P1772, DOI 10.1056/NEJMra045004; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Troiani T, 2013, CLIN CANCER RES, V19, P6751, DOI 10.1158/1078-0432.CCR-13-0423; Weatherill EE, 2012, PROTEIN ENG DES SEL, V25, P321, DOI 10.1093/protein/gzs021; Wheeler DL, 2008, ONCOGENE, V27, P3944, DOI 10.1038/onc.2008.19; Yang HY, 2009, MOL CELLS, V27, P225, DOI 10.1007/s10059-009-0028-9; Zwick E, 2001, ENDOCR-RELAT CANCER, V8, P161, DOI 10.1677/erc.0.0080161	48	15	15	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	34					4437	4446		10.1038/onc.2015.514	http://dx.doi.org/10.1038/onc.2015.514			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU4AC	26853467				2022-12-17	WOS:000382153100002
J	Kimura, T; Wang, L; Tabu, K; Tsuda, M; Tanino, M; Maekawa, A; Nishihara, H; Hiraga, H; Taga, T; Oda, Y; Tanaka, S				Kimura, T.; Wang, L.; Tabu, K.; Tsuda, M.; Tanino, M.; Maekawa, A.; Nishihara, H.; Hiraga, H.; Taga, T.; Oda, Y.; Tanaka, S.			Identification and analysis of CXCR4-positive synovial sarcoma-initiating cells	ONCOGENE			English	Article							CHEMOKINE RECEPTOR CXCR4; CANCER STEM-CELLS; PROTO-ONCOPROTEIN SYT; BREAST-CANCER; TUMOR-GROWTH; BONE-MARROW; ANTAGONIST CTCE-9908; PROSTATE-CANCER; EXPRESSION; METASTASIS	Synovial sarcoma accounts for almost 10% of all soft tissue sarcomas, and its prognosis is poor with 5-year survival rates at 36%. Thus, new treatments and therapeutic targets for synovial sarcoma are required. Tumor-initiating cells have been defined by the ability for self-renewal and multipotent differentiation, and they exhibit higher tumorigenic capacity, chemoresistance and radiation resistance, expecting to be a new therapeutic target. In synovial sarcoma, the presence of such stemness remains largely unclear; thus, we analyzed whether synovial sarcoma possessed tumor-initiating cells and explored specific markers, and we discovered that synovial sarcoma cell lines possessed heterogeneity by way of containing a sphere-forming subpopulation highly expressing NANOG, OCT4 and SOX2. By expression microarray analysis, CXCR4 was identified to be highly expressed in the sphere subpopulation and correlated with stem-cell-associated markers. Inhibition of CXCR4 suppressed the cell proliferation of synovial sarcoma cell lines in vitro. The tumor-initiating ability of CXCR4-positive cells was demonstrated by xenograft propagation assay. CXCR4-positive cells showed higher tumorigenicity than negative ones and possessed both self-renewal and multipotent differentiation ability. Immunohistochemical analysis of 39 specimens of synovial sarcoma patients revealed that CXCR4 strongly correlated with poor prognosis of synovial sarcoma. Thus, we conclude that CXCR4 is the marker of synovial sarcoma-initiating cells, a new biomarker for prognosis and a new potential therapeutic target.	[Kimura, T.; Wang, L.; Nishihara, H.] Hokkaido Univ, Grad Sch Med, Dept Translat Pathol, Sapporo, Hokkaido, Japan; [Tabu, K.; Taga, T.] Tokyo Med & Dent Univ TMDU, Med Res Inst, Dept Stem Cell Regulat, Bunkyo Ku, Tokyo, Japan; [Tsuda, M.; Tanino, M.; Tanaka, S.] Hokkaido Univ, Grad Sch Med, Dept Canc Pathol, Sapporo, Hokkaido, Japan; [Maekawa, A.; Oda, Y.] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Higashi Ku, Fukuoka, Japan; [Hiraga, H.] Natl Hosp Org Hokkaido Canc Ctr, Div Orthoped, Sapporo, Hokkaido, Japan	Hokkaido University; Tokyo Medical & Dental University (TMDU); Hokkaido University; Kyushu University	Kimura, T; Tanaka, S (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Translat Pathol, Kita Ku, N15,W7, Sapporo, Hokkaido 0608638, Japan.; Kimura, T; Tanaka, S (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Canc Pathol, Kita Ku, N15,W7, Sapporo, Hokkaido 0608638, Japan.	ktaichi@syd.odn.ne.jp; tanaka@med.hokudai.ac.jp	Tanaka, Shinya/D-3586-2011; Tabu, Kouichi/AAW-1225-2020	Tabu, Kouichi/0000-0002-3524-967X; Taga, Tetsuya/0000-0002-1625-0122	Joint Usage/Research Program of Medical Research Institute, Tokyo Medical and Dental University (TMDU)	Joint Usage/Research Program of Medical Research Institute, Tokyo Medical and Dental University (TMDU)	We thank Dr T Akagi for pCX4bleo vector. This work was supported in part by the Joint Usage/Research Program of Medical Research Institute, Tokyo Medical and Dental University (TMDU).	Adhikari AS, 2010, CANCER RES, V70, P4602, DOI 10.1158/0008-5472.CAN-09-3463; Akashi T, 2008, CANCER SCI, V99, P539, DOI 10.1111/j.1349-7006.2007.00712.x; Chapman MR, 2013, INTEGR BIOL-UK, V5, P692, DOI 10.1039/c3ib20290a; De Falco V, 2007, CANCER RES, V67, P11821, DOI 10.1158/0008-5472.CAN-07-0899; Dubrovska A, 2012, BRIT J CANCER, V107, P43, DOI 10.1038/bjc.2012.105; Dubrovska A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031226; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; Geminder H, 2001, J IMMUNOL, V167, P4747, DOI 10.4049/jimmunol.167.8.4747; Haldar M, 2008, CLIN ORTHOP RELAT R, V466, P2156, DOI 10.1007/s11999-008-0340-2; Haldar M, 2007, CANCER CELL, V11, P375, DOI 10.1016/j.ccr.2007.01.016; Hall JM, 2003, MOL ENDOCRINOL, V17, P792, DOI 10.1210/me.2002-0438; Hassan S, 2011, INT J CANCER, V129, P225, DOI 10.1002/ijc.25665; Hirata K, 2013, BRIT J CANCER, V109, P379, DOI 10.1038/bjc.2013.314; Hirotsu M, 2009, BRIT J CANCER, V101, P2030, DOI 10.1038/sj.bjc.6605407; Huang EH, 2009, J SURG RES, V155, P231, DOI 10.1016/j.jss.2008.06.044; Ito T, 2004, LAB INVEST, V84, P1484, DOI 10.1038/labinvest.3700174; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Jung MJ, 2013, ONCOGENE, V32, P209, DOI 10.1038/onc.2012.37; Kadoch C, 2013, CELL, V153, P71, DOI 10.1016/j.cell.2013.02.036; Kaifi JT, 2005, J NATL CANCER I, V97, P1840, DOI 10.1093/jnci/dji431; Kim M, 2010, CANCER RES, V70, P10411, DOI 10.1158/0008-5472.CAN-10-2591; Kim SY, 2008, CLIN EXP METASTAS, V25, P201, DOI 10.1007/s10585-007-9133-3; Kimura T, 2012, CANCER INVEST, V30, P390, DOI 10.3109/07357907.2012.672607; Kimura Y, 2013, ONCOTARGET, V4, P785, DOI 10.18632/oncotarget.1048; Kioi M, 2010, J CLIN INVEST, V120, P694, DOI 10.1172/JCI40283; Lee CG, 2012, BRIT J HAEMATOL, V158, P79, DOI 10.1111/j.1365-2141.2012.09123.x; Liu AG, 2013, INT J ONCOL, V42, P1399, DOI 10.3892/ijo.2013.1826; Minami Y, 2014, CANCER SCI, V105, P1152, DOI 10.1111/cas.12479; Mohseny AB, 2011, STEM CELLS, V29, P397, DOI 10.1002/stem.596; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murase M, 2009, BRIT J CANCER, V101, P1425, DOI 10.1038/sj.bjc.6605330; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Naka N, 2010, STEM CELLS, V28, P1119, DOI 10.1002/stem.452; Oda Y, 2009, INT J CANCER, V124, P1852, DOI 10.1002/ijc.24128; Olsson E, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-418; Palmerini E, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-014-0222-5; Perani M, 2005, J BIOL CHEM, V280, P42863, DOI 10.1074/jbc.M502963200; Porvasnik S, 2009, PROSTATE, V69, P1460, DOI 10.1002/pros.21008; Ratajczak MZ, 2006, LEUKEMIA, V20, P1915, DOI 10.1038/sj.leu.2404357; Rubin JB, 2003, P NATL ACAD SCI USA, V100, P13513, DOI 10.1073/pnas.2235846100; Saigusa S, 2010, ANN SURG ONCOL, V17, P2051, DOI 10.1245/s10434-010-0970-y; Scala S, 2005, CLIN CANCER RES, V11, P1835, DOI 10.1158/1078-0432.CCR-04-1887; Sherwood RI, 2004, CELL, V119, P543, DOI 10.1016/j.cell.2004.10.021; Smith MCP, 2004, CANCER RES, V64, P8604, DOI 10.1158/0008-5472.CAN-04-1844; Su L, 2012, CANCER CELL, V21, P333, DOI 10.1016/j.ccr.2012.01.010; Suva ML, 2009, CANCER RES, V69, P1776, DOI 10.1158/0008-5472.CAN-08-2242; Taichman RS, 2002, CANCER RES, V62, P1832; Tan L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023383; Tirino V, 2011, FASEB J, V25, P2022, DOI 10.1096/fj.10-179036; Tsuda M, 2005, ONCOGENE, V24, P7984, DOI 10.1038/sj.onc.1208942; Watanabe T, 2006, MOL CANCER RES, V4, P499, DOI 10.1158/1541-7786.MCR-05-0141; Watanabe T, 2009, CELL RES, V19, P638, DOI 10.1038/cr.2009.40; Wynn RF, 2004, BLOOD, V104, P2643, DOI 10.1182/blood-2004-02-0526; Xu L, 2009, CANCER RES, V69, P7905, DOI 10.1158/0008-5472.CAN-09-2099; Yopp AC, 2012, ANN SURG ONCOL, V19, pS339, DOI 10.1245/s10434-011-1774-4; Zagzag D, 2005, CANCER RES, V65, P6178, DOI 10.1158/0008-5472.CAN-04-4406; Zeilstra J, 2014, ONCOGENE, V33, P665, DOI 10.1038/onc.2012.611; Zheng XS, 2011, ONCOL RES, V19, P555, DOI 10.3727/096504012X13340632812631	58	15	15	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2016	35	30					3932	3943		10.1038/onc.2015.461	http://dx.doi.org/10.1038/onc.2015.461			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8DJ	26640147				2022-12-17	WOS:000381013100005
J	Wunsch, D; Hahlbrock, A; Jung, S; Schirmeister, T; van den Boom, J; Schilling, O; Knauer, SK; Stauber, RH				Wuensch, D.; Hahlbrock, A.; Jung, S.; Schirmeister, T.; van den Boom, J.; Schilling, O.; Knauer, S. K.; Stauber, R. H.			Taspase1: a 'misunderstood' protease with translational cancer relevance	ONCOGENE			English	Review							NECK-CANCER; MLL TRANSLOCATIONS; MOLECULAR-BASIS; HEAD; MATRIX; BREAST; PROTEINS; INHIBITORS; EXPRESSION; CELLS	Proteolysis is not only a critical requirement for life, but the executing enzymes also play important roles in numerous pathological conditions, including cancer. Therefore, targeting proteases is clearly relevant for improving cancer patient care. However, to effectively control proteases, a profound knowledge of their mechanistic function as well as their regulation and downstream signalling in health and disease is required. The highly conserved protease Threonine Aspartase1 (Taspase1) is overexpressed in numerous liquid and solid malignancies and was characterized as a 'non-oncogene addiction' protease. Although Taspase1 was shown to cleave various regulatory proteins in humans as well as leukaemia provoking mixed lineage leukaemia fusions, our knowledge on its detailed functions and the underlying mechanisms contributing to cancer is still incomplete. Despite superficial similarity to type 2 asparaginases as well as Ntn proteases, such as the proteasome, Taspase1-related research so far gives us the picture of a unique protease exhibiting special features. Moreover, neither effective genetic nor chemical inhibitors for this enzyme are available so far, thus hampering not only to further dissect Taspase1's pathobiological functions but also precluding the assessment of its clinical impact. Based on recent insights, we here critically review the current knowledge of Taspase1's structurefunction relationship and its mechanistic relevance for tumorigenesis obtained from in vitro and in vivo cancer models. We provide a comprehensive overview of tumour entities for which Taspase1 might be of predictive and therapeutic value, and present the respective experimental evidence. To stimulate progress in the field, a comprehensive overview of Taspase1 targeting approaches is presented, including coverage of Taspase1-related patents. We conclude by discussing future inhibition strategies and relevant challenges, which need to be resolved by the field.	[Wuensch, D.; Hahlbrock, A.; Stauber, R. H.] ENT Univ Med Ctr Mainz, Mol & Cellular Oncol, Langenbeckstr 1, D-55101 Mainz, Germany; [Jung, S.; Schirmeister, T.] Johannes Gutenberg Univ Mainz, Inst Pharm & Biochem, Mainz, Germany; [van den Boom, J.] Univ Duisburg Essen, Ctr Med Biotechnol ZMB, Struct Biochem, Essen, Germany; [Schilling, O.] Univ Freiburg, Inst Mol Med & Cell Res, Freiburg, Germany; [Knauer, S. K.] Univ Duisburg Essen, Ctr Med Biotechnol ZMB, Inst Mol Biol, Essen, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; University of Duisburg Essen; University of Freiburg; University of Duisburg Essen	Wunsch, D (corresponding author), ENT Univ Med Ctr Mainz, Mol & Cellular Oncol, Langenbeckstr 1, D-55101 Mainz, Germany.	wuensch@uni-mainz.de	Schirmeister, Tanja/N-6886-2016; Gül, Désirée/AAB-5965-2022; Schilling, O/AAC-8302-2019; Knauer, Shirley K/E-7931-2012	Schirmeister, Tanja/0000-0002-4587-5076; Knauer, Shirley K/0000-0003-4321-0924; Guel, Desiree/0000-0002-2446-5756; Schilling, Oliver/0000-0001-7678-7653	IFF Mainz Intramural Research Funding; Zeiss foundation ChemBioMed	IFF Mainz Intramural Research Funding; Zeiss foundation ChemBioMed	Grant support: IFF Mainz Intramural Research Funding, Zeiss foundation ChemBioMed.	Aklilu M, 2011, NAT REV CLIN ONCOL, V8, P649, DOI 10.1038/nrclinonc.2011.118; Arkin MR, 2009, CURR OPIN CHEM BIOL, V13, P284, DOI 10.1016/j.cbpa.2009.05.125; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Benedikt A, 2011, LEUKEMIA, V25, P135, DOI 10.1038/leu.2010.249; Bier C, 2012, FASEB J, V26, P3421, DOI 10.1096/fj.11-202432; Bier C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034142; Bier C, 2011, TRAFFIC, V12, P703, DOI 10.1111/j.1600-0854.2011.01191.x; Bier C, 2011, J BIOL CHEM, V286, P3007, DOI 10.1074/jbc.M110.161646; Bonnans C, 2014, NAT REV MOL CELL BIO, V15, P786, DOI 10.1038/nrm3904; Bursen A, 2010, BLOOD, V115, P3570, DOI 10.1182/blood-2009-06-229542; Chan N, 2015, SCI REP-UK, V5, DOI 10.1038/srep11777; Chen DY, 2012, CANCER RES, V72, P2913, DOI 10.1158/0008-5472.CAN-12-1074; Chen DY, 2012, CANCER RES, V72, P736, DOI 10.1158/0008-5472.CAN-11-2584; Chen DY, 2010, CANCER RES, V70, P5358, DOI 10.1158/0008-5472.CAN-10-0027; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Dehart MP, 2007, J PHARM SCI-US, V96, P2667, DOI 10.1002/jps.20905; Demircan K, 2009, HEAD NECK-J SCI SPEC, V31, P793, DOI 10.1002/hed.21045; Docter D, 2015, NANOMEDICINE-UK, V10, P503, DOI 10.2217/nnm.14.184; Dong YY, 2014, CELL RES, V24, P1354, DOI 10.1038/cr.2014.129; Drag M, 2010, NAT REV DRUG DISCOV, V9, P690, DOI 10.1038/nrd3053; Dufour A, 2013, TRENDS PHARMACOL SCI, V34, P233, DOI 10.1016/j.tips.2013.02.004; Fakhry C, 2008, JNCI-J NATL CANCER I, V100, P261, DOI 10.1093/jnci/djn011; Falini B, 2009, LEUKEMIA, V23, P1731, DOI 10.1038/leu.2009.124; Fisher RI, 2006, J CLIN ONCOL, V24, P4867, DOI 10.1200/JCO.2006.07.9665; Gavert N, 2007, CANCER RES, V67, P7703, DOI 10.1158/0008-5472.CAN-07-0991; Gibellini L, 2014, FASEB J, V28, P5122, DOI 10.1096/fj.14-255869; Hadler-Olsen E, 2013, TUMOR BIOL, V34, P2041, DOI 10.1007/s13277-013-0842-8; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hoffmann M, 2013, ONCOL REP, V29, P1962, DOI 10.3892/or.2013.2327; Hsieh JJ, 2011, Pat.No.US 7 964,700 B2, Patent No. 7694700; Hsieh JJ, 2013, Pat.No.US 8,501,811 B2, Patent No. 8501811; Hsieh JJD, 2003, CELL, V115, P293, DOI 10.1016/S0092-8674(03)00816-X; Hsieh JJD, 2003, MOL CELL BIOL, V23, P186, DOI 10.1128/MCB.23.1.186-194.2003; Huber EM, 2015, STRUCTURE, V23, P407, DOI 10.1016/j.str.2014.11.019; Huber EM, 2012, ANGEW CHEM INT EDIT, V51, P8708, DOI 10.1002/anie.201201616; Hutchinson L, 2010, NAT REV CLIN ONCOL, V7, P669, DOI 10.1038/nrclinonc.2010.192; Kar G, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000601; Khan JA, 2005, STRUCTURE, V13, P1443, DOI 10.1016/j.str.2005.07.006; Knauer SK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018253; Koblinski JE, 2000, CLIN CHIM ACTA, V291, P113, DOI 10.1016/S0009-8981(99)00224-7; Kornfeld JW, 2011, BRIT J CANCER, V104, P138, DOI 10.1038/sj.bjc.6606017; Kramer OH, 2013, LEUKEMIA, V27, P792, DOI 10.1038/leu.2012.284; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Kumler I, 2014, CANCER TREAT REV, V40, P259, DOI 10.1016/j.ctrv.2013.09.002; Lagadec C, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-152; Lee JT, 2009, BIOORG MED CHEM LETT, V19, P5086, DOI 10.1016/j.bmcl.2009.07.045; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Liu H, 2009, CANCER BIOL THER, V8, P1204, DOI 10.4161/cbt.8.13.8924; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; Lopez-Otin C, 2008, J BIOL CHEM, V283, P30433, DOI 10.1074/jbc.R800035200; Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Marchant DJ, 2014, NAT MED, V20, P497, DOI 10.1038/nm.3508; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Mason SD, 2011, TRENDS CELL BIOL, V21, P228, DOI 10.1016/j.tcb.2010.12.002; Michalska K, 2006, ACTA BIOCHIM POL, V53, P627, DOI 10.18388/abp.2006_3291; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; National Comprehensive Cancer Network, 2008, J Natl Compr Canc Netw, V6, P646; Niehof M, 2008, GASTROENTEROLOGY, V134, P1191, DOI 10.1053/j.gastro.2008.01.027; Omuro A, 2013, JAMA-J AM MED ASSOC, V310, P1842, DOI 10.1001/jama.2013.280319; Ordonez Gonzalo R., 2009, V539, P33, DOI 10.1007/978-1-60327-003-8_2; Ottmann C, 2009, J MOL BIOL, V386, P913, DOI 10.1016/j.jmb.2009.01.005; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Oyama T, 2013, DEV CELL, V27, P188, DOI 10.1016/j.devcel.2013.09.025; Pal A, 2014, CANCER RES, V74, P4955, DOI 10.1158/0008-5472.CAN-14-1211; Pless B, 2011, LEUKEMIA, V25, P663, DOI 10.1038/leu.2010.308; POOLE AR, 1978, NATURE, V273, P545, DOI 10.1038/273545a0; Rao VH, 2012, ONCOGENE, V31, P2888, DOI 10.1038/onc.2011.460; Rawlings ND, 2011, J BIOL CHEM, V286, P38321, DOI 10.1074/jbc.M111.260026; Romero-Garcia S, 2011, CANCER BIOL THER, V12, P939, DOI 10.4161/cbt.12.11.18140; Rose R, 2010, ANGEW CHEM INT EDIT, V49, P4129, DOI 10.1002/anie.200907203; Rosenthal EL, 2006, HEAD NECK-J SCI SPEC, V28, P639, DOI 10.1002/hed.20365; Sabiani S, 2015, EBIOMEDICINE, V2, P386, DOI 10.1016/j.ebiom.2015.04.009; Saunders LP, 2008, MOL CANCER THER, V7, P3352, DOI 10.1158/1535-7163.MCT-08-0463; Scarbaci K, 2014, CHEMMEDCHEM, V9, P1801, DOI 10.1002/cmdc.201402075; Singh JC, 2014, BRIT J CANCER, V111, P1888, DOI 10.1038/bjc.2014.388; STAUBER R, 1995, VIROLOGY, V213, P439, DOI 10.1006/viro.1995.0016; Stauber RH, 2007, CANCER RES, V67, P5999, DOI 10.1158/0008-5472.CAN-07-0494; Stauber RH, 2012, ONCOTARGET, V3, P31; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; Sturm D, 2014, NAT REV CANCER, V14, P92, DOI 10.1038/nrc3655; Takeda S, 2006, GENE DEV, V20, P2397, DOI 10.1101/gad.1449406; Thiel P, 2012, ANGEW CHEM INT EDIT, V51, P2012, DOI 10.1002/anie.201107616; Tomasetti C, 2015, P NATL ACAD SCI USA, V112, P118, DOI 10.1073/pnas.1421839112; Turk B, 2006, NAT REV DRUG DISCOV, V5, P785, DOI 10.1038/nrd2092; van den Boom J, 2014, CHEMBIOCHEM, V15, P2233, DOI 10.1002/cbic.201402108; Vandenbroucke RE, 2014, NAT REV DRUG DISCOV, V13, P904, DOI 10.1038/nrd4390; Witt S, 2006, STRUCTURE, V14, P1179, DOI 10.1016/j.str.2006.05.019; Wunsch D, 2012, BLOOD CANCER J, V2, DOI 10.1038/bcj.2012.22; Wunsch D, 2015, FASEB J, V29, P1973, DOI 10.1096/fj.14-262451; Wunsch D, 2015, BIOL CHEM, V396, P367, DOI 10.1515/hsz-2014-0318; Xu QA, 1999, CELL, V98, P651, DOI 10.1016/S0092-8674(00)80052-5; Zhou HQ, 2006, MOL CELL BIOL, V26, P2728, DOI 10.1128/MCB.26.7.2728-2735.2006; Zudaire E, 2011, Pat.No.EP2461806, Patent No. 2461806	96	15	15	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2016	35	26					3351	3364		10.1038/onc.2015.436	http://dx.doi.org/10.1038/onc.2015.436			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DQ5UI	26657154				2022-12-17	WOS:000379270100001
J	Mukhopadhyay, P; Ferguson, B; Muller, HK; Handoko, HY; Walker, GJ				Mukhopadhyay, P.; Ferguson, B.; Muller, H. K.; Handoko, H. Y.; Walker, G. J.			Murine melanomas accelerated by a single UVR exposure carry photoproduct footprints but lack UV signature C > T mutations in critical genes	ONCOGENE			English	Article							ULTRAVIOLET-RADIATION; SOMATIC MUTATIONS; NORMAL SKIN; DNA; REPAIR; MECHANISMS; MUTAGENESIS; DRIVEN; CANCER; RISK	Ultraviolet radiation (UVR) exposure increases malignant melanoma (MM) risk, but in the context of acute, not cumulative exposure. C > T and CC > TT changes make up the overwhelming majority of single base substitutions (SBS) in MM DNA, as both precursor melanocytes and melanocytic lesions have incurred incidental exposures to sunlight. To study the mutagenic mechanisms by which acute sunburn accelerates MM, we sequenced the exomes of spontaneous and neonatal UVB-induced Cdk4-R24C::Tyr-NRASQ61K mouse MMs. UVR-induced MMs carried more SBSs than spontaneous MMs, but the levels of genomic instability, reflected by translocations and copy number changes, were not different. C > T/G > A was the most common SBS in spontaneous and UVR-induced MMs, only modestly increased in the latter. However, they tended to occur at the motif A/GpCpG (reflecting C > T transition due to spontaneous deamination of cytosine at CpG) in spontaneous MMs, and T/CpCpC/T (reflecting the effects of pyrimidine dimers on either side of the mutated C) in UVR-induced MMs. Unlike MMs associated with repetitive exposures, we observed no CC > TT changes. In addition, we also found UVR `footprints' at T > A/A > Ts (at NpTpT) and T > C/A > G (at CpTpC). These footprints are also present in MMs from a chronic UVR mouse model, and in some human MMs, suggesting that they may be minor UVR signature changes. We found few significantly somatically mutated genes (similar to 6 per spontaneous and 15 per UVR-induced melanoma) in addition to the Cdk4 and NRAS mutations already present. Trp53 was the most convincing recurrently mutated gene; however, in the UVR-induced MMs no Trp53 mutations were at C > T/G > A, suggesting that it was probably mutated during tumour progression, not directly induced by UVR photoproducts. The very low load of recurrent mutations convincingly induced by classical UVB-induced dimer photoproducts may support a role for cell extrinsic mechanisms, such as photoimmunosuppression and inflammation in driving MM after acute UVB exposure.	[Mukhopadhyay, P.; Ferguson, B.; Handoko, H. Y.; Walker, G. J.] QIMR Berghofer Med Res Inst, 300 Herston Rd, Herston, Qld 4006, Australia; [Muller, H. K.] Univ Tasmania, Sch Med, Hobart, Tas, Australia	QIMR Berghofer Medical Research Institute; University of Tasmania	Walker, GJ (corresponding author), QIMR Berghofer Med Res Inst, 300 Herston Rd, Herston, Qld 4006, Australia.	Graeme.Walker@qimrberghofer.edu.au	, Herlina/F-4193-2015	, Herlina/0000-0003-3153-2248; Ferguson, Blake/0000-0002-5643-6976	Cancer Council of Queensland; National Health and Medical Research Council of Australia	Cancer Council of Queensland(Cancer Council Queensland); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by The Cancer Council of Queensland, and the National Health and Medical Research Council of Australia. We thank Nick Hayward and Peter Johansson for helpful discussions, and Grant Morahan for prompting us to consider the influence of genetic background on cancer incidence.	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Alexandrov LB, 2013, CELL REP, V3, P246, DOI 10.1016/j.celrep.2012.12.008; Besaratinia A, 2004, BIOCHEMISTRY-US, V43, P8169, DOI 10.1021/bi049761v; Besaratinia A, 2008, FASEB J, V22, P2379, DOI 10.1096/fj.07-105437; Brash DE, 2015, PHOTOCHEM PHOTOBIOL, V91, P15, DOI 10.1111/php.12377; Bryan DS, 2014, GENOME RES, V24, P1534, DOI 10.1101/gr.174052.114; Carstens MJ, 2004, J BIOL CHEM, V279, P35984, DOI 10.1074/jbc.M400408200; Ferguson B, 2015, ONCOGENE, V34, P2879, DOI 10.1038/onc.2014.227; Fulci G, 2002, CANCER RES, V62, P2897; Furney SJ, 2013, J PATHOL, V230, P261, DOI 10.1002/path.4204; Gandini S, 2005, EUR J CANCER, V41, P45, DOI 10.1016/j.ejca.2004.10.016; Giglia-Mari G, 2003, HUM MUTAT, V21, P217, DOI 10.1002/humu.10179; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Ikehata H, 2013, J INVEST DERMATOL, V133, P1850, DOI 10.1038/jid.2012.504; Ikehata H, 2011, J RADIAT RES, V52, P115, DOI 10.1269/jrr.10175; Jans J, 2006, MOL CELL BIOL, V26, P8515, DOI 10.1128/MCB.00807-06; Jia PL, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-11; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Malcikova J, 2009, BLOOD, V114, P5307, DOI 10.1182/blood-2009-07-234708; Martincorena I, 2015, SCIENCE, V348, P880, DOI 10.1126/science.aaa6806; Matin RN, 2013, J EXP MED, V210, P581, DOI 10.1084/jem.20121439; Metz CHD, 2013, CANCER MED-US, V2, P208, DOI 10.1002/cam4.61; Mitchell DL, 2009, PHOTOCHEM PHOTOBIOL, V85, P1384, DOI 10.1111/j.1751-1097.2009.00591.x; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; Otoshi E, 2000, CANCER RES, V60, P1729; Ouhtit A, 1998, J NATL CANCER I, V90, P523, DOI 10.1093/jnci/90.7.523; Pattison DI, 2006, EXP SUPPL, V96, P131; Pfeifer GP, 2005, MUTAT RES-FUND MOL M, V571, P19, DOI 10.1016/j.mrfmmm.2004.06.057; Ravanat JL, 2001, J PHOTOCH PHOTOBIO B, V63, P88, DOI 10.1016/S1011-1344(01)00206-8; Robert C, 1996, J INVEST DERMATOL, V106, P721, DOI 10.1111/1523-1747.ep12345616; SELVANAYAGAM CS, 1995, CANCER RES, V55, P3310; Sheppard KE, 2013, CLIN CANCER RES, V19, P5320, DOI 10.1158/1078-0432.CCR-13-0259; Slovackova J, 2010, CELL CYCLE, V9, P2141, DOI 10.4161/cc.9.11.11808; Song Q, 2014, NUCLEIC ACIDS RES, V42, P13122, DOI 10.1093/nar/gku1049; Su DGT, 2010, CHEM RES TOXICOL, V23, P474, DOI 10.1021/tx9003962; Viros A, 2014, NATURE, V511, P478, DOI 10.1038/nature13298; Wolnicka-Glubisz A, 2006, PHOTOCH PHOTOBIO SCI, V5, P254, DOI 10.1039/b506974b; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451; Zaidi MR, 2011, NATURE, V469, P548, DOI 10.1038/nature09666	41	15	15	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 23	2016	35	25					3342	3350		10.1038/onc.2015.386	http://dx.doi.org/10.1038/onc.2015.386			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP2GN	26477315				2022-12-17	WOS:000378306400013
J	Wang, H; Liu, B; Al-Aidaroos, AQO; Shi, H; Li, L; Guo, K; Li, J; Tan, BCP; Loo, JM; Tang, JP; Thura, M; Zeng, Q				Wang, H.; Liu, B.; Al-Aidaroos, A. Q. O.; Shi, H.; Li, L.; Guo, K.; Li, J.; Tan, B. C. P.; Loo, J. M.; Tang, J. P.; Thura, M.; Zeng, Q.			Dual-faced SH3BGRL: oncogenic in mice, tumor suppressive in humans	ONCOGENE			English	Article							C-SRC; PROTEIN; CANCER; KINASES; FAMILY; IDENTIFICATION; METASTASIS; TARGETS; FAK; ACTIVATION	Despite abundant data supporting c-Src as a metastasis-promoting oncogene, activating mutations of c-Src are rare. This suggests that trans-interacting proteins may have a critical role in regulating c-Src activation. Here, we first report the discovery of Src homology 3 (SH3) domain-binding glutamic acid-rich-like protein (SH3BGRL), a novel c-Src activator in mice. Ectopic expression of murine SH3BGRL (mSH3BGRL) strongly promoted both tumor cell invasion and lung metastasis. Molecularly, mSH3BGRL specifically bound the inactive form of c-Src phosphorylated at Tyr527, promoting Tyr416 phosphorylation of c-Src and subsequent FAK-mediated activation of ERK and AKT signaling pathways. Targeting endogenous c-Src alone was sufficient to abolish mSH3BGRL-induced cancer metastasis in vivo. Unexpectedly, human SH3BGRL (hSH3BGRL) in turn suppressed tumorigenesis and metastasis in nature. We attempted site-specific reversion of hSH3BGRL amino-acid sequence to mSH3BGRL and found V108A substitution sufficient to restore SH3BGRL function as a c-Src activator and metastasis promoter. Notably, the somatic mutation R76C of hSH3BGRL can similarly act as hSH3BGRL-V108A and mSH3BGRL in tumorigenesis and metastasis. Our results uncover an evolutionarily controversial role of SH3BGRL in driving tumor metastasis through c-Src activation, and suggests that hSH3BGRL mutation status could be relevant to cancer diagnosis and therapy.	[Wang, H.; Liu, B.; Shi, H.; Li, L.] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, 74 Second Zhonshan Rd, Guangzhou 510080, Guangdong, Peoples R China; [Wang, H.; Liu, B.; Shi, H.; Li, L.] Sun Yat Sen Univ, Ctr Stem Cell Biol & Tissue Engn, Guangzhou 510275, Guangdong, Peoples R China; [Al-Aidaroos, A. Q. O.; Guo, K.; Li, J.; Tan, B. C. P.; Tang, J. P.; Thura, M.; Zeng, Q.] ASTAR, Inst Mol & Cell Biol, Singapore, Singapore; [Loo, J. M.] Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA; [Zeng, Q.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117548, Singapore	Sun Yat Sen University; Sun Yat Sen University; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Rockefeller University; National University of Singapore	Wang, H (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, 74 Second Zhonshan Rd, Guangzhou 510080, Guangdong, Peoples R China.; Zeng, Q (corresponding author), 61 Biopolis Dr,Room 3-02, Singapore 138673, Singapore.	wanghaih@mail.sysu.edu.cn; mcbzengq@imcb.astar.edu.sg	Haihe, Wang/AAD-4036-2021	Loo, Jia Min/0000-0002-6605-4031; LIU, BIN/0000-0003-0467-3678	National Natural Science Foundation of China [81171947]; Project of International Collaboration in Science and Technology, Guangdong Province [2014A050503030]; Agency of Science, Technology and Research (A* STAR), Singapore	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Project of International Collaboration in Science and Technology, Guangdong Province; Agency of Science, Technology and Research (A* STAR), Singapore(Agency for Science Technology & Research (A*STAR))	This work was supported by research grants from the National Natural Science Foundation of China (WH; No. 81171947), Project of International Collaboration in Science and Technology, Guangdong Province (WH; No. 2014A050503030) and The Agency of Science, Technology and Research (A* STAR), Singapore. We are also thankful to Professor Wanjin Hong, Professor Shulan Yang and Mr Mingming Zhang in our group for critical reading of the manuscript.	Abba MC, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-37; Arcaro A, 2007, CELL SIGNAL, V19, P1081, DOI 10.1016/j.cellsig.2006.12.003; Berleth ES, 2000, INT J IMMUNOPHARMACO, V22, P1137, DOI 10.1016/S0192-0561(00)00071-0; Berleth ES, 1999, CANCER RES, V59, P5497; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; BRATTAIN MG, 1980, CANCER RES, V40, P2142; Egeo A, 1998, BIOCHEM BIOPH RES CO, V247, P302, DOI 10.1006/bbrc.1998.8763; Elkin Michael, 2001, Curr Protoc Cell Biol, VChapter 19, DOI 10.1002/0471143030.cb1902s12; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Garritano S, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.15; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Henn AD, 2001, FASEB J, V15, P1315, DOI 10.1096/fj.00-0543fje; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Johnson FM, 2007, ANTI-CANCER AGENT ME, V7, P651, DOI 10.2174/187152007784111278; Liu WS, 2015, ONCOTARGET, V6, P8851, DOI 10.18632/oncotarget.3316; Majid SM, 2006, ONCOGENE, V25, P756, DOI 10.1038/sj.onc.1209107; Mazzocco M, 2002, GENE, V291, P233, DOI 10.1016/S0378-1119(02)00602-9; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Nilbert M, 2000, CANCER GENET CYTOGEN, V121, P94, DOI 10.1016/S0165-4608(00)00226-0; Piguet AC, 2011, J HEPATOL, V54, P1317, DOI 10.1016/j.jhep.2010.12.013; Rao S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117215; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V337, P1, DOI 10.1016/j.bbrc.2005.08.055; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Schaller MD, 2010, J CELL SCI, V123, P1007, DOI 10.1242/jcs.045112; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sen Banibrata, 2011, J Signal Transduct, V2011, P865819, DOI 10.1155/2011/865819; Sigal A, 2000, CANCER RES, V60, P6788; Tan YX, 2005, WORLD J GASTROENTERO, V11, P2351, DOI 10.3748/wjg.v11.i15.2351; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang HH, 2007, CANCER RES, V67, P2922, DOI 10.1158/0008-5472.CAN-06-3598; Warmuth M, 2003, CURR PHARM DESIGN, V9, P2043, DOI 10.2174/1381612033454126; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Zeng Q, 2003, CANCER RES, V63, P2716	35	15	15	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 23	2016	35	25					3303	3313		10.1038/onc.2015.391	http://dx.doi.org/10.1038/onc.2015.391			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP2GN	26455318	Green Published, hybrid			2022-12-17	WOS:000378306400009
J	Nanos-Webb, A; Bui, T; Karakas, C; Zhang, D; Carey, JPW; Mills, GB; Hunt, KK; Keyomarsi, K				Nanos-Webb, A.; Bui, T.; Karakas, C.; Zhang, D.; Carey, J. P. W.; Mills, G. B.; Hunt, K. K.; Keyomarsi, K.			PKCiota promotes ovarian tumor progression through deregulation of cyclin E	ONCOGENE			English	Article							KINASE-C-IOTA; BREAST-CANCER; PKC-IOTA; E OVEREXPRESSION; POOR-PROGNOSIS; ATYPICAL PKC; CELL-CYCLE; EXPRESSION; ACTIVATION; CARCINOMA	The high frequency of relapse of epithelial ovarian tumors treated with standard chemotherapy has highlighted the necessity to identify targeted therapies that can improve patient outcomes. The dynamic relationship between cyclin E and PKCiota frequent overexpression in high-grade ovarian tumors poses a novel pathway for therapeutic investigation. We hypothesized that a phosphoinositide 3-kinase (PI3K)-dependent signaling pathway activating PKCiota perpetuates cyclin E deregulation during ovarian tumorigenesis. We observed a positive correlation between PKCiota and cyclin E in a panel of 19 ovarian cancer cell lines. Modulation of cyclin E had no effect on PKCiota knockdown/overexpression; however, PKCiota differentially regulated cyclin E expression. In the serous ovarian cancer cells (IGROV and OVCAR-3), shPKCiota decreased proliferation, caused a G1 arrest and significantly prolonged overall survival in xenograft mouse models. In vitro, shPKCiota decreased the ability of IGROV cells to grow under anchorage-independent conditions and form aberrant acini, which was dependent on Ad-cyclin E or Ad-LMW-E expression. Reverse-phase protein array analysis of PKCiota wild-type, catalytic active, dominant-negative protein isoforms strengthened the association between phospho-PKCiota levels and PI3K pathway activation. Inhibitors of PI3K coordinately decreased phospho-PKCiota and cyclin E protein levels. In conclusion, we have identified a PI3K/PKCiota/cyclin E signaling pathway as a therapeutic target during ovarian tumorigenesis.	[Nanos-Webb, A.; Bui, T.; Karakas, C.; Carey, J. P. W.; Keyomarsi, K.] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, 6565 MD Anderson Blvd,Unit 1052, Houston, TX 77030 USA; [Zhang, D.; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Hunt, K. K.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Keyomarsi, K (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, 6565 MD Anderson Blvd,Unit 1052, Houston, TX 77030 USA.	kkeyomar@mdanderson.org	Keyomarsi, Khandan/H-2716-2016	Keyomarsi, Khandan/0000-0002-5440-0849; Carey, Jason PW/0000-0002-9729-1742	NIH [CA87458, CA1522228]; NCI CCSG [CA16672]; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA087548, P50CA083639, P50CA116199, R01CA152228] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI CCSG; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by NIH grants CA87458 and CA1522228 to KK and by NCI CCSG grant CA16672 to MD Anderson Cancer Center.	Akimoto K, 1998, BIOCHEM J, V335, P417, DOI 10.1042/bj3350417; Akli S, 2004, BREAST CANCER RES, V6, P188, DOI 10.1186/bcr905; Akli S, 2007, CANCER RES, V67, P7212, DOI 10.1158/0008-5472.CAN-07-0599; Akli S, 2011, CANCER RES, V71, P3377, DOI 10.1158/0008-5472.CAN-10-4086; Awadelkarim KD, 2012, INT J CANCER, V131, P2852, DOI 10.1002/ijc.27600; Bagheri-Yarmand R, 2010, CANCER RES, V70, P5074, DOI 10.1158/0008-5472.CAN-09-4094; Bagheri-Yarmand R, 2010, CANCER RES, V70, P5085, DOI 10.1158/0008-5472.CAN-09-4095; Baldwin RM, 2006, ONCOGENE, V25, P2909, DOI 10.1038/sj.onc.1209312; Bales E, 2005, CANCER RES, V65, P692; Bedrosian I, 2004, ONCOGENE, V23, P2648, DOI 10.1038/sj.onc.1207408; Bedrosian I, 2007, CLIN CANCER RES, V13, P4800, DOI 10.1158/1078-0432.CCR-07-0142; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Coghlan MP, 2000, MOL CELL BIOL, V20, P2880, DOI 10.1128/MCB.20.8.2880-2889.2000; Courjal F, 1996, INT J CANCER, V69, P247; Duong MT, 2013, CANCER RES, V73, P5556, DOI 10.1158/0008-5472.CAN-13-0013; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Erdogan E, 2009, CLIN CANCER RES, V15, P1527, DOI 10.1158/1078-0432.CCR-08-2459; Evans JD, 2003, AM J CLIN PATHOL, V119, P392, DOI 10.1309/BKPC9DX98R781B87; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Farley J, 2003, CANCER RES, V63, P1235; Fields AP, 2007, PHARMACOL RES, V55, P487, DOI 10.1016/j.phrs.2007.04.015; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; Justilien V, 2014, CANCER CELL, V25, P139, DOI 10.1016/j.ccr.2014.01.008; Kang JS, 1996, MOL CELL BIOL, V16, P3370; Kanoh Y, 2003, ENDOCRINOLOGY, V144, P947, DOI 10.1210/en.2002-221017; Karst AM, 2014, CANCER RES, V74, P1141, DOI 10.1158/0008-5472.CAN-13-2247; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Lakhani SR, 2004, CLIN CANCER RES, V10, P2473, DOI 10.1158/1078-0432.CCR-1029-3; Murray NR, 2011, J CELL PHYSIOL, V226, P879, DOI 10.1002/jcp.22463; Nanos-Webb A, 2012, BREAST CANCER RES TR, V132, P575, DOI 10.1007/s10549-011-1638-4; Paget JA, 2012, ONCOGENE, V31, P3584, DOI 10.1038/onc.2011.524; Rath SL, 2014, BIOCHEMISTRY-US, V53, P4612, DOI 10.1021/bi5004052; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; Rosse C, 2014, P NATL ACAD SCI USA, V111, pE1872, DOI 10.1073/pnas.1400749111; Standaert ML, 1999, J BIOL CHEM, V274, P14074, DOI 10.1074/jbc.274.20.14074; Tan DSP, 2008, J CLIN ONCOL, V26, P5530, DOI 10.1200/JCO.2008.16.1703; Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535-7163.MCT-06-0334; Weichert W, 2003, INT J ONCOL, V23, P633; Wingate H, 2003, CELL CYCLE, V2, P461, DOI 10.4161/cc.2.5.464; Zhang L, 2006, CANCER RES, V66, P4627, DOI 10.1158/0008-5472.CAN-05-4527	41	15	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2016	35	19					2428	2440		10.1038/onc.2015.301	http://dx.doi.org/10.1038/onc.2015.301			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GQ	26279297	Green Accepted			2022-12-17	WOS:000376165500002
J	Luddecke, S; Ertych, N; Stenzinger, A; Weichert, W; Beissbarth, T; Dyczkowski, J; Gaedcke, J; Valerius, O; Braus, GH; Kschischo, M; Bastians, H				Lueddecke, S.; Ertych, N.; Stenzinger, A.; Weichert, W.; Beissbarth, T.; Dyczkowski, J.; Gaedcke, J.; Valerius, O.; Braus, G. H.; Kschischo, M.; Bastians, H.			The putative oncogene CEP72 inhibits the mitotic function of BRCA1 and induces chromosomal instability	ONCOGENE			English	Article							CENTROSOME AMPLIFICATION; BREAST-CANCER; EXPRESSION; SUSCEPTIBILITY	BRCA1 is a tumor-suppressor gene associated with, but not restricted to, breast and ovarian cancer and implicated in various biological functions. During mitosis, BRCA1 and its positive regulator Chk2 are localized at centrosomes and are required for the regulation of microtubule plus end assembly, thereby ensuring faithful mitosis and numerical chromosome stability. However, the function of BRCA1 during mitosis has not been defined mechanistically. To gain insights into the mitotic role of BRCA1 in regulating microtubule assembly, we systematically identified proteins interacting with BRCA1 during mitosis and found the centrosomal protein Cep72 as a novel BRCA1-interacting protein. CEP72 is frequently upregulated in colorectal cancer tissues and overexpression of CEP72 mirrors the consequences of BRCA1 loss during mitosis. In detail, the overexpression of CEP72 causes an increase in microtubule plus end assembly, abnormal mitotic spindle formation and the induction of chromosomal instability. Moreover, we show that high levels of Cep72 counteract Chk2 as a positive regulator of BRCA1 to ensure proper mitotic microtubule assembly. Thus, CEP72 represents a putative oncogene in colorectal cancer that might negatively regulate the mitotic function of BRCA1 to ensure chromosomal stability.	[Lueddecke, S.; Ertych, N.; Bastians, H.] Univ Gottingen, Sect Cellular Oncol, Gottingen Ctr Mol Biosci GZMB, Grisebachstr 8, D-37073 Gottingen, Germany; [Lueddecke, S.; Ertych, N.; Bastians, H.] Univ Med Ctr Gottingen UMG, Inst Mol Oncol, Grisebachstr 8, D-37073 Gottingen, Germany; [Stenzinger, A.; Weichert, W.] Heidelberg Univ, Inst Pathol, Univ Med Ctr, Neuenheimer Feld 220, Heidelberg, Germany; [Weichert, W.] Natl Ctr Tumor Dis NCT, Heidelberg, Germany; [Beissbarth, T.; Dyczkowski, J.] Univ Med Ctr Gottingen UMG, Sect Stat Bioinformat, Inst Med Stat, D-37077 Gottingen, Germany; [Gaedcke, J.] Univ Med Ctr Gottingen UMG, Dept Gen & Visceral Surg, D-37077 Gottingen, Germany; [Valerius, O.; Braus, G. H.] Univ Gottingen, Inst Microbiol & Genet, Dept Mol Microbiol & Genet, D-37073 Gottingen, Germany; [Kschischo, M.] Univ Appl Sci Koblenz, Dept Math & Technol, Remagen, Germany	University of Gottingen; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; University of Gottingen	Bastians, H (corresponding author), Univ Gottingen, Sect Cellular Oncol, Gottingen Ctr Mol Biosci GZMB, Grisebachstr 8, D-37073 Gottingen, Germany.	holger.bastians@uni-goettingen.de	Braus, Gerhard/ABC-6293-2021; Braus, Gerhard H/G-3999-2012	Braus, Gerhard/0000-0002-3117-5626; Braus, Gerhard H/0000-0002-3117-5626	Deutsche Forschungsgemeinschaft; DFG	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); DFG(German Research Foundation (DFG))	We thank Linda Wordeman, Sigrid Hoyer-Fender, Bert Vogelstein, Ingrid Hoffmann and Olaf Stemmann for materials and Heike Krebber for microscopy support. We thank Dennis Vollweiter and Eric Schoger for general lab support. We thank the TCGA Research Network (http://cancergenome.nih.gov/) for the open access of gene expression data. This work was supported by the Deutsche Forschungsgemeinschaft (HB and GHB) and by a DFG funded Heisenberg professorship awarded to HB.	Brouhard GJ, 2008, CELL, V132, P79, DOI 10.1016/j.cell.2007.11.043; Burrell RA, 2013, NATURE, V494, P492, DOI 10.1038/nature11935; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Derry WB, 1998, CANCER RES, V58, P1177; Ertych N, 2014, NAT CELL BIOL, V16, P779, DOI 10.1038/ncb2994; Gregan J, 2011, TRENDS CELL BIOL, V21, P374, DOI 10.1016/j.tcb.2011.01.003; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Joukov V, 2006, CELL, V127, P539, DOI 10.1016/j.cell.2006.08.053; Kais Z, 2008, CANCER BIOL THER, V7, P1540, DOI 10.4161/cbt.7.10.7053; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Oshimori N, 2006, NAT CELL BIOL, V8, P1095, DOI 10.1038/ncb1474; Oshimori N, 2009, EMBO J, V28, P2066, DOI 10.1038/emboj.2009.161; Pujana MA, 2007, NAT GENET, V39, P1338, DOI 10.1038/ng.2007.2; Sankaran S, 2007, CANCER RES, V67, P11186, DOI 10.1158/0008-5472.CAN-07-2578; Savage IK, 2014, FEBS J; Silver DP, 2012, CANCER DISCOV, V2, P679, DOI 10.1158/2159-8290.CD-12-0221; Starita LM, 2006, CANCER BIOL THER, V5, P137, DOI 10.4161/cbt.5.2.2479; Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004; Stecklein SR, 2012, P NATL ACAD SCI USA, V109, P13650, DOI 10.1073/pnas.1203326109; Stolz A, 2010, NAT CELL BIOL, V12, P492, DOI 10.1038/ncb2051; Stowe TR, 2012, MOL BIOL CELL, V23, P3322, DOI 10.1091/mbc.E12-02-0134; Weaver Z, 2002, ONCOGENE, V21, P5097, DOI 10.1038/sj.onc.1205636; Weichert W, 2008, LANCET ONCOL, V9, P139, DOI 10.1016/S1470-2045(08)70004-4; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zhang PL, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-14	28	15	16	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2016	35	18					2398	2406		10.1038/onc.2015.290	http://dx.doi.org/10.1038/onc.2015.290			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GL	26300001				2022-12-17	WOS:000376165000012
J	Sayadi, A; Jeyakani, J; Seet, SH; Wei, CL; Bourque, G; Bard, FA; Jenkins, NA; Copeland, NG; Bard-Chapeau, EA				Sayadi, A.; Jeyakani, J.; Seet, S. H.; Wei, C-L; Bourque, G.; Bard, F. A.; Jenkins, N. A.; Copeland, N. G.; Bard-Chapeau, E. A.			Functional features of EVI1 and EVI1 Delta 324 isoforms of MECOM gene in genome-wide transcription regulation and oncogenicity	ONCOGENE			English	Article							HOMOLOGOUS RECOMBINATION; MEIOTIC RECOMBINATION; MYELOID-LEUKEMIA; INTEGRATION SITE; BINDING-SITES; STEM-CELLS; OVARIAN; EXPRESSION; CHROMATIN; MOUSE	The MDS1 and ecotropic viral integration site 1 (EVI1) complex locus (MECOM) gene encodes several transcription factor variants including MDS1-EVI1, EVI1 and EVI1 Delta 324. Although MDS1-EVI1 has been associated with tumor-suppressing activity, EVI1 is a known oncogene in various cancers, whose expression is associated with poor patient survival. Although EVI1 Delta 324 is co-transcribed with EVI1, its activity in cancer cells is not fully understood. Previous reports described that unlike EVI1, EVI1 Delta 324 protein cannot transform fibroblasts because of its disrupted N-terminal zinc finger (ZNF) domain. To better understand EVI1 Delta 324 biology and function, we obtained genome-wide binding occupancies and expression data in ovarian cancer cells. We characterized its DNA-binding sites, binding motif and target genes. Comparative analyses with previous study show that EVI1 and EVI1 Delta 324 share similar transcriptional activities linked to their common C-terminus ZNF domain. They bind to an E-twenty-six family (ETS)-like motif, target to a large extent the same genes and cooperate with AP1 transcription factor. EVI1 Delta 324-occupied genes were 70.7% similar to EVI1-bound genes. More strikingly, EVI1 and EVI1 Delta 324 differentially expressed genes were 99.87% identical, indicating comparable transcriptional regulatory functions. Consistently with gene ontologies linked to these target genes, EVI1 Delta 324 expression in HeLa cells could enhance anchorage-independent growth, such as EVI1, showing that EVI1 Delta 324 expression also lead to pro-oncogenic effects. The main specific feature of EVI1 variant is its N-terminus ZNF domain that binds DNA through GATA-like motif. We found that most GATA-like EVI1 chromatin immunoprecipitation sequencing peaks are far from genes and are not involved in transcriptional regulation. These genomic regions were enriched in simple sequence repeats and displayed high meiotic recombination rates. Overall, our genomics analyses uncovered common and specific features of two major MECOM isoforms. Their influence on transcription and downstream cell proliferation was comparable. However, EVI1-specific GATA-like binding sites, from its N-terminus ZNF domain, associated with high recombination rates, suggesting possible additional oncogenic potential for EVI1 in modulating genomic stability.	[Sayadi, A.; Seet, S. H.; Bard, F. A.; Jenkins, N. A.; Copeland, N. G.; Bard-Chapeau, E. A.] Natl Univ Singapore, Inst Mol & Cell Biol, 10 Kent Ridge Crescent, Singapore 117548, Singapore; [Jeyakani, J.; Wei, C-L; Bourque, G.] Genome Inst Singapore, Singapore, Singapore; [Bard-Chapeau, E. A.] Novartis Inst Biomed Res, WKL 125-1-05A, CH-4002 Basel, Switzerland; [Jenkins, N. A.; Copeland, N. G.] Methodist Hosp Res Inst, Houston, TX USA	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Novartis; The Methodist Hospital System; The Methodist Hospital - Houston; The Methodist Hospital Research Institute	Bard-Chapeau, EA (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, 10 Kent Ridge Crescent, Singapore 117548, Singapore.; Bard-Chapeau, EA (corresponding author), Novartis Inst Biomed Res, WKL 125-1-05A, CH-4002 Basel, Switzerland.	emilie.chapeau@novartis.com	Bourque, Guillaume/AFR-2927-2022; Bard, Frederic Andre Jean/G-9914-2011	Bourque, Guillaume/0000-0002-3933-9656; Bard, Frederic Andre Jean/0000-0002-3783-4805	Agency for Science, Technology and Research (Singapore)	Agency for Science, Technology and Research (Singapore)(Agency for Science Technology & Research (A*STAR))	This work was supported by the Agency for Science, Technology and Research (Singapore). We thank Archibald Perkins, University of Rochester, for sharing his mouse Evi1 antibodies.	Aytekin M, 2005, GENE, V356, P160, DOI 10.1016/j.gene.2005.04.032; Bard-Chapeau EA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089397; Bard-Chapeau EA, 2013, P NATL ACAD SCI USA, V110, pE2885, DOI 10.1073/pnas.1309310110; Bard-Chapeau EA, 2012, P NATL ACAD SCI USA, V109, P2168, DOI 10.1073/pnas.1119229109; BARTHOLOMEW C, 1994, ONCOGENE, V9, P939; Baudat F, 2010, SCIENCE, V327, P836, DOI 10.1126/science.1183439; Bonome T, 2008, CANCER RES, V68, P5478, DOI 10.1158/0008-5472.CAN-07-6595; BORDEREAUX D, 1990, ONCOGENE, V5, P925; BORUM K, 1961, EXP CELL RES, V24, P495, DOI 10.1016/0014-4827(61)90449-9; Bouma GJ, 2007, GENE EXPR PATTERNS, V7, P113, DOI 10.1016/j.modgep.2006.05.011; Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; Brooks DJ, 1996, BRIT J CANCER, V74, P1518, DOI 10.1038/bjc.1996.583; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Dutta P, 2013, MOL ONCOL, V7, P647, DOI 10.1016/j.molonc.2013.02.008; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; Fog CK, 2012, BIOESSAYS, V34, P50, DOI 10.1002/bies.201100107; Fujiwara T, 2009, MOL CELL, V36, P667, DOI 10.1016/j.molcel.2009.11.001; Goyama S, 2008, CELL STEM CELL, V3, P207, DOI 10.1016/j.stem.2008.06.002; Goyama S, 2010, INT J HEMATOL, V91, P753, DOI 10.1007/s12185-010-0618-5; Goyama S, 2009, CANCER SCI, V100, P990, DOI 10.1111/j.1349-7006.2009.01152.x; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heyer WD, 2010, ANNU REV GENET, V44, P113, DOI 10.1146/annurev-genet-051710-150955; Hirai H, 2001, CANCER CHEMOTH PHARM, V48, pS35, DOI 10.1007/s002800100303; Hohenauer T, 2012, DEVELOPMENT, V139, P2267, DOI 10.1242/dev.070110; Hoyt PR, 1997, MECH DEVELOP, V65, P55, DOI 10.1016/S0925-4773(97)00057-9; Janz C, 2002, ONCOGENE, V21, P5929, DOI 10.1038/sj.onc.1205757; Jazaeri AA, 2010, GYNECOL ONCOL, V118, P189, DOI 10.1016/j.ygyno.2010.04.007; Ji HK, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl803; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Karakaya K, 2012, CELL CYCLE, V11, P3492, DOI 10.4161/cc.21801; Kilbey A, 1998, ONCOGENE, V16, P2287, DOI 10.1038/sj.onc.1201732; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Lugthart S, 2008, BLOOD, V111, P4329, DOI 10.1182/blood-2007-10-119230; Medina-Rivera A, 2011, NUCLEIC ACIDS RES, V39, P808, DOI 10.1093/nar/gkq710; Metais JY, 2008, MOL THER, V16, P439, DOI 10.1038/sj.mt.6300372; Mitani K, 2004, ONCOGENE, V23, P4263, DOI 10.1038/sj.onc.1207777; Mok SC, 2009, CANCER CELL, V16, P521, DOI 10.1016/j.ccr.2009.10.018; MORISHITA K, 1990, ONCOGENE, V5, P963; Mullan PB, 2006, ONCOGENE, V25, P5854, DOI 10.1038/sj.onc.1209872; Namekawa SH, 2006, CURR BIOL, V16, P660, DOI 10.1016/j.cub.2006.01.066; Nanjundan M, 2007, CANCER RES, V67, P3074, DOI 10.1158/0008-5472.CAN-06-2366; Nicolas A, 1998, P NATL ACAD SCI USA, V95, P87, DOI 10.1073/pnas.95.1.87; Nucifora G, 2006, GENE, V368, P1, DOI 10.1016/j.gene.2005.09.020; Ogawa S, 1996, LEUKEMIA, V10, P788; Palmer S, 2001, J BIOL CHEM, V276, P25834, DOI 10.1074/jbc.M102343200; Parvanov ED, 2010, SCIENCE, V327, P835, DOI 10.1126/science.1181495; Pavesi G, 2006, NUCLEIC ACIDS RES, V34, pW566, DOI 10.1093/nar/gkl285; Schultz N, 2003, P NATL ACAD SCI USA, V100, P12201, DOI 10.1073/pnas.1635054100; Segurel L, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001211; SPEED RM, 1982, CHROMOSOMA, V85, P427, DOI 10.1007/BF00330366; Stein S, 2010, NAT MED, V16, P198, DOI 10.1038/nm.2088; Sunde JS, 2006, CANCER RES, V66, P8404, DOI 10.1158/0008-5472.CAN-06-0683; Tan FJ, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002633; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; Turatsinze JV, 2008, NAT PROTOC, V3, P1578, DOI 10.1038/nprot.2008.97; Wei GH, 2010, EMBO J, V29, P2147, DOI 10.1038/emboj.2010.106; Wieser R, 2007, GENE, V396, P346, DOI 10.1016/j.gene.2007.04.012; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; Wu S, 2007, NAT STRUCT MOL BIOL, V14, P1165, DOI 10.1038/nsmb1332; Xia WL, 2007, J ENDOCRINOL, V192, P563, DOI 10.1677/JOE-06-0158; Yanowitz J, 2010, CURR OPIN CELL BIOL, V22, P744, DOI 10.1016/j.ceb.2010.08.016; Yatsula B, 2005, J BIOL CHEM, V280, P30712, DOI 10.1074/jbc.M504293200; Yoshimi A, 2011, ONCOTARGET, V2, P575, DOI 10.18632/oncotarget.304; Yuan JS, 2010, FEBS LETT, V584, P3717, DOI 10.1016/j.febslet.2010.05.021; Yuasa H, 2005, EMBO J, V24, P1976, DOI 10.1038/sj.emboj.7600679; Zaprazna K, 2012, MOL CELL BIOL, V32, P1542, DOI 10.1128/MCB.05989-11; Zhang Y, 2011, BLOOD, V118, P3853, DOI 10.1182/blood-2011-02-334680; Zhou LY, 2014, EXP THER MED, V8, P85, DOI 10.3892/etm.2014.1716	71	15	15	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2016	35	18					2311	2321		10.1038/onc.2015.286	http://dx.doi.org/10.1038/onc.2015.286			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GL	26234679	Bronze			2022-12-17	WOS:000376165000004
J	Seoane, S; Montero, JC; Ocana, A; Pandiella, A				Seoane, S.; Montero, J. C.; Ocana, A.; Pandiella, A.			Breast cancer dissemination promoted by a neuregulin-collagenase 3 signalling node	ONCOGENE			English	Article							ADJUVANT TRASTUZUMAB; BINDING-SITES; EXPRESSION; METASTASIS; RECEPTORS; HEREGULIN; CELL; DIFFERENTIATION; TUMORIGENICITY; ACTIVATION	Advances in the treatment of breast cancer have resulted in increased survival. However, in the metastatic setting, the disease remains incurable. Therefore, understanding of the mechanisms that promote dissemination of breast cancer cells may favor the development of novel therapeutic strategies to fight those tumors. Here, we show that the ErbB ligands, Neuregulins (NRGs), promote metastatic dissemination of breast cancer cells by switching on a kinase-metalloproteinase network. Clinicopathological analyses demonstrated that NRG expression in breast tumors associated to lymph node invasion and poor patient outcome. Preclinical in vivo analyses showed that NRG expression favored in situ tumor growth, local spreading and metastatic dissemination. Genomic, biochemical and functional studies identified matrix metalloproteinases, particularly stromelysin 2 and collagenase 3, as key mediators of the NRG-induced dissemination properties of breast cancer cells. Mechanistic analyses demonstrated that NRG augmented metalloproteinase expression through a route controlled by ERK1/2 kinases. ERK1/2 increased collagenase 3 expression by controlling the activity of an SBF1-related transcription factor. In conclusion, we describe a pathway linked to breast cancer dissemination. The clinical availability of agents that target some of the components of this signalling pathway suggests that patients with tumors fed by NRGs or other factors able to activate the ERK-Collagenase 3 route may benefit from agents that act on that signalling axis.	[Seoane, S.; Montero, J. C.; Pandiella, A.] Univ Salamanca, Inst Biol Mol & Celular Canc, CSIC, CIC Campus Miguel de Unamuno,Ave Univ Coimbra, Salamanca 37007, Spain; [Ocana, A.] Complejo Hosp Univ Albacete, Med Oncol Serv, Albcete, Spain; AECC Unit, Albcete, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Pandiella, A (corresponding author), Univ Salamanca, Inst Biol Mol & Celular Canc, CSIC, CIC Campus Miguel de Unamuno,Ave Univ Coimbra, Salamanca 37007, Spain.	atanasio@usal.es	Pandiella, Atanasio/O-5180-2014; Seoane, Samuel/H-6299-2015; Montero, Juan Carlos/AAO-1780-2020	Pandiella, Atanasio/0000-0002-4704-8971; Seoane, Samuel/0000-0002-9178-0887; Montero, Juan Carlos/0000-0003-4773-053X; Ocana, Alberto/0000-0002-1067-9630	Instituto de Salud Carlos III through Spanish Cancer Centers Network Program [RD06/0020/0041, RD12/0036/0003]; Juan de la Cierva contract; Miguel Servet fellowship program	Instituto de Salud Carlos III through Spanish Cancer Centers Network Program; Juan de la Cierva contract; Miguel Servet fellowship program	Ministry of Economy and Competitiveness of Spain (BFU2009-07728 and BFU2012-39151), the Instituto de Salud Carlos III through the Spanish Cancer Centers Network Program (RD06/0020/0041 and RD12/0036/0003) and the Scientific Foundation of the Spanish Association Against Cancer (AECC). SSR was supported by a Juan de la Cierva contract. JCM is a recipient of a Miguel Servet fellowship program.	Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Atlas E, 2003, MOL CANCER RES, V1, P165; Cabrera N, 1996, J CELL BIOL, V132, P427, DOI 10.1083/jcb.132.3.427; Dawson SJ, 2013, EMBO J, V32, P617, DOI 10.1038/emboj.2013.19; de Alava E, 2007, J CLIN ONCOL, V25, P2656, DOI 10.1200/JCO.2006.08.6850; Diaz-Rodriguez E, 2002, MOL BIOL CELL, V13, P2031, DOI 10.1091/mbc.01-11-0561; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kiran U, 2012, BIOINFORMATION, V8, P886, DOI 10.6026/97320630008886; Krane IM, 1996, ONCOGENE, V12, P1781; Kumler I, 2014, CANCER TREAT REV, V40, P259, DOI 10.1016/j.ctrv.2013.09.002; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; LAWTON MA, 1991, PLANT MOL BIOL, V16, P235, DOI 10.1007/BF00020555; Lee CYF, 2014, CANCER RES, V74, P341, DOI 10.1158/0008-5472.CAN-13-1055; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Montero JC, 2014, ONCOGENE, V33, P148, DOI 10.1038/onc.2012.572; Montero JC, 2000, MOL CELL NEUROSCI, V16, P631, DOI 10.1006/mcne.2000.0896; Montero JC, 2007, MOL BIOL CELL, V18, P380, DOI 10.1091/mbc.E06-06-0511; Montero JC, 2008, CLIN CANCER RES, V14, P3237, DOI 10.1158/1078-0432.CCR-07-5133; Morrison C, 2011, J BIOL CHEM, V286, P34271, DOI 10.1074/jbc.M111.222513; Ocana A, 2013, CURR PHARM DESIGN, V19, P808, DOI 10.2174/138161213804547303; Paik S, 2008, NEW ENGL J MED, V358, P1409, DOI 10.1056/NEJMc0801440; Perez EA, 2010, J CLIN ONCOL, V28, P4307, DOI 10.1200/JCO.2009.26.2154; Phillips GDL, 2014, CLIN CANCER RES, V20, P456, DOI 10.1158/1078-0432.CCR-13-0358; Pivetta E, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3047; Revillion F, 2008, ANN ONCOL, V19, P73, DOI 10.1093/annonc/mdm431; Roy R, 2009, J CLIN ONCOL, V27, P5287, DOI 10.1200/JCO.2009.23.5556; Seoane S, 2010, JNCI-J NATL CANCER I, V102, P1432, DOI 10.1093/jnci/djq315; Shah M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029615; Shames DS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056765; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Tsai MS, 2003, ONCOGENE, V22, P761, DOI 10.1038/sj.onc.1206130; Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007; Yuste L, 2005, CANCER RES, V65, P6801, DOI 10.1158/0008-5472.CAN-04-4023; Zhang B, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-83; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017	41	15	15	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2016	35	21					2756	2765		10.1038/onc.2015.337	http://dx.doi.org/10.1038/onc.2015.337			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MJ	26364598				2022-12-17	WOS:000377472700009
J	Lee, CK; Yang, Y; Chen, C; Liu, J				Lee, C. K.; Yang, Y.; Chen, C.; Liu, J.			Syk-mediated tyrosine phosphorylation of mule promotes TNF-induced JNK activation and cell death	ONCOGENE			English	Article							NF-KAPPA-B; ARF TUMOR-SUPPRESSOR; E3 UBIQUITIN LIGASE; RECEPTOR GAMMA-CHAIN; DNA-DAMAGE; PROTEIN-KINASE; JUN KINASES; APOPTOSIS; MIZ1; P53	The transcription factor Miz1 negatively regulates TNF-induced JNK activation and cell death by suppressing TRAF2 K63-polyubiquitination; upon TNF stimulation, the suppression is relieved by Mule/ARF-BP1-mediated Miz1 ubiquitination and subsequent degradation. It is not known how Mule is activated by TNF. Here we report that TNF activates Mule by inducing the dissociation of Mule from its inhibitor ARF. ARF binds to and thereby inhibits the E3 ligase activity of Mule in the steady state. TNF induces tyrosine phosphorylation of Mule, which subsequently dissociates from ARF and becomes activated. Inhibition of Mule phosphorylation by silencing of the Spleen Tyrosine Kinase (Syk) prevents its dissociation from ARF, thereby inhibiting Mule E3 ligase activity and TNF-induced JNK activation and cell death. Our data provides a missing link in TNF signaling pathway that leads to JNK activation and cell death.	[Lee, C. K.; Chen, C.; Liu, J.] Northwestern Univ, Feinberg Sch Med, Div Pulm & Crit Care Med, McGaw Pavil Suite M-300,240 E Huron, Chicago, IL 60611 USA; [Yang, Y.] Fudan Univ, Inst Biomed Sci, Shanghai 200433, Peoples R China	Northwestern University; Feinberg School of Medicine; Fudan University	Liu, J (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Pulm & Crit Care Med, McGaw Pavil Suite M-300,240 E Huron, Chicago, IL 60611 USA.	jing@northwestern.edu			National Institutes of Health [GM081603-03, HL114763-01A1]; Lung Science Training Program [2T32HL076139-11A1]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL114763, T32HL076139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM081603] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Lung Science Training Program; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Anning Lin (University of Chicago) for valuable reagents that made this work possible. We thank Jie Yan (University of Chicago), Hong Kuang (Northwestern University) and Chi Do (Northwestern University) for excellent technical assistance. This work was partially supported by National Institutes of Health (GM081603-03, HL114763-01A1) (JL), and the Lung Science Training Program (2T32HL076139-11A1) (CL).	Abida WM, 2008, CANCER RES, V68, P352, DOI 10.1158/0008-5472.CAN-07-2069; Adhikary S, 2005, CELL, V123, P409, DOI 10.1016/j.cell.2005.08.016; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Cheng PL, 2011, NEURON, V69, P231, DOI 10.1016/j.neuron.2010.12.021; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Do-Umehara HC, 2013, NAT IMMUNOL, V14, P461, DOI 10.1038/ni.2566; Gallagher E, 2006, P NATL ACAD SCI USA, V103, P1717, DOI 10.1073/pnas.0510664103; Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414; GU J, 1994, MOL BRAIN RES, V24, P77, DOI 10.1016/0169-328X(94)90120-1; GU J, 1995, ONCOGENE, V11, P2175; Hall JR, 2007, MOL BIOL CELL, V18, P3340, DOI 10.1091/mbc.E07-02-0173; Herold S, 2008, EMBO J, V27, P2851, DOI 10.1038/emboj.2008.200; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Inoue S, 2013, GENE DEV, V27, P1101, DOI 10.1101/gad.214577.113; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; Kosan C, 2010, IMMUNITY, V33, P917, DOI 10.1016/j.immuni.2010.11.028; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu J, 2004, MOL CELL BIOL, V24, P10844, DOI 10.1128/MCB.24.24.10844-10856.2004; Liu J, 2006, MOL CELL, V21, P467, DOI 10.1016/j.molcel.2005.12.020; Liu J, 2012, P NATL ACAD SCI USA, V109, P191, DOI 10.1073/pnas.1105176108; Liu J, 2009, P NATL ACAD SCI USA, V106, P18279, DOI 10.1073/pnas.0906328106; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Liu ZQ, 2005, MOL CELL BIOL, V25, P2819, DOI 10.1128/MCB.25.7.2819-2831.2005; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Mocsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101; Mocsai A, 2002, IMMUNITY, V16, P547, DOI 10.1016/S1074-7613(02)00303-5; Mocsai A, 2006, NAT IMMUNOL, V7, P1326, DOI 10.1038/ni1407; Noy T, 2012, BIOCHEM BIOPH RES CO, V418, P408, DOI 10.1016/j.bbrc.2012.01.045; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; Parsons JL, 2009, EMBO J, V28, P3207, DOI 10.1038/emboj.2009.243; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Reef S, 2006, MOL CELL, V22, P463, DOI 10.1016/j.molcel.2006.04.014; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Rotin D, 2009, NAT REV MOL CELL BIO, V10, P398, DOI 10.1038/nrm2690; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Tada K, 2001, J BIOL CHEM, V276, P36530, DOI 10.1074/jbc.M104837200; Takada Y, 2004, J IMMUNOL, V173, P1066, DOI 10.4049/jimmunol.173.2.1066; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Vines CM, 2001, IMMUNITY, V15, P507, DOI 10.1016/S1074-7613(01)00221-7; Wanzel M, 2005, NAT CELL BIOL, V7, P30, DOI 10.1038/ncb1202; Yang Y, 2010, P NATL ACAD SCI USA, V107, P13444, DOI 10.1073/pnas.0913690107; Yeh KW, 1997, PLANT MOL BIOL, V33, P565, DOI 10.1023/A:1005764702510; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009	54	15	15	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2016	35	15					1988	1995		10.1038/onc.2015.275	http://dx.doi.org/10.1038/onc.2015.275			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ2CC	26212014	Green Accepted			2022-12-17	WOS:000374010300011
J	Wang, JY; Chen, SY; Sun, CN; Chien, T; Chern, Y				Wang, J-Y; Chen, S-Y; Sun, C-N; Chien, T.; Chern, Y.			A central role of TRAX in the ATM-mediated DNA repair	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; FACTOR-X TRAX; A(2A) ADENOSINE RECEPTOR; SUPPRESSES TUMOR-GROWTH; KINESIN FAMILY-MEMBER; INDUCED CELL-DEATH; MRN COMPLEX; MRE11-RAD50-NBS1 COMPLEX; SACCHAROMYCES-CEREVISIAE; DAMAGE RESPONSE	DNA repair is critical for the maintenance of genome stability. Upon genotoxic stress, dysregulated DNA repair may induce apoptosis. Translin-associated factor X (TRAX), which was initially identified as a binding partner of Translin, has been implicated in genome stability. However, the exact role of TRAX in DNA repair remains largely unknown. Here, we showed that TRAX participates in the ATM/H2AX-mediated DNA repair machinery by interacting with ATM and stabilizing the MRN complex at double-strand breaks. The exogenous expression of wild-type (WT) TRAX, but not a TRAX variant lacking the nuclear localization signal (NLS), rescued the vulnerability of TRAX-null mouse embryo fibroblasts (MEFs). This finding confirms the importance of the nuclear localization of TRAX in the repair of DNA damage. Compared with WT MEFs, TRAX-null MEFs exhibited impaired DNA repair (for example, reduced phosphorylation of ATM and H2AX) after treatment with ultra violet-C or.-ray irradiation and a higher incidence of p53-mediated apoptosis. Our findings demonstrate that TRAX is required for MRN complex-ATM-H2AX signaling, which optimizes DNA repair by interacting with the activated ATM and protects cells from genotoxic stress-induced apoptosis.	[Wang, J-Y] Kaohsiung Med Univ, Sch Med, Dept Neurol, Coll Med, Kaohsiung, Taiwan; [Wang, J-Y; Chen, S-Y; Sun, C-N; Chern, Y.] Acad Sinica, Inst Biomed Sci, Neurosci Div, N333 IBMS, Taipei 115, Taiwan; [Chien, T.; Chern, Y.] Natl Def Med Ctr, Inst Life Sci, Taipei, Taiwan	Kaohsiung Medical University; Academia Sinica - Taiwan; National Defense Medical Center	Chern, Y (corresponding author), Acad Sinica, Inst Biomed Sci, Neurosci Div, N333 IBMS, Taipei 115, Taiwan.	bmychern@ibms.sinica.edu.tw	chern, yijuang/S-7013-2018	chern, yijuang/0000-0002-5842-5429	Ministrant of Technology and Science of Taiwan [NSC96-2321-B-001-015, NSC97-2321-B-001-012, 100-2320-B-001-0110MY3]; Institute of Biomedical Sciences of Academia Sinica; Kaohsiung Medical University [KMU-Q102011]	Ministrant of Technology and Science of Taiwan; Institute of Biomedical Sciences of Academia Sinica(Academia Sinica - Taiwan); Kaohsiung Medical University	We thank Hsing-Lin Lai and Shuyung Chang for technical support. This work was supported by grants from the Ministrant of Technology and Science of Taiwan (NSC96-2321-B-001-015, NSC97-2321-B-001-012 and 100-2320-B-001-0110MY3 to YC), the Institute of Biomedical Sciences of Academia Sinica (to YC) and the Kaohsiung Medical University (KMU-Q102011 to J-YW).	Aisiku OR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015001; AJIMURA M, 1993, GENETICS, V133, P51; Amano T, 2009, J NEURO-ONCOL, V92, P357, DOI 10.1007/s11060-009-9844-1; Aoki K, 1997, FEBS LETT, V401, P109, DOI 10.1016/S0014-5793(96)01444-5; AOKI K, 1995, NAT GENET, V10, P167, DOI 10.1038/ng0695-167; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bray JD, 2004, MOL REPROD DEV, V69, P387, DOI 10.1002/mrd.20171; Bray JD, 2002, GENOMICS, V79, P799, DOI 10.1006/geno.2002.6779; Chalk JG, 1997, ONCOGENE, V15, P1199, DOI 10.1038/sj.onc.1201285; Chen SH, 2007, MOL BIOL CELL, V18, P2525, DOI 10.1091/mbc.e07-02-0188; Chen WSV, 2003, METHOD ENZYMOL, V365, P367; Chennathukuzhi VM, 2001, J BIOL CHEM, V276, P13256, DOI 10.1074/jbc.M009707200; Colton SL, 2006, J BIOL CHEM, V281, P27117, DOI 10.1074/jbc.M602826200; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Delmas S, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000552; Devon RS, 2000, MAMM GENOME, V11, P395, DOI 10.1007/s003350010074; Dupre A, 2008, NAT CHEM BIOL, V4, P119, DOI 10.1038/nchembio.63; Erdemir T, 2002, MOL MICROBIOL, V46, P947, DOI 10.1046/j.1365-2958.2002.03224.x; Erdemir T, 2002, J CELL SCI, V115, P207; GAME JC, 1974, MUTAT RES, V24, P281, DOI 10.1016/0165-1218(74)90185-2; Hakem R, 2008, EMBO J, V27, P589, DOI 10.1038/emboj.2008.15; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Hong SH, 2012, ONCOL REP, V27, P1251, DOI 10.3892/or.2012.1641; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Kaina B, 2003, BIOCHEM PHARMACOL, V66, P1547, DOI 10.1016/S0006-2952(03)00510-0; Kerzendorfer C, 2009, DNA REPAIR, V8, P1139, DOI 10.1016/j.dnarep.2009.04.018; Kim GD, 1999, J BIOL CHEM, V274, P31127, DOI 10.1074/jbc.274.44.31127; Lamarche BJ, 2010, FEBS LETT, V584, P3682, DOI 10.1016/j.febslet.2010.07.029; Lavin MF, 2007, CELL CYCLE, V6, P931, DOI 10.4161/cc.6.8.4180; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lee JH, 2010, EMBO J, V29, P574, DOI 10.1038/emboj.2009.372; Li Z, 2008, BBA-GENE REGUL MECH, V1779, P479, DOI 10.1016/j.bbagrm.2008.03.008; LIMOLI CL, 1993, RADIAT RES, V134, P160, DOI 10.2307/3578455; Limoli CL, 2002, P NATL ACAD SCI USA, V99, P233, DOI 10.1073/pnas.231611798; Liu Y, 2009, SCIENCE, V325, P750, DOI 10.1126/science.1176325; Malmlof M, 2007, J BIOL CHEM, V282, P2288, DOI 10.1074/jbc.M604953200; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meng G, 2000, J HUM GENET, V45, P305, DOI 10.1007/s100380070022; Mochan TA, 2004, DNA REPAIR, V3, P945, DOI 10.1016/j.dnarep.2004.03.017; Mochan TA, 2003, CANCER RES, V63, P8586; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Pabla N, 2008, J BIOL CHEM, V283, P6572, DOI 10.1074/jbc.M707568200; Robison JG, 2007, CELL CYCLE, V6, P2408, DOI 10.4161/cc.6.19.4773; Roos WP, 2006, TRENDS MOL MED, V12, P440, DOI 10.1016/j.molmed.2006.07.007; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Schroer U, 2007, EUR J NEUROSCI, V26, P2169, DOI 10.1111/j.1460-9568.2007.05849.x; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Sun CN, 2006, MOL PHARMACOL, V70, P454, DOI 10.1124/mol.105.021261; Sun CN, 2010, DEV NEUROBIOL, V70, P604, DOI 10.1002/dneu.20802; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; van den Bosch M, 2003, EMBO REP, V4, P844, DOI 10.1038/sj.embor.embor925; Warmerdam DO, 2010, MUTAT RES-REV MUTAT, V704, P2, DOI 10.1016/j.mrrev.2009.12.001; Wu YC, 2011, J NEUROCHEM, V116, P1112, DOI 10.1111/j.1471-4159.2010.07166.x; Xu M, 2004, INT J HYPERTHER, V20, P157, DOI 10.1080/02656730310001625986; Yajima H, 2009, J MOL BIOL, V385, P800, DOI 10.1016/j.jmb.2008.11.036; Yang L, 2004, WORLD J GASTROENTERO, V10, P155; Yavuzer U, 1998, GENE DEV, V12, P2188, DOI 10.1101/gad.12.14.2188; Ye XC, 2011, NAT STRUCT MOL BIOL, V18, P650, DOI 10.1038/nsmb.2032; Yuan JS, 2010, FEBS LETT, V584, P3717, DOI 10.1016/j.febslet.2010.05.021; Zgheib O, 2005, RADIOTHER ONCOL, V76, P119, DOI 10.1016/j.radonc.2005.06.026; Zhao X, 2008, J VIROL, V82, P5316, DOI 10.1128/JVI.02677-07; Zheng L, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh110; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	66	15	15	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2016	35	13					1657	1670		10.1038/onc.2015.228	http://dx.doi.org/10.1038/onc.2015.228			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RP	26096928				2022-12-17	WOS:000373064200005
J	Yu, J; Wu, WKK; Liang, Q; Zhang, N; He, J; Li, X; Zhang, X; Xu, L; Chan, MTV; Ng, SSM; Sung, JJY				Yu, J.; Wu, W. K. K.; Liang, Q.; Zhang, N.; He, J.; Li, X.; Zhang, X.; Xu, L.; Chan, M. T. V.; Ng, S. S. M.; Sung, J. J. Y.			Disruption of NCOA2 by recurrent fusion with LACTB2 in colorectal cancer	ONCOGENE			English	Article							COLON-CANCER; TRANSCRIPTIONAL COACTIVATOR; DEPENDENT ACTIVATION; NUCLEAR RECEPTORS; GENE FUSION; GRIP1; TIF2; DIFFERENTIATION; DISCOVERY; LEUKEMIA	Whole-genome and transcriptome sequencing were used to discover novel gene fusions in a case of colon cancer. A tumor-specific LACTB2-NCOA2 fusion originating from intra-chromosomal rearrangement of chromosome 8 was identified at both DNA and RNA levels. Unlike conventional oncogenic chimeric proteins, the fusion product lacks functional domain from respective genes, indicative of an amorphic rearrangement. This chimeric LACTB2-NCOA2 transcript was detected in 6 out of 99 (6.1%) colorectal cancer (CRC) cases, where NCOA2 was significantly downregulated. Enforced expression of wild-type NCOA2 but not the LACTB2-NCOA2 fusion protein impaired the pro-tumorigenic phenotypes of CRC cells, whereas knockdown of endogenous NCOA2 in normal colonocytes had opposite effects. Mechanistically, NCOA2 inhibited Wnt/beta-catenin signaling through simultaneously upregulating inhibitors and downregulating stimulators of Wnt/beta-catenin pathway. Collectively, our data supports that NCOA2 is a novel negative growth regulatory gene repressing the Wnt/beta-catenin pathway in CRC, where recurrent fusion with LACTB2 contributes to its disruption.	[Yu, J.; Wu, W. K. K.; Liang, Q.; Zhang, N.; He, J.; Li, X.; Zhang, X.; Xu, L.; Sung, J. J. Y.] Chinese Univ Hong Kong, Prince Wales Hosp, State Key Lab Digest Dis,Shenzhen Res Inst, Inst Digest Dis,Dept Med & Therapeut,Li Ka Shing, Shatin, Hong Kong, Peoples R China; [Wu, W. K. K.; Chan, M. T. V.] Chinese Univ Hong Kong, Dept Anaesthesia & Intens Care, Shatin, Hong Kong, Peoples R China; [Zhang, N.] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastroenterol, Guangzhou 510275, Guangdong, Peoples R China; [Ng, S. S. M.] Chinese Univ Hong Kong, Dept Surg, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Sun Yat Sen University; Chinese University of Hong Kong	Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, State Key Lab Digest Dis,Shenzhen Res Inst, Inst Digest Dis,Dept Med & Therapeut,Li Ka Shing, Room 707A,7-F,Li Ka Shing Med Sci Bldg, Shatin, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	Li, Xiao-xing/B-9114-2008; Liang, Qiaoyi Jessie/G-9612-2019; Chan, Matthew/J-2884-2013; Wu, William K.K./A-3277-2009; Yu, Jun/D-8569-2015; Ng, Simon S. M./M-1219-2018; Sung, Joseph J. Y./R-3203-2018; ZHANG, Xiang/N-7918-2015	Li, Xiao-xing/0000-0001-8791-7505; Liang, Qiaoyi Jessie/0000-0001-8496-3442; Chan, Matthew/0000-0002-3574-7855; Wu, William K.K./0000-0002-5662-5240; Yu, Jun/0000-0001-5008-2153; Ng, Simon S. M./0000-0002-5389-9297; Sung, Joseph J. Y./0000-0003-3125-5199; ZHANG, Xiang/0000-0002-3222-5824	Shenzhen Municipal Science and Technology RD fund [JCYJ20120619152326450]; Shenzhen Technology and Innovation Project Fund [JSGG20130412171021059]; 863 Program China [2012AA02A506]; 973 Program China [2013CB531401]; Theme-based Research Scheme of the Hong Kong Research Grants Council [T12-403-11]; Shenzhen Virtual University Park Support Scheme	Shenzhen Municipal Science and Technology RD fund; Shenzhen Technology and Innovation Project Fund; 863 Program China(National High Technology Research and Development Program of China); 973 Program China(National Basic Research Program of China); Theme-based Research Scheme of the Hong Kong Research Grants Council; Shenzhen Virtual University Park Support Scheme	Grant Support: The work was supported by Shenzhen Municipal Science and Technology R&D fund (JCYJ20120619152326450), the Shenzhen Technology and Innovation Project Fund (JSGG20130412171021059), 863 Program China (2012AA02A506), 973 Program China (2013CB531401), the Theme-based Research Scheme of the Hong Kong Research Grants Council (T12-403-11) and the Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute.	Aguilera O, 2007, CARCINOGENESIS, V28, P1877, DOI 10.1093/carcin/bgm094; Akiva P, 2006, GENOME RES, V16, P30, DOI 10.1101/gr.4137606; Annala MJ, 2013, CANCER LETT, V340, P192, DOI 10.1016/j.canlet.2013.01.011; Arbajian E, 2013, GENE CHROMOSOME CANC, V52, P330, DOI 10.1002/gcc.22033; Bass AJ, 2011, NAT GENET, V43, P964, DOI 10.1038/ng.936; Blackledge NP, 2010, MOL CELL, V38, P179, DOI 10.1016/j.molcel.2010.04.009; Bunting SF, 2013, NAT REV CANCER, V13, P443, DOI 10.1038/nrc3537; Carapeti M, 1998, BLOOD, V91, P3127, DOI 10.1182/blood.V91.9.3127.3127_3127_3133; D'Errico I, 2008, CELL MOL LIFE SCI, V65, P1523, DOI 10.1007/s00018-008-7552-1; Dib Amel, 2008, J Natl Cancer Inst Monogr, P25, DOI 10.1093/jncimonographs/lgn011; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Frenkel-Morgenstern M, 2012, GENOME RES, V22, P1231, DOI 10.1101/gr.130062.111; Gingeras TR, 2009, NATURE, V461, P206, DOI 10.1038/nature08452; Guo GW, 2013, NAT GENET, V45, P1459, DOI 10.1038/ng.2798; Herai RH, 2010, BRIEF BIOINFORM, V11, P198, DOI 10.1093/bib/bbp041; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kefalopoulou Z, 2012, J NEURO-ONCOL, V106, P23, DOI 10.1007/s11060-011-0637-y; Liang J, 1998, BLOOD, V92, P2118, DOI 10.1182/blood.V92.6.2118.418k09_2118_2122; Lipson D, 2012, NAT MED, V18, P382, DOI 10.1038/nm.2673; Maher CA, 2012, CELL, V148, P29, DOI 10.1016/j.cell.2012.01.006; Maher CA, 2009, P NATL ACAD SCI USA, V106, P12353, DOI 10.1073/pnas.0904720106; Malkova A, 2013, CURR OPIN GENET DEV, V23, P271, DOI 10.1016/j.gde.2013.05.007; Mulholland DJ, 2005, ENDOCR REV, V26, P898, DOI 10.1210/er.2003-0034; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nakayama R, 2012, PATHOL INT, V62, P823, DOI 10.1111/pin.12022; Nothwang HG, 2001, HUM MOL GENET, V10, P797, DOI 10.1093/hmg/10.8.797; Parker BC, 2013, J CLIN INVEST, V123, P855, DOI 10.1172/JCI67144; Quintas-Cardama A, 2009, BLOOD, V113, P1619, DOI 10.1182/blood-2008-03-144790; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; Strehl S, 2008, CLIN CANCER RES, V14, P977, DOI 10.1158/1078-0432.CCR-07-4022; Takeyama KI, 1999, MOL CELL BIOL, V19, P1049; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Walfish PG, 1997, P NATL ACAD SCI USA, V94, P3697, DOI 10.1073/pnas.94.8.3697; Wong SH, 2013, SEMIN CANCER BIOL, V23, P502, DOI 10.1016/j.semcancer.2013.09.005; Wu J, 2013, CANCER LETT, V329, P155, DOI 10.1016/j.canlet.2012.10.038; Wu WKK, 2013, CRIT REV ONCOL HEMAT, V86, P251, DOI 10.1016/j.critrevonc.2012.11.009; Xi YG, 2006, BIOMARK INSIGHTS, V1, P113; Yoshida H, 2014, ONCOGENE, V33, P5601, DOI 10.1038/onc.2013.491; Yu J, 2014, GUT	42	15	18	2	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2016	35	2					187	195		10.1038/onc.2015.72	http://dx.doi.org/10.1038/onc.2015.72			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB0JH	25823027	hybrid, Green Published			2022-12-17	WOS:000368193900005
J	George, SHL; Milea, A; Sowamber, R; Chehade, R; Tone, A; Shaw, PA				George, S. H. L.; Milea, A.; Sowamber, R.; Chehade, R.; Tone, A.; Shaw, P. A.			Loss of LKB1 and p53 synergizes to alter fallopian tube epithelial phenotype and high-grade serous tumorigenesis	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; INTRAEPITHELIAL CARCINOMA; CANCER; BRCA; SUPPRESSION; EXPRESSION; MUTATIONS; DIAGNOSIS; PATHWAYS; FEATURES	Liver kinase B1 (LKB1) is a tumor suppressor ubiquitously expressed serine/threonine protein kinase involved in energy metabolism and cellular polarity. In microarray experiments that compared normal tubal epithelium with high-grade serous carcinoma (HGSC), we observed a decrease in LKB1 mRNA expression in HGSC. In this study, we demonstrate that loss of cytoplasmic and nuclear LKB1 protein expression is frequently observed in tubal cancer precursor lesions as well as in both sporadic and hereditary HGSCs compared with other ovarian cancer histotypes. Bi-allelic genomic loss of LKB1 in HGSC did not account for the majority of cases with a decrease in protein expression. In vitro, shLKB1-fallopian tube epithelial (FTE) cells underwent premature cellular arrest and in ex vivo FTE culture, LKB1 loss and p53 mutant synergized to disrupt apical to basal polarity and decrease the number of ciliated cells. Overexpression of cyclin E1 allowed for bypass of LKB1-induced cellular arrest, and increased both proliferation and anchorage-independent growth of transformed FTE cells. These data suggest that LKB1 loss early in ovarian serous tumorigenesis has an integral role in tumor promotion by disrupting apical to basal polarity in the presence of mutated p53 in fallopian tube cells.	[George, S. H. L.; Milea, A.; Sowamber, R.; Chehade, R.; Tone, A.; Shaw, P. A.] Campbell Family Inst Breast Canc Res, Toronto, ON, Canada; [George, S. H. L.; Milea, A.; Sowamber, R.; Chehade, R.; Shaw, P. A.] Ontario Canc Inst, Toronto, ON M4X 1K9, Canada; [George, S. H. L.; Milea, A.; Sowamber, R.; Tone, A.; Shaw, P. A.] Univ Hlth Network, Dept Lab Med, Toronto, ON, Canada; [Chehade, R.; Tone, A.; Shaw, P. A.] Univ Toronto, Toronto, ON, Canada; [Shaw, P. A.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Shaw, PA (corresponding author), Toronto Gen Hosp, Dept Pathol, Eaton Wing,Room 11-444,200 Elizabeth St, Toronto, ON M5G 2C4, Canada.	patricia.shaw@uhn.ca	GEORGE, SOPHIA/AAZ-7443-2020	GEORGE, SOPHIA/0000-0003-1013-1883	CDMRP Ovarian Cancer program [W81WH-0701-0371]; Princess Margaret Cancer Centre Foundation	CDMRP Ovarian Cancer program; Princess Margaret Cancer Centre Foundation(University of Toronto)	We thank the UHN Cancer Biobank Core Laboratory for sample acquisition, the UHN Pathology Research Program for immunohistochemistry, Doug Holmyard at Mount Sinai Hospital for the SEM, as well as the Gynecological Oncologists at the Princess Margaret Cancer Centre. This study was funded by the CDMRP Ovarian Cancer program (W81WH-0701-0371) and the Princess Margaret Cancer Centre Foundation.	Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Carretero J, 2010, CANCER CELL, V17, P547, DOI 10.1016/j.ccr.2010.04.026; Chen EY, 2010, J PATHOL, V222, P110, DOI 10.1002/path.2739; Contreras CM, 2010, DIS MODEL MECH, V3, P181, DOI 10.1242/dmm.004440; George SHL, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00005; George SHL, 2012, CLIN CANCER RES, V18, P6199, DOI 10.1158/1078-0432.CCR-12-2155; George SHL, 2011, J PATHOL, V225, P106, DOI 10.1002/path.2927; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hezel AF, 2008, ONCOGENE, V27, P6908, DOI 10.1038/onc.2008.342; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Jarboe EA, 2008, HISTOPATHOLOGY, V53, P127, DOI 10.1111/j.1365-2559.2007.02938.x; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; Karst AM, 2014, CANCER RES, V74, P1141, DOI 10.1158/0008-5472.CAN-13-2247; Karst AM, 2012, NAT PROTOC, V7, P1755, DOI 10.1038/nprot.2012.097; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Kuhn E, 2012, J PATHOL, V226, P421, DOI 10.1002/path.3023; Kuo KT, 2009, CANCER RES, V69, P4036, DOI 10.1158/0008-5472.CAN-08-3913; Launonen V, 2005, HUM MUTAT, V26, P291, DOI 10.1002/humu.20222; Lee Y, 2007, J PATHOL, V211, P26, DOI 10.1002/path.2091; Levanon K, 2010, ONCOGENE, V29, P1103, DOI 10.1038/onc.2009.402; Matulonis UA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024433; May T, 2010, GYNECOL ONCOL, V117, P9, DOI 10.1016/j.ygyno.2010.01.006; McCarthy A, 2009, J PATHOL, V219, P306, DOI 10.1002/path.2599; Milea A, 2014, MODERN PATHOL, V27, P991, DOI 10.1038/modpathol.2013.218; Morton JP, 2010, GASTROENTEROLOGY, V139, P586, DOI 10.1053/j.gastro.2010.04.055; Ning G, 2013, INT J GYNECOL PATHOL, V32, P345, DOI 10.1097/PGP.0b013e31826feee2; Norquist BM, 2010, CANCER-AM CANCER SOC, V116, P5261, DOI 10.1002/cncr.25439; Partanen JI, 2012, P NATL ACAD SCI USA, V109, pE388, DOI 10.1073/pnas.1120421109; Partanen JI, 2009, CELL CYCLE, V8, P716, DOI 10.4161/cc.8.5.7786; Sehdev AS, 2010, MODERN PATHOL, V23, P844, DOI 10.1038/modpathol.2010.60; Shaw PA, 2009, MODERN PATHOL, V22, P1133, DOI 10.1038/modpathol.2009.89; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Tanwar PS, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002906; ten Klooster JP, 2009, DEV CELL, V16, P551, DOI 10.1016/j.devcel.2009.01.016; Tone AA, 2008, CLIN CANCER RES, V14, P4067, DOI 10.1158/1078-0432.CCR-07-4959; van Veelen W, 2011, ONCOGENE, V30, P2289, DOI 10.1038/onc.2010.630; Vang R, 2012, INT J GYNECOL PATHOL, V31, P243, DOI 10.1097/PGP.0b013e31823b8831; Visvanathan K, 2011, AM J SURG PATHOL, V35, P1766, DOI 10.1097/PAS.0b013e31822f58bc; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031	39	15	18	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2016	35	1					59	68		10.1038/onc.2015.62	http://dx.doi.org/10.1038/onc.2015.62			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DA4ZT	25798842				2022-12-17	WOS:000367812400006
J	Wimmer, P; Berscheminski, J; Blanchette, P; Groitl, P; Branton, PE; Hay, RT; Dobner, T; Schreiner, S				Wimmer, P.; Berscheminski, J.; Blanchette, P.; Groitl, P.; Branton, P. E.; Hay, R. T.; Dobner, T.; Schreiner, S.			PML isoforms IV and V contribute to adenovirus-mediated oncogenic transformation by functionally inhibiting the tumor-suppressor p53	ONCOGENE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; NUCLEAR-BODY FORMATION; REGION-1B 55-KDA ONCOPROTEIN; E1B 55-KILODALTON PROTEIN; HUMAN-EMBRYO RETINOBLASTS; SUMO-1 MODIFICATION; E1B-55K ONCOPROTEIN; INFECTED-CELLS; RAR-ALPHA; PREMATURE SENESCENCE	Although modulation of the cellular tumor-suppressor p53 is considered to have the major role in E1A/E1B-55K-mediated tumorigenesis, other promyelocytic leukemia nuclear body (PML-NB)/PML oncogenic domain (POD)-associated factors including SUMO, Mre11, Daxx, as well as the integrity of these nuclear bodies contribute to the transformation process. However, the biochemical consequences and oncogenic alterations of PML-associated E1B-55K by SUMO-dependent PML-IV and PML-V interaction have so far remained elusive. We performed mutational analysis to define a PML interaction motif within the E1B-55K polypeptide. Our results showed that E1B-55K/PML binding is not required for p53, Mre11 and Daxx interaction. We also observed that E1B-55K lacking subnuclear PML localization because of either PML-IV or PML-V-binding deficiency was no longer capable of mediating E1B-55K-dependent SUMOylation of p53, inhibition of p53-mediated transactivation or efficiently transforming primary rodent cells. These results together with the observation that E1B-55K-dependent SUMOylation of p53 is required for efficient cell transformation, provides evidence for the idea that the SUMO ligase activity of the E1B-55K viral oncoprotein is intimately linked to its growth-promoting oncogenic activities.	[Wimmer, P.; Berscheminski, J.; Groitl, P.; Dobner, T.; Schreiner, S.] Leibniz Inst Expt Virol, Heinrich Pette Inst, Dept Viral Transformat, D-20251 Hamburg, Germany; [Blanchette, P.; Branton, P. E.] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Branton, P. E.] McGill Univ, Dept Oncol, Montreal, PQ, Canada; [Branton, P. E.] McGill Univ, Dept Goodman Canc Ctr, Montreal, PQ, Canada; [Hay, R. T.] Univ Dundee, Coll Life Sci, Wellcome Trust Ctr Gene Regulat & Express, Dundee, Scotland	Heinrich Pette Institute; McGill University; McGill University; McGill University; University of Dundee	Schreiner, S (corresponding author), Leibniz Inst Expt Virol, Heinrich Pette Inst, Dept Viral Transformat, Martinistr 52, D-20251 Hamburg, Germany.	sabrina.schreiner@tum.de	Hay, Ronald/S-3233-2019; Hay, Ronald T/F-9338-2011	Hay, Ronald/0000-0001-7113-9024; Hay, Ronald T/0000-0001-7113-9024; Schreiner, Sabrina/0000-0002-5744-7159	Freie und Hansestadt Hamburg; Bundesministerium fur Gesundheit (BMG); Peter und Traudl Engelhorn Stiftung; Erich und Gertrud Roggenbuck Stiftung; Else Kroner-Fresenius-Stiftung; Deutsche Krebshilfe e. V.; Deutsche Forschungsgemeinschaft (DFG); Wilhelm Sander-Stiftung; B Braun Stiftung; Drager Stiftung; Fonds der Chemischen Industrie; Canadian Institutes of Health Research; Canadian Foundation for Innovation (CFI); Ministere du Developpement economique, innovation et exportation Quebec (MDEIE); Cancer Research UK [13067] Funding Source: researchfish	Freie und Hansestadt Hamburg; Bundesministerium fur Gesundheit (BMG); Peter und Traudl Engelhorn Stiftung; Erich und Gertrud Roggenbuck Stiftung; Else Kroner-Fresenius-Stiftung; Deutsche Krebshilfe e. V.(Deutsche Krebshilfe); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Wilhelm Sander-Stiftung; B Braun Stiftung; Drager Stiftung; Fonds der Chemischen Industrie(Fonds der Chemischen IndustrieEuropean Commission); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Foundation for Innovation (CFI)(Canada Foundation for Innovation); Ministere du Developpement economique, innovation et exportation Quebec (MDEIE); Cancer Research UK(Cancer Research UK)	We thank Roger D Everett for providing reagents, and greatly appreciate the critical comments and very helpful advise from Thomas Sternsdorf. We thank Ellis Jaffray, Gabriele Dobner and Thomas Speiseder for technical support and Hannah Staege for animal work. The Heinrich Pette Institute, Leibniz Institute for Experimental Virology is supported by the Freie und Hansestadt Hamburg and the Bundesministerium fur Gesundheit (BMG). SS was supported by the Peter und Traudl Engelhorn Stiftung and additional grants from the Erich und Gertrud Roggenbuck Stiftung, the Else Kroner-Fresenius-Stiftung and the Deutsche Krebshilfe e. V. TD is supported by the Deutsche Forschungsgemeinschaft (DFG) and the Wilhelm Sander-Stiftung. Part of this work was supported by the B Braun Stiftung, the Drager Stiftung and the Fonds der Chemischen Industrie. PB and PEB were supported by grants from the Canadian Institutes of Health Research. Image collection for the manuscript was performed in the McGill University Life Sciences Complex Imaging Facility. Purchase of equipment in the facility was made possible with funding from the Canadian Foundation for Innovation (CFI) and the Ministere du Developpement economique, innovation et exportation Quebec (MDEIE).	ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; Baker A, 2007, J VIROL, V81, P7034, DOI 10.1128/JVI.00029-07; Bernardi R, 2003, ONCOGENE, V22, P9048, DOI 10.1038/sj.onc.1207106; Berscheminski J, 2013, J VIROL, V87, P965, DOI 10.1128/JVI.02023-12; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Blanchette P, 2004, MOL CELL BIOL, V24, P9619, DOI 10.1128/MCB.24.21.9619-9629.2004; Brand Peter, 2010, PMC Biophys, V3, P3, DOI 10.1186/1757-5036-3-3; BRANTON PE, 1984, BIOCHIM BIOPHYS ACTA, V780, P67, DOI 10.1016/0304-419X(84)90007-6; BYRD P, 1982, NATURE, V298, P69, DOI 10.1038/298069a0; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; CHANG KS, 1992, MOL CELL BIOL, V12, P800, DOI 10.1128/MCB.12.2.800; Condemine W, 2006, CANCER RES, V66, P6192, DOI 10.1158/0008-5472.CAN-05-3792; Dallaire F, 2009, J VIROL, V83, P5329, DOI 10.1128/JVI.00089-09; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Dobner T, 2001, CURR TOP MICROBIOL, V259, P25; Dosch T, 2001, J VIROL, V75, P5677, DOI 10.1128/JVI.75.12.5677-5683.2001; Duprez E, 1999, J CELL SCI, V112, P381; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Endter C, 2005, ONCOGENE, V24, P55, DOI 10.1038/sj.onc.1208170; Endter C, 2004, CURR TOP MICROBIOL, V273, P163; Endter C, 2001, P NATL ACAD SCI USA, V98, P11312, DOI 10.1073/pnas.191361798; Everett RD, 1999, J CELL SCI, V112, P4581; Everett RD, 2001, ONCOGENE, V20, P7266, DOI 10.1038/sj.onc.1204759; Everett RD, 2007, BIOCHIMIE, V89, P819, DOI 10.1016/j.biochi.2007.01.004; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Fallaux FJ, 1998, HUM GENE THER, V9, P1909, DOI 10.1089/hum.1998.9.13-1909; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; GALLIMORE PH, 1986, ANTICANCER RES, V6, P499; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; Geng YY, 2012, J BIOL CHEM, V287, P30729, DOI 10.1074/jbc.M112.374769; GODDARD AD, 1995, MAMM GENOME, V6, P732, DOI 10.1007/BF00354296; GODDARD AD, 1992, LEUKEMIA, V6, pS117; Goodrum FD, 1996, J VIROL, V70, P6323, DOI 10.1128/JVI.70.9.6323-6335.1996; Gostissa M, 2003, CURR OPIN CELL BIOL, V15, P351, DOI 10.1016/S0955-0674(03)00038-3; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Graham F.L., 1984, ADENOVIRUSES, P339; GRAHAM FL, 1984, J CELL PHYSIOL, P151; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Gurrieri C, 2004, BLOOD, V103, P2358, DOI 10.1182/blood-2003-07-2200; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Hartl B, 2008, ONCOGENE, V27, P3673, DOI 10.1038/sj.onc.1211039; HALEY KP, 1984, P NATL ACAD SCI-BIOL, V81, P5734, DOI 10.1073/pnas.81.18.5734; Hofmann TG, 2003, CELL DEATH DIFFER, V10, P1290, DOI 10.1038/sj.cdd.4401313; Ishov AM, 1996, J CELL BIOL, V134, P815, DOI 10.1083/jcb.134.4.815; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Kentsis A, 2002, P NATL ACAD SCI USA, V99, P667, DOI 10.1073/pnas.012317299; Kindsmuller K, 2007, P NATL ACAD SCI USA, V104, P6684, DOI 10.1073/pnas.0702158104; Kindsmuller K, 2009, J VIROL, V83, P9045, DOI 10.1128/JVI.00728-09; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Konig C, 1999, J VIROL, V73, P2253; Kratzer F, 2000, ONCOGENE, V19, P850, DOI 10.1038/sj.onc.1203395; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lethbridge KJ, 2003, J GEN VIROL, V84, P259, DOI 10.1099/vir.0.18820-0; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Logan J, 1984, CANCER CELL, V2, P527; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Martin MED, 1999, MOL CELL BIOL, V19, P3403; Martin MED, 1998, J VIROL, V72, P3146, DOI 10.1128/JVI.72.4.3146-3154.1998; Maul GG, 1998, BIOESSAYS, V20, P660, DOI 10.1002/(SICI)1521-1878(199808)20:8<660::AID-BIES9>3.0.CO;2-M; MCLORIE W, 1991, J GEN VIROL, V72, P1467, DOI 10.1099/0022-1317-72-6-1467; Melnick A, 1999, LEUKEMIA, V13, P1534, DOI 10.1038/sj.leu.2401513; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MORAN E, 1986, J VIROL, V57, P765, DOI 10.1128/JVI.57.3.765-775.1986; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 2008, CELL CYCLE, V7, P754, DOI 10.4161/cc.7.6.5495; Nevels M, 2006, ADENOVIRUS METHODS P, P187; Nevins JR, 1996, VIROLOGY, P301; Nisole S, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00125; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Owerbach D, 2005, BIOCHEM BIOPH RES CO, V337, P517, DOI 10.1016/j.bbrc.2005.09.090; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pearson M, 2001, ONCOGENE, V20, P7250, DOI 10.1038/sj.onc.1204856; Pennella MA, 2010, J VIROL, V84, P12210, DOI 10.1128/JVI.01442-10; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Querido E, 2001, J VIROL, V75, P699, DOI 10.1128/JVI.75.2.699-709.2001; Ricciardi R, 1995, DNA TUMOR VIRUSES ON, P195; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Salomoni P, 2008, CELL RES, V18, P620, DOI 10.1038/cr.2008.58; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Scaglioni PP, 2006, CELL, V126, P269, DOI 10.1016/j.cell.2006.05.041; Schiedner G, 2000, HUM GENE THER, V11, P2105, DOI 10.1089/104303400750001417; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schreiner S, 2011, J VIROL, V85, P8752, DOI 10.1128/JVI.00440-11; Schreiner S, 2010, J VIROL, V84, P7029, DOI 10.1128/JVI.00074-10; Sieber T, 2007, J VIROL, V81, P95, DOI 10.1128/JVI.01608-06; Stadler M, 1995, ONCOGENE, V11, P2565; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Takahashi Y, 2004, ONCOGENE, V23, P2819, DOI 10.1038/sj.onc.1207533; Tavalai N, 2008, BBA-MOL CELL RES, V1783, P2207, DOI 10.1016/j.bbamcr.2008.08.004; Torok D, 2009, FRONT BIOSCI-LANDMRK, V14, P1325, DOI 10.2741/3311; TRENTIN JJ, 1962, SCIENCE, V137, P835, DOI 10.1126/science.137.3533.835; Turnell AS, 2000, EMBO J, V19, P4759, DOI 10.1093/emboj/19.17.4759; Ullman AJ, 2008, J VIROL, V82, P7325, DOI 10.1128/JVI.00723-08; Ullman AJ, 2007, J VIROL, V81, P4744, DOI 10.1128/JVI.02385-06; Van Damme E, 2011, FRONT BIOSCI-LANDMRK, V16, P2910, DOI 10.2741/3889; Van Damme E, 2010, INT J BIOL SCI, V6, P51, DOI 10.7150/ijbs.6.51; VANDENHEUVEL SJL, 1992, J VIROL, V66, P591, DOI 10.1128/JVI.66.1.591-595.1992; Wang ZG, 1998, SCIENCE, V279, P1547; Weidtkamp-Peters S, 2008, J CELL SCI, V121, P2731, DOI 10.1242/jcs.031922; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WHITE E, 1993, P SOC EXP BIOL MED, V204, P30; White E, 2001, ONCOGENE, V20, P7836, DOI 10.1038/sj.onc.1204861; WHITTAKER JL, 1984, MOL CELL BIOL, V4, P110, DOI 10.1128/MCB.4.1.110; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; Wimmer P, 2013, ONCOGENE, V32, P1626, DOI 10.1038/onc.2012.187; Wimmer P, 2010, ONCOGENE, V29, P5511, DOI 10.1038/onc.2010.284; Wimmer P, 2012, J VIROL, V86, P642, DOI 10.1128/JVI.06227-11; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	139	15	20	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2016	35	1					69	82		10.1038/onc.2015.63	http://dx.doi.org/10.1038/onc.2015.63			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DA4ZT	25772236				2022-12-17	WOS:000367812400007
J	Parisi, T; Bronson, RT; Lees, JA				Parisi, T.; Bronson, R. T.; Lees, J. A.			Inactivation of the retinoblastoma gene yields a mouse model of malignant colorectal cancer	ONCOGENE			English	Article							PROSTATE-CANCER; DEFICIENT CELLS; MOLECULAR-BASIS; BETA-CATENIN; RB; PRB; TUMORS; TUMORIGENESIS; EXPRESSION; MICE	The retinoblastoma gene (Rb) is mutated at significant frequency in various human epithelial tumors, including colorectal cancer, and is strongly associated with metastatic disease. However, sole inactivation of Rb in the mouse has so far failed to yield epithelial cancers. Here, we specifically inactivate Rb and/or p53 in the urogenital epithelium and the intestine. We find that the loss of both tumor suppressors is unable to yield tumors in the transitional epithelium lining the bladder, kidneys and ureters. Instead, these mice develop highly metastatic tumors of neuroendocrine, not epithelial, origin within the urogenital tract to give prostate cancer in the males and vaginal tumors in the females. Additionally, we discovered that the sole inactivation of Rb in the intestine was sufficient to induce formation of metastatic colorectal adenocarcinomas. These tumors closely mirror the human disease in regard to the age of onset, histological appearance, invasiveness and metastatic potential. Like most human colorectal carcinomas, our murine Rb-deficient tumors demonstrate genomic instability and they show activation of beta-catenin. Deregulation of the Wnt/beta-catenin pathway is specific to the intestinal tumors, as genomic instability but not activation of beta-catenin was observed in the neuroendocrine tumors. To date, attempts to generate genetically engineered mouse models of colorectal cancer tumors have yielded mostly cancer of the small intestine, which rarely occurs in humans. Our system provides the opportunity to accurately model and study colorectal cancer in the mouse via a single gene mutation.	[Parisi, T.; Lees, J. A.] Koch Inst Integrat Canc Res, Cambridge, MA USA; [Bronson, R. T.] Tufts Cummings Sch Vet Med, Dept Pathol, North Grafton, MA USA; [Lees, J. A.] MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Lees, JA (corresponding author), MIT, David H Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	jalees@mit.edu			NIH/NCI [P30-CA14051, P01-CA42063, RO1-CA121921]; NATIONAL CANCER INSTITUTE [R01CA121921, P01CA042063, P30CA014051] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are indebted to Omer Yilmaz for scientific suggestions and professional evaluation of the pathology slides, Kevin Haigis for unpublished information and reagents, A. Amsterdam and S. Frank for critical reading of the manuscript, and the Koch Institute Swanson Biotechnology Center for technical support, particularly the Histology Core. This work was supported by NIH/NCI grants to the Koch Institute (P30-CA14051), and to JAL (P01-CA42063 and RO1-CA121921), a Ludwig Scholar at MIT.	Aparicio A, 2011, NAT REV UROL, V8, P562, DOI 10.1038/nrurol.2011.107; Blache P, 2004, J CELL BIOL, V166, P37, DOI 10.1083/jcb.200311021; Burgess AW, 2011, EXP CELL RES, V317, P2748, DOI 10.1016/j.yexcr.2011.08.010; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Coschi CH, 2010, GENE DEV, V24, P1351, DOI 10.1101/gad.1917610; Dinney CPN, 2004, CANCER CELL, V6, P111, DOI 10.1016/j.ccr.2004.08.002; GOPE R, 1990, J NATL CANCER I, V82, P310, DOI 10.1093/jnci/82.4.310; Haigis K, 2006, J BIOL CHEM, V281, P638, DOI 10.1074/jbc.M509053200; He F, 2009, CANCER RES, V69, P9413, DOI 10.1158/0008-5472.CAN-09-2158; Henley SA, 2012, CELL DIV, V7, DOI 10.1186/1747-1028-7-10; Horst D, 2009, CANCER, V115, P2063, DOI 10.1002/cncr.24254; Humbert PO, 2000, MOL CELL, V6, P281, DOI 10.1016/S1097-2765(00)00029-0; Humphrey PA, 2012, HISTOPATHOLOGY, V60, P59, DOI 10.1111/j.1365-2559.2011.04039.x; Hung KE, 2010, P NATL ACAD SCI USA, V107, P1565, DOI 10.1073/pnas.0908682107; Johnson RL, 2013, CANCER METAST REV, V32, P39, DOI 10.1007/s10555-012-9404-6; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kaplan-Lefko PJ, 2003, PROSTATE, V55, P219, DOI 10.1002/pros.10215; Kucherlapati MH, 2008, P NATL ACAD SCI USA, V105, P15493, DOI 10.1073/pnas.0802933105; Kucherlapati MH, 2006, CANCER RES, V66, P3576, DOI 10.1158/0008-5472.CAN-05-2699; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; Manning AL, 2014, MOL CELL, V53, P993, DOI 10.1016/j.molcel.2014.01.032; Manning AL, 2010, GENE DEV, V24, P1364, DOI 10.1101/gad.1917310; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Moran A, 2010, WORLD J GASTRO ONCOL, V2, P151, DOI 10.4251/wjgo.v2.i3.151; Morris EJ, 2008, NATURE, V455, P552, DOI 10.1038/nature07310; Nandan MO, 2010, CURR COLORECT CANC R, V6, P51, DOI 10.1007/s11888-010-0046-1; Parisi T, 2009, ONCOGENE, V28, P500, DOI 10.1038/onc.2008.406; Parisi T, 2007, MOL CELL BIOL, V27, P2283, DOI 10.1128/MCB.01854-06; Rosenberg JE, 2009, GENE DEV, V23, P655, DOI 10.1101/gad.1789109; Saam JR, 1999, J BIOL CHEM, V274, P38071, DOI 10.1074/jbc.274.53.38071; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Schwitalla S, 2013, CANCER CELL, V23, P93, DOI 10.1016/j.ccr.2012.11.014; Sharma A, 2010, J CLIN INVEST, V120, P4478, DOI 10.1172/JCI44239; Terry S, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00060; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; Wu XR, 2005, NAT REV CANCER, V5, P713, DOI 10.1038/nrc1697; Yang HS, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-6; Yoo LI, 2006, CANCER RES, V66, P1929, DOI 10.1158/0008-5472.CAN-05-1986; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760; Zeineldin M, 2013, CANCER RES, V73, P2389, DOI 10.1158/0008-5472.CAN-12-4607; Zhang ZT, 1999, CANCER RES, V59, P3512; Zhou ZX, 2006, CANCER RES, V66, P7889, DOI 10.1158/0008-5472.CAN-06-0486	45	15	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2015	34	48					5890	5899		10.1038/onc.2015.30	http://dx.doi.org/10.1038/onc.2015.30			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CX1CO	25745996	Green Submitted, Green Accepted			2022-12-17	WOS:000365434000003
J	Frances, D; Sharma, N; Pofahl, R; Maneck, M; Behrendt, K; Reuter, K; Krieg, T; Klein, CA; Haase, I; Niemann, C				Frances, D.; Sharma, N.; Pofahl, R.; Maneck, M.; Behrendt, K.; Reuter, K.; Krieg, T.; Klein, C. A.; Haase, I.; Niemann, C.			A role for Rac1 activity in malignant progression of sebaceous skin tumors	ONCOGENE			English	Article							PROSTATE-CANCER; HAIR; DIFFERENTIATION; EXPRESSION; EPIDERMIS; CELLS; MORPHOGENESIS; MUTATIONS; LEF1	The small GTPase Rac1 is crucial for maintaining stem cells (SCs) in mammalian epidermis, and Rac1 activation leads to SC expansion. Loss or inhibition of Rac1 correlates with decreased frequency of skin cancer formation in a chemical carcinogenesis model. Here, we have addressed whether Rac1 activation would enhance carcinogenesis and result in tumor progression. We used K14 Delta NLef1 mice, a model for differentiated sebaceous adenomas (SAs), and activated Rac1 in an epidermis-specific manner (K14L61Rac1). Surprisingly, Rac1 activation did not change the incidence and frequency of sebaceous tumors. However, tumors, which occurred exclusively in K14 Delta NLef1/K14L61Rac1 double-transgenic mice, were poorly differentiated resembling malignant sebaceous tumors and were termed sebaceous carcinoma-like tumors (SCLTs). Compared with SAs, SCLTs showed an aberrant pattern of cell proliferation, invasive growth and less abundant expression of sebocyte differentiation markers, including stearoyl-CoA desaturase-1 and adipophilin. Interestingly, the adnexal SC marker Lrig1 was upregulated in SCLTs, showing that active Rac1 leads to the accumulation of sebocyte precursors in the context of K14 Delta NLef1-induced skin tumors. In a search for targets of Rac1, we found cancer progression-related proteins, Dhcr24/Seladin1 and Nuclear protein 1/P8, to be strongly regulated in SCLTs. At last, Rac1 and Dhcr24/Seladin1 were detected in human sebaceous tumors demonstrating a potential high impact of our findings for human skin disease. This is the first study showing that Rac1 activity can lead to malignant progression of skin tumors.	[Frances, D.; Sharma, N.; Reuter, K.; Niemann, C.] Univ Cologne, CMMC, D-50931 Cologne, Germany; [Pofahl, R.; Behrendt, K.; Krieg, T.; Haase, I.] Univ Cologne, Dept Dermatol, D-50931 Cologne, Germany; [Maneck, M.; Klein, C. A.] Univ Regensburg, Expt Med & Therapy Res, Cologne, Germany; [Niemann, C.] Univ Cologne, Fac Med, Ctr Biochem, D-50931 Cologne, Germany	University of Cologne; University of Cologne; University of Regensburg; University of Cologne	Niemann, C (corresponding author), Univ Cologne, CMMC, Robert Koch Str 21, D-50931 Cologne, Germany.	cnieman1@uni-koeln.de		S, Neha/0000-0002-4287-5994; Klein, Christoph A./0000-0001-7128-1725	Deutsche Krebshilfe;  [SFB 829];  [A3];  [B10]	Deutsche Krebshilfe(Deutsche Krebshilfe); ; ; 	We thank Vera Czichowski, Dagmar Fehrenschild, Peter Schettina, Margot Junker and Michael Tscharntke for expert technical support and are grateful for technical support by Wilhelm Bloch and Cornelia Mauch (SFB 829, Z2). This work was funded by the Deutsche Krebshilfe (to CN and CK) and the SFB 829 (A3 to CN, B10 to IH).	Battista MC, 2010, PROSTATE, V70, P921, DOI 10.1002/pros.21126; Behrendt K, 2012, J CELL SCI, V125, P896, DOI 10.1242/jcs.091868; Benitah SA, 2005, SCIENCE, V309, P933, DOI 10.1126/science.1113579; Calonje J. E., 2011, MCKEES PATHOLOGY SKI; Castilho RM, 2007, ONCOGENE, V26, P5078, DOI 10.1038/sj.onc.1210322; Chrostek A, 2006, MOL CELL BIOL, V26, P6957, DOI 10.1128/MCB.00075-06; Fehrenschild D, 2012, J INVEST DERMATOL, V132, P337, DOI 10.1038/jid.2011.301; Goruppi S, 2010, J BIOL CHEM, V285, P1577, DOI 10.1074/jbc.R109.080887; Gu LH, 2008, AM J PATHOL, V173, P752, DOI 10.2353/ajpath.2008.071089; Hartmann CH, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl740; Jaks V, 2010, EXP CELL RES, V316, P1422, DOI 10.1016/j.yexcr.2010.03.014; Jiang WG, 2006, INT J MOL MED, V18, P981; Kakanj P, 2013, CELL REP, V4, P340, DOI 10.1016/j.celrep.2013.06.037; Kamai T, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-164; Karlsson R, 2009, BBA-REV CANCER, V1796, P91, DOI 10.1016/j.bbcan.2009.03.003; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Niemann C, 2002, DEVELOPMENT, V129, P95; Niemann C, 2007, CANCER RES, V67, P2916, DOI 10.1158/0008-5472.CAN-06-3427; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Ree AH, 1999, CANCER RES, V59, P4675; Scheid S, 2005, BIOINFORMATICS, V21, P2921, DOI 10.1093/bioinformatics/bti436; Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5; Stachelscheid H, 2008, EMBO J, V27, P2091, DOI 10.1038/emboj.2008.141; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Takeda H, 2006, NAT MED, V12, P395, DOI 10.1038/nm1386; Wang Z, 2010, ONCOGENE, V29, P3362, DOI 10.1038/onc.2010.95	26	15	15	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2015	34	43					5505	5512		10.1038/onc.2014.471	http://dx.doi.org/10.1038/onc.2014.471			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EM	25659584				2022-12-17	WOS:000363479700010
J	Long, JS; Schoonen, PM; Graczyk, D; O'Prey, J; Ryan, KM				Long, J. S.; Schoonen, P. M.; Graczyk, D.; O'Prey, J.; Ryan, K. M.			p73 engages A2B receptor signalling to prime cancer cells to chemotherapy-induced death	ONCOGENE			English	Article							OUTER-MEMBRANE PERMEABILIZATION; KINASE C-ABL; DNA-DAMAGE; APOPTOTIC RESPONSE; P53; ADENOSINE; ACTIVATION; INDUCTION; AUTOPHAGY; PROTEINS	Tumour cells often acquire the ability to escape cell death, a key event leading to the development of cancer. In almost half of all human cancers, the capability to induce cell death is reduced by the mutation and inactivation of p53, a tumour suppressor protein that is a central regulator of apoptosis. As a result, there is a crucial need to identify different cell death pathways that could be targeted in malignancies lacking p53. p73, the closely related p53 family member, can regulate many p53 target genes and therefore some of the same cellular responses as p53. Unlike p53, however, p73 is seldom mutated in cancer, making it an attractive, alternative death effector to target. We report here the ability of p73 to upregulate the expression of the A2B receptor, a recently characterized p53 target that effectively promotes cell death in response to extracellular adenosine-a metabolite that accumulates during various forms of cellular stress. Importantly, we show that p73-dependent stimulation of A2B signalling markedly enhances apoptosis in cancer cells that are devoid of p53. This mode of death is caspase-and puma-dependent, and can be prevented by the overexpression of anti-apoptotic Bcl-XL. Moreover, treatment of p53-null cancer cells with the chemotherapeutic drug adriamycin (doxorubicin) induces A2B in a p73-dependent manner and, in combination with an A2B agonist, substantially enhances apoptotic death. We therefore propose an alternate and distinct p53-independent pathway to stimulate programmed cell death involving p73-mediated engagement of adenosine signalling.	[Long, J. S.; Schoonen, P. M.; Graczyk, D.; O'Prey, J.; Ryan, K. M.] Canc Res UK Beatson Inst, Glasgow G61 1BD, Lanark, Scotland; [Schoonen, P. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, NL-9713 AV Groningen, Netherlands	Beatson Institute; University of Groningen	Ryan, KM (corresponding author), Canc Res UK Beatson Inst, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	k.ryan@beatson.gla.ac.uk	Graczyk, Damian/J-6494-2016	Graczyk, Damian/0000-0002-6006-647X; Ryan, Kevin M./0000-0002-1059-9681	Worldwide Cancer Research; Cancer Research UK; Cancer Research UK [15816] Funding Source: researchfish; Worldwide Cancer Research [09-0170, 11-0285] Funding Source: researchfish	Worldwide Cancer Research; Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK); Worldwide Cancer Research	We thank members of the Tumour Cell Death laboratory for critical reading of the manuscript. Work in the Tumour Cell Death Laboratory is supported by Worldwide Cancer Research and Cancer Research UK.	Agami R, 1999, NATURE, V399, P809; Bell HS, 2007, J CLIN INVEST, V117, P1008, DOI 10.1172/JCI28920; Blay J, 1997, CANCER RES, V57, P2602; Borrmann T, 2009, J MED CHEM, V52, P3994, DOI 10.1021/jm900413e; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007; Crighton D, 2004, BBA-REV CANCER, V1705, P3, DOI 10.1016/j.bbcan.2004.09.001; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Fricker M, 2010, J NEUROCHEM, V114, P772, DOI 10.1111/j.1471-4159.2010.06804.x; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gong JG, 1999, NATURE, V399, P806; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Klanrit P, 2008, CELL CYCLE, V7, P205, DOI 10.4161/cc.7.2.5361; Lapi E, 2008, MOL CELL, V32, P803, DOI 10.1016/j.molcel.2008.11.019; Leong CO, 2007, J CLIN INVEST, V117, P1370, DOI 10.1172/JCI30866; Levrero M, 2000, J CELL SCI, V113, P1661; Long JS, 2012, ONCOGENE, V31, P5045, DOI 10.1038/onc.2012.7; Long JS, 2013, MOL CELL, V50, P394, DOI 10.1016/j.molcel.2013.03.016; Lunghi P, 2004, BLOOD, V104, P519, DOI 10.1182/blood-2003-08-2743; Martin AG, 2009, AGING-US, V1, P335, DOI 10.18632/aging.100026; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27; O'Prey J, 2009, CELL CYCLE, V8, P2260, DOI 10.4161/cc.8.14.9050; Ohta A, 2006, P NATL ACAD SCI USA, V103, P13132, DOI 10.1073/pnas.0605251103; Oswald C, 2008, CELL CYCLE, V7, P1726, DOI 10.4161/cc.7.12.6148; PELLICCIARI C, 1993, EUR J HISTOCHEM, V37, P381; Raskovalova T, 2005, J IMMUNOL, V175, P4383, DOI 10.4049/jimmunol.175.7.4383; Sauer M, 2008, NUCLEIC ACIDS RES, V36, P1900, DOI 10.1093/nar/gkn044; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Stiewe T, 2002, CANCER RES, V62, P3598; Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952; Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308; Tomasini R, 2009, P NATL ACAD SCI USA, V106, P797, DOI 10.1073/pnas.0812096106; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036; Waterhouse NJ, 2003, CELL DEATH DIFFER, V10, P853, DOI 10.1038/sj.cdd.4401263; Wilkinson S, 2009, GENE DEV, V23, P1283, DOI 10.1101/gad.521709; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	49	15	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2015	34	40					5152	5162		10.1038/onc.2014.436	http://dx.doi.org/10.1038/onc.2014.436			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CS6ZP	25659586	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000362233400005
J	Zhou, X; Matskova, L; Rathje, LS; Xiao, X; Gish, G; Werner, M; Ignatyev, I; Yu, N; Zhao, W; Tian, F; Hou, B; Zhang, Z; Pawson, T; Chen, F; Ernberg, I				Zhou, X.; Matskova, L.; Rathje, L-Sz; Xiao, X.; Gish, G.; Werner, M.; Ignatyev, I.; Yu, N.; Zhao, W.; Tian, F.; Hou, B.; Zhang, Z.; Pawson, T.; Chen, F.; Ernberg, I.			SYK interaction with ITG beta 4 suppressed by Epstein-Barr virus LMP2A modulates migration and invasion of nasopharyngeal carcinoma cells	ONCOGENE			English	Article							MEMBRANE-PROTEIN 2A; BREAST-CANCER PROGRESSION; BETA(4) INTEGRIN SUBUNIT; TYROSINE KINASE; ALPHA(6)BETA(4) INTEGRIN; ALPHA-6-BETA-4 INTEGRIN; CYTOPLASMIC DOMAIN; EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; ENCODED LMP2A	Epstein-Barr virus (EBV)-encoded Latent Membrane Protein 2A (LMP2A) is an EBV latency-associated protein regularly expressed in nasopharyngeal carcinoma (NPC). In B cells, LMP2A activity resembles that of a constitutively activated antigen receptor, which recruits the Syk tyrosine kinase to activate a set of downstream signaling pathways. LMP2A also downregulates cellular Syk levels. In the present study, we demonstrate that Syk interacts with the integrin beta 4 subunit (ITG beta 4) of integrin alpha 6 beta 4 in epithelial cells and that concurrent LMP2A expression interferes with this interaction by competitive binding to Syk. We find that both Syk and LMP2A have an effect on ITG beta 4 cell surface expression. However, in LMP2A expressing cells, ITG beta 4 remains concentrated at the cellular protrusions, an expression pattern characteristic of motile cells, including NPC-derived epithelial cells. This effect of LMP2A on ITG beta 4 localization is associated with a greater propensity for migration and invasion in-vitro, and may contribute to the invasive property of LMP2A-expressing NPC.	[Zhou, X.; Matskova, L.; Rathje, L-Sz; Xiao, X.; Werner, M.; Ignatyev, I.; Chen, F.; Ernberg, I.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, SE-17177 Stockholm, Sweden; [Zhou, X.; Xiao, X.; Yu, N.; Zhao, W.; Tian, F.; Hou, B.; Zhang, Z.] Guangxi Med Univ, Affiliated Hosp 1, Dept Otolaryngol Head & Neck Surg, Nanning, Peoples R China; [Gish, G.; Pawson, T.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Karolinska Institutet; Guangxi Medical University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Ernberg, I (corresponding author), Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, SE-17177 Stockholm, Sweden.	ingemar.ernberg@ki.se	Gish, Gerald D/C-7228-2017; Zhou, Xiaoying/Y-4217-2019; Pawson, Tony J/E-4578-2013; Matskova, Liudmila/J-3843-2017; Matskova, Liudmila/AAF-4201-2020	Zhou, Xiaoying/0000-0003-3298-5089; Matskova, Liudmila/0000-0002-3174-1560; Matskova, Liudmila/0000-0002-3174-1560; Zhao Rathje, Li-Sophie/0000-0002-8258-8914	Swedish Cancer Society; Swedish Research Council; Karolinska Institutet Research funds; Maths O Sundqvist family foundation; National Key Basic Research Program of China [2012CB526607]; Guangxi Natural Science Foundation [2013GXNSFGA019002]	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Karolinska Institutet Research funds; Maths O Sundqvist family foundation; National Key Basic Research Program of China(National Basic Research Program of China); Guangxi Natural Science Foundation(National Natural Science Foundation of Guangxi Province)	This work was supported by the Swedish Cancer Society, the Swedish Research Council, Karolinska Institutet Research funds and by the Maths O Sundqvist family foundation; National Key Basic Research Program of China (2012CB526607) and Guangxi Natural Science Foundation (2013GXNSFGA019002). We thank Gosta Winberg for valuable comments to the manuscript.	Allen MD, 2005, J VIROL, V79, P1789, DOI 10.1128/JVI.79.3.1789-1802.2005; Bertotti A, 2005, CANCER RES, V65, P10674, DOI 10.1158/0008-5472.CAN-05-2827; Bon G, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1651; Borradori L, 1999, J INVEST DERMATOL, V112, P411, DOI 10.1046/j.1523-1747.1999.00546.x; Brennan B, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-23; Buettner M, 2006, VIRCHOWS ARCH, V449, P513, DOI 10.1007/s00428-006-0294-2; BUSSON P, 1992, J VIROL, V66, P3257, DOI 10.1128/JVI.66.5.3257-3262.1992; Caswell PT, 2006, TRAFFIC, V7, P14, DOI 10.1111/j.1600-0854.2005.00362.x; Chami M, 2006, BBA-MOL CELL RES, V1763, P1344, DOI 10.1016/j.bbamcr.2006.09.025; Chao C, 1996, CANCER RES, V56, P4811; CLARK EA, 1994, J BIOL CHEM, V269, P28859; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; Dawson CW, 2001, VIROLOGY, V289, P192, DOI 10.1006/viro.2001.1142; Draheim KM, 2010, ONCOGENE, V29, P5032, DOI 10.1038/onc.2010.250; Du ZM, 2012, HEAD NECK-J SCI SPEC, V34, P1456, DOI 10.1002/hed.21953; Dutta U, 2008, CANCER RES, V68, P8779, DOI 10.1158/0008-5472.CAN-08-2125; Dykstra ML, 2001, IMMUNITY, V14, P57, DOI 10.1016/S1074-7613(01)00089-9; Ephstein Y, 2013, J BIOL CHEM, V288, P2191, DOI 10.1074/jbc.M112.404780; FLUCK M, 1995, BIOCHEM BIOPH RES CO, V213, P273, DOI 10.1006/bbrc.1995.2126; Fotheringham JA, 2012, J VIROL, V86, P10308, DOI 10.1128/JVI.00853-12; Fruehling S, 1997, VIROLOGY, V235, P241, DOI 10.1006/viro.1997.8690; Fung LF, 2000, LIFE SCI, V67, P923, DOI 10.1016/S0024-3205(00)00684-6; Galan JA, 2011, J AM SOC MASS SPECTR, V22, P319, DOI 10.1007/s13361-010-0030-7; GIANCOTTI FG, 1992, J CELL BIOL, V118, P951, DOI 10.1083/jcb.118.4.951; Giancotti FG, 2007, TRENDS PHARMACOL SCI, V28, P506, DOI 10.1016/j.tips.2007.08.004; Grenklo S, 2008, EUR J CELL BIOL, V87, P905, DOI 10.1016/j.ejcb.2008.06.006; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Heussinger N, 2004, J PATHOL, V203, P696, DOI 10.1002/path.1569; Hino R, 2009, CANCER RES, V69, P2766, DOI 10.1158/0008-5472.CAN-08-3070; Humphries JD, 2006, J CELL SCI, V119, P3901, DOI 10.1242/jcs.03098; Ikeda M, 2001, J VIROL, V75, P5711, DOI 10.1128/JVI.75.12.5711-5718.2001; Kashyap T, 2011, LAB INVEST, V91, P1414, DOI 10.1038/labinvest.2011.104; Kong QL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000940; Koster J, 2001, J INVEST DERMATOL, V117, P1405, DOI 10.1046/j.0022-202x.2001.01567.x; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; Li Q, 2013, ONCOGENE, V32, P1772, DOI 10.1038/onc.2012.205; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; Lo AKF, 2001, CANCER LETT, V163, P117, DOI 10.1016/S0304-3835(00)00683-2; Lu J, 2006, J BIOL CHEM, V281, P8806, DOI 10.1074/jbc.M507305200; Lynch DT, 2002, J GEN VIROL, V83, P1025, DOI 10.1099/0022-1317-83-5-1025; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; Matskova L, 2001, J VIROL, V75, P10941, DOI 10.1128/JVI.75.22.10941-10949.2001; Matskova LV, 2007, ONCOGENE, V26, P4908, DOI 10.1038/sj.onc.1210298; Merdek KD, 2007, J BIOL CHEM, V282, P30322, DOI 10.1074/jbc.M703156200; Moroni M, 2004, CANCER RES, V64, P7346, DOI 10.1158/0008-5472.CAN-03-3520; Murgia C, 1998, EMBO J, V17, P3940, DOI 10.1093/emboj/17.14.3940; Nakaya T, 2013, VIRUS RES, V174, P108, DOI 10.1016/j.virusres.2013.03.009; Neuhaus B, 2011, CELL MOL LIFE SCI, V68, P3757, DOI 10.1007/s00018-011-0676-8; Nievers MG, 1998, J CELL SCI, V111, P1659; Pegtel DM, 2005, J VIROL, V79, P15430, DOI 10.1128/JVI.79.24.15430-15442.2005; POTTS AJ, 1994, EXP CELL RES, V212, P2, DOI 10.1006/excr.1994.1111; Rabinovitz I, 2004, MOL CELL BIOL, V24, P4351, DOI 10.1128/MCB.24.10.4351-4360.2004; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Soung YH, 2011, CURR PROTEIN PEPT SC, V12, P23; SPINARDI L, 1993, MOL BIOL CELL, V4, P871, DOI 10.1091/mbc.4.9.871; Tohyama Y, 2009, J BIOCHEM, V145, P267, DOI 10.1093/jb/mvp001; Underwood RA, 2009, J HISTOCHEM CYTOCHEM, V57, P123, DOI 10.1369/jhc.2008.952176; Utskarpen A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010944; Winberg G, 2000, MOL CELL BIOL, V20, P8526, DOI 10.1128/MCB.20.22.8526-8535.2000; Wolfenson H, 2013, DEV CELL, V24, P447, DOI 10.1016/j.devcel.2013.02.012; Yan SR, 1997, J IMMUNOL, V158, P1902; Yang XF, 2009, J CELL SCI, V122, P2473, DOI 10.1242/jcs.049148; Yang XQ, 2010, MOL CELL BIOL, V30, P5306, DOI 10.1128/MCB.00326-10; Yoon SO, 2005, CANCER RES, V65, P2761, DOI 10.1158/0008-5472.CAN-04-4122; Yoshioka T, 2013, J CLIN INVEST, V123, P682, DOI 10.1172/JCI60720; Zhao JH, 2013, CANCER-AM CANCER SOC, V119, P304, DOI 10.1002/cncr.27724	66	15	16	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2015	34	34					4491	4499		10.1038/onc.2014.380	http://dx.doi.org/10.1038/onc.2014.380			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BR	25531330				2022-12-17	WOS:000360189200008
J	Shanzer, M; Ricardo-Lax, I; Keshet, R; Reuven, N; Shaul, Y				Shanzer, M.; Ricardo-Lax, I.; Keshet, R.; Reuven, N.; Shaul, Y.			The polyomavirus middle T-antigen oncogene activates the Hippo pathway tumor suppressor Lats in a Src-dependent manner	ONCOGENE			English	Article							CELL CONTACT INHIBITION; MAMMARY-TUMORS; SIZE-CONTROL; TAZ; YAP; PHOSPHORYLATION; INDUCTION; IDENTIFICATION; TRANSFORMATION; PROLIFERATION	The polyomavirus middle T antigen (PyMT) is an oncogene that activates the non-receptor tyrosine kinase, c-Src, and physically interacts with Taz (WWTR1). Taz is a pro-oncogenic transcription coactivator of the Tead transcription factors. The Hippo tumor suppressor pathway activates the kinase Lats, which phosphorylates Taz, leading to its nuclear exclusion and blunting Tead coactivation. We found that Taz was required for transformation by PyMT, but counter-intuitively, Taz was exclusively cytoplasmic in the presence of PyMT. We demonstrate that in the presence of PyMT, wild-type Taz was phosphorylated by Lats, in a Src-dependent manner. Consistently, a Lats refractory Taz mutant did not undergo cytoplasmic retention by PyMT. We show that Yap, the Taz paralog, and Shp2 phosphatase were nuclear excluded as well. Our findings describe a noncanonical activation of Lats, and an unprecedented Tead-independent role for Taz and Yap in viral-mediated oncogenesis.	[Shanzer, M.; Ricardo-Lax, I.; Keshet, R.; Reuven, N.; Shaul, Y.] Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shaul, Y (corresponding author), Weizmann Inst Sci, Dept Mol Genet, Herzel 1, IL-76100 Rehovot, Israel.	yosef.shaul@weizmann.ac.il	Reuven, Nina/AAM-8711-2020; Ricardo-Lax, Inna/ABE-7179-2020	Reuven, Nina/0000-0003-1569-3818; Ricardo-Lax, Inna/0000-0002-9590-9692	Israel Science Foundation [551/11]; Minerva Foundation; Federal German Ministry for Education and Research	Israel Science Foundation(Israel Science Foundation); Minerva Foundation; Federal German Ministry for Education and Research(Federal Ministry of Education & Research (BMBF))	We thank Drs R Bassel-Duby for pCDNA3-Flag-mTaz, pCDNA-myc-mTaz and pCDNA-myc-mTazWA plasmids; M Sudol for pCMV-Yap1 plasmid; J Zhang for pBP-GFP-hTaz-4SA plasmid; H Sasaki for pBS-8xGTIIC-Luc (8xGTIIC) Tead reporter plasmid; A Elson for mSrc sequence; M Oren for Myc-tagged human Lats2 constructs; and XJ Yang for HA-tagged Lats2, Lats-KM, Mst1 and WW45 constructs; B Neel for Shp2 C459S and E76K constructs. We thank Dr Z Porat for his help with ImageStream technology. This work was supported by grants from the Israel Science Foundation (grant No. 551/11), Israel Cancer Research Fund and from the Minerva Foundation with funding from the Federal German Ministry for Education and Research.	CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; Carey MF, 2009, COLD SPRING HARB PRO, V2009; COOK DN, 1990, J VIROL, V64, P1879, DOI 10.1128/JVI.64.5.1879-1887.1990; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; Dilworth Stephen M., 1995, Trends in Microbiology, V3, P31, DOI 10.1016/S0966-842X(00)88866-6; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Fluck MM, 2009, MICROBIOL MOL BIOL R, V73, P542, DOI 10.1128/MMBR.00009-09; GLENN GM, 1995, J VIROL, V69, P3729, DOI 10.1128/JVI.69.6.3729-3736.1995; Gottlieb KA, 2001, MICROBIOL MOL BIOL R, V65, P288, DOI 10.1128/MMBR.65.2.288-318.2001; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Halder G, 2011, DEVELOPMENT, V138, P9, DOI 10.1242/dev.045500; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; HARVEY R, 1984, MOL CELL BIOL, V4, P1334, DOI 10.1128/MCB.4.7.1334; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Levy D, 2007, CELL DEATH DIFFER, V14, P743, DOI 10.1038/sj.cdd.4402063; Liu CY, 2010, J BIOL CHEM, V285, P37159, DOI 10.1074/jbc.M110.152942; Mahoney WM, 2005, BIOCHEM J, V388, P217, DOI 10.1042/BJ20041434; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; O'Shea CC, 2005, CURR OPIN GENET DEV, V15, P18, DOI 10.1016/j.gde.2004.12.010; Ota M, 2008, DEVELOPMENT, V135, P4059, DOI 10.1242/dev.027151; Primo L, 2000, ONCOGENE, V19, P3632, DOI 10.1038/sj.onc.1203708; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; SCHAFFHAUSEN B, 1981, J VIROL, V40, P184, DOI 10.1128/JVI.40.1.184-196.1981; Schaffhausen BS, 2009, VIROLOGY, V384, P304, DOI 10.1016/j.virol.2008.09.042; Tian Y, 2004, J VIROL, V78, P12657, DOI 10.1128/JVI.78.22.12657-12664.2004; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; Tsutsumi R, 2013, DEV CELL, V26, P658, DOI 10.1016/j.devcel.2013.08.013; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7; Yang Y, 2011, VIROLOGY, V409, P204, DOI 10.1016/j.virol.2010.09.032; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zhao B, 2009, CANCER RES, V69, P1089, DOI 10.1158/0008-5472.CAN-08-2997	39	15	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4190	4198		10.1038/onc.2014.347	http://dx.doi.org/10.1038/onc.2014.347			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	25362852				2022-12-17	WOS:000359199800005
J	Davies, EM; Kong, AM; Tan, A; Gurung, R; Sriratana, A; Bukczynska, PE; Ooms, LM; McLean, CA; Tiganis, T; Mitchell, CA				Davies, E. M.; Kong, A. M.; Tan, A.; Gurung, R.; Sriratana, A.; Bukczynska, P. E.; Ooms, L. M.; McLean, C. A.; Tiganis, T.; Mitchell, C. A.			Differential SKIP expression in PTEN-deficient glioblastoma regulates cellular proliferation and migration	ONCOGENE			English	Article							FOCAL ADHESION KINASE; TUMOR-SUPPRESSOR GENE; PLECKSTRIN-HOMOLOGY DOMAINS; GROWTH-FACTOR RECEPTOR; HUMAN GLIOMA-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDES; IDENTIFICATION; LOCALIZATION; ACTIVATION	Glioblastoma is the most common and lethal primary malignant brain tumor in adults. The tumor suppressor gene PTEN is deleted, mutated or hypermethylated in more than 60% of glioblastoma cases resulting in hyperactivation of the phosphoinositide 3-kinase pathway, which leads to sustained PI(3,4,5)P-3 signaling, and thereby hyperactivation of Akt and other effectors. PI(3,4,5) P-3 is also hydrolyzed to PI(3,4)P-2 by inositol polyphosphate 5-phosphatases such as SKIP, but the role this pathway has in glioblastoma is unknown. Microarray expression profiling of SKIP in human glioblastoma has revealed both increased and decreased SKIP gene expression. Here we have screened PTEN-deficient glioblastoma for SKIP protein expression by immunohistochemistry and report that SKIP expression is increased in some cases or decreased relative to normal brain. Using the U-87MG PTEN-deficient cell line we show that SKIP knockdown did not further enhance cell proliferation or survival. However, SKIP overexpression in U-87MG cells suppressed anchorage-independent cell growth and growth factor-induced PI(3,4,5) P3/Akt signaling. Although, SKIP knockdown did not affect cell proliferation or survival, cell migration was significantly retarded, associated with significantly increased PI(4,5)P-2 signals, and decreased phosphorylation of the actin-regulatory protein cofilin, a PI(4,5)P-2-binding protein. Notably, overexpression of SKIP also inhibited migration of U-87MG cells to a similar degree as observed with PTEN reconstitution, however, via distinct mechanisms. PTEN reconstitution promoted sustained lamellipodia generation and focal adhesion formation. In contrast, SKIP overexpression reduced sustained lamellipodia formation, talin incorporation into focal adhesions and recruitment of PI(4,5)P-2-binding proteins to the plasma membrane. Notably, analysis of two independent ONCOMINE microarray data sets revealed a significant correlation between increased SKIP mRNA expression in glioblastoma and improved long-term survival. Therefore, SKIP expression in glioblastoma may affect the local invasion of PTEN-deficient tumors.	[Davies, E. M.; Kong, A. M.; Tan, A.; Gurung, R.; Sriratana, A.; Bukczynska, P. E.; Ooms, L. M.; Tiganis, T.; Mitchell, C. A.] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; [McLean, C. A.] Alfred Hosp, Dept Anat Pathol, Prahran, Vic 3181, Australia	Monash University; Florey Institute of Neuroscience & Mental Health	Mitchell, CA (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Bldg 64,SOBS,Wellington Rd, Clayton, Vic 3800, Australia.	christina.mitchell@monash.edu	Tiganis, Tony/AAV-3495-2020; Ooms, Lisa/AGZ-7420-2022	Tiganis, Tony/0000-0002-8065-9942; Ooms, Lisa Michelle/0000-0002-8918-9932; McLean, Catriona/0000-0002-0302-5727; Mitchell, Christina A/0000-0001-9372-3192	National Health & Medical Research Council (NHMRC), Australia [384083]	National Health & Medical Research Council (NHMRC), Australia(National Health and Medical Research Council (NHMRC) of Australia)	We thank Dr Tamas Balla (NIH) for kindly providing the GFP-PH/Btk and GFP-PH/PLC delta constructs and Dr Jelena Becanovic for assistance with ONCOMINE data analysis. This work was supported by the National Health & Medical Research Council (NH&MRC), Australia, grant number 384083. We also thank the Biochemistry Imaging Facility, Department of Biochemistry and Molecular Biology, Monash University and the Monash Micro Imaging Facility for technical advice with image acquisition and analysis. Tony Tiganis is a NHMRC research fellow. The results shown here are in part based upon data generated by The Cancer Genome Atlas Research Network http://cancergenome.nih.gov/.	Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Baeza N, 2003, ACTA NEUROPATHOL, V106, P479, DOI 10.1007/s00401-003-0748-4; Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104; Bertagnolo V, 2007, CARCINOGENESIS, V28, P1638, DOI 10.1093/carcin/bgm078; BIEGEL JA, 1992, CANCER RES, V52, P3391; Bredel M, 2005, CANCER RES, V65, P4088, DOI 10.1158/0008-5472.CAN-04-4229; Cain RJ, 2009, BIOL CELL, V101, P13, DOI 10.1042/BC20080079; Calderwood DA, 2003, NAT CELL BIOL, V5, P694, DOI 10.1038/ncb0803-694; Campbell RB, 2003, J BIOL CHEM, V278, P33617, DOI 10.1074/jbc.C300296200; Carico C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033684; Chalhoub N, 2009, GENE DEV, V23, P1619, DOI 10.1101/gad.1799609; Davies Elizabeth M, 2012, Subcell Biochem, V58, P281, DOI 10.1007/978-94-007-3012-0_8; Davies MA, 1998, CANCER RES, V58, P5285; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; Di Paolo G, 2006, NATURE, V443, P651, DOI 10.1038/nature05185; Duxbury MS, 2004, SURGERY, V135, P555, DOI 10.1016/j.surg.2003.10.017; Dyson Jennifer M, 2012, Subcell Biochem, V58, P215, DOI 10.1007/978-94-007-3012-0_7; Filippini G, 2008, NEURO-ONCOLOGY, V10, P79, DOI 10.1215/15228517-2007-038; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Frame M, 2008, NAT CELL BIOL, V10, P1017, DOI 10.1038/ncb0908-1017; Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Golub T, 2005, J CELL BIOL, V169, P151, DOI 10.1083/jcb.200407058; Gorbatyuk VY, 2006, MOL CELL, V24, P511, DOI 10.1016/j.molcel.2006.10.007; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Guadamillas MC, 2011, J CELL SCI, V124, P3189, DOI 10.1242/jcs.072165; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Gurung R, 2003, J BIOL CHEM, V278, P11376, DOI 10.1074/jbc.M209991200; Hammond GRV, 2009, BIOCHEM J, V422, P23, DOI 10.1042/BJ20090428; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hinchliffe KA, 1996, EMBO J, V15, P6516, DOI 10.1002/j.1460-2075.1996.tb01042.x; Huang SH, 2004, MOL CELL BIOL, V24, P9102, DOI 10.1128/MCB.24.20.9102-9123.2004; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Iijima M, 2004, J BIOL CHEM, V279, P16606, DOI 10.1074/jbc.M312098200; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Ijuin T, 2000, J BIOL CHEM, V275, P10870, DOI 10.1074/jbc.275.15.10870; Ijuin T, 2003, MOL CELL BIOL, V23, P1209, DOI 10.1128/MCB.23.4.1209-1220.2003; Ijuin T, 2008, MOL CELL BIOL, V28, P5184, DOI 10.1128/MCB.01990-06; Ijuin T, 2012, J BIOL CHEM, V287, P6991, DOI 10.1074/jbc.M111.335539; KAPLAN PL, 1982, P NATL ACAD SCI-BIOL, V79, P485, DOI 10.1073/pnas.79.2.485; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kisseleva M, 2005, MOL CELL BIOL, V25, P3956, DOI 10.1128/MCB.25.10.3956-3966.2005; Klingler-Hoffmann M, 2003, INT J CANCER, V105, P331, DOI 10.1002/ijc.11085; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Koul D, 2001, ONCOGENE, V20, P6669, DOI 10.1038/sj.onc.1204799; Koul D, 2008, CANCER BIOL THER, V7, P1321, DOI 10.4161/cbt.7.9.6954; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Leslie NR, 2007, CURR BIOL, V17, P115, DOI 10.1016/j.cub.2006.12.026; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li Z, 2005, NAT CELL BIOL, V7, P399, DOI 10.1038/ncb1236; Liang Y, 2005, P NATL ACAD SCI USA, V102, P5814, DOI 10.1073/pnas.0402870102; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; Mise-Omata S, 2005, BIOCHEM BIOPH RES CO, V328, P1034, DOI 10.1016/j.bbrc.2005.01.066; Murat A, 2008, J CLIN ONCOL, V26, P3015, DOI 10.1200/JCO.2007.15.7164; Nutt CL, 2003, CANCER RES, V63, P1602; Ooms LM, 2006, MOL BIOL CELL, V17, P607, DOI 10.1091/mbc.E05-05-0469; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Rood BR, 2002, CANCER RES, V62, P3794; Sano T, 1999, CANCER RES, V59, P1820; Sasaki J, 2005, J EXP MED, V201, P859, DOI 10.1084/jem.20041891; SAXENA A, 1992, CANCER RES, V52, P6716; Schmid AC, 2004, FEBS LETT, V576, P9, DOI 10.1016/j.febslet.2004.08.052; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Takenawa T, 2001, BBA-MOL CELL BIOL L, V1533, P190, DOI 10.1016/S1388-1981(01)00165-2; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tamura M, 1999, CANCER RES, V59, P442; Van Troys M, 2008, EUR J CELL BIOL, V87, P649, DOI 10.1016/j.ejcb.2008.04.001; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Varnai P, 2005, J CELL SCI, V118, P4879, DOI 10.1242/jcs.02606; Watt SA, 2002, BIOCHEM J, V363, P657, DOI 10.1042/0264-6021:3630657; Yamanaka R, 2006, ONCOGENE, V25, P5994, DOI 10.1038/sj.onc.1209585; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517; Zhang Li, 2012, Subcell Biochem, V59, P177, DOI 10.1007/978-94-007-3015-1_6; Zhao HX, 2010, BIOPHYS J, V98, P2327, DOI 10.1016/j.bpj.2010.01.046	84	15	17	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	28					3711	3727		10.1038/onc.2014.303	http://dx.doi.org/10.1038/onc.2014.303			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM4TZ	25241900				2022-12-17	WOS:000357679100009
J	Hu, J; Muller, KA; Furnari, FB; Cavenee, WK; VandenBerg, SR; Gonias, SL				Hu, J.; Muller, K. A.; Furnari, F. B.; Cavenee, W. K.; VandenBerg, S. R.; Gonias, S. L.			Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling	ONCOGENE			English	Article							EPIDERMAL-GROWTH-FACTOR; UROKINASE PLASMINOGEN-ACTIVATOR; BREAST-CANCER CELLS; SRC-FAMILY KINASES; CONFERS ENHANCED TUMORIGENICITY; TYROSINE KINASE; MUTANT EGFR; PHASE-II; IN-VIVO; C-SRC	In glioblastoma (GBM), the EGF receptor (EGFR) and Src family kinases (SFKs) contribute to an aggressive phenotype. EGFR may be targeted therapeutically; however, resistance to EGFR-targeting drugs such as Erlotinib and Gefitinib develops quickly. In many GBMs, a truncated form of the EGFR (EGFRvIII) is expressed. Although EGFRvIII is constitutively active and promotes cancer progression, its activity is attenuated compared with EGF-ligated wild-type EGFR, suggesting that EGFRvIII may function together with other signaling receptors in cancer cells to induce an aggressive phenotype. In this study, we demonstrate that in EGFRvIII-expressing GBM cells, the urokinase receptor (uPAR) functions as a major activator of SFKs, controlling phosphorylation of downstream targets, such as p130Cas and Tyr-845 in the EGFR in vitro and in vivo. When EGFRvIII expression in GBM cells was neutralized, either genetically or by treating the cells with Gefitinib, paradoxically, the cells demonstrated increased cell migration. The increase in cell migration was explained by a compensatory increase in expression of urokinase-type plasminogen activator, which activates uPAR-dependent cell signaling. GBM cells that were selected for their ability to grow in vivo in the absence of EGFRvIII also demonstrated increased cell migration, due to activation of the uPAR signaling system. The increase in GBM cell migration, induced by genetic or pharmacologic targeting of the EGFR, was blocked by Dasatinib, highlighting the central role of SFKs in uPAR-promoted cell migration. These results suggest that compensatory activation of uPAR-dependent cell signaling, in GBM cells treated with targeted therapeutics, may adversely affect the course of the disease by promoting cell migration, which may be associated with tumor progression.	[Hu, J.; Muller, K. A.; Furnari, F. B.; VandenBerg, S. R.; Gonias, S. L.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Furnari, F. B.; Cavenee, W. K.] Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; [Cavenee, W. K.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego	Gonias, SL (corresponding author), UCSD, Sch Med, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	sgonias@ucsd.edu	Jones, Karra A/GXM-8805-2022	Jones, Karra A/0000-0002-8819-8992; Furnari, Frank/0000-0003-1909-4361	NIH [R01 CA169096, R01 NS080939]; Defeat GBM Research Collaborative; subsidiary of National Brain Tumor Society; NATIONAL CANCER INSTITUTE [P30CA023100, R01CA169096] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS080939] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Defeat GBM Research Collaborative; subsidiary of National Brain Tumor Society; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by NIH R01 CA169096 (to SLG), R01 NS080939 (to FBF) and the Defeat GBM Research Collaborative, a subsidiary of National Brain Tumor Society (to WKC and FBF). WKC is a Fellow of the National Foundation for Cancer Research. We would like to thank Aran Merati and Nancy Du for their technical assistance with some of the experiments.	Ahluwalia MS, 2010, CANCER LETT, V298, P139, DOI 10.1016/j.canlet.2010.08.014; Alfano D, 2005, THROMB HAEMOSTASIS, V93, P205, DOI 10.1160/TH04-09-0592; Alfano D, 2006, J BIOL CHEM, V281, P17758, DOI 10.1074/jbc.M601812200; Alper O, 2005, CURR PHARM DESIGN, V11, P1119, DOI 10.2174/1381612053507576; BesnardGuerin C, 1996, HUM GENET, V97, P163, DOI 10.1007/BF02265259; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Boerner JL, 2004, MOL CELL BIOL, V24, P7059, DOI 10.1128/MCB.24.16.7059-7071.2004; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; Carriero MV, 2011, CURR DRUG TARGETS, V12, P1761; Carriero MV, 1999, CANCER RES, V59, P5307; Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016; Chandrasekar N, 2003, ONCOGENE, V22, P392, DOI 10.1038/sj.onc.1206164; Chumbalkar V, 2011, J PROTEOME RES, V10, P1343, DOI 10.1021/pr101075e; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; Degryse B, 1999, BLOOD, V94, P649, DOI 10.1182/blood.V94.2.649.414k34_649_662; Du JY, 2009, NAT BIOTECHNOL, V27, P77, DOI 10.1038/nbt.1513; Eastman BM, 2012, CELL SIGNAL, V24, P1847, DOI 10.1016/j.cellsig.2012.05.011; ELLIS V, 1993, METHOD ENZYMOL, V223, P223; Felsenfeld DP, 1999, NAT CELL BIOL, V1, P200, DOI 10.1038/12021; Franceschi E, 2007, BRIT J CANCER, V96, P1047, DOI 10.1038/sj.bjc.6603669; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Hu JJ, 2011, P NATL ACAD SCI USA, V108, P15984, DOI 10.1073/pnas.1113416108; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Huveldt D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056505; Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510; Jo M, 2007, ONCOGENE, V26, P2585, DOI 10.1038/sj.onc.1210066; Jo M, 2009, J BIOL CHEM, V284, P22825, DOI 10.1074/jbc.M109.023960; Jo M, 2009, AM J PATHOL, V175, P190, DOI 10.2353/ajpath.2009.081053; Jo MJ, 2005, J BIOL CHEM, V280, P17449, DOI 10.1074/jbc.M413141200; Kjoller L, 2001, J CELL BIOL, V152, P1145, DOI 10.1083/jcb.152.6.1145; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kloth MT, 2003, J BIOL CHEM, V278, P1671, DOI 10.1074/jbc.M207289200; Kubota Y, 2001, EMBO J, V20, P5666, DOI 10.1093/emboj/20.20.5666; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Lu KV, 2009, CANCER RES, V69, P6889, DOI 10.1158/0008-5472.CAN-09-0347; Lu-Emerson C, 2011, J NEURO-ONCOL, V104, P287, DOI 10.1007/s11060-010-0489-x; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Ma Z, 2002, J CELL BIOL, V159, P1061, DOI 10.1083/jcb.200207070; Ma Z, 2001, J CELL SCI, V114, P3387; Mazar AP, 2011, CURR PHARM DESIGN, V17, P1970; Montuori N, 2013, THROMB HAEMOSTASIS, V109, P309, DOI 10.1160/TH12-08-0546; Mukasa A, 2010, P NATL ACAD SCI USA, V107, P2616, DOI 10.1073/pnas.0914356107; Nagane M, 1996, CANCER RES, V56, P5079; Nguyen DHD, 2000, J BIOL CHEM, V275, P19382, DOI 10.1074/jbc.M909575199; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; Parker JJ, 2013, NEURO-ONCOLOGY, V15, P1048, DOI 10.1093/neuonc/not053; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Rich JN, 2004, J CLIN ONCOL, V22, P133, DOI 10.1200/JCO.2004.08.110; Sarkaria JN, 2007, MOL CANCER THER, V6, P1167, DOI 10.1158/1535-7163.MCT-06-0691; Sato K, 2013, INT J MOL SCI, V14, P10761, DOI 10.3390/ijms140610761; SCHLEGEL J, 1994, J NEURO-ONCOL, V22, P201, DOI 10.1007/BF01052920; SCHLEGEL J, 1994, INT J CANCER, V56, P72; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Shi ZG, 2011, MOL CELL BIOCHEM, V357, P151, DOI 10.1007/s11010-011-0885-3; Smith HW, 2008, J CELL BIOL, V182, P777, DOI 10.1083/jcb.200712050; Stettner AR, 2005, CANCER RES, V65, P5535, DOI 10.1158/0008-5472.CAN-04-3688; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Wykosky J, 2010, CELL CYCLE, V9, P1661, DOI 10.4161/cc.9.9.11592; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yu W, 1997, J CELL BIOL, V137, P767, DOI 10.1083/jcb.137.3.767; Zhang SY, 2012, TRENDS PHARMACOL SCI, V33, P122, DOI 10.1016/j.tips.2011.11.002	67	15	17	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	31					4078	4088		10.1038/onc.2014.336	http://dx.doi.org/10.1038/onc.2014.336			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN9PE	25347738	Green Accepted, Green Submitted			2022-12-17	WOS:000358780500006
J	Gole, B; Baumann, C; Mian, E; Ireno, CI; Wiesmuller, L				Gole, B.; Baumann, C.; Mian, E.; Ireno, C. I.; Wiesmueller, L.			Endonuclease G initiates DNA rearrangements at the MLL breakpoint cluster upon replication stress	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; TOPOISOMERASE-II; HISTONE H2B; CELL-DEATH; HOMOLOGOUS RECOMBINATION; CHROMOSOMAL INSTABILITY; OXIDATIVE STRESS; FRAGILE SITES; STEM-CELLS; APOPTOSIS	MLL (myeloid/lymphoid or mixed-lineage leukemia) rearrangements are frequent in therapy-related and childhood acute leukemia, and are associated with poor prognosis. The majority of the rearrangements fall within a 7.3-kb MLL breakpoint cluster region (MLLbcr), particularly in a 0.4-kb hotspot at the intron11-exon12 boundary. The underlying mechanisms are poorly understood, though multiple pathways including early apoptotic signaling, accompanied by high-order DNA fragmentation, have been implicated. We introduced the MLLbcr hotspot in an EGFP-based recombination reporter system and demonstrated enhancement of both spontaneous and genotoxic treatment-induced DNA recombination by the MLLbcr in various human cell types. We identified Endonuclease G (EndoG), an apoptotic nuclease, as an essential factor for MLLbcr-specific DNA recombination after induction of replication stress. We provide evidence for replication stress-induced nuclear accumulation of EndoG, DNA binding by EndoG as well as cleavage of the chromosomal MLLbcr locus in a manner requiring EndoG. We demonstrate additional dependency of MLLbcr breakage on ATM signaling to histone H2B monoubiquitinase RNF20, involved in chromatin relaxation. Altogether our findings provide a novel mechanism underlying MLLbcr destabilization in the cells of origin of leukemogenesis, with replication stress-activated, EndoG-mediated cleavage at the MLLbcr, which may serve resolution of the stalled forks via recombination repair, however, also permits MLL rearrangements.	[Gole, B.; Baumann, C.; Mian, E.; Ireno, C. I.; Wiesmueller, L.] Univ Ulm, Dept Obstet & Gynecol, Gynecol Oncol, D-89075 Ulm, Baden Wuerttemb, Germany	Ulm University	Gole, B (corresponding author), Univ Ulm, Dept Obstet & Gynecol, Gynecol Oncol, Prittwitzstr 43, D-89075 Ulm, Baden Wuerttemb, Germany.	boris.gole@uniklinik-ulm.de; lisa.wiesmueller@uni-ulm.de	Gole, Boris/GWQ-9292-2022	Gole, Boris/0000-0002-2461-6729	German Research Foundation [WI 3099/7-1, WI 3099/7-2]; European/German Space Agency (ESA/DLR); German Ministry of Economy (BMWi) [A0-10-IBER-2, 50WB1225]	German Research Foundation(German Research Foundation (DFG)); European/German Space Agency (ESA/DLR); German Ministry of Economy (BMWi)(Federal Ministry for Economic Affairs and Energy (BMWi))	We thank Daniela Waldraff, Regina Hafele, Rahel Wiehe (all Department of Obstetrics and Gynecology, University of Ulm, Germany) and Dre van der Merwe (Core facility FACS, Medical Faculty, University of Ulm, Germany) for their contributions to this work. This work was supported by the German Research Foundation (WI 3099/7-1, WI 3099/7-2) and by the European/German Space Agency (ESA/DLR) and German Ministry of Economy (BMWi), A0-10-IBER-2 funding 50WB1225.	Abdulwahab A, 2012, CANCER-AM CANCER SOC, V118, P3962, DOI 10.1002/cncr.26735; Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Barlow JH, 2013, CELL, V152, P620, DOI 10.1016/j.cell.2013.01.006; Baumann C, 2006, NUCLEIC ACIDS RES, V34, P1036, DOI 10.1093/nar/gkj509; Betti CJ, 2003, CANCER RES, V63, P1377; Boehden GS, 2004, CARCINOGENESIS, V25, P1305, DOI 10.1093/carcin/bgh092; Bolderson E, 2004, HUM MOL GENET, V13, P2937, DOI 10.1093/hmg/ddh316; Britton S, 2009, CANCER RES, V69, P8120, DOI 10.1158/0008-5472.CAN-08-4400; Buttner S, 2007, MOL CELL, V25, P233, DOI 10.1016/j.molcel.2006.12.021; Carrassa L, 2004, CELL CYCLE, V3, P1177; Chernikova SB, 2012, CANCER RES, V72, P2111, DOI 10.1158/0008-5472.CAN-11-2209; Diener T, 2010, EXP GERONTOL, V45, P638, DOI 10.1016/j.exger.2010.03.002; Ezoe S, 2012, INT J ENV RES PUB HE, V9, P2444, DOI 10.3390/ijerph9072444; Fierz B, 2011, NAT CHEM BIOL, V7, P113, DOI [10.1038/nchembio.501, 10.1038/NCHEMBIO.501]; Flynn RL, 2011, TRENDS BIOCHEM SCI, V36, P133, DOI 10.1016/j.tibs.2010.09.005; Grabarz A, 2012, AM J CANCER RES, V2, P249; Hars ES, 2006, CANCER RES, V66, P8975, DOI 10.1158/0008-5472.CAN-06-1724; Labi V, 2010, GENE DEV, V24, P1602, DOI 10.1101/gad.1940210; Lee JS, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.181; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Libura J, 2008, EUR J HAEMATOL, V81, P185, DOI 10.1111/j.1600-0609.2008.01103.x; Maddams J, 2011, INT J CANCER, V129, P2885, DOI 10.1002/ijc.26240; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Meyer C, 2013, LEUKEMIA, V27, P2165, DOI 10.1038/leu.2013.135; Milyavsky M, 2010, CELL STEM CELL, V7, P186, DOI 10.1016/j.stem.2010.05.016; Mirault ME, 2006, AM J HUM GENET, V79, P779, DOI 10.1086/507791; Mosad E, 2012, ONCOLOGY-BASEL, V83, P128, DOI 10.1159/000338769; Moyal L, 2011, MOL CELL, V41, P529, DOI 10.1016/j.molcel.2011.02.015; Ousset M, 2010, CELL CYCLE, V9, P2814, DOI 10.4161/cc.9.14.12253; Ozeri-Galai E, 2008, ONCOGENE, V27, P2109, DOI 10.1038/sj.onc.1210849; Ozeri-Galai E, 2011, MOL CELL, V43, P122, DOI 10.1016/j.molcel.2011.05.019; RUIZCARRILLO A, 1987, EMBO J, V6, P401, DOI 10.1002/j.1460-2075.1987.tb04769.x; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Samejima K, 2005, NAT REV MOL CELL BIO, V6, P677, DOI 10.1038/nrm1715; Shivakumar R, 2008, ANN ONCOL, V19, P1634, DOI 10.1093/annonc/mdn182; Sim SP, 2001, J BIOL CHEM, V276, P31590, DOI 10.1074/jbc.M103962200; Sordet O, 2004, J BIOL CHEM, V279, P50499, DOI 10.1074/jbc.M410277200; Stam RW, 2006, BRIT J HAEMATOL, V132, P539, DOI 10.1111/j.1365-2141.2005.05909.x; Stanulla M, 1997, MOL CELL BIOL, V17, P4070, DOI 10.1128/MCB.17.7.4070; Stanulla M, 2001, HUM MOL GENET, V10, P2481, DOI 10.1093/hmg/10.22.2481; Strissel PL, 1998, BLOOD, V92, P3793, DOI 10.1182/blood.V92.10.3793.422a24_3793_3803; Sun JY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013554; Tichy ED, 2013, STEM CELL RES, V10, P428, DOI 10.1016/j.scr.2013.01.010; Varecha M, 2012, MOL CELL BIOCHEM, V363, P301, DOI 10.1007/s11010-011-1182-x; Wu JX, 2009, MOL CELL BIOL, V29, P849, DOI 10.1128/MCB.01302-08; Yang SH, 2006, EXP MOL MED, V38, P435, DOI 10.1038/emm.2006.51; Zan H, 2011, MOL IMMUNOL, V48, P610, DOI 10.1016/j.molimm.2010.10.023; Zhang F, 2009, TRENDS GENET, V25, P298, DOI 10.1016/j.tig.2009.05.005	48	15	15	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	26					3391	3401		10.1038/onc.2014.268	http://dx.doi.org/10.1038/onc.2014.268			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CL3SU	25132265				2022-12-17	WOS:000356871700005
J	Watnick, RS; Rodriguez, RK; Wang, S; Blois, AL; Rangarajan, A; Ince, T; Weinberg, RA				Watnick, R. S.; Rodriguez, R. K.; Wang, S.; Blois, A. L.; Rangarajan, A.; Ince, T.; Weinberg, R. A.			Thrombospondin-1 repression is mediated via distinct mechanisms in fibroblasts and epithelial cells	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; LARGE T-ANTIGEN; C-MYC ONCOGENE; PROTEIN-KINASE; TUMOR ANGIOGENESIS; SIGNAL-TRANSDUCTION; TRANSCRIPTION FACTOR; GENE-EXPRESSION; CANCER CELLS; FACTOR-I	Tumor-associated angiogenesis is postulated to be regulated by the balance between pro- and anti-angiogenic factors. We demonstrate here that the critical step in establishing the angiogenic capability of human tumor cells is the repression of a key secreted anti-angiogenic factor, thrombospondin-1 (Tsp-1). This repression is essential for tumor formation by mammary epithelial cells and kidney cells engineered to express SV40 early region proteins, hTERT, and H-RasV12. In transformed epithelial cells, a signaling pathway leading from Ras to Tsp-1 repression induces the sequential activation of PI3 kinase, Rho and ROCK, leading to activation of Myc through phosphorylation, thereby enabling Myc to repress Tsp-1 transcription. In transformed fibroblasts, however, the repression of Tsp-1 can be achieved by an alternative mechanism involving inactivation of both p53 and pRb. We thus describe novel mechanisms by which the activation of oncogenes in epithelial cells and the inactivation of tumor suppressors in fibroblasts permits angiogenesis and, in turn, tumor formation.	[Watnick, R. S.; Rodriguez, R. K.; Wang, S.; Blois, A. L.] Boston Childrens Hosp, Vasc Biol Program, Boston, MA USA; [Watnick, R. S.; Rodriguez, R. K.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; [Watnick, R. S.; Rangarajan, A.; Ince, T.; Weinberg, R. A.] Whitehead Inst Biomed Res, Cambridge, MA 02139 USA; [Rodriguez, R. K.; Weinberg, R. A.] MIT, Dept Biol, Cambridge, MA USA; [Blois, A. L.] Univ Bergen, Fac Med, Dept Clin Med, Ctr Canc Biomarkers CCBIO, Bergen, Norway	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); University of Bergen	Weinberg, RA (corresponding author), Whitehead Inst Biomed Res, Whitehead Inst, Biol, 9 Cambridge Ctr, Cambridge, MA 02139 USA.	Weinberg@wi.mit.edu		Ince, Tan/0000-0003-0315-6425	NIH/NCI [5 R01CA78461]; Merck/MIT; Damon Runyon Cancer Research Foundation; NATIONAL CANCER INSTITUTE [R01CA078461] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Merck/MIT(Merck & Company); Damon Runyon Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Dr Richard O Hynes, Dr Alan Hall, Dr Michael Detmar, Dr Yoshiyuki Kuchino and Dr James DiCaprio for reagents. We would like to thank Drs Ittai Ben-Porath, Scott Dessain, Lisa Spirio, Sendurai Mani and Sheila Stewart for useful discussions. This work was supported by NIH/NCI grant 5 R01CA78461 and Merck/MIT to RAW. We also thank the Damon Runyon Cancer Research Foundation for post-doctoral support to RSW.	Adhikary S, 2003, MOL CELL BIOL, V23, P7648, DOI 10.1128/MCB.23.21.7648-7657.2003; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; Beachy TM, 2002, J VIROL, V76, P3145, DOI 10.1128/JVI.76.7.3145-3157.2002; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brown LF, 1999, CLIN CANCER RES, V5, P1041; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Burger P, 2012, BLOOD, V119, P5512, DOI 10.1182/blood-2011-10-386805; Cardone RA, 2005, MOL BIOL CELL, V16, P3117, DOI 10.1091/mbc.e04-10-0945; CASTLE V, 1991, J CLIN INVEST, V87, P1883, DOI 10.1172/JCI115212; Chao HHA, 2000, MOL CELL BIOL, V20, P7624, DOI 10.1128/MCB.20.20.7624-7633.2000; Che XM, 1998, ANN SURG ONCOL, V5, P585, DOI 10.1007/BF02303826; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; DUBIK D, 1987, CANCER RES, V47, P6517; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Eriksson A, 2002, CANCER CELL, V1, P99, DOI 10.1016/S1535-6108(02)00028-4; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fleming JB, 2005, MOL CANCER RES, V3, P413, DOI 10.1158/1541-7786.MCR-04-0206; Folkman J, 1991, Princess Takamatsu Symp, V22, P339; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Galiana C, 1995, MOL CARCINOGEN, V14, P286, DOI 10.1002/mc.2940140409; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GOULD GW, 1995, BIOCHEM J, V311, P735, DOI 10.1042/bj3110735; Guo NH, 1997, CANCER RES, V57, P1735; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 1996, EUR J CANCER, V32A, P2386, DOI 10.1016/S0959-8049(96)00401-7; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He ZQ, 2003, J BIOL CHEM, V278, P26435, DOI 10.1074/jbc.M303859200; Heighway J, 1996, GENOMICS, V35, P207, DOI 10.1006/geno.1996.0340; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; Hoover RR, 2001, ONCOGENE, V20, P5826, DOI 10.1038/sj.onc.1204549; JALLAL B, 1992, J BIOL CHEM, V267, P4357; JANOCKO LE, 1995, CYTOMETRY, V21, P18, DOI 10.1002/cyto.990210106; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KOZMA SC, 1987, NUCLEIC ACIDS RES, V15, P5963; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEBWOHL DE, 1994, ONCOGENE, V9, P1925; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Leung T, 1996, MOL CELL BIOL, V16, P5313; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Li YZ, 2013, CELL MOL IMMUNOL, V10, P506, DOI 10.1038/cmi.2013.32; Li ZP, 2006, MOL CELL BIOL, V26, P4240, DOI 10.1128/MCB.02124-05; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Liu SJ, 2009, CANCER RES, V69, P8742, DOI 10.1158/0008-5472.CAN-09-1541; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; MacGregor D, 1996, J CELL PHYSIOL, V167, P95, DOI 10.1002/(SICI)1097-4652(199604)167:1<95::AID-JCP11>3.3.CO;2-Q; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; Martin-Manso G, 2008, CANCER RES, V68, P7090, DOI 10.1158/0008-5472.CAN-08-0643; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Mizukami Y, 2006, J BIOL CHEM, V281, P13957, DOI 10.1074/jbc.M511763200; MOTRO B, 1990, P NATL ACAD SCI USA, V87, P3092, DOI 10.1073/pnas.87.8.3092; Nagy A, 2001, ANTICANCER RES, V21, P1321; Naito T, 2004, AM J PHYSIOL-RENAL, V286, pF278, DOI 10.1152/ajprenal.00139.2003; NAU MM, 1984, CURR TOP MICROBIOL, V113, P172; Ngo CV, 2000, CELL GROWTH DIFFER, V11, P201; Noguchi K, 1999, J BIOL CHEM, V274, P32580, DOI 10.1074/jbc.274.46.32580; OLIVE PL, 1992, INT J RADIAT ONCOL, V22, P397, DOI 10.1016/0360-3016(92)90840-E; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Ou Y C, 1998, Zhonghua Yi Xue Za Zhi (Taipei), V61, P441; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; PRIVES C, 1979, COLD SPRING HARB SYM, V44, P123, DOI 10.1101/SQB.1980.044.01.014; RAK J, 1995, CANCER RES, V55, P4575; Rak J, 2000, CANCER RES, V60, P490; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Ribatti D, 1998, INT J CANCER, V77, P449; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Rummukainen J, 2001, CANCER GENET CYTOGEN, V126, P1, DOI 10.1016/S0165-4608(00)00387-3; Rundell K, 2001, SEMIN CANCER BIOL, V11, P5, DOI 10.1006/scbi.2000.0341; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; Sauzeau V, 2010, ONCOGENE, V29, P3781, DOI 10.1038/onc.2010.134; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; SEPPLORENZINO L, 1994, CELL GROWTH DIFFER, V5, P1077; SESHADRI R, 1989, INT J CANCER, V43, P270, DOI 10.1002/ijc.2910430218; SETH A, 1991, J BIOL CHEM, V266, P23521; SHENK TE, 1976, J VIROL, V18, P664, DOI 10.1128/JVI.18.2.664-671.1976; SHENK TE, 1976, P NATL ACAD SCI USA, V73, P1513, DOI 10.1073/pnas.73.5.1513; Short SM, 2005, J CELL BIOL, V168, P643, DOI 10.1083/jcb.200407060; SINGHAL RL, 1994, LIFE SCI, V55, P1487, DOI 10.1016/0024-3205(94)00690-3; Tikhonenko AT, 1996, J BIOL CHEM, V271, P30741, DOI 10.1074/jbc.271.48.30741; TRENT J, 1986, P NATL ACAD SCI USA, V83, P470, DOI 10.1073/pnas.83.2.470; Udagawa T, 2002, FASEB J, V16, P1361, DOI 10.1096/fj.01-0813com; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; Venkatesha S, 2006, MOL CANCER RES, V4, P821, DOI 10.1158/1541-7786.MCR-06-0110; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VOLCKAERT G, 1979, J VIROL, V30, P674, DOI 10.1128/JVI.30.3.674-682.1979; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798; Weng LP, 1999, CANCER RES, V59, P5808; White E, 2003, GENE DEV, V17, P1813, DOI 10.1101/gad.1123103; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wojta J, 1999, LAB INVEST, V79, P427; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; ZERRAHN J, 1993, EMBO J, V12, P4739, DOI 10.1002/j.1460-2075.1993.tb06162.x; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100	119	15	16	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2015	34	22					2823	2835		10.1038/onc.2014.228	http://dx.doi.org/10.1038/onc.2014.228			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CJ2OM	25109329	Green Accepted			2022-12-17	WOS:000355324300002
J	Zhu, B; Yan, K; Li, L; Lin, M; Zhang, S; He, Q; Zheng, D; Yang, H; Shao, G				Zhu, B.; Yan, K.; Li, L.; Lin, M.; Zhang, S.; He, Q.; Zheng, D.; Yang, H.; Shao, G.			K63-linked ubiquitination of FANCG is required for its association with the Rap80-BRCA1 complex to modulate homologous recombination repair of DNA interstand crosslinks	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; BINDING PROTEIN; DAMAGE RESPONSE; DEUBIQUITINATING ENZYME; CANCER SUSCEPTIBILITY; TARGETS BRCA1; ANEMIA; PATHWAY; REPLICATION; GENE	DNA interstrand crosslinks (ICLs) are extremely deleterious lesions that are repaired by homologous recombination (HR) through coordination of Fanconi anemia (FA) proteins and breast cancer susceptibility gene 1 (BRCA1) product, but the exact role these proteins have remains unclear. Here we report that FANCG was modified by the addition of lysine63-linked polyubiquitin chains (K63Ub) in response to DNA damage. We show that FANCG K63Ub was dispensable for monoubiquitination of FANCD2, but was required for FANCG to interact with the Rap80-BRCA1 (receptor-associated protein 80-BRCA1) complex for subsequent modulation of HR repair of ICLs induced by mitomycin C. Mutation of three lysine residues within FANCG to arginine (K182, K258 and K347, 3KR) reduced FANCG K63Ub modification, as well as its interaction with the Rap80-BRCA1 complex, and therefore impeded HR repair. In addition, we demonstrated that K63Ub-modified FANCG was deubiquitinated by BRCC36 complex in vitro and in vivo. Inhibition of BRCC36 resulted in increased K63Ub modification of FANCG. Taken together, our results identify a new role of FANCG in HR repair of ICL through K63Ub-mediated interaction with the Rap80-BRCA1 complex.	[Zhu, B.; Yan, K.; Li, L.; Lin, M.; Zhang, S.; Yang, H.; Shao, G.] Peking Univ, Sch Basic Med Sci, Dept fo Cell Biol, Beijing 100191, Peoples R China; [Zhu, B.; Shao, G.] Peking Univ, Inst Syst Biol, Beijing 100191, Peoples R China; [He, Q.] Peking Univ, Ctr Med & Hlth Anal, Beijing 100191, Peoples R China; [Zheng, D.] Shenzhen Univ, Sch Med, Shenzhen, Guangdong, Peoples R China	Peking University; Peking University; Peking University; Shenzhen University	Yang, H (corresponding author), Peking Univ, Sch Basic Med Sci, Dept fo Cell Biol, 38 Xueyuan Rd, Beijing 100191, Peoples R China.	yanghua@bjmu.edu.cn; gzshao@bjmu.edu.cn	Li, Li/B-8842-2019	Li, Li/0000-0002-8630-3699	Beijing Natural Science Foundation [7122099]; Natural Science Foundation of China [81272915]; Research Fund for the Doctoral Program of Higher Education [20110001110013]; Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry [JWSL44-8]; 985 Program, Ministry of Education of China	Beijing Natural Science Foundation(Beijing Natural Science Foundation); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research Fund for the Doctoral Program of Higher Education(Research Fund for the Doctoral Program of Higher Education of China (RFDP)); Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry(Scientific Research Foundation for the Returned Overseas Chinese Scholars); 985 Program, Ministry of Education of China(Ministry of Education, China)	This work was supported by Beijing Natural Science Foundation (Grant 7122099); Natural Science Foundation of China (Grant 81272915); the Research Fund for the Doctoral Program of Higher Education (20110001110013); the Project Sponsored by the Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry (JWSL44-8); 985 Program, Ministry of Education of China.	Akkari YMN, 2000, MOL CELL BIOL, V20, P8283, DOI 10.1128/MCB.20.21.8283-8289.2000; Bin W, 2007, P NATL ACAD SCI USA, V104, P20759, DOI 10.1073/pnas.0710061104; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Clague MJ, 2006, TRENDS CELL BIOL, V16, P551, DOI 10.1016/j.tcb.2006.09.002; Coleman KA, 2011, J BIOL CHEM, V286, P13669, DOI 10.1074/jbc.M110.213728; Cooper EM, 2010, J BIOL CHEM, V285, P10344, DOI 10.1074/jbc.M109.059667; Cooper EM, 2009, EMBO J, V28, P621, DOI 10.1038/emboj.2009.27; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Deans AJ, 2011, NAT REV CANCER, V11, P467, DOI 10.1038/nrc3088; Deans AJ, 2009, MOL CELL, V36, P943, DOI 10.1016/j.molcel.2009.12.006; Dikic I, 2009, NAT REV MOL CELL BIO, V10, P659, DOI 10.1038/nrm2767; Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1; Enoiu M, 2012, NUCLEIC ACIDS RES, V40, P8953, DOI 10.1093/nar/gks670; Feng L, 2012, NAT STRUCT MOL BIOL, V19, P201, DOI 10.1038/nsmb.2211; Feng L, 2010, J BIOL CHEM, V285, P30982, DOI 10.1074/jbc.M110.135392; Feng L, 2009, GENE DEV, V23, P719, DOI 10.1101/gad.1770609; Folias A, 2002, HUM MOL GENET, V11, P2591, DOI 10.1093/hmg/11.21.2591; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Greenberg RA, 2006, GENE DEV, V20, P34, DOI 10.1101/gad.1381306; Hofmann K, 2009, DNA REPAIR, V8, P544, DOI 10.1016/j.dnarep.2009.01.003; Hu YD, 2011, GENE DEV, V25, P685, DOI 10.1101/gad.2011011; Huang TT, 2006, NAT REV MOL CELL BIO, V7, P323, DOI 10.1038/nrm1908; Huen MSY, 2007, CELL, V131, P901, DOI 10.1016/j.cell.2007.09.041; Hussain S, 2003, HUM MOL GENET, V12, P2503, DOI 10.1093/hmg/ddg266; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; Kim H, 2007, NAT STRUCT MOL BIOL, V14, P710, DOI 10.1038/nsmb1277; Kim H, 2007, SCIENCE, V316, P1202, DOI 10.1126/science.1139621; Kim Y, 2011, NAT GENET, V43, P142, DOI 10.1038/ng.750; Knipscheer P, 2009, SCIENCE, V326, P1698, DOI 10.1126/science.1182372; Kolas NK, 2007, SCIENCE, V318, P1637, DOI 10.1126/science.1150034; Kratz K, 2010, CELL, V142, P77, DOI 10.1016/j.cell.2010.06.022; Liu ZX, 2007, NAT STRUCT MOL BIOL, V14, P716, DOI 10.1038/nsmb1279; Long DT, 2011, SCIENCE, V333, P84, DOI 10.1126/science.1204258; MacKay C, 2010, CELL, V142, P65, DOI 10.1016/j.cell.2010.06.021; Mailand N, 2007, CELL, V131, P887, DOI 10.1016/j.cell.2007.09.040; Moldovan GL, 2009, ANNU REV GENET, V43, P223, DOI 10.1146/annurev-genet-102108-134222; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; Nakanishi K, 2011, NAT STRUCT MOL BIOL, V18, P500, DOI 10.1038/nsmb.2029; Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431; Niedzwiedz W, 2004, MOL CELL, V15, P607, DOI 10.1016/j.molcel.2004.08.009; Raschle M, 2008, CELL, V134, P969, DOI 10.1016/j.cell.2008.08.030; Rahman N, 2007, NAT GENET, V39, P165, DOI 10.1038/ng1959; Rothfuss A, 2004, MOL CELL BIOL, V24, P123, DOI 10.1128/MCB.24.1.123-134.2004; Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181; Sato Y, 2009, EMBO J, V28, P2461, DOI 10.1038/emboj.2009.160; Shao G, P NATL ACAD SCI; Shao G, 2009, GENE DEV, V23, P740, DOI 10.1101/gad.1739609; Sims JJ, 2009, MOL CELL, V33, P775, DOI 10.1016/j.molcel.2009.02.011; Smogorzewska A, 2007, CELL, V129, P289, DOI 10.1016/j.cell.2007.03.009; Smogorzewska A, 2010, MOL CELL, V39, P36, DOI 10.1016/j.molcel.2010.06.023; Sobhian B, 2007, SCIENCE, V316, P1198, DOI 10.1126/science.1139516; Stoepker C, 2011, NAT GENET, V43, P138, DOI 10.1038/ng.751; Thompson LH, 2009, MUTAT RES-FUND MOL M, V668, P54, DOI 10.1016/j.mrfmmm.2009.02.003; Tischkowitz MD, 2003, J MED GENET, V40, P1, DOI 10.1136/jmg.40.1.1; Vaz F, 2010, NAT GENET, V42, P406, DOI 10.1038/ng.570; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wang B, 2007, SCIENCE, V316, P1194, DOI 10.1126/science.1139476; Wang B, 2009, GENE DEV, V23, P729, DOI 10.1101/gad.1770309; Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159; Wang X, 2001, MOL CELL BIOL, V21, P713, DOI 10.1128/MCB.21.3.713-720.2001; Ward IM, 2004, J CELL BIOL, V165, P459, DOI 10.1083/jcb.200403021; Weake VM, 2008, MOL CELL, V29, P653, DOI 10.1016/j.molcel.2008.02.014; Wilson JB, 2008, ONCOGENE, V27, P3641, DOI 10.1038/sj.onc.1211034; Yamamoto K, 2003, MOL CELL BIOL, V23, P5421, DOI 10.1128/MCB.23.15.5421-5430.2003; Yan ZJ, 2012, MOL CELL, V47, P61, DOI 10.1016/j.molcel.2012.05.026; Yang YG, 2005, CARCINOGENESIS, V26, P1731, DOI 10.1093/carcin/bgi134; Yu XC, 2004, MOL CELL BIOL, V24, P9478, DOI 10.1128/MCB.24.21.9478-9486.2004; Zhang NX, 2007, DNA REPAIR, V6, P1670, DOI 10.1016/j.dnarep.2007.06.002; Zhao GY, 2007, MOL CELL, V25, P663, DOI 10.1016/j.molcel.2007.01.029	72	15	16	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2015	34	22					2867	2878		10.1038/onc.2014.229	http://dx.doi.org/10.1038/onc.2014.229			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CJ2OM	25132264				2022-12-17	WOS:000355324300006
J	Tung, PY; Knoepfler, PS				Tung, P-Y; Knoepfler, P. S.			Epigenetic mechanisms of tumorigenicity manifesting in stem cells	ONCOGENE			English	Review							POLYCOMB GROUP PROTEINS; H3 LYSINE 27; DNA METHYLATION; SELF-RENEWAL; BREAST-CANCER; METHYLTRANSFERASE ACTIVITY; DEVELOPMENTAL REGULATORS; HISTONE MODIFICATIONS; SWI/SNF COMPLEX; IDH2 MUTATIONS	One of the biggest roadblocks to using stem cells as the basis for regenerative medicine therapies is the tumorigenicity of stem cells. Unfortunately, the unique abilities of stem cells to self-renew and differentiate into a variety of cell types are also mechanistically linked to their tumorigenic behaviors. Understanding the mechanisms underlying the close relationship between stem cells and cancer cells has therefore become a primary goal in the field. In addition, knowledge gained from investigating the striking parallels between mechanisms orchestrating normal embryogenesis and those that invoke tumorigenesis may well serve as the foundation for developing novel cancer treatments. Emerging discoveries have demonstrated that epigenetic regulatory machinery has important roles in normal stem cell functions, cancer development and cancer stem cell (CSC) identity. These studies provide valuable insights into both the shared and distinct mechanisms by which pluripotency and oncogenicity are established and regulated. In this review, the cancer-related epigenetic mechanisms found in pluripotent stem cells and cancer cells will be discussed, focusing on both the similarities and the differences.	[Tung, P-Y; Knoepfler, P. S.] Univ Calif Davis, Dept Cell Biol & Human Anat, Sch Med, Davis, CA 95616 USA; [Tung, P-Y; Knoepfler, P. S.] Univ Calif Davis, UC Davis Genome Ctr, Davis, CA 95616 USA; [Tung, P-Y; Knoepfler, P. S.] UC Davis Comprehens Canc Ctr, Sacramento, CA USA; [Tung, P-Y; Knoepfler, P. S.] Shriners Hosp Children Northern Calif, Inst Pediat Regenerat Med, Sacramento, CA USA	University of California System; University of California Davis; University of California System; University of California Davis	Knoepfler, PS (corresponding author), Univ Calif Davis, Dept Cell Biol & Human Anat, 4303 Tupper Hall,1 Shields Ave, Davis, CA 95616 USA.	knoepfler@ucdavis.edu		Knoepfler, Paul/0000-0001-5444-334X	NIH [1R01GM100782]; CIRM [RN2-00922-1]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM100782] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CIRM(California Institute for Regenerative Medicine); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Bonnie Barrilleaux and Benjamin Yuen for providing feedback on this manuscript. This work was supported by an NIH Grant 1R01GM100782 and a CIRM Grant RN2-00922-1 (both to PSK).	Abdouh M, 2009, J NEUROSCI, V29, P8884, DOI 10.1523/JNEUROSCI.0968-09.2009; Amente S, 2013, BBA-GENE REGUL MECH, V1829, P981, DOI 10.1016/j.bbagrm.2013.05.002; Andrews PW, 2005, BIOCHEM SOC T, V33, P1526, DOI 10.1042/BST0331526; Ang YS, 2011, CELL, V145, P183, DOI 10.1016/j.cell.2011.03.003; Ansari KI, 2013, ONCOGENE, V32, P3359, DOI 10.1038/onc.2012.352; Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22; Bao B, 2012, CANCER RES, V72, P335, DOI 10.1158/0008-5472.CAN-11-2182; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Ben-David U, 2011, NAT REV CANCER, V11, P268, DOI 10.1038/nrc3034; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Cao LX, 2011, J CELL BIOCHEM, V112, P2729, DOI 10.1002/jcb.23234; Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002; Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540; Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035; Chen K, 2013, ACTA PHARMACOL SIN, V34, P732, DOI 10.1038/aps.2013.27; Chen TP, 2003, MOL CELL BIOL, V23, P5594, DOI 10.1128/MCB.23.16.5594-5605.2003; Chiba T, 2008, CANCER RES, V68, P7742, DOI 10.1158/0008-5472.CAN-07-5882; Costa Y, 2013, NATURE, V495, P370, DOI 10.1038/nature11925; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Crea F, 2012, ANN ONCOL, V23, P1207, DOI 10.1093/annonc/mdr387; Crea F, 2011, EPIGENOMICS-UK, V3, P127, DOI [10.2217/EPI.11.4, 10.2217/epi.11.4]; Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854; Dalerba P, 2013, CELL STEM CELL, V13, P5, DOI 10.1016/j.stem.2013.06.012; de la Serna IL, 2006, NAT REV GENET, V7, P461, DOI 10.1038/nrg1882; Ding XL, 2014, STEM CELLS DEV, V23, P931, DOI 10.1089/scd.2013.0267; Ding XL, 2012, STEM CELLS DEV, V21, P121, DOI 10.1089/scd.2010.0539; Doege CA, 2012, NATURE, V488, P652, DOI 10.1038/nature11333; Dou YL, 2006, NAT STRUCT MOL BIOL, V13, P713, DOI 10.1038/nsmb1128; Easwaran H, 2012, GENOME RES, V22, P837, DOI 10.1101/gr.131169.111; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Facchino Sabrina, 2011, Cancers (Basel), V3, P1777, DOI 10.3390/cancers3021777; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; Ficz G, 2013, CELL STEM CELL, V13, P351, DOI 10.1016/j.stem.2013.06.004; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Fisher CL, 2011, CURR OPIN GENET DEV, V21, P140, DOI 10.1016/j.gde.2011.01.015; Gao Q, 2011, P NATL ACAD SCI USA, V108, P18061, DOI 10.1073/pnas.1114946108; Gao YW, 2013, CELL STEM CELL, V12, P453, DOI 10.1016/j.stem.2013.02.005; Greber B, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-46; Grimaud C, 2006, CHROMOSOME RES, V14, P363, DOI 10.1007/s10577-006-1069-y; Gu TP, 2011, NATURE, V477, P606, DOI 10.1038/nature10443; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; Habibi E, 2013, CELL STEM CELL, V13, P360, DOI 10.1016/j.stem.2013.06.002; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harris WJ, 2012, CANCER CELL, V21, P473, DOI 10.1016/j.ccr.2012.03.014; HAUPT Y, 1993, ONCOGENE, V8, P3161; Heddleston JM, 2012, CELL DEATH DIFFER, V19, P428, DOI 10.1038/cdd.2011.109; Ho L, 2009, P NATL ACAD SCI USA, V106, P5181, DOI 10.1073/pnas.0812889106; Hochedlinger K, 2005, CELL, V121, P465, DOI 10.1016/j.cell.2005.02.018; Hochedlinger K, 2009, DEVELOPMENT, V136, P509, DOI 10.1242/dev.020867; Huang H, 2013, P NATL ACAD SCI USA, V110, P11994, DOI 10.1073/pnas.1310656110; JACOB F, 1978, PROC R SOC SER B-BIO, V201, P249, DOI 10.1098/rspb.1978.0044; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Jiang H, 2011, CELL, V144, P513, DOI 10.1016/j.cell.2011.01.020; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Jones PA, 2009, NAT REV GENET, V10, P805, DOI 10.1038/nrg2651; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570; Khan SN, 2013, LEUKEMIA, V27, P1301, DOI 10.1038/leu.2013.80; Kim W, 2013, NAT CHEM BIOL, V9, P643, DOI [10.1038/NCHEMBIO.1331, 10.1038/nchembio.1331]; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Knoepfler PS, 2008, CELL STEM CELL, V2, P18, DOI 10.1016/j.stem.2007.12.004; Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152; Knoepfler PS, 2009, STEM CELLS, V27, P1050, DOI 10.1002/stem.37; Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]; Ko M, 2010, NATURE, V468, P839, DOI 10.1038/nature09586; Koh KP, 2011, CELL STEM CELL, V8, P200, DOI 10.1016/j.stem.2011.01.008; Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159; Korkaya H, 2013, CANCER RES, V73, P3489, DOI 10.1158/0008-5472.CAN-13-0260; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Krasteva V, 2012, BLOOD, V120, P4720, DOI 10.1182/blood-2012-04-427047; Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Leitch HG, 2013, NAT STRUCT MOL BIOL, V20, P311, DOI 10.1038/nsmb.2510; Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143; Li M, 2012, NAT REV MOL CELL BIO, V13, P524, DOI 10.1038/nrm3393; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Lian CG, 2012, CELL, V150, P1135, DOI 10.1016/j.cell.2012.07.033; Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324; Liu L, 2006, ONCOGENE, V25, P4370, DOI 10.1038/sj.onc.1209454; Mack GS, 2006, J NATL CANCER I, V98, P1443, DOI 10.1093/jnci/djj447; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Milne TA, 2010, MOL CELL, V38, P853, DOI 10.1016/j.molcel.2010.05.011; Moon JH, 2011, CELL RES, V21, P1305, DOI 10.1038/cr.2011.107; Moran-Crusio K, 2011, CANCER CELL, V20, P11, DOI 10.1016/j.ccr.2011.06.001; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; Neri F, 2012, MOL CELL BIOL, V32, P840, DOI 10.1128/MCB.06148-11; Nguyen LV, 2012, NAT REV CANCER, V12, P133, DOI 10.1038/nrc3184; Nishigaki M, 2005, CANCER RES, V65, P2115, DOI 10.1158/0008-5472.CAN-04-3340; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Ohm JE, 2010, CANCER RES, V70, P7662, DOI 10.1158/0008-5472.CAN-10-1361; Ohnishi K, 2014, CELL, V156, P663, DOI 10.1016/j.cell.2014.01.005; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Onder TT, 2012, NATURE, V483, P598, DOI 10.1038/nature10953; Orkin SH, 2011, CELL, V145, P835, DOI 10.1016/j.cell.2011.05.019; Patra SK, 2011, CLIN EPIGENETICS, V2, P27, DOI 10.1007/s13148-010-0016-0; Pawlak M, 2011, GENE DEV, V25, P1035, DOI 10.1101/gad.2039011; Pereira CF, 2010, CELL STEM CELL, V6, P547, DOI 10.1016/j.stem.2010.04.013; Raimondi C, 2010, CURR CANCER DRUG TAR, V10, P496, DOI 10.2174/156800910791517154; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Richly H, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.84; Riggs JW, 2013, STEM CELLS DEV, V22, P37, DOI 10.1089/scd.2012.0375; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Schuettengruber B, 2011, NAT REV MOL CELL BIO, V12, P799, DOI 10.1038/nrm3230; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Sharma A, 2010, WIRES SYST BIOL MED, V2, P654, DOI 10.1002/wsbm.89; Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Siddique HR, 2012, STEM CELLS, V30, P372, DOI 10.1002/stem.1035; Singhal N, 2010, CELL, V141, P943, DOI 10.1016/j.cell.2010.04.037; Smith LL, 2011, CELL STEM CELL, V8, P649, DOI 10.1016/j.stem.2011.05.004; Smith ZD, 2013, NAT REV GENET, V14, P204, DOI 10.1038/nrg3354; Solter D, 2006, NAT REV GENET, V7, P319, DOI 10.1038/nrg1827; Song SJ, 2013, CELL, V154, P311, DOI 10.1016/j.cell.2013.06.026; Song SJ, 2013, CELL STEM CELL, V13, P87, DOI 10.1016/j.stem.2013.06.003; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Spivakov M, 2007, NAT REV GENET, V8, P263, DOI 10.1038/nrg2046; STEVENS LC, 1954, P NATL ACAD SCI USA, V40, P1080, DOI 10.1073/pnas.40.11.1080; Stower H, 2014, NAT REV GENET, V15, DOI [10.1038/nrg3659, 10.1038/nrg3657]; Sun M, 2013, P NATL ACAD SCI USA, V110, P9920, DOI 10.1073/pnas.1305172110; Suva ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184; Suva ML, 2009, CANCER RES, V69, P9211, DOI 10.1158/0008-5472.CAN-09-1622; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Thiel AT, 2013, HAEMATOLOGICA, V98, P918, DOI 10.3324/haematol.2012.074195; Tomasson MH, 2009, J CELL BIOCHEM, V106, P745, DOI 10.1002/jcb.22050; Trowbridge JJ, 2012, GENE DEV, V26, P344, DOI 10.1101/gad.184341.111; Tsumura A, 2006, GENES CELLS, V11, P805, DOI 10.1111/j.1365-2443.2006.00984.x; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wang JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003769; Wang JX, 2007, NATURE, V446, P882, DOI 10.1038/nature05671; Wang J, 2011, CANCER RES, V71, P7238, DOI 10.1158/0008-5472.CAN-11-0896; Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268; Whyte WA, 2012, NATURE, V482, P221, DOI 10.1038/nature10805; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Wu CY, 2012, TRENDS GENET, V28, P454, DOI 10.1016/j.tig.2012.05.005; Wu SC, 2010, NAT REV MOL CELL BIO, V11, P607, DOI 10.1038/nrm2950; Xu C, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1237; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67; Yang H, 2012, CLIN CANCER RES, V18, P5562, DOI 10.1158/1078-0432.CCR-12-1773; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yang P, 2011, STEM CELLS, V29, P791, DOI 10.1002/stem.634; Ying QL, 2008, NATURE, V453, P519, DOI 10.1038/nature06968; Yoo MH, 2008, MOL CELLS, V26, P514; Yoshikawa R, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-461; You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008; Yuen BTK, 2013, CANCER CELL, V24, P567, DOI 10.1016/j.ccr.2013.09.015; Zhang HK, 2010, CELL RES, V20, P1390, DOI 10.1038/cr.2010.156; Zhou VW, 2011, NAT REV GENET, V12, P7, DOI 10.1038/nrg2905	163	15	15	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2015	34	18					2288	2296		10.1038/onc.2014.172	http://dx.doi.org/10.1038/onc.2014.172			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH2AH	24931168	Green Accepted			2022-12-17	WOS:000353824800002
J	Dodd, K; Nance, S; Quezada, M; Janke, L; Morrison, JB; Williams, RT; Beere, HM				Dodd, K.; Nance, S.; Quezada, M.; Janke, L.; Morrison, J. B.; Williams, R. T.; Beere, H. M.			Tumor-derived inducible heat-shock protein 70 (HSP70) is an essential component of anti-tumor immunity	ONCOGENE			English	Article							HEAT-SHOCK PROTEINS; ANTIGEN; CELLS; PEPTIDES; TOLERANCE; FACTOR-1; INNATE; ROLES	The anti-apoptotic function and tumor-associated expression of heat-shock protein 70 (HSP70) is consistent with HSP70 functioning as a survival factor to promote tumorigenesis. However, its immunomodulatory activities to induce anti-tumor immunity predict the suppression of tumor growth. Using the Hsp70.1/3(-/-) (Hsp70(-/-)) mouse model, we observed that tumor-derived HSP70 was neither required for cellular transformation nor for in vivo tumor growth. Hsp70(-/-) murine embryonic fibroblasts (MEFs) were transformed by E1A/Ras and generated tumors in immunodeficient hosts as efficiently as wild-type (WT) transformants. Comparison of Bcr-Abl-mediated transformation of WT and Hsp70(-/-) bone marrow and progression of B-cell leukemogenesis in vivo revealed no differences in disease onset or survival rates, and E mu-Myc-driven lymphoma in Hsp70(-/-) mice was phenotypically indistinguishable from that in WT E mu-Myc mice. However, Hsp70(-/-)E1A/Ras MEFs generated significantly larger tumors than their WT counterparts in C57BL/6 J immune-competent hosts. Concurrent with this was a reduction in intra-tumoral infiltration of innate and adaptive immune cells, including macrophages and CD8(+) T cells. Evaluation of several potential mechanisms revealed an HSP70-chemokine-like activity to promote cellular migration. These observations support a role for tumor-derived HSP70 in facilitating anti-tumor immunity to limit tumor growth and highlight the potential consequences of anti-HSP70 therapy as an efficacious anti-cancer strategy.	[Dodd, K.; Nance, S.; Quezada, M.; Beere, H. M.] St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; [Janke, L.] St Jude Childrens Res Hosp, Vet Pathol Core, Memphis, TN 38105 USA; [Morrison, J. B.; Williams, R. T.] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA; [Williams, R. T.] PUMA Biotechnol, Los Angeles, CA USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Beere, HM (corresponding author), St Jude Childrens Res Hosp, Dept Immunol, 262 Danny Thomas Pl, Memphis, TN 38105 USA.	helen.beere@stjude.org	Janke, Laura/N-8121-2018	Janke, Laura/0000-0002-9871-6239	core funding; Cancer Center Supporting Grant (CCSG) developmental funds [5P30CA021765-29]; American Lebanese-Syrian Associated Charities of St Jude Children's Research Hospital; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	core funding; Cancer Center Supporting Grant (CCSG) developmental funds; American Lebanese-Syrian Associated Charities of St Jude Children's Research Hospital(American Lebanese Syrian Associated Charities (ALSAC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Douglas Green for discussion during the preparation of this manuscript and Eleanora Puetz and Alex Yu for genotyping. Special thanks to the husbandry staff of the Animal Resource Center and to the Animal Imaging Center, including Christopher Calabrese, Melissa Johnson and Monique Payton. We are grateful to the flow cytometry facility for their assistance in FACS and flow analysis. This work was funded in part by core funding and Cancer Center Supporting Grant (CCSG) developmental funds (5P30CA021765-29) (to HMB) and the American Lebanese-Syrian Associated Charities of St Jude Children's Research Hospital.	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Binder RJ, 2005, NAT IMMUNOL, V6, P593, DOI 10.1038/ni1201; Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315; Borges TJ, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00095; Chalmin F, 2010, J CLIN INVEST, V120, P457, DOI 10.1172/JCI40483; Chen TY, 2009, J IMMUNOL, V182, P1449, DOI 10.4049/jimmunol.182.3.1449; Ciocca DR, 2013, ARCH TOXICOL, V87, P19, DOI 10.1007/s00204-012-0918-z; Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; DuPage M, 2012, NATURE, V482, P405, DOI 10.1038/nature10803; Effendi K, 2010, ONCOLOGY-BASEL, V78, P157, DOI 10.1159/000312658; Elsner L, 2007, J IMMUNOL, V179, P5523, DOI 10.4049/jimmunol.179.8.5523; Gross C, 2003, BIOL CHEM, V384, P267, DOI 10.1515/BC.2003.030; Hunt CR, 2004, MOL CELL BIOL, V24, P899, DOI 10.1128/MCB.24.2.899-911.2004; Kottke T, 2009, CANCER RES, V69, P7767, DOI 10.1158/0008-5472.CAN-09-1597; Leu JIJ, 2009, MOL CELL, V36, P15, DOI 10.1016/j.molcel.2009.09.023; Li ZH, 2002, CURR OPIN IMMUNOL, V14, P45, DOI 10.1016/S0952-7915(01)00297-7; Malusecka E, 2008, ANTICANCER RES, V28, P501; Mambula SS, 2006, J IMMUNOL, V177, P7849, DOI 10.4049/jimmunol.177.11.7849; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Mignot G, 2011, AM J PATHOL, V178, P1403, DOI 10.1016/j.ajpath.2010.11.078; Millar DG, 2003, NAT MED, V9, P1469, DOI 10.1038/nm962; Min JN, 2007, ONCOGENE, V26, P5086, DOI 10.1038/sj.onc.1210317; Multhoff G, INT J HYPERTHERMIA, V18, P576; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Rohde M, 2005, GENE DEV, V19, P570, DOI 10.1101/gad.305405; Srivastava P, 2002, NAT REV IMMUNOL, V2, P185, DOI 10.1038/nri749; Srivastava P, 2002, ANNU REV IMMUNOL, V20, P395, DOI 10.1146/annurev.immunol.20.100301.064801; Stocki P, 2012, AUTOIMMUN DIS, V2012, DOI 10.1155/2012/617213; Stocki P, 2012, J BIOL CHEM, V287, P12387, DOI 10.1074/jbc.M111.307579; Torronteguy C, 2006, CELL STRESS CHAPERON, V11, P34, DOI 10.1379/CSC-159R.1; UDONO H, 1993, J EXP MED, V178, P1391, DOI 10.1084/jem.178.4.1391; van Eden W, 2012, CELL STRESS CHAPERON, V17, P281, DOI 10.1007/s12192-011-0311-5; van Herwijnen MJC, 2012, P NATL ACAD SCI USA, V109, P14134, DOI 10.1073/pnas.1206803109; Vega VL, 2008, J IMMUNOL, V180, P4299, DOI 10.4049/jimmunol.180.6.4299; Wachstein J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051747; Williams RT, 2006, P NATL ACAD SCI USA, V103, P6688, DOI 10.1073/pnas.0602030103; Zietara N, 2009, J IMMUNOL, V183, P1099, DOI 10.4049/jimmunol.0803214	39	15	15	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2015	34	10					1312	1322		10.1038/onc.2014.63	http://dx.doi.org/10.1038/onc.2014.63			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC9JX	24662819	Green Accepted			2022-12-17	WOS:000350687100011
J	Chudasama, P; Konrad, A; Jochmann, R; Lausen, B; Holz, P; Naschberger, E; Neipel, F; Britzen-Laurent, N; Sturzl, M				Chudasama, P.; Konrad, A.; Jochmann, R.; Lausen, B.; Holz, P.; Naschberger, E.; Neipel, F.; Britzen-Laurent, N.; Stuerzl, M.			Structural proteins of Kaposi's sarcoma-associated herpesvirus antagonize p53-mediated apoptosis	ONCOGENE			English	Article						KSHV; p53; apoptosis; reversely transfected cell microarray; early infection; lytic replication	P53 TUMOR-SUPPRESSOR; SMALL-MOLECULE ANTAGONISTS; LYTIC REPLICATION; DNA-SEQUENCES; CELL-LINE; BOVINE HERPESVIRUS-1; ENDOTHELIAL ORIGIN; SYSTEMS BIOLOGY; EXPRESSION; KSHV	The tumor suppressor p53 is a central regulatory molecule of apoptosis and is commonly mutated in tumors. Kaposi's sarcoma-associated herpesvirus (KSHV)-related malignancies express wild-type p53. Accordingly, KSHV encodes proteins that counteract the cell death-inducing effects of p53. Here, the effects of all KSHV genes on the p53 signaling pathway were systematically analyzed using the reversely transfected cell microarray technology. With this approach we detected eight KSHV-encoded genes with potent p53 inhibiting activity in addition to the previously described inhibitory effects of KSHV genes ORF50, K10 and K10.5. Interestingly, the three most potent newly identified inhibitors were KSHV structural proteins, namely ORF22 (glycoprotein H), ORF25 (major capsid protein) and ORF64 (tegument protein). Validation of these results with a classical transfection approach showed that these proteins inhibited p53 signaling in a dose-dependent manner and that this effect could be reversed by small interfering RNA-mediated knockdown of the respective viral gene. All three genes inhibited p53-mediated apoptosis in response to Nutlin-3 treatment in non-infected and KSHV-infected cells. Addressing putative mechanisms, we could show that these proteins could also inhibit the transactivation of the promoters of apoptotic mediators of p53 such as BAX and PIG3. Altogether, we demonstrate for the first time that structural proteins of KSHV can counteract p53-induced apoptosis. These proteins are expressed in the late lytic phase of the viral life cycle and are incorporated into the KSHV virion. Accordingly, these genes may inhibit cell death in the productive and in the early entrance phase of KSHV infection.	[Chudasama, P.; Konrad, A.; Jochmann, R.; Holz, P.; Naschberger, E.; Britzen-Laurent, N.; Stuerzl, M.] Univ Erlangen Nurnberg, Univ Med Ctr Erlangen, Dept Surg, Div Mol & Expt Surg, D-91054 Erlangen, Germany; [Lausen, B.] Univ Essex, Dept Math Sci, Colchester CO4 3SQ, Essex, England; [Neipel, F.] Univ Erlangen Nurnberg, Univ Med Ctr Erlangen, Inst Clin & Mol Virol, D-91054 Erlangen, Germany	University of Erlangen Nuremberg; University of Essex; University of Erlangen Nuremberg	Sturzl, M (corresponding author), Univ Erlangen Nurnberg, Univ Med Ctr Erlangen, Dept Surg, Div Mol & Expt Surg, Schwabachanlage 10, D-91054 Erlangen, Germany.	michael.stuerzl@uk-erlangen.de	Britzen-Laurent, Nathalie/HDM-6965-2022; Naschberger, Elisabeth/AAV-5289-2021; Lausen, Berthold/D-4063-2012; Stürzl, Michael/B-3019-2015	Britzen-Laurent, Nathalie/0000-0002-0494-7117; Naschberger, Elisabeth/0000-0003-1291-622X; Lausen, Berthold/0000-0002-0594-7258; Stürzl, Michael/0000-0002-9276-2824	German Federal Ministry of Education and Research (BMBF); Deutsche Forschungsgemeinschaft [DFG-GRK1071, STU238/6-1, SFB796]; German Cancer Aid [109510]; Interdisciplinary Center for Clinical Research (IZKF); Emerging Fields Initiative of the Friedrich-Alexander University of Erlangen; Programm zur Forderung der Chancengleichheit fur Frauen in Forschung und Lehre (FFL); University Medical Center Erlangen	German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); German Cancer Aid(Deutsche Krebshilfe); Interdisciplinary Center for Clinical Research (IZKF); Emerging Fields Initiative of the Friedrich-Alexander University of Erlangen; Programm zur Forderung der Chancengleichheit fur Frauen in Forschung und Lehre (FFL); University Medical Center Erlangen	We thank Professor Moshe Oren, Professor Wafik S El-Deiry and Professor Bert Vogelstein for sharing plasmids. In addition, we thank PD Dr Reiner Strick and PD Dr Pamela Strissel (University Medical Center Erlangen, Department of Obstetrics and Gynecology) for providing the MCF7 cells. This work was supported by grants of the German Federal Ministry of Education and Research (BMBF, Polyprobe-Study), the Deutsche Forschungsgemeinschaft (DFG-GRK1071, STU238/6-1, SFB796 (sub-project B9)) and the German Cancer Aid (109510). Additional support was obtained from the Interdisciplinary Center for Clinical Research (IZKF) and the Emerging Fields Initiative of the Friedrich-Alexander University of Erlangen to MS, by a grant for the promotion of young researchers (ELAN) of the University Medical Center Erlangen to AK and a grant of the 'Programm zur Forderung der Chancengleichheit fur Frauen in Forschung und Lehre (FFL)' to PC.	Austgen K, 2012, J VIROL, V86, P1877, DOI 10.1128/JVI.06600-11; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Blasig C, 1997, J VIROL, V71, P7963, DOI 10.1128/JVI.71.10.7963-7968.1997; Britzen-Laurent N, 2013, CARCINOGENESIS, V34, P153, DOI 10.1093/carcin/bgs310; Burbelo PD, 2010, J INFECT DIS, V201, P1919, DOI 10.1086/652869; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Chandran B, 2010, J VIROL, V84, P2188, DOI 10.1128/JVI.01334-09; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen WG, 2010, J VIROL, V84, P3898, DOI 10.1128/JVI.01321-09; de Oliveira DE, 2010, TRENDS MICROBIOL, V18, P248, DOI 10.1016/j.tim.2010.04.001; Dittmer DP, 2011, MBIO, V2, DOI 10.1128/mBio.00138-11; Dittmer DP, 2003, CANCER RES, V63, P2010; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Grundhoff A, 2004, J CLIN INVEST, V113, P124, DOI 10.1172/JCI200417803; Gwack Y, 2001, J VIROL, V75, P6245, DOI 10.1128/JVI.75.13.6245-6248.2001; Hahn A, 2009, J VIROL, V83, P396, DOI 10.1128/JVI.01170-08; Hahn AS, 2012, NAT MED, V18, P961, DOI 10.1038/nm.2805; Hanon E, 1998, J VIROL, V72, P7638, DOI 10.1128/JVI.72.9.7638-7641.1998; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUTCHINSON L, 1992, J VIROL, V66, P2240, DOI 10.1128/JVI.66.4.2240-2250.1992; Ilkow CS, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001291; Inn KS, 2011, J VIROL, V85, P10899, DOI 10.1128/JVI.00690-11; Jerome KR, 2001, J IMMUNOL, V167, P3928, DOI 10.4049/jimmunol.167.7.3928; Jochmann R, 2013, GLYCOBIOLOGY, V23, P1114, DOI 10.1093/glycob/cwt028; Katano H, 2000, VIROLOGY, V269, P335, DOI 10.1006/viro.2000.0196; Konrad A, 2011, METHODS MOL BIOL, V706, P107, DOI 10.1007/978-1-61737-970-3_9; Konrad A, 2009, J VIROL, V83, P2563, DOI 10.1128/JVI.01512-08; Kuhn E, 2012, LAB CHIP, V12, P1363, DOI 10.1039/c2lc20724a; Kurosu T, 2010, APOPTOSIS, V15, P608, DOI 10.1007/s10495-010-0457-0; Kwon JA, 2003, BIOL CHEM, V384, P203, DOI 10.1515/BC.2003.022; Lagunoff M, 2003, INT REV IMMUNOL, V22, P373, DOI 10.1080/08830180305218; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lee HR, 2009, J VIROL, V83, P6739, DOI 10.1128/JVI.02353-08; Leida AM, 2012, CELL HOST MICROBE, V11, P167, DOI 10.1016/j.chom.2012.01.005; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Marcelin AG, 2007, J INFECT DIS, V196, P1163, DOI 10.1086/521625; MIYASHITA T, 1995, CELL, V80, P293; Moore PS, 2007, HUMAN HERPESVIRUSES: BIOLOGY, THERAPY, AND IMMUNOPROPHYLAXIS, P540; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; Morris SJ, 1999, J GEN VIROL, V80, P137, DOI 10.1099/0022-1317-80-1-137; Myoung J, 2011, J VIROL METHODS, V174, P12, DOI 10.1016/j.jviromet.2011.03.012; Nakamichi K, 2001, VIROLOGY, V279, P488, DOI 10.1006/viro.2000.0740; Nakamura H, 2001, J VIROL, V75, P7572, DOI 10.1128/JVI.75.16.7572-7582.2001; Naranatt PP, 2002, ARCH VIROL, V147, P1349, DOI 10.1007/s00705-002-0813-7; Naschberger E, 2004, BIOCHEM J, V379, P409, DOI 10.1042/BJ20031873; Nealon K, 2001, J VIROL, V75, P2866, DOI 10.1128/JVI.75.6.2866-2878.2001; Pertel PE, 2002, J VIROL, V76, P4390, DOI 10.1128/JVI.76.9.4390-4400.2002; Petre CE, 2007, J VIROL, V81, P1912, DOI 10.1128/JVI.01757-06; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Raftery MJ, 1999, J EXP MED, V190, P1103, DOI 10.1084/jem.190.8.1103; Rivas C, 2001, J VIROL, V75, P429, DOI 10.1128/JVI.75.1.429-438.2001; Rozen R, 2008, J VIROL, V82, P4742, DOI 10.1128/JVI.02745-07; Sander G, 2008, J VIROL, V82, P1908, DOI 10.1128/JVI.01716-07; Sarek G, 2013, ONCOGENE, V32, P1091, DOI 10.1038/onc.2012.118; Sarek G, 2007, J CLIN INVEST, V117, P1019, DOI 10.1172/JCI30945; Sathish N, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00098; Schulz TF, 2007, HUMAN HERPESVIRUSES: BIOLOGY, THERAPY, AND IMMUNOPROPHYLAXIS, P490; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; SPAETE RR, 1993, VIROLOGY, V193, P853, DOI 10.1006/viro.1993.1194; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; Sturzl M, 2008, COMB CHEM HIGH T SCR, V11, P159, DOI 10.2174/138620708783744499; Sturzl M, 2013, INT J CANCER, V132, P1954, DOI 10.1002/ijc.27849; Sturzl M, 2009, THROMB HAEMOSTASIS, V102, P1117, DOI 10.1160/TH09-07-0472; Sturzl M, 1997, INT J CANCER, V72, P68, DOI 10.1002/(SICI)1097-0215(19970703)72:1&lt;68::AID-IJC10&gt;3.0.CO;2-6; Sun R, 1999, J VIROL, V73, P2232, DOI 10.1128/JVI.73.3.2232-2242.1999; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; Tornesello ML, 2009, ONCOLOGY-BASEL, V77, P328, DOI 10.1159/000260905; Urbanowski MD, 2013, J VIROL, V87, P872, DOI 10.1128/JVI.02030-12; Vassilev LT, 2004, CELL CYCLE, V3, P419; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Voltan R, 2014, MOL CARCINOGEN, V53, P498, DOI 10.1002/mc.21985; Ye FC, 2012, CELL CYCLE, V11, P1393, DOI 10.4161/cc.19756; Ziauddin J, 2001, NATURE, V411, P107, DOI 10.1038/35075114	76	15	15	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2015	34	5					639	649		10.1038/onc.2013.595	http://dx.doi.org/10.1038/onc.2013.595			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DD	24469037				2022-12-17	WOS:000348853500011
J	Savar, A; Acin, S; Gonzalez, CL; El-Sawy, T; Mejia, O; Li, Z; Esmaeli, B; Lacy-Hulbert, A; El-Naggar, AK; McCarty, JH; Caulin, C				Savar, A.; Acin, S.; Gonzalez, C. L.; El-Sawy, T.; Mejia, O.; Li, Z.; Esmaeli, B.; Lacy-Hulbert, A.; El-Naggar, A. K.; McCarty, J. H.; Caulin, C.			Loss of epithelial p53 and alpha v integrin cooperate through Akt to induce squamous cell carcinoma yet prevent remodeling of the tumor microenvironment	ONCOGENE			English	Article						p53; squamous cell carcinoma; mouse model; integrins; tumor microenvironment	GAIN-OF-FUNCTION; SKIN-CANCER; MOUSE MODEL; EXPRESSION; MUTATIONS; KERATINOCYTES; INACTIVATION; NEOPLASIA; ABLATION; LEADS	Most of the squamous cell carcinomas (SCCs) of the skin and head and neck contain p53 mutations. The presence of p53 mutations in premalignant lesions suggests that they represent early events during tumor progression and additional alterations may be required for SCC development. Here we show that codeletion of the p53 and alpha v integrin genes in mouse stratified epithelia induced SCCs in 100% of the mice, more frequently and with much shorter latency than deletion of either gene alone. The SCCs that lacked p53 and alpha v in the epithelial tumor cells exhibited high Akt activity, lacked multiple types of infiltrating immune cells, contained a defective vasculature and grew slower than tumors that expressed p53 or alpha v. These results reveal that loss of alpha v in epithelial cells that lack p53 promotes SCC development, but also prevents remodeling of the tumor microenvironment and delays tumor growth. We observed that Akt inactivation in SCC cells that lack p53 and alpha v promoted anoikis. Thus, tumors may arise in these mice as a result of the increased cell survival induced by Akt activation triggered by loss of alpha v and p53, and by the defective recruitment of immune cells to these tumors, which may allow immune evasion. However, the defective vasculature and lack of a supportive stroma create a restrictive microenvironment in these SCCs that slows their growth. These mechanisms may underlie the rapid onset and slow growth of SCCs that lack p53 and alpha v.	[Savar, A.; Acin, S.; Gonzalez, C. L.; El-Sawy, T.; Mejia, O.; Li, Z.; Esmaeli, B.; Caulin, C.] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; [Lacy-Hulbert, A.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; [El-Naggar, A. K.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [McCarty, J. H.] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; [Caulin, C.] Univ Texas MD Anderson Canc Ctr, Dept Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Harvard University; Massachusetts General Hospital; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Caulin, C (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Unit 123, 1515 Holcombe Blvd, Houston, TX 77030 USA.	ccaulin@mdanderson.org	Acin, Sergio/S-5185-2017	Acin, Sergio/0000-0001-7335-2865	National Institutes of Health [DE015344]; Pilot Project grant from the American Cancer Society Institutional Research Grant Program; National Institutes of Health through Cancer Center Support Grant [CA16672]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015344] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS078402] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pilot Project grant from the American Cancer Society Institutional Research Grant Program; National Institutes of Health through Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dennis Roop for the K14.CrePR1 mice, Anton Berns for the floxed p53 mice and Sarah Bronson and Dawn Chalaire for editorial assistance. This study was supported by the National Institutes of Health through Grant DE015344 (C Caulin) and a Pilot Project grant from the American Cancer Society Institutional Research Grant Program (JH McCarty). Veterinary services and core facilities at The University of Texas MD Anderson Cancer Center were supported in part by the National Institutes of Health through Cancer Center Support Grant CA16672.	Acin S, 2011, J PATHOL, V225, P479, DOI 10.1002/path.2971; Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; Bao WJ, 2004, J CELL BIOL, V167, P745, DOI 10.1083/jcb.200404018; Bolshakov S, 2003, CLIN CANCER RES, V9, P228; Brantsch KD, 2008, LANCET ONCOL, V9, P713, DOI 10.1016/S1470-2045(08)70178-5; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BREUSS JM, 1995, J CELL SCI, V108, P2241; CAMPBELL C, 1993, J INVEST DERMATOL, V100, P746, DOI 10.1111/1523-1747.ep12475717; Caulin C, 2004, CANCER RES, V64, P5054, DOI 10.1158/0008-5472.CAN-04-1488; Caulin C, 2007, J CLIN INVEST, V117, P1893, DOI 10.1172/JCI31721; DELUCA M, 1990, P NATL ACAD SCI USA, V87, P6888, DOI 10.1073/pnas.87.17.6888; Euvrard S, 2003, NEW ENGL J MED, V348, P1681, DOI 10.1056/NEJMra022137; Haapasalmi K, 1996, J INVEST DERMATOL, V106, P42, DOI 10.1111/1523-1747.ep12327199; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; HERTLE MD, 1992, J CLIN INVEST, V89, P1892, DOI 10.1172/JCI115794; Hsu A, 2011, J CUTAN PATHOL, V38, P570, DOI 10.1111/j.1600-0560.2011.01687.x; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Janes SM, 2004, J CELL BIOL, V166, P419, DOI 10.1083/jcb.200312074; Jin H, 2006, CANCER RES, V66, P2146, DOI 10.1158/0008-5472.CAN-05-2704; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Jones J, 1996, ONCOGENE, V12, P119; Jones J, 1997, J ORAL PATHOL MED, V26, P63, DOI 10.1111/j.1600-0714.1997.tb00023.x; Jones SM, 2006, NAT REV CANCER, V6, P175, DOI 10.1038/nrc1817; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Lacy-Hulbert A, 2007, P NATL ACAD SCI USA, V104, P15823, DOI 10.1073/pnas.0707421104; Lindelof B, 2000, BRIT J DERMATOL, V143, P513, DOI 10.1111/j.1365-2133.2000.03703.x; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Martinez-Cruz AB, 2008, CANCER RES, V68, P683, DOI 10.1158/0008-5472.CAN-07-3049; McCarty JH, 2005, DEVELOPMENT, V132, P165, DOI 10.1242/dev.01551; McCarty JH, 2008, AM J PATHOL, V172, P1740, DOI 10.2353/ajpath.2008.070700; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; NAPPI O, 1989, J CUTAN PATHOL, V16, P114, DOI 10.1111/j.1600-0560.1989.tb00024.x; PELTONEN J, 1989, J CLIN INVEST, V84, P1916, DOI 10.1172/JCI114379; Spike Benjamin T, 2011, Genes Cancer, V2, P404, DOI 10.1177/1947601911410224; Streuli CH, 2009, BIOCHEM J, V418, P491, DOI 10.1042/BJ20081948; Stromblad S, 2002, J BIOL CHEM, V277, P13371, DOI 10.1074/jbc.C200044200; Torchia EC, 2012, ONCOGENE, V31, P2680, DOI 10.1038/onc.2011.441; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	41	15	15	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2015	34	4					516	524		10.1038/onc.2013.585	http://dx.doi.org/10.1038/onc.2013.585			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ8FU	24469034	Green Accepted			2022-12-17	WOS:000348451300012
J	Yoshida, H; Miyachi, M; Sakamoto, K; Ouchi, K; Yagyu, S; Kikuchi, K; Kuwahara, Y; Tsuchiya, K; Imamura, T; Iehara, T; Kakazu, N; Hojo, H; Hosoi, H				Yoshida, H.; Miyachi, M.; Sakamoto, K.; Ouchi, K.; Yagyu, S.; Kikuchi, K.; Kuwahara, Y.; Tsuchiya, K.; Imamura, T.; Iehara, T.; Kakazu, N.; Hojo, H.; Hosoi, H.			PAX3-NCOA2 fusion gene has a dual role in promoting the proliferation and inhibiting the myogenic differentiation of rhabdomyosarcoma cells	ONCOGENE			English	Article						rhabdomyosarcoma; PAX3-NCOA2; PAX3-FOXO1A; tumorigenesis; inhibiting differentiation	STEROID-RECEPTOR COACTIVATOR; NUCLEAR-RECEPTOR; ALVEOLAR RHABDOMYOSARCOMA; LXXLL MOTIF; EMBRYONAL RHABDOMYOSARCOMA; TRANSCRIPTIONAL ACTIVITY; PAX3-FKHR; BINDING; PAX; DOMAIN	We analyzed a complex chromosomal translocation in a case of embryonal rhabdomyosarcoma (RMS) and showed that it generates the fusion gene PAX3 (paired box 3)-NCOA2 (nuclear receptor coactivator 2). To understand the role of this translocation in RMS tumorigenesis, we established two types of stable mouse myoblast C2C12 cell lines expressing PAX3-NCOA2 and PAX3-FOXO1A (forkhead box O1A), respectively. Compared with control cells, PAX3-NCOA2 cells grew faster, were more motile, were less anchorage dependent, progressed more quickly through the G1/S phase of cell cycle and showed greater transcriptional activation of the PAX3 consensus-binding site. However, PAX3-NCOA2 cells proliferated more slowly and differentiated more weakly than did PAX3-FOXO1A cells. Both PAX3-NCOA2 cells and PAX3-FOXO1A cells formed tumors in nude mice, although the PAX3-NCOA2-induced tumors grew more slowly. Our results may explain why NCOA2 rearrangement is mainly found in embryonal rhabdomyosarcoma, which has a better prognosis than alveolar rhabdomyosarcoma, which expresses the PAX3-FOXO1A fusion gene. These results indicate that the PAX3-NCOA2 fusion gene has a dual role in the tumorigenesis of RMS: promotion of the proliferation and inhibition of the myogenic differentiation of RMS cells.	[Yoshida, H.; Miyachi, M.; Sakamoto, K.; Ouchi, K.; Yagyu, S.; Kikuchi, K.; Kuwahara, Y.; Tsuchiya, K.; Imamura, T.; Iehara, T.; Hosoi, H.] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pediat, Kyoto 6028566, Japan; [Kakazu, N.] Shimane Univ, Dept Environm & Prevent Med, Sch Med, Matsue, Shimane, Japan; [Hojo, H.] Fukushima Med Univ, Sch Med, Dept Pathol 1, Fukushima, Japan	Kyoto Prefectural University of Medicine; Shimane University; Fukushima Medical University	Hosoi, H (corresponding author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pediat, Kamigyo Ku, Kajii Cho Hirokoji, Kyoto 6028566, Japan.	hhosoi@koto.kpu-m.ac.jp	Kikuchi, Ken/ABG-8290-2020; Yagyu, Shigeki/H-9070-2019	Kikuchi, Ken/0000-0003-3097-7480; Yagyu, Shigeki/0000-0003-4256-9783; Miyachi, Mitsuru/0000-0003-4522-2478	Ministry of Education, Culture, Sports, Science and Technology of Japan [21249085, 25253095, 22390239, 22591166, 24791078]; Grants-in-Aid for Scientific Research [24659500] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by Grant-in-aid for Scientific Research (A) 21249085, (A) 25253095, (B) 22390239, (C) 22591166, Grant-in-aid for Young Scientists (B) 24791078 and Grant-in-aid for Project for Development of Innovative Research on Cancer Therapeutics from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Anderson J, 2001, AM J PATHOL, V159, P1089, DOI 10.1016/S0002-9440(10)61784-1; Barr FG, 2001, ONCOGENE, V20, P5736, DOI 10.1038/sj.onc.1204599; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Calhabeu F, 2013, ONCOGENE, V32, P651, DOI 10.1038/onc.2012.73; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Chen SL, 2000, GENE DEV, V14, P1209; Deguchi K, 2003, CANCER CELL, V3, P259, DOI 10.1016/S1535-6108(03)00051-5; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Finckenstein FG, 2008, ONCOGENE, V27, P2004, DOI 10.1038/sj.onc.1210835; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; Hamburger AW, 1978, CANCER RES, V38, P4118; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4946; Hosoi H, 2009, CANCER GENET CYTOGEN, V189, P98, DOI 10.1016/j.cancergencyto.2008.10.016; JOSTES B, 1990, MECH DEVELOP, V33, P27, DOI 10.1016/0925-4773(90)90132-6; Jothi M, 2012, CELL CYCLE, V11, P895, DOI 10.4161/cc.11.5.19346; Kikuchi K, 2008, BIOCHEM BIOPH RES CO, V365, P568, DOI 10.1016/j.bbrc.2007.11.017; Lam PYP, 1999, MOL CELL BIOL, V19, P594; Lee YH, 2005, P NATL ACAD SCI USA, V102, P3611, DOI 10.1073/pnas.0407159102; Litterst CM, 2002, J BIOL CHEM, V277, P36052, DOI 10.1074/jbc.M203556200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ma H, 1999, MOL CELL BIOL, V19, P6164; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Mosquera JM, 2013, GENE CHROMOSOME CANC, V52, P538, DOI 10.1002/gcc.22050; Naini S, 2008, CANCER RES, V68, P9583, DOI 10.1158/0008-5472.CAN-07-6178; Nakae J, 2006, J CLIN INVEST, V116, P2473, DOI 10.1172/JCI25518; Parker D, 1999, MOL CELL BIOL, V19, P5601; Robson EJD, 2006, NAT REV CANCER, V6, P52, DOI 10.1038/nrc1778; Sorensen PHB, 2002, J CLIN ONCOL, V20, P2672, DOI 10.1200/JCO.2002.03.137; Sumegi J, 2010, GENE CHROMOSOME CANC, V49, P224, DOI 10.1002/gcc.20731; Teyssier C, 2002, J BIOL CHEM, V277, P46066, DOI 10.1074/jbc.M207623200; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TREMBLAY P, 1994, PHARMACOL THERAPEUT, V61, P205, DOI 10.1016/0163-7258(94)90063-9; Tsuchiya K, 2007, INT J ONCOL, V31, P41; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang W, 1998, CANCER RES, V58, P4426; Zhang YB, 2009, INT J CLIN EXP PATHO, V2, P370	41	15	17	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2014	33	49					5601	5608		10.1038/onc.2013.491	http://dx.doi.org/10.1038/onc.2013.491			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZW	24213582				2022-12-17	WOS:000346088700004
J	Rajurkar, M; Huang, H; Cotton, JL; Brooks, JK; Sicklick, J; McMahon, AP; Mao, J				Rajurkar, M.; Huang, H.; Cotton, J. L.; Brooks, J. K.; Sicklick, J.; McMahon, A. P.; Mao, J.			Distinct cellular origin and genetic requirement of Hedgehog-Gli in postnatal rhabdomyosarcoma genesis	ONCOGENE			English	Article						Hedgehog; Gli; progenitor; rhbdomyosarcoma	FOLLICLE STEM-CELLS; SONIC HEDGEHOG; HUMAN HOMOLOG; MOUSE MODEL; EXPRESSION; AMPLIFICATION; PATHWAY; TARGET; CANCER; SOX4	Dysregulation of the Hedgehog (Hh)-Gli signaling pathway is implicated in a variety of human cancers, including basal cell carcinoma (BCC), medulloblastoma (MB) and embryonal rhabdhomyosarcoma (eRMS), three principle tumors associated with human Gorlin syndrome. However, the cells of origin of these tumors, including eRMS, remain poorly understood. In this study, we explore the cell populations that give rise to Hh-related tumors by specifically activating Smoothened (Smo) in both Hhproducing and -responsive cell lineages in postnatal mice. Interestingly, we find that unlike BCC and MB, eRMS originates from the stem/progenitor populations that do not normally receive active Hh signaling. Furthermore, we find that the myogenic lineage in postnatal mice is largely Hh quiescent and that Pax7-expressing muscle satellite cells are not able to give rise to eRMS upon Smo or Gli1/2 overactivation in vivo, suggesting that Hh-induced skeletal muscle eRMS arises from Hh/Gli quiescent non-myogenic cells. In addition, using the Gli1 null allele and a Gli3 repressor allele, we reveal a specific genetic requirement for Gli proteins in Hh-induced eRMS formation and provide molecular evidence for the involvement of Sox4/11 in eRMS cell survival and differentiation.	[Rajurkar, M.; Huang, H.; Cotton, J. L.; Brooks, J. K.; Mao, J.] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; [Huang, H.] Cent S Univ, Xiangya Sch Med, Dept Histol & Embryol, Changsha, Hunan, Peoples R China; [Sicklick, J.] Univ Calif San Diego, Moores Canc Ctr, Div Surg Oncol, La Jolla, CA 92093 USA; [McMahon, A. P.] Univ So Calif, WM Keck Sch Med, Broad CIRM Ctr Regenerat Med & Stem Cell Res, Dept Stem Cell Biol & Regenerat Med, Los Angeles, CA USA	University of Massachusetts System; University of Massachusetts Worcester; Central South University; University of California System; University of California San Diego; University of Southern California	Mao, J (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, 364 Plantat St,LRB417, Worcester, MA 01605 USA.	junhao.mao@umassmed.edu	McMahon, Andrew P/ABE-7520-2020; Rajurkar, Mihir/I-6238-2019	Rajurkar, Mihir/0000-0002-0573-1705; Cotton, Jennifer/0000-0003-0106-1801	American Cancer Society [120376-RSG-11-04001-DDC]; Charles H Hood Foundation; Worcester Foundation for Biomedical Research; NIH [NS033642]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS033642, R01NS033642] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); Charles H Hood Foundation; Worcester Foundation for Biomedical Research; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work is supported by grants from American Cancer Society (120376-RSG-11-040-01-DDC), Charles H Hood Foundation and Worcester Foundation for Biomedical Research to JM. APM is supported by a grant from NIH (NS033642). The authors thank Drs Michael Rudnicki (University of Ottawa) and Amy Wagers (Joslin Diabetes Center) for providing cell isolation protocols, Joe Vaughan and Zhiwei Pang for technical support, and members of the Mao lab for helpful discussion.	Ahn S, 2005, NATURE, V437, P894, DOI 10.1038/nature03994; Ahn S, 2004, CELL, V118, P505, DOI 10.1016/j.cell.2004.07.023; Asakura A, 2007, P NATL ACAD SCI USA, V104, P16552, DOI 10.1073/pnas.0708145104; Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Bai CB, 2002, DEVELOPMENT, V129, P4753; Barakat MT, 2010, TRENDS MOL MED, V16, P337, DOI 10.1016/j.molmed.2010.05.003; Bhattaram P, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1008; Breneman JC, 2003, J CLIN ONCOL, V21, P78, DOI 10.1200/JCO.2003.06.129; Brennana DJ, 2009, EUR J CANCER, V45, P1510, DOI 10.1016/j.ejca.2009.01.028; Bridge JA, 2002, GENE CHROMOSOME CANC, V33, P310, DOI 10.1002/gcc.10026; Bridge JA, 2000, GENE CHROMOSOME CANC, V27, P337, DOI 10.1002/(SICI)1098-2264(200004)27:4<337::AID-GCC1>3.0.CO;2-1; Brownell I, 2011, CELL STEM CELL, V8, P552, DOI 10.1016/j.stem.2011.02.021; Gerber AN, 2007, ONCOGENE, V26, P1122, DOI 10.1038/sj.onc.1209891; Gibson P, 2010, NATURE, V468, P1095, DOI 10.1038/nature09587; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Grachtchouk M, 2011, J CLIN INVEST, V121, P1768, DOI 10.1172/JCI46307; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Harfe BD, 2004, CELL, V118, P517, DOI 10.1016/j.cell.2004.07.024; Hatley ME, 2012, CANCER CELL, V22, P536, DOI 10.1016/j.ccr.2012.09.004; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; Hettmer S, 2011, P NATL ACAD SCI USA, V108, P20002, DOI 10.1073/pnas.1111733108; Hettmer S, 2010, NAT MED, V16, P171, DOI 10.1038/nm0210-171; Hirai H, 2010, J CELL BIOL, V191, P347, DOI 10.1083/jcb.201006025; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Hui CC, 2011, ANNU REV CELL DEV BI, V27, P513, DOI 10.1146/annurev-cellbio-092910-154048; Jiang J, 2008, DEV CELL, V15, P801, DOI 10.1016/j.devcel.2008.11.010; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kasper M, 2011, P NATL ACAD SCI USA, V108, P4099, DOI 10.1073/pnas.1014489108; Kimura H, 2005, ONCOGENE, V24, P4026, DOI 10.1038/sj.onc.1208567; Koleva M, 2005, CELL MOL LIFE SCI, V62, P1863, DOI 10.1007/s00018-005-5072-9; Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104; Lee CJ, 2002, J NEURO-ONCOL, V57, P201, DOI 10.1023/A:1015773818302; Lee J, 1997, DEVELOPMENT, V124, P2537; Lepper C, 2009, NATURE, V460, P627, DOI 10.1038/nature08209; Liao YL, 2008, ONCOGENE, V27, P5578, DOI 10.1038/onc.2008.168; Liu PB, 2006, CANCER RES, V66, P4011, DOI 10.1158/0008-5472.CAN-05-3055; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; Mao J, 2006, CANCER RES, V66, P10171, DOI 10.1158/0008-5472.CAN-06-0657; McMahon AP, 2003, CURR TOP DEV BIOL, V53, P1, DOI 10.1016/S0070-2153(03)53002-2; Medina PP, 2009, HUM MOL GENET, V18, P1343, DOI 10.1093/hmg/ddp034; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Oliver TG, 2005, DEVELOPMENT, V132, P2425, DOI 10.1242/dev.01793; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Pappo Alberto S., 1995, Current Opinion in Oncology, V7, P361, DOI 10.1097/00001622-199507000-00012; Ridky TW, 2010, CELL STEM CELL, V6, P292, DOI 10.1016/j.stem.2010.03.009; ROBERTS WM, 1989, CANCER RES, V49, P5407; Rowitch DH, 1999, J NEUROSCI, V19, P8954, DOI 10.1523/JNEUROSCI.19-20-08954.1999; Rubin BP, 2011, CANCER CELL, V19, P177, DOI 10.1016/j.ccr.2010.12.023; Rubin LL, 2006, NAT REV DRUG DISCOV, V5, P1026, DOI 10.1038/nrd2086; Schuller U, 2008, CANCER CELL, P123; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stecca B, 2010, J MOL CELL BIOL, V2, P84, DOI 10.1093/jmcb/mjp052; Teglund S, 2010, BBA-REV CANCER, V1805, P181, DOI 10.1016/j.bbcan.2010.01.003; Tiffin N, 2003, BRIT J CANCER, V89, P327, DOI 10.1038/sj.bjc.6601040; Tostar U, 2006, J PATHOL, V208, P17, DOI 10.1002/path.1882; Tostar Ulrica, 2010, Genes Cancer, V1, P941, DOI 10.1177/1947601910385449; Vokes SA, 2008, GENE DEV, V22, P2651, DOI 10.1101/gad.1693008; Vokes SA, 2007, DEVELOPMENT, V134, P1977, DOI 10.1242/dev.001966; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Wang GY, 2011, CANCER CELL, V19, P114, DOI 10.1016/j.ccr.2010.11.007; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Youssef KK, 2010, NAT CELL BIOL, V12, P299, DOI 10.1038/ncb2031; Zibat A, 2010, ONCOGENE, V29, P6323, DOI 10.1038/onc.2010.368	65	15	15	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2014	33	46					5370	5378		10.1038/onc.2013.480	http://dx.doi.org/10.1038/onc.2013.480			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MF	24276242	Green Accepted			2022-12-17	WOS:000345120600007
J	Chang, YW; Mai, RT; Fang, WH; Lin, CC; Chiu, CC; Lee, YHW				Chang, Y-W; Mai, R-T; Fang, W-H; Lin, C-C; Chiu, C-C; Lee, Y-H Wu			YB-1 disrupts mismatch repair complex formation, interferes with MutS alpha recruitment on mismatch and inhibits mismatch repair through interacting with PCNA	ONCOGENE			English	Article						YB-1; PCNA; PIP-box; mismatch repair; MutS alpha; genome instability	CELL NUCLEAR ANTIGEN; VIRUS CORE PROTEIN; BOX BINDING-PROTEIN; MICROSATELLITE INSTABILITY; ALKYLATING-AGENTS; MISPAIRED BASES; DNA-DAMAGE; GLIOBLASTOMA-MULTIFORME; GENE-EXPRESSION; REPLICATION	Y-box binding protein-1 (YB-1) is highly expressed in tumors and it participates in various cellular processes. Previous studies indicated that YB-1 binds to mispaired DNA and interacts with several mismatch repair (MMR)-related factors. However, its role in the MMR system remains undefined. Here, we found that YB-1 represses mutS homolog 6 (MSH6)-containing MMR complex formation and reduces MutS alpha mismatch binding activity by disrupting interactions among MMR-related factors. In an effort to elucidate how YB-1 exerts this inhibitory effect, we have identified two functional proliferating cell nuclear antigen (PCNA)interacting protein (PIP)-boxes that mediate YB-1/PCNA interaction and locate within the C-terminal region of YB-1. This interaction is critical for the regulatory role of YB-1 in repressing MutSa mismatch binding activity, disrupting MutS alpha/PCNA/G/T heteroduplex ternary complex formation and inhibiting in vitro MMR activity. The differential regulation of 3' and 5' nick-directed MMR activity by YB-1 was also observed. Moreover, YB-1 overexpression is associated with the alteration of microsatellite pattern and the enhancement of N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced and spontaneous mutations. Furthermore, upregulation of other PIP-box-containing proteins, such as myeloid cell leukemia-1 (Mcl-1) and inhibitor of growth protein 1b (ING1b), has no impact on MMR complex formation and mutation accumulation, thus revealing the significant effect of YB-1 on regulating the MMR system. In conclusion, our study suggests that YB-1 functions as a PCNA-interacting factor to exert its regulatory role on the MMR process and involves in the induction of genome instability, which may partially account for the oncogenic potential of YB-1.	[Chang, Y-W; Mai, R-T; Lin, C-C; Chiu, C-C; Lee, Y-H Wu] Natl Yang Ming Univ, Sch Life Sci, Inst Biochem & Mol Biol, Taipei 112, Taiwan; [Mai, R-T; Lee, Y-H Wu] Natl Chiao Tung Univ, Coll Biol Sci & Technol, Dept Biol Sci & Technol, Hsinchu 300, Taiwan; [Fang, W-H] Natl Taiwan Univ Hosp, Dept Clin Lab Sci & Med Biotechnol, Taipei, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Taiwan University; National Taiwan University Hospital	Lee, YHW (corresponding author), Natl Chiao Tung Univ, Coll Biol Sci & Technol, Dept Biol Sci & Technol, 1001 Ta Hsueh Rd, Hsinchu 300, Taiwan.	yhwulee@nctu.edu.tw		FANG, WOEI-HORNG/0000-0003-4728-5931	National Health Research Institute [NHRI-EX100-10014BI, NHRI-EX101-10014BI, NHRI-EX102-10014BI]; National Science Council [NSC-94-2320-B-010-005, NSC-95-2320-B-010-049-MY3, NSC-97-2320-B-010-014-MY3, NSC-97-2320-B-009-003-MY3, NSC-100-2320-B-009-007-MY3, NSC-101-2811-B-009-006, NSC-102-2811-B-009-007]; National Yang-Ming University; National Chiao-Tung University; Ministry of Education, Taiwan, Republic of China	National Health Research Institute(National Health Research Institutes - Taiwan); National Science Council(Ministry of Science and Technology, Taiwan); National Yang-Ming University; National Chiao-Tung University; Ministry of Education, Taiwan, Republic of China(Ministry of Education, Taiwan)	This study was supported by the following grants to Dr Yan-Hwa Wu Lee: the National Health Research Institute (NHRI-EX100-10014BI, NHRI-EX101-10014BI and NHRI-EX102-10014BI), the National Science Council (NSC-94-2320-B-010-005, NSC-95-2320-B-010-049-MY3, NSC-97-2320-B-010-014-MY3, NSC-97-2320-B-009-003-MY3, NSC-100-2320-B-009-007-MY3, NSC-101-2811-B-009-006 and NSC-102-2811-B-009-007) and the 'Aim for the Top University Program' of the National Yang-Ming University, the National Chiao-Tung University and the Ministry of Education, Taiwan, Republic of China. We thank Dr Tsung-Sheng Su and Dr Tzu-Hao Cheng for helpful discussions and suggestions, Dr Josef Jiricny, Dr Hsin-Fang Yang-Yen and Dr Zee-Fen Chang for kindly providing plasmids used in this study, Dr Shr-Jeng Leu for sharing experiences on baculovirus expression system and Dr Li-Li Li for critical reading and comments on this manuscript. We acknowledge the High-throughput Genome Analysis Core Facility of National Core Facility Program for Biotechnology, Taiwan (NSC 101-2319-B-010-001), for capillary electrophoresis and DNA sequencing.	Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Bignami M, 2000, MUTAT RES-REV MUTAT, V462, P71, DOI 10.1016/S1383-5742(00)00016-8; Blanco G, 1998, AM J PHYSIOL-RENAL, V275, pF633, DOI 10.1152/ajprenal.1998.275.5.F633; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; Casorelli I, 2008, ANTI-CANCER AGENT ME, V8, P368, DOI 10.2174/187152008784220276; Chen C, 1999, MOL CELL BIOL, V19, P7801; Chou CH, 2006, MOL BIOL CELL, V17, P3952, DOI 10.1091/mbc.E06-04-0319; Christmann M, 2000, J BIOL CHEM, V275, P36256, DOI 10.1074/jbc.M005377200; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; Constantin N, 2005, J BIOL CHEM, V280, P39752, DOI 10.1074/jbc.M509701200; de Souza-Pinto NC, 2009, DNA REPAIR, V8, P704, DOI 10.1016/j.dnarep.2009.01.021; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Dietmaier W, 1997, CANCER RES, V57, P4749; Drobinskaya I, 2005, ANTICANCER RES, V25, P3251; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Dzantiev L, 2004, MOL CELL, V15, P31, DOI 10.1016/j.molcel.2004.06.016; Eliseeva IA, 2011, BIOCHEMISTRY-MOSCOW+, V76, P1402, DOI 10.1134/S0006297911130049; Evdokimova V, 2006, CELL CYCLE, V5, P1143, DOI 10.4161/cc.5.11.2784; Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017; Faury D, 2007, J CLIN ONCOL, V25, P1196, DOI 10.1200/JCO.2006.07.8626; Flores-Rozas H, 2000, NAT GENET, V26, P375, DOI 10.1038/81708; Fu D, 2012, NAT REV CANCER, V12, P104, DOI 10.1038/nrc3185; Fujise K, 2000, J BIOL CHEM, V275, P39458, DOI 10.1074/jbc.M006626200; Gao YY, 2009, MOL CANCER THER, V8, P3276, DOI 10.1158/1535-7163.MCT-09-0478; Gaudreault I, 2004, NUCLEIC ACIDS RES, V32, P316, DOI 10.1093/nar/gkh170; Genschel J, 2002, J BIOL CHEM, V277, P13302, DOI 10.1074/jbc.M111854200; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Guo SL, 2004, J BIOL CHEM, V279, P16912, DOI 10.1074/jbc.M313213200; Hidaka M, 2005, NUCLEIC ACIDS RES, V33, P5703, DOI 10.1093/nar/gki878; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Huang DY, 2001, BIOCHEM J, V356, P829, DOI 10.1042/0264-6021:3560829; Huang YM, 2004, J BIOL CHEM, V279, P30228, DOI 10.1074/jbc.M401675200; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; Imai K, 2008, CARCINOGENESIS, V29, P673, DOI 10.1093/carcin/bgm228; Ise T, 1999, CANCER RES, V59, P342; Iyer RR, 2010, J BIOL CHEM, V285, P11730, DOI 10.1074/jbc.M110.104125; Iyer RR, 2006, CHEM REV, V106, P302, DOI 10.1021/cr0404794; Jascur T, 2011, J BIOL CHEM, V286, P29531, DOI 10.1074/jbc.M111.221341; Jiricny J, 2006, NAT REV MOL CELL BIO, V7, P335, DOI 10.1038/nrm1907; JIRICNY J, 1988, P NATL ACAD SCI USA, V85, P8860, DOI 10.1073/pnas.85.23.8860; Johnson RE, 1996, J BIOL CHEM, V271, P27987, DOI 10.1074/jbc.271.45.27987; Jorgensen PL, 2001, BBA-BIOENERGETICS, V1505, P57, DOI 10.1016/S0005-2728(00)00277-2; Kadyrov FA, 2006, CELL, V126, P297, DOI 10.1016/j.cell.2006.05.039; Kaina B, 2007, DNA REPAIR, V6, P1079, DOI 10.1016/j.dnarep.2007.03.008; Karran P, 2001, CARCINOGENESIS, V22, P1931, DOI 10.1093/carcin/22.12.1931; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; Koptyra M, 2006, BLOOD, V108, P319, DOI 10.1182/blood-2005-07-2815; Kunkel TA, 2005, ANNU REV BIOCHEM, V74, P681, DOI 10.1146/annurev.biochem.74.082803.133243; Kunz C, 2009, CELL MOL LIFE SCI, V66, P1021, DOI 10.1007/s00018-009-8739-9; Lau PJ, 2003, J BIOL CHEM, V278, P14, DOI 10.1074/jbc.C200627200; Lee SD, 2006, J MOL BIOL, V355, P175, DOI 10.1016/j.jmb.2005.10.059; Li GM, 2008, CELL RES, V18, P85, DOI 10.1038/cr.2007.115; Liberti SE, 2011, DNA REPAIR, V10, P73, DOI 10.1016/j.dnarep.2010.09.023; Lingrel JB, 1998, ACTA PHYSIOL SCAND, V163, P69; Lu ZH, 2005, MOL CELL BIOL, V25, P4625, DOI 10.1128/MCB.25.11.4625-4637.2005; Mai RT, 2006, ONCOGENE, V25, P448, DOI 10.1038/sj.onc.1209052; Marsischky GT, 1999, J BIOL CHEM, V274, P26668, DOI 10.1074/jbc.274.38.26668; Martinez R, 2004, ONCOLOGY-BASEL, V66, P395, DOI 10.1159/000079488; Masih PJ, 2008, NUCLEIC ACIDS RES, V36, P67, DOI 10.1093/nar/gkm943; Matsumoto Ken, 2005, J Mol Genet Med, V1, P11; Modrich P, 2006, J BIOL CHEM, V281, P30305, DOI 10.1074/jbc.R600022200; Moldovan GL, 2007, CELL, V129, P665, DOI 10.1016/j.cell.2007.05.003; Montecucco A, 1998, EMBO J, V17, P3786, DOI 10.1093/emboj/17.13.3786; O'Brien V, 2006, CARCINOGENESIS, V27, P682, DOI 10.1093/carcin/bgi298; Oda Y, 2003, J PATHOL, V199, P251, DOI 10.1002/path.1282; Perez-Garcia A, 2012, FRONT BIOSCI-LANDMRK, V17, P1469, DOI 10.2741/3998; Pizzi C, 2007, ONCOL REP, V17, P193; Pluciennik A, 2010, P NATL ACAD SCI USA, V107, P16066, DOI 10.1073/pnas.1010662107; Sarkaria JN, 2008, CLIN CANCER RES, V14, P2900, DOI 10.1158/1078-0432.CCR-07-1719; Scott M, 2001, J CELL SCI, V114, P3455; Shell SS, 2007, MOL CELL, V26, P565, DOI 10.1016/j.molcel.2007.04.024; SHIH CM, 1993, J VIROL, V67, P5823, DOI 10.1128/JVI.67.10.5823-5832.1993; Soreide K, 2007, TUMOR BIOL, V28, P290, DOI 10.1159/000110427; Stojic L, 2004, DNA REPAIR, V3, P1091, DOI 10.1016/j.dnarep.2004.06.006; Stoklosa T, 2008, CANCER RES, V68, P2576, DOI 10.1158/0008-5472.CAN-07-6858; Tomita-Mitchell A, 2000, MUTAT RES-FUND MOL M, V450, P125, DOI 10.1016/S0027-5107(00)00020-8; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Umar A, 1997, CANCER RES, V57, P3949; Valentini AM, 2006, CANCER TREAT REV, V32, P607, DOI 10.1016/j.ctrv.2006.08.001; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Woolley AG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020603; Xie WX, 2012, TUMOR BIOL, V33, P63, DOI 10.1007/s13277-011-0246-6; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; Zhang YB, 2005, CELL, V122, P693, DOI 10.1016/j.cell.2005.06.027	85	15	16	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2014	33	43					5065	5077		10.1038/onc.2013.450	http://dx.doi.org/10.1038/onc.2013.450			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OF	24141788				2022-12-17	WOS:000343768400002
J	Zhang, H; Yu, C; Dai, J; Keller, JM; Hua, A; Sottnik, JL; Shelley, G; Hall, CL; Park, SI; Yao, Z; Zhang, J; McCauley, LK; Keller, ET				Zhang, H.; Yu, C.; Dai, J.; Keller, J. M.; Hua, A.; Sottnik, J. L.; Shelley, G.; Hall, C. L.; Park, S. I.; Yao, Z.; Zhang, J.; McCauley, L. K.; Keller, E. T.			Parathyroid hormone-related protein inhibits DKK1 expression through c-Jun-mediated inhibition of beta-catenin activation of the DKK1 promoter in prostate cancer	ONCOGENE			English	Article						prostate cancer; DKK1; PTHrP; Wnt/beta-catenin signaling; skeletal metastasis	WNT ANTAGONIST DICKKOPF-1; BONE METASTASES; RECEPTOR; GROWTH; CELLS; PTHRP; TUMOR; GENE; TRANSCRIPTION; TARGET	Prostate cancer (PCa) bone metastases are unique in that majority of them induce excessive mineralized bone matrix, through undefined mechanisms, as opposed to most other cancers that induce bone resorption. Parathyroid hormone-related protein (PTHrP) is produced by PCa cells and intermittent PTHrP exposure has bone anabolic effects, suggesting that PTHrP could contribute to the excess bone mineralization. Wnts are bone-productive factors produced by PCa cells, and the Wnt inhibitor Dickkopfs-1 (DKK1) has been shown to promote PCa progression. These findings, in conjunction with the observation that PTHrP expression increases and DKK1 expression decreases as PCa progresses, led to the hypothesis that PTHrP could be a negative regulator of DKK1 expression in PCa cells and, hence, allow the osteoblastic activity of Wnts to be realized. To test this, we first demonstrated that PTHrP downregulated DKK1 mRNA and protein expression. We then found through multiple mutated DKK1 promoter assays that PTHrP, through c-Jun activation, downregulated the DKK1 promoter through a transcription factor (TCF) response element site. Furthermore, chromatin immunoprecipitation (ChIP) and re-ChIP assays revealed that PTHrP mediated this effect through inducing c-Jun to bind to a transcriptional activator complex consisting of beta-catenin, which binds the most proximal DKK1 promoter, the TCF response element. Together, these results demonstrate a novel signaling linkage between PTHrP and Wnt signaling pathways that results in downregulation of a Wnt inhibitor allowing for Wnt activity that could contribute the osteoblastic nature of PCa.	[Zhang, H.; Yu, C.; Dai, J.; Keller, J. M.; Hua, A.; Sottnik, J. L.; Shelley, G.; Hall, C. L.; Keller, E. T.] Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI 48109 USA; [Yu, C.; Yao, Z.] Tianjin Med Univ, Dept Immunol, Tianjin Key Lab Cellular & Mol Immunol, Key Lab Educ Minist, Tianjin, Peoples R China; [Park, S. I.; McCauley, L. K.] Univ Michigan, Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA; [Zhang, J.] Guangxi Med Univ, Ctr Translat Med Res, Guangxi, Peoples R China; [McCauley, L. K.; Keller, E. T.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; Tianjin Medical University; University of Michigan System; University of Michigan; Guangxi Medical University; University of Michigan System; University of Michigan	Keller, ET (corresponding author), Univ Michigan, Sch Med, Dept Urol, 5308 CC,1500 East Med Ctr Dr, Ann Arbor, MI 48109 USA.	etkeller@umich.edu	Keller, Evan T/M-1446-2016; Park, Serk In/D-2840-2011; Dai, Jin/GVT-2414-2022; ZHANG, JIAN/Q-6334-2018	Keller, Evan T/0000-0002-7592-7535; Park, Serk In/0000-0001-8643-5096; Dai, Jin/0000-0003-3063-746X; Hall, Christopher/0000-0003-1421-1733	NIH [PO1-CA939000]; US Department of Defense [W81XWH-10-1-0546]; NATIONAL CANCER INSTITUTE [P01CA093900] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000114] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by the NIH PO1-CA939000 (ETK and LKM), and the US Department of Defense W81XWH-10-1-0546 (SIP).	Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; Akiyama H, 2004, GENE DEV, V18, P1072, DOI 10.1101/gad.1171104; Asadi F, 1996, HUM PATHOL, V27, P1319, DOI 10.1016/S0046-8177(96)90344-5; Azarani A, 1996, J BIOL CHEM, V271, P14931, DOI 10.1074/jbc.271.25.14931; Azari S, 2007, BIOLOGICALS, V35, P195, DOI 10.1016/j.biologicals.2006.10.001; BROWN PH, 1994, ONCOGENE, V9, P791; Chirgwin J. M., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P308; Clines GA, 2007, MOL ENDOCRINOL, V21, P486, DOI 10.1210/me.2006-0346; Cowling VH, 2007, MOL CELL BIOL, V27, P5135, DOI 10.1128/MCB.02282-06; Dai JL, 2005, CANCER RES, V65, P8274, DOI 10.1158/0008-5472.CAN-05-1891; Deftos LJ, 2005, BIOCHEM BIOPH RES CO, V327, P468, DOI 10.1016/j.bbrc.2004.11.162; Dennler S, 2000, J BIOL CHEM, V275, P28858, DOI 10.1074/jbc.M910358199; Dougherty KM, 1999, CANCER RES, V59, P6015; Grotewold L, 2002, EMBO J, V21, P966, DOI 10.1093/emboj/21.5.966; GUISE TA, 1993, J CLIN ENDOCR METAB, V77, P40, DOI 10.1210/jc.77.1.40; Hall CL, 2008, PROSTATE, V68, P1396, DOI 10.1002/pros.20805; Hall CL, 2006, CANCER METAST REV, V25, P551, DOI 10.1007/s10555-006-9022-2; Hall CL, 2005, CANCER RES, V65, P7554, DOI 10.1158/0008-5472.CAN-05-1317; HENDERSON E, 1994, MOL CELL BIOL, V14, P655, DOI 10.1128/MCB.14.1.655; IWAMURA M, 1993, CANCER RES, V53, P1724; Kane N, 2008, MOL ENDOCRINOL, V22, P716, DOI 10.1210/me.2007-0316; Keller ET, 2004, J CELL BIOCHEM, V91, P718, DOI 10.1002/jcb.10662; Kitagawa Y, 2005, CANCER RES, V65, P10921, DOI 10.1158/0008-5472.CAN-05-1809; Koh AJ, 1999, ENDOCRINOLOGY, V140, P3154, DOI 10.1210/en.140.7.3154; Koppen A, 2007, CANCER LETT, V256, P218, DOI 10.1016/j.canlet.2007.06.011; Kremer R, 2012, ADV EXP MED BIOL, V720, P145, DOI 10.1007/978-1-4614-0254-1_12; Lee J, 2008, GYNECOL ONCOL, V109, P270, DOI 10.1016/j.ygyno.2008.01.034; Lee YC, 2011, CANCER RES, V71, P5194, DOI 10.1158/0008-5472.CAN-10-4374; Li J, 2008, NAT CELL BIOL, V10, P160, DOI 10.1038/ncb1684; Li ZG, 2008, J CLIN INVEST, V118, P2697, DOI 10.1172/JCI33093; Liao JH, 2008, INT J CANCER, V123, P2267, DOI 10.1002/ijc.23602; Lu Y, 2007, CANCER RES, V67, P3646, DOI 10.1158/0008-5472.CAN-06-1210; Lupp A, 2010, EUR J ENDOCRINOL, V162, P979, DOI 10.1530/EJE-09-0821; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Maehata T, 2008, WORLD J GASTROENTERO, V14, P2702, DOI 10.3748/wjg.14.2702; McCauley LK, 2012, J BONE MINER RES, V27, P1231, DOI 10.1002/jbmr.1617; Muller M, 2009, INT J MOL MED, V24, P373, DOI 10.3892/ijmm_00000242; Muncan V, 2006, MOL CELL BIOL, V26, P8418, DOI 10.1128/MCB.00821-06; Navarro D, 2010, CARCINOGENESIS, V31, P394, DOI 10.1093/carcin/bgp317; Nelson JB, 2003, J UROLOGY, V169, P1143, DOI 10.1097/01.ju.0000042162.08938.27; Perez-Martinez FC, 2007, J CLIN PATHOL, V60, P290, DOI 10.1136/jcp.2006.037853; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; Qin L, 2003, J BIOL CHEM, V278, P19723, DOI 10.1074/jbc.M212226200; Rabbani SA, 1999, INT J CANCER, V80, P257, DOI 10.1002/(SICI)1097-0215(19990118)80:2<257::AID-IJC15>3.3.CO;2-V; Robinson DR, 2008, CURR DRUG TARGETS, V9, P571; Sepulveda VAT, 2002, REGUL PEPTIDES, V105, P109, DOI 10.1016/S0167-0115(02)00007-1; Thompson EJ, 2002, MOL CARCINOGEN, V35, P157, DOI 10.1002/mc.10090; UY HL, 1995, ENDOCRINOLOGY, V136, P3207, DOI 10.1210/en.136.8.3207; van Bokhoven A, 2003, PROSTATE, V57, P205, DOI 10.1002/pros.10290; Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055; Zhang J, 2011, J BONE MINER RES, V26, P1953, DOI 10.1002/jbmr.377; Zhong Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022129	52	15	20	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2014	33	19					2464	2477		10.1038/onc.2013.203	http://dx.doi.org/10.1038/onc.2013.203			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH3OK	23752183	Green Accepted			2022-12-17	WOS:000336033600006
J	Zhou, W; Srinivasan, S; Nawaz, Z; Slingerland, JM				Zhou, W.; Srinivasan, S.; Nawaz, Z.; Slingerland, J. M.			ER alpha, SKP2 and E2F-1 form a feed forward loop driving late ER alpha targets and G1 cell cycle progression	ONCOGENE			English	Article						cyclin E-CDK2; ER alpha; E2F-1; SCFSKP2; ubiquitylation; coactivator	ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER-CELLS; UBIQUITIN LIGASE COMPLEX; CDK INHIBITOR P27; BOX PROTEIN SKP2; TRANSCRIPTIONAL ACTIVATION; HORMONE-RECEPTORS; DOWN-REGULATION; BINDING-SITES; DEPENDENT PHOSPHORYLATION	Estrogen triggers transactivation coupled estrogen receptor a (ER alpha) proteolysis, but mechanisms thereof remain obscure. Present data link estrogen: ER alpha-driven transcription with cell cycle progression. Although liganded ER alpha induces many genes within 1-4 h, gene activation after 6 h is thought to be indirect. Here, we identify SKP2 as a late-acting coactivator that drives ERa targets to promote G1-to-S progression. Data support a model in which estrogen-activated cyclin E-CDK2 binds and phosphorylates ER alpha S341, to prime ER alpha-SCFSKP2 binding via SKP2-L(248)QTLL(252) in late G1. SKP2 activates ERa ubiquitylation and proteolysis. Putative late ER alpha targets were identified by expression profiling. SKP2 knockdown attenuated E2F-1 and BLM induction. SKP2 overexpression, but not coactivator motif mutant SKP2-L(248)QTAA(252), enhanced estrogen-induced E2F-1 and BLM expression. SKP2 knockdown impaired estrogen-stimulated ER alpha, SKP2, SRC3 and RNA polymerase II recruitment to E2F-1 and BLM promoters. This work not only identifies these late-activated genes as bona fide ERa targets but describes a novel mechanism for their periodic activation. SKP2 serves as dual ER alpha E3 ligase/coactivator for late-activated target genes, revealing a novel mechanism whereby ER alpha/SCFSKP2 transactivation of E2F-1 feeds forward to drive G1-to-S.	[Zhou, W.; Srinivasan, S.; Nawaz, Z.; Slingerland, J. M.] Univ Miami, Sylvester Comprehens Canc Ctr, Braman Family Breast Canc Inst, Miami, FL 33136 USA; [Zhou, W.; Srinivasan, S.; Nawaz, Z.; Slingerland, J. M.] Univ Miami, Miller Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA; [Slingerland, J. M.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA	University of Miami; University of Miami; University of Miami	Slingerland, JM (corresponding author), Univ Miami, Sylvester Comprehens Canc Ctr, Braman Family Breast Canc Inst, 1501 NW 10th Ave,BRB708, Miami, FL 33136 USA.	jslingerland@med.miami.edu	Zhou, Wen/A-5763-2010	Zhou, Wen/0000-0002-5496-5815	NIH [R01CA123415]; US DOD Pre-doctoral grant [W81XWH-11-1-0097]; NATIONAL CANCER INSTITUTE [R01CA123415] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US DOD Pre-doctoral grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank M Pagano for bacculovirus stocks (CUL1, SKP1, RBX1, SKP2), WL Kraus for pPK-FLAG-ER alpha plasmid, H-K Lin for pcDNA4-His-Max-Xpress SKP2, and J Sun for technical intellectual input. This work was supported by NIH R01CA123415 (JMS and ZN), and a US DOD Pre-doctoral grant W81XWH-11-1-0097 (WZ).	Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; Alarid ET, 2003, ENDOCRINOLOGY, V144, P3469, DOI 10.1210/en.2002-0092; Atsriku C, 2009, MOL CELL PROTEOMICS, V8, P467, DOI 10.1074/mcp.M800282-MCP200; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Bhatt S, 2012, MOL CELL BIOL, V32, P1928, DOI 10.1128/MCB.06561-11; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Chi Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-10-r149; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; Chu I, 2007, J CLIN INVEST, V117, P2205, DOI 10.1172/JCI21739; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Dace A, 2000, P NATL ACAD SCI USA, V97, P8985, DOI 10.1073/pnas.160257997; DALY RJ, 1990, CANCER RES, V50, P5868; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DUBIK D, 1987, CANCER RES, V47, P6517; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fan MY, 2004, MOL ENDOCRINOL, V18, P2603, DOI 10.1210/me.2004-0164; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hao B, 2005, MOL CELL, V20, P9, DOI 10.1016/j.molcel.2005.09.003; Harper JW, 2001, CHEM REV, V101, P2511, DOI 10.1021/cr0001030; Held JM, 2012, MOL CANCER RES, V10, P1120, DOI 10.1158/1541-7786.MCR-12-0099; Iso T, 2007, BIOL PHARM BULL, V30, P266, DOI 10.1248/bpb.30.266; Johnson AE, 2007, MOL CELL BIOCHEM, V301, P13, DOI 10.1007/s11010-006-9392-3; Kennedy BA, 2010, NUCLEIC ACIDS RES, V38, pD676, DOI 10.1093/nar/gkp734; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039-128X(99)00107-5; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Li XH, 2003, J BIOL CHEM, V278, P30854, DOI 10.1074/jbc.C300251200; Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087; Lin ZH, 2007, CANCER RES, V67, P5017, DOI 10.1158/0008-5472.CAN-06-3696; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Moro L, 2006, J BIOL CHEM, V281, P22100, DOI 10.1074/jbc.M604636200; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Nawaz Z, 2004, MOL ENDOCRINOL, V18, P493, DOI 10.1210/me.2003-0388; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Nilsson S, 2000, BREAST CANCER RES, V2, P360, DOI 10.1186/bcr81; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Saji S, 2001, BIOCHEM BIOPH RES CO, V281, P259, DOI 10.1006/bbrc.2001.4339; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Shen TJ, 2001, MOL CELL BIOL, V21, P6122, DOI 10.1128/MCB.21.18.6122-6131.2001; Sherr CJ, 2000, CANCER RES, V60, P3689; Sun J, 2007, MOL ENDOCRINOL, V21, P2651, DOI 10.1210/me.2007-0082; Sun J, 2012, MOL ENDOCRINOL, V26, P1567, DOI 10.1210/me.2012-1140; Tansey WP, 2001, GENE DEV, V15, P1045, DOI 10.1101/gad.896501; TSAI LH, 1993, ONCOGENE, V8, P1593; Wang WL, 1999, MOL ENDOCRINOL, V13, P1373, DOI 10.1210/me.13.8.1373; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Woo RA, 2003, CELL CYCLE, V2, P316, DOI 10.4161/cc.2.4.468; Wu J, 2012, MOL CELL, V46, P351, DOI 10.1016/j.molcel.2012.02.018; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; Zhang L, 2006, ONCOGENE, V25, P2615, DOI 10.1038/sj.onc.1209286	62	15	18	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2014	33	18					2341	2353		10.1038/onc.2013.197	http://dx.doi.org/10.1038/onc.2013.197			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AG5ID	23770852				2022-12-17	WOS:000335451800007
J	Bonito, NA; Drechsler, J; Stoecker, S; Carmo, CR; Seckl, MJ; Hermanns, HM; Costa-Pereira, AP				Bonito, N. A.; Drechsler, J.; Stoecker, S.; Carmo, C. R.; Seckl, M. J.; Hermanns, H. M.; Costa-Pereira, A. P.			Control of gp130 expression by the mitogen-activated protein kinase ERK2	ONCOGENE			English	Article						ERK; gp130; IL-6-type cytokines; JAK/STAT signalling; receptor expression	LEUKEMIA INHIBITORY FACTOR; CYTOKINE RECEPTOR GP130; INFLAMMATORY CYTOKINES; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; STAT3 ACTIVATION; CANCER; GROWTH; IL-6; TRANSFORMATION	Interleukin (IL)-6-type cytokines such as IL-6, oncostatin M (OSM) and leukaemia inhibitory factor (LIF) signal through receptor complexes that are critically dependent on gp130. The latter is the common signal-transducing molecule that couples these cytokines to their downstream effectors, Janus kinases (JAKs) and signal transducers and activators of transcription (STATs). IL-6-type cytokine signalling additionally involves the recruitment and activation of extracellular signal-regulated kinase (ERK) 1 and ERK2. Both STATs and ERKs regulate responses mediated by members of the IL-6 family. Here, we show that ERK2, but not ERK1, also controls the expression and function of gp130 per se, as silencing ERK2 in human osteosarcoma U2OS cells inhibits the expression of gp130. This does not simply reflect quantitative differences between ERK1 and ERK2, and the effects are not restricted to osteosarcoma cells, as they can be extended to several other cancer cell types analysed to date (such as breast, prostate, lung and cervical cancer cells). Importantly, ERK2 binds to the GP130 promoter, where it perhaps interacts with the transcriptional machinery. Indeed, its role in the transcriptional regulation of the GP130 gene was corroborated using luciferase reporter assays and messenger RNA stability experiments. Considering the pivotal role that gp130 has in cancer and inflammation these data thus identify novel non-overlapping functions for ERK1 and ERK2 that are biologically relevant.	[Bonito, N. A.; Stoecker, S.; Carmo, C. R.; Seckl, M. J.; Costa-Pereira, A. P.] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Fac Med, London W12 0NN, England; [Drechsler, J.; Hermanns, H. M.] Rudolf Virchow Ctr, DFG Res Ctr Expt Biomed, Wurzburg, Germany; [Carmo, C. R.] Inst Gulbenkian Ciencias, Oeiras, Portugal	Imperial College London; German Research Foundation (DFG); University of Wurzburg; Instituto Gulbenkian de Ciencia	Costa-Pereira, AP (corresponding author), Univ London Imperial Coll Sci Technol & Med, ICTEM, Dept Surg & Canc, Fac Med, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	a.costa-pereira@imperial.ac.uk	Costa-Pereira, Ana/AAE-8192-2020	Ramos do Carmo, Catarina/0000-0001-9717-6667; Costa-Pereira, Ana/0000-0001-8265-8065	Foundation for Science and Technology (FCT) ( Lisbon, Portugal), [SFRH/BD/61857/2009]; Cancer Treatment and Research Trust (CTRT); Cancer Research UK; Deutsche Forschungsgemeinschaft (DFG) [FZ82]; Elsie Widdowson Fellowship	Foundation for Science and Technology (FCT) ( Lisbon, Portugal),(Portuguese Foundation for Science and Technology); Cancer Treatment and Research Trust (CTRT); Cancer Research UK(Cancer Research UK); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Elsie Widdowson Fellowship	We are grateful to Dr Charles A O'Brien (University of Arkansas for Medical Sciences, Little Rock, USA) for control and full-length gp130 (p2433) luciferase constructs. Within Imperial College London, the authors are indebted to Dr Charlotte Bevan and her research team, Dr Rajat Roy, Mr Richard Schlegel and Dr Olivier Pardo for many helpful discussions, and Dr Anna Maria Tommasi for technical help. NB is funded by a PhD studentship (SFRH/BD/61857/2009) from the Foundation for Science and Technology (FCT) ( Lisbon, Portugal), and CRC is funded by Cancer Treatment and Research Trust (CTRT). APC-P and MJS are funded by Cancer Research UK and CTRT. JD and HMH are funded by the Deutsche Forschungsgemeinschaft (DFG, FZ82). APC-P is also the recipient of an Elsie Widdowson Fellowship.	Bourcier C, 2006, CANCER RES, V66, P2700, DOI 10.1158/0008-5472.CAN-05-3129; Bromberg J, 2009, CANCER CELL, V15, P79, DOI 10.1016/j.ccr.2009.01.009; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Cohen-Armon M, 2007, MOL CELL, V25, P297, DOI 10.1016/j.molcel.2006.12.012; Costa-Pereira AP, 2011, AM J CANCER RES, V1, P806; Ernst M, 2004, TRENDS GENET, V20, P23, DOI 10.1016/j.tig.2003.11.003; Fasnacht N, 2008, SEMIN CELL DEV BIOL, V19, P379, DOI 10.1016/j.semcdb.2008.07.001; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gough DJ, 2009, SCIENCE, V324, P1713, DOI 10.1126/science.1171721; Grivennikov SI, 2011, ANN RHEUM DIS, V70, pI104, DOI 10.1136/ard.2010.140145; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hermanns HM, 2000, J BIOL CHEM, V275, P40742, DOI 10.1074/jbc.M005408200; Hirai H, 2011, BIOCHEM J, V438, P11, DOI 10.1042/BJ20102152; Hu SH, 2009, CELL, V139, P610, DOI 10.1016/j.cell.2009.08.037; Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510; Inghirami G, 2005, CELL CYCLE, V4, P1131, DOI 10.4161/cc.4.9.1985; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; Kamimura D, 2004, REV PHYSIOL BIOCH P, V149, P1, DOI 10.1007/s10254-003-0012-2; Koskela HLM, 2012, NEW ENGL J MED, V366, P1905, DOI 10.1056/NEJMoa1114885; Krens SFG, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-196; Lavagni P, 2009, J MOL NEUROSCI, V37, P212, DOI 10.1007/s12031-008-9118-y; Lefloch R, 2008, MOL CELL BIOL, V28, P511, DOI 10.1128/MCB.00800-07; Marchetti A, 2004, CELL DEATH DIFFER, V11, P596, DOI 10.1038/sj.cdd.4401368; Marchi M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003873; Mebratu Y, 2009, CELL CYCLE, V8, P1168, DOI 10.4161/cc.8.8.8147; Neurath MF, 2011, CYTOKINE GROWTH F R, V22, P83, DOI 10.1016/j.cytogfr.2011.02.003; OBrien CA, 1997, J BIOL CHEM, V272, P15003, DOI 10.1074/jbc.272.23.15003; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pokholok DK, 2006, SCIENCE, V313, P533, DOI 10.1126/science.1127677; Pouyssegur J, 2003, EUR J BIOCHEM, V270, P3291, DOI 10.1046/j.1432-1033.2003.03707.x; Radtke S, 2010, J CELL SCI, V123, P947, DOI 10.1242/jcs.065326; Rebouissou S, 2009, NATURE, V457, P200, DOI 10.1038/nature07475; Rodriguez J, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002324; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Roy SK, 2002, P NATL ACAD SCI USA, V99, P7945, DOI 10.1073/pnas.122075799; Saba-El-Leil MK, 2003, EMBO REP, V4, P964, DOI 10.1038/sj.embor.embor939; Santos CI, 2011, BBA-REV CANCER, V1816, P38, DOI 10.1016/j.bbcan.2011.03.003; Schiemann WP, 1997, J BIOL CHEM, V272, P16631, DOI 10.1074/jbc.272.26.16631; Schlessinger K, 2005, CANCER RES, V65, P5828, DOI 10.1158/0008-5472.CAN-05-0317; Shapiro PS, 1999, MOL CELL BIOL, V19, P3551; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Song LX, 2003, ONCOGENE, V22, P4150, DOI 10.1038/sj.onc.1206479; Stuhlmann-Laeisz C, 2006, MOL BIOL CELL, V17, P2986, DOI 10.1091/mbc.E05-12-1129; Vantaggiato Chiara, 2006, J Biol, V5, P14, DOI 10.1186/jbiol38; Voisin L, 2010, MOL CELL BIOL, V30, P2918, DOI 10.1128/MCB.00131-10; Watling D, 2008, P NATL ACAD SCI USA, V105, P6051, DOI 10.1073/pnas.0710814105; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; Yoshimura A, 2006, CANCER SCI, V97, P439, DOI 10.1111/j.1349-7006.2006.00197.x; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734	53	15	15	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2014	33	17					2255	2263		10.1038/onc.2013.159	http://dx.doi.org/10.1038/onc.2013.159			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF8WJ	23686311				2022-12-17	WOS:000334996000011
J	Moreno, A; Soleto, I; Garcia-Sanz, P; Moreno-Bueno, G; Palmero, I				Moreno, A.; Soleto, I.; Garcia-Sanz, P.; Moreno-Bueno, G.; Palmero, I.			ING4 regulates a secretory phenotype in primary fibroblasts with dual effects on cell proliferation and tumor growth	ONCOGENE			English	Article						ING4; p53; tumor suppression; secretory phenotype	SUPPRESSOR PROTEIN ING4; SENESCENCE; CANCER; GENES; P53; ACETYLATION; INHIBITOR; STRESS; TUMORIGENESIS; ANGIOGENESIS	ING proteins have an essential role in the control of a variety of cellular functions whose deregulation is associated with tumor formation and dissemination, such as proliferation, apoptosis, senescence or invasion. Accordingly, loss of function of ING proteins is a frequent event in many types of human tumors. In this report, we have studied the function of ING4, a member of the ING family of tumor suppressors, in the context of normal, non-transformed primary fibroblasts. We show that ING4 negatively regulates cell proliferation in this cell type. The antiproliferative action of ING4 requires its ability to recognize chromatin marks, it is p53-dependent at least in part, and it is lost in an ING4 cancer-associated mutant. Gene expression analysis shows that ING4 regulates the expression and release of soluble factors of the chemokine family. The secretory phenotype regulated by ING4 in primary fibroblasts displays a selective paracrine effect on proliferation, fostering the division of tumor cells, while inhibiting division in primary fibroblasts. Consistently, ING4-expressing fibroblasts promoted tumor growth in vivo in co-injection tumorigenesis assays. Collectively, our results show that ING4 not only can regulate the proliferation of primary non-transformed human fibroblasts, but also orchestrates a secretory phenotype in these cells that promotes tumor cell proliferation in vitro and in vivo. These findings support a critical role for ING4 expression in normal cells in the non-cell-autonomous regulation of tumor growth.	[Moreno, A.; Soleto, I.; Garcia-Sanz, P.; Moreno-Bueno, G.; Palmero, I.] CSIC UAM, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain; [Garcia-Sanz, P.; Moreno-Bueno, G.] Univ Autonoma Madrid, IdiPAZ Inst Invest Sanitaria La Paz, Dept Bioquim, Madrid, Spain; [Garcia-Sanz, P.; Moreno-Bueno, G.] Fdn MD Anderson Int, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; University of Texas System; UTMD Anderson Cancer Center	Palmero, I (corresponding author), CSIC UAM, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, E-28029 Madrid, Spain.	ipalmero@iib.uam.es	Moreno-Bueno, Gema/K-9354-2016; Palmero, Ignacio/B-4346-2013; soleto, irene/AAF-8123-2019	Moreno-Bueno, Gema/0000-0002-5030-6687; soleto, irene/0000-0002-8005-2411	Spanish Ministry of Science and Innovation [SAF2009-09031, SAF2012-32117]; Madrid Regional Government [S2010/BMD-2303];  [SAF2010-20175]	Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Madrid Regional Government; 	We thank R Gomis, J Massague, G Peters, D Peeper and A Cano for providing cell lines and reagents, V Miguel for help in some experiments and I Peruzza for technical assistance. This work was supported by grants from the Spanish Ministry of Science and Innovation to IP (SAF2009-09031 and SAF2012-32117) and GM-B (SAF2010-20175), and from the Madrid Regional Government (S2010/BMD-2303) to GM-B.	Abad M, 2011, AGING CELL, V10, P158, DOI 10.1111/j.1474-9726.2010.00651.x; Acosta JC, 2008, CELL CYCLE, V7, P2956, DOI 10.4161/cc.7.19.6780; Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Aguissa-Toure AH, 2011, CELL MOL LIFE SCI, V68, P45, DOI 10.1007/s00018-010-0509-1; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Chien YC, 2011, GENE DEV, V25, P2125, DOI 10.1101/gad.17276711; Coles AH, 2010, P NATL ACAD SCI USA, V107, P11423, DOI 10.1073/pnas.0912116107; Coles AH, 2009, J CELL PHYSIOL, V218, P45, DOI 10.1002/jcp.21583; Colla S, 2007, BLOOD, V110, P4464, DOI 10.1182/blood-2007-02-074617; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Garkavtsev I, 2004, NATURE, V428, P328, DOI 10.1038/nature02329; Goeman F, 2005, MOL CELL BIOL, V25, P422, DOI 10.1128/MCB.25.1.422-431.2005; Gomez-Cabello D, 2010, CANCER RES, V70, P1866, DOI 10.1158/0008-5472.CAN-09-2088; Hung T, 2009, MOL CELL, V33, P248, DOI 10.1016/j.molcel.2008.12.016; Jafarnejad SM, 2012, CANCER METAST REV, V31, P55, DOI 10.1007/s10555-011-9329-5; Kim S, 2004, P NATL ACAD SCI USA, V101, P16251, DOI 10.1073/pnas.0407158101; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Kuilman T, 2009, NAT REV CANCER, V9, P81, DOI 10.1038/nrc2560; Larrieu D, 2009, EMBO REP, V10, P1168, DOI 10.1038/embor.2009.180; Lazennec G, 2010, TRENDS MOL MED, V16, P133, DOI 10.1016/j.molmed.2010.01.003; Li J, 2008, CARCINOGENESIS, V29, P1373, DOI 10.1093/carcin/bgn086; Liu F, 2011, NAT CELL BIOL, V13, P254, DOI 10.1038/ncb2167; Menendez C, 2009, CURR DRUG TARGETS, V10, P406, DOI 10.2174/138945009788185077; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Moreno A, 2010, CARCINOGENESIS, V31, P1932, DOI 10.1093/carcin/bgq171; Nozell S, 2008, MOL CELL BIOL, V28, P6632, DOI 10.1128/MCB.00697-08; Palmero I, 2002, ONCOGENE, V21, P2939, DOI 10.1038/sj/onc/1205371; Pedeux R, 2005, MOL CELL BIOL, V25, P6639, DOI 10.1128/MCB.25.15.6639-6648.2005; Pena PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shen JC, 2007, CANCER RES, V67, P2552, DOI 10.1158/0008-5472.CAN-06-3870; Shiseki M, 2003, CANCER RES, V63, P2373; Tapia C, 2011, HUM PATHOL, V42, P983, DOI 10.1016/j.humpath.2010.10.012; Wong RPC, 2011, NUCLEIC ACIDS RES, V39, P3632, DOI 10.1093/nar/gkq1337; Ythier D, 2008, INT J CANCER, V123, P1483, DOI 10.1002/ijc.23790	43	15	15	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2014	33	15					1945	1953		10.1038/onc.2013.145	http://dx.doi.org/10.1038/onc.2013.145			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RK	23604125				2022-12-17	WOS:000334346300007
J	Guenther, GG; Liu, G; Ramirez, MU; McMonigle, RJ; Kim, SM; McCracken, AN; Joo, Y; Ushach, I; Nguyen, NL; Edinger, AL				Guenther, G. G.; Liu, G.; Ramirez, M. U.; McMonigle, R. J.; Kim, S. M.; McCracken, A. N.; Joo, Y.; Ushach, I.; Nguyen, N. L.; Edinger, A. L.			Loss of TSC2 confers resistance to ceramide and nutrient deprivation	ONCOGENE			English	Article						TSC2; mTOR; nutrient transporters; 4F2hc; GLUT1; ceramide	ACTIVATED PROTEIN-KINASE; TUBEROUS SCLEROSIS COMPLEX; TSC1-TSC2 COMPLEX; AMINO-ACIDS; INDUCED APOPTOSIS; CELL-GROWTH; TRANSLATIONAL CONTROL; TRANSPORTER PROTEINS; TSC2-NULL CELLS; MESSENGER-RNA	Nutrient stress that produces quiescence and catabolism in normal cells is lethal to cancer cells, because oncogenic mutations constitutively drive anabolism. One driver of biosynthesis in cancer cells is the mammalian target of rapamycin complex 1 (mTORC1) signaling complex. Activating mTORC1 by deleting its negative regulator tuberous sclerosis complex 2 (TSC2) leads to hypersensitivity to glucose deprivation. We have previously shown that ceramide kills cells in part by triggering nutrient transporter loss and restricting access to extracellular amino acids and glucose, suggesting that TSC2-deficient cells would be hypersensitive to ceramide. However, murine embryonic fibroblasts (MEFs) lacking TSC2 were highly resistant to ceramide-induced death. Consistent with the observation that ceramide limits access to both amino acids and glucose, TSC2(-/-) MEFs also had a survival advantage when extracellular amino acids and glucose were both reduced. As TSC2(-/-) MEFs were resistant to nutrient stress despite sustained mTORC1 activity, we assessed whether mTORC1 signaling might be beneficial under these conditions. In low amino acid and glucose medium, and following ceramide-induced nutrient transporter loss, elevated mTORC1 activity significantly enhanced the adaptive upregulation of new transporter proteins for amino acids and glucose. Strikingly, the introduction of oncogenic Ras abrogated the survival advantage of TSC2(-/-) MEFs upon ceramide treatment most likely by increasing nutrient demand. These results suggest that, in the absence of oncogene-driven biosynthetic demand, mTORC1-dependent translation facilitates the adaptive cellular response to nutrient stress.	[Guenther, G. G.; Liu, G.; Ramirez, M. U.; McMonigle, R. J.; Kim, S. M.; McCracken, A. N.; Joo, Y.; Ushach, I.; Nguyen, N. L.; Edinger, A. L.] Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA	University of California System; University of California Irvine	Edinger, AL (corresponding author), Univ Calif Irvine, Dept Dev & Cell Biol, 2128 Nat Sci 1, Irvine, CA 92697 USA.	aedinger@uci.edu	Liu, Gang/B-7635-2012	Ushach, Irina/0000-0002-3223-4202; Kim, Seong Min/0000-0001-8328-8211	NIH [R01-GM089919]; American Cancer Society grant from the Army Medical Research & Materiel Command [120976-RSG-11-111-01-CDD, W81XWH-11-1-0535]; UCI CORCL [SIIG-1-2007-2008]; National Cancer Institute [T32CA009054]; NATIONAL CANCER INSTITUTE [T32CA009054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM089919] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society grant from the Army Medical Research & Materiel Command; UCI CORCL; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by NIH R01-GM089919, American Cancer Society grant 120976-RSG-11-111-01-CDD, W81XWH-11-1-0535 from the Army Medical Research & Materiel Command, and SIIG-1-2007-2008 from the UCI CORCL to ALE. GGG and ANM were supported by grant number T32CA009054 from the National Cancer Institute.	Aronova S, 2008, CELL METAB, V7, P148, DOI 10.1016/j.cmet.2007.11.015; Avruch J, 2009, AM J PHYSIOL-ENDOC M, V296, pE592, DOI 10.1152/ajpendo.90645.2008; Bain PJ, 2002, J NUTR, V132, P3023, DOI 10.1093/jn/131.10.3023; Bhaskar PT, 2009, MOL CELL BIOL, V29, P5136, DOI 10.1128/MCB.01946-08; Bhattacharyya SN, 2006, CELL, V125, P1111, DOI 10.1016/j.cell.2006.04.031; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Choo AY, 2010, MOL CELL, V38, P487, DOI 10.1016/j.molcel.2010.05.007; Curatolo P, 2008, LANCET, V372, P657, DOI 10.1016/S0140-6736(08)61279-9; Dazert E, 2011, CURR OPIN CELL BIOL, V23, P744, DOI 10.1016/j.ceb.2011.09.003; Dibble CC, 2012, MOL CELL, V47, P535, DOI 10.1016/j.molcel.2012.06.009; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; Duran RV, 2012, EMBO REP, V13, P121, DOI 10.1038/embor.2011.257; Edinger AL, 2004, ONCOGENE, V23, P5654, DOI 10.1038/sj.onc.1207738; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Fernandez J, 2001, J BIOL CHEM, V276, P12285, DOI 10.1074/jbc.M009714200; Gaccioli F, 2006, J BIOL CHEM, V281, P17929, DOI 10.1074/jbc.M600341200; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gazzola RF, 2001, FEBS LETT, V490, P11; Guenther GG, 2008, P NATL ACAD SCI USA, V105, P17402, DOI 10.1073/pnas.0802781105; Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Huang JX, 2008, MOL CELL BIOL, V28, P4104, DOI 10.1128/MCB.00289-08; Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Jewell JL, 2013, NAT REV MOL CELL BIO, V14, P133, DOI 10.1038/nrm3522; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; Kang YJ, 2011, CELL DEATH DIFFER, V18, P133, DOI 10.1038/cdd.2010.82; Kaper F, 2006, CANCER RES, V66, P1561, DOI 10.1158/0008-5472.CAN-05-3375; Kim E, 2008, NAT CELL BIOL, V10, P935, DOI 10.1038/ncb1753; Kim J, 2011, ANNU REV BIOCHEM, V80, P1001, DOI 10.1146/annurev-biochem-062209-094414; Kim SG, 2013, MOL CELL, V49, P172, DOI 10.1016/j.molcel.2012.10.003; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Lacher MD, 2010, ONCOGENE, V29, P6543, DOI 10.1038/onc.2010.393; Le Stunff H, 2007, J BIOL CHEM, V282, P34372, DOI 10.1074/jbc.M703329200; Li BH, 2010, CANCER CELL, V17, P469, DOI 10.1016/j.ccr.2010.03.019; Manel N, 2003, CELL, V115, P449, DOI 10.1016/S0092-8674(03)00881-X; Matsumoto S, 2002, GENETICS, V161, P1053; Menon S, 2008, Oncogene, V27 Suppl 2, pS43, DOI 10.1038/onc.2009.352; Ng S, 2011, AUTOPHAGY, V7, P1173, DOI 10.4161/auto.7.10.16681; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Ogretmen B, 2002, J BIOL CHEM, V277, P12960, DOI 10.1074/jbc.M110699200; Park NS, 2008, ANTICANCER RES, V28, P2649; Parkhitko A, 2011, P NATL ACAD SCI USA, V108, P12455, DOI 10.1073/pnas.1104361108; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Roccio M, 2006, ONCOGENE, V25, P657, DOI 10.1038/sj.onc.1209106; Rosales KR, 2011, BIOCHEM J, V439, P299, DOI 10.1042/BJ20110853; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; Shah OJ, 2006, MOL CELL BIOL, V26, P6425, DOI 10.1128/MCB.01254-05; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Short JD, 2008, CANCER RES, V68, P6496, DOI 10.1158/0008-5472.CAN-07-5756; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Teske BF, 2011, METHOD ENZYMOL, V490, P333, DOI 10.1016/B978-0-12-385114-7.00019-2; Tremblay F, 2007, P NATL ACAD SCI USA, V104, P14056, DOI 10.1073/pnas.0706517104; Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007; Yecies JL, 2011, J MOL MED, V89, P221, DOI 10.1007/s00109-011-0726-6; Yuan HX, 2013, MOL CELL, V49, P379, DOI 10.1016/j.molcel.2013.01.019; Zhang HH, 2009, PLOS ONE, V4, DOI [10.1371/journal.pone.0006189, 10.1371/journal.pone.0007826]; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568	64	15	15	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2014	33	14					1776	1787		10.1038/onc.2013.139	http://dx.doi.org/10.1038/onc.2013.139			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RE	23604129	Green Accepted			2022-12-17	WOS:000334345500004
J	Li, Y; Teo, WL; Low, MJ; Meijer, L; Sanderson, I; Pettersson, S; Greicius, G				Li, Y.; Teo, W. L.; Low, M. J.; Meijer, L.; Sanderson, I.; Pettersson, S.; Greicius, G.			Constitutive TLR4 signalling in intestinal epithelium reduces tumor load by increasing apoptosis in APC(Min/+) mice	ONCOGENE			English	Article						TLR4; APC(Min/+); Cox-2; apoptosis; Paneth cells; tumorigenesis	HUMAN COLON-CANCER; FAMILIAL ADENOMATOUS POLYPOSIS; CELLS IN-VITRO; CYCLOOXYGENASE-2 INHIBITOR; TRANSGENIC MICE; GROWTH; EXPRESSION; PROTEIN; VIVO; LIPOPOLYSACCHARIDE	The microbial pattern-recognizing Toll-like receptors (TLRs) are major signal transducers known to shape and influence the postnatal maturation of host intestinal epithelium. Perturbations in this intricate host-microbe cross-talk have been reported to be associated with uncontrolled epithelial cell growth and thus potential cancer development by mechanisms which are largely unknown. We therefore generated transgenic mice carrying a constitutively active TLR4 (CD4-TLR4) linked to an intestinal epithelial cell-specific promoter. Ex vivo analysis of transgenic crypt-villus organoid cultures revealed an increased proliferative capacity and a lowered cyclooxygenase 2 (Cox-2) expression in these organoids compared with wild-type control cultures. Introducing the CD4-TLR4 transgene into APC(Min/+) mice (CD4-TLR4-APC(Min/+)), a model of colorectal carcinoma, resulted in a dramatic drop in tumor load as compared with control APC(Min/+) mice. Intestinal tumors from CD4-TLR4-APC(Min/+) mice displayed reduced Cox-2 protein, elevated interferon beta expression and increased caspase-3 activity, which correlated with increased apoptosis in vivo. Thus, our data reveal that host microbiota-mediated signal transduction via TLR4 in intestinal epithelial cells is far more complex than what is previously reported.	[Li, Y.; Meijer, L.; Pettersson, S.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, S-17177 Stockholm, Sweden; [Li, Y.] ASTAR, Singapore Immunol Network SIgN, Singapore, Singapore; [Teo, W. L.; Low, M. J.; Pettersson, S.; Greicius, G.] Natl Canc Ctr, Singapore, Singapore; [Sanderson, I.] Barts & London Queen Marys Sch Med & Dent, Digest Dis Clin Acad Unit, London, England; [Pettersson, S.] Nanyang Technol Univ, Sch Biol Sci, Singapore 639798, Singapore	Karolinska Institutet; Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Immunology Network (SIgN); National Cancer Centre Singapore (NCCS); University of London; Queen Mary University London; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Pettersson, S (corresponding author), Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, Theorells Vag 3, S-17177 Stockholm, Sweden.	Sven.Pettersson@ki.se	Pettersson, Sven/F-9511-2015; Li, Yinghui/K-8253-2018	Li, Yinghui/0000-0002-9023-9466; Greicius, Gediminas/0000-0001-8333-787X; Sanderson, Ian/0000-0002-9814-0161	Singapore Immunology Network [(SIgN)-SIgN 10-038]	Singapore Immunology Network(Agency for Science Technology & Research (A*STAR))	Our research work was funded by a grant from Singapore Immunology Network (SIgN)-SIgN 10-038. We would like to thank Dr Robert Wallin for his great expertise and assistance in using the deconvolution microscope for anti-CD4 fluorescence imaging. We thank Velmurugesan Arulampalam for valuable discussions regarding our study. We also thank Arlaine Anne Bautista Amoyo, Jieshun Wong and Annika Samuelsson for their technical support with animal care and handling.	Andreani V, 2007, CANCER RES, V67, P10519, DOI 10.1158/0008-5472.CAN-07-0079; ARULAMPALAM V, 1994, EUR J IMMUNOL, V24, P1671, DOI 10.1002/eji.1830240732; Bohnhorst J, 2006, LEUKEMIA, V20, P1138, DOI 10.1038/sj.leu.2404225; Brown SL, 2007, J CLIN INVEST, V117, P258, DOI 10.1172/JCI29159; Chicoine MR, 2007, NEUROSURGERY, V60, P372, DOI 10.1227/01.NEU.0000249280.61761.2E; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; Cursio R, 2008, TRANSPL P, V40, P2038, DOI 10.1016/j.transproceed.2008.05.039; Fukata M, 2006, GASTROENTEROLOGY, V131, P862, DOI 10.1053/j.gastro.2006.06.017; Fukata M, 2011, INFLAMM BOWEL DIS, V17, P1464, DOI 10.1002/ibd.21527; Garay RP, 2007, EUR J PHARMACOL, V563, P1, DOI 10.1016/j.ejphar.2007.02.018; Nunez NG, 2012, CANCER RES, V72, P592, DOI 10.1158/0008-5472.CAN-11-0534; Gregorieff A, 2005, GASTROENTEROLOGY, V129, P626, DOI 10.1053/j.gastro.2005.06.007; Harmey JH, 2002, INT J CANCER, V101, P415, DOI 10.1002/ijc.10632; KARGMAN SL, 1995, CANCER RES, V55, P2556; Klampfer L, 2007, ONCOGENE, V26, P2071, DOI 10.1038/sj.onc.1210015; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Li YH, 2012, CARCINOGENESIS, V33, P1231, DOI 10.1093/carcin/bgs137; Luo JL, 2004, CANCER CELL, V6, P297, DOI 10.1016/j.ccr.2004.08.012; MAEHARA Y, 1994, AM J SURG, V168, P36, DOI 10.1016/S0002-9610(05)80068-6; Matsushita K, 2009, NATURE, V458, P1185, DOI 10.1038/nature07924; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Nakamoto N, 2006, INT J ONCOL, V29, P625; Ohtsuka Y, 2001, GUT, V49, P526, DOI 10.1136/gut.49.4.526; Otto F, 1996, EUR J CANCER, V32A, P1712, DOI 10.1016/0959-8049(96)00186-4; Pidgeon GP, 1999, BRIT J CANCER, V81, P1311, DOI 10.1038/sj.bjc.6694369; Rakoff-Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488; Razack AHA, 2007, ASIAN J SURG, V30, P302, DOI 10.1016/S1015-9584(08)60045-7; Sato M, 1997, APOPTOSIS, V2, P227, DOI 10.1023/A:1026428918301; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Singh B, 2005, INT J ONCOL, V26, P1393; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Swamy MV, 2006, CANCER RES, V66, P7370, DOI 10.1158/0008-5472.CAN-05-4619; SWEETSER DA, 1988, P NATL ACAD SCI USA, V85, P9611, DOI 10.1073/pnas.85.24.9611; Trifan OC, 2003, J CELL MOL MED, V7, P207, DOI 10.1111/j.1582-4934.2003.tb00222.x; Wang D, 2006, GUT, V55, P115, DOI 10.1136/gut.2004.047100; Yokota S, 2010, INFECT IMMUN, V78, P468, DOI 10.1128/IAI.00903-09	41	15	16	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2014	33	3					369	377		10.1038/onc.2012.581	http://dx.doi.org/10.1038/onc.2012.581			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VR	23318418	Green Submitted			2022-12-17	WOS:000330214000011
J	Agrelo, R; Kishimoto, H; Novatchkova, M; Peraza, V; Paolino, M; Souabni, A; Wutz, A				Agrelo, R.; Kishimoto, H.; Novatchkova, M.; Peraza, V.; Paolino, M.; Souabni, A.; Wutz, A.			SATB1 collaborates with loss of p16 in cellular transformation	ONCOGENE			English	Article						senescence; SATB1; p16; tumor; cell cycle; RB; E2F	BINDING PROTEIN-1 SATB1; RETINOBLASTOMA PROTEIN; GASTRIC-CANCER; T-CELLS; EXPRESSION; GENE; CHROMATIN; SENESCENCE; GROWTH; DIFFERENTIATION	Tumor progression is associated with invasiveness and metastatic potential. The special AT-rich binding protein 1 (SATB1) has been identified as a key factor in the progression of breast cancer cells to a malignant phenotype and is associated with progression of human tumors. In normal development, SATB1 coordinates gene expression of progenitor cells by functioning as a genome organizer. In contrast to progenitor and tumor cells, SATB1 expression in nontransformed cells is not compatible with proliferation. Here we show that SATB1 expression in mouse embryonic fibroblasts induces cell cycle arrest and senescence that is associated with elevated p16 protein levels. Deletion of p16 overcomes the SATB1-induced senescence. We further provide evidence for an interaction of SATB1 with the retinoblastoma (RB)/E2F pathway downstream of p16. A combined deletion of the RB proteins, RB, p107 and p130 (triple-mutant; TM), prevents SATB1-induced G1 arrest, which is restored upon the reintroduction of RB into SATB1-expressing TM fibroblasts. SATB1 interacts with the E2F/RB complex and regulates the cyclin E promoter in an E2F-dependent manner. These findings demonstrate that p16 and the RB/E2F pathway are critical for SATB1-induced cell cycle arrest. In the absence of p16, SATB1 causes anchorage-independent growth and invasive phenotype in fibroblasts. Our data illustrate that p16 mutations collaborate with the oncogenic activity of SATB1. Consistent with our finding, a literature survey shows that deletion of p16 is generally associated with SATB1 expressing human cell lines and tumors.	[Agrelo, R.; Peraza, V.] Inst Pasteur Montevideo, Epigenet Canc & Aging Lab, Montevideo 11400, Uruguay; [Agrelo, R.; Kishimoto, H.; Novatchkova, M.; Paolino, M.; Souabni, A.; Wutz, A.] Res Inst Mol Pathol, A-1030 Vienna, Austria; [Kishimoto, H.] Univ Tsukuba, Life Sci Ctr, Tsukuba Adv Res Alliance, Tsukuba, Ibaraki, Japan; [Kishimoto, H.; Wutz, A.] Univ Cambridge, Dept Biochem, Wellcome Trust, Cambridge CB2 1QW, England; [Kishimoto, H.; Wutz, A.] Univ Cambridge, Med Res Council Stem Cell Inst, Cambridge CB2 1QW, England; [Wutz, A.] Swiss Fed Inst Technol, Inst Mol Hlth Sci, Zurich, Switzerland	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur de Montevideo; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University of Tsukuba; University of Cambridge; Wellcome Trust Sanger Institute; University of Cambridge; Swiss Federal Institutes of Technology Domain; ETH Zurich	Agrelo, R (corresponding author), Inst Pasteur Montevideo, Epigenet Canc & Aging Lab, Mataojo 2020, Montevideo 11400, Uruguay.	agrelo@pasteur.edu.uy		Paolino, Magdalena/0000-0001-9724-9029	IMP; Vienna Science and Technology Fund (WWTF); Austrian Science Fund (FWF); ANII (Program ) INNOVA URU-European Union; Wellcome Trust [087530/Z/08/A]	IMP; Vienna Science and Technology Fund (WWTF); Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); ANII (Program ) INNOVA URU-European Union; Wellcome Trust(Wellcome TrustEuropean Commission)	We thank M Saltik, MH Idarraga, G Stengl and P Pasierbek for technical assistance, V Bhaskara for helpful discussions, S Galande, JM Peters, H Beug and R Foisner for reagents and advice. This research was supported by the IMP, the Vienna Science and Technology Fund (WWTF), and the Austrian Science Fund (FWF). RA is supported by ANII (Program INNOVA URUGUAY-DCI-ALA/2007/19.040 URU-European Union). AW is supported by a Wellcome Trust Senior Research Fellowship (Grant reference 087530/Z/08/A).	Agrelo R, 2009, DEV CELL, V16, P507, DOI 10.1016/j.devcel.2009.03.006; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Alvarez JD, 2000, GENE DEV, V14, P521; Asanoma K, 2012, J BIOL CHEM, V287, P2257, DOI 10.1074/jbc.M111.287128; Beyer M, 2011, NAT IMMUNOL, V12, P898, DOI 10.1038/ni.2084; Cai ST, 2006, NAT GENET, V38, P1278, DOI 10.1038/ng1913; Cai ST, 2003, NAT GENET, V34, P42, DOI 10.1038/ng1146; Chen HX, 2011, J DERMATOL SCI, V64, P39, DOI 10.1016/j.jdermsci.2011.06.007; Cheng C, 2010, APMIS, V118, P855, DOI 10.1111/j.1600-0463.2010.02673.x; Conklin JF, 2009, J CELL BIOCHEM, V108, P1023, DOI 10.1002/jcb.22342; de Belle I, 1998, J CELL BIOL, V141, P335, DOI 10.1083/jcb.141.2.335; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; Fessing MY, 2011, J CELL BIOL, V194, P825, DOI 10.1083/jcb.201101148; Fiorentino FP, 2009, CELL RES, V19, P1044, DOI 10.1038/cr.2009.96; Geng Y, 1996, ONCOGENE, V12, P1173; Han HJ, 2008, NATURE, V452, P187, DOI 10.1038/nature06781; Hanker LC, 2011, BREAST, V20, P309, DOI 10.1016/j.breast.2010.10.002; Harb G, 2009, DIABETES, V58, P1852, DOI 10.2337/db08-0759; Iorns E, 2010, JNCI-J NATL CANCER I, V102, P1284, DOI 10.1093/jnci/djq243; Khan MZ, 2008, CELL DEATH DIFFER, V15, P1663, DOI 10.1038/cdd.2008.95; Kim H, 2001, ONCOGENE, V20, P3306, DOI 10.1038/sj.onc.1204423; Kim M, 2000, CELL DEATH DIFFER, V7, P706, DOI 10.1038/sj.cdd.4400703; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Kohwi-Shigematsu T, 2010, J NATL CANCER I, V102, P1879, DOI 10.1093/jnci/djq440; Leeb M, 2007, J CELL BIOL, V178, P219, DOI 10.1083/jcb.200612127; Lu XM, 2010, ONCOL REP, V24, P981, DOI 10.3892/or_00000945; McInnes N, 2012, ONCOGENE, V31, P1045, DOI 10.1038/onc.2011.293; Meng WJ, 2012, INT J COLORECTAL DIS, V27, P143, DOI 10.1007/s00384-011-1302-9; Meyyappan M, 1998, MOL CELL BIOL, V18, P3163, DOI 10.1128/MCB.18.6.3163; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Notani D, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000296; Odell A, 2010, AGING-US, V2, P160, DOI 10.18632/aging.100129; Ordinario E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051786; Pavan KP, 2006, MOL CELL, V22, P231, DOI 10.1016/j.molcel.2006.03.010; Purbey PK, 2009, MOL CELL BIOL, V29, P1321, DOI 10.1128/MCB.00822-08; Quesnel B, 1996, BRIT J HAEMATOL, V95, P291, DOI 10.1046/j.1365-2141.1996.d01-1913.x; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Savarese F, 2009, GENE DEV, V23, P2625, DOI 10.1101/gad.1815709; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Takahashi A, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-10; Tan JAT, 2008, J BIOL CHEM, V283, P18124, DOI 10.1074/jbc.M800512200; White J, 2005, STEM CELL REV, V1, P131, DOI 10.1385/SCR:1:2:131; Yamayoshi A, 2011, OLIGONUCLEOTIDES, V21, P115, DOI 10.1089/oli.2010.0277; Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084; Zhao XD, 2010, ORL-J OTO-RHIN-LARYN, V72, P1, DOI 10.1159/000264777	45	15	16	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2013	32	48					5492	5500		10.1038/onc.2013.158	http://dx.doi.org/10.1038/onc.2013.158			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263BE	23686316	Green Published, hybrid			2022-12-17	WOS:000327780800006
J	Scales, TME; Jayo, A; Obara, B; Holt, MR; Hotchin, NA; Berditchevski, F; Parsons, M				Scales, T. M. E.; Jayo, A.; Obara, B.; Holt, M. R.; Hotchin, N. A.; Berditchevski, F.; Parsons, M.			alpha 3 beta 1 integrins regulate CD151 complex assembly and membrane dynamics in carcinoma cells within 3D environments	ONCOGENE			English	Article						alpha 3 integrin; CD151; migration; protrusion; actin cytoskeleton; 3D ECM	LAMININ-BINDING INTEGRINS; TETRASPANIN CD151; TRANSMEMBRANE-4 SUPERFAMILY; CLINICAL-SIGNIFICANCE; ADHESION DYNAMICS; PROTEIN COMPLEXES; GENE-EXPRESSION; RAC ACTIVATION; BREAST-CANCER; IN-VIVO	Integrins are extracellular matrix (ECM) receptors that are key players in the regulation of tumour cell invasion. The laminin-binding integrin alpha 3 beta 1 has previously been shown to regulate adhesion and migration of carcinoma cells in part through co-operative signalling with the tetraspanin family of transmembrane proteins. However, the spatial and temporal regulation of crosstalk between these families of transmembrane proteins in intact cells remains poorly understood. Here we have used fluorescence resonance energy transfer (FRET) to demonstrate for the first time that alpha 3 beta 1 and the tetraspanin CD151 directly associate at the front and retracting rear of polarised migrating breast carcinoma cells in both two-dimentional (2D) and three-dimentional (3D) matrices. Furthermore, localised alpha 3 beta 1-CD151 binding correlates with lower CD151 homodimerisation in cells migrating on laminin or within matrigel. Loss of alpha 3 beta 1 integrin leads to increased CD151 homodimer formation, increased activation of Rho GTPase, loss of cell polarity and decreased invasion in 3D ECM. As a result, alpha 3-silenced cells show decreased actin-based membrane protrusion and retraction in both 2D and 3D environments. These data demonstrate that associations between alpha 3 beta 1 and CD151 occur dynamically within discrete subcellular compartments and act to establish local GTPase signalling to promote tumour cell invasion. These novel findings shed light on the complex crosstalk and switching between receptor complexes in response to different extracellular cues during cell invasion in 3D environments.	[Scales, T. M. E.; Jayo, A.; Holt, M. R.; Parsons, M.] Kings Coll London, Randall Div Cell & Mol Biophys, London SE1 1UL, England; [Obara, B.] Univ Oxford, Oxford E Res Ctr, Oxford, England; [Obara, B.] Univ Oxford, Oxford Ctr Integrat Syst Biol, Oxford, England; [Hotchin, N. A.] Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham, W Midlands, England; [Berditchevski, F.] Univ Birmingham, Sch Biosci, Birmingham, W Midlands, England	University of London; King's College London; University of Oxford; University of Oxford; Cancer Research UK; University of Birmingham; University of Birmingham	Parsons, M (corresponding author), Kings Coll London, Randall Div Cell & Mol Biophys, Room 3-22B,New Hunts House,Guys Campus, London SE1 1UL, England.	maddy.parsons@kcl.ac.uk	Jayo, Asier/A-8419-2015; Jayo, Asier/A-2359-2010; Jayo, Asier/AAE-5895-2021; Parsons, Maddy/B-2203-2013	Jayo, Asier/0000-0002-9899-8723; Jayo, Asier/0000-0002-9899-8723; Jayo, Asier/0000-0002-9899-8723; Parsons, Maddy/0000-0002-2021-8379; Holt, Mark/0000-0001-7775-8539; Obara, Boguslaw/0000-0003-4084-7778; Hotchin, Neil/0000-0002-1844-7607	Cancer Research UK; Wellcome Trust; Biotechnology and Biological Sciences Research Council; Engineering and Physical Sciences Research Council; Royal Society University Research Fellowship; MRC [MR/J000647/1] Funding Source: UKRI; Medical Research Council [MR/J000647/1] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Royal Society University Research Fellowship(Royal Society of London); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We would like to thank Simon Ameer-Beg and Daniel Matthews for technical assistance and support with the multiphoton FLIM. This research was funded by grants from Cancer Research UK (to MP, FB and NH), the Wellcome Trust (to NH), the Biotechnology and Biological Sciences Research Council and Engineering and Physical Sciences Research Council (to BO) and a Royal Society University Research Fellowship (to MP).	Ang J, 2004, CANCER EPIDEM BIOMAR, V13, P1717; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Baldwin G, 2008, J BIOL CHEM, V283, P35445, DOI 10.1074/jbc.M806394200; Berditchevski F, 2001, J BIOL CHEM, V276, P41165, DOI 10.1074/jbc.M104041200; Calderwood DA, 2004, J BIOL CHEM, V279, P28889, DOI 10.1074/jbc.M402161200; Carmona-Fontaine C, 2008, NATURE, V456, P957, DOI 10.1038/nature07441; Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200; Egeblad M, 2010, CURR OPIN CELL BIOL, V22, P697, DOI 10.1016/j.ceb.2010.08.015; Frank DE, 2004, J CELL SCI, V117, P1351, DOI 10.1242/jcs.01003; Fukushima Y, 1998, INT J CANCER, V76, P63, DOI 10.1002/(SICI)1097-0215(19980330)76:1<63::AID-IJC11>3.0.CO;2-H; Gu JG, 2001, J BIOL CHEM, V276, P27090, DOI 10.1074/jbc.M102284200; Hashida H, 2003, BRIT J CANCER, V89, P158, DOI 10.1038/sj.bjc.6601015; Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736; Hodivala-Dilke KM, 1998, J CELL BIOL, V142, P1357, DOI 10.1083/jcb.142.5.1357; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kazarov AR, 2002, J CELL BIOL, V158, P1299, DOI 10.1083/jcb.200204056; Latysheva N, 2006, MOL CELL BIOL, V26, P7707, DOI 10.1128/MCB.00849-06; Lichtner RB, 1998, EXP CELL RES, V240, P368, DOI 10.1006/excr.1998.4012; Liu L, 2007, J BIOL CHEM, V282, P31631, DOI 10.1074/jbc.M701165200; Matthews HK, 2008, DEVELOPMENT, V135, P1771, DOI 10.1242/dev.017350; MELCHIORI A, 1995, EXP CELL RES, V219, P233, DOI 10.1006/excr.1995.1223; Mitchell K, 2010, CANCER RES, V70, P6359, DOI 10.1158/0008-5472.CAN-09-4283; Morini M, 2000, INT J CANCER, V87, P336, DOI 10.1002/1097-0215(20000801)87:3<336::AID-IJC5>3.0.CO;2-3; Morton PE, 2011, METHODS MOL BIOL, V769, P403, DOI 10.1007/978-1-61779-207-6_27; Nakamura T, 2006, METHOD ENZYMOL, V406, P315, DOI 10.1016/S0076-6879(06)06023-X; Nguyen BP, 2000, J BIOL CHEM, V275, P31896, DOI 10.1074/jbc.M006379200; Nishiya N, 2005, NAT CELL BIOL, V7, P343, DOI 10.1038/ncb1234; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OKADA T, 1994, CLIN EXP METASTAS, V12, P305, DOI 10.1007/BF01753837; Parsons M, 2005, MOL CELL BIOL, V25, P1680, DOI 10.1128/MCB.25.5.1680-1695.2005; Parsons M, 2008, J CELL SCI, V121, P265, DOI 10.1242/jcs.018440; Ramirez NE, 2011, J CLIN INVEST, V121, P226, DOI 10.1172/JCI42328; Reynolds LE, 2008, J CLIN INVEST, V118, P965, DOI 10.1172/JCI33538; Ridley AJ, 2011, CELL, V145, P1012, DOI 10.1016/j.cell.2011.06.010; Sadej R, 2009, MOL CANCER RES, V7, P787, DOI 10.1158/1541-7786.MCR-08-0574; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sarmiento C, 2008, J CELL BIOL, V180, P1245, DOI 10.1083/jcb.200708123; Sterk LMT, 2002, J CELL SCI, V115, P1161; Stipp CS, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399409001355; Stipp CS, 2003, TRENDS BIOCHEM SCI, V28, P106, DOI 10.1016/S0968-0004(02)00014-2; Sugiura T, 1999, J CELL BIOL, V146, P1375, DOI 10.1083/jcb.146.6.1375; Takeda Y, 2011, BLOOD, V118, P464, DOI 10.1182/blood-2010-08-302240; Tokuhara T, 2001, CLIN CANCER RES, V7, P4109; Turner FE, 2006, J BIOL CHEM, V281, P21321, DOI 10.1074/jbc.M509731200; Vicente-Manzanares M, 2009, NAT REV MOL CELL BIO, V10, P778, DOI 10.1038/nrm2786; Wang ZM, 1999, J CELL SCI, V112, P2925; Winterwood NE, 2006, MOL BIOL CELL, V17, P2707, DOI 10.1091/mbc.E05-11-1042; Worth DC, 2008, INT J BIOCHEM CELL B, V40, P2397, DOI 10.1016/j.biocel.2008.04.008; Worth DC, 2010, J CELL BIOL, V189, P369, DOI 10.1083/jcb.200912014; Yanez-Mo M, 2009, TRENDS CELL BIOL, V19, P434, DOI 10.1016/j.tcb.2009.06.004; Yang XWH, 2008, CANCER RES, V68, P3204, DOI 10.1158/0008-5472.CAN-07-2949; Yang XW, 2002, MOL BIOL CELL, V13, P767, DOI 10.1091/mbc.01-05-0275; Yauch RL, 2000, J BIOL CHEM, V275, P9230, DOI 10.1074/jbc.275.13.9230; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200; Zhou H, 2005, J BIOL CHEM, V280, P10624, DOI 10.1074/jbc.M411900200; Zijlstra A, 2008, CANCER CELL, V13, P221, DOI 10.1016/j.ccr.2008.01.031	57	15	16	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2013	32	34					3965	3979		10.1038/onc.2012.415	http://dx.doi.org/10.1038/onc.2012.415			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IC	22986527				2022-12-17	WOS:000323748100005
J	Nakanome, A; Brydun, A; Matsumoto, M; Ota, K; Funayama, R; Nakayama, K; Ono, M; Shiga, K; Kobayashi, T; Igarashi, K				Nakanome, A.; Brydun, A.; Matsumoto, M.; Ota, K.; Funayama, R.; Nakayama, K.; Ono, M.; Shiga, K.; Kobayashi, T.; Igarashi, K.			Bach1 is critical for the transformation of mouse embryonic fibroblasts by Ras(V12) and maintains ERK signaling	ONCOGENE			English	Article						Bach1; ROS; cancer; Ras; ERK	CELL-PROLIFERATION; OXIDATIVE STRESS; FEEDBACK PHOSPHORYLATION; GENETIC ABLATION; DNA-DAMAGE; TNF-ALPHA; SMALL MAF; RAS; PATHWAY; PROTEIN	Reactive oxygen species (ROS), by-products of aerobic respiration, promote genetic instability and contribute to the malignant transformation of cells. Among the genes related to ROS metabolism, Bach1 is a repressor of the oxidative stress response, and a negative regulator of ROS-induced cellular senescence directed by p53 in higher eukaryotes. While ROS are intimately involved in carcinogenesis, it is not clear whether Bach1 is involved in this process. We found that senescent Bach1-deficient mouse embryonic fibroblasts (MEFs) underwent spontaneous immortalization the same as did the wild-type cells. When transduced with constitutively active Ras (H-Ras(V12)), the proliferation and colony formation of these cells in vitro were markedly reduced. When transplanted into athymic nude mice, the growth and vascularization of tumors derived from Bach1-deficient cells were also decreased. Gene expression profiling of the MEFs revealed a new H-Ras(V12) signature, which was distinct from the previously reported signatures in epithelial tumors, and was partly dependent on Bach1. The Bach1-deficient cells showed diminished phosphorylation of MEK and ERK1/2 in response to H-Ras(V12), which was consistent with the alterations in the gene expression profile, including phosphatase genes. Finally, Bach1-deficient mice were less susceptible to 4-nitroquinoline-1-oxidide (4-NQO)-induced tongue carcinoma than wild-type mice. Our data provide evidence for a critical role of Bach1 in cell transformation and tumor growth induced by activated H-Ras(V12).	[Nakanome, A.; Brydun, A.; Matsumoto, M.; Ota, K.; Igarashi, K.] Tohoku Univ, Grad Sch Med, Dept Biochem, Sendai, Miyagi 980, Japan; [Nakanome, A.; Shiga, K.; Kobayashi, T.] Tohoku Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Sendai, Miyagi 980, Japan; [Brydun, A.; Igarashi, K.] Tohoku Univ, Grad Sch Med, Ctr Regulatory Epigenome & Dis, Sendai, Miyagi 980, Japan; [Matsumoto, M.] Tohoku Univ, Grad Sch Med, Dept Obstet & Gynecol, Sendai, Miyagi 980, Japan; [Funayama, R.; Nakayama, K.] Tohoku Univ, Grad Sch Med, Div Cell Proliferat, Sendai, Miyagi 980, Japan; [Funayama, R.; Igarashi, K.] Japan Sci & Technol Agcy, CREST, Sendai, Miyagi, Japan; [Ono, M.] Tohoku Univ, Grad Sch Med, Dept Pathol, Sendai, Miyagi 980, Japan	Tohoku University; Tohoku University; Tohoku University; Tohoku University; Tohoku University; Japan Science & Technology Agency (JST); Tohoku University	Igarashi, K (corresponding author), Tohoku Univ, Grad Sch Med, Dept Biochem, Seiryo Machi 2-1, Sendai, Miyagi 980, Japan.	igarashi@med.tohoku.ac.jp	Matsumoto, Mitsuyo/AAC-3065-2019	Igarashi, Kazuhiko/0000-0002-2470-2475	Network Medicine Global-COE Program from the Ministry of Education, Culture, Sports, Science and Technology of Japan	Network Medicine Global-COE Program from the Ministry of Education, Culture, Sports, Science and Technology of Japan	We are grateful to Nobuyuki Tanaka from Nippon Medical University and Fuyuki Ishikawa from Kyoto University for kindly providing plasmids. This work was supported by Grants-in-aid and the Network Medicine Global-COE Program from the Ministry of Education, Culture, Sports, Science and Technology of Japan. Additional initial support was provided by the Uehara Foundation, the Takeda Foundation and the Astelas Foundation for Research on Metabolic Disorders. Restoration of laboratory damage from the 2011 Tohoku earthquake was provided in part by the Astelas Foundation for Research on Metabolic Disorders, the Banyu Foundation, the Naito Foundation, A Miyazaki and A Iida.	Alexandrova AY, 2006, EXP CELL RES, V312, P2066, DOI 10.1016/j.yexcr.2006.03.004; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; Chiarugi P, 2001, IUBMB LIFE, V52, P55, DOI 10.1080/15216540252774775; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Dohi Y, 2008, NAT STRUCT MOL BIOL, V15, P1246, DOI 10.1038/nsmb.1516; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Filleur S, 2009, CANCER CELL INT, V9, DOI 10.1186/1475-2867-9-28; Friedberg I, 2007, FEBS LETT, V581, P2527, DOI 10.1016/j.febslet.2007.04.059; Gregory SG, 2006, NATURE, V441, P315, DOI 10.1038/nature04727; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; Igarashi K, 2006, ANTIOXID REDOX SIGN, V8, P107, DOI 10.1089/ars.2006.8.107; Igarashi K, 1998, J BIOL CHEM, V273, P11783, DOI 10.1074/jbc.273.19.11783; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x; Jackson AL, 2001, MUTAT RES-FUND MOL M, V477, P7, DOI 10.1016/S0027-5107(01)00091-4; Karin M, 2001, BIOFACTORS, V15, P87, DOI 10.1002/biof.5520150207; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Kim EY, 2010, ONCOGENE, V29, P1167, DOI 10.1038/onc.2009.412; Kuroishi T, 2008, J LEUKOCYTE BIOL, V83, P912, DOI 10.1189/jlb.0607428; Liu CJ, 2005, EXP CELL RES, V309, P410, DOI 10.1016/j.yexcr.2005.06.022; Liu RG, 2001, ONCOGENE, V20, P1486, DOI 10.1038/sj.onc.1204214; Loboda A, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-26; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; MacLeod AK, 2009, CARCINOGENESIS, V30, P1571, DOI 10.1093/carcin/bgp176; Masuda K, 2010, BIOCHEM BIOPH RES CO, V393, P201, DOI 10.1016/j.bbrc.2010.01.097; Matheu A, 2007, NATURE, V448, P375, DOI 10.1038/nature05949; Moore KA, 1997, BIOCHEM J, V326, P17, DOI 10.1042/bj3260017; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; Omura S, 2005, GENES CELLS, V10, P277, DOI 10.1111/j.1365-2443.2005.00832.x; Oshima Y, 2003, INVEST OPHTH VIS SCI, V44, P1814, DOI 10.1167/iovs.02-0664; Ota K, 2011, ANTIOXID REDOX SIGN, V14, P2441, DOI 10.1089/ars.2010.3574; Owens DM, 2007, ONCOGENE, V26, P3203, DOI 10.1038/sj.onc.1210412; Oyake T, 1996, MOL CELL BIOL, V16, P6083; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Pratilas CA, 2009, P NATL ACAD SCI USA, V106, P4519, DOI 10.1073/pnas.0900780106; Ritt DA, 2010, MOL CELL BIOL, V30, P806, DOI 10.1128/MCB.00569-09; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sun JY, 2004, P NATL ACAD SCI USA, V101, P1461, DOI 10.1073/pnas.0308083100; Sun JY, 2002, EMBO J, V21, P5216, DOI 10.1093/emboj/cdf516; Suzui M, 1995, MOL CARCINOGEN, V14, P294, DOI 10.1002/mc.2940140410; Swift S, 2001, CURR PROTOC IMMUNOL; Tang XH, 2004, CLIN CANCER RES, V10, P301, DOI 10.1158/1078-0432.CCR-0999-3; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tumurbaatar I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014711; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Weinberg F, 2009, CELL MOL LIFE SCI, V66, P3663, DOI 10.1007/s00018-009-0099-y; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; Xia C, 2007, CANCER RES, V67, P10823, DOI 10.1158/0008-5472.CAN-07-0783; Yamasaki C, 2005, J BIOCHEM, V137, P287, DOI 10.1093/jb/mvi031; Yano Y, 2006, GENES CELLS, V11, P791, DOI 10.1111/j.1365-2443.2006.00979.x; Yu W, 2007, ONCOGENE, V26, P1178, DOI 10.1038/sj.onc.1209899	58	15	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 4	2013	32	27					3231	3245		10.1038/onc.2012.336	http://dx.doi.org/10.1038/onc.2012.336			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	176JZ	22847612				2022-12-17	WOS:000321301600003
J	Laisney, JAGC; Mueller, TD; Schartl, M; Meierjohann, S				Laisney, J. A. G. C.; Mueller, T. D.; Schartl, M.; Meierjohann, S.			Hyperactivation of constitutively dimerized oncogenic EGF receptors by autocrine loops	ONCOGENE			English	Article						receptor tyrosine kinase; EGFR ligands; melanoma	EPIDERMAL-GROWTH-FACTOR; RENAL EPITHELIAL-CELLS; EXTRACELLULAR DOMAIN; TYROSINE KINASE; LUNG-CANCER; MONOCLONAL-ANTIBODIES; THERAPEUTIC TARGETS; EXPRESSION ANALYSIS; MALIGNANT-MELANOMA; LIGAND-BINDING	The epidermal growth factor (EGF) receptor (EGFR) has a key role in normal embryonic development, adult tissue homeostasis and many pathological processes, in particular tumour formation. Aberrant EGFR activation occurs in many cancer types, and inhibition of this receptor is a promising anti-tumour strategy. Besides overexpression of the wild-type receptor, mutated oncogenic EGFR variants are often associated with malignant transformation. In human non-small-cell lung cancers, kinase mutants of the EGFR are rather common. Human glioblastoma often express the truncated EGFRvIII version as well as other dimerized and permanently activated mutants of the receptor, which are considered as tumour drivers. Similarly, the mutated and dimerized EGFR variant Xiphophorus melanoma receptor kinase (Xmrk) is causative for the development of malignant pigment cell tumours in medaka and Xiphophorus melanoma models. It is generally believed that oncogenic receptors that are active due to dimerizing mutations are ligand independent. Here, we show that different EGFR variants from fish and human efficiently induce autocrine loops by inducing EGFR ligands such as amphiregulin and HB-EGF. Importantly, the pre-dimerized oncogenic EGFR versions Xmrk from Xiphophorus and human EGFR(C600F), though already active in absence of ligands, respond to ligand stimulation with enhanced oncogenic signalling. In summary, our data show that autocrine or paracrine loops are still acting on pre-dimerized oncogenic EGFRs and contribute to their pro-tumorigenic signalling.	[Laisney, J. A. G. C.; Schartl, M.; Meierjohann, S.] Univ Wurzburg, Dept Physiol Chem Bioctr 1, D-97074 Wurzburg, Germany; [Mueller, T. D.] Univ Wurzburg, Julius Von Sachs Inst, Dept Mol Plant Physiol & Biophys, D-97070 Wurzburg, Germany	University of Wurzburg; University of Wurzburg	Laisney, JAGC (corresponding author), Univ Wurzburg, Dept Physiol Chem Bioctr 1, D-97074 Wurzburg, Germany.	juliette.laisney@biozentrum.uni-wuerzburg.de; svenja.meierjohann@biozentrum.uni-wuerzburg.de		Schartl, Manfred/0000-0001-9882-5948; Mueller, Thomas/0000-0003-1862-7357	Deutsche Forschungsgesellschaft [SFB487, Transregio 17]	Deutsche Forschungsgesellschaft(German Research Foundation (DFG))	This work was supported by the Deutsche Forschungsgesellschaft, SFB487 ('Regulatory membrane proteins') and Transregio 17 ('Ras-dependent pathways in human cancer').	Akslen LA, 2008, MELANOMA RES, V18, P29, DOI 10.1097/CMR.0b013e3282f32517; Amin DN, 2006, CANCER RES, V66, P2173, DOI 10.1158/0008-5472.CAN-05-3387; Astsaturov I, 2007, CURR CANCER DRUG TAR, V7, P650, DOI 10.2174/156800907782418365; Bardeesy N, 2005, MOL CELL BIOL, V25, P4176, DOI 10.1128/MCB.25.10.4176-4188.2005; Bellone S, 2007, GYNECOL ONCOL, V106, P513, DOI 10.1016/j.ygyno.2007.04.028; Berardi R, 2010, CORE EVID, V5, P61, DOI 10.2147/CE.S7035; Boone B, 2011, J CUTAN PATHOL, V38, P492, DOI 10.1111/j.1600-0560.2011.01673.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Dawson JP, 2007, STRUCTURE, V15, P942, DOI 10.1016/j.str.2007.06.013; DEWIT PEJ, 1992, J INVEST DERMATOL, V99, P168, DOI 10.1111/1523-1747.ep12616793; Djerf EA, 2009, MELANOMA RES, V19, P156, DOI 10.1097/CMR.0b013e32832c6339; Domingo G, 2010, EXPERT REV ANTICANC, V10, P1577, DOI [10.1586/era.10.141, 10.1586/ERA.10.141]; Gan HK, 2009, J CLIN NEUROSCI, V16, P748, DOI 10.1016/j.jocn.2008.12.005; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Gomez A, 2004, MOL BIOL EVOL, V21, P266, DOI 10.1093/molbev/msh017; Gomez A, 2001, J BIOL CHEM, V276, P3333, DOI 10.1074/jbc.M006574200; Hong YH, 1998, DEV GENES EVOL, V208, P595, DOI 10.1007/s004270050220; Hong YH, 2004, P NATL ACAD SCI USA, V101, P8011, DOI 10.1073/pnas.0308668101; Huang PH, 2007, CELL CYCLE, V6, P2750, DOI 10.4161/cc.6.22.4922; Joy AA, 2009, CLIN LUNG CANCER, V10, pS24, DOI 10.3816/CLC.2009.s.004; Kansra S, 2005, MOL PHARMACOL, V67, P1145, DOI 10.1124/mol.104.004689; Kasahara M, 2007, NATURE, V447, P714, DOI 10.1038/nature05846; Kitamura S, 2001, INT J CANCER, V94, P335, DOI 10.1002/ijc.1470; Krasagakis K, 1995, Recent Results Cancer Res, V139, P169; Laisney JAGC, 2010, BMC EVOL BIOL, V10, DOI 10.1186/1471-2148-10-27; Leikam C, 2008, ONCOGENE, V27, P7070, DOI 10.1038/onc.2008.323; Li CW, 2009, THORAX, V64, P306, DOI 10.1136/thx.2008.106096; Li JX, 2003, ONCOGENE, V22, P211, DOI 10.1038/sj.onc.1206102; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu CF, 2010, MOL CELL BIOL, V30, P5432, DOI 10.1128/MCB.00742-10; MATTEI S, 1994, INT J CANCER, V56, P853, DOI 10.1002/ijc.2910560617; Mattoon D, 2004, P NATL ACAD SCI USA, V101, P923, DOI 10.1073/pnas.0307286101; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; Meierjohann S, 2006, CANCER RES, V66, P3145, DOI 10.1158/0008-5472.CAN-05-2667; Meierjohann S, 2004, COMP BIOCHEM PHYS C, V138, P281, DOI 10.1016/j.cca.2004.06.002; Meierjohann S, 2006, ZEBRAFISH, V3, P359, DOI 10.1089/zeb.2006.3.359; Mitsudomi T, 2010, FEBS J, V277, P301, DOI 10.1111/j.1742-4658.2009.07448.x; Modjtahedi H, 2009, ANTI-CANCER DRUG, V20, P851, DOI 10.1097/CAD.0b013e3283330590; Moriki T, 2001, J MOL BIOL, V311, P1011, DOI 10.1006/jmbi.2001.4923; Nagy P, 2003, EXP CELL RES, V285, P39, DOI 10.1016/S0014-4827(02)00050-2; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Park JM, 1999, AM J PHYSIOL-CELL PH, V277, pC294, DOI 10.1152/ajpcell.1999.277.2.C294; Pines G, 2010, FEBS LETT, V584, P2699, DOI 10.1016/j.febslet.2010.04.019; Ramnarain DB, 2006, CANCER RES, V66, P867, DOI 10.1158/0008-5472.CAN-05-2753; Riese DJ, 2007, BIOESSAYS, V29, P558, DOI 10.1002/bies.20582; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; Sakai M, 2001, EXP NEPHROL, V9, P28; Saxon ML, 1999, J BIOL CHEM, V274, P28356, DOI 10.1074/jbc.274.40.28356; Schartl M, 2010, J INVEST DERMATOL, V130, P249, DOI 10.1038/jid.2009.213; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055; Sihto H, 2005, J MOL MED, V83, P976, DOI 10.1007/s00109-005-0699-4; Singh B, 2009, INT J CANCER, V124, P531, DOI 10.1002/ijc.23974; Sparrow L E, 1999, Australas J Dermatol, V40, P19, DOI 10.1046/j.1440-0960.1999.00310.x; Tao RH, 2008, J CELL SCI, V121, P3207, DOI 10.1242/jcs.033399; Teutschbein J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-386; Tworkoski K, 2011, MOL CANCER RES, V9, P801, DOI 10.1158/1541-7786.MCR-10-0512; Vivanco I, 2010, CURR OPIN ONCOL, V22, P573, DOI 10.1097/CCO.0b013e32833edbdf; Walther A, 2009, NAT REV CANCER, V9, P489, DOI 10.1038/nrc2645; Ward CW, 2007, TRENDS BIOCHEM SCI, V32, P129, DOI 10.1016/j.tibs.2007.01.001; Wellbrock C, 2002, J BIOL CHEM, V277, P6443, DOI 10.1074/jbc.M110684200; Winnemoeller D, 2005, INT J CANCER, V117, P723, DOI 10.1002/ijc.21232; WITTBRODT J, 1992, EMBO J, V11, P4239, DOI 10.1002/j.1460-2075.1992.tb05518.x; Wittbrodt J, 2002, NAT REV GENET, V3, P53, DOI 10.1038/nrg704; Yotsumoto F, 2008, BIOCHEM BIOPH RES CO, V365, P555, DOI 10.1016/j.bbrc.2007.11.015; Zhuang S, 2008, AM J PHYSIOL-RENAL, V294, pF459, DOI 10.1152/ajprenal.00473.2007	68	15	15	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2013	32	19					2403	2411		10.1038/onc.2012.267	http://dx.doi.org/10.1038/onc.2012.267			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140ZL	22751127				2022-12-17	WOS:000318694900004
J	Lang, JY; Shi, Y; Chin, YE				Lang, J-Y; Shi, Y.; Chin, Y. E.			Reprogramming cancer cells: back to the future	ONCOGENE			English	Editorial Material							PLURIPOTENT STEM-CELLS; C-MYC; HYBRIDOMAS; DEATH	Reprogramming healthy somatic cells into induced pluripotent stem cells (iPSCs) with four defined factors (Oct4, Sox2, c-Myc and Klf4) has been intensively investigated. However, reprogramming diseased cells such as cancer cells has fallen much behind. In this issue of Oncogene, Zhang et al. demonstrated that reprogrammed sarcoma cells with defined factors, as well as Nanog and Lin28, lost their tumorigenicity and dedifferentiated to mesenchymal stem cells (MSC) and hematopoietic stem cell (HSC)-like cells that can be terminally differentiated into mature connective tissues and red blood cells, suggesting sarcoma cells may be reversed back to a stage of common ancestor iPSC bifurcating for HSC and MSC ontogeny. It may, therefore, provide a novel strategy for cancer treatment via ancestor pluripotency induction	[Lang, J-Y; Shi, Y.; Chin, Y. E.] Chinese Acad Sci, Shanghai Jiao Tong Univ, Sch Med, Inst Hlth Sci,Shanghai Inst Biol Sci,Lab Stem Cel, Shanghai 200025, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University	Chin, YE (corresponding author), Chinese Acad Sci, Shanghai Jiao Tong Univ, Sch Med, Inst Hlth Sci,Shanghai Inst Biol Sci,Lab Stem Cel, 225 South Chongqing Rd, Shanghai 200025, Peoples R China.	yechin@sibs.ac.cn	Shi, Yufang/AAE-4431-2020	Shi, Yufang/0000-0001-8964-319X				BERNS EMJJ, 1992, CANCER RES, V52, P1107; Carette JE, 2010, BLOOD, V115, P4039, DOI 10.1182/blood-2009-07-231845; Chang G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010320; Choi SM, 2011, BLOOD, V118, P1801, DOI 10.1182/blood-2011-03-340620; Hochedlinger K, 2004, GENE DEV, V18, P1875, DOI 10.1101/gad.1213504; Houghton J, 2004, SCIENCE, V306, P1568, DOI 10.1126/science.1099513; Hu KJ, 2011, BLOOD, V117, pE109, DOI 10.1182/blood-2010-07-298331; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Lin SL, 2008, RNA, V14, P2115, DOI 10.1261/rna.1162708; Miyoshi N, 2010, P NATL ACAD SCI USA, V107, P40, DOI 10.1073/pnas.0912407107; Muller LUW, 2009, MOL THER, V17, P947, DOI 10.1038/mt.2009.72; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Ramos-Mejia V, 2012, TRENDS MOL MED, V18, P245, DOI 10.1016/j.molmed.2012.04.001; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Utikal J, 2009, J CELL SCI, V122, P3502, DOI 10.1242/jcs.054783; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307	18	15	17	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2013	32	18					2247	2248		10.1038/onc.2012.349	http://dx.doi.org/10.1038/onc.2012.349			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140VF	22869153				2022-12-17	WOS:000318683600001
J	Sakakibara, S; Espigol-Frigole, G; Gasperini, P; Uldrick, TS; Yarchoan, R; Tosato, G				Sakakibara, S.; Espigol-Frigole, G.; Gasperini, P.; Uldrick, T. S.; Yarchoan, R.; Tosato, G.			A20/TNFAIP3 inhibits NF-kappa B activation induced by the Kaposi's sarcoma-associated herpesvirus vFLIP oncoprotein	ONCOGENE			English	Article						KSHV; NF-kappa B; vFLIP/K13; endothelial cells; Kaposi's sarcoma; AIDS	ZINC-FINGER PROTEIN; DEPENDENT GENE-EXPRESSION; IKK-GAMMA; ENDOTHELIAL-CELLS; UBIQUITIN CHAINS; KINASE COMPLEX; A20 INTERACTS; KSHV VFLIP; ENZYME A20; RECEPTOR	Kaposi's sarcoma-associated herpesvirus (KSHV) K13/vFLIP (viral Flice-inhibitory protein) induces transcription of numerous genes through NF-kappa B activation, including pro-inflammatory cytokines, which contribute to the pathogenesis of Kaposi's sarcoma (KS). In this study, we report that KSHV vFLIP induces the expression of the NF-kappa B regulatory proteins A20, ABIN-1 and ABIN-3 (A20-binding NF-kappa B inhibitors) in primary human endothelial cells, and that KS spindle cells express A20 in KS tissue. In reporter assays, A20 strongly impaired vFLIP-induced NF-kappa B activation in 293T cells, but ABIN-1 and ABIN-3 did not. Mutational analysis established that the C-terminal domain (residues 427-790) is critical for A20 modulation of NF-kappa B, but the ubiquitin-editing OTU (ovarian tumor) domain is not. In functional assays, A20 inhibited vFLIP-induced expression of the chemokine IP-10, reduced vFLIP-induced cell proliferation and increased IKK1 protein levels. Thus, we demonstrate that A20 negatively regulates NF-kappa B activation directly induced by KSHV vFLIP. By attenuating excessive and prolonged vFLIP-induced NF-kappa B activation that could be harmful to KSHV-infected cells, A20 likely has an important role in the pathogenesis of KSHV-associated diseases, in which vFLIP is expressed. Oncogene (2013) 32, 1223-1232; doi:10.1038/onc.2012.145; published online 23 April 2012	[Sakakibara, S.; Espigol-Frigole, G.; Gasperini, P.; Tosato, G.] NCI, Cellular Oncol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Uldrick, T. S.; Yarchoan, R.] NCI, HIV & AIDS Malignancy Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Espigol-Frigole, G (corresponding author), NCI, Cellular Oncol Lab, CCR, NIH, Bldg 37,Room 4134, Bethesda, MD 20892 USA.	GESPIGOL@clinic.ub.es		Tosato, Giovanna/0000-0003-1663-3227; Sakakibara, Shuhei/0000-0003-3157-5870; Gasperini, Paola/0000-0002-3016-9742	intramural research program in Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA; NATIONAL CANCER INSTITUTE [ZIASC010356, ZIABC010885] Funding Source: NIH RePORTER	intramural research program in Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank G Nolan (Stanford University), BK Weaver (Missouri State University), J-M Peloponese Jr, K-T Jeang (NIAID, NIH), DB Conze, JD Ashwell (NCI, NIH), AV Grishin (University of Southern California), A Leonardi (University of Naples, Italy), R Lin (Jewish General Hospital, Canada) for reagents; the patients who volunteered for this study; Dr MN Polizzotto (NCI, NIH), K Aleman and K Wyvill for patient care; the Confocal Microscopy Core Facility (Laboratory of Experimental Carcinogenesis, CCR, NCI) for providing LSM510 and the DNA Minicore Facility (Laboratory of Experimental Carcinogenesis, CCR, NCI) for DNA sequencing, and K Sakakibara (NCI, NIH) for her help in reporter assay. We also thank Drs D Lowy, O Salvucci, H Ohnuki and all members of Laboratory of Cellular Oncology Branch for their advice and help on this work. This study was supported by the intramural research program in Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD20892, USA.	Ambinder RF, 2007, HUMAN HERPESVIRUSES: BIOLOGY, THERAPY, AND IMMUNOPROPHYLAXIS, P885; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Bagneris C, 2008, MOL CELL, V30, P620, DOI 10.1016/j.molcel.2008.04.029; Ballon G, 2011, J CLIN INVEST, V121, P1141, DOI 10.1172/JCI44417; Beyaert R, 2000, BIOCHEM PHARMACOL, V60, P1143, DOI 10.1016/S0006-2952(00)00404-4; Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Chugh P, 2005, P NATL ACAD SCI USA, V102, P12885, DOI 10.1073/pnas.0408577102; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; Cooper JT, 1996, J BIOL CHEM, V271, P18068, DOI 10.1074/jbc.271.30.18068; Daniel S, 2004, BLOOD, V104, P2376, DOI 10.1182/blood-2003-02-0635; De Valck D, 1999, ONCOGENE, V18, P4182, DOI 10.1038/sj.onc.1202787; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Field N, 2003, J CELL SCI, V116, P3721, DOI 10.1242/jcs.00691; Ganem D, 2006, ANNU REV PATHOL-MECH, V1, P273, DOI 10.1146/annurev.pathol.1.110304.100133; Giulino L, 2011, BLOOD, V117, P4852, DOI 10.1182/blood-2010-10-310995; Grossmann C, 2006, J VIROL, V80, P7179, DOI 10.1128/JVI.01603-05; Grundhoff A, 2001, J VIROL, V75, P1857, DOI 10.1128/JVI.75.4.1857-1863.2001; Guasparri I, 2006, EMBO REP, V7, P114, DOI 10.1038/sj.embor.7400580; Guasparri I, 2004, J EXP MED, V199, P993, DOI 10.1084/jem.20031467; Hacker Hans, 2006, Sci STKE, V2006, pre13, DOI 10.1126/stke.3572006re13; Hadian K, 2011, J BIOL CHEM, V286, P26107, DOI 10.1074/jbc.M111.233163; Harhaj EW, 2011, CELL RES, V21, P22, DOI 10.1038/cr.2010.166; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Heyninck K, 1999, J CELL BIOL, V145, P1471, DOI 10.1083/jcb.145.7.1471; Kato M, 2009, NATURE, V459, P712, DOI 10.1038/nature07969; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Li QT, 2005, P NATL ACAD SCI USA, V102, P12425, DOI 10.1073/pnas.0505997102; Li XH, 2001, J BIOL CHEM, V276, P4494, DOI 10.1074/jbc.M008353200; Lin RT, 2006, J BIOL CHEM, V281, P2095, DOI 10.1074/jbc.M510326200; Liu B, 2007, CELL, V129, P903, DOI 10.1016/j.cell.2007.03.056; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Matta H, 2003, J BIOL CHEM, V278, P52406, DOI 10.1074/jbc.M307308200; Matta H, 2007, J BIOL CHEM, V282, P24858, DOI 10.1074/jbc.M700118200; Matta H, 2011, J BIOL CHEM, V286, P21555, DOI 10.1074/jbc.M111.224048; Mauro C, 2006, J BIOL CHEM, V281, P18482, DOI 10.1074/jbc.M601502200; Narazaki M, 2006, BLOOD, V107, P3892, DOI 10.1182/blood-2005-10-4113; Natoli G, 1998, J BIOL CHEM, V273, P31262, DOI 10.1074/jbc.273.47.31262; O'Reilly SM, 2003, BIOCHEM BIOPH RES CO, V303, P586, DOI 10.1016/S0006-291X(03)00389-9; OHMORI Y, 1993, J BIOL CHEM, V268, P6677; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Punj V, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-50; Rahighi S, 2009, CELL, V136, P1098, DOI 10.1016/j.cell.2009.03.007; Sakakibara S, 2011, J VIROL, V85, P3179, DOI 10.1128/JVI.02333-10; Sakakibara S, 2009, J VIROL, V83, P2140, DOI 10.1128/JVI.01871-08; Salvucci O, 2009, BLOOD, V114, P1707, DOI 10.1182/blood-2008-12-192294; Schulz TF, 2007, HUMAN HERPESVIRUSES: BIOLOGY, THERAPY, AND IMMUNOPROPHYLAXIS, P490; Shembade N, 2011, NAT IMMUNOL, V12, P834, DOI 10.1038/ni.2066; Shembade N, 2010, SCIENCE, V327, P1135, DOI 10.1126/science.1182364; Shembade N, 2009, EMBO J, V28, P513, DOI 10.1038/emboj.2008.285; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Stilo R, 2008, J CELL SCI, V121, P1165, DOI 10.1242/jcs.021105; Thurau M, 2009, J VIROL, V83, P598, DOI 10.1128/JVI.00629-08; Uldrick TS, 2010, CLIN INFECT DIS, V51, P350, DOI 10.1086/654798; Verstrepen L, 2010, BIOCHEM PHARMACOL, V80, P2009, DOI 10.1016/j.bcp.2010.06.044; Wagner S, 2008, ONCOGENE, V27, P3739, DOI 10.1038/sj.onc.1211042; Weaver BK, 2007, MOL CELL BIOL, V27, P4603, DOI 10.1128/MCB.00223-07; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Wullaert A, 2007, J BIOL CHEM, V282, P81, DOI 10.1074/jbc.M607481200; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yoshikawa A, 2009, FEBS LETT, V583, P3317, DOI 10.1016/j.febslet.2009.09.028; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	65	15	22	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2013	32	10					1223	1232		10.1038/onc.2012.145	http://dx.doi.org/10.1038/onc.2012.145			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OP	22525270	Green Accepted			2022-12-17	WOS:000316454500003
J	Patrick, BA; Jaiswal, AK				Patrick, B. A.; Jaiswal, A. K.			RETRACTED: Stress-induced NQO1 controls stability of C/EBP alpha against 20S proteasomal degradation to regulate p63 expression with implications in protection against chemical-induced skin cancer (Retracted article. See vol. 36, pg. 2920, 2017)	ONCOGENE			English	Article; Retracted Publication						NQO1; C/EBP alpha; 20S proteasome; skin differentiation; p63	QUINONE OXIDOREDUCTASE-1; NAD(P)H-QUINONE OXIDOREDUCTASE-1; SKIN CARCINOGENESIS; MICE LEADS; MOUSE SKIN; P53; GENE; APOPTOSIS; NAD(P)H; SUSCEPTIBILITY	Previously, we have shown a role of cytosolic NAD(P)H: quinone oxidoreductase 1 (NQO1) in the stabilization of p63 against 20S proteasomal degradation resulting in thinning of the epithelium and chemical-induced skin cancer (Oncogene (2011) 30, 1098-1107). Current studies have demonstrated that NQO1 control of CCAAT-enhancer binding protein (C/EBP alpha) against 20S proteasomal degradation also contributes to the upregulation of p63 expression and protection. Western and immunohistochemistry analysis revealed that disruption of the NQO1 gene in mice and mouse keratinocytes led to degradation of C/EBP alpha and loss of p63 gene expression. p63 promoter mutagenesis, transfection and chromatin immunoprecipitation assays identified a C/EBP alpha-binding site between nucleotide position -185 and -174 that bound to C/EBP alpha and upregulated p63 gene expression. Co-immunoprecipitation and immunoblot analysis demonstrated that 20S proteasomes directly interacted and degraded C/EBP alpha. NQO1 direct interaction with C/EBP alpha led to stabilization of C/EBP alpha against 20S proteasomal degradation. NQO1 protection of C/EBP alpha required binding of NADH with NQO1. Exposure of skin and keratinocytes to the chemical stress agent benzo(a)pyrene led to induction of NQO1 and stabilization of C/EBP alpha protein, resulting in an increase in p63 RNA and protein in wildtype but not in NQO1-/- mice. Collectively, the current data combined with previous data suggest that stress induction of NQO1 through both stabilization of C/EBP alpha and increase in p63 and direct stabilization of p63 controls keratinocyte differentiation, leading to protection against chemical-induced skin carcinogenesis. The studies are significant as 2-4% human individuals are homozygous and 23% are heterozygous for the NQO1P187S mutation and might be susceptible to stress-induced skin diseases. Oncogene (2012) 31, 4362-4371; doi:10.1038/onc.2011.600; published online 16 January 2012	[Patrick, B. A.; Jaiswal, A. K.] Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, 655 W Baltimore St,Howard Hall 404, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Jaiswal, AK (corresponding author), Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, 655 W Baltimore St,Howard Hall 404, Baltimore, MD 21201 USA.	ajaiswal@som.umaryland.edu			NIH [RO1 ES007943]; NIEHS [RO1 ES007943]; NIEHS training grant [ES007263]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007943, T32ES007263] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS training grant; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank our colleagues for helpful discussions and suggestions. This study was supported by NIH Grant RO1 ES007943. BAP was partly supported by grant ES007263. AKJ was supported by NIEHS grant RO1 ES007943. BAP was supported by grant RO1 ES007943 and also in part is supported by NIEHS training grant ES007263.	Adler J, 2010, MOL CELL BIOL, V30, P3767, DOI 10.1128/MCB.00899-09; Ahn KS, 2006, J BIOL CHEM, V281, P19798, DOI 10.1074/jbc.M601162200; Asher G, 2005, GENE DEV, V19, P316, DOI 10.1101/gad.319905; Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; Asher G, 2002, P NATL ACAD SCI USA, V99, P13125, DOI 10.1073/pnas.202480499; Garate M, 2008, EMBO REP, V9, P576, DOI 10.1038/embor.2008.48; Gong X, 2007, CANCER RES, V67, P5380, DOI 10.1158/0008-5472.CAN-07-0323; Higashikawa K, 2007, CANCER RES, V67, P9207, DOI 10.1158/0008-5472.CAN-07-0932; Iskander K, 2005, CANCER RES, V65, P2054, DOI 10.1158/0008-5472.CAN-04-3157; Jaiswal AK, 1999, PHARMACOGENETICS, V9, P413, DOI 10.1097/00008571-199906000-00020; Kaspar JW, 2009, FREE RADICAL BIO MED, V47, P1304, DOI 10.1016/j.freeradbiomed.2009.07.035; King KE, 2007, MOL CARCINOGEN, V46, P716, DOI 10.1002/mc.20337; Long DJ, 2000, CANCER RES, V60, P5913; Long DJ, 2001, JNCI-J NATL CANCER I, V93, P1166, DOI 10.1093/jnci/93.15.1166; Long DJ, 2000, CHEM-BIOL INTERACT, V129, P99, DOI 10.1016/S0009-2797(00)00200-3; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Moll UM, 2004, MOL CANCER RES, V2, P371; Patrick BA, 2011, ONCOGENE, V30, P1098, DOI 10.1038/onc.2010.491; Pietsch EC, 2008, ONCOGENE, V27, P6507, DOI 10.1038/onc.2008.315; Radjendirane V, 1998, J BIOL CHEM, V273, P7382, DOI 10.1074/jbc.273.13.7382; Ross D, 2004, DRUG METAB REV, V36, P639, DOI 10.1081/DMR-200033465; Siegel D, 2001, MOL PHARMACOL, V59, P263, DOI 10.1124/mol.59.2.263; Sigrist CJA, 2010, NUCLEIC ACIDS RES, V38, pD161, DOI 10.1093/nar/gkp885; TRAVER RD, 1992, CANCER RES, V52, P797; Vasiliou Vasilis, 2006, Human Genomics, V2, P329; ZHANG YS, 1994, P NATL ACAD SCI USA, V91, P3147, DOI 10.1073/pnas.91.8.3147	26	15	17	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	40					4362	4371		10.1038/onc.2011.600	http://dx.doi.org/10.1038/onc.2011.600			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017LL	22249251	Green Accepted			2022-12-17	WOS:000309591300003
J	Aimbetov, R; Chen, CH; Bulgakova, O; Abetov, D; Bissenbaev, AK; Bersimbaev, RI; Sarbassov, DD				Aimbetov, R.; Chen, C-H; Bulgakova, O.; Abetov, D.; Bissenbaev, A. K.; Bersimbaev, R. I.; Sarbassov, D. D.			Integrity of mTORC2 is dependent on the rictor Gly-934 site	ONCOGENE			English	Article						cell signaling; mTORC2; Akt; complex assembly; kinase	PROTEIN-KINASE B; CAENORHABDITIS-ELEGANS; TYROSINE KINASE; GROWTH-FACTORS; BREAST-CANCER; PHOSPHORYLATION; ACTIVATION; PATHWAY; COMPONENT; AKT/PKB	Growth factor signaling coupled to activation of the phosphatidylinositol-3-OH kinase (PI3K)/Akt pathway plays a crucial role in the regulation of cell proliferation and survival. The key regulatory kinase of Akt has been identified as mammalian target of rapamycin complex 2 (mTORC2), which functions as the PI3K-dependent Ser-473 kinase of Akt. This kinase complex is assembled by mTOR and its essential components rictor, Sin1 and mLST8. The recent genetic screening study in Caenorhabditis elegans has linked a specific point mutation of rictor to an elevated storage of fatty acids that resembles the rictor deficiency phenotype. In our study, we show that in mammalian cells the analogous single rictor point mutation (G934E) prevents the binding of rictor to Sin1 and the assembly of mTORC2, but this mutation does not interfere with the binding of the rictor-interacting protein Protor. A substitution of the rictor Gly-934 residue to a charged amino acid prevents formation of the rictor/Sin1 heterodimer. The cells expressing the rictor G934E mutant remain deficient in the mTORC2 signaling, as detected by the reduced phosphorylation of Akt on Ser-473 and a low cell proliferation rate. Thus, although a full length of rictor is required to interact with its binding partner Sin1, a single amino acid of rictor Gly-934 controls its interaction with Sin1 and assembly of mTORC2. Oncogene (2012) 31, 2115-2120; doi: 10.1038/onc.2011.404; published online 12 September 2011	[Aimbetov, R.; Chen, C-H; Bulgakova, O.; Abetov, D.; Sarbassov, D. D.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Aimbetov, R.; Abetov, D.; Bissenbaev, A. K.] al Farabi Kazakh Natl Univ, Dept Genet & Mol Biol, Alma Ata, Kazakhstan; [Chen, C-H; Sarbassov, D. D.] Univ Texas Grad Sch Biomed Sci Houston, Houston, TX USA; [Bulgakova, O.; Bersimbaev, R. I.] LN Gumilyov Eurasian Natl Univ, Dept Nat Sci, Astana, Kazakhstan	University of Texas System; UTMD Anderson Cancer Center; Al-Farabi Kazakh National University; L.N. Gumilyov Eurasian National University	Sarbassov, DD (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	dsarbass@mdanderson.org	Sarbassov, Dos/AAS-4950-2020; Bulgakova, Olga/P-7825-2014; Aimbetov, Rakhan/H-2966-2015; Abetov, Danysh/P-7853-2014; Bissenbaev, Amangeldy/B-1767-2015	Bulgakova, Olga/0000-0003-3272-0638; Aimbetov, Rakhan/0000-0003-0131-4530; Bissenbaev, Amangeldy/0000-0001-7837-8685; Sarbassov, Dos/0000-0002-6848-1133	MD Anderson Trust; NIH [CA133522]; Ph.D. training grants from Kazakhstan; NATIONAL CANCER INSTITUTE [R01CA133522] Funding Source: NIH RePORTER	MD Anderson Trust; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ph.D. training grants from Kazakhstan; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the MD Anderson Trust Fellow Fund and NIH grant CA133522 (DDS). R Aimbetov and O Bulgakova have been partially supported by the Ph.D. training grants from Kazakhstan. We are thankful to our laboratory member Dr Tattym Shaikenov for providing the Akt substrate. We are also thankful to Dr Dario Alessi (University of Dundee, Dundee, England) for providing the Protor 1 alpha expression plasmid.	Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bayascas JR, 2008, CELL CYCLE, V7, P2978, DOI 10.4161/cc.7.19.6810; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bozulic L, 2008, MOL CELL, V30, P203, DOI 10.1016/j.molcel.2008.02.024; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chen C-H, 2011, J BIOL CHEM UNPUB; Chen CH, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001731; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Cordes MHJ, 1996, CURR OPIN STRUC BIOL, V6, P3, DOI 10.1016/S0959-440X(96)80088-1; Frias MA, 2006, CURR BIOL, V16, P1865, DOI 10.1016/j.cub.2006.08.001; Gross JM, 2003, CANCER METAST REV, V22, P327, DOI 10.1023/A:1023720928680; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; Jones KT, 2009, PLOS BIOL, V7, P604, DOI 10.1371/journal.pbio.1000060; Pearce LR, 2007, BIOCHEM J, V405, P513, DOI 10.1042/BJ20070540; Pearce LR, 2011, BIOCHEM J, V436, P169, DOI 10.1042/BJ20102103; Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schlessinger Joseph, 2003, Sci STKE, V2003, pRE12, DOI 10.1126/stke.2003.191.re12; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Soukas AA, 2009, GENE DEV, V23, P496, DOI 10.1101/gad.1775409; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Woo SY, 2007, J BIOL CHEM, V282, P25604, DOI 10.1074/jbc.M704343200; Zhang XH, 2000, BREAST CANCER RES, V2, P170, DOI 10.1186/bcr50	27	15	15	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	16					2115	2120		10.1038/onc.2011.404	http://dx.doi.org/10.1038/onc.2011.404			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	928TP	21909137	Green Published, Green Accepted			2022-12-17	WOS:000303008600011
J	Tognon, CE; Martin, MJ; Moradian, A; Trigo, G; Rotblat, B; Cheng, SWG; Pollard, M; Uy, E; Chow, C; Carboni, JM; Gottardis, MM; Pollak, M; Morin, GB; Sorensen, PHB				Tognon, C. E.; Martin, M. J.; Moradian, A.; Trigo, G.; Rotblat, B.; Cheng, S-W G.; Pollard, M.; Uy, E.; Chow, C.; Carboni, J. M.; Gottardis, M. M.; Pollak, M.; Morin, G. B.; Sorensen, P. H. B.			A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation	ONCOGENE			English	Article						ETV6-NTRK3; insulin-like growth factor 1 receptor (IGF1R); insulin receptor substrate 1 (IRS1); BMS-536924; chimeric tyrosine kinase	FACTOR-I RECEPTOR; PROTEIN-TYROSINE KINASE; GENE FUSION; CONGENITAL FIBROSARCOMA; MESOBLASTIC NEPHROMA; INSULIN; CELLS; SUBSTRATE-1; CARCINOMA; DOMAINS	ETV6-NTRK3 (EN), a chimeric tyrosine kinase generated by t(12; 15) translocations, is a dominantly acting oncoprotein in diverse tumor types. We previously showed that insulin-like growth factor 1 receptor (IGF1R) is essential for EN-mediated oncogenesis and that insulin receptor substrate 1 (IRS1) is constitutively tyrosine phosphorylated and bound by EN in transformed cells. Given that IRS1 is also an adapter for IGF1R, we hypothesized that IRS1 might localize EN to IGF1R at the membrane to activate phosphatidylinositol 3-kinase (PI3K)-Akt, which is critical for EN oncogenesis. In this study, we examined EN/IRS1/IGF1R complexes in detail. We find that both IRS1 and kinase active IGF1R are required for EN transformation, that tyrosine phosphorylated IRS1 is present in high molecular weight complexes with EN and IGF1R, and that EN colocalizes with IGF1R at the plasma membrane. Both IGF1R kinase activity and an intact cytoplasmic Y950 residue, the IRS1-docking site of IGF1R, are required, confirming the importance of the IGF1R/IRS1 interaction for EN oncogenesis. The dual specificity IGF1R and insulin receptor (INSR) inhibitor, BMS-536924, blocks EN transformation activity, cell survival and its interaction with IRS proteins, and induces a striking shift of EN proteins to smaller sized molecular complexes. We conclude that a tripartite complex of EN, IRS1 and IGF1R localizes EN to the membrane and that this is essential for EN-mediated transformation. These findings provide an explanation for the observed IGF1R dependency of EN transformation. Blocking IGF1R kinase activity may, therefore, provide a tractable therapeutic strategy for the many tumor types driven by the EN oncoprotein. Oncogene (2012) 31, 1334-1340; doi: 10.1038/onc.2011.323; published online 1 August 2011	[Tognon, C. E.; Martin, M. J.; Trigo, G.; Rotblat, B.; Pollard, M.; Uy, E.; Chow, C.; Sorensen, P. H. B.] BC Canc Res Ctr, Dept Mol Oncol, Vancouver, BC V5Z 1L3, Canada; [Moradian, A.; Cheng, S-W G.; Morin, G. B.] BC Canc Res Ctr, Michael Smith Genome Sci Ctr, Vancouver, BC V5Z 1L3, Canada; [Carboni, J. M.; Gottardis, M. M.] Bristol Myers Squibb Co, Oncol Drug Discovery, Princeton, NJ USA; [Pollak, M.] McGill Univ, Jewish Gen Hosp, SMBD, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; [Morin, G. B.] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada	British Columbia Cancer Agency; British Columbia Cancer Agency; Bristol-Myers Squibb; Lady Davis Institute; McGill University; University of British Columbia	Sorensen, PHB (corresponding author), BC Canc Res Ctr, Dept Mol Oncol, 675 W10th Ave, Vancouver, BC V5Z 1L3, Canada.	psor@interchange.ubc.ca	Pollak, Michael/G-9094-2011; Morin, Gregg B/E-9123-2012; Rotblat, Barak/H-5970-2019	Pollak, Michael/0000-0003-3047-0604; Morin, Gregg B/0000-0001-8949-4374; Rotblat, Barak/0000-0003-2985-7115; , Matthew/0000-0002-8948-961X	ReThink Breast Cancer Career Development Award; Canadian Institutes of Health Research (CIHR); British Columbia Cancer Foundation	ReThink Breast Cancer Career Development Award; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); British Columbia Cancer Foundation	This work was supported by the following grants: a ReThink Breast Cancer Career Development Award to CET, a Canadian Institutes of Health Research (CIHR) Graduate Studentship to MJM, a CIHR grant to PHBS, and funds from the British Columbia Cancer Foundation through donations to PHBS from Team Finn and other generous riders in the Ride to Conquer Cancer. We thank Adrian Wan and Darren Saunders for assistance with the BiFC cloning.	Argani P, 2000, MODERN PATHOL, V13, P29, DOI 10.1038/modpathol.3880006; Baserga R, 2005, EXPERT OPIN THER TAR, V9, P753, DOI 10.1517/14728222.9.4.753; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; Eguchi M, 1999, BLOOD, V93, P1355, DOI 10.1182/blood.V93.4.1355; Forghieri F, 2011, EUR J HAEMATOL, V86, P352, DOI 10.1111/j.1600-0609.2011.01576.x; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Kazakov DV, 2010, AM J SURG PATHOL, V34, P1226, DOI 10.1097/PAS.0b013e3181e4f49d; Kerppola TK, 2009, CHEM SOC REV, V38, P2876, DOI 10.1039/b909638h; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Knezevich SR, 1998, CANCER RES, V58, P5046; Lannon CL, 2005, SEMIN CANCER BIOL, V15, P215, DOI 10.1016/j.semcancer.2005.01.003; Lannon CL, 2004, J BIOL CHEM, V279, P6225, DOI 10.1074/jbc.M307388200; Martin MJ, 2006, MOL CELL BIOL, V26, P1754, DOI 10.1128/MCB.26.5.1754-1769.2006; Morrison KB, 2002, ONCOGENE, V21, P5684, DOI 10.1038/sj.onc.1205669; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; Sun HZ, 2004, ENDOCRINOLOGY, V145, P5332, DOI 10.1210/en.2004-0668; Tognon C, 2001, CANCER RES, V61, P8909; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; Tognon CE, 2004, MOL CELL BIOL, V24, P4636, DOI 10.1128/MCB.24.11.4636-4650.2004; Tognon CE, 2011, CANCER RES, V71, P1060, DOI 10.1158/0008-5472.CAN-10-3096; Wai DH, 2000, ONCOGENE, V19, P906, DOI 10.1038/sj.onc.1203396; Wittman M, 2005, J MED CHEM, V48, P5639, DOI 10.1021/jm050392q	23	15	16	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	10					1334	1340		10.1038/onc.2011.323	http://dx.doi.org/10.1038/onc.2011.323			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906KS	21804605				2022-12-17	WOS:000301344600012
J	Bertrand, J; Despeaux, M; Joly, S; Bourogaa, E; Gallay, N; Demur, C; Bonnevialle, P; Louache, F; Maguer-Satta, V; Vergnolle, N; Payrastre, B; Racaud-Sultan, C				Bertrand, J.; Despeaux, M.; Joly, S.; Bourogaa, E.; Gallay, N.; Demur, C.; Bonnevialle, P.; Louache, F.; Maguer-Satta, V.; Vergnolle, N.; Payrastre, B.; Racaud-Sultan, C.			Sex differences in the GSK3 beta-mediated survival of adherent leukemic progenitors	ONCOGENE			English	Article						cell survival; cell adhesion; GSK3 beta; leukemia	ACUTE MYELOID-LEUKEMIA; GLYCOGEN-SYNTHASE KINASE-3; RECEPTOR-ALPHA CHAIN; STEM-CELLS; EXPRESSION; INTEGRIN; INHIBITION; PROTEIN; MICROENVIRONMENT; PROLIFERATION	Therapeutic resistance of acute myeloid leukemia stem cells, enriched in the CD34(+)38(-)123(+) progenitor population, is supported by extrinsic factors such as the bone marrow niche. Here, we report that when adherent onto fibronectin or osteoblast components, CD34(+)38(-)123(+) progenitors survive through an integrin-dependent activation of glycogen synthase kinase 3 beta (GSK3 beta) by serine 9-dephosphorylation. Strikingly, GSK3 beta-mediated survival was restricted to leukemic progenitors from female patients. GSK3 beta inhibition restored sensitivity to etoposide, and impaired the clonogenic capacities of adherent leukemic progenitors from female patients. In leukemic progenitors from female but not male patients, the scaffolding protein RACK1, activated downstream of alpha 5 beta 1- integrin engagement, was specifically upregulated and controlled GSK3 beta activation through the phosphatase protein phosphatase 2A (PP2A). In a mirrored manner, survival of adherent progenitors (CD34(+)38(-)) from male but not female healthy donors was partially dependent on this pathway. We conclude that the GSK3 beta-dependent survival pathway might be sex-specific in normal immature population and flip-flopped upon leukemogenesis. Taken together, our results strengthen GSK3 beta as a promising target for leukemic stem cell therapy and reveal gender differences as a new parameter in anti-leukemia therapy. Oncogene (2012) 31, 694-705; doi:10.1038/onc.2011.258; published online 4 July 2011	[Bertrand, J.; Despeaux, M.; Bourogaa, E.; Gallay, N.; Vergnolle, N.; Racaud-Sultan, C.] Univ Toulouse UPS, Inserm U1043, CNRS U5282, CPTP, F-31024 Toulouse 3, France; [Joly, S.; Maguer-Satta, V.] CRCL, CNRS U5286, Inserm U1052, Lyon, France; [Demur, C.] Univ Toulouse, Ctr Rech Cancerol Toulouse, Inserm UMR1037, CNRS ERL5294, Toulouse, France; [Demur, C.; Payrastre, B.] CHU Toulouse, Hematol Lab, Toulouse, France; [Bonnevialle, P.] CHU Toulouse, Serv Clin Chirurg Orthoped & Traumatol, Toulouse, France; [Louache, F.] Inst Gustave Roussy, Inserm U790, Villejuif, France; [Payrastre, B.] Univ Toulouse UPS, Inserm U1048, Inst Malad Metab & Cardiovasc, F-31024 Toulouse 3, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Federale Toulouse Midi-Pyrenees (ComUE); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Centre de Recherche en cancerologie (CRCL); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite Federale Toulouse Midi-Pyrenees (ComUE)	Racaud-Sultan, C (corresponding author), Univ Toulouse UPS, CHU Purpan, Hop Purpan, INSERM U1043,CNRS U5282,CPTP, Pl Dr Baylac, F-31024 Toulouse 3, France.	claire.racaud@inserm.fr	Maguer-Satta, Veronique/U-8857-2019; Vergnolle, Nathalie/C-7677-2018; Payrastre, Bernard/M-5295-2014	Maguer-Satta, Veronique/0000-0002-1556-068X; Vergnolle, Nathalie/0000-0003-1825-6015; Racaud-Sultan, Claire/0000-0002-6549-1088; , Bernard/0000-0002-8693-0190; , Nathalie GALLAY/0000-0002-4236-4780	Association de Recherche contre le Cancer [3638, 8407]; Institut National du Cancer [07/3D1616/IABC-23-8/NC-NG]; DGRSRT/INSERM cooperation	Association de Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Institut National du Cancer(Institut National du Cancer (INCA) France); DGRSRT/INSERM cooperation(Institut National de la Sante et de la Recherche Medicale (Inserm))	We thank Dr Jean-Emmanuel Sarry for critical reading of the manuscript and the 'plateforme de cytometrie' of IFR150. Association de Recherche contre le Cancer (Contract Nos. 3638 and 8407), Institut National du Cancer (Contract no. 07/3D1616/IABC-23-8/NC-NG), DGRSRT/INSERM cooperation.	Berghofer B, 2006, J IMMUNOL, V177, P2088, DOI 10.4049/jimmunol.177.4.2088; Bhatia R, 1996, BLOOD, V87, P3883, DOI 10.1182/blood.V87.9.3883.bloodjournal8793883; De Toni F, 2006, ONCOGENE, V25, P3113, DOI 10.1038/sj.onc.1209346; De Toni-Costes F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009807; de Vries JF, 2006, HAEMATOL-HEMATOL J, V91, P912; Del Vecchio I, 2009, GENE, V430, P17, DOI 10.1016/j.gene.2008.10.005; Despeaux M, 2011, LEUKEMIA, V25, P1789, DOI 10.1038/leu.2011.145; Dick JE, 2005, INT J HEMATOL, V82, P389, DOI 10.1532/IJH97.05144; Ding QQ, 2007, MOL CELL BIOL, V27, P4006, DOI 10.1128/MCB.00620-06; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Edderkaoui M, 2007, J BIOL CHEM, V282, P26646, DOI 10.1074/jbc.M702836200; Guzman ML, 2005, BLOOD, V105, P4163, DOI 10.1182/blood-2004-10-4135; Holmes T, 2008, STEM CELLS, V26, P1288, DOI 10.1634/stemcells.2007-0600; Ishikawa F, 2007, NAT BIOTECHNOL, V25, P1315, DOI 10.1038/nbt1350; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483; Jin LQ, 2009, CELL STEM CELL, V5, P31, DOI 10.1016/j.stem.2009.04.018; Jordan CT, 2000, LEUKEMIA, V14, P1777, DOI 10.1038/sj.leu.2401903; Kiely PA, 2008, J BIOL CHEM, V283, P22952, DOI 10.1074/jbc.M800802200; Kornblau SM, 2009, BLOOD, V113, P154, DOI 10.1182/blood-2007-10-119438; Kubota T, 2002, J VIROL, V76, P12676, DOI 10.1128/JVI.76.24.12676-12682.2002; Li ZW, 2006, BLOOD REV, V20, P333, DOI 10.1016/j.blre.2005.08.003; Luo J, 2009, CANCER LETT, V273, P194, DOI 10.1016/j.canlet.2008.05.045; Matsunaga T, 2003, NAT MED, V9, P1158, DOI 10.1038/nm909; Mayack SR, 2010, NATURE, V463, P495, DOI 10.1038/nature08749; Ougolkov AV, 2007, BLOOD, V110, P735, DOI 10.1182/blood-2006-12-060947; Papasozomenos SC, 2002, P NATL ACAD SCI USA, V99, P1140, DOI 10.1073/pnas.032646799; Recher C, 2004, CANCER RES, V64, P3191, DOI 10.1158/0008-5472.CAN-03-3005; Saito Y, 2010, NAT BIOTECHNOL, V28, P275, DOI 10.1038/nbt.1607; Sampaio ALF, 2010, J LEUKOCYTE BIOL, V87, P877, DOI 10.1189/jlb.1009670; SCHILLER G, 1994, LEUKEMIA LYMPHOMA, V15, P85, DOI 10.3109/10428199409051682; Sun M, 2008, CELL DEATH DIFFER, V15, P1887, DOI 10.1038/cdd.2008.124; Trowbridge JJ, 2006, NAT MED, V12, P89, DOI 10.1038/nm1339; Vialle-Castellano A, 2004, LEUKEMIA, V18, P426, DOI 10.1038/sj.leu.2403273; Wang Z, 2008, NATURE, V455, P1205, DOI 10.1038/nature07284; Wang Z, 2010, CANCER CELL, V17, P597, DOI 10.1016/j.ccr.2010.04.024; Xu Q, 2005, BLOOD, V106, P4261, DOI 10.1182/blood-2004-11-4468; Ysebaert L, 2006, LEUKEMIA, V20, P1211, DOI 10.1038/sj.leu.2404239	38	15	15	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	6					694	705		10.1038/onc.2011.258	http://dx.doi.org/10.1038/onc.2011.258			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MU	21725365				2022-12-17	WOS:000300222100003
J	Poschl, J; Lorenz, A; Hartmann, W; von Bueren, AO; Kool, M; Li, S; Peraud, A; Tonn, JC; Herms, J; Xiang, M; Rutkowski, S; Kretzschmar, HA; Schuller, U				Poeschl, J.; Lorenz, A.; Hartmann, W.; von Bueren, A. O.; Kool, M.; Li, S.; Peraud, A.; Tonn, J-C; Herms, J.; Xiang, M.; Rutkowski, S.; Kretzschmar, H. A.; Schueller, U.			Expression of BARHL1 in medulloblastoma is associated with prolonged survival in mice and humans	ONCOGENE			English	Article						cerebellum; medulloblastoma; Barhl1; survival; Sonic hedgehog; tumor	CENTRAL-NERVOUS-SYSTEM; HEDGEHOG PATHWAY; GENE-EXPRESSION; HOMEOBOX GENE; MOUSE MODEL; CELLS; CEREBELLUM; SUBTYPES; GROWTH	Medulloblastoma is the most common malignant brain tumor in childhood, and development of targeted therapies is highly desired. Although the molecular mechanisms of malignant transformation are not fully understood, it is known that medulloblastomas may arise from cerebellar granule neuron precursors. The homeodomain transcription factor Barhl1 is known to regulate migration and survival of granule cell precursors, but its functional role in medulloblastoma is unknown. We show here that the expression of BARHL1 is significantly upregulated during human cerebellar development and in human medulloblastoma samples as compared with the normal adult cerebellum. We also detected high levels of Barhl1 expression in medulloblastomas of Math1-cre:SmoM2 mice, a mouse model for Sonic hedgehog-associated medulloblastomas that we developed previously. To investigate Barhl1 function in vivo during tumor development, we generated Barhl1(-/-) Math1-cre: SmoM2 mice. Interestingly, tumors that developed in these mice displayed increased mitotic activity and decreased neuronal differentiation. Moreover, survival of these mice was significantly decreased. Similarly, low expression of BARHL1 in human medulloblastoma cases was associated with a less favorable prognosis for patients. These results suggest that the expression of Barhl1 decelerates tumor growth both in human and in murine medulloblastomas and should be further investigated with respect to potential implications for individualized therapeutic strategies. Oncogene (2011) 30, 4721-4730; doi:10.1038/onc.2011.173; published online 23 May 2011	[Poeschl, J.; Lorenz, A.; Herms, J.; Kretzschmar, H. A.; Schueller, U.] Univ Munich, Ctr Neuropathol, D-81377 Munich, Germany; [Hartmann, W.] Univ Bonn, Med Ctr, Dept Pathol, Bonn, Germany; [von Bueren, A. O.; Rutkowski, S.] Univ Med Ctr, Dept Pediat Hematol & Oncol, Hamburg, Germany; [Kool, M.] Univ Amsterdam, Acad Med Ctr, Dept Human Genet, NL-1105 AZ Amsterdam, Netherlands; [Li, S.; Xiang, M.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; [Li, S.; Xiang, M.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pediat, Piscataway, NJ 08854 USA; [Peraud, A.; Tonn, J-C] Univ Munich, Dept Neurosurg, D-81377 Munich, Germany	University of Munich; University of Bonn; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Amsterdam; Academic Medical Center Amsterdam; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Munich	Schuller, U (corresponding author), Univ Munich, Ctr Neuropathol, Feodor Lynen Str 23, D-81377 Munich, Germany.	ulrich.schueller@lmu.de	Tonn, Joerg/AAK-8509-2021; Hartmann, Wolfgang/G-1893-2017; Herms, Jochen/D-3518-2011; von Bueren, Andre/AAF-2065-2020; Kool, Marcel/H-2541-2013	Hartmann, Wolfgang/0000-0002-7609-5021; von Bueren, Andre/0000-0003-4197-6264; Schuller, Ulrich/0000-0002-8731-1121; Neumann, Julia E./0000-0002-1162-8771	Wilhelm-Sander-Stiftung; Friedrich-Baur-Stiftung; German Children's Cancer Foundation (Deutsche Kinderkrebsstiftung); Fordergemeinschaft Kinderkrebszentrum Hamburg e. V.; NATIONAL CANCER INSTITUTE [P30CA072720] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY015777, R01EY012020] Funding Source: NIH RePORTER	Wilhelm-Sander-Stiftung; Friedrich-Baur-Stiftung; German Children's Cancer Foundation (Deutsche Kinderkrebsstiftung); Fordergemeinschaft Kinderkrebszentrum Hamburg e. V.; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	We are indebted to Michael Schmidt, Veronika Kaltenbrunn, Dagmar Metzger, Philipp Neumann and Silvia Occhionero for excellent technical support, to Dr Mehdi Shakarami and Dr Stefanie Ohlemeyer for animal husbandry. We acknowledge Dr Rosalind Segal for providing Zic antibodies. This work was supported by grants from the Wilhelm-Sander-Stiftung and the Friedrich-Baur-Stiftung (all to US). US is a member of the Max-Eder-junior-research-program of the German Cancer Aid. The HIT-trial-office at the University Medical Center Hamburg-Eppendorf is supported by the German Children's Cancer Foundation (Deutsche Kinderkrebsstiftung) and by the Fordergemeinschaft Kinderkrebszentrum Hamburg e. V.	Bulfone A, 2000, HUM MOL GENET, V9, P1443, DOI 10.1093/hmg/9.9.1443; Chellappa R, 2008, MOL CELL BIOL, V28, P1905, DOI 10.1128/MCB.01454-07; Corrales JMD, 2004, DEVELOPMENT, V131, P5581, DOI 10.1242/dev.01438; Crawford JR, 2007, LANCET NEUROL, V6, P1073, DOI 10.1016/S1474-4422(07)70289-2; Eberhart CG, 2001, J NEUROPATH EXP NEUR, V60, P462, DOI 10.1093/jnen/60.5.462; Gibson P, 2010, NATURE, V468, P1095, DOI 10.1038/nature09587; Gilbertson RJ, 2004, LANCET ONCOL, V5, P209, DOI 10.1016/S1470-2045(04)01424-X; Hartmann W, 2005, AM J PATHOL, V166, P1153, DOI 10.1016/S0002-9440(10)62335-8; Heine VM, 2009, J CLIN INVEST, V119, P267, DOI 10.1172/JCI36376; Jeong JH, 2004, GENE DEV, V18, P937, DOI 10.1101/gad.1190304; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Li SG, 2004, J NEUROSCI, V24, P3104, DOI 10.1523/JNEUROSCI.4444-03.2004; Li SG, 2002, DEVELOPMENT, V129, P3523; Louis DN, 2007, WHO CLASSIFICATION T; Mao J, 2006, CANCER RES, V66, P10171, DOI 10.1158/0008-5472.CAN-06-0657; Millen KJ, 1995, DEVELOPMENT, V121, P3935; Mo ZQ, 2004, DEVELOPMENT, V131, P1607, DOI 10.1242/dev.01071; Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Scales SJ, 2009, TRENDS PHARMACOL SCI, V30, P303, DOI 10.1016/j.tips.2009.03.007; Schuller U, 2008, CANCER CELL, V14, P123, DOI 10.1016/j.ccr.2008.07.005; Schuller U, 2007, MOL CELL BIOL, V27, P8259, DOI 10.1128/MCB.00707-07; SEGAL RA, 1994, P NATL ACAD SCI USA, V91, P12867, DOI 10.1073/pnas.91.26.12867; Sutter R, 2010, ONCOGENE, V29, P1845, DOI 10.1038/onc.2009.472; Weyer A, 2003, J NEUROSCI RES, V73, P400, DOI 10.1002/jnr.10655; Yokota N, 2004, ONCOGENE, V23, P3444, DOI 10.1038/sj.onc.1207475; Yokota N, 1996, CANCER RES, V56, P377	27	15	15	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2011	30	47					4721	4730		10.1038/onc.2011.173	http://dx.doi.org/10.1038/onc.2011.173			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	861QG	21602885	Green Accepted			2022-12-17	WOS:000298033700004
J	Fan, LC; Chiang, WF; Liang, CH; Tsai, YT; Wong, TY; Chen, KC; Hong, TM; Chen, YL				Fan, L-C; Chiang, W-F; Liang, C-H; Tsai, Y-T; Wong, T-Y; Chen, K-C; Hong, T-M; Chen, Y-L			alpha-Catulin knockdown induces senescence in cancer cells	ONCOGENE			English	Article						alpha-catulin; senescence; p53; DNA damage; cDNA microarray; cancer	ONCOGENE-INDUCED SENESCENCE; DOUBLE-STRAND BREAKS; DNA-DAMAGE RESPONSE; NUCLEOTIDE EXCISION-REPAIR; CELLULAR SENESCENCE; IN-VIVO; CHROMOSOMAL INSTABILITY; TUMORIGENESIS; CATENIN; ACTIVATION	Cellular senescence functions as a tumor suppressor that protects against cancer progression. alpha-Catulin, an alpha-catenin-related protein, is reported to have tumorigenic potential because it regulates the nuclear factor-kappa B (NF-kappa B) pathway, but little is known about its clinical relevance and the mechanism through which it regulates cancer progression. Here, we found that alpha-catulin mRNA levels were significantly upregulated in cancer cell lines and clinical oral squamous cell carcinomas, which positively correlated with tumor size (P = 0.001) and American Joint Committee on Cancer (AJCC) stage (P = 0.004). alpha-Catulin knockdown in the OC2 and A549 cancer cell lines dramatically decreased cell proliferation and contributed to cellular senescence, and inhibited OC2 xenograft growth. Mechanistic dissection showed that alpha-catulin depletion strongly induced the DNA-damage response (DDR) in both cell lines, via a p53/p21-dependent pathway in A549 cells, but a p53/p21-independent pathway in OC2 cells carrying mutant p53. Global gene expression analysis revealed that alpha-catulin knockdown altered cell-cycle regulation and DDR pathways at the presenescent stage as well as significantly downregulate several crucial genes related to mitotic chromosome condensation, DDR and DNA repair systems, which suggests that its depletion-induced cellular senescence might be caused by chromosome condensation failures, severe DNA damage and impaired DNA repair ability. Our study provides evidence that alpha-catulin promotes tumor growth by preventing cellular senescence and suggests that downregulating alpha-catulin may be a promising therapeutic approach for cancer treatment. Oncogene (2011) 30, 2610-2621; doi:10.1038/onc.2010.637; published online 31 January 2011	[Tsai, Y-T; Wong, T-Y; Chen, K-C; Chen, Y-L] Natl Cheng Kung Univ, Inst Oral Med, Coll Med, Tainan 70101, Taiwan; [Fan, L-C; Liang, C-H; Hong, T-M; Chen, Y-L] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 70101, Taiwan; [Chiang, W-F] Chi Mei Med Ctr, Dept Dent, Liouying, Taiwan; [Chiang, W-F] Natl Yang Ming Univ, Sch Dent, Taipei 112, Taiwan; [Hong, T-M] Natl Cheng Kung Hosp, Dept Clin Med Res, Tainan, Taiwan; [Hong, T-M] Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan 70101, Taiwan	National Cheng Kung University; National Cheng Kung University; Chi Mei Hospital; National Yang Ming Chiao Tung University; National Cheng Kung University; National Cheng Kung University	Chen, YL (corresponding author), Natl Cheng Kung Univ, Inst Oral Med, Coll Med, 1 Univ Rd, Tainan 70101, Taiwan.	tmhong@mail.ncku.edu.tw; yuhling@mail.ncku.edu.tw	Chiang, Wei-Fan/L-6537-2019; Chen, Yuh-Ling/AAS-7957-2021	Chiang, Wei-Fan/0000-0002-9240-1404; 	National Science Council [NSC 96-2311-B-006-005-MY3, NSC 97-2314-B-384-003-MY3, NSC 99-3112-B-006-011, NSC 99-2627-B-006-003]; Department of Health, Taiwan [DOH99-TD-C-111-003]; National Science Council, Taiwan [NSC 97-3112-B-001-016]	National Science Council(Ministry of Science and Technology, Taiwan); Department of Health, Taiwan; National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by grants NSC 96-2311-B-006-005-MY3, NSC 97-2314-B-384-003-MY3, NSC 99-3112-B-006-011 and NSC 99-2627-B-006-003 from the National Science Council, and DOH99-TD-C-111-003 from the Department of Health, Taiwan. RNAi reagents were obtained from the National RNAi Core Facility located at the Institute of Molecular Biology/Genomic Research Center, Academia Sinica, supported by the National Research Program for Genomic Medicine Grants of National Science Council, Taiwan (NSC 97-3112-B-001-016).	Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Coelho PA, 2003, J CELL SCI, V116, P4763, DOI 10.1242/jcs.00799; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; de Vries A, 2002, P NATL ACAD SCI USA, V99, P2948, DOI 10.1073/pnas.052713099; di Fagagna FD, 2008, NAT REV CANCER, V8, P512, DOI 10.1038/nrc2440; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Huck JJ, 2010, MOL CANCER RES, V8, P373, DOI 10.1158/1541-7786.MCR-09-0300; Hudson DF, 2009, CHROMOSOME RES, V17, P131, DOI 10.1007/s10577-008-9009-7; Janssens B, 1999, BBA-GENE STRUCT EXPR, V1447, P341, DOI 10.1016/S0167-4781(99)00170-0; Kunkel TA, 2005, ANNU REV BIOCHEM, V74, P681, DOI 10.1146/annurev.biochem.74.082803.133243; Li WJ, 2008, CLIN CANCER RES, V14, P3722, DOI 10.1158/1078-0432.CCR-07-4137; Li YF, 2009, J GENE MED, V11, P3, DOI 10.1002/jgm.1270; LLeonart ME, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-3; Merdek KD, 2004, MOL CELL BIOL, V24, P2410, DOI 10.1128/MCB.24.6.2410-2422.2004; Mikhailov A, 2002, CURR BIOL, V12, P1797, DOI 10.1016/S0960-9822(02)01226-5; Miura K, 1996, CANCER RES, V56, P1629; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Park B, 2002, J BIOL CHEM, V277, P45361, DOI 10.1074/jbc.M202447200; Pastink A, 2001, MUTAT RES-FUND MOL M, V480, P37, DOI 10.1016/S0027-5107(01)00167-1; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; SCHULTZ DC, 1995, CANCER RES, V55, P2150; Shrivastav M, 2008, CELL RES, V18, P134, DOI 10.1038/cr.2007.111; Siafakas AR, 2009, INT J BIOCHEM CELL B, V41, P986, DOI 10.1016/j.biocel.2008.06.018; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Suzuki T, 2002, EXP GERONTOL, V37, P1005, DOI 10.1016/S0531-5565(02)00061-X; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; Wakasugi M, 2002, J BIOL CHEM, V277, P1637, DOI 10.1074/jbc.C100610200; Walen KH, 2007, CELL BIOL INT, V31, P1447, DOI 10.1016/j.cellbi.2007.06.015; Wiesner C, 2008, ONCOGENE, V27, P2159, DOI 10.1038/sj.onc.1210863; Yang HL, 2006, CANCER RES, V66, P3096, DOI 10.1158/0008-5472.CAN-05-3620; Zhang JS, 1998, GENOMICS, V54, P149, DOI 10.1006/geno.1998.5458; Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002	41	15	20	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	23					2610	2621		10.1038/onc.2010.637	http://dx.doi.org/10.1038/onc.2010.637			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778CV	21278790				2022-12-17	WOS:000291677800002
J	Wang, LT; Lin, CS; Chai, CY; Liu, KY; Chen, JY; Hsu, SH				Wang, L-T; Lin, C-S; Chai, C-Y; Liu, K-Y; Chen, J-Y; Hsu, S-H			Functional interaction of Ugene and EBV infection mediates tumorigenic effects	ONCOGENE			English	Article						EBV; LMP1; LMPIP; tumorigenesis	EPSTEIN-BARR-VIRUS; ENCODED LATENT MEMBRANE-PROTEIN-1; NASOPHARYNGEAL CARCINOMA-CELLS; ZIP TRANSCRIPTION FACTOR; NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; BURKITT-LYMPHOMA; CYCLIN D1; LMP1; GROWTH	Epstein-Barr virus (EBV) infection is associated with many human neoplasms, in which EBV-derived latent membrane protein-1 (LMP1) appears to be critical, but its exact oncogenic mechanism remains to be defined. To this end, our initial microarray analyses identified a LMP1-inducible gene, Ugene, originally characterized as a binding partner for uracil DNA glycosylase 2, which is highly expressed in malignant colon cancer. In this report, it was found that Ugene, designated herein as LMP1-induced protein (LMPIP), was induced, in a time-dependent manner, in EBV-infected peripheral blood mononuclear cells and LMP1-transfected 293 cells. Functionally, when compared with mock-transfected cells, overexpression of LMPIP in nasopharyngeal carcinoma (NPC) cell lines resulted in a decrease in reactive oxygen species production and maintained mitochondria membrane potential (Delta psi) loss induced by H2O2. The NPC cells transfected with LMPIP also showed a decrease in G1 population and an increase in the cell population in sub-G1 and multiploid phase, concomitant with increased levels of cell cycle activators, including cyclin D1 and CDK4. In contrast, silencing of LMPIP expression in the NPC tumor cell lines with short hairpin RNA interference revealed significantly decreased cell population at G1/S phase, while the number of cells in multiploid phase increased. Significantly, NPC cells with LMPIP knock-down also showed a decrease in tumorigenic and transforming activity induced by ectopic LMP1 expression, as determined by analyses of soft agar foci and tumor size in nude mice. Further, elevated LMPIP expression was also noted in cytoplasm and nuclei in EBV-infected NPC tumor cell mass and non-EBV-infected tumor cell lines. These results suggested that LMPIP may have an important mediator role in EBV-mediated neoplasm and may serve as a new target for therapy of tumors induced by EBV infection. Oncogene (2011) 30, 2921-2932; doi:10.1038/onc.2011.16; published online 14 February 2011	[Wang, L-T; Lin, C-S; Liu, K-Y; Hsu, S-H] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung 807, Taiwan; [Chai, C-Y] Kaohsiung Med Univ, Fac Med, Coll Med, Dept Pathol, Kaohsiung 807, Taiwan; [Chen, J-Y] Natl Hlth Res Inst, Inst Canc Res, Zhunan, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; National Health Research Institutes - Taiwan	Hsu, SH (corresponding author), Kaohsiung Med Univ, Grad Inst Med, Coll Med, 100,Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.	jackhsu@kmu.edu.tw	Chen, Jen-Yang/D-2085-2010; Lin, Chang-Shen/X-2189-2019; Lin, Chang-Shen/D-5140-2009	Lin, Chang-Shen/0000-0001-7415-2187; Hsu, Shih Hsien/0000-0003-2102-0505; Wang, Li-Ting/0000-0002-3335-8055; Chai, Chee-Yin/0000-0003-0486-9742	National Science Council, Taiwan [NSC-97-2311-B-037-002-MY3, NSC-97-2314-B-037-015, NSC-98-2320-B- 037-026-MY3]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	We thank Dr SK Huang for critically reviewing this paper. This work was supported in part by Research Grants NSC-97-2311-B-037-002-MY3, NSC-97-2314-B-037-015 and NSC-98-2320-B- 037-026-MY3 from the National Science Council, Taiwan.	Ai MD, 2005, CELL RES, V15, P777, DOI 10.1038/sj.cr.7290347; Bartosz G, 2009, BIOCHEM PHARMACOL, V77, P1303, DOI 10.1016/j.bcp.2008.11.009; Behrend L, 2003, BIOCHEM SOC T, V31, P1441; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Burhans WC, 2009, FREE RADICAL BIO MED, V47, P1282, DOI 10.1016/j.freeradbiomed.2009.05.026; Chang Y, 1998, LAB INVEST, V78, P715; Demetriades C, 2009, J VIROL, V83, P5269, DOI 10.1128/JVI.00097-09; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; Eliopoulos AG, 1998, CURR BIOL, V8, pR196, DOI 10.1016/S0960-9822(98)70123-X; Esposito F, 2001, IUBMB LIFE, V52, P67, DOI 10.1080/15216540252774793; Fang CY, 2009, INT J CANCER, V124, P2016, DOI 10.1002/ijc.24179; Guo CG, 2008, CANCER RES, V68, P6118, DOI 10.1158/0008-5472.CAN-08-1259; Hour TC, 2010, BIOCHEM PHARMACOL, V80, P325, DOI 10.1016/j.bcp.2010.04.007; Hsu SH, 2005, CANCER RES, V65, P4041, DOI 10.1158/0008-5472.CAN-04-3658; Hsu SH, 2004, EXP CELL RES, V294, P185, DOI 10.1016/j.yexcr.2003.10.029; Hsu SH, 2001, MECH DEVELOP, V100, P177, DOI 10.1016/S0925-4773(00)00513-X; Zheng H, 2007, CELL MOL IMMUNOL, V4, P185; Kanegane H, 2002, CRIT REV ONCOL HEMAT, V44, P239, DOI 10.1016/S1040-8428(02)00115-4; Kieser A, 2008, BIOL CHEM, V389, P1261, DOI 10.1515/BC.2008.144; Kis LL, 2006, BLOOD, V107, P2928, DOI 10.1182/blood-2005-06-2569; Laurent A, 2005, CANCER RES, V65, P948; LIEBOWITZ D, 1992, J VIROL, V66, P4612, DOI 10.1128/JVI.66.7.4612-4616.1992; LINDAHL T, 1974, INT J CANCER, V13, P764, DOI 10.1002/ijc.2910130605; Liu MT, 2005, ONCOGENE, V24, P2635, DOI 10.1038/sj.onc.1208319; Menon SG, 2007, ONCOGENE, V26, P1101, DOI 10.1038/sj.onc.1209895; Menon SG, 2007, CANCER RES, V67, P6392, DOI 10.1158/0008-5472.CAN-07-0225; Menon SG, 2003, CANCER RES, V63, P2109; MILLER G, 1973, P NATL ACAD SCI USA, V70, P190, DOI 10.1073/pnas.70.1.190; Munz C, 2008, SEMIN CANCER BIOL, V18, P381, DOI 10.1016/j.semcancer.2008.10.002; Pai S, 2001, SEMIN CANCER BIOL, V11, P455, DOI 10.1006/scbi.2001.0412; Queiroga EM, 2008, AM J CLIN PATHOL, V130, P186, DOI 10.1309/2CNAWY6GAR0VQAXX; Sakamaki T, 2006, MOL CELL BIOL, V26, P5449, DOI 10.1128/MCB.02074-05; Sarsour EH, 2009, ANTIOXID REDOX SIGN, V11, P2985, DOI [10.1089/ars.2009.2513, 10.1089/ARS.2009.2513]; Sauer H, 2001, CELL PHYSIOL BIOCHEM, V11, P173, DOI 10.1159/000047804; Shackelford RE, 1999, ENVIRON HEALTH PERSP, V107, P5, DOI 10.2307/3434468; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; Soni V, 2007, ADV EXP MED BIOL, V597, P173; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Thorley-Lawson DA, 2008, NAT REV MICROBIOL, V6, P913, DOI 10.1038/nrmicro2015; Tsao SW, 2002, SEMIN CANCER BIOL, V12, P473, DOI 10.1016/S1044579X02000901; Yu JS, 2002, ONCOGENE, V21, P8047, DOI 10.1038/sj.onc.1205990	42	15	17	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	26					2921	2932		10.1038/onc.2011.16	http://dx.doi.org/10.1038/onc.2011.16			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	785QZ	21317926				2022-12-17	WOS:000292245100003
J	Hanashiro, K; Brancaccio, M; Fukasawa, K				Hanashiro, K.; Brancaccio, M.; Fukasawa, K.			Activated ROCK II by-passes the requirement of the CDK2 activity for centrosome duplication and amplification	ONCOGENE			English	Article						CDK2; cyclin E; nucleophosmin; ROCK II; centrosome; morgana/chp-1	RHO-ASSOCIATED KINASE; CYCLIN-E; PHOSPHORYLATION; MYOSIN; NUCLEOPHOSMIN/B23; GTPASES; TARGET; ROLES	Initiation of centrosome duplication and DNA replication is coupled, which is primarily achieved by the late G1 phase-specific activation of cyclin-dependent kinase 2 (CDK2)-cyclin E, which triggers both centrosome duplication and DNA replication. Uncoupling of these two events contributes to overduplication of centrosomes, resulting in the presence of more than two centrosomes (centrosome amplification). Centrosome amplification, which is frequently observed in cancers, contributes to tumor development through destabilizing genomes. Nucleophosmin (NPM/B23) is one of the phosphorylation targets of CDK2-cyclin E for the initiation of centrosome duplication. It has been found that NPM/B23 phosphorylated on Thr199 by CDK2-cyclin E acquires a high binding affinity to ROCK II kinase. The Thr199-phosphorylated NPM/B23 physically interacts with and super-activates the centrosomally localized ROCK II, which is a critical event for centrosomes to initiate duplication. Here, we provide direct evidence for the activation of ROCK II as a primary and sufficient downstream event of CDK2-cyclin E for the initiation of centrosome duplication and for the induction of centrosome amplification. Oncogene (2011) 30, 2188-2197; doi:10.1038/onc.2010.607; published online 17 January 2011	[Hanashiro, K.; Fukasawa, K.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; [Brancaccio, M.] Univ Turin, Dept Genet Biol & Biochem, Turin, Italy	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; University of Turin	Fukasawa, K (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA.	kenji.fukasawa@moffitt.org			National Institutes of Health [CA90522, GM87328, AIRC2008]; NATIONAL CANCER INSTITUTE [R01CA090522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM087328] Funding Source: NIH RePORTER; Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	Cyclin E <SUP>/</SUP> MEFs lacking functional p53 were provided by Dr P Sicinski (Harvard Medical School), and p53 <SUP>/</SUP> MEFs from Dr Donehower (Baylor College of Medicine). We thank M Crow, B Nepon-Sixt and M Rowland for technical assistance, and M Lloyd and J Johnson for technical assistance on microscopic analysis. This research is supported by the grants from the National Institutes of Health (CA90522 and GM87328) to KF and from AIRC2008 to MB.	Amano M, 1999, J BIOL CHEM, V274, P32418, DOI 10.1074/jbc.274.45.32418; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Chen ZH, 2002, DEV CELL, V3, P339, DOI 10.1016/S1534-5807(02)00258-7; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; Ferretti R, 2010, DEV CELL, V18, P486, DOI 10.1016/j.devcel.2009.12.020; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Hanashiro K, 2008, ONCOGENE, V27, P5288, DOI 10.1038/onc.2008.161; Hinchcliffe EH, 2002, ONCOGENE, V21, P6154, DOI 10.1038/sj.onc.1205826; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Kamai T, 2003, CLIN CANCER RES, V9, P2632; Kamai T, 2004, CLIN CANCER RES, V10, P4799, DOI 10.1158/1078-0432.CCR-0436-03; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Leung T, 1996, MOL CELL BIOL, V16, P5313; Ma Z, 2006, MOL CELL BIOL, V26, P9016, DOI 10.1128/MCB.01383-06; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Ridley AJ, 2004, BREAST CANCER RES TR, V84, P13, DOI 10.1023/B:BREA.0000018423.47497.c6; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Totsukawa G, 2000, J CELL BIOL, V150, P797, DOI 10.1083/jcb.150.4.797; Wong CCL, 2009, HEPATOLOGY, V49, P1583, DOI 10.1002/hep.22836; Wu JC, 2005, FEBS LETT, V579, P421, DOI 10.1016/j.febslet.2004.12.005	33	15	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	19					2188	2197		10.1038/onc.2010.607	http://dx.doi.org/10.1038/onc.2010.607			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	762XD	21242972				2022-12-17	WOS:000290514600002
J	Emde, A; Pradeep, CR; Ferraro, DA; Ben-Chetrit, N; Sela, M; Ribba, B; Kam, Z; Yarden, Y				Emde, A.; Pradeep, C-R; Ferraro, D. A.; Ben-Chetrit, N.; Sela, M.; Ribba, B.; Kam, Z.; Yarden, Y.			Combining epitope-distinct antibodies to HER2: cooperative inhibitory effects on invasive growth	ONCOGENE			English	Article						breast cancer; growth factor; trastuzumab; tyrosine kinase; 3D culture	HUMAN-BREAST-CANCER; ANTI-ERBB-2 MONOCLONAL-ANTIBODIES; FACTOR RECEPTOR; IN-VIVO; TYROSINE KINASES; NEU ONCOGENE; ERBB2; CELL; TRASTUZUMAB; PROGRESSION	Monoclonal antibodies (mAbs) to HER2 are currently used to treat breast cancer, but low clinical efficacy, along with primary and acquired resistance to therapy, commonly limit clinical applications. We previously reported that combinations of antibodies directed at non-overlapping epitopes of HER2 are endowed with enhanced antitumor effects, probably due to accelerated receptor degradation. Here, we extend these observations to three-dimensional mammary cell models, and compare the effects of single mAbs with the effects of antibody combinations. Collectively, our in vitro assays and computational image analyses indicate that combining mAbs against different epitopes of HER2 better inhibits invasive growth. Importantly, while growth factors are able to reduce intraluminal apoptosis and induce an invasive phenotype, combinations of mAbs better than single mAbs can reverse the growth factor-induced phenotypes of HER2-overexpressing spheroids. In conclusion, our studies propose that mAb combinations negate the biological effects of growth factors on invasive growth of HER2-overexpressing cells. Hence, combining mAbs offers a therapeutic strategy, potentially able to enhance clinical efficacy of existing antireceptor immunotherapeutics. Oncogene (2011) 30, 1631-1642; doi:10.1038/onc.2010.547; published online 6 December 2010	[Emde, A.; Pradeep, C-R; Ferraro, D. A.; Ben-Chetrit, N.; Yarden, Y.] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; [Sela, M.] Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; [Ribba, B.] Ecole Normale Super Lyon, Project Team NUMED, INRIA Rhone Alpes, F-69364 Lyon, France; [Kam, Z.] Weizmann Inst Sci, Dept Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Ecole Normale Superieure de Lyon (ENS de LYON); Weizmann Institute of Science	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, Candiotty Bldg,Room 302,1 Hertzl St, IL-76100 Rehovot, Israel.	yosef.yarden@weizmann.ac.il	YARDEN, YOSEF/K-1467-2012		Minerva Foundation; Centre Leon-Berard; Canceropole Lyon Auvegne Rhone-Alpes; Weizmann Institute; National Cancer Institute [CA072981]; European Commission; Cooperation (DIP/DFG); Israel Cancer Research Fund; Dr Miriam and Sheldon G Adelson Medical Research Foundation; Kekst Family Institute for Medical Genetics; Kirk Center for Childhood Cancer and Immunological Disorders; Bennett-Pritzker Endowment Fund; Marvelle Koffler Program for Breast Cancer Research; Estate of John M, Lang and the MD Moross Institute for Cancer Research; NATIONAL CANCER INSTITUTE [R01CA072981, R37CA072981] Funding Source: NIH RePORTER	Minerva Foundation; Centre Leon-Berard; Canceropole Lyon Auvegne Rhone-Alpes; Weizmann Institute; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); European Commission(European CommissionEuropean Commission Joint Research Centre); Cooperation (DIP/DFG)(German Research Foundation (DFG)); Israel Cancer Research Fund; Dr Miriam and Sheldon G Adelson Medical Research Foundation; Kekst Family Institute for Medical Genetics; Kirk Center for Childhood Cancer and Immunological Disorders; Bennett-Pritzker Endowment Fund; Marvelle Koffler Program for Breast Cancer Research; Estate of John M, Lang and the MD Moross Institute for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of our group for insightful comments. AE is supported by a post-doctoral fellowship of the Minerva Foundation. YY is the incumbent of the Harold and Zelda Goldenberg Professorial Chair, and MS is the incumbent of the W Garfield Weston Professorial Chair in Immunolgy. Our work is supported by a collaborative program between Centre Leon-Berard, Canceropole Lyon Auvegne Rhone-Alpes and the Weizmann Institute, as well as by grants from the National Cancer Institute (CA072981), the European Commission, the German-Israeli Project Cooperation (DIP/DFG), the Israel Cancer Research Fund, the Dr Miriam and Sheldon G Adelson Medical Research Foundation, the Kekst Family Institute for Medical Genetics, the Kirk Center for Childhood Cancer and Immunological Disorders, the Women's Health Research Center funded by Bennett-Pritzker Endowment Fund, the Marvelle Koffler Program for Breast Cancer Research, the Estate of John M, Lang and the MD Moross Institute for Cancer Research.	Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485; Baselga J, 2006, SCIENCE, V312, P1175, DOI 10.1126/science.1125951; Baselga J, 2009, J CLIN ONCOL, V27, P2630, DOI 10.1200/JCO.2008.18.8391; Ben-Kasus T, 2007, MOL ONCOL, V1, P42, DOI 10.1016/j.molonc.2007.01.003; Ben-Kasus T, 2009, P NATL ACAD SCI USA, V106, P3294, DOI 10.1073/pnas.0812059106; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; DREBIN JA, 1988, ONCOGENE, V2, P273; Friedman LM, 2005, P NATL ACAD SCI USA, V102, P1915, DOI 10.1073/pnas.0409610102; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; HOU L, 1992, CANCER LETT, V65, P215, DOI 10.1016/0304-3835(92)90234-M; Hu M, 2008, CANCER CELL, V13, P394, DOI 10.1016/j.ccr.2008.03.007; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; KASPRZYK PG, 1992, CANCER RES, V52, P2771; Klapper LN, 1997, ONCOGENE, V14, P2099, DOI 10.1038/sj.onc.1201029; Lemieux J, 2009, CURR ONCOL, V16, P316; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nahta R, 2006, CANCER LETT, V232, P123, DOI 10.1016/j.canlet.2005.01.041; Nahta R, 2004, CANCER RES, V64, P2343, DOI 10.1158/0008-5472.CAN-03-3856; Pedersen MW, 2010, CANCER RES, V70, P588, DOI 10.1158/0008-5472.CAN-09-1417; Pickl M, 2009, ONCOGENE, V28, P461, DOI 10.1038/onc.2008.394; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Scheuer W, 2009, CANCER RES, V69, P9330, DOI 10.1158/0008-5472.CAN-08-4597; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; Seton-Rogers SE, 2004, CELL CYCLE, V3, P597, DOI 10.4161/cc.3.5.886; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Spangler JB, 2010, P NATL ACAD SCI USA, V107, P13252, DOI 10.1073/pnas.0913476107; Spiridon CI, 2002, CLIN CANCER RES, V8, P1720; Ueda Y, 2004, J BIOL CHEM, V279, P24505, DOI 10.1074/jbc.M400081200; WEINER DB, 1990, CANCER RES, V50, P421; Xia WL, 2002, ONCOGENE, V21, P6255, DOI 10.1038/sj.onc.1205794; Xia WY, 1997, CLIN CANCER RES, V3, P3; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yip YL, 2001, J IMMUNOL, V166, P5271, DOI 10.4049/jimmunol.166.8.5271; YOSHIDA K, 1989, VIRCHOWS ARCH B, V57, P285, DOI 10.1007/BF02899093; Zhan LX, 2006, CANCER RES, V66, P5201, DOI 10.1158/0008-5472.CAN-05-4081	38	15	18	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	14					1631	1642		10.1038/onc.2010.547	http://dx.doi.org/10.1038/onc.2010.547			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	746IS	21132012	Green Accepted			2022-12-17	WOS:000289239400002
J	Asciutti, S; Akiri, G; Grumolato, L; Vijayakumar, S; Aaronson, SA				Asciutti, S.; Akiri, G.; Grumolato, L.; Vijayakumar, S.; Aaronson, S. A.			Diverse mechanisms of Wnt activation and effects of pathway inhibition on proliferation of human gastric carcinoma cells	ONCOGENE			English	Article						beta-catenin; DNTCF4; c-Myc; gastric cancer	BETA-CATENIN; SIGNALING PATHWAY; CANCER-CELLS; MAMMARY TUMORIGENESIS; EPITHELIAL-CELLS; GAMMA-CATENIN; C-MYC; APC; MUTATIONS; TRANSCRIPTION	Human gastric carcinomas are among the most treatment-refractory epithelial malignancies. Increased understanding of the underlying molecular aberrations in such tumors could provide insights leading to improved therapeutic approaches. In this study, we characterized diverse genetic aberrations leading to constitutive Wnt signaling activation in a series of human gastric carcinoma cell lines. Downregulation of TCF signaling by stable transduction of dominant negative TCF4 (DNTCF4) resulted in inhibition of proliferation in Wnt-activated AGS tumor cells. c-Myc downregulation and the associated upregulation of its repression target, p21 observed in these tumor cells, as well as the profound growth inhibition induced by c-Myc small hairpin RNA (shRNA) implied their c-Myc addiction. In striking contrast, Wnt-activated MKN-28 and MKN-74 tumor cells appeared refractory to DNTCF4 inhibition of proliferation despite comparably decreased c-Myc expression levels. The resistance of these same tumor cells to growth inhibition by c-Myc shRNA established that their refractoriness to DNTCF was because of their independence from c-Myc for proliferation. There was no correlation between this resistance phenotype and the presence or absence of constitutive mitogen-activated protein kinase (MAPK) and/or AKT pathway activation, commonly observed in gastrointestinal tumors. However, in both DNTCF-sensitive and -resistant tumor cells with MAPK and/or AKT pathway activation, the ability of small molecule antagonists directed against either pathway to inhibit tumor cell growth was enhanced by Wnt pathway inhibition. These findings support the concept that although certain Wnt-activated tumors may escape c-Myc dependence for proliferation, disruption of other oncogenic pathways can unmask cooperative antiproliferative effects for Wnt pathway downregulation. Oncogene (2011) 30, 956-966; doi:10.1038/onc.2010.475; published online 1 November 2010	[Asciutti, S.; Akiri, G.; Grumolato, L.; Vijayakumar, S.; Aaronson, S. A.] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Aaronson, SA (corresponding author), Mt Sinai Sch Med, Dept Oncol Sci, Box 1130,1 Gustave L Levy Pl, New York, NY 10029 USA.	stuart.aaronson@mssm.edu	Grumolato, Luca/A-1697-2015	Grumolato, Luca/0000-0001-8231-3032	American Urological Association; National Cancer Institute [5R01CA071672]; NATIONAL CANCER INSTITUTE [R01CA071672] Funding Source: NIH RePORTER	American Urological Association; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Dr Yoshio Yamaoka (Baylor College of Medicine, Houston, TX, USA) for MKN-7 and MKN-28 cells; Dr Gary Schwartz (Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA) for MKN-74 cells and Dr Reuben Lotan (MD Anderson Cancer Center, Houston, TX, USA) for KATO-II cells. SV is a recipient of a post-doctoral fellowship award from the American Urological Association. Grant support: This work was supported by grant number 5R01CA071672 from the National Cancer Institute.	Akiri G, 2009, ONCOGENE, V28, P2163, DOI 10.1038/onc.2009.82; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bafico A, 1998, ONCOGENE, V16, P2819, DOI 10.1038/sj.onc.1201797; BAS PLW, 2000, INT J CANCER, V86, P533; Bechard M, 2009, MOL CELL BIOL, V29, P2092, DOI 10.1128/MCB.01405-08; Caca K, 1999, CELL GROWTH DIFFER, V10, P369; Clements WM, 2002, CANCER RES, V62, P3503; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Filali M, 2002, J BIOL CHEM, V277, P33398, DOI 10.1074/jbc.M107977200; GIARDIELLO FM, 1993, GUT, V34, P1394, DOI 10.1136/gut.34.10.1394; Grabsch H, 2001, HISTOPATHOLOGY, V39, P141, DOI 10.1046/j.1365-2559.2001.01177.x; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ikenoue T, 2002, JPN J CANCER RES, V93, P1213, DOI 10.1111/j.1349-7006.2002.tb01226.x; Jang JW, 2006, MOL CELL BIOL, V26, P8109, DOI 10.1128/MCB.00404-06; Janssen KP, 2006, GASTROENTEROLOGY, V131, P1096, DOI 10.1053/j.gastro.2006.08.011; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kim JS, 2002, CANCER RES, V62, P2744; Kim SE, 2007, CELL SIGNAL, V19, P511, DOI 10.1016/j.cellsig.2006.08.008; Kolligs FT, 2000, GENE DEV, V14, P1319; Michl P, 2005, Z GASTROENTEROL, V43, P1133, DOI 10.1055/s-2005-858638; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Overman Michael J, 2009, Gastrointest Cancer Res, V3, P90; Park KS, 2006, J CELL SCI, V119, P819, DOI 10.1242/jcs.02779; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Shimizu M, 2008, MOL CELL BIOL, V28, P825, DOI 10.1128/MCB.02375-06; Slinker BK, 1998, J MOL CELL CARDIOL, V30, P723, DOI 10.1006/jmcc.1998.0655; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; Sunaga N, 2001, GENE CHROMOSOME CANC, V30, P316, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1097>3.0.CO;2-9; Suriano G, 2005, GENE CHROMOSOME CANC, V42, P238, DOI 10.1002/gcc.20135; Teuliere J, 2004, MOL CELL BIOL, V24, P8649, DOI 10.1128/MCB.24.19.8649-8661.2004; Tomita H, 2007, CANCER RES, V67, P4079, DOI 10.1158/0008-5472.CAN-06-4025; Van Cutsem E, 2006, ANN ONCOL, V17, P13, DOI 10.1093/annonc/mdl976; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Woo DK, 2001, INT J CANCER, V95, P108, DOI 10.1002/1097-0215(20010320)95:2<108::AID-IJC1019>3.0.CO;2-#; Zhurinsky J, 2000, MOL CELL BIOL, V20, P4238, DOI 10.1128/MCB.20.12.4238-4252.2000	39	15	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	8					956	966		10.1038/onc.2010.475	http://dx.doi.org/10.1038/onc.2010.475			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	726CJ	21042278	Green Accepted			2022-12-17	WOS:000287695900007
J	Teissier, S; Pang, CL; Thierry, F				Teissier, S.; Pang, C. L.; Thierry, F.			The E2F5 repressor is an activator of E6/E7 transcription and of the S-phase entry in HPV18-associated cells	ONCOGENE			English	Article						papillomavirus; transcription; HPV; E2F; cell cycle	MITOTIC PATHWAY; PROTEIN; CYCLE; IDENTIFICATION; ENHANCEOSOME; REPLICATION; EXPRESSION; HMG-I(Y); FAMILY; E6	High-risk papillomavirus type 18 (HPV18) is one of the less represented HPV types in low-grade lesions of the anogenital tract, whereas it occupies the second place in cervical cancer, where it can be found in 16% of the cases worldwide, after HPV16 present in 54% of them. These epidemiological data indicate that HPV18 infection is more prone to carcinogenic progression. The main oncogenic proteins, E6 and E7 of HPV18, are functionally comparable to the homologous proteins of the other high-risk viruses, including HPV16. In this work, we investigated the possibility that the higher oncogenic potential of HPV18 might be due to transcriptional regulation of the E6/E7 oncogenes. By comparing the E6/E7 promoter and enhancer sequences of the mucosal HPV genomes, we identified E2F binding sites specific for HPV18. The E2F family of transcription factors contains activators (E2F1-3) and repressors (E2F4-8) that regulate the transcription of S-phase and mitotic genes and thereby have a crucial role in cell-cycle progression. Surprisingly, we identified E2F5 as a direct activator of HPV18 E6/E7 transcription by sequential silencing of E2F members in HeLa cells. In addition, we could show that E2F5 positively regulates S-phase entry in HeLa cells and that this activation of the cell cycle by a member of the E2F repressor family is specific for HPV18-expressing cells. Diverting the function of E2F5 from a cell-cycle repressor into an activator might contribute to the higher oncogenic potential of HPV18 when compared with other high-risk HPV types. Oncogene (2010) 29, 5061-5070; doi:10.1038/onc.2010.246; published online 19 July 2010	[Teissier, S.; Thierry, F.] ASTAR, Inst Med Biol, Singapore 138648, Singapore; [Pang, C. L.] Natl Univ Singapore, Grad Sch Integrat Sci & Engn, Singapore 117548, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); National University of Singapore	Thierry, F (corresponding author), ASTAR, Inst Med Biol, Immunos 06-05,8A Biomed Grove, Singapore 138648, Singapore.	francoise.thierry@imb.a-star.edu.sg						Apostolova MD, 2002, J BIOL CHEM, V277, P34471, DOI 10.1074/jbc.M205827200; BERNARD BA, 1989, J VIROL, V63, P4317, DOI 10.1128/JVI.63.10.4317-4324.1989; Bouallaga I, 2000, EMBO REP, V1, P422, DOI 10.1093/embo-reports/kvd091; Bouallaga I, 2003, MOL CELL BIOL, V23, P2329, DOI 10.1128/MCB.23.7.2329-2340.2003; Caracciolo V, 2007, J CELL PHYSIOL, V212, P96, DOI 10.1002/jcp.21005; CASTELLSAGUE X, 2007, VACCINE, V25; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Elkon R, 2003, GENOME RES, V13, P773, DOI 10.1101/gr.947203; Grinstein E, 2002, J EXP MED, V196, P1067, DOI 10.1084/jem.20011053; Heino P, 2000, VIROLOGY, V276, P304, DOI 10.1006/viro.2000.0342; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kong LJ, 2007, ONCOGENE, V26, P321, DOI 10.1038/sj.onc.1209817; Kuner R, 2007, J MOL MED, V85, P1253, DOI 10.1007/s00109-007-0230-1; Linhart C, 2005, CELL CYCLE, V4, P1788, DOI 10.4161/cc.4.12.2173; McLaughlin-Drubin ME, 2008, J VIROL, V82, P8695, DOI 10.1128/JVI.00579-08; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; Polager S, 2003, J BIOL CHEM, V278, P1443, DOI 10.1074/jbc.M210327200; Reed SA, 2007, J CELL BIOCHEM, V101, P1394, DOI 10.1002/jcb.21256; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Teissier S, 2007, J VIROL, V81, P9368, DOI 10.1128/JVI.00427-07; Thierry F, 2004, CANCER RES, V64, P895, DOI 10.1158/0008-5472.CAN-03-2349; THIERRY F, 1991, NEW BIOL, V3, P90; THIERRY F, 1987, EMBO J, V6, P3391, DOI 10.1002/j.1460-2075.1987.tb02662.x; Thierry F, 2009, VIROLOGY, V384, P375, DOI 10.1016/j.virol.2008.11.014; VILLA LL, 1991, VIROLOGY, V181, P374; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Zhang BY, 2006, P NATL ACAD SCI USA, V103, P437, DOI 10.1073/pnas.0510012103; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459	31	15	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	36					5061	5070		10.1038/onc.2010.246	http://dx.doi.org/10.1038/onc.2010.246			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	647LN	20639900				2022-12-17	WOS:000281620100006
J	Krapf, G; Kaindl, U; Kilbey, A; Fuka, G; Inthal, A; Joas, R; Mann, G; Neil, JC; Haas, OA; Panzer-Grumayer, ER				Krapf, G.; Kaindl, U.; Kilbey, A.; Fuka, G.; Inthal, A.; Joas, R.; Mann, G.; Neil, J. C.; Haas, O. A.; Panzer-Gruemayer, E. R.			ETV6/RUNX1 abrogates mitotic checkpoint function and targets its key player MAD2L1	ONCOGENE			English	Article						ETV6/RUNX1; t(12;21); acute lymphoblastic leukemia; mitotic checkpoint MAD2L1; tetraploidy	ACUTE LYMPHOBLASTIC-LEUKEMIA; PROMOTES ANEUPLOIDY; NEAR-TETRAPLOIDY; CBF ONCOPROTEINS; CELL BIOLOGY; DNA-BINDING; FUSION; CANCER; PROTEIN; GENE	Approximately 25% of childhood B-cell precursor acute lymphoblastic leukemia have an ETV6/RUNX1 (E/R) gene fusion that results from a t(12;21). This genetic subgroup of leukemia is associated with near-triploidy, near-tetraploidy, and trisomy 21 as rather specific types of secondary changes. Here, we show that, unlike various controls, E/R-expressing Ba/F3 clones acquire a tetraploid karyotype on prolonged culture, corroborating the assumption that E/R may attenuate the mitotic checkpoint (MC). Consistent with this notion, E/R-expressing diploid murine and human cell lines have decreased proportions of cells with 4N DNA content and a lower mitotic index when treated with spindle toxins. Moreover, both RUNX1 and E/R regulate mitotic arrest-deficient 2 L1 (MAD2L1), an essential MC component, by binding to promoter-inherent RUNX1 sites, which results in down-regulation of MAD2L1 mRNA and protein in E/R-expressing cells. Forced expression of E/R also abolishes RUNX1-induced reporter activation, whereas E/R with a mutant DNA-binding site leads to only minor effects. Our data link for the first time E/R, MC, and MAD2L1 and provide new insights into the function of the E/R fusion gene product. Although tetraploidy is an almost exclusive feature of E/R-positive leukemias, its rarity within this particular subgroup implies that further yet unknown factors are required for its manifestation. Oncogene (2010) 29, 3307-3312; doi: 10.1038/onc.2010.53; published online 1 March 2010	[Panzer-Gruemayer, E. R.] Childrens Canc Res Inst, Leukemia Biol Grp, A-1090 Vienna, Austria; [Kilbey, A.; Neil, J. C.] Fac Vet Med, Inst Comparat Med, Mol Oncol Lab, Glasgow, Lanark, Scotland; [Mann, G.; Haas, O. A.; Panzer-Gruemayer, E. R.] St Anna Childrens Hosp, Vienna, Austria	Saint Anna Children's Hospital; University of Glasgow; Saint Anna Children's Hospital	Panzer-Grumayer, ER (corresponding author), Childrens Canc Res Inst, Leukemia Biol Grp, Zimmermannpl 10, A-1090 Vienna, Austria.	renate.panzer@ccri.at	Haas, Oskar/AAM-5794-2020		FWF [P17551-B14]; Austrian Ministry for Education, Science and Culture; St Anna Kinderkrebsforschung; Leukaemia Research Fund	FWF(Austrian Science Fund (FWF)); Austrian Ministry for Education, Science and Culture; St Anna Kinderkrebsforschung; Leukaemia Research Fund	We thank O Williams for expression vectors containing E/R or the mutant E/R, D-E Zhang for the RUNX1-expression vector, A Friedman for CBFb-expression vector, D Guardavaccaro for the luciferase reporter plasmid for the MAD2L1 promoter in pGL3, JD Rowley for AT-2 cell line, L Orel for the Myc-ETV6/RUNX1 vector, Idriss M Bennani-Baiti for stimulating discussions, and Marion Zavadil for proofreading the paper. This study was supported in part by a grant from the FWF P17551-B14 and the Austrian Ministry for Education, Science and Culture (GENAU-Ch.I.L.D) and the St Anna Kinderkrebsforschung to ER P-G. A Kilbey is funded by the Leukaemia Research Fund. GK participated in the design of the study, performed experiments, interpreted data, and wrote the paper. UK, GF, AI, RJ performed research and interpreted data. AK performed and interpreted ChIP experiments. JCN participated in study design and interpretation of ChIP data. GM contributed patient samples. OAH participated in the interpretation of data and writing of the paper. ER P-G designed and supervised research and wrote the paper.	Attarbaschi A, 2006, GENE CHROMOSOME CANC, V45, P608, DOI 10.1002/gcc.20324; Attarbaschi A, 2004, LEUKEMIA, V18, P1611, DOI 10.1038/sj.leu.2403471; Boyapati A, 2007, BLOOD, V109, P3963, DOI 10.1182/blood-2006-09-045583; Diakos C, 2007, BLOOD, V109, P2607, DOI 10.1182/blood-2006-04-019612; Fang Y, 2006, ONCOGENE, V25, P3598, DOI 10.1038/sj.onc.1209392; Ford AM, 2009, J CLIN INVEST, V119, P826, DOI 10.1172/JCI36428; Friedman AD, 1999, LEUKEMIA, V13, P1932, DOI 10.1038/sj.leu.2401590; Guardavaccaro D, 2008, NATURE, V452, P365, DOI 10.1038/nature06641; Ha GH, 2007, CANCER RES, V67, P7155, DOI 10.1158/0008-5472.CAN-06-3392; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Hong DL, 2008, SCIENCE, V319, P336, DOI 10.1126/science.1150648; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Li Z, 2003, J BIOL CHEM, V278, P33088, DOI 10.1074/jbc.M303973200; Lou JR, 2000, ONCOGENE, V19, P2695, DOI 10.1038/sj.onc.1203588; Michel L, 2004, CELL CYCLE, V3, P990; Morrow M, 2007, ONCOGENE, V26, P4404, DOI 10.1038/sj.onc.1210227; Perez de Castro I, 2007, CARCINOGENESIS, V28, P899, DOI 10.1093/carcin/bgm019; Peters JM, 2007, NATURE, V446, P868, DOI 10.1038/446868a; Pines J, 2006, TRENDS CELL BIOL, V16, P55, DOI 10.1016/j.tcb.2005.11.006; Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001; Raimondi SC, 2006, CANCER GENET CYTOGEN, V169, P50, DOI 10.1016/j.cancergencyto.2006.04.006; Ross ME, 2003, BLOOD, V102, P2951, DOI 10.1182/blood-2003-01-0338; Roudaia L, 2009, BLOOD, V113, P3070, DOI 10.1182/blood-2008-03-147207; Sasaki A, 2004, BIOCHEM BIOPH RES CO, V317, P1128, DOI 10.1016/j.bbrc.2004.03.172; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; Weaver BAA, 2005, CANCER CELL, V8, P7, DOI 10.1016/j.ccr.2005.06.011; Wolyniec K, 2009, ONCOGENE, V28, P2502, DOI 10.1038/onc.2009.101; Wotton S, 2008, ONCOGENE, V27, P5856, DOI 10.1038/onc.2008.195; Zelent A, 2004, ONCOGENE, V23, P4275, DOI 10.1038/sj.onc.1207672	32	15	15	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	2010	29	22					3307	3312		10.1038/onc.2010.53	http://dx.doi.org/10.1038/onc.2010.53			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	605BA	20190817	Green Accepted			2022-12-17	WOS:000278321100013
J	Trong-Tue, N; Thao, DTP; Yamaguchi, M				Trong-Tue, N.; Thao, D. T. P.; Yamaguchi, M.			Role of DREF in transcriptional regulation of the Drosophila p53 gene	ONCOGENE			English	Article						Drosophila; DREF; p53; transcriptional regulation	REPLICATION-RELATED ELEMENT; DNA-REPLICATION; BINDING-FACTOR; CELL-PROLIFERATION; P53 HOMOLOG; IDENTIFICATION; MELANOGASTER; EXPRESSION; PROMOTER; SYSTEM	The tumor suppressor protein p53 has a critical role in safeguarding the integrity of the genome. Its functions are well understood but factors responsible for the transcriptional regulation of the p53 gene are almost entirely unknown. The DNA replication-related element (DRE)/DNA replication-related element-binding factor (DREF) transcriptional regulatory system is established as a master key to cell proliferation in Drosophila. DREF binds specifically to DRE sequences in the Drosophila p53 (dmp53) gene promoter as shown using anti-DREF antibodies in chromatin immunoprecipitation assays. Furthermore, a rough eye phenotype because of overexpression of DREF in Drosophila eye imaginal disks could be suppressed by half dose reduction of the dmp53 gene. In addition, the level of mRNA of dmp53 was decreased in DREF-knockdown cells and transient expression of the luciferase gene under control of the wild-type dmp53 gene promoter showed strong promoter activity in S2 cells, but this was almost completely abrogated with a DRE-mutated promoter. Requirement of DREs for dmp53 promoter activity was further confirmed by anti-beta-galactosidase antibody-staining of various tissues from transgenic flies carrying dmp53 promoter-lacZ fusion genes. These results indicate that DREF is necessary for dmp53 gene promoter activity. Oncogene (2010) 29, 2060-2069; doi: 10.1038/onc.2009.483; published online 18 January 2010	[Trong-Tue, N.; Thao, D. T. P.; Yamaguchi, M.] Kyoto Inst Technol, Dept Appl Biol, Sakyo Ku, Kyoto 6068585, Japan; [Yamaguchi, M.] Kyoto Inst Technol, Sakyo Ku, Insect Biomed Res Ctr, Kyoto 6068585, Japan	Kyoto Institute of Technology; Kyoto Institute of Technology	Yamaguchi, M (corresponding author), Kyoto Inst Technol, Dept Appl Biol, Sakyo Ku, Kyoto 6068585, Japan.	myamaguc@kit.ac.jp	Dang, Thao/AFC-0112-2022	Yamaguchi, Masamitsu/0000-0002-6321-9750; Dang, Thao/0000-0002-5713-323X	KIT	KIT	We are grateful to Dr M Abrams for dmp53 mutant stock, Dr Dean P Smith for kindly providing the casper-nls-LacZ plasmid, Dr Fumiko Hirose for the anti-DREF monoclonal antibodies and Dr Malcolm Moore for comments on the English language in the paper. This study was partially supported by a scholarship and grants from the KIT.	Bauer JH, 2005, CURR BIOL, V15, P2063, DOI 10.1016/j.cub.2005.10.051; Brodsky MH, 2004, MOL CELL BIOL, V24, P1219, DOI 10.1128/MCB.24.3.1219-1231.2004; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; Choi TY, 2000, FEBS LETT, V483, P71, DOI 10.1016/S0014-5793(00)02085-8; Galindo K, 2001, GENETICS, V159, P1059; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; Hayashi Y, 2006, BBA-GENE STRUCT EXPR, V1759, P359, DOI 10.1016/j.bbaexp.2006.07.002; Hirose F, 1996, J BIOL CHEM, V271, P3930; Hirose F, 2001, MOL CELL BIOL, V21, P7231, DOI 10.1128/MCB.21.21.7231-7242.2001; HIROSE F, 1993, J BIOL CHEM, V268, P2092; Hirose F, 1999, MOL CELL BIOL, V19, P6020; Hyun JY, 2005, MOL CELL BIOL, V25, P5590, DOI 10.1128/MCB.25.13.5590-5598.2005; Ida H, 2007, EXP CELL RES, V313, P4208, DOI 10.1016/j.yexcr.2007.08.016; Ida H, 2009, NUCLEIC ACIDS RES, V37, P1423, DOI 10.1093/nar/gkn1068; Jasper H, 2002, DEV CELL, V3, P511, DOI 10.1016/S1534-5807(02)00297-6; Jin SK, 2000, P NATL ACAD SCI USA, V97, P7301, DOI 10.1073/pnas.97.13.7301; Kim YS, 2007, GENES CELLS, V12, P569, DOI 10.1111/j.1365-2443.2007.01075.x; Matsukage A, 2008, BBA-GENE REGUL MECH, V1779, P81, DOI 10.1016/j.bbagrm.2007.11.011; Morrison TB, 1998, BIOTECHNIQUES, V24, P954; Nakamura K, 2008, NUCLEIC ACIDS RES, V36, P3905, DOI 10.1093/nar/gkn291; Ohno K, 1996, NUCLEIC ACIDS RES, V24, P3942, DOI 10.1093/nar/24.20.3942; Ohshima N, 2003, J BIOL CHEM, V278, P22928, DOI 10.1074/jbc.M303109200; Okudaira K, 2005, BBA-GENE STRUCT EXPR, V1732, P23, DOI 10.1016/j.bbaexp.2005.10.009; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; Rebollar E, 2006, FEBS LETT, V580, P642, DOI 10.1016/j.febslet.2005.12.083; ROBERTSON HM, 1988, GENETICS, V118, P461; Ryu JR, 1997, NUCLEIC ACIDS RES, V25, P794, DOI 10.1093/nar/25.4.794; Sawado T, 1998, J BIOL CHEM, V273, P26042, DOI 10.1074/jbc.273.40.26042; Seto H, 2006, GENES CELLS, V11, P499, DOI 10.1111/j.1365-2443.2006.00956.x; Sharpless NE, 2002, CANCER RES, V62, P2761; Sogame N, 2003, P NATL ACAD SCI USA, V100, P4696, DOI 10.1073/pnas.0736384100; Somasundaram K, 2000, FRONT BIOSCI, V5, pD424, DOI 10.2741/Somasund; Spradling A. C, 1986, DROSOPHILA PRACTICAL; Suyari O, 2009, EXP CELL RES, V315, P1403, DOI 10.1016/j.yexcr.2008.12.017; Takahashi Y, 1996, J BIOL CHEM, V271, P14541, DOI 10.1074/jbc.271.24.14541; Takahashi Y, 1999, NUCLEIC ACIDS RES, V27, P510, DOI 10.1093/nar/27.2.510; Thao DTP, 2006, EXP CELL RES, V312, P3641, DOI DOI 10.1016/J.YEXCR.2006.08.005; Tsuchiya A, 2007, FEBS J, V274, P1818, DOI 10.1111/j.1742-4658.2007.05730.x; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P15808, DOI 10.1074/jbc.270.26.15808; Yamaguchi M, 1996, GENES CELLS, V1, P47, DOI 10.1046/j.1365-2443.1996.03003.x; Yamaguchi M, 1999, ONCOGENE, V18, P6767, DOI 10.1038/sj.onc.1203113; Yamashita D, 2007, MOL CELL BIOL, V27, P2003, DOI 10.1128/MCB.01462-06; Yoshida H, 2004, GENES CELLS, V9, P935, DOI 10.1111/j.1365-2443.2004.00775.x; ZHAO K, 1995, CELL, V81, P879, DOI 10.1016/0092-8674(95)90008-X	45	15	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2010	29	14					2060	2069		10.1038/onc.2009.483	http://dx.doi.org/10.1038/onc.2009.483			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579UX	20101238				2022-12-17	WOS:000276402800005
J	Jaskelioff, M; Song, W; Xia, J; Liu, C; Kramer, J; Koido, S; Gendler, SJ; Calderwood, SK; Gong, J				Jaskelioff, M.; Song, W.; Xia, J.; Liu, C.; Kramer, J.; Koido, S.; Gendler, S. J.; Calderwood, S. K.; Gong, J.			Telomerase deficiency and telomere dysfunction inhibit mammary tumors induced by polyomavirus middle T oncogene	ONCOGENE			English	Article						telomerase; telomeres; PyMT; MUC1; mammary carcinoma	LIFE-SPAN; IMMORTAL CELLS; CANCER; MICE; TUMORIGENESIS; EXPRESSION; CARCINOMA; SKIN; P53; TRANSLOCATIONS	Mice transgenic for MUC1 (mucin 1) and polyomavirus middle T (PyMT) develop mammary carcinomas within 15 weeks with 100% penetrance. PyMT-induced mammary tumorigenesis is closely correlated with robust telomerase expression and activity. To assess the role of telomerase activation and telomere maintenance in mammary carcinoma tumorigenesis, we generated mice expressing MUC1 and PyMT (MMT mice) but deficient in the telomerase RNA component, mTerc, on the C57BL/6 background. Successive generational intercrosses of mTerc(-/-)MMT mice produced cohorts with progressively shorter telomeres that were audited for mammary tumor formation. Relative to MMT (N=14) and G0 mTerc(+/-) female controls (G0=14), mTerc(-/-)MMT females (G1=11, G2=15, G3=15 and G4=5) showed decreased tumor volumes and increased tumor latency-MMT=95.6 days; G0 mTerc(+/-) MMT=98.6 days versus G1, G2, G3 and G4 mTerc(-/-)MMT mice with latencies of 122.6, 138.9, 140.7 and 220.9 days, respectively (controls versus G1-G4, P<0.005). The progressive impairment of lung metastasis was also observed with each successive mTerc(-/-)MMT generation. The impairment of tumorigenesis was associated with decreased proliferation of mammary epithelial and tumor cells and increased apoptosis of tumor cells. Together, these results indicate that, in the setting of viral oncoprotein mammary tumorigenesis, telomerase-dependent telomere maintenance facilitates the formation and metastatic progression of mammary tumors. Oncogene (2009) 28, 4225-4236; doi: 10.1038/onc.2009.268; published online 7 September 2009	[Gong, J.] Boston Univ, Sch Med, Dept Med, Med Ctr, Boston, MA 02215 USA; [Jaskelioff, M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Koido, S.] Jikei Univ, Sch Med, Dept Internal Med, Tokyo, Japan; [Gendler, S. J.] Mayo Clin, Dept Biochem & Mol Biol, Scottsdale, AZ USA; [Calderwood, S. K.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA	Boston University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Jikei University; Mayo Clinic; Mayo Clinic Phoenix; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Gong, J (corresponding author), Boston Univ, Sch Med, Dept Med, Med Ctr, 650 Albany St,Room 309, Boston, MA 02215 USA.	jgong@bu.edu		Gong, Jianlin/0000-0003-0910-014X	Susan G Komen Breast Cancer Foundation [BCTR0503792, PDF060881]; US Department of Defense Breast Cancer Research	Susan G Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); US Department of Defense Breast Cancer Research(United States Department of Defense)	This work was supported by the Susan G Komen Breast Cancer Foundation (BCTR0503792 to JG and PDF060881 to MJ) and the US Department of Defense Breast Cancer Research programs (JG). We thank Dr Ronald A DePinho for providing mTerc<SUP>-/-</SUP> mice, advice and comments on the paper.	Argilla D, 2004, CANCER CELL, V6, P373, DOI 10.1016/j.ccr.2004.08.032; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Artandi SE, 2005, BIOCHEM BIOPH RES CO, V331, P881, DOI 10.1016/j.bbrc.2005.03.211; Artandi SE, 2002, P NATL ACAD SCI USA, V99, P8191, DOI 10.1073/pnas.112515399; Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Blanco R, 2007, GENE DEV, V21, P206, DOI 10.1101/gad.406207; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Canela A, 2004, MOL CELL BIOL, V24, P4275, DOI 10.1128/MCB.24.10.4275-4293.2004; Canela Andres, 2007, Methods Mol Biol, V371, P45; Chang S, 2004, NAT GENET, V36, P877, DOI 10.1038/ng1389; Chang S, 2003, GENE DEV, V17, P88, DOI 10.1101/gad.1029903; Chen DS, 2000, BREAST CANCER RES TR, V60, P107, DOI 10.1023/A:1006332009414; Chen DS, 2003, IMMUNOLOGY, V109, P300, DOI 10.1046/j.1365-2567.2003.01656.x; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Choudhury AR, 2007, NAT GENET, V39, P99, DOI 10.1038/ng1937; Cosme-Blanco W, 2007, EMBO REP, V8, P497, DOI 10.1038/sj.embor.7400937; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; d'Adda di Fagagna F, 2003, NATURE, V426, P194, DOI [10.1038/nature02118, DOI 10.1038/NATURE02118]; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; DePinho RA, 2004, NAT GENET, V36, P932, DOI 10.1038/ng0904-932; Espejel S, 2004, J CELL BIOL, V167, P627, DOI 10.1083/jcb.200407178; Farazi PA, 2003, CANCER RES, V63, P5021; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; Khoo CM, 2007, P NATL ACAD SCI USA, V104, P3931, DOI 10.1073/pnas.0700093104; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Martinez P, 2009, AGING CELL, V8, P2, DOI 10.1111/j.1474-9726.2008.00441.x; Maser RS, 2007, NATURE, V447, P966, DOI 10.1038/nature05886; McClintock B, 1941, GENETICS, V26, P234; Meeker AK, 2004, J MAMMARY GLAND BIOL, V9, P285, DOI 10.1023/B:JOMG.0000048775.04140.92; O'Hagan RC, 2002, CANCER CELL, V2, P149, DOI 10.1016/S1535-6108(02)00094-6; Perera SA, 2008, CARCINOGENESIS, V29, P747, DOI 10.1093/carcin/bgn050; Pulaski BA, 1998, CANCER RES, V58, P1486; Qi L, 2005, NAT CELL BIOL, V7, P706, DOI 10.1038/ncb1276; Qi L, 2003, CANCER RES, V63, P8188; Rasband W., 2022, IMAGEJ; Rowse GJ, 1998, CANCER RES, V58, P315; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Siegl-Cachedenier I, 2007, GENE DEV, V21, P2234, DOI 10.1101/gad.430107; Sun BC, 2004, CANCER RES, V64, P6144, DOI 10.1158/0008-5472.CAN-04-1376; Tomas-Loba A, 2008, CELL, V135, P609, DOI 10.1016/j.cell.2008.09.034; Vasiljeva O, 2008, ONCOGENE, V27, P4191, DOI 10.1038/onc.2008.59; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Xia JC, 2003, J IMMUNOL, V170, P1980, DOI 10.4049/jimmunol.170.4.1980; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	54	15	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2009	28	48					4225	4236		10.1038/onc.2009.268	http://dx.doi.org/10.1038/onc.2009.268			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DS	19734944				2022-12-17	WOS:000272876300001
J	Feng, X; Lu, X; Man, X; Zhou, W; Jiang, LQ; Knyazev, P; Lei, L; Huang, Q; Ullrich, A; Zhang, Z; Chen, Z				Feng, X.; Lu, X.; Man, X.; Zhou, W.; Jiang, L. Q.; Knyazev, P.; Lei, L.; Huang, Q.; Ullrich, A.; Zhang, Z.; Chen, Z.			Overexpression of Csk-binding protein contributes to renal cell carcinogenesis	ONCOGENE			English	Article						Csk-binding protein; renal cell carcinoma; carcinogenesis; RhoA; PDZ-binding motif	TRANSMEMBRANE ADAPTER PROTEIN; FAMILY TYROSINE KINASES; LIPID RAFTS; DOWN-REGULATION; CARCINOMA; SRC; ACTIVATION; PHOSPHOPROTEIN; CYTOSKELETON; EXPRESSION	C-terminal Src kinase (Csk)-binding protein (Cbp) is a transmembrane adaptor protein that localizes exclusively in lipid rafts, where it regulates Src family kinase (SFK) activities through recruitment of Csk. Although SFKs are well known for their involvement in cancer, the function of Cbp in carcinogenesis remains largely unknown. In this study, we reported overexpression of Cbp in more than 70% of renal cell carcinoma (RCC) specimens and in the majority of tested RCC cell lines. Depletion of Cbp in RCC cells by RNA interference led to remarkable inhibition of cell proliferation, migration, anchorage-independent growth as well as tumorigenicity in nude mice. Strikingly, silencing of Cbp negatively affected the sustaining of Erk1/2 activation but not c-Src activation induced by serum. Besides, the RhoA activity in RCC cells was remarkably impaired when Cbp was knocked down. Overexpression of wild-type Cbp, but not its mutant Cbp/Delta CP lacking C-terminal PDZ-binding motif, significantly enhanced RhoA activation and cell migration of RCC cells. These results provided new insights into the function of Cbp in modulating RhoA activation, by which Cbp might contribute to renal cell carcinogenesis. Oncogene (2009) 28, 3320-3331; doi:10.1038/onc.2009.185; published online 6 July 2009	[Feng, X.; Lu, X.; Zhou, W.; Jiang, L. Q.; Lei, L.; Huang, Q.; Zhang, Z.; Chen, Z.] Chinese Acad Sci, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, State Key Lab Mol Biol, Shanghai 200031, Peoples R China; [Feng, X.; Lu, X.; Zhou, W.; Lei, L.; Huang, Q.] Chinese Acad Sci, Grad Univ, Beijing, Peoples R China; [Man, X.] Second Mil Med Univ, Int Cooperat Lab Signal Transduct, Eastern Hepotabiliary Surg Inst, Shanghai, Peoples R China; [Knyazev, P.; Ullrich, A.] Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Naval Medical University; Max Planck Society	Chen, Z (corresponding author), Chinese Acad Sci, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, State Key Lab Mol Biol, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	zhangzhe@sibs.ac.cn; zjchen@sibs.ac.cn			National Natural Science Foundation of China [30730055, 30623002]; National Key Scientific Program of China [2007CB914504]; Chinese Academy of Sciences [KSCX1-YW-R-67, KSCX2-YW-R108]; Program of Shanghai Subject Chief Scientist [08XD14051]; National High Technology Research and Development Programme of China [2006AA02A308]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Scientific Program of China; Chinese Academy of Sciences(Chinese Academy of Sciences); Program of Shanghai Subject Chief Scientist; National High Technology Research and Development Programme of China(National High Technology Research and Development Program of China)	We thank Dr Vaclav Horejsi (Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Videnska 1083, 14220 Prague 4, Czech Republic) for kindly and generously giving us the monoclonal antibody against Cbp. This work was supported by grants from National Natural Science Foundation of China (30730055 and 30623002), National Key Scientific Program of China (2007CB914504), the Chinese Academy of Sciences (KSCX1-YW-R-67, KSCX2-YW-R108), Program of Shanghai Subject Chief Scientist (08XD14051) and the National High Technology Research and Development Programme of China (2006AA02A308).	Lacalle RA, 2007, J CELL BIOL, V179, P1539, DOI 10.1083/jcb.200705044; Baumgartner M, 2003, BLOOD, V101, P1874, DOI 10.1182/blood-2002-02-0456; Bratslavsky G, 2007, CLIN CANCER RES, V13, P4667, DOI 10.1158/1078-0432.CCR-06-2510; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Brdickova N, 2001, FEBS LETT, V507, P133, DOI 10.1016/S0014-5793(01)02955-6; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; D'Angelo R, 2007, MOL BIOL CELL, V18, P4780, DOI 10.1091/mbc.E06-12-1144; D'Hondt V, 2005, EUR J CANCER, V41, P1246, DOI 10.1016/j.ejca.2004.11.025; Davidson D, 2003, MOL CELL BIOL, V23, P2017, DOI 10.1128/MCB.23.6.2017-2028.2003; Davidson D, 2007, MOL CELL BIOL, V27, P1960, DOI 10.1128/MCB.01983-06; Hayashi M, 2005, J CLIN ENDOCR METAB, V90, P1712, DOI 10.1210/jc.2004-1547; Ingley E, 2006, J BIOL CHEM, V281, P31920, DOI 10.1074/jbc.M602637200; Itoh K, 2002, J IMMUNOL, V168, P541, DOI 10.4049/jimmunol.168.2.541; Jiang LQ, 2006, ONCOGENE, V25, P5495, DOI 10.1038/sj.onc.1209554; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Klatte T, 2007, CLIN CANCER RES, V13, P7388, DOI 10.1158/1078-0432.CCR-07-0411; Lam JS, 2005, UROLOGY, V66, P1, DOI 10.1016/j.urology.2005.06.112; Lindquist JA, 2003, IMMUNOL REV, V191, P165, DOI 10.1034/j.1600-065X.2003.00007.x; Mathivanan S, 2008, NAT BIOTECHNOL, V26, P164, DOI 10.1038/nbt0208-164; Matsuoka H, 2004, J BIOL CHEM, V279, P5975, DOI 10.1074/jbc.M311278200; Niggli V, 2008, INT J BIOCHEM CELL B, V40, P344, DOI 10.1016/j.biocel.2007.02.012; Oneyama C, 2008, MOL CELL, V30, P426, DOI 10.1016/j.molcel.2008.03.026; Pike LJ, 2005, BBA-MOL CELL RES, V1746, P260, DOI 10.1016/j.bbamcr.2005.05.005; Quest AFG, 2004, BIOCHEM CELL BIOL, V82, P129, DOI 10.1139/o03-071; Rathmell WK, 2008, EXPERT REV ANTICANC, V8, P63, DOI 10.1586/14737140.8.1.63; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Shima T, 2003, P NATL ACAD SCI USA, V100, P14897, DOI 10.1073/pnas.2432139100; Solheim SA, 2008, J BIOL CHEM, V283, P2773, DOI 10.1074/jbc.M705215200; Svec A, 2005, IMMUNOL LETT, V100, P94, DOI 10.1016/j.imlet.2005.05.002; Svec A, 2007, PATHOL RES PRACT, V203, P193, DOI 10.1016/j.prp.2007.01.005; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; Tauzin S, 2008, BLOOD, V111, P2310, DOI 10.1182/blood-2007-05-090985; Tedoldi S, 2006, BLOOD, V107, P213, DOI 10.1182/blood-2005-06-2273; Torgersen KM, 2001, J BIOL CHEM, V276, P29313, DOI 10.1074/jbc.C100014200; Turcotte S, 2003, J CELL SCI, V116, P2247, DOI 10.1242/jcs.00427; Ueno S, 2006, J BIOL CHEM, V281, P7756, DOI 10.1074/jbc.M509668200; Uhlen M, 2005, MOL CELL PROTEOMICS, V4, P1920, DOI 10.1074/mcp.M500279-MCP200; Yamada T, 2005, J BIOL CHEM, V280, P19358, DOI 10.1074/jbc.M414561200; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4	40	15	20	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2009	28	37					3320	3331		10.1038/onc.2009.185	http://dx.doi.org/10.1038/onc.2009.185			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495LS	19581936	Bronze			2022-12-17	WOS:000269893700006
J	Miyake, I; Ohira, M; Nakagawara, A; Sakai, R				Miyake, I.; Ohira, M.; Nakagawara, A.; Sakai, R.			Distinct role of ShcC docking protein in the differentiation of neuroblastoma	ONCOGENE			English	Article						Shc family; ERK; neuroblastoma; differentiation; RNAi	PHOSPHOTYROSINE-BINDING DOMAINS; ANAPLASTIC LYMPHOMA KINASE; GROWTH-FACTOR RECEPTOR; SRC HOMOLOGY 2; ADAPTER PROTEIN; PLASMA-MEMBRANE; P190 RHOGAP; N-SHC; ACTIVATION; EXPRESSION	The biological and clinical heterogeneityof neuroblastoma is closely associated with signaling pathways that control cellular characteristics such as proliferation, survival and differentiation. The Shc family of docking proteins is important in these pathways by mediating cellular signaling. In this study, we analysed the expression levels of ShcA and ShcC proteins in 46 neuroblastoma samples and showed that a significantly high er level of ShcC protein is observed in neuroblastomas with poor prognostic factors such as advanced stage and MYCN amplification (P < 0.005), whereas the expression level of ShcA showed no signi. cant association with these factors. Using TNB1 cells that express a high level of ShcC protein, it was demonstrated that knockdown of ShcC by RNAi caused elevation in the phosphorylation of ShcA, which resulted in sustained extracellular signal-regulated kinase activation and neurite outgrowth. The neurites induced by ShcC knockdown expressed several markers of neuronal differentiation suggesting that the expression of ShcC potentially has a function in inhibiting the differentiation of neuroblastoma cells. In addition, marked suppression of in vivo tumorigenicity of TNB1 cells in nude mice was observed by stable knockdown of ShcC protein. These findings indicate that ShcC is a therapeutic target that might induce differentiation in the aggressive type of neuroblastomas.	[Sakai, R.] Natl Canc Ctr, Res Inst, Div Growth Factor, Chuo Ku, Tokyo 1040045, Japan; [Ohira, M.; Nakagawara, A.] Chiba Canc Ctr, Res Inst, Div Biochem, Chiba 2608717, Japan	National Cancer Center - Japan; Chiba Cancer Center	Sakai, R (corresponding author), Natl Canc Ctr, Res Inst, Div Growth Factor, Chuo Ku, Tokyo 1040045, Japan.	rsakai@ncc.go.jp		Sakai, Ryuichi/0000-0001-6833-1103	Ministry of Health, Labor and Welfare of Japan for the third-term Comprehensive 10-year Strategy for Cancer Control; Grants-in-Aid for Scientific Research [21390317] Funding Source: KAKEN	Ministry of Health, Labor and Welfare of Japan for the third-term Comprehensive 10-year Strategy for Cancer Control(Ministry of Health, Labour and Welfare, Japan); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by a Grant-in-Aid from the Ministry of Health, Labor and Welfare of Japan for the third-term Comprehensive 10-year Strategy for Cancer Control.	Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; Brouns MR, 2000, DEVELOPMENT, V127, P4891; Brouns MR, 2001, NAT CELL BIOL, V3, P361, DOI 10.1038/35070042; Dhillon AS, 2003, MOL CELL BIOL, V23, P1983, DOI 10.1128/MCB.23.6.1983-1993.2003; GIUDICI AM, 1992, EUR J CELL BIOL, V58, P383; Hecht M, 2004, CANCER RES, V64, P6109, DOI 10.1158/0008-5472.CAN-04-1014; Hecker TP, 2002, CANCER RES, V62, P2699; Hinsby AM, 2004, J NEUROCHEM, V91, P694, DOI 10.1111/j.1471-4159.2004.02772.x; IWAMOTO T, 1993, BRIT J CANCER, V67, P504, DOI 10.1038/bjc.1993.94; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Liu HY, 2002, J BIOL CHEM, V277, P26046, DOI 10.1074/jbc.M111659200; Magrassi L, 2005, ONCOGENE, V24, P5198, DOI 10.1038/sj.onc.1208708; Marshall GM, 1997, CANCER RES, V57, P5399; Miyake I, 2005, ONCOGENE, V24, P3206, DOI 10.1038/sj.onc.1208523; Miyake I, 2002, ONCOGENE, V21, P5823, DOI 10.1038/sj.onc.1205735; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Nakagawara A, 1997, EUR J CANCER, V33, P2050, DOI 10.1016/S0959-8049(97)00280-3; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Nakamura T, 1996, ONCOGENE, V13, P1111; Nakamura T, 1998, J BIOL CHEM, V273, P6960, DOI 10.1074/jbc.273.12.6960; Nakamura T, 2002, ONCOGENE, V21, P22, DOI 10.1038/sj.onc.1205019; O'Bryan JP, 1998, J BIOL CHEM, V273, P20431, DOI 10.1074/jbc.273.32.20431; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; Ohira M, 2003, ONCOGENE, V22, P5525, DOI 10.1038/sj.onc.1206853; Opel D, 2007, CANCER RES, V67, P735, DOI 10.1158/0008-5472.CAN-06-2201; Osajima-Hakomori Y, 2005, AM J PATHOL, V167, P213, DOI 10.1016/S0002-9440(10)62966-5; Pelicci G, 1996, ONCOGENE, V13, P633; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Sakai R, 2000, NEURON, V28, P819, DOI 10.1016/S0896-6273(00)00156-2; Schwab M, 2003, LANCET ONCOL, V4, P472, DOI 10.1016/S1470-2045(03)01166-5; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Terui E, 2005, CLIN CANCER RES, V11, P3280, DOI 10.1158/1078-0432.CCR-04-1681; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wellbrock C, 2002, J BIOL CHEM, V277, P6443, DOI 10.1074/jbc.M110684200; Yaka R, 1998, J CELL BIOCHEM, V70, P425, DOI 10.1002/(SICI)1097-4644(19980901)70:3<425::AID-JCB15>3.0.CO;2-J; Yamada M, 2002, BRAIN RES, V955, P183, DOI 10.1016/S0006-8993(02)03432-7	39	15	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2009	28	5					662	673		10.1038/onc.2008.413	http://dx.doi.org/10.1038/onc.2008.413			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	403IN	18997821				2022-12-17	WOS:000263076400004
J	Tang, Z; Jiang, S; Du, R; Petri, ET; El-Telbany, A; Chan, PSO; Kijima, T; Dietrich, S; Matsui, K; Kobayashi, M; Sasada, S; Okamoto, N; Suzuki, H; Kawahara, K; Iwasaki, T; Nakagawa, K; Kawase, I; Christensen, JG; Hirashima, T; Halmos, B; Salgia, R; Boggon, TJ; Kern, JA; Ma, PC				Tang, Z.; Jiang, S.; Du, R.; Petri, E. T.; El-Telbany, A.; Chan, P. S. O.; Kijima, T.; Dietrich, S.; Matsui, K.; Kobayashi, M.; Sasada, S.; Okamoto, N.; Suzuki, H.; Kawahara, K.; Iwasaki, T.; Nakagawa, K.; Kawase, I.; Christensen, J. G.; Hirashima, T.; Halmos, B.; Salgia, R.; Boggon, T. J.; Kern, J. A.; Ma, P. C.			Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity	ONCOGENE			English	Article						EGFR; MET; mutation; tyrosine kinase inhibitor; structure; kinome	GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; C-MET; KINASE DOMAIN; THERAPEUTIC INHIBITION; SOMATIC MUTATIONS; TYROSINE KINASE; GEFITINIB; PATHWAY; COMPLEX	Targeted therapy against epidermal growth factor receptor (EGFR) represents a major therapeutic advance in lung cancer treatment. Somatic mutations of the EGFR gene, most commonly L858R (exon 21) and short in-frame exon 19 deletions, have been found to confer enhanced sensitivity toward the inhibitors gefitinib and erlotinib. We have recently identified an EGFR mutation E884K, in combination with L858R, in a patient with advanced lung cancer who progressed on erlotinib maintenance therapy, and subsequently had leptomeningeal metastases that responded to gefitinib. The somatic E884K substitution appears to be relatively infrequent and resulted in a mutant lysine residue that disrupts an ion pair with residue R958 in the EGFR kinase domain C-lobe, an interaction that is highly conserved within the human kinome as demonstrated by our sequence analysis and structure analysis. Our studies here, using COS-7 transfection model system, show that E884K works in concert with L858R in-cis, in a dominant manner, to change downstream signaling, differentially induce Mitogen-activated protein kinase (extracellular signaling-regulated kinase 1/2) signaling and associated cell proliferation and differentially alter sensitivity of EGFR phosphorylation inhibition by ERBB family inhibitors in an inhibitor-specific manner. Mutations of the conserved ion pair E884-R958 may result in conformational changes that alter kinase substrate recognition. The analogous E1271K-MET mutation conferred differential sensitivity toward preclinical MET inhibitors SU11274 (unchanged) and PHA665752 (more sensitive). Systematic bioinformatics analysis of the mutation catalog in the human kinome revealed the presence of cancer-associated mutations involving the conserved E884 homologous residue, and adjacent residues at the ion pair, in known proto-oncogenes (KIT, RET, MET and FAK) and tumor-suppressor gene (LKB1). Targeted therapy using small-molecule inhibitors should take into account potential cooperative effects of multiple kinase mutations, and their specific effects on downstream signaling and inhibitor sensitivity. Improved efficacy of targeted kinase inhibitors may be achieved by targeting the dominant activating mutations present.	[Tang, Z.; Jiang, S.; Du, R.; El-Telbany, A.; Dietrich, S.; Halmos, B.; Ma, P. C.] Case Western Reserve Univ, Sch Med, Univ Hosp Case Med Ctr, Div Hematol Oncol, Cleveland, OH 44106 USA; [Tang, Z.; Jiang, S.; Du, R.; El-Telbany, A.; Dietrich, S.; Halmos, B.; Kern, J. A.; Ma, P. C.] Case Comprehens Canc Ctr, Ireland Canc Ctr, Cleveland, OH USA; [Petri, E. T.; Boggon, T. J.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA; [Chan, P. S. O.] Elpidex Biosci Inc, Los Angeles, CA USA; [Kijima, T.; Kawase, I.] Osaka Univ, Grad Sch Med, Dept Resp Med Allergy & Rheumat Dis, Osaka, Japan; [Matsui, K.; Kobayashi, M.; Sasada, S.; Okamoto, N.; Suzuki, H.; Hirashima, T.] Osaka Prefecture Med Ctr Resp & Allerg Dis, Dept Thorac Malignancy, Osaka, Japan; [Kawahara, K.] Osaka Prefectural Med Ctr Resp & Allerg Dis, Dept Pathol, Osaka, Japan; [Iwasaki, T.; Nakagawa, K.] Osaka Prefectural Med Ctr Resp & Allerg Dis, Dept Thorac Surg, Osaka, Japan; [Christensen, J. G.] Pfizer Inc, Global Res & Dev, San Diego, CA USA; [Salgia, R.] Univ Chicago, Pritzker Sch Med, Canc Res Ctr, Hematol Oncol Sect, Chicago, IL 60637 USA; [Kern, J. A.] Case Western Reserve Univ, Sch Med, Univ Hosp Case Med Ctr, Div Pulm, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University Hospital; Case Western Reserve University; Yale University; Osaka University; Osaka Prefectural Medical Center Respiratory & Allergic Diseases; Osaka Prefectural Medical Center Respiratory & Allergic Diseases; Osaka Prefectural Medical Center Respiratory & Allergic Diseases; Pfizer; University of Chicago; Case Western Reserve University; Case Western Reserve University Hospital	Ma, PC (corresponding author), Case Western Reserve Univ, Sch Med, Univ Hosp Case Med Ctr, Div Hematol Oncol, 10900 Euclid Ave,WRB 2-123, Cleveland, OH 44106 USA.	patrick.ma@case.edu	Dietrich, Sascha/J-2562-2015	Dietrich, Sascha/0000-0002-0648-1832; Petri, Edward/0000-0002-3650-1523; Kern, Jeffrey/0000-0001-9709-9622	NIH; National Cancer Institute [K08, 5K08CA102545-04, 5T32CA009085-32]; American Cancer Society (Ohio) [IRG-91-022]; Case Comprehensive Cancer Center; Ohio Cancer Research Associates; NATIONAL CANCER INSTITUTE [R01CA100750, R01CA129501, K08CA102545, T32CA009085, R01CA125541] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL058064] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society (Ohio)(American Cancer Society); Case Comprehensive Cancer Center; Ohio Cancer Research Associates; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Patrick C Ma is supported by NIH/National Cancer Institute-K08 Career Development Award (5K08CA102545-04), American Cancer Society (Ohio)-Institutional Research Grant (IRG-91-022, Case Comprehensive Cancer Center) and Ohio Cancer Research Associates (Give New Ideas A Chance) Grant Award. Titus J Boggon is an American Society of Hematology Junior Faculty Scholar. Edward T Petri is supported by an NIH/National Cancer Institute T32 training Grant (5T32CA009085-32). We thank Dr Zhenghe J Wang (Department of Genetics, Case Western Reserve University) for critically reading the manuscript and for helpful suggestions.	Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Bellon SF, 2008, J BIOL CHEM, V283, P2675, DOI 10.1074/jbc.M705774200; BRODSKY LI, 1992, DIMACS SERIES DISCRE, V8, P127; Chen Z, 2008, ONCOGENE, V27, P4336, DOI 10.1038/onc.2008.71; Choong NW, 2006, NAT CLIN PRACT ONCOL, V3, P50, DOI 10.1038/ncponc0400; Clamp M, 2004, BIOINFORMATICS, V20, P426, DOI 10.1093/bioinformatics/btg430; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Frohling S, 2007, CANCER CELL, V12, P501, DOI 10.1016/j.ccr.2007.11.005; Guo A, 2008, P NATL ACAD SCI USA, V105, P692, DOI 10.1073/pnas.0707270105; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Jackman DM, 2006, J CLIN ONCOL, V24, P4517, DOI 10.1200/JCO.2006.06.6126; Jagadeeswaran R, 2006, CANCER RES, V66, P352, DOI 10.1158/0008-5472.CAN-04-4567; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Jin L, 2004, J BIOL CHEM, V279, P42818, DOI 10.1074/jbc.M407096200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Ma PC, 2007, BRIT J CANCER, V97, P368, DOI 10.1038/sj.bjc.6603884; Ma PC, 2005, CLIN CANCER RES, V11, P2312, DOI 10.1158/1078-0432.CCR-04-1708; Ma PC, 2005, CANCER RES, V65, P1479, DOI 10.1158/0008-5472.CAN-04-2650; Ma PC, 2003, CANCER RES, V63, P6272; Ma PC, 2003, CANCER METAST REV, V22, P309, DOI 10.1023/A:1023768811842; Mazzone M, 2006, FASEB J, V20, P1611, DOI 10.1096/fj.06-5947rev; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Peruzzi B, 2006, CLIN CANCER RES, V12, P3657, DOI 10.1158/1078-0432.CCR-06-0818; Pevarello P, 2004, J MED CHEM, V47, P3367, DOI 10.1021/jm031145u; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Scapin G, 2003, CHEM BIOL, V10, P705, DOI 10.1016/S1074-5521(03)00159-5; Shigematsu H, 2006, INT J CANCER, V118, P257, DOI 10.1002/ijc.21496; Shinomiya N, 2004, CANCER RES, V64, P7962, DOI 10.1158/0008-5472.CAN-04-1043; Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; Tam IYS, 2006, CLIN CANCER RES, V12, P1647, DOI 10.1158/1078-0432.CCR-05-1981; Tang Z, 2008, BRIT J CANCER, V99, P911, DOI 10.1038/sj.bjc.6604559; Thomas RK, 2007, NAT GENET, V39, P347, DOI 10.1038/ng1975; Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013; Zhu XT, 1999, STRUCTURE, V7, P651, DOI 10.1016/S0969-2126(99)80086-0	41	15	16	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					518	533		10.1038/onc.2008.411	http://dx.doi.org/10.1038/onc.2008.411			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	19015641	Bronze, Green Accepted			2022-12-17	WOS:000262866500006
J	Blair, GE; Cook, GP				Blair, G. E.; Cook, G. P.			Cancer and the immune system: an overview - Introduction	ONCOGENE			English	Editorial Material									[Blair, G. E.] Univ Leeds, Fac Biol Sci, Inst Mol & Cellular Biol, Leeds LS2 9JT, W Yorkshire, England; [Cook, G. P.] Univ Leeds, Leeds Inst Mol Med, Leeds LS2 9JT, W Yorkshire, England	University of Leeds; University of Leeds	Blair, GE (corresponding author), Univ Leeds, Fac Biol Sci, Inst Mol & Cellular Biol, Garstang Bldg,Room 8-52D, Leeds LS2 9JT, W Yorkshire, England.	g.e.blair@leeds.ac.uk	Blair, George Eric/A-5906-2008	Blair, George Eric/0000-0003-0440-1795; Cook, Graham/0000-0003-0223-3652				Bonavida B, 2007, ONCOGENE, V26, P3592, DOI 10.1038/sj.onc.1210369; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Kaufmann SHE, 2008, NAT IMMUNOL, V9, P705, DOI 10.1038/ni0708-705; O'Neill LAJ, 2008, ONCOGENE, V27, P158, DOI 10.1038/sj.onc.1210903; TENG MWL, 2008, J LEUKOCYTE BIOL, V84, P1	5	15	16	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 6	2008	27	45					5868	5868		10.1038/onc.2008.277	http://dx.doi.org/10.1038/onc.2008.277			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QE	18836467				2022-12-17	WOS:000259722600001
J	Bijl, J; Krosl, J; Lebert-Ghali, CE; Vacher, J; Mayotte, N; Sauvageau, G				Bijl, J.; Krosl, J.; Lebert-Ghali, C-E; Vacher, J.; Mayotte, N.; Sauvageau, G.			Evidence for Hox and E2A-PBX1 collaboration in mouse T-cell leukemia	ONCOGENE			English	Article						Hoxb4; E2A-PBX1; collaborator oncogenes; T-ALL	ACUTE LYMPHOBLASTIC-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; BONE-MARROW-CELLS; ACUTE MYELOID-LEUKEMIA; GENE-EXPRESSION; TRANSGENIC MICE; PRE-B; TRANSCRIPTIONAL ACTIVATOR; TRANSLOCATION PROTEIN; HOMEODOMAIN PROTEIN	Using murine Moloney leukemia virus (MMLV)-based proviral insertional mutagenesis, we previously showed a preferential targeting of a small region in the Hoxa gene locus in E2A-PBX1-induced lymphoid leukemia resulting in the overexpression of several Hoxa genes including Hoxa10, Hoxa9 and Hoxa7. This observation suggested a functional interaction between Hox gene overexpression and E2A-PBX1-induced lymphoid tumors. To further explore this possibility, we generated a series of compound E2A-PBX1 x Hox transgenic mice and tested the genetic interaction between these genes in the generation of lymphoid leukemia in vivo. Results presented in this report show that the onset of T-cell leukemia is significantly ccelerated in E2A-PBX1 x Hoxb4 compound transgenic animals when compared with control E2A-PBX1 or Hoxb4 littermates. Hoxa9 appears less potent than Hoxb4 to accelerate E2A-PBX1-induced T-cell leukemia in mice. E2A-PBX1-induced T-cell leukemias express much higher levels of Hoxa genes than MMLV-induced counterparts, possibly suggesting a contribution of these genes to T-cell transformation by E2A-PBX1. Collectively, these data provide the first genetic evidence showing oncogenic collaboration between E2A-PBX1 and a Hox gene in lymphoid malignancies in vivo and document the specific deregulation of a subgroup of Hoxa genes in these leukemias.	[Bijl, J.; Krosl, J.; Sauvageau, G.] Univ Montreal, Inst Res Immunol & Canc IRIC, Lab Mol Genet Hematopoiet Stem Cells, Montreal, PQ, Canada; [Bijl, J.; Lebert-Ghali, C-E; Sauvageau, G.] Hop Maison Neuve Rosemont, Res Ctr, Div Hematol, Montreal, PQ H1T 2M4, Canada; [Bijl, J.; Sauvageau, G.] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; [Vacher, J.] Clin Res Inst Montreal, Sect Cellular Interact & Dev, Montreal, PQ H2W 1R7, Canada; [Sauvageau, G.] Hop Maison Neuve Rosemont, Leukemia Cell Bank Quebec, Montreal, PQ H1T 2M4, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal	Bijl, J (corresponding author), Hop Maison Neuve Rosemont, Ctr Rech Hop, 5415 Boul Lassompt, Montreal, PQ H1T 2M4, Canada.	jbijl.hmr@ssss.gouv.qc.ca		Sauvageau, Guy/0000-0002-4333-7266	Institute for Clinical Research of Montreal (IRCM); Canadian Cancer Society [018478]; Canada Research Chair	Institute for Clinical Research of Montreal (IRCM); Canadian Cancer Society(Canadian Cancer Society (CCS)); Canada Research Chair(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs)	We thank Melanie Frechette for assistance with the animal care and transplantation experiments, and to the personnel from the transgenic animal facility at the Institute for Clinical Research of Montreal (IRCM) for the generation of Hoxb4 and Hoxa9 transgenic lines. We also thank Eric Massicotte and Martine Dupuis from the flow cytometry service of IRCM, and Danielle Gagne from the. ow cytometry service of IRIC for assistance in FACS analysis. Dr Alex Thompson (Queen's University, Belfast, UK) is thanked for critically reading the manuscript. This work was supported by funds from the Canadian Cancer Society through a NCIC grant to GS(no. 018478) and the Canada Research Chair program also to GS.	Armstrong SA, 2005, J CLIN ONCOL, V23, P6306, DOI 10.1200/JCO.2005.05.047; Azpiazu N, 1998, GENE DEV, V12, P261, DOI 10.1101/gad.12.2.261; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Bergeron J, 2006, LEUKEMIA, V20, P1184, DOI 10.1038/sj.leu.2404187; Bijl J, 2005, GENE DEV, V19, P224, DOI 10.1101/gad.1268505; Caudell D, 2007, CANCER RES, V67, P8022, DOI 10.1158/0008-5472.CAN-06-3749; Cauwelier B, 2007, LEUKEMIA, V21, P121, DOI 10.1038/sj.leu.2404410; Cellot S, 2007, EXP HEMATOL, V35, P802, DOI 10.1016/j.exphem.2007.02.013; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; Dik WA, 2005, LEUKEMIA, V19, P1948, DOI 10.1038/sj.leu.2403891; Ferrando AA, 2003, BLOOD, V102, P262, DOI 10.1182/blood-2002-10-3221; HOGAN B, 1983, NATURE, V306, P313, DOI 10.1038/306313a0; HOUGH MR, 1994, J EXP MED, V179, P177, DOI 10.1084/jem.179.1.177; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Kroon E, 2001, EMBO J, V20, P350, DOI 10.1093/emboj/20.3.350; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Krosl J, 2000, ONCOGENE, V19, P5134, DOI 10.1038/sj.onc.1203897; Krosl J, 2003, NAT MED, V9, P1428, DOI 10.1038/nm951; LEBRUN DP, 1994, ONCOGENE, V9, P1641; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; MANN RS, 1995, BIOESSAYS, V17, P855, DOI 10.1002/bies.950171007; Medina-Martinez O, 2003, DEV BIOL, V264, P77, DOI 10.1016/j.ydbio.2003.07.020; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Pineault N, 2004, MOL CELL BIOL, V24, P1907, DOI 10.1128/MCB.24.5.1907-1917.2004; Sanyal M, 2007, BLOOD, V109, P4191, DOI 10.1182/blood-2006-10-054213; Sauvageau G, 1997, IMMUNITY, V6, P13, DOI 10.1016/S1074-7613(00)80238-1; Sauvageau G, 2001, BLOOD, V98, p836A; Soulier J, 2005, BLOOD, V106, P274, DOI 10.1182/blood-2004-10-3900; Speleman F, 2005, LEUKEMIA, V19, P358, DOI 10.1038/sj.leu.2403657; Su X, 2006, GENE CHROMOSOME CANC, V45, P846, DOI 10.1002/gcc.20348; Taghon T, 2002, BLOOD, V99, P1197, DOI 10.1182/blood.V99.4.1197; Taghon T, 2003, LEUKEMIA, V17, P1157, DOI 10.1038/sj.leu.2402947; Thompson A, 2003, BLOOD, V101, P1558, DOI 10.1182/blood.V101.4.1558; Thorsteinsdottir U, 1999, MOL CELL BIOL, V19, P6355; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495; Thorsteinsdottir U, 2002, BLOOD, V99, P121, DOI 10.1182/blood.V99.1.121; TROUSSARD X, 1995, BRIT J HAEMATOL, V89, P516, DOI 10.1111/j.1365-2141.1995.tb08357.x; Van Vlierberghe P, 2008, BLOOD, V111, P4668, DOI 10.1182/blood-2007-09-111872; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VANDIJK MA, 1995, MECH DEVELOP, V52, P99, DOI 10.1016/0925-4773(95)00394-G; Zhang XB, 2008, J CLIN INVEST, V118, P1502, DOI 10.1172/JCI34371	45	15	16	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2008	27	49					6356	6364		10.1038/onc.2008.233	http://dx.doi.org/10.1038/onc.2008.233			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363JK	18679416				2022-12-17	WOS:000260263400005
J	Frechet, M; Warrick, E; Vioux, C; Chevallier, O; Spatz, A; Benhamou, S; Sarasin, A; Bernerd, F; Magnaldo, T				Frechet, M.; Warrick, E.; Vioux, C.; Chevallier, O.; Spatz, A.; Benhamou, S.; Sarasin, A.; Bernerd, F.; Magnaldo, T.			Overexpression of matrix metalloproteinase 1 in dermal fibroblasts from DNA repair-deficient/cancer-prone xeroderma pigmentosum group C patients	ONCOGENE			English	Article						xeroderma pigmentosum; skin; cancer; MMP1; AP-1; ROS	SQUAMOUS-CELL CARCINOMA; MATRIX METALLOPROTEINASES; GENE-EXPRESSION; SUPEROXIDE-DISMUTASE; HYDROGEN-PEROXIDE; COLLAGENASE GENE; MOLECULAR-BASIS; SKIN; CANCER; INDUCTION	Xeroderma pigmentosum (XP) is a rare, recessively inherited genetic disease characterized by skin cancer proneness and premature aging in photoexposed area. The disease results from defective nucleotide excision repair of ultraviolet (UV)-induced DNA lesions. Reconstruction of group C (XP-C) skin in vitro previously suggested that patients' dermal fibroblasts might be involved in promoting skin cancer development, as they elicited microinvasions of both control and XP-C keratinocytes within dermal equivalents. Here we show that in the absence of UV exposure XP-C fibroblasts exhibit aged-like features such as an elongated and dendritic shape. We analysed the repertoire of expression of matrix metalloproteinases ( MMPs) involved in skin aging and cancer. All XP-C fibroblasts tested in this study overexpressed specifically and significantly MMP1. MMP1 expression was also found increased in the dermis of XP-C skin sections suggesting the active contribution of XP-C mesenchymal cells to skin aging and exacerbated carcinogenesis. Increased MMP1 expression in cultured XP-C fibroblasts resulted from MMP1 mRNA accumulation and enhanced transcriptional activity of the MMP1 gene promoter. Deletion analysis revealed the essential role of AP-1 activation in constitutive MMP1 overexpression in XP-C primary fibroblasts. In parallel, levels of reactive oxygen species and FOSB DNA-binding activity were found increased in XP-C fibroblasts. Altogether, these observations suggest that beyond its role in nucleotide excision repair the XPC protein may be important in cell metabolism and fate in the absence of UV.	[Frechet, M.; Warrick, E.; Chevallier, O.; Spatz, A.; Benhamou, S.; Sarasin, A.; Magnaldo, T.] Inst Gustave Roussy, CNRS, FRE 2939, F-94805 Villejuif, France; [Warrick, E.; Vioux, C.; Bernerd, F.] LOreal, Life Sci Adv Res, Ctr C Zviak, F-92583 Clichy, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; L'Oreal Group	Magnaldo, T (corresponding author), Inst Gustave Roussy, CNRS, FRE 2939, Rue Camille Desmoulins, F-94805 Villejuif, France.	magnaldo@igr.fr	Benhamou, Simone/K-6554-2015; Benhamou, Simone/ABD-2590-2020; SPATZ, ALAN/B-8645-2009	SPATZ, ALAN/0000-0003-3020-1420; BENHAMOU, Simone/0000-0001-5853-8047	Association pour la Recherche sur le Cancer [3590]; Fondation de l'Avenir, the Societe Francaise de Dermatologie, the Association Francaise contre les Myopathies; Les enfants de la Lune	Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Fondation de l'Avenir, the Societe Francaise de Dermatologie, the Association Francaise contre les Myopathies(Association Francaise contre les Myopathies); Les enfants de la Lune	Dr Asselineau and Dr J Leclaire are gratefully acknowledged for continuous support and encouragements. We are indebted to V Marty, C Pierrard and Dr C Marionnet for their expert help. We are also grateful to Dr A Jalil for confocal microscopy. We thank Professor P Herrlich and Professor CE Brinckerhoff for DNA reporter constructs. Many thanks to F Duvigneau for editing English usage in the article. TM gratefully acknowledges fundings from the Association pour la Recherche sur le Cancer (no. 3590), the Fondation de l'Avenir, the Societe Francaise de Dermatologie, the Association Francaise contre les Myopathies. AS thanks the association 'Les enfants de la Lune' for its support.	Airola K, 2001, J INVEST DERMATOL, V116, P85, DOI 10.1046/j.1523-1747.2001.00223.x; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Arnaudeau-Begard C, 2003, HUM GENE THER, V14, P983, DOI 10.1089/104303403766682241; ASSELINEAU D, 1985, EXP CELL RES, V159, P536, DOI 10.1016/S0014-4827(85)80027-6; Benbow U, 1999, J BIOL CHEM, V274, P25371, DOI 10.1074/jbc.274.36.25371; Bernerd F, 2005, PHOTOCHEM PHOTOBIOL, V81, P19, DOI 10.1562/2004-07-29-IR-250.1; Bernerd F, 1997, DEV BIOL, V183, P123, DOI 10.1006/dbio.1996.8465; Bernerd F, 2001, P NATL ACAD SCI USA, V98, P7817, DOI 10.1073/pnas.141221998; BOOTSMA D, 1995, PHILOS T ROY SOC B, V347, P75, DOI 10.1098/rstb.1995.0012; Brenneisen P, 1997, FREE RADICAL BIO MED, V22, P515, DOI 10.1016/S0891-5849(96)00404-2; Brinckerhoff CE, 2000, CLIN CANCER RES, V6, P4823; Cat B, 2006, J CELL SCI, V119, P2727, DOI 10.1242/jcs.03011; Chung JH, 2001, J INVEST DERMATOL, V117, P1218, DOI 10.1046/j.0022-202x.2001.01544.x; Chung JH, 2000, J INVEST DERMATOL, V115, P177, DOI 10.1046/j.1523-1747.2000.00009.x; COLLIER IE, 1988, J BIOL CHEM, V263, P10711; Comoglio PM, 2005, NAT MED, V11, P1156, DOI 10.1038/nm1105-1156; D'Errico M, 2006, EMBO J, V25, P4305, DOI 10.1038/sj.emboj.7601277; Del Rio M, 2002, HUM GENE THER, V13, P959, DOI 10.1089/10430340252939069; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Fligiel SEG, 2003, J INVEST DERMATOL, V120, P842, DOI 10.1046/j.1523-1747.2003.12148.x; Fratelli M, 2005, P NATL ACAD SCI USA, V102, P13998, DOI 10.1073/pnas.0504398102; Frechet Mathilde, 2006, Methods Mol Biol, V314, P9; FRISCH SM, 1990, ONCOGENE, V5, P75; GRAY ST, 1992, AM J PATHOL, V141, P301; Inoue D, 2004, J BIOL CHEM, V279, P49795, DOI 10.1074/jbc.M404096200; Jorissen HJMM, 2007, BIOCHEMISTRY-US, V46, P8360, DOI 10.1021/bi700494v; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kerkela E, 2003, EXP DERMATOL, V12, P109, DOI 10.1034/j.1600-0625.2003.120201.x; Kerkela E, 2002, J PATHOL, V198, P258, DOI 10.1002/path.1198; Khorramizadeh MR, 1999, MOL CELL BIOCHEM, V194, P99, DOI 10.1023/A:1006909021352; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; Milde-Langosch K, 2004, BREAST CANCER RES TR, V86, P139, DOI 10.1023/B:BREA.0000032982.49024.71; Monhian N, 2005, ARCH FACIAL PLAST S, V7, P238, DOI 10.1001/archfaci.7.4.238; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; NISHIGORI C, 1989, J INVEST DERMATOL, V93, P506, DOI 10.1111/1523-1747.ep12284060; Otto AI, 1999, CANCER RES, V59, P1212; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Rhie GE, 2001, J INVEST DERMATOL, V117, P1212, DOI 10.1046/j.0022-202x.2001.01469.x; Rosenfeldt H, 1998, MOL CELL BIOL, V18, P2659, DOI 10.1128/MCB.18.5.2659; Rutter JL, 1997, J CELL BIOCHEM, V66, P322, DOI 10.1002/(SICI)1097-4644(19970901)66:3<322::AID-JCB5>3.3.CO;2-D; Shimizu Y, 2003, EMBO J, V22, P164, DOI 10.1093/emboj/cdg016; Shimokawa N, 2005, J CELL PHYSIOL, V205, P77, DOI 10.1002/jcp.20369; Shin MH, 2005, J INVEST DERMATOL, V125, P221, DOI 10.1111/j.0022-202X.2005.23823.x; Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Tsukifuji R, 1999, BRIT J CANCER, V80, P1087, DOI 10.1038/sj.bjc.6690468; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Varani J, 2004, J INVEST DERMATOL, V122, P1471, DOI 10.1111/j.0022-202X.2004.22614.x; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; VUILLAUME M, 1992, CARCINOGENESIS, V13, P321, DOI 10.1093/carcin/13.3.321; Wenk J, 1999, J BIOL CHEM, V274, P25869, DOI 10.1074/jbc.274.36.25869; White LA, 1995, MATRIX BIOL, V14, P715, DOI 10.1016/S0945-053X(05)80014-9	55	15	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2008	27	39					5223	5232		10.1038/onc.2008.153	http://dx.doi.org/10.1038/onc.2008.153			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GO	18469853				2022-12-17	WOS:000258915100006
J	Vercammen, E; Staal, J; Van den Broeke, A; Haegman, M; Vereecke, L; Schotte, P; Beyaert, R				Vercammen, E.; Staal, J.; Van den Broeke, A.; Haegman, M.; Vereecke, L.; Schotte, P.; Beyaert, R.			Prolonged exposure to IL-1 beta and IFN gamma induces necrosis of L929 tumor cells via a p38MAPK/NF-kappa B/NO-dependent mechanism	ONCOGENE			English	Article						interleukin-1; interferon; necrosis; nitric oxide; NF-kappa B	NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION; INTERFERON-GAMMA; IMMUNE-RESPONSE; P38 MAPK; DEATH; EXPRESSION; INTERLEUKIN-1	Interleukin-1 beta (IL-1 beta)is a cytokine that shares with tumor necrosis factor (TNF) the ability to initiate largely similar signaling pathways, leading to proinflammatory gene expression. In contrast to TNF, however, IL-1 beta is not believed to induce tumor cell death. Here we demonstrate that prolonged treatment with IL-1 beta, in combination with interferon-gamma (IFN gamma), is cytotoxic for L929 tumor cells. IL-1 beta/IFN gamma- induced cytotoxicity requires only minimal amounts of IL-1b and shows morphological features of necrosis. Although TNF induces a similar response, we could exclude a contribution of endogenous TNF production in the effect of IL-1 beta/IFN gamma. Cell death in response to IL-1 beta/IFN gamma is independent of caspases, but requires the IL-1 beta/IFN gamma- induced production of inducible nitric oxide synthase ( iNOS) and NO. Moreover, necrosis and iNOS/ NO production could be prevented by treatment of the cells with a p38 mitogen activated protein kinase ( p38MAPK) or I kappa B kinase beta inhibitor. Altogether, these findings demonstrate that prolonged exposure to IL-1 beta plus IFN gamma induces L929 tumor cell necrosis, via a p38MAPK and nuclear factor-kappa B ( NF-kappa B)- dependent signaling pathway, leading to the expression of iNOS and the production of toxic NO levels.	[Vercammen, E.; Staal, J.; Van den Broeke, A.; Haegman, M.; Vereecke, L.; Schotte, P.; Beyaert, R.] Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, B-9052 Ghent, Zwijnaarde, Belgium; [Vercammen, E.; Staal, J.; Van den Broeke, A.; Haegman, M.; Vereecke, L.; Schotte, P.; Beyaert, R.] Univ Ghent, Dept Mol Biol, B-9000 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University	Beyaert, R (corresponding author), Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, Technol Pk 927, B-9052 Ghent, Zwijnaarde, Belgium.	rudi.beyaert@dmbr.ugent.be	Beyaert, Rudi/B-2589-2009; Vereecke, Lars/ABH-2926-2020; Staal, Jens/B-7383-2008; Vereecke, Lars/H-6639-2016	Vereecke, Lars/0000-0002-1593-862X; Staal, Jens/0000-0003-2664-3357; Beyaert, Rudi/0000-0002-5704-582X; Haegman, Mira/0000-0002-4883-312X				BEYAERT R, 1993, J IMMUNOL, V151, P291; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Beyaert R, 2002, INT REV CYTOL, V214, P225; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; Cnop M, 2005, DIABETES, V54, pS97, DOI 10.2337/diabetes.54.suppl_2.S97; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; DUNNE A, 2003, SCI STKE, pRE3, DOI DOI 10.1126/STKE.2003.171.RE3; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Eizirik DL, 2001, DIABETOLOGIA, V44, P2115, DOI 10.1007/s001250100021; Festjens N, 2006, BBA-BIOENERGETICS, V1757, P1371, DOI 10.1016/j.bbabio.2006.06.014; FRANSEN L, 1986, EUR J CANCER CLIN ON, V22, P419, DOI 10.1016/0277-5379(86)90107-0; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Golstein P, 2007, TRENDS BIOCHEM SCI, V32, P37, DOI 10.1016/j.tibs.2006.11.001; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Heitmeier MR, 1997, J BIOL CHEM, V272, P13697, DOI 10.1074/jbc.272.21.13697; Huang H, 2004, MOL PHARMACOL, V66, P302, DOI 10.1124/mol.66.2.302; Itoh S, 1999, J IMMUNOL, V162, P7434; Janik JE, 1996, JNCI-J NATL CANCER I, V88, P44, DOI 10.1093/jnci/88.1.44; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; Kim HJ, 2006, CELL DEATH DIFFER, V13, P738, DOI 10.1038/sj.cdd.4401877; Kim YS, 2007, MOL CELL, V26, P675, DOI 10.1016/j.molcel.2007.04.021; Kim YJ, 2006, J NEUROSCI RES, V84, P1037, DOI 10.1002/jnr.21011; Kishore N, 2003, J BIOL CHEM, V278, P32861, DOI 10.1074/jbc.M211439200; Kleinert H, 2004, EUR J PHARMACOL, V500, P255, DOI 10.1016/j.ejphar.2004.07.030; Kleinert H, 2003, BIOL CHEM, V384, P1343, DOI 10.1515/BC.2003.152; Kobayashi T, 2004, MICROBES INFECT, V6, P1333, DOI 10.1016/j.micinf.2004.09.001; Larsen CM, 1998, J BIOL CHEM, V273, P15294, DOI 10.1074/jbc.273.24.15294; Lejeune F J, 2006, Bull Cancer, V93, pE90; Lejeune Ferdy J, 2006, Cancer Immun, V6, P6; Liu DB, 2000, DIABETES, V49, P1116, DOI 10.2337/diabetes.49.7.1116; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; MORINAGA Y, 1989, J IMMUNOL, V143, P3538; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; O'Neill LAJ, 2006, NAT REV DRUG DISCOV, V5, P549, DOI 10.1038/nrd2070; ONOZAKI K, 1985, J IMMUNOL, V135, P3962; Perkins ND, 2006, CELL DEATH DIFFER, V13, P759, DOI 10.1038/sj.cdd.4401838; Rabinovitch A, 1998, BIOCHEM PHARMACOL, V55, P1139, DOI 10.1016/S0006-2952(97)00492-9; Ricci MS, 2006, ONCOLOGIST, V11, P342, DOI 10.1634/theoncologist.11-4-342; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Saldeen J, 2004, EUR CYTOKINE NETW, V15, P47; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SMITH JW, 1992, J CLIN ONCOL, V10, P1141, DOI 10.1200/JCO.1992.10.7.1141; VANHAESEBROECK B, 1992, J IMMUNOL, V148, P2785; VANHAESEBROECK B, 1991, CANCER RES, V51, P2229; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; YAMADA K, 1993, DIABETES, V42, P1026, DOI 10.2337/diabetes.42.7.1026; Yoshimura A, 2006, CANCER SCI, V97, P439, DOI 10.1111/j.1349-7006.2006.00197.x	50	15	16	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2008	27	27					3780	3788		10.1038/onc.2008.4	http://dx.doi.org/10.1038/onc.2008.4			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18246123				2022-12-17	WOS:000256904700002
J	Falvella, FS; Colombo, F; Spinola, M; Campiglio, M; Pastorino, U; Dragani, TA				Falvella, F. S.; Colombo, F.; Spinola, M.; Campiglio, M.; Pastorino, U.; Dragani, T. A.			BHLHB3: a candidate tumor suppressor in lung cancer	ONCOGENE			English	Article						BHLHB2; DEC1; DEC2; SHARP-1; STRA13; lung cancer	E-BOX; DEC2; DIFFERENTIATION; EXPRESSION	BHLHB3 is a basic helix-loop-helix (bHLH) domain-containing protein that acts as a transcriptional repressor. We found that BHLHB3 transcript levels were low in three human lung cancer cell lines and downregulated in human lung adenocarcinomas as compared to normal lung tissue. BHLHB3 gene overexpression inhibited colony formation of A549, NCI-H520 and NCI-H596 lung cancer cells. The reduced colony growth was likely due to inhibition of cell proliferation as suggested by the downregulation of cyclin D1 (CCND1) expression in NCI-H520 cells transfected to overexpress the BHLHB3 gene; no evidence of apoptosis was observed. These results point to the potential role of the BHLHB3 protein as a tumor suppressor for lung cancer.	[Falvella, F. S.; Colombo, F.; Spinola, M.; Campiglio, M.; Dragani, T. A.] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Labs, I-20133 Milan, Italy; [Pastorino, U.] Fdn IRCCS Ist Nazl Tumori, Unit Thorac Surg, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Dragani, TA (corresponding author), Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Labs, Via G Venezian 1, I-20133 Milan, Italy.	tommaso.dragani@istitutotumori.mi.it	Dragani, Tommaso A./K-4493-2016; Colombo, Francesca/B-4617-2013; Colombo, Francesca/Q-5292-2019; Pastorino, Ugo/C-2712-2017	Dragani, Tommaso A./0000-0001-5915-4598; Colombo, Francesca/0000-0003-2015-4317; Colombo, Francesca/0000-0003-2015-4317; Pastorino, Ugo/0000-0001-9974-7902	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Allenspach EJ, 2002, CANCER BIOL THER, V1, P466, DOI 10.4161/cbt.1.5.159; Azmi S, 2004, J BIOL CHEM, V279, P52643, DOI 10.1074/jbc.M409188200; Azmi S, 2003, J BIOL CHEM, V278, P20098, DOI 10.1074/jbc.M210427200; Berthet C, 2007, ONCOGENE, V26, P4469, DOI 10.1038/sj.onc.1210243; Davis RL, 2001, ONCOGENE, V20, P8342, DOI 10.1038/sj.onc.1205094; Falvella FS, 2007, LUNG CANCER, V56, P1, DOI 10.1016/j.lungcan.2006.11.008; Fujimoto K, 2001, BIOCHEM BIOPH RES CO, V280, P164, DOI 10.1006/bbrc.2000.4133; Honma S, 2002, NATURE, V419, P841, DOI 10.1038/nature01123; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Li YX, 2003, J BIOL CHEM, V278, P16899, DOI 10.1074/jbc.M300596200; Noshiro M, 2004, GENES CELLS, V9, P317, DOI 10.1111/j.1356-9597.2004.00722.x; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949	12	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	26					3761	3764		10.1038/sj.onc.1211038	http://dx.doi.org/10.1038/sj.onc.1211038			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18223678				2022-12-17	WOS:000256659300014
J	Shahrzad, S; Shirasawa, S; Sasazuki, T; Rak, JW; Coomber, BL				Shahrzad, S.; Shirasawa, S.; Sasazuki, T.; Rak, J. W.; Coomber, B. L.			Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts	ONCOGENE			English	Article						hypoxia; antiangiogenic therapy; K-ras mutation; tumor microenvironment; metronomic cyclophosphamide	METASTATIC BREAST-CANCER; GROWTH-FACTOR RECEPTOR-2; HUMAN LIVER-MICROSOMES; MISMATCH-REPAIR GENES; TUMOR-CELL LINES; MICROSATELLITE INSTABILITY; ANTIANGIOGENIC THERAPY; ANGIOGENESIS; HYPOXIA; BEVACIZUMAB	Antiangiogenic therapies are promising approaches to cancer control, but the details of their effects on subsequent tumor progression are not fully understood. Such therapies have the potential to eventually generate extensive amounts of tumor ischemia, and we previously demonstrated that ischemic conditions induce K-ras mutations in cells with deficient mismatch repair (MMR) mechanisms. This suggested that similar effects on oncogene mutagenesis may accompany antiangiogenic therapy. To test this, MMR-deficient colorectal cancer cells (Dks-8) were xenografted into immune-deficient mice and treated with the antiangiogenic regimen of low-dose/metronomic cyclophosphamide for 2 weeks followed by a 2-week recovery period without therapy. This treatment resulted in transient tumor growth inhibition, increased hypoxia, and decreased microvessel density, and cancer cells from treated tumors acquired activating mutations of the K-ras oncogene (K-ras(G13D)). In vitro exposure of Dks-8 cells to the active metabolite of cyclophosphamide (4-hydroxycyclophosphamide) had no effect on the K-ras status, indicating that there was no direct action of this alkylating agent on K-ras mutagenesis. In addition, cells sorted from hypoxic regions of Dks-8 tumors were enriched in K-ras(G13D) mutants. Collectively, our studies suggest that increases in tumor hypoxia induced by antiangiogenic treatment may lead to K-ras mutation and consequently tumor progression, especially in susceptible individuals.	[Shahrzad, S.; Coomber, B. L.] Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada; [Shirasawa, S.] Fukuoka Univ, Sch Med, Dept Cell Biol, Fukuoka 81401, Japan; [Sasazuki, T.] Int Med Ctr Japan, Res Inst, Tokyo, Japan; [Rak, J. W.] McGill Univ, Montreal Childrens Hosp, Dept Pediat, Montreal, PQ H3H 1P3, Canada	University of Guelph; Fukuoka University; National Center for Global Health & Medicine - Japan; McGill University	Coomber, BL (corresponding author), Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada.	bcoomber@uoguelph.ca						Aarnio M, 1999, INT J CANCER, V81, P214, DOI 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.0.CO;2-L; Bernhard EJ, 2000, CANCER RES, V60, P6597; BOS JL, 1989, CANCER RES, V49, P4682; BOYER JC, 1995, CANCER RES, V55, P6063; Browder T, 2000, CANCER RES, V60, P1878; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Brown JM, 2000, DRUG RESIST UPDATE, V3, P7, DOI 10.1054/drup.2000.0120; CHANG TKH, 1993, CANCER RES, V53, P5629; CHEN JZ, 1994, CURR OPIN IMMUNOL, V6, P313, DOI 10.1016/0952-7915(94)90107-4; DeLisser HM, 1997, AM J PATHOL, V151, P671; DEXTER DL, 1981, AM J MED, V71, P949, DOI 10.1016/0002-9343(81)90312-0; Emmenegger U, 2006, CANCER RES, V66, P1664, DOI 10.1158/0008-5472.CAN-05-2598; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Franco M, 2006, CANCER RES, V66, P3639, DOI 10.1158/0008-5472.CAN-05-3295; Galmarini Carlos Maria, 2003, Curr Opin Investig Drugs, V4, P1416; Gasparini G, 2005, NAT CLIN PRACT ONCOL, V2, P562, DOI 10.1038/ncponc0342; Halvarsson B, 2004, VIRCHOWS ARCH, V444, P135, DOI 10.1007/s00428-003-0922-z; HERMAN TS, 1989, CANCER RES, V49, P3338; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Janssen HL, 2005, HEAD NECK-J SCI SPEC, V27, P622, DOI 10.1002/hed.20223; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Jubb AM, 2006, NAT REV CANCER, V6, P626, DOI 10.1038/nrc1946; Kane MF, 1997, CANCER RES, V57, P808; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kerbel RS, 2006, SCIENCE, V312, P1171, DOI 10.1126/science.1125950; Kerbel RS, 2001, CANCER METAST REV, V20, P79, DOI 10.1023/A:1013172910858; Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829; Koukourakis MI, 2000, INT J RADIAT ONCOL, V48, P545, DOI 10.1016/S0360-3016(00)00677-5; LIOTTA LA, 1974, CANCER RES, V34, P997; Miller KD, 2005, CLIN CANCER RES, V11, P3369, DOI 10.1158/1078-0432.CCR-04-1923; Miller KD, 2005, J CLIN ONCOL, V23, P792, DOI 10.1200/JCO.2005.05.098; Minamoto Toshinari, 2002, Expert Rev Mol Diagn, V2, P565, DOI 10.1586/14737159.2.6.565; Mitchell RJ, 2002, AM J EPIDEMIOL, V156, P885, DOI 10.1093/aje/kwf139; Motzer RJ, 2006, J CLIN ONCOL, V24, P5601, DOI 10.1200/JCO.2006.08.5415; Peltomaki P, 2004, DIS MARKERS, V20, P269, DOI 10.1155/2004/305058; Perona R, 2004, BRIT J CANCER, V90, P573, DOI 10.1038/sj.bjc.6601552; Rak J, 1996, EUR J CANCER, V32A, P2438, DOI 10.1016/S0959-8049(96)00396-6; RAK J, 1995, CANCER RES, V55, P4575; Rak JW, 2006, CANC DRUG DISC DEV, P67, DOI 10.1007/978-1-59745-035-5_4; Ren S, 1997, CANCER RES, V57, P4229; Rofstad EK, 2007, CLIN CANCER RES, V13, P1971, DOI 10.1158/1078-0432.CCR-06-1967; Shahrzad S, 2005, CANCER RES, V65, P8134, DOI 10.1158/0008-5472.CAN-05-0713; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; SRIVASTAVA A, 1988, AM J PATHOL, V133, P419; TAKAMIZAWA A, 1975, J MED CHEM, V18, P376, DOI 10.1021/jm00238a011; Toyooka S, 2003, ONCOL REP, V10, P1455; Varker KA, 2007, ANN SURG ONCOL, V14, P2367, DOI 10.1245/s10434-007-9389-5; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491; Yu JL, 2002, SCIENCE, V295, P1526, DOI 10.1126/science.1068327; Yu JL, 2001, AM J PATHOL, V158, P1325, DOI 10.1016/S0002-9440(10)64083-7; Yu L, 1996, DRUG METAB DISPOS, V24, P1254; Yuan JL, 1998, MUTAT RES-FUND MOL M, V400, P439, DOI 10.1016/S0027-5107(98)00042-6; ZON G, 1984, J MED CHEM, V27, P466, DOI 10.1021/jm00370a008	56	15	15	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	26					3729	3738		10.1038/sj.onc.1211031	http://dx.doi.org/10.1038/sj.onc.1211031			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18223682				2022-12-17	WOS:000256659300010
J	Mathieu, J; Flexor, M; Lanotte, M; Besancon, F				Mathieu, J.; Flexor, M.; Lanotte, M.; Besancon, F.			A PARP-1/JNK1 cascade participates in the synergistic apoptotic effect of TNF alpha and all-trans retinoic acid in APL cells	ONCOGENE			English	Article						TNF alpha; apoptosis; ATRA; PARP-1	NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; EWING SARCOMA-CELLS; POLY(ADP-RIBOSE) POLYMERASE; INDUCED ACTIVATION; JNK ACTIVATION; TUMOR-CELLS; IFN-GAMMA; DEATH; INDUCTION	When administrated by isolated limb perfusion, tumor necrosis factor alpha (TNF alpha) is an efficient antitumor agent that improves drug penetration and destroys angiogenic vessels. Moreover, the pronounced potentiation of TNF alpha-induced apoptosis by NF-kappa B inhibitors suggest that these compounds could enhance TNF alpha antitumor efficacy through direct induction of tumor cell apoptosis. Therefore, attempts at amplifying signaling pathways that mediate TNF alpha antitumor effects could help to design combination therapies improving its efficiency. We report that nanomolar concentrations of all-trans retinoic acid (ATRA) amplify TNF alpha-induced apoptosis in APL cells expressing a specific repressor of NF-kappa B activation. This effect is abolished by the pan-caspase inhibitor, Z-V AD-fmk and by caspase-8 and -9 inhibitors. Cell death is accompanied by a drop of mitochondrial potential and by poly (ADP-ribose) polymerase (PARP) activation. Using specific PARP-1 inhibitors and siRNAs, we show that PARP-1 is essential for the synergistic apoptotic effect and c-Jun N-terminal kinase 1 (JNK1) activation triggered by the ATRA/TNF alpha combination. JNK1 siRNAs reduce ATRA/TNF alpha-induced apoptosis, mitochondrial release of cytochrome c and caspase-9 activation. Altogether, these results identify a novel mechanism of PARP-1-induced apoptosis, in which JNK1 provides a link between PARP-1 activation and mitochondrial pathway of caspase-9 activation. This study also suggests that inclusion of nanomolar doses of ATRA could be clinically beneficial in amplifying TNF alpha-induced antitumor signals.	[Mathieu, J.; Lanotte, M.; Besancon, F.] Hop St Louis, INSERM, Unite 685, Inst Univ Hematol, F-75475 Paris 10, France; [Flexor, M.] Hop St Louis, AP HP, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP	Besancon, F (corresponding author), Hop St Louis, INSERM, Unite 685, Inst Univ Hematol, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.	Francoise.Besancon@stlouis.inserm.fr						Abadie A, 2004, ONCOGENE, V23, P4911, DOI 10.1038/sj.onc.1207614; Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; AMRAN D, 2007, BIOCHIM BIOPHYS ACTA, V1173, P1653; Boulares AH, 2001, J BIOL CHEM, V276, P38185; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Dutta J, 2006, ONCOGENE, V25, P6800, DOI 10.1038/sj.onc.1209938; Garrido C, 2006, CELL DEATH DIFFER, V13, P1423, DOI 10.1038/sj.cdd.4401950; Javelaud D, 2000, ONCOGENE, V19, P61, DOI 10.1038/sj.onc.1203246; Javelaud D, 2001, ONCOGENE, V20, P4365, DOI 10.1038/sj.onc.1204570; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kukekov NV, 2006, J BIOL CHEM, V281, P15517, DOI 10.1074/jbc.M601056200; LAINE A, 2005, SCI STKE, V281, pRE5; LANOTTE M, 1991, BLOOD, V77, P1080; Lejeune FJ, 2006, B CANC, V93, pE90; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Manna SK, 2000, ONCOGENE, V19, P2110, DOI 10.1038/sj.onc.1203547; Mathieu J, 2005, ONCOGENE, V24, P7145, DOI 10.1038/sj.onc.1208889; Mathieu J, 2006, INT J CANCER, V119, P1723, DOI 10.1002/ijc.21970; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; NAKAMURA J, 2003, NUCLEIC ACIDS RES, V31, P1; Nguewa PA, 2003, MOL PHARMACOL, V64, P1007, DOI 10.1124/mol.64.5.1007; Ruegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498-408; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Suk K, 2001, J BIOL CHEM, V276, P13153, DOI 10.1074/jbc.M007646200; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; TOBLER A, 1987, BLOOD, V70, P1940; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; van Horssen R, 2006, ONCOLOGIST, V11, P397, DOI 10.1634/theoncologist.11-4-397; Van Molle W, 2002, IMMUNITY, V16, P685, DOI 10.1016/S1074-7613(02)00310-2; Weston CR, 2007, CURR OPIN CELL BIOL, V19, P142, DOI 10.1016/j.ceb.2007.02.001; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Witcher M, 2003, BLOOD, V102, P237, DOI 10.1182/blood-2002-09-2725; Xu Y, 2006, J BIOL CHEM, V281, P8788, DOI 10.1074/jbc.M508135200; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221	36	15	17	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	24					3361	3370		10.1038/sj.onc.1210997	http://dx.doi.org/10.1038/sj.onc.1210997			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18084321				2022-12-17	WOS:000256309900001
J	Arany, PR; Rane, SG; Roberts, AB				Arany, P. R.; Rane, S. G.; Roberts, A. B.			Smad3 deficiency inhibits v-ras-induced transformation by suppression of JNK MAPK signaling and increased farnesyl transferase inhibition	ONCOGENE			English	Article						TGF-beta 1; Smad3; JNK MAPK; Ras; malignant transformation; farnesyl transferase inhibition	GROWTH-FACTOR-BETA; EXTRACELLULAR-MATRIX; KINASE; PROTEIN; GROWTH-FACTOR-BETA-1; PHOSPHORYLATION; MECHANISM; CELLS; OVEREXPRESSION; TRANSDUCTION	The ability of transforming growth factor-beta ( TGF- beta) to modulate various effects on distinct cell lineages has been a central feature of its multi- faceted nature. The purpose of this study was to access the effects of deletion of a key TGF- beta signal transducer, Smad3, on MAPK activation and v- Ras(Ha)- transformation of primary mouse embryonic. broblasts ( MEFs). We observe reduced TGF- beta 1 and v- ras(Ha) mediated activation of the JNK and ERK MAPK pathway upon ablation of Smad3. Further, Smad3-deficient MEFs demonstrate resistance to v- ras(Ha)- induced transformation while the absence of Smad3 results in increased inhibition of farnesyl transferase activity. Taken together, these observations demonstrate that the absence of Smad3 protects. broblasts from oncogenic transformation by ( i) augmenting farnesyl transferase inhibition and ( ii) suppressing the Ras - JNK MAPK pathway. These results provide new insights into the molecular mechanisms involved in v- Ras(Ha) oncogene- induced mesenchymal phenotypic transformation.	[Arany, P. R.; Rane, S. G.; Roberts, A. B.] NCI, NIH, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; [Rane, S. G.] NIDDK, NIH, Diabet Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Arany, PR (corresponding author), Harvard Univ, Harvard Sch Dent Med, 188 Longwood Ave,REB 203, Boston, MA 02115 USA.	arany@fas.harvard.edu; ranes@mail.nih.gov	Arany, Praveen/S-5329-2019	Arany, Praveen/0000-0002-6116-2340	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK055107, ZIADK055107, Z01DK055106, ZIADK055106] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arany PR, 2006, P NATL ACAD SCI USA, V103, P9250, DOI 10.1073/pnas.0602473103; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bost F, 1999, MOL CELL BIOL, V19, P1938; Brassard DL, 2002, EXP CELL RES, V273, P138, DOI 10.1006/excr.2001.5440; Byfield SD, 2004, TRENDS CELL BIOL, V14, P107; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; COX AD, 1994, J BIOL CHEM, V269, P19203; Egeblad M, 2005, COLD SH Q B, V70, P383, DOI 10.1101/sqb.2005.70.007; FILMUS J, 1992, ONCOGENE, V7, P521; Fong LG, 2006, SCIENCE, V311, P1621, DOI 10.1126/science.1124875; Hayashida T, 2003, FASEB J, V17, P1576, DOI 10.1096/fj.03-0037fje; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; Kennedy NJ, 2003, GENE DEV, V17, P629, DOI 10.1101/gad.1062903; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Laping NJ, 2007, CLIN CANCER RES, V13, P3087, DOI 10.1158/1078-0432.CCR-06-1811; Lebowitz PF, 1998, ONCOGENE, V17, P1439, DOI 10.1038/sj.onc.1202175; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Matsuura I, 2005, BIOCHEMISTRY-US, V44, P12546, DOI 10.1021/bi050560g; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Park BJ, 2000, CANCER RES, V60, P3031; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; Radisky DC, 2007, J CELL BIOCHEM, V101, P830, DOI 10.1002/jcb.21186; ROBERTS AB, 1980, P NATL ACAD SCI-BIOL, V77, P3494, DOI 10.1073/pnas.77.6.3494; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; Saha D, 2001, J BIOL CHEM, V276, P29531, DOI 10.1074/jbc.M100069200; Santibanez JF, 2003, INT J CANCER, V107, P715, DOI 10.1002/ijc.11457; Santibanez JF, 2002, FEBS LETT, V520, P171, DOI 10.1016/S0014-5793(02)02760-6; Sekimoto G, 2007, CANCER RES, V67, P5090, DOI 10.1158/0008-5472.CAN-06-4629; Ten Dijke Peter, 1994, Progress in Growth Factor Research, V5, P55, DOI 10.1016/0955-2235(94)90017-5; Ventura JJ, 2004, MOL CELL, V15, P269, DOI 10.1016/j.molcel.2004.06.007; Vijayachandra K, 2003, CANCER RES, V63, P3447; Wisdom R, 2005, ONCOGENE, V24, P7043, DOI 10.1038/sj.onc.1208870; Yamagata H, 2005, CANCER RES, V65, P157; Yoshida K, 2005, AM J PATHOL, V166, P1029, DOI 10.1016/S0002-9440(10)62324-3; Yue JB, 2001, PHARMACOL THERAPEUT, V91, P1, DOI 10.1016/S0163-7258(01)00143-7	44	15	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2507	2512		10.1038/sj.onc.1210889	http://dx.doi.org/10.1038/sj.onc.1210889			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17952112				2022-12-17	WOS:000254844900016
J	Moulin, S; Llanos, S; Kim, SH; Peters, G				Moulin, S.; Llanos, S.; Kim, S-H; Peters, G.			Binding to nucleophosmin determines the localization of human and chicken ARF but not its impact on p53	ONCOGENE			English	Article						ARF; nucleophosmin; nucleolus; p53; MDM2; chicken embryo fibroblasts	TUMOR-SUPPRESSOR PROTEIN; CELL-CYCLE ARREST; NUCLEOLAR LOCALIZATION; STABILIZES P53; NUCLEAR EXPORT; MDM2; P14(ARF); LOCUS; DEGRADATION; P19(ARF)	The ARF tumour suppressor gene encodes a small highly basic protein whose known functions are largely determined by the amino acids encoded within the first exon. In mammals, the protein incorporates additional residues specified by an alternative reading frame in the second exon of INK4a, but this arrangement does not apply to the chicken homologue. In exploring the intracellular localization of chicken p7(ARF), we found that while the FLAG- and HA- tagged versions localize in the nucleolus, in line with mammalian ARF, the GFP- tagged version is excluded from the nucleolus. Here we show that irrespective of the source or composition of the ARF fusion proteins, versions that accumulate in the nucleolus share the ability to bind to nucleophosmin ( NPM). Depletion of NPM with siRNA results in the re- location and destabilization of nucleolar forms of ARF but has little effect on the location or stability of a nucleoplasmic form of ARF. Importantly, knockdown of endogenous NPM does not impair the ability of ARF to bind to MDM2 and stabilize p53. These findings support the view that nucleolar localization determines the stability of ARF but not its primary function.	[Moulin, S.; Llanos, S.; Kim, S-H; Peters, G.] London Res Inst, Canc Res UK, Mol Oncol Lab, London WC2A 3PX, England	Cancer Research UK	Peters, G (corresponding author), London Res Inst, Canc Res UK, Mol Oncol Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	gordon.peters@cancer.org.uk	Kim, Soo Hyun/ABG-8773-2020; , Susana/AAA-9282-2019	Kim, Soo Hyun/0000-0002-9394-1437; Llanos, Susana/0000-0002-8555-9326				Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Brady SN, 2004, MOL CELL BIOL, V24, P9327, DOI 10.1128/MCB.24.21.9327-9338.2004; Clark PA, 2002, ONCOGENE, V21, P4498, DOI 10.1038/sj.onc.1205558; Colombo E, 2006, CANCER RES, V66, P3044, DOI 10.1158/0008-5472.CAN-05-2378; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; den Besten W, 2005, CELL CYCLE, V4, P1593; Enomoto T, 2006, J BIOL CHEM, V281, P18463, DOI 10.1074/jbc.M602788200; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Kim SH, 2003, P NATL ACAD SCI USA, V100, P211, DOI 10.1073/pnas.0135557100; Kim SH, 2006, J CELL SCI, V119, P2435, DOI 10.1242/jcs.02989; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Kuo ML, 2004, GENE DEV, V18, P1862, DOI 10.1101/gad.1213904; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; Rodway H, 2004, ONCOGENE, V23, P6186, DOI 10.1038/sj.onc.1207854; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	31	15	15	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2382	2389		10.1038/sj.onc.1210887	http://dx.doi.org/10.1038/sj.onc.1210887			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17968318				2022-12-17	WOS:000254844900003
J	Yu, PJ; Ferrari, G; Pirelli, L; Galloway, AC; Mignatti, P; Pintucci, G				Yu, P-J; Ferrari, G.; Pirelli, L.; Galloway, A. C.; Mignatti, P.; Pintucci, G.			Thrombin cleaves the high molecular weight forms of basic fibroblast growth factor (FGF-2): a novel mechanism for the control of FGF-2 and thrombin activity	ONCOGENE			English	Article						endothelial cells; inflammation; migration; proliferation; proteolysis; serine proteinases	ACTIVATED RECEPTORS; ENDOTHELIAL-CELLS; EXPRESSION; MIGRATION; TRANSLATION; METHYLATION; TRANSACTIVATION; ANGIOGENESIS; DIVERSITY; ISOFORMS	The fgf-2 gene encodes low molecular weight (LMW, 18 kDa) and high molecular weight (HMW, 22-24 kDa) forms that originate from alternative translation of a single mRNA and exhibit diverse biological functions. HMW fibroblast growth factor-2 (FGF-2) inhibits cell migration and induces cell transformation or growth arrest in a cell type-and dose-dependent fashion. Conversely, LMW FGF-2 upregulates both cell proliferation and migration in most cell types. Although transcriptional and translational regulation of HMW and LMW FGF-2 has been extensively investigated, little is known about post-translational control of their relative expression. Here we report that thrombin, a key coagulation factor and inflammatory mediator, cleaves HMW FGF-2 into an LMW FGF-2-like form that stimulates endothelial cell migration and proliferation. The effect of thrombin on these cell functions requires HMW FGF-2 cleavage. This post-translational control mechanism adds a novel level of complexity to the regulation of FGF-2, and links the activities of thrombin and FGF-2 in patho-physiological processes in which both molecules are expressed.	[Yu, P-J; Ferrari, G.; Pirelli, L.; Galloway, A. C.; Mignatti, P.; Pintucci, G.] NYU, Sch Med, Seymour Cohn Cardiovasc Res Lab, Dept Cardiothorac Surg, New York, NY 10016 USA; [Mignatti, P.] NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA	New York University; New York University	Pintucci, G (corresponding author), NYU, Sch Med, Seymour Cohn Cardiovasc Res Lab, Dept Cardiothorac Surg, 530 1st Ave,NB-15W16, New York, NY 10016 USA.	pintug01@med.nyu.edu	Ferrari, Giovanni/A-3390-2009	Mignatti, Paolo/0000-0002-8157-457X; Galoway, Aubrey/0000-0001-5461-3820; Ferrari, Giovanni/0000-0002-8863-2496	NHLBI NIH HHS [5R01 HL70203-01, R01 HL070203] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070203] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arai T, 2005, J BIOL CHEM, V280, P5145, DOI 10.1074/jbc.M409234200; Balcaitis S, 2003, NEUROREPORT, V14, P2373, DOI 10.1097/00001756-200312190-00017; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BURGESS WH, 1991, CELL REGUL, V2, P87, DOI 10.1091/mbc.2.2.87; Claus P, 2004, NEUROSCI LETT, V360, P117, DOI 10.1016/j.neulet.2004.01.046; Coughlin SR, 2005, J THROMB HAEMOST, V3, P1800, DOI 10.1111/j.1538-7836.2005.01377.x; Counter CM, 1998, ONCOGENE, V16, P1217, DOI 10.1038/sj.onc.1201882; Cucina A, 2002, CELL BIOCHEM FUNCT, V20, P39, DOI 10.1002/cbf.938; DANIEL TO, 1986, J BIOL CHEM, V261, P9579; Ding L, 2002, J BIOL CHEM, V277, P31056, DOI 10.1074/jbc.M203658200; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Ferrari G, 2006, P NATL ACAD SCI USA, V103, P17260, DOI 10.1073/pnas.0605556103; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; HERBERT JM, 1994, BIOCHEM J, V303, P227, DOI 10.1042/bj3030227; Ishibashi T, 2003, ARTERIOSCL THROM VAS, V23, P681, DOI 10.1161/01.ATV.0000065194.00822.C7; Itoh N, 2004, TRENDS GENET, V20, P563, DOI 10.1016/j.tig.2004.08.007; Klein S, 2000, J BIOL CHEM, V275, P3150, DOI 10.1074/jbc.275.5.3150; Klein S, 1996, J BIOL CHEM, V271, P22583, DOI 10.1074/jbc.271.37.22583; LOBB RR, 1988, BIOCHEMISTRY-US, V27, P2572, DOI 10.1021/bi00407a045; Malecki J, 2004, MOL BIOL CELL, V15, P801, DOI 10.1091/mbc.E03-08-0589; Mann KG, 2003, CHEST, V124, p1S, DOI 10.1378/chest.124.3_suppl.1S; MIGNATTI P, 1991, P NATL ACAD SCI USA, V88, P11007, DOI 10.1073/pnas.88.24.11007; O'Brien PJ, 2000, J BIOL CHEM, V275, P13502, DOI 10.1074/jbc.275.18.13502; Ornitz DM, 2001, GENOME BIOL, V2; Papadimitriou E, 1997, AM J PHYSIOL-CELL PH, V272, pC1112, DOI 10.1152/ajpcell.1997.272.4.C1112; Pintucci G, 1996, MOL BIOL CELL, V7, P1249, DOI 10.1091/mbc.7.8.1249; Pintucci G, 2002, FASEB J, V16, P598, DOI 10.1096/fj.01-0815fje; Piotrowicz RS, 1997, J BIOL CHEM, V272, P7042, DOI 10.1074/jbc.272.11.7042; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; Quarto N, 2005, GENE, V356, P49, DOI 10.1016/j.gene.2005.05.014; Rauch BH, 2005, J BIOL CHEM, V280, P17507, DOI 10.1074/jbc.M410848200; Rauch BH, 2004, CIRC RES, V94, P340, DOI 10.1161/01.RES.0000111805.09592.D8; Rickles FR, 2003, CHEST, V124, p58S, DOI 10.1378/chest.124.3_suppl.58S; Sharony R, 2006, AM J PHYSIOL-HEART C, V290, pH1651, DOI 10.1152/ajpheart.00530.2005; Sorensen V, 2006, BIOESSAYS, V28, P504, DOI 10.1002/bies.20405; Taverna S, 2003, J BIOL CHEM, V278, P51911, DOI 10.1074/jbc.M304192200; Touriol C, 2003, BIOL CELL, V95, P169, DOI 10.1016/S0248-4900(03)00033-9; Tsopanoglou NE, 1999, J BIOL CHEM, V274, P23969, DOI 10.1074/jbc.274.34.23969; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Yu PJ, 2007, J CELL BIOCHEM, V100, P1100, DOI 10.1002/jcb.21116	40	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2008	27	18					2594	2601		10.1038/sj.onc.1210899	http://dx.doi.org/10.1038/sj.onc.1210899			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	17968311	Green Accepted			2022-12-17	WOS:000255057000009
J	Falvella, FS; Spinola, M; Pignatiello, C; Noci, S; Conti, B; Pastorino, U; Carbone, A; Dragani, TA				Falvella, F. S.; Spinola, M.; Pignatiello, C.; Noci, S.; Conti, B.; Pastorino, U.; Carbone, A.; Dragani, T. A.			AZGP1 mRNA levels in normal human lung tissue correlate with lung cancer disease status	ONCOGENE			English	Article						genetic susceptibility; complex diseases; gene expression; inherited predisposition; lung neoplasms; microarray	DIFFERENTIAL GENE-EXPRESSION; SEGREGATION ANALYSIS; PROSTATE-CANCER; MICE; PREDISPOSITION; SUSCEPTIBILITY; EPITHELIUM; SMOKING	Evidence in animal models has suggested an association between susceptibility to lung tumorigenesis and geneexpression profiles in normal lung. Here, we compared RNA pools from normal lung tissue of lung adenocarcinoma patients (cases) or non-lung cancer patients (controls) by hybridization of whole-human genome expression arrays. Principal component analysis identified a gene-expression signature of 85 genes that distinguishes cases from controls as well as smokers from nonsmokers. Elevated mRNA levels of one of these genes, AZGP1, were significantly associated with disease status. These results support the hypothesis that differences in the gene-expression levels of the normal tissue may be predictive of genetic predisposition to lung cancer in humans.	[Falvella, F. S.; Spinola, M.; Pignatiello, C.; Noci, S.; Dragani, T. A.] Ist Nazl Tumori, Fdn IRCCS, Dept Expt Oncol & Labs, I-20133 Milan, Italy; [Conti, B.; Pastorino, U.] Ist Nazl Tumori, Fdn IRCCS, Dept Thorac Surg, I-20133 Milan, Italy; [Carbone, A.] Ist Nazl Tumori, Fdn IRCCS, Dept Pathol, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Dragani, TA (corresponding author), Ist Nazl Tumori, Fdn IRCCS, Dept Expt Oncol & Labs, Via G Venezian 1, I-20133 Milan, Italy.	tommaso.dragani@istitutotumori.mi.it	Carbone, Antonino/AAA-2217-2019; Pastorino, Ugo/C-2712-2017; Dragani, Tommaso A./K-4493-2016; Noci, Sara/E-5425-2017	Carbone, Antonino/0000-0003-2211-639X; Pastorino, Ugo/0000-0001-9974-7902; Dragani, Tommaso A./0000-0001-5915-4598; Noci, Sara/0000-0002-6227-3907	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Bailey-Wilson JE, 2004, AM J HUM GENET, V75, P460, DOI 10.1086/423857; Bing C, 2004, P NATL ACAD SCI USA, V101, P2500, DOI 10.1073/pnas.0308647100; CROFTS F, 1994, CARCINOGENESIS, V15, P2961, DOI 10.1093/carcin/15.12.2961; Dragani TA, 2003, CANCER RES, V63, P3011; Falvella FS, 2002, CARCINOGENESIS, V23, P1933, DOI 10.1093/carcin/23.11.1933; Fujiwara K, 2003, CANCER SCI, V94, P672, DOI 10.1111/j.1349-7006.2003.tb01501.x; Gariboldi M, 2003, CARCINOGENESIS, V24, P1819, DOI 10.1093/carcin/bgg133; Harvey BG, 2007, J MOL MED, V85, P39, DOI 10.1007/s00109-006-0103-z; Henshall SM, 2006, J NATL CANCER I, V98, P1420, DOI 10.1093/jnci/djj378; Hoover RN, 2000, NEW ENGL J MED, V343, P135, DOI 10.1056/NEJM200007133430210; Kendziorski C, 2005, P NATL ACAD SCI USA, V102, P4252, DOI 10.1073/pnas.0500607102; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Larsen JE, 2006, CARCINOGENESIS, V27, P525, DOI 10.1093/carcin/bgi227; Riggs PK, 2005, MOL CARCINOGEN, V44, P122, DOI 10.1002/mc.20127; SELLERS TA, 1994, AM J MED GENET, V52, P308, DOI 10.1002/ajmg.1320520311; Spira A, 2004, P NATL ACAD SCI USA, V101, P10143, DOI 10.1073/pnas.0401422101; TADA T, 1991, J HISTOCHEM CYTOCHEM, V39, P1221, DOI 10.1177/39.9.1918940; Thum T, 2006, ENVIRON HEALTH PERSP, V114, P1655, DOI 10.1289/ehp.8861; Wu PF, 2004, EUR J CANCER, V40, P260, DOI 10.1016/j.ejca.2003.08.021	19	15	15	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2008	27	11					1650	1656		10.1038/sj.onc.1210775	http://dx.doi.org/10.1038/sj.onc.1210775			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17724461				2022-12-17	WOS:000253815800018
J	Cano, F; Drynan, LF; Pannell, R; Rabbitts, TH				Cano, F.; Drynan, L. F.; Pannell, R.; Rabbitts, T. H.			Leukaemia lineage specification caused by cell-specific Mll-Enl translocations	ONCOGENE			English	Article						MLL; leukaemia; translocation; translocator; mouse disease models	CHROMOSOMAL TRANSLOCATIONS; CRE-LOXP; GENE; 11Q23; RECOMBINATION	Chromosomal translocations involving the Mixed-Lineage Leukaemia (MLL) gene underlie many human leukaemias and MLL rearrangements are found in both acute myelogenous and acute lymphoblastic leukaemias. To assess the functionally relevant haematopoietic cell contexts for MLL fusions to be tumorigenic, we have generated different lines of mice in which de novo Mll-associated translocations occur. In these models, reciprocal chromosomal translocations occur by means of Cre-loxPmediated recombination (translocator mice) in different cells of the haematopoietic system (namely haematopoietic stem cells, semi-committed progenitors or committed T or B cells). Translocations between Mll and Enl cause myeloid neoplasias, initiating in stem cells or progenitors while no tumours arose when the translocation was restricted to the B-cell compartment. Despite the absence of tumorigenesis, Mll-Enl translocations did occur and Mll-Enl fusion mRNA was expressed in B-cell-restricted translocators. A permissive cellular environment is therefore required for oncogenicity of Mll-associated translocations since the occurrence of Mll-Enl does not promote unrestricted proliferation in all haematopoietic cellular contexts, consistent with a specific instructive role of the MLL-fusion proteins in leukaemogenesis.	[Rabbitts, T. H.] St James Univ Hosp, Leeds Inst Mol Med, Sect Expt Therapeut, Leeds LS9 7TF, W Yorkshire, England; [Cano, F.; Drynan, L. F.; Pannell, R.; Rabbitts, T. H.] MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Saint James's University Hospital; University of Leeds; MRC Laboratory Molecular Biology	Rabbitts, TH (corresponding author), St James Univ Hosp, Leeds Inst Mol Med, Sect Expt Therapeut, Wellcome Trust Brenner Bldg, Leeds LS9 7TF, W Yorkshire, England.	thr@leeds.ac.uk	Drynan, Lesley/V-2984-2019; Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609	MRC [G0600914] Funding Source: UKRI; Medical Research Council [MC_U105178807, G0600914] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Bloomfield CD, 2002, GENE CHROMOSOME CANC, V33, P362, DOI 10.1002/gcc.10046; Collins EC, 2000, EMBO REP, V1, P127, DOI 10.1093/embo-reports/kvd021; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Daser A, 2004, GENE DEV, V18, P965, DOI 10.1101/gad.1195504; Drynan LF, 2005, EMBO J, V24, P3136, DOI 10.1038/sj.emboj.7600760; Felix CA, 2001, MED PEDIATR ONCOL, V36, P525, DOI 10.1002/mpo.1125; Forster A, 2003, CANCER CELL, V3, P449, DOI 10.1016/S1535-6108(03)00106-5; Huret JL, 2001, LEUKEMIA, V15, P987, DOI 10.1038/sj.leu.2402135; Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238; McCormack MP, 2003, MOL CELL BIOL, V23, P9003, DOI 10.1128/MCB.23.24.9003-9013.2003; Metzler M, 2006, ONCOGENE, V25, P3093, DOI 10.1038/sj.onc.1209636; Milne TA, 2005, CANCER RES, V65, P11367, DOI 10.1158/0008-5472.CAN-05-1041; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Pui CH, 2007, LEUKEMIA, V21, P593, DOI 10.1038/sj.leu.2404598; Pui CH, 2002, LANCET, V359, P1909, DOI 10.1016/S0140-6736(02)08782-2; Pui Ching-Hon, 2002, Rev Clin Exp Hematol, V6, P161, DOI 10.1046/j.1468-0734.2002.00067.x; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; Rickert RC, 1997, NUCLEIC ACIDS RES, V25, P1317, DOI 10.1093/nar/25.6.1317; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4	21	15	16	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2008	27	13					1945	1950		10.1038/sj.onc.1210818	http://dx.doi.org/10.1038/sj.onc.1210818			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17906700				2022-12-17	WOS:000254150600014
J	Lee, OH; Xu, J; Fueyo, J; Alonso, MM; Liu, D; Martin, V; Jiang, H; Piao, Y; Liu, TJ; Gomez-Manzano, C				Lee, O-H; Xu, J.; Fueyo, J.; Alonso, M. M.; Liu, D.; Martin, V.; Jiang, H.; Piao, Y.; Liu, T. J.; Gomez-Manzano, C.			Angiopoietin-2 decreases vascular endothelial growth factor expression by modulating HIF-1 alpha levels in gliomas	ONCOGENE			English	Article						Tie2; angiopoietin-2; HIF-1 alpha; VEGF; gliomas	RECEPTOR TYROSINE KINASE; VESSEL FORMATION; ANGIOGENESIS; TIE2; INTEGRIN; CANCER; CELLS; ADHESION; MATRIX; RAT	Angiogenesis is thought to depend on a perfectly coordinated balance between endogenous-positive and negative regulatory factors. Of these factors, the vascular endothelial growth factor (VEGF) and angiopoietins (Angs) seem to play an essential role. Recently, we reported the expression of the Ang-natural receptor, Tie2, in neoplastic astrocytic cells within gliomas. Because of the VEGF/Ang2 functional partnership together with the presence of Tie2 in gliomas, we hypothesized a role of Ang2 on the modulation of VEGF levels in these tumors. We examined the effect of Ang2 on VEGF expression in a panel of glioma cells, which showed that Ang2 inhibited VEGF expression at both mRNA and protein levels in Tie2-expressing cells, but not in Tie2-negative cells. VEGF promoter analysis showed that Ang2 regulated VEGF expression at the transcriptional level in relation to a decrease in HIF-1 alpha expression and HIF-DNA-binding activity. Tie2 silencing by siRNA rescued the Ang2-mediated downmodulation of VEGF, suggesting an essential role for Tie2 in this regulatory loop. To our knowledge, this is the first report on the role of Ang2/Tie2 in the regulation of HIF-1 alpha/VEGF expression, providing additional evidence of the intrinsic coordination that occurs among these factors during angiogenesis.	[Lee, O-H; Xu, J.; Fueyo, J.; Alonso, M. M.; Liu, D.; Martin, V.; Jiang, H.; Piao, Y.; Liu, T. J.; Gomez-Manzano, C.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Neurooncol, Unit 1002, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center	Gomez-Manzano, C (corresponding author), Univ Texas Houston, MD Anderson Canc Ctr, Dept Neurooncol, Unit 1002, 1515 Holcombe Blvd, Houston, TX 77030 USA.	cmanzano@mdanderson.org	MARTIN, VANESA/A-7312-2012; Alonso, Marta M/AAI-9457-2020	MARTIN, VANESA/0000-0001-6923-2529; Alonso, Marta M/0000-0002-7520-7351; Gomez-Manzano, Candelaria/0000-0002-1259-2133; Fueyo, Juan/0000-0001-6941-2335	NATIONAL CANCER INSTITUTE [P30CA016672, R01CA083127] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA83127, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beck H, 2000, AM J PATHOL, V157, P1473, DOI 10.1016/S0002-9440(10)64786-4; Cascone I, 2005, J CELL BIOL, V170, P993, DOI 10.1083/jcb.200507082; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Goede V, 1998, LAB INVEST, V78, P1385; Gomez-Manzano C, 2003, ANN NEUROL, V53, P109, DOI 10.1002/ana.10396; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Hu B, 2006, CANCER RES, V66, P775, DOI 10.1158/0008-5472.CAN-05-1149; Kukk E, 1997, BRIT J HAEMATOL, V98, P195, DOI 10.1046/j.1365-2141.1997.1732989.x; Lee OH, 2006, MOL CANCER RES, V4, P915, DOI 10.1158/1541-7786.MCR-06-0184; Lee OH, 2006, NEOPLASIA, V8, P419, DOI 10.1593/neo.06109; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loureiro RMB, 2005, CYTOKINE GROWTH F R, V16, P77, DOI 10.1016/j.cytogfr.2005.01.005; Machein MR, 2004, AM J PATHOL, V165, P1557, DOI 10.1016/S0002-9440(10)63413-X; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Shirakawa K, 2002, INT J CANCER, V99, P344, DOI 10.1002/ijc.10336; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Wang J, 2005, BIOCHEM BIOPH RES CO, V337, P386, DOI 10.1016/j.bbrc.2005.09.051; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	18	15	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2008	27	9					1310	1314		10.1038/sj.onc.1210731	http://dx.doi.org/10.1038/sj.onc.1210731			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17704802				2022-12-17	WOS:000253407000014
J	Kwong, LN; Weiss, KR; Haigis, KM; Dove, WF				Kwong, L. N.; Weiss, K. R.; Haigis, K. M.; Dove, W. F.			Atm is a negative regulator of intestinal neoplasia	ONCOGENE			English	Article						gastrointestinal cancer; Atm; Apc; Blm; Lig4; modifier	ATAXIA-TELANGIECTASIA; CANCER PREDISPOSITION; GENOMIC INSTABILITY; TUMOR-FORMATION; TUMORIGENESIS; MOUSE; MICE; APC; PROGRESSION; ADENOMAS	The ataxia telangiectasia-mutated (ATM) gene has been implicated as an early barrier to the growth and progression of incipient solid tumors. Here, we show that germ-line nullizygosity for the mouse Atm gene significantly increases the proliferative index, net growth rate and multiplicity of intestinal adenomas in two distinct models of familial colon cancer: Apc(Min/+) and Apc(1638N/+). These effects of Atm deficiency are quantitatively different from deficiency for either of the genomic stability genes Bloom's syndrome helicase or DNA ligase 4, and the effect of Atm loss on tumor multiplicity is largely independent of the effect of ionizing radiation. Furthermore, the loss of heterozygosity rates at the adenomatous polyposis coli (Apc) locus are unaffected by Atm loss. Taken together, these data implicate the Atm gene product as a barrier to dysplastic growth in the early stages of intestinal tumor progression, independent of its effects on genomic stability.	[Kwong, L. N.; Weiss, K. R.; Haigis, K. M.; Dove, W. F.] Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Dove, WF (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	dove@oncology.wisc.edu			NCI NIH HHS [T32 CA009135, R37CA63677, CA009135, R37 CA063677, R37 CA063677-14] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA063677, T32CA009135] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amos-Landgraf JM, 2007, P NATL ACAD SCI USA, V104, P4036, DOI 10.1073/pnas.0611690104; Bai AHC, 2004, INT J CANCER, V112, P846, DOI 10.1002/ijc.20485; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Frank KM, 2000, MOL CELL, V5, P993, DOI 10.1016/S1097-2765(00)80264-6; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Goss KH, 2002, SCIENCE, V297, P2051, DOI 10.1126/science.1074340; Grabsch H, 2006, CLIN CANCER RES, V12, P1494, DOI 10.1158/1078-0432.CCR-05-2105; Haigis KM, 2002, P NATL ACAD SCI USA, V99, P8927, DOI 10.1073/pnas.132275099; Haigis KM, 2004, P NATL ACAD SCI USA, V101, P9769, DOI 10.1073/pnas.0403338101; Halberg RB, 2000, P NATL ACAD SCI USA, V97, P3461, DOI 10.1073/pnas.050585597; Hill R, 2005, CELL, V123, P1001, DOI 10.1016/j.cell.2005.09.030; Janssen KP, 2006, GASTROENTEROLOGY, V131, P1096, DOI 10.1053/j.gastro.2006.08.011; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; Luongo C, 1996, GENE CHROMOSOME CANC, V17, P194, DOI 10.1002/1098-2264(199611)17:3<194::AID-GCC2870170302>3.0.CO;2-E; Mann MB, 2005, HUM MOL GENET, V14, P813, DOI 10.1093/hmg/ddi075; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Rao CV, 2005, P NATL ACAD SCI USA, V102, P4365, DOI 10.1073/pnas.0407822102; Renwick A, 2006, NAT GENET, V38, P873, DOI 10.1038/ng1837; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Sharpless NE, 2001, MOL CELL, V8, P1187, DOI 10.1016/S1097-2765(01)00425-7; Sugai T, 2001, ONCOGENE, V20, P6095, DOI 10.1038/sj.onc.1204731; Taketo MM, 2006, CANCER SCI, V97, P355, DOI 10.1111/j.1349-7006.2006.00190.x; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397	26	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2008	27	7					1013	1018		10.1038/sj.onc.1210708	http://dx.doi.org/10.1038/sj.onc.1210708			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17700532	Green Accepted			2022-12-17	WOS:000252946300013
J	To-Ho, KW; Cheung, HW; Ling, MT; Wong, YC; Wang, X				To-Ho, K. W.; Cheung, H. W.; Ling, M-T; Wong, Y. C.; Wang, X.			MAD2 Delta C induces aneuploidy and promotes anchorage-independent growth in human prostate epithelial cells	ONCOGENE			English	Article						MAD2; mitotic; prostate epithelial cells; transformation	COMPARATIVE GENOMIC HYBRIDIZATION; NASOPHARYNGEAL CARCINOMA-CELLS; MITOTIC CHECKPOINT; CANCER-CELLS; CHROMOSOME MISSEGREGATION; PREMATURE ANAPHASE; MAMMALIAN-CELLS; SHORT TELOMERES; RAS MUTATION; MAD2 PROTEIN	The mitotic arrest deficient 2 (MAD2) is suggested to play a key role in a functional mitotic checkpoint because of its inhibitory effect on anaphase-promoting complex/cyclosome (APC/C) during mitosis. The binding of MAD2 to mitotic checkpoint regulators MAD1 and Cdc20 is thought to be crucial for its function and loss of which leads to functional inactivation of the MAD2 protein. However, little is known about the biological significance of this MAD2 mutant in human cells. In this study, we stably transfected a C-terminal-deleted MAD2 gene (MAD2 Delta C) into a human prostate epithelial cell line, Hpr-1 and studied its effect on chromosomal instability, cell proliferation, mitotic checkpoint control and soft agar colony-forming ability. We found that MAD2DC was able to induce aneuploidy through promoting chromosomal duplication, which was a result of an impaired mitotic checkpoint and cytokinesis, suggesting a crucial role of MAD2-mediated mitotic checkpoint in chromosome stability in human cells. In addition, the MAD2 Delta C-transfected cells displayed anchorage- independent growth in soft agar after challenged by 7,12-dimethylbenz[A]anthracene (DMBA), demonstrating a cancer-promoting effect of a defective mitotic checkpoint in human cells. Furthermore, the DMBA-induced transformation was accompanied by a complete loss of DNA damage-induced p53 response and activation of the MAPK pathway in MAD2 Delta C cells. These results indicate that a defective mitotic checkpoint alone is not a direct cause of tumorigenesis, but it may predispose human cells to carcinogen-induced malignant transformation. The evidence presented here provides a link between MAD2 inactivation and malignant transformation of epithelial cells.	[To-Ho, K. W.; Cheung, H. W.; Ling, M-T; Wong, Y. C.; Wang, X.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Wang, X (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, 1-F Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	xhwang@hkucc.hku.hk						Babu JR, 2003, J CELL BIOL, V160, P341, DOI 10.1083/jcb.200211048; Baker DJ, 2004, NAT GENET, V36, P744, DOI 10.1038/ng1382; Bernardino J, 1997, CANCER GENET CYTOGEN, V96, P123, DOI 10.1016/S0165-4608(96)00258-0; Burds AA, 2005, P NATL ACAD SCI USA, V102, P11296, DOI 10.1073/pnas.0505053102; BUTZ K, 1995, ONCOGENE, V10, P927; Cheung BW, 2005, CANCER RES, V65, P1450, DOI 10.1158/0008-5472.CAN-04-0567; Cho ES, 2002, YONSEI MED J, V43, P145, DOI 10.3349/ymj.2002.43.2.145; Choo CK, 1999, PROSTATE, V40, P150, DOI 10.1002/(SICI)1097-0045(19990801)40:3<150::AID-PROS2>3.0.CO;2-7; Dai W, 2004, CANCER RES, V64, P440, DOI 10.1158/0008-5472.CAN-03-3119; DE AA, 2005, CURR BIOL, V15, P214; Deliveliotis C, 2003, WORLD J UROL, V21, P171, DOI 10.1007/s00345-003-0345-0; Deng W, 2004, ONCOGENE, V23, P9090, DOI 10.1038/sj.onc.1208119; Deng W, 2003, GENE CHROMOSOME CANC, V37, P92, DOI 10.1002/gcc.10190; Di Cristofaro J, 2006, HUM PATHOL, V37, P824, DOI 10.1016/j.humpath.2006.01.030; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; DOHNER H, 1992, GENE CHROMOSOME CANC, V5, P392, DOI 10.1002/gcc.2870050415; Eid MA, 1998, CANCER RES, V58, P2461; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Fung MKL, 2006, BRIT J CANCER, V95, P475, DOI 10.1038/sj.bjc.6603284; Gioeli D, 1999, CANCER RES, V59, P279; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; Haapala K, 2001, CANCER GENET CYTOGEN, V131, P74, DOI 10.1016/S0165-4608(01)00491-5; Hanks S, 2004, NAT GENET, V36, P1159, DOI 10.1038/ng1449; JERRY DJ, 1994, MOL CARCINOGEN, V9, P175, DOI 10.1002/mc.2940090309; Johannsdottir HK, 2004, ANTICANCER RES, V24, P2681; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Kops GJPL, 2004, P NATL ACAD SCI USA, V101, P8699, DOI 10.1073/pnas.0401142101; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Krishnan R, 1998, GENOMICS, V49, P475, DOI 10.1006/geno.1998.5233; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Luo XL, 2004, NAT STRUCT MOL BIOL, V11, P338, DOI 10.1038/nsmb748; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Millband DN, 2002, MOL CELL BIOL, V22, P2728, DOI 10.1128/MCB.22.8.2728-2742.2002; Nasmyth K, 2005, CELL, V120, P739, DOI 10.1016/j.cell.2005.03.006; OSAKA M, 1995, CANCER LETT, V91, P25, DOI 10.1016/0304-3835(94)03714-T; Ouyang XS, 2001, BBA-MOL CELL RES, V1541, P212, DOI 10.1016/S0167-4889(01)00157-4; Phillips JL, 2001, CANCER RES, V61, P8143; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Rashid A, 1999, BRIT J CANCER, V80, P59, DOI 10.1038/sj.bjc.6690321; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Sironi L, 2001, EMBO J, V20, P6371, DOI 10.1093/emboj/20.22.6371; Skibbens RV, 1998, ANNU REV GENET, V32, P307, DOI 10.1146/annurev.genet.32.1.307; Stewart SL, 2004, CANCER RES, V64, P8177, DOI 10.1158/0008-5472.CAN-04-1702; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Takahashi N, 1999, SOFTWARE STUDIES, V2, P55; Wang XH, 1998, CANCER RES, V58, P5019; Wang XH, 2002, CANCER RES, V62, P1662; Wang XH, 2000, CARCINOGENESIS, V21, P2293, DOI 10.1093/carcin/21.12.2293; Webb HD, 1996, CANCER GENET CYTOGEN, V88, P126, DOI 10.1016/0165-4608(95)00305-3; Zhang YK, 2001, MOL CELL BIOL, V21, P5190, DOI 10.1128/MCB.21.15.5190-5199.2001; Zhao YF, 2006, CARCINOGENESIS, V27, P1692, DOI 10.1093/carcin/bgl037; Zitzelsberger H, 1996, CANCER GENET CYTOGEN, V90, P37, DOI 10.1016/0165-4608(96)00065-9	54	15	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					347	357		10.1038/sj.onc.1210633	http://dx.doi.org/10.1038/sj.onc.1210633			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17621272				2022-12-17	WOS:000252256000011
J	Budhram-Mahadeo, V; Irshad, S; Bowen, S; Lee, S; Samady, L; Tonini, G; Latchman, D				Budhram-Mahadeo, Vs; Irshad, S.; Bowen, S.; Lee, Sa; Samady, L.; Tonini, Gp; Latchman, Ds			Proliferation-associated Brn-3b transcription factor can activate cyclin D1 expression in neuroblastoma and breast cancer cells	ONCOGENE			English	Article						breast cancer; neuroblastoma; cyclin D1; Brn-3b; gene expression	RETINAL GANGLION-CELLS; NEURONAL CELLS; ESTROGEN-RECEPTOR; GENE-EXPRESSION; GROWTH; DIFFERENTIATION; PROMOTER; SERUM; MICE	Brn-3b transcription factor enhances proliferation of neuroblastoma (NB) and breast cancer cell lines in vitro and increases the rate and size of in vivo tumour growth, whereas reducing Brn-3b slows growth, both in vitro and in vivo. Brn-3b is elevated in > 65% of breast cancer biopsies, and here we demonstrate that Brn-3b is also elevated in NB tumours. We show a significant correlation between Brn-3b and cyclin D1 (CD1) in breast cancers and NB tumours and cell lines. Brn-3b directly transactivates the CD1 promoter in co-transfection experiments, whereas electrophoretic mobility shift assay and chromatin immunoprecipitation assays demonstrate that Brn-3b protein binds to an octamer sequence located in the proximal CD1 promoter. Site-directed mutagenesis of this sequence resulted in loss of transactivation of the CD1 promoter by Brn-3b. Thus, Brn-3b may act to alter growth properties of breast cancer and NB cells by enhancing CD1 expression in these cells.	[Budhram-Mahadeo, Vs; Irshad, S.; Bowen, S.; Lee, Sa; Samady, L.; Latchman, Ds] UCL, Med Mol Biol Unit, Inst Child Hlth, London WC1N 1EH, England; [Tonini, Gp] Natl Inst Canc Res IST, Genoa, Italy	University of London; University College London; University of Genoa; IRCCS AOU San Martino IST	Budhram-Mahadeo, V (corresponding author), UCL, Med Mol Biol Unit, Inst Child Hlth, 30 Guilford St, London WC1N 1EH, England.	v.mahadeo@ich.ucl.ac.uk						ARNOLD A, 1991, COLD SPRING HARB SYM, V56, P93; Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; Bienvenu F, 2001, J BIOL CHEM, V276, P16840, DOI 10.1074/jbc.M100795200; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Budhram-Mahadeo V, 1999, ONCOGENE, V18, P6684, DOI 10.1038/sj.onc.1203072; Budhram-Mahadeo V, 2001, INT J BIOCHEM CELL B, V33, P1027, DOI 10.1016/S1357-2725(01)00069-3; Budhram-Mahadeo VS, 2006, EXPERT OPIN THER TAR, V10, P15, DOI 10.1517/14728222.10.1.15; BUDHRAMMAHADEO V, 1994, NUCLEIC ACIDS RES, V22, P3092, DOI 10.1093/nar/22.15.3092; BUDHRAMMAHADEO V, 1995, NEUROSCI LETT, V185, P48, DOI 10.1016/0304-3940(94)11222-5; Dennis JH, 2001, ONCOGENE, V20, P4961, DOI 10.1038/sj.onc.1204491; Erkman L, 1996, NATURE, V381, P603, DOI 10.1038/381603a0; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Gan L, 1996, P NATL ACAD SCI USA, V93, P3920, DOI 10.1073/pnas.93.9.3920; Guo Y, 2005, ONCOGENE, V24, P2599, DOI 10.1038/sj.onc.1208326; Irshad S, 2004, J BIOL CHEM, V279, P21617, DOI 10.1074/jbc.M312506200; Israels E D, 2000, Oncologist, V5, P510, DOI 10.1634/theoncologist.5-6-510; Knudsen KE, 1999, CANCER RES, V59, P2297; Latchman DS, 1998, INT J BIOCHEM CELL B, V30, P1153, DOI 10.1016/S1357-2725(98)00090-9; LATCHMAN DS, 1998, GENE THER MOL BIOL, V2, P95; Lee SA, 2005, CANCER RES, V65, P3072, DOI 10.1158/0008-5472.CAN-04-2865; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; Molenaar JJ, 2003, GENE CHROMOSOME CANC, V36, P242, DOI 10.1002/gcc.10166; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Mu XQ, 2001, NUCLEIC ACIDS RES, V29, P4983, DOI 10.1093/nar/29.24.4983; Redeuilh G, 2002, ONCOGENE, V21, P5773, DOI 10.1038/sj.onc.1205753; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Samady L, 2004, CANCER BIOL THER, V3, P317, DOI 10.4161/cbt.3.3.698; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Smith MD, 1996, INT J CANCER, V67, P653; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xiang MQ, 1998, DEV BIOL, V197, P155, DOI 10.1006/dbio.1998.8868; XIANG MQ, 1993, NEURON, V11, P689, DOI 10.1016/0896-6273(93)90079-7; Xiang MQ, 1996, VISUAL NEUROSCI, V13, P955, DOI 10.1017/S0952523800009184; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	38	15	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2008	27	1					145	154		10.1038/sj.onc.1210621	http://dx.doi.org/10.1038/sj.onc.1210621			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17637757				2022-12-17	WOS:000252118700015
J	Karlsson, J; Pietras, A; Beckman, S; Pettersson, HM; Larsson, C; Pahlman, S				Karlsson, J.; Pietras, A.; Beckman, S.; Pettersson, H. M.; Larsson, C.; Pahlman, S.			Arsenic trioxide-induced neuroblastoma cell death is accompanied by proteolytic activation of nuclear Bax	ONCOGENE			English	Article						arsenic trioxide; neuroblastoma; Bax; calpain; nuclear localization	ACUTE PROMYELOCYTIC LEUKEMIA; INDUCED APOPTOSIS; ENDOPLASMIC-RETICULUM; POLY(ADP-RIBOSE) POLYMERASE; CALPAIN ACTIVATION; CLEAVAGE; PROTEIN; BCL-2; LINES; P53	Arsenic trioxide (As2O3) is toxic to multidrug-resistant neuroblastoma cells in vivo and in vitro. In neuroblastoma, As2O3 does not exert its cell death-promoting effects via a classical apoptotic pathway. A death mechanism involving proteolytic cleavage of Bax to a p18 form seems to be of importance, because inhibition of Bax cleavage coincides with diminished cell death. As existing models of cell death implicate Bax in the intrinsic apoptotic pathway, triggering death after Bax translocation to the mitochondria, we investigated the cellular localization of p18 Bax by subcellular fractionation. After As2O3 treatment, p18 Bax was only present in nuclei-enriched, mitochondria-depleted fractions. Cytoplasmic p21 Bax levels decreased, whereas total (p21 and p18) nuclear Bax increased. Overexpressed p21 Bax localized to the cytoplasm and nuclei, whereas overexpressed p18 Bax localized to extranuclear structures only. The inability of overexpressed p18 Bax to locate to the nucleus, and the As2O3-induced reduction of p21 Bax in the cytosol, suggest an As2O3-induced mechanism where p18 Bax gets cleaved and 'trapped' in the nucleus. This model is strengthened by the observation that calpain, the protease responsible for p18 Bax generation, is present in the nuclei, and that nuclear calpain is induced by increasing As2O3 and Ca-2(+) levels.	Lund Univ, Univ Hosp MAS, Dept Lab Med, Div Mol Med, SE-20502 Malmo, Sweden	Lund University; Skane University Hospital	Pahlman, S (corresponding author), Lund Univ, Univ Hosp MAS, Dept Lab Med, Div Mol Med, SE-20502 Malmo, Sweden.	sven.pahlman@med.lu.se		Pietras, Alexander/0000-0002-5783-9347; Karlsson, Jenny/0000-0001-7681-0059				Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Cai X, 2000, LEUKEMIA, V14, P262, DOI 10.1038/sj.leu.2401650; Cao XF, 2003, BLOOD, V102, P2605, DOI 10.1182/blood-2003-01-0211; Cartron PF, 2004, J BIOL CHEM, V279, P11503, DOI 10.1074/jbc.M311922200; Cartron PF, 2003, J BIOL CHEM, V278, P11633, DOI 10.1074/jbc.M208955200; Choi WS, 2001, J NEUROCHEM, V77, P1531, DOI 10.1046/j.1471-4159.2001.00368.x; Cohen MH, 2001, ONCOLOGIST, V6, P4, DOI 10.1634/theoncologist.6-1-4; Feldstein AE, 2004, HEPATOLOGY, V40, P185, DOI 10.1002/hep.20283; Friedrich P, 2004, BIOCHEM BIOPH RES CO, V323, P1131, DOI 10.1016/j.bbrc.2004.08.194; Gao G, 2000, J CELL BIOCHEM, V80, P53; Gobeil S, 2001, CELL DEATH DIFFER, V8, P588, DOI 10.1038/sj.cdd.4400851; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Ho YS, 1999, BIOCHEM PHARMACOL, V57, P143, DOI 10.1016/S0006-2952(98)00272-X; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Karlsson J, 2005, MOL CANCER THER, V4, P1128, DOI 10.1158/1535-7163.MCT-05-0047; Karlsson J, 2004, CLIN CANCER RES, V10, P3179, DOI 10.1158/1078-0432.CCR-03-0309; Keshelava N, 2001, CANCER RES, V61, P6185; Keshelava N, 1998, CANCER RES, V58, P5396; Mandal M, 1998, ONCOGENE, V17, P999, DOI 10.1038/sj.onc.1202020; Mattaj IW, 2004, NAT REV MOL CELL BIO, V5, P65, DOI 10.1038/nrm1263; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Miller WH, 2002, CANCER RES, V62, P3893; Mishra S, 2005, TRENDS MOL MED, V11, P192, DOI 10.1016/j.molmed.2005.02.004; Niu C, 1999, BLOOD, V94, P3315, DOI 10.1182/blood.V94.10.3315.422k16_3315_3324; Oh SH, 2004, BIOCHEM PHARMACOL, V68, P1845, DOI 10.1016/j.bcp.2004.06.021; Ora I, 2000, BIOCHEM BIOPH RES CO, V277, P179, DOI 10.1006/bbrc.2000.3651; Pearson ADJ, 2000, NEUROBLASTOMA, P551; Philip T, 1997, EUR J CANCER, V33, P2130, DOI 10.1016/S0959-8049(97)00324-9; Poot M, 1997, CYTOMETRY, V27, P358, DOI 10.1002/(SICI)1097-0320(19970401)27:4<358::AID-CYTO7>3.0.CO;2-8; Raffo AJ, 2000, ONCOGENE, V19, P6216, DOI 10.1038/sj.onc.1203995; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shah GM, 1996, BIOCHEM BIOPH RES CO, V229, P838, DOI 10.1006/bbrc.1996.1889; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Toyota H, 2003, CANCER LETT, V189, P221, DOI 10.1016/S0304-3835(02)00552-9; Tweddle DA, 2001, CANCER RES, V61, P8; Vandesompele J, 2002, ANAL BIOCHEM, V303, P95, DOI 10.1006/abio.2001.5564; Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944; Wood DE, 2000, EXP CELL RES, V256, P375, DOI 10.1006/excr.2000.4859; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Zhang TD, 2001, ONCOGENE, V20, P7146, DOI 10.1038/sj.onc.1204762	43	15	17	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2007	26	42					6150	6159		10.1038/sj.onc.1210439	http://dx.doi.org/10.1038/sj.onc.1210439			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17404572				2022-12-17	WOS:000249401300005
J	Buchsbaum, S; Morris, C; Bochard, V; Jalinot, P				Buchsbaum, S.; Morris, C.; Bochard, V.; Jalinot, P.			Human INT6 interacts with MCM7 and regulates its stability during Sphase of the cell cycle	ONCOGENE			English	Article						INT6; MCM7; polyubiquitylation; protein degradation; DNA replication	MAMMARY-TUMOR VIRUS; DNA HELICASE ACTIVITY; EUKARYOTIC TRANSLATION INITIATION-FACTOR-3; FISSION YEAST HOMOLOG; COP9 SIGNALOSOME; NUCLEAR-BODIES; 26S PROTEASOME; HUMAN CLASPIN; SUBUNIT; PROTEIN	The mouse int6 gene is a frequent integration site of the mouse mammary tumor virus and INT6 silencing by RNA interference in HeLa cells causes an increased number of cells in the G2/M phases of the cell cycle, along with mitotic defects. In this report, we investigated the functional significance of the interaction between INT6 and MCM7, which was observed in a two-hybrid screen performed with INT6 as bait. It was found that proteasome inhibition strengthens interaction between both proteins and that INT6 stabilizes MCM7. Removal of MCM7 from chromatin as replication proceeds was accelerated in INT6-silenced cells and reduced amounts of protein were transiently observed, followed by a correction resulting from stimulation of mcm7 gene expression. Synchronized cells depleted for either INT6 or MCM7 display a reduction in thymidine incorporation and a reinforced association of RPA and claspin with chromatin. These data show that INT6 stabilizes chromatin-bound MCM7 and that alteration of this effect is associated with replication deficency.	Ecole Normale Super Lyon, CNRS, Lab Biol Mol Cellule, UMR 5161,IFR 128 Biosci Lyon Gerland, F-69364 Lyon 07, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet	Jalinot, P (corresponding author), Ecole Normale Super Lyon, CNRS, Lab Biol Mol Cellule, UMR 5161,IFR 128 Biosci Lyon Gerland, 46 Allee Italie, F-69364 Lyon 07, France.	pjalinot@ens-lyon.fr	Morris, Christelle/M-8168-2014	Morris, Christelle/0000-0003-1575-4609				Akiyoshi Y, 2001, J BIOL CHEM, V276, P10056, DOI 10.1074/jbc.M010188200; Alves KH, 2002, FEBS LETT, V527, P15, DOI 10.1016/S0014-5793(02)03147-2; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Bandyopadhyay A, 2000, MOL BIOL CELL, V11, P4005, DOI 10.1091/mbc.11.11.4005; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Burks EA, 2001, J BIOL CHEM, V276, P2122, DOI 10.1074/jbc.M007236200; Buttitta F, 2005, CLIN CANCER RES, V11, P3198, DOI 10.1158/1078-0432.CCR-04-2308; Cook JG, 2004, J BIOL CHEM, V279, P9625, DOI 10.1074/jbc.M311933200; Crane R, 2000, MOL BIOL CELL, V11, P3993, DOI 10.1091/mbc.11.11.3993; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fitch MJ, 2003, J BIOL CHEM, V278, P25408, DOI 10.1074/jbc.M300699200; Fujita M, 1996, J BIOL CHEM, V271, P4349; Gillespie PJ, 2001, BMC BIOCHEM, V2, DOI 10.1186/1472-2091-2-15; Guo JJ, 2000, J VIROL, V74, P1892, DOI 10.1128/JVI.74.4.1892-1899.2000; Harlow E., 1988, ANTIBODIES LAB MANUA, P447; Holthoff HP, 1998, J BIOL CHEM, V273, P7320, DOI 10.1074/jbc.273.13.7320; Hwang GW, 2005, MOL PHARMACOL, V68, P1074, DOI 10.1124/mol.105.013516; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; KIMURA H, 1995, NUCLEIC ACIDS RES, V23, P2097, DOI 10.1093/nar/23.12.2097; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Kuo ML, 1997, INT J ONCOL, V10, P515; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; Maiorano D, 2005, CELL, V120, P315, DOI 10.1016/j.cell.2004.12.010; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Mayeur GL, 2002, FEBS LETT, V514, P49, DOI 10.1016/S0014-5793(02)02307-4; Morris C, 2005, ONCOGENE, V24, P1203, DOI 10.1038/sj.onc.1208268; Morris-Desbois C, 1999, J CELL SCI, V112, P3331; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Rasmussen SB, 2001, ONCOGENE, V20, P5291, DOI 10.1038/sj.onc.1204624; Sar F, 2004, J BIOL CHEM, V279, P39289, DOI 10.1074/jbc.M405793200; Wang Y, 2000, FEBS LETT, V484, P17, DOI 10.1016/S0014-5793(00)02117-7; Yahalom A, 2001, J BIOL CHEM, V276, P334, DOI 10.1074/jbc.M006721200; Yanagi K, 2002, J BIOL CHEM, V277, P40871, DOI 10.1074/jbc.M206202200; Yen HCS, 2003, CELL, V112, P207, DOI 10.1016/S0092-8674(03)00043-6; Yen HCS, 2000, P NATL ACAD SCI USA, V97, P14370, DOI 10.1073/pnas.97.26.14370; You ZY, 2002, J BIOL CHEM, V277, P42471, DOI 10.1074/jbc.M205769200; Zhang X, 2004, J BIOL CHEM, V279, P25122, DOI 10.1074/jbc.M403287200; Zhou CS, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-14; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	41	15	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2007	26	35					5132	5144		10.1038/sj.onc.1210314	http://dx.doi.org/10.1038/sj.onc.1210314			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17310990				2022-12-17	WOS:000248487400012
J	Appierto, V; Villani, MG; Cavadini, E; Gariboldi, M; De Cecco, L; Pierotti, MA; Lambert, JR; Reid, J; Tiberio, P; Colombo, N; Formelli, F				Appierto, V.; Villani, M. G.; Cavadini, E.; Gariboldi, M.; De Cecco, L.; Pierotti, M. A.; Lambert, J. R.; Reid, J.; Tiberio, P.; Colombo, N.; Formelli, F.			Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cells	ONCOGENE			English	Article						4-HPR; retinoids; PLAB; ovarian cancer; cDNA microarray	LUNG-CARCINOMA CELLS; DRUG-ACTIVATED GENE; TUMOR AGGRESSIVENESS; RANDOMIZED-TRIAL; INDUCTION; P53; N-(4-HYDROXYPHENYL)RETINAMIDE; LINES; 4-OXO-FENRETINIDE; ASSOCIATION	Fenretinide ( 4-HPR) is a synthetic retinoid with antitumor activity, which induces apoptosis in cancer cell lines of different histotypes. To identify genes contributing to its apoptotic activity in ovarian cancer cells, we monitored, by cDNA arrays, gene expression changes after 4-HPR exposure in A2780, a human ovarian carcinoma cell line sensitive to the retinoid. Among the differentially expressed transcripts, PLAcental Bone morphogenetic protein ( PLAB), a proapoptotic gene, was the most highly induced. In a panel of ovarian carcinoma cell lines with different 4-HPR sensitivities, PLAB upregulation was associated with cellular response to 4-HPR, its overexpression increased basal apoptosis and its silencing by small interfering RNA decreased the ability of 4-HPR to induce apoptosis. PLAB induction by 4-HPR was p53- and EGR-1 independent and was regulated, at least in part, by increased stability of PLAB mRNA. PLAB up-modulation by 4-HPR also occurred in vivo: in ascitic cells collected from patients with ovarian cancer before and after 4-HPR treatment, PLAB was upmodulated in 2/4 patients. Our results in certain ovarian cancer cell lines indicate a role for PLAB as a mediator of 4-HPR-induced apoptosis. The correlation of increased PLAB in vivo with antitumor activity remains to be established.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Fdn Ist FIRC Oncol Mol, Mol Canc Genet Grp, Milan, Italy; Univ Colorado, Dept Pathol, Denver, CO 80202 USA; Hlth Sci Ctr, Aurora, CO USA; Univ Milano Bicocca, Div Gynecol Oncol, European Inst Oncol, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; IFOM - FIRC Institute of Molecular Oncology; University of Colorado System; University of Colorado Denver; IRCCS European Institute of Oncology (IEO); University of Milano-Bicocca	Formelli, F (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via Venezian 1, I-20133 Milan, Italy.	franca.formelli@istitutotumori.mi.it	Appierto, Valentina/B-9325-2017; De Cecco, Loris/K-7036-2016; Pierotti, Marco Alessandro/AAC-4728-2022; Colombo, Nicoletta/AAB-8319-2019; Gariboldi, Manuela/K-4744-2016	Appierto, Valentina/0000-0002-8726-6981; De Cecco, Loris/0000-0002-7066-473X; Pierotti, Marco Alessandro/0000-0002-7431-8332; Gariboldi, Manuela/0000-0001-8406-165X; Reid, James/0000-0001-6997-2850				Albertoni M, 2002, ONCOGENE, V21, P4212, DOI 10.1038/sj.onc.1205610; Appierto V, 2004, CELL DEATH DIFFER, V11, P270, DOI 10.1038/sj.cdd.4401349; Appierto V, 2001, BRIT J CANCER, V84, P1528, DOI 10.1054/bjoc.2001.1826; Baek SJ, 2006, PROG LIPID RES, V45, P1, DOI 10.1016/j.plipres.2005.10.001; Baek SJ, 2002, CARCINOGENESIS, V23, P425, DOI 10.1093/carcin/23.3.425; Balmer JE, 2002, J LIPID RES, V43, P1773, DOI 10.1194/jlr.R100015-JLR200; Chiesa F, 2005, INT J CANCER, V115, P625, DOI 10.1002/ijc.20923; Clifford JL, 1999, CANCER RES, V59, P14; Colombo N, 2006, CANCER EPIDEM BIOMAR, V15, P1914, DOI 10.1158/1055-9965.EPI-06-0183; Cui WC, 2001, MOL BIOL REP, V28, P123, DOI 10.1023/A:1015288412047; De Cecco L, 2004, ONCOGENE, V23, P8171, DOI 10.1038/sj.onc.1207979; De Palo G, 2002, GYNECOL ONCOL, V86, P24, DOI 10.1006/gyno.2002.6663; DZIADEK M, 1985, DEV BIOL, V111, P372, DOI 10.1016/0012-1606(85)90491-9; FORMELLI F, 1993, CANCER RES, V53, P5374; Garaventa A, 2003, CLIN CANCER RES, V9, P2032; Hail N, 2001, J BIOL CHEM, V276, P45614, DOI 10.1074/jbc.M106559200; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Kadara H, 2006, CANCER BIOL THER, V5, P518, DOI 10.4161/cbt.5.5.2602; Lovat PE, 2004, ANN NY ACAD SCI, V1028, P81, DOI 10.1196/annals.1322.009; Lu XH, 2001, CLIN CANCER RES, V7, P2114; Ma Y, 2003, ONCOGENE, V22, P4924, DOI 10.1038/sj.onc.1206728; Modlich O, 2004, CLIN CANCER RES, V10, P6418, DOI 10.1158/1078-0432.CCR-04-1031; Myatt SS, 2005, CLIN CANCER RES, V11, P3136, DOI 10.1158/1078-0432.CCR-04-2050; Nagy L, 1998, CELL DEATH DIFFER, V5, P11, DOI 10.1038/sj.cdd.4400337; Newman D, 2003, MOL PHARMACOL, V63, P557, DOI 10.1124/mol.63.3.557; OConnor PM, 1997, CANCER RES, V57, P4285; PELLEGRINI R, 1995, CELL GROWTH DIFFER, V6, P863; Perego P, 1996, CANCER RES, V56, P556; Prinetti A, 2003, J BIOL CHEM, V278, P5574, DOI 10.1074/jbc.M207269200; Sharma A, 2005, GYNECOL ONCOL, V99, P58, DOI 10.1016/j.ygyno.2005.05.024; Shishodia S, 2005, CANCER RES, V65, P9555, DOI 10.1158/0008-5472.CAN-05-1585; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Supino R, 1996, INT J CANCER, V65, P491, DOI 10.1002/(SICI)1097-0215(19960208)65:4<491::AID-IJC17>3.0.CO;2-D; Tsai MS, 2002, ONCOGENE, V21, P964, DOI 10.1038/sj/onc/1205131; Veronesi U, 2006, ANN ONCOL, V17, P1065, DOI 10.1093/annonc/mdl047; Veronesi U, 1999, J NATL CANCER I, V91, P1847, DOI 10.1093/jnci/91.21.1847; Villani MG, 2006, CANCER RES, V66, P3238, DOI 10.1158/0008-5472.CAN-05-3362; Villani MG, 2004, CLIN CANCER RES, V10, P6265, DOI 10.1158/1078-0432.CCR-04-0655; Wang HT, 2001, CANCER RES, V61, P5102; Wei JS, 2005, ONCOGENE, V24, P7976, DOI 10.1038/sj.onc.1208947; Zhao Q, 2004, LEUKEMIA, V18, P285, DOI 10.1038/sj.leu.2403226	41	15	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2007	26	27					3952	3962		10.1038/sj.onc.1210171	http://dx.doi.org/10.1038/sj.onc.1210171			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213814				2022-12-17	WOS:000247144500005
J	Tuupanen, S; Karhu, A; Jarvinen, H; Mecklin, JP; Launonen, V; Aaltonen, LA				Tuupanen, S.; Karhu, A.; Jarvinen, H.; Mecklin, J. P.; Launonen, V.; Aaltonen, L. A.			No evidence for dual role of loss of heterozygosity in hereditary non-polyposis colorectal cancer	ONCOGENE			English	Article						allele; LOH; HNPCC; MMR; tumor	MISMATCH REPAIR DEFICIENCY; MICROSATELLITE INSTABILITY; HMLH1 PROMOTER; COLON-CANCER; SOMATIC MUTATIONS; CELL-LINES; TUMORS; GERMLINE; GENE; HYPERMETHYLATION	Hereditary non-polyposis colorectal cancer (HNPCC) is caused by germline mutations in mismatch repair (MMR) genes, mostly MLH1 and MSH2. Somatic inactivation of the wild-type allele of the respective MMR gene is required for tumor development. Unexpectedly, a recent study utilizing DNA from paraffin-embedded tissue material detected frequent loss of the mutant MMR gene allele in HNPCC tumors. Dual role for loss of heterozygosity (LOH) was proposed. If somatic loss of the wild-type MMR gene allele had occurred through point mutation or promoter hypermethylation, frequent somatic deletions at the region of the MMR gene locus, perhaps targeting other relevant cancer genes, could quite commonly lead to loss of the mutant allele. To test this hypothesis, we studied a population-based series of 25 fresh-frozen HNPCC tumors with a germline mutation in MLH1 or MSH2 for LOH. Fourteen of the 25 tumors (56%) showed LOH at the respective locus, and all 14 losses targeted the wild-type allele (P=0.00006). These results strongly support the traditional two-hit model of HNPCC gene inactivation.	Univ Helsinki, Biomedicum Helsinki, Dept Med Genet, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Surg 2, Helsinki, Finland; Cent Hosp Jyvaskyla, Dept Surg, Jyvaskyla, Finland	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Central Finland Central Hospital	Aaltonen, LA (corresponding author), Univ Helsinki, Biomedicum Helsinki, Dept Med Genet, Room B520a,POB 63,Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	lauri.aaltonen@helsinki.fi	Mecklin, Jukka-Pekka/AAC-9650-2019; Mecklin, Jukka-Pekka/AAB-5378-2020; Aaltonen, Lauri/A-5375-2010	Mecklin, Jukka-Pekka/0000-0003-4895-2249; Aaltonen, Lauri/0000-0001-6839-4286; Karhu, Auli/0000-0002-7927-0796				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101; BENEZRA J, 1991, J HISTOCHEM CYTOCHEM, V39, P351, DOI 10.1177/39.3.1704393; Canzian F, 1996, CANCER RES, V56, P3331; Chadwick RB, 2001, J MED GENET, V38, P461, DOI 10.1136/jmg.38.7.461; Cunningham JM, 1998, CANCER RES, V58, P3455; Cunningham JM, 2001, AM J HUM GENET, V69, P780, DOI 10.1086/323658; de Abajo AS, 2006, ONCOGENE, V25, P2124, DOI 10.1038/sj.onc.1209233; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kane MF, 1997, CANCER RES, V57, P808; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; Kuismanen SA, 2000, AM J PATHOL, V156, P1773, DOI 10.1016/S0002-9440(10)65048-1; Lamlum H, 1999, NAT MED, V5, P1071, DOI 10.1038/12511; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Lu SL, 1996, JPN J CANCER RES, V87, P279, DOI 10.1111/j.1349-7006.1996.tb00218.x; NYSTROMLAHTI M, 1995, NAT MED, V1, P1203, DOI 10.1038/nm1195-1203; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Peltomaki P, 2004, DIS MARKERS, V20, P269, DOI 10.1155/2004/305058; Potocnik U, 2001, CANCER GENET CYTOGEN, V126, P85, DOI 10.1016/S0165-4608(00)00399-X; Salovaara R, 2000, J CLIN ONCOL, V18, P2193, DOI 10.1200/JCO.2000.18.11.2193; Tannergard P, 1997, HUM GENET, V101, P51, DOI 10.1007/s004390050585; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296; Williams C, 1999, AM J PATHOL, V155, P1467, DOI 10.1016/S0002-9440(10)65461-2; Yuen ST, 2002, ONCOGENE, V21, P7585, DOI 10.1038/sj.onc.1205968	28	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 12	2007	26	17					2513	2517		10.1038/sj.onc.1210038	http://dx.doi.org/10.1038/sj.onc.1210038			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17043646				2022-12-17	WOS:000245831000012
J	Ong, CK; Leong, C; Tan, PH; Van, T; Huynh, H				Ong, C. K.; Leong, C.; Tan, P. H.; Van, T.; Huynh, H.			The role of 5 ' untranslated region in translational suppression of OKL38 mRNA in hepatocellular carcinoma	ONCOGENE			English	Article						OKL38; hepatocellular carcinoma; cell death; 5 ' untranslated region; translational suppression	OPEN READING FRAMES; GROWTH INHIBITOR; EXPRESSION; CANCER; MECHANISMS; SEQUENCES; ELEMENT; GLAND; GENE	Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide. OKL38 is a pregnancy-induced growth inhibitory gene and its expression is lost in various breast cancer cell lines and kidney tumor. To determine the role of OKL38 expression in HCC, we investigated its expression in various HCC samples and liver cancer cell lines. Western blot analysis revealed that OKL38 protein was absent or reduced in 64.2% ( 18 of 28) of the HCCs examined and four liver cancer cell lines. Immunohistochemistry study demonstrated that OKL38 protein was undetectable in 41.3% ( 38 of 92) of HCC, whereas 39.1% ( 36 of 92) of HCC showed low expression of the protein. Lost or reduced expression level of OKL38 protein was significantly correlated to high tumor stages in HCC ( P = 0.0042). Overexpression of the OKL38 caused cell death in Chang liver cells. 50 Untranslated region (5'UTR) deletion studies demonstrated that OKL38 was downregulated via translation suppression associated with the 5'UTR of its mRNA. Taken together, the 5'UTRs of OKL38 might play an important role in downregulation of its protein and the absence of OKL38 could lead to the development or progression of HCC.	Natl Canc Ctr Singapore, Div Cellular & Mol Res, Mol Endocrinol Lab, Singapore 169610, Singapore; Singapore Gen Hosp, Dept Pathol, Singapore 0316, Singapore; Binh Dan Hosp, Ho Chi Minh City, Vietnam	National Cancer Centre Singapore (NCCS); Singapore General Hospital	Huynh, H (corresponding author), Natl Canc Ctr Singapore, Div Cellular & Mol Res, Mol Endocrinol Lab, 11 Hosp Dr, Singapore 169610, Singapore.	cmrhth@nccs.com.sg		Ong, Choon Kiat/0000-0001-6402-4288				Akriviadis EA, 1998, BRIT J SURG, V85, P1319; Altman DG, 2000, STAT CONFIDENCE; CHAN ES, 2000, COCHRANE DB SYST REV, pPP199; Claudio PP, 2002, CLIN CANCER RES, V8, P1808; Clemens MJ, 2004, ONCOGENE, V23, P3180, DOI 10.1038/sj.onc.1207544; COLOMBO M, 1992, J HEPATOL, V15, P225, DOI 10.1016/0168-8278(92)90041-M; Dua K, 2001, PROTEOMICS, V1, P1191, DOI 10.1002/1615-9861(200110)1:10<1191::AID-PROT1191>3.0.CO;2-8; Gasteiger E., 2005, PROTEOMICS PROTOCOLS, DOI [10.1385/1-59259-890-0:571, DOI 10.1385/1-59259-890-0:571]; Harigai M, 1996, ONCOGENE, V12, P1369; HUGUET CSF, 2000, SURG LIVER BILLARY T, P1365; Huynh H, 2002, CELL GROWTH DIFFER, V13, P115; Huynh H, 2001, ENDOCRINOLOGY, V142, P3607, DOI 10.1210/en.142.8.3607; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kullmann M, 2002, GENE DEV, V16, P3087, DOI 10.1101/gad.248902; LAI E, 1994, SURG LIVER BILIARY T, P1349; LAI ECS, 1995, ANN SURG, V221, P291, DOI 10.1097/00000658-199503000-00012; Meijer HA, 2002, BIOCHEM J, V367, P1, DOI 10.1042/BJ20011706; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; OKUDA K, 1985, CANCER, V56, P918, DOI 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E; Ong CK, 2004, ENDOCRINOLOGY, V145, P4763, DOI 10.1210/en.2004-0446; Ong CK, 2004, J BIOL CHEM, V279, P743, DOI 10.1074/jbc.M308668200; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pickering BM, 2005, SEMIN CELL DEV BIOL, V16, P39, DOI 10.1016/j.semcdb.2004.11.006; Riou P, 2002, CLIN CANCER RES, V8, P3178; SPIESSL B, 1992, ILLUSTRATED GUIDE TN, P104; Takenaka K, 1996, ARCH SURG-CHICAGO, V131, P71; Wang T, 2005, J BIOL CHEM, V280, P4374, DOI 10.1074/jbc.M408708200; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2	29	15	15	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2007	26	8					1155	1165		10.1038/sj.onc.1209896	http://dx.doi.org/10.1038/sj.onc.1209896			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16924236				2022-12-17	WOS:000244406400006
J	Bourette, RP; Grasset, MF; Mouchiroud, G				Bourette, R. P.; Grasset, M-F; Mouchiroud, G.			E2a/Pbx1 oncogene inhibits terminal differentiation but not myeloid potential of pro-T cells	ONCOGENE			English	Article						leukemia; hematopoiesis; differentiation	STIMULATING FACTOR-RECEPTOR; HEMATOPOIETIC PROGENITORS; ACUTE LEUKEMIAS; TRANSCRIPTION FACTORS; INTERACTING PROTEIN; LINEAGE COMMITMENT; MARROW CULTURES; FDC-P1 CELLS; IN-VITRO; GENE	E2a/Pbx1 is a fusion oncoprotein resulting from the t(1; 19) translocation found in human pre-B acute lymphocytic leukemia and in a small number of acute T-lymphoid and myeloid leukemias. It was previously suggested that E2a/Pbx1 could cooperate with normal or oncogenic signaling pathways to immortalize myeloid and lymphoid progenitor cells. To address this question, we introduced the receptor of the macrophage-colony-stimulating factor (M-CSF-R) in pro-T cells immortalized by a conditional, estradiol-dependent, E2a/Pbx1-protein, and continuously proliferating in response to stem cell factor and interleukin-7. We asked whether M-CSF-R would be functional in an early T progenitor cell and influence the fate of E2a/Pbx1-immortalized cells. E2a-Pbx1 immortalized pro-T cells could proliferate and shifted from lymphoid to myeloid lineage after signaling through exogenously expressed M-CSF-R, irrespective of the presence of estradiol. However, terminal macrophage differentiation of the cells was obtained only when estradiol was withdrawn from cultures. This demonstrated that M-CSF-R is functional for proliferation and differentiation signaling in a T-lymphoid progenitor cell, which, in addition, unveiled myeloid potential of pro-T progenitors. Moreover, the block of differentiation induced by the E2a/Pbx1 oncogene could be modulated by hematopoietic cytokines such as M-CSF, suggesting plasticity of leukemic progenitor cells. Finally, additional experiments suggested that PU.1 and eight twenty-one transcriptional regulators might be implicated in the mechanisms of oncogenesis by E2a/Pbx1.	CNRS, UMR 5534, Ctr Genet Mol & Cellulaire, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS)	Bourette, RP (corresponding author), CNRS, UMR 5534, Ctr Genet Mol & Cellulaire, 16 Rue Dubois, F-69622 Villeurbanne, France.	bourette@biomserv.univ-lyon1.fr	Bourette, Roland/ABB-3343-2020; Mouchiroud, Guy/K-1153-2018	Bourette, Roland/0000-0003-2074-4878				ARNAUD S, 2002, BMC IMMUNOL, V3, P15; Bakri Y, 2005, BLOOD, V105, P2707, DOI 10.1182/blood-2004-04-1448; Balciunaite G, 2005, BLOOD, V105, P1930, DOI 10.1182/blood-2004-08-3087; Beutler B, 2003, J LEUKOCYTE BIOL, V74, P479, DOI 10.1189/jlb.0203082; BORZILLO GV, 1989, MOL CELL BIOL, V9, P3973, DOI 10.1128/MCB.9.9.3973; Bourette RP, 2000, GROWTH FACTORS, V17, P155, DOI 10.3109/08977190009001065; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; Bourgin C, 2000, FEBS LETT, V480, P113, DOI 10.1016/S0014-5793(00)01906-2; Calabi F, 2001, MOL CELL BIOL, V21, P5658, DOI 10.1128/MCB.21.16.5658-5666.2001; Carnicer MJ, 2004, LEUKEMIA RES, V28, P19, DOI 10.1016/S0145-2126(03)00125-5; CARROLL AJ, 1984, BLOOD, V63, P721; Chen D, 2001, EXP HEMATOL, V29, P971, DOI 10.1016/S0301-472X(01)00670-1; CHENG GY, 1986, J EXP MED, V163, P414, DOI 10.1084/jem.163.2.414; Chevallier N, 2004, BLOOD, V103, P1454, DOI 10.1182/blood-2003-06-2081; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; Dakic A, 2005, J EXP MED, V201, P1487, DOI 10.1084/jem.20050075; Davis JN, 2003, GENE, V303, P1, DOI 10.1016/S0378-1119(02)01172-1; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; Du Y, 2002, EXP HEMATOL, V30, P649, DOI 10.1016/S0301-472X(02)00817-2; Duval D, 2000, FASEB J, V14, P1577, DOI 10.1096/fj.14.11.1577; Erickson PF, 1996, BLOOD, V88, P1813; Follows GA, 2005, ONCOGENE, V24, P3643, DOI 10.1038/sj.onc.1208655; Fukuyama T, 2001, ONCOGENE, V20, P6225, DOI 10.1038/sj.onc.1204794; Gilliland D Gary, 2004, Hematology Am Soc Hematol Educ Program, P80; Gosse SG, 2005, CELL SIGNAL, V17, P1352, DOI 10.1016/j.cellsig.2005.02.002; HOFFBRAND AV, 1988, BLOOD REV, V2, P9, DOI 10.1016/0268-960X(88)90003-3; Ibanez V, 2004, CANCER RES, V64, P4547, DOI 10.1158/0008-5472.CAN-03-3689; Iwasaki-Arai J, 2003, J EXP MED, V197, P1311, DOI 10.1084/jem.20021843; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1994, ONCOGENE, V9, P3159; Katsura Y, 2002, NAT REV IMMUNOL, V2, P127, DOI 10.1038/nri721; Kelly LM, 2000, EMBO J, V19, P1987, DOI 10.1093/emboj/19.9.1987; King AG, 2002, P NATL ACAD SCI USA, V99, P4508, DOI 10.1073/pnas.072087899; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Kondo M, 2000, NATURE, V407, P383, DOI 10.1038/35030112; Krause DS, 2002, ONCOGENE, V21, P3262, DOI 10.1038/sj.onc.1205316; Lacaud G, 2002, BLOOD, V100, P458, DOI 10.1182/blood-2001-12-0321; Lee CK, 2001, J IMMUNOL, V166, P5964, DOI 10.4049/jimmunol.166.10.5964; Lindberg SR, 2005, EXP HEMATOL, V33, P189, DOI 10.1016/j.exphem.2004.10.011; Lodie TA, 1997, J IMMUNOL, V158, P1848; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; Mancini A, 2004, ONCOGENE, V23, P6581, DOI 10.1038/sj.onc.1207841; Matsuoka T, 2003, MOL CELL BIOL, V23, P6049, DOI 10.1128/MCB.23.17.6049-6062.2003; Metcalf D, 1998, BLOOD, V92, P345, DOI 10.1182/blood.V92.2.345b.Con2_345_347; Nutt SL, 2005, J EXP MED, V201, P221, DOI 10.1084/jem.20041535; Pawlak G, 2000, EXP HEMATOL, V28, P1164, DOI 10.1016/S0301-472X(00)00522-1; Rochford JJ, 2004, MOL CELL BIOL, V24, P9863, DOI 10.1128/MCB.24.22.9863-9872.2004; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; Sasmono RT, 2003, BLOOD, V101, P1155, DOI 10.1182/blood-2002-02-0569; Scheijen B, 2002, ONCOGENE, V21, P3314, DOI 10.1038/sj.onc.1205317; STANLEY ER, 1994, STEM CELLS, V12, P15; Stirewalt DL, 2003, NAT REV CANCER, V3, P650, DOI 10.1038/nrc1169; Sykes DB, 2004, MOL CELL BIOL, V24, P1256, DOI 10.1128/MCB.24.3.1256-1269.2004; Sykes DB, 2003, LEUKEMIA LYMPHOMA, V44, P1187, DOI 10.1080/1042819031000090273; Sykes DB, 2001, BLOOD, V98, P2308, DOI 10.1182/blood.V98.8.2308; Tagoh H, 2002, GENE DEV, V16, P1721, DOI 10.1101/gad.222002; Tamura T, 1999, ONCOGENE, V18, P6488, DOI 10.1038/sj.onc.1203062; TORRES H, 1990, LEUKEMIA, V4, P673; TROUSSARD X, 1995, BRIT J HAEMATOL, V89, P516, DOI 10.1111/j.1365-2141.1995.tb08357.x; Zheng R, 2004, LEUKEMIA RES, V28, P121, DOI 10.1016/S0145-2126(03)00184-X; Zheng R, 2004, BLOOD, V103, P267, DOI 10.1182/blood-2003-06-1969; Zhu J, 2002, ONCOGENE, V21, P3295, DOI 10.1038/sj.onc.1205318	63	15	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	2					234	247		10.1038/sj.onc.1209777	http://dx.doi.org/10.1038/sj.onc.1209777			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16819510				2022-12-17	WOS:000243398300007
J	Sun, L; Trausch-Azar, JS; Ciechanover, A; Schwartz, AL				Sun, L.; Trausch-Azar, J. S.; Ciechanover, A.; Schwartz, A. L.			E2A protein degradation by the ubiquitin-proteasome system is stage-dependent during muscle differentiation	ONCOGENE			English	Article						E2A; E12; E47; ubiquitin; proteasome; muscle differentiation	LOOP-HELIX PROTEINS; LYMPHOCYTE DEVELOPMENT; MEDIATED DEGRADATION; DNA-BINDING; TRANSCRIPTION; LOCALIZATION; E47; MYOD; ASSOCIATION; TURNOVER	The E2A proteins are basic helix-loop-helix transcription factors that regulate proliferation and differentiation in many cell types. In muscle cells, the E2A proteins form heterodimers with muscle regulatory factors such as MyoD, which then bind to DNA and regulate the transcription of target genes essential for muscle differentiation. We now demonstrate that E2A proteins are primarily localized in the nucleus in both C2C12 myoblasts and myotubes, and are degraded by the ubiquitin proteasome system evidenced by stabilization following treatment with the proteasome inhibitor, MG132. During the differentiation from myoblast to myotube, the cellular abundance of E2A proteins is relatively unaltered, despite significant changes ( each similar to 5-fold) in the relative rates of protein synthesis and protein degradation via the ubiquitin-proteasome system. The rate of ubiquitin-proteasome-mediated E2A protein degradation depends on the myogenic differentiation state (t 1/2 similar to 2 h in proliferating myoblasts versus t 1/2 > 10h in differentiated myotubes), and is also associated with cell cycle in non-muscle cells. Our findings reveal an important role for both translational and post-translational regulatory mechanisms in mediating the complex program of muscle differentiation determined by the E2A proteins.	Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; St Louis Childrens Hosp, St Louis, MO 63178 USA; Technion Israel Inst Technol, Fac Med, Vasc & Tumor Biol Res Ctr, Haifa, Israel	Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Schwartz, AL (corresponding author), Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, 660 S Euclid Ave,CB 8116, St Louis, MO 63110 USA.	Schwartz@kids.wustl.edu	Ciechanover, Aaron J/C-9166-2017					ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Coulombe P, 2003, MOL CELL BIOL, V23, P4542, DOI 10.1128/MCB.23.13.4542-4558.2003; Dearth LR, 2003, J BIOL CHEM, V278, P11246, DOI 10.1074/jbc.M207930200; Deed RW, 1996, J BIOL CHEM, V271, P23603, DOI 10.1074/jbc.271.39.23603; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; Huggins GS, 1999, J BIOL CHEM, V274, P28690, DOI 10.1074/jbc.274.40.28690; Kho CJ, 1997, J BIOL CHEM, V272, P3845, DOI 10.1074/jbc.272.6.3845; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lazorchak A, 2005, TRENDS IMMUNOL, V26, P334, DOI 10.1016/j.it.2005.03.011; Lingbeck JM, 2005, ONCOGENE, V24, P6376, DOI 10.1038/sj.onc.1208789; Lluis F, 2005, EMBO J, V24, P974, DOI 10.1038/sj.emboj.7600528; Nie L, 2003, EMBO J, V22, P5780, DOI 10.1093/emboj/cdg567; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Quong MW, 2002, ANNU REV IMMUNOL, V20, P301, DOI 10.1146/annurev.immunol.20.092501.162048; Riera L, 2003, FEBS LETT, V550, P23, DOI 10.1016/S0014-5793(03)00808-1; Riley RL, 2005, SEMIN IMMUNOL, V17, P330, DOI 10.1016/j.smim.2005.05.011; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; Sun LP, 2005, J BIOL CHEM, V280, P26448, DOI 10.1074/jbc.M500373200; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; Van der Put E, 2004, J IMMUNOL, V173, P818, DOI 10.4049/jimmunol.173.2.818; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317	26	15	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	3					441	448		10.1038/sj.onc.1209793	http://dx.doi.org/10.1038/sj.onc.1209793			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16909127				2022-12-17	WOS:000243544000012
J	Tzircotis, G; Thorne, RF; Isacke, CM				Tzircotis, G.; Thorne, R. F.; Isacke, C. M.			Directional sensing of a phorbol ester gradient requires CD44 and is regulated by CD44 phosphorylation	ONCOGENE			English	Article						CD44; chemotaxis; phorbol ester; protein kinase C; protein kinase A; metastasis	DEPENDENT PROTEIN-KINASE; BREAST-CANCER CELLS; CYTOPLASMIC DOMAIN; ENDOTHELIAL-CELLS; UP-REGULATION; CYTOSKELETAL INTERACTION; FACILITATES INVASION; SELECTIVE INHIBITOR; TUMOR PROGRESSION; BONE-MARROW	Cancer progression is associated with enhanced directional cell migration, both of the tumour cells invading into the stroma and stromal cells infiltrating the tumour site. In cell-based assays to study directional cell migration, phorbol esters are frequently used as a chemotactic agent. However, the molecular mechanism by which these activators of protein kinase C (PKC) result in the establishment of a polarized migratory phenotype is not known. Here we show that CD44 expression is essential for chemotaxis towards a phorbol ester gradient. In an investigation of CD44 phosphorylation kinetics in resting and stimulated cells, Ser316 was identified as a novel site of phosphorylation following activation of PKC. PKC does not phosphorylate Ser316 directly, but rather mediates the activation of downstream Ser316 kinase(s). In transfection studies, a phosphorylation-deficient Ser316 mutant was shown to act in a dominant-negative fashion to impair chemotaxis mediated by endogenous CD44 in response to a phorbol ester gradient. Importantly, this mutation had no effect on random cell motility or the ability of cells to migrate directionally towards a cocktail of chemoattractants. These studies demonstrate that CD44 functions to provide directional cues to migrating cells without affecting the motility apparatus.	Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Isacke, CM (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.	clare.isacke@icr.ac.uk		Isacke, Clare/0000-0002-9222-3345	Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline	Breast Cancer Now		Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Alstergren P, 2004, CELL IMMUNOL, V231, P146, DOI 10.1016/j.cellimm.2005.01.007; Avigdor A, 2004, BLOOD, V103, P2981, DOI 10.1182/blood-2003-10-3611; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bourguignon LYW, 2003, J BIOL CHEM, V278, P29420, DOI 10.1074/jbc.M301885200; Caloca MJ, 1999, P NATL ACAD SCI USA, V96, P11854, DOI 10.1073/pnas.96.21.11854; CAMP RL, 1991, J CELL BIOL, V115, P1283, DOI 10.1083/jcb.115.5.1283; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Cichy J, 2005, BBA-MOL CELL RES, V1745, P59, DOI 10.1016/j.bbamcr.2005.02.006; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Dingemans KP, 2002, LAB INVEST, V82, P313, DOI 10.1038/labinvest.3780425; Draffin JE, 2004, CANCER RES, V64, P5702, DOI 10.1158/0008-5472.CAN-04-0389; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Eccles SA, 2005, CURR OPIN GENET DEV, V15, P77, DOI 10.1016/j.gde.2004.12.001; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; ESTENSEN RD, 1973, NATURE, V245, P458, DOI 10.1038/245458a0; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fujisaki T, 1999, CANCER RES, V59, P4427; GLASS DB, 1989, J BIOL CHEM, V264, P14579; Gomez-Mouton C, 2004, J CELL BIOL, V164, P759, DOI 10.1083/jcb.200309101; Herrera-Gayol A, 1999, EXP MOL PATHOL, V66, P99, DOI 10.1006/exmp.1999.2236; Herrera-Gayol A, 2001, INT J EXP PATHOL, V82, P193, DOI 10.1111/j.1365-2613.2001.iep196.x; ISACKE CM, 1986, IMMUNOGENETICS, V23, P326, DOI 10.1007/BF00398797; Jones GE, 2000, J LEUKOCYTE BIOL, V68, P593; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; Kim HR, 2004, CANCER RES, V64, P4569, DOI 10.1158/0008-5472.CAN-04-0202; Kobayashi H, 2002, INT J CANCER, V102, P379, DOI 10.1002/ijc.10710; Legg JW, 2002, NAT CELL BIOL, V4, P399, DOI 10.1038/ncb797; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; Lewis CA, 2001, BIOCHEM J, V357, P843, DOI 10.1042/0264-6021:3570843; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Martin TA, 2003, CRIT REV ONCOL HEMAT, V46, P165, DOI 10.1016/S1040-8428(02)00172-5; Miletti-Gonzalez KE, 2005, CANCER RES, V65, P6660, DOI 10.1158/0008-5472.CAN-04-3478; Mine S, 2003, EXP CELL RES, V288, P189, DOI 10.1016/S0014-4827(03)00184-8; Nagano O, 2004, J CELL BIOL, V165, P893, DOI 10.1083/jcb.200310024; NEAME SJ, 1995, J CELL SCI, V108, P3127; NEAME SJ, 1993, J CELL BIOL, V121, P1299, DOI 10.1083/jcb.121.6.1299; NEAME SJ, 1992, EMBO J, V11, P4733, DOI 10.1002/j.1460-2075.1992.tb05578.x; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Peck D, 1998, J CELL SCI, V111, P1595; Peck D, 1996, CURR BIOL, V6, P884, DOI 10.1016/S0960-9822(02)00612-7; PERSCHL A, 1995, J CELL SCI, V108, P1033; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Pure E, 2001, TRENDS MOL MED, V7, P213, DOI 10.1016/S1471-4914(01)01963-3; PURE E, 1995, J EXP MED, V181, P55, DOI 10.1084/jem.181.1.55; Ratliff Timothy L, 2005, J Urol, V173, P1045, DOI 10.1016/S0022-5347(05)60440-5; Sim ATR, 1999, CELL CALCIUM, V26, P209, DOI 10.1054/ceca.1999.0072; Thorne RF, 2004, J CELL SCI, V117, P373, DOI 10.1242/jcs.00954; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Tzircotis G, 2005, J CELL SCI, V118, P5119, DOI 10.1242/jcs.02629; Van Haastert PJM, 2004, NAT REV MOL CELL BIO, V5, P626, DOI 10.1038/nrm1435; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Weber GF, 2002, CANCER RES, V62, P2281; Weiner OD, 2002, CURR OPIN CELL BIOL, V14, P196, DOI 10.1016/S0955-0674(02)00310-1; Xu Y, 2003, J BIOL CHEM, V278, P8661, DOI 10.1074/jbc.M208181200; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Zhao ZZ, 1996, J BIOL CHEM, V271, P22251, DOI 10.1074/jbc.271.36.22251; Zhu BQ, 2004, J CELL PHYSIOL, V198, P155, DOI 10.1002/jcp.10394; Zhu H, 2006, STEM CELLS, V24, P928, DOI 10.1634/stemcells.2005-0186; ZICHA D, 1991, J CELL SCI, V99, P769	64	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	56					7401	7410		10.1038/sj.onc.1209724	http://dx.doi.org/10.1038/sj.onc.1209724			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16785995				2022-12-17	WOS:000242419100009
J	Manuvakhova, M; Thottassery, JV; Hays, S; Qu, Z; Rentz, SS; Westbrook, L; Kern, FG				Manuvakhova, M.; Thottassery, J. V.; Hays, S.; Qu, Z.; Rentz, S. S.; Westbrook, L.; Kern, F. G.			Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells	ONCOGENE			English	Article						breast cancer; antiestrogen resistance; FGF; SNT-1 PTB domain; signal transduction	P70 S6 KINASE; SIGNAL-TRANSDUCTION PATHWAYS; DOCKING-PROTEIN FRS2-ALPHA; PC12 CELLS; FACTOR RECEPTORS; TYROSINE KINASE; RAPAMYCIN TOR; MCF-7 CELLS; NUDE-MICE; FACTOR-IV	Fibroblast growth factor (FGF) signaling can bypass the requirement for estrogen receptor (ER) activation in the growth of ER-positive (ER+) breast cancer cells. Fibroblast growth factor-1 stimulation leads to phosphorylation of the adaptor protein Suc1-associated neurotrophic factor-induced tyrosine-phosphorylated target (SNT-1) on C-terminal tyrosine residues, whereas it is constitutively bound through its N-terminal phosphotyrosine-binding domain (PTB) to FGF receptors (FGFRs). By expressing the PTB domain of SNT-1 (SNT-1 PTB) in an inducible manner in an ER+ breast carcinoma line, ML20, we asked whether we could uncouple FGFR activation from its downstream signaling components and abrogate FGF-1-induced antiestrogen-resistant growth. Induction of SNT-1 PTB resulted in a significant decrease of FGF-1-dependent tyrosine phosphorylation of endogenous SNT-1, strong inhibition of complex formation between SNT-1, Gab-1 and Sos-1, and reduced activation of Ras, mitogen-activated protein kinase (MAP kinase), and Akt. SNT-1 PTB also inhibited the phosphorylation of p70S6K on Thr421/Ser424 and Ser411, which may result from the abrogation of MAP kinase activity. Moreover, we also observed a decreased phosphorylation of the MAP kinase-independent site Thr389. This may reflect both inhibition of PI-3 kinase pathways and mammalian target of rapamycin (mTOR)-dependent signaling, as the phosphorylation of Thr389 site was sensitive to treatment with the PI3-K and mTOR inhibitors, LY294002 and rapamycin, respectively. Collectively these results suggest that SNT-1 plays a pivotal role in FGF-dependent activation of the Ras-MAP kinase, PI-3 kinase, and mTOR pathways in these cells. Fibroblast growth factor-1 dependent colony formation of ML20 cells in media containing the pure antiestrogen ICI 182,780 was also markedly inhibited upon induction of SNT-1 PTB, suggesting that blockade of FGFR-SNT-1 interactions might abrogate FGF-mediated antiestrogen resistance in breast cancers.	Lexicon Genet Inc, Div Pharmaceut Biol, The Woodlands, TX 77381 USA; So Res Inst, Drug Discovery Div, Dept Biochem & Mol Biol, Birmingham, AL 35255 USA; UAB Comprehens Canc Ctr, Birmingham, AL USA	Lexicon Pharmaceuticals; University of Alabama System; University of Alabama Birmingham	Kern, FG (corresponding author), Lexicon Genet Inc, Div Pharmaceut Biol, 8800 Technol Forest Pl, The Woodlands, TX 77381 USA.	fkern@lexgen.com			NCI NIH HHS [CA50376, P30CA13148] Funding Source: Medline; NIAID NIH HHS [P30AI27767] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013148, R01CA050376] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027767] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447; Califano D, 2000, J BIOL CHEM, V275, P19297, DOI 10.1074/jbc.M905866199; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; Dennis PB, 1998, J BIOL CHEM, V273, P14845, DOI 10.1074/jbc.273.24.14845; Dhalluin C, 2000, MOL CELL, V6, P921, DOI 10.1016/S1097-2765(00)00089-7; Dunican DJ, 2001, CELL GROWTH DIFFER, V12, P255; Ehrhard KN, 2000, NAT BIOTECHNOL, V18, P1075, DOI 10.1038/80274; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Gonzalez-Garcia A, 2002, J BIOL CHEM, V277, P1500, DOI 10.1074/jbc.M103808200; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Iijima Y, 2002, J BIOL CHEM, V277, P23065, DOI 10.1074/jbc.M200328200; JAAKKOLA S, 1993, INT J CANCER, V54, P378, DOI 10.1002/ijc.2910540305; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kimpinski K, 2001, J NEUROSCI RES, V63, P486, DOI 10.1002/jnr.1043; Klint P, 1999, ONCOGENE, V18, P3354, DOI 10.1038/sj.onc.1202680; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Koziczak M, 2004, ONCOGENE, V23, P3501, DOI 10.1038/sj.onc.1207331; KUREBAYASHI J, 1993, CANCER RES, V53, P2178; Kurokawa K, 2001, ONCOGENE, V20, P1929, DOI 10.1038/sj.onc.1204290; Lamothe B, 2004, MOL CELL BIOL, V24, P5657, DOI 10.1128/MCB.24.13.5657-5666.2004; Lax I, 2002, MOL CELL, V10, P709, DOI 10.1016/S1097-2765(02)00689-5; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; McLeskey SW, 1998, CLIN CANCER RES, V4, P697; MCLESKEY SW, 1993, CANCER RES, V53, P2168; McLeskey SW, 1996, BREAST CANCER RES TR, V39, P103, DOI 10.1007/BF01806082; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; Moffa AB, 2004, MOL CANCER RES, V2, P643; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; Ong SH, 1996, BIOCHEM BIOPH RES CO, V225, P1021, DOI 10.1006/bbrc.1996.1288; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; PRICE DJ, 1991, J BIOL CHEM, V266, P16281; Qu ZC, 2004, GENE, V327, P61, DOI 10.1016/j.gene.2003.10.029; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Romanelli A, 2002, J BIOL CHEM, V277, P40281, DOI 10.1074/jbc.M205168200; Stoletov KV, 2002, FASEB J, V16, P1283, DOI 10.1096/fj.01-0835fje; Tsoulfas P, 1996, J BIOL CHEM, V271, P5691, DOI 10.1074/jbc.271.10.5691; Urlinger S, 2000, P NATL ACAD SCI USA, V97, P7963, DOI 10.1073/pnas.130192197; Wang F, 2002, IN VITRO CELL DEV-AN, V38, P178; Wang JK, 1996, ONCOGENE, V13, P721; Wu YJ, 2003, BIOL CHEM, V384, P1215, DOI 10.1515/BC.2003.134; XIE WQ, 1991, BIOTECHNIQUES, V11, P324; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; Xu H, 2001, J BIOL CHEM, V276, P13049, DOI 10.1074/jbc.M009925200; Yonezawa K, 2004, BIOCHEM BIOPH RES CO, V313, P437, DOI 10.1016/j.bbrc.2003.07.018; Yoshimura N, 1998, CLIN IMMUNOL IMMUNOP, V89, P28, DOI 10.1006/clin.1998.4551; Yuen EC, 1999, EXP NEUROL, V159, P297, DOI 10.1006/exnr.1999.7148; Zhang LR, 1997, ONCOGENE, V15, P2093, DOI 10.1038/sj.onc.1201386; Zhang YG, 2001, J BIOL CHEM, V276, P20913, DOI 10.1074/jbc.M009047200; Zhang YY, 2004, J BIOL CHEM, V279, P55348, DOI 10.1074/jbc.M409230200	59	15	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2006	25	44					6003	6014		10.1038/sj.onc.1209592	http://dx.doi.org/10.1038/sj.onc.1209592			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16682955				2022-12-17	WOS:000240826300009
J	Tomkova, K; El-Rifai, W; Vilgelm, A; Kelly, MC; Wang, TC; Zaika, AI				Tomkova, K.; El-Rifai, W.; Vilgelm, A.; Kelly, M. C.; Wang, T. C.; Zaika, A. I.			The gastrin gene promoter is regulated by p73 isoforms in tumor cells	ONCOGENE			English	Article						p53; p63; p73; gastric tumor; esophageal tumor; colorectal tumor	INTESTINAL EPITHELIAL-CELLS; GLYCINE-EXTENDED GASTRIN; WILD-TYPE P73; COLORECTAL-CARCINOMA; TRANSGENIC MICE; FAMILY-MEMBERS; HUMAN CANCERS; LUNG-CANCER; IN-VITRO; EXPRESSION	p73, a new p53 family member, is a transcription factor that is increasingly recognized in cancer research as an important player in tumorigenesis as well as in chemotherapeutic drug sensitivity. Despite the substantial structural and functional similarities to p53, accumulating evidence suggests that p53 and p73 may differently regulate their transcriptional targets. In this study, we have investigated the role of p73 in regulation of the gastrin gene promoter. Gastrin is a peptide hormone and an important factor in determining the progression of a number of human malignancies. Our results show that p73 can bind to the gastrin promoter. This leads to transcriptional upregulation of gastrin mRNA. We also found that the levels of gastrin and p73 transcripts correlate in primary gastric tumors. Taken together, our results demonstrate a novel mechanism for regulation of gastrin gene transcription and support a concept that p53 and p73 may have different biological roles in tumors.	Vanderbilt Univ, Med Ctr, Dept Surg, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Columbia Univ, Med Ctr, Div Digest & Liver Dis, New York, NY USA	Vanderbilt University; Vanderbilt University; Columbia University	Zaika, AI (corresponding author), Vanderbilt Univ, Med Ctr, Dept Surg, 1255 Light Hall, Nashville, TN 37232 USA.	alex.zaika@vanderbilt.edu		Vilgelm, Anna/0000-0002-4446-913X; Tomkova, Katarina/0000-0003-0482-5707; Wang, Timothy/0000-0001-5730-3019	NCI NIH HHS [CA-108956] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA108956] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aly A, 2004, BBA-REV CANCER, V1704, P1, DOI 10.1016/j.bbcan.2004.01.004; Aly A, 2001, INT J CANCER, V94, P307, DOI 10.1002/ijc.1483; Baldwin GS, 2001, J BIOL CHEM, V276, P7791, DOI 10.1074/jbc.M009985200; Benard J, 2003, HUM MUTAT, V21, P182, DOI 10.1002/humu.10172; Brown D, 2003, ENDOCRINOLOGY, V144, P201, DOI 10.1210/en.2002-220501; Caplin M, 2000, BRIT J SURG, V87, P1035, DOI 10.1046/j.1365-2168.2000.01488.x; CICCOTOSTO GD, 1995, GASTROENTEROLOGY, V109, P1142, DOI 10.1016/0016-5085(95)90572-3; Cobb S, 2004, CANCER-AM CANCER SOC, V100, P1311, DOI 10.1002/cncr.20094; Daulhac L, 1999, J BIOL CHEM, V274, P20657, DOI 10.1074/jbc.274.29.20657; FINLEY GG, 1993, CANCER RES, V53, P2919; Fox JG, 2003, GASTROENTEROLOGY, V124, P1879, DOI 10.1016/S0016-5085(03)00406-2; Goetze JP, 2000, CANCER, V88, P2487, DOI 10.1002/1097-0142(20000601)88:11<2487::AID-CNCR9>3.0.CO;2-E; Guan M, 2003, JPN J CLIN ONCOL, V33, P215, DOI 10.1093/jjco/hyg045; Han S, 1999, EUR J SURG ONCOL, V25, P194, DOI 10.1053/ejso.1998.0626; HANSEN OH, 1976, GUT, V17, P536, DOI 10.1136/gut.17.7.536; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Kang MJ, 2000, CLIN CANCER RES, V6, P1767; KOCHMAN ML, 1992, BIOCHEM BIOPH RES CO, V189, P1165, DOI 10.1016/0006-291X(92)92326-S; Koh TJ, 2000, J CLIN INVEST, V106, P533, DOI 10.1172/JCI9476; Koh TJ, 1999, J CLIN INVEST, V103, P1119, DOI 10.1172/JCI4910; Koh TJ, 2004, CANCER RES, V64, P196, DOI 10.1158/0008-5472.CAN-03-2112; Liu L, 2001, J INT MED RES, V29, P297, DOI 10.1177/147323000102900406; Moll UM, 2001, BBA-REV CANCER, V1552, P47, DOI 10.1016/S0304-419X(01)00036-1; Ng SW, 2000, ONCOGENE, V19, P1885, DOI 10.1038/sj.onc.1203512; Nimura Y, 1998, INT J CANCER, V78, P437, DOI 10.1002/(SICI)1097-0215(19981109)78:4<437::AID-IJC8>3.0.CO;2-V; Pilozzi E, 2003, J CLIN PATHOL-MOL PA, V56, P60, DOI 10.1136/mp.56.1.60; SEVA C, 1994, SCIENCE, V265, P410, DOI 10.1126/science.8023165; Seva C, 1996, FEBS LETT, V378, P74, DOI 10.1016/0014-5793(95)01414-4; Singh P, 2000, GASTROENTEROLOGY, V119, P162, DOI 10.1053/gast.2000.8527; Singh P, 2003, AM J PHYSIOL-GASTR L, V284, pG328, DOI 10.1152/ajpgi.00351.2002; Stiewe T, 2004, CLIN CANCER RES, V10, P626, DOI 10.1158/1078-0432.CCR-0153-03; Sun XF, 2002, CLIN CANCER RES, V8, P165; Tannapfel A, 1999, J NATL CANCER I, V91, P1154, DOI 10.1093/jnci/91.13.1154; Tannapfel A, 2001, J PATHOL, V195, P163, DOI 10.1002/path.947; Tokuchi Y, 1999, BRIT J CANCER, V80, P1623, DOI 10.1038/sj.bjc.6690572; Tomkova K, 2004, CANCER RES, V64, P6390, DOI 10.1158/0008-5472.CAN-04-2176; Wang TC, 1996, J CLIN INVEST, V98, P1918, DOI 10.1172/JCI118993; Wang TC, 2000, GASTROENTEROLOGY, V118, P36, DOI 10.1016/S0016-5085(00)70412-4; Weber A, 2002, INT J CANCER, V99, P22, DOI 10.1002/ijc.10296; Zaika AI, 1999, CANCER RES, V59, P3257; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179	41	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2006	25	44					6032	6036		10.1038/sj.onc.1209610	http://dx.doi.org/10.1038/sj.onc.1209610			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16636659				2022-12-17	WOS:000240826300012
J	De Falco, G; Giordano, A				De Falco, G.; Giordano, A.			pRb2/p130: A new candidate for retinoblastoma tumor formation	ONCOGENE			English	Review						cell cycle; cancer; RB family; retinoblastoma; pRb2/p130; tumor suppressors	ISOLATED UNILATERAL RETINOBLASTOMA; RB1 GENE-MUTATIONS; CELL-CYCLE; SUSCEPTIBILITY GENE; HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; SPORADIC RETINOBLASTOMA; GROWTH SUPPRESSION; AMINO-TERMINUS; LARGE-T	Retinoblastoma is the most common primary intraocular tumor in childhood. Mutations in both the alleles of the RB1 gene represent the causative agent for the tumor to occur. It is becoming evident that, although these alterations represent key events in the genesis of retinoblastoma, they are not sufficient per se for the tumor to develop, and other additional genetic or epigenetic alterations must occur. A supportive role in the genesis of retinoblastoma has recently been proposed for the RB1-related gene RB2/p130. Additionally, several other genetic alterations involving different chromosomes have been described as relevant in the tumorigenic process. In this review we will analyse current knowledge about the molecular mechanisms involved in retinoblastoma, paying particular attention to the mechanisms of inactivation of the biological function of the retinoblastoma family of proteins.	Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Siena	Giordano, A (corresponding author), Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Biolife Sci Bldg,Suite 333, Philadelphia, PA 19122 USA.	giordano@temple.edu	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X				Adams PD, 1996, MOL CELL BIOL, V16, P6623; ARHEDEN K, 1988, CYTOGENET CELL GENET, V48, P174, DOI 10.1159/000132619; Bellan C, 2002, INVEST OPHTH VIS SCI, V43, P3602; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Bremner R, 1997, AM J HUM GENET, V61, P556, DOI 10.1086/515499; BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; CANO J, 1994, CANCER GENET CYTOGEN, V76, P112, DOI 10.1016/0165-4608(94)90459-6; Chen CF, 1996, MOL CELL BIOL, V16, P4691; CHEN CS, 1995, CYTOGENET CELL GENET, V69, P260, DOI 10.1159/000133976; Chen D, 2002, CANCER RES, V62, P967; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHEN TT, 2000, CRIT REV EUKAR GENE, V5, P79; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; Choy KW, 2002, INVEST OPHTH VIS SCI, V43, P1344; Claudio P, 2002, GENOME BIOL, V3; Claudio PP, 2000, CANCER RES, V60, P372; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COWELL JK, 1992, CANCER GENET CYTOGEN, V64, P1, DOI 10.1016/0165-4608(92)90314-X; D'Andrilli G, 2004, CLIN CANCER RES, V10, P3098, DOI 10.1158/1078-0432.CCR-03-0524; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; De Falco G, 2003, ONCOGENE, V22, P6214, DOI 10.1038/sj.onc.1206637; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DESUTTER E, 1987, OPHTHALMIC PAED GEN, V8, P85, DOI 10.3109/13816818709028522; DiCiommo D, 2000, SEMIN CANCER BIOL, V10, P255, DOI 10.1006/scbi.2000.0326; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709; HALL JG, 1988, AM J HUM GENET, V43, P355; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HORSTHEMKE B, 1992, CANCER GENET CYTOGEN, V63, P1, DOI 10.1016/0165-4608(92)90055-D; Huang Q, 2003, MOL VIS, V9, P502; Imbert I, 2001, CANCER GENET CYTOGEN, V128, P141, DOI 10.1016/S0165-4608(01)00402-2; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KAELIN A, 1955, ARCH J KLAUS STIFTUN, V30, P442; KATO J, 1993, GENE DEV, V7, P331; Klutz M, 1999, AM J HUM GENET, V64, P667, DOI 10.1086/302254; KNUDSON AG, 1973, PROG MED GENET, V9, P113; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; KUSNETSOVA LE, 1982, HUM GENET, V61, P201, DOI 10.1007/BF00296442; Lacy S, 1997, ONCOGENE, V14, P2395, DOI 10.1038/sj.onc.1201085; Laj A, 1999, MOL CELL BIOL, V19, P6632; Lazzi S, 2002, HUM PATHOL, V33, P723, DOI 10.1053/hupa.2002.125372; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; Lohmann DR, 1999, HUM MUTAT, V14, P283, DOI 10.1002/(SICI)1098-1004(199910)14:4<283::AID-HUMU2>3.0.CO;2-J; Lohmann DR, 2004, AM J MED GENET C, V129C, P23, DOI 10.1002/ajmg.c.30024; Lohmann DR, 1997, AM J HUM GENET, V61, P282, DOI 10.1086/514845; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; Mutti L, 1998, DEV BIOL STAND, V94, P47; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; OhtaniFujita N, 1997, CANCER GENET CYTOGEN, V98, P43, DOI 10.1016/S0165-4608(96)00395-0; OLIVEROS O, 1995, CANCER GENET CYTOGEN, V82, P155, DOI 10.1016/0165-4608(94)00212-T; ONADIM Z, 1992, P NATL ACAD SCI USA, V89, P6177, DOI 10.1073/pnas.89.13.6177; POGOSIANZ H E, 1986, Archiv fuer Geschwulstforschung, V56, P135; QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; Sampieri K, 2006, J HUM GENET, V51, P209, DOI 10.1007/s10038-005-0348-3; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; SHEN WJ, 1995, J BIOL CHEM, V270, P20525, DOI 10.1074/jbc.270.35.20525; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIMIZU T, 1994, AM J HUM GENET, V54, P793; Sivakumaran T. A., 1997, Acta Geneticae Medicae et Gemellologiae, V46, P193; SQUIRE J, 1984, HUM GENET, V66, P46, DOI 10.1007/BF00275185; STERNER JM, 1995, J BIOL CHEM, V270, P9281, DOI 10.1074/jbc.270.16.9281; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Sterner JM, 1996, CELL GROWTH DIFFER, V7, P53; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; SUCKLING RD, 1982, BRIT J CANCER, V46, P729, DOI 10.1038/bjc.1982.265; TOGUCHIDA J, 1993, GENOMICS, V17, P535, DOI 10.1006/geno.1993.1368; Tosi GM, 2005, ONCOGENE, V24, P5827, DOI 10.1038/sj.onc.1208630; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; TURLEAU C, 1995, CANCER GENET CYTOGEN, V16, P321; VOGEL FRIEDRICH, 1954, ZEITSCHR MENSCHL VERERBUNGS U KONSTITUTIONSLEHRE, V32, P308; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Whitaker LL, 1998, MOL CELL BIOL, V18, P4032, DOI 10.1128/MCB.18.7.4032; Zeschnigk M, 1997, HUM MOL GENET, V6, P387, DOI 10.1093/hmg/6.3.387; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zheng L, 2002, CANCER RES, V62, P2498	94	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5333	5340		10.1038/sj.onc.1209614	http://dx.doi.org/10.1038/sj.onc.1209614			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936755				2022-12-17	WOS:000240064100020
J	Ito, S; Ito, Y; Senga, T; Hattori, S; Matsuo, S; Hamaguchi, M				Ito, S; Ito, Y; Senga, T; Hattori, S; Matsuo, S; Hamaguchi, M			v-Src requires Ras signaling for the suppression of gap junctional intercellular communication	ONCOGENE			English	Article						v-Src; Ras; gap junction; cell-cell communication; Connexin43	TYROSINE PHOSPHORYLATION; PROTEIN; CONNEXIN-43; INHIBITION; TRANSFORMATION; PERMEABILITY; MUTANT; STAT3	Cell transformation by v-Src causes suppression of gap junctional intercellular communication (GJIC). Although tyrosine phosphorylation of connexin43 (Cx43), a gap junctional component, appears to be necessary for the suppression, involvement of other signaling remains unclear. We investigated the role of Ras signaling in the suppression of GJIC by v-Src. Conditional expression of either S17N Ras or mtGap1m dramatically recovered GJIC in v-Src-transformed cells. Although expression of S17N Ras or mtGap1m substantially decreased the levels of active Ras, tyrosine phosphorylation of cellular proteins including Cx43 remained unchanged. Similarly, treatment of v-Src-transfomed cells with a Ras farnesyltransferase inhibitor, manumycin A, restored GJIC, whereas tyrosine phosphorylation of Cx43 remained unchanged. Thus, these results strongly suggest that, in addition to Cx43 phosphorylation, constitutive activation of Ras signaling is required for the suppression of GJIC by v-Src.	Nagoya Univ, Grad Sch Med, Div Canc Biol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Dept Internal Med, Div Clin Immunol,Showa Ku, Nagoya, Aichi 4668550, Japan; Univ Tokyo, Inst Med Sci, Div Cellular Genome Prote, Minato Ku, Tokyo, Japan	Nagoya University; Nagoya University; University of Tokyo	Hamaguchi, M (corresponding author), Nagoya Univ, Grad Sch Med, Div Canc Biol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	mhamagu@med.nagoya-u.ac.jp						ATKINSON M, 1984, J CELL BIOL, V99, pA401; ATKINSON MM, 1981, J CELL BIOL, V91, P573, DOI 10.1083/jcb.91.2.573; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Cameron SJ, 2003, J BIOL CHEM, V278, P18682, DOI 10.1074/jbc.M213283200; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Cottrell GT, 2003, AM J PHYSIOL-CELL PH, V284, pC511, DOI 10.1152/ajpcell.00214.2002; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Evans WH, 2002, MOL MEMBR BIOL, V19, P121, DOI 10.1080/09687680210139839; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HARA M, 1993, P NATL ACAD SCI USA, V90, P2281, DOI 10.1073/pnas.90.6.2281; Lampe PD, 2004, INT J BIOCHEM CELL B, V36, P1171, DOI 10.1016/S1357-2725(03)00264-4; Lin R, 2001, J CELL BIOL, V154, P815, DOI 10.1083/jcb.200102027; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; Saez JC, 2003, PHYSIOL REV, V83, P1359, DOI 10.1152/physrev.00007.2003; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; Turkson J, 1999, MOL CELL BIOL, V19, P7519; VANHAMME L, 1989, EXP CELL RES, V180, P297, DOI 10.1016/0014-4827(89)90234-6; Warn-Cramer BJ, 2004, BBA-BIOMEMBRANES, V1662, P81, DOI 10.1016/j.bbamem.2003.10.018; WarnCramer BJ, 1996, J BIOL CHEM, V271, P3779; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhou L, 1999, J CELL BIOL, V144, P1033, DOI 10.1083/jcb.144.5.1033	28	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2420	2424		10.1038/sj.onc.1209263	http://dx.doi.org/10.1038/sj.onc.1209263			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16301992				2022-12-17	WOS:000236764300013
J	Chen, E; Lim, MS; Rosic-Kablar, S; Liu, J; Jolicoeur, P; Dube, ID; Hough, MR				Chen, E; Lim, MS; Rosic-Kablar, S; Liu, J; Jolicoeur, P; Dube, ID; Hough, MR			Dysregulated expression of mitotic regulators is associated with B-cell lymphomagenesis in HOX11-transgenic mice	ONCOGENE			English	Article						HOX11; homeobox; aneuploidy; insertional mutagenesis	ACUTE LYMPHOBLASTIC-LEUKEMIA; INSERTIONAL MUTAGENESIS; DISEASE GENES; IDENTIFICATION; HOX11; IMMUNODEFICIENCY; VIRUS; INDUCTION; PATHWAY	Dysregulated expression of the homeobox gene, HOX11 is a frequent etiologic event in T-cell acute lymphoblastic leukemias. HOX11-transgenic mice ( IgH mu-HOX11(Tg))-expressing HOX11 in the B-cell compartment develop B-cell lymphomas with extended latency. The latency suggests that additional genetic events are required prior to the onset of malignant lymphoma. We report the identification of 17 HOX11 collaborating genes, revealed through their propensity to be targeted in a proviral insertional mutagenesis screen. Seven integrations disrupted genes in mitotic spindle checkpoint control, suggesting that cells with elevated HOX11 expression are especially sensitive to dysregulation of chromosome segregation during mitosis. IgH mu-HOX11(Tg) primary B-lymphocyte cultures exposed to the aneugenic agents, colchicine and colcemid, exhibited increased incidences of chromosome missegregation as assessed by cytokinesis-block micronucleus assays. Additionally, IgH mu-HOX11(Tg) cultures were shown to exhibit aberrant bypass of spindle checkpoint arrest, as assessed by the increased presence of cycling cells determined by assessment of DNA content and by BrdU immunolabelling. Western immunoblotting revealed elevated expression of the mitotic effector molecules, cyclin A, cyclin B1 and cdc20 in IgH mu-HOX11(Tg) cultures. Moreover, spontaneously arising lymphoid neoplasms in IgH mu-HOX11(Tg) mice frequently exhibit aberrant expression of mitotic regulators, concomitant with increased development of micronuclei, abnormal mitotic checkpoint control and increased incidences of abnormal karyotypes when expanded in culture. Collectively, these findings indicate that abnormal regulation of spindle checkpoint control as a result of HOX11 overexpression leads to a heightened predisposition for development of aneuploidy, contributing to oncogenesis.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Mol & Cellular Biol, Toronto, ON M4N 3M5, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A1, Canada; Univ Utah, Dept Pathol, Salt Lake City, UT USA; McGill Univ, Clin Res Inst Montreal, Montreal, PQ, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Toronto; Utah System of Higher Education; University of Utah; Institut de Recherche Clinique de Montreal (IRCM); McGill University; Universite de Montreal	Hough, MR (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Mol & Cellular Biol, 2075 Bayview Ave,Room S232, Toronto, ON M4N 3M5, Canada.	margaret.hough@sw.ca	Liu, Ju/Q-6319-2016; Hough, Margaret/AAA-1026-2019	Liu, Ju/0000-0001-9932-2613; Hough, Margaret/0000-0001-8539-6398; Chen, Edwin/0000-0003-0742-9734; Lim, Megan/0000-0002-0415-2867				Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; Asnafi V, 2005, BLOOD, V105, P3072, DOI 10.1182/blood-2004-09-3666; Asnafi V, 2004, BLOOD, V104, P4173, DOI 10.1182/blood-2003-11-3944; AZIZ DC, 1989, NATURE, V338, P505, DOI 10.1038/338505a0; BERNS A, 1991, J CELL BIOCHEM, V47, P130, DOI 10.1002/jcb.240470206; Bourner RDP, 1998, MUTAT RES-FUND MOL M, V404, P191, DOI 10.1016/S0027-5107(98)00113-4; Casabianca A, 2003, J VIROL METHODS, V110, P81, DOI 10.1016/S0166-0934(03)00104-6; CHATTOPADHYAY SK, 1989, P NATL ACAD SCI USA, V86, P3862, DOI 10.1073/pnas.86.10.3862; DUBE ID, 1986, BLOOD, V67, P1181; DUBE ID, 1991, BLOOD, V78, P2996; Erkeland SJ, 2004, J VIROL, V78, P1971, DOI 10.1128/JVI.78.4.1971-1980.2004; Ferrando AA, 2004, LANCET, V363, P535, DOI 10.1016/S0140-6736(04)15542-6; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Hough MR, 1998, P NATL ACAD SCI USA, V95, P13853, DOI 10.1073/pnas.95.23.13853; HUANG M, 1995, J VIROL, V69, P4069, DOI 10.1128/JVI.69.7.4069-4078.1995; HUANG M, 1989, SCIENCE, V246, P1614, DOI 10.1126/science.2480643; HUANG M, 1991, J VIROL, V65, P6562, DOI 10.1128/JVI.65.12.6562-6571.1991; HUANG M, 1992, J VIROL, V66, P2398, DOI 10.1128/JVI.66.4.2398-2406.1992; Hwang HC, 2002, P NATL ACAD SCI USA, V99, P11293, DOI 10.1073/pnas.162356099; Iwasaki M, 2005, BLOOD, V105, P784, DOI 10.1182/blood-2004-04-1508; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Kees UR, 2003, LEUKEMIA, V17, P887, DOI 10.1038/sj.leu.2402892; Kim R, 2003, J VIROL, V77, P2056, DOI 10.1128/JVI.77.3.2056-2062.2003; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; LICHTY BD, 1995, LEUKEMIA LYMPHOMA, V16, P209, DOI 10.3109/10428199509049759; Mauvieux L, 2002, LEUKEMIA, V16, P2417, DOI 10.1038/sj.leu.2402709; Morse HC, 2002, BLOOD, V100, P246, DOI 10.1182/blood.V100.1.246; Muehlbauer PA, 2005, MUTAT RES-GEN TOX EN, V585, P156, DOI 10.1016/j.mrgentox.2005.05.002; Rao H, 2001, NATURE, V410, P955, DOI 10.1038/35073627; Riz I, 2005, ONCOGENE, V24, P5561, DOI 10.1038/sj.onc.1208727; Rosic-Kablar S, 2000, P NATL ACAD SCI USA, V97, P13300, DOI 10.1073/pnas.240221297; Shin MS, 2004, CANCER RES, V64, P4419, DOI 10.1158/0008-5472.CAN-03-3885; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142	36	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2575	2587		10.1038/sj.onc.1209285	http://dx.doi.org/10.1038/sj.onc.1209285			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16407851				2022-12-17	WOS:000237099400002
J	Wang, Y; Zhang, Z; Lubet, RA; You, M				Wang, Y; Zhang, Z; Lubet, RA; You, M			A mouse model for tumor progression of lung cancer in ras and p53 transgenic mice	ONCOGENE			English	Article						lung; cancer; progression; ras; p53; transgenic mice	ONCOGENE ACTIVATION; SUPPRESSOR GENE; LIVER-TUMORS; MUTATIONS; PROTOONCOGENE; ADENOCARCINOMAS; ABSENCE; A/J; 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE; PREDISPOSITION	Although ras and p53 are the most commonly found oncogene and tumor suppressor gene, respectively, in human cancers, their collective roles in tumor progression have yet to be defined in animal models. Here, we demonstrated the synergistic effect between ras and p53 in promoting tumor progression during lung tumorigenesis using bitransgenic mice. Mice with a heterozygous knockout of K-ras (K-ras(wt/ko)) were mated to p53 transgenic mice (p53(val135/wt)) in lung tumorigenesis ( K-ras(wt/ko) x p53(val135/wt)). F-1 mice exhibited a significant increase in lung tumor load (tumor multiplicity x tumor volume) when compared to those seen in either K-ras(wt/ko) mice or p53(val135/wt) mice alone. Furthermore, over 50% of the lung tumors were lung adenocarcinomas in bitransgenic mice compared to only 3% in wild-type mice. Alterations of ras and p53 appear to promote the development of lung adenocarcinomas. These results provide the in vivo experimental evidence of synergistic interactions of ras and p53 in lung tumor progression.	Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA; NCI, Chemoprevent Branch, Bethesda, MD USA	Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	You, M (corresponding author), Washington Univ, Sch Med, Dept Surg, 660 S Euclid Ave, St Louis, MO 63110 USA.	youm@msnotes.wustl.edu			NATIONAL CANCER INSTITUTE [R01CA078797, R01CA058554] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA78797, R01CA58554] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; CANDRIAN U, 1991, CANCER RES, V51, P1148; CHEN B, 1994, CARCINOGENESIS, V15, P2031, DOI 10.1093/carcin/15.9.2031; CHEN B, 1994, P NATL ACAD SCI USA, V91, P1589, DOI 10.1073/pnas.91.4.1589; CHEN B, 1993, CARCINOGENESIS, V14, P1603, DOI 10.1093/carcin/14.8.1603; DEVEREUX TR, 1991, CARCINOGENESIS, V12, P299, DOI 10.1093/carcin/12.2.299; Diaz R, 2004, CARCINOGENESIS, V25, P535, DOI 10.1093/carcin/bgh026; Diaz R, 2002, CANCER RES, V62, P4514; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; Herzog CR, 1997, J CELL BIOCHEM, P49; HUSGAFVELPURSIAINEN K, 1993, INT J CANCER, V53, P250, DOI 10.1002/ijc.2910530213; Hwang SJ, 2003, HUM GENET, V113, P238, DOI 10.1007/s00439-003-0968-7; James RM, 2003, MOL CANCER RES, V1, P820; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; Lubet R, 2005, EXP LUNG RES, V31, P117, DOI 10.1080/01902140490495499; Lubet RA, 2000, EXP LUNG RES, V26, P581, DOI 10.1080/01902140150216684; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; MATZINGER SA, 1995, CARCINOGENESIS, V16, P2487, DOI 10.1093/carcin/16.10.2487; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P445, DOI 10.1002/mc.2940040606; SLEBOS RJC, 1992, J NATL CANCER I MONO, V13, P23; Thompson TA, 2002, ONCOGENE, V21, P2797, DOI 10.1038/sj.onc.1205391; Vachtenheim J, 1997, NEOPLASMA, V44, P145; Wang Y, 2003, CANCER RES, V63, P4389; WANG Y, 1993, CANCER RES, V53, P1620; WESTRA WH, 1993, CANCER-AM CANCER SOC, V72, P432, DOI 10.1002/1097-0142(19930715)72:2<432::AID-CNCR2820720219>3.0.CO;2-#; WESTRA WH, 1993, AM J SURG PATHOL, V17, P213, DOI 10.1097/00000478-199303000-00001; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; YOU M, 1991, EXP LUNG RES, V17, P389, DOI 10.3109/01902149109064426; YOU M, 1993, CARCINOGENESIS, V14, P1247, DOI 10.1093/carcin/14.6.1247; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721; Zhang ZQ, 2003, ONCOGENE, V22, P6257, DOI 10.1038/sj.onc.1206630; Zhang ZQ, 2000, CANCER RES, V60, P901; Zhang ZQ, 2002, CANCER RES, V62, P3024	40	15	16	3	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1277	1280		10.1038/sj.onc.1209182	http://dx.doi.org/10.1038/sj.onc.1209182			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16247444				2022-12-17	WOS:000235537500015
J	Passioura, T; Shen, S; Symonds, G; Dolnikov, A				Passioura, T; Shen, S; Symonds, G; Dolnikov, A			A retroviral library genetic screen identifies IRF-2 as an inhibitor of N-ras-induced growth suppression in leukemic cells	ONCOGENE			English	Article						N-ras; IRF-2; leukemia	FULL-LENGTH HUMAN; MESSENGER-RNA; ONCOGENIC RAS; P53; EXPRESSION; PML; DIFFERENTIATION; PROLIFERATION; PROTOONCOGENES; ACTIVATION	Activating mutations of the N- ras gene occur at relatively high frequency in acute myeloid leukemia and myelodysplastic syndrome. Somewhat paradoxically, ectopic expression of activated N-ras in primary hematopoietic cells and myeloid cell lines (in some cases) can lead to inhibition of proliferation. Expression of mutant N-ras in murine hematopoietic stem/progenitor cells is sufficient to induce myeloid malignancies, but these pathologies occur with long latency. This suggests that mutations that disable the growth suppressive properties of N-ras in hematopoietic cells are required for the development of frank malignancy. In the present work, the growth suppression induced by a mutant N- ras gene in U937 myeloid cells was used as the basis to screen a retroviral cDNA library for genes that prevent mutant N-ras-induced growth suppression (i.e., putative cooperating oncogenes). This screen identifi. ed the gene for the transcription factor interferon regulatory factor-2 ( IRF-2), and as con. firmation of the screen, overexpression of this gene in U937 cells was shown to inhibit mutant N-ras-induced growth suppression. Also recovered from the screen were two truncated clones of an uncharacterized gene ( interim of. ficial symbol: PP2135). Overexpression of this truncated PP2135 gene in U937 cells did not appear to abrogate mutant N-ras-induced growth suppression, but rather appeared to confer an increased sensitivity of U937 cells to retroviral infection, accounting for the recovery of this gene from the genetic screen.	Univ New S Wales, Sch Med Sci, Sydney, NSW, Australia; Johnson & Johnson Res, Childrens Canc Inst Australia, Sydney, NSW 2012, Australia	University of New South Wales Sydney; Children's Cancer Institute; Johnson & Johnson	Symonds, G (corresponding author), Univ New S Wales, Sch Med Sci, Sydney, NSW, Australia.	gsymonds@medau.jnj.com		Passioura, Toby/0000-0002-6089-5067				Appelbaum F R, 2001, Hematology Am Soc Hematol Educ Program, P62; Chan IT, 2004, J CLIN INVEST, V113, P528, DOI 10.1172/JCI200420476; Clark HF, 2003, GENOME RES, V13, P2265, DOI 10.1101/gr.1293003; Coccia EM, 1999, ONCOGENE, V18, P2129, DOI 10.1038/sj.onc.1202536; Darley RL, 1997, J EXP MED, V185, P1337, DOI 10.1084/jem.185.7.1337; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; Delgado MD, 2000, ONCOGENE, V19, P783, DOI 10.1038/sj.onc.1203384; Dolnikov A, 2000, CANCER GENE THER, V7, P1491, DOI 10.1038/sj.cgt.7700229; Dolnikov A, 2003, J GEN VIROL, V84, P3131, DOI 10.1099/vir.0.19099-0; Dolnikov A, 2003, CANCER GENE THER, V10, P745, DOI 10.1038/sj.cgt.7700603; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ferbeyre G, 2000, GENE DEV, V14, P2015; HARADA H, 1994, ONCOGENE, V9, P3313; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Lallemand C, 2002, EMBO REP, V3, P153, DOI 10.1093/embo-reports/kvf032; Lallemand C, 1997, J BIOL CHEM, V272, P29801, DOI 10.1074/jbc.272.47.29801; MacKenzie KL, 1999, BLOOD, V93, P2043, DOI 10.1182/blood.V93.6.2043.406k17_2043_2056; Maher J, 1996, LEUKEMIA, V10, P83; Matsumura I, 2000, BLOOD, V96, P2440; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; NEUBAUER A, 1994, LEUKEMIA, V8, P638; NEUBAUER A, 1994, BLOOD, V83, P1603; Ota T, 2004, NAT GENET, V36, P40, DOI 10.1038/ng1285; Passioura T, 2005, CANCER RES, V65, P797; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Preisler HD, 2001, AM J HEMATOL, V68, P23, DOI 10.1002/ajh.1144; Rubinstein YR, 2000, ONCOGENE, V19, P1411, DOI 10.1038/sj.onc.1203435; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shen SW, 2004, EXP HEMATOL, V32, P852, DOI 10.1016/j.exphem.2004.06.001; Shiohara M, 1996, J CELL PHYSIOL, V166, P568, DOI 10.1002/(SICI)1097-4652(199603)166:3<568::AID-JCP11>3.0.CO;2-3; Stadler M, 1995, ONCOGENE, V11, P2565; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Xi HK, 2003, MOL IMMUNOL, V39, P677, DOI 10.1016/S0161-5890(02)00214-6; Xie RL, 2002, CANCER RES, V62, P2510	39	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7327	7336		10.1038/sj.onc.1208877	http://dx.doi.org/10.1038/sj.onc.1208877			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16007130				2022-12-17	WOS:000233142100009
J	Tynan, JA; Wen, F; Muller, WJ; Oshima, RG				Tynan, JA; Wen, F; Muller, WJ; Oshima, RG			Ets2-dependent microenvironmental support of mouse mammary tumors	ONCOGENE			English	Article						Ets2; breast cancer; Cre recombinase; stroma	EXPRESSION; ONCOGENE; MODEL; ETS2; MICE	Decreasing the amount of active mouse Ets2 transcription factor by half in mice or use of a MAP kinase insensitive hypomorphic targeted Ets2 allele restricts the appearance of transgenic mammary tumors caused by either Polyoma middle T antigen (PyMT) or activated Neu/ErbB2. In addition, the early growth of transplanted mammary tumors is limited by restricted Ets2 activity of the host. Here we have tested genetically, with the use of a conditional Ets2(flox) allele and tissue specific Cre recombinase expression, whether Ets2 also functions within tumor cells by inactivating Ets2 within mammary luminal epithelial cells from which transgenic PyMTY315/(322F) tumors arise. We find that inactivation of Ets2 within tumor cells has no effect on tumor appearance or growth. By contrast, complete inactivation of Ets2 in both epithelial and stromal cells moderates the early hyperplastic phase of tumor development and the time of tumor appearance but does not prevent tumor occurrence and has no detectable effect on tumor growth. Thus, Ets2 supports mammary tumors exclusively through their microenvironment.	Burnham Inst, Canc Res Ctr, Oncodev Biol Program, La Jolla, CA 92037 USA; Univ Calif San Diego, Grad Program Mol Pathol, La Jolla, CA 92093 USA; McGill Univ, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego; McGill University	Oshima, RG (corresponding author), Burnham Inst, Canc Res Ctr, Oncodev Biol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rgoshima@burnham.org			NCI NIH HHS [1T32CA77109-04, CA098778, CA74547] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074547, T32CA077109, R01CA098778] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hayakawa T, 2001, J STAT PLAN INFER, V97, P101, DOI 10.1016/S0378-3758(00)00348-7; Hever A, 2003, EXP CELL RES, V290, P132, DOI 10.1016/S0014-4827(03)00315-X; Lelievre E, 2001, INT J BIOCHEM CELL B, V33, P391, DOI 10.1016/S1357-2725(01)00025-5; Man AK, 2003, MOL CELL BIOL, V23, P8614, DOI 10.1128/MCB.23.23.8614-8625.2003; Neznanov N, 1999, CANCER RES, V59, P4242; Oshima RG, 2004, CANCER RES, V64, P169, DOI 10.1158/0008-5472.CAN-03-1944; Sapi E, 1998, CANCER RES, V58, P1027; Sato Y, 2001, CELL STRUCT FUNCT, V26, P19, DOI 10.1247/csf.26.19; Tallquist MD, 2000, GENESIS, V26, P113, DOI 10.1002/(SICI)1526-968X(200002)26:2<113::AID-GENE3>3.0.CO;2-2; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; Wei G, 2004, J IMMUNOL, V173, P1374, DOI 10.4049/jimmunol.173.2.1374; WERNERT N, 1992, AM J PATHOL, V140, P119; Yamamoto H, 1998, GENE DEV, V12, P1315, DOI 10.1101/gad.12.9.1315	15	15	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6870	6876		10.1038/sj.onc.1208856	http://dx.doi.org/10.1038/sj.onc.1208856			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007139	Green Submitted			2022-12-17	WOS:000232701700002
J	Aouacheria, A; Navratil, V; Wen, WY; Jiang, M; Mouchiroud, D; Gautier, C; Gouy, M; Zhang, MJ				Aouacheria, A; Navratil, V; Wen, WY; Jiang, M; Mouchiroud, D; Gautier, C; Gouy, M; Zhang, MJ			In silico whole-genome scanning of cancer-associated nonsynonymous SNPs and molecular characterization of a dynein light chain tumour variant	ONCOGENE			English	Article						single-nucleotide polymorphism; DNCL1; cancer genomics; cancer association study; dynein light chain; expressed sequence tags	SINGLE-NUCLEOTIDE POLYMORPHISMS; ACID SUBSTITUTION VARIANTS; INITIATION-FACTORS EIF-4E; AFFECT PROTEIN FUNCTION; NITRIC-OXIDE SYNTHASE; DNA-REPAIR GENES; SEQUENCE VARIATION; STRUCTURAL BASIS; MOTOR COMPLEX; CELL-ADHESION	Last decade has led to the accumulation of large amounts of data on cancer genetics, opening an unprecedented access to the mapping of cancer genes in the human genome. Single-nucleotide polymorphisms ( SNPs), the most common form of DNA variation in humans, emerge as an invaluable tool for cancer association studies. These genotypic markers can be used to assay how alleles of candidate genes correlate with the malignant phenotype, and may provide new clues into the genetic modi. cations that characterize cancer onset. In this cancer-oriented study, we detail an SNP mining strategy based on the analysis of expressed sequence tags among publicly available databases. Our whole-genome approach provides a comprehensive and unbiased description of nonsynonymous SNPs ( nsSNPs) in tumoral versus normal tissues. To gain further insights into the possible relationships between genetic variation and altered phenotype, locations of a subset of nsSNPs were mapped onto protein domains known to be critical for protein function. Computational methods were also used to predict the potential impact of these cancer-associated nsSNPs on protein structure and function. We illustrate our approach through the detailed biochemical and structural characterization of a previously unknown cancer-associated mutation ( G79C) affecting the 8 kDa dynein light chain ( DNCL1).	Univ Lyon 1, CNRS, UMR 5558, Lab Biometr & Biol Evolut, F-69622 Villeurbanne, France; Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; VetAgro Sup; Hong Kong University of Science & Technology	Aouacheria, A (corresponding author), Univ Lyon 1, CNRS, UMR 5558, Lab Biometr & Biol Evolut, F-69622 Villeurbanne, France.	aouacher@biomserv.univ-lyon1.fr	navratil, vincent/C-4193-2008	Zhang, Mingjie/0000-0001-9404-0190; navratil, vincent/0000-0001-9974-1877				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Bassen R, 2000, B CANCER, V87, P703; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Buetow KH, 2001, P NATL ACAD SCI USA, V98, P581, DOI 10.1073/pnas.021506298; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Cerni C, 2002, ONCOGENE, V21, P447, DOI 10.1038/sj.onc.1205107; Chakravarti A, 1998, NAT GENET, V19, P216, DOI 10.1038/885; Chasman D, 2001, J MOL BIOL, V307, P683, DOI 10.1006/jmbi.2001.4510; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; Dick T, 1996, MOL CELL BIOL, V16, P1966; Draptchinskaia N, 1999, NAT GENET, V21, P169, DOI 10.1038/5951; Fan JS, 2001, J MOL BIOL, V306, P97, DOI 10.1006/jmbi.2000.4374; Fan JS, 1998, J BIOL CHEM, V273, P33472, DOI 10.1074/jbc.273.50.33472; Farmer BT, 1996, NAT STRUCT BIOL, V3, P995, DOI 10.1038/nsb1296-995; Fleming MA, 2003, P NATL ACAD SCI USA, V100, P1151, DOI 10.1073/pnas.0237285100; Fuhrmann JC, 2002, J NEUROSCI, V22, P5393; Gorelik E, 2001, CANCER METAST REV, V20, P245, DOI 10.1023/A:1015535427597; GOUY M, 1985, COMPUT APPL BIOSCI, V1, P167; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Iida A, 2002, J HUM GENET, V47, P285, DOI 10.1007/s100380200041; Imyanitov EN, 2004, CANCER LETT, V204, P3, DOI 10.1016/j.canlet.2003.09.026; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Jin H, 2004, BRIT J CANCER, V90, P561, DOI 10.1038/sj.bjc.6601576; Johnson JP, 1999, CANCER METAST REV, V18, P345, DOI 10.1023/A:1006304806799; Liang J, 1999, NAT STRUCT BIOL, V6, P735; Lo KWH, 2001, J BIOL CHEM, V276, P14059, DOI 10.1074/jbc.M010320200; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Mohrenweiser HW, 2002, CANCER EPIDEM BIOMAR, V11, P1054; Mulder NJ, 2003, NUCLEIC ACIDS RES, V31, P315, DOI 10.1093/nar/gkg046; Naisbitt S, 2000, J NEUROSCI, V20, P4524, DOI 10.1523/JNEUROSCI.20-12-04524.2000; Naora H, 1998, J CELL BIOL, V141, P741, DOI 10.1083/jcb.141.3.741; Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509; Ng PC, 2002, GENOME RES, V12, P436, DOI 10.1101/gr.212802; Nomoto S, 1999, ONCOGENE, V18, P7180, DOI 10.1038/sj.onc.1203141; Phillis R, 1996, DEVELOPMENT, V122, P2955; POTEETE AR, 1992, PROTEINS, V13, P38, DOI 10.1002/prot.340130104; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj/cdd/4400998; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Qiu P, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-4; Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493; Reich DE, 2003, NAT GENET, V33, P457, DOI 10.1038/ng1133; Rosenwald IB, 1996, CANCER LETT, V102, P113, DOI 10.1016/0304-3835(96)04171-7; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Sajantila A, 1999, EUR J HUM GENET, V7, P263, DOI 10.1038/sj.ejhg.5200257; Sass PM, 1998, CANCER INVEST, V16, P322, DOI 10.3109/07357909809084652; Schnorrer F, 2000, NAT CELL BIOL, V2, P185, DOI 10.1038/35008601; Stitziel NO, 2003, J MOL BIOL, V327, P1021, DOI 10.1016/S0022-2836(03)00240-7; Strausberg RL, 2003, NAT REV GENET, V4, P409, DOI 10.1038/nrg1085; Sunyaev S, 2000, TRENDS GENET, V16, P198, DOI 10.1016/S0168-9525(00)01988-0; Sunyaev S, 2001, HUM MOL GENET, V10, P591, DOI 10.1093/hmg/10.6.591; Sunyaev S, 2001, CURR OPIN STRUC BIOL, V11, P125, DOI 10.1016/S0959-440X(00)00175-5; Turk V, 2004, CANCER CELL, V5, P409, DOI 10.1016/S1535-6108(04)00117-5; Vadlamudi RK, 2004, CANCER CELL, V5, P575, DOI 10.1016/j.ccr.2004.05.022; Wall Steven J., 2003, Cancer Research, V63, P4750; Wang WN, 2003, J BIOL CHEM, V278, P41491, DOI 10.1074/jbc.M307118200; Wang Z, 2001, HUM MUTAT, V17, P263, DOI 10.1002/humu.22; Xi T, 2004, GENOMICS, V83, P970, DOI 10.1016/j.ygeno.2003.12.016	63	15	18	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6133	6142		10.1038/sj.onc.1208745	http://dx.doi.org/10.1038/sj.onc.1208745			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	15897869				2022-12-17	WOS:000231718100007
J	Kuns, R; Kissil, JL; Newsham, IF; Jacks, T; Gutmann, DH; Sherman, LS				Kuns, R; Kissil, JL; Newsham, IF; Jacks, T; Gutmann, DH; Sherman, LS			Protein 4.1B expression is induced in mammary epithelial cells during pregnancy and regulates their proliferation	ONCOGENE			English	Article						protein 4.1B; erbB2; mammary epithelial cells; pregnancy; mammary carcinoma	BREAST-CANCER CELLS; NEUROFIBROMATOSIS-2 TUMOR-SUPPRESSOR; EPIDERMAL-GROWTH-FACTOR; FUNCTIONAL-CHARACTERIZATION; CARCINOMA-CELLS; FAMILY MEMBERS; LUNG-CANCER; FERM DOMAIN; EZRIN; GENE	4.1B is a member of the protein 4.1 superfamily of proteins that link transmembrane proteins to the actin cytoskeleton. The 4.1B gene localizes to chromosome 18p11.3, which undergoes loss of heterozygosity in mammary tumors. Here, we examine the expression of 4.1B in murine mammary epithelium and find that 4.1B is dramatically upregulated in mammary epithelial cells during pregnancy when there is extensive cell proliferation. In contrast, 4.1B is not expressed in virgin, lactating, or involuting mammary epithelium. To examine the consequence of 4.1B loss on mammary epithelial cell proliferation, we analysed mammary glands in 4.1B-null mice. 4.1B loss results in a significant increase in mammary epithelial cell proliferation during pregnancy, but has no effect on mammary epithelial cell proliferation, in virgin or involuting mice. Furthermore, we show that 4.1B inhibits the proliferation of mammary epithelial cell lines by inducing a G(1) cell cycle arrest, characterized by decreased cyclin A expression and reduced Rb phosphorylation, and accompanied by reduced erbB2 phosphorylation. This cell cycle arrest does not involve alterations in the activities of MAPK, JNK, or Akt. Collectively, our findings demonstrate that 4.1B regulates mammary epithelial cell proliferation during pregnancy and suggest that its loss may influence mammary carcinoma pathogenesis in multiparous women.	Oregon Hlth Sci Univ, Oregon Natl Primate Res Ctr, Div Neurosci, Beaverton, OR 97006 USA; Univ Cincinnati, Sch Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA; Wistar Inst Anat & Biol, Mol & Cellular Oncogenom Program, Philadelphia, PA 19104 USA; Henry Ford Hosp, Hermelin Brain Tumor Ctr, Dept Neurosurg, David & Hermelin Lab Mol Oncogenet, Detroit, MI 48202 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Canc Res Ctr, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Oregon Health & Science University; Oregon National Primate Research Center; University System of Ohio; University of Cincinnati; The Wistar Institute; Henry Ford Health System; Henry Ford Hospital; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Washington University (WUSTL)	Sherman, LS (corresponding author), Oregon Hlth Sci Univ, Oregon Natl Primate Res Ctr, Div Neurosci, 505 NW 185th Ave, Beaverton, OR 97006 USA.	shermanl@ohsu.edu		Gutmann, David/0000-0002-3127-5045	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041520, R01NS039550] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00163] Funding Source: Medline; NINDS NIH HHS [NS41520, NS39550] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akisawa N, 1999, BIOCHEM BIOPH RES CO, V258, P395, DOI 10.1006/bbrc.1999.0653; Allred DC, 2000, J MAMMARY GLAND BIOL, V5, P351, DOI 10.1023/A:1009573710675; Batchelor CL, 2004, EXP CELL RES, V296, P208, DOI 10.1016/j.yexcr.2004.02.010; Charboneau AL, 2002, INT J CANCER, V100, P181, DOI 10.1002/ijc.10470; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Chu I, 2005, CANCER RES, V65, P18; Cuppen E, 1999, J CELL SCI, V112, P3299; Daniel CW, 1999, J MAMMARY GLAND BIOL, V4, P3, DOI 10.1023/A:1018796301609; Faltus T, 2004, NEOPLASIA, V6, P786, DOI 10.1593/neo.04313; Fraenzer JT, 2003, INT J ONCOL, V23, P1493; Gascard P, 2004, BBA-GENE STRUCT EXPR, V1680, P71, DOI 10.1016/j.bbaexp.2004.08.006; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; GERDES J, 1984, J IMMUNOL, V133, P1710; Ghatak S, 2005, J BIOL CHEM, V280, P8875, DOI 10.1074/jbc.M410882200; Gimm JA, 2002, BIOCHEMISTRY-US, V41, P7275, DOI 10.1021/bi0256330; Gutmann DH, 2001, NEUROBIOL DIS, V8, P266, DOI 10.1006/nbdi.2000.0376; Gutmann DH, 2000, HUM MOL GENET, V9, P1495, DOI 10.1093/hmg/9.10.1495; Hall IJ, 2005, AM J EPIDEMIOL, V161, P40, DOI 10.1093/aje/kwh331; Hunter KW, 2004, TRENDS MOL MED, V10, P201, DOI 10.1016/j.molmed.2004.03.001; Jhabvala-Romero F, 2003, ONCOGENE, V22, P8178, DOI 10.1038/sj.onc.1206912; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Kittiniyom K, 2004, GENE CHROMOSOME CANC, V40, P190, DOI 10.1002/gcc.20034; Kittiniyom K, 2001, BREAST CANCER RES, V3, P192, DOI 10.1186/bcr294; LUTCHMAN M, 1995, CANCER RES, V55, P2270; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; Muranen T, 2005, ONCOGENE, V24, P1150, DOI 10.1038/sj.onc.1208283; Parra M, 2000, J BIOL CHEM, V275, P3247, DOI 10.1074/jbc.275.5.3247; Peters LL, 1998, GENOMICS, V54, P348, DOI 10.1006/geno.1998.5537; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Richert MM, 2000, J MAMMARY GLAND BIOL, V5, P227, DOI 10.1023/A:1026499523505; Robb VA, 2003, NEUROBIOL DIS, V13, P191, DOI 10.1016/S0969-9961(03)00071-8; Robb VA, 2005, ONCOGENE, V24, P1946, DOI 10.1038/sj.onc.1208335; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Sebastian J, 1998, CELL GROWTH DIFFER, V9, P777; Singh PK, 2002, MODERN PATHOL, V15, P526, DOI 10.1038/modpathol.3880558; Singh V, 2004, ONCOGENE, V23, P7761, DOI 10.1038/sj.onc.1208057; Stern DF, 2003, EXP CELL RES, V284, P89, DOI 10.1016/S0014-4827(02)00103-9; Stull MA, 2004, J MAMMARY GLAND BIOL, V9, P15, DOI 10.1023/B:JOMG.0000023585.95430.f4; Surace EI, 2004, J NEUROPATH EXP NEUR, V63, P1015, DOI 10.1093/jnen/63.10.1015; Tran Y, 1998, ONCOGENE, V17, P3499, DOI 10.1038/sj.onc.1202258; Tran YK, 1999, CANCER RES, V59, P35; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Whiteman MK, 2004, OBSTET GYNECOL, V104, P146, DOI 10.1097/01.AOG.0000128173.01611.ff; Wobus M, 2002, APPL IMMUNOHISTO M M, V10, P34, DOI 10.1097/00022744-200203000-00006; Yageta M, 2002, CANCER RES, V62, P5129; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966	53	15	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6502	6515		10.1038/sj.onc.1208813	http://dx.doi.org/10.1038/sj.onc.1208813			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16007173	Bronze			2022-12-17	WOS:000232204100004
J	Rong, R; Montalbano, J; Jin, WX; Zhang, J; Garling, M; Sheikh, MS; Huang, Y				Rong, R; Montalbano, J; Jin, WX; Zhang, J; Garling, M; Sheikh, MS; Huang, Y			Oncogenic Ras-mediated downregulation of Gadd153/CHOP is required for Ras-induced cellular transformation	ONCOGENE			English	Article						Ras; Gadd153; gene regulation; transformation	MESSENGER-RNA STABILITY; INTESTINAL EPITHELIAL-CELLS; INDUCED APOPTOSIS; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; SENSITIZES CELLS; DEATH RECEPTOR-5; GENOTOXIC STRESS; GROWTH ARREST; PROTEIN PAR-4	Oncogenic Ras proteins transform cells via multiple downstream signaling cascades that are important for cell proliferation and survival. Gadd153, also known as CHOP, is a growth inhibitory and proapoptotic protein and its expression is upregulated by many agents that induce apoptosis. Here, we report our novel findings that oncogenic Ras downregulates Gadd153 expression at both protein and mRNA levels and that such downregulation occurs, at least in part, via decreases in GADD153 mRNA stability. Gadd153 downregulation is specific to oncogenic Ras since another oncogenic family member R-Ras2/TC21 does not downregulate Gadd153. W e further demonstrate that the expression of exogenous Gadd153 interferes with Ras-induced oncogenic transformation, which suggests that downregulation of Gadd153 appears to be an important mechanism by which oncogenic Ras promotes cellular transformation. Thus, oncogenic Ras-mediated cellular transformation also involves down-modulation of important molecules such as Gadd153 that negatively regulate cell growth and survival.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Huang, Y (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	huangy@upstate.edu			NATIONAL CANCER INSTITUTE [R01CA086945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK067271, R21DK062136] Funding Source: NIH RePORTER; NCI NIH HHS [CA86945] Funding Source: Medline; NIDDK NIH HHS [DK067271-01, DK62136-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; Barradas M, 1999, EMBO J, V18, P6362, DOI 10.1093/emboj/18.22.6362; BARTLETT JD, 1992, J BIOL CHEM, V267, P20465; BOS JL, 1995, TRENDS BIOCHEM SCI, V20, P441, DOI 10.1016/S0968-0004(00)89097-0; BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; Chen CH, 1996, ONCOGENE, V13, P1659; CHOI AMK, 1994, FASEB J, V8, P1048, DOI 10.1096/fasebj.8.13.7926370; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Gotoh T, 2004, CELL DEATH DIFFER, V11, P390, DOI 10.1038/sj.cdd.4401369; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; Halleck MM, 1997, J BIOL CHEM, V272, P21760, DOI 10.1074/jbc.272.35.21760; He Q, 2002, ONCOGENE, V21, P2623, DOI 10.1038/sj.onc.1205345; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Huang Y, 2001, CANCER RES, V61, P6918; HUANG Y, 1995, ONCOGENE, V11, P1255; JACKMAN J, 1994, CANCER RES, V54, P5656; Jousse C, 2001, NUCLEIC ACIDS RES, V29, P4341, DOI 10.1093/nar/29.21.4341; Kim DG, 2002, J BIOL CHEM, V277, P38930, DOI 10.1074/jbc.M205941200; LopezBarahona M, 1996, ONCOGENE, V12, P463; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; LUETHY JD, 1992, CANCER RES, V52, P5; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; Maytin EV, 2001, EXP CELL RES, V267, P193, DOI 10.1006/excr.2001.5248; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Murphy GA, 2002, J BIOL CHEM, V277, P9966, DOI 10.1074/jbc.M109059200; Nalca A, 1999, J BIOL CHEM, V274, P29976, DOI 10.1074/jbc.274.42.29976; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; PRICE BD, 1992, CANCER RES, V52, P3814; Qiu SG, 1999, ONCOGENE, V18, P7115, DOI 10.1038/sj.onc.1203199; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Rong R, 2002, ONCOGENE, V21, P1062, DOI 10.1038/sj.onc.1205154; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; Rosario M, 2001, MOL CELL BIOL, V21, P3750, DOI 10.1128/MCB.21.11.3750-3762.2001; Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7; Sato N, 2000, NAT CELL BIOL, V2, P863, DOI 10.1038/35046500; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheng HM, 2001, J BIOL CHEM, V276, P14498, DOI 10.1074/jbc.M010093200; Ubeda M, 1999, BIOCHEM BIOPH RES CO, V262, P31, DOI 10.1006/bbrc.1999.1140; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang XZ, 1996, MOL CELL BIOL, V16, P4273	53	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4867	4872		10.1038/sj.onc.1208660	http://dx.doi.org/10.1038/sj.onc.1208660			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15870698				2022-12-17	WOS:000230477900014
J	Elias, B; Laine, A; Ronai, Z				Elias, B; Laine, A; Ronai, Z			Phosphorylation of MdmX by CDK2/Cdc2(p34) is required for nuclear export of Mdm2	ONCOGENE			English	Article						CDK2; mdm2; MdmX; nuclear export; phosphorylation; stability	P53-BINDING PROTEIN; UBIQUITIN LIGASE; DNA-DAMAGE; P53; EXPRESSION; TRANSACTIVATION; OVEREXPRESSION; AMPLIFICATION; DEGRADATION; MECHANISMS	Mdm2 and MdmX function as cellular regulators of the p53 tumor suppressor protein. Intriguingly, the activities of these proteins are interdependent; MdmX stabilizes Mdm2, enabling its activities towards p53, but it also requires Mdm2 for its nuclear localization. Here we demonstrate that via its phosphorylation by CDK2/Cdc2(p34), MdmX regulates nuclear export of Mdm2. Cdc2(p34) phosphorylates MdmX on Ser 96 in vitro. Mutation within this site (MdmXS96A) impairs, whereas phosphomimic substitution (MdmXS96D) increases the cytoplasmic localization of MdmX, suggesting that CDK2/Cdc2p34 phosphorylation is required for export of MdmX from the nucleus. Consequently, cells that express MdmXS96A retain Mdm2 in their nuclei, suggesting that export of Mdm2 to the cytoplasm is MdmX-dependent. Similarly, treatment of cells with the pharmacologicalinhibitor of CDK2/Cdc2p34 or with a dominant-negative Cdc2 results in nuclear localization of MdmX and Mdm2 and decreases the level of Mdm2 expression. Since Cdc2p34 is active in nonstressed conditions, our finding provides a novel insight into the signaling cascade involved in the regulation of MdmX localization and for regulation of Mdm2 localization and stability.	Mt Sinai Sch Med, Ctr Canc, Dept Oncol Sci, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Ronai, Z (corresponding author), Mt Sinai Sch Med, Ctr Canc, Dept Oncol Sci, 1 Gustave Levy L Pl,Box 1130, New York, NY 10029 USA.	zeev.ronai@mssm.edu		RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA59908] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059908] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALARCONVARGAS D, 2003, ADV CANCER RES, V89, P1; Badciong JC, 2002, J BIOL CHEM, V277, P49668, DOI 10.1074/jbc.M208593200; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Finch RA, 2002, CANCER RES, V62, P3221; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Ghosh M, 2003, BIOCHEMISTRY-US, V42, P2291, DOI 10.1021/bi0271291; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Jackson MW, 1999, DNA CELL BIOL, V18, P693, DOI 10.1089/104454999314971; Li CG, 2002, MOL CELL BIOL, V22, P7562, DOI 10.1128/MCB.22.21.7562-7571.2002; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Migliorini D, 2002, J BIOL CHEM, V277, P7318, DOI 10.1074/jbc.M108795200; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Parant JM, 2001, GENE, V270, P277, DOI 10.1016/S0378-1119(01)00432-2; Ramos YFM, 2001, CANCER RES, V61, P1839; Riemenschneider MJ, 1999, CANCER RES, V59, P6091; Sabbatini P, 2002, DNA CELL BIOL, V21, P519, DOI 10.1089/104454902320219077; Shah OJ, 2003, J BIOL CHEM, V278, P16433, DOI 10.1074/jbc.M300435200; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Shvarts A, 1997, GENOMICS, V43, P34, DOI 10.1006/geno.1997.4775; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Zhang TT, 2001, J BIOL CHEM, V276, P29702, DOI 10.1074/jbc.M011326200	27	15	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2574	2579		10.1038/sj.onc.1208488	http://dx.doi.org/10.1038/sj.onc.1208488			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735705				2022-12-17	WOS:000228180600015
J	Wasylyk, C; Criqui-Filipe, P; Wasylyk, B				Wasylyk, C; Criqui-Filipe, P; Wasylyk, B			Sumoylation of the net inhibitory domain (NID) is stimulated by PIAS1 and has a negative effect on the transcriptional activity of Net	ONCOGENE			English	Article						Ubc9; E3 ligase; ternary complex factor; Elk-3; Sap-2; Erp	UBIQUITIN-CONJUGATING ENZYME; ACTIVATED STAT; ANDROGEN RECEPTOR; PROTEIN INHIBITOR; SUMO MODIFICATION; FAMILY PROTEINS; FOS PROMOTER; NUCLEAR; REPRESSION; BINDING	Net (Elk-3, Sap-2, Erp) and the related ternary complex factors Elk-1 and Sap-1 are effectors of multiple signalling pathways at the transcriptional level and play a key role in the dynamic regulation of gene expression. Net is distinct from Elk-1 and Sap-1, in that it is a strong repressor of transcription that is converted to an activator by the Ras/Erk signalling pathway. Two autonomous repression domains of Net, the NID and the CID, mediate repression. We have previously shown that the corepressor CtBP is implicated in repression by the CID. In this report we show that repression by the NID involves a different pathway, sumoylation by Ubc9 and PIAS1. PIAS1 interacts with the NID in the two-hybrid assay and in vitro. Ubc9 and PIAS1 stimulate sumoylation in vivo of lysine 162 in the NID. Sumoylation of lysine 162 increases repression by Net and decreases the positive activity of Net. These results increase our understanding of how one of the ternary complex factors regulates transcription, and contribute to the understanding of how different domains of a transcription factor participate in the complexity of regulation of gene expression.	ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Wasylyk, B (corresponding author), ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 10142, F-67404 Illkirch Graffenstaden, France.	boh@igbmc.u-strasbg.fr	Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chinnadurai G, 2003, BIOESSAYS, V25, P9, DOI 10.1002/bies.10212; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Giovane A, 1997, MOL CELL BIOL, V17, P5667, DOI 10.1128/MCB.17.10.5667; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Hahn SL, 1997, ONCOGENE, V15, P1489, DOI 10.1038/sj.onc.1201301; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; Janknecht R, 1996, ONCOGENE, V12, P1961; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kim J, 2002, J BIOL CHEM, V277, P38037, DOI 10.1074/jbc.M207235200; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Le Drean Y, 2002, ENDOCRINOLOGY, V143, P3482, DOI 10.1210/en.2002-220135; Lin X, 2003, MOL CELL, V11, P1389, DOI 10.1016/S1097-2765(03)00175-8; Long JY, 2003, P NATL ACAD SCI USA, V100, P9791, DOI 10.1073/pnas.1733973100; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; Megidish T, 2002, J BIOL CHEM, V277, P8255, DOI 10.1074/jbc.C200001200; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Salinas S, 2004, J CELL BIOL, V165, P767, DOI 10.1083/jcb.200310136; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018-003-3129-1; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Sharrocks AD, 2002, BIOCHEM SOC T, V30, P1; Shaw PE, 2003, INT J BIOCHEM CELL B, V35, P1210, DOI 10.1016/S1357-2725(03)00031-1; Subramanian L, 2003, J BIOL CHEM, V278, P9134, DOI 10.1074/jbc.M210440200; Tan JA, 2002, J BIOL CHEM, V277, P16993, DOI 10.1074/jbc.M109217200; Tussie-Luna MI, 2002, P NATL ACAD SCI USA, V99, P12807, DOI 10.1073/pnas.192464499; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378-1119(03)00816-3; Yang SH, 2002, MOL CELL BIOL, V22, P5036, DOI 10.1128/MCB.22.14.5036-5046.2002; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X	43	15	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					820	828		10.1038/sj.onc.1208226	http://dx.doi.org/10.1038/sj.onc.1208226			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15580297				2022-12-17	WOS:000226577100008
J	Kim, Y; McBride, J; Zhang, R; Zhou, XF; Wong, DT				Kim, Y; McBride, J; Zhang, R; Zhou, XF; Wong, DT			p12(CDK2-AP1) mediates DNA damage responses induced by cisplatin	ONCOGENE			English	Article						p12(CDK2-AP1); DNA-damaging agent; cisplatin; cell cycle; human oral cancer	HUMAN OVARIAN-CANCER; SQUAMOUS-CELL CARCINOMA; NUCLEOTIDE EXCISION-REPAIR; TUMOR-SUPPRESSOR GENE; MISMATCH REPAIR; ACQUIRED-RESISTANCE; DRUG ACCUMULATION; GROWTH SUPPRESSOR; CYCLE ARREST; NECK-CANCER	We examined the biological role of p12(CDK2-AP1) in cisplatin-mediated responses by using murine ES p12(CDK2-AP1) knockout clones generated by a targeted disruption of murine p12(CDK2-AP1). Homozygous knockout clones showed an increased cellular proliferation along with an increase in Sand a decrease in G2/M phase populations. Interestingly, ES p12(CDK2-AP1) knockout clones showed a resistance to cisplatin treatment along with an increased DNA repair activity assessed by host cell reactivation assay using a cisplatin-damaged reporter DNA and a significant reduction of apoptosis upon cisplatin treatment. By using stable p12(CDK2-AP1) short interfering RNA ( siRNA) clones from human normal oral keratinocytes, we confirmed that downregulation of p12(CDK2-AP1) resulted in a resistance to cisplatin. More interestingly, cisplatin treatment resulted in a reduction of CDK2 kinase activity in control clones, but p12(CDK2-AP1) knockout clones showed a sustained CDK2 kinase activity. These data suggest that p12(CDK2-AP1) plays a role in cisplatin-mediated cellular responses by modulating CDK2 activity. These data further suggest p12(CDK2-AP1) is a potential gene therapeutic agent for oral/head and neck cancer in conjunction with DNA-damaging agents such as cisplatin.	Univ Calif Los Angeles, Sch Dent, Dent Res Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Wong, DT (corresponding author), Univ Calif Los Angeles, Sch Dent, Dent Res Inst, 10833 Le Conte Ave,73-017 CHS, Los Angeles, CA 90095 USA.	dtww@ucla.edu			NIDCR NIH HHS [T32 DE 007296-08, R01 DE 14857] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014857, T32DE007296] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aebi S, 1996, CANCER RES, V56, P3087; Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; AHN HJ, 1994, J UROLOGY, V151, P263, DOI 10.1016/S0022-5347(17)34929-7; Andreadis C, 2003, ORAL ONCOL, V39, P380, DOI 10.1016/S1368-8375(02)00141-0; ANDREWS PA, 1990, CANCER COMMUN-US, V2, P93, DOI 10.3727/095535490820874641; ANDREWS PA, 1990, CANCER CELL-MON REV, V2, P35; Anthoney DA, 1996, CANCER RES, V56, P1374; Bergoglio V, 2001, ONCOGENE, V20, P6181, DOI 10.1038/sj.onc.1204743; Boulikas T, 2004, ONCOL REP, V11, P559; Bradford CR, 2003, HEAD NECK-J SCI SPEC, V25, P654, DOI 10.1002/hed.10274; Cwikla SJ, 2000, J ORAL MAXIL SURG, V58, P406, DOI 10.1016/S0278-2391(00)90924-8; DEDON PC, 1987, BIOCHEM PHARMACOL, V36, P1955, DOI 10.1016/0006-2952(87)90494-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Donze O, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e46; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Ferry KV, 2000, BIOCHEM PHARMACOL, V60, P1305, DOI 10.1016/S0006-2952(00)00441-X; Fink D, 1998, CLIN CANCER RES, V4, P1; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; FOSSA SD, 1995, ONCOLOGY-BASEL, V52, P300; FRITSCHE M, 1993, ONCOGENE, V8, P307; Gately DP, 1996, BRIT J CANCER, V73, P18, DOI 10.1038/bjc.1996.4; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; Higuchi E, 2003, HEAD NECK-J SCI SPEC, V25, P187, DOI 10.1002/hed.10204; Hoffmann TK, 2002, ANTI-CANCER DRUG, V13, P93, DOI 10.1097/00001813-200201000-00011; Hu MG, 2004, CANCER RES, V64, P490, DOI 10.1158/0008-5472.CAN-03-2284; Johnson SW, 1997, CANCER RES, V57, P850; JOHNSON SW, 1994, BIOCHEM PHARMACOL, V47, P689, DOI 10.1016/0006-2952(94)90132-5; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; KASTAN MB, 1991, CANCER RES, V51, P6304; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Khuri FR, 2000, SEMIN ONCOL, V27, P25; Kim ES, 2003, CANC TREAT, V114, P295; Kim Y, 2001, INT J ORAL BIOL  DEC, V2001, P87; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Kohno Y, 2002, ORAL ONCOL, V38, P274, DOI 10.1016/S1368-8375(01)00055-0; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; LAI GM, 1988, BIOCHEM PHARMACOL, V37, P4597, DOI 10.1016/0006-2952(88)90325-5; Lan ZD, 2002, J BIOL CHEM, V277, P8372, DOI 10.1074/jbc.M108906200; Leirdal M, 2002, BIOCHEM BIOPH RES CO, V295, P744, DOI 10.1016/S0006-291X(02)00736-2; Li QD, 2000, ANTICANCER RES, V20, P645; LOEHRER PJ, 1984, ANN INTERN MED, V100, P704, DOI 10.7326/0003-4819-100-5-704; MASUDA H, 1988, CANCER RES, V48, P5713; Matsuo K, 2000, FASEB J, V14, P1318, DOI 10.1096/fj.14.10.1318; Milas L, 2003, HEAD NECK-J SCI SPEC, V25, P152, DOI 10.1002/hed.10232; MISTRY P, 1993, INT J CANCER, V55, P848, DOI 10.1002/ijc.2910550526; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Mukai M, 2002, ONCOL REP, V9, P839; Offer H, 2002, CARCINOGENESIS, V23, P1025, DOI 10.1093/carcin/23.6.1025; OZOLS RF, 1989, CURR PROB CANCER, V13, P287; OZOLS RF, 1992, CURR PROB CANCER, V16, pU63; PARKER RJ, 1991, J CLIN INVEST, V87, P772, DOI 10.1172/JCI115080; Pendyala L, 1997, CLIN CANCER RES, V3, P793; PEREZ RP, 1990, PHARMACOL THERAPEUT, V48, P19, DOI 10.1016/0163-7258(90)90015-T; Perez RP, 1998, EUR J CANCER, V34, P1535, DOI 10.1016/S0959-8049(98)00227-5; RUBIN E, 1992, CANCER RES, V52, P878; Runger TM, 2000, J INVEST DERMATOL, V114, P34, DOI 10.1046/j.1523-1747.2000.00844.x; Shintani S, 2001, CLIN CANCER RES, V7, P2776; Shintani S, 2000, MOL CELL BIOL, V20, P6300, DOI 10.1128/MCB.20.17.6300-6307.2000; Song H, 2004, INT J ONCOL, V24, P1017; TODD R, 1995, FASEB J, V9, P1362, DOI 10.1096/fasebj.9.13.7557027; Tsuji T, 1998, J BIOL CHEM, V273, P6704, DOI 10.1074/jbc.273.12.6704; Tsutsumi T, 1991, Gan To Kagaku Ryoho, V18, P1003; WALKER DH, 1995, CELL GROWTH DIFFER, V6, P1053; Yuan ZQ, 2003, ONCOGENE, V22, P6304, DOI 10.1038/sj.onc.1206609; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zhang X, 1999, BIOCHEM BIOPH RES CO, V255, P59, DOI 10.1006/bbrc.1999.0148	69	15	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					407	418		10.1038/sj.onc.1208222	http://dx.doi.org/10.1038/sj.onc.1208222			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15543230				2022-12-17	WOS:000226279700012
J	Dugast-Darzacq, C; Pirity, M; Blanck, JK; Scherl, A; Schreiber-Agus, N				Dugast-Darzacq, C; Pirity, M; Blanck, JK; Scherl, A; Schreiber-Agus, N			Mxi1-SR alpha: a novel Mxi1 isoform with enhanced transcriptional repression potential	ONCOGENE			English	Article						Mxi1; Myc; Sin3; transcriptional repression; isoforms	HISTONE DEACETYLASES; MEDIATES REPRESSION; GENE-EXPRESSION; MAX NETWORK; MYC; PROMOTERS; PROTEIN; DOMAIN; INTERACTS; HOMOLOG	Mxi1 belongs to the Myc/Max/Mad network of proteins that have been implicated in the control of multiple aspects of cellular behavior. Previously, we had reported that the mouse mxi1 gene gives rise to two distinct transcript forms that can encode proteins with dramatically different functional abilities. The Mxi1-SR protein (here termed Mxi1-SRb) can interact with Sin3/histone deacetylase and function as a potent transcriptional repressor and growth suppressor, while the Mxi1-WR protein lacks these activities. Here, we describe a new mxi1-derived transcript form (termed mxi1-SRa) whose expression is governed by its own promoter, resulting in a spatiotemporally distinct expression pro. le from that of the highly related mxi1-SRb form. Moreover, the Mxi1-SRa protein product, with its unique Sin3 interacting domain, has a greater affinity than its Mxi1-SRb counterpart for the Sin3 adapter proteins as well as an enhanced potential for transcriptional repression in transient reporter assays. Our identification of this novel Mxi1 isoform that results from alternative 50 exon usage adds an additional layer of complexity to the Mad/Mxi1 family. In addition, our findings warrant re-evaluation of mxi1 expression patterns on the cellular level and its status in human cancer samples, with a renewed focus on the distinct isoforms.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Schreiber-Agus, N (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, 1300 Morris Pk Ave,Ullmann 809, Bronx, NY 10461 USA.	agus@aecom.yu.edu		Dugast-Darzacq, Claire/0000-0001-8602-3534	NCI NIH HHS [1 R01 CA92558] Funding Source: Medline; NIGMS NIH HHS [T32GM07288] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092558] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Antequera F, 1999, CURR BIOL, V9, pR661, DOI 10.1016/S0960-9822(99)80418-7; Ariyanayagam-Baksh SM, 2003, MODERN PATHOL, V16, P992, DOI 10.1097/01.MP.0000087421.44975.1C; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; Baudino TA, 2001, MOL CELL BIOL, V21, P691, DOI 10.1128/MCB.21.3.691-702.2001; Benson LQ, 1999, J BIOL CHEM, V274, P28794, DOI 10.1074/jbc.274.40.28794; Billin AN, 1999, J BIOL CHEM, V274, P36344, DOI 10.1074/jbc.274.51.36344; Boue S, 2003, BIOESSAYS, V25, P1031, DOI 10.1002/bies.10371; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cowley SM, 2004, MOL CELL BIOL, V24, P2698, DOI 10.1128/MCB.24.7.2698-2709.2004; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Eilers AL, 1999, J BIOL CHEM, V274, P32750, DOI 10.1074/jbc.274.46.32750; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Harper SE, 1996, P NATL ACAD SCI USA, V93, P8536, DOI 10.1073/pnas.93.16.8536; Hurlin PJ, 2003, EMBO J, V22, P4584, DOI 10.1093/emboj/cdg442; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; KINGSTON RE, 2004, CURRENT PROTOCOLS MO; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Krakauer DC, 1999, SEMIN CELL DEV BIOL, V10, P555, DOI 10.1006/scdb.1999.0337; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Landry JR, 2003, TRENDS GENET, V19, P640, DOI 10.1016/j.tig.2003.09.014; Lee C, 2003, NUCLEIC ACIDS RES, V31, P101, DOI 10.1093/nar/gkg029; Lee TC, 1999, J BIOL CHEM, V274, P595, DOI 10.1074/jbc.274.2.595; Luo Q, 2001, J UROLOGY, V166, P1071, DOI 10.1016/S0022-5347(05)65924-1; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; Mao DYL, 2003, CURR BIOL, V13, P882, DOI 10.1016/S0960-9822(03)00297-5; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Modrek B, 2003, NAT GENET, V34, P177, DOI 10.1038/ng1159; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; PIRITY M, IN PRESS CURRENT TOP; Prochownik EV, 1998, GENE CHROMOSOME CANC, V22, P295, DOI 10.1002/(SICI)1098-2264(199808)22:4<295::AID-GCC5>3.3.CO;2-R; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; Resch A, 2004, J PROTEOME RES, V3, P76, DOI 10.1021/pr034064v; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SCHREIBERAGUS N, 1994, ONCOGENE, V9, P3167; Skotheim RI, 2002, CANCER RES, V62, P2359; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Sun LX, 2004, ONCOGENE, V23, P4722, DOI 10.1038/sj.onc.1207589; Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x; van Ingen H, 2004, BIOCHEMISTRY-US, V43, P46, DOI 10.1021/bi0355645; Yin XY, 2001, ONCOGENE, V20, P4650, DOI 10.1038/sj.onc.1204606	51	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8887	8899		10.1038/sj.onc.1208107	http://dx.doi.org/10.1038/sj.onc.1208107			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15467743				2022-12-17	WOS:000225354600004
J	Nagy, N; Takahara, M; Nishikawa, J; Bourdon, JC; Kis, LL; Klein, G; Klein, E				Nagy, N; Takahara, M; Nishikawa, J; Bourdon, JC; Kis, LL; Klein, G; Klein, E			Wild-type p53 activates SAP expression in lymphoid cells	ONCOGENE			English	Article						SAP; XLP; p53; lymphoma	LINKED LYMPHOPROLIFERATIVE-DISEASE; BARR-VIRUS INFECTION; NF-KAPPA-B; MICE DEFICIENT; ENCODING GENE; SH2 DOMAIN; EBV; MUTATIONS; MUTANT; SLAM	SAP is an adaptor molecule with one SH2 domain and it is expressed in activated T and NK cells, where it is required for the appropriate signaling from the SLAM family of surface receptors. Deleted or mutated SAP genes that encode functionally defective protein are associated with the X-linked lymphoproliferative disease(XLP). This primary immunodeficiency is characterized by extreme sensitivity to Epstein-Barr virus (EBV) infection, dysgammaglobulinemia and a high rate of lymphoma development. The vigorous T- and B-cell proliferation that follows EBV infection and the high incidence of lymphomas (30%) in XLP patients might reflect functional defects in cell cycle and/or apoptosis control. Our experiments show that SAP is a target of p53. In Burkitt lymphoma (BL) lines transfected with a temperatur-sensitive (ts) p53, SAP mRNA and protein expression was dependent on wild-type (wt) p53. Activation of endogenous wt p53 in BLs and lymphoblastoid cell lines led to the induction of SAP and this was inhibited by the specific p53 inhibitor pifithrin-a. Cell lines that carried mutant p53 did not express SAP under similar conditions. Moreover, we have shown binding of wt p53 to the promoter region of SAP by ChIP assay. Our results suggest that SAP contributes to the execution of some p53 functions.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland	Karolinska Institutet; University of Dundee	Nagy, N (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden.	Noemi.Nagy@mtc.ki.se	Nagy, Noemi/J-2936-2012; JC, Bourdon/A-4439-2008; Nishikawa, Jun/AAE-5355-2020	JC, Bourdon/0000-0003-4623-9386; Nagy, Noemi/0000-0002-7800-3493				Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; Chan B, 2003, NAT CELL BIOL, V5, P155, DOI 10.1038/ncb920; Coffey AJ, 1998, NAT GENET, V20, P129, DOI 10.1038/2424; Czar MJ, 2001, P NATL ACAD SCI USA, V98, P7449, DOI 10.1073/pnas.131193098; Fei PW, 2002, CANCER RES, V62, P7316; Gorgoulis VG, 2003, EMBO J, V22, P1567, DOI 10.1093/emboj/cdg157; GRIERSON H, 1987, ANN INTERN MED, V106, P538, DOI 10.7326/0003-4819-106-4-538; HARADA S, 1982, INT J CANCER, V30, P739, DOI 10.1002/ijc.2910300610; HARRINGTON DS, 1987, CANCER-AM CANCER SOC, V59, P1419, DOI 10.1002/1097-0142(19870415)59:8<1419::AID-CNCR2820590807>3.0.CO;2-P; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Latour S, 2003, NAT CELL BIOL, V5, P149, DOI 10.1038/ncb919; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Mori T, 2002, ONCOGENE, V21, P2914, DOI 10.1038/sj.onc.1205459; Nagy N, 2000, INT J CANCER, V88, P439, DOI 10.1002/1097-0215(20001101)88:3<439::AID-IJC17>3.0.CO;2-#; Nagy N, 2002, INT J CANCER, V100, P433, DOI 10.1002/ijc.10498; Nichols KE, 1998, P NATL ACAD SCI USA, V95, P13765, DOI 10.1073/pnas.95.23.13765; OKAN I, 1995, ONCOGENE, V11, P1027; Parolini S, 2000, J EXP MED, V192, P337, DOI 10.1084/jem.192.3.337; RAMQVIST T, 1993, ONCOGENE, V8, P1495; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; SEEMAYER TA, 1995, PEDIATR RES, V38, P471, DOI 10.1203/00006450-199510000-00001; Shlapatska LM, 2001, J IMMUNOL, V166, P5480, DOI 10.4049/jimmunol.166.9.5480; Strahm B, 2000, BRIT J HAEMATOL, V108, P377; Sumegi J, 2000, BLOOD, V96, P3118; Sylla BS, 2000, P NATL ACAD SCI USA, V97, P7470, DOI 10.1073/pnas.130193097; VOELKERDING KV, 1995, ONCOGENE, V10, P515; WILLIAMS LL, 1993, LANCET, V342, P587, DOI 10.1016/0140-6736(93)91413-G; Wu CB, 2001, NAT IMMUNOL, V2, P410, DOI 10.1038/87713; Yin L, 2003, J MED VIROL, V71, P446, DOI 10.1002/jmv.10504; Zhou XZ, 1999, J IMMUNOL, V162, P3957	30	15	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	2004	23	53					8563	8570		10.1038/sj.onc.1207908	http://dx.doi.org/10.1038/sj.onc.1207908			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15378026				2022-12-17	WOS:000224988800001
J	Wang, H; Zhang, Y; Toratani, S; Okamoto, T				Wang, H; Zhang, Y; Toratani, S; Okamoto, T			Transformation of vascular endothelial cells by a point mutation in the Tie2 gene from human intramuscular haemangioma	ONCOGENE			English	Article						Tie2; VEGF; haemangioma; angiosarcoma; endothelial cell	GROWTH-FACTOR; MOUSE; ACTIVATION; INHIBITION; EXPRESSION; ONCOGENE; DELIVERY; PROTEIN; DOMAIN	Tie2, an endothelial-cell-specific receptor tyrosine kinase, collaborates with vascular endothelial growth factor (VEGF) in regulating angiogenesis and vascular maturation. Here, we report a mutation of glycine to aspartic acid at the second glycine of the GXGXXG motif of Tie2 ((G833D)Tie2) in human intramuscular haemangiomas (IMHs) of the capillary type. Murine endothelial cells (ECs) overexpressing this (G833D)Tie2 receptor exhibited an increase in cell proliferation at low serum concentrations and angiosarcomas developed in nude mice, whereas cells overexpressing either wild-type Tie2 or (Q837H)Tie2 failed to elicit these responses. Furthermore, the (G833D)Tie2 receptor increased VEGF expression in ECs. These findings provide molecular mechanisms for pathogenesis of IMH.	Hiroshima Univ, Grad Sch Biomed Sci, Div Frontier Med Sci, Dept Mol Oral Med & Maxillofacial Surg, Hiroshima 7348553, Japan; Second Mil Med Univ, Shanghai Changhai Hosp, Dept Oral Med & Maxillofacial Surg, Shanghai 200433, Peoples R China	Hiroshima University; Naval Medical University	Okamoto, T (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Div Frontier Med Sci, Dept Mol Oral Med & Maxillofacial Surg, Hiroshima 7348553, Japan.	tetsuok@hiroshima-u.ac.jp						Akada T, 2002, J CELL PHYSIOL, V193, P253, DOI 10.1002/jcp.10169; Balmain A, 2000, CARCINOGENESIS, V21, P371, DOI 10.1093/carcin/21.3.371; Brown LF, 2000, AM J PATHOL, V156, P2179, DOI 10.1016/S0002-9440(10)65088-2; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1994, GENE DEV, V8, P1879; ENZINGER FM, 1995, SOFT TISSUE TUMORS, P512; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Holliday R, 1996, CANCER SURV, V28, P103; Lee RJ, 2000, CIRCULATION, V102, P898; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; Shewchuk LM, 2000, STRUCTURE, V8, P1105, DOI 10.1016/S0969-2126(00)00516-5; Spitaler M, 2000, J BIOL CHEM, V275, P33289, DOI 10.1074/jbc.M002742200; Springer ML, 1998, MOL CELL, V2, P549, DOI 10.1016/S1097-2765(00)80154-9; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TONG L, 1989, NATURE, V337, P90, DOI 10.1038/337090a0; YANAI N, 1991, CELL STRUCT FUNCT, V16, P87, DOI 10.1247/csf.16.87; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P11336, DOI 10.1073/pnas.191377098	19	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8700	8704		10.1038/sj.onc.1208006	http://dx.doi.org/10.1038/sj.onc.1208006			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15377998				2022-12-17	WOS:000224988800017
J	Schmidt, HH; Dyomin, VG; Palanisamy, N; Itoyama, T; Nanjangud, G; Pirc-Danoewinata, H; Haas, OA; Chaganti, R				Schmidt, HH; Dyomin, VG; Palanisamy, N; Itoyama, T; Nanjangud, G; Pirc-Danoewinata, H; Haas, OA; Chaganti, R			Deregulation of the carbohydrate (chondroitin 4) sulfotransferase 11 (CHST11) gene in a B-cell chronic lymphocytic leukemia with a t(12;14)(q23;q32)	ONCOGENE			English	Article						B-CLL; translocation; carbohydrate (chondroitin 4) sulfotransferase 11; CHST11; Golgi retention	HEPARAN-SULFATE; MOLECULAR-CLONING; EXPRESSION; TRANSLOCATIONS; FAMILY; ENZYME; PROTEOGLYCANS; LOCALIZATION; MALIGNANCIES; LYMPHOMA	The t(12; 14)(q23; q32) breakpoints in a case of B-cell chronic lymphocytic leukemia (B-CLL) were mapped by fluorescence in situ hybridization ( FISH) and Southern blot analysis and cloned using an IGH switch-c probe. The translocation affected a productively rearranged IGH allele and the carbohydrate ( chondroitin 4) sulfotransferase 11 (CHST11) locus at 12q23, with a reciprocal break in intron 2 of the CHST11 gene. CHST11 belongs to the HNK1 family of Golgi-associated sulfotransferases, a group of glycosaminoglycan-modifying enzymes, and is expressed mainly in the hematopoietic lineage. Northern Blot analysis of tumor RNA using CHST11-specific probes showed expression of two CHST11 forms of abnormal size. 5'- and 3'-Rapid Amplification of cDNA Ends( RACE) revealed IGH/CHST11 as well as CHST11/IGH fusion RNAs expressed from the der(14) and der(12) chromosomes. Both fusion species contained open reading frames making possible the translation of two truncated forms of CHST11 protein. The biological consequence of t(12; 14)(q23; q32) in this case presumably is a disturbance of the cellular distribution of CHST11 leading to deregulation of a chondroitin-sulfate-dependent pathway specific to the hematopoietic lineage.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Saint Anna Children's Hospital	Schmidt, HH (corresponding author), Univ Med Ctr, Dept Internal Med, Div Hematol, Auenbruggerpl 38, A-8036 Graz, Austria.	helmut.schmidt@klinikum-graz.at	Palanisamy, Nallasivam/ABC-8844-2020; Haas, Oskar/AAM-5794-2020	Palanisamy, Nallasivam/0000-0002-0633-9772; 				Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; BURKE J, 1994, J BIOL CHEM, V269, P12049; Chaganti RSK, 2000, SEMIN HEMATOL, V37, P396; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; Duncan G, 2001, J CLIN INVEST, V108, P511, DOI 10.1172/JCI13737; Dyomin VG, 2000, BLOOD, V95, P2666; GAHRTON G, 1982, NATURE, V297, P513, DOI 10.1038/297513a0; Greenfield B, 1999, J BIOL CHEM, V274, P2511, DOI 10.1074/jbc.274.4.2511; Hacker U, 1997, DEVELOPMENT, V124, P3565; Hiraoka N, 2000, J BIOL CHEM, V275, P20188, DOI 10.1074/jbc.M002443200; Maiti A, 1998, SCIENCE, V282, P941, DOI 10.1126/science.282.5390.941; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; MCKEITHAN TW, 1987, P NATL ACAD SCI USA, V84, P9257, DOI 10.1073/pnas.84.24.9257; Milland J, 2002, J BIOL CHEM, V277, P10374, DOI 10.1074/jbc.M111799200; NAUJOKAS MF, 1993, CELL, V74, P257, DOI 10.1016/0092-8674(93)90417-O; Okuda T, 2000, J BIOCHEM, V128, P763, DOI 10.1093/oxfordjournals.jbchem.a022813; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; RAO PH, 1993, GENOMICS, V16, P426, DOI 10.1006/geno.1993.1206; Satterwhite E, 2001, BLOOD, V98, P3413, DOI 10.1182/blood.V98.12.3413; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Willis TG, 2000, BLOOD, V96, P808, DOI 10.1182/blood.V96.3.808.015k30_808_822	24	15	17	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	2004	23	41					6991	6996		10.1038/sj.onc.1207934	http://dx.doi.org/10.1038/sj.onc.1207934			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15273723				2022-12-17	WOS:000223750700016
J	Preto, A; Singhrao, SK; Haughton, MF; Kipling, D; Wynford-Thomas, D; Jones, CJ				Preto, A; Singhrao, SK; Haughton, MF; Kipling, D; Wynford-Thomas, D; Jones, CJ			Telomere erosion triggers growth arrest but not cell death in human cancer cells retaining wild-type p53: implications for antitelomerase therapy	ONCOGENE			English	Article						p53; telomerase; cancer; senescence; therapy	THYROID EPITHELIAL-CELLS; TUMOR-SUPPRESSOR GENE; LIFE-SPAN; HUMAN FIBROBLASTS; MUTATIONS; SENESCENCE; INHIBITION; EXPRESSION; MECHANISMS; LINES	Telomerase activity in tumours is often associated with p53 mutation. Many antitelomerase therapies take advantage of the inability of cells expressing mutant p53 to undergo replicative senescence, since this allows telomere erosion to continue until 'crisis', hence providing the desired cytotoxic effect. However, some tumour types, including breast, melanomas and thyroid, retain wild-type p53 function and the effectiveness of antitelomerase therapies in such tumour cells have not been adequately addressed. To explore this, we made use of two thyroid cancer cell lines K1 and K2, which retain wt p53. Telomere erosion induced by the expression of a dominant-negative (DN) hTERT resulted in delayed onset of growth arrest in K1 and K2 cells, reminiscent of replicative senescence, with low levels of BrdU labelling and apoptosis, associated with high p21(WAF1) and senescence-associated beta galactosidase expression. In contrast, abrogation of p53 function by the expression of HPV16 E6 in K1 and K2 cells either at the same time as DNhTERT or just prior to the onset of senescence allowed cells to continue growing until 'crisis'. Likewise, microinjection of a p53 neutralizing antibody into 'senescent' K1 DNhTERT cells permitted re-entry into the cell cycle. We conclude that thyroid tumour cells with wild-type p53 retain an intact p53-mediated growth arrest response to telomere erosion. This raises the intriguing question of why, therefore, p53 mutation is not selected for in such cancers, and also calls into question the therapeutic value of telomerase inhibitors in such cases.	Univ Wales Coll Med, Dept Pathol, Cardiff CF14 4XN, S Glam, Wales; Univ Porto, IPATIMUP, Inst Mol Pathol & Immunol, P-4200465 Oporto, Portugal	Cardiff University; Universidade do Porto	Jones, CJ (corresponding author), Univ Wales Coll Med, Dept Pathol, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	Jonescj@cf.ac.uk	Preto, Ana/H-8112-2012	Preto, Ana/0000-0002-7302-0630; Jones, Christopher/0000-0002-5447-8187				Balint E, 2001, BRIT J CANCER, V85, P1813, DOI 10.1054/bjoc.2001.2128; Bond JA, 1996, INT J CANCER, V67, P563, DOI 10.1002/(SICI)1097-0215(19960807)67:4<563::AID-IJC16>3.0.CO;2-8; BOND JA, 1995, CANCER RES, V55, P2404; Bond JA, 1999, MOL CELL BIOL, V19, P3103; Brousset P, 1997, J CLIN ENDOCR METAB, V82, P4214, DOI 10.1210/jc.82.12.4214; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; Davis T, 2003, J CELL SCI, V116, P1349, DOI 10.1242/jcs.00331; Delhommeau FO, 2002, ONCOGENE, V21, P8262, DOI 10.1038/sj.onc.1206054; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; FLORENES VA, 1994, BRIT J CANCER, V69, P253, DOI 10.1038/bjc.1994.48; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Goldman MA, 2003, DRUG DISCOV TODAY, V8, P294, DOI 10.1016/S1359-6446(03)02625-4; Granger MP, 2002, CRIT REV ONCOL HEMAT, V41, P29, DOI 10.1016/S1040-8428(01)00188-3; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Jones CJ, 1996, MOL CELL ENDOCRINOL, V116, P115, DOI 10.1016/0303-7207(95)03697-0; Jones CJ, 1998, EXP CELL RES, V240, P333, DOI 10.1006/excr.1998.3944; LUBBE J, 1994, J INVEST DERMATOL, V102, P819, DOI 10.1111/1523-1747.ep12381544; Matthews P, 2001, J PATHOL, V194, P183, DOI 10.1002/path.848; Pharoah PDP, 1999, BRIT J CANCER, V80, P1968, DOI 10.1038/sj.bjc.6690628; Saretzki G, 2003, CANCER LETT, V194, P209, DOI 10.1016/S0304-3835(02)00708-5; SHAY JW, 1993, ONCOGENE, V8, P1407; Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706; Soussi T, 2000, ANN NY ACAD SCI, V910, P121; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; WYLLIE FS, 1995, ONCOGENE, V10, P49; Wyllie FS, 1999, BRIT J CANCER, V79, P1111, DOI 10.1038/sj.bjc.6690177; Wynford-Thomas D, 1998, CARCINOGENESIS, V19, P29, DOI 10.1093/carcin/19.1.29; WynfordThomas D, 1997, HORM RES, V47, P145, DOI 10.1159/000185458	30	15	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4136	4145		10.1038/sj.onc.1207564	http://dx.doi.org/10.1038/sj.onc.1207564			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064743				2022-12-17	WOS:000221520200012
J	Dietze, EC; Troch, MM; Bean, GR; Heffner, JB; Bowie, ML; Rosenberg, P; Ratliff, B; Seewaldt, VL				Dietze, EC; Troch, MM; Bean, GR; Heffner, JB; Bowie, ML; Rosenberg, P; Ratliff, B; Seewaldt, VL			Tamoxifen and tamoxifen ethyl bromide induce apoptosis in acutely damaged mammary epithelial cells through modulation of AKT activity	ONCOGENE			English	Article						tamoxifen; apoptosis; AKT; plasma membrane; mammary epithelial cells	ESTROGEN-RECEPTOR-ALPHA; PROTEIN-KINASE-B; BREAST-CANCER; MEMBRANE-RECEPTOR; GROWTH ARREST; ER-ALPHA; ACTIVATION; ANTIESTROGEN; PATHWAY; P53	Normal human mammary epithelial cells (HMECs), unlike estrogen receptor-positive (ER+) breast cancers, typically express low nuclear levels of ER (ER-'poor'). We previously demonstrated that 1.0 muM tamoxifen (Tam) induced apoptosis in ER-'poor' HMECs acutely transduced with human papillomavirus-16 E6 (HMEC-E6) through a rapid mitochondrial signaling pathway. Here, we show that plasma membrane-associated E2-binding sites initiate the rapid apoptotic effects of Tam in HMEC-E6 cells through modulation of AKT activity. At equimolar concentrations, Tam and tamoxifen ethyl bromide (QTam), a membrane impermeant analog of Tam, rapidly induced apoptosis in HMEC-E6 cells associated with an even more rapid decrease in phosphorylation of AKT at serine-473. Treatment of HMEC-E6 cells with 1.0 muM QTam resulted in a 50% decrease in mitochondrial transmembrane potential, sequential activation of caspase-9 and -3, and a 90% decrease in AKT Ser-473 phosphorylation. The effects of both Tam and QTam were blocked by expression of constitutively active AKT (myristoylated AKT or AKT-Thr308Asp/Ser473Asp). These data indicate that Tam and QTam induce apoptosis in HMEC-E6 cells through a plasma membrane-activated AKT-signaling pathway that results in (1) decreased AKT phosphorylation at Ser-473, (2) mitochondrial membrane depolarization, and (3) activated caspase-9 and -3.	Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Div Cardiol, Durham, NC 27710 USA	Duke University; Duke University	Seewaldt, VL (corresponding author), DUMC, Box 2628, Durham, NC 27710 USA.	seewa001@mc.duke.edu		Rosenberg, Paul/0000-0002-5659-160X	NATIONAL CANCER INSTITUTE [R01CA098441, R01CA088799, P30CA014236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK035816] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA88799, R01CA98441, 2P30CA14236-26] Funding Source: Medline; NIDDK NIH HHS [2P30DK 35816-11] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen MC, 2000, BBA-BIOMEMBRANES, V1509, P229, DOI 10.1016/S0005-2736(00)00297-2; Anderson E, 1998, J MAMMARY GLAND BIOL, V3, P23, DOI 10.1023/A:1018718117113; Aoudjit F, 2001, ONCOGENE, V20, P4995, DOI 10.1038/sj.onc.1204554; ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846; BOSERMA AWM, 1996, CYTOMETRY, V24, P123; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Chambliss KL, 2002, MOL ENDOCRINOL, V16, P938, DOI 10.1210/me.16.5.938; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; Dick GM, 2002, MOL PHARMACOL, V61, P1105, DOI 10.1124/mol.61.5.1105; Dietze EC, 2001, J BIOL CHEM, V276, P5384, DOI 10.1074/jbc.M007915200; Doolan CM, 2003, MOL CELL ENDOCRINOL, V199, P87, DOI 10.1016/S0303-7207(02)00303-9; FERNANDEZ A, 1993, GEN PHARMACOL-VASC S, V24, P391, DOI 10.1016/0306-3623(93)90322-O; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Friedman ZY, 1998, CANCER INVEST, V16, P391, DOI 10.3109/07357909809115779; Ho KJ, 2002, ARTERIOSCL THROM VAS, V22, P1952, DOI 10.1161/01.ATV.0000041200.85946.4A; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Improta-Brears T, 1999, P NATL ACAD SCI USA, V96, P4686, DOI 10.1073/pnas.96.8.4686; JARMAN M, 1986, ANTI-CANCER DRUG DES, V1, P259; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KIRK J, 1994, BIOCHEM PHARMACOL, V48, P277, DOI 10.1016/0006-2952(94)90098-1; Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935; Kozikowski AP, 2003, J AM CHEM SOC, V125, P1144, DOI 10.1021/ja0285159; Levin ER, 2002, STEROIDS, V67, P471, DOI 10.1016/S0039-128X(01)00179-9; Li L, 2003, P NATL ACAD SCI USA, V100, P4807, DOI 10.1073/PNAS.0831079100; Linford N, 2000, J NEUROCYTOL, V29, P367, DOI 10.1023/A:1007113323582; Marquez DC, 2001, ONCOGENE, V20, P5420, DOI 10.1038/sj.onc.1204729; O'Regan RM, 2002, LANCET ONCOL, V3, P207, DOI 10.1016/S1470-2045(02)00711-8; Okano J, 2000, J BIOL CHEM, V275, P30934, DOI 10.1074/jbc.M004112200; Pietras RJ, 2001, ENDOCRINE, V14, P417, DOI 10.1385/ENDO:14:3:417; Razandi M, 2000, MOL ENDOCRINOL, V14, P1434, DOI 10.1210/me.14.9.1434; Razandi M, 2003, MOL CELL BIOL, V23, P1633, DOI 10.1128/MCB.23.5.1633-1646.2003; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Razandi M, 2003, J BIOL CHEM, V278, P2701, DOI 10.1074/jbc.M205692200; Ropero AB, 2002, MOL ENDOCRINOL, V16, P497, DOI 10.1210/me.16.3.497; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Schlegel A, 1999, J BIOL CHEM, V274, P33551, DOI 10.1074/jbc.274.47.33551; Schwertfeger KL, 2001, MOL ENDOCRINOL, V15, P867, DOI 10.1210/me.15.6.867; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Seewaldt VL, 1999, CELL GROWTH DIFFER, V10, P49; Seewaldt VL, 1997, CELL GROWTH DIFFER, V8, P631; Seewaldt VL, 2001, CANCER RES, V61, P616; Seewaldt VL, 2001, J CELL BIOL, V155, P471, DOI 10.1083/jcb.200011001; Seewaldt VL, 1999, EXP CELL RES, V249, P70, DOI 10.1006/excr.1999.4462; Seewaldt VL, 1997, EXP CELL RES, V236, P16, DOI 10.1006/excr.1997.3694; Segars JH, 2002, TRENDS ENDOCRIN MET, V13, P349, DOI 10.1016/S1043-2760(02)00633-1; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; Stoica GE, 2003, MOL ENDOCRINOL, V17, P818, DOI 10.1210/me.2002-0330; Stoica GE, 2003, ONCOGENE, V22, P2073, DOI 10.1038/sj.onc.1206311; Strange R, 2001, MICROSC RES TECHNIQ, V52, P171, DOI 10.1002/1097-0029(20010115)52:2<171::AID-JEMT1003>3.3.CO;2-K; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Whitehead JP, 2001, J BIOL CHEM, V276, P27816, DOI 10.1074/jbc.M011590200; Zhang ZG, 2002, BIOCHEM BIOPH RES CO, V294, P926, DOI 10.1016/S0006-291X(02)00348-0	60	15	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3851	3862		10.1038/sj.onc.1207480	http://dx.doi.org/10.1038/sj.onc.1207480			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	14990993				2022-12-17	WOS:000221242500012
J	de Fraipont, F; Keramidas, M; El Atifi, M; Chambaz, EM; Berger, F; Feige, JJ				de Fraipont, F; Keramidas, M; El Atifi, M; Chambaz, EM; Berger, F; Feige, JJ			Expression of the thrombospondin 1 fragment 167-569 in C6 glioma cells stimulates tumorigenicity despite reduced neovascularization	ONCOGENE			English	Article						tumor angiogenesis; thrombospondin; glioma	INTEGRIN-ASSOCIATED PROTEIN; ENDOTHELIAL GROWTH-FACTOR; TUMOR ANGIOGENESIS; BRAIN-TUMORS; FACTOR-BETA; TGF-BETA; INHIBITION; PROGRESSION; MECHANISMS; CARCINOMA	Gliomas are among the most malignant and most highly vascularized human tumors. We studied the therapeutic action of an angiostatic fragment of human thrombospondin 1 (named TSP1ang) on experimental glioma tumor growth. TSP1ang (enclosing amino acids 167-569) comprised the procollagen-homology domain and the three type I repeats of the original molecule. C6 glioma cells that stably express TSP1ang were generated, and their rate of in vitro growth did not appear to differ from that of C6 cells transfected with an empty plasmid. TSP1ang expressing C6 cells were then injected either subcutaneously or intracerebrally into nude mice. The resulting tumors appeared to be less vascularized, but unexpectedly started to grow earlier and had a much more invasive phenotype than tumors derived from control C6 cells. They were also much more aggressive, since the mice bearing intracerebral TSP1ang-expressing tumor cells died before day 19 post-implantation, whereas all mice bearing control C6 tumors were alive at this time point. These results indicate that careful attention should be paid at designing smaller fragments from the multimodular angiostatic molecule TSP1 since, as observed in this study, it may unmask protumorigenic properties that counteract its antiangiogenic activity.	CEA G, ANGIO, DRDC, Dept Cellular Response & Dynam,INSERM EMI 01 05, F-38054 Grenoble 09, France; Univ Hosp Grenoble, Dept Integrat Biol, F-38043 Grenoble, France; Univ Hosp Grenoble, INSERM, U318, F-38043 Grenoble, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm)	Feige, JJ (corresponding author), CEA G, ANGIO, DRDC, Dept Cellular Response & Dynam,INSERM EMI 01 05, 17 Rue Martyrs, F-38054 Grenoble 09, France.	jjfeige@cea.fr	Feige, Jean-Jacques/M-8905-2017; de Fraipont, Florence/P-4936-2014	Feige, Jean-Jacques/0000-0002-1354-7692; de Fraipont, Florence/0000-0001-9594-6584				ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; Bailly S, 1997, J BIOL CHEM, V272, P16329, DOI 10.1074/jbc.272.26.16329; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; BLACK PM, 1991, NEW ENGL J MED, V324, P1555, DOI 10.1056/NEJM199105303242205; BLACK PM, 1991, NEW ENGL J MED, V324, P1471, DOI 10.1056/NEJM199105233242105; Bleuel K, 1999, P NATL ACAD SCI USA, V96, P2065, DOI 10.1073/pnas.96.5.2065; BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Bunone G, 1999, AM J PATHOL, V155, P1967, DOI 10.1016/S0002-9440(10)65515-0; CASTLE V, 1991, J CLIN INVEST, V87, P1883, DOI 10.1172/JCI115212; Chandrasekaran L, 2000, MOL BIOL CELL, V11, P2885, DOI 10.1091/mbc.11.9.2885; Claffey KP, 1996, CANCER RES, V56, P172; de Fraipont F, 2000, J CLIN ENDOCR METAB, V85, P4734, DOI 10.1210/jc.85.12.4734; de Fraipont F, 2001, TRENDS MOL MED, V7, P401, DOI 10.1016/S1471-4914(01)02102-5; FEIGE JJ, 2000, ENCY REFERENCE VASCU, P285; Filleur S, 2001, GENE DEV, V15, P1373, DOI 10.1101/gad.193501; Folkman J, 1998, P NATL ACAD SCI USA, V95, P9064, DOI 10.1073/pnas.95.16.9064; Freyberg MA, 2000, BIOCHEM BIOPH RES CO, V271, P584, DOI 10.1006/bbrc.2000.2678; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Goldbrunner RH, 2000, J NEURO-ONCOL, V50, P53, DOI 10.1023/A:1006462504447; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Grainger DJ, 2000, BIOCHEM J, V350, P291, DOI 10.1042/0264-6021:3500291; Grossfeld GD, 1997, J NATL CANCER I, V89, P219, DOI 10.1093/jnci/89.3.219; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harpel JG, 2001, BIOCHEM BIOPH RES CO, V284, P11, DOI 10.1006/bbrc.2001.4922; Hsu SC, 1996, CANCER RES, V56, P5684; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; IruelaArispe ML, 1997, THROMB HAEMOSTASIS, V78, P672; Jennings MT, 1998, J NEURO-ONCOL, V36, P123, DOI 10.1023/A:1005863419880; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Lawler J, 2000, CURR OPIN CELL BIOL, V12, P634, DOI 10.1016/S0955-0674(00)00143-5; Murphy-Ullrich JE, 2000, CYTOKINE GROWTH F R, V11, P59, DOI 10.1016/S1359-6101(99)00029-5; Ohta Y, 1999, CANCER, V85, P2570, DOI 10.1002/(SICI)1097-0142(19990615)85:12<2570::AID-CNCR12>3.0.CO;2-F; Piek E, 1999, INT J CANCER, V80, P756, DOI 10.1002/(SICI)1097-0215(19990301)80:5<756::AID-IJC21>3.0.CO;2-N; PLATE KH, 1995, GLIA, V15, P339, DOI 10.1002/glia.440150313; SAGE EH, 1991, J BIOL CHEM, V266, P14831; Siemeister G, 1998, CANCER METAST REV, V17, P241, DOI 10.1023/A:1006027124696; Stratmann A, 1997, ADV STER F, V12, P105; Streit M, 1999, AM J PATHOL, V155, P441, DOI 10.1016/S0002-9440(10)65140-1; Taraboletti G, 2000, FASEB J, V14, P1674; Tenan M, 2000, J EXP MED, V191, P1789, DOI 10.1084/jem.191.10.1789; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; TUSZYNSKI GP, 1993, J CELL BIOL, V120, P513, DOI 10.1083/jcb.120.2.513; Vailhe B, 2003, CURR PHARM DESIGN, V9, P583, DOI 10.2174/1381612033391342; VOLPERT OV, 1995, BIOCHEM BIOPH RES CO, V217, P326, DOI 10.1006/bbrc.1995.2780; Wang TN, 1996, SURGERY, V120, P449, DOI 10.1016/S0039-6060(96)80322-9; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; Yoshida Y, 1999, INT J ONCOL, V15, P1221; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407	51	15	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3642	3649		10.1038/sj.onc.1207438	http://dx.doi.org/10.1038/sj.onc.1207438			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15077189				2022-12-17	WOS:000221101700016
J	Lewis, MD; Roberts, BJ				Lewis, MD; Roberts, BJ			Role of the C-terminal alpha-helical domain of the von Hippel-Lindau protein in its E3 ubiquitin ligase activity	ONCOGENE			English	Article						VHL; HIF; ubiquitin; cancer	TUMOR-SUPPRESSOR PROTEIN; HYPOXIA-INDUCIBLE FACTOR-1; TRANSCRIPTIONAL ACTIVITY; PROLYL HYDROXYLATION/; REGULATE HIF; DISEASE; MUTATIONS; VHL; GENE; HYDROXYPROLINE	In the present study, the role of the C-terminal alpha-helical domain (amino acid (aa) 195-208) of the von Hippel Lindau (VHL) tumour suppressor was investigated. Deletions of the VHL C-terminus up to the naturally occurring 195-Gln-Term resulted in hypoxia-inducible factor (HIF)-1alpha downregulation in renal cell carcinoma (RCC)4 cells during normoxia, suggesting that this domain is not an absolute requirement for the ubiquitination of HIF-1alpha. However, detailed investigation of the ubiquitin protein isopeptide ligase ubiquitin ligase properties of VHL revealed C-terminal deletions to cause a significant impairment of HIF-1alpha ubiquitination, which is shown to be due to a loss in high-affinity binding to the target substrate. When VHL regulation of both HIF-1alpha N- and C-terminal oxygen-dependent degradation domains (HIF-ODDD) was investigated, it was found that only ubiquitination of the C-terminal HIF-ODDD was affected by the deletion of the VHL C-terminus. When RCC4 cells expressing C-terminal truncations of VHL were exposed to graded hypoxia, differences in the induction of HIF-1alpha were observed in comparison with full-length VHL, with a shift in the maximal induction of HIF-1alpha to a higher oxygen tension. These changes were accompanied by increased glucose transporter 1 expression, p300 CH1 domain binding and HIF-mediated reporter activity. We have thus defined a role for the C-terminal alpha-helical domain of VHL in the regulation of HIF-1alpha.	Univ S Australia, Sch Pharmaceut Mol & Biomed Sci, Adelaide, SA 5000, Australia	University of South Australia	Roberts, BJ (corresponding author), Univ S Australia, Sch Pharmaceut Mol & Biomed Sci, Reid Bldg,Frome Rd, Adelaide, SA 5000, Australia.	Ben.Roberts@unisa.edu.au	Lewis, Martin/A-8489-2008; Lewis, Martin/A-3881-2010	Lewis, Martin/0000-0002-3332-3776				Clifford SC, 2001, ADV CANCER RES, V82, P85, DOI 10.1016/S0065-230X(01)82003-0; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Ohh M, 1999, MOL MED TODAY, V5, P257, DOI 10.1016/S1357-4310(99)01481-1; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Roberts BJ, 1999, J BIOL CHEM, V274, P36351, DOI 10.1074/jbc.274.51.36351; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; WHALEY JM, 1994, AM J HUM GENET, V55, P1092; Zbar B, 1996, HUM MUTAT, V8, P348, DOI 10.1002/(SICI)1098-1004(1996)8:4<348::AID-HUMU8>3.3.CO;2-9	23	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2315	2323		10.1038/sj.onc.1207384	http://dx.doi.org/10.1038/sj.onc.1207384			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14691445				2022-12-17	WOS:000220427700005
J	Ramirez, CJ; Fleming, MA; Potter, JD; Ostrander, GK; Ostrander, EA				Ramirez, CJ; Fleming, MA; Potter, JD; Ostrander, GK; Ostrander, EA			Marsupial BRCA1: conserved regions in mammals and the potential effect of missense changes	ONCOGENE			English	Article						breast cancer; comparative analysis; exon 11; gene evolution; missense; phylogenetics	OVARIAN-CANCER FAMILIES; SPONTANEOUS PROLIFERATIONS; AUSTRALIAN MARSUPIALS; INFORMATION CORE; MUTATIONS; BREAST; GENE; SEQUENCES; FREQUENCY; EVOLUTION	More than half of the reported missense changes in the breast cancer susceptibility protein BRCA1 occur in exon 11, but none has been clearly identified as disease associated and only 28 are designated 'probable' neutral polymorphisms. Previously, in a comparison of sequences from 57 eutherian mammal species, we found seven 'highly conserved regions' between amino acids 282 and 1103, and identified 38 missense changes as likely to disrupt gene function. These conserved regions were also present in birds and amphibians and included only six of the mutations predicted to affect function. In this new analysis, we hypothesized that using 37 ancestral sequences derived from the 57 GenBank sequences and including eight marsupial sequences would allow us to identify regions unique to mammals and re. ne our predictions of disease-associated missense changes. We identified 13 conserved regions, three of which appear to be unique to mammals, and 21 likely disease-associated missense changes, 11 of which occur in conserved regions. Seven regions identified in this analysis, including the three found only in mammalian sequences, and nine missense changes predicted to affect function are in the putative STAT1-interaction domain, suggesting that the role of STAT1 in immune response is important to mammary function. The reduction in the number of missense changes predicted to be disease associated and the identification of conserved regions specific to mammals can facilitate the further study of the role of missense changes in BRCA1-associated breast cancers.	Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; Univ Washington, Dept Mol & Cellular Biol, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Comparat Med, Baltimore, MD 21218 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Johns Hopkins University; Johns Hopkins University	Ostrander, EA (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,D4-100, Seattle, WA 98109 USA.	eostrand@fhcrc.org		Potter, John/0000-0001-5439-1500; Ostrander, Elaine/0000-0001-6075-9738	NATIONAL CANCER INSTITUTE [K05CA090754, U24CA078164] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG000035] Funding Source: NIH RePORTER; NCI NIH HHS [U24 CA-78164, K05 CA-90754-01] Funding Source: Medline; NHGRI NIH HHS [T32-HG00035] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; Brown JR, 2001, NAT GENET, V28, P281, DOI 10.1038/90129; Brzovic PS, 2001, J BIOL CHEM, V276, P41399, DOI 10.1074/jbc.M106551200; CANFIELD PJ, 1990, J COMP PATHOL, V103, P147, DOI 10.1016/S0021-9975(08)80171-5; CANFIELD PJ, 1990, J COMP PATHOL, V103, P135, DOI 10.1016/S0021-9975(08)80170-3; Casey H W, 1979, Recent Results Cancer Res, V66, P129; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Chapman MA, 2003, GENOMICS, V81, P249, DOI 10.1016/S0888-7543(03)00005-3; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Durocher F, 1996, HUM MOL GENET, V5, P835, DOI 10.1093/hmg/5.6.835; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Findlay L., 1984, Symposia of the Zoological Society of London, P403; Fleming MA, 2003, P NATL ACAD SCI USA, V100, P1151, DOI 10.1073/pnas.0237285100; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Ganesh S, 2001, BIOCHEM BIOPH RES CO, V283, P1046, DOI 10.1006/bbrc.2001.4914; GONNET GH, 1992, SCIENCE, V256, P1443, DOI 10.1126/science.1604319; Hamilton J M, 1974, Adv Cancer Res, V19, P1, DOI 10.1016/S0065-230X(08)60051-2; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Huttley GA, 2000, NAT GENET, V25, P410, DOI 10.1038/78092; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; KNIGHT CH, 1984, PHYSL STRATEGIES LAC, V51, P147; KOEBERL DD, 1990, AM J HUM GENET, V47, P202; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Lee WH, 2001, LANCET, pS5, DOI 10.1016/S0140-6736(01)07018-0; Maddison DR, 2001, MACCLADE 4 ANAL PHYL; Malone KE, 2000, CANCER, V88, P1393, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1393::AID-CNCR17>3.0.CO;2-P; Misdorp W, 1996, VET QUART, V18, P32, DOI 10.1080/01652176.1996.9694610; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Newman B, 1998, JAMA-J AM MED ASSOC, V279, P915, DOI 10.1001/jama.279.12.915; Nielsen R, 1998, GENETICS, V148, P929; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Rose TM, 1998, NUCLEIC ACIDS RES, V26, P1628, DOI 10.1093/nar/26.7.1628; Shen DJ, 1999, ONCOL RES, V11, P63; Siegel S, 1956, NONPARAMETRIC STAT B; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; Sokal R. R., 1995, BIOMETRY PRINCIPLES; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; STRAUBE EF, 1980, J COMP PATHOL, V90, P495, DOI 10.1016/0021-9975(80)90020-1; SWOFFORD DL, 1998, PAUP ASTERISK PHYLOG; Szabo C, 2000, HUM MUTAT, V16, P123, DOI 10.1002/1098-1004(200008)16:2<123::AID-HUMU4>3.0.CO;2-Y; TYNDALEBISCOE CH, 1984, PHYSL STRATEGIES LAC, V51, P389; Vail DM, 2000, CANCER INVEST, V18, P781, DOI 10.3109/07357900009012210; Vallon-Christersson J, 2001, HUM MOL GENET, V10, P353, DOI 10.1093/hmg/10.4.353; Venkitaraman AR, 2001, J CELL SCI, V114, P3591; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705	47	15	15	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1780	1788		10.1038/sj.onc.1207292	http://dx.doi.org/10.1038/sj.onc.1207292			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	15001988				2022-12-17	WOS:000220029300013
J	He, Q; Huang, Y; Sheikh, MS				He, Q; Huang, Y; Sheikh, MS			Bax deficiency affects caspase-2 activation during ultraviolet radiation-induced apoptosis	ONCOGENE			English	Article						caspase-2; ultraviolet radiation; Bax deficiency; colon cancer cells	FAMILY-MEMBERS; CELL-DEATH; MITOCHONDRIA; REQUIREMENT; FAS/APO-1; RECEPTORS; SULINDAC; PATHWAY	There has been a considerable debate as to whether caspase-2 is an initiator or effector caspase. Recently, a new model of intrinsic pathway of apoptosis has been proposed, which suggests caspase-2 to be an initiator caspase. For example, ultraviolet radiation (UV) and other DNA damage-inducing agents were shown to first activate caspase-2 and then regulate the mitochondrial and postmitochondrial events. Active caspase-2 was found to engage mitochondria by promoting Bax translocation to the mitochondria. Consequently, Bax was proposed to play a central role in bridging the active caspase-2 with mitochondria by affecting mitochondrial permeability, cytochrome c release into the cytosol and caspase- 9 activation. In the present study, we investigated the role of Bax in UV-induced apoptosis and caspase- 2 activation. Our results indicate that UV-induced apoptosis and caspase- 2 activation were diminished in Bax-deficient cells, suggesting that Bax appears to play an important role in UV-induced apoptosis as well as caspase- 2 activation, and that it also appears to reside upstream of caspase-2. Bax deficiency also affected the activation of caspase- 3 and - 8 and abolished caspase- 9 activation during UV-induced apoptosis, suggesting that the absence of caspase- 9 activation may affect caspase- 2, - 3 and - 8 activation in Bax-deficient cells. Based on our results, we propose that activation of caspases is not a linear cascade of events, but is rather connected via complex feedback loops.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Sheikh, MS (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	sheikhm@mail.upstate.edu			NCI NIH HHS [CA86945, CA89043] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA089043, R01CA086945] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Cowling V, 2002, CELL DEATH DIFFER, V9, P1046, DOI 10.1038/sj.cdd.4401065; Fujita E, 2001, CELL DEATH DIFFER, V8, P335, DOI 10.1038/sj.cdd.4400824; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; He Q, 2002, ONCOGENE, V21, P6032, DOI 10.1038/sj.onc.1205897; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Huang Y, 2001, CANCER RES, V61, P6918; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Paroni G, 2001, J BIOL CHEM, V276, P21907, DOI 10.1074/jbc.M011565200; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; Sitailo LA, 2002, J BIOL CHEM, V277, P19346, DOI 10.1074/jbc.M200401200; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wang XD, 2001, GENE DEV, V15, P2922; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	25	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1321	1325		10.1038/sj.onc.1207212	http://dx.doi.org/10.1038/sj.onc.1207212			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14647455				2022-12-17	WOS:000188892200018
J	Sugihara, E; Kanai, M; Matsui, A; Onodera, M; Schwab, M; Miwa, M				Sugihara, E; Kanai, M; Matsui, A; Onodera, M; Schwab, M; Miwa, M			Enhanced expression of MYCN leads to centrosome hyperamplification after DNA damage in neuroblastoma cells	ONCOGENE			English	Article						MYCN; centrosome; micronuclei; DNA damage	GENETIC INSTABILITY; N-MYC; AMPLIFICATION; CYCLE; P53; OVERDUPLICATION; ABNORMALITIES; DUPLICATION; DEFECTS; ABSENCE	Centrosomes play important roles in cell polarity, regulation of cell cycle and chromosomal stability. Centrosome abnormality is frequently found in many cancers and contributes to chromosomal instability (including aneuploidy, tetraploidy, and/or micronuclei) in daughter cells through the assembly of multipolar or monopolar spindles during mitosis. It has recently been reported that loss of tumor suppressor genes or overexpression of oncogenes causes centrosome hyperamplification. Amplification and overexpression of the MYCN oncogene is found in a subgroup of neuroblastomas. In this study, we examined whether overexpression of MYCN causes centrosome hyperamplification in neuroblastoma cells. We show that ectopic expression of MYCN alone in a neuroblastoma cell line did not cause centrosome hyperamplification. However, centrosome hyperamplification and micronuclei formation were seen in these cells after DNA damage. These findings suggest that overexpression of MYCN abrogates the regulation of the centrosome cycle after DNA damage.	Univ Tsukuba, Inst Basic Med Sci, Dept Biochem & Mol Oncol, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Clin Med, Dept Pediat, Tsukuba, Ibaraki 305, Japan; Deutsch Krebsforschungszentrum, Dept Tumour Genet B030, D-69120 Heidelberg, Germany; Univ Tsukuba, Inst Clin Med, Dept Hematol, Tsukuba, Ibaraki 305, Japan	University of Tsukuba; University of Tsukuba; Helmholtz Association; German Cancer Research Center (DKFZ); University of Tsukuba	Miwa, M (corresponding author), Univ Tsukuba, Inst Basic Med Sci, Dept Biochem & Mol Oncol, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058575, Japan.	m-miwa@md.tsukuba.ac.jp	Sugihara, Eiji/J-8058-2013	Sugihara, Eiji/0000-0002-3233-1045				BREIT S, 1989, J NEUROSCI RES, V24, P21, DOI 10.1002/jnr.490240105; Brinkley BR, 1998, CELL MOTIL CYTOSKEL, V41, P281, DOI 10.1002/(SICI)1097-0169(1998)41:4<281::AID-CM1>3.0.CO;2-C; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Chernova OB, 1998, MOL CELL BIOL, V18, P536, DOI 10.1128/MCB.18.1.536; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Fukasawa K, 2002, ONCOGENE, V21, P6140, DOI 10.1038/sj.onc.1205771; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GILBERT F, 1982, CANCER GENET CYTOGEN, V7, P33, DOI 10.1016/0165-4608(82)90105-4; Kanai M, 2003, MOL CELL BIOL, V23, P2451, DOI 10.1128/MCB.23.7.2451-2462.2003; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Lutz W, 1996, ONCOGENE, V13, P803; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Muller WU, 1996, MUTAT RES-REV GENET, V366, P163, DOI 10.1016/S0165-1110(96)90037-8; Pihan GA, 1998, CANCER RES, V58, P3974; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Saavedra HI, 1999, J BIOL CHEM, V274, P38083, DOI 10.1074/jbc.274.53.38083; Sato N, 2000, ONCOGENE, V19, P5281, DOI 10.1038/sj.onc.1203902; Sato N, 1999, CLIN CANCER RES, V5, P963; Savelyeva L, 2001, CANCER LETT, V167, P115, DOI 10.1016/S0304-3835(01)00472-4; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; Schwab M, 2003, LANCET ONCOL, V4, P472, DOI 10.1016/S1470-2045(03)01166-5; Suzuki A, 2002, J NEUROCHEM, V82, P953, DOI 10.1046/j.1471-4159.2002.01048.x; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Toledo F, 2000, NUCLEIC ACIDS RES, V28, P4805, DOI 10.1093/nar/28.23.4805; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Tweddle DA, 2001, AM J PATHOL, V158, P2067, DOI 10.1016/S0002-9440(10)64678-0; Wartiovaara K, 2002, J NEUROSCI, V22, P815, DOI 10.1523/JNEUROSCI.22-03-00815.2002; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	33	15	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					1005	1009		10.1038/sj.onc.1207216	http://dx.doi.org/10.1038/sj.onc.1207216			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647433				2022-12-17	WOS:000188486600017
J	Zou, MX; Butcher, DT; Sadikovic, B; Groves, TC; Yee, SP; Rodenhiser, DI				Zou, MX; Butcher, DT; Sadikovic, B; Groves, TC; Yee, SP; Rodenhiser, DI			Characterization of functional elements in the neurofibromatosis (NF1) proximal promoter region	ONCOGENE			English	Article						neurofibromatosis; promoter; transcription; methylation	DNA METHYLATION; TRANSCRIPTION FACTOR; GENE; BINDING; ACTIVATION; PROTEIN; CANCER; FAMILY; CREB; SP1	An essential requirement to understand how genes contribute to genetic disease is the thorough knowledge of the transcriptional regulation of gene expression. Here, we have characterized transcription factor binding sites within the type 1 neurofibromatosis (NF1) proximal regulatory region, and addressed the molecular mechanisms that regulate NF1 transcription. Overlapping regions of the NF1 proximal promoter have been cloned and characterized for use in luciferase reporter assays. These assays have identified a 500 bp region displaying activities up to 80-fold higher than control reporter levels. Mutations at putative CRE and SP1-binding sites immediately 5' to the transcription start site have dramatic effects that lead to a 70-90% decrease in reporter activity in all cell lines tested. Gelshift assays confirm binding of CREB and SP1/KLF family members to their putative recognition sequences, and provide the first evidence identifying functional sites likely involved in regulating NF1 transcription. These assays have also revealed a putative repressor region within the NF1 promoter region corresponding to CCCTC-rich sequences between the transcription and translation start sites. This work provides new information concerning the transcriptional regulation of the NF1 gene, and is the most thorough attempt to date to map functionally relevant regions within the NF1 proximal promoter region.	Univ Western Ontario, London Reg Canc Ctr, London, ON N6A 4L6, Canada; Univ Western Ontario, Child Hlth Res Inst, London, ON, Canada; Univ Western Ontario, Dept Biochem, London, ON, Canada; Univ Western Ontario, Dept Paediat, London, ON, Canada; Univ Western Ontario, Dept Oncol, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Rodenhiser, DI (corresponding author), Univ Western Ontario, London Reg Canc Ctr, Room A4-134,Victoria Res Tower,790 Commissioners, London, ON N6A 4L6, Canada.	drodenhi@uwo.ca						Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; [Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Cichowski K, 2001, CELL, V104, P593, DOI 10.1016/S0092-8674(01)00245-8; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; Evans DGR, 2002, J MED GENET, V39, P311, DOI 10.1136/jmg.39.5.311; GETMAN DK, 1995, J BIOL CHEM, V270, P23511, DOI 10.1074/jbc.270.40.23511; Guha A, 1998, CAN J NEUROL SCI, V25, P267, DOI 10.1017/S0317167100034272; HAJRA A, 1994, GENOMICS, V21, P649, DOI 10.1006/geno.1994.1328; HOFMAN KJ, 1994, J PEDIATR-US, V124, pS1, DOI 10.1016/S0022-3476(05)83163-4; Horan MP, 2000, HUM GENET, V107, P33, DOI 10.1007/s004390050007; Jiang JG, 2000, BIOCHEM BIOPH RES CO, V272, P882, DOI 10.1006/bbrc.2000.2848; Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597; Kim HA, 2001, J NEUROSCI, V21, P1110; Kino T, 2001, GENES CELLS, V6, P441, DOI 10.1046/j.1365-2443.2001.00432.x; Luijten M, 2000, EUR J HUM GENET, V8, P939, DOI 10.1038/sj.ejhg.5200565; Mancini DN, 1999, ONCOGENE, V18, P4108, DOI 10.1038/sj.onc.1202764; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MANCINIDINARDO DN, 2001, ONCOGENE, V20, P5331; Plass C, 2002, EUR J HUM GENET, V10, P6, DOI 10.1038/sj.ejhg.5200768; Reed N, 2001, TRENDS MOL MED, V7, P157, DOI 10.1016/S1471-4914(01)01955-4; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; RUBENSTEIN A, 1990, NEUROFIBROMATOSIS HD; STILLER CA, 1994, BRIT J CANCER, V70, P969, DOI 10.1038/bjc.1994.431; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Tong JY, 2002, NAT NEUROSCI, V5, P95, DOI 10.1038/nn792; ZOLLER M, 1995, ACTA DERM-VENEREOL, V75, P136	30	15	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					330	339		10.1038/sj.onc.1207053	http://dx.doi.org/10.1038/sj.onc.1207053			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14647436				2022-12-17	WOS:000188098300002
J	Iwahara, T; Akagi, T; Shishido, T; Hanafusa, H				Iwahara, T; Akagi, T; Shishido, T; Hanafusa, H			CrkII induces serum response factor activation and cellular transformation through its function in Rho activation	ONCOGENE			English	Article						CrkII; Rho; transformation	BINDING PROTEIN-RHO; HETEROTRIMERIC G-PROTEINS; GROWTH-FACTOR RECEPTOR; C-FOS PROMOTER; HTLV-I TAX; ADAPTER PROTEIN; V-CRK; LYSOPHOSPHATIDIC ACID; SIGNALING PATHWAY; TYROSINE PHOSPHORYLATION	CrkII belongs to the adaptor protein family that plays a crucial role in signal transduction. In order to better understand the biological functions of CrkII, we focused on the regulation of gene expression by CrkII. Various transcriptional control elements were examined for their activation by CrkII-expression, and we found that CrkII selectively activates the serum response element (SRE), a transcriptional control element of immediate-early genes. This SRE activation induced by CrkII-overexpression was mediated by the serum response factor (SRF) via Rho. Indeed, we confirmed that the amount of activated Rho was increased in the CrkII-expressing cells. Moreover, we showed that when overexpressed, CrkII induces the cellular transformation of NIH 3T3 cells and that a dominant negative mutant of Rho suppresses this transformation, strongly suggesting that activation of Rho is essential for the transforming activity by CrkII. Furthermore, we also found that CrkII and Galpha12, a member of the heterotrimeric G proteins, synergistically activates Rho as well as the SRF, and that an SH3 mutant of CrkII can inhibit the Galpha12-induced activation of SRF. These results strongly suggest that CrkII is involved in the activation of Rho and SRF by Galpha12. Our study provides strong evidence that Rho activation plays a crucial role in CrkII-mediated signals to induce gene expression and cellular transformation.	Osaka Biosci Inst, Mol Oncol Lab, Osaka 5650874, Japan		Hanafusa, H (corresponding author), Osaka Biosci Inst, Mol Oncol Lab, 6-2-4 Furuedai, Osaka 5650874, Japan.	saburo@obisun1.obi.or.jp						Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; ALLEY MC, 1991, CANCER RES, V51, P1247; Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Brouns MR, 2001, NAT CELL BIOL, V3, P361, DOI 10.1038/35070042; Casamassima A, 1997, J BIOL CHEM, V272, P9363; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; FUJII M, 1995, ONCOGENE, V11, P7; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Haskell MD, 2001, J CELL SCI, V114, P1699; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; Hu WM, 1999, J BIOL CHEM, V274, P3396, DOI 10.1074/jbc.274.6.3396; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; KizakaKondoh S, 1996, P NATL ACAD SCI USA, V93, P12177, DOI 10.1073/pnas.93.22.12177; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lowry WE, 2002, DEV CELL, V2, P733, DOI 10.1016/S1534-5807(02)00175-2; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Meijne AML, 1997, EXP CELL RES, V234, P477, DOI 10.1006/excr.1997.3637; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; Nakashima N, 1999, J BIOL CHEM, V274, P3001, DOI 10.1074/jbc.274.5.3001; Nolan KM, 1998, GENE DEV, V12, P3337, DOI 10.1101/gad.12.21.3337; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Posern G, 2000, ONCOGENE, V19, P6361, DOI 10.1038/sj.onc.1204027; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Senechal K, 1998, MOL CELL BIOL, V18, P5082, DOI 10.1128/MCB.18.9.5082; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; Shishido T, 2001, GENES CELLS, V6, P431, DOI 10.1046/j.1365-2443.2001.00431.x; Smith JJ, 2002, MOL CELL BIOL, V22, P1412, DOI 10.1128/MCB.22.5.1412-1423.2002; Stam JC, 2001, J BIOL CHEM, V276, P25176, DOI 10.1074/jbc.M009825200; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Tolkacheva T, 1997, ONCOGENE, V15, P727, DOI 10.1038/sj.onc.1201229; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Tsuda M, 2002, CELL GROWTH DIFFER, V13, P131; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; Zohn IE, 2000, ONCOGENE, V19, P3866, DOI 10.1038/sj.onc.1203731	82	15	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					5946	5957		10.1038/sj.onc.1206633	http://dx.doi.org/10.1038/sj.onc.1206633			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955073				2022-12-17	WOS:000185137800003
J	Pan, W; Datta, A; Adami, GR; Raychaudhuri, P; Bagchi, S				Pan, W; Datta, A; Adami, GR; Raychaudhuri, P; Bagchi, S			P19ARF inhibits the functions of the HPV16 E7 oncoprotein	ONCOGENE			English	Article						ARF; HPV16 E7 oncoprotein; nucleolar localization; E7 relocalization; Rb proteolysis	HUMAN-PAPILLOMAVIRUS TYPE-16; E7 PROTEIN; DNA-REPLICATION; DIFFERENTIAL REGULATION; CARCINOMA-CELLS; GENE; P53; E2F; TRANSFORMATION; KERATINOCYTES	The E7 oncoprotein encoded by high-risk types of human papillomavirus (HPV) plays a significant role in the development of HPV-related cancers. E7 is a potent stimulator of S phase and host DNA replication. These functions of E7 are linked to the deregulation of the Rb family of proteins. For example, E7 binds and induces proteolysis of Rb through the ubiquitin-proteasome pathway. Despite advances in our understanding of E7, reagents that inhibit E7 with promise in therapy have not been developed or identified. Here, we provide evidence that the tumor suppressor ARF can inhibit E7. We show that the expression of ARF causes a relocalization of E7 from the nucleoplasm to the nucleolus. Two distinct regions in ARF overlapping with the MDM2-binding sites are necessary for the relocalization of E7. Furthermore, we show that ARF blocks the proteolysis of Rb induced by E7. In addition, ARF expression inhibits DNA replication induced by E7. Although it is not known whether the endogenous ARF, which is expressed at a low level, interferes with E7, our results suggest that ARF is an effective inhibitor of E7. We speculate that ARF or an ARF-derived molecule might have a significant impact in therapy against HPV-related tumors.	Univ Illinois, Coll Dent, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA; Univ Illinois, Dept Biochem & Mol Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Bagchi, S (corresponding author), Univ Illinois, Coll Dent, Ctr Mol Biol Oral Dis, M-C 860,801 S Paulina St, Chicago, IL 60612 USA.	sbagchi@uic.edu			NATIONAL CANCER INSTITUTE [R01CA076276] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012506] Funding Source: NIH RePORTER; NCI NIH HHS [CA76276] Funding Source: Medline; NIDCR NIH HHS [DE12506] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Berezutskaya E, 1997, CELL GROWTH DIFFER, V8, P1277; Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; Bohl J, 2001, J VIROL, V75, P513, DOI 10.1128/JVI.75.1.513-521.2001; Boyer SN, 1996, CANCER RES, V56, P4620; CHANG FJ, 1991, J ORAL PATHOL MED, V20, P305, DOI 10.1111/j.1600-0714.1991.tb00936.x; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; Datta A, 2002, MOL CELL BIOL, V22, P8398, DOI 10.1128/MCB.22.24.8398-8408.2002; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Flores ER, 2000, J VIROL, V74, P6622, DOI 10.1128/JVI.74.14.6622-6631.2000; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HICKMAN ES, 1994, ONCOGENE, V9, P2177; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Jian YC, 1999, CELL GROWTH DIFFER, V10, P101; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; LAIMINS LA, 1993, INFECT AGENT DIS, V2, P74; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Morozov A, 1997, J VIROL, V71, P3451, DOI 10.1128/JVI.71.5.3451-3457.1997; MUNGER K, 1989, J VIROL, V63, P4417; NEVINS JR, 1992, SCIENCE, V258, P424; QUELLE DE, 1995, CELL, V83, P993; Ruesch MN, 1997, J VIROL, V71, P5570, DOI 10.1128/JVI.71.7.5570-5578.1997; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SHILLITOE EJ, 1992, ANN NY ACAD SCI, V660, P286, DOI 10.1111/j.1749-6632.1992.tb21087.x; SHILLITOE EJ, 1994, CANCER GENE THER, V1, P193; STEELE C, 1992, CANCER RES, V52, P4706; Wang J, 2001, ONCOGENE, V20, P4740, DOI 10.1038/sj.onc.1204655; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wettergreen MA, 2001, EUR J ORAL SCI, V109, P415, DOI 10.1034/j.1600-0722.2001.00105.x; Zatsepina O, 1997, ONCOGENE, V14, P1137, DOI 10.1038/sj.onc.1200946; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	38	15	16	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5496	5503		10.1038/sj.onc.1206857	http://dx.doi.org/10.1038/sj.onc.1206857			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934109				2022-12-17	WOS:000184735000014
J	Montigiani, S; Muller, R; Kontermann, RE				Montigiani, S; Muller, R; Kontermann, RE			Inhibition of cell proliferation and induction of apoptosis by novel tetravalent peptides inhibiting DNA binding of E2F	ONCOGENE			English	Article						E2F; phage display; inhibitor of DNA binding; peptidomimetics; tat; cell cycle; apoptosis	RETINOBLASTOMA GENE-PRODUCT; MULTIPLE ANTIGEN PEPTIDE; TRANSCRIPTION FACTOR; FUNCTIONALLY ANTAGONIZE; CYCLE REGULATION; MAMMALIAN-CELLS; FAMILY MEMBERS; PROTEIN; REPRESSOR; DP-1	We have isolated several peptides from random peptide phage display libraries that specifically recognize the cell cycle regulatory transcription factor E2F and inhibit DNA binding of E2F/DP heterodimers (E2F-1, E2F-2, E2F-3, E2F-4 or EM-5, and DP-1). The inhibitory efficiency could be strongly enhanced by generating branched tetravalent molecules. To analyse the biological consequences of peptide-mediated E2F inhibition, we fused two of these branched molecules to a cell-penetrating peptide derived from the HTV-Tat protein. Incubation of human tumor cells with these branched Tat-containing peptides led to an inhibition of cell proliferation and induction of apoptosis. These results provide new insights into the function of E2F and further validate E2F as a potential therapeutic target in proliferative diseases.	Univ Marburg, Inst Mol Biol & Tumor Res IMT, D-35033 Marburg, Germany	Philipps University Marburg	Muller, R (corresponding author), Univ Marburg, Inst Mol Biol & Tumor Res IMT, Emil Mannkopff Str 2, D-35033 Marburg, Germany.		Kontermann, Roland E./F-9263-2014; Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				AHLBORG N, 1995, J IMMUNOL METHODS, V179, P269, DOI 10.1016/0022-1759(94)00328-T; Bandara LR, 1997, NAT BIOTECHNOL, V15, P896, DOI 10.1038/nbt0997-896; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUCK V, 1995, ONCOGENE, V11, P31; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; Delia D, 1997, ONCOGENE, V14, P2137, DOI 10.1038/sj.onc.1201050; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOORBAR J, 1994, J MOL BIOL, V244, P361, DOI 10.1006/jmbi.1994.1736; ENDRESEN PC, 1995, CYTOMETRY, V20, P162, DOI 10.1002/cyto.990200209; Fabbrizio E, 1999, ONCOGENE, V18, P4357, DOI 10.1038/sj.onc.1202825; Fan JG, 1997, ONCOGENE, V14, P1191, DOI 10.1038/sj.onc.1200940; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; FURUKAWA Y, 2002, J BIOL CHEM, V30, P30; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishizaki J, 1996, NAT MED, V2, P1386, DOI 10.1038/nm1296-1386; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; Loughran O, 2002, CURR BIOL, V12, pR377, DOI 10.1016/S0960-9822(02)00876-X; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Phillips AC, 2001, APOPTOSIS, V6, P173, DOI 10.1023/A:1011332625740; Santoni-Rugiu E, 2002, ONCOGENE, V21, P6498, DOI 10.1038/sj.onc.1205828; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; TAM JP, 1989, J IMMUNOL METHODS, V124, P53, DOI 10.1016/0022-1759(89)90185-3; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wu CL, 1996, MOL CELL BIOL, V16, P3698; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zwicker J, 1995, Prog Cell Cycle Res, V1, P91; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	54	15	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 7	2003	22	32					4943	4952		10.1038/sj.onc.1206495	http://dx.doi.org/10.1038/sj.onc.1206495			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902977				2022-12-17	WOS:000184578900002
J	Modena, P; Testi, MA; Facchinetti, F; Mezzanzanica, D; Radice, MT; Pilotti, S; Sozzi, G				Modena, P; Testi, MA; Facchinetti, F; Mezzanzanica, D; Radice, MT; Pilotti, S; Sozzi, G			UQCRH gene encoding mitochondrial Hinge protein is interrupted by a translocation in a soft-tissue sarcoma and epigenetically inactivated in some cancer cell lines	ONCOGENE			English	Article						EWS; sarcoma; ovarian carcinoma; hinge protein; mitochondrial complex III	CYTOCHROME-C OXIDOREDUCTASE; 17-KDA SUBUNIT-VI; YEAST UBIQUINOL; COMPLEX; EXPRESSION; MUTATIONS; DELETION; SITE	We previously reported the identification of a novel zinc-finger gene, designated ZSG, fused to Ewing sarcoma gene (EWS) by a submicroscopic paracentric inversion of 22q12 in a small round cell sarcoma presenting a translocation t(1;22)(p34;q12). We report here the molecular cloning and characterization of the breakpoint in 1p34, which encompasses the gene coding for mitochondrial Hinge protein ubiquinol-cytochrome C reductase hinge gene (UQCRH). All the three breakpoints, two on 22q12 and one in 1p34, interrupt different genes: EWS, ZSG and UQCRH. We determined the genomic structure of UQCRH, characterized its splicing variants and identified a transcribed processed pseudogene. The analysis of UQCRH expression in normal tissues and cancer cell lines revealed absent expression of UQCRH in two ovarian and one breast cancer cell lines and reduced expression in a further breast carcinoma cell line. CpG island methylation upstream exon 1 was detected in all the three cell lines with absent expression. Moreover, treatment with demethylating agent 5-azacytidine restored UQCRH expression in OAW42 ovarian cancer cells. These data provide preliminary evidence of the inactivation of UQCRH gene in cancer either by structural rearrangements or epigenetic mechanisms.	Ist Nazl Tumori, Unit Mol Cytogenet, I-20133 Milan, Italy; Ist Nazl Tumori, Dept Pathol, I-20133 Milan, Italy; Ist Nazl Tumori, Unit Mol Therapies, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Sozzi, G (corresponding author), Ist Nazl Tumori, Unit Mol Cytogenet, Via G Venezian 1, I-20133 Milan, Italy.		sozzi, gabriella/G-8259-2011; Mezzanzanica, Delia/C-2607-2017; Testi, Maria Adele/D-6994-2017	sozzi, gabriella/0000-0001-9360-6914; Mezzanzanica, Delia/0000-0002-9664-6871; Testi, Maria Adele/0000-0002-9462-0336				Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Jones DH, 1997, BIOTECHNIQUES, V23, P132, DOI 10.2144/97231rr01; KIM CH, 1983, J BIOL CHEM, V258, P3543; KIM CH, 1989, BIOCHEMISTRY-US, V28, P1439, DOI 10.1021/bi00430a002; Kovar Heinrich, 1998, Current Opinion in Oncology, V10, P334, DOI 10.1097/00001622-199807000-00010; LIU AY, 1993, CANCER RES, V53, P2460; Mastrangelo T, 2000, ONCOGENE, V19, P3799, DOI 10.1038/sj.onc.1203762; Megonigal MD, 1998, P NATL ACAD SCI USA, V95, P6413, DOI 10.1073/pnas.95.11.6413; MUKAI K, 1985, J BIOCHEM-TOKYO, V98, P1417, DOI 10.1093/oxfordjournals.jbchem.a135409; OHTA S, 1987, FEBS LETT, V226, P171, DOI 10.1016/0014-5793(87)80573-2; Okazaki M, 1998, BIOCHEM BIOPH RES CO, V243, P131, DOI 10.1006/bbrc.1997.7979; Rustin P, 2002, NAT GENET, V30, P352, DOI 10.1038/ng0402-352; Santiard-Baron D, 1999, EXP NEUROL, V158, P206, DOI 10.1006/exnr.1999.7076; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; SCHOPPINK PJ, 1989, BIOCHIM BIOPHYS ACTA, V974, P192, DOI 10.1016/S0005-2728(89)80372-X; SCHOPPINK PJ, 1988, EUR J BIOCHEM, V173, P115, DOI 10.1111/j.1432-1033.1988.tb13974.x; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849	20	15	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4586	4593		10.1038/sj.onc.1206472	http://dx.doi.org/10.1038/sj.onc.1206472			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881716				2022-12-17	WOS:000184054700015
J	Zhang, XH; Ma, L; Enkemann, SA; Pledger, WJ				Zhang, XH; Ma, L; Enkemann, SA; Pledger, WJ			Role of Gadd45 alpha in the density-dependent G1 arrest induced by p27(Kip1)	ONCOGENE			English	Article						Gadd45 alpha; p27(Kip1); culture density	MESSENGER-RNA EXPRESSION; KINASE INHIBITOR; GROWTH ARREST; MAMMALIAN-CELLS; P53-REGULATED PROTEIN; T-LYMPHOCYTES; MICE LACKING; GENES; TRANSCRIPTION; FIBROBLASTS	p27(Kip1), an inhibitor of cyclin-dependent kinases, is an important regulator of cell cycle progression. We have previously shown that p27(Kip1) inhibits the G0 to S transition when ectopically expressed in p27-47 mouse fibroblasts arrested at high but not low densities. In the study described here, we identify Gadd45alpha, a member of the growth arrest- and DNA damage-inducible family of proteins, as a potential mediator of the density-dependent effects of p27(Kip1) on cell proliferation. Gadd45alpha mRNA and protein were more abundant in p27-47 cells arrested at high densities than at low densities. Amounts of both decreased and remained low when cells arrested at high densities were exposed to mitogens in the absence, but not in the presence, of ectopically expressed p27(Kip1). Importantly, enforced expression of Gadd45alpha prevented density-arrested mouse fibroblasts from initiating DNA synthesis in response to mitogens. We suggest that amounts of Gadd45alpha above a certain threshold are growth inhibitory and that such amounts are achieved in cells arrested at high but not low densities. For cultures arrested at high densities, the resumption of cell cycle traverse requires a sustained reduction in Gadd45alpha abundance, a process that is induced by mitogens and inhibited by p27(Kip1).	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Pledger, WJ (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.				NCI NIH HHS [CA67370] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abcouwer SF, 1999, J BIOL CHEM, V274, P28645, DOI 10.1074/jbc.274.40.28645; Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Boussiotis VA, 2000, NAT MED, V6, P290, DOI 10.1038/73144; BREVIARIO F, 1992, J BIOL CHEM, V267, P22190; Carrier F, 1999, MOL CELL BIOL, V19, P1673; CARRIER F, 1994, J BIOL CHEM, V269, P32672; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Deschenes C, 2001, GASTROENTEROLOGY, V120, P423, DOI 10.1053/gast.2001.21199; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dong F, 1998, MOL BIOL CELL, V9, P2081, DOI 10.1091/mbc.9.8.2081; Dong F, 1998, J BIOL CHEM, V273, P6190, DOI 10.1074/jbc.273.11.6190; Fan W, 1999, ONCOGENE, V18, P6573, DOI 10.1038/sj.onc.1203054; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; Fong WF, 2001, BBA-GENE STRUCT EXPR, V1517, P250, DOI 10.1016/S0167-4781(00)00287-6; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kettenhofen R, 2001, CELL SIGNAL, V13, P787, DOI 10.1016/S0898-6568(01)00198-X; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; LABOW MA, 1990, MOL CELL BIOL, V10, P3343, DOI 10.1128/MCB.10.7.3343; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Miskimins R, 2002, J NEUROSCI RES, V67, P100, DOI 10.1002/jnr.10080.abs; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PESTOV DG, 1994, P NATL ACAD SCI USA, V91, P12549, DOI 10.1073/pnas.91.26.12549; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; THELANDER L, 1986, MOL CELL BIOL, V6, P3433, DOI 10.1128/MCB.6.10.3433; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; Yang Q, 2000, J BIOL CHEM, V275, P36892, DOI 10.1074/jbc.M005319200; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang W, 2001, INT J ONCOL, V18, P749; Zhang XH, 2000, MOL BIOL CELL, V11, P2117, DOI 10.1091/mbc.11.6.2117	52	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2003	22	27					4166	4174		10.1038/sj.onc.1206599	http://dx.doi.org/10.1038/sj.onc.1206599			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833139				2022-12-17	WOS:000183979800003
J	DuHadaway, JB; Du, W; Donover, S; Baker, J; Liu, AX; Sharp, DM; Muller, AJ; Prendergast, GC				DuHadaway, JB; Du, W; Donover, S; Baker, J; Liu, AX; Sharp, DM; Muller, AJ; Prendergast, GC			Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1	ONCOGENE			English	Article						FTI; farnesyltransferase; Ras; RhoB; SV40T antigen; amphiphysin	TUMOR-SUPPRESSOR BIN1; GENE-EXPRESSION; YEAST HOMOLOG; SMALL GTPASE; CELL-CYCLE; KINASE 2; PROTEIN; ACTIN; RAS; MYC	Neoplastic transformation sensitizes many cells to apoptosis. This phenomenon may underlie the therapeutic benefit of many anticancer drugs, but its molecular basis is poorly understood. We have used a selective and potent farnesyltransferase inhibitor (FTI) to probe a mechanism of apoptosis that is peculiarly linked to neoplastic transformation. While nontoxic to untransformed mouse cells, FTI triggers a massive RhoB-dependent, p53-independent apoptosis in mouse cells that are neoplastically transformed. Here we offer evidence that the BAR adapter-encoding tumor suppressor gene Bin1 is required for this transformation-selective death program. Targeted deletion of Bin1 in primary mouse embyro fibroblasts (MEFs) transformed by E1A + Ras did not affect FTI-induced reversion, actin fiber formation, or growth inhibition, but it abolished FTI-induced apoptosis. The previously defined requirement for RhoB in these effects suggests that BinI adapter proteins act downstream or in parallel to RhoB in cell death signaling. The death defect in Bin1 null cells was significant insofar as it abolished FTI efficacy in tumor xenograft assays. p53 deletion did not phenocopy the effects of Bin1 deletion. However, MEFs transformed by SV40 large T antigen + Ras were also resistant to apoptosis by FTI, consistent with other evidence that large T inhibits Bin1-dependent cell death by a p53-independent mechanism. Taken together, the results define a function for Bin1 in apoptosis that is conditional on transformation stress. This study advances understanding of the functions of BAR adapter proteins, which are poorly understood, by revealing genetic interactions with an Rho small GTPase that functions in stress signaling. The frequent losses of Bin1 expression that occur in human breast and prostate cancers may promote tumor progression and limit susceptibility to FTI or other therapeutic agents that exploit the heightened sensitivity of neoplastic cells to apoptosis.	Lankenau Inst Med Res, Wynnewood, PA 19096 USA; DuPont Pharmaceut Co, Canc Res Grp, Glenolden, PA USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Lankenau Medical Center; Lankenau Institute for Medical Research; DuPont; The Wistar Institute; Jefferson University	Prendergast, GC (corresponding author), Lankenau Inst Med Res, 100 Lancaster Ave, Wynnewood, PA 19096 USA.	prendergastg@mlhs.org		Muller, Alexander/0000-0001-7854-6933	NATIONAL CANCER INSTITUTE [R01CA082222] Funding Source: NIH RePORTER; NCI NIH HHS [CA82222] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; AMBERG DC, 1995, NAT STRUCT BIOL, V2, P28, DOI 10.1038/nsb0195-28; Balguerie A, 1999, J CELL SCI, V112, P2529; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; Bon E, 2000, YEAST, V16, P1229, DOI 10.1002/1097-0061(20000930)16:13<1229::AID-YEA618>3.0.CO;2-Q; Breton AM, 1998, CURR GENET, V34, P280, DOI 10.1007/s002940050397; Colwill K, 1999, GENETICS, V152, P881; Cox AD, 2001, DRUGS, V61, P723, DOI 10.2165/00003495-200161060-00002; Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; Du W, 1999, MOL CELL BIOL, V19, P1831; Du W, 1999, CANCER RES, V59, P4208; DuHadaway JB, 2001, CANCER RES, V61, P3151; Elliott K, 1999, ONCOGENE, V18, P3564, DOI 10.1038/sj.onc.1202670; Elliott K, 2000, ONCOGENE, V19, P4669, DOI 10.1038/sj.onc.1203681; Galderisi U, 1999, J CELL BIOCHEM, V74, P313, DOI 10.1002/(SICI)1097-4644(19990901)74:3<313::AID-JCB1>3.3.CO;2-Q; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; Ge K, 2000, INT J CANCER, V86, P155, DOI 10.1002/(SICI)1097-0215(20000415)86:2<155::AID-IJC2>3.0.CO;2-M; Ge K, 1999, P NATL ACAD SCI USA, V96, P9689, DOI 10.1073/pnas.96.17.9689; Ge K, 2000, INT J CANCER, V85, P376; Hogarty MD, 2000, MED PEDIATR ONCOL, V35, P559, DOI 10.1002/1096-911X(20001201)35:6<559::AID-MPO14>3.3.CO;2-A; Huang HT, 2000, CANCER RES, V60, P6868; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; Koh H, 2000, J BIOL CHEM, V275, P34451, DOI 10.1074/jbc.M001753200; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; LEBOWITZ P, 1998, CELL ADHES COMMUN, V4, P1; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; Lebowitz PF, 1997, CANCER RES, V57, P708; Lee EY, 2002, SCIENCE, V297, P1193, DOI 10.1126/science.1071362; Lee J, 1998, CURR BIOL, V8, P1310, DOI 10.1016/S0960-9822(07)00561-1; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Liu AX, 2000, MOL CELL BIOL, V20, P6105, DOI 10.1128/MCB.20.16.6105-6113.2000; Mangues R, 1998, CANCER RES, V58, P1253; Mellor H, 1998, J BIOL CHEM, V273, P4811, DOI 10.1074/jbc.273.9.4811; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; Prendergast GC, 2000, CURR OPIN CELL BIOL, V12, P166, DOI 10.1016/S0955-0674(99)00072-1; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; Prendergast GC, 1999, CANCER RES, V59, P5924; Routhier EL, 2003, ONCOGENE, V22, P637, DOI 10.1038/sj.onc.1206162; Sakamuro D, 1995, ONCOGENE, V11, P2411; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P15356, DOI 10.1073/pnas.95.26.15356; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; Wechsler-Reya RJ, 1998, MOL CELL BIOL, V18, P566, DOI 10.1128/MCB.18.1.566; WechslerReya R, 1997, CANCER RES, V57, P3258; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; ZALCMAN G, 1995, ONCOGENE, V10, P1935	53	15	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2003	22	23					3578	3588		10.1038/sj.onc.1206481	http://dx.doi.org/10.1038/sj.onc.1206481			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789266				2022-12-17	WOS:000183399200008
J	Li, YJ; Song, RL; Korkola, JE; Archer, MC; Ben-David, Y				Li, YJ; Song, RL; Korkola, JE; Archer, MC; Ben-David, Y			Cyclin D1 is necessary but not sufficient for anchorage-independent growth of rat mammary tumor cells and is associated with resistance of the Copenhagen rat to mammary carcinogenesis	ONCOGENE			English	Article						mammary carcinogenesis; anoikis; cyclin D1; beta-catenin	INTESTINAL EPITHELIAL-CELLS; BETA-CATENIN; BREAST-CANCER; ACTIVATED RAS; OVEREXPRESSION; EXPRESSION; LINES; GENE; PROGRESSION; ERYTHROLEUKEMIA	To identify genes associated with the resistance of Copenhagen (Cop) rats to mammary carcinogenesis, we infused a retrovirus harboring v-Ha-ras directly into the main mammary ducts of resistant F1 rats from a cross between Cop and susceptible Wistar Furth (WIT) rats. Adenocarcinomas formed in approximately 50% of infused glands. Cell lines derived from these tumors were clonal, but did not share a common viral integration site, suggesting that a high level of v-Ha-ras expression was able to overcome resistance in the F1 rats. Some of the cell lines were able to grow in soft agar, but a significant number did not display anchorage-independent growth. These growth characteristics were independent of v-Ha-ras expression levels. The ability to grow in soft agar was associated with the size of tumors induced by injecting the cells into nude mice, and showed a striking positive association with the expression of cyclin D1. Furthermore, while resistance to anchorage-independent growth was fully overcome by transfection of cyclin D1 in some clones, in the others the effect was partial. A similar pattern of cyclin D1 upregulation and growth in soft agar was also observed when the cells were transfected with an active form of beta-catenin. Hybrid cells from the somatic fusion of an anchorage-dependent to an anchorage-independent clone did not grow in soft agar. These results suggest that while a high expression level of cyclin D1 is necessary for anchorage-independent growth in all clones, it is not sufficient for full growth capacity in soft agar, raising the possibility that the loss of a tumor suppressor gene in the cell lines is required to fully confer anchorage-independent growth. Our anchorage-dependent and independent rat mammary tumor-derived cell lines may recapitulate the resistance and susceptibility of Cop and WF rats, respectively, to mammary carcinogenesis that could facilitate the identification of breast cancer susceptibility genes.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Toronto, Dept Nutrit Sci, Toronto, ON, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto	Ben-David, Y (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, 2075 Bayview Ave,Res Bldg,Room S218, Toronto, ON M4N 3M5, Canada.			, James/0000-0002-0030-6216				Bani MR, 1996, CANCER RES, V56, P3075; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BEN-DAVID Y, 1990, New Biologist, V2, P1015; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BESTWICK RK, 1985, J VIROL, V56, P660, DOI 10.1128/JVI.56.3.660-664.1985; Espada J, 1999, J CELL BIOL, V146, P967, DOI 10.1083/jcb.146.5.967; FILMUS J, 1994, ONCOGENE, V9, P3627; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GOULD MN, 1989, GENES SIGNAL TRANSDU, P19; HAN EKH, 1995, ONCOGENE, V10, P953; JIANG W, 1993, ONCOGENE, V8, P3447; Korkola J E, 1999, Breast Cancer Res, V1, P88, DOI 10.1186/bcr18; Korkola JE, 1999, CARCINOGENESIS, V20, P221, DOI 10.1093/carcin/20.2.221; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; PRICE JE, 1990, CANCER RES, V50, P717; QUARONI A, 1981, J NATL CANCER I, V67, P1353; RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; RUDLAND PS, 1986, DEV BIOL, V113, P388, DOI 10.1016/0012-1606(86)90174-0; Russo J, 2000, J MAMMARY GLAND BIOL, V5, P187, DOI 10.1023/A:1026443305758; Shepel LA, 1998, GENETICS, V149, P289; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; Teodori L, 2000, IN VITRO CELL DEV-AN, V36, P153; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; WANG BC, 1991, CANCER RES, V51, P5298; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Wood GA, 2002, CARCINOGENESIS, V23, P1, DOI 10.1093/carcin/23.1.1; Zhou Q, 2000, BREAST CANCER RES TR, V59, P27, DOI 10.1023/A:1006370603147; Zhou Q, 2001, CANCER LETT, V162, P3, DOI 10.1016/S0304-3835(00)00657-1	37	15	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3452	3462		10.1038/sj.onc.1206411	http://dx.doi.org/10.1038/sj.onc.1206411			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776197				2022-12-17	WOS:000183128500012
J	Junqueira, D; Cilenti, L; Musumeci, L; Sedivy, JM; Zervos, AS				Junqueira, D; Cilenti, L; Musumeci, L; Sedivy, JM; Zervos, AS			Random mutagenesis of PDZ(Omi) domain and selection of mutants that specifically bind the Myc proto-oncogene and induce apoptosis	ONCOGENE			English	Article						Omi/HtrA2; PDZ domains; protein-protein interactions; protein design; Myc proto-oncogene; apoptosis; yeast two-hybrid system	TUMOR-SUPPRESSOR PROTEIN; SERINE-PROTEASE; PDZ DOMAINS; C-MYC; CELL-DEATH; MOLECULAR CHARACTERIZATION; TISSUE DISTRIBUTION; SEPTATE JUNCTIONS; CRYSTAL-STRUCTURE; MEMBRANE PROTEIN	Omi is a mammalian serine protease that is localized in the mitochondria and released to the cytoplasm in response to apoptotic stimuli. Omi induces cell death in a caspase-dependent manner by interacting with the X-chromosome linked inhibitor of apoptosis protein, as well as in a caspase-independent way that relies on its proteolytic activity. Omi is synthesized as a precursor polypeptide and is processed to an active serine protease with a unique PDZ domain. PDZ domains recognize the extreme carboxyl terminus of target proteins. Internal peptides that are able to fold into a beta-finger are also reported to bind some PDZ domains. Using a modified yeast two-hybrid system, PDZ(Omi) mutants were isolated by their ability to bind the carboxyl terminus of human Myc oncoprotein in yeast as well as in mammalian cells. One such PDZ(m) domain (PDZ-M1), when transfected into mammalian cells, was able to bind to endogenous Myc protein and induce cell death. PDZ-M1-induced apoptosis was entirely dependent on the presence of Myc protein and was not observed when c-myc null fibroblasts were used. Our studies indicate that the PDZ domain of Omi can provide a prototype that could easily be exploited to target specifically and inactivate oncogenes by binding to their unique carboxyl terminus.	Univ Cent Florida, Biomol Sci Ctr, Orlando, FL 32826 USA; Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32826 USA; Brown Univ, Dept Biochem Mol Biol & Cell Biol, Providence, RI 02912 USA	State University System of Florida; University of Central Florida; State University System of Florida; University of Central Florida; Brown University	Zervos, AS (corresponding author), Univ Cent Florida, Biomol Sci Ctr, 12722 Res Pkwy, Orlando, FL 32826 USA.				NIDDK NIH HHS [R01 DK55734-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055734] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; Aiyar A, 2000, Methods Mol Biol, V132, P221; Bezprozvanny I, 2001, FEBS LETT, V509, P457, DOI 10.1016/S0014-5793(01)03214-8; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; EVAN G, 1994, PHILOS T R SOC B, V345, P269, DOI 10.1098/rstb.1994.0105; Faccio L, 2000, J BIOL CHEM, V275, P2581, DOI 10.1074/jbc.275.4.2581; Faccio L, 2000, GENOMICS, V68, P343, DOI 10.1006/geno.2000.6263; Faccio L, 2000, AM J PHYSIOL-CELL PH, V278, pC781, DOI 10.1152/ajpcell.2000.278.4.C781; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Fusco C, 1999, YEAST, V15, P715, DOI 10.1002/(SICI)1097-0061(19990615)15:8<715::AID-YEA406>3.0.CO;2-K; Gee SH, 2000, BIOCHEMISTRY-US, V39, P14638, DOI 10.1021/bi001633t; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Gray CW, 2000, EUR J BIOCHEM, V267, P5699, DOI 10.1046/j.1432-1327.2000.01589.x; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hoskins R, 1996, DEVELOPMENT, V122, P97; Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406; HUNG AY, 2001, J BIOL CHEM, V10, P10; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Krojer T, 2002, NATURE, V416, P455, DOI 10.1038/416455a; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; Littlewood T D, 1990, Adv Dent Res, V4, P69; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x; Riefler GM, 2001, J BIOL CHEM, V276, P48262, DOI 10.1074/jbc.M106503200; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Schneider S, 1999, NAT BIOTECHNOL, V17, P170, DOI 10.1038/6172; Schneider S, 1996, BIOTECHNIQUES, V20, P960; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; VACCARO P, 2001, J BIOL CHEM, V16, P16; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X	50	15	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2772	2781		10.1038/sj.onc.1206359	http://dx.doi.org/10.1038/sj.onc.1206359			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743600	Green Published			2022-12-17	WOS:000182569300008
J	Kim, JH; Leem, SH; Sunwoo, Y; Kouprina, N				Kim, JH; Leem, SH; Sunwoo, Y; Kouprina, N			Separation of long-range human TERT gene haplotypes by transformation-associated recombination cloning in yeast	ONCOGENE			English	Article						hTERT; VNTR; polymorphism; haplotypes; TAR cloning	TELOMERASE ACTIVITY; DNA; MINISATELLITES; AMPLIFICATION; POLYMORPHISMS; CHROMOSOMES; EXPRESSION; SEQUENCE	The hTERT gene encoding a catalytic subunit of human telomerase contains four blocks of variable number of tandem repeats (VNTRs) - two in intron 2 and two in intron 6. The segregation of hTERT VNTRs was analysed in families, revealing that all of them were transmitted through meiosis following a Mendelian inheritance. The work reports a further characterization of the minisatellites in hTERT. We employed transformation-associated recombination (TAR) cloning to isolate parental hTERT alleles and determined the specific combination of minisatellites at each of the polymorphic sites. A long-range haplotyping of hTERT determined by TAR cloning was verified by classical Mendelian analysis. Since such a strategy can be applied for any chromosomal locus, we conclude that recombinational gene capture could greatly facilitate haplotypes analysis.	NCI, Lab Biosyst & Canc, NIH, Bethesda, MD 20892 USA; Dong A Univ, Dept Biol, Pusan 604714, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Dong A University	Kouprina, N (corresponding author), NCI, Lab Biosyst & Canc, NIH, Bldg 37,Room 5032, Bethesda, MD 20892 USA.	kouprinn@mail.nih.gov						Chiu CP, 1997, P SOC EXP BIOL MED, V214, P99; FUKE S, 2001, PHARMACOGENOMICS J, V2, P152; JEFFREYS AJ, 1990, CELL, V60, P473, DOI 10.1016/0092-8674(90)90598-9; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kouprina N, 1998, P NATL ACAD SCI USA, V95, P4469, DOI 10.1073/pnas.95.8.4469; KOUPRINA N, 1999, CURRENT PROTOCOLS HU, V1; Larionov V, 1997, P NATL ACAD SCI USA, V94, P7384, DOI 10.1073/pnas.94.14.7384; Larionov V, 1996, P NATL ACAD SCI USA, V93, P491, DOI 10.1073/pnas.93.1.491; Leem SH, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng029; Leem SH, 2002, ONCOGENE, V21, P769, DOI 10.1038/sj.onc.1205122; LI HH, 1988, NATURE, V335, P414, DOI 10.1038/335414a0; LUDECKE HJ, 1989, NATURE, V338, P348, DOI 10.1038/338348a0; Noskov V, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e8; Noskov VN, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.6.e32; NOSKOV VN, 2003, IN PRESS J MOL EVOL, V56; Paquette J, 1998, J BIOL CHEM, V273, P14158, DOI 10.1074/jbc.273.23.14158; RUANO G, 1990, P NATL ACAD SCI USA, V87, P6296, DOI 10.1073/pnas.87.16.6296; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Szutorisz H, 2001, ONCOGENE, V20, P2600, DOI 10.1038/sj.onc.1204346; Yan P, 1999, J PATHOL, V189, P207, DOI 10.1002/(SICI)1096-9896(199910)189:2<207::AID-PATH424>3.0.CO;2-H; Yoshida R, 1999, ANTICANCER RES, V19, P2167	21	15	17	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2003	22	16					2452	2456		10.1038/sj.onc.1206316	http://dx.doi.org/10.1038/sj.onc.1206316			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717422				2022-12-17	WOS:000182383500008
J	Qiu, CP; Yu, MS; Shan, L; Snyderwine, EG				Qiu, CP; Yu, MS; Shan, L; Snyderwine, EG			Allelic imbalance and altered expression of genes in chromosome 2q11-2q16 from rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine	ONCOGENE			English	Article						heterocyclic amines; allelic imbalance; quantitative real-time polymerase chain reaction; microsatellite instability; loss of heterozygosity; gene expression; rat chromosome 2q	RASGTPASE ACTIVATING PROTEIN; SPRAGUE-DAWLEY RATS; BREAST-CANCER; EPITHELIAL-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; MICROSATELLITE INSTABILITY; PROSTATE-CANCER; ONCOSTATIN-M; DIETARY-FAT; TUMORS	2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), a compound found in cooked meat, is a mammary gland carcinogen in rats. Comparative genomic hybridization of PhIP-induced rat mammary gland carcinomas revealed loss in the centromeric region of 2q, a region known to carry the mammary carcinoma susceptibility 1 (Mcs1) gene and several other genes relevant to carcinogenesis. Allelic imbalance, specifically microsatellite instability and loss of heterozygosity, was examined in mammary gland carcinomas induced by PhIP in Sprague-Dawley (SD) x Wistar Furth F1 hybrid rats. In a polymerase chain reaction (PCR)-based assay with 34 microsatellite markers coinciding to 2q11-2q16, nine markers revealed allelic imbalance. The frequency of imbalance in the tumors varied from 10 to 100% depending on the specific marker. However, none of the markers coinciding with the Mcs1 gene locus showed allelic imbalance, suggesting that alterations at this locus were not associated with PhIP-induced rat mammary gland cancer. The expression of several genes physically mapped to 2q11-2q16 and potentially involved in carcinogenesis including Ccnb (cyclin B1), Ccnh (cyclin H), Rasa (Ras GAP), RasgrJ2, Pi3kr1 (p85alpha), and Il6st (gp130) was also examined by quantitative real-time PCR and immunohistochemistry (IHC) across a large bank of PhIP-induced SD rat mammary gland carcinomas. By quantitative real-time PCR, the mRNA expression of Rasa, Pi3kr1, Ccnh, and 1l6st in carcinomas was, respectively, 22-, 20-, three- and threefold higher in carcinomas than in control mammary gland tissues (P<0.05, Student's t-test). A statistically sixfold lower expression of Rasgrf 2 was detected in carcinomas whereas no significant change in Ccnb1 expression was observed. The findings from quantitative real-time PCR were confirmed by IHC for each gene. In addition, the proliferation index in mammary gland carcinomas as assessed by PCNA was found to correlate with the overexpression of Cyclin H by IHC analysis (P<0.05, Spearman Rank Order Correlation). The findings from the current study implicate molecular alterations in the proximal region of 2q in PhIP-induced rat mammary gland carcinomas.	NCI, Ctr Canc Res,Lab Expt Carcinogenesis, Chem Carcinogenesis Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Snyderwine, EG (corresponding author), NCI, Ctr Canc Res,Lab Expt Carcinogenesis, Chem Carcinogenesis Sect, NIH, Bldg 37,Room 4134,37 Convent Dr MSC 4262, Bethesda, MD 20892 USA.				DIVISION OF BASIC SCIENCES - NCI [Z01BC010037] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barshack I, 1998, MODERN PATHOL, V11, P271; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Christian AT, 2002, MUTAT RES-FUND MOL M, V506, P113, DOI 10.1016/S0027-5107(02)00157-4; Crichton MB, 1996, MOL CELL ENDOCRINOL, V118, P215, DOI 10.1016/0303-7207(96)03761-6; Davidson B, 1998, PATHOL RES PRACT, V194, P399, DOI 10.1016/S0344-0338(98)80030-7; Fernandez-Medarde A, 2002, MOL CELL BIOL, V22, P2498, DOI 10.1128/MCB.22.8.2498-2504.2002; Gershtein ES, 1999, CLIN CHIM ACTA, V287, P59, DOI 10.1016/S0009-8981(99)00118-7; GHOSHAL A, 1994, CARCINOGENESIS, V15, P2429, DOI 10.1093/carcin/15.11.2429; Gire V, 2000, ONCOGENE, V19, P2269, DOI 10.1038/sj.onc.1203544; Grant SL, 2001, GROWTH FACTORS, V19, P153, DOI 10.3109/08977190109001083; Haag JD, 1996, MOL CARCINOGEN, V17, P134, DOI 10.1002/(SICI)1098-2744(199611)17:3<134::AID-MC5>3.3.CO;2-N; Hokaiwado N, 2001, CANCER LETT, V163, P187, DOI 10.1016/S0304-3835(00)00693-5; HSU LC, 1994, CANCER RES, V54, P2765; Karan D, 2002, CARCINOGENESIS, V23, P967, DOI 10.1093/carcin/23.6.967; Kerangueven F, 1997, CANCER RES, V57, P5469; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Laes JF, 2001, MAMM GENOME, V12, P199, DOI 10.1007/s003350010268; LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39; Leblanc V, 1999, ONCOGENE, V18, P4884, DOI 10.1038/sj.onc.1202855; Liu JW, 1998, CYTOKINE, V10, P295, DOI 10.1006/cyto.1997.0283; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Mills GB, 2001, SEMIN ONCOL, V28, P125, DOI 10.1053/sonc.2001.28554; Quan X, 2000, CYTOGENET CELL GENET, V88, P119, DOI 10.1159/000015503; Roberts-Thomson SJ, 1997, MOL CARCINOGEN, V20, P348, DOI 10.1002/(SICI)1098-2744(199712)20:4<348::AID-MC4>3.0.CO;2-F; Rodriguez-Viciana P, 2001, METHOD ENZYMOL, V333, P37; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; RUSSO J, 1990, LAB INVEST, V62, P244; Schultz P, 2000, CELL, V102, P599, DOI 10.1016/S0092-8674(00)00082-9; Shan L, 2002, CARCINOGENESIS, V23, P1561, DOI 10.1093/carcin/23.10.1561; Shepel LA, 1998, GENETICS, V149, P289; Sinha R, 2000, J NATL CANCER I, V92, P1352, DOI 10.1093/jnci/92.16.1352; Snyderwine EG, 1998, NUTR CANCER, V31, P160, DOI 10.1080/01635589809514698; SNYDERWINE EG, 2000, FOOD BORNE CARCINOGE, P241; Szpirer C, 1999, MAMM GENOME, V10, P30, DOI 10.1007/s003359900937; Tomlinson IPM, 2002, GENE CHROMOSOME CANC, V34, P349, DOI 10.1002/gcc.10085; Toyota M, 1996, MOL CARCINOGEN, V15, P176, DOI 10.1002/(SICI)1098-2744(199603)15:3<176::AID-MC3>3.0.CO;2-G; Watanabe N, 2001, CANCER RES, V61, P2632; Yang JY, 2002, J BIOL CHEM, V277, P14641, DOI 10.1074/jbc.M111540200; Yu MS, 2002, CARCINOGENESIS, V23, P2123, DOI 10.1093/carcin/23.12.2123; Yu MS, 2000, MOL CARCINOGEN, V27, P76, DOI 10.1002/(SICI)1098-2744(200002)27:2<76::AID-MC3>3.0.CO;2-7	41	15	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 27	2003	22	8					1253	1260		10.1038/sj.onc.1206233	http://dx.doi.org/10.1038/sj.onc.1206233			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606953				2022-12-17	WOS:000181249700015
J	Visconti, R; Schepis', F; Iuliano, R; Pierantoni, GM; Zhang, L; Carlomagno, F; Battaglia, C; Martelli, ML; Trapasso, F; Santoro, M; Fusco, A				Visconti, R; Schepis', F; Iuliano, R; Pierantoni, GM; Zhang, L; Carlomagno, F; Battaglia, C; Martelli, ML; Trapasso, F; Santoro, M; Fusco, A			Cloning and molecular characterization of a novel gene strongly induced by the adenovirus E1A gene in rat thyroid cells	ONCOGENE			English	Article						thyroid; carcinoma; E1A; transformation	NUCLEAR TRANSLOCATION; ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; EARLY REGION-1A; LINE; ONCOGENES; PROTEIN; GROWTH; TRANSFORMATION; LOCALIZATION	Expression of the adenovirus E1A gene in the rat thyroid differentiated cell line PC CI 3 induces thyrotropin-independent cell growth and impairs differentiation. However, the malignant phenotype is achieved only when the PC E1A cells are infected with other murine retroviruses carrying the v-abl, v-raf or polyoma middle-T genes. To determine through which genes E1A affects thyroid cells, we differentially screened PC Cl 3 and PC E1A cells. Here we report a new gene, named CL2, that is upregulated in PC E1A cells. The CL2 transcript is 4.4 kb long and encodes a 949 amino-acid protein. Conceptual translation of the open reading frame showed one product with a signal peptide, multiple nuclear localization signals and three newly described domains. Furthermore, in vivo, this protein was located juxtanuclear, which is suggestive of Golgian localization, and also in cytoplasm and nucleus/nucleolus. Finally, CL2 gene expression was drastically downregulated in human thyroid neoplastic cell lines and tissues.	Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol L Calif, I-80131 Naples, Italy; CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Catanzaro Magna Graecia, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); Magna Graecia University of Catanzaro	Fusco, A (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol L Calif, Via Pansini 5, I-80131 Naples, Italy.		Visconti, Roberta/C-5299-2009; schepis, filippo/H-9417-2014	schepis, filippo/0000-0001-6549-5102; Pierantoni, Giovanna Maria/0000-0003-4078-8528; Fusco, Alfredo/0000-0003-3332-5197; Visconti, Roberta/0000-0001-7613-3801				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Antoine M, 1997, J BIOL CHEM, V272, P29475, DOI 10.1074/jbc.272.47.29475; Bailey TL, 1998, J COMPUT BIOL, V5, P211, DOI 10.1089/cmb.1998.5.211; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; Basolo F, 2002, INT J CANCER, V97, P608, DOI 10.1002/ijc.10116; BERLINGIERI MT, 1993, ONCOGENE, V8, P249; BERLINGIERI MT, 1988, MOL CELL BIOL, V8, P2261, DOI 10.1128/MCB.8.5.2261; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; CHINNADURAI G, 1992, ONCOGENE, V7, P1255; CONE RD, 1988, MOL CELL BIOL, V8, P1036, DOI 10.1128/MCB.8.3.1036; DRY KL, 1995, HUM MOL GENET, V4, P2347, DOI 10.1093/hmg/4.12.2347; ESTOUR B, 1989, VIRCHOWS ARCH B, V57, P167, DOI 10.1007/BF02899078; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FABIEN N, 1994, CANCER, V73, P2206, DOI 10.1002/1097-0142(19940415)73:8<2206::AID-CNCR2820730828>3.0.CO;2-M; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; Fearnhead HO, 1997, GENE DEV, V11, P1266, DOI 10.1101/gad.11.10.1266; Fiore L, 1997, J CLIN ENDOCR METAB, V82, P4094, DOI 10.1210/jc.82.12.4094; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; Hill DJ, 1992, GROWTH FACTORS, V6, P277, DOI 10.3109/08977199209021540; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; Kurosawa H, 1999, BLOOD, V93, P321, DOI 10.1182/blood.V93.1.321.401k05_321_332; LYNCH MJ, 1989, CANCER RES, V49, P5429; MAHER DW, 1989, MOL CELL BIOL, V9, P2251, DOI 10.1128/MCB.9.5.2251; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; MOROIANU J, 1994, P NATL ACAD SCI USA, V91, P1677, DOI 10.1073/pnas.91.5.1677; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Pan J, 1996, FEBS LETT, V383, P21; PANG XP, 1989, ENDOCRINOLOGY, V125, P1783, DOI 10.1210/endo-125-4-1783; PARASKEVA C, 1980, INT J CANCER, V25, P631, DOI 10.1002/ijc.2910250513; ROSSINI M, 1983, VIROLOGY, V131, P49, DOI 10.1016/0042-6822(83)90532-9; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Sambrook J, 1989, MOL CLONING LAB MANU; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; STOW ND, 1982, NUCLEIC ACIDS RES, V10, P5105, DOI 10.1093/nar/10.17.5105; TANAKA J, 1987, VIROLOGY, V161, P62, DOI 10.1016/0042-6822(87)90171-1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; White E, 2001, ONCOGENE, V20, P7836, DOI 10.1038/sj.onc.1204861; WHITE E, 1995, CURR TOP MICROBIOL, V199, P33; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; ZEKI K, 1991, ACTA ENDOCRINOL-COP, V124, P60, DOI 10.1530/acta.0.1240060	48	15	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 20	2003	22	7					1087	1097		10.1038/sj.onc.1206194	http://dx.doi.org/10.1038/sj.onc.1206194			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592395				2022-12-17	WOS:000180926100014
J	La, P; Morgan, TA; Sykes, SM; Mao, H; Schnepp, RW; Petersen, CD; Hua, XX				La, P; Morgan, TA; Sykes, SM; Mao, H; Schnepp, RW; Petersen, CD; Hua, XX			Fusion proteins of retinoid receptors antagonize TGF-beta-induced growth inhibition of lung epithelial cells	ONCOGENE			English	Article						TGF-beta; retinoic acid; RXR beta; PLZF-RAR alpha; p15(ink4b)	ACUTE PROMYELOCYTIC LEUKEMIA; PLZF-RAR-ALPHA; TREATED HL-60 CELLS; SMAD PROTEINS; INDUCED TRANSCRIPTION; FUNCTIONAL INTERACTIONS; INDUCED PHOSPHORYLATION; MOLECULAR PATHOGENESIS; TARGETED DISRUPTION; SIGNAL-TRANSDUCTION	Transforming growth factor-beta1 (TGF-beta) is a growth factor that has multiple functions including potent inhibition of cell growth. TGF-beta signals by binding to its cell surface serine/threonine kinase receptors, which in turn phosphorylate downstream signal transducers, Smad2 and Smad3. Phosphorylated Smad2 and Smad3, together with Smad4, enter the nucleus and associate with various transcription factors. This complex of transcription factors regulates transcription of a diverse group of genes, leading to growth arrest at G1 phase. Through a functional expression cloning approach, a gag-retinoid X receptor beta (gag-RXRbeta) fusion protein was found to antagonize TGF-beta-induced growth inhibition of mink lung epithelial cells and the fusion between gag and RXRbeta is essential for resistance to the growth inhibition. Like gag-RXRbeta, the oncogenic PLZF-RARalpha fusion protein also antagonizes TGF-beta-induced growth inhibition, and the fusion between PLZF and RARalpha is essential for resistance to TGF-beta. Moreover, TGF-beta and retinoic acid (RA) cooperatively induce growth inhibition as well as transcription of the p15(inkb) gene, while PLZF-RARalpha represses TGF-beta-induced expression of the p15(ink4b) gene. Together, these results suggest that the TGF-beta and RA pathways cooperate to inhibit cell growth and that PLZF-RARalpha -mediated resistance to TGF-beta may facilitate the development of the PLZF-RARalpha-induced leukemia.	Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Hua, XX (corresponding author), Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.	huax@mail.med.upenn.edu			NATIONAL CANCER INSTITUTE [K01CA078592] Funding Source: NIH RePORTER; NCI NIH HHS [1K01CA78592] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; BATOVA A, 1992, CELL GROWTH DIFFER, V3, P763; Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200; Borger DR, 2000, VIROLOGY, V270, P397, DOI 10.1006/viro.2000.0282; Bottinger EP, 1997, EMBO J, V16, P2621, DOI 10.1093/emboj/16.10.2621; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; Danielpour D, 1996, J CELL PHYSIOL, V166, P231, DOI 10.1002/(SICI)1097-4652(199601)166:1<231::AID-JCP24>3.0.CO;2-G; Datta PK, 2000, J BIOL CHEM, V275, P40014, DOI 10.1074/jbc.C000508200; Datto MB, 1999, MOL CELL BIOL, V19, P2495; Defacque H, 1999, J CELL PHYSIOL, V178, P109, DOI 10.1002/(SICI)1097-4652(199901)178:1<109::AID-JCP14>3.3.CO;2-O; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; DICKENS TA, 1993, BIOESSAYS, V15, P71, DOI 10.1002/bies.950150111; Dragnev KH, 2001, ANN NY ACAD SCI, V952, P13, DOI 10.1111/j.1749-6632.2001.tb02724.x; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FALK LA, 1991, BLOOD, V77, P1248; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Han GR, 1997, J BIOL CHEM, V272, P13711, DOI 10.1074/jbc.272.21.13711; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hayes SA, 2001, CANCER RES, V61, P2112; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; Imai S, 1997, FEBS LETT, V411, P102, DOI 10.1016/S0014-5793(97)00673-X; Imai Y, 2001, ONCOGENE, V20, P88, DOI 10.1038/sj.onc.1204057; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kim RH, 2000, GENE DEV, V14, P1605; Kishi H, 2001, CELL BIOL INT, V25, P1125, DOI 10.1006/cbir.2001.0795; KOJIMA S, 1993, J CELL PHYSIOL, V155, P323, DOI 10.1002/jcp.1041550213; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lardon F, 1996, LEUKEMIA, V10, P1937; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MEYSKENS FL, 1995, AM J CLIN NUTR, V62, P1417, DOI 10.1093/ajcn/62.6.1417S; MORALES TI, 1992, ARCH BIOCHEM BIOPHYS, V293, P79, DOI 10.1016/0003-9861(92)90368-7; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nunes I, 1996, CANCER RES, V56, P495; Okuno M, 1997, HEPATOLOGY, V26, P913, DOI 10.1053/jhep.1997.v26.pm0009328313; Okuno M, 2002, FRONT BIOSCI-LANDMRK, V7, pD204, DOI 10.2741/okuno; Onishi M, 1996, EXP HEMATOL, V24, P324; Pandolfi PP, 2001, HUM MOL GENET, V10, P769, DOI 10.1093/hmg/10.7.769; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Razani B, 2001, J BIOL CHEM, V276, P6727, DOI 10.1074/jbc.M008340200; ROBERTS AB, 1992, CANCER SURV, V14, P205; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; Sambrook J., 1989, MOL CLONING; Schiemann WP, 2002, J BIOL CHEM, V277, P27367, DOI 10.1074/jbc.M200148200; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Slack James L., 1999, Current Opinion in Oncology, V11, P9, DOI 10.1097/00001622-199901000-00003; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Thormeyer D, 1999, INT J MOL MED, V4, P351; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Valette A, 1990, GROWTH FACTORS, V2, P283, DOI 10.3109/08977199009078016; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	89	15	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2003	22	2					198	210		10.1038/sj.onc.1206100	http://dx.doi.org/10.1038/sj.onc.1206100			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527889				2022-12-17	WOS:000180322400005
J	Plug-Demaggio, AW; McDougall, JK				Plug-Demaggio, AW; McDougall, JK			The human papillomavirus type 16 E6 oncogene induces premature mitotic chromosome segregation	ONCOGENE			English	Article						genetic instability; chromosome segregation; HPV 16 E6	CERVICAL INTRAEPITHELIAL NEOPLASIA; HUMAN KERATINOCYTES; GENOMIC INSTABILITY; SPINDLE CHECKPOINT; MAMMALIAN-CELLS; ONCOPROTEINS; P53; DEGRADATION; PROGRESSION; DISRUPTION	Expression of the human papillomavirus type 16 E6 and E7 oncogenes initiates and maintains abnormal cell replication, by interacting with the p53 and retinoblastoma (Rb) gene products. Subsequent changes in host cell gene expression, as a consequence of genetic instability, can result in progression to invasive carcinoma. In addition to previously described effects of these viral oncogenes on centrosome synthesis, primarily associated with the expression of E7, the results described herein demonstrate that the E6 oncogene can induce premature chromosome segregation in human cells.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Canc Biol Program, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	McDougall, JK (corresponding author), Univ Washington, Dept Pathol, 1959 Pacific St NE, Seattle, WA 98195 USA.	jmcdouga@fhcrc.org			NATIONAL CANCER INSTITUTE [P01CA042792] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42792] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Burger MPM, 1997, INT J GYNECOL PATHOL, V16, P10, DOI 10.1097/00004347-199701000-00002; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2001, J VIROL, V75, P7712, DOI 10.1128/JVI.75.16.7712-7716.2001; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GARRETT LR, 1993, CARCINOGENESIS, V14, P329, DOI 10.1093/carcin/14.2.329; Giannoudis A, 2000, BRIT J CANCER, V82, P424, DOI 10.1054/bjoc.1999.0937; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kalitsis P, 2000, GENE DEV, V14, P2277, DOI 10.1101/gad.827500; MANTOVANI F, 2001, SEMIN CANCER BIOL, V9, P387; Matthews CP, 2000, P SOC EXP BIOL MED, V223, P316, DOI 10.1046/j.1525-1373.2000.22345.x; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; MUNGER K, 1989, J VIROL, V63, P4417; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Skibbens RV, 1998, ANNU REV GENET, V32, P307, DOI 10.1146/annurev.genet.32.1.307; SolinasToldo S, 1997, P NATL ACAD SCI USA, V94, P3854, DOI 10.1073/pnas.94.8.3854; THERMAN E, 1984, CANCER GENET CYTOGEN, V11, P185, DOI 10.1016/0165-4608(84)90113-4; Thomas JT, 1998, J VIROL, V72, P1131, DOI 10.1128/JVI.72.2.1131-1137.1998; Thompson DA, 1997, ONCOGENE, V15, P3025, DOI 10.1038/sj.onc.1201495; VANLEEUWEN AM, 1995, VIRCHOWS ARCH, V427, P139, DOI 10.1007/BF00196518; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666	28	15	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2002	21	49					7507	7513		10.1038/sj.onc.1205903	http://dx.doi.org/10.1038/sj.onc.1205903			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386813				2022-12-17	WOS:000178618200006
J	Mochizuki, Y; Tsuda, S; Kanetake, H; Kanda, S				Mochizuki, Y; Tsuda, S; Kanetake, H; Kanda, S			Negative regulation of urokinase-type plasminogen activator production through FGF-2-mediated activation of phosphoinositide 3-kinase	ONCOGENE			English	Article						FGF-2; uPA; endothelial cells; L6 myoblasts; PI3-kinase; Ras	FIBROBLAST-GROWTH-FACTOR; PROTEIN-KINASE-B; FACTOR-BETA-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; ENDOTHELIAL-CELLS; HIGH-AFFINITY; EXPRESSION; DIFFERENTIATION; ANGIOGENESIS; INHIBITION	Activation of phosphoinositide 3-kinase (PI3-kinase) is involved in many cellular responses. FGF-2 is one of the potent inducers of urokinase-type plasminogen activator (uPA) production in endothelial cells. However, little is known about the molecular mechanisms underlying FGF-2-mediated uPA production. Here we examined the signal transduction pathways involved in the regulation of uPA production by FGF-2-treatment. FGF-2 potently upregulated uPA production in murine brain capillary endothelial cells (IBE cells), as well as porcine aortic endothelial (PAE) cells and L6 myoblasts ectopically expressing FGFR1. PI3-kinase inhibitors, wortmannin and LY294002, both enhanced FGF-2-dependent uPA production by these cells. Stable expression of activated mutant p110alpha catalytic subunit of PI3-kinase into IBE cells decreased FGF-2-mediated uPA production, suggesting that PI3-kinase exhibited the negative regulatory effect on uPA production. No increase in FGF-2-induced PI3-kinase activity was observed in proteins immunoprecipitated by anti-phosphotyrosine antibody. Although stable expression of deleted mutant p85alpha regulatory subunit, which lacks association with p110 catalytic subunit, in IBE cells showed no dominant negative effect, transient expression of dominant negative Ras inhibited FGF-2-mediated PI3-kinase activation. These results suggest that only activated Ras contributed the FGF-2-mediated PI3-kinase activation. In cells stably expressing mutant p85a subunit, FGF-2 efficiently induced uPA production. Taken together, activation of PI3-kinase by FGF-2 is Ras-dependent and results in down-regulation of uPA production.	Nagasaki Univ, Dept Urol, Nagasaki 8528051, Japan; Nagasaki Univ, Grad Sch Med, Dept Mol Microbiol & Immunol, Div Endothelial Cell Biol, Nagasaki 8528051, Japan	Nagasaki University; Nagasaki University	Kanda, S (corresponding author), Nagasaki Univ, Dept Urol, 1-7-1 Sakamoto, Nagasaki 8528051, Japan.	shigeruk@net.nagasaki-u.ac.jp						Aguirre-Ghiso JA, 1999, ONCOGENE, V18, P4718, DOI 10.1038/sj.onc.1202850; Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; Boilly B, 2000, CYTOKINE GROWTH F R, V11, P295, DOI 10.1016/S1359-6101(00)00014-9; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Ghiso JAA, 1999, EUR J BIOCHEM, V263, P295, DOI 10.1046/j.1432-1327.1999.00507.x; Giuliani R, 1999, J CELL SCI, V112, P2597; Gum R, 1998, ONCOGENE, V17, P213, DOI 10.1038/sj.onc.1201917; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Klint Peter, 1999, Frontiers in Bioscience, V4, pD165, DOI 10.2741/Klint; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Koziczak M, 2000, MOL CELL BIOL, V20, P2014, DOI 10.1128/MCB.20.6.2014-2022.2000; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Pepper MS, 1996, ENZYME PROTEIN, V49, P138, DOI 10.1159/000468622; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Roghani M, 1996, J BIOL CHEM, V271, P31154, DOI 10.1074/jbc.271.49.31154; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Roymans D, 2001, EUR J BIOCHEM, V268, P487, DOI 10.1046/j.1432-1327.2001.01936.x; Stein RC, 2000, MOL MED TODAY, V6, P347, DOI 10.1016/S1357-4310(00)01770-6; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; VASSALLI JD, 1987, FEBS LETT, V214, P187, DOI 10.1016/0014-5793(87)80039-X; Wang WX, 1999, ONCOGENE, V18, P4554, DOI 10.1038/sj.onc.1202833; WENNSTROM S, 1992, J BIOL CHEM, V267, P13749; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	43	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2002	21	46					7027	7033		10.1038/sj.onc.1205736	http://dx.doi.org/10.1038/sj.onc.1205736			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370824				2022-12-17	WOS:000178424900005
J	Takahashi, T				Takahashi, T			Lung cancer: an ever increasing store of in-depth basic knowledge and the beginning of its clinical application	ONCOGENE			English	Editorial Material						lung cancer; molecular pathogenesis; clinical application			Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.		Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001					0	15	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	2002	21	45					6868	6869		10.1038/sj.onc.1205830	http://dx.doi.org/10.1038/sj.onc.1205830			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604UV	12362268				2022-12-17	WOS:000178640200001
J	Miyaki, M; Iijima, T; Yasuno, M; Kita, Y; Hishima, T; Kuroki, T; Mori, T				Miyaki, M; Iijima, T; Yasuno, M; Kita, Y; Hishima, T; Kuroki, T; Mori, T			High incidence of protein-truncating mutations of the p53 gene in liver metastases of colorectal carcinomas	ONCOGENE			English	Article						p53 mutation; protein-truncating mutation; liver metastasis; colorectal carcinoma	PROGNOSTIC-SIGNIFICANCE; ADENOMATOUS POLYPOSIS; TERM SURVIVAL; KI-RAS; CANCER; OVEREXPRESSION; ACCUMULATION; EXPRESSION; DOMAIN; BREAST	To clarify the significance of p53 mutations in liver metastasis of colorectal carcinogenesis, the characteristics of p53 mutations from 51 liver metastases and 76 primary invasive carcinomas without liver metastasis (Dukes' A, B and C) were compared. The frequency of tumors with p53 mutations was 61% (31 out of 51) in the liver metastases, and 51% (39 out of 76) in the primary carcinomas without liver metastasis. Approximately 90% of the informative cases having p53 mutation showed 17pLOH. Mutations detected within exons 4-10 of the p53 gene included missense, nonsense, frameshift, inframe deletion, and inframe insertion mutations. Out of the tumors with p53 mutations, we found that the percentage of tumors with protein-truncating mutations (nonsense and frameshift mutations) was extremely higher in liver metastases (16 out of 31, 52%) than in primary carcinomas without liver metastasis (5 out of 39, 13%) (P=0.0005). The present results suggest that protein-truncating mutations of the p53 gene are more relevant than missense mutations as one of the prognostic factors in liver metastasis of colorectal carcinomas.	Tokyo Metropolitan Komagome Hosp, Hereditary Tumor Res Project, Bunkyo Ku, Tokyo 1138677, Japan; Tokyo Metropolitan Komagome Hosp, Dept Surg, Tokyo 1138677, Japan; Tokyo Metropolitan Komagome Hosp, Dept Pathol, Tokyo 1138677, Japan; Showa Univ, Inst Mol Oncol, Tokyo 1428666, Japan	Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Showa University	Miyaki, M (corresponding author), Tokyo Metropolitan Komagome Hosp, Hereditary Tumor Res Project, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138677, Japan.		Kuroki, Toshio/A-9500-2011	Kuroki, Toshio/0000-0001-6369-4351				AUVINEN A, 1994, BRIT J CANCER, V70, P293, DOI 10.1038/bjc.1994.295; BELL SM, 1993, GASTROENTEROLOGY, V104, P57, DOI 10.1016/0016-5085(93)90835-Z; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GOH HS, 1995, CANCER RES, V55, P5217; HAMELIN R, 1994, GASTROENTEROLOGY, V106, P42, DOI 10.1016/S0016-5085(94)94217-X; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HARTMANN A, 1995, ONCOGENE, V10, P681; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3965; Lanza G, 1996, AM J CLIN PATHOL, V105, P604; Lim BHG, 1996, INT J CANCER, V69, P200, DOI 10.1002/(SICI)1097-0215(19960621)69:3<200::AID-IJC9>3.0.CO;2-3; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MIYAKI M, 1994, CANCER RES, V54, P3011; MORRIN M, 1994, GUT, V35, P1627, DOI 10.1136/gut.35.11.1627; MULDER JWR, 1995, BRIT J CANCER, V71, P1257, DOI 10.1038/bjc.1995.243; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; SAITOH S, 1994, ONCOGENE, V9, P2869; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Smith DR, 1996, BRIT J CANCER, V74, P216, DOI 10.1038/bjc.1996.340; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219	22	15	15	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6689	6693		10.1038/sj.onc.1205887	http://dx.doi.org/10.1038/sj.onc.1205887			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242668				2022-12-17	WOS:000178202300016
J	Black, EJ; Walker, M; Clark, W; MacLaren, A; Gillespie, DAF				Black, EJ; Walker, M; Clark, W; MacLaren, A; Gillespie, DAF			Cell transformation by v-Jun deactivates ERK MAP kinase signalling	ONCOGENE			English	Article						v-Jun; MAP kinase; autocrine; transformation	ACTIVATED PROTEIN-KINASE; NIH 3T3 CELLS; GROWTH-FACTOR; CYCLE ARREST; RAS; EXPRESSION; PROLIFERATION; FIBROBLASTS; ENTRY; GENE	Previous studies have shown that v-Jun accelerates G1 progression and enables cells to sustain S phase entry in the absence of serum growth factors. Since growth factor-dependent ERK MAP kinase signalling plays an important role in regulating the G1/S transition, we investigated whether aberrant ERK regulation might contribute to cell cycle deregulation by v-Jun. Contrary to expectation, we find that cells transformed by v-Jun exhibit a profound reduction in the basal level of active, dual-phosphorylated ERK. In addition, ERK becomes refractory to stimulation by a subset of agonists including serum, LPA, and EGF, but remains partially responsive to the phorbol ester, TPA. Biochemical analysis indicates that these defects are attributable to a combination of inefficient signal propagation between Ras and Raf within the ERK pathway and increased tonic deactivation by MAP kinase phosphatases. Taken together, these results demonstrate that cell transformation by v-Jun induces alterations in cell physiology which antagonize ERK signalling at multiple levels. The potential significance of this phenotype for oncogenesis by v-Jun is discussed.	Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Canc Res UK Beatson Labs, Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	University of Glasgow; Beatson Institute	Gillespie, DAF (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland.		Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544				Barnard D, 1998, ONCOGENE, V17, P1539, DOI 10.1038/sj.onc.1202061; Black EJ, 2000, CURR BIOL, V10, P1119, DOI 10.1016/S0960-9822(00)00699-0; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Clark W, 2000, MOL CELL BIOL, V20, P2529, DOI 10.1128/MCB.20.7.2529-2542.2000; Clark W, 1997, CELL GROWTH DIFFER, V8, P371; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; Fu SL, 2000, ONCOGENE, V19, P3537, DOI 10.1038/sj.onc.1203691; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kilbey A, 1996, ONCOGENE, V12, P2409; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; MacLaren A, 2000, ONCOGENE, V19, P5906, DOI 10.1038/sj.onc.1203954; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sommer A, 2000, FEBS LETT, V474, P146, DOI 10.1016/S0014-5793(00)01566-0; SU HY, 1991, ONCOGENE, V6, P1759; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Treinies I, 1999, MOL CELL BIOL, V19, P321; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	31	15	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2002	21	42					6540	6548		10.1038/sj.onc.1205851	http://dx.doi.org/10.1038/sj.onc.1205851			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226757				2022-12-17	WOS:000177925300014
J	Zhuang, SM; Wiseman, RW; Soderkvist, P				Zhuang, SM; Wiseman, RW; Soderkvist, P			Frequent mutations of the Trp53, Hras1 and beta-catenin (Catnb) genes in 1,3-butadiene-induced mammary adenocarcinomas in B6C3F1 mice	ONCOGENE			English	Article						Trp53; Hras1; Catnb; 1,3-butadiene; mammary adenocarcinomas	TUMOR-SUPPRESSOR GENE; SOMATIC MUTATIONS; RAS GENES; CYCLIN D1; K-RAS; EXPRESSION; CANCER; MOUSE; ACTIVATION; P53	DNAs from 1,3-butadiene-induced mammary adenocarcinomas of B6C3F1 mice were examined for mutations in the Trp53 gene, the ras gene family and several components of the Wnt signaling pathway, including beta-catenin (Catnb), Ape and Axin. Trp53 mutations were detected in 41% (7 out of 17) of tumors. Each tumor with a Trp53 mutation also exhibited loss of the wildtype Trp53 allele, supporting the importance of Trp53 inactivation during development of these tumors. Analyses of the Hras1, Kras2 and Nras proto-oncogenes revealed Hras1 mutations in 53% (9 out of 17) of tumors. Seven of these mutations were a G-C transversion in Hras1 codon 13, consistent with a 1,3-butadiene-specific Kras2 mutation previously reported in several other tumor types. Mutation screens in Catnb exon 2, the Ape mutation cluster region and the Catnb-binding domain of the Axin gene identified Catnb missense mutations in 3 out of 17 (18%) tumors. In total, mutations of the Trp53, Hras] and/or Catnb genes were identified in 15 out of 17 1,3-butadiene-induced mammary adenocarcinomas. These results indicate that multiple genetic pathways are disrupted in chemically induced mammary tumors, and that studies in mouse models may help to understand the etiology of human breast cancers.	Linkoping Univ, Fac Hlth Sci, Dept Biomed & Surg, Div Cell Biol, SE-58185 Linkoping, Sweden; NIEHS, Lab Womens Hlth, Res Triangle Pk, NC 27709 USA	Linkoping University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Zhuang, SM (corresponding author), Linkoping Univ, Fac Hlth Sci, Dept Biomed & Surg, Div Cell Biol, SE-58185 Linkoping, Sweden.	shizh@mcb.liu.se		Zhuang, Shi-Mei/0000-0002-2512-3942				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BOS JL, 1989, CANCER RES, V49, P4682; Dashwood RH, 1998, CANCER RES, V58, P1127; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Devereux TR, 1999, ONCOGENE, V18, P4726, DOI 10.1038/sj.onc.1202858; GOODROW T, 1990, CANCER RES, V50, P4818; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hartmann A, 1997, TRENDS GENET, V13, P27, DOI 10.1016/S0168-9525(96)10043-3; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hennighausen L, 2000, ONCOGENE, V19, P966, DOI 10.1038/sj.onc.1203346; Hong HHL, 2000, TOXICOL PATHOL, V28, P529, DOI 10.1177/019262330002800404; *IARC, 1992, IARC MON EV CARC RIS, V54, P237; Koivisto P, 1999, CARCINOGENESIS, V20, P1253, DOI 10.1093/carcin/20.7.1253; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Martin AM, 2000, JNCI-J NATL CANCER I, V92, P1126, DOI 10.1093/jnci/92.14.1126; Melnick RL, 2001, CHEM-BIOL INTERACT, V135, P27, DOI 10.1016/S0009-2797(01)00213-7; MELNICK RL, 1990, CANCER RES, V50, P6592; Meng QX, 2000, MUTAT RES-GEN TOX EN, V464, P169, DOI 10.1016/S1383-5718(99)00157-6; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; *NAT TOX PROGR, 2000, 9 REP CARC, P14; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Osborne RJ, 2000, CANCER RES, V60, P3706; POLARD P, 1995, MOL MICROBIOL, V15, P13, DOI 10.1111/j.1365-2958.1995.tb02217.x; Rubinfeld B, 1997, CANCER RES, V57, P4624; Russo IH, 1996, ENVIRON HEALTH PERSP, V104, P938, DOI 10.2307/3433143; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Sills RC, 2001, CHEM-BIOL INTERACT, V135, P373, DOI 10.1016/S0009-2797(01)00179-X; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THOR A, 1986, LAB INVEST, V55, P603; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; WISEMAN RW, 1994, P NATL ACAD SCI USA, V91, P3759, DOI 10.1073/pnas.91.9.3759; Zhuang SM, 1997, CANCER RES, V57, P2710	39	15	17	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2002	21	36					5643	5648		10.1038/sj.onc.1205649	http://dx.doi.org/10.1038/sj.onc.1205649			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165863				2022-12-17	WOS:000177442000014
J	De Juan, C; Iniesta, P; Gonzalez-Quevedo, R; Moran, A; Sanchez-Pernaute, A; Torres, AJ; Balibrea, JL; Diaz-Rubio, E; Cruces, J; Benito, M				De Juan, C; Iniesta, P; Gonzalez-Quevedo, R; Moran, A; Sanchez-Pernaute, A; Torres, AJ; Balibrea, JL; Diaz-Rubio, E; Cruces, J; Benito, M			Genomic organization of a novel glycosylphosphatidylinositol MAM gene expressed in human tissues and tumors	ONCOGENE			English	Article						novel gene; GPI motif; MAM domain; adhesion molecule; cancer	CARCINOEMBRYONIC ANTIGEN; NEURITE OUTGROWTH; MESSENGER-RNA; CELL; SUPERFAMILY; DOMAIN; MEMBER; FAMILY; LUNG; LAMP	We report the genomic organization of a novel human gene mapped to chromosome 6p21, encoding a putative glycosylphosphatidylinositol (GPI) anchored protein containing a MAM (meprin, A5 antigen, protein tyrosine phosphatase mu) domain, that we have termed as GPIM (GPI and MAM) protein. GPIM gene consists of an 8.9 kb transcript composed of 17 coding exons spanning about 65.5 kb of genomic DNA. The deduced polypeptide consists of 955 amino acids and exhibits structural features found in different types of cell adhesion molecules (CAMs), such as the presence of immunoglobulin domains, the presence of a MAM domain or the capacity to anchor to the cell membrane by a GPI motif. Expression analysis in normal human tissues revealed that this gene is expressed as a 5 kb and 9.5 kb mRNA. Furthermore, the smaller transcript is highly expressed in some human cancer cell lines, as well as in different primary tumors (lung, colon, uterus, stomach and breast). Interestingly, the gene was higher expressed in several tumor tissues analysed as compared to their corresponding normal tissues. Thus, GPIM is a novel gene codifying a protein with structural features characteristics of some CAMs, which might be involved in the tumor progression.	Univ Complutense Madrid, Fac Farm, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain; Univ Autonoma Madrid, Fac Med, Dept Bioquim, E-28029 Madrid, Spain; Hosp Univ San Carlos, Serv Cirugia, Madrid 28040, Spain; Hosp Univ San Carlos, Serv Oncol, Madrid 28040, Spain	Complutense University of Madrid; Autonomous University of Madrid	Benito, M (corresponding author), Univ Complutense Madrid, Fac Farm, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain.	benito@farm.ucm.es	Sánchez-Pernaute, Andrés/J-9588-2016; Benito, Manuel/J-5637-2014	Benito, Manuel/0000-0002-7218-406X; Sanchez-Pernaute, Andres/0000-0002-0226-286X; Diaz-Rubio, Eduardo/0000-0003-2792-5348				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; Chen H, 1998, NEURON, V21, P1283, DOI 10.1016/S0896-6273(00)80648-0; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; De Juan C, 1999, INT J CANCER, V84, P344, DOI 10.1002/(SICI)1097-0215(19990820)84:4<344::AID-IJC2>3.0.CO;2-D; Funatsu N, 1999, J BIOL CHEM, V274, P8224, DOI 10.1074/jbc.274.12.8224; Ilantzis C, 1997, LAB INVEST, V76, P703; JIANG WP, 1992, J BIOL CHEM, V267, P9185; Jones DR, 1998, INT J BIOCHEM CELL B, V30, P313, DOI 10.1016/S1357-2725(97)00144-1; KIM J, 1992, INT J CANCER, V52, P718, DOI 10.1002/ijc.2910520509; KOZAK M, 1986, CELL, V6, P563; McConville MJ, 2000, MOL MEMBR BIOL, V17, P1; PECK D, 1993, J CELL BIOL, V123, P1587, DOI 10.1083/jcb.123.6.1587; Pimenta AF, 1996, GENE, V170, P189, DOI 10.1016/0378-1119(96)84698-1; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; Takayama M, 1999, EXP NEPHROL, V7, P295; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wilson DJA, 1996, J CELL SCI, V109, P3129; YOSHIHARA Y, 1994, NEURON, V13, P415, DOI 10.1016/0896-6273(94)90357-3; ZONDAG GCM, 1995, J BIOL CHEM, V270, P14247, DOI 10.1074/jbc.270.24.14247	21	15	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3089	3094		10.1038/sj.onc.1205383	http://dx.doi.org/10.1038/sj.onc.1205383			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082541				2022-12-17	WOS:000175262700018
J	Maher, P				Maher, P			Phorbol esters inhibit fibroblast growth factor-2-stimulated fibroblast proliferation by a p38 MAP kinase dependent pathway	ONCOGENE			English	Article						FGF; p38 MAPK; ERK; PKC; proliferation; fibroblasts	ACTIVATED PROTEIN-KINASE; FACTOR RECEPTOR-1; CYTOSKELETAL REORGANIZATION; TYROSINE PHOSPHORYLATION; CELL-PROLIFERATION; NEURITE OUTGROWTH; MITOGEN; PHOSPHATASE; EXPRESSION; ROLES	Treatment of fibroblasts with the phorbol ester, 12-O-tetradecanoyl phorbol 13-acetate (TPA), specifically inhibits fibroblast growth factor-2 (FGF-2) induced proliferation. TPA treatment has little or no effect on FGF receptor activation but specifically inhibits the activation of p38 MAPK but not other downstream signaling pathways implicated in cell proliferation. p38 MAPK was recently shown to be required for the FGF-2-stimulated proliferation of fibroblasts. The effect of TPA on both p38 MAPK activation and cell proliferation can be reversed by treatment with the PKC inhibitor Go6983. The TPA-mediated inhibition of p38 MAPK activation requires phosphatase activity and is at least partially mediated by ERKs since it is reduced by treatment with the MEK inhibitor PD98059. In contrast, the FGF-2-stimulated differentiation of PC12 cells, which express the same FGF receptor as Swiss 3T3 fibroblasts, is not affected by TPA treatment, consistent with a lack of involvement of p38 MAPK activity in this process. These data indicate that the effects of TPA treatment on cellular function are not only cell type but also stimulus specific and are dependent upon the distinct pathways activated downstream of each stimulus.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Maher, P (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	pmaher@scripps.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054604] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54604] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARITA Y, 1994, INT J CANCER, V56, P229, DOI 10.1002/ijc.2910560215; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; Cross MJ, 2000, J CELL SCI, V113, P643; Deacon EM, 1997, J CLIN PATHOL-MOL PA, V50, P124, DOI 10.1136/mp.50.3.124; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HUANG TS, 1995, P NATL ACAD SCI USA, V92, P4793, DOI 10.1073/pnas.92.11.4793; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347; Keyse SM, 1999, FREE RADICAL RES, V31, P341, DOI 10.1080/10715769900300911; KLINT P, 1999, FRONT BIOSCI, V4, P165; KWAK SP, 1994, J BIOL CHEM, V269, P3596; LAPPI DA, 1994, J BIOL CHEM, V269, P12552; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEWIS TS, 1998, CANCER RES, P47; Lin HY, 1996, J NEUROSCI, V16, P4579; Maher P, 1999, J BIOL CHEM, V274, P17491, DOI 10.1074/jbc.274.25.17491; MAHER PA, 1993, P NATL ACAD SCI USA, V90, P11177, DOI 10.1073/pnas.90.23.11177; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Mochly-Rosen D, 1998, ADV PHARMACOL, V44, P91, DOI 10.1016/S1054-3589(08)60126-X; Mudgett JS, 2000, P NATL ACAD SCI USA, V97, P10454, DOI 10.1073/pnas.180316397; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PASQUALE EB, 1988, J CELL PHYSIOL, V137, P146, DOI 10.1002/jcp.1041370118; Presta M, 1998, J BIOL CHEM, V273, P7911, DOI 10.1074/jbc.273.14.7911; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SIGMUND O, 1990, J BIOL CHEM, V265, P2257; Skaletz-Rorowski A, 1999, ARTERIOSCL THROM VAS, V19, P1608, DOI 10.1161/01.ATV.19.7.1608; Szebenyi G, 1999, INT REV CYTOL, V185, P45; Tanaka K, 1999, JPN J CANCER RES, V90, P647, DOI 10.1111/j.1349-7006.1999.tb00796.x; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Traub O, 1997, J BIOL CHEM, V272, P31251, DOI 10.1074/jbc.272.50.31251; Tsuchida M, 2000, J BIOL CHEM, V275, P1344, DOI 10.1074/jbc.275.2.1344; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Weinstein IB, 1997, ADV EXP MED BIOL, V400, P313; Weiss RH, 1996, AM J PHYSIOL-CELL PH, V270, pC619, DOI 10.1152/ajpcell.1996.270.2.C619; WEISS RH, 1995, KIDNEY INT, V48, P738, DOI 10.1038/ki.1995.345; ZACHARY I, 1985, CANCER SURV, V4, P729; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115; Zeidman R, 1999, INT J CANCER, V81, P494, DOI 10.1002/(SICI)1097-0215(19990505)81:3<494::AID-IJC26>3.0.CO;2-L; Zhu T, 2000, J BIOL CHEM, V275, P2103, DOI 10.1074/jbc.275.3.2103	56	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					1978	1988		10.1038/sj.onc.1205268	http://dx.doi.org/10.1038/sj.onc.1205268			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960370				2022-12-17	WOS:000174827000004
J	Chen, J; Kremer, CS; Bender, TP				Chen, J; Kremer, CS; Bender, TP			A Myb dependent pathway maintains Friend murine erythroleukemia cells in an immature and proliferating state	ONCOGENE			English	Article						c-Myb; A-Myb; B-Myb; erythroleukemia; transcription factor; differentiation	HUMAN HEMATOPOIETIC-CELLS; UP-REGULATES BCL-2; C-MYB; B-MYB; A-MYB; ERYTHROID-DIFFERENTIATION; TERMINAL DIFFERENTIATION; DOWN-REGULATION; TRANSCRIPTION FACTOR; MESSENGER-RNA	Friend murine erythroleukemia (MEL) cells are transformed erythroid precursors that are held in an immature and proliferating state but can be induced to differentiate in vivo by treatment with a variety of chemical agents such as N, N-hexamethylene bisacetamide (HMBA). To investigate the role of Myb proteins in maintaining MEL cells in an immature and proliferating state we have produced stable transfectants in the C19 MEL cell line that contain a dominant interfering Myb allele (MEnT) under the control of an inducible mouse metallothionein I promoter. When expression of MEnT protein was induced with ZnCl2, the stable transfectants differentiated with kinetics that were similar to wild type C19 MEL cells treated with HMBA, including induction of alpha-globin mRNA expression, assembly of hemoglobin and growth arrest. Expression of endogenous c-myb and c-myc was also decreased in response to MEnT. Expression of mad-1 mRNA was rapidly increased in response to expression of MEnT resulting in a shift from predominantly c-Myc/Max complexes to predominantly Mad/Max containing complexes. These results strongly suggest that C19 MEL cells are held in an immature and proliferating state by a pathway that is dependent on Myb activity.	Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Mol Physiol, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Biol Phys, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Bender, TP (corresponding author), Univ Virginia Hlth Syst, Dept Microbiol, POB 800734, Charlottesville, VA 22908 USA.				NIGMS NIH HHS [GM55985] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; Bies J, 1996, ONCOGENE, V12, P355; CASADEVALL N, 1991, J BIOL CHEM, V266, P16015; CHERN YJ, 1991, BLOOD, V78, P991, DOI 10.1182/blood.V78.4.991.bloodjournal784991; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; CRAIG RW, 1984, CANCER RES, V44, P442; Cultraro CM, 1997, MOL CELL BIOL, V17, P2353, DOI 10.1128/MCB.17.5.2353; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; Ess KC, 1999, ONCOGENE, V18, P1103, DOI 10.1038/sj.onc.1202387; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GOLAY J, 1991, BLOOD, V77, P149; Golay J, 1996, BLOOD, V87, P1900; Golay J, 1998, J IMMUNOL, V160, P2786; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; Lipsick JS, 1996, ONCOGENE, V13, P223; Lyon JJ, 1996, GENE, V182, P123, DOI 10.1016/S0378-1119(96)00531-8; LYON JJ, 1995, DIFFERENTIATION, V59, P171, DOI 10.1046/j.1432-0436.1995.5930171.x; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; Marks PA, 1996, INT J HEMATOL, V63, P1; Matushansky I, 2000, FRONT BIOSCI, V5, pD488, DOI 10.2741/Matushan; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; RICHON VM, 1989, ONCOGENE, V4, P165; Saville MK, 1998, ADV CANCER RES, V72, P109; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; Spadaccini A, 1998, J BIOL CHEM, V273, P23793, DOI 10.1074/jbc.273.37.23793; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; YEN A, 1992, J CELL PHYSIOL, V153, P147, DOI 10.1002/jcp.1041530119; ZHUO SQ, 1995, P NATL ACAD SCI USA, V92, P4234, DOI 10.1073/pnas.92.10.4234; ZOBEL A, 1992, BIOCHEM BIOPH RES CO, V186, P715, DOI 10.1016/0006-291X(92)90805-U	58	15	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2002	21	12					1859	1869		10.1038/sj.onc.1205003	http://dx.doi.org/10.1038/sj.onc.1205003			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896618				2022-12-17	WOS:000174284500008
J	Frade, R; Balbo, M; Barel, M				Frade, R; Balbo, M; Barel, M			RB18A regulates p53-dependent apoptosis	ONCOGENE			English	Article						RB18A; TRAP220; DRIP205; PBP; p53-dependent apoptosis; co-transcriptional factor	NUCLEAR RECEPTORS; PROTEIN; P53; INTERACTS; TRAP220; SUBUNIT; GENE	We previously demonstrated that RB18A, a member of TRAP220/DRIP205/PBP family, in vivo acted as a cofactor of transcription by differently regulating p53wt transactivating activity on physiological promoters. Using p53-negative cells transfected with different constructs, we herein demonstrated that RB18A down-regulated p53wt-dependent apoptosis. This biological regulation was due to a specific diminution of p53wt protein level, as level of p91mut and GAPDH proteins was not modified. This p53wt diminution was dependent on proteasome activity, as inhibited by MG-132 inhibitor. This specific p53wt degradation was correlated with an increase in expression of MDM2, which promoted p53wt degradation into proteasome. RB18A up-regulated MDM2 expression by activating MDM2 promoter, even in absence of p53wt. Altogether, these data emphasized that RB18A could regulate p53wt function not only by direct interaction between both proteins, but also by up-regulating promoter activity of MDM2, a p53-regulating partner.	Hop St Antoine, Ctr INSERM, INSERM,U354, Immunochim Regulat Cellulaires & Interact Virales, F-75012 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Frade, R (corresponding author), Hop St Antoine, Ctr INSERM, INSERM,U354, Immunochim Regulat Cellulaires & Interact Virales, F-75012 Paris, France.	frade354@easynet.fr	BAREL, Monique/K-3772-2017	BAREL, Monique/0000-0001-8171-7027				Atkins GB, 1999, MOL ENDOCRINOL, V13, P1550, DOI 10.1210/me.13.9.1550; BAREL M, 1989, P NATL ACAD SCI USA, V86, P10054, DOI 10.1073/pnas.86.24.10054; Burakov D, 2000, J BIOL CHEM, V275, P20928, DOI 10.1074/jbc.M002013200; Drane P, 1997, ONCOGENE, V15, P3013, DOI 10.1038/sj.onc.1201492; Frade R, 2000, CANCER RES, V60, P6585; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kodera Y, 2000, J BIOL CHEM, V275, P33201, DOI 10.1074/jbc.C000517200; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Ren YS, 2000, MOL CELL BIOL, V20, P5433, DOI 10.1128/MCB.20.15.5433-5446.2000; Warnmark A, 2001, J BIOL CHEM, V276, P23397, DOI 10.1074/jbc.M011651200; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P14584; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhu YJ, 2000, J BIOL CHEM, V275, P14779, DOI 10.1074/jbc.C000121200; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848	19	15	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2002	21	6					861	866		10.1038/sj.onc.1205177	http://dx.doi.org/10.1038/sj.onc.1205177			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840331				2022-12-17	WOS:000173427100001
J	Coates, PJ; Lorimore, SA; Rigat, BA; Lane, DP; Wright, EG				Coates, PJ; Lorimore, SA; Rigat, BA; Lane, DP; Wright, EG			Induction of endogenous beta-galactosidase by ionizing radiation complicates the analysis of p53-LacZ transgenic mice	ONCOGENE			English	Article						lacZ; beta-galactosidase; radiation; macrophage; transgenic mice	SENSITIVITY; LACZ	Studies of the response of p53-lacZ transgenic mice have uncovered an unexpected induction of endogenous acid-beta -galactosidase activity following whole body irradiation. Strong induction of endogenous enzyme activity is seen in a variety of mouse strains commonly used in the production of transgenes. The induction of endogenous enzyme activity therefore complicates the analysis of p53-lacZ transgenes and may also influence the analysis of radiation responses in other lacZ-reporter mice.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Wright, EG (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland.		Lane, David P/C-4920-2008; Coates, Philip J/H-6854-2019	Coates, Philip J/0000-0003-1518-6306; Lane, David/0000-0003-0551-3545				Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; HATTON JD, 1992, J NEUROSCI METH, V45, P147, DOI 10.1016/0165-0270(92)90070-T; HENDRIKX PJ, 1994, ANAL BIOCHEM, V222, P456, DOI 10.1006/abio.1994.1516; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; Lorimore SA, 2001, ONCOGENE, V20, P7085, DOI 10.1038/sj.onc.1204903; MACCALLUM DE, 1996, ONCOGENE, V13, P2576; Nowroozi N, 1998, J CRAN GENET DEV BIO, V18, P51; Weiss DJ, 1999, HISTOCHEM J, V31, P231, DOI 10.1023/A:1003642025421	8	15	17	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 25	2001	20	48					7096	7097		10.1038/sj.onc.1204904	http://dx.doi.org/10.1038/sj.onc.1204904			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704833				2022-12-17	WOS:000171739300012
J	Judd, BA; Koretzky, GA				Judd, BA; Koretzky, GA			The role of the adapter molecule SLP-76 in platelet function	ONCOGENE			English	Article						SLP-76; adapter molecule; signal transduction; platelet; GPVI; alpha IIb beta 3	RECEPTOR-GAMMA-CHAIN; T-CELL RECEPTOR; PROTEIN-TYROSINE KINASE; GUANINE-NUCLEOTIDE EXCHANGE; STIMULATED PHOSPHOPROTEIN VASP; COLLAGEN-LIKE PEPTIDES; VON-WILLEBRAND-FACTOR; GLYCOPROTEIN-VI; PHOSPHOLIPASE C-GAMMA-2; INTEGRIN ALPHA(IIB)BETA(3)	Following vascular injury, one of the most critical initial events is activation of platelets followed by formation of a hemostatic plug. Platelets are capable of responding to a diverse array of agonists resulting in adhesion and granule release. The biochemical events underlying platelet activation are just beginning to be understood. One class of molecules shown to play important roles in this process is adapters. Adapter molecules contain distinct modular domains which mediate protein-protein or protein-lipid interactions giving these proteins the ability to nucleate signal transduction complexes. In this review we will discuss the function of the hematopoietic cell specific adapter molecule, SLP-76 in both platelet activation and hemostasis. Because many parallels exist between signal transduction pathways in platelets and lymphocytes, we will also review the function of SLP-76 in coordinating signal transduction pathways following antigen bind to the T cell receptor.	Univ Penn, Abraham Family Canc Res Inst, Signal Transduct Program, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Koretzky, GA (corresponding author), Univ Penn, Abraham Family Canc Res Inst, Signal Transduct Program, Philadelphia, PA 19104 USA.		Koretzky, Gary/AAU-5381-2021					Asada H, 1999, J EXP MED, V189, P1383, DOI 10.1084/jem.189.9.1383; Asazuma N, 2000, J BIOL CHEM, V275, P33427, DOI 10.1074/jbc.M001439200; Aszodi A, 1999, EMBO J, V18, P37, DOI 10.1093/emboj/18.1.37; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bearer EL, 2000, CELL MOTIL CYTOSKEL, V47, P351, DOI 10.1002/1097-0169(200012)47:4<351::AID-CM8>3.0.CO;2-8; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Bezprozvanny I, 2001, P NATL ACAD SCI USA, V98, P787, DOI 10.1073/pnas.98.3.787; BLAKE RA, 1994, FEBS LETT, V353, P212, DOI 10.1016/0014-5793(94)01037-4; Boerth NJ, 2000, J EXP MED, V192, P1047, DOI 10.1084/jem.192.7.1047; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; BRASS LF, 1985, J BIOL CHEM, V260, P5172; Brass S, 2001, NATURE, V409, P145, DOI 10.1038/35051688; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Bunnell SC, 2000, J BIOL CHEM, V275, P2219, DOI 10.1074/jbc.275.3.2219; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; CASTAGNA M, 1985, ADV EXP MED BIOL, V192, P249; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Clements JL, 1999, J CLIN INVEST, V103, P19, DOI 10.1172/JCI5317; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; DANIEL JL, 1994, BIOCHEM J, V302, P617, DOI 10.1042/bj3020617; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; Ezumi Y, 2000, BIOCHEM BIOPH RES CO, V277, P27, DOI 10.1006/bbrc.2000.3624; Fang N, 1996, J IMMUNOL, V157, P3769; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Forman-Kay JD, 1999, CURR OPIN STRUC BIOL, V9, P690, DOI 10.1016/S0959-440X(99)00031-7; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; GINSBERG MH, 1995, THROMB HAEMOSTASIS, V74, P352; Gross BS, 1999, J BIOL CHEM, V274, P5963, DOI 10.1074/jbc.274.9.5963; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; Hauser W, 1999, P NATL ACAD SCI USA, V96, P8120, DOI 10.1073/pnas.96.14.8120; Hers I, 1998, ARTERIOSCL THROM VAS, V18, P404, DOI 10.1161/01.ATV.18.3.404; Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Jandrot-Perrus M, 2000, BLOOD, V96, P1798, DOI 10.1182/blood.V96.5.1798.h8001798_1798_1807; JOHNSON SA, 1995, J IMMUNOL, V155, P4596; Judd BA, 2000, P NATL ACAD SCI USA, V97, P12056, DOI 10.1073/pnas.97.22.12056; Kehrel B, 1998, BLOOD, V91, P491; Kiefer F, 1998, MOL CELL BIOL, V18, P4209, DOI 10.1128/MCB.18.7.4209; Krause M, 2000, J CELL BIOL, V149, P181, DOI 10.1083/jcb.149.1.181; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Marie-Cardine A, 1998, FEBS LETT, V435, P55, DOI 10.1016/S0014-5793(98)01040-0; Marie-Cardine A, 1998, J BIOL CHEM, V273, P25789, DOI 10.1074/jbc.273.40.25789; MarieCardine A, 1997, J BIOL CHEM, V272, P16077, DOI 10.1074/jbc.272.26.16077; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; MURPHY CT, 1991, BIOCHEM J, V278, P255, DOI 10.1042/bj2780255; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; Myung PS, 2000, CURR OPIN IMMUNOL, V12, P256, DOI 10.1016/S0952-7915(00)00085-6; Nieswandt B, 2000, J BIOL CHEM, V275, P23998, DOI 10.1074/jbc.M003803200; Nieswandt B, 2001, EMBO J, V20, P2120, DOI 10.1093/emboj/20.9.2120; Obergfell A, 2001, J BIOL CHEM, V276, P5916, DOI 10.1074/jbc.M010639200; Offermanns S, 2000, BIOL CHEM, V381, P389, DOI 10.1515/BC.2000.051; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; Pasquet JM, 1999, MOL CELL BIOL, V19, P8326; Patil S, 2001, BLOOD, V97, P1727, DOI 10.1182/blood.V97.6.1727; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Quek LS, 1998, CURR BIOL, V8, P1137, DOI 10.1016/S0960-9822(98)70471-3; Quek LS, 2000, BLOOD, V96, P4246; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Schneider H, 2000, J BIOL CHEM, V275, P3835, DOI 10.1074/jbc.275.6.3835; Schulte V, 2001, J BIOL CHEM, V276, P364, DOI 10.1074/jbc.M007536200; Shattil SJ, 1999, THROMB HAEMOSTASIS, V82, P318; Su YW, 1999, EUR J IMMUNOL, V29, P3702, DOI 10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; Tomiyama Y, 2000, INT J HEMATOL, V72, P448; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Verkleij MW, 1998, BLOOD, V91, P3808; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; Watson SP, 1998, IMMUNOL TODAY, V19, P260, DOI 10.1016/S0167-5699(98)01267-5; WERNER MH, 1992, MOL PHARMACOL, V41, P382; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; YAMAMOTO N, 1992, BRIT J HAEMATOL, V81, P86, DOI 10.1111/j.1365-2141.1992.tb08177.x; Yoder J, 2001, SCIENCE, V291, P1987, DOI 10.1126/science.1057176; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	98	15	15	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	2001	20	44					6291	6299		10.1038/sj.onc.1204772	http://dx.doi.org/10.1038/sj.onc.1204772			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607831				2022-12-17	WOS:000171640600004
J	Bannasch, D; Madge, B; Schwab, M				Bannasch, D; Madge, B; Schwab, M			Functional interaction of Yaf2 with the central region of MycN	ONCOGENE			English	Article						expression; immunofluorescence; MycN; protein-protein interactions; Yaf2; yeast two-hybrid	TRANSCRIPTION FACTOR YY1; C-MYC; NEUROBLASTOMA-CELLS; BINDING-PROTEIN; TRANSFORMATION; COMPLEX; GROWTH; NETWORK; VECTOR; NMI	MYCN is often amplified in advanced-stage neuroblastomas with the consequence of enhanced MycN protein expression. By employing the yeast two-hybrid system we found that Yaf2 binds to the central region of MycN. Binding was also seen in vitro and in vivo. Ectopically expressed Yaf2, like MycN, is localized in the nuclei of neuroblastoma cells. Endogenous Yaf2 is expressed in all three tested neuroblastoma cell lines, all of which also express MycN. Yaf2 was able to enhance MycN-mediated transactivation from an E-box promoter, deletion of the Yaf2 binding region in MycN abrogates this effect. Thus, the binding of Yaf2 to the central region of MycN is functional in mammalian cells.	Deutsch Krebsforschungszentrum, Div Cytogenet H0400, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Schwab, M (corresponding author), Deutsch Krebsforschungszentrum, Div Cytogenet H0400, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.			Madge, Britta/0000-0002-5948-8552				Bannasch D, 1999, ONCOGENE, V18, P6810, DOI 10.1038/sj.onc.1203090; Bannasch D, 1999, PLASMID, V42, P139, DOI 10.1006/plas.1999.1413; Bao JX, 1996, ONCOGENE, V12, P2171; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Brown JL, 1998, MOL CELL, V1, P1057, DOI 10.1016/S1097-2765(00)80106-9; CHATTON B, 1995, BIOTECHNIQUES, V18, P5527; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Dang CV, 1999, MOL CELL BIOL, V19, P1; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Garcia E, 1999, EMBO J, V18, P3404, DOI 10.1093/emboj/18.12.3404; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Kalenik JL, 1997, NUCLEIC ACIDS RES, V25, P843, DOI 10.1093/nar/25.4.843; Lutz W, 1996, ONCOGENE, V13, P803; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Savelyeva L, 2001, CANCER LETT, V167, P115, DOI 10.1016/S0304-3835(01)00472-4; Schwab M, 1998, BIOESSAYS, V20, P473, DOI 10.1002/(SICI)1521-1878(199806)20:6<473::AID-BIES5>3.3.CO;2-N; SCHWAB M, 2000, PATHOLOGY GENETICS T, P153; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; Taira T, 1998, GENES CELLS, V3, P549, DOI 10.1046/j.1365-2443.1998.00206.x; Tsai RYL, 1997, BIOTECHNIQUES, V23, P794, DOI 10.2144/97235bm06; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X	24	15	18	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5913	5919		10.1038/sj.onc.1204747	http://dx.doi.org/10.1038/sj.onc.1204747			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593398				2022-12-17	WOS:000171037200016
J	Yu, WP; Pallen, CJ; Tay, A; Jirik, FR; Brenner, S; Tan, YH; Venkatesh, B				Yu, WP; Pallen, CJ; Tay, A; Jirik, FR; Brenner, S; Tan, YH; Venkatesh, B			Conserved synteny between the Fugu and human PTEN locus and the evolutionary conservation of vertebrate PTEN function	ONCOGENE			English	Article						PTEN; phosphatase; tumor suppressor; Fugu	INOSITOL POLYPHOSPHATE PHOSPHATASE; RILEY-RUVALCABA-SYNDROME; TUMOR-SUPPRESSOR GENE; GERMLINE MUTATIONS; MOLECULAR-CLONING; FAMILY; BREAST; 10Q23; IDENTIFICATION; PTEN/MMAC1	Mutations of PTEN, which encodes a protein-tyrosine and lipid phosphatase, are prevalent in a variety of human cancers. The human genome 'draft' sequence still lacks organization and much of the PTEN and adjacent loci remain undefined. The pufferfish, Fugu rubripes, by virtue of having a compact genome represents an excellent template for rapid vertebrate gene discovery. Sequencing of 56 kb from the Fugu pten (fpten) locus identified four complete genes and one partial gene homologous to human genes. Genes neighboring fpten include a PAPS synthase (fpapss2) differentially expressed between non-metastatic/metastatic human carcinoma cell lines, an inositol phosphatase (fminpp1) and an omega class glutathione-S-transferase (fgsto). We have determined the order of human BAC clones at the hPTEN locus and that the locus contains hPAPSS2 and hMINPP1 genes oriented as are their Fugu orthologs. Although the human genes span 500 kb, the Fugu genes lie within only 22 kb due to the compressed intronic and intergenic regions that typify this genome. Interestingly, and providing striking evidence of regulatory element conservation between widely divergent vertebrate species, the compact 2.1 kb fpten promoter is active in human cells. Also, like hPTEN, fpten has a growth and tumor suppressor activity in human glioblastoma cells, demonstrating conservation of protein function.	Inst Mol & Cell Biol, Singapore 117609, Singapore; Univ British Columbia, British Columbia Res Inst Childrens & Womens Hlth, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); University of British Columbia	Pallen, CJ (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.	mcbcp@imcb.nus.edu.sg		Venkatesh, Byrappa/0000-0003-3620-0277; Pallen, Catherine/0000-0002-3576-5295				AUSABEL FM, 1995, CURRENT PROTOCOLS MO, V2; Bostrom J, 1998, CANCER RES, V58, P29; BRENNER S, 1993, NATURE, V366, P265, DOI 10.1038/366265a0; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chi HB, 2000, MOL CELL BIOL, V20, P6496, DOI 10.1128/MCB.20.17.6496-6507.2000; Chi HB, 1999, GENOMICS, V56, P324, DOI 10.1006/geno.1998.5736; Craxton A, 1997, BIOCHEM J, V328, P75, DOI 10.1042/bj3280075; Dahia PM, 2000, J MED GENET, V37, P715, DOI 10.1136/jmg.37.9.715; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Feilotter HE, 1999, BRIT J CANCER, V79, P718, DOI 10.1038/sj.bjc.6690115; Feilotter HE, 1998, ONCOGENE, V16, P1743, DOI 10.1038/sj.onc.1200205; Franzon VL, 1999, INT J BIOCHEM CELL B, V31, P613, DOI 10.1016/S1357-2725(98)00155-1; Fujisawa H, 1999, AM J PATHOL, V155, P387, DOI 10.1016/S0002-9440(10)65135-8; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Huang H, 1999, DEVELOPMENT, V126, P5365; Kurima K, 1998, P NATL ACAD SCI USA, V95, P8681, DOI 10.1073/pnas.95.15.8681; Kurima K, 1999, J BIOL CHEM, V274, P33306, DOI 10.1074/jbc.274.47.33306; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Marsh DJ, 1999, HUM MOL GENET, V8, P1461, DOI 10.1093/hmg/8.8.1461; MUTTER GL, 2000, JNCI-J NATL CANCER I, V92, P861; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; NOGIMORI K, 1991, J BIOL CHEM, V266, P16499; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Reynolds SD, 1996, EXP CELL RES, V226, P197, DOI 10.1006/excr.1996.0219; Romano PR, 1998, J CELL SCI, V111, P803; Rouault JP, 1999, CURR BIOL, V9, P329, DOI 10.1016/S0960-9822(99)80143-2; Simpkins SB, 1998, GYNECOL ONCOL, V71, P391, DOI 10.1006/gyno.1998.5208; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ul Haque MF, 1998, NAT GENET, V20, P157, DOI 10.1038/2458; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Venkatesh B, 2000, FEBS LETT, V476, P3, DOI 10.1016/S0014-5793(00)01659-8; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0; Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5	46	15	16	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2001	20	39					5554	5561		10.1038/sj.onc.1204679	http://dx.doi.org/10.1038/sj.onc.1204679			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571655				2022-12-17	WOS:000170781100018
J	Yin, XY; Grove, LE; Prochownik, EV				Yin, XY; Grove, LE; Prochownik, EV			Mmip-2/Rnf-17 enhances c-Myc function and regulates some target genes in common with glucocorticoid hormones	ONCOGENE			English	Article						RING finger proteins; Mad; Max; apoptosis; ornithine decarboxylase; gamma-interferon	TRANSCRIPTION FACTOR NETWORK; CELL-CYCLE PROGRESSION; RING-FINGER DOMAIN; DNA-BINDING; ONCOGENIC ACTIVITY; LEUCINE-ZIPPER; MAX; PROTEIN; GROWTH; DIFFERENTIATION	Members of the Mad family of basic-helix-loop-helix-leucine zipper proteins inhibit the transcriptional activity of the c-Myc oncoprotein. Mmip-2/Rnf-17 is a RING-finger protein that interacts with all four known Mad proteins, redistributes them to the cytoplasm, and thus enhances c-Myc function, We generated cell lines in in which Mmip-2/Rnf-17 was rendered glucocorticoid (GC)-inducible, Stable expression of Mmip-/Rnf-17 resulted in the expected transport of the most abundant endogenous mad protein, Mxi1, to the cytoplasm, Compensatory increases in Mxi1 and Mad3 transcripts, similar to those previously described in Mad1 null hematopoietic cells, genes were also seen, Mmip-2/Rnf-17 also sensitized cells to several different pro-apoptotic stimuli and regulated a subset of c-Myc target genes, Unexpectedly, some of these genes were also found to be modulated solely by GCs, Thus, the inhibition of Mad proteins by Mmip-2/Rnf-17 modulates c-Myc function by enhancing its ability to regulate a subset of its potential target genes, Our results also identify a previously unrecognized overlap between genes regulated by c-Myc- and GCs and provide a potential molecular basis for their regulation of common cellular functions. Oncogene (2001) 20, 2908-2917.	Childrens Hosp Pittsburgh, Hematol Oncol Sect, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Inst Canc, Program Mol Genet, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Childrens Hosp Pittsburgh, Hematol Oncol Sect, 3705 5th Ave, Pittsburgh, PA 15213 USA.				NATIONAL CANCER INSTITUTE [R33CA083219] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER; NCI NIH HHS [CA83219] Funding Source: Medline; NHLBI NIH HHS [HL33741] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Billin AN, 1999, J BIOL CHEM, V274, P36344, DOI 10.1074/jbc.274.51.36344; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Cato ACB, 1996, BIOESSAYS, V18, P371, DOI 10.1002/bies.950180507; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; Dang CV, 1999, MOL CELL BIOL, V19, P1; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; FORSTHOEFEL AM, 1987, MOL ENDOCRINOL, V1, P899, DOI 10.1210/mend-1-12-899; Geley S, 1996, REV PHYSIOL BIOCH P, V128, P1; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; GOLDE DW, 1976, J CLIN INVEST, V57, P57, DOI 10.1172/JCI108269; Gupta K, 1998, ONCOGENE, V16, P1149, DOI 10.1038/sj.onc.1201634; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hurlin PJ, 1999, EMBO J, V18, P7019, DOI 10.1093/emboj/18.24.7019; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; HURLIN PJ, 1994, COLD SPRING HARB SYM, V59, P109, DOI 10.1101/SQB.1994.059.01.014; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Landay M, 2000, CELL DEATH DIFFER, V7, P697, DOI 10.1038/sj.cdd.4400701; LONGENECKER JP, 1984, J CELL BIOL, V98, P534, DOI 10.1083/jcb.98.2.534; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Meroni G, 2000, ONCOGENE, V19, P3266, DOI 10.1038/sj.onc.1203634; Nesbit CE, 1998, CELL GROWTH DIFFER, V9, P731; Nesbit CE, 2000, ONCOGENE, V19, P3200, DOI 10.1038/sj.onc.1203636; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RHEE K, 1995, CANCER RES, V55, P4188; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; SCHER W, 1978, P NATL ACAD SCI USA, V75, P3851, DOI 10.1073/pnas.75.8.3851; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; THULASI R, 1993, J BIOL CHEM, V268, P18306; von Lindern M, 1999, BLOOD, V94, P550, DOI 10.1182/blood.V94.2.550.414k39_550_559; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410; Yin XY, 1999, ONCOGENE, V18, P6621, DOI 10.1038/sj.onc.1203097; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416	68	15	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2001	20	23					2908	2917		10.1038/sj.onc.1204417	http://dx.doi.org/10.1038/sj.onc.1204417			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420703				2022-12-17	WOS:000168901800006
J	Jaks, V; Joers, A; Kristjuhan, A; Maimets, T				Jaks, V; Joers, A; Kristjuhan, A; Maimets, T			p53 protein accumulation in addition to the transactivation activity is required for p53-dependent cell cycle arrest after treatment of cells with camptothecin	ONCOGENE			English	Article						p53; DNA damage; cell cycle; apoptosis	TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGE; UV-LIGHT; TRANSCRIPTIONAL ACTIVITY; DEPENDENT KINASES; HUMAN FIBROBLASTS; GENE-EXPRESSION; STRAND BREAKS; APOPTOSIS; RADIATION	In this studyw we characterize the connections between p53-dependent G1 cell cycle arrest, transcriptional activation of the protein and the increase of its intracellular steady-state concentration, Several cell lines expressing wild-type p53 protein were treated with increasing concentrations of DNA-damaging drug camptothecin, Lower doses of the drug caused transcriptional activation of p53, but no accumulation of the protein was detected. Only after a certain threshold dose of camptothecin does the amount of the protein rapidly increase and reach its plateau levels. The threshold dose was different for different cell lines, but the general non-linear profile was similar, Increase of p53 level was accompanied by additional transcriptional activation of some p53 target genes (i,e, waf1), but not the others (mdm2), We demonstrate here that transcriptional activation of p53 after the treatment of camptothecin is not sufficient to cause p53-dependent G1 cell cycle arrest. The latter is observable only after the inrease of steady-state level of p53, Low drug concentrations, although accompanied by transcriptional activation of p53, do not cause either p53 protein accumulation nor cell cycle arrest at G1, We propose a model for p53 acting as a part of cellular sensor system detecting the severity of DNA damage.	Univ Tartu, Inst Mol & Cell Biol, Dept Cell Biol, EE-51010 Tartu, Estonia	University of Tartu	Maimets, T (corresponding author), Univ Tartu, Inst Mol & Cell Biol, Dept Cell Biol, Riia 23, EE-51010 Tartu, Estonia.		Jaks, Viljar/H-2467-2012; Maimets, Toivo/E-9268-2017	Jaks, Viljar/0000-0002-2221-6262; Maimets, Toivo/0000-0001-6461-3365; Kristjuhan, Arnold/0000-0002-5842-4952; Joers, Arvi/0000-0003-2083-3977				AVEMANN K, 1998, MOL CELL BIOL, V8, P3206; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CANMAN C, 1995, GENE DEV, V12, P600; Carrier F, 1999, MOL CELL BIOL, V19, P1673; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chernov MV, 1998, P NATL ACAD SCI USA, V95, P2284, DOI 10.1073/pnas.95.5.2284; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; DEIRY WS, 1993, CELL, V75, P817; Deptala A, 1999, INT J ONCOL, V15, P861; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Ewen ME, 1996, J LAB CLIN MED, V128, P355, DOI 10.1016/S0022-2143(96)80006-0; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Haapajarvi T, 1997, MOL CELL BIOL, V17, P3074, DOI 10.1128/MCB.17.6.3074; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1993, ADV EXP MED BIOL, V339, P291; KASTAN MB, 1993, ADV EXP MED BIOL, V339, P295; Kristjuhan A, 1995, EUR J BIOCHEM, V234, P827, DOI 10.1111/j.1432-1033.1995.827_a.x; Kristjuhan A, 1998, ONCOGENE, V16, P2413, DOI 10.1038/sj.onc.1201749; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Li G, 1998, BRIT J DERMATOL, V139, P3; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu X, 1996, ONCOGENE, V13, P413; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Maxwell SA, 1996, ELECTROPHORESIS, V17, P1772, DOI 10.1002/elps.1150171115; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; RADFORD IR, 1994, INT J RADIAT BIOL, V66, P557, DOI 10.1080/09553009414551621; RYAN AJ, 1991, NUCLEIC ACIDS RES, V19, P3295, DOI 10.1093/nar/19.12.3295; Selkirk JK, 1996, ELECTROPHORESIS, V17, P1764, DOI 10.1002/elps.1150171114; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Shieh SY, 2000, GENE DEV, V14, P289; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P704; ZHANG W, 1994, CELL GROWTH DIFFER, V5, P705	55	15	15	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1212	1219		10.1038/sj.onc.1204232	http://dx.doi.org/10.1038/sj.onc.1204232			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313865				2022-12-17	WOS:000167570100008
J	Kim, KW; Chung, HH; Chung, CW; Kim, IK; Miura, M; Wang, SY; Zhu, H; Moon, KD; Rha, GB; Park, JH; Jo, DG; Woo, HN; Song, YH; Kim, BJ; Yuan, JY; Jung, YK				Kim, KW; Chung, HH; Chung, CW; Kim, IK; Miura, M; Wang, SY; Zhu, H; Moon, KD; Rha, GB; Park, JH; Jo, DG; Woo, HN; Song, YH; Kim, BJ; Yuan, JY; Jung, YK			Inactivation of farnesyltransferase and geranylgeranyltransferase I by caspase-3: Cleavage of the common alpha subunit during apoptosis	ONCOGENE			English	Article						apoptosis; caspase; farnesyltransferase; geranylgeranyltransferase	FARNESYL TRANSFERASE INHIBITORS; INTERLEUKIN-1-BETA-CONVERTING ENZYME; PROTEIN FARNESYLTRANSFERASE; CELL-DEATH; H-RAS; TRANSFORMED-CELLS; TRANSGENIC MICE; GROWTH-FACTOR; ACTIVATION; SUPPRESSION	Caspase plays an important role in apoptosis. We report here that farnesyltransferase(geranylgeranyltransferase (FTase/GGTase)-alpha, a common subunit of FTase (alpha/beta (FTase)) and GGTase I (alpha/beta (GGTase)), was cleaved by caspase-3 during apoptosis, FTase/GGTase-alpha (49 kDa) was cleaved to 35 kDa (p35) in the Rat-2/H-ras, W4 and Rat-1 cells treated with FTase inhibitor (LB42708), anti-Fas antibody and etoposide, respectively. This cleavage was inhibited by caspase-inhibitors (YVAD-cmk, DEVID-cho), Serial N-terminal deletions and site-directed mutagenesis showed that Asp59 of FTase/GGTase-alpha was cleaved by caspase-3. The common FTase/GGTase-alpha subunit, but not the beta subunits, of the FTase or GGTase I protein complexes purified from baculovirus-infected SF-9 cells was cleaved to be inactivated by purified caspase-3. In contrast, FTase mutant protein complex [(D(59)A)alpha/beta (FTase)] was resistant to caspase-3. Expression of either the cleavage product (60-379) or anti-sense of FTase/GGTase-alpha induced cell death in Rat-2/H-ras cells. Furthermore, expression of (D(59)A)FTase/GCTase-alpha mutant significantly desensitized cells to etoposide-induced death. Taken together, we suggest that cleavage of prenyltransferase by caspase contributes to the progression of apoptosis.	Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Biotech Res Inst, LG Chem, Taejon, South Korea; Osaka Univ, Sch Med, Dept Neuroanat, Osaka, Japan; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Gwangju Institute of Science & Technology (GIST); LG Chem; Osaka University; Harvard University; Harvard Medical School	Jung, YK (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea.		Jo, Dong-Gyu/AAN-9278-2021	Jo, Dong-Gyu/0000-0003-2271-1076; Kim, Ki Woo/0000-0002-7790-1515; Zhu, Hong/0000-0002-2575-4031; Jung, Yong-Keun/0000-0002-9686-3120; Woo, Ha-Na/0000-0002-6771-8151				Ahmad M, 1998, CANCER RES, V58, P5201; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; Bernhard EJ, 1996, CANCER RES, V56, P1727; Bernhard EJ, 1998, CANCER RES, V58, P1754; DeSmedt F, 1996, J BIOL CHEM, V271, P10419, DOI 10.1074/jbc.271.17.10419; Du W, 1999, CANCER RES, V59, P5492; Du W, 1999, CANCER RES, V59, P4208; Feldkamp MM, 1999, ONCOGENE, V18, P7514, DOI 10.1038/sj.onc.1203105; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Ghosh PM, 1999, ONCOGENE, V18, P4120, DOI 10.1038/sj.onc.1202792; GULBILNS E, 1996, J BIOL CHEM, V271, P26390; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Humke EW, 1998, J BIOL CHEM, V273, P15702, DOI 10.1074/jbc.273.25.15702; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; JANSEN B, 1997, CANCER RES, V57, P1846; Jung YK, 1996, J BIOL CHEM, V271, P5112; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KINOSHITA T, 1995, ONCOGENE, V10, P2207; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lebowitz PF, 1997, CANCER RES, V57, P708; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; Margolin N, 1997, J BIOL CHEM, V272, P7223, DOI 10.1074/jbc.272.11.7223; McKenna WG, 1996, ONCOGENE, V12, P237; Miquel K, 1997, CANCER RES, V57, P1846; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Norgaard P, 1999, CLIN CANCER RES, V5, P35; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; O'Reilly LA, 1999, INFLAMM RES, V48, P5, DOI 10.1007/s000110050369; Park HW, 1997, CURR OPIN STRUC BIOL, V7, P873; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Stark WW, 1998, AM J PHYSIOL-LUNG C, V275, pL55, DOI 10.1152/ajplung.1998.275.1.L55; SUMMERS MD, 1998, TEXAS AGR EXP ST B, V1555, P29; SUN JZ, 1995, CANCER RES, V55, P4243; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P15356, DOI 10.1073/pnas.95.26.15356; Tatton WG, 1999, BBA-BIOENERGETICS, V1410, P195, DOI 10.1016/S0005-2728(98)00167-4; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhivotovsky B, 1999, EXP CELL RES, V248, P10, DOI 10.1006/excr.1999.4452	49	15	16	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					358	366		10.1038/sj.onc.1204099	http://dx.doi.org/10.1038/sj.onc.1204099			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313965				2022-12-17	WOS:000166411000010
J	Yam, JWP; Chan, KW; Hsiao, WLW				Yam, JWP; Chan, KW; Hsiao, WLW			Suppression of the tumorigenicity of mutant p53-transformed rat embryo fibroblasts through expression of a newly cloned rat nonmuscle myosin heavy chain-B	ONCOGENE			English	Article						nmMHC; cytoskeletal protein; tumor suppression; Rat 6; mutant p53	PROTEIN KINASE-C; SMOOTH-MUSCLE; II-B; CELLS; CDNA; CLONING; ISOFORM; DISRUPTION; ANTIBODIES; TISSUES	In our previous study, a rat homolog of human nonmuscle myosin heavy chain-B (nmMHC-B) was identified by mRNA differential display comparing of transformed against nontransformed Rat 6 cells overexpressing mutant p53(val135) gene. The nmMHC-B was found to be expressed in normal Rat 6 embryo fibroblast cell line, but markedly suppressed in the mutant p53(val135) transformed Rat 6 cells. To examine the possible involvement of nmMHC-B in cell transformation, we first cloned and sequenced the full length cDNA of rat nmMHC-B, which was then cloned into an ecdysone-expression vector. The resulting construct was introduced into the T2 cell line, a mutant p53(val135)-transformed Rat 6 cells lacking the expression of the endogenous nmMHC-B, The clonal transfectants, expressing muristerone A-induced nmMHC-B, displayed a slightly flatter morphology and reached to a lower saturation density compared to the parental transformed cells. Reconstitution of actin filamental bundles was also clearly seen in cells overexpressing the nmMHC-B, In soft agar assays, nmMHC-B transfectants formed fewer and substantially smaller colonies than the parental cells in response to muristerone A induction. Moreover, it was strikingly effective in suppressing the tumorigenicity of the T2 cells when tested in nude mice. Thus, the nmMHC-B, known as a component of the cytoskeletal network, may act as a tumor suppressor gene. Our current finding may reveal a novel role of nmMHC-B in regulating cell growth and cell signaling in nonmuscle cells.	Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Hsiao, WLW (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.		Yam, Judy Wai Ping/C-4454-2009	Yam, Judy Wai Ping/0000-0002-5637-121X				BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; BHATIADEY N, 1993, P NATL ACAD SCI USA, V90, P2856, DOI 10.1073/pnas.90.7.2856; BOYD J, 1995, P NATL ACAD SCI USA, V92, P11534, DOI 10.1073/pnas.92.25.11534; Choi OH, 1996, J MUSCLE RES CELL M, V17, P69, DOI 10.1007/BF00140325; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; Esteve P, 1998, ONCOGENE, V17, P1855, DOI 10.1038/sj.onc.1202082; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FREEMAN AE, 1967, P NATL ACAD SCI USA, V58, P1205, DOI 10.1073/pnas.58.3.1205; FUKUI Y, 1990, J CELL BIOL, V110, P367, DOI 10.1083/jcb.110.2.367; Gimona M, 1996, P NATL ACAD SCI USA, V93, P9618, DOI 10.1073/pnas.93.18.9618; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; Gulick AM, 1997, BIOESSAYS, V19, P561, DOI 10.1002/bies.950190707; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HONER B, 1988, J CELL BIOL, V107, P2181, DOI 10.1083/jcb.107.6.2181; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1986, MOL CELL BIOL, V6, P1943, DOI 10.1128/MCB.6.6.1943; HSIAO WLW, 1992, MOL CARCINOGEN, V5, P140, DOI 10.1002/mc.2940050210; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; ITOH K, 1995, J BIOL CHEM, V270, P14533, DOI 10.1074/jbc.270.24.14533; KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x; Kelley CA, 1996, J CELL BIOL, V134, P675, DOI 10.1083/jcb.134.3.675; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Mummert CM, 1997, J NEUROCHEM, V68, P596; PHILLIPS CL, 1995, J MUSCLE RES CELL M, V16, P379, DOI 10.1007/BF00114503; ROVNER AS, 1986, J BIOL CHEM, V261, P4740; Sablina AA, 1999, CELL BIOL INT, V23, P323, DOI 10.1006/cbir.1999.0362; SAEZ CG, 1990, P NATL ACAD SCI USA, V87, P1164, DOI 10.1073/pnas.87.3.1164; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; SIMONS M, 1992, CIRC RES, V70, P835, DOI 10.1161/01.RES.70.4.835; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; STANBRIDGE EJ, 1980, INT J CANCER, V26, P1, DOI 10.1002/ijc.2910260102; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; Tullio AN, 1997, P NATL ACAD SCI USA, V94, P12407, DOI 10.1073/pnas.94.23.12407; VERKHOVSKY AB, 1995, J CELL BIOL, V131, P989, DOI 10.1083/jcb.131.4.989; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; Weir L, 1996, GENE EXPRESSION, V6, P45; Yam JWP, 1999, BIOCHEM BIOPH RES CO, V266, P472, DOI 10.1006/bbrc.1999.1852	41	15	15	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					58	68		10.1038/sj.onc.1203982	http://dx.doi.org/10.1038/sj.onc.1203982			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244504				2022-12-17	WOS:000166361400007
J	Du Villard, J; Wicker, R; Crespo, P; Russo, D; Filetti, S; Gutkind, JS; Sarasin, A; Suarez, HG				Du Villard, J; Wicker, R; Crespo, P; Russo, D; Filetti, S; Gutkind, JS; Sarasin, A; Suarez, HG			Role of the cAMP and MAPK pathways in the transformation of mouse 3T3 fibroblasts by a TSHR gene constitutively activated by point mutation	ONCOGENE			English	Article						TSHR gene; mouse fibroblasts; transformation; pathways	HUMAN THYROTROPIN RECEPTOR; PROTEIN-COUPLED RECEPTORS; BETA-GAMMA-SUBUNITS; ALPHA-1B-ADRENERGIC RECEPTOR; MALIGNANT TRANSFORMATION; SIGNAL-TRANSDUCTION; GERMLINE MUTATIONS; THYROID CARCINOMAS; KINASE-A; RAS	Constitutive activating mutations of the TSHR gene, have been detected in about 30 per cent of hyperfunctioning human thyroid adenomas and in a minority of differentiated thyroid carcinomas. The mutations activating the TSHR gene(s) in the thyroid carcinomas, were located at the codon 623 changing an Ala to a Ser (GCC-->TCC) or in codon 632 changing a Thr to Ala or Ile (ACC-->GCC or ACC-->ATC). In order to study if the constitutively activated TSHR gene(s) has played a role in the determination of the malignant phenotype presented by these tumors, we investigated: (1) the transforming capacity after transfection of mouse 3T3 cells, of a TSHR cDNA activated by an Ala-->Ser mutation in codon 623 or an Thr-Ile mutation in codon 632 and (2) the pathway(s) eventually responsable(s) for the malignant phenotype of the cells transformed by these constitutively activated TSHR cDNAs, Our results show that (1) the TSHRM623 or(M632) cDNAs give rise to 3T3 clones presenting a fully neoplastic phenotype (growth in agar and nude mouse tumorigenesis); this phenotype was weaker in the cells transformed by the 632 cDNA; (2) suggest that the fully transformed phenotype of our 3T3 cells, may be the consequence of the additive effect of the activation of at least two different pathways: the cAMP pathway through G(alpha s) and the Ras dependent MAPK pathway through G(beta gamma) and PI3K and (3) show that the PI3K isoform playing a key role as an effector in the MAPK pathway activation in our 3T3-transformed cells is PI3K gamma. Signaling from PI3K gamma to MAPK appears to require in our murine cellular system a tyrosine kinase (still not characterized), Shc, Grb2, Sos, Ras and Raf. It is proposed that the constitutively activated TSHR genes detected in the thyroid carcinomas, may have played an oncogenic role, participating in their development through these two pathways.	Inst Rech Canc, CNRS IFR 89, Lab Instabil Genet & Canc, UPR 2169, F-94801 Villejuif, France; Univ Cantabria, Fac Med, Dept Mol Biol, Santander 39011, Spain; Univ Catanzaro, Dip Med Sperimentale & Clin, Cattedra Endocrinol, I-88100 Catanzaro, Italy; NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD USA	Universidad de Cantabria; Magna Graecia University of Catanzaro; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Suarez, HG (corresponding author), Inst Rech Canc, CNRS IFR 89, Lab Instabil Genet & Canc, UPR 2169, 7 Rue Guy Moquet,BP 8, F-94801 Villejuif, France.		Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009; Crespo, Piero/M-3273-2014	Gutkind, J. Silvio/0000-0002-5150-4482; Crespo, Piero/0000-0003-2825-7783	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; Cass LA, 1999, MOL CELL BIOL, V19, P5882; CHAZENBALK GD, 1991, MOL ENDOCRINOL, V5, P1523, DOI 10.1210/mend-5-10-1523; CHAZENBALK GD, 1990, J BIOL CHEM, V265, P20970; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; DUMONT JE, 1989, METABOLIC BASIS INHE, P555; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; Fournes B, 1998, ONCOGENE, V16, P985, DOI 10.1038/sj.onc.1201626; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; Gire V, 2000, ONCOGENE, V19, P2269, DOI 10.1038/sj.onc.1203544; Gire V, 1999, ONCOGENE, V18, P4819, DOI 10.1038/sj.onc.1202857; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MICHELIN S, 1991, ONCOGENE, V196, P314; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; RUSSO D, 1995, J CLIN ENDOCR METAB, V80, P1347, DOI 10.1210/jc.80.4.1347; RUSSO D, 1995, ONCOGENE, V11, P1907; SAID S, 1994, J ENDOCRINOL INVEST, V17, P371, DOI 10.1007/BF03349004; Schoneberg T, 1999, MOL CELL ENDOCRINOL, V151, P181, DOI 10.1016/S0303-7207(99)00017-9; SHARIF M, 1994, MOL CELL ENDOCRINOL, V100, P115, DOI 10.1016/0303-7207(94)90289-5; Spambalg D, 1996, J CLIN ENDOCR METAB, V81, P3898, DOI 10.1210/jc.81.11.3898; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; SUAREZ HG, 1991, ONCOGENE, V6, P677; SUAREZ HG, 1988, ONCOGENE, V2, P403; Tonacchera M, 1996, J CLIN ENDOCR METAB, V81, P547, DOI 10.1210/jc.81.2.547; VAN BT, 1995, NATURE, V376, P781	38	15	16	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4896	4905		10.1038/sj.onc.1203852	http://dx.doi.org/10.1038/sj.onc.1203852			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039907				2022-12-17	WOS:000089757800012
J	Arlt, DH; Baur, B; Wagner, B; Hoppner, W				Arlt, DH; Baur, B; Wagner, B; Hoppner, W			A novel type of mutation in the cysteine rich domain of the RET receptor causes ligand independent activation	ONCOGENE			English	Article						MEN 2; RET-proto-oncogene; additional cysteine 634; ligand independent dimerization	NEOPLASIA TYPE 2A; TYROSINE KINASE; PROTOONCOGENE; GDNF; EXPRESSION; NEURTURIN	Multiple endocrine neoplasia type 2A (MEN 2A) is a dominantly inherited canter syndrome, which involves the triad of MTC, pheochromocytoma, and hypcrparathyridism, Missense mutations in one of sis cysteine codons in the extracellular cysteine-rich domain of the RET proto-oncogene predispose to this disease. These mutations cause ligand-independent constitutive activation of the tyrosine kinase receptor by the formation of disulfide-bonded homodimers. We examined a different type of mutation, which results in an additional cysteine in the cysteine rich domain. A duplication of 9 bp in the first case resulted in an insertion of three amino acids between codon 633 and 634, In the second case a 12 bp duplication in exon 11 results in four additional amino acids between codon 634 and 635. Here we demonstrate that an additional cysteine causes a ligand independent dimerization of the RET receptor in transfected NIH3T3 cells, which results in an activation of the intracellular tyrosine kinase.	Univ Hamburg, Inst Hormone & Fertil Res, D-22529 Hamburg, Germany; Univ Hamburg, Hosp Eppendorf, Dept Neurosci, D-20246 Hamburg, Germany	University of Hamburg; University of Hamburg	Hoppner, W (corresponding author), Univ Hamburg, Inst Hormone & Fertil Res, Grandweg 64, D-22529 Hamburg, Germany.							AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; Berndt I, 1998, J CLIN ENDOCR METAB, V83, P770, DOI 10.1210/jc.83.3.770; Bongarzone I, 1999, ONCOGENE, V18, P4833, DOI 10.1038/sj.onc.1202848; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BORRELLO MG, 1994, ONCOGENE, V9, P1661; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; FATTORUSO O, 1998, HUM MUTAT S, V1, P167, DOI DOI 10.1002/HUMU.1380110156); Hoppner W, 1997, HUM MOL GENET, V6, P587, DOI 10.1093/hmg/6.4.587; Hoppner W, 1998, HUM MUTAT, pS128; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0	19	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2000	19	30					3445	3448		10.1038/sj.onc.1203688	http://dx.doi.org/10.1038/sj.onc.1203688			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918602				2022-12-17	WOS:000088198100013
J	Fognani, C; Rondi, R; Romano, A; Blasi, F				Fognani, C; Rondi, R; Romano, A; Blasi, F			cRel-TD kinase: a serine/threonine kinase binding in vivo and in vitro c-Rel and phosphorylating its transactivation domain	ONCOGENE			English	Article						MAP kinase; protein-protein interaction; Rel; NF-kappa B transcription factor; signal transduction; transcriptional regulation	NF-KAPPA-B; SITE-SPECIFIC PHOSPHORYLATION; UBIQUITIN-PROTEASOME PATHWAY; PROTEIN-KINASE; V-REL; TRANSCRIPTIONAL ACTIVITY; P65 SUBUNIT; DNA-BINDING; IN-VIVO; ACTIVATION	The activity of transcription factors is often modulated by signal responsive protein kinases, Rel/NF-kappa B transcription factors are regulated by I kappa B inhibitors, the phospharylation of which causes ubiquitination and degradation, resulting in nuclear translocation of NF-kappa B and activation of target genes. Here we report pull-down and immunoprecipitation experiments showing that a mammalian 66 kDa protein kinase binds murine c-Rel, both in vitro and in vitro. This kinase appears to hare at least two binding sites on c-Rel, a proline-directed serine/ threonine substrate specificity similar to MAP kinases and to specifically phosphorylate the C-terminal domain of murine c-Rel at an ERI: consensus site.	Univ Vita Salute San Raffaele, Dept Mol Pathol & Med, Mol Genet Unit, I-20132 Milan, Italy; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); Vita-Salute San Raffaele University; IRCCS European Institute of Oncology (IEO)	Blasi, F (corresponding author), Univ Vita Salute San Raffaele, Dept Mol Pathol & Med, Mol Genet Unit, Via Olgettina 58, I-20132 Milan, Italy.			Blasi, Francesco/0000-0001-9406-1784				Abe MK, 1999, MOL CELL BIOL, V19, P1301; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Berthelsen J, 1998, EMBO J, V17, P1423, DOI 10.1093/emboj/17.5.1423; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; BOEHMELT G, 1995, CELL, V80, P341, DOI 10.1016/0092-8674(95)90417-4; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Chen CL, 1999, MOL CELL BIOL, V19, P307; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Cheng M, 1996, J BIOL CHEM, V271, P8951, DOI 10.1074/jbc.271.15.8951; Drier EA, 1999, GENE DEV, V13, P556, DOI 10.1101/gad.13.5.556; DRUKER BJ, 1994, J BIOL CHEM, V269, P5387; HANSEN SK, 1994, MOL CELL BIOL, V14, P2593, DOI 10.1128/MCB.14.4.2593; HAYASHI T, 1993, J BIOL CHEM, V268, P26790; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pellicioli A, 1999, EMBO J, V18, P6561, DOI 10.1093/emboj/18.22.6561; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; ZAPPAVIGNA V, 1994, GENE DEV, V8, P732, DOI 10.1101/gad.8.6.732; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	48	15	15	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2000	19	18					2224	2232		10.1038/sj.onc.1203543	http://dx.doi.org/10.1038/sj.onc.1203543			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822372				2022-12-17	WOS:000086974100007
J	Pao, MM; Liang, GN; Tsai, YC; Xiong, ZG; Laird, PW; Jones, PA				Pao, MM; Liang, GN; Tsai, YC; Xiong, ZG; Laird, PW; Jones, PA			DNA methylator and mismatch repair phenotypes are not mutually exclusive in colorectal cancer cell lines	ONCOGENE			English	Article						DNA mismatch repair; DNA methylation; colorectal cancer; retrovirus	NONPOLYPOSIS COLON-CANCER; GENETIC INSTABILITY; CPG ISLAND; MICROSATELLITE INSTABILITY; PROMOTER HYPERMETHYLATION; DENOVO METHYLATION; HMLH1; EXPRESSION; MUTATIONS; CLONING	A potential link between DNA repair and de novo methylation of exogenous sequences in colorectal cancer cell lines suggested that cells deficient in mismatch repair (MMR-) had an increased ability to silence the introduced virus promoter by DIVA methylation due to the presence of a methylator phenotype (MET+) (Lengauer et al., 1997a), We explored this relationship in more detail and found that although there was a clear difference in the abilities of MMR cells to express the viral promoter compared to their MMR- counterparts, this difference was not consistently explained by levels of methylation in the viral promoter. Furthermore, we were unable to distinguish differences between the levels of methylation of six endogenous known CpG islands or 100 random DNA fragments containing CCGG sites within the cells. No consistent differences between the abilities of the cells to methylate the CpG island in exon 2 of the p16 gene were observed after transient demethylation by 5-aza-2'-deoxycytidine nor in the levels of expression of three human methyltransferase enzymes. Our results do not therefore support the existence of mutually exclusive DNA methylation (MET) and DNA repair (MMR) phenotypes.	Univ So Calif, Dept Biochem & Mol Biol, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Dept Surg, Norris Comprehens Canc Ctr, Urol Canc Res Lab, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Jones, PA (corresponding author), Univ So Calif, Dept Biochem & Mol Biol, Norris Comprehens Canc Ctr, MS73,1441 Eastlake Ave, Los Angeles, CA 90033 USA.		Laird, Peter W/G-8683-2012	Laird, Peter W/0000-0001-9117-3641; Liang, Gangning/0000-0001-8664-922X	NCI NIH HHS [R01-CA75090-01, R01 CA075090, R35 CA 49758] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075090, R35CA049758] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Ahuja N, 1997, CANCER RES, V57, P3370; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Boland CR, 1998, CANCER RES, V58, P5248; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; delaChapelle A, 1995, ANNU REV GENET, V29, P329, DOI 10.1146/annurev.ge.29.120195.001553; Deng GR, 1999, CANCER RES, V59, P2029; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Edelmann W, 1999, NAT GENET, V21, P123, DOI 10.1038/5075; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; EVERSOLECIRE P, 1993, MOL CELL BIOL, V13, P4928, DOI 10.1128/MCB.13.8.4928; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; FUJII H, 1989, J BIOL CHEM, V264, P10057; Goggins M, 1998, AM J PATHOL, V152, P1501; Gonzalgo ML, 1997, CANCER RES, V57, P594; Gonzalgo ML, 1997, NUCLEIC ACIDS RES, V25, P2529, DOI 10.1093/nar/25.12.2529; GREZ M, 1991, J VIROL, V65, P4691, DOI 10.1128/JVI.65.9.4691-4698.1991; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAN HJ, 1993, CANCER RES, V53, P5087; Her C, 1998, GENOMICS, V52, P50, DOI 10.1006/geno.1998.5374; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HORII A, 1994, BIOCHEM BIOPH RES CO, V204, P1257, DOI 10.1006/bbrc.1994.2598; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; Kane MF, 1997, CANCER RES, V57, P808; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; Liang G, 1998, GENOMICS, V53, P260, DOI 10.1006/geno.1998.5502; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Myohanen SK, 1998, CANCER RES, V58, P591; NAN HJ, 1995, HUM MOL GENET, V4, P237, DOI 10.1093/hmg/4.2.237; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; Nelson JB, 1997, CANCER RES, V57, P35; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PaquisFlucklinger V, 1997, GENOMICS, V44, P188, DOI 10.1006/geno.1997.4857; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; RADMAN M, 1986, ANNU REV GENET, V20, P523, DOI 10.1146/annurev.ge.20.120186.002515; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Watanabe A, 1996, GENOMICS, V31, P311, DOI 10.1006/geno.1996.0053; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; ZION M, 1994, P NATL ACAD SCI USA, V91, P10722, DOI 10.1073/pnas.91.22.10722	55	15	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2000	19	7					943	952		10.1038/sj.onc.1203414	http://dx.doi.org/10.1038/sj.onc.1203414			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MW	10702803				2022-12-17	WOS:000085567700012
J	Yustein, JT; Li, DS; Robinson, D; Kung, HJ				Yustein, JT; Li, DS; Robinson, D; Kung, HJ			KFC, a Ste20-like kinase with mitogenic potential and capability to activate the SAPK/JNK pathway	ONCOGENE			English	Article						Ste20; KFC; mitogenesis; SAPK/JNK; chicken embryo fibroblast	GERMINAL CENTER KINASE; N-TERMINAL KINASE; PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; MYOSIN-I; STRESS; APOPTOSIS; CASCADES	The Sterile-20 (Ste20) family of serine-threonine kinases has been implicated in the activation of the stress-activated protein kinase pathways. Howe,er, the physiological role has remained ambiguous for most of the investigated mammalian Ste20's, Here we report the cloning of a novel Ste20-like kinase, from chicken embryo fibroblast (CEF) cells, which me have named KFC, for Kinase From Chicken. The 898 amino acid full-length KFC protein contains an amino-terminal kinase domain, an adjacent downstream serine-rich region, and a C-terminal tail containing a coiled-coil domain. Here we show that the coiled-coil domain of KFC negatively regulates the intrinsic kinase activity. We have also identified a splice variant of KFC in which there is a 207 nucleotide in-frame deletion. This deletion of 69 amino acids encompasses the serine-rich region. These two isoforms, called KFCL, for full-length, and KFCS for spliced (or short) form, not only differ in structure, but also in biological properties. Stable CEF cells overexpressing KFCL, but not KFCS, have a significant increase in growth rate when compared to parental cells. This mitogenic effect is the first such reported for this family of kinases. Finally, we found that KFC, when activated by truncation of the regulatory C-terminus, has a specific activation of the stress-activated protein kinase (SAPK/JNK) pathway.	Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA; Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA	University of California System; University of California Davis; Case Western Reserve University	Kung, HJ (corresponding author), Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA.		Kung, Hsing-Jien/C-7651-2013		NATIONAL CANCER INSTITUTE [R37CA046613, R01CA046613, U01CA057179, R37CA039207, R01CA057179, R01CA039207] Funding Source: NIH RePORTER; NCI NIH HHS [CA46613, CA57179, CA39207] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTCZAK M, 1990, J VIROL, V64, P1451, DOI 10.1128/JVI.64.4.1451-1458.1990; Brzeska H, 1997, P NATL ACAD SCI USA, V94, P1092, DOI 10.1073/pnas.94.4.1092; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; HATZ P, 1994, J BIOL CHEM, V269, P16802; Hutchison M, 1998, J BIOL CHEM, V273, P28625, DOI 10.1074/jbc.273.44.28625; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; Ling P, 1999, MOL CELL BIOL, V19, P1359; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; POPOVA O, 1997, J BIOL CHEM, V272, P14041; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; Robinson D, 1998, J BIOMED SCI, V5, P93, DOI 10.1159/000025318; Schrick K, 1997, GENETICS, V147, P19; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Wu CL, 1996, J BIOL CHEM, V271, P31787, DOI 10.1074/jbc.271.50.31787; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133	33	15	17	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2000	19	5					710	718		10.1038/sj.onc.1203342	http://dx.doi.org/10.1038/sj.onc.1203342			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZU	10698516				2022-12-17	WOS:000085192000013
J	Liu, R; Liu, CB; Mohi, MG; Arai, K; Watanabe, S				Liu, R; Liu, CB; Mohi, MG; Arai, K; Watanabe, S			Analysis of mechanisms involved in the prevention of gamma irradiation-induced apoptosis by hGM-CSF	ONCOGENE			English	Article						cytokine receptor; signal transduction; JAK2; cell death; gamma irradiation	COLONY-STIMULATING FACTOR; RADIATION-INDUCED APOPTOSIS; CELL-PROLIFERATION; FACTOR-RECEPTOR; TYROSINE KINASE; PROTEIN-KINASE; ATAXIA-TELANGIECTASIA; HEMATOPOIETIC-CELLS; SIGNALING PATHWAYS; RAF-1 KINASE	Human granulocyte-macrophage colony-stimulating factor (hGM-CSF) induces proliferation and sustains viability of the mouse interleukin (IL)-3 dependent lymphoid cell line BA/F3 expressing the hGM-CSF receptor. Caspase-3 like enzyme activity and DNA fragmentation were augmented by depletion of this factor from the cell, and exposure to gamma irradiation accelerated kinetics of these events. Anti gamma irradiation-induced apoptosis occurred through various mutant GM-CSF receptors and only the box1 region was essential while the C terminal region, including tyrosine residues which are required for MAPK cascade activation, was dispensable. Consistent with this notion, the addition of PD98059 had no effect on this activity thereby indicating that activation of MAPK is not essential for the activity. As expected, gamma irradiation increased p53 protein and bax mRNA levels and the presence of hGM-CSF dramatically modulated bax/bcl-X-L ratio. The PI-3K specific inhibitor wortmannin did not affect hGM-CSF dependent anti gamma irradiation induced apoptosis nor bcl-X-L induction, thus bcl-X-L but not PI-3K pathway seems to be involved in hGM-CSF dependent anti gamma irradiation-induced apoptosis. It is well documented that the boxl region is essential for GM-CSF dependent activation of JAK2 and JAK2 specific inhibitor AG490 suppressed anti gamma irradiation-induced apoptosis by hGM-CSF. An artificial JAK2 activating molecule in which extracellular and the transmembrane of beta c fused with whole JAK2 can sustain BA/F3 cells survival and proliferation mIL-3 independently, but these cells are susceptible to gamma irradiation. Furthermore GyrB/Jak2, which can activate STAT5 but not the MAPK cascade nor survival of BA/F3 cells, also could not prevent gamma irradiation-induced apoptosis. Although JAK2 is essential for hGM-CSF dependent anti gamma irradiation-induced apoptosis, it appeared that JAK2 does not seem sufficient for the activity.	Univ Tokyo, Inst Med Sci, Dept Mol & Dev Biol, Tokyo, Japan; Japan Sci & Technol Corp, CREST, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Watanabe, S (corresponding author), Univ Tokyo, Inst Med Sci, Dept Mol & Dev Biol, Tokyo, Japan.							ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GORCZYCA W, 1993, CANCER RES, V53, P1945; Itoh T, 1998, MOL CELL BIOL, V18, P742, DOI 10.1128/MCB.18.2.742; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kumar S, 1998, J BIOL CHEM, V273, P25654, DOI 10.1074/jbc.273.40.25654; Liu CB, 1999, J BIOL CHEM, V274, P6342, DOI 10.1074/jbc.274.10.6342; Liu R, 1999, MOL BIOL CELL, V10, P3959, DOI 10.1091/mbc.10.11.3959; LIU R, 1999, IN PRESS J ALLERGY C; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Marrero MB, 1997, J BIOL CHEM, V272, P24684, DOI 10.1074/jbc.272.39.24684; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MIYAJIMA A, 1993, BLOOD, V82, P1960; MIYAJIMA A, 1987, GENE, V58, P273, DOI 10.1016/0378-1119(87)90382-9; Mohi MG, 1998, MOL BIOL CELL, V9, P3299, DOI 10.1091/mbc.9.12.3299; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; OKUDA K, 1994, J BIOL CHEM, V269, P24602; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Pazdrak K, 1998, J EXP MED, V188, P421, DOI 10.1084/jem.188.3.421; PESO LD, 1997, SCIENCE, V278, P687; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; Quelle FW, 1998, GENE DEV, V12, P1099, DOI 10.1101/gad.12.8.1099; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; WATANABE S, 1993, MOL BIOL CELL, V4, P983, DOI 10.1091/mbc.4.10.983; WATANABE S, 1995, J BIOL CHEM, V270, P9615, DOI 10.1074/jbc.270.16.9615; Wei S, 1996, J IMMUNOL, V157, P5155; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	46	15	18	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 27	2000	19	4					571	579		10.1038/sj.onc.1203364	http://dx.doi.org/10.1038/sj.onc.1203364			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	280LL	10698527				2022-12-17	WOS:000085104200011
J	Ismail, RS; Cada, M; Vanderhyden, BC				Ismail, RS; Cada, M; Vanderhyden, BC			Transforming growth factor-beta regulates Kit ligand expression in rat ovarian surface epithelial cells	ONCOGENE			English	Article						ovary; receptor tyrosine kinase; ovulation; cytokine; cell-cell communication	FACTOR RECEPTOR EXPRESSION; LEUKEMIA INHIBITORY FACTOR; COLONY-STIMULATING FACTORS; PRIMORDIAL GERM-CELLS; MOUSE SERTOLI CELLS; C-KIT; MESSENGER-RNA; STEEL FACTOR; OOCYTE GROWTH; CANCER	In preparation for ovulation, paracrine communication between the preovulatory follicle and overlying theca/ stromal cells and ovarian surface epithelium (OSE) must take place to facilitate the degradative and apoptotic events associated with ovulation. Kit tyrosine kinase receptors and their ligand, kit ligand (KL) are expressed within ovarian follicles. and ligand-induced receptor activation appears to account for some of the cell-cell interactions important for oocyte development. We investigated the expression of Kit receptors and KL in OSE cells and the possibility that modulation of their expression could affect OSE cell activity.. KL mRNA and protein,were detected in the OSE cell layer of rat ovaries, and primary cultures of rat OSE as well as the immortalized rat OSE cell line, ROSE 199, expressed KL, but not Kit receptors, Both primary and immortalized OSE cells preferentially expressed KL-1, rather than KL-2. transcripts, suggesting that these cells produce predominantly the soluble form of KL. Activation of the cAMP signalling pathway using dibutyryl cAMP decreased proliferation of ROSE 199 cells and elicited a threefold increase in KL expression. TGF-P similarly inhibited ROSE 199 cell proliferation but strongly inhibited dibutyryl cAMP-induced KL expression, indicating that changes in KL expression were not directly associated with OSE cell proliferation. The expression of mostly soluble KL in the surface epithelium suggests that this cytokine may be acting in a paracrine fashion, perhaps interacting with nearby Kit receptor-bearing theca cells.	Univ Ottawa, Ottawa Reg Canc Ctr, Dept Cellular & Mol Med, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Ottawa Reg Canc Ctr, Dept Med, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Ottawa Reg Canc Ctr, Dept Obstet & Gynaecol, Ottawa, ON K1H 8L6, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute	Vanderhyden, BC (corresponding author), Univ Ottawa, Ottawa Reg Canc Ctr, Dept Cellular & Mol Med, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.		xu, huanfang/I-4315-2012					ADAMS AT, 1981, CANCER RES, V41, P2063; ADAMS AT, 1985, EXP CELL BIOL, V53, P181; Allard EK, 1996, BIOL REPROD, V55, P185, DOI 10.1095/biolreprod55.1.185; BERCHUCK A, 1991, AM J OBSTET GYNECOL, V164, P669, DOI 10.1016/S0002-9378(11)80044-X; BERCHUCK A, 1992, AM J OBSTET GYNECOL, V166, P676, DOI 10.1016/0002-9378(92)91697-9; BJERSING L, 1975, EXPERIENTIA, V31, P605, DOI 10.1007/BF01932485; Cass LA, 1998, ENDOCRINOLOGY, V139, P1991, DOI 10.1210/en.139.4.1991; CHEGINI N, 1992, ENDOCRINOLOGY, V130, P1707, DOI 10.1210/en.130.3.1707; Chen TC, 1998, LAB INVEST, V78, P165; DAngelo G, 1997, J CELL BIOCHEM, V67, P353, DOI 10.1002/(SICI)1097-4644(19971201)67:3<353::AID-JCB7>3.3.CO;2-2; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; GODWIN AK, 1992, HEMATOL ONCOL CLIN N, V6, P829; HEINRICH MC, 1995, BLOOD, V85, P1769, DOI 10.1182/blood.V85.7.1769.bloodjournal8571769; HORIE K, 1991, BIOL REPROD, V45, P547, DOI 10.1095/biolreprod45.4.547; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; Ismail RS, 1997, DEV BIOL, V184, P333, DOI 10.1006/dbio.1997.8531; Ismail RS, 1996, MOL REPROD DEV, V43, P458, DOI 10.1002/(SICI)1098-2795(199604)43:4&lt;458::AID-MRD8&gt;3.0.CO;2-O; JINDAL SK, 1994, GYNECOL ONCOL, V53, P17, DOI 10.1006/gyno.1994.1080; JULIAN C G, 1974, Clinical Obstetrics and Gynecology, V17, P241, DOI 10.1097/00003081-197403000-00019; KARLAN BY, 1995, GYNECOL ONCOL, V59, P67, DOI 10.1006/gyno.1995.1269; KRUK PA, 1994, IN VITRO CELL DEV-AN, V30A, P217; LAMMIE A, 1994, J HISTOCHEM CYTOCHEM, V42, P1417, DOI 10.1177/42.11.7523489; LIDOR YJ, 1993, EXP CELL RES, V207, P332, DOI 10.1006/excr.1993.1200; MANOVA K, 1993, DEV BIOL, V157, P85, DOI 10.1006/dbio.1993.1114; MATSUI Y, 1991, NATURE, V353, P750, DOI 10.1038/353750a0; MEKORI YA, 1994, J IMMUNOL, V153, P2194; METCALF D, 1991, P NATL ACAD SCI USA, V88, P6239, DOI 10.1073/pnas.88.14.6239; MOTRO B, 1993, DEV DYNAM, V197, P69, DOI 10.1002/aja.1001970107; Murdoch WJ, 1996, BIOL REV, V71, P529, DOI 10.1111/j.1469-185X.1996.tb01283.x; MURPHY ED, 1972, J NATL CANCER I, V48, P1283; NICOSIA SV, 1985, INT J GYNECOL PATHOL, V4, P58, DOI 10.1097/00004347-198501000-00005; NISHINA Y, 1992, EXP CELL RES, V198, P352, DOI 10.1016/0014-4827(92)90390-T; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; OGAWA K, 1995, BLOOD, V85, P1496, DOI 10.1182/blood.V85.6.1496.bloodjournal8561496; OSTERHOLZER HO, 1985, BIOL REPROD, V33, P247, DOI 10.1095/biolreprod33.1.247; PACKER AI, 1994, DEV BIOL, V161, P194, DOI 10.1006/dbio.1994.1020; Parrott JA, 1997, ENDOCRINOLOGY, V138, P3819, DOI 10.1210/en.138.9.3819; PESCE M, 1993, DEVELOPMENT, V118, P1089; Ramsfjell V, 1997, J IMMUNOL, V158, P5169; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; RODRIGUEZ GC, 1991, AM J OBSTET GYNECOL, V164, P745, DOI 10.1016/0002-9378(91)90508-O; ROSSI P, 1991, BIOCHEM BIOPH RES CO, V176, P910, DOI 10.1016/S0006-291X(05)80272-4; ROSSI P, 1993, DEV BIOL, V155, P68, DOI 10.1006/dbio.1993.1007; Sambrook J, 1989, MOL CLONING LAB MANU; SKINNER MK, 1987, ENDOCRINOLOGY, V121, P786, DOI 10.1210/endo-121-2-786; Tisdall DJ, 1997, J MOL ENDOCRINOL, V18, P127, DOI 10.1677/jme.0.0180127; Tortora G, 1997, CANCER RES, V57, P5107; TSAI M, 1991, P NATL ACAD SCI USA, V88, P6382, DOI 10.1073/pnas.88.14.6382; Vadiveloo PK, 1996, ONCOGENE, V13, P599; VIGNE JL, 1994, BIOL REPROD, V51, P1213, DOI 10.1095/biolreprod51.6.1213; Zheng WX, 1996, AM J PATHOL, V148, P47; ZILTENER HJ, 1993, BIOL REPROD, V49, P635, DOI 10.1095/biolreprod49.3.635	53	15	16	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	1999	18	33					4734	4741		10.1038/sj.onc.1202865	http://dx.doi.org/10.1038/sj.onc.1202865			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467421				2022-12-17	WOS:000082154400011
J	Reddy, UR; Basu, A; Bannerman, P; Ikegaki, N; Reddy, CD; Pleasure, D				Reddy, UR; Basu, A; Bannerman, P; Ikegaki, N; Reddy, CD; Pleasure, D			ZPK inhibits PKA induced transcriptional activation by CREB and blocks retinoic acid induced neuronal differentiation	ONCOGENE			English	Article						ZPK; CREB; NT2 differentiation	ZIPPER-BEARING KINASE; PROTEIN-KINASE; MONOCLONAL-ANTIBODIES; CELLS; FAMILY; PHOSPHORYLATION; IDENTIFICATION; PRODUCT; MEMBER; DNA	Zipper Protein Kinase (ZPK) is a leucine zipper protein localized to the nucleus which exhibits serine-threonine kinase activity and is associated with the stress dependent signal transduction pathway. ZPK forms heterodimers with leucine zipper containing transcription factors such as the cyclic AMP responsive element binding protein (CREB) and MSc. Furthermore ZPK phosphorylates both Myc and CREB. Overexpression of ZPK in NTera-2 human teratocarcinoma cells results in inhibition of PKA induced transcriptional activation by CREB and prevents retinoic acid induced differentiation of the cells to neurons. Our results suggest that ZPK stifles neural differentiation of NT-2 cells partly due to its inhibitory effect on CREB function.	Univ Penn, Childrens Hosp Philadelphia, Dept Neurol Res, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Dept Oncol, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Dept Neurooncol, Philadelphia, PA 19104 USA; Wistar Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania; Childrens Hospital of Philadelphia; The Wistar Institute	Reddy, UR (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Dept Neurol Res, Room 516F, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025044, P20NS031102, P50NS008075, P01NS008075] Funding Source: NIH RePORTER; NINDS NIH HHS [NS08075, NS31102, NS25044] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAHAM I, 1991, J NEUROSCI RES, V28, P29, DOI 10.1002/jnr.490280104; AUSUBEL FM, 1996, CURRENT PROTOCOLS MO, V3; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; Cheung WMW, 1996, NEUROREPORT, V7, P1204, DOI 10.1097/00001756-199604260-00022; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARLOW E, 1988, ANTIOBODIES LAB MANU; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Hirai S, 1996, ONCOGENE, V12, P641; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; Martin KC, 1996, NEURON, V17, P567, DOI 10.1016/S0896-6273(00)80188-9; Mata M, 1996, J BIOL CHEM, V271, P16888, DOI 10.1074/jbc.271.28.16888; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; REEDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; STOCKSCHLAEDER MAR, 1991, HUM GENE THER, V2, P33, DOI 10.1089/hum.1991.2.1-33; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4	29	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4474	4484		10.1038/sj.onc.1202813	http://dx.doi.org/10.1038/sj.onc.1202813			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442638				2022-12-17	WOS:000081813500009
J	Galloway, AM; Spencer, CA; Anderson, CW; Allalunis-Turner, MJ				Galloway, AM; Spencer, CA; Anderson, CW; Allalunis-Turner, MJ			Differential stability of the DNA-activated protein kinase catalytic subunit mRNA in human glioma cells	ONCOGENE			English	Article						DNA-PKcs; radiation sensitivity; M059J cell line; mRNA stability; transcription rates	STRAND BREAK REPAIR; MESSENGER-RNA DECAY; NONSENSE CODONS; TRANSLATION; RADIATION; REGION; GENE; TRANSCRIPTION; SITE; KU	DNA-dependent protein kinase (DNA-PK) functions in double-strand break repair and immunoglobulin [V(D)J] recombination. We previously established a radiation-sensitive human cell line, M059J, derived from malignant glioma, which lacks the catalytic subunit (DNA-PKcs) of the DNA-PK multiprotein complex, Although previous Northern blot analysis failed to detect the DNA-PKcs transcript in these cells, we show here through quantitative studies that the transcript is present, albeit at greatly reduced ( similar to 20x) levels. Sequencing revealed no genetic alteration in either the promoter region, the kinase domain, or the 3' untranslated region of the DNA-PKcs gene to account for the reduced transcript levels. Nuclear run-on transcription assays indicated that the rate of DNA-PKcs transcription in M059J and DNA-PKcs proficient cell lines was similar, but the stability of the DNA-PKcs message in the M059J cell line was drastically ( similar to 20x) reduced. Furthermore, M059J cells lack an alternately spliced DNA-PKcs transcript that accounts for a minor (5 - 20%) proportion of the DNA-PKcs message in all other cell lines tested. Thus, alterations in DNA-PKcs mRNA stability and/or the lack of the alternate mRNA may result in the loss of DNA-PKcs activity, This finding has important implications as DNA-PKcs activity is essential to cells repairing damage induced by radiation or radiomimetric agents.	Univ Alberta, Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	University of Alberta; University of Alberta; United States Department of Energy (DOE); Brookhaven National Laboratory	Allalunis-Turner, MJ (corresponding author), Univ Alberta, Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLALUNISTURNER MJ, 1995, RADIAT RES, V144, P288, DOI 10.2307/3578948; ALLALUNISTURNER MJ, 1993, RADIAT RES, V134, P349, DOI 10.2307/3578196; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; Anderson Carl W., 1994, Seminars in Cell Biology, V5, P427, DOI 10.1006/scel.1994.1050; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; Anderson CW, 1996, CURR TOP MICROBIOL, V217, P91; Belasco J.G., 2012, CONTROL MESSENGER RN; BELGRADER P, 1993, P NATL ACAD SCI USA, V90, P482, DOI 10.1073/pnas.90.2.482; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; Chen P, 1996, INT J RADIAT BIOL, V69, P385, DOI 10.1080/095530096145940; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; Connelly MA, 1998, GENOMICS, V47, P71, DOI 10.1006/geno.1997.5076; Connelly MA, 1996, GENE, V175, P271, DOI 10.1016/0378-1119(96)00135-7; CURATOLA AM, 1995, MOL CELL BIOL, V15, P6331; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; FALZON M, 1993, J BIOL CHEM, V268, P10546; HAGAN KW, 1995, MOL CELL BIOL, V15, P809; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HORIKOSHI T, 1992, CANCER RES, V52, P108; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Jin SF, 1997, CANCER SURV, V29, P221; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LIM SK, 1992, MOL CELL BIOL, V12, P1149, DOI 10.1128/MCB.12.3.1149; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NANBU R, 1994, MOL CELL BIOL, V14, P4920, DOI 10.1128/MCB.14.7.4920; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; SCHIAVI SC, 1994, J BIOL CHEM, V269, P3441; SIPLEY JD, 1995, P NATL ACAD SCI USA, V92, P7515, DOI 10.1073/pnas.92.16.7515; Spencer CA, 1997, J VIROL, V71, P2031, DOI 10.1128/JVI.71.3.2031-2040.1997; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; THOMPSON LH, 1995, MUTAT RES-DNA REPAIR, V337, P131, DOI 10.1016/0921-8777(95)00018-F; YUN DF, 1995, MOL CELL BIOL, V15, P1021; ZHANG SA, 1995, MOL CELL BIOL, V15, P2231	35	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1361	1368		10.1038/sj.onc.1202433	http://dx.doi.org/10.1038/sj.onc.1202433			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022818				2022-12-17	WOS:000078510900012
J	Perez, M; Haschke, B; Donato, NJ				Perez, M; Haschke, B; Donato, NJ			Differential expression and translocation of protein tyrosine phosphatase 1B-related proteins in ME-180 tumor cells expressing apoptotic sensitivity and resistance to tumor necrosis factor: potential interaction with epidermal growth factor receptor	ONCOGENE			English	Article						apoptosis; protein tyrosine; phosphate; TNF	FAS-MEDIATED APOPTOSIS; MANGANOUS SUPEROXIDE-DISMUTASE; RADIATION-INDUCED APOPTOSIS; KAPPA-B ACTIVATION; CARCINOMA-CELLS; FACTOR-ALPHA; TRANSCRIPTION FACTOR; CELLULAR-RESISTANCE; SIGNAL-TRANSDUCTION; GAMMA-RADIATION	Tumor necrosis factor (TNF)-induced apoptosis can be inhibited by overexpression of specific tyrosine kinases or activation of tyrosine kinase cascades, suggesting potential antagonism between apoptotic and tyrosine kinase signaling processes. In this report, the effects of TNF on EGF receptor tyrosine phosphorylation in ME-180 cell variants selected for apoptotic sensitivity (Sen) or resistance (Res) to TNF, previously shown to differentially express EGFr, were examined, Prior to the onset of apoptosis, TNF caused a significant reduction in the level of EGFr tyrosine phosphorylation in Sen cells but mediated only limited suppression of EGFr tyrosine phosphorylation in apoptotically resistant Res cells, In vitro incubation of cellular membranes with TNF derived from Sen cells stimulated a resident protein tyrosine phosphatase (PTP) activity which was able to dephosphorylate EGFr or tyrosine phosphopeptides mimicking an EGFr autophosphorylation site, In membrane preparations, PTP1B complexed with tyrosine phosphorylated EGFr and this association was disrupted by TNF through an apparent stimulation of PTP activity and turnover of phosphotyrosine, Intrinsic enzymatic activity of PTP1B was 2-3-fold higher in Sen versus Res cell lysates and a family of PTP1B-related proteins with altered C-termini was found to be highly expressed in Sen cells but absent or expressed at reduced levels in Res cells, Cytoplasmic extracts of Sen cells contained PTP1B-like proteins and TNF incubation resulted in the time dependent accumulation of PTP1B-like proteins in Sen cells but did not effect these proteins in Res cells, Together, these results suggest that specific changes in expression and subcellular distribution of phosphotyrosine modulatory proteins may play a role in conveying intrinsic apoptotic sensitivity to TNF in some tumor cell types.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy & Drug Carriers, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Donato, NJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy & Drug Carriers, Box 44,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA073018, R29CA048906, R01CA048906] Funding Source: NIH RePORTER; NCI NIH HHS [CA48906, CA73018] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGGARWAL BB, 1994, FEBS LETT, V345, P219, DOI 10.1016/0014-5793(94)00441-2; Atherton E., 1989, SOLID PHASE PEPTIDE; Bandyopadhyay D, 1997, J BIOL CHEM, V272, P1639, DOI 10.1074/jbc.272.3.1639; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Byon JCH, 1997, P SOC EXP BIOL MED, V216, P1; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; CHANG DJ, 1992, BIOCHEM BIOPH RES CO, V188, P538, DOI 10.1016/0006-291X(92)91089-9; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DONATO NJ, 1992, CELL GROWTH DIFFER, V3, P259; DONATO NJ, 1993, CELL GROWTH DIFFER, V4, P411; Donato NJ, 1998, J BIOL CHEM, V273, P5067, DOI 10.1074/jbc.273.9.5067; DOWD DR, 1995, ADV SEC MESS PHOSPH, V30, P255; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; EASTMAN A, 1995, SEMIN CANCER BIOL, V6, P45, DOI 10.1006/scbi.1995.0006; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; FREEMAN BA, 1982, LAB INVEST, V47, P412; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GarciaLloret MI, 1996, J CELL PHYSIOL, V167, P324, DOI 10.1002/(SICI)1097-4652(199605)167:2<324::AID-JCP17>3.0.CO;2-7; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HUDZIAK RM, 1988, P NATL ACAD SCI USA, V85, P5102, DOI 10.1073/pnas.85.14.5102; JAATTELA M, 1995, ONCOGENE, V10, P2297; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; Liu F, 1997, BIOCHEM J, V327, P139, DOI 10.1042/bj3270139; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Liu F, 1998, MOL CELL BIOL, V18, P250, DOI 10.1128/MCB.18.1.250; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lumelsky NL, 1996, CANCER RES, V56, P3909; MAEGAWA H, 1995, J BIOL CHEM, V270, P7724, DOI 10.1074/jbc.270.13.7724; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; MIGITA K, 1995, IMMUNOLOGY, V85, P550; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; NISHIKAWA K, 1994, LYMPHOKINE CYTOK RES, V13, P37; Perez M, 1996, J INTERF CYTOK RES, V16, P307, DOI 10.1089/jir.1996.16.307; Rock MT, 1997, J BIOL CHEM, V272, P33377, DOI 10.1074/jbc.272.52.33377; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SCHIEVEN GL, 1995, J BIOL CHEM, V270, P20824, DOI 10.1074/jbc.270.35.20824; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHEPARD HM, 1988, J CLIN IMMUNOL, V8, P333, DOI 10.1007/BF00917148; Shifrin VI, 1997, J BIOL CHEM, V272, P2957, DOI 10.1074/jbc.272.5.2957; Stefanis L, 1996, J BIOL CHEM, V271, P30663, DOI 10.1074/jbc.271.48.30663; SU X, 1995, IMMUNITY, V2, P353, DOI 10.1016/1074-7613(95)90143-4; SUGARMAN BJ, 1987, CANCER RES, V47, P781; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; TILLY JL, 1992, MOL ENDOCRINOL, V6, P1942, DOI 10.1210/me.6.11.1942; TONKS NK, 1988, J BIOL CHEM, V263, P6722; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; WARREN S, 1993, LYMPHOKINE CYTOK RES, V12, P75; WIENER JR, 1994, J NATL CANCER I, V86, P372, DOI 10.1093/jnci/86.5.372; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871; Wu YL, 1996, J CELL PHYSIOL, V168, P499, DOI 10.1002/(SICI)1097-4652(199609)168:3<499::AID-JCP2>3.0.CO;2-K; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868; ZHAI YF, 1993, CANCER RES, V53, P2272; ZIMMERMAN RJ, 1989, CANCER RES, V49, P164	76	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					967	978		10.1038/sj.onc.1202368	http://dx.doi.org/10.1038/sj.onc.1202368			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023672				2022-12-17	WOS:000078510600013
J	Mangano, R; Piddini, E; Carramusa, L; Duhig, T; Feo, S; Fried, M				Mangano, R; Piddini, E; Carramusa, L; Duhig, T; Feo, S; Fried, M			Chimeric amplicons containing the c-myc gene in HL60 cells	ONCOGENE			English	Article						HL60 chimeric amplicon; fiber-FISH; MYC amplification; amplicon organization; illegitimate recombination; inverted and direct repeats	HUMAN BREAST-CANCER; HUMAN NEUROBLASTOMA; FRAGILE SITES; AMPLIFICATION; ONCOGENE; EXPRESSION; DNA; DIFFERENTIATION; PROLIFERATION; SEQUENCES	The major amplicon present in HL60 cells is chimeric in nature being composed of 70 kb of DNA sequence derived from the MYC locus linked to 80 kb of novel DNA sequence derived from a non contiguous region located telomeric to the c-myc gene at 8q24 (Feo et al,, 1996), Here we show by fluorescence in situ hybridization (FISH) that these coamplified sequences, MCR (Myc Coamplified Region), are derived from a locus located 3-4 Mb telomeric to the c-myc gene in the q24.2-24.3 region of chromosome 8. Genomic cloning and Southern blot analysis indicate the arrangement of chimeric amplicons are in tandem arrays, Analysis of the DNA sequences at the juncture of the MYC locus and the NICR suggest that these non syntenic regions were joined by nonhomologous recombination events, Visualization of the organization of the amplified DNA by fiber-FISH analysis illustrates we have cloned the complete amplicon, This is the first complete mammalian amplicon to be cloned and have its structure visualized. In addition to the major class of tandemly repeated amplicons, a second class of amplicons was detected by fiber-FISH in which the extent of the MCR component is about twice the size of the MCR component in the major amplicon, These longer amplicons most likely contain inverted repeats of MCR and MYC region sequences. Whether the amplicons contain mixtures of these two types of structures or separate amplicons only contain one type of structure has not yet been resolved. Properties of the MCR sequences responsible for retention in the chimeric HL60 amplicons upon long term passage are discussed.	Imperial Canc Res Fund, London WC2A 3PX, England; Univ Palermo, Dipartimento Biol Cellulare & Sviluppo, I-90123 Palermo, Italy; Univ Palermo, Ctr Oncobiol Sperimentale, I-90123 Palermo, Italy	Cancer Research UK; University of Palermo; University of Palermo	Fried, M (corresponding author), Imperial Canc Res Fund, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Feo, Salvatore/C-1333-2012	Feo, Salvatore/0000-0003-3877-2906; Piddini, Eugenia/0000-0003-3901-076X				AKIYAMA K, 1994, NUCLEIC ACIDS RES, V22, P187, DOI 10.1093/nar/22.2.187; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COLLINS SJ, 1987, BLOOD, V70, P1233; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; CORVI R, 1994, P NATL ACAD SCI USA, V91, P5523, DOI 10.1073/pnas.91.12.5523; Elkahloun AG, 1996, GENE CHROMOSOME CANC, V17, P205, DOI 10.1002/(SICI)1098-2264(199612)17:4<205::AID-GCC2>3.3.CO;2-#; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P820, DOI 10.1073/pnas.80.3.820; EVAN G, 1994, PHILOS T R SOC B, V345, P269, DOI 10.1098/rstb.1994.0105; Feo S, 1996, ONCOGENE, V13, P1521; FEO S, 1994, ONCOGENE, V9, P955; FORD M, 1986, CELL, V45, P425, DOI 10.1016/0092-8674(86)90328-4; Forozan F, 1997, TRENDS GENET, V13, P405, DOI 10.1016/S0168-9525(97)01244-4; FRIED M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P143, DOI 10.1016/0167-4781(91)90095-4; GAUWERKY CE, 1993, SEMIN CANCER BIOL, V4, P333; HECHT F, 1990, CANCER GENET CYTOGEN, V44, P37, DOI 10.1016/0165-4608(90)90195-G; Heiskanen M, 1996, GENET ANAL-BIOMOL E, V12, P179, DOI 10.1016/1050-3862(95)00134-4; KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108; Korn Bernhard, 1992, Human Molecular Genetics, V1, P235, DOI 10.1093/hmg/1.4.235; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; SCHNEIDER SS, 1992, MOL CELL BIOL, V12, P5563, DOI 10.1128/MCB.12.12.5563; SHTIVELMAN E, 1989, MOL CELL BIOL, V9, P1148, DOI 10.1128/MCB.9.3.1148; TAKAHASHI E, 1991, CYTOGENET CELL GENET, V57, P109, DOI 10.1159/000133124; Tanner MM, 1996, CANCER RES, V56, P3441; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375	27	15	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2771	2777		10.1038/sj.onc.1202434	http://dx.doi.org/10.1038/sj.onc.1202434			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840941				2022-12-17	WOS:000077146700010
J	Mangues, R; Corral, T; Lu, SY; Symmans, WF; Liu, L; Pellicer, A				Mangues, R; Corral, T; Lu, SY; Symmans, WF; Liu, L; Pellicer, A			NF1 inactivation cooperates with N-Ras in in vivo lymphogenesis activating Erk by a mechanism independent of its Ras-GTPase accelerating activity	ONCOGENE			English	Article						NF1; N-ras proto-oncogene; lymphoma; Erk; Ras-GTPase	NEUROFIBROMATOSIS TYPE-1 GENE; INDUCED MALIGNANT PHENOTYPE; TRANSGENIC MICE; CELL-LINES; MUTATIONS; GROWTH; PROTOONCOGENE; PATHWAY; NEUROBLASTOMA; TUMORIGENESIS	We crossed transgenic mice overexpressing the N-ras proto-oncogene (RasTg) with mice carrying one inactivated copy of the NF1 tumor suppressor gene (NF1+/-)to assess their possible cooperation in tumorigenesis. We have found a significant increase in the incidence of lymphomas in animals with both lesions (RasTg NF1+/-), as compared with animals with single lesions, The mechanism of this cooperation appears to be independent of the NF1 GTPase activating activity since the level of Ras-GTP in primary cultures of tumor tissue do not differ among animals with double and with single lesions. Nevertheless, the finding of significantly higher levels of Erk-1 and Erk-2 activation in lymphomas in the RasTg NF1+/- than in the RasTg group suggests that this cooperative effect may be in part explained by increased signaling through the Erk pathways. Consistent with a role for Erk activation in transformation is the additional observation that Erk-1 and Erk-2 activation is significantly increased in lymphomas as compared with normal spleen. This activation is likely to occur by phosphorylation of previously synthesized and inactive Erk proteins since, despite differences in activation, Erk-1 and:Erk-2 expression is similar in normal and lymphoid tissue in all groups. The observed cooperation in in vivo lymphomagenesis between N-ras overexpression and NF1 inactivation emphasizes the importance of searching for additional functions for the NF1 protein and of intensifying the screening for NF1 mutations in human lymphomas.	NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; NYU, Med Ctr, Kaplan Canc Ctr, New York, NY 10016 USA	New York University; New York University	Pellicer, A (corresponding author), NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA.		MARTINEZ, ANTONIO PELLICER/C-4832-2015; Mangues, Ramon/J-6396-2014	Mangues, Ramon/0000-0003-2661-9525; Pellicer, Angel/0000-0002-5062-0692; Corral, Teresa/0000-0003-2959-9910	NATIONAL CANCER INSTITUTE [R37CA036327, T32CA009161, R01CA036327, R01CA050434] Funding Source: NIH RePORTER; NCI NIH HHS [CA50434, CA36327, 5T32 CA09161] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSEN LB, 1993, NAT GENET, V3, P118, DOI 10.1038/ng0293-118; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Blakesley VA, 1997, J BIOL CHEM, V272, P16211, DOI 10.1074/jbc.272.26.16211; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOS JL, 1989, CANCER RES, V49, P4682; Carel K, 1996, J BIOL CHEM, V271, P30625, DOI 10.1074/jbc.271.48.30625; Clark GJ, 1996, P NATL ACAD SCI USA, V93, P1577, DOI 10.1073/pnas.93.4.1577; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; FRIDMAN M, 1994, J BIOL CHEM, V269, P30105; HEIM RA, 1995, HUM MOL GENET, V4, P975, DOI 10.1093/hmg/4.6.975; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; JOHNSON MR, 1994, MOL CELL BIOL, V14, P641, DOI 10.1128/MCB.14.1.641; KALRA R, 1994, BLOOD, V84, P3435; Largaespada DA, 1996, NAT GENET, V12, P137, DOI 10.1038/ng0296-137; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; Li Y, 1996, CANCER RES, V56, P2872; Malumbres M, 1997, BIOTECHNIQUES, V22, P1114, DOI 10.2144/97226st03; MANGUES R, 1994, CANCER RES, V54, P6395; MANGUES R, 1995, MOL CARCINOGEN, V14, P94, DOI 10.1002/mc.2940140205; Mangues R, 1996, ONCOGENE, V13, P1053; MANGUES R, 1992, ONCOGENE, V7, P2073; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MIYAUCHI J, 1994, BLOOD, V83, P2248; NEUBAUER A, 1991, BLOOD, V77, P594; NUREKAMAL MSA, 1993, J BIOL CHEM, V268, P22331; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; SHANNON KM, 1994, NEW ENGL J MED, V330, P597, DOI 10.1056/NEJM199403033300903; Shen MH, 1996, J MED GENET, V33, P2, DOI 10.1136/jmg.33.1.2; STILLER CA, 1994, BRIT J CANCER, V70, P969, DOI 10.1038/bjc.1994.431; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; UPADHYAYA M, 1994, HUM MUTAT, V4, P83, DOI 10.1002/humu.1380040202; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9	39	15	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1705	1716		10.1038/sj.onc.1202097	http://dx.doi.org/10.1038/sj.onc.1202097			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796699				2022-12-17	WOS:000076200100008
J	Dhanasekaran, N				Dhanasekaran, N			Cell signaling: An overview	ONCOGENE			English	Editorial Material						signal transduction; receptors; G proteins; GTPases; kinases; oncogenes			Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Dhanasekaran, N (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA.								0	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1329	1330		10.1038/sj.onc.1202170	http://dx.doi.org/10.1038/sj.onc.1202170			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779980				2022-12-17	WOS:000076161900001
J	Taylor, GA; Jeffers, M; Webb, CP; Koo, HM; Anver, M; Sekiguchi, K; Woude, GFV				Taylor, GA; Jeffers, M; Webb, CP; Koo, HM; Anver, M; Sekiguchi, K; Woude, GFV			Decreased fibronectin expression in Met/HGF-mediated tumorigenesis	ONCOGENE			English	Article						Met; HGF; fibronectin; TGF beta	HEPATOCYTE GROWTH-FACTOR; C-MET RECEPTOR; SCATTER FACTOR; EPITHELIAL-CELLS; EXTRACELLULAR-MATRIX; PROTOONCOGENE; INDUCTION; MUTATIONS; METASTASIS; ADHESION	The tyrosine kinase receptor Met and its ligand, hepatocyte growth factor (HGF)/scatter factor are involved in the etiology and progression of a number of human cancers. Coexpression of Met and HGF in mesenchymal cells increases the tumorigenic and metastatic potential of the cells. In the studies described here, we used differential display screening to identify changes in gene expression that are initiated by Met/HGF, and that may lead to these phenotypes. We learned that Met/HGF signaling resulted in greatly decreased fibronectin mRNA production in three different human and mouse tumor cell lines; these decreases in fibronectin mRNA were paralleled by decreases in fibronectin protein. We also found a progressive decrease in fibronectin in tumor explants and metastases derived from the Met/HGF transformed cells. The absence of fibronectin expression is a frequent cancer phenotype; our results indicate that decreases in fibronectin correlate with, but are not essential for, MetHGF/SF-mediated tumorigenesis.	NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Sci Applicat Int Corp, Frederick, MD 21702 USA; Osaka Med Ctr Maternal & Child Hlth, Inst Res, Osaka 59002, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Woude, GFV (corresponding author), NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21702 USA.		Webb, Craig/I-8123-2012					Akamatsu H, 1996, CANCER RES, V56, P4541; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Borset M, 1996, BLOOD, V88, P3998, DOI 10.1182/blood.V88.10.3998.bloodjournal88103998; Faletto D L, 1993, EXS, V65, P107; GIANCOTTI FG, 1994, BBA-REV CANCER, V1198, P47, DOI 10.1016/0304-419X(94)90005-1; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; HYNES RO, 1990, FIBRONECTINS, P301; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Jeffers M, 1996, ONCOGENE, V13, P853; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Koochekpour S, 1997, CANCER RES, V57, P5391; Laterra J, 1997, LAB INVEST, V76, P565; Matsumoto K, 1993, EXS, V65, P225; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; RUOSLAHTI E, 1984, CANCER METAST REV, V3, P43, DOI 10.1007/BF00047692; SAITOH K, 1994, J PATHOL, V174, P191, DOI 10.1002/path.1711740308; SANTOS OFP, 1993, DEV BIOL, V160, P293, DOI 10.1006/dbio.1993.1308; SANTOS OFP, 1994, DEV BIOL, V163, P525, DOI 10.1006/dbio.1994.1169; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; STREIT A, 1995, DEVELOPMENT, V121, P813; Taipale J, 1996, J BIOL CHEM, V271, P4342; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597	31	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 3	1998	17	9					1179	1183		10.1038/sj.onc.1202004	http://dx.doi.org/10.1038/sj.onc.1202004			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764829				2022-12-17	WOS:000075598400014
J	Fukuda, K; Kawata, S; Tamura, S; Matsuda, Y; Inui, Y; Igura, T; Inoue, S; Kudara, T; Matsuzawa, Y				Fukuda, K; Kawata, S; Tamura, S; Matsuda, Y; Inui, Y; Igura, T; Inoue, S; Kudara, T; Matsuzawa, Y			Transforming growth factor-beta 1-induced degradation of activated Src tyrosine kinase in rat fibroblasts	ONCOGENE			English	Article						TGF-beta 1; c-Src; v-Src; MAPK; PDGF	HUMAN-COLON-CARCINOMA; FACTOR-BETA-RECEPTOR; SMOOTH-MUSCLE CELLS; ROUS-SARCOMA VIRUS; TGF-BETA; PHOSPHOLIPASE C-GAMMA-1; ANGIOTENSIN-II; CANCER CELLS; INHIBITION; FAMILY	Transforming growth factors-beta (TGF-beta s) play pivotal roles in the regulation of cell growth and differentiation, although little is known regarding the regulation of cytoplasmic components by TGF-beta s, Src tyrosine kinase is required for signal transduction of various cytokine receptors, including epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and G-protein coupled receptors, Moreover, Src tyrosine kinase is important in signal cross-talk between these receptors, To determine whether Src kinase is also involved in TGF-beta signaling,,ce examined the effects of TGF-beta 1 on Src in the rat fibroblast cell line 3Y1 and in v-Src-transformed 3Y1 (SR-3Y1), TGF-beta 1 inhibited mitogen-activated protein kinase activity and inhibited growth in SR-3Y1 cells, while it did not affect the growth of 3Y1 cells. TGF-beta 1 significantly decreased v-Src kinase activity and protein abundance in SR-3Y1 cells, mainly by accelerating the degradation of v-Src. In contrast, in 3Y1 cells, TGF-beta 1 did not affect c-Src abundance or kinase activity. However, upon activation of c-Src in 3Y1 cells by PDGF, TGF-beta 1 decreased Src abundance. Additionally, in 3Y1 cells transfected with an activated c-Src mutant which lacks the SH3 domain, its level was decreased by TGF-beta 1 treatment. These findings suggest that TGF-beta 1 specifically induces degradation of activated Src kinase, This may be a novel mechanism for cross-talk between growth factors and TGF-beta.	Osaka Univ, Sch Med, Dept Internal Med 2, Suita, Osaka 565, Japan	Osaka University	Fukuda, K (corresponding author), Osaka Univ, Sch Med, Dept Internal Med 2, 2-2 Yamadaoka, Suita, Osaka 565, Japan.							ATFI A, 1994, J BIOL CHEM, V269, P30688; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; FILMUS J, 1992, ONCOGENE, V7, P521; GRUPPUSO PA, 1991, J BIOL CHEM, V266, P3444; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; HOWE PH, 1993, J BIOL CHEM, V268, P21448; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KAWAI S, 1980, J VIROL, V34, P772, DOI 10.1128/JVI.34.3.772-776.1980; KISO S, 1994, HEPATOLOGY, V20, P1303, DOI 10.1016/0270-9139(94)90772-2; Knaus PI, 1996, MOL CELL BIOL, V16, P3480; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kumble S, 1997, GASTROENTEROLOGY, V112, P348, DOI 10.1053/gast.1997.v112.pm9024288; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LESCHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; MORI S, 1993, J BIOL CHEM, V268, P577; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OHTSUKI M, 1992, MOL CELL BIOL, V12, P261, DOI 10.1128/MCB.12.1.261; Oshikawa O, 1996, BIOCHEM BIOPH RES CO, V222, P770, DOI 10.1006/bbrc.1996.0819; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PARK S, 1992, J BIOL CHEM, V267, P17194; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PENG ZY, 1995, ONCOGENE, V11, P1955; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROSEN N, 1986, J BIOL CHEM, V261, P3754; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Song QZ, 1996, J EXP MED, V184, P619, DOI 10.1084/jem.184.2.619; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	50	15	16	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 2	1998	16	26					3349	3356		10.1038/sj.onc.1201896	http://dx.doi.org/10.1038/sj.onc.1201896			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692542				2022-12-17	WOS:000074544100001
J	King, JA; Bridger, JM; Lochelt, M; Lichter, P; Schulz, TF; Schirrmacher, V; Khazaie, K				King, JA; Bridger, JM; Lochelt, M; Lichter, P; Schulz, TF; Schirrmacher, V; Khazaie, K			Nucleocytoplasmic transport of HTLV-1 RNA is regulated by two independent LTR encoded nuclear retention elements	ONCOGENE			English	Article						HTLV-1; RxRE; CRS; nuclear export	VIRUS TYPE-I; STRUCTURAL GENE-EXPRESSION; REV-RESPONSIVE ELEMENT; CIS-ACTING ELEMENTS; ENV MESSENGER-RNA; PROTEIN; SEQUENCE; BINDING; EXPORT; IDENTIFICATION	Appropriate expression of HTLV-1 genes requires transcriptional transactivation by Tax and post-transcriptional regulation by Rex, both mediated by LTR encoded RNA sequences. Using a combination of deletion mutagenesis, Rex-reporter CAT assays, fluorescence in situ hybridization (FISH) and confocal laser scanning microscopy it was established that in the absence of Rex, CAT mRNAs harboring HTLV-1 LTR sequences were unable to leave the nucleus. Deletion of the known U5 encoded cis-acting repressing sequence (CRS) led to a partial release of nuclear retention. A novel regulatory element overlapping the 3' Rex responsive element (RxRE) region was shown to prevent export and expression of these transcripts. Deletion of both the 5' LTR encoded CRS and 3' LTR encoded downstream repressive sequence (3' CRS) led to constitutive mRNA nuclear export and gene expression, independently of Rex. The locations of the two regulatory elements indicate that while the 5' CRS selectively acts to hinder export of unspliced transcripts, the 3' CRS has the capacity to induce nuclear retention of all HTLV-1 transcripts, and therefore could potentially contribute to viral latency in infected cells.	German Canc Res Ctr, Dept Cellular Immunol, D-69120 Heidelberg, Germany; German Canc Res Ctr, Dept Org Complex Genomes, D-69120 Heidelberg, Germany; German Canc Res Ctr, Dept Retroviral Gene Express, D-69120 Heidelberg, Germany; Royal Liverpool Univ Hosp, Dept Med Microbiol & Genet Urinary Med, Liverpool L69 3BX, Merseyside, England; Dept Surg, Sect Mol Diag & Therapy, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Khazaie, K (corresponding author), German Canc Res Ctr, Dept Cellular Immunol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.			King, Jason/0000-0001-6886-8728; Schulz, Thomas/0000-0001-8792-5345				BLACK AC, 1991, VIROLOGY, V181, P433, DOI 10.1016/0042-6822(91)90875-C; BOGERD HP, 1992, J VIROL, V66, P7572, DOI 10.1128/JVI.66.12.7572-7575.1992; BRIGHTY DW, 1994, P NATL ACAD SCI USA, V91, P8314, DOI 10.1073/pnas.91.18.8314; CAMPBELL LH, 1994, J VIROL, V68, P5433, DOI 10.1128/JVI.68.9.5433-5438.1994; Chlichlia K, 1997, ONCOGENE, V14, P2265, DOI 10.1038/sj.onc.1201070; CHLICHLIA K, 1995, ONCOGENE, V10, P269; Churchill MJ, 1996, J VIROL, V70, P5786, DOI 10.1128/JVI.70.9.5786-5790.1996; COCHRANE AW, 1991, J VIROL, V65, P5305, DOI 10.1128/JVI.65.10.5305-5313.1991; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DAGOSTINO DM, 1992, MOL CELL BIOL, V12, P1375, DOI 10.1128/MCB.12.3.1375; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; HASELTINE WA, 1991, REGULATION HIV 1 REP; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; INOUE JI, 1986, FEBS LETT, V209, P187, DOI 10.1016/0014-5793(86)81108-5; LICHTER P, 1990, P NATL ACAD SCI USA, V87, P6634, DOI 10.1073/pnas.87.17.6634; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; Mikaelian I, 1996, J MOL BIOL, V257, P246, DOI 10.1006/jmbi.1996.0160; NASIOULAS G, 1994, J VIROL, V68, P2986, DOI 10.1128/JVI.68.5.2986-2993.1994; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; Rehberger S, 1997, EXP CELL RES, V233, P363, DOI 10.1006/excr.1997.3562; SCHWARTZ S, 1992, J VIROL, V66, P150, DOI 10.1128/JVI.66.1.150-159.1992; SCHWARTZ S, 1992, J VIROL, V66, P7176, DOI 10.1128/JVI.66.12.7176-7182.1992; SEIKI M, 1990, VIROLOGY, V176, P81, DOI 10.1016/0042-6822(90)90232-G; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; STAUBER R, 1995, VIROLOGY, V213, P439, DOI 10.1006/viro.1995.0016; TILEY LS, 1992, P NATL ACAD SCI USA, V89, P758, DOI 10.1073/pnas.89.2.758; TOYOSHIMA H, 1990, J VIROL, V64, P2825, DOI 10.1128/JVI.64.6.2825-2832.1990; Zhang GH, 1996, J CELL BIOL, V135, P9, DOI 10.1083/jcb.135.1.9; Zirbel RM, 1993, CHROMOSOME RES, V1, P93, DOI 10.1007/BF00710032	32	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3309	3316		10.1038/sj.onc.1201884	http://dx.doi.org/10.1038/sj.onc.1201884			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681830				2022-12-17	WOS:000074343600012
J	Cabibbo, A; Consalez, GG; Sardella, M; Sitia, R; Rubartelli, A				Cabibbo, A; Consalez, GG; Sardella, M; Sitia, R; Rubartelli, A			Changes in gene expression during the growth arrest of HepG2 hepatoma cells induced by reducing agents or TGF beta 1	ONCOGENE			English	Article						redox regulation; redox signalling; proliferation; RNA fingerprinting; placental type alkaline phosphatase; Cytokeratin K17	DNA-BINDING ACTIVITY; DIFFERENTIAL DISPLAY; REDOX REGULATION; CYSTEINE RESIDUES; FACTOR-I; IDENTIFICATION; RECEPTOR; INVITRO; LINE; TRANSCRIPTION	The growth of hepatoma cells can be inhibited by treatment with TGF beta 1 or with exogenous reducing agents. To gain information on the molecular mechanisms underlying growth arrest, we visualized and compared gene expression profiles of proliferating ver sus non proliferating HepG2 cells by computer-assisted gene fishing, an improved technique of RNA fingerprinting that allows the selective amplification of coding regions within transcripts. While many transcripts are selectively regulated by either treatment, a set of bands appear to be coordinately regulated by 2ME and TGF beta 1, suggesting their possible involvement in the mechanisms of growth arrest. Display tags corresponding to 18 differentially expressed genes were cloned and, in most cases, identified as known genes or, more frequently, as their homospecific/cross-specific homologues. A novel member of the kinesin superfamily was identified amongst the genes induced by both 2ME and TGF beta 1. This gene, KIF3C, is upregulated in several cell lines undergoing growth arrest. Taken together, our findings show that computer-assisted gene fishing is a powerful tool for the identification and cloning of genes involved in the control of cell proliferation and indicate that extracellular reducing agents can regulate cell growth through modulation of gene expression.	Hosp San Raffaele, San Raffaele Sci Inst, Dept Biol & Technol Res, DIBIT, I-20132 Milan, Italy; Ist Nazl Ric Canc, I-16132 Genoa, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Genoa; IRCCS AOU San Martino IST	Cabibbo, A (corresponding author), Hosp San Raffaele, San Raffaele Sci Inst, Dept Biol & Technol Res, DIBIT, Via Olgettina 58, I-20132 Milan, Italy.		Consalez, Giacomo/AAA-2146-2019; Sitia, Roberto/AAB-5005-2019; Rubartelli, Anna/AAA-1259-2021	Consalez, Giacomo/0000-0003-4594-6273; Sitia, Roberto/0000-0001-7086-4152; 				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AIZENMAN E, 1989, NEURON, V2, P1257, DOI 10.1016/0896-6273(89)90310-3; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARNONE MI, 1995, J BIOL CHEM, V270, P12048, DOI 10.1074/jbc.270.20.12048; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; COLLINS SJ, 1987, BLOOD, V70, P1233; Consalez GG, 1996, TRENDS GENET, V12, P455; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Francia G, 1996, CANCER RES, V56, P3855; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; HUANG LE, 1994, J BIOL CHEM, V269, P30718; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; IWATA S, 1994, J IMMUNOL, V152, P5633; JACKSON A, 1995, J BIOL CHEM, V270, P33, DOI 10.1074/jbc.270.1.33; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1995, METHOD ENZYMOL, V254, P304; LIANG P, 1992, CANCER RES, V52, P6966; LIN JK, 1992, CANCER RES, V52, P385; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; NARAYANAN S, 1983, ANN CLIN LAB SCI, V13, P133; RUBARTELLI A, 1995, CANCER RES, V55, P675; SALESIOTIS AN, 1995, CANCER LETT, V91, P47, DOI 10.1016/0304-3835(95)03717-B; Sambrook J, 1989, MOL CLONING LAB MANU; Sardella M, 1998, GENOMICS, V47, P405, DOI 10.1006/geno.1997.5123; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SIDELL N, 1982, J NATL CANCER I, V68, P589; SULLIVAN JM, 1994, NEURON, V13, P929, DOI 10.1016/0896-6273(94)90258-5; Vignali G, 1996, EUR J NEUROSCI, V8, P536, DOI 10.1111/j.1460-9568.1996.tb01238.x; Wang FL, 1996, CANCER RES, V56, P3634; Wu XS, 1996, MOL CELL BIOL, V16, P1035; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	36	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2935	2943		10.1038/sj.onc.1201825	http://dx.doi.org/10.1038/sj.onc.1201825			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671414				2022-12-17	WOS:000073988200012
J	Zhang, HT; O'Rourke, DM; Zhao, HZ; Murali, R; Mikami, Y; Davis, JG; Greene, MI; Qian, XL				Zhang, HT; O'Rourke, DM; Zhao, HZ; Murali, R; Mikami, Y; Davis, JG; Greene, MI; Qian, XL			Absence of autophosphorylation site Y882 in the p185(neu) oncogene product correlates with a reduction of transforming potential	ONCOGENE			English	Article						p185(neu); tyrosine kinase; Y882; transformation	EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; FACTOR-I RECEPTOR; NEU-ONCOGENE; SIGNAL-TRANSDUCTION; INTERMOLECULAR ASSOCIATION; CELL-TRANSFORMATION; RET PROTOONCOGENE; PROTEIN-KINASE; POINT MUTATION	Autophosphorylation of type I receptor tyrosine kinases (RTKs) comprises one step in the signaling events mediated by erbB receptors such as p185(neu) and EGFR. Previous analysis of p185(neu) has indicated that there are at least five tyrosine autophosphorylation sites, Y882, Y1028, E1143, Y1226/7 and Y1253, of which Y882 might be important because of its location in the kinase activity domain. We have specifically analysed the effect of a Y882F (phenylalanine substituted for tyrosine at position 882) mutation in the enzymatic active domain. We also deleted the carboxyl terminal 122 amino acids which contained three other autophosphorylation sites (TAPstop) and combined mutants of that deletion with Y882F (Y882F/APstop). Both in vitro and in vivo transformation assays showed that substitution of tyrosine(882) by phenylalanine significantly decreased the transforming potential of activated, oncogenic p185(neu), although no significant difference in the total phosphotyrosine levels of the mutant proteins were observed. To analyse mitogenic signaling in response to ligand, the intracellular domains of p185(neu) and Y882F were fused with the extracellular domain of the EGF receptor. The proliferation of cells expressing these chimeric receptors was EGF-dependent, and cells expressing EGFR/Y882F chimeric receptors were less responsive to EGF stimulation than those expressing EGFR/neu receptors. In vitro kinase assays demonstrated that abolishing the autophosphorylation site Y882 diminished the enzymatic tyrosine kinase activity of p185(neu). These studies, taken together with the phenotypic inhibition observed with cells expressing Y882F, suggest that the tyrosine(882). residue may be important for p185(neu)-mediated transformation by affecting the enzymatic kinase function of the p185(neu) receptor.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; NCI, Cellular Oncol Lab, Bethesda, MD 20892 USA	University of Pennsylvania; University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Greene, MI (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 36th & Hamilton Walk, Philadelphia, PA 19104 USA.		O'Rourke, Donald/AAC-3376-2021	Murali, Ramachandran/0000-0002-8384-2793; O'Rourke, Donald/0000-0002-8479-7314				CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CARTER TH, 1994, CRIT REV ONCOGENESIS, V5, P389, DOI 10.1615/CritRevOncog.v5.i4.40; CHANTRY A, 1995, J BIOL CHEM, V270, P3068; COLA C, 1989, BIOCHIM BIOPHYS ACTA, V1012, P191, DOI 10.1016/0167-4889(89)90095-5; DECKER SJ, 1993, J BIOL CHEM, V268, P9176; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; Groenen LC, 1997, BIOCHEMISTRY-US, V36, P3826, DOI 10.1021/bi9614141; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LI NX, 1994, ONCOGENE, V9, P3457; MIKAMI Y, 1992, P NATL ACAD SCI USA, V89, P7335, DOI 10.1073/pnas.89.16.7335; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; Murali R, 1996, P NATL ACAD SCI USA, V93, P6252, DOI 10.1073/pnas.93.13.6252; MYERS JN, 1992, RECEPTOR, V2, P1; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; QIAN XL, 1995, ONCOGENE, V10, P211; Qian XL, 1996, ONCOGENE, V13, P2149; QIAN XL, 1994, ONCOGENE, V9, P1507; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SATO KI, 1995, BIOCHEM BIOPH RES CO, V215, P1078, DOI 10.1006/bbrc.1995.2574; TIMMS JF, 1995, BIOCHEM J, V308, P219, DOI 10.1042/bj3080219; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6	42	15	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2835	2842		10.1038/sj.onc.1201820	http://dx.doi.org/10.1038/sj.onc.1201820			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671404				2022-12-17	WOS:000073988200002
J	Jensen, NA; Pedersen, KM; Celis, JE; West, MJ				Jensen, NA; Pedersen, KM; Celis, JE; West, MJ			Failure of central nervous system myelination in MBP/c-myc transgenic mice: evidence for c-myc cytotoxicity	ONCOGENE			English	Article						hypomyelination; programmed cell death; oligodendrocytes	PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; GLIOMA CELL-LINES; NEU ONCOGENE; OPTIC-NERVE; EXPRESSION; BRAIN; DIFFERENTIATION; DEATH; OLIGODENDROCYTE; INDUCTION	c-myc is a member of the helix-loop-helix/leucine zipper family of proteins that modulate the transcriptional activity of specific target genes, Although aberrant c-myc expression has been reported to play a role in multistage carcinogenesis in astrocytic gliomas, little is known about the effects of the expression of c-myc on oligodendrocytes. Using transgenic animals expressing a human C-myc oncogene under transcriptional control of the myelin basic protein gene, we investigated the effect of overexpression of this oncogene in oligodendrocytes, The MBP/c-myc transgenic mice developed severe neurological disturbances characterized by action tremors and recurrent seizures? and premature death during postnatal weeks three to five. Affected transgenic mice of various strains had severely hypomyelinated central nervous systems and expressed low levels of c-myc, myelin basic protein (MBP) and proteolipid protein (PLP) mRNAs in the brain, These c-myc transgenic mice also exhibited an increased number of TUNEL positive nuclei, which in most cases were located in cells that expressed c-myc, as judged by double immunohistochemistry. There was no evidence of brain tumors in the c-myc transgenic mice, including heterozygous mice from two strains that had normal lifespans, These observations indicate that the myelin deficiency observed in the MBP/c-myc transgenic animals results from a cytotoxic effect of the c-myc transgene.	Univ Aarhus, Dept Biochem Med, DK-8000 Aarhus C, Denmark; Univ Aarhus, Dept Neurobiol, DK-8000 Aarhus C, Denmark	Aarhus University; Aarhus University	Jensen, NA (corresponding author), Univ Aarhus, Dept Biochem Med, DK-8000 Aarhus C, Denmark.							ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; Banerjee M, 1996, INT J CANCER, V65, P730, DOI 10.1002/(SICI)1097-0215(19960315)65:6<730::AID-IJC3>3.0.CO;2-#; BARNETT SC, 1995, CELL GROWTH DIFFER, V6, P69; Benjamins JA, 1984, MYELIN, P225; BERGER JR, 1995, J NEUROVIROL, V1, P5, DOI 10.3109/13550289509111006; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Bunge Richard P., 1995, P44; BUTT AM, 1993, J COMP NEUROL, V338, P141, DOI 10.1002/cne.903380110; Campagnoni Anthony T., 1995, P555; Chattopadhyay P, 1995, ONCOGENE, V11, P2711; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; FEDDERSEN RM, 1992, NEURON, V9, P955, DOI 10.1016/0896-6273(92)90247-B; GANJU V, 1994, CANCER-AM CANCER SOC, V74, P920, DOI 10.1002/1097-0142(19940801)74:3<920::AID-CNCR2820740320>3.0.CO;2-4; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HAYES C, 1992, J NEUROSCI RES, V31, P175, DOI 10.1002/jnr.490310123; HEINTZ N, 1993, TRENDS BIOCHEM SCI, V18, P157, DOI 10.1016/0968-0004(93)90103-T; HIRVONEN HE, 1994, BRIT J CANCER, V69, P16, DOI 10.1038/bjc.1994.3; JENSEN NA, 1993, J NEUROSCI RES, V34, P257, DOI 10.1002/jnr.490340302; LAROCCA RV, 1989, J NEUROSCI RES, V24, P97, DOI 10.1002/jnr.490240114; LIN X, 1991, MOL CELL BIOL, V11, P6007, DOI 10.1128/MCB.11.12.6007; MACGREGOR DN, 1990, PEDIATR RES, V28, P63, DOI 10.1203/00006450-199007000-00014; MAJOR EO, 1992, CLIN MICROBIOL REV, V5, P49, DOI 10.1128/CMR.5.1.49-73.1992; Mirsky R, 1996, CURR OPIN NEUROBIOL, V6, P89, DOI 10.1016/S0959-4388(96)80013-4; Morell Pierre, 1994, P117; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; ORIAN JM, 1994, J NEUROSCI RES, V39, P604, DOI 10.1002/jnr.490390512; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; Pfeiffer Steve E., 1993, Trends in Cell Biology, V3, P191, DOI 10.1016/0962-8924(93)90213-K; RADNER H, 1993, ACTA NEUROPATHOL, V86, P456; Raine C., 1984, MYELIN, P1, DOI 10.1007/978-1-4757-1830-0_1; Ransom BR, 1996, TRENDS NEUROSCI, V19, P352, DOI 10.1016/0166-2236(96)10045-X; REMAHL S, 1990, J NEUROCYTOL, V19, P313, DOI 10.1007/BF01188401; Rencic A, 1996, P NATL ACAD SCI USA, V93, P7352, DOI 10.1073/pnas.93.14.7352; Rosenbluth Jack, 1995, P613; RUSSELL DS, 1989, PATHOLOGY TUMOURS NE, P83; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; Szuchet Sara, 1995, P23; TRENT J, 1986, P NATL ACAD SCI USA, V83, P470, DOI 10.1073/pnas.83.2.470; Waxman Stephen G., 1995, P587	41	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	1998	16	16					2123	2129		10.1038/sj.onc.1201739	http://dx.doi.org/10.1038/sj.onc.1201739			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZJ077	9572493				2022-12-17	WOS:000073177200010
J	Li, KKC; Lee, KAW				Li, KKC; Lee, KAW			MMSP tumor cells expressing the EWS/ATF1 oncogene do not support cAMP-inducible transcription	ONCOGENE			English	Article						EWS/ATF1; cAMP; oncogene; phosphorylation	DEPENDENT PROTEIN-KINASE; ELEMENT-BINDING PROTEIN; C-FOS PROMOTER; MULTIPLE SEQUENCE ELEMENTS; CYCLIC-AMP; FACTOR CREB; MALIGNANT-MELANOMA; DNA-BINDING; SOFT PARTS; CHROMOSOME-TRANSLOCATION	Malignant Melanoma of Soft Parts (MMSP) is associated with the EWS/ATF1 fusion protein that arises due to chromosomal fusion of the Ewings Sarcoma oncogene (EWS) and the cellular transcription factor ATF1. EWS/ATF1 can activate several cAMP-inducible promoters, suggesting that cellular transformation in MMSP might involve constitutive activation of cAMP-inducible promoters. To assess this possibility we have examined the status of the cAMP-signaling pathway in the available MMSP-derived cell lines (DTC1 and Su-ccs-1) and find that both cell lines share several features. First, in contrast to previous effects observed in transient assays, three chromosomal promoters containing ATF binding sites are not constitutively activated by endogenous EWS/ATF1 in MMSP cells. Second, all the components that are known to be required for cAMP-inducible transcription are present. Third, phosphorylation of the cAMP-response-element-binding protein (CREB) can be efficiently induced by cAMP, Fourth, cAMP is unable to activate transcription, as assessed by a GAL4/ATF1 reporter assay and analysis of the c-fos and adenovirus early promoters. Thus, cell lines derived from MMSP have a block to cAMP-signaling that lies downstream of CREB phosphorylation. In light of the cAMP-responsiveness of almost all mammalian cell types, our findings suggest that the inability to respond to cAMP might be an important feature of MMSP cells.	Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong	Hong Kong University of Science & Technology	Lee, KAW (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Clear Water Bay, Kowloon, Hong Kong.							ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bannister AJ, 1995, ONCOGENE, V11, P2509; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BRINDLE P, 1995, P NATL ACAD SCI USA, V92, P10521, DOI 10.1073/pnas.92.23.10521; BROWN AD, 1995, ONCOGENE, V10, P1749; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CHUNG EB, 1983, AM J SURG PATHOL, V7, P405, DOI 10.1097/00000478-198307000-00003; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; EPSTEIN AL, 1984, CANCER RES, V44, P1265; Favaloro J, 1980, Methods Enzymol, V65, P718; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; Fujimura Y, 1996, ONCOGENE, V12, P159; GINTY DD, 1991, J BIOL CHEM, V266, P17454; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GUTIERREZ AA, 1992, LANCET, V339, P715, DOI 10.1016/0140-6736(92)90606-4; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HEMMINGS BA, 1986, FEBS LETT, V196, P126, DOI 10.1016/0014-5793(86)80226-5; HUBER BE, 1991, P NATL ACAD SCI USA, V88, P8039, DOI 10.1073/pnas.88.18.8039; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; Janknecht R, 1996, ONCOGENE, V12, P1961; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LADANYI M, 1994, CANCER RES, V54, P2837; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEE KAW, 1989, MOL CELL BIOL, V9, P4390, DOI 10.1128/MCB.9.10.4390; LEE KAW, 1987, EMBO J, V6, P1345, DOI 10.1002/j.1460-2075.1987.tb02374.x; MASSON N, 1992, MOL CELL BIOL, V12, P1096, DOI 10.1128/MCB.12.3.1096; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; OHNO T, 1993, CANCER RES, V53, P5859; Parker D, 1996, MOL CELL BIOL, V16, P694; RIBEIRO A, 1994, J BIOL CHEM, V269, P31124; SASSONECORSI P, 1988, P NATL ACAD SCI USA, V85, P7192, DOI 10.1073/pnas.85.19.7192; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; SUN PQ, 1995, J BIOL CHEM, V270, P7041, DOI 10.1074/jbc.270.13.7041; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	62	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 12	1998	16	10					1325	1331		10.1038/sj.onc.1201649	http://dx.doi.org/10.1038/sj.onc.1201649			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546434				2022-12-17	WOS:000072422000011
J	Luo, WP; Earley, K; Tantingco, V; Hixson, DC; Liang, TC; Lin, SH				Luo, WP; Earley, K; Tantingco, V; Hixson, DC; Liang, TC; Lin, SH			Association of an 80 kDa protein with C-CAM1 cytoplasmic domain correlates with C-CAM1-mediated growth inhibition	ONCOGENE			English	Article						cell adhesion molecule; tumor suppressor; cross linker; associated protein	CELL-ADHESION MOLECULE; RECEPTOR TYROSINE KINASE; C-CAM; ECTO-ATPASE; HEPATOCELLULAR CARCINOMAS; ENDOGENOUS SUBSTRATE; BILIARY GLYCOPROTEIN; IMMUNOGLOBULIN; EXPRESSION; ISOFORMS	Decreased expression of C-CAM, a member of the CEA family of immunoglobulin like cell adhesion molecules, occurs in carcinomas of the colon, liver and prostate. Down regulation of C-CAM during the early stages of carcinogenesis in rat liver and human prostate has also been reported, We have recently shown that restoration of the expression of the isoform with long cytoplasmic domain, C-CAM1, leads to suppression of the tumorigenicity of prostatic carcinoma cells in vivo and growth suppression in vitro. These observations suggest that C-CAM1 may play an important role in regulating cell growth in normal tissues, Previous studies have demonstrated that the function of many members of the Ig-supergene family is dependent on interactions with cytoplasmic proteins, Tn the present study, we have used a bifunctional cross-linker to identify cellular proteins that interact directly with C-CAM1, Immunoblot analysis of WGA bound membrane proteins crosslinked with DSS identified a 180 kDa complex composed of C-CAM1 and an 80 kDa protein designated CAP-80 (C-CAM Associated Protein), Immunoprecipitation with anti-C-CAM antibodies showed that CAP-80 was co-precipitated with C-CAM from detergent solubilized, WGA-purified proteins, To assess the specificity of CAP-80 binding, the ability of CAP-80 to form stable complexes with C-CAM1 mutants expressed in insect cells was tested, Deletion of the cytoplasmic domain of C-CAM1 abolished complex formation whereas deletion of the extracellular Ig domains had no effect, These results suggest that a CAP-80 homologue (ICAP-80) is present in insect cells and ICAP-80 interacts with the cytoplasmic domain of C-CAM1. Replacement of Tyr488, a residue in the cytoplasmic domain known to be phosphorylated in vivo, with Phe did not diminish the association between C-CAM1 and ICAP-80, suggesting that Tyr488 phosphorylation is not required for association, The ability of various C-CAM1 mutants to associate with ICAP-80 correlated with their growth inhibitory activities, suggesting that ICAP-80/CAP-80 may play an important role in C-CAM1-mediated growth inhibition.	Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; Brown Univ, Rhode Isl Hosp, Dept Med Oncol, Providence, RI 02903 USA; Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; University of Texas System	Lin, SH (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, Box 89,1515 Holcombe Blvd, Houston, TX 77030 USA.							AURIVILLIUS M, 1990, FEBS LETT, V264, P267, DOI 10.1016/0014-5793(90)80264-J; CAMBIER JC, 1992, FASEB J, V6, P3207, DOI 10.1096/fasebj.6.13.1397843; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; CHEUNG PH, 1993, J BIOL CHEM, V268, P24303; CHEUNG PH, 1993, BIOCHEM J, V295, P427, DOI 10.1042/bj2950427; Edlund M, 1996, J BIOL CHEM, V271, P1393, DOI 10.1074/jbc.271.3.1393; EDLUND M, 1993, FEBS LETT, V327, P90, DOI 10.1016/0014-5793(93)81046-3; HIXSON DC, 1989, CANCER RES, V49, P6788; HIXSON DC, 1985, CANCER RES, V45, P3742; HSIEH JT, 1995, CANCER RES, V55, P190; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; LIM Y P, 1990, Journal of Cell Biology, V111, p355A; LIN SH, 1995, BIOCHEM J, V311, P239, DOI 10.1042/bj3110239; LIN SH, 1991, BIOCHEM J, V278, P155, DOI 10.1042/bj2780155; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; NAJJAR SM, 1995, BIOCHEMISTRY-US, V34, P9341, DOI 10.1021/bi00029a009; NAJJAR SM, 1993, J BIOL CHEM, V268, P1201; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; NEVILLE DM, 1968, BIOCHIM BIOPHYS ACTA, V154, P540, DOI 10.1016/0005-2795(68)90014-7; OLSSON H, 1995, FEBS LETT, V365, P51, DOI 10.1016/0014-5793(95)00436-D; ROSENBERG M, 1993, CANCER RES, V53, P4938; SALAMOV AA, 1995, J MOL BIOL, V247, P11, DOI 10.1006/jmbi.1994.0116	22	15	15	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 5	1998	16	9					1141	1147		10.1038/sj.onc.1201619	http://dx.doi.org/10.1038/sj.onc.1201619			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA170	9528856				2022-12-17	WOS:000072336000005
J	Bednarek, AK; Chu, YL; Aldaz, CM				Bednarek, AK; Chu, YL; Aldaz, CM			Constitutive telomerase activity in cells with tissue-renewing potential from estrogen-regulated rat tissues	ONCOGENE			English	Article						telomerase; stem cells; estrogen; proliferation	IMMORTAL CELLS; DIFFERENTIATION; CANCER; LINES; PROGRESSION; PROSTATE; SKIN	To investigate the role of telomerase in estrogen-regulated rodent tissues, we assayed the activity levels of this enzyme and measured cell proliferation and indicators of cellularity in vagina, mammary gland, and uterus from virgin, pregnant, ovariectomized, and ovariectomized estradiol-treated rats. No association was observed between telomerase activity and increased cell proliferation. Telomerase activity was significantly higher (P=0.003) in vagina obtained from ovariectomized rats (very low proliferation) than in vagina from ovariectomized and estradiol-treated rats (high proliferation, high differentiation). The high telomerase levels observed in vagina from ovariectomized rats indicates that the same epithelial compartment (i.e., basal layer) that has the potential to reconstitute the epithelium also contains the cells that express telomerase. The lower telomerase activity in the keratinized (differentiated) vagina was probably due to dilution of the number of telomerase-producing cells by the terminally differentiated non-telomerase-producing cells. Similar results were observed in uterus from ovariectomized ver sus ovariectomized and estradiol-treated rats. Telomerase activity was highest in uterus from pregnant rats. Telomerase levels in samples from total mammary gland fat pads varied considerably between groups and appeared to be representative of the amount of epithelium present in the sample. Interestingly, when mammary gland samples from the same animals were obtained from pure epithelial organoid preparations, no differences in telomerase activity could be distinguished between animals or groups. Overall these data suggest that telomerase activity, particularly in rat vagina and uterus, appears to be associated with a cell subpopulation showing proliferative and tissue reconstitution potential and not directly associated with proliferation status per se.	Univ Texas, Md Anderson Canc Ctr, Dept Carcinogenesis, Div Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Aldaz, CM (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Carcinogenesis, Div Res, Sci Pk, Smithville, TX 78957 USA.		Bednarek, Andrzej K./S-9664-2016; Aldaz, C. Marcelo/E-7868-2011	Bednarek, Andrzej K./0000-0002-4570-4154; Aldaz, C. Marcelo/0000-0002-2453-2939	NATIONAL CANCER INSTITUTE [R01CA059967] Funding Source: NIH RePORTER; NCI NIH HHS [CA59967] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albanell J, 1996, CANCER RES, V56, P1503; ALDAZ CM, 1992, CANCER RES, V52, P4791; BEDNAREK A, 1995, CANCER RES, V55, P4566; Bestilny LJ, 1996, CANCER RES, V56, P3796; CHADENEAU C, 1995, ONCOGENE, V11, P893; CHADENEAU C, 1995, CANCER RES, V55, P2533; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; Holt SE, 1996, NAT BIOTECHNOL, V14, P836, DOI 10.1038/nbt0796-836; Holt SE, 1996, MOL CELL BIOL, V16, P2932; HORVAT B, 1995, EXP CELL RES, V199, P234; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kyo S, 1997, CANCER RES, V57, P610; Meeker AK, 1996, ENDOCRINOLOGY, V137, P5743, DOI 10.1210/en.137.12.5743; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; Sommerfeld HJ, 1996, CANCER RES, V56, P218; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; Yasumoto S, 1996, ONCOGENE, V13, P433	19	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	1998	16	3					381	385		10.1038/sj.onc.1201553	http://dx.doi.org/10.1038/sj.onc.1201553			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467963				2022-12-17	WOS:000071582100010
J	Shiohara, M; Gombart, AF; Berman, JD; Koike, K; Komiyama, A; Koeffler, HP				Shiohara, M; Gombart, AF; Berman, JD; Koike, K; Komiyama, A; Koeffler, HP			Cytostatic effect of TNF alpha on cancer cells is independent of p21(WAF1)	ONCOGENE			English	Article						ME180; p21(WAF1); TNF alpha; antisense	TUMOR-NECROSIS-FACTOR; CYCLIN-DEPENDENT KINASES; NF-KAPPA-B; MANGANOUS SUPEROXIDE-DISMUTASE; HUMAN LEUKEMIC-CELLS; POSTTRANSCRIPTIONAL STABILIZATION; P53-INDEPENDENT INDUCTION; TERMINAL DIFFERENTIATION; INHIBITOR P21; G(1) ARREST	Tumor necrosis factor alpha (TNF alpha) is a cytotoxic/cgtostatic compound for a variety of human cancer cells. The p21(WAF1) protein is a cyclin-dependent kinase inhibitor (CDKI) that binds to cyclin/cyclin-dependent kinase (CDK) complexes and inhibits their kinase activities, thereby leading to cell cycle arrest. We found that the cytostatic effect of TNF alpha on the cervical cancer cell line, ME180, was concomitant with an arrest of these cells in the G0/G1 phase of the cell-cycle. This corresponded with an increase in both p21(WAF1) mRNA and protein levels which likely occurred via a p53-independent pathway since ME180 is infected with the human papilloma virus. To elucidate the role of p21(WAF1) in the TNF alpha-mediated growth and cell cycle arrest, we stably transformed ME180 cells with an antisense p21(WAF1)- expression vector. Two clones with reduced levels of p21(WAF1) both in their basal state as well as after their exposure to TNF alpha were selected. The growth of these cells was still inhibited by TNF alpha and they arrested in G0/G1 similar to wildtype or empty vector transfected cells. These results indicate that although p21(WAF1) expression increases dramatically with TNF alpha treatment, it may not play a critical role in the cytostatic effect of TNF alpha on ME180 cervical cancer cells.	SHINSHU UNIV, SCH MED, DEPT PEDIAT, MATSUMOTO, NAGANO 390, JAPAN	Shinshu University	Shiohara, M (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, CEDARS SINAI RES INST, DEPT MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90048 USA.				NCI NIH HHS [CA26038, CA42710] Funding Source: Medline; NIDDK NIH HHS [DK42792] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042710, R01CA026038, P30CA042710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKASHI M, 1995, J BIOL CHEM, V270, P19181, DOI 10.1074/jbc.270.32.19181; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elstner E, 1997, J CLIN INVEST, V99, P349, DOI 10.1172/JCI119164; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; Gorospe M, 1996, CANCER RES, V56, P475; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; GUO K, 1995, MOL CELL BIOL, V15, P3823; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HERZOG TJ, 1992, CYTOKINE, V4, P214, DOI 10.1016/1043-4666(92)90058-Y; HIRAMA T, 1995, BLOOD, V86, P841; HOLTMANN H, 1988, IMMUNOBIOLOGY, V177, P7, DOI 10.1016/S0171-2985(88)80087-1; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LI Y, 1994, ONCOGENE, V9, P2261; MANCHESTER KM, 1993, BIOCHEM J, V290, P185, DOI 10.1042/bj2900185; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; ROSENBLUM MG, 1989, CRIT REV IMMUNOL, V9, P21; Sambrook J., 1989, MOL CLONING; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWALLER J, 1995, J CLIN INVEST, V95, P973, DOI 10.1172/JCI117806; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shiohara M, 1996, J CELL PHYSIOL, V166, P568, DOI 10.1002/(SICI)1097-4652(199603)166:3<568::AID-JCP11>3.0.CO;2-3; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SRIVASTAVA S, 1992, CARCINOGENESIS, V13, P1273, DOI 10.1093/carcin/13.7.1273; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang QM, 1996, CANCER RES, V56, P264; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG W, 1995, CANCER RES, V55, P668	50	15	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	1997	15	13					1605	1609		10.1038/sj.onc.1201315	http://dx.doi.org/10.1038/sj.onc.1201315			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380413				2022-12-17	WOS:A1997XX36900012
J	Gartenhaus, RB				Gartenhaus, RB			Allelic loss determination in chronic lymphocytic leukemia by immunomagnetic bead sorting and microsatellite marker analysis	ONCOGENE			English	Article						allelic losses; chronic lymphocytic leukemia; microsatellite markers	CELL LUNG-CANCER; LYMPHOBLASTIC-LEUKEMIA; HOMOZYGOUS DELETION; CHROMOSOME-3; LYMPHOMAS; REGION; GENES; ARM	Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the western world. Details of the molecular mechanisms involved in the pathogenesis of this leukemia are unclear at present. In other malignancies tumorigenesis has been shown to proceed via a multistep progression model with a causal relation between the accumulation of genetic abnormalities and more aggressive clinical behavior. The loss of chromosomal segments in malignant cells has proven useful in mapping regions of DNA that contain candidate tumor suppressor genes. The detection of loss of heterozygosity (LOH) has been greatly facilitated by the analysis of highly polymorphic microsatellite markers enabling the identification of submicroscopic losses. Utilizing immunomagnetic bead sorting to separate leukemic from normal cells we identified at least one allelic losses in 8/29 (28%) of analysed CLL cases with a PCR-based assay. On chromosomal arm 3p we have identified homozygous deletions in 3/29 cases at locus D3S1284 residing in the vicinity of the newly described FHIT gene. Several cases of CLL manifested LOH at a locus telomeric to the p15 and p16 tumor suppressor genes, all being early to intermediate stage disease. Our findings suggest that losses at these loci may contribute to the development and/or progression of CLL in at least a subset of cases.			Gartenhaus, RB (corresponding author), ALLEGHENY UNIV HLTH SCI,CTR NEUROVIROL,ONCOL MOL LAB,PHILADELPHIA,PA 19102, USA.							BINET JL, 1977, CANCER-AM CANCER SOC, V40, P855, DOI 10.1002/1097-0142(197708)40:2<855::AID-CNCR2820400239>3.0.CO;2-1; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Califano J, 1996, CANCER RES, V56, P2488; CHAGANTI SR, 1995, GENE CHROMOSOME CANC, V12, P32, DOI 10.1002/gcc.2870120106; DALY MC, 1993, ONCOGENE, V8, P1721; DOHNER H, 1995, BLOOD, V85, P1580, DOI 10.1182/blood.V85.6.1580.bloodjournal8561580; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FENAUX P, 1992, LEUKEMIA, V6, P246; GANLY PS, 1992, GENOMICS, V12, P221, DOI 10.1016/0888-7543(92)90369-4; Gartenhaus R, 1996, BLOOD, V87, P38; Gartenhaus RB, 1996, J MOL MED-JMM, V74, P143, DOI 10.1007/BF01575446; GIADANO G, 1991, P NATL ACAD SCI USA, V88, P5413; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HANNAMHARRIS A, 1984, P AM ASSOC CANC RES, V25, P157; JULIUSSON G, 1990, NEW ENGL J MED, V323, P710; LIU Y, 1995, BLOOD, V86, P1911, DOI 10.1182/blood.V86.5.1911.bloodjournal8651911; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P286, DOI 10.1002/gcc.2870100411; MERLO A, 1994, CANCER RES, V54, P640; NOWELL PC, 1988, CANCER GENET CYTOGEN, V33, P155, DOI 10.1016/0165-4608(88)90025-8; OBRIEN S, 1995, BLOOD, V85, P307; OFFIT K, 1994, BLOOD, V83, P2608; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; OTSUKI T, 1995, CANCER RES, V55, P1436; PARSA NZ, 1994, GENE CHROMOSOME CANC, V9, P8; RAGHOEBIER S, 1991, BLOOD, V77, P1560; RAI KR, 1975, BLOOD, V46, P219, DOI 10.1182/blood.V46.2.219.219; RUPPERT JM, 1993, CANCER RES, V53, P5093; SCHENA M, 1992, BLOOD, V79, P2981; SIEBERT R, 1995, BRIT J HAEMATOL, V91, P350, DOI 10.1111/j.1365-2141.1995.tb05302.x; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; Thiagalingam S, 1996, CANCER RES, V56, P2936	32	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					375	378		10.1038/sj.onc.1200867	http://dx.doi.org/10.1038/sj.onc.1200867			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018124				2022-12-17	WOS:A1997WD51600014
J	Russo, S; Tato, F; Grossi, M				Russo, S; Tato, F; Grossi, M			Transcriptional down-regulation of myogenin expression is associated with v-ras-induced block of differentiation in unestablished quail muscle cells	ONCOGENE			English	Article						v-ras; oncogenes; transformation; myogenesis; myogenin	MYOBLAST DIFFERENTIATION; POSITIVE AUTOREGULATION; GENE-EXPRESSION; UP-REGULATION; DNA-BINDING; ACTIN GENE; MYOD; TRANSFORMATION; MYC; ONCOGENES	Unestablished quail myoblasts were infected with a retroviral vector encoding the oncogenic form of II-Pas in order to investigate the mechanism by which this oncoprotein interferes with terminal differentiation. Primary quail myogenic cells exhibit the simultaneous expression of the muscle regulatory genes myf-5, MyoD and myogenin in proliferative conditions. v-ras-transformed myoblasts displayed an altered growth control and lost the competence for terminal differentiation. When expression of myogenic regulatory genes was analysed, it was immediately apparent that the difference between normal and v-ras-transformed cells was limited to a severely decreased level of myogenin expression. Forced expression of exogenous myogenin in v-ras-transformed quail myoblasts led to a striking recovery of the competence for terminal differentiation. The present data show that: (i) repression of myogenin expression is linked to the differentiation defective phenotype of quail myoblasts transformed by v-ras as well as other retroviral oncogenes; (ii) correction of the differentiation-defective phenotype of v-uas-transformed myoblasts by exogenous myogenin entailed reactivation of endogenous myogenin and of the E-box-dependent transactivating function. These results strongly indicate that myogenin expression plays a central role in regulating the transition into the terminally differentiated state and that its transcriptional down-regulation represents a nodal step in v-ras-induced block of differentiation.	UNIV ROMA LA SAPIENZA,DIPARTIMENTO BIOL CELLULARE & SVILUPPO,ROME,ITALY	Sapienza University Rome			Grossi, Milena/D-2955-2009					ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; ARNOLD HH, 1992, J CELL BIOL, V118, P877, DOI 10.1083/jcb.118.4.877; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BIGNAMI M, 1982, EXP CELL RES, V137, P239, DOI 10.1016/0014-4827(82)90024-6; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; CARUSO M, 1993, ONCOGENE, V8, P267; CASSARMALEK I, 1994, ONCOGENE, V9, P2197; DECHESNE CA, 1994, MOL CELL BIOL, V14, P5474, DOI 10.1128/MCB.14.8.5474; DEPONTIZILLI L, 1988, P NATL ACAD SCI USA, V85, P1389, DOI 10.1073/pnas.85.5.1389; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ELDRIDGE J, 1985, GENE, V36, P55, DOI 10.1016/0378-1119(85)90069-1; ENRIETTO PJ, 1994, SEMIN CANCER BIOL, V5, P91; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GROSSI M, 1991, ONCOGENE, V6, P1767; GROSSI M, 1989, PATHOLOGY GENE EXPRE, P233; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KNIGHT J, 1988, ONCOGENE, V2, P317; KONG YF, 1995, MOL CELL BIOL, V15, P5205; KONIECZNY SF, 1989, ONCOGENE, V4, P473; LAROCCA SA, 1994, ONCOGENE, V9, P3499; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LI L, 1992, ADV CANCER RES, V58, P95, DOI 10.1016/S0065-230X(08)60292-4; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; LYONS GE, 1992, SEM DEV BIOL, V3, P243; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; OKAZAKI K, 1966, P NATL ACAD SCI USA, V56, P1484, DOI 10.1073/pnas.56.5.1484; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PETERSON CA, 1990, CELL, V62, P493, DOI 10.1016/0092-8674(90)90014-6; POWNALL ME, 1992, DEV BIOL, V151, P67, DOI 10.1016/0012-1606(92)90214-2; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; TATO F, 1983, DIFFERENTIATION, V24, P131, DOI 10.1111/j.1432-0436.1983.tb01312.x; TEDESCO D, 1995, J VIROL, V69, P6947, DOI 10.1128/JVI.69.11.6947-6957.1995; VOGEL Z, 1972, P NATL ACAD SCI USA, V69, P3180, DOI 10.1073/pnas.69.11.3180; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YOON HY, 1994, ONCOGENE, V9, P801; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; YUTZEY KE, 1989, MOL CELL BIOL, V9, P1397, DOI 10.1128/MCB.9.4.1397; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	56	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 9	1997	14	1					63	73		10.1038/sj.onc.1200805	http://dx.doi.org/10.1038/sj.onc.1200805			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010233				2022-12-17	WOS:A1997WB76000006
J	Aprelikova, O; Kuthiala, A; Bessho, M; Ethier, S; Liu, ET				Aprelikova, O; Kuthiala, A; Bessho, M; Ethier, S; Liu, ET			BRCA1 protein level is not affected by peptide growth factors in MCF1OA cell line	ONCOGENE			English	Article						breast cancer; BRCA1 protein; cell cycle; EGF; NDF	OVARIAN-CANCER; BREAST-CANCER; MUTATIONS; FAMILIES; GENE; LOCALIZATION; EXPRESSION	The breast cancer susceptibility gene (BRCA1) has been identified as a putative tumor suppressor on chromosome 17. We raised antibody against Ring-finger domain of BRCA1, The antibody recognizes a specific BRCA1 protein doublet of about 220 kD, The majority of BRCA1 protein is localized to the nuclear fraction of untreated MCF10A cells. Though BRCA1 is thought to be a growth suppressor gene, no change in BRCA1 protein level was found when MCF10A cells were arrested by growth factor deprivation or stimulation of cell proliferation by re-addition of growth factors, Furthermore the subcellular localization of the BRCA1 protein does not change throughout the cell cycle, These results suggest that BRCA1 may not be directly involved in the regulation of the cell cycle of breast cancer cell line.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,DEPT MED,CURRICULUM GENET & MOL BIOL,CHAPEL HILL,NC 27599; UNIV MICHIGAN,MED CTR,DEPT RADIAT ONCOL,DIV RADIAT & CANC BIOL,ANN ARBOR,MI 48109	University of North Carolina; University of North Carolina Chapel Hill; University of Michigan System; University of Michigan			Liu, Edison/C-4141-2008					CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; ETHIER SP, 1991, CELL GROWTH DIFFER, V2, P593; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GUDAS JM, 1995, CANCER RES, V55, P4561; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; MARQUIS ST, 1995, NAT GENET, V11, P444; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; RAM TG, 1995, J CELL PHYSIOL, V163, P589, DOI 10.1002/jcp.1041630320; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	17	15	15	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2487	2491						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957093				2022-12-17	WOS:A1996VX10800024
J	Kao, CT; Lin, M; OSheaGreenfield, A; Weinstein, J; Sakamoto, KM				Kao, CT; Lin, M; OSheaGreenfield, A; Weinstein, J; Sakamoto, KM			Over-expression of p55Cdc inhibits granulocyte differentiation and accelerates apoptosis in myeloid cells	ONCOGENE			English	Article						cell division cycle; granulocyte differentiation; apoptosis; myeloid cells	COLONY-STIMULATING FACTOR; CYCLIN-DEPENDENT KINASES; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; MOLECULAR CONTROLS; SUPPRESSOR GENES; WD-40 REPEAT; PROTEIN; ARREST	p55Cdc is a protein identified in cycling mammalian cells. It is highly expressed in proliferating but not in differentiated or growth-arrested cells. Structurally, p55Cdc is similar to the Cdc4 and Cdc20 proteins, which have been proposed to regulate DNA synthesis and mitosis in Saccharomyces cerevisiae. To define the role of p55Cdc during myelopoiesis, me studied the expression and regulation of this protein in response to the hematopoietic growth factors, granulocyte-macrophage colony stimulating factor (GM-CSF) and granulocyte-colony stimulating factor (G-CSF). We analysed the time course of expression of p55Cdc in response to GM-CSF and G-CSF stimulation in the murine factor-dependent myeloid leukemic cell line, 32Dc13, and demonstrated differential regulation of p55Cdc in response to these two growth factors, Over-expression of p55Cdc resulted in acceleration of apoptosis in growth factor- and serum-free conditions, although no difference was observed in the rate of cell proliferation, Decreases in p55Cdc protein levels correlated with cells undergoing apoptosis, p55Cdc over-expression also inhibited granulocyte differentiation of 32Dc13 cells treated with G-CSF, Our studies suggest that p55Cdc regulation is critical for normal cell cycle control during myeloid cell proliferation and differentiation.	UNIV CALIF LOS ANGELES,SCH MED,GWYNNE HAZEN CHERRY MEM LABS,DEPT PATHOL & LAB MED,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,DIV HEMATOL ONCOL,LOS ANGELES,CA 90095; JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90095; AMGEN INC,THOUSAND OAKS,CA 91320	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; Amgen					NCI NIH HHS [1R55 CA68221-01, K08 CA59463-01, R29 CA68221] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA059463, R55CA068221, R29CA068221] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; ASKEW DS, 1991, ONCOGENE, V6, P1915; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHOI WJ, 1994, BIOCHEM BIOPH RES CO, V172, P1324; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; DAWSON IA, 1993, DEVELOPMENT, V117, P359; ELLEDGE RM, 1995, BIOESSAYS, V17, P923, DOI 10.1002/bies.950171105; EVAN G, 1995, CURR OPIN CELL BIOL, V6, P825; FEUCHTER AE, 1992, GENOMICS, V13, P1237, DOI 10.1016/0888-7543(92)90041-P; GRANA X, 1995, ONCOGENE, V11, P211; GUILLOUF C, 1995, ONCOGENE, V10, P2263; GUTJAHR T, 1995, EMBO J, V14, P4296, DOI 10.1002/j.1460-2075.1995.tb00104.x; HALLEK M, 1994, LEUKEMIA, V8, P740; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; HOCKENBERY DM, 1995, BIOESSAYS, V17, P631, DOI 10.1002/bies.950170709; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KIYOKAWA H, 1993, P NATL ACAD SCI USA, V90, P6746, DOI 10.1073/pnas.90.14.6746; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; KORSMEYER SJ, 1992, BLOOD, V80, P879; KOUZARIDES T, 1995, TRENDS CELL BIOL, V5, P448, DOI 10.1016/S0962-8924(00)89109-6; KREIDER BL, 1992, ONCOGENE, V7, P135; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; LEE HJJ, 1995, J BIOL CHEM, V270, P15979, DOI 10.1074/jbc.270.27.15979; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; SAKAMOTO KM, 1994, RECEPTOR CHANNEL, V2, P175; SAKAMOTO KM, 1994, MOL CELL BIOL, V14, P5975, DOI 10.1128/MCB.14.9.5975; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; TKATCH LS, 1993, LYMPHOKINE CYTOK RES, V12, P477; TOMEI LD, 1991, APOPTOSIS MOL BASIS; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WEINSTEIN J, 1994, MOL CELL BIOL, V14, P3350, DOI 10.1128/MCB.14.5.3350; Wong A, 1995, J BIOL CHEM, V270, P30271, DOI 10.1074/jbc.270.51.30271; Xiong Y, 1991, Curr Biol, V1, P362, DOI 10.1016/0960-9822(91)90193-Z	48	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1221	1229						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808696				2022-12-17	WOS:A1996VJ20200013
J	Aronica, MG; Brizzi, MF; Dentelli, P; Rosso, A; Yarden, Y; Pegoraro, L				Aronica, MG; Brizzi, MF; Dentelli, P; Rosso, A; Yarden, Y; Pegoraro, L			p91 STAT1 activation in interleukin-3-stimulated primary acute myeloid leukemia cells	ONCOGENE			English	Article						leukemia; growth factors; signaling; STATs	COLONY-STIMULATING FACTOR; ACUTE MYELOBLASTIC-LEUKEMIA; JAK2 TYROSINE KINASE; COMMON BETA-SUBUNIT; GM-CSF RECEPTOR; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; BLAST CELLS; PROLIFERATIVE RESPONSE; TRANSCRIPTION FACTOR	Interleukin-3 (IL-3) stimulates in vitro blast cell proliferation in a consistent proportion of acute myeloid leukemia (AML) cases, however the degree of response varies from case to case and it is not related to the FAB subtype or to other clinical parameters, IL-3-induced proliferation of myeloid cells is mediated by the interaction with an heterodimeric receptor (IL-3R) comprised of a ligand binding subunit denoted alpha and a common transducing subunit designated as beta (beta(c)). Ligand binding to the receptor activates a number of signaling molecules including proteins of the STATs (signal transducing and activators of transcription) family, To elucidate the mechanisms responsible for the abnormal proliferative response of AML cells to IL-3, we evaluated, both in the IL-3-dependent M-07e cell line and in 20 AML cases, the activation of STAT1 p91 and its association with the beta(c) subunit, On the basis of the in vitro proliferation assay, 11 out of 20 cases were found to be responsive to IL-3 and eight out of 16 to GM-CSF, Our results demonstrated that in M-07e cells and in six AML cases (five IL-3 responsive and one unresponsive) p91 tyrosine phosphorylation was ligand dependent, Ligand independent p91 tyrosine phosphorylation was detected in 10 AML cases (five responsive and five unresponsive), p91 association with the beta(c) subunit was consistent with its ligand dependent activation and with the ability to form a DNA-binding complex containing p91, In the remaining four cases (three unresponsive and one responsive) no p91 tyrosine phosphorylation and/or association were detected, These findings, together with the observation that in five IL-3 responsive cases p91 was constitutively phosphorylated, suggest that IL-3-mediated AML proliferation is only partially sustained by p91 activation and that other post-receptor molecules are required to achieve maximal proliferative response, Moreover structural abnormalities of the receptor or of post-receptor signaling proteins may account for the constitutive p91 phosphorylation and growth factor independent proliferation observed in the unresponsive AML cases.	UNIV TURIN,DIPARTIMENTO SCI BIOMED & ONCOL UMANA,TURIN,ITALY; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	University of Turin; Weizmann Institute of Science			Brizzi, Maria Felice/J-7882-2016; YARDEN, YOSEF/K-1467-2012					AVANZI GC, 1990, J CELL PHYSIOL, V145, P458, DOI 10.1002/jcp.1041450310; AVANZI GC, 1991, CANCER RES, V51, P1741; BASHEY A, 1992, BLOOD, V79, P981; BEGLEY CG, 1987, LEUKEMIA, V1, P1; BRIZZI MF, 1994, J BIOL CHEM, V269, P31680; BRIZZI MF, 1995, BRIT J HAEMATOL, V90, P258, DOI 10.1111/j.1365-2141.1995.tb05145.x; Brizzi MF, 1996, J BIOL CHEM, V271, P3562; BUDEL LM, 1990, BLOOD, V75, P1439; BUDEL LM, 1989, BLOOD, V74, P565; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DELWEL R, 1988, BLOOD, V72, P1944; DELWEL R, 1987, BLOOD, V70, P333; GAVOSTO F, 1964, NATURE, V203, P92, DOI 10.1038/203092a0; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GouilleuxGruart V, 1996, BLOOD, V87, P1692; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GRIFFIN JD, 1986, BLOOD, V67, P1448; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HOANG T, 1986, BLOOD, V68, P313; HORIE M, 1993, J BIOL CHEM, V268, P968; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IKEDA H, 1991, BLOOD, V78, P2962; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; JUBINSKY PT, 1994, BLOOD, V84, P4174, DOI 10.1182/blood.V84.12.4174.bloodjournal84124174; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEARY AG, 1987, BLOOD, V70, P1343; MCCOLL SR, 1991, BLOOD, V78, P1842; MIYAUCHI J, 1987, BLOOD, V70, P657; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; OKUDA K, 1992, BLOOD, V79, P2880; PAZDRAK K, 1995, J IMMUNOL, V155, P397; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RADICH JP, 1990, BLOOD, V76, P801; REILLY IAG, 1989, BRIT J HAEMATOL, V72, P363, DOI 10.1111/j.1365-2141.1989.tb07717.x; REILLY IAG, 1989, LEUKEMIA, V3, P145; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SADOWSKI HB, 1993, NATURE, V366, P580; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TOKSOZ D, 1987, ONCOGENE, V1, P409; TSUJIMURA T, 1994, BLOOD, V83, P2619; VANDERBRUGGEN T, 1995, BLOOD, V85, P1442, DOI 10.1182/blood.V85.6.1442.bloodjournal8561442; VELLENGA E, 1987, LEUKEMIA, V1, P584; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; YOUNG DC, 1986, BLOOD, V68, P1178; ZHONG Z, 1994, SCIENCE, V265, P1701; [No title captured]	62	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					1017	1026						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806691				2022-12-17	WOS:A1996VG76600015
J	Hofmann, TJ; Cole, MD				Hofmann, TJ; Cole, MD			The TAL1/Scl basic helix-loop-helix protein blocks myogenic differentiation and E-box dependent transactivation	ONCOGENE			English	Article						TAL1; leukemogenesis; bHLH; transactivation; myogenesis	T-CELL LEUKEMIA; DNA-BINDING; TRANSCRIPTIONAL-ACTIVATION; MYELOID DIFFERENTIATION; ENHANCER-BINDING; IN-VIVO; GENE; MOTIF; ONCOPROTEIN; ASSOCIATION	The TAL1 gene is transcriptionally activated by chromosomal translocation in the most common genetic lesion associated with T-cell acute lymphoblastic leukemia. TAL1 encodes a bHLH protein that exhibits sequence-specific DNA binding activity when it forms dimers with another bHLH protein such as E2A. We show that ectopic expression of TAL1 blocks the ability of the bHLH gene myogenin to induce myotube differentiation in C3H10T1/2 cells. Cotransfection of TAL1 with either myogenin or E2-5 suppresses the transcriptional activation function of each gene on its respective reporter constructs. TAL1 was as effective as Id in both transcriptional suppression and inhibition of differentiation. Deletion of the C-terminal domain of TAL1 reduces or eliminates its ability to suppress transcription while preserving the bHLH domain that determines the sequence-specificity of DNA binding. These data suggest that the C-terminal domain of TAL1 may directly mask the transactivation domain of E2A-related proteins. Since E2A-related genes are involved in lymphocyte differentiation, the dominant inhibition of E2A-related proteins may be the primary mechanism by which the TAL1 oncogene promotes leukemia.	PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544	Princeton University								APLAN PD, 1991, MOL CELL BIOL, V11, P5462, DOI 10.1128/MCB.11.11.5462; BAER R, 1993, SEMIN CANCER BIOL, V4, P341; BAIN G, 1994, CELL, V79, P85; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DOYLE K, 1994, J BIOL CHEM, V269, P12099; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; GOLDFARB AN, 1995, BLOOD, V85, P465; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OELLERS N, 1994, MOL GEN GENET, V244, P465, DOI 10.1007/BF00583897; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; ROBB L, 1995, ONCOGENE, V10, P205; RUEZINSKY D, 1991, GENE DEV, V5, P29, DOI 10.1101/gad.5.1.29; Sambrook J, 1989, MOL CLONING LAB MANU; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VANDOREN M, 1994, GENE DEV, V8, P2729, DOI 10.1101/gad.8.22.2729; VORONOVA AF, 1994, P NATL ACAD SCI USA, V91, P5952, DOI 10.1073/pnas.91.13.5952; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	41	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					617	624						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760303				2022-12-17	WOS:A1996VB32800019
J	Cosgaya, JM; Aranda, A				Cosgaya, JM; Aranda, A			Ras- and Raf-mediated regulation of transforming growth factor beta 1 gene expression by ligands of tyrosine kinase receptors in PC12 cells	ONCOGENE			English	Article						PC12 cells; TGF-beta 1; Egr-1; Ras; Raf; growth factors	PHEOCHROMOCYTOMA CELLS; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; B-RAF; NERVE; DIFFERENTIATION; ONCOGENE; INHIBITION; ACTIVATION; LINE	Different ligands of tyrosine kinase receptors have neurotrophic or mitogenic effects in PC12 cells, NFG and FGF, which-cause morphological differentiation, as well as EGF, that induces cell growth, produce a significant increase of TGF-beta 1 transcripts in PC12 cells. Sequences responsible for the transcriptional effects of the growth factors are located in the 5'-flanking region of the TGF-beta 1 gene, The TGF-beta 1 gene has two promoters and the growth factors significantly enhance the activity of constructs containing either the first or the second promoter, A functional p21(ras) is required for the regulation of TGF-beta 1 by ligands of tyrosine kinase receptors since expression of oncogenic I as in PC12 cells also increases TGF-beta 1 transcripts, and a dominant inhibitory ras mutant blocks activation of TGF-beta 1 gene expression by NGF, Oncogenic raf stimulates the activity of both promoters and a dominant negative raf also significantly inhibits growth factor activation. As determined by Mv1Lu cell proliferation inhibition assay, PC12 cells release a significant amount of TGF-beta 1 in a latent form and incubation with growth factors or expression of oncogenic ras further increase TGF-beta 1 production. These results suggest that during proliferation or growth factor-induced differentiation of sympathetic neurons there is an increase in TGF-beta 1 that could be an important mediator of neural cells function.	CSIC, INST INVEST BIOMED, E-28029 MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Aranda, Ana/ABG-8820-2020; Cosgaya, Jose M/B-4936-2008	Aranda, Ana/0000-0002-8338-9589; Cosgaya, Jose Miguel/0000-0002-6005-2916				BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; CHALAZONITIS A, 1992, DEV BIOL, V152, P121, DOI 10.1016/0012-1606(92)90162-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COSGAYA JM, 1995, J NEUROCHEM, V65, P2484; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DACUNHA A, 1993, J NEUROIMMUNOL, V42, P71, DOI 10.1016/0165-5728(93)90214-J; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DERYNK R, 1996, J BIOL CHEM, V261, P4377; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FLANDERS KC, 1991, DEVELOPMENT, V113, P183; GEISER AG, 1991, MOL CELL BIOL, V11, P84, DOI 10.1128/MCB.11.1.84; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUERRERO I, 1988, BIOCHEM BIOPH RES CO, V150, P1185, DOI 10.1016/0006-291X(88)90754-1; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; KIM SJ, 1989, J BIOL CHEM, V264, P19373; KIM SJ, 1994, J BIOL CHEM, V269, P3739; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCKINNON RD, 1993, J CELL BIOL, V121, P1397, DOI 10.1083/jcb.121.6.1397; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MUROYA K, 1992, ONCOGENE, V7, P277; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Qui MS, 1991, NEURON, V7, P937, DOI [DOI 10.1016/0896-6273(91)90339-2, 10.1016/0896-6273(91)90339-2]; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; ROGERS SL, 1992, DEV BIOL, V151, P192, DOI 10.1016/0012-1606(92)90226-7; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; THOMSON TM, 1990, MOL CELL BIOL, V10, P1556, DOI 10.1128/MCB.10.4.1556; TOGARI A, 1983, BIOCHEM BIOPH RES CO, V114, P1189, DOI 10.1016/0006-291X(83)90688-5; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	50	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2651	2660						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700524				2022-12-17	WOS:A1996UW48700019
J	Wang, YS; Okan, I; Pokrovskaja, K; Wiman, KG				Wang, YS; Okan, I; Pokrovskaja, K; Wiman, KG			Abrogation of p53-induced G1 arrest by the HPV 16 E7 protein does not inhibit p53-induced apoptosis	ONCOGENE			English	Article						HPV16 E7; p53-induced G1 arrest; apoptosis	WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; ERYTHROLEUKEMIA-CELLS; E6 ONCOPROTEIN; TUMOR-ANTIGEN; LINE; GENE; SUPPRESSION; IRRADIATION; INDUCTION	Wild type (wt) p53 expressed from a temperature-sensitive construct (ts p53) can induce both G1 cell cycle arrest and apoptosis in the p53-negative J3D mouse T lymphoma line (Wang et al., 1995). The human papillomavirus (HPV) 16 E7 protein has been shown to prevent p53-induced G1 cell cycle arrest following DNA damage. We asked whether inhibition of p53-induced G1 arrest by overexpression of the HPV16 E7 protein in the ts p53-transfected J3D cells would interfere with p53-induced apoptosis. Whereas a majority of the ts p53-expressing J3D cells were arrested in the G1 phase 22 h after induction of wt p53 by temperature shift to 32 degrees C, the E7/ts p53-expressing cells showed only a minor increase in the number of cells in G1 at this time point. In addition, the E7/ts p53-expressing cells showed a much less dramatic reduction in number of cells in S phase than the ts p53-expressing cells. This demonstrates that E7 at least partially rescues the cells from p53-induced G1 arrest. In contrast, overexpression of HPV16 E7 did not have any effect on the kinetics nor the frequency of p53-triggered apoptotic death, as shown by PACS analysis, trypan blue exclusion, and DNA fragmentation analysis. These findings support the notion that p53-induced G1 arrest and p53-induced apoptosis are two separate independent pathways.			Wang, YS (corresponding author), KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN.		Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X; Pokrovskaja Tamm, Katja/0000-0001-6359-1256				CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRITSCHE M, 1993, ONCOGENE, V8, P307; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HICKMAN ES, 1994, ONCOGENE, V9, P2177; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAMQVIST T, 1993, ONCOGENE, V8, P1495; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; Sambrook J, 1989, MOL CLONING LAB MANU; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SELIVANOVA G, 1995, ADV CANCER RES, V66, P143, DOI 10.1016/S0065-230X(08)60253-5; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG YS, 1993, ONCOGENE, V8, P3427; WANG YS, 1993, CELL GROWTH DIFFER, V4, P467; WANG YS, 1995, CELL GROWTH DIFFER, V6, P1071; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	47	15	15	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2731	2735						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700534				2022-12-17	WOS:A1996UW48700029
J	Miyazaki, T; Liu, ZJ; Taniguchi, T				Miyazaki, T; Liu, ZJ; Taniguchi, T			Selective cooperation of HTLV-1-encoded p40(tax-1) with cellular oncoproteins in the induction of hematopoietic cell proliferation	ONCOGENE			English	Article						HTLV-1; p40(tax-1); lck F505; c-myc; bcl-2; IL-2	VIRUS TYPE-I; RECEPTOR-BETA-CHAIN; LEUKEMIA-VIRUS; IL-2 RECEPTOR; HTLV-I; SIGNAL TRANSDUCTION; TRANS-ACTIVATION; LIGAND-BINDING; TAX PROTEIN; C-MYC	Human T cell leukemia virus type 1 (HTLV-1) is the etiologic agent of adult T cell leukemia (ATL). The virus-encoded p40(tax-1), a nuclear oncoprotein, is known to promote transcription of its own as well as a variety of cellular genes, However, the mechanism by which p40(tax-1) promotes lymphocyte transformation is not fully understood, In the present study, we examined whether p40(tax-1) can induce hematopoietic cell proliferation by cooperating with the products of cellular proto-oncogenes; i.e. an activated form of the src-family protein tyrosine kinase p56(lck) (lck F505), c-Myc or Bcl-2, These oncoproteins are critical mediators of interleukin 2 (IL-2)-induced proliferative signals. We show that p40(tax-1) alone cannot render the hematopoietic cell line, BAF-B03, able to proliferate in the absence of cytokines, but it can do so in cooperation with lckF505, or c-Myc but not with Bcl-2.	UNIV TOKYO,FAC MED,DEPT IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN; OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN; NIPPON BOEHRINGER INGELHEIM CO LTD,DEPT MOLEC & CELLULAR BIOL,KAWANISHI,HYOGO 66601,JAPAN	University of Tokyo; Osaka University; Boehringer Ingelheim			Miyazaki, Tadaaki/D-9368-2012					ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CARON C, 1993, EMBO J, V12, P4269, DOI 10.1002/j.1460-2075.1993.tb06111.x; DOI T, 1989, EUR J IMMUNOL, V19, P2375, DOI 10.1002/eji.1830191229; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3551; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; HIRAI H, P NATL ACAD US, V91; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; KORSMEYER SJ, 1992, IMMUNOL TODAY, V13, P285, DOI 10.1016/0167-5699(92)90037-8; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MATTHEWS MAH, 1992, MOL CELL BIOL, V12, P1986, DOI 10.1128/MCB.12.5.1986; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TANAKA Y, 1990, JPN J CANCER RES, V81, P225, DOI 10.1111/j.1349-7006.1990.tb02554.x; UCHIUMI F, 1992, MOL CELL BIOL, V12, P3784, DOI 10.1128/MCB.12.9.3784; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WONGSTAAL F, 1983, NATURE, V302, P626, DOI 10.1038/302626a0; Yoshida M, 1993, Trends Microbiol, V1, P131, DOI 10.1016/0966-842X(93)90127-D; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIDA M, 1987, ANNU REV IMMUNOL, V5, P541, DOI 10.1146/annurev.iy.05.040187.002545; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	43	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2403	2408						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649781				2022-12-17	WOS:A1996UQ22000018
J	Tornell, J; Farzad, S; EspanderJansson, A; Matejka, G; Isaksson, O; Rymo, L				Tornell, J; Farzad, S; EspanderJansson, A; Matejka, G; Isaksson, O; Rymo, L			Expression of Epstein-Barr nuclear antigen 2 in kidney tubule cells induces tumors in transgenic mice	ONCOGENE			English	Article						Epstein-Barr virus; EBNA(2); transgenic mice; renal cancer	LYMPHOEPITHELIOMA-LIKE CARCINOMA; FACTOR-II GENE; HODGKINS-DISEASE; LYMPHOMA-CELLS; VIRAL GENOME; WILMS-TUMOR; VIRUS; DNA; PROTEIN; RNA	The effect of EBNA2 in normal cells in vivo has not as yet been explored. The experiments described here were initiated to follow the consequences of the expression of EBNA2 in different tissues in transgenic mice. EBNA2 transgenic strains were generated using a vector containing EBNA2 encoding sequences under the control of the simian virus 40 (SV40) early enhancer/promoter fused to the endogenous EBNA2 Wp promoter. Control mice carrying a transgene with the same sequence but lacking the EBV DNA part remained healthy during observation periods of up to 15 months. The SV-EBNA2 transgenic animals, however, over time developed abdominal masses that on necropsy showed to be due to kidney tumors. Histological examination revealed the presence of tumors with the morphology of kidney adenocarcinoma with a solid growth pattern. At the age of 20 weeks the kidneys of all animals investigated showed disseminated islands of tubular hyperplasia but no true malignant neoplasms. At about 50 weeks of age multiple foci of microscopic tubular adenocarcinomas were found in both kidneys. Eventually, tumors could be diagnosed in about 90% of the SV-EBNA2 transgenic mice. EBNA2-encoding RNA was expressed in both non-malignant kidney tissue and in tumors as shown by cDNA/PCR analysis. Immunoprecipitation and immunoblot analysis showed that the tumor cells contained a polypeptide of the same size as EBNA2 in B95-8 cells that reacted with a monoclonal anti-EBNA2 antibody. Immunohistochemistry demonstrated nuclear expression of EBNA2 in hyperplastic tubules and in tumor tissue.	GOTHENBURG UNIV,DEPT PHYSIOL & PHARMACOL,S-41345 GOTHENBURG,SWEDEN; GOTHENBURG UNIV,DEPT CLIN CHEM & TRANSFUS MED,S-41345 GOTHENBURG,SWEDEN; GOTHENBURG UNIV,DEPT CELL BIOL,S-41345 GOTHENBURG,SWEDEN; GOTHENBURG UNIV,DEPT INTERNAL MED,S-41345 GOTHENBURG,SWEDEN	University of Gothenburg; University of Gothenburg; University of Gothenburg; University of Gothenburg					NCI NIH HHS [CA 28380-08] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028380] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBOT SD, 1990, J VIROL, V64, P2126, DOI 10.1128/JVI.64.5.2126-2134.1990; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BEGIN LR, 1987, J SURG ONCOL, V36, P280, DOI 10.1002/jso.2930360413; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; CALENDER A, 1987, P NATL ACAD SCI USA, V84, P8060, DOI 10.1073/pnas.84.22.8060; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; CORDIER M, 1990, J VIROL, V64, P1002, DOI 10.1128/JVI.64.3.1002-1013.1990; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FINKE J, 1987, J VIROL, V61, P3870, DOI 10.1128/JVI.61.12.3870-3878.1987; GOSH D, 1990, J VIROL, V64, P1855; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; HIRSHFELD H, 1995, P 5 INT C HORM CANC, P140; Hogan B., 1986, MANIPULATING MOUSE E; HUEN DS, 1993, J GEN VIROL, V74, P1381, DOI 10.1099/0022-1317-74-7-1381; HUFF JE, 1991, IARC SCI PUBL, V115, P229; KING W, 1980, J VIROL, V36, P506, DOI 10.1128/JVI.36.2.506-518.1980; KNUTSON JC, 1990, J VIROL, V64, P2530, DOI 10.1128/JVI.64.6.2530-2536.1990; Koike K, 1993, Nihon Rinsho, V51, P536; LABRECQUE LG, 1995, CANCER RES, V55, P39; LEE ES, 1995, NEW ENGL J MED, V332, P19, DOI 10.1056/NEJM199501053320104; Liebowitz David, 1993, P107; MCCLAIN KL, 1995, NEW ENGL J MED, V332, P12, DOI 10.1056/NEJM199501053320103; OFVERSTEDT LG, 1984, BIOCHIM BIOPHYS ACTA, V782, P120, DOI 10.1016/0167-4781(84)90014-9; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PITTALUGA S, 1992, MODERN PATHOL, V5, P661; RAABTRAUB N, 1991, J VIROL, V65, P7032, DOI 10.1128/JVI.65.12.7032-7036.1991; RICKSTEN A, 1987, J GEN VIROL, V68, P2407, DOI 10.1099/0022-1317-68-9-2407; RING CJA, 1994, J GEN VIROL, V75, P1, DOI 10.1099/0022-1317-75-1-1; RYMO L, 1985, P NATL ACAD SCI USA, V82, P3435, DOI 10.1073/pnas.82.10.3435; Sambrook J, 1989, MOL CLONING LAB MANU; SCHAEFER BC, 1995, P NATL ACAD SCI USA, V92, P10565, DOI 10.1073/pnas.92.23.10565; SEARLE PF, 1994, J GEN VIROL, V75, P1125, DOI 10.1099/0022-1317-75-5-1125; SHIBATA D, 1992, AM J PATHOL, V140, P769; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; STADLER W, 1993, ANN ONCOL, V4, P451, DOI 10.1093/oxfordjournals.annonc.a058550; SU IJ, 1991, BLOOD, V77, P799; WANG F, 1987, P NATL ACAD SCI USA, V84, P3452, DOI 10.1073/pnas.84.10.3452; WEISS LM, 1987, AM J PATHOL, V129, P86; Wilson J B, 1992, Curr Top Microbiol Immunol, V182, P375; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; Yamamura K, 1990, Gastroenterol Jpn, V25 Suppl 2, P49; ZIMBERSTROBL U, 1991, J VIROL, V65, P415, DOI 10.1128/JVI.65.1.415-423.1991	47	15	16	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1521	1528						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622868				2022-12-17	WOS:A1996UF07600016
J	Morris, C; Jeffs, A; Smith, T; McDonald, M; Board, P; Kennedy, M; Fitzgerald, P				Morris, C; Jeffs, A; Smith, T; McDonald, M; Board, P; Kennedy, M; Fitzgerald, P			BCR gene recombines with genomically distinct sites on band 11Q13 in complex BCR-ABL translocations of chronic myeloid leukemia	ONCOGENE			English	Article						CML (chronic myeloid leukemia); BCR; complex Ph; recombination	CHRONIC MYELOGENOUS LEUKEMIA; VARIANT PHILADELPHIA TRANSLOCATIONS; BREAKPOINT CLUSTER REGION; INTERPHASE CELL-NUCLEI; ALU-ALU RECOMBINATION; CHROMOSOME BANDS; MOLECULAR ANALYSIS; POSITIVE LEUKEMIA; HOMOLOGOUS RECOMBINATION; DNA-SEQUENCES	We have analysed a cloned 11q13/3'BCR junction fragment, one recombination product of a complex t(9;11;22) translocation in a patient with chronic myeloid leukemia. 3'M-Bcr recombined with chromosome band 11q13 at a specific point between two Alu elements lying in opposite orientation. We present new molecular data comparing the genomic location of the 11q13 breakpoint in our patient with that of one other recently reported to lie within the GSTP1 gene. This is the first time that specific breakpoint sites within a chromosomal region highly involved in complex Ph translocations have been relatively mapped. These early results argue against a precise site in 11q13 with which M-Bcr preferentially recombines and favour instead a larger recombination-prone domain. Both of the 11q13 breakpoint regions show Alu repeat elements in close proximity to the site of recombination.	AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,MOLEC GENET GRP,CANBERRA,ACT 2601,AUSTRALIA	Australian National University; John Curtin School of Medical Research	Morris, C (corresponding author), CHRISTCHURCH SCH MED,DEPT PATHOL,CYTOGENET & MOLEC ONCOL UNIT,CHRISTCHURCH,NEW ZEALAND.		Kennedy, Martin A/A-4942-2008; Morris, Christine/G-1690-2011; Kennedy, Martin/O-4540-2019; Jeffs, Aaron/B-4324-2008	Kennedy, Martin A/0000-0002-6445-8526; Kennedy, Martin/0000-0002-6445-8526; 				BOARD PG, 1989, ANN HUM GENET, V53, P205, DOI 10.1111/j.1469-1809.1989.tb01786.x; BOARD PG, 1992, GENOMICS, V14, P470, DOI 10.1016/S0888-7543(05)80243-5; CHEN SJ, 1988, LEUKEMIA, V2, P634; CHEN SJ, 1989, ONCOGENE, V4, P195; CHEN SJ, 1989, BLOOD, V73, P1312; COWELL IG, 1988, BIOCHEM J, V255, P79, DOI 10.1042/bj2550079; CRAIG JM, 1993, BIOESSAYS, V15, P349, DOI 10.1002/bies.950150510; CRAIG JM, 1994, NATURE GENETIDS, V7, P367; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEBRAEKELEER M, 1986, CANCER GENET CYTOGEN, V23, P167, DOI 10.1016/0165-4608(86)90414-0; DEKLEIN A, 1986, NUCLEIC ACIDS RES, V14, P7071, DOI 10.1093/nar/14.17.7071; DENNY CT, 1989, P NATL ACAD SCI USA, V86, P4254, DOI 10.1073/pnas.86.11.4254; DEVLIN RH, 1990, AM J HUM GENET, V46, P112; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HAGEMEIJER A, 1984, CANCER GENET CYTOGEN, V13, P1, DOI 10.1016/0165-4608(84)90083-9; HEIM S, 1985, CANCER GENET CYTOGEN, V18, P205; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HEISTERKAMP N, 1988, NUCLEIC ACIDS RES, V16, P10069, DOI 10.1093/nar/16.21.10069; HOLMQUIST GP, 1992, AM J HUM GENET, V51, P17; HURET JL, 1986, HUM GENETY, V4, P447; JIANG XY, 1990, BLOOD, V76, P597; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; KODURU PRK, 1993, ONCOGENE, V8, P3239; KORENBERG JR, 1988, CELL, V53, P391, DOI 10.1016/0092-8674(88)90159-6; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; LEFRANC MP, 1986, CELL, V45, P237, DOI 10.1016/0092-8674(86)90388-0; LI L, 1993, AM J HUM GENET, V53, P140; MARCUS S, 1993, HUM GENET, V90, P477; MARKERT ML, 1988, J CLIN INVEST, V81, P1323, DOI 10.1172/JCI113458; MITELMAN F, 1991, CATALOG CHROMOSOME A; MORRIS C, 1993, HUM GENET, V91, P31, DOI 10.1007/BF00230218; MORRIS CM, 1991, BLOOD, V78, P1078; MORRIS CM, 1988, CANCER GENET CYTOGEN, V35, P179, DOI 10.1016/0165-4608(88)90240-3; MORRIS CM, 1990, BLOOD, V76, P1812; NAKAMURA Y, 1993, BRIT J HAEMATOL, V83, P53, DOI 10.1111/j.1365-2141.1993.tb04630.x; ROUYER F, 1987, CELL, V51, P417, DOI 10.1016/0092-8674(87)90637-4; Sambrook J., 1989, MOL CLONING; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA, P438; SOWERBY SJ, 1993, ONCOGENE, V8, P1679; STALLINGS RL, 1993, GENOME ANAL, V7, P59; TENHOEVE J, 1993, GENOMICS, V18, P588, DOI 10.1016/S0888-7543(05)80360-X; TENHOEVE J, 1993, ONCOGENE, V8, P2469; TOTH G, 1994, GENE, V140, P285, DOI 10.1016/0378-1119(94)90559-2; TRASK B, 1989, GENOMICS, V5, P710, DOI 10.1016/0888-7543(89)90112-2; TRASK BJ, 1991, AM J HUM GENET, V48, P1; ZHANG JG, 1995, BRIT J HAEMATOL, V90, P138, DOI 10.1111/j.1365-2141.1995.tb03392.x	48	15	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					677	685						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637725				2022-12-17	WOS:A1996TV59700025
J	Sacchi, N; Schiaffonati, L; Magnani, I; Pappalardo, C; Hughes, AJ; Darfler, M; Hoogeveen, AT				Sacchi, N; Schiaffonati, L; Magnani, I; Pappalardo, C; Hughes, AJ; Darfler, M; Hoogeveen, AT			Detection and subcellular localization of an AML1 chimeric protein in the t(8;21) positive acute myeloid leukemia	ONCOGENE			English	Article						acute myeloid leukemia; translocation (8;21); AML1 gene; chimeric protein	FUSION TRANSCRIPT; NUCLEAR FACTOR; VIRUS ENHANCERS; DNA-BINDING; GENE; RUNT; TRANSLOCATION; IDENTIFICATION; DOMAIN; CORE	AML1, a gene encoding a protein of the PEBP2/CBF family of transcription factors is disrupted by translocations associated with human leukemia. In the t(8;21) acute myelogenous leukemia (AML), AML1 was found fused to a gene on chromosome 8 that we designated CDR (also known as ETO and MTG8). Immunoprecipitation experiments followed by immunoblotting using a combination of antibodies against different epitopes of one of the predicted chimeric proteins encoded by a fully characterized fusion transcript enabled us to visualize a chimeric protein in the t(8;21) Kasumi-1 cell line. The estimated size of this protein is 64 kDa, Immunoblotting of leukemic blasts containing the t(8;21) detected a protein of the same size, Immunofluorescence experiments indicate that the chimeric protein is localized in the nucleus. A normal AML1 protein of 27 kDa was also detected in t(8;21) Kasumi-1 cells, It remains to be established by which mechanism the mutant AML1 isoform may contribute to the leukemogenesis process of t(8;21)-positive acute myeloid leukemia.	UNIV MILAN, SCH MED, DEPT PATHOL, I-20133 MILAN, ITALY; LIFE TECHNOL INC, GAITHERSBURG, MD USA; ERASMUS UNIV ROTTERDAM, SCH MED, DEPT CLIN GENET, ROTTERDAM, NETHERLANDS	University of Milan; Thermo Fisher Scientific; Erasmus University Rotterdam	Sacchi, N (corresponding author), UNIV MILAN, SCH MED, DEPT BIOL & GENET, VIA VIOTTI 3-5, I-20133 MILAN, ITALY.							ASOU H, 1991, BLOOD, V77, P2031; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; BORAL AL, 1989, J VIROL, V63, P76, DOI 10.1128/JVI.63.1.76-84.1989; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; DEGREEF GE, 1995, LEUKEMIA, V9, P282; ERICKSON P, 1992, BLOOD, V80, P1825; HARLOW E, 1988, ANTIBODIES LABORATOR; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1993, BLOOD, V81, P2728; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; OHKI M, 1993, SEMIN CANCER BIOL, V4, P369; PIETTE J, 1987, EMBO J, V6, P1331, DOI 10.1002/j.1460-2075.1987.tb02372.x; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; SACCHI N, 1994, GENE CHROMOSOME CANC, V11, P226, DOI 10.1002/gcc.2870110405; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; THORNELL A, 1988, MOL CELL BIOL, V8, P1625, DOI 10.1128/MCB.8.4.1625; TIGHE JE, 1994, BLOOD, V84, P2115, DOI 10.1182/blood.V84.7.2115.bloodjournal8472115; VANDELOCHT LTF, 1994, LEUKEMIA, V8, P1780; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89	35	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	1996	12	2					437	444						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570222				2022-12-17	WOS:A1996TR53800024
J	CASINI, T; GRAF, T				CASINI, T; GRAF, T			BICISTRONIC RETROVIRAL VECTOR REVEALS CAPACITY OF V-ERBA TO INDUCE ERYTHROLEUKEMIA AND TO COOPERATE WITH V-MYB	ONCOGENE			English	Article						BICISTRONIC RETROVIRUS; AVIAN ACUTE LEUKEMIA; VIRUS; THYROID HORMONE RECEPTOR; ERYTHROBLASTOSIS; ONCOGENE COOPERATIVITY	AVIAN ERYTHROBLASTOSIS VIRUS; CHICKEN ERYTHROID-CELLS; LEUKEMIA-VIRUS; THYROID-HORMONE; MONOCLONAL-ANTIBODIES; SELF-RENEWAL; DIFFERENTIATION; E26; ONCOGENES; GENE	Previous studies have shown that v-erbA and v-myb can induce the proliferation of avian erythroid cells in culture, To study the combined effects of v-erbA and v-myb, the two oncogenes were engineered into a retrovirus bicistronic vector with an internal ribosomal entry site (IRES) or into a vector with a splice acceptor (SPL), This allowed coexpression of the two proteins and a comparison with the same vector containing either v-erbA or v-myb only, Both the erbA IRES and the erbA/myb IRES virus constructs transformed erythroid cells after infection of bone marrow or blastoderm cultures. The erbA/myb IRES virus exhibited a 5-10-fold higher transformed colony forming efficiency than the erbA IRES virus in the blastoderm assay, Surprisingly, when injected into chicken embryos in the presence of helper virus, both viruses induced an erythroleukemia in about half of the animals, In contrast, no leukemia was observed with a myb IRES virus, with spliced vectors containing v-erbA alone or v-erbA in combination with v-myb nor with erbA IRES and erbA/myb IRES viruses produced in the absence of helper virus, The average latency of leukemia induction was shorter for the erbA/myb IRES virus (3.5 weeks) than for the erbA IRES virus (5 weeks), Nevertheless, for both leukemic blasts retained full factor growth, These results show that v-erbA is capable of inducing an erythroleukemia when expressed by a high titer bicistronic retrovirus under conditions of virus spreading and that its in vitro and in vivo transforming potential can be enhanced by v-myb.	EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,D-69012 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Graf, Thomas/B-4252-2015	Graf, Thomas/0000-0003-2774-4117				BARLOW C, 1994, EMBO J, V13, P4241, DOI 10.1002/j.1460-2075.1994.tb06744.x; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1981, VIROLOGY, V111, P201, DOI 10.1016/0042-6822(81)90665-6; BEUG H, 1989, EUR J CLIN INVEST, V19, P491, DOI 10.1111/j.1365-2362.1989.tb00265.x; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1982, EMBO J, V1, P1069, DOI 10.1002/j.1460-2075.1982.tb01298.x; DAMM K, 1969, NATURE, V339, P593; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; Frykberg L, 1988, Oncogene Res, V3, P313; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; GANDRILLON O, 1994, ONCOGENE, V9, P749; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; GOLDBERG Y, 1988, EMBO J, V7, P269; GRAESSER F A, 1991, Molecular and Cellular Biology, V11, P3987; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; KAHN P, 1986, CELL, V44, P349; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; LUSCHER B, 1990, GENE DEV, V4, P2239; MCNAGNY KM, 1992, LEUKEMIA, V6, P975; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; METZ T, 1992, ONCOGENE, V7, P597; MOSCOVICI C, 1982, EXPRESSION DIFFERENT, P435; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SCHROEDER C, 1990, ONCOGENE, V5, P1445; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SCHROEDER C, 1992, ONCOGENE, V7, P217; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOKER AW, 1992, MOL VIROLOGY PRACTIC; STOKER AW, 1909, J VIROL; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	42	15	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1019	1026						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566959				2022-12-17	WOS:A1995RX18000002
J	SACHDEV, S; ROTTJAKOB, EM; DIEHL, JA; HANNINK, M				SACHDEV, S; ROTTJAKOB, EM; DIEHL, JA; HANNINK, M			I-KAPPA-B-ALPHA-MEDIATED INHIBITION OF NUCLEAR TRANSPORT AND DNA-BINDING BY REL PROTEINS ARE SEPARABLE FUNCTIONS - PHOSPHORYLATION OF C-TERMINAL SERINE RESIDUES OF I-KAPPA-B-ALPHA IS SPECIFICALLY REQUIRED FOR INHIBITION OF DNA-BINDING	ONCOGENE			English	Article						I-KAPPA-B; NF-KAPPA-B; REL; TRANSCRIPTIONAL REGULATION; PHOSPHORYLATION	TRANSCRIPTION FACTORS; ACTIVATION; CELLS; GENE; TRANSFORMATION; EXPRESSION; MECHANISM; ONCOGENE; ENCODES; BETA	I kappa B-alpha inhibits both DNA-binding and nuclear translocation of dimeric Rel complexes that contain either the RelA or c-Rel proteins. These inhibitory functions of I kappa B-alpha proteins are regulated by both constitutive and inducible phosphorylation. We have mapped the constitutive phosphorylation sites of p40, the avian I kappa B-alpha protein, to a C-terminal acidic serine-rich region that contains four serine residues. Deletions or point mutations that significantly alter the overall negatively charged character of this region abolish association of p40 with Rel proteins in vitro. Serine-to-alanine amino acid substitutions in this region modulate the association of p40 with Rel proteins in vitro and abolish p40-mediated inhibition of DNA-binding by c-Rel. Substitution of aspartic acid residues for the phosphorylated serine residues has no effect on p40-mediated inhibition of DNA-binding. In contrast, the C-terminal acidic serine-rich region is not required for p40-mediated inhibition of nuclear translocation of Rel proteins. Our results demonstrate that p40-mediated inhibition of nuclear translocation and inhibition of DNA-binding by Rel proteins are separable functions. Our results suggest that the phosphorylation status of C-terminal serine residues of I kappa B-alpha proteins will be an important aspect of the autoregulatory feedback loop that enforces temporal control of Rel-regulated gene expression.	UNIV MISSOURI, DEPT BIOCHEM, COLUMBIA, MO 65211 USA	University of Missouri System; University of Missouri Columbia					NCI NIH HHS [CA55027] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA055027] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P21; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; CRESSMAN DE, 1993, ONCOGENE, V8, P2567; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DIEHL JA, 1993, MOL CELL BIOL, V13, P1769, DOI 10.1128/MCB.13.3.1769; DIEHL JA, 1995, J BIOL CHEM, V270, P2703, DOI 10.1074/jbc.270.6.2703; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; ERNST MK, 1995, MOL CELL BIOL, V15, P872; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GILLESPIE SKH, 1994, MOL CELL BIOL, V14, P3559, DOI 10.1128/MCB.14.6.3559; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KOONG AC, 1994, CANCER RES, V54, P1425; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LINK E, 1992, J BIOL CHEM, V267, P239; MOSIALOS G, 1994, MOL CELL BIOL, V91, P12740; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; Sambrook J., 1989, MOL CLONING LAB MANU; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TZEN CY, 1994, EXP CELL RES, V211, P12, DOI 10.1006/excr.1994.1052; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	41	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	1995	11	5					811	823						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675442				2022-12-17	WOS:A1995RU79800001
J	KRIEG, J; OELGESCHLAGER, M; JANKNECHT, R; LUSCHER, B				KRIEG, J; OELGESCHLAGER, M; JANKNECHT, R; LUSCHER, B			HIGH-AFFINITY DNA-BINDING OF NATIVE FULL-LENGTH C-MYB AND DIFFERENTIAL PROTEOLYTIC SENSITIVITY OF ITS N-TERMINAL AND C-TERMINAL DOMAINS	ONCOGENE			English	Article						LEUCINE ZIPPER; PHOSPHORYLATION; PROTEIN EXPRESSION; TRANSCRIPTION; VACCINIA VIRUS	HELIX-RELATED MOTIF; V-MYB; TRANSCRIPTIONAL ACTIVATION; ONCOGENE PRODUCT; LEUCINE-ZIPPER; PROTEIN; GENE; EXPRESSION; SITES; PHOSPHORYLATION	c-Myb is the prototype of a family of transcription factors characterised by a unique DNA binding domain. Previous analyses have concentrated on truncated versions of c-Myb as it has been very difficult to produce full length c-Myb. To overcome these difficulties we expressed full length c-Myb in HeLa cells using a recombinant vaccinia virus. Partially purified native full length c-Myb bound efficiently and specifically to DNA ,vith a dissociation constant similar to that obtained with bacterially expressed DNA binding domains. No evidence was found for a negative effect of the leucine zipper on DNA binding. Furthermore the DNA binding domain was protease resistant in contrast to the transactivation and negative regulatory domains. Phosphorylation had no apparent effect on this differential protease sensitivity. The increased sensitivity of the C-terminal domain suggests a mote open conformation, which may be relevant in the integration of signals and/or in protein-protein interactions.	HANNOVER MED SCH,INST MOLEK BIOL,D-30623 HANNOVER,GERMANY	Hannover Medical School			Luscher, Bernhard/A-7330-2011	Luscher, Bernhard/0000-0002-9622-8709; Janknecht, Ralf/0000-0003-1741-1562				ANTON IA, 1988, NATURE, V236, P719; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOUSSET K, 1993, ONCOGENE, V8, P3211; DUDENDORFF JW, 1992, GENE DEV, V6, P2524; EBNETH A, 1994, FEBS LETT, V337, P265, DOI 10.1016/0014-5793(94)80205-X; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FRAMPTON J, 1991, PROTEIN ENG, V4, P891, DOI 10.1093/protein/4.8.891; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; JAMIN N, 1993, EUR J BIOCHEM, V216, P147, DOI 10.1111/j.1432-1033.1993.tb18126.x; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KANEIISHII C, 1995, J BIOL CHEM, V265, P19990; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KU DH, 1993, J BIOL CHEM, V268, P2255; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MADAN A, 1994, BIOCHEMISTRY-US, V33, P7120, DOI 10.1021/bi00189a015; MELOTTI P, 1994, J EXP MED, V179, P1023, DOI 10.1084/jem.179.3.1023; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; NOMURA T, 1993, J BIOL CHEM, V268, P21914; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; ORDING E, 1994, EUR J BIOCHEM, V222, P113, DOI 10.1111/j.1432-1033.1994.tb18848.x; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; RAMSAY RG, 1992, J BIOL CHEM, V267, P5656; RAMSAY RG, 1991, ONCOGENE, V6, P1875; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SUREAU A, 1992, P NATL ACAD SCI USA, V89, P11683, DOI 10.1073/pnas.89.24.11683; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; VORBRUEGGEN G, 1994, NUCLEIC ACIDS RES, V22, P2466, DOI 10.1093/nar/22.13.2466; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; ZOBEL A, 1991, ONCOGENE, V6, P1397	46	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2221	2228						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784067				2022-12-17	WOS:A1995RB70300018
J	KANEKO, Y; NONOGUCHI, K; FUKUYAMA, H; TAKANO, S; HIGASHITSUJI, H; NISHIYAMA, H; TAKENAWA, J; NAKAYAMA, H; FUJITA, J				KANEKO, Y; NONOGUCHI, K; FUKUYAMA, H; TAKANO, S; HIGASHITSUJI, H; NISHIYAMA, H; TAKENAWA, J; NAKAYAMA, H; FUJITA, J			PRESENCE OF ALTERNATIVE 5'-UNTRANSLATED SEQUENCES AND IDENTIFICATION OF CELLS EXPRESSING CTK TRANSCRIPTS IN THE BRAIN AND TESTIS	ONCOGENE			English	Article						CTK; PROTEIN TYROSINE KINASE; BRAIN; TESTIS; ALTERNATIVE SPLICING; MALE GERM CELLS	PROTEIN-TYROSINE KINASES; RAT-BRAIN; C-SRC; MOUSE; FAMILY; GENE; CSK; LOCALIZATION; ACTIVATION; PP60C-SRC	From a mouse brain cDNA library, two species of the Csk-type tyrosine kinase (ctk) gene containing different 5' untranslated sequences were cloned, Using the common as well as specific nucleotide sequences of the two clones as probes, we examined the expression of ctk in various mouse tissues by Northern blot analysis, The results indicated that both species of ctk were expressed in the brain, testis and bone marrow, By in sits histochemistry of the brain, ctk transcript was detected in neurons throughout the entire brain, especially those of the cortex, the hippocampus and the cerebellum. This distribution pattern is similar to that of the Src family kinases including Yes, Src, Fyn and Lyn. In the testis, the major transcript (0.7 kb) was shorter than that expressed in the brain and the bone marrow (2.0 kb), A subsequent Northern blot analysis of fractionated germ cell populations and in situ histochemistry revealed that the short and long transcripts were expressed in germ cells and somatic cells, respectively, and that the expression level was quantitatively regulated during germ cell development. These results suggest that Ctk is involved in the regulation of neural function and differentiation of male germ cells through interactions with member(s) of the Src family kinases.	KYOTO UNIV, FAC MED, DEPT CLIN MOLEC BIOL, SAKYO KU, KYOTO 606, JAPAN; KYOTO UNIV, FAC MED, DEPT NEUROSCI, SAKYO KU, KYOTO 606, JAPAN; NIIGATA UNIV, FAC SCI, DEPT BIOL, NIIGATA 95021, JAPAN	Kyoto University; Kyoto University; Niigata University								BARE DJ, 1993, ONCOGENE, V8, P1429; BENNETT BD, 1994, J BIOL CHEM, V269, P1068; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; Bishop JM, 1985, RNA TUMOR VIRUSES, P249; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CAUGHMAN SW, 1988, J BIOL CHEM, V263, P19048; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; DUGGAL RN, 1987, ANN NY ACAD SCI, V513, P112, DOI 10.1111/j.1749-6632.1987.tb25002.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; KANEKO Y, 1993, BIOCHEM BIOPH RES CO, V197, P625, DOI 10.1006/bbrc.1993.2525; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MCVICAR DW, 1994, ONCOGENE, V9, P2037; MISKIMINS K, 1990, IRON TRANSPORT STORA, P119; MIYASAKA H, 1992, BIOCHEM BIOPH RES CO, V185, P818, DOI 10.1016/0006-291X(92)91700-Z; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; ROSS CA, 1988, P NATL ACAD SCI USA, V85, P9831, DOI 10.1073/pnas.85.24.9831; ROSSI P, 1992, DEV BIOL, V152, P203, DOI 10.1016/0012-1606(92)90172-D; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SAKANO S, 1994, ONCOGENE, V9, P1155; SANCHEZ MP, 1994, P NATL ACAD SCI USA, V91, P1819, DOI 10.1073/pnas.91.5.1819; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; ZHAO YH, 1991, ONCOGENE, V6, P1725	35	15	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	1995	10	5					945	952						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898936				2022-12-17	WOS:A1995QL03800016
J	DECSI, A; PEIFFER, RL; QIU, TH; LEE, DC; FRIDAY, JT; BAUTCH, VL				DECSI, A; PEIFFER, RL; QIU, TH; LEE, DC; FRIDAY, JT; BAUTCH, VL			LENS EXPRESSION OF TGF-ALPHA IN TRANSGENIC MICE PRODUCES 2 DISTINCT EYE PATHOLOGIES IN THE ABSENCE OF TUMORS	ONCOGENE			English	Article							GROWTH-FACTOR-ALPHA; MESSENGER-RNAS; DEVELOPMENTAL EXPRESSION; GERM-LINE; GENE; DIFFERENTIATION; OVEREXPRESSION; BETA; EGF; SEQUENCES	Transgenic mice carrying the rat TGF alpha minigene linked to the alpha A crystallin promoter were generated to investigate the effects of expression of this growth factor in the lens of the eye. All transgenic mice exhibited eye abnormalities in the absence of overt tumors, and two distinct and heritable phenotypes were observed. Five lineages produced 'squinting' transgenic mice characterized by microphthalmic eyes with severe lens and retinal dysplasia, and four lineages produced 'bulged' transgenic mice with eyes that exhibited enlarged globes, lens epithelial hyperplasia, anterior segment dysgenesis, and in some cases retinal dysplasia. The eye perturbations of both phenotypes were evident histologically by 1 week of age, and the eyes of squinting mice were abnormal during embryonic development. The squinting phenotype was dominant over the bulged phenotype in intercrosses, suggesting that position effects from the transgene integration site resulted in differences in TGF alpha expression between the two phenotypes. In situ hybridization showed that TGF alpha transgene expression was confined to the lens or lens rudiment of all transgenic eyes despite the involvement of non-lenticular tissues in the pathology. These results show that inappropriate expression of TGF alpha in the eye can disrupt the communication required to coordinate normal eye development.	UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT OPHTHALMOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043174] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43174] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANCHAN RM, 1991, NEURON, V6, P923, DOI 10.1016/0896-6273(91)90233-P; BALKAN W, 1992, DEV BIOL, V151, P622, DOI 10.1016/0012-1606(92)90200-Z; BAUTCH VL, 1986, J VIROL, V60, P693, DOI 10.1128/JVI.60.2.693-701.1986; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BREITMAN ML, 1987, SCIENCE, V238, P1563, DOI 10.1126/science.3685993; CAPETANAKI Y, 1989, J CELL BIOL, V109, P1653, DOI 10.1083/jcb.109.4.1653; CHEPELINSKY AB, 1985, P NATL ACAD SCI USA, V82, P2334, DOI 10.1073/pnas.82.8.2334; COULOMBRE AJ, 1964, J EXP ZOOL, V156, P39, DOI 10.1002/jez.1401560104; DELARCO JE, 1980, J CELL PHYSIOL, V102, P267, DOI 10.1002/jcp.1041020218; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DERYNCK R, 1987, CANCER RES, V47, P707; GORING DR, 1987, SCIENCE, V235, P456, DOI 10.1126/science.3099390; Green M.C., 1981, GENETIC VARIANTS STR; GRIEP A E, 1990, New Biologist, V2, P727; GRIEP AE, 1993, J VIROL, V67, P1373, DOI 10.1128/JVI.67.3.1373-1384.1993; GRIEP AE, 1989, GENE DEV, V3, P1075, DOI 10.1101/gad.3.7.1075; HAN VKM, 1987, MOL CELL BIOL, V7, P2335, DOI 10.1128/MCB.7.7.2335; HEM E, 1992, OPHTHALMIC PAEDIATRI, V13, P137; HOGEN B, 1986, MANIPULATING MOUSE E; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; KHILLAN JS, 1987, GENE DEV, V1, P1327, DOI 10.1101/gad.1.10.1327; LEE DC, 1985, MOL CELL BIOL, V5, P3644, DOI 10.1128/MCB.5.12.3644; LILLIEN L, 1992, DEVELOPMENT, V115, P253; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MCAVOY J W, 1990, Progress in Growth Factor Research, V2, P29, DOI 10.1016/0955-2235(90)90008-8; NAKAMURA T, 1989, New Biologist, V1, P193; NISTER M, 1988, CANCER RES, V48, P3910; OVERBEEK PA, 1985, P NATL ACAD SCI USA, V82, P7815, DOI 10.1073/pnas.82.23.7815; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PEI YF, 1970, ANAT REC, V168, P105, DOI 10.1002/ar.1091680109; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; REISS M, 1991, CANCER RES, V51, P6254; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SCHULTZ GS, 1987, SCIENCE, V235, P350, DOI 10.1126/science.3492044; SCHULZ MW, 1993, DEVELOPMENT, V118, P117; SHIELDS MB, 1985, SURV OPHTHALMOL, V29, P387, DOI 10.1016/0039-6257(85)90205-X; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; VARNUM DS, 1968, J HERED, V59, P147, DOI 10.1093/oxfordjournals.jhered.a107667; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WANG R, 1991, J VIROL, V65, P5174, DOI 10.1128/JVI.65.10.5174-5183.1991; WILCOX JN, 1988, MOL CELL BIOL, V8, P3415, DOI 10.1128/MCB.8.8.3415; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; ZWANN J, 1975, DEV BIOL, V44, P306	51	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1965	1975						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208543				2022-12-17	WOS:A1994NR68500021
J	BARTHOLOMEW, C; CLARK, AM				BARTHOLOMEW, C; CLARK, AM			INDUCTION OF 2 ALTERNATIVELY SPLICED EVI-1 PROTOONCOGENE TRANSCRIPTS BY CAMP IN KIDNEY-CELLS	ONCOGENE			English	Note							MYELOID TRANSFORMING GENE; MOUSE MYELOBLASTIC LEUKEMIAS; ZINC FINGER PROTEIN; RETROVIRAL INSERTIONS; EXPRESSION; SITE; IDENTIFICATION; TRANSLOCATIONS; ACTIVATION; KILOBASES	The evi-1 proto-oncogene is normally predominantly expressed in the kidney. We report here that evi-1 transcripts are also abundant in foetal kidney and expression is retained in primary kidney cell cultures. However available kidney cell lines express low or no evi-1 mRNA. In the human renal cell carcinoma cell line, A704, evi-1 is inducible approximately 16-fold by elevating intra-cellular cAMP levels with either forskolin or dibutyryl cAMP. TPA down-regulates evi-1 mRNA production and blocks forskolin mediated induction. Similar effects are seen in NIH3T3 cells and primary kidney cell cultures. Induction of evi-1 gene expression by forskolin does not alter the ratio of full length and an alternatively spliced transcript which encodes a protein lacking two repeats of the zinc finger motif. Potential regulation of evi-1 expression in kidney by hormones which modulate intra-cellular cAMP levels suggest that h can respond to environmental cues which might be important to the normal physiological role of this protein in kidney differentiation, development and function.			BARTHOLOMEW, C (corresponding author), BEATSON INST CANC RES,CANC RES CAMPAIGN BEATSON LABS,GARSCUBE ESTATE,SWITCHBACK RD,GLASGOW G61 1BD,SCOTLAND.							BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; BERGERON D, 1992, VIROLOGY, V191, P661, DOI 10.1016/0042-6822(92)90241-G; BORDEREAUX D, 1987, J VIROL, V61, P4043, DOI 10.1128/JVI.61.12.4043-4045.1987; BORDEREAUX D, 1990, ONCOGENE, V5, P925; DRESSLER GR, 1993, NATURE, V362, P65, DOI 10.1038/362065a0; FICHELSON S, 1992, LEUKEMIA, V6, P93; HOLLAND PWH, 1988, DEVELOPMENT, V102, P159; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1990, ONCOGENE RES, V5, P221; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MORISHITA K, 1990, ONCOGENE, V5, P1419; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; NGUYEN VC, 1989, HUM GENET, V81, P257; NIBBS RJB, 1993, MOL CELL BIOL, V13, P5582, DOI 10.1128/MCB.13.9.5582; PERKINS AS, 1991, DEVELOPMENT, V111, P479; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; Saxen L., 1987, ORGANOGENESIS KIDNEY; TAUB M, 1979, P NATL ACAD SCI USA, V76, P3338, DOI 10.1073/pnas.76.7.3338; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	26	15	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					939	942						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108138				2022-12-17	WOS:A1994MW55100031
J	LI, L; WYSK, M; GONZALEZ, FA; DAVIS, RJ				LI, L; WYSK, M; GONZALEZ, FA; DAVIS, RJ			GENOMIC LOCI OF HUMAN MITOGEN-ACTIVATED PROTEIN-KINASES	ONCOGENE			English	Note							INSULIN; RAF	Mitogen-activated protein (MAP) kinases [also known as Erks] have been established to function as important mediators of signal transduction by growth factor receptors. Several components of the MAP kinase signal transduction pathway have been demonstrated to be oncogenically activated in malignant tumors. These include growth factor receptors, the GTP-binding protein Ras, and the protein kinase Raf. The genes that encode MAP kinases therefore represent potential targets of carcinogenic insults. Here, we report the genomic loci of three MAP kinase genes are widely distributed within the human genome: p41(mapk) (Erk2) at 22q11.2; p44(mapk) (Euk1) at 16p11.2; and p63(mapk) (Erk3-related) at 18q12-21.	UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,PROGRAM MOLEC MED,WORCESTER,MA 01605	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester					NATIONAL CANCER INSTITUTE [R01CA058396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037845] Funding Source: NIH RePORTER; NCI NIH HHS [CA58396] Funding Source: Medline; NIGMS NIH HHS [GM37845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GILE H, 1992, NATURE, V358, P414; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HEIM S, 1987, CANCER CYTOGENETICS; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA; SETH A, 1992, J BIOL CHEM, V267, P24796; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VERMA RS, 1989, HUMAN CHROMOSOMES; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; 1993, GENOME DATA BASE	33	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					647	649						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290275				2022-12-17	WOS:A1994MW24800033
J	CHEN, JH; WRIGHT, CD				CHEN, JH; WRIGHT, CD			PEA3, OCT-1 AND OCT-2 POSITIVELY REGULATE THE HUMAN ETS1 PROMOTER	ONCOGENE			English	Article							LONG TERMINAL REPEAT; GLUTATHIONE-S-TRANSFERASE; C-ETS; TRANSCRIPTIONAL ACTIVATION; EXPRESSION SYSTEM; ESCHERICHIA-COLI; DNA-BINDING; GENE; ONCOGENE; C-ETS-1	The promoter of the human ETS1 gene contains binding site motifs for transcription factors Sp1, Ap1, Ap2, ETS, PEA3 and Oct. It has been shown previously that Ap1, Ap2, and ETS are positive regulators for the transcription of the ETS1 gene and that the ETS1 gene is autoregulated. In addition, two regions on the ETS1 promoter that contain negative regulatory sequences have also been identified. In this study, GST/PEA3 and GST/ets1 fusion proteins were used in gel mobility assays to analyse the interaction between these transcription factors with the binding motifs of PEA3 and ETS in the ETS1 promoter. Promoter constructs in which the binding site motifs are mutated were used to examine the effect of mutation on the activities of transcription factors PEA3, ets1 and Oct. Reporter plasmids containing different deletion mutants of the ETS1 promoter were used to examine the effect of different transcription factors (PEA3, Oct 1 and Oct 2) upon the expression of the ETS1 gene. The results of these studies indicate that PEA3 is a strong positive regulator of the ETS1 promoter and that other transcription factors increase the activity of the ETS1 promoter in an additive rather than synergistic fashion.			CHEN, JH (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT EXPTL PEDIAT,HOUSTON,TX 77030, USA.							BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; CHEN JH, 1993, ONCOGENE, V8, P133; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CHEN JH, 1990, ONCOGENE RES, V5, P277; FISHER RJ, 1991, ONCOGENE, V6, P2249; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; JORCYK CL, 1991, ONCOGENE, V6, P523; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OKA T, 1991, ONCOGENE, V6, P2077; PROGNONEC B, 1988, EMBO J, V7, P979; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; Sambrook J., 1989, MOL CLONING LAB MANU; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WASYLYK C, 1992, GENE DEV, V6, P9665; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WOOD WM, 1989, J BIOL CHEM, V264, P14840; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	30	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3375	3383						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247540				2022-12-17	WOS:A1993MG78200022
J	BOCCO, JL; REIMUND, B; CHATTON, B; KEDINGER, C				BOCCO, JL; REIMUND, B; CHATTON, B; KEDINGER, C			RB MAY ACT AS A TRANSCRIPTIONAL COACTIVATOR IN UNDIFFERENTIATED F9 CELLS	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; EIIA EARLY PROMOTER; HUMAN MYC PROMOTER; SV40 LARGE-T; SUSCEPTIBILITY GENE; FACTOR E2F; DNA-BINDING; TRANS-ACTIVATION; ADENOVIRUS-E1A PREVENTS; MOLECULAR-CLONING	The reversible interaction of the retinoblastoma susceptibility gene product (Rb) with the cellular transcription factor E2F has recently been demonstrated. Activation of the adenovirus E2a promoter by the products of the viral E1a gene correlates with the ability of both early E1a proteins to sequester Rb, thereby releasing E2F from inactive complexes with this protein. The E2a promoter is also efficiently stimulated by a product (17.5 kDa) of the viral E4 gene. The specific interaction of this E4 protein with E2F results in the formation of complexes that bind cooperatively to the two neighboring E2F binding sites in the E2a promoter. We have previously shown that in undifferentiated F9 cells (F9EC) the E2a promoter is refractory to E2F-mediated activation by E1a, but not by E4. Using both band-shift and transfection experiments, we now demonstrate (i) that in F9EC cells the E4 product, in combination with E2F, recruits Rb into a stable multiprotein complex and (ii) that in these undifferentiated cells, as opposed to their differentiated counterpart, Rb is actively involved in the transcriptional stimulation of the E2a promoter by E4. Our results suggest that, depending on the cell state, Rb may behave either as a transcriptional activator (F9EC cells) or as a transcriptional inhibitor (differentiated F9 cells).	INST CHIM BIOL,GENET MOLEC EUCARYOTES LAB,CNRS,INSERM,U184,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			CHATTON, Bruno/R-3813-2019	Bocco, Jose Luis/0000-0002-9682-1270; CHATTON, Bruno/0000-0003-4515-7119				ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOEUF H, 1990, ONCOGENE, V5, P691; BOEUF H, 1990, P NATL ACAD SCI USA, V87, P1782, DOI 10.1073/pnas.87.5.1782; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GODING C, 1985, EMBO J, V4, P1523, DOI 10.1002/j.1460-2075.1985.tb03812.x; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HARDY S, 1989, GENE DEV, V3, P1062, DOI 10.1101/gad.3.7.1062; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; HUANG S, 1992, DNA CELL BIOL, V11, P539, DOI 10.1089/dna.1992.11.539; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P875, DOI 10.1128/MCB.4.5.875; JACKS T, 1992, NATURE, V359, P395; JALINOT P, 1987, MOL CELL BIOL, V7, P3806, DOI 10.1128/MCB.7.10.3806; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEFF T, 1984, P NATL ACAD SCI-BIOL, V81, P4381, DOI 10.1073/pnas.81.14.4381; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; MORAN E, 1991, Current Biology, V1, P281, DOI 10.1016/0960-9822(91)90084-A; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; NEILL SD, 1991, J VIROL, V65, P5364, DOI 10.1128/JVI.65.10.5364-5373.1991; NEVINS JR, 1991, TRENDS BIOCHEM SCI, V16, P435, DOI 10.1016/0968-0004(91)90171-Q; NEVINS JR, 1992, SCIENCE, V258, P424; OCONNOR RJ, 1991, NUCLEIC ACIDS RES, V19, P6579, DOI 10.1093/nar/19.23.6579; PARTRIDGE JF, 1991, EMBO J, V10, P3819, DOI 10.1002/j.1460-2075.1991.tb04951.x; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SCHONTHAL A, 1993, ONCOGENE, V8, P433; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHEW JY, 1990, CELL GROWTH DIFFER, V1, P17; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZAJCHOWSKI DA, 1987, GENE, V58, P243, DOI 10.1016/0378-1119(87)90379-9; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	83	15	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2977	2986						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414500				2022-12-17	WOS:A1993MC09300011
J	FRIEDRICH, TD; LAFFIN, J; LEHMAN, JM				FRIEDRICH, TD; LAFFIN, J; LEHMAN, JM			HYPOPHOSPHORYLATED RETINOBLASTOMA GENE-PRODUCT ACCUMULATES IN SV40-INFECTED CV-1 CELLS ACQUIRING A TETRAPLOID DNA CONTENT	ONCOGENE			English	Note							CHINESE-HAMSTER CELLS; SV40 LARGE-T; SUSCEPTIBILITY GENE; SIMIAN VIRUS-40; TRANSCRIPTION FACTOR; CYCLE PROGRESSION; TUMOR SUPPRESSOR; CARCINOMA-CELLS; RB PROTEIN; G1 PHASE	Simian virus 40 (SV40) infection of monkey kidney cells induces successive rounds of cellular DNA synthesis without intervening mitosis. To gain an understanding of the mechanisms responsible for disruption of cell cycle control during lytic infection, pRB phosphorylation and cell cycle distribution were examined following SV40 infection of CV-1 cells. The hypophosphorylated pRB present in confluent CV-1 cells was phosphorylated within 14 h following SV40 infection. Phosphorylated pRB then remained the predominant form as cells progressed from late G1 through S phase. Hypophosphorylated pRB reappeared as cells moved through G2 and acquired a tetraploid (>G2) DNA content. The reappearance of hypophosphorylated pRB in a population with decreasing numbers of cells in G1 phase and increasing numbers of cells in >G2 suggests that accumulation of hypophosphorylated pRB may be involved in T antigen-induced tetraploidy.	ALBANY MED COLL, DEPT MICROBIOL IMMUNOL & MOLEC GENET, A-68, 47 NEW SCOTLAND AVE, ALBANY, NY 12208 USA	Albany Medical College			Lehman, John M./AAU-4849-2020	Lehman, John/0000-0002-4478-4885	NCI NIH HHS [CA 41608] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041608, R55CA041608] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BARTEK J, 1992, ONCOGENE, V7, P101; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; EVANS GA, 1992, BIOCHEM J, V282, P759, DOI 10.1042/bj2820759; FRIEDRICH TD, 1992, J VIROL, V66, P4576, DOI 10.1128/JVI.66.7.4576-4579.1992; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HOFFMAN BD, 1991, CYTOMETRY, V12, P26, DOI 10.1002/cyto.990120105; HORAN PK, 1974, INT J CANCER, V14, P514, DOI 10.1002/ijc.2910140411; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KHANDJIAN EW, 1992, ONCOGENE, V7, P909; KITAGAWA M, 1992, ONCOGENE, V7, P1067; Laffin J, 1990, Methods Cell Biol, V33, P271; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEHMAN JM, 1974, INT J CANCER, V14, P771, DOI 10.1002/ijc.2910140611; LEHMAN JM, 1988, CYTOMETRY, V9, P52, DOI 10.1002/cyto.990090109; LEHMAN JM, 1970, J VIROL, V6, P738, DOI 10.1128/JVI.6.6.738-749.1970; LEHMAN JM, 1992, IN VITRO CELL DEV-AN, V28A, P306; LEHMAN JM, 1974, INT J CANCER, V13, P164, DOI 10.1002/ijc.2910130203; LEHMAN JM, 1990, FLOW CYTOMETRY SORTI, P623; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUCAS JJ, 1992, J IMMUNOL, V148, P1804; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; PARSONS N, 1991, THESIS ALBANY MED CO; SHACKNEY SE, 1989, CANCER RES, V49, P3344; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TERADA N, 1991, J IMMUNOL, V147, P698; THOMAS NSB, 1991, ONCOGENE, V6, P317; TRIFILLIS P, 1990, J VIROL, V64, P1345, DOI 10.1128/JVI.64.3.1345-1347.1990; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WATSON PA, 1991, CYTOMETRY, V12, P242, DOI 10.1002/cyto.990120306; WILLIAMS RT, 1992, ONCOGENE, V7, P423; ZHANG HZ, 1992, BIOCHEM BIOPH RES CO, V189, P21, DOI 10.1016/0006-291X(92)91519-V	50	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1993	8	6					1673	1677						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8389034				2022-12-17	WOS:A1993LE06400032
J	SNIJDERS, AJ; HAASE, VH; BERNARDS, A				SNIJDERS, AJ; HAASE, VH; BERNARDS, A			4 TISSUE-SPECIFIC MOUSE LTK MESSENGER-RNAS PREDICT TYROSINE KINASES THAT DIFFER UPSTREAM OF THEIR TRANSMEMBRANE SEGMENT	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM; PROTEIN; RETENTION; GENE; GLYCOPROTEIN; SIGNAL; ER; IDENTIFICATION; EXPRESSION; TRANSPORT	Two alternatively spliced mouse lymphocyte and brain ltk cDNAs predict small transmembrane tyrosine kinases that use CUG translational start codons and that differ upstream of their transmembrane segment. A recently isolated human neuroblastoma ltk cDNA, in contrast, includes a regular AUG start codon and predicts a more conventional receptor kinase with a larger N-terminal segment. This raised the suggestion that previous mouse cDNAs may have been aberrantly spliced or incomplete and questioned the significance of a recent study that localized the lymphoid ltk protein to the endoplasmic reticulum. Here we show that mice tissue-specifically express four ltk mRNAs. In addition to the two previously described lymphoid and brain mRNAs, we now describe two mRNAs from C1300 neuroblastoma cells that start with five exons which are absent from lymphoid or brain transcripts. The pair of C1300 mRNAs differ by the same alternatively spliced exon that distinguishes brain from lymphoid mRNAs and predict much larger receptor-type kinases that use regular AUG start codons. Our results also show that at least one of the larger, more conventional C1300 ltk receptors shares the endoplasmic reticulum localization of the shorter lymphoid protein.	MASSACHUSETTS GEN HOSP,CTR CANC,MOLEC GENET LAB,BLDG 149,13TH ST,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Haase, Volker Hans/AAJ-5061-2021; Haase, Volker Hans/A-6758-2013	Haase, Volker Hans/0000-0002-7051-8994				BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GABATHULER R, 1990, J CELL BIOL, V111, P1803, DOI 10.1083/jcb.111.5.1803; GREEN SA, 1992, J CELL BIOL, V117, P47, DOI 10.1083/jcb.117.1.47; HAASE VH, 1991, ONCOGENE, V6, P2319; HURTLEY SM, 1989, ANN REV CELL BIOL, V5, P227; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KROLEWSKI JJ, 1991, EMBO J, V10, P2911, DOI 10.1002/j.1460-2075.1991.tb07841.x; KROLEWSKI JJ, 1990, ONCOGENE, V5, P277; KUROKI K, 1989, MOL CELL BIOL, V9, P4459, DOI 10.1128/MCB.9.10.4459; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MARU Y, 1990, ONCOGENE RES, V5, P199; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; PAABO S, 1987, CELL, V50, P311, DOI 10.1016/0092-8674(87)90226-1; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; ROTHMAN JE, 1987, CELL, V50, P521, DOI 10.1016/0092-8674(87)90024-9; STIRZAKER SC, 1989, CELL, V56, P741, DOI 10.1016/0092-8674(89)90677-6; TORENTINO AL, 1974, J BIOL CHEM, V249, P811; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	29	15	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					27	35						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380920				2022-12-17	WOS:A1993KN00500004
J	BONHAM, L; MACKENZIE, K; WOOD, S; ROWE, PB; SYMONDS, G				BONHAM, L; MACKENZIE, K; WOOD, S; ROWE, PB; SYMONDS, G			BOTH MYELOPROLIFERATIVE DISEASE AND LEUKEMIA ARE INDUCED BY TRANSPLANTATION OF BONE-MARROW CELLS EXPRESSING V-MYC	ONCOGENE			English	Article							HEMATOPOIETIC STEM-CELLS; RECOMBINANT MURINE RETROVIRUS; CHRONIC MYELOGENOUS LEUKEMIA; C-MYC; TRANSGENIC MICE; ADENOSINE-DEAMINASE; MEDIATED TRANSFER; GENE-TRANSFER; VIRUS; TRANSFORMATION	An in vivo system has been established to investigate v-myc-induced hematopoietic neoplasia in mice. A Moloney murine leukemia virus (Mo-MLV)-derived recombinant retrovirus containing v-myc was used to infect immature bone marrow cells, and these celts were then transplanted into lethally irradiated recipients. All provirus-positive reconstituted mice were found to develop hematopoietic proliferative disorders and, in certain cases, overt leukemia-myeloblastic, myelomonocytic and T lymphocytic. In all cases expression of v-myc was high and the disease type did not correlate with the level of expression. We have isolated immortalized monocytes, myeloid progenitors and T lymphocytes from several of these mice and shown tumorigenicity in secondary syngeneic recipients. This system provides a model for investigating the progression from a pre-leukemic disease to malignancy. In addition, we describe a recombinant v-myc-containing retrovirus that directs high-level v-myc expression from the Mo-MLV promoter in all the hematopoietic cell types examined.	CHILDRENS MED RES FDN, 214 HAWKESBURY RD, SYDNEY, NSW 2145, AUSTRALIA	Children's Medical Research Institute - Australia			Wood, Stephen A/E-8357-2011; Mackenzie, Karen/F-1310-2011; MacKenzie, Karen/N-5849-2019	Wood, Stephen A/0000-0002-2576-7457; MacKenzie, Karen/0000-0003-2996-1617				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BECKENGESER G, 1991, HUM GENE THER, V2, P61, DOI 10.1089/hum.1991.2.1-61; BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BIRCHENALLROBERTS MC, 1989, ONCOGENE, V4, P731; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BISHOP JM, 1985, MOL BIOL TUMOR VIRUS, P249; BOWTELL DDL, 1988, J VIROL, V62, P2464, DOI 10.1128/JVI.62.7.2464-2473.1988; BOWTELL DDL, 1987, MOL BIOL MED, V4, P229; BRIGHTMAN BK, 1988, J IMMUNOL, V141, P2844; BRIGHTMAN BK, 1986, J VIROL, V60, P68, DOI 10.1128/JVI.60.1.68-81.1986; BURGESS A, 1983, GROWTH FACTORS STEM, P68; CHANG JM, 1989, BLOOD, V73, P1487; CHATIS PA, 1983, P NATL ACAD SCI-BIOL, V80, P4408, DOI 10.1073/pnas.80.14.4408; CHISHOLM O, 1992, IN PRESS ONCOGENE; CHUNG SW, 1991, P NATL ACAD SCI USA, V88, P1585, DOI 10.1073/pnas.88.4.1585; COFFMAN RL, 1983, IMMUNOL REV, V69, P5, DOI 10.1111/j.1600-065X.1983.tb00446.x; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DARLIX JL, 1986, J MOL BIOL, V189, P421, DOI 10.1016/0022-2836(86)90314-1; DUNBAR CE, 1991, ONCOGENE RES, V6, P39; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; EMERMAN M, 1984, J VIROL, V50, P42, DOI 10.1128/JVI.50.1.42-49.1984; EMERMAN M, 1986, MOL CELL BIOL, V6, P792, DOI 10.1128/MCB.6.3.792; ERBA HP, 1988, MOL CELL BIOL, V8, P1775, DOI 10.1128/MCB.8.4.1775; GAUSTCH JW, 1976, VIROLOGY, V72, P509; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GREEN SM, 1989, ONCOGENE, V4, P737; GREENBERG PL, 1983, BLOOD, V61, P1035; GREZ M, 1990, P NATL ACAD SCI USA, V87, P9202, DOI 10.1073/pnas.87.23.9202; GREZ M, 1991, J VIROL, V65, P4691, DOI 10.1128/JVI.65.9.4691-4698.1991; GRIESSER H, 1989, BLOOD, V73, P1402; HAYFLICK J, 1985, P NATL ACAD SCI USA, V82, P2718, DOI 10.1073/pnas.82.9.2718; HEARD JM, 1987, CELL, V51, P663, DOI 10.1016/0092-8674(87)90135-8; HIDDEMANN W, 1984, CYTOMETRY, V5, P445, DOI 10.1002/cyto.990050502; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KELLER G, 1989, GENE DEV, V3, P827, DOI 10.1101/gad.3.6.827; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Maniatis T, 1989, MOL CLONING; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MCIVOR RS, 1990, VIROLOGY, V176, P652, DOI 10.1016/0042-6822(90)90039-T; MCIVOR RS, 1987, MOL CELL BIOL, V7, P838, DOI 10.1128/MCB.7.2.838; MORELLO D, 1989, ONCOGENE RES, V4, P111; PULSINELLI GA, 1991, J VIROL, V65, P4786, DOI 10.1128/JVI.65.9.4786-4797.1991; RALPH P, 1975, J IMMUNOL, V114, P898; SACHS L, 1987, SCIENCE, V238, P1374, DOI 10.1126/science.3317831; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SCOTT ML, 1991, P NATL ACAD SCI USA, V88, P6506, DOI 10.1073/pnas.88.15.6506; STAPLETON P, 1991, ONCOGENE, V6, P807; SYMONDS G, 1982, EMBO J, V1, P1343, DOI 10.1002/j.1460-2075.1982.tb01320.x; SYMONDS G, 1989, ONCOGENE, V4, P285; THIESEN HJ, 1988, J VIROL, V62, P614, DOI 10.1128/JVI.62.2.614-618.1988; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; WAGNER EF, 1990, EMBO J, V9, P3025, DOI 10.1002/j.1460-2075.1990.tb07498.x; WEINBERG RA, 1989, CANCER RES, V49, P3713; WILLIAMS DA, 1986, P NATL ACAD SCI USA, V83, P2566, DOI 10.1073/pnas.83.8.2566; WILLIAMS WJ, 1983, HEMATOLOGY; WOLFF L, 1990, J VIROL, V64, P155, DOI 10.1128/JVI.64.1.155-160.1990; WONG PMC, 1989, MOL CELL BIOL, V9, P798, DOI 10.1128/MCB.9.2.798; XU L, 1989, VIROLOGY, V171, P331, DOI 10.1016/0042-6822(89)90600-4	69	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1992	7	11					2219	2229						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437146				2022-12-17	WOS:A1992JW66500014
J	VANDERHOORN, FA				VANDERHOORN, FA			IDENTIFICATION OF THE TESTIS C-MOS PROMOTER - SPECIFIC ACTIVITY IN A SEMINIFEROUS TUBULE-DERIVED EXTRACT AND BINDING OF A TESTIS-SPECIFIC NUCLEAR FACTOR	ONCOGENE			English	Article							PROTO-ONCOGENE; INVITRO TRANSCRIPTION; MOUSE PROTAMINE-1; TRANSGENIC MICE; GERM-CELLS; EXPRESSION; GENE; PRODUCT; RNA; ENHANCER	The c-mos proto-oncogene is predominantly expressed in male and female germ cells and is involved in the regulation of meiosis. To investigate the mechanism of testis-specific regulation of c-mos transcription, I set out to identify the rat testis c-mos promoter. This was achieved by characterization of the rat testis c-mos transcription start site by primer extension and sequence analysis of cDNAs obtained by polymerase chain reaction amplification of 5' ends of c-mos RNA. The rat testis c-mos transcription start site is located 0.56 kb upstream of the coding region. A fragment containing the rat testis c-mos promoter directs transcription in a nuclear extract derived from rat seminiferous tubules, but not in a liver nuclear extract. DNAase I footprint analysis and gel-retardation assays showed binding of a novel testis-specific nuclear factor to the rat testis c-mos promoter at a site homologous to the testis-specific cis-acting element identified in the promoter of the RT7 gene, which is specifically expressed in haploid male germ cells.			VANDERHOORN, FA (corresponding author), UNIV CALGARY, DEPT MED BIOCHEM, 3330 HOSP DR NW, CALGARY T2N 4N1, ALBERTA, CANADA.							BUNICK D, 1990, P NATL ACAD SCI USA, V87, P891, DOI 10.1073/pnas.87.3.891; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HERZOG NK, 1988, ONCOGENE, V3, P225; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; JOHNSON PA, 1988, BIOCHIM BIOPHYS ACTA, V950, P45, DOI 10.1016/0167-4781(88)90071-1; LANGFORD KG, 1991, J BIOL CHEM, V266, P15559; LEIBOVITCH SA, 1990, ONCOGENE, V5, P1149; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; OLIVA R, 1991, PROG NUCLEIC ACID RE, V40, P25; PAL SK, 1991, MOL CELL BIOL, V11, P5190, DOI 10.1128/MCB.11.10.5190; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PESCHON JJ, 1989, ANN NY ACAD SCI, V564, P186, DOI 10.1111/j.1749-6632.1989.tb25897.x; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; ROBINSON MO, 1989, P NATL ACAD SCI USA, V86, P8437, DOI 10.1073/pnas.86.21.8437; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SAMBROOK J, 1988, MOL CLONING LABORATO; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; STEWART TA, 1988, MOL CELL BIOL, V8, P1748, DOI 10.1128/MCB.8.4.1748; VANDERHOORN FA, 1987, J MOL BIOL, V193, P255, DOI 10.1016/0022-2836(87)90217-8; VANDERHOORN FA, 1992, P NATL ACAD SCI USA, V89, P703, DOI 10.1073/pnas.89.2.703; VANDERHOORN FA, 1991, ONCOGENE, V6, P929; VANDERHOORN FA, 1990, DEV BIOL, V142, P147, DOI 10.1016/0012-1606(90)90158-F; VANDERHOORN FA, 1989, BIOCHEM BIOPH RES CO, V161, P8, DOI 10.1016/0006-291X(89)91552-0; WOOD TG, 1984, P NATL ACAD SCI-BIOL, V81, P7817, DOI 10.1073/pnas.81.24.7817	29	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1992	7	6					1093	1099						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1375715				2022-12-17	WOS:A1992HU64200006
J	KHANDJIAN, EW; TREMBLAY, S				KHANDJIAN, EW; TREMBLAY, S			PHOSPHORYLATION OF THE RETINOBLASTOMA PROTEIN IS MODULATED IN MOUSE KIDNEY-CELLS INFECTED WITH POLYOMAVIRUS	ONCOGENE			English	Article							LARGE T-ANTIGEN; SUSCEPTIBILITY GENE-PRODUCT; LARGE TUMOR-ANTIGEN; RESOLUTION 2-DIMENSIONAL ELECTROPHORESIS; DNA-BINDING PROTEIN; SIMIAN-VIRUS 40; CELLULAR RNA; RB GENE; NUCLEAR MATRIX; EXPRESSION	Lytic infection with polyomavirus, an oncogenic DNA-containing virus, leads in G0-arrested primary baby mouse kidney (BMK) cell cultures to a mitotic host reaction. In the present work, we examined the expression of the retinoblastoma gene (RB) and of its product (Rb) in virus-infected BMK with the aim of correlating its modulation with the sequential activation of cellular processes leading to the induction of S phase by virus. In contrast to cell cycle-regulated genes whose expression is induced by viral infection, expression of RB is not altered during the transition from G0/G1 to S phase. In BMK cell cultures irreversibly arrested in the G0 phase of the cell cycle, an unphosphorylated species is the only detectable form of the RB protein (Rb). Time course analysis showed that in polyoma-infected cells induced to re-enter the S phase of the cell cycle the appearance of the phosphorylated forms of Rb coincided in time with the accumulation of large T antigen and preceded DNA synthesis. During the late phase of infection, the majority of Rb was present as phosphorylated forms. Ongoing DNA synthesis was not required for the cells to phosphorylate Rb, indicating that this post-translational modification takes place during the activation of the cellular DNA-synthesizing apparatus. Using hamster anti-polyoma tumor serum, it was observed that the underphosphorylated form of Rb co-precipitated with polyoma large T antigen extracted from infected cells late during infection. Our data add more evidence to the proposal that interactions between viral early proteins encoded by DNA tumor viruses and the product of RB may play a pivotal role in the mitogenic effect induced by viral infection.	HOP ST FRANCOIS ASSISE,UNITE RECH GENET HUMAINE & MOLEC,QUEBEC CITY G1L 3L5,QUEBEC,CANADA	Laval University	KHANDJIAN, EW (corresponding author), UNIV LAVAL,FAC MED,DEPT BIOCHIM,QUEBEC CITY G1K 7P4,QUEBEC,CANADA.							BASERGA R, 1985, BIOL CELL REPRODUCTI; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CARROLL RB, 1988, ONCOGENE, V2, P437; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CLEGHON VG, 1986, P NATL ACAD SCI USA, V83, P8947, DOI 10.1073/pnas.83.23.8947; CRAWFORD LV, 1979, J VIROL, V29, P587, DOI 10.1128/JVI.29.2.587-596.1979; DARLIX JL, 1984, P NATL ACAD SCI-BIOL, V81, P5425, DOI 10.1073/pnas.81.17.5425; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFROMENTEL CC, 1986, EXP CELL RES, V164, P35, DOI 10.1016/0014-4827(86)90452-0; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DUTHU A, 1985, VIROLOGY, V147, P275, DOI 10.1016/0042-6822(85)90130-8; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1350; Fakan S, 1980, Int Rev Cytol, V65, P255; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GALLINARO H, 1983, EMBO J, V2, P953, DOI 10.1002/j.1460-2075.1983.tb01527.x; GRENSPAN DS, 1979, VIROLOGY, V99, P413; HANCOCK R, 1982, INT REV CYTOL, V79, P165; HASSOUNA N, 1984, NUCLEIC ACIDS RES, V12, P3563, DOI 10.1093/nar/12.8.3563; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HRABARENEVEY S, 1989, ONCOGENE, V4, P601; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUMPHREY GW, 1987, EXP CELL RES, V171, P122, DOI 10.1016/0014-4827(87)90256-4; KESSLER SW, 1975, J IMMUNOL, V115, P1617; KHANDJIAN EW, 1982, P NATL ACAD SCI-BIOL, V79, P1139, DOI 10.1073/pnas.79.4.1139; KHANDJIAN EW, 1983, MOL CELL BIOL, V3, P1; KHANDJIAN EW, 1980, P NATL ACAD SCI-BIOL, V77, P1476, DOI 10.1073/pnas.77.3.1476; KHANDJIAN EW, 1986, MOL BIOL REP, V11, P107, DOI 10.1007/BF00364822; KHANDJIAN EW, 1988, ONCOGENE, V3, P195; KLEIN H, 1979, J BIOL CHEM, V254, P1051; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LIU HT, 1985, MOL CELL BIOL, V5, P2936, DOI 10.1128/MCB.5.11.2936; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MARRIOTT SJ, 1985, J VIROL, V56, P365, DOI 10.1128/JVI.56.2.365-372.1985; MATTER JM, 1983, NUCLEIC ACIDS RES, V11, P6611, DOI 10.1093/nar/11.19.6611; MATTER JM, 1983, NUCLEIC ACIDS RES, V11, P1039, DOI 10.1093/nar/11.4.1039; MATTER JM, 1982, NUCLEIC ACIDS RES, V10, P7643, DOI 10.1093/nar/10.23.7643; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; NIELSCH U, 1991, ONCOGENE, V6, P1031; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PALME K, 1980, FEBS LETT, V118, P229, DOI 10.1016/0014-5793(80)80225-0; PALME K, 1983, ELECTROPHORESIS, P403; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; POCHRON S, 1980, J BIOL CHEM, V255, P4411; PUVION E, 1988, EXP CELL RES, V177, P73, DOI 10.1016/0014-4827(88)90026-2; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROSE TM, 1992, BIOCHEM CELL BIOL, V70, P149, DOI 10.1139/o92-022; ROSSINI M, 1979, P NATL ACAD SCI USA, V76, P4441, DOI 10.1073/pnas.76.9.4441; SALOMON C, 1977, NUCLEIC ACIDS RES, V4, P1483, DOI 10.1093/nar/4.5.1483; SALZMAN NP, 1986, PAPOVAVIRUSES, V1; SAMAD A, 1991, MOL CELL BIOL, V11, P1598, DOI 10.1128/MCB.11.3.1598; SCHWYZER M, 1980, J BIOL CHEM, V255, P5627; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; THOMAS NSB, 1991, ONCOGENE, V6, P317; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; Tooze J., 1980, MOL BIOL TUMOR VIR 2; TURLER H, 1980, MOL CELL BIOCHEM, V32, P63; WAHRMANN JP, 1980, BIOCHIM BIOPHYS ACTA, V612, P421, DOI 10.1016/0005-2744(80)90125-4; WEIL R, 1978, BIOCHIM BIOPHYS ACTA, V516, P301, DOI 10.1016/0304-419X(78)90012-4; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1989, ONCOGENE, V4, P807; XU HJ, 1991, ONCOGENE, V6, P1139; YOKOTA J, 1988, ONCOGENE, V3, P471	73	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					909	917						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373878				2022-12-17	WOS:A1992HP64200010
J	LAZARUS, P				LAZARUS, P			THE REGULATION OF TRANSLATION BY THE 5' UNTRANSLATED REGION OF XENOPUS C-MYC-I MESSENGER-RNA DURING EARLY DEVELOPMENT	ONCOGENE			English	Note							NONCODING REGION; EMBRYONIC-DEVELOPMENT; CELL-DIFFERENTIATION; SECONDARY STRUCTURE; MAMMALIAN-CELLS; DNA-REPLICATION; PROTO-ONCOGENE; EXPRESSION; LAEVIS; TRANSITION	The translational efficiency of chloramphenicol acetyltransferase (CAT) mRNA containing 5' untranslated region (UTR) sequences of Xenopus c-myc I mRNA was examined in the Xenopus oocyte and early embryo. In contrast to their reduced translation in the oocyte, CAT mRNAs containing 5' UTR sequences located between the c-myc I P0 and P2 promoters translate as efficiently as CAT mRNA controls when injected into early embryos. This pattern of differential regulation of c-myc I translation is similar to that observed for mouse c-myc 5' UTR-containing CAT transcripts during Xenopus oogenesis and early embryogenesis [Lazarus, P., Parkin, N. & Sonenberg, N. (1988). Oncogene, 3, 517-521]. Ooctye-specific translational inhibition was not observed for CAT mRNAs containing c-myc I 5' UTR sequences located 3' of the P2 promoter. No significant alteration in c-myc I 5' UTR/CAT mRNA stability was observed in the oocyte as compared with CAT mRNA controls. The significance of this promoter-dependent translational regulation with respect to c-myc expression and early Xenopus development is discussed.			LAZARUS, P (corresponding author), MCGILL UNIV,DEPT BIOCHEM,MCINTYRE MED BLDG,3655 DRUMMOND ST,MONTREAL H3G 1Y6,QUEBEC,CANADA.							BAIM SB, 1985, MOL CELL BIOL, V5, P1839, DOI 10.1128/MCB.5.8.1839; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; FU LN, 1991, SCIENCE, V251, P807, DOI 10.1126/science.1990443; GODEAU F, 1986, EMBO J, V5, P3571, DOI 10.1002/j.1460-2075.1986.tb04684.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HOURDRY J, 1988, DEVELOPMENT, V104, P631; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135, DOI 10.1002/j.1460-2075.1988.tb03180.x; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; LAZARUS P, 1988, ONCOGENE, V3, P517; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; PRINCIPAUD F, 1991, NUCLEIC ACIDS RES, V19, P3081; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; SCHWEINFEST CW, 1988, MOL CELL BIOL, V8, P3080, DOI 10.1128/MCB.8.8.3080; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; VRIZ S, 1989, EMBO J, V8, P4091, DOI 10.1002/j.1460-2075.1989.tb08593.x; WAGNER RW, 1988, MOL CELL BIOL, V8, P770, DOI 10.1128/MCB.8.2.770	27	15	16	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					1037	1041						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1570150				2022-12-17	WOS:A1992HP64200028
J	VOLINIA, S; PATRACCHINI, P; OTSU, M; HILES, I; GOUT, I; CALZOLARI, E; BERNARDI, F; ROOKE, L; WATERFIELD, MD				VOLINIA, S; PATRACCHINI, P; OTSU, M; HILES, I; GOUT, I; CALZOLARI, E; BERNARDI, F; ROOKE, L; WATERFIELD, MD			CHROMOSOMAL LOCALIZATION OF HUMAN P85-ALPHA, A SUBUNIT OF PHOSPHATIDYLINOSITOL 3-KINASE, AND ITS HOMOLOG P85-BETA	ONCOGENE			English	Note							SOMATIC-CELL HYBRIDS; HUMAN-MOUSE HYBRIDS; MONOCLONAL-ANTIBODY; GENE; TRANSLOCATION; EXPRESSION; ANTIGEN; SUBLOCALIZATION; HYBRIDIZATION; KINASE	The human phosphatidylinositol (PI) 3-kinase p85-alpha subunit gene and its homologue p85-beta were assigned to human chromosomes by analysis of their segregation in a panel of somatic cell hybrids using human-specific polymerase chain reaction primers. The p85-alpha locus was only present in hybrids retaining the human chromosome 5q. The presence of the p85-beta locus coincided with the presence of chromosome 19. The precise chromosomal sublocalization of these two genes was then determined by in situ hybridization. We confirmed the localization of the p85-alpha gene at 5q12-q13, as recently described (Cannizzaro, L.A., Skolnik, E.Y., Margolis, B., Croce, C.M., Schlesinger, J. & Huebner, K. (1991). Cancer Res., 51, 3818-3820) and positioned the p85-beta locus at 19q13.2-q13.4.	LUDWIG INST CANC RES,91 RIDING HOUSE ST,LONDON W1P 8BT,ENGLAND; UNIV FERRARA,IST GENET MED,I-44100 FERRARA,ITALY; UNIV FERRARA,IST CHIM BIOL,I-44100 FERRARA,ITALY; IMPERIAL CANC RES FUND,S MIMMS EN6 3LD,ENGLAND	Ludwig Institute for Cancer Research; University of Ferrara; University of Ferrara			Volinia, Stefano/A-3029-2010; Volinia, Stefano/AAA-9264-2019; bernardi, francesco/F-5443-2013	Volinia, Stefano/0000-0003-0910-3893; Volinia, Stefano/0000-0003-0910-3893; 				BAI Y, 1982, ANN HUM GENET, V46, P337, DOI 10.1111/j.1469-1809.1982.tb01584.x; BISHOP DP, 1990, CYTOGENET CELL GENET, V55, P218; CALZOLARI E, 1987, HUM GENET, V77, P51; CANNIZZARO LA, 1991, CANCER RES, V51, P3818; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARRITT B, 1980, TISSUE CULTURE MED R, V2, P169; CHANDLER ME, 1978, CYTOGENET CELL GENET, V22, P352, DOI 10.1159/000130970; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; CROCE CM, 1974, J EXP MED, V140, P1221, DOI 10.1084/jem.140.5.1221; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; EDWARDS YH, 1985, ANN HUM GENET, V49, P101, DOI 10.1111/j.1469-1809.1985.tb01681.x; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FISHER JH, 1987, AM J HUM GENET, V40, P503; GOODFELLOW P, 1980, SOMAT CELL GENET, V6, P777, DOI 10.1007/BF01538976; GOODFELLOW PN, 1982, P NATL ACAD SCI-BIOL, V79, P1190, DOI 10.1073/pnas.79.4.1190; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HEISTERKAMP N, 1982, NATURE, V299, P747, DOI 10.1038/299747a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; IKEMURA T, 1991, NUCLEIC ACIDS RES, V19, P4333, DOI 10.1093/nar/19.16.4333; JONES EA, 1976, SOMAT CELL GENET, V2, P483, DOI 10.1007/BF01542686; KIELTY CM, 1982, ANN HUM GENET, V46, P307, DOI 10.1111/j.1469-1809.1982.tb01582.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MULLEY JC, 1986, HUM GENET, V74, P423, DOI 10.1007/BF00280498; NABHOLZ M, 1969, NATURE, V223, P358, DOI 10.1038/223358a0; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PATRACCHINI P, 1989, HUM GENET, V81, P191, DOI 10.1007/BF00293902; PATRACCHINI P, 1989, HUM GENET, V83, P264, DOI 10.1007/BF00285168; PHILLIPS IR, 1985, ANN HUM GENET, V49, P267, DOI 10.1111/j.1469-1809.1985.tb01702.x; POVEY S, 1980, ANN HUM GENET, V43, P241, DOI 10.1111/j.1469-1809.1980.tb01557.x; ROOPERS HH, 1990, CYTOGENET CELL GENET, V55, P111; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH B, 1988, AM J HUM GENET, V42, P335; SWALLOW DM, 1977, CYTOGENET CELL GENET, V18, P136, DOI 10.1159/000130758; VARESCO L, 1989, P NATL ACAD SCI USA, V86, P10118, DOI 10.1073/pnas.86.24.10118; WHITEHEAD AS, 1982, P NATL ACAD SCI USA, V79, P5012	38	15	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					789	793						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1314371				2022-12-17	WOS:A1992HQ68200025
J	MCGREW, BR; NICHOLS, DW; STANTON, VP; CAI, H; WHORF, RC; PATEL, V; COOPER, GM; LAUDANO, AP				MCGREW, BR; NICHOLS, DW; STANTON, VP; CAI, H; WHORF, RC; PATEL, V; COOPER, GM; LAUDANO, AP			PHOSPHORYLATION OCCURS IN THE AMINO TERMINUS OF THE RAF-1 PROTEIN	ONCOGENE			English	Article								The ability of the Raf-1 protein to morphologically transform murine fibroblasts can be activated by amino-terminal deletions or substitutions. We have compared the phosphorylation states of full-length and representative transforming and non-transforming amino-terminal deletion mutants of the Raf-1 protein using phosphoamino acid analysis and tryptic phosphopeptide mapping. Several [P-32]orthophosphate-labeled tryptic phosphopeptides that were present in the full-length Raf-1 protein were absent from the highly transforming 22W Raf-1 mutant (lacking 305 amino-terminal residues). Peptide-specific antisera localized Raf-1 phosphorylation sites to several amino-terminal cyanogen bromide and tryptic peptides that are deleted from the 22W protein. A major phosphorylated tryptic peptide of the Raf-1 protein was immunoprecipitated by antiserum directed against amino acid residues 257-275, a highly conserved region of the raf family. This tryptic peptide is entirely deleted from the highly transforming 22W protein. Subtractive Edman degradation and electrophoretic analysis of the immunoprecipitated tryptic peptide indicated that phosphorylation of the Raf-1 protein occurs at serine 259. Multiple phosphorylated tryptic peptide forms were immunoprecipitated by antiserum directed against Raf-1 residues 283-309. The majority of this tryptic peptide is also deleted from the highly transforming Raf-1 mutant 22W.	UNIV NEW HAMPSHIRE, DEPT BIOCHEM, SPAULDING LIFE SCI BLDG, DURHAM, NH 03824 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	University System Of New Hampshire; University of New Hampshire; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School				Stanton, Vincent/0000-0002-2205-6000	NCI NIH HHS [CA18689, K08 CA01052] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA018689, K08CA001052] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DEPAOLIROACH AA, 1983, J BIOL CHEM, V258, P702; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FUKUI M, 1987, MOL CELL BIOL, V7, P1776, DOI 10.1128/MCB.7.5.1776; GRAY WR, 1970, ANAL BIOCHEM, V33, P36, DOI 10.1016/0003-2697(70)90436-7; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; ISHIKAWA F, 1988, ONCOGENE, V3, P653; KAGAN A, 1979, METHOD HORM RADIOIMM, P328; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KARESS RE, 1981, CELL, V24, P155, DOI 10.1016/0092-8674(81)90511-0; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LAUDANO AP, 1986, P NATL ACAD SCI USA, V83, P892, DOI 10.1073/pnas.83.4.892; MARK GE, 1984, SCIENCE, V224, P285, DOI 10.1126/science.6324342; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MITSUNOBU F, 1989, ONCOGENE, V4, P437; MOLDERS H, 1985, EMBO J, V4, P693, DOI 10.1002/j.1460-2075.1985.tb03685.x; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; OSHIMA RG, 1981, J BIOL CHEM, V256, P8124; PANTAZIS P, 1981, J BIOL CHEM, V256, P4669; PERCY ME, 1972, ANAL BIOCHEM, V45, P60, DOI 10.1016/0003-2697(72)90007-3; PICTON C, 1982, FEBS LETT, V150, P191, DOI 10.1016/0014-5793(82)81332-X; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1988, HDB ONCOGENES, P213; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; Stewart JM, 1984, SOLID PHASE PEPTIDE; SULLIVAN WP, 1988, J BIOL CHEM, V263, P14717; TAHIRA T, 1987, NUCLEIC ACIDS RES, V15, P4809, DOI 10.1093/nar/15.12.4809; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247	42	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1992	7	1					33	42						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741164				2022-12-17	WOS:A1992HC22700005
J	WEIRTHOMPSON, E; CONDIE, A; LEONARD, RCF; PROSSER, J				WEIRTHOMPSON, E; CONDIE, A; LEONARD, RCF; PROSSER, J			A FAMILIAL RB1 MUTATION DETECTED BY THE HOT TECHNIQUE IS HOMOZYGOUS IN A 2ND-PRIMARY NEOPLASM	ONCOGENE			English	Note							HUMAN RETINOBLASTOMA GENE; OSTEO-SARCOMA; BREAST-TUMORS; T-ANTIGEN; EXPRESSION; CARCINOMA; PROTEIN; BINDING; POLYMORPHISMS; INACTIVATION	Using the hydroxylamine-osmium tetroxide (HOT) technique, we have identified a constitutional point mutation in the retinoblastoma susceptibility gene (RB1) which segregates with the expression of retinoblastoma in five affected family members. One member developed a second primary tumour, a small-cell lung carcinoma (SCLC), which metastasized to the liver. Analysis of liver tumour DNA revealed homozygosity for the constitutional mutation, a G --> A transition at the fifth base of intron 21, resulting in the excision of exon 21 from the mRNA. This is the first demonstration of homozygotization of a constitutional RB mutation in a metastatic second primary tumour and underlines the usefulness of the HOT technique for identification of mutations of the RB1 gene.	WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,CREWE RD,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; WESTERN GEN HOSP,IMPERIAL CANC RES FUND,MED ONCOL UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Edinburgh								BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CHENG J, 1990, BLOOD, V75, P730; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; FRIEND S, 1989, MOL GENETICS CANCER, P19; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HAY FG, 1991, BRIT J CANCER, V63, P43; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MORI N, 1990, ONCOGENE, V5, P1713; MURAKAMI Y, 1991, ONCOGENE, V6, P37; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; PROSSER J, 1990, ONCOGENE, V5, P1573; PROSSER J, 1991, BRIT J CANCER, V63, P181, DOI 10.1038/bjc.1991.44; REISSMANN PT, 1989, CANCER CEL, V7, P229; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; STANBRIDGE EJ, 1990, GENETIC BASIS FOR CARCINOGENESIS, P3; STEWART CC, 1989, ARCH PATHOL LAB MED, V113, P634; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOGUCHIDA J, 1989, NATURE, V338, P156, DOI 10.1038/338156a0; VARLEY JM, 1989, ONCOGENE, V4, P725; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305; YANDELL DW, 1989, AM J HUM GENET, V45, P547; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; YOKOTA J, 1988, ONCOGENE, V3, P471; 1988, CYTOGENET CELL GENET, V51, P762	34	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2353	2356						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1662795				2022-12-17	WOS:A1991GX73500026
J	LANG, JC; WILKIE, NM; CLARK, AM; CHUDLEIGH, A; TALBOT, S; WHITELAW, B; FRAME, MC				LANG, JC; WILKIE, NM; CLARK, AM; CHUDLEIGH, A; TALBOT, S; WHITELAW, B; FRAME, MC			REGULATORY DOMAINS WITHIN THE P0 PROMOTER OF HUMAN C-MYC	ONCOGENE			English	Article							IMMEDIATE EARLY GENE; TRANSCRIPTIONAL REGULATION; MODULATE EXPRESSION; BURKITT-LYMPHOMA; TRANS-ACTIVATION; THYMIDINE KINASE; PROTEIN-BINDING; MAMMALIAN-CELLS; DNA-BINDING; CCAAT BOX	Expression of P0 RNA in some Burkitt lymphoma cell lines varies independently of levels of RNA derived from P1 and P2. These data suggest the possibility that expression of P0 RNA may be capable of independent regulation. In order to investigate this possibility we have isolated putative regulatory domains flanking P0 RNA starts within the human c-myc gene and analysed both their ability to direct expression of control reporter genes and their ability to interact with specific transcription factors. Regulatory regions necessary for expression of P0 RNA have been located within 131 bp 5' of the first major P0 RNA start. DNAase 1 footprint analysis and gel retardation assays demonstrate binding of transcription factors Sp1, NF1 and CBP to this region. NF1 binds specifically to two consensus sequences. The more distal site overlaps with the binding site for CBP, and it is likely that concomitant binding of NF1 and CBP within the distal region of the P0 promoter is not possible. Previous work from our laboratory has described a negative regulatory domain within the 5' flanking region of c-myc. The P0 promoter resides within this domain and therefore may contain a negative regulator of c-myc gene expression.	BEATSON INST CANC RES, GLASGOW G61 1BD, SCOTLAND; AFRC, INST ANIM PHYSIOL & GENET RES, EDINBURGH EH9 3JQ, MIDLOTHIAN, SCOTLAND	Beatson Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute								ASSELIN C, 1989, ONCOGENE, V4, P549; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BATLEY J, 1983, CELL, V34, P779; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; COHEN RB, 1986, MOL CELL BIOL, V6, P821, DOI 10.1128/MCB.6.3.821; CONNELLY S, 1989, MOL CELL BIOL, V9, P5254, DOI 10.1128/MCB.9.11.5254; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CORCORAN LM, 1984, CELL, V37, P113, DOI 10.1016/0092-8674(84)90306-4; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; EICK D, 1987, ONCOGENE, V2, P61; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1990, ONCOGENE, V5, P1397; FRAME MC, 1991, ONCOGENE, V6, P205; GAFFNEY DF, 1985, NUCLEIC ACIDS RES, V13, P7847, DOI 10.1093/nar/13.21.7847; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HALL DJ, 1990, ONCOGENE, V5, P47; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KAKKIS E, 1987, P NATL ACAD SCI USA, V84, P7031, DOI 10.1073/pnas.84.20.7031; KIT S, 1963, BIOCHEM BIOPH RES CO, V11, P55, DOI 10.1016/0006-291X(63)90027-5; LANG JC, 1983, J GEN VIROL, V64, P2679, DOI 10.1099/0022-1317-64-12-2679; LANG JC, 1988, BRIT J CANCER, V58, P62; LANG JC, 1984, EMBO J, V3, P389, DOI 10.1002/j.1460-2075.1984.tb01817.x; LEMAIGRE FP, 1990, MOL CELL BIOL, V10, P1811, DOI 10.1128/MCB.10.4.1811; LIPP M, 1989, ONCOGENE, V4, P535; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LITTLEFIELD JW, 1964, SCIENCE, V145, P709, DOI 10.1126/science.145.3633.709; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P6177, DOI 10.1073/pnas.80.20.6177; NEIL JC, 1984, NATURE, V308, P814, DOI 10.1038/308814a0; NEPVEU A, 1987, ONCOGENE, V1, P243; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PEI DQ, 1990, J VIROL, V64, P1517, DOI 10.1128/JVI.64.4.1517-1522.1990; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; RAY D, 1987, MOL CELL BIOL, V7, P940, DOI 10.1128/MCB.7.2.940; REMMERS EF, 1986, EMBO J, V5, P899, DOI 10.1002/j.1460-2075.1986.tb04301.x; ROMAN D, 1990, New Biologist, V2, P642; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SPANDIDOS DA, 1983, EMBO J, V2, P1193, DOI 10.1002/j.1460-2075.1983.tb01566.x; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; TOURKINE N, 1989, ONCOGENE, V4, P973; WEISINGER G, 1988, ONCOGENE, V3, P635; WHITELAW B, 1988, UCLA S MOL CELL BIOL, V58, P337; WRIGHT S, 1989, P NATL ACAD SCI USA, V86, P505, DOI 10.1073/pnas.86.2.505	62	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1991	6	11					2067	2075						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1945411				2022-12-17	WOS:A1991GX11900018
J	WERNER, S; ROTH, WK; BATES, B; GOLDFARB, M; HOFSCHNEIDER, PH				WERNER, S; ROTH, WK; BATES, B; GOLDFARB, M; HOFSCHNEIDER, PH			FIBROBLAST GROWTH-FACTOR 5 PROTOONCOGENE IS EXPRESSED IN NORMAL HUMAN FIBROBLASTS AND INDUCED BY SERUM GROWTH-FACTORS	ONCOGENE			English	Article							KAPOSIS SARCOMA-CELLS; MYC MESSENGER-RNA; C-MYC; NUCLEOTIDE-SEQUENCE; KINASE-C; GENE; INDUCTION; FAMILY; FOS; 3T3-CELLS	Fibroblast growth factor 5 (FGF-5) is a member of the fibroblast growth factor family with transforming potential. It has been found to be expressed in several human tumor cell lines, but nothing is known about expression of this growth factor in normal cells and its biological functions. Here we show that the FGF-5 gene is expressed in exponentially growing normal human fibroblasts. In quiescent fibroblasts, expression of FGF-5 is strongly induced by serum and several growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF) and transforming growth factor alpha (TGF-alpha). This induction can be mediated by at least two different pathways involving protein kinase C or cAMP-dependent kinases. Since the effect is independent of de novo protein synthesis, FGF-5 represents the product of a primary response gene. In addition our data suggest that FGF-5 is mitogenic for human fibroblasts, indicating the existence of an FGF-5-mediated positive feedback in these cells which could amplify and prolong the cellular response to the initial stimulus.	MAX PLANCK INST BIOCHEM, KLOPFERSPITZ 18A, W-8033 MARTINSRIED, GERMANY; COLUMBIA UNIV COLL PHYS & SURG, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA	Max Planck Society; Columbia University				Werner, Sabine/0000-0001-7397-8710				ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BATES B, 1991, MOL CELL BIOL, V11, P1840, DOI 10.1128/MCB.11.4.1840; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; Bravo R., 1990, GROWTH FACTORS DIFFE, P324; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DELAPEYRIERE O, 1990, ONCOGENE, V5, P823; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; HAUB O, 1990, P NATL ACAD SCI USA, V87, P8022, DOI 10.1073/pnas.87.20.8022; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINZER DIH, 1983, P NATL ACAD SCI-BIOL, V80, P4271, DOI 10.1073/pnas.80.14.4271; MARICS I, 1989, ONCOGENE, V4, P335; MCCAFFREY P, 1987, J BIOL CHEM, V262, P1442; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PAULSSON Y, 1987, NATURE, V328, P715, DOI 10.1038/328715a0; RAN W, 1986, P NATL ACAD SCI USA, V83, P8216, DOI 10.1073/pnas.83.21.8216; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROTH WK, 1988, INT J CANCER, V42, P767, DOI 10.1002/ijc.2910420523; ROTH WK, 1989, ONCOGENE, V4, P483; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; THOMAS KA, 1987, FASEB J, V1, P434, DOI 10.1096/fasebj.1.6.3315806; WERNER S, 1989, INT J CANCER, V43, P1137, DOI 10.1002/ijc.2910430629; ZHAN X, 1987, ONCOGENE, V1, P369; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	34	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1991	6	11					2137	2144						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1658709				2022-12-17	WOS:A1991GX11900026
J	HAMER, PJ; LAVECCHIO, J; NG, S; DELELLIS, R; WOLFE, H; CARNEY, WP				HAMER, PJ; LAVECCHIO, J; NG, S; DELELLIS, R; WOLFE, H; CARNEY, WP			ACTIVATED VAL-12 RAS P21 IN CELL-CULTURE FLUIDS AND MOUSE PLASMA	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; MONOCLONAL-ANTIBODIES; HUMAN CARCINOMAS; POINT MUTATIONS; GENE-MUTATIONS; PROTO-ONCOGENE; HUMAN-COLON; HUMAN-LUNG; ADENOCARCINOMA; EXPRESSION	Activation of ras oncogenes has been associated with a variety of cancers as well as their precursor lesions. Ras proteins activated by substitutions at amino acid positions 12, 13 or 61 have not been identified in normal tissues and therefore their detection may have clinical value. In this study our objective was to determine whether activated ras proteins could be released into the extracellular environment. To test this hypothesis, we used ras-transformed NIH3T3 cells that express an activated p21 containing valine (Val-12 p21) at position 12 instead of the normal glycine (Gly-12 p21) and a monoclonal antibody (mAb) designated DWP that is specific for the activated Val-12 ras proteins. Culture fluids collected from NIH3T3 cells transformed by the activated Val-12 p21 were shown, using mAb DWP in a sandwich ELISA format, to contain the activated Val-12 p21. In contrast, culture fluids from non-Val-12-containing cells were unreactive with mAb DWP. PSV-LM-EJ cells which overexpress the activated Val-12 p21 were injected subcutaneously (SQ) into nude mice to produce tumors. At the time of gross tumor appearance (14-21 days after tumor cell inoculation), plasma was collected from the PSV-LM-EJ tumor-bearing mice as well as from a series of control mice. Employing mAb DWP as a detection reagent in the sandwich ELISA format, we were able to detect the Val-12 p21 in the plasma of the PSV-LM-EJ tumor-bearing mice. Activated Val-12 p21 was not present in the plasma of non-tumor-bearing mice, or in the plasma of mice bearing SQ tumors composed of non-Val-12 p21 ras-transformed cells. This report is the first description of an activated ras protein (Val-12 p21) in the plasma of tumor-bearing mice and demonstrates that the results of the Val-12 p21-specific ELISA could be validated with Western blot format.	DUPONT CO,DEPT MED PROD,BIOTECHNOL SYST,331 TREBLE COVE RD,N BILLERICA,MA 01862; TUFTS NEW ENGLAND MED CTR,DEPT PATHOL,BOSTON,MA 02115	DuPont; Tufts Medical Center								ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1989, CANCER RES, V49, P4682; BRANDTRAUF PW, 1988, BRIT J IND MED, V45, P689; BRANDTRAUF PW, 1991, IN PRESS J SOC OCCUP; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CARNEY WP, 1986, J CELL BIOCHEM, V32, P207, DOI 10.1002/jcb.240320307; CARNEY WP, 1986, P NATL ACAD SCI USA, V83, P7485, DOI 10.1073/pnas.83.19.7485; CARNEY WP, 1989, HUMAN TUMOR ANTIGENS, P53; CARUSO A, 1986, INT J CANCER, V38, P587, DOI 10.1002/ijc.2910380420; CLAIR T, 1987, CANCER RES, V47, P5290; DER CJ, 1983, CELL, V32, P201, DOI 10.1016/0092-8674(83)90510-X; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GALLICK GE, 1985, P NATL ACAD SCI USA, V82, P1795, DOI 10.1073/pnas.82.6.1795; GREENBERG PL, 1979, AM J MED, V66, P951, DOI 10.1016/0002-9343(79)90450-9; HAMER PJ, 1990, HYBRIDOMA, V9, P573, DOI 10.1089/hyb.1990.9.573; KAKKANAS A, 1990, In Vivo (Attiki), V4, P115; KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364; LAVECCHIO JA, 1990, ONCOGENE, V5, P1173; LERNER EA, 1980, J EXP MED, V152, P1085, DOI 10.1084/jem.152.4.1085; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; MCKENZIE SJ, 1989, ONCOGENE, V4, P543; NIMAN HL, 1985, P NATL ACAD SCI USA, V82, P7924, DOI 10.1073/pnas.82.23.7924; PADUA RA, 1988, LEUKEMIA, V2, P503; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; RODENHUIS S, 1988, CANCER RES, V48, P5738; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TOKSOZ D, 1987, ONCOGENE, V1, P409; UPDYKE TV, 1984, J IMMUNOL METHODS, V73, P83, DOI 10.1016/0022-1759(84)90034-6; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; YANEZ L, 1987, ONCOGENE, V1, P315	35	15	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1609	1615						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923528				2022-12-17	WOS:A1991GX27400016
J	TAINSKY, MA; YIM, SO; KRIZMAN, DB; KANNAN, P; CHIAO, PJ; MUKHOPADHYAY, T; BUETTNER, R				TAINSKY, MA; YIM, SO; KRIZMAN, DB; KANNAN, P; CHIAO, PJ; MUKHOPADHYAY, T; BUETTNER, R			MODULATION OF DIFFERENTIATION IN PA-1 HUMAN TERATOCARCINOMA CELLS AFTER N-RAS ONCOGENE-INDUCED TUMORIGENICITY	ONCOGENE			English	Article							RETINOIC ACID RECEPTOR; EMBRYONAL CARCINOMA-CELLS; VITAMIN-A; MOLECULAR-CLONING; LINE; EXPRESSION; IDENTIFICATION; INDUCTION; PROTEIN; PATTERN	We have been studying the effect of oncogenes on differentiation using the human ovarian teratoma-derived cell line PA-1. From this study we have characterized variants representing four stages relevant to multistage carcinogenesis, two non-tumorigenic and two tumorigenic. The two non-tumorigenic cell variants differ in that one is resistant to transformation by ras oncogenes whereas the other can be transformed to tumorigenicity. When these non-tumorigenic PA-1 variants are treated with retinoic acid (RA), a morphogen, they stop dividing, begin to express homeobox genes, and change in morphology. Transfection of an activated N-ras oncogene into ras-resistant non-tumorigenic PA-1 cells does not alter the RA responsiveness of the cells, indicating that expression of the activated oncogene is not sufficient for blocking RA-induced differentiation. Spontaneous activation of an N-ras oncogene leading to tumorigenic transformants and gene transfer-induced N-ras transformants are resistant to these effects of RA. However, another spontaneous transformant of PA-1 cells that does not contain an activated N-ras is responsive to RA. We prepared somatic cell hybrids of the RA-non-responsive, N-ras-transformed and tumorigenic PA-1 cell and the RA-responsive, ras-resistant non-tumorigenic PA-1 cell; the hybrid cell lines continue to express the oncogene but are non-tumorigenic. These non-tumorigenic hybrids are responsive to RA with regard to morphological changes, growth arrest and induction of homeobox gene expression. Tumorigenic revertants of these hybrids arise as a result of the loss of some chromosomes; these hybrid cells express the oncogene but have lost RA responsiveness. These results indicate that tumorigenic transformation in general is not sufficient to induce RA resistance, and resistance to differentiation may be oncogene-specific. In addition, the expression of an activated N-ras oncogene alone is insufficient to induce resistance to RA and ras-induced tumorigenicity is necessary. Therefore, some feature of cellular metabolism that is altered by and discordantly segregates with tumorigenic transformation controls responsiveness to RA. This controlling element is presumably a tumor suppressor.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT THORAC SURG,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	TAINSKY, MA (corresponding author), UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT TUMOR BIOL,BOX 79,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.			Tainsky, Michael/0000-0002-0261-831X	NCI NIH HHS [CA-09299, CA-42180] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042180, T32CA009299] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BELL JC, 1986, MOL CELL BIOL, V6, P617, DOI 10.1128/MCB.6.2.617; BORASIO GD, 1989, NEURON, V2, P1087; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BUETTNER R, 1991, MOL CELL BIOL, V2, P3573; CHIAO PJ, 1991, ONCOGENE, V6, P713; CHIAO PJ, 1991, IN PRESS ONCOGENE, V6; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P165, DOI 10.1007/BF01542629; DAVIS RC, 1987, DEV BIOL, V119, P164, DOI 10.1016/0012-1606(87)90218-1; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; EICHELE G, 1985, J CELL BIOL, V101, P1913, DOI 10.1083/jcb.101.5.1913; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRANKEL J, 1979, ADV COMP LEUKEMIA RE, P555; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GUMERLOCK PH, 1989, ANAL BIOCHEM, V180, P158, DOI 10.1016/0003-2697(89)90105-X; HARRIS H, 1990, J CELL SCI, V97, P65; HAUSSLER M, 1983, P NATL ACAD SCI-BIOL, V80, P5525, DOI 10.1073/pnas.80.18.5525; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; JETTEN AM, 1986, MOL CELL BIOL, V6, P3341, DOI 10.1128/MCB.6.10.3341; JETTEN AM, 1989, ENVIRON HEALTH PERSP, V80, P149, DOI 10.2307/3430740; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LAROSA GJ, 1988, P NATL ACAD SCI USA, V85, P329, DOI 10.1073/pnas.85.2.329; LAUTENBERGER JA, 1981, P NATL ACAD SCI-BIOL, V78, P1518, DOI 10.1073/pnas.78.3.1518; LEE J, 1985, J EMBRYOL EXP MORPH, V90, P139; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; LOTAN R, 1979, CANCER RES, V39, P1014; LUESCHER B, 1989, GENE DEV, V3, P1507; MILLER WH, 1990, ONCOGENE, V5, P511; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PEEHL DM, 1982, INT J CANCER, V30, P113, DOI 10.1002/ijc.2910300119; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SEIFTER E, 1976, J NATL CANCER I, V57, P355, DOI 10.1093/jnci/57.2.355; SEIFTER E, 1973, LIFE SCI, V13, P945, DOI 10.1016/0024-3205(73)90084-2; SHERMAN MI, 1986, CURR TOP DEV BIOL, V20, P345, DOI 10.1016/S0070-2153(08)60674-2; SHUBEITA HE, 1987, P NATL ACAD SCI USA, V84, P5645, DOI 10.1073/pnas.84.16.5645; STANBRIDGE EJ, 1981, CANCER RES, V41, P573; TAINSKY MA, 1987, CANCER RES, V47, P3235; TAINSKY MA, 1984, SCIENCE, V225, P643, DOI 10.1126/science.6740333; TAINSKY MA, 1988, ANTICANCER RES, V8, P899; TAYLOR DD, 1990, DIFFERENTIATION, V43, P123, DOI 10.1111/j.1432-0436.1990.tb00438.x; TICKLE C, 1985, DEV BIOL, V109, P82, DOI 10.1016/0012-1606(85)90348-3; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; YOAKUM GH, 1984, BIOTECHNIQUES    JAN, P24; ZEUTHEN J, 1980, INT J CANCER, V25, P19, DOI 10.1002/ijc.2910250104	48	15	15	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1575	1582						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1681491				2022-12-17	WOS:A1991GX27400012
J	BRONDYK, WH; BOECKMAN, FA; FAHL, WE				BRONDYK, WH; BOECKMAN, FA; FAHL, WE			N-MYC ONCOGENE ENHANCES MITOGENIC RESPONSIVENESS OF DIPLOID HUMAN FIBROBLASTS TO GROWTH-FACTORS BUT FAILS TO IMMORTALIZE	ONCOGENE			English	Article							MALIGNANT TRANSFORMATION; HUMAN NEUROBLASTOMAS; PROTO-ONCOGENE; NEOPLASTIC TRANSFORMATION; ANCHORAGE-INDEPENDENCE; EMBRYO FIBROBLASTS; SIMIAN VIRUS-40; MAMMALIAN-CELLS; NEURO-BLASTOMA; GENE FAMILY	The N-myc gene is amplified in several types of human tumors. To assess the role of the N-myc gene in the transformation of normal human cells, we transfected an N-myc expression vector into diploid human fibroblasts. Transfected clones were isolated and found to express the N-myc gene at levels similar to those seen in a tumor cell line (neuroblastoma LA-N-1) which contains an amplified N-myc gene. The level of N-myc expression decreased as the N-myc clones senesced. Clones expressing N-myc had an increased saturation density and an altered morphology but did not have an extended lifespan. Under low serum conditions, neither the clones expressing N-myc nor the control cells showed anchorage-independent growth. Clones expressing N-myc were compared to control cells to determine if different growth factors would affect the ability of cells to grow in soft agarose. Clones expressing N-myc and the control cells did not grow in soft agarose supplemented with epidermal growth factor (EGF) or transforming growth factor-alpha (TGF-alpha). However, compared to control cells, clones expressing N-myc grew in agarose 2.8- to 18-fold higher in response to basic fibroblast growth factor (bFGF) and 5.5- to 55-fold higher in response to platelet-derived growth factor B-chain homodimer (PDGF-BB).	UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	FAHL, WE (corresponding author), UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706, USA.				NATIONAL CANCER INSTITUTE [P30CA007175, R37CA042024] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA07175, R37-CA42024] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BERNARD O, 1989, J NEUROSCI RES, V24, P9, DOI 10.1002/jnr.490240104; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CURATOLO L, 1984, IN VITRO CELL DEV B, V20, P597; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; DIAS P, 1990, INT J CANCER, V45, P593, DOI 10.1002/ijc.2910450403; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; GARSON JA, 1986, LANCET, V1, P1496; HARLOW E, 1988, ANTIBODIES LABORATOR; HAYASHI Y, 1990, INT J CANCER, V45, P705, DOI 10.1002/ijc.2910450423; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HIRVONEN H, 1989, J CELL BIOL, V108, P1093, DOI 10.1083/jcb.108.3.1093; HJELLE B, 1988, P NATL ACAD SCI USA, V85, P4355, DOI 10.1073/pnas.85.12.4355; HURLIN PJ, 1989, P NATL ACAD SCI USA, V86, P187, DOI 10.1073/pnas.86.1.187; HURLIN PJ, 1987, CANCER RES, V47, P5752; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; INGVARSSON S, 1988, MOL CELL BIOL, V8, P3168, DOI 10.1128/MCB.8.8.3168; JAKOBOVITS A, 1985, NATURE, V318, P188, DOI 10.1038/318188a0; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; KRAEMER PM, 1986, J NATL CANCER I, V76, P703, DOI 10.1093/jnci/76.4.703; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; MACIEIRACOELHO A, 1980, GERONTOLOGY, V26, P276, DOI 10.1159/000212428; MAKELA TP, 1989, MOL CELL BIOL, V9, P1545; MATLASHEWSKI G, 1988, INT J CANCER, V42, P232, DOI 10.1002/ijc.2910420215; MCCORMICK JJ, 1988, MUTAT RES, V199, P273; MEEK RL, 1977, EXP CELL RES, V107, P277, DOI 10.1016/0014-4827(77)90350-0; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NEUFELD DS, 1987, MOL CELL BIOL, V7, P2794, DOI 10.1128/MCB.7.8.2794; NORWOOD TH, 1985, HDB BIOL AGING, P291; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PALMER H, 1988, J CELL PHYSIOL, V137, P588, DOI 10.1002/jcp.1041370328; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SCHWAB M, 1988, P NATL ACAD SCI USA, V85, P9585, DOI 10.1073/pnas.85.24.9585; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; SLAMON DJ, 1986, SCIENCE, V232, P768, DOI 10.1126/science.3008339; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; SMITH JR, 1980, SCIENCE, V207, P82; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STEVENS CW, 1988, MOL CELL BIOL, V8, P2089, DOI 10.1128/MCB.8.5.2089; STEVENS CW, 1989, J CANCER RES CLIN, V115, P118, DOI 10.1007/BF00397911; STINSKI MF, 1985, J VIROL, V55, P431, DOI 10.1128/JVI.55.2.431-441.1985; STRAUSS M, 1990, ONCOGENE, V5, P1223; TUBO RA, 1987, ONCOGENE RES, V1, P407; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	59	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1269	1276						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861869				2022-12-17	WOS:A1991GV26000024
J	JENSEN, DE; FRANKIS, RC; SANDO, JJ				JENSEN, DE; FRANKIS, RC; SANDO, JJ			DEFECTIVE INDUCTION OF JUN AND FOS-RELATED PROTEINS IN PHORBOL ESTER-RESISTANT EL4 MOUSE THYMOMA CELLS	ONCOGENE			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR AP-1; HUMAN INTERLEUKIN-2 GENE; C-JUN; GROWTH-FACTOR; PROTO-ONCOGENE; AUTO-REGULATION; LYMPHOCYTES-T; DNA; EXPRESSION	Treatment of sensitive EL4 mouse thymoma cells with phorbol esters causes growth inhibition, adherence to substrate and production of several lymphokines including Interleukin 2. Resistant cells lack all of these responses. Since production of Interleukin 2 mRNA is dependent on protein synthesis, and the Interleukin 2 gene has a phorbol ester responsive element, we examined both cell lines for expression of the various Jun and Fos species which bind to this element. Phorbol ester induced c-fos, jun-B, and jun-D RNAs within 20 min in both cell lines. Fos-B was similarly induced in sensitive cells but induction was delayed and greatly enhanced in resistant cells. C-jun RNA induction was detected only in sensitive cells. Western analysis confirmed the induction of c-Jun and a Fos-related protein in sensitive cells only. Southern analysis indicated that both cell lines contain c-jun and fra-1 genes. These results suggest that defective induction of c-Jun and/or Fos-related proteins may contribute to the absence of phorbol ester-induced lymphokine production in resistant EL4 cells.	UNIV VIRGINIA,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,CTR CANC,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia	JENSEN, DE (corresponding author), UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599, USA.				NIDDK NIH HHS [DK40031] Funding Source: Medline; NIGMS NIH HHS [GM31184] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK040031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031184] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1984, CELL, V36, P259; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; EISELONIS B, 1987, TRANSFER IMMOBILIZAT, P5; FARRAR JJ, 1980, J IMMUNOL, V125, P2555; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; FUSE A, 1984, NUCLEIC ACIDS RES, V12, P93; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GIARDINA SL, 1987, ANAL BIOCHEM, V161, P109, DOI 10.1016/0003-2697(87)90659-2; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRISON JR, 1987, J BIOL CHEM, V262, P234; HOMAN EC, 1991, J BIOL CHEM, V266, P5676; KAMPS MP, 1990, MOL CELL BIOL, V10, P5464, DOI 10.1128/MCB.10.10.5464; KASHIMA N, 1985, NATURE, V313, P402, DOI 10.1038/313402a0; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LI L, 1990, J BIOL CHEM, V265, P1556; LORD KA, 1990, ONCOGENE, V5, P387; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NOVAK TJ, 1990, MOL CELL BIOL, V10, P6325, DOI 10.1128/MCB.10.12.6325; PEARLSTEIN KT, 1983, J NATL CANCER I, V71, P583; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; Sambrook J., 1989, MOL CLONING LAB MANU; SANDO JJ, 1982, CANCER RES, V42, P1676; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHONTHAL A, 1989, ONCOGENE, V4, P629; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SHAPIRO DJ, 1988, DNA CELL BIOL, V7, P44; SHAW J, 1987, MOL IMMUNOL, V24, P409, DOI 10.1016/0161-5890(87)90014-9; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; Strauss WM, 1987, CURRENT PROTOCOLS MO, P631; Suggs S. V., 1981, ICN UCLA S DEV BIOL, V23, P683; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	56	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1219	1225						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1713662				2022-12-17	WOS:A1991GV26000018
J	OVERELL, RW; WEISSER, KE; HESS, B; NAMEN, AE; GRABSTEIN, KH				OVERELL, RW; WEISSER, KE; HESS, B; NAMEN, AE; GRABSTEIN, KH			STAGE-SPECIFIC TRANSFORMATION OF MURINE-B LINEAGE CELLS BY RAS AND MYC	ONCOGENE			English	Article									IMMUNEX CORP, DEPT CELLULAR IMMUNOL, SEATTLE, WA 98101 USA; IMMUNEX CORP, DEPT BIOCHEM, SEATTLE, WA 98101 USA	Immunex Corporation; Immunex Corporation	OVERELL, RW (corresponding author), IMMUNEX CORP, DEPT MOLEC BIOL, 51 UNIV ST, SEATTLE, WA 98101 USA.							ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; BALTIMORE D, 1979, IMMUNOL REV, V48, P3, DOI 10.1111/j.1600-065X.1979.tb00296.x; BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BRAUN J, 1983, J IMMUNOL, V130, P2113; BRIGHTMAN BK, 1986, J VIROL, V60, P68, DOI 10.1128/JVI.60.1.68-81.1986; CEROTTINI JC, 1974, J EXP MED, V140, P703, DOI 10.1084/jem.140.3.703; COFFMAN RL, 1983, IMMUNOL REV, V69, P5, DOI 10.1111/j.1600-065X.1983.tb00446.x; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; GAUWERKY CE, 1988, ONCOGENE, V2, P431; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; GLASEBROOK AL, 1980, J EXP MED, V151, P876, DOI 10.1084/jem.151.4.876; GRABSTEIN K, 1986, J EXP MED, V163, P1405, DOI 10.1084/jem.163.6.1405; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; HOLMES KL, 1986, J EXP MED, V164, P443, DOI 10.1084/jem.164.2.443; KLEIN G, 1979, P NATL ACAD SCI USA, V76, P2442, DOI 10.1073/pnas.76.5.2442; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LICHTMAN AH, 1986, NATURE, V324, P489, DOI 10.1038/324489a0; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MANN RB, 1979, AM J PATHOL, V94, P103; MILLER AD, 1985, MOL CELL BIOL, V5, P431, DOI 10.1128/MCB.5.3.431; MISHELL RI, 1967, J EXP MED, V126, P423, DOI 10.1084/jem.126.3.423; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; NEWBOLD RF, 1982, NATURE, V299, P633, DOI 10.1038/299633a0; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; OSMOND DG, 1986, IMMUNOL REV, V93, P103, DOI 10.1111/j.1600-065X.1986.tb01504.x; OVERELL RW, 1988, MOL CELL BIOL, V8, P1803, DOI 10.1128/MCB.8.4.1803; OVERELL RW, 1987, MOL CELL BIOL, V7, P3394, DOI 10.1128/MCB.7.10.3394; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; POTTER M, 1987, SCIENCE, V235, P787, DOI 10.1126/science.3810165; ROSENBERG N, 1976, J EXP MED, V143, P1453, DOI 10.1084/jem.143.6.1453; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SERUNIAN LA, 1986, MOL CELL BIOL, V6, P183, DOI 10.1128/MCB.6.1.183; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; VANSNICK J, 1987, J EXP MED, V165, P641, DOI 10.1084/jem.165.3.641; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; VOGT M, 1986, MOL CELL BIOL, V6, P3545, DOI 10.1128/MCB.6.10.3545; WHITLOCK C, 1985, ANNU REV IMMUNOL, V3, P213; WHITLOCK CA, 1985, ADV IMMUNOL, V37, P73, DOI 10.1016/S0065-2776(08)60338-7; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608; WILLIAMS DA, 1984, NATURE, V310, P476, DOI 10.1038/310476a0; WILLIMAS DE, 1989, UNPUB BLOOD; WU DD, 1987, J IMMUNOL METHODS, V101, P279, DOI 10.1016/0022-1759(87)90161-X	48	15	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1989	4	12					1425	1432						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659	2687765				2022-12-17	WOS:A1989CB65900002
J	ZHENG, XF; PODELL, S; SEFTON, BM; KAPLAN, PL				ZHENG, XF; PODELL, S; SEFTON, BM; KAPLAN, PL			THE SEQUENCE OF CHICKEN C-YES AND P61C-YES	ONCOGENE			English	Article									HARVARD UNIV,SCH MED,DANA FARBER CANC INST,D1030,44 BINNEY ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115; SALK INST BIOL STUDIES,LA JOLLA,CA 92037	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Salk Institute					NATIONAL CANCER INSTITUTE [P30CA014195, R01CA017289] Funding Source: NIH RePORTER; NCI NIH HHS [CA06515, CA17289, CA14195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KAMPS MP, 1988, ONCOGENE, V2, P305; KAPLAN PL, 1987, J VIROL, V61, P1731, DOI 10.1128/JVI.61.5.1731-1734.1987; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KAWAI S, 1980, P NATL ACAD SCI-BIOL, V77, P6199, DOI 10.1073/pnas.77.10.6199; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; KITAMURA N, 1982, NATURE, V297, P205, DOI 10.1038/297205a0; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; Maniatis T., 1982, MOL CLONING; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; NEIL JC, 1981, VIROLOGY, V108, P98, DOI 10.1016/0042-6822(81)90530-4; NISHIZAWA M, 1986, MOL CELL BIOL, V6, P511, DOI 10.1128/MCB.6.2.511; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SHIBUYA M, 1982, J VIROL, V42, P143, DOI 10.1128/JVI.42.1.143-152.1982; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STREBHARDT K, 1987, P NATL ACAD SCI USA, V84, P8778, DOI 10.1073/pnas.84.24.8778; SUDOL M, 1988, ONCOGENE RES, V2, P345; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YOSHIDA M, 1980, NATURE, V287, P653, DOI 10.1038/287653a0; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	52	15	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1989	4	1					99	104						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5674	2464785				2022-12-17	WOS:A1989U567400015
J	LYMAN, SD; PARK, L; ROHRSCHNEIDER, LR				LYMAN, SD; PARK, L; ROHRSCHNEIDER, LR			COLONY STIMULATING FACTOR-I INDUCED GROWTH-STIMULATION OF V-FMS TRANSFORMED FIBROBLASTS	ONCOGENE			English	Article									IMMUNEX CORP,SEATTLE,WA 98101	Immunex Corporation	LYMAN, SD (corresponding author), FRED HUTCHINSON CANC RES CTR,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.				NATIONAL CANCER INSTITUTE [R01CA020551, R01CA040987, T32CA009229] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40987, CA 20551, CA 09229] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTOCCI A, 1986, J EXP MED, V164, P956, DOI 10.1084/jem.164.3.956; CERRETTI DP, 1988, MOL IMMUNOL, V25, P761, DOI 10.1016/0161-5890(88)90112-5; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; HOPP TP, 1988, ICSU SHORT REP, V8, P138; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KAWASAKI ES, 1985, SCIENCE, V230, P291, DOI 10.1126/science.2996129; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KOURY MJ, 1982, NATURE, V299, P638, DOI 10.1038/299638a0; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; LYMAN SD, 1987, MOL CELL BIOL, V7, P3287, DOI 10.1128/MCB.7.9.3287; MCDONOUGH SK, 1971, CANCER RES, V31, P953; OVERELL RW, 1987, MOL CELL BIOL, V7, P3394, DOI 10.1128/MCB.7.10.3394; PARK LS, 1986, J BIOL CHEM, V261, P4177; POLLARD JW, 1987, NATURE, V330, P484, DOI 10.1038/330484a0; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; ROBBINS KC, 1983, NATURE, V305, P605, DOI 10.1038/305605a0; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; SACCA R, 1986, P NATL ACAD SCI USA, V83, P3331, DOI 10.1073/pnas.83.10.3331; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SKLAR MD, 1985, MACROPHAGE BIOL, P673; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; STANLEY ER, 1985, METHOD ENZYMOL, V116, P564; STANLEY ER, 1981, J IMMUNOL METHODS, V42, P253, DOI 10.1016/0022-1759(81)90156-3; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WHEELER EF, 1987, MOL CELL BIOL, V7, P1673, DOI 10.1128/MCB.7.5.1673; WHEELER EF, 1986, NATURE, V324, P377, DOI 10.1038/324377a0	33	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					391	395						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	2856249				2022-12-17	WOS:A1988Q773900006
J	DONAHUE, LM; STEIN, GH				DONAHUE, LM; STEIN, GH			HIGH-EFFICIENCY DNA-MEDIATED TRANSFORMATION OF HUMAN-DIPLOID FIBROBLASTS	ONCOGENE			English	Article											DONAHUE, LM (corresponding author), UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309, USA.				NIA NIH HHS [AG00947] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BELL E, 1978, SCIENCE, V202, P1158, DOI 10.1126/science.725592; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN S, 1987, J VIROL, V61, P3521, DOI 10.1128/JVI.61.11.3521-3527.1987; CORSARO CM, 1977, NATURE, V268, P737, DOI 10.1038/268737a0; CORSARO CM, 1977, P NATL ACAD SCI USA, V74, P4476, DOI 10.1073/pnas.74.10.4476; CORSARO CM, 1975, EXP CELL RES, V95, P39, DOI 10.1016/0014-4827(75)90606-0; DONIGER J, 1983, SCIENCE, V222, P114; FRY DG, 1986, J CELL PHYSIOL, V128, P313, DOI 10.1002/jcp.1041280225; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GRAHAM FL, 1980, INTRO MACROMOLECULES, P3; GRODZICKER T, 1980, CELL, V21, P453, DOI 10.1016/0092-8674(80)90482-1; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HOEIJMAKERS JHJ, 1987, EXP CELL RES, V169, P111, DOI 10.1016/0014-4827(87)90230-8; Maniatis T., 1982, MOL CLONING; MULLIGAN RC, 1980, SCIENCE, V209, P1422, DOI 10.1126/science.6251549; NICHOLS WW, 1977, SCIENCE, V196, P60, DOI 10.1126/science.841339; PALMER TD, 1987, MOL MECH REGULATION, P307; SAGER R, 1983, P NATL ACAD SCI-BIOL, V80, P7601, DOI 10.1073/pnas.80.24.7601; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUTHERLAND BM, 1985, P NATL ACAD SCI USA, V82, P2399, DOI 10.1073/pnas.82.8.2399; SUTHERLAND BM, 1984, CANCER RES, V44, P2769; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YANISHEVSKY R, 1974, J CELL PHYSIOL, V84, P165, DOI 10.1002/jcp.1040840202	23	15	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1988	3	2					221	224						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	3412775				2022-12-17	WOS:A1988Q053400014
J	MORIKE, M; QUAISER, A; MULLER, D; MONTENARH, M				MORIKE, M; QUAISER, A; MULLER, D; MONTENARH, M			EARLY GENE-EXPRESSION AND CELLULAR DNA-SYNTHESIS AFTER STIMULATION OF QUIESCENT NIH3T3 CELLS WITH SERUM OR PURIFIED SIMIAN-VIRUS 40	ONCOGENE			English	Article									UNIV ULM,DEPT BIOCHEM,POB 4066,D-7900 ULM,FED REP GER	Ulm University			Montenarh, Mathias/AAB-6689-2020					Baserga R., 1976, MULTIPLICATION DIVIS; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BOWENPOPE DF, 1984, P NATL ACAD SCI-BIOL, V81, P2396, DOI 10.1073/pnas.81.8.2396; CAMPISI J, 1984, MOL CELL BIOL, V4, P1807, DOI 10.1128/MCB.4.9.1807; CHOU JY, 1975, J VIROL, V15, P145, DOI 10.1128/JVI.15.1.145-150.1975; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; CRAWFORD L, 1983, INT REV EXP PATHOL, V25, P1; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DENHARDT DT, 1986, BIOCH BIOPHYS ACTA, V865, P82; DEUEL TF, 1983, SCIENCE, V221, P1348, DOI 10.1126/science.6310754; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; GERSHON D, 1966, P NATL ACAD SCI USA, V56, P918, DOI 10.1073/pnas.56.3.918; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HELDIN CH, 1985, MOL CELL ENDOCRINOL, V39, P169, DOI 10.1016/0303-7207(85)90061-9; HENRY P, 1966, P NATL ACAD SCI USA, V56, P1170, DOI 10.1073/pnas.56.4.1170; HISCOTT JB, 1981, J VIROL, V37, P802, DOI 10.1128/JVI.37.2.802-812.1981; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; IDE T, 1977, P NATL ACAD SCI USA, V74, P3189, DOI 10.1073/pnas.74.8.3189; KAHANA C, 1984, P NATL ACAD SCI-BIOL, V81, P3645, DOI 10.1073/pnas.81.12.3645; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KHANDJIAN EW, 1980, P NATL ACAD SCI-BIOL, V77, P1476, DOI 10.1073/pnas.77.3.1476; KIT S, 1966, VIROLOGY, V29, P69, DOI 10.1016/0042-6822(66)90197-8; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEOF EB, 1982, EXP CELL RES, V141, P107, DOI 10.1016/0014-4827(82)90073-8; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MONTENARH M, 1984, J VIROL, V49, P658, DOI 10.1128/JVI.49.3.658-664.1984; MOORE JP, 1986, J BIOL CHEM, V261, P8158; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; PLEDGER WJ, 1981, P NATL ACAD SCI-BIOL, V78, P4358, DOI 10.1073/pnas.78.7.4358; POCKL E, 1980, J VIROL, V35, P8; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; POSTEL EH, 1976, VIROLOGY, V73, P206, DOI 10.1016/0042-6822(76)90075-1; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; ROSENBERG BH, 1981, J VIROL METHODS, V3, P167, DOI 10.1016/0166-0934(81)90051-3; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SMITH HS, 1971, VIROLOGY, V44, P357; SOPRANO KJ, 1979, P NATL ACAD SCI US, V79, P3885; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STEWART CJ, 1987, MOL CELL BIOL, V7, P1156, DOI 10.1128/MCB.7.3.1156; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; THOMAS G, 1981, P NATL ACAD SCI-BIOL, V78, P5712, DOI 10.1073/pnas.78.9.5712; THOMAS R, 1983, VIROLOGY, V131, P502, DOI 10.1016/0042-6822(83)90516-0; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WEIL R, 1978, BIOCHIM BIOPHYS ACTA, V516, P301, DOI 10.1016/0304-419X(78)90012-4; WINBERRY L, 1985, VIROLOGY, V147, P154, DOI 10.1016/0042-6822(85)90235-1; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; ZULLO J, 1987, P NATL ACAD SCI USA, V84, P1210, DOI 10.1073/pnas.84.5.1210; [No title captured]	61	15	15	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1988	3	2					151	158						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	2842713				2022-12-17	WOS:A1988Q053400004
J	VANDERFELTZ, MJM; SHIVJI, MKK; GROSVELD, G; WIEDEMANN, LM				VANDERFELTZ, MJM; SHIVJI, MKK; GROSVELD, G; WIEDEMANN, LM			CHARACTERIZATION OF THE TRANSLOCATION BREAKPOINT IN A PATIENT WITH PHILADELPHIA POSITIVE, BCR NEGATIVE ACUTE LYMPHOBLASTIC-LEUKEMIA	ONCOGENE			English	Article									INST CANC RES,CHESTER BEATTY LABS,LEUKAEMIA RES FUND CTR,237 FULHAM RD,LONDON SW3 6JB,ENGLAND; ERASMUS UNIV,DEPT CELL BIOL & GENET,3000 DR ROTTERDAM,NETHERLANDS	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Erasmus University Rotterdam			Wiedemann, Leanne/E-3316-2010	Wiedemann, Leanne/0000-0002-0964-4676				BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; DEKLEIN A, 1986, BLOOD, V68, P1369; ERIDANI S, 1987, LEUKEMIA RES, V11, P965, DOI 10.1016/0145-2126(87)90114-7; ERIKSON J, 1986, P NATL ACAD SCI USA, V83, P1807, DOI 10.1073/pnas.83.6.1807; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FORD AM, 1983, EMBO J, V2, P997, DOI 10.1002/j.1460-2075.1983.tb01533.x; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GROSVELD G, 1986, MOL CELL BIOL, V6, P607, DOI 10.1128/MCB.6.2.607; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; KURZROCK R, 1987, BLOOD, V70, P1584; RIBEIRO RC, 1987, BLOOD, V70, P948; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; RUBIN CM, 1988, P NATL ACAD SCI USA, V85, P2795, DOI 10.1073/pnas.85.8.2795; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; VANKESSEL AHMG, 1981, SOMAT CELL GENET, V7, P645, DOI 10.1007/BF01538754; VANKESSEL AHMG, 1981, HUM GENET, V58, P162, DOI 10.1007/BF00278702; WALKER LC, 1987, NATURE, V329, P851, DOI 10.1038/329851a0; 1981, CANCER GENET CYTOGEN, V4, P101	28	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1988	3	2					215	219						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	3166123				2022-12-17	WOS:A1988Q053400013
J	KUPPUSWAMY, M; SUBRAMANIAN, T; CHINNADURAI, G				KUPPUSWAMY, M; SUBRAMANIAN, T; CHINNADURAI, G			SEPARATION OF IMMORTALIZATION AND T24-RAS ONCOGENE COOPERATIVE FUNCTIONS OF ADENOVIRUS E1A	ONCOGENE			English	Article									ST LOUIS UNIV,MED CTR,INST MOLEC VIROL,3681 PK AVE,ST LOUIS,MO 63110	Saint Louis University					NCI NIH HHS [CA-31719, CA-33616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033616, R01CA031719] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1984, ADENOVIRUSES, P339; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; KUPPUSWAMY MN, 1987, VIROLOGY, V159, P31, DOI 10.1016/0042-6822(87)90344-8; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; STEPHENS C, 1987, EMBO J, V6, P2027, DOI 10.1002/j.1460-2075.1987.tb02467.x; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P2329; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULFENDAHL PJ, 1987, EMBO J, V6, P2037, DOI 10.1002/j.1460-2075.1987.tb02468.x; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	24	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1988	2	6					613	615						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N8415	2968534				2022-12-17	WOS:A1988N841500013
J	LI, WJ; KLOETZER, WS; ARLINGHAUS, RB				LI, WJ; KLOETZER, WS; ARLINGHAUS, RB			A NOVEL 53 KDA PROTEIN COMPLEXED WITH P210BCR-ABL IN HUMAN CHRONIC MYELOGENOUS LEUKEMIA-CELLS	ONCOGENE			English	Article									JOHNSON & JOHNSON BIOTECHNOL CTR INC,SAN DIEGO,CA 92121	Johnson & Johnson	LI, WJ (corresponding author), UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.				NATIONAL CANCER INSTITUTE [P30CA016672, R01CA045125] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA45125] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; GALE RP, 1984, P NATL ACAD SCI-BIOL, V81, P5648, DOI 10.1073/pnas.81.18.5648; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HOUGHTEN RA, 1986, BIOTECHNIQUES, V4, P522; HUHN RD, 1987, IN PRESS P NATL ACAD; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JAY G, 1981, P NATL ACAD SCI-BIOL, V78, P2932, DOI 10.1073/pnas.78.5.2932; KIT S, 1969, INT J CANCER, V4, P383; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KONOPKA JB, 1985, P NATL ACAD SCI USA, V82, P1810, DOI 10.1073/pnas.82.6.1810; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MAXWELL SA, 1987, CANCER RES, V47, P1731; NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85; PRYWES R, 1985, J VIROL, V54, P114, DOI 10.1128/JVI.54.1.114-122.1985; RICHARDSON JM, 1987, CANCER RES, V47, P4066; ROTTER V, 1985, ADV CANCER RES, V43, P113, DOI 10.1016/S0065-230X(08)60944-6; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SEKI J, 1986, CANCER RES, V46, P907; SHTIVELMAN E, 1985, NATURE, V315, P758; SMITH AE, 1983, ADV VIRAL ONCOL, V3, P3; STAM K, 1985, NEW ENGL J MED, V313, P1429, DOI 10.1056/NEJM198512053132301; WALTER G, 1982, P NATL ACAD SCI-BIOL, V79, P4025, DOI 10.1073/pnas.79.13.4025; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0	37	15	16	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1988	2	6					559	566						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N8415	3133627				2022-12-17	WOS:A1988N841500005
J	PEAR, WS; NELSON, SF; AXELSON, H; WAHLSTROM, G; BAZIN, H; KLEIN, G; SUMEGI, J				PEAR, WS; NELSON, SF; AXELSON, H; WAHLSTROM, G; BAZIN, H; KLEIN, G; SUMEGI, J			ABERRANT CLASS SWITCHING JUXTAPOSES C-MYC WITH A MIDDLE REPETITIVE ELEMENT (LINE) AND AN IGH INTRON IN 2 SPONTANEOUSLY ARISING RAT IMMUNOCYTOMAS	ONCOGENE			English	Article									KAROLINSKA INST,DEPT TUMOR BIOL,BOX 60400,S-10401 STOCKHOLM 60,SWEDEN; FREE UNIV BRUSSELS,EXPTL IMMUNOL UNIT,B-1050 BRUSSELS,BELGIUM	Karolinska Institutet; Universite Libre de Bruxelles; Vrije Universiteit Brussel			Nelson, Stanley F/D-4771-2009	Nelson, Stanley F/0000-0002-2082-3114	NCI NIH HHS [3R01CA4054] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; ALT FW, 1986, IMMUNOL REV, V89, P5, DOI 10.1111/j.1600-065X.1986.tb01470.x; BAZIN H, 1972, INT J CANCER, V10, P568, DOI 10.1002/ijc.2910100316; BAZIN H, 1987, IN PRESS ADV CANCER; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BRUGGEMANN M, 1986, P NATL ACAD SCI USA, V83, P6075, DOI 10.1073/pnas.83.16.6075; CESARMAN E, 1987, IN PRESS SCIENCE; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; CORY S, 1983, EMBO J, V2, P697, DOI 10.1002/j.1460-2075.1983.tb01487.x; Croce C M, 1986, Adv Immunol, V38, P245, DOI 10.1016/S0065-2776(08)60008-5; DAMBROSIO E, 1986, MOL CELL BIOL, V6, P411, DOI 10.1128/MCB.6.2.411; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUNNICK W, 1980, NATURE, V286, P669, DOI 10.1038/286669a0; DURDIK J, 1984, NATURE, V307, P749, DOI 10.1038/307749a0; EARLY P, 1980, CELL, V19, P981, DOI 10.1016/0092-8674(80)90089-6; ECONOMOUPACHNIS A, 1985, P NATL ACAD SCI USA, V82, P2857, DOI 10.1073/pnas.82.9.2857; FAWCETT DH, 1986, CELL, V47, P1007, DOI 10.1016/0092-8674(86)90815-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FURANO AV, 1986, NUCLEIC ACIDS RES, V14, P3717, DOI 10.1093/nar/14.9.3717; HALUSKA FG, 1987, TRENDS GENET, V3, P11, DOI 10.1016/0168-9525(87)90155-7; HALUSKA FG, 1986, NATURE, V324, P158, DOI 10.1038/324158a0; HAMMARSKJOLD ML, 1986, GENE, V43, P41, DOI 10.1016/0378-1119(86)90006-5; HARTL P, 1987, IN PRESS MOL CELL BI; HATTORI M, 1986, NATURE, V321, P625, DOI 10.1038/321625a0; HELLMAN L, 1982, P NATL ACAD SCI-BIOL, V79, P1264, DOI 10.1073/pnas.79.4.1264; HOCHTL J, 1983, NATURE, V302, P260, DOI 10.1038/302260a0; KATZIR N, 1985, P NATL ACAD SCI USA, V82, P1054, DOI 10.1073/pnas.82.4.1054; KIRSCH IR, 1981, NATURE, V293, P583; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; Klein G, 1981, NATURE, V294, P313, DOI 10.1038/294313a0; KLOBECK HG, 1987, NUCLEIC ACIDS RES, V15, P4877, DOI 10.1093/nar/15.12.4877; LOEB DD, 1986, MOL CELL BIOL, V6, P168, DOI 10.1128/MCB.6.1.168; LUEDERS KK, 1984, MOL CELL BIOL, V4, P2128, DOI 10.1128/MCB.4.10.2128; MANIATIS T, 1982, MOL CLONING LABORATO; MARTIN SL, 1984, P NATL ACAD SCI-BIOL, V81, P2308, DOI 10.1073/pnas.81.8.2308; Maxam A M, 1980, Methods Enzymol, V65, P499; NIKAIDO T, 1982, J BIOL CHEM, V257, P7322; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; PEAR WS, 1986, IMMUNOGENETICS, V23, P393, DOI 10.1007/BF00372672; PEAR WS, 1986, P NATL ACAD SCI USA, V83, P7376, DOI 10.1073/pnas.83.19.7376; PEAR WS, 1987, IN PRESS MOL CELL BI; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; PICOLLI SP, 1984, NATURE, V310, P327; RADBRUCH A, 1986, IMMUNOL REV, V89, P70; REMMERS EF, 1986, EMBO J, V5, P895; SAKANO H, 1980, NATURE, V286, P676, DOI 10.1038/286676a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SHIMIZU A, 1984, CELL, V36, P801, DOI 10.1016/0092-8674(84)90029-1; SHOWE LC, 1987, P NATL ACAD SCI USA, V84, P2824, DOI 10.1073/pnas.84.9.2824; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SIMINOVITCH KA, 1985, NATURE, V316, P260, DOI 10.1038/316260a0; SINGER MF, 1985, TRENDS BIOCHEM SCI, V10, P119, DOI 10.1016/0968-0004(85)90271-3; SOARES MB, 1985, J MOL EVOL, V22, P117, DOI 10.1007/BF02101690; STADEN R, 1980, NUCLEIC ACIDS RES, V8, P3673, DOI 10.1093/nar/8.16.3673; STAVNEZERNORDGREN J, 1986, EMBO J, V5, P95, DOI 10.1002/j.1460-2075.1986.tb04182.x; STEEN ML, 1984, J MOL BIOL, V177, P19, DOI 10.1016/0022-2836(84)90055-X; SUMEGI J, 1983, NATURE, V306, P497, DOI 10.1038/306497a0; TAKAHASHI N, 1982, CELL, V29, P671, DOI 10.1016/0092-8674(82)90183-0; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; WIENER F, 1982, INT J CANCER, V29, P431, DOI 10.1002/ijc.2910290412; YANCOPOULOS GD, 1986, EMBO J, V5, P3259, DOI 10.1002/j.1460-2075.1986.tb04637.x; YANG JQ, 1985, EMBO J, V4, P1441, DOI 10.1002/j.1460-2075.1985.tb03800.x	65	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1988	2	5					499	507						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N4348	3131719				2022-12-17	WOS:A1988N434800012
J	Magrin, L; Fanale, D; Brando, C; Fiorino, A; Corsini, LR; Sciacchitano, R; Filorizzo, C; Dimino, A; Russo, A; Bazan, V				Magrin, Luigi; Fanale, Daniele; Brando, Chiara; Fiorino, Alessia; Corsini, Lidia Rita; Sciacchitano, Roberta; Filorizzo, Clarissa; Dimino, Alessandra; Russo, Antonio; Bazan, Viviana			POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes	ONCOGENE			English	Review							PROOFREADING DOMAIN MUTATIONS; FAMILIAL COLORECTAL-CANCER; LYNCH-SYNDROME; GERMLINE MUTATIONS; MISMATCH-REPAIR; DNA-POLYMERASE; ADENOMATOUS POLYPOSIS; PATHOGENIC VARIANTS; PD-1 BLOCKADE; GUIDELINES	POLE, POLD1, and NTHL1 are involved in DNA replication and have recently been recognized as hereditary cancer-predisposing genes, because their alterations are associated with colorectal cancer and other tumors. POLE/POLD1-associated syndrome shows an autosomal dominant inheritance, whereas NTHL1-associated syndrome follows an autosomal recessive pattern. Although the prevalence of germline monoallelic POLE/POLD1 and biallelic NTHL1 pathogenic variants is low, they determine different phenotypes with a broad tumor spectrum overlapping that of other hereditary conditions like Lynch Syndrome or Familial Adenomatous Polyposis. Endometrial and breast cancers, and probably ovarian and brain tumors are also associated with POLE/POLD1 alterations, while breast cancer and other unusual tumors are correlated with NTHL1 pathogenic variants. POLE-mutated colorectal and endometrial cancers are associated with better prognosis and may show favorable responses to immunotherapy. Since POLE/POLD1-mutated tumors show a high tumor mutational burden producing an increase in neoantigens, the identification of POLE/POLD1 alterations could help select patients suitable for immunotherapy treatment. In this review, we will investigate the role of POLE, POLD1, and NTHL1 genetic variants in cancer predisposition, discussing the potential future therapeutic applications and assessing the utility of performing a routine genetic testing for these genes, in order to implement prevention and surveillance strategies in mutation carriers.	[Magrin, Luigi; Fanale, Daniele; Brando, Chiara; Fiorino, Alessia; Corsini, Lidia Rita; Sciacchitano, Roberta; Filorizzo, Clarissa; Dimino, Alessandra; Russo, Antonio] Univ Palermo, Dept Surg Oncol & Oral Sci, Sect Med Oncol, I-90127 Palermo, Italy; [Bazan, Viviana] Univ Palermo, Dept Biomed Neurosci & Adv Diag, I-90127 Palermo, Italy	University of Palermo; University of Palermo	Russo, A (corresponding author), Univ Palermo, Dept Surg Oncol & Oral Sci, Sect Med Oncol, I-90127 Palermo, Italy.	antonio.russo@usa.net						ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; Aoude LG, 2015, FAM CANCER, V14, P621, DOI 10.1007/s10689-015-9826-8; Belhadj S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45281-1; Bellido F, 2016, GENET MED, V18, P325, DOI 10.1038/gim.2015.75; Bourdais R, 2017, CRIT REV ONCOL HEMAT, V113, P242, DOI 10.1016/j.critrevonc.2017.03.027; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Briggs S, 2013, J PATHOL, V230, P148, DOI 10.1002/path.4185; Campbell BB, 2017, CELL, V171, P1042, DOI 10.1016/j.cell.2017.09.048; Chubb D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11883; Church DN, 2013, HUM MOL GENET, V22, P2820, DOI 10.1093/hmg/ddt131; Colas C, 2012, ADV CANCER RES, V113, P121, DOI 10.1016/B978-0-12-394280-7.00004-X; Das L, 2020, DNA REPAIR, V93, DOI 10.1016/j.dnarep.2020.102920; Dhooge M, 2020, EUR J MED GENET, V63, DOI 10.1016/j.ejmg.2020.104080; Djursby M, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.566266; Domingo E, 2016, LANCET GASTROENTEROL, V1, P207, DOI 10.1016/S2468-1253(16)30014-0; Drost J, 2017, SCIENCE, V358, P234, DOI 10.1126/science.aao3130; Elsayed FA, 2020, GASTROENTEROLOGY, V159, DOI 10.1053/j.gastro.2020.08.042; Esteban-Jurado C, 2017, ONCOTARGET, V8, P26732, DOI 10.18632/oncotarget.15810; Fabrizio DA, 2018, J GASTROINTEST ONCOL, V9, P610, DOI 10.21037/jgo.2018.05.06; Fanale D, 2020, CANCERS, V12, DOI 10.3390/cancers12092415; Fancello L, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0647-4; Fang H, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008572; Forgo E, 2020, HISTOPATHOLOGY, V76, P366, DOI 10.1111/his.13984; Gao SC, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108833; Gelsomino F, 2016, CANCER TREAT REV, V51, P19, DOI 10.1016/j.ctrv.2016.10.005; Gong J, 2017, J NATL COMPR CANC NE, V15, P142, DOI 10.6004/jnccn.2017.0016; Grolleman JE, 2019, CANCER CELL, V35, P256, DOI 10.1016/j.ccell.2018.12.011; Groves A, 2019, FAM CANCER, V18, P179, DOI 10.1007/s10689-018-0107-1; Hamzaoui N, 2020, GENET MED, V22, P1533, DOI 10.1038/s41436-020-0828-z; Hansen MF, 2015, FAM CANCER, V14, P437, DOI 10.1007/s10689-015-9803-2; Haradhvala NJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04002-4; He JJ, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-20-7553; He Y, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000019281; Hegde M, 2014, GENET MED, V16, P101, DOI 10.1038/gim.2013.166; Hocke S, 2016, ONCOTARGET, V7, P7080, DOI 10.18632/oncotarget.6857; Howitt BE, 2015, JAMA ONCOL, V1, P1319, DOI 10.1001/jamaoncol.2015.2151; Hu HG, 2021, CANCER MED-US, V10, P135, DOI 10.1002/cam4.3579; Imboden S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214318; Jansen AML, 2016, EUR J HUM GENET, V24, P1089, DOI 10.1038/ejhg.2015.252; Job A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76033-1; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Leon-Castillo A, 2020, J PATHOL, V250, P323, DOI 10.1002/path.5372; Lewis KM, 2014, CURR PROB CANCER, V38, P216, DOI 10.1016/j.currproblcancer.2014.10.002; Li, 2019, ABSTRACT 5137 COMPRE, P5137; Li N, 2021, NPJ BREAST CANCER, V7, DOI 10.1038/s41523-021-00255-3; Limpose KL, 2018, NUCLEIC ACIDS RES, V46, P4515, DOI 10.1093/nar/gky162; Lindor NM, 2005, JAMA-J AM MED ASSOC, V293, P1979, DOI 10.1001/jama.293.16.1979; Liu J, 2020, MOL GENET GENOM MED, V8, DOI 10.1002/mgg3.1280; Mao R, 2021, GENET MED, V23, P1807, DOI 10.1038/s41436-021-01207-9; McConechy MK, 2016, CLIN CANCER RES, V22, P2865, DOI 10.1158/1078-0432.CCR-15-2233; Mehnert JM, 2016, J CLIN INVEST, V126, P2334, DOI 10.1172/JCI84940; Mertz TM, 2017, ONCOGENE, V36, P4427, DOI 10.1038/onc.2017.22; Mur P, 2020, GENET MED, V22, P2089, DOI 10.1038/s41436-020-0922-2; Nieuwenhuis MH, 2012, GUT, V61, P734, DOI 10.1136/gut.2010.229104; Nijman SMB, 2011, FEBS LETT, V585, P1, DOI 10.1016/j.febslet.2010.11.024; Palles C, 2022, FAM CANCER, V21, P197, DOI 10.1007/s10689-021-00256-y; Palles C, 2013, NAT GENET, V45, P136, DOI 10.1038/ng.2503; Pilati C, 2017, J PATHOL, V242, P10, DOI 10.1002/path.4880; Pursell ZF, 2007, SCIENCE, V317, P127, DOI 10.1126/science.1144067; Rayner E, 2016, NAT REV CANCER, V16, P71, DOI 10.1038/nrc.2015.12; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Rivera B, 2015, NEW ENGL J MED, V373, P1985, DOI 10.1056/NEJMc1506878; Rosner G, 2018, DIS COLON RECTUM, V61, P1073, DOI 10.1097/DCR.0000000000001150; Rousseau B, 2021, NEW ENGL J MED, V384, P1168, DOI 10.1056/NEJMc2031965; Schubert SA, 2020, MUTAGENESIS, V35, P221, DOI 10.1093/mutage/gez027; Short E, 2015, J MED GENET, V52, P791, DOI 10.1136/jmedgenet-2015-103298; Silberman R, 2019, JCO PRECIS ONCOL, V3, P1, DOI 10.1200/PO.18.00214; Siraj AK, 2020, ENDOCR CONNECT, V9, P923, DOI 10.1530/EC-20-0258; Siraj AK, 2020, MOL GENET GENOM MED, V8, DOI 10.1002/mgg3.1368; Siraj AK, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-1058-9; Spier I, 2015, INT J CANCER, V137, P320, DOI 10.1002/ijc.29396; Stjepanovic N, 2019, ANN ONCOL, V30, P1558, DOI 10.1093/annonc/mdz233; Strickler JH, 2021, CLIN CANCER RES, V27, P1236, DOI 10.1158/1078-0432.CCR-20-3054; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; Urso EDL, 2021, DIGEST LIVER DIS, V53, P409, DOI 10.1016/j.dld.2020.11.018; Valle L, 2014, HUM MOL GENET, V23, P3506, DOI 10.1093/hmg/ddu058; Vande Perre P, 2019, FAM CANCER, V18, P173, DOI 10.1007/s10689-018-0102-6; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; Wang F, 2019, JAMA ONCOL, V5, P1504, DOI 10.1001/jamaoncol.2019.2963; Weren RDA, 2018, J PATHOL, V244, P135, DOI 10.1002/path.5002; Weren RDA, 2015, NAT GENET, V47, P668, DOI 10.1038/ng.3287; Wong A, 2016, GYNECOL ONCOL, V141, P113, DOI 10.1016/j.ygyno.2015.12.031; Yao JQ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46064-4; Zhao PF, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0738-1	85	14	15	2	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2021	40	40					5893	5901		10.1038/s41388-021-01984-2	http://dx.doi.org/10.1038/s41388-021-01984-2		AUG 2021	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD5KT	34363023				2022-12-17	WOS:000682519100003
J	Xiang, Z; Zhou, ZJ; Song, SZ; Li, J; Ji, J; Yan, RL; Wang, JX; Cai, W; Hu, WJ; Zang, L; Zhu, ZG; Zhang, Z; Li, M; Yu, YY				Xiang, Zhen; Zhou, Zhijun; Song, Shuzheng; Li, Jun; Ji, Jun; Yan, Ranlin; Wang, Jiexuan; Cai, Wei; Hu, Wenjun; Zang, Lu; Zhu, Zhenggang; Zhang, Zhen; Li, Min; Yu, Yingyan			Dexamethasone suppresses immune evasion by inducing GR/STAT3 mediated downregulation of PD-L1 and IDO1 pathways	ONCOGENE			English	Article							GLUCOCORTICOIDS; EXPRESSION; COVID-19; CELLS	T cell exhaustion plays critical roles in tumor immune evasion. Novel strategies to suppress immune evasion are in urgent need. We aimed to identify potential compounds to target T cell exhaustion and increase response to immune checkpoint inhibitors (ICIs). Differentially expressed genes (DEGs) were identified between tumors with different immune evasion potential by comparing the transcriptome data. DEGs were then analyzed in the Connectivity Map (CMap) platform to identify potential compounds to increase response to ICIs. Gene set enrichment analysis, LDH release assay, Chromatin immunoprecipitation (ChIP), and Co-IP were performed to explore the potential mechanisms in vitro. Patients derived organoids and humanized xenograft mouse model were utilized to validate the finding ex vivo and in vivo. We identified 25 potential compounds that may play critical roles in regulating tumor immune evasion. We further pinpointed a specific compound, dexamethasone, which shows potent anti-tumor effect in multiple cancer cell lines when cocultured with T cells. Dexamethasone can suppress T cell exhaustion by decreasing the activity of two immune checkpoints simultaneously, including PD-L1 and IDO1. Functional study shows dexamethasone can increase the sensitivity of ICIs in coculture system, 3D organoid model and humanized mouse model. Mechanism study shows dexamethasone mediated transcriptional suppression of PD-L1 and IDO1 depends on the nuclear translocation of GR/STAT3 complex. These findings demonstrate dexamethasone can suppress immune evasion by inducing GR/STAT3 mediated downregulation of PD-L1 and IDO1 pathways.	[Xiang, Zhen; Song, Shuzheng; Li, Jun; Ji, Jun; Yan, Ranlin; Wang, Jiexuan; Cai, Wei; Hu, Wenjun; Zang, Lu; Zhu, Zhenggang; Yu, Yingyan] Shanghai Jiao Tong Univ, Dept Gen Surg, Sch Med, Ruijin Hosp,Shanghai Inst Digest Surg, Shanghai, Peoples R China; [Xiang, Zhen; Song, Shuzheng; Li, Jun; Ji, Jun; Yan, Ranlin; Wang, Jiexuan; Cai, Wei; Hu, Wenjun; Zang, Lu; Zhu, Zhenggang; Yu, Yingyan] Shanghai Jiao Tong Univ, Shanghai Key Lab Gastr Neoplasms, Sch Med, Shanghai, Peoples R China; [Zhou, Zhijun; Li, Min] Univ Oklahoma, Dept Med, Hlth Sci Ctr, Oklahoma City, OK 73104 USA; [Zhou, Zhijun; Li, Min] Univ Oklahoma, Dept Surg, Hlth Sci Ctr, Oklahoma City, OK 73104 USA; [Zhang, Zhen] Fudan Univ, Shanghai Med Coll, Dept Radiat Oncol, Shanghai Canc Ctr, 270 Dong An Rd, Shanghai 200032, Peoples R China; [Zhang, Zhen] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai Canc Ctr, 270 Dong An Rd, Shanghai 200032, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Fudan University; Fudan University	Yu, YY (corresponding author), Shanghai Jiao Tong Univ, Dept Gen Surg, Sch Med, Ruijin Hosp,Shanghai Inst Digest Surg, Shanghai, Peoples R China.; Yu, YY (corresponding author), Shanghai Jiao Tong Univ, Shanghai Key Lab Gastr Neoplasms, Sch Med, Shanghai, Peoples R China.; Li, M (corresponding author), Univ Oklahoma, Dept Med, Hlth Sci Ctr, Oklahoma City, OK 73104 USA.; Li, M (corresponding author), Univ Oklahoma, Dept Surg, Hlth Sci Ctr, Oklahoma City, OK 73104 USA.; Zhang, Z (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Radiat Oncol, Shanghai Canc Ctr, 270 Dong An Rd, Shanghai 200032, Peoples R China.; Zhang, Z (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai Canc Ctr, 270 Dong An Rd, Shanghai 200032, Peoples R China.	zhen_zhang@fudan.edu.cn; Min-Li@ouhsc.edu; yingyan3y@sjtu.edu.cn	Zhou, Zhijun/AAU-9428-2021	Zhou, Zhijun/0000-0003-2226-2223	Chinese National Key Program [MOST-2017YFC0908300, 2016YFC1303200]; National Natural Science Foundation of China [82072602, 81772505]; Shanghai Science and Technology Committee [20DZ2201900, 18411953100]; cross-institute innovation foundation of Shanghai Jiao Tong University [YG2017ZD01]; Innovation Foundation of Translational Medicine of Shanghai Jiao Tong University School of Medicine [TM202001, 15ZH4001, TM201617, TM 201702]; Technology Transfer Project of Science & Technology Dept. Shanghai Jiao Tong University School of Medicine; Innovation Foundation for Doctor's Degree [BXJ201914]	Chinese National Key Program; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Committee(Shanghai Science & Technology Committee); cross-institute innovation foundation of Shanghai Jiao Tong University; Innovation Foundation of Translational Medicine of Shanghai Jiao Tong University School of Medicine; Technology Transfer Project of Science & Technology Dept. Shanghai Jiao Tong University School of Medicine; Innovation Foundation for Doctor's Degree	We acknowledge the open database of CCLE, TCGA and CMap. This project is partially supported by the Chinese National Key Program (MOST-2017YFC0908300 and 2016YFC1303200), the National Natural Science Foundation of China (82072602 and 81772505), Shanghai Science and Technology Committee (20DZ2201900 and 18411953100), the cross-institute innovation foundation of Shanghai Jiao Tong University (YG2017ZD01), the Innovation Foundation of Translational Medicine of Shanghai Jiao Tong University School of Medicine (TM202001, 15ZH4001, TM201617 and TM 201702), Technology Transfer Project of Science & Technology Dept. Shanghai Jiao Tong University School of Medicine, and Innovation Foundation for Doctor's Degree (BXJ201914) grants to Y. Yu.	AlBahrani S, 2021, J EPIDEMIOL GLOB HEA, V11, P233, DOI 10.2991/jegh.k.210112.001; [Anonymous], 2017, Cancer Discov, V7, pOF2, DOI 10.1158/2159-8290.CD-NB2017-100; Arbour KC, 2018, J CLIN ONCOL, V36, P2872, DOI 10.1200/JCO.2018.79.0006; Arumuggam N, 2015, PHYTOTHER RES, V29, P805, DOI 10.1002/ptr.5327; Badros A, 2017, BLOOD, V130, P1189, DOI 10.1182/blood-2017-03-775122; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Calagua C, 2017, CLIN CANCER RES, V23, P6812, DOI 10.1158/1078-0432.CCR-17-0807; Charles P, 2021, ANN RHEUM DIS, DOI 10.1136/annrheumdis-2021-219986; CONN DL, 1988, J RHEUMATOL, V15, P1181; De Santis M, 2021, ANN RHEUM DIS, DOI 10.1136/annrheumdis-2021-220044; Delavan B, 2018, DRUG DISCOV TODAY, V23, P382, DOI 10.1016/j.drudis.2017.10.009; Egberts JH, 2008, CANCER BIOL THER, V7, P1044, DOI 10.4161/cbt.7.7.6099; Fu HY, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2854186; Gaestel M, 2006, NAT REV MOL CELL BIO, V7, P120, DOI 10.1038/nrm1834; Gruver-Yates Amanda L, 2013, Cells, V2, P202, DOI 10.3390/cells2020202; Harpaz I, 2013, EUR J IMMUNOL, V43, P758, DOI 10.1002/eji.201242613; Hsieh TC, 2022, ANN HEMATOL, V101, P431, DOI 10.1007/s00277-021-04457-4; Keller MJ, 2020, J HOSP MED, V15, P489, DOI 10.12788/jhm.3497; Komiya T, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00423; Langlais D, 2012, MOL CELL, V47, P38, DOI 10.1016/j.molcel.2012.04.021; Langut Y, 2017, P NATL ACAD SCI USA, V114, P13655, DOI 10.1073/pnas.1714587115; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Lau J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14572; Li GR, 2020, DIABETES RES CLIN PR, V168, DOI 10.1016/j.diabres.2020.108441; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Manzotti G, 2015, CELL CYCLE, V14, P2578, DOI 10.1080/15384101.2015.1033591; Marzec M, 2008, P NATL ACAD SCI USA, V105, P20852, DOI 10.1073/pnas.0810958105; Muller AJ, 2019, SEMIN IMMUNOPATHOL, V41, P41, DOI 10.1007/s00281-018-0702-0; Nanki K, 2018, CELL, V174, P856, DOI 10.1016/j.cell.2018.07.027; Neal JT, 2018, CELL, V175, P1972, DOI 10.1016/j.cell.2018.11.021; Opitz CA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019823; Ott M, 2015, GLIA, V63, P78, DOI 10.1002/glia.22734; Pitt JM, 2016, IMMUNITY, V44, P1255, DOI 10.1016/j.immuni.2016.06.001; Pontali E, 2021, J ALLERGY CLIN IMMUN, V147, P1217, DOI 10.1016/j.jaci.2021.01.024; Ramiro S, ANN RHEUM DIS, P2021; Ramiro S, 2020, ANN RHEUM DIS, V79, P1143, DOI 10.1136/annrheumdis-2020-218479; Robinson PC, 2021, LANCET RHEUMATOL, V3, pE168, DOI 10.1016/S2665-9913(21)00005-9; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049; Sun C, 2018, IMMUNITY, V48, P434, DOI 10.1016/j.immuni.2018.03.014; Sun YP, 2009, J IMMUNOL, V182, P5899, DOI 10.4049/jimmunol.0804388; Venkitaraman R, 2015, EUR UROL, V67, P673, DOI 10.1016/j.eururo.2014.10.004; Wang J, 2019, CELL, V176, P334, DOI 10.1016/j.cell.2018.11.010; Xiang Z, 2017, ONCOGENE, V36, P5122, DOI 10.1038/onc.2017.108; Xiang Z, 2019, FRONT MED-PRC, V13, P24, DOI 10.1007/s11684-019-0679-7; Xiang Z, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00861; Yang RX, 2021, INT J BIOL SCI, V17, P1530, DOI 10.7150/ijbs.58695	49	14	14	1	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2021	40	31					5002	5012		10.1038/s41388-021-01897-0	http://dx.doi.org/10.1038/s41388-021-01897-0		JUN 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV5MG	34175886	Green Published, hybrid			2022-12-17	WOS:000666835600001
J	Zhang, XL; Hu, LP; Yang, Q; Qin, WT; Wang, X; Xu, CJ; Tian, GA; Yang, XM; Yao, LL; Zhu, L; Nie, HZ; Li, Q; Xu, Q; Zhang, ZG; Zhang, YL; Li, J; Wang, YH; Jiang, SH				Zhang, Xue-Li; Hu, Li-Peng; Yang, Qin; Qin, Wei-Ting; Wang, Xu; Xu, Chun-Jie; Tian, Guang-Ang; Yang, Xiao-Mei; Yao, Lin-Li; Zhu, Lei; Nie, Hui-Zhen; Li, Qing; Xu, Qing; Zhang, Zhi-Gang; Zhang, Yan-Li; Li, Jun; Wang, Ya-Hui; Jiang, Shu-Heng			CTHRC1 promotes liver metastasis by reshaping infiltrated macrophages through physical interactions with TGF-beta receptors in colorectal cancer	ONCOGENE			English	Article							TRIPLE-HELIX REPEAT; TUMOR-ASSOCIATED MACROPHAGES; CELL; EXPRESSION; PROGRESSION; STATISTICS; MIGRATION; INVASION; GENES	Metastasis is a major cause of cancer-related deaths. Tumor-intrinsic properties can determine whether tumor metastasis occurs or not. Here, by comparing the gene expression patterns in primary colorectal cancer (CRC) patients with or without metastasis, we found that Collagen Triple Helix Repeat Containing 1 (CTHRC1) in primary CRC served as a metastasis-associated gene. Animal experiments verified that CTHRC1 secreted by CRC cells promoted hepatic metastasis, which was closely correlated with macrophage infiltration. Depletion of macrophages by liposomal clodronate largely abolished the promoting effect of CTHRC1 on CRC liver metastasis. Furthermore, we demonstrated that CTHRC1 modulated macrophage polarization to M2 phenotypes through TGF-beta signaling. A mechanistic study revealed that CTHRC1 bound directly to TGF-beta receptor II and TGF-beta receptor III, stabilized the TGF-beta receptor complex, and activated TGF-beta signaling. The combination treatment of CTHRC1 monoclonal antibody and anti-PD-1 blocking antibody effectively suppressed CRC hepatic metastasis. Taken together, our data demonstrated that CTHRC1 is an intrinsic marker of CRC metastasis and further revealed that CTHRC1 promoted CRC liver metastasis by reshaping infiltrated macrophages through TGF-beta signaling, suggesting that CTHRC1 could be a potential biomarker for the early prediction of and a therapeutic target of CRC hepatic metastasis.	[Zhang, Xue-Li; Hu, Li-Peng; Yang, Qin; Wang, Xu; Tian, Guang-Ang; Yang, Xiao-Mei; Yao, Lin-Li; Zhu, Lei; Nie, Hui-Zhen; Li, Qing; Zhang, Zhi-Gang; Zhang, Yan-Li; Li, Jun; Wang, Ya-Hui; Jiang, Shu-Heng] Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes, Ren Ji Hosp,Shanghai Canc Inst, Shanghai, Peoples R China; [Qin, Wei-Ting] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Radiat Oncol, Shanghai, Peoples R China; [Xu, Chun-Jie; Xu, Qing] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Gastrointestinal Surg, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Zhang, YL; Li, J; Wang, YH; Jiang, SH (corresponding author), Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes, Ren Ji Hosp,Shanghai Canc Inst, Shanghai, Peoples R China.	ylzhang@shsci.org; junli@shsci.org; yhwang@shsci.org; shjiang@shsci.org		Zhang, Xueli/0000-0001-8306-0639; Zhang, Yan-Li/0000-0002-8942-5325; Wang, Xu/0000-0002-3768-777X	National Natural Science Foundation of China [81802890, 81902370, 81871923, 31801212, 81872242]; Natural Science Foundation of Shanghai [18ZR1436900]; Shanghai Municipal Health Commission [202040092, 202040104, 201740105]; Program of Shanghai Academic/Technology Research Leader [19XD1403400]; Shanghai International Science and Technology Cooperation Fund [18410721000]; Excellent Academic Leader of Shanghai Municipal Health Bureau [2018BR32]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20191809]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai); Shanghai Municipal Health Commission; Program of Shanghai Academic/Technology Research Leader; Shanghai International Science and Technology Cooperation Fund; Excellent Academic Leader of Shanghai Municipal Health Bureau; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support	This study was supported by the National Natural Science Foundation of China (No. 81802890 to X-LZ; No. 81902370 to S-HJ; No. 81871923 to JL; No. 31801212 to L-LY, No. 81872242 to Y-LZ), the Natural Science Foundation of Shanghai (No. 18ZR1436900 to X-LZ), the Shanghai Municipal Health Commission (No. 202040092 to X-LZ; No. 202040104, to Y-LZ; No. 201740105 to H-ZN), Program of Shanghai Academic/Technology Research Leader (No. 19XD1403400, to Z-GZ), Shanghai International Science and Technology Cooperation Fund (No. 18410721000, to Z-GZ), Excellent Academic Leader of Shanghai Municipal Health Bureau (No. 2018BR32, to Z-GZ), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (No. 20191809, to JL). We thank Dr Dong-Xue Li, Dr Shan Huang, Dr Li-li Zhu, Dr Shan Zhang, Yue Sun, and Kai-Xia Zhou for assistance with our experiments.	Balkwill FR, 2012, J CELL SCI, V125, P5591, DOI 10.1242/jcs.116392; Chang GJ, 2007, J NATL CANCER I, V99, P433, DOI 10.1093/jnci/djk092; Charoentong P, 2017, CELL REP, V18, P248, DOI 10.1016/j.celrep.2016.12.019; Chen XF, 2018, INT J CANCER, V143, P2561, DOI 10.1002/ijc.31730; Chen YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070324; Chevrier S, 2017, CELL, V169, P736, DOI 10.1016/j.cell.2017.04.016; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Dehnel N, 2017, CURR OPIN PHARMACOL, V35, P12, DOI 10.1016/j.coph.2017.04.007; Dhupkar P, 2018, CANCER MED-US, V7, P2654, DOI 10.1002/cam4.1518; Gao B, 2016, INT J ONCOL, V49, P1108, DOI 10.3892/ijo.2016.3591; Gao Y, 2019, DEV CELL, V49, P375, DOI 10.1016/j.devcel.2019.04.012; Gordon SR, 2017, NATURE, V545, P495, DOI 10.1038/nature22396; Jiang N, 2016, J CANCER, V7, P2213, DOI 10.7150/jca.16539; Jin YR, 2017, BONE, V97, P153, DOI 10.1016/j.bone.2017.01.022; Jorissen RN, 2009, CLIN CANCER RES, V15, P7642, DOI 10.1158/1078-0432.CCR-09-1431; Ki DH, 2007, INT J CANCER, V121, P2005, DOI 10.1002/ijc.22975; Kim HC, 2014, ONCOTARGET, V5, P519, DOI 10.18632/oncotarget.1714; Kim J, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6058147; Kim SK, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0319-y; Kimura H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003174; Leclere L, 2020, GENOME BIOL EVOL, V12, P3957, DOI 10.1093/gbe/evaa020; Li J, 2019, EBIOMEDICINE, V40, P43, DOI 10.1016/j.ebiom.2019.01.009; Li LY, 2019, CLIN EXP METASTAS, V36, P351, DOI 10.1007/s10585-019-09971-4; Lin EY, 2006, CANCER RES, V66, P11238, DOI 10.1158/0008-5472.CAN-06-1278; Lind H, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000433; Lu D, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/1919082; Lu M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169439; Manfredi S, 2006, ANN SURG, V244, P254, DOI 10.1097/01.sla.0000217629.94941.cf; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Muller S, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1362-4; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Ni SJ, 2018, CANCER MED-US, V7, P5643, DOI 10.1002/cam4.1807; Obenauf AC, 2015, TRENDS CANCER, V1, P76, DOI 10.1016/j.trecan.2015.07.009; Park EH, 2013, CARCINOGENESIS, V34, P694, DOI 10.1093/carcin/bgs378; Peinado H, 2017, NAT REV CANCER, V17, P302, DOI 10.1038/nrc.2017.6; Perilli L, 2014, GENOM DATA, V2, P184, DOI 10.1016/j.gdata.2014.06.017; Pyagay P, 2005, CIRC RES, V96, P261, DOI 10.1161/01.RES.0000154262.07264.12; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Qian ZY, 2017, ONCOTARGET, V8, P25500, DOI 10.18632/oncotarget.16064; Qin S, 2019, BIOMED PHARMACOTHER, V113, DOI 10.1016/j.biopha.2019.01.055; Rivera LB, 2013, CANCER CELL, V24, P687, DOI 10.1016/j.ccr.2013.11.014; Santoni M, 2018, BBA-REV CANCER, V1869, P78, DOI 10.1016/j.bbcan.2017.10.007; Segnan N, 2017, CANCER-AM CANCER SOC, V123, P4767, DOI 10.1002/cncr.31032; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stange DE, 2010, GUT, V59, P1236, DOI 10.1136/gut.2009.195701; Takeshita S, 2013, J CLIN INVEST, V123, P3914, DOI 10.1172/JCI69493; Tang L, 2006, CLIN CANCER RES, V12, P3716, DOI 10.1158/1078-0432.CCR-06-0030; Vitale I, 2019, CELL METAB, V30, P36, DOI 10.1016/j.cmet.2019.06.001; Wang P, 2012, CANCER SCI, V103, P1327, DOI 10.1111/j.1349-7006.2012.02292.x; Xu CJ, 2017, BIOMED PHARMACOTHER, V91, P1167, DOI 10.1016/j.biopha.2017.05.056; Yamasaki M, 2007, INT J ONCOL, V30, P129; Yan L, 2015, AM J CANCER RES, V5, P1447; Yang XM, 2015, INT J CLIN EXP PATHO, V8, P12793; Zumsteg A, 2009, CURR OPIN ONCOL, V21, P60, DOI 10.1097/CCO.0b013e32831bed7e	56	14	15	7	25	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2021	40	23					3959	3973		10.1038/s41388-021-01827-0	http://dx.doi.org/10.1038/s41388-021-01827-0		MAY 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SQ8GV	33986509				2022-12-17	WOS:000650146400002
J	Chen, Z; Shao, YL; Wang, LL; Lin, J; Zhang, JB; Ding, Y; Gao, BB; Liu, DH; Gao, XN				Chen, Ze; Shao, Yang-Liu; Wang, Li-Li; Lin, Ji; Zhang, Ji-Bin; Ding, Yi; Gao, Bin-bin; Liu, Dai-Hong; Gao, Xiao-Ning			YTHDF2 is a potential target of AML1/ETO-HIF1 alpha loop-mediated cell proliferation in t(8;21) AML	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; GENE-EXPRESSION PROFILES; CANCER; DIFFERENTIATION; LEUKEMOGENESIS; AML1-ETO; PROMOTE	The t(8;21) fusion product, AML1/ETO, and hypoxia-inducible factor 1 alpha (HIF1 alpha) form a feed-forward transcription loop that cooperatively transactivates the DNA methyltransferase 3a gene promoter that leads to DNA hypermethylation and drives leukemia cell growth. Suppression of the RNA N-6-methyladenosine (m(6)A)-reader enzyme YTH N-6-methyladenosine RNA binding protein 2 (YTHDF2) specifically compromises cancer stem cells in acute myeloid leukemia (AML) but promotes hematopoietic stem cell expansion without derailing normal hematopoiesis. However, the relevance of expression between AML1/ETO-HIF1 alpha loop and YTHDF2, and its functional relationship with t(8;21) AML have not been documented. Here, we show that YTHDF2 is highly expressed in t(8;21) AML patients and associated with a higher risk of relapse and inferior relapse-free survival. Knockdown of YTHDF2 in leukemia cells causes an impaired cell proliferation rate in vitro and in mice. Mechanistically, HIF1 alpha is able to bind to the hypoxia-response elements of the 5 '-untranslated region of the YTHDF2 gene and promotes the transactivity of the YTHDF2 promoter. Knockdown and overexpression of either AML1/ETO or HIF1 alpha resulted in decreased and increased YTHDF2 protein and mRNA expression in t(8;21) AML cells. In particular, knockdown of YTHDF2 resulted in increased global mRNA m(6)A levels in t(8;21) AML cells, accompanied by increased TNF receptor superfamily member 1b (TNFRSF1b) mRNA and protein expression levels. Last, we demonstrated that the m(6)A methylation and expression levels of the TNFRSF1b gene were both negatively correlated with HIF1 alpha expression levels. In conclusion, YTHDF2 is a downstream target of the AML1/ETO-HIF1 alpha loop and promotes cell proliferation probably by modulating the global m(6)A methylation in t(8;21) AML.	[Chen, Ze; Shao, Yang-Liu; Wang, Li-Li; Ding, Yi; Gao, Bin-bin; Liu, Dai-Hong; Gao, Xiao-Ning] Chinese Peoples Liberat Army Gen Hosp, Dept Hematol, Beijing, Peoples R China; [Lin, Ji] Chinese Peoples Liberat Army Gen Hosp, Grad Sch, Dept Basic Med, Beijing, Peoples R China; [Zhang, Ji-Bin] Chinese Peoples Liberat Army Gen Hosp, Dept Cardiol, Beijing, Peoples R China	Chinese People's Liberation Army General Hospital; Chinese People's Liberation Army General Hospital; Chinese People's Liberation Army General Hospital	Liu, DH; Gao, XN (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Dept Hematol, Beijing, Peoples R China.	daihongrm@163.com; gaoxn@263.net	wang, lili/HDL-7210-2022	Gao, Xiaoning/0000-0003-2035-7472; Yu, Li/0000-0001-6872-2665	National Natural Science Foundation of China [82070149, 81870109, 81670135]; Natural Science Foundation of Beijing Municipality [7202191]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Beijing Municipality(Beijing Natural Science Foundation)	This work was partially supported by grants from the National Natural Science Foundation of China (82070149, 81870109, and 81670135 to X-NG), the Natural Science Foundation of Beijing Municipality (7202191 to X-NG).	Al-Harbi S, 2020, BLOOD ADV, V4, P229, DOI 10.1182/bloodadvances.2019000168; Appelbaum FR, 2006, BRIT J HAEMATOL, V135, P165, DOI 10.1111/j.1365-2141.2006.06276.x; Barbieri I, 2017, NATURE, V552, P126, DOI 10.1038/nature24678; Cheng JM, 2017, CELL CYCLE, V16, P1404, DOI 10.1080/15384101.2017.1327488; de Jonge HJM, 2010, BLOOD, V116, P1747, DOI 10.1182/blood-2010-03-270991; Du H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12626; Fazi F, 2007, CANCER CELL, V12, P457, DOI 10.1016/j.ccr.2007.09.020; Gao XN, 2015, LEUKEMIA, V29, P1730, DOI 10.1038/leu.2015.56; Hou J, 2019, CANCER RES, V79; Hou JJ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1082-3; Kuhnl A, 2011, BLOOD, V118, P6362, DOI 10.1182/blood-2011-04-350850; Li JF, 2018, ONCOTARGET, V9, P3752, DOI 10.18632/oncotarget.23365; Li Zejuan, 2017, Cancer Cell, V31, P127, DOI 10.1016/j.ccell.2016.11.017; Li ZR, 2018, CELL RES, V28, P904, DOI 10.1038/s41422-018-0072-0; Marcucci G, 2005, J CLIN ONCOL, V23, P5705, DOI 10.1200/JCO.2005.15.610; Paris J, 2019, CELL STEM CELL, V25, P137, DOI 10.1016/j.stem.2019.03.021; Prebet T, 2009, J CLIN ONCOL, V27, P4747, DOI 10.1200/JCO.2008.21.0674; Schlenk RF, 2004, J CLIN ONCOL, V22, P3741, DOI 10.1200/JCO.2004.03.012; Scrucca L, 2007, BONE MARROW TRANSPL, V40, P381, DOI 10.1038/sj.bmt.1705727; Sheng H, 2020, CARCINOGENESIS, V41, P541, DOI 10.1093/carcin/bgz152; Shia WJ, 2012, BLOOD, V119, P4953, DOI 10.1182/blood-2011-04-347476; Su R, 2018, CELL, V172, P90, DOI 10.1016/j.cell.2017.11.031; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; Vu LP, 2017, NAT MED, V23, P1369, DOI 10.1038/nm.4416; Wang H, 2018, CELL RES, V28, P1035, DOI 10.1038/s41422-018-0082-y; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang L, 2011, SCIENCE, V333, P765, DOI 10.1126/science.1201662; Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014; Weng HY, 2018, CELL STEM CELL, V22, P191, DOI 10.1016/j.stem.2017.11.016; Yan M, 2004, P NATL ACAD SCI USA, V101, P17468, DOI 10.1073/pnas.0406142101; Zhong L, 2019, CANCER LETT, V442, P252, DOI 10.1016/j.canlet.2018.11.006	31	14	14	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2021	40	22					3786	3798		10.1038/s41388-021-01818-1	http://dx.doi.org/10.1038/s41388-021-01818-1		MAY 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SM7LL	33958724				2022-12-17	WOS:000648041500006
J	Duarte, HO; Rodrigues, JG; Gomes, C; Hensbergen, PJ; Ederveen, ALH; de Ru, AH; Mereiter, S; Polonia, A; Fernandes, E; Ferreira, JA; van Veelen, PA; Santos, LL; Wuhrer, M; Gomes, J; Reis, CA				Duarte, Henrique O.; Rodrigues, Joana G.; Gomes, Catarina; Hensbergen, Paul J.; Ederveen, Agnes L. Hipgrave; de Ru, Arnoud H.; Mereiter, Stefan; Polonia, Antonio; Fernandes, Elisabete; Ferreira, Jose A.; van Veelen, Peter A.; Santos, Lucio L.; Wuhrer, Manfred; Gomes, Joana; Reis, Celso A.			ST6Gal1 targets the ectodomain of ErbB2 in a site-specific manner and regulates gastric cancer cell sensitivity to trastuzumab	ONCOGENE			English	Article							GLYCOSYLATION; RECEPTOR; SIALYLATION; EXPRESSION; EGFR	The clinical performance of the therapeutic monoclonal antibody trastuzumab in the treatment of ErbB2-positive unresectable gastric cancer (GC) is severely hampered by the emergence of molecular resistance. Trastuzumab's target epitope is localized within the extracellular domain of the oncogenic cell surface receptor tyrosine kinase (RTK) ErbB2, which is known to undergo extensive N-linked glycosylation. However, the site-specific glycan repertoire of ErbB2, as well as the detailed molecular mechanisms through which specific aberrant glycan signatures functionally impact the malignant features of ErbB2-addicted GC cells, including the acquisition of trastuzumab resistance, remain elusive. Here, we demonstrate that ErbB2 is modified with both alpha 2,6- and alpha 2,3-sialylated glycan structures in GC clinical specimens. In-depth mass spectrometry-based glycomic and glycoproteomic analysis of ErbB2's ectodomain disclosed a site-specific glycosylation profile in GC cells, in which the ST6Gal1 sialyltransferase specifically targets ErbB2 N-glycosylation sites occurring within the receptor's trastuzumab-binding domain. Abrogation of ST6Gal1 expression reshaped the cellular and ErbB2-specific glycomes, expanded the cellular half-life of the ErbB2 receptor, and sensitized ErbB2-dependent GC cells to trastuzumab-induced cytotoxicity through the stabilization of ErbB dimers at the cell membrane, and the decreased activation of both ErbB2 and EGFR RTKs. Overall, our data demonstrates that ST6Gal1-mediated aberrant alpha 2,6-sialylation actively tunes the resistance of ErbB2-driven GC cells to trastuzumab.	[Duarte, Henrique O.; Rodrigues, Joana G.; Gomes, Catarina; Mereiter, Stefan; Polonia, Antonio; Gomes, Joana; Reis, Celso A.] Univ Porto, i3S Inst Invest & Inovacao Saude, Porto, Portugal; [Duarte, Henrique O.; Rodrigues, Joana G.; Gomes, Catarina; Mereiter, Stefan; Polonia, Antonio; Gomes, Joana; Reis, Celso A.] Univ Porto, IPATIMUP Inst Mol Pathol & Immunol, Porto, Portugal; [Duarte, Henrique O.; Rodrigues, Joana G.; Reis, Celso A.] Univ Porto, ICBAS Inst Biomed Sci Abel Salazar, Porto, Portugal; [Hensbergen, Paul J.; Ederveen, Agnes L. Hipgrave; de Ru, Arnoud H.; van Veelen, Peter A.; Wuhrer, Manfred] Leiden Univ, Ctr Prote & Metabol, Med Ctr, Leiden, Netherlands; [Polonia, Antonio] Univ Porto, Dept Pathol, IPATIMUP, IPATIMUP Diagnost, Porto, Portugal; [Fernandes, Elisabete; Ferreira, Jose A.; Santos, Lucio L.] Portuguese Inst Oncol, IPO Porto Res Ctr, Expt Pathol & Therapeut Grp, Porto, Portugal; [Santos, Lucio L.] Portuguese Inst Oncol, Dept Surg Oncol, Porto, Portugal; [Reis, Celso A.] Univ Porto, Fac Med, Porto, Portugal; [Mereiter, Stefan] Austrian Acad Sci, Inst Mol Biotechnol, IMBA, Vienna, Austria	Universidade do Porto; i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto; Universidade do Porto; Universidade do Porto; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Universidade do Porto; Universidade de Coimbra; Universidade de Coimbra; Universidade do Porto; Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)	Gomes, J; Reis, CA (corresponding author), Univ Porto, i3S Inst Invest & Inovacao Saude, Porto, Portugal.; Gomes, J; Reis, CA (corresponding author), Univ Porto, IPATIMUP Inst Mol Pathol & Immunol, Porto, Portugal.; Reis, CA (corresponding author), Univ Porto, ICBAS Inst Biomed Sci Abel Salazar, Porto, Portugal.; Reis, CA (corresponding author), Univ Porto, Fac Med, Porto, Portugal.	joanag@ipatimup.pt; celsor@ipatimup.pt	REIS, Celso A/B-9969-2008; Gomes, Catarina/CAJ-5505-2022; Wuhrer, Manfred/ABE-9168-2020; Ferreira, José Alexandre/ABM-1695-2022; Oliveira Duarte, Henrique/AAZ-7387-2021; Gomes, Joana/K-9031-2013	REIS, Celso A/0000-0002-0286-6639; Wuhrer, Manfred/0000-0002-0814-4995; Ferreira, José Alexandre/0000-0002-0097-6148; Hipgrave Ederveen, Agnes/0000-0003-1689-0442; Rodrigues, Joana/0000-0001-5890-6620; Hensbergen, Paul/0000-0002-3193-5445; Gomes, Joana/0000-0002-8832-2703; Gomes, Catarina/0000-0002-0352-6783; van Veelen, Peter/0000-0002-7898-9408; Mereiter, Stefan/0000-0002-4832-3090; Fernandes, Elisabete/0000-0002-9907-7432; Duarte, Henrique/0000-0001-8641-8368	FEDER funds through the Operational Program for Competitiveness Factors COMPETE 2020 [POCI-01-0145-FEDER-016585, POCI-01-0145-FEDER-007274]; Foundation for Science and Technology (FCT) [PTDC/BBB-EBI/0567/2014, UID/BIM/04293/2013, PTDC/MED-QUI/29780/2017]; Norte Portugal Regional Program (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF) [NORTE-01-0145-FEDER-000051]; FCT; Programa Operacional Potencial Humano (POPH); BiotechHealth Program (Doctoral Program on Cellular and Molecular Biotechnology Applied to Health Sciences) - FCT [PD/0016/2012]; FCT [PD/BD/128407/2017, SFRH/BD/136736/2018, CEECIND/03186/2017]; Investment Grant NWO Medium - ZonMw [91116004]	FEDER funds through the Operational Program for Competitiveness Factors COMPETE 2020; Foundation for Science and Technology (FCT)(Portuguese Foundation for Science and TechnologyEuropean Commission); Norte Portugal Regional Program (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF); FCT(Portuguese Foundation for Science and TechnologyEuropean Commission); Programa Operacional Potencial Humano (POPH); BiotechHealth Program (Doctoral Program on Cellular and Molecular Biotechnology Applied to Health Sciences) - FCT; FCT(Portuguese Foundation for Science and TechnologyEuropean Commission); Investment Grant NWO Medium - ZonMw	This work was funded by FEDER funds through the Operational Program for Competitiveness Factors COMPETE 2020 (POCI-01-0145-FEDER-016585; POCI-01-0145-FEDER-007274) and national funds through the Foundation for Science and Technology (FCT), under the projects: PTDC/BBB-EBI/0567/2014 to CAR and UID/BIM/04293/2013; PTDC/MED-QUI/29780/2017 to CG; and the project NORTE-01-0145-FEDER-000051, supported by Norte Portugal Regional Program (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF). HOD was supported by FCT through the FCT Ph.D. Programs and by Programa Operacional Potencial Humano (POPH), specifically by the BiotechHealth Program (Doctoral Program on Cellular and Molecular Biotechnology Applied to Health Sciences), with the reference PD/0016/2012 funded by FCT. HOD (PD/BD/128407/2017), JGR (SFRH/BD/136736/2018), and JAF (CEECIND/03186/2017) are financially supported by FCT. This work was supported in part by an Investment Grant NWO Medium with project number 91116004 to PAvV, which is (partially) financed by ZonMw.	Alexander KL, 2020, J BIOL CHEM, V295, P14153, DOI 10.1074/jbc.RA120.014887; Bang YJ, 2010, LANCET, V376, P1302; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Bern Marshall, 2012, Curr Protoc Bioinformatics, VChapter 13, DOI 10.1002/0471250953.bi1320s40; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brinkman EK, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku936; Britain CM, 2018, J OVARIAN RES, V11, DOI 10.1186/s13048-018-0385-0; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; COLCHER D, 1981, P NATL ACAD SCI-BIOL, V78, P3199, DOI 10.1073/pnas.78.5.3199; Contessa JN, 2008, CANCER RES, V68, P3803, DOI 10.1158/0008-5472.CAN-07-6389; Cristescu R, 2015, NAT MED, V21, P449, DOI 10.1038/nm.3850; D'Errico M, 2009, EUR J CANCER, V45, P461, DOI 10.1016/j.ejca.2008.10.032; Duarte HO, 2018, HELICOBACTER, V23, DOI 10.1111/hel.12523; Duarte HO, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112262; Duarte HO, 2020, MASSIVE, DOI [10.25345/C5B38P, DOI 10.25345/C5B38P]; Freitas D, 2019, EBIOMEDICINE, V40, P349, DOI 10.1016/j.ebiom.2019.01.017; Gomes C, 2019, THERANOSTICS, V9, P7431, DOI 10.7150/thno.33858; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Kaszuba K, 2015, P NATL ACAD SCI USA, V112, P4334, DOI 10.1073/pnas.1503262112; Klinger M, 2004, CANCER RES, V64, P1087, DOI 10.1158/0008-5472.CAN-03-2435; Lageveen-Kammeijer GSM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09910-7; Liu B, 2019, J COMB OPTIM, V38, P1, DOI 10.1007/s10878-018-0361-z; Liu NH, 2018, ONCOL REP, V40, P2997, DOI 10.3892/or.2018.6680; Liu QQ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1208-x; Liu YC, 2011, P NATL ACAD SCI USA, V108, P11332, DOI 10.1073/pnas.1107385108; Lonowski LA, 2017, NAT PROTOC, V12, P581, DOI 10.1038/nprot.2016.165; Maadi H, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4143-x; Marcos NT, 2004, CANCER RES, V64, P7050, DOI 10.1158/0008-5472.CAN-04-1921; Mereiter S, 2019, CANCER CELL, V36, P6, DOI 10.1016/j.ccell.2019.06.006; Mereiter S, 2019, FEBS LETT, V593, P1675, DOI 10.1002/1873-3468.13432; Narimatsu Y, 2018, GLYCOBIOLOGY, V28, P295, DOI 10.1093/glycob/cwx101; Peiris D, 2017, SCI REP-UK, V7, DOI 10.1038/srep43006; Pinho SS, 2015, NAT REV CANCER, V15, P540, DOI 10.1038/nrc3982; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Seales EC, 2005, CANCER RES, V65, P4645, DOI 10.1158/0008-5472.CAN-04-3117; Smyth EC, 2016, ANN ONCOL, V27, pv38, DOI 10.1093/annonc/mdw350; Swindall AF, 2013, CANCER RES, V73, P2368, DOI 10.1158/0008-5472.CAN-12-3424; Swindall AF, 2011, J BIOL CHEM, V286, P22982, DOI 10.1074/jbc.M110.211375; Terashima M, 2012, CLIN CANCER RES, V18, P5992, DOI 10.1158/1078-0432.CCR-12-1318; Vizcaino JA, 2014, NAT BIOTECHNOL, V32, P223, DOI 10.1038/nbt.2839; Wang YC, 2015, SCI REP-UK, V5, DOI 10.1038/srep13317	42	14	14	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2021	40	21					3719	3733		10.1038/s41388-021-01801-w	http://dx.doi.org/10.1038/s41388-021-01801-w		MAY 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SI8ZW	33947960	Green Published, hybrid			2022-12-17	WOS:000647084500005
J	Kim, H; Son, S; Ko, Y; Shin, I				Kim, Hyungjoo; Son, Seogho; Ko, Yunhyo; Shin, Incheol			CTGF regulates cell proliferation, migration, and glucose metabolism through activation of FAK signaling in triple-negative breast cancer	ONCOGENE			English	Article								Connective tissue growth factor (CTGF), also known as CCN2, is a member of the CCN protein family of secreted proteins with roles in diverse biological processes. CTGF regulates biological functions such as cell proliferation, migration, adhesion, wound healing, and angiogenesis. In this study, we demonstrate a mechanistic link between CTGF and enhanced aerobic glycolysis in triple-negative breast cancer (TNBC). We found that CTGF is overexpressed in TNBC and high CTGF expression is correlated with a poor prognosis. Also, CTGF was required for in vivo tumorigenesis and in vitro proliferation, migration, invasion, and adhesion of TNBC cells. Our results indicate that extracellular CTGF binds directly to integrin alpha v beta 3, activating the FAK/Src/NF-kappa B p65 signaling axis, which results in transcriptional upregulation of Glut3. Neutralization of CTGF decreased cell proliferation, migration, and invasion through downregulation of Glut3-mediated glycolytic phenotypes. Overall, our work suggests a novel function for CTGF as a modulator of cancer metabolism, indicating that CTGF is a potential therapeutic target in TNBC.	[Kim, Hyungjoo; Son, Seogho; Ko, Yunhyo; Shin, Incheol] Hanyang Univ, Dept Life Sci, Seoul 04763, South Korea; [Shin, Incheol] Hanyang Univ, Inst Nat Sci, Seoul 04763, South Korea	Hanyang University; Hanyang University	Shin, I (corresponding author), Hanyang Univ, Dept Life Sci, Seoul 04763, South Korea.; Shin, I (corresponding author), Hanyang Univ, Inst Nat Sci, Seoul 04763, South Korea.	incheol@hanyang.ac.kr		Kim, Hyungjoo/0000-0003-1627-4797	National Research Foundation of Korea (NRF) [2019R1H1A2079999, 2020R1F1A1048616, 2020R1A6A3A13074546]	National Research Foundation of Korea (NRF)(National Research Foundation of Korea)	Grant source, National Research Foundation of Korea (NRF); Grant numbers (grant recipient), 2019R1H1A2079999 (Incheol Shin), 2020R1F1A1048616 (Incheol Shin), 2020R1A6A3A13074546 (Hyungjoo Kim).	Adekola K, 2012, CURR OPIN ONCOL, V24, P650, DOI 10.1097/CCO.0b013e328356da72; Altenberg B, 2004, GENOMICS, V84, P1014, DOI 10.1016/j.ygeno.2004.08.010; Ancey PB, 2018, FEBS J, V285, P2926, DOI 10.1111/febs.14577; Aysola K, 2013, HEREDITARY GENET, V2013; Bennewith KL, 2009, CANCER RES, V69, P775, DOI 10.1158/0008-5472.CAN-08-0987; Bosch A, 2010, CANCER TREAT REV, V36, P206, DOI 10.1016/j.ctrv.2009.12.002; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Braig S, 2011, BRIT J CANCER, V105, P231, DOI 10.1038/bjc.2011.226; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen PS, 2007, J CELL SCI, V120, P2053, DOI 10.1242/jcs.03460; Chen PP, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000534; Chien WW, 2011, INT J ONCOL, V38, P1741, DOI 10.3892/ijo.2011.985; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Dornhofer N, 2006, CANCER RES, V66, P5816, DOI 10.1158/0008-5472.CAN-06-0081; Garcia P, 2013, INT J EXP PATHOL, V94, P195, DOI 10.1111/iep.12023; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Hall-Glenn F, 2011, CELL MOL LIFE SCI, V68, P3209, DOI 10.1007/s00018-011-0782-7; Han DF, 2015, ONCOTARGET, V6, P26119, DOI 10.18632/oncotarget.4444; Han TY, 2013, CELL ADHES MIGR, V7, P395, DOI 10.4161/cam.26345; Jun JI, 2011, NAT REV DRUG DISCOV, V10, P945, DOI 10.1038/nrd3599; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kawauchi K, 2008, NAT CELL BIOL, V10, P611, DOI 10.1038/ncb1724; Kikuchi R, 2007, CANCER RES, V67, P7095, DOI 10.1158/0008-5472.CAN-06-4567; Kim H, 2018, BMB REP, V51, P486, DOI 10.5483/BMBRep.2018.51.10.192; Krzeslak A, 2012, PATHOL ONCOL RES, V18, P721, DOI 10.1007/s12253-012-9500-5; Kuo MH, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121568; Ladwa R, 2011, J CLIN PATHOL, V64, P58, DOI 10.1136/jcp.2010.082768; Leask A, 2006, J CELL SCI, V119, P4803, DOI 10.1242/jcs.03270; Lee HK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054652; Lee HS, 2007, J IMMUNOL, V179, P7001, DOI 10.4049/jimmunol.179.10.7001; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Lipson KE, 2012, FIBROGENESIS TISSUE, V5, DOI 10.1186/1755-1536-5-S1-S24; Lluis JM, 2007, CANCER RES, V67, P7368, DOI 10.1158/0008-5472.CAN-07-0515; Londhe P, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00104; Mauro C, 2011, NAT CELL BIOL, V13, P1272, DOI 10.1038/ncb2324; Neesse A, 2013, P NATL ACAD SCI USA, V110, P12325, DOI 10.1073/pnas.1300415110; Pille JY, 2005, MOL THER, V11, P267, DOI 10.1016/j.ymthe.2004.08.029; Shakunaga T, 2000, CANCER, V89, P1466, DOI 10.1002/1097-0142(20001001)89:7<1466::AID-CNCR8>3.0.CO;2-G; Shimo T, 2001, ONCOLOGY-BASEL, V61, P315, DOI 10.1159/000055339; Shimo T, 2006, J BONE MINER RES, V21, P1045, DOI 10.1359/JBMR.060416; Sun XY, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00428; Tai YL, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/690690; Wang GM, 2013, J INT MED RES, V41, P1214, DOI 10.1177/0300060513476595; Wang MY, 2009, CANCER RES, V69, P3482, DOI 10.1158/0008-5472.CAN-08-2524; Wang XJ, 2019, MOL CELL, V76, P148, DOI 10.1016/j.molcel.2019.07.007; Watanabe M, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.21; Welch MD, 2013, BRIT J HAEMATOL, V162, P537, DOI 10.1111/bjh.12417; Wozniak MA, 2004, BBA-MOL CELL RES, V1692, P103, DOI 10.1016/j.bbamcr.2004.04.007; Xie D, 2001, CANCER RES, V61, P8917; Yang F, 2005, CANCER RES, V65, P8887, DOI 10.1158/0008-5472.CAN-05-1702; Yin D, 2010, INT J CANCER, V127, P2257, DOI 10.1002/ijc.25257; Yoshida T, 2010, MOL CANCER THER, V9, P1657, DOI 10.1158/1535-7163.MCT-09-0906; Zha XJ, 2015, CANCER LETT, V359, P97, DOI 10.1016/j.canlet.2015.01.001	53	14	14	0	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2021	40	15					2667	2681		10.1038/s41388-021-01731-7	http://dx.doi.org/10.1038/s41388-021-01731-7		MAR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN8NW	33692467				2022-12-17	WOS:000627285600002
J	Lee, HC; Ou, CH; Huang, YC; Hou, PC; Creighton, CJ; Lin, YS; Hu, CY; Lin, SC				Lee, Hsiu-Chi; Ou, Chien-Hui; Huang, Yun-Chen; Hou, Pei-Chi; Creighton, Chad J.; Lin, Yi-Syuan; Hu, Che-Yuan; Lin, Shih-Chieh			YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer	ONCOGENE			English	Article							HIPPO PATHWAY; INCREASED SURVIVAL; SIZE-CONTROL; MITOXANTRONE; ABIRATERONE; PREDNISONE; DOCETAXEL; GROWTH	Metastatic castration-resistant prostate cancer (mCRPC) is a malignant and lethal disease caused by relapse after androgen-deprivation (ADT) therapy. Since enzalutamide is innovated and approved by US FDA as a new treatment option for mCRPC patients, drug resistance for enzalutamide is a critical issue during clinical usage. Although several underlying mechanisms causing enzalutamide resistance were previously identified, most of them revealed that drug resistant cells are still highly addicted to androgen and AR functions. Due to the numerous physical functions of AR in men, innovated AR-independent therapy might alleviate enzalutamide resistance and prevent production of adverse side effects. Here, we have identified that yes-associated protein 1 (YAP1) is overexpressed in enzalutamide-resistant (EnzaR) cells. Furthermore, enzalutamide-induced YAP1 expression is mediated through the function of chicken ovalbumin upstream promoter transcription factor 2 (COUP-TFII) at the transcriptional and the post-transcriptional levels. Functional analyses reveal that YAP1 positively regulates numerous genes related to cancer stemness and lipid metabolism and interacts with COUP-TFII to form a transcriptional complex. More importantly, YAP1 inhibitor attenuates the growth and cancer stemness of EnzaR cells in vitro and in vivo. Finally, YAP1, COUP-TFII, and miR-21 are detected in the extracellular vesicles (EVs) isolated from EnzaR cells and sera of patients. In addition, treatment with EnzaR-EVs induces the abilities of cancer stemness, lipid metabolism and enzalutamide resistance in its parental cells. Taken together, these results suggest that YAP1 might be a crucial factor involved in the development of enzalutamide resistance and can be an alternative therapeutic target in prostate cancer.	[Lee, Hsiu-Chi; Hou, Pei-Chi; Lin, Shih-Chieh] Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan, Taiwan; [Ou, Chien-Hui; Hu, Che-Yuan] Natl Cheng Kung Univ & Hosp, Coll Med, Dept Urol, Tainan, Taiwan; [Huang, Yun-Chen; Lin, Shih-Chieh] Natl Cheng Kung Univ, Coll Med, Inst Mol Med, Tainan, Taiwan; [Creighton, Chad J.] Baylor Coll Med, Dan L Duncan Canc Ctr, Div Biostat, Dept Med, Houston, TX 77030 USA; [Lin, Yi-Syuan; Lin, Shih-Chieh] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan, Taiwan; [Hu, Che-Yuan] Natl Cheng Kung Univ, Inst Clin Med, Coll Med, Tainan, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; Baylor College of Medicine; National Cheng Kung University; National Cheng Kung University	Lee, HC (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan, Taiwan.	Jaylin@mail.ncku.edu.tw	Hu, Che-Yuan/AGP-5540-2022	Hu, Che-Yuan/0000-0001-5151-4552; Hou, Pei-Chi/0000-0002-3709-5934	Ministry of Science and Technology [MOST 108-2628-B-006-003, MOST 109-2636-B-006-006]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea)	We thank Yen-Yu Lai and Yi-Chen Tang for technical assistance and Chu-An Wang for proofreading the manuscript. This study was supported by research grants from Ministry of Science and Technology (MOST 108-2628-B-006-003 and MOST 109-2636-B-006-006).	Abel S, 2019, J AM OSTEOPATH ASSOC, V119, P763, DOI 10.7556/jaoa.2019.126; Abudurexiti M, 2020, PROSTATE, V80, P950, DOI 10.1002/pros.24027; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012; Bainbridge A, 2020, NUCLEIC ACIDS RES, V48, P5366, DOI 10.1093/nar/gkaa271; Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095; Borgmann H, 2018, EUR UROL, V73, P4, DOI 10.1016/j.eururo.2017.08.012; Brave M, 2020, CLIN CANCER RES, V26, P4717, DOI 10.1158/1078-0432.CCR-19-3835; Cerasuolo M, 2020, CANCER RES, V80, P1564, DOI 10.1158/0008-5472.CAN-18-3637; Coutinho I, 2016, ENDOCR-RELAT CANCER, V23, pT179, DOI 10.1530/ERC-16-0422; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Del Re M, 2017, EUR UROL, V71, P680, DOI 10.1016/j.eururo.2016.08.012; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Henry N, 2009, NAT CLIN PRACT UROL, V6, P164, DOI 10.1038/ncpuro1317; Hussain M, 2018, NEW ENGL J MED, V378, P2465, DOI 10.1056/NEJMoa1800536; Jiang N, 2015, ONCOGENE, V34, P2764, DOI 10.1038/onc.2014.206; Jiang N, 2017, ONCOTARGET, V8, P115054, DOI 10.18632/oncotarget.23014; Klein EA, 2009, UROL ONCOL-SEMIN ORI, V27, P67, DOI 10.1016/j.urolonc.2008.04.001; Kong YF, 2018, J BIOL CHEM, V293, P14328, DOI 10.1074/jbc.RA118.004442; Korpal M, 2013, CANCER DISCOV, V3, P1030, DOI 10.1158/2159-8290.CD-13-0142; Kuser-Abali G, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9126; Li HC, 2020, THERANOSTICS, V10, P7053, DOI 10.7150/thno.41388; Lin SC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11418; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Lukka H, 2006, Curr Oncol, V13, P81; Miyazawa Y, 2019, PROSTATE, V79, P1462, DOI 10.1002/pros.23865; Nguyen LT, 2015, CANCER CELL, V27, P797, DOI 10.1016/j.ccell.2015.05.005; Ning YM, 2015, ONCOLOGIST, V20, P960, DOI 10.1634/theoncologist.2015-0166; Peak TC, 2020, MOL CARCINOGEN, V59, P62, DOI 10.1002/mc.23129; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Stoykova GE, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112626; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Tumaneng K, 2012, CURR BIOL, V22, pR368, DOI 10.1016/j.cub.2012.03.003; Wang LM, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz8031; Yanez-Mo M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066; Zadra G, 2019, P NATL ACAD SCI USA, V116, P631, DOI 10.1073/pnas.1808834116; Zhang L, 2015, MOL CELL BIOL, V35, P1350, DOI 10.1128/MCB.00102-15; Zhang ZD, 2020, CANCER CELL, V37, P584, DOI 10.1016/j.ccell.2020.03.001; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907	42	14	14	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2021	40	13					2407	2421		10.1038/s41388-021-01718-4	http://dx.doi.org/10.1038/s41388-021-01718-4		MAR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RH1BQ	33664454	hybrid, Green Published			2022-12-17	WOS:000625833000001
J	Chen, H; Bian, AW; Yang, LF; Yin, X; Wang, J; Ti, CW; Miao, Y; Peng, SH; Xu, SF; Liu, MY; Qiu, WW; Yi, ZF				Chen, Huang; Bian, Aiwu; Yang, Lian-fang; Yin, Xuan; Wang, Jie; Ti, Chaowen; Miao, Ying; Peng, Shihong; Xu, Shifen; Liu, Mingyao; Qiu, Wen-Wei; Yi, Zhengfang			Targeting STAT3 by a small molecule suppresses pancreatic cancer progression	ONCOGENE			English	Article							TRANSCRIPTION FACTOR STAT3; SIGNAL TRANSDUCER; MITOCHONDRIAL STAT3; HUMAN BREAST; INHIBITOR; ACTIVATION; GROWTH; TOFACITINIB; SUPPORTS; PATHWAY	Pancreatic cancer is lethal in over 90% of cases since it is resistant to current therapeutic strategies. The key role of STAT3 in promoting pancreatic cancer progression has been proven, but effective interventions that suppress STAT3 activities are limited. The development of novel anticancer agents that directly target STAT3 may have potential clinical benefits for pancreatic cancer treatment. Here, we report a new small-molecule inhibitor (N4) with potent antitumor bioactivity, which inhibits multiple oncogenic processes in pancreatic cancer. N4 blocked STAT3 and phospho-tyrosine (pTyr) peptide interactions in fluorescence polarization (FP) assay, specifically abolished phosphor-STAT3 (Tyr705), and suppressed expression of STAT3 downstream genes. The mechanism involved the direct binding of N4 to the STAT3 SH2 domain, thereby, the STAT3 dimerization, STAT3-EGFR, and STAT3-NF-kappa B cross-talk were efficiently inhibited. In animal models of pancreatic cancer, N4 was well tolerated, suppressed tumor growth and metastasis, and significantly prolonged survival of tumor-bearing mice. Our results offer a preclinical proof of concept for N4 as a candidate therapeutic compound for pancreatic cancer.	[Chen, Huang; Bian, Aiwu; Ti, Chaowen; Miao, Ying; Peng, Shihong; Liu, Mingyao; Yi, Zhengfang] East China Normal Univ, Shanghai 200241, Peoples R China; [Chen, Huang; Bian, Aiwu; Ti, Chaowen; Miao, Ying; Peng, Shihong; Liu, Mingyao; Yi, Zhengfang] East China Normal Univ, Shanghai Fengxian Dist Cent Hosp Joint Ctr Transl, Shanghai Key Lab Regulatory Biol Inst Biomed Sci, Shanghai 200241, Peoples R China; [Chen, Huang; Bian, Aiwu; Ti, Chaowen; Miao, Ying; Peng, Shihong; Liu, Mingyao; Yi, Zhengfang] East China Normal Univ, Sch Life Sci, Shanghai 200241, Peoples R China; [Yang, Lian-fang; Wang, Jie; Qiu, Wen-Wei; Yi, Zhengfang] East China Normal Univ, Shanghai Engn Res Ctr Mol Therapeut & New Drug De, Sch Chem & Mol Engn, Shanghai 200241, Peoples R China; [Yin, Xuan; Xu, Shifen] Shanghai Univ Tradit Chinese Med, Shanghai Municipal Hosp Tradit Chinese Med, Shanghai, Peoples R China	East China Normal University; East China Normal University; East China Normal University; East China Normal University; Shanghai University of Traditional Chinese Medicine	Liu, MY; Yi, ZF (corresponding author), East China Normal Univ, Shanghai 200241, Peoples R China.; Liu, MY; Yi, ZF (corresponding author), East China Normal Univ, Shanghai Fengxian Dist Cent Hosp Joint Ctr Transl, Shanghai Key Lab Regulatory Biol Inst Biomed Sci, Shanghai 200241, Peoples R China.; Liu, MY; Yi, ZF (corresponding author), East China Normal Univ, Sch Life Sci, Shanghai 200241, Peoples R China.; Qiu, WW; Yi, ZF (corresponding author), East China Normal Univ, Shanghai Engn Res Ctr Mol Therapeut & New Drug De, Sch Chem & Mol Engn, Shanghai 200241, Peoples R China.	myliu@bio.ecnu.edu.cn; wwqiu@chem.ecnu.edu.cn; zfyi@bio.ecnu.edu.cn		chen, huang/0000-0003-2507-5044	National Natural Science Foundation of China [82073310, 81773204, 81830083, 81802970]; Science and Technology Commission of Shanghai Municipality [20JC1417900, 11DZ2260300]; National Key R&D Program of China [2018YFA0507001]; Innovation program of Shanghai Municipal Education Commission [2017-01-07-00-05-E00011]; Shanghai Science and Technology Council [18ZR1411200]; Shenzhen Municipal Government of China [KQTD20170810160226082]; ECNU Construction Fund of Innovation and Entrepreneurship Laboratory [44400-20201-532300/021]; ECNU Public Platform for Innovation [011]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); National Key R&D Program of China; Innovation program of Shanghai Municipal Education Commission(Innovation Program of Shanghai Municipal Education Commission); Shanghai Science and Technology Council; Shenzhen Municipal Government of China; ECNU Construction Fund of Innovation and Entrepreneurship Laboratory; ECNU Public Platform for Innovation	This study was supported by National Natural Science Foundation of China (82073310, 81773204, 81830083, and 81802970), The Science and Technology Commission of Shanghai Municipality (20JC1417900, 11DZ2260300), National Key R&D Program of China (2018YFA0507001), Innovation program of Shanghai Municipal Education Commission (2017-01-07-00-05-E00011), Shanghai Science and Technology Council (18ZR1411200), Shenzhen Municipal Government of China (KQTD20170810160226082), ECNU Construction Fund of Innovation and Entrepreneurship Laboratory (44400-20201-532300/021), and ECNU Public Platform for Innovation (011).	Ahmad R, 2008, CANCER RES, V68, P2920, DOI 10.1158/0008-5472.CAN-07-3036; Bharadwaj U, 2016, ONCOTARGET, V7, P26307, DOI 10.18632/oncotarget.8368; Brambilla L, 2015, MOL ONCOL, V9, P1194, DOI 10.1016/j.molonc.2015.02.012; Carpenter RL, 2014, CANCERS, V6, P897, DOI 10.3390/cancers6020897; Corcoran RB, 2011, CANCER RES, V71, P5020, DOI 10.1158/0008-5472.CAN-11-0908; Fukuda A, 2011, CANCER CELL, V19, P441, DOI 10.1016/j.ccr.2011.03.002; Furtek SL, 2016, ACS CHEM BIOL, V11, P308, DOI 10.1021/acschembio.5b00945; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Genini D, 2017, P NATL ACAD SCI USA, V114, pE4924, DOI 10.1073/pnas.1615730114; Gough DJ, 2009, SCIENCE, V324, P1713, DOI 10.1126/science.1171721; He YD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13122; Houg DS, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0842-9; Huang C, 2012, CYTOKINE GROWTH F R, V23, P25, DOI 10.1016/j.cytogfr.2012.01.003; Huynh J, 2019, NAT REV CANCER, V19, P82, DOI 10.1038/s41568-018-0090-8; Jerabek-Willemsen M, 2011, ASSAY DRUG DEV TECHN, V9, P342, DOI 10.1089/adt.2011.0380; Jung KH, 2017, CLIN CANCER RES, V23, P5537, DOI 10.1158/1078-0432.CCR-16-2253; Kleeff J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.22; Lai PS, 2015, EXPERT OPIN THER PAT, V25, P1397, DOI 10.1517/13543776.2015.1086749; Lee JW, 2019, NATURE, V567, P249, DOI 10.1038/s41586-019-1004-y; Lee JY, 2005, BIOCHEM BIOPH RES CO, V334, P764, DOI 10.1016/j.bbrc.2005.06.162; Lesina M, 2011, CANCER CELL, V19, P456, DOI 10.1016/j.ccr.2011.03.009; Miklossy G, 2013, NAT REV DRUG DISCOV, V12, P611, DOI 10.1038/nrd4088; Nagathihalli NS, 2016, ONCOTARGET, V7, P65982, DOI 10.18632/oncotarget.11786; Scholz A, 2003, GASTROENTEROLOGY, V125, P891, DOI 10.1016/S0016-5085(03)01064-3; Schwartz DM, 2017, NAT REV DRUG DISCOV, V16, P843, DOI 10.1038/nrd.2017.201; Shao H, 2003, CANCER RES, V63, P3923; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Tolcher A, 2018, ONCOLOGIST, V23, P658, DOI 10.1634/theoncologist.2017-0325; Toyonaga T, 2003, CANCER LETT, V201, P107, DOI 10.1016/S0304-3835(03)00482-8; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; van Vollenhoven RF, 2012, NEW ENGL J MED, V367, P508, DOI 10.1056/NEJMoa1112072; Wegrzyn J, 2009, SCIENCE, V323, P793, DOI 10.1126/science.1164551; Wienken CJ, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1093; Wilkinson B, 2014, NEW ENGL J MED, V371, P1164, DOI 10.1056/NEJMc1408607; Wong ALA, 2017, EXPERT OPIN INV DRUG, V26, P883, DOI 10.1080/13543784.2017.1351941; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Zhang B, 2019, CELL, V176, P636, DOI 10.1016/j.cell.2019.01.003; Zhang T, 2017, ONCOGENE, V36, P6627, DOI 10.1038/onc.2017.270; Zhang XL, 2013, CANCER RES, V73, P1922, DOI 10.1158/0008-5472.CAN-12-3175; Zhang XL, 2012, P NATL ACAD SCI USA, V109, P9623, DOI 10.1073/pnas.1121606109; Zhao W, 2010, J BIOL CHEM, V285, P35855, DOI 10.1074/jbc.M110.154088	42	14	14	5	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2021	40	8					1440	1457		10.1038/s41388-020-01626-z	http://dx.doi.org/10.1038/s41388-020-01626-z		JAN 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QM6NM	33420372	hybrid, Green Published			2022-12-17	WOS:000607346000003
J	Yin, XK; Wang, YL; Wang, F; Feng, WX; Bai, SM; Zhao, WW; Feng, LL; Wei, MB; Qin, CL; Wang, F; Chen, ZL; Yi, HJ; Huang, Y; Xie, PY; Kim, T; Wang, YN; Hou, JW; Li, CW; Liu, QT; Fan, XJ; Hung, MC; Wan, XB				Yin, Xin-Ke; Wang, Yun-Long; Wang, Fei; Feng, Wei-Xing; Bai, Shao-Mei; Zhao, Wan-Wen; Feng, Li-Li; Wei, Ming-Biao; Qin, Cao-Litao; Wang, Fang; Chen, Zhi-Li; Yi, Hong-Jun; Huang, Yan; Xie, Pei-Yi; Kim, Taewan; Wang, Ying-Nai; Hou, Jun-Wei; Li, Chia-Wei; Liu, Quentin; Fan, Xin-Juan; Hung, Mien-Chie; Wan, Xiang-Bo			PRMT1 enhances oncogenic arginine methylation of NONO in colorectal cancer	ONCOGENE			English	Article							STRAND BREAK REPAIR; RECTAL-CANCER; LUNG-CANCER; PROTEIN; P54(NRB); REGULATOR; METHYLTRANSFERASES; PROGRESSION; MUTATIONS; CETUXIMAB	Arginine methylation is an important posttranslational modification catalyzed by protein arginine methyltransferases (PRMTs). However, the role of PRMTs in colorectal cancer (CRC) progression is not well understood. Here we report that non-POU domain-containing octamer-binding protein (NONO) is overexpressed in CRC tissue and is a potential marker for poor prognosis in CRC patients. NONO silencing resulted in decreased proliferation, migration, and invasion of CRC cells, whereas overexpression had the opposite effect. In a xenograft model, tumors derived from NONO-deficient CRC cells were smaller than those derived from wild-type (WT) cells, and PRMT1 inhibition blocked CRC xenograft progression. A mass spectrometry analysis indicated that NONO is a substrate of PRMT1. R251 of NONO was asymmetrically dimethylated by PRMT1 in vitro and in vivo. Compared to NONO WT cells, NONO R251K mutant-expressing CRC cells showed reduced proliferation, migration, and invasion, and PRMT1 knockdown or pharmacological inhibition abrogated the malignant phenotype associated with NONO asymmetric dimethylation in both KRAS WT and mutant CRC cells. Compared to adjacent normal tissue, PRMT1 was highly expressed in the CRC zone in clinical specimens, which was correlated with poor overall survival in patients with locally advanced CRC. These results demonstrate that PRMT1-mediated methylation of NONO at R251 promotes CRC growth and metastasis, and suggest that PRMT1 inhibition may be an effective therapeutic strategy for CRC treatment regardless of KRAS mutation status.	[Yin, Xin-Ke; Wang, Yun-Long; Zhao, Wan-Wen; Wang, Fang; Fan, Xin-Juan; Wan, Xiang-Bo] Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Prov Key Lab Colorectal & Pelv Floor Di, Guangzhou 510655, Guangdong, Peoples R China; [Wang, Yun-Long; Feng, Wei-Xing; Bai, Shao-Mei; Feng, Li-Li; Wei, Ming-Biao; Qin, Cao-Litao; Wan, Xiang-Bo] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Radiat Oncol, Guangzhou 510655, Guangdong, Peoples R China; [Wang, Fei] Sun Yat Sen Univ, Affiliated Hosp 7, Dept Gastroenterol, Shenzhen 518107, Guangdong, Peoples R China; [Chen, Zhi-Li; Yi, Hong-Jun; Huang, Yan; Fan, Xin-Juan] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Pathol, Guangzhou 510655, Guangdong, Peoples R China; [Xie, Pei-Yi] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Radiol, Guangzhou 510655, Guangdong, Peoples R China; [Kim, Taewan] Shenzhen Univ, Carson Canc Stem Cell Vaccines R&D Ctr, Int Canc Ctr, Base Int Sci & Technol Cooperat,Hlth Sci Ctr, Shenzhen 518055, Peoples R China; [Kim, Taewan] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Wang, Ying-Nai; Hou, Jun-Wei; Li, Chia-Wei; Hung, Mien-Chie] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Li, Chia-Wei] Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; [Liu, Quentin] Dalian Med Univ, Inst Canc Stem Cell, Dalian 116044, Liaoning, Peoples R China; [Liu, Quentin] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China; [Hung, Mien-Chie] China Med Univ, Grad Inst Biomed Sci, Taichung 404, Taiwan; [Hung, Mien-Chie] China Med Univ, Res Ctr Canc Biol, Taichung 404, Taiwan; [Hung, Mien-Chie] China Med Univ, Res Ctr Mol Med, Taichung 404, Taiwan; [Hung, Mien-Chie] Asia Univ, Dept Biotechnol, Taichung 413, Taiwan; [Wan, Xiang-Bo] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Med Engn, Guangzhou 510655, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Shenzhen University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Texas System; UTMD Anderson Cancer Center; Academia Sinica - Taiwan; Dalian Medical University; State Key Lab Oncology South China; Sun Yat Sen University; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; Asia University Taiwan; Sun Yat Sen University	Fan, XJ; Wan, XB (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Prov Key Lab Colorectal & Pelv Floor Di, Guangzhou 510655, Guangdong, Peoples R China.; Wan, XB (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 6, Dept Radiat Oncol, Guangzhou 510655, Guangdong, Peoples R China.; Hung, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.; Hung, MC (corresponding author), China Med Univ, Grad Inst Biomed Sci, Taichung 404, Taiwan.; Hung, MC (corresponding author), China Med Univ, Res Ctr Canc Biol, Taichung 404, Taiwan.; Hung, MC (corresponding author), China Med Univ, Res Ctr Mol Med, Taichung 404, Taiwan.; Hung, MC (corresponding author), Asia Univ, Dept Biotechnol, Taichung 413, Taiwan.; Wan, XB (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 6, Dept Med Engn, Guangzhou 510655, Guangdong, Peoples R China.	fanxjuan@mail.sysu.edu.cn; mhung@cmu.edu.tw; wanxbo@mail.sysu.edu.cn	Kim, Taewan/M-5867-2013; Hou, Junwei/ADR-3580-2022; Li, Chia-Wei/AAC-8660-2019; Hung, Mien-Chie/ABD-5911-2021	Kim, Taewan/0000-0002-7202-009X; Li, Chia-Wei/0000-0002-2531-2866; Hung, Mien-Chie/0000-0003-4317-4740; Wang, Ying-Nai/0000-0002-5275-6729; Wang, Yun-Long/0000-0002-5925-6938	Guangdong Science and Technology Project [2017B090901065, 2019B030316003]; Natural Science Foundation of China [81872188, 81902867, 81903152]; Natural Science Foundation of Guangdong Province [2019A1515010901, 2020A1515010314]; China Postdoctoral Science Foundation [2019M663301]	Guangdong Science and Technology Project; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This study was supported by the Guangdong Science and Technology Project (No. 2017B090901065, No. 2019B030316003), Natural Science Foundation of China (No. 81872188, No. 81902867, No. 81903152), Natural Science Foundation of Guangdong Province (No. 2019A1515010901, No. 2020A1515010314), and China Postdoctoral Science Foundation (No. 2019M663301).	Alfano L, 2016, ONCOGENE, V35, P567, DOI 10.1038/onc.2015.107; Alfano L, 2018, J CELL PHYSIOL, V233, P4338, DOI 10.1002/jcp.26269; Amelio AL, 2007, P NATL ACAD SCI USA, V104, P20314, DOI 10.1073/pnas.0707999105; Ansorena E, 2002, HEPATOLOGY, V35, P274, DOI 10.1053/jhep.2002.30419; Bang YJ, 2010, LANCET, V376, P1302; Bedford MT, 2005, MOL CELL, V18, P263, DOI 10.1016/j.molcel.2005.04.003; Benson A, 2018, J NATL COMPR CANC NE, V16, P874, DOI 10.6004/jnccn.2018.0061; Blanc RS, 2017, MOL CELL, V65, P8, DOI 10.1016/j.molcel.2016.11.003; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen ZR, 2016, J CLIN INVEST, V126, P2267, DOI 10.1172/JCI85250; Deshar R, 2019, NUCLEIC ACIDS RES, V47, P762, DOI 10.1093/nar/gky1166; Dienstmann R, 2015, J CLIN ONCOL, V33, P1787, DOI 10.1200/JCO.2014.60.0213; Eram MS, 2016, ACS CHEM BIOL, V11, P772, DOI 10.1021/acschembio.5b00839; Feng PF, 2020, J CELL MOL MED, V24, P4368, DOI 10.1111/jcmm.15141; Greenblatt SM, 2016, EXP HEMATOL, V44, P435, DOI 10.1016/j.exphem.2016.03.009; Herrmann F, 2005, J BIOL CHEM, V280, P38005, DOI 10.1074/jbc.M502458200; Ho TT, 2016, SCI REP-UK, V6, DOI 10.1038/srep34529; Hsu JM, 2011, NAT CELL BIOL, V13, P174, DOI 10.1038/ncb2158; Hu SB, 2015, GENE DEV, V29, P630, DOI 10.1101/gad.257048.114; Hu ZX, 2020, HEPATOLOGY, V72, P548, DOI 10.1002/hep.31062; Iino K, 2020, CANCER SCI, V111, P148, DOI 10.1111/cas.14240; Jaafar L, 2017, NUCLEIC ACIDS RES, V45, P1848, DOI 10.1093/nar/gkw1209; Lei NZ, 2009, NUCLEIC ACIDS RES, V37, P832, DOI 10.1093/nar/gkn941; Li SY, 2009, NUCLEIC ACIDS RES, V37, P6746, DOI 10.1093/nar/gkp741; Li X, 2019, EXPERT OPIN THER PAT, V29, P97, DOI 10.1080/13543776.2019.1567711; Liao HW, 2015, J CLIN INVEST, V125, P4529, DOI 10.1172/JCI82826; Lievre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906; Luo MK, 2012, ACS CHEM BIOL, V7, P443, DOI 10.1021/cb200519y; Mircsof D, 2015, NAT NEUROSCI, V18, P1731, DOI 10.1038/nn.4169; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(01)00269-0; Petti E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08863-1; Prasanth KV, 2005, CELL, V123, P249, DOI 10.1016/j.cell.2005.08.033; Proteau A, 2005, J MOL BIOL, V346, P1163, DOI 10.1016/j.jmb.2004.12.034; Qin YY, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaw9960; Sauer R, 2012, J CLIN ONCOL, V30, P1926, DOI 10.1200/JCO.2011.40.1836; Schiffnery S, 2011, CARCINOGENESIS, V32, P1176, DOI 10.1093/carcin/bgr103; Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Snijders AP, 2015, RNA, V21, P347, DOI 10.1261/rna.045138.114; Teyssier C, 2005, GENE DEV, V19, P1466, DOI 10.1101/gad.1295005; Tsofack SP, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-145; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; Van den Eynde M, 2018, CANCER CELL, V34, P1012, DOI 10.1016/j.ccell.2018.11.003; Wang L, 2014, CANCER CELL, V25, P21, DOI 10.1016/j.ccr.2013.12.007; Yamamoto Ryuji, 2018, Oncotarget, V9, P10510, DOI 10.18632/oncotarget.24063; Yang YZ, 2013, NAT REV CANCER, V13, P37, DOI 10.1038/nrc3409; Yu T, 2017, CANCER RES, V77, P5782, DOI 10.1158/0008-5472.CAN-17-0671; Zhao X, 2008, GENE DEV, V22, P640, DOI 10.1101/gad.1632608; Zhu Z, 2016, ONCOGENE, V35, P1399, DOI 10.1038/onc.2015.197	49	14	14	5	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2021	40	7					1375	1389		10.1038/s41388-020-01617-0	http://dx.doi.org/10.1038/s41388-020-01617-0		JAN 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QK0LS	33420374	Green Published, hybrid			2022-12-17	WOS:000607346000009
J	Haldrup, J; Strand, SH; Cieza-Borrella, C; Jakobsson, ME; Riedel, M; Norgaard, M; Hedensted, S; Dagnaes-Hansen, F; Ulhoi, BP; Eeles, R; Borre, M; Olsen, JV; Thomsen, M; Kote-Jarai, Z; Sorensen, KD				Haldrup, Jakob; Strand, Siri H.; Cieza-Borrella, Clara; Jakobsson, Magnus E.; Riedel, Maria; Norgaard, Maibritt; Hedensted, Stine; Dagnaes-Hansen, Frederik; Ulhoi, Benedicte Parm; Eeles, Rosalind; Borre, Michael; Olsen, Jesper, V; Thomsen, Martin; Kote-Jarai, Zsofia; Sorensen, Karina D.			FRMD6 has tumor suppressor functions in prostate cancer	ONCOGENE			English	Article							EXPRESSION ANALYSIS; GENE; YAP/TAZ; TOPHAT; WILLIN	Available tools for prostate cancer (PC) prognosis are suboptimal but may be improved by better knowledge about genes driving tumor aggressiveness. Here, we identified FRMD6 (FERM domain-containing protein 6) as an aberrantly hypermethylated and significantly downregulated gene in PC. Low FRMD6 expression was associated with postoperative biochemical recurrence in two large PC patient cohorts. In overexpression and CRISPR/Cas9 knockout experiments in PC cell lines, FRMD6 inhibited viability, proliferation, cell cycle progression, colony formation, 3D spheroid growth, and tumor xenograft growth in mice. Transcriptomic, proteomic, and phospho-proteomic profiling revealed enrichment of Hippo/YAP and c-MYC signaling upon FRMD6 knockout. Connectivity Map analysis and drug repurposing experiments identified pyroxamide as a new potential therapy for FRMD6 deficient PC cells. Finally, we established orthotropic Frmd6 and Pten, or Pten only (control) knockout in the ROSA26 mouse prostate. After 12 weeks, Frmd6/Pten double knockouts presented high-grade prostatic intraepithelial neoplasia (HG-PIN) and hyperproliferation, while Pten single-knockouts developed only regular PIN lesions and displayed lower proliferation. In conclusion, FRMD6 was identified as a novel tumor suppressor gene and prognostic biomarker candidate in PC.	[Haldrup, Jakob; Strand, Siri H.; Norgaard, Maibritt; Hedensted, Stine; Sorensen, Karina D.] Aarhus Univ Hosp, Dept Mol Med, Aarhus, Denmark; [Haldrup, Jakob; Strand, Siri H.; Riedel, Maria; Norgaard, Maibritt; Hedensted, Stine; Sorensen, Karina D.] Aarhus Univ, Dept Clin Med, Aarhus, Denmark; [Cieza-Borrella, Clara; Eeles, Rosalind; Kote-Jarai, Zsofia] Inst Canc Res, Div Genet & Epidemiol, Oncogenet, London, England; [Jakobsson, Magnus E.; Olsen, Jesper, V] Univ Copenhagen, Novo Nordisk Fdn, Ctr Prot Res, Copenhagen, Denmark; [Jakobsson, Magnus E.] Lund Univ, Dept Immunotechnol, S-22100 Lund, Sweden; [Dagnaes-Hansen, Frederik; Thomsen, Martin] Aarhus Univ, Dept Biomed, Aarhus, Denmark; [Ulhoi, Benedicte Parm] Aarhus Univ Hosp, Inst Pathol, Aarhus, Denmark; [Eeles, Rosalind] Inst Canc Res, London, England; [Eeles, Rosalind] Royal Marsden NHS Fdn Trust, London, England; [Borre, Michael] Aarhus Univ Hosp, Dept Urol, Aarhus, Denmark	Aarhus University; Aarhus University; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Novo Nordisk Foundation; University of Copenhagen; Lund University; Aarhus University; Aarhus University; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; Aarhus University	Sorensen, KD (corresponding author), Aarhus Univ Hosp, Dept Mol Med, Aarhus, Denmark.; Sorensen, KD (corresponding author), Aarhus Univ, Dept Clin Med, Aarhus, Denmark.	kdso@clin.au.dk	Olsen, Jesper/ABH-4638-2020; Thomsen, Martin/AAU-5014-2021	Olsen, Jesper/0000-0002-4747-4938; Thomsen, Martin/0000-0002-5055-7531; Cieza-Borrella, Clara/0000-0003-2739-1040; Riedel, Maria/0000-0002-6545-0243; Borre, Michael/0000-0002-1519-9185; Strand, Siri/0000-0001-6596-9945; Sorensen, Karina Dalsgaard/0000-0002-4902-5490; Eeles, Rosalind/0000-0002-3698-6241	Royal Marsden NHS Foundation Trust; de Laszlo Foundation; Danish Cancer Society; Velux Foundation (KDS); Novo Nordisk Foundation [NNF16OC0023048, NNF16OC0022946, NNF14CC0001]; Independent Research Fund Denmark, The Harboe Foundation; Lundbeck Foundation [R231-2016-2682]; National Institute of Health Research; Aarhus University; NIHR	Royal Marsden NHS Foundation Trust(Royal Society of New ZealandMarsden Fund (NZ)); de Laszlo Foundation; Danish Cancer Society(Danish Cancer Society); Velux Foundation (KDS); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Independent Research Fund Denmark, The Harboe Foundation; Lundbeck Foundation(Lundbeckfonden); National Institute of Health Research(National Institute for Health Research (NIHR)); Aarhus University; NIHR(National Institute for Health Research (NIHR))	Prof. Raymond C. Bergan (Department of Medicine, Northwestern University, Chicago, USA) generously provided the PC-3M cell line. The DU145-MN1 cell line was kindly provided by Dr Volker Jung (Institute of Urology and Pediatric Urology, University of Saarland, Hamburg/Saar, Germany). We thank Dr SOren Vang, Dr Morten Muhlig, and Dr Michael Knudsen for bioinformatics support. The Danish Cancer Biobank (DCB) is acknowledged for biological material. Ros Eeles and Zsofia Kote-Karai are supported by NIHR support to the Biomedical Research Centre at The Institute of Cancer Research and Royal Marsden NHS Foundation Trust. Clara Cieza-Borella was supported by a donation from the Burstons and by research donations from the de Laszlo Foundation. This work was supported by The Danish Cancer Society (KDS), The Velux Foundation (KDS), The Novo Nordisk Foundation [NNF16OC0023048 (KDS); NNF16OC0022946 (MEJ); NNF14CC0001 (JVO)], The Independent Research Fund Denmark, The Harboe Foundation (JHJ), The Lundbeck Foundation [R231-2016-2682 (MEJ)], National Institute of Health Research (RE), The Biomedical Research Centre at the Institute of Cancer Research and Royal Marsden NHS Foundation Trust (RE), Richard and Debbi Burston, Nick Phillips and Bradshaw Foundation (CCB), and Aarhus University (JHJ/SHS).	Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Angus L, 2012, ONCOGENE, V31, P238, DOI 10.1038/onc.2011.224; [Anonymous], 2013, P NATL ACAD SCI USA, V110, P17160; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bocci F, 2019, INTEGR BIOL-UK, V11, P251, DOI 10.1093/intbio/zyz021; Brawer Michael K, 2005, Rev Urol, V7 Suppl 3, pS11; Dart DA, 2017, ONCOGENESIS, V6, DOI 10.1038/s41389-017-0007-5; Feber A, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r30; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Guan CJ, 2019, BIOCHEM BIOPH RES CO, V515, P112, DOI 10.1016/j.bbrc.2019.05.025; Gunn-Moore FJ, 2005, FEBS LETT, V579, P5089, DOI 10.1016/j.febslet.2005.07.097; Gunn-Moore FJ, 2016, GENES-BASEL, V7, DOI 10.3390/genes7070037; Haldrup C, 2018, MOL ONCOL, V12, P545, DOI 10.1002/1878-0261.12183; Haldrup C, 2016, MOL ONCOL, V10, P825, DOI 10.1016/j.molonc.2016.02.001; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hedegaard J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098187; Hieronymus H, 2014, P NATL ACAD SCI USA, V111, P11139, DOI 10.1073/pnas.1411446111; Ishiuchi T, 2012, GENES CELLS, V17, P387, DOI 10.1111/j.1365-2443.2012.01593.x; Ishiuchi T, 2011, NAT CELL BIOL, V13, P860, DOI 10.1038/ncb2274; Jamaspishvili T, 2018, NAT REV UROL, V15, P222, DOI 10.1038/nrurol.2018.9; Jolly MK, 2019, PHARMACOL THERAPEUT, V194, P161, DOI 10.1016/j.pharmthera.2018.09.007; Jolly MK, 2016, ONCOTARGET, V7, P27067, DOI 10.18632/oncotarget.8166; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Long Q, 2014, CANCER RES, V74, P3228, DOI 10.1158/0008-5472.CAN-13-2699; Morris TJ, 2014, BIOINFORMATICS, V30, P428, DOI 10.1093/bioinformatics/btt684; Moya IM, 2019, NAT REV MOL CELL BIO, V20, P211, DOI 10.1038/s41580-018-0086-y; Nebbioso A, 2017, CLIN CANCER RES, V23, P2542, DOI 10.1158/1078-0432.CCR-15-2388; Nishimoto M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47301-6; Platt RJ, 2014, CELL, V159, P440, DOI 10.1016/j.cell.2014.09.014; Poole CJ, 2017, GENES-BASEL, V8, DOI 10.3390/genes8050142; Riedel M, 2018, JOVE-J VIS EXP, DOI 10.3791/57525; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Schmidt L, 2018, BRIT J CANCER, V119, P1527, DOI 10.1038/s41416-018-0321-5; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Stauffer S, 2016, FEBS J, V283, P1800, DOI 10.1111/febs.13718; Steineck G, 2002, NEW ENGL J MED, V347, P790, DOI 10.1056/NEJMoa021483; Strand SH, 2017, ONCOTARGET, V8, P5774, DOI 10.18632/oncotarget.14391; Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Visser-Grieve S, 2012, ONCOGENE, V31, P1189, DOI 10.1038/onc.2011.318; Wang JZ, 2018, BIOCHEM BIOPH RES CO, V506, P590, DOI 10.1016/j.bbrc.2018.10.088; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Xu Y, 2016, ONCOTARGET, V7, P70080, DOI 10.18632/oncotarget.12148; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zhou PJ, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0609-y; Zhu YT, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv129; Zhu YT, 2014, NAT METHODS, V11, P599, DOI 10.1038/nmeth.2956	52	14	14	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2021	40	4					763	776		10.1038/s41388-020-01548-w	http://dx.doi.org/10.1038/s41388-020-01548-w		NOV 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA4GO	33249427				2022-12-17	WOS:000594680900001
J	Fu, JJ; Liao, L; Balaji, KS; Wei, CL; Kim, J; Peng, JZ				Fu, Junjiang; Liao, Li; Balaji, Kyathegowdanadoddi Srinivasa; Wei, Chunli; Kim, Jaehoon; Peng, Jiangzhou			Epigenetic modification and a role for the E3 ligase RNF40 in cancer development and metastasis	ONCOGENE			English	Review							HISTONE H2B MONOUBIQUITINATION; UBIQUITIN-PROTEIN LIGASE; DNA-DAMAGE; TUMOR-SUPPRESSOR; RING DOMAIN; RNF20; UBIQUITYLATION; TRANSCRIPTION; ELONGATION; ATM	RNF40 (OMIM: 607700) is a really interesting new gene (RING) finger E3 ubiquitin ligase containing multiple coiled-coil domains and a C-terminal RING finger motif, which engage in protein-DNA and protein-protein interactions. RNF40 encodes a polypeptide of 1001 amino acids with a predicted molecular mass of 113,678 Da. RNF40 and its paralog RNF20 form a stable heterodimer complex that can monoubiquitylate histone H2B at lysine 120 as well as other nonhistone proteins. Cancer is a major public health problem and the second leading cause of death. Through its protein ubiquitylation activity, RNF40 acts as a tumor suppressor or oncogene to play major epigenetic roles in cancer development, progression, and metastasis, highlighting the essential function of RNF40 and the importance of studying it. In this review, we summarize current knowledge about RNF40 gene structure and the role of RNF40 in histone H2B monoubiquitylation, DNA damage repair, apoptosis, cancer development, and metastasis. We also underscore challenges in applying this information to cancer prognosis and prevention and highlight the urgent need for additional investigations of RNF40 as a potential target for cancer therapeutics.	[Fu, Junjiang; Liao, Li; Wei, Chunli] Southwest Med Univ, Res Ctr Preclin Med, Key Lab Epigenet & Oncol, Luzhou 646000, Sichuan, Peoples R China; [Balaji, Kyathegowdanadoddi Srinivasa] Univ Mysore, Teresian Coll, Teresian Res Ctr, Post Graduat Dept Studies & Res Biotechnol, Mysore 570011, Karnataka, India; [Kim, Jaehoon] Korea Adv Inst Sci & Technol, Dept Biol Sci, Daejeon 34141, South Korea; [Peng, Jiangzhou] Southern Med Univ, Affiliated Hosp 3, Dept Thorac Surg, Guangzhou 510500, Guangdong, Peoples R China	Southwest Medical University; University of Mysore; Korea Advanced Institute of Science & Technology (KAIST); Southern Medical University - China	Fu, JJ (corresponding author), Southwest Med Univ, Res Ctr Preclin Med, Key Lab Epigenet & Oncol, Luzhou 646000, Sichuan, Peoples R China.; Kim, J (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Daejeon 34141, South Korea.; Peng, JZ (corresponding author), Southern Med Univ, Affiliated Hosp 3, Dept Thorac Surg, Guangzhou 510500, Guangdong, Peoples R China.	fujunjiang@hotmail.com; kimjaehoon@kaist.edu; jiangzhou83@163.com	K, Balaji/HGB-2214-2022; Kim, Jaehoon/G-2711-2011	Kim, Jaehoon/0000-0003-4035-0438; Fu, Junjiang/0000-0002-0708-2200; /0000-0002-7236-8993; peng, jiangzhou/0000-0002-8058-8988	National Natural Science Foundation of China [82073263, 81672887, 81172049, 30371493]; Joint Research Foundation of Luzhou City and Southwest Medical University [2018LZXNYDYL01]; Foundation of Department of Science and Technology of Guangdong Province [2011B061300016]; National Research Foundation of Korea [2018R1A5A1024261, 2019R1A2C2090830]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Joint Research Foundation of Luzhou City and Southwest Medical University; Foundation of Department of Science and Technology of Guangdong Province; National Research Foundation of Korea(National Research Foundation of Korea)	This study is financially supported by grants from the National Natural Science Foundation of China (82073263, 81672887, 81172049, and 30371493) and the Joint Research Foundation of Luzhou City and Southwest Medical University (2018LZXNYDYL01) to JF, from Foundation of Department of Science and Technology of Guangdong Province (2011B061300016) to JP, and from the National Research Foundation of Korea (2018R1A5A1024261 and 2019R1A2C2090830) to JK.	Ahmad A, 2019, ADV EXP MED BIOL, V1152, P217, DOI 10.1007/978-3-030-20301-6_10; Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22; Bedi U, 2015, ONCOGENE, V34, P465, DOI 10.1038/onc.2013.558; Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brown P, 2013, HEMATOL-AM SOC HEMAT, P596, DOI 10.1182/asheducation-2013.1.596; Burke MJ, 2014, FRONT PEDIATR, V2, DOI 10.3389/fped.2014.00042; Castro PG, 2018, LEUKEMIA, V32, P323, DOI 10.1038/leu.2017.216; Chatterton Z, 2014, EPIGENETICS-US, V9, P459, DOI 10.4161/epi.27585; Chen JQ, 2009, BBA-REV CANCER, V1796, P162, DOI 10.1016/j.bbcan.2009.06.003; Chen S, 2012, CELL RES, V22, P1402, DOI 10.1038/cr.2012.114; Chen ZJ, 2019, ELIFE, V8, DOI 10.7554/eLife.48281; Chernikova SB, 2012, CANCER RES, V72, P2111, DOI 10.1158/0008-5472.CAN-11-2209; Chin LS, 2002, J BIOL CHEM, V277, P35071, DOI 10.1074/jbc.M203300200; Clouaire T, 2018, MOL CELL, V72, P250, DOI 10.1016/j.molcel.2018.08.020; Cole AJ, 2015, ENDOCR-RELAT CANCER, V22, pT19, DOI 10.1530/ERC-14-0185; Dantuma NP, 2016, EMBO J, V35, P6, DOI 10.15252/embj.201592595; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Dickson KA, 2016, HUM MOL GENET, V25, P5460, DOI 10.1093/hmg/ddw362; Diebold ML, 2010, J BIOL CHEM, V285, P38389, DOI 10.1074/jbc.M110.146696; Duan Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12648; Fan P, 2019, CANCER DRUG RESIST, V2, P198, DOI 10.20517/cdr.2019.13; Feng RM, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-019-0368-6; Foglizzo M, 2016, J MOL BIOL, V428, P4073, DOI 10.1016/j.jmb.2016.07.025; Fu JW, 2020, MOL BIOL REP, V47, P4383, DOI 10.1007/s11033-020-05478-4; Fu SY, 2017, ONCOTARGET, V8, P43866, DOI 10.18632/oncotarget.16704; Fuchs G, 2014, BBA-GENE REGUL MECH, V1839, P694, DOI 10.1016/j.bbagrm.2014.01.002; Fujita K, 2019, WORLD J MENS HEALTH, V37, P288, DOI 10.5534/wjmh.180040; Gallego LD, 2020, NATURE, V579, P592, DOI 10.1038/s41586-020-2097-z; Ghouri Yezaz Ahmed, 2017, J Carcinog, V16, P1, DOI 10.4103/jcar.JCar_9_16; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hahn MA, 2012, HUM MOL GENET, V21, P559, DOI 10.1093/hmg/ddr490; Helt CE, 2005, J BIOL CHEM, V280, P1186, DOI 10.1074/jbc.M410873200; Hwang WW, 2003, MOL CELL, V11, P261, DOI 10.1016/S1097-2765(02)00826-2; In S, 2019, NUCLEIC ACIDS RES, V47, P2840, DOI 10.1093/nar/gkz006; Jaaskelainen T, 2012, MOL CELL ENDOCRINOL, V350, P87, DOI 10.1016/j.mce.2011.11.025; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Karpiuk O, 2012, MOL CELL, V46, P705, DOI 10.1016/j.molcel.2012.05.022; Kim J, 2009, CELL, V137, P459, DOI 10.1016/j.cell.2009.02.027; Kosinsky RL, 2019, J CROHNS COLITIS, V13, P362, DOI 10.1093/ecco-jcc/jjy165; Lee NS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10463; Li CL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03455-x; Li XS, 2010, MOL CELL BIOL, V30, P1673, DOI 10.1128/MCB.00540-09; Liu L, 2018, ONCOGENE, V37, P148, DOI 10.1038/onc.2017.313; Liu ZQ, 2020, DIGEST LIVER DIS, V52, P240, DOI 10.1016/j.dld.2019.11.001; Liu ZX, 2009, MOL BIOL CELL, V20, P757, DOI 10.1091/mbc.E08-09-0983; Ma Xiaomei, 2006, Yale J Biol Med, V79, P85; Marsh DJ, 2019, GENES-BASEL, V10, DOI 10.3390/genes10010067; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Melling N, 2016, PATHOL ONCOL RES, V22, P95, DOI 10.1007/s12253-015-9977-9; Minsky N, 2004, MOL CELL, V16, P631, DOI 10.1016/j.molcel.2004.10.016; Mladenov E, 2016, SEMIN CANCER BIOL, V37-38, P51, DOI 10.1016/j.semcancer.2016.03.003; Moyal L, 2011, MOL CELL, V41, P529, DOI 10.1016/j.molcel.2011.02.015; Nakamura K, 2011, MOL CELL, V41, P515, DOI 10.1016/j.molcel.2011.02.002; Nyame YA, 2020, EUR UROL, V77, P53, DOI 10.1016/j.eururo.2019.09.018; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Palomera-Sanchez Z, 2011, DNA REPAIR, V10, P119, DOI 10.1016/j.dnarep.2010.10.010; Pavri R, 2006, CELL, V125, P703, DOI 10.1016/j.cell.2006.04.029; Pirngruber J, 2009, EMBO REP, V10, P894, DOI 10.1038/embor.2009.108; Prenzel T, 2011, CANCER RES, V71, P5739, DOI 10.1158/0008-5472.CAN-11-1896; Ramachandran S, 2016, CELL REP, V15, P1554, DOI 10.1016/j.celrep.2016.04.041; Rawla P, 2019, GASTROENTEROL REV, V14, P89, DOI 10.5114/pg.2018.81072; Rawla P, 2019, WORLD J ONCOL, V10, P63, DOI 10.14740/wjon1191; Rawla P, 2018, WSPOLCZESNA ONKOL, V22, P141, DOI 10.5114/wo.2018.78941; Ren ZH, 2020, CANCER COMMUN, V40, P81, DOI 10.1002/cac2.12009; Robson A, 2019, P NATL ACAD SCI USA, V116, P14049, DOI 10.1073/pnas.1808341116; Roos WP, 2016, NAT REV CANCER, V16, P20, DOI 10.1038/nrc.2015.2; Sadeghi L, 2014, NAT STRUCT MOL BIOL, V21, P236, DOI 10.1038/nsmb.2776; Schneider D, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0698-x; Shah VJ, 2018, J CELL SCI, V131, DOI 10.1242/jcs.213868; Shema E, 2008, GENE DEV, V22, P2664, DOI 10.1101/gad.1703008; Shema E, 2011, MOL CELL, V42, P477, DOI 10.1016/j.molcel.2011.03.011; Shiloh Y, 2011, FEBS LETT, V585, P2795, DOI 10.1016/j.febslet.2011.07.034; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; So CC, 2019, MOL CELL BIOL, V39, DOI 10.1128/MCB.00488-18; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; Tarcic O, 2017, CELL DEATH DIFFER, V24, P694, DOI 10.1038/cdd.2016.126; Tarcic O, 2016, CELL REP, V14, P1462, DOI 10.1016/j.celrep.2016.01.020; Thaler S, 2015, INT J CANCER, V137, P686, DOI 10.1002/ijc.29404; Torre LA, 2017, CANCER EPIDEM BIOMAR, V26, P444, DOI 10.1158/1055-9965.EPI-16-0858; Trujillo KM, 2012, MOL CELL, V48, P734, DOI 10.1016/j.molcel.2012.09.019; Urasaki Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036775; Wei CL, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20193443; Wei CL, 2016, SCI REP-UK, V6, DOI 10.1038/srep29822; Wood A, 2003, MOL CELL, V11, P267, DOI 10.1016/S1097-2765(02)00802-X; Wu C, 2020, J MOL CELL BIOL, V12, P113, DOI 10.1093/jmcb/mjz045; Xie WH, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2482-4; Xie WH, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1159-5; Zhang F, 2014, J AM CHEM SOC, V136, P12884, DOI 10.1021/ja507863d; Zhang F, 2011, MOL CELL, V41, P384, DOI 10.1016/j.molcel.2011.01.024; Zheng XY, 2018, INT J CLIN EXP PATHO, V11, P2901; Zhu B, 2005, MOL CELL, V20, P601, DOI 10.1016/j.molcel.2005.09.025	92	14	14	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					465	474		10.1038/s41388-020-01556-w	http://dx.doi.org/10.1038/s41388-020-01556-w		NOV 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33199825	Green Published, hybrid			2022-12-17	WOS:000590042900001
J	Girondel, C; Levesque, K; Langlois, MJ; Pasquin, S; Saba-El-Leil, MK; Rivard, N; Friesel, R; Servant, MJ; Gauchat, JF; Lesage, S; Meloche, S				Girondel, Charlotte; Levesque, Kim; Langlois, Marie-Josee; Pasquin, Sarah; Saba-El-Leil, Marc K.; Rivard, Nathalie; Friesel, Robert; Servant, Marc J.; Gauchat, Jean-Francois; Lesage, Sylvie; Meloche, Sylvain			Loss of interleukin-17 receptor D promotes chronic inflammation-associated tumorigenesis	ONCOGENE			English	Article							SIMILAR EXPRESSION; COLORECTAL-CANCER; DOWN-REGULATION; IL-17 RECEPTOR; SEF; CELLS; CARCINOGENESIS; INHIBITOR; CYTOKINES; INTERACTS	Interleukin-17 receptor D (IL-17RD), also known as similar expression to Fgf genes (SEF), is proposed to act as a signaling hub that negatively regulates mitogenic signaling pathways, like the ERK1/2 MAP kinase pathway, and innate immune signaling. The expression of IL-17RD is downregulated in certain solid tumors, which has led to the hypothesis that it may exert tumor suppressor functions. However, the role of IL-17RD in tumor biology remains to be studied in vivo. Here, we show that genetic disruption of Il17rd leads to the increased formation of spontaneous tumors in multiple tissues of aging mice. Loss of IL-17RD also promotes tumor development in a model of colitis-associated colorectal cancer, associated with an exacerbated inflammatory response. Colon tumors from IL-17RD-deficient mice are characterized by a strong enrichment in inflammation-related gene signatures, elevated expression of pro-inflammatory tumorigenic cytokines, such as IL-17A and IL-6, and increased STAT3 tyrosine phosphorylation. We further show that RNAi depletion of IL-17RD enhances Toll-like receptor and IL-17A signaling in colon adenocarcinoma cells. No change in the proliferation of normal or tumor intestinal epithelial cells was observed upon genetic inactivation of IL-17RD. Our findings establish IL-17RD as a tumor suppressor in mice and suggest that the protein exerts its function mainly by limiting the extent and duration of inflammation.	[Girondel, Charlotte; Levesque, Kim; Saba-El-Leil, Marc K.; Meloche, Sylvain] Inst Res Immunol & Canc, Montreal, PQ, Canada; [Girondel, Charlotte; Pasquin, Sarah; Gauchat, Jean-Francois; Meloche, Sylvain] Univ Montreal, Dept Pharmacol & Physiol, Fac Med, Montreal, PQ, Canada; [Langlois, Marie-Josee; Rivard, Nathalie] Univ Sherbrooke, Dept Immunol & Cell Biol, Fac Med & Hlth Sci, Sherbrooke, PQ, Canada; [Friesel, Robert] Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME USA; [Servant, Marc J.] Univ Montreal, Fac Pharm, Montreal, PQ, Canada; [Lesage, Sylvie] Maisonneuve Rosemont Hosp, Dept Immunol Oncol, Montreal, PQ, Canada; [Lesage, Sylvie] Univ Montreal, Fac Med, Dept Microbiol Infectiol & Immunol, Montreal, PQ, Canada; [Meloche, Sylvain] Univ Montreal, Mol Biol Program, Fac Med, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal; University of Sherbrooke; Maine Medical Center; Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal	Meloche, S (corresponding author), Inst Res Immunol & Canc, Montreal, PQ, Canada.; Meloche, S (corresponding author), Univ Montreal, Dept Pharmacol & Physiol, Fac Med, Montreal, PQ, Canada.; Meloche, S (corresponding author), Univ Montreal, Mol Biol Program, Fac Med, Montreal, PQ, Canada.	sylvain.meloche@umontreal.ca		Servant, Marc/0000-0003-2014-4127; Lesage, Sylvie/0000-0002-0968-2795	Fonds de recherche Sante Quebec; Cancer Research Society	Fonds de recherche Sante Quebec; Cancer Research Society	We thank C. Kuo and G.R. van den Brink for reagents, J. Hinsinger for histology, L. Gaboury for pathology assistance, P. Melancon for qPCR analysis, J. Huber for RNA-seq, and P. Gendron for help with bioinformatic analyses. CG is recipient of a studentship from the Fonds de recherche Sante Quebec. SM held the Canada Research Chair in Cellular Signaling. Work in the Meloche laboratory was supported by a grant from the Cancer Research Society.	Beringer A, 2016, TRENDS MOL MED, V22, P230, DOI 10.1016/j.molmed.2016.01.001; Cua DJ, 2010, NAT REV IMMUNOL, V10, P479, DOI 10.1038/nri2800; Darby S, 2006, ONCOGENE, V25, P4122, DOI 10.1038/sj.onc.1209428; Darby S, 2009, BRIT J CANCER, V101, P1891, DOI 10.1038/sj.bjc.6605379; Duhamel S, 2012, CANCER RES, V72, P626, DOI 10.1158/0008-5472.CAN-11-2126; Fichtner-Feigl S, 2015, TRENDS IMMUNOL, V36, P451, DOI 10.1016/j.it.2015.06.007; Fuchs Y, 2012, DEV CELL, V23, P611, DOI 10.1016/j.devcel.2012.07.013; Furman D, 2019, NAT MED, V25, P1822, DOI 10.1038/s41591-019-0675-0; Furthauer M, 2002, NAT CELL BIOL, V4, P170, DOI 10.1038/ncb750; Gaffen SL, 2009, NAT REV IMMUNOL, V9, P556, DOI 10.1038/nri2586; Gonneaud A, 2016, SCI REP-UK, V6, DOI 10.1038/srep38195; He Q, 2016, J CELL BIOCHEM, V117, P2346, DOI 10.1002/jcb.25532; He Q, 2014, J BONE MINER RES, V29, P1217, DOI 10.1002/jbmr.2114; Hurtado CG, 2018, GASTROENTEROLOGY, V155, P1706, DOI 10.1053/j.gastro.2018.08.056; Kovalenko D, 2003, J BIOL CHEM, V278, P14087, DOI 10.1074/jbc.C200606200; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Mellett M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7669; Mellett M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2127; Monin L, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028522; Murphy T, 2010, J PATHOL, V220, P452, DOI 10.1002/path.2657; Neurath MF, 2014, NAT REV IMMUNOL, V14, P329, DOI 10.1038/nri3661; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/nmeth.3337, 10.1038/NMETH.3337]; Parang B, 2016, METHODS MOL BIOL, V1422, P297, DOI 10.1007/978-1-4939-3603-8_26; Pekow J, 2017, CLIN CANCER RES, V23, P5281, DOI 10.1158/1078-0432.CCR-17-0171; Peng DH, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaq1238; Razi S, 2019, CYTOKINE, V116, P7, DOI 10.1016/j.cyto.2018.12.021; Ren YM, 2008, CELL SIGNAL, V20, P518, DOI 10.1016/j.cellsig.2007.11.010; Ren YM, 2006, BIOCHEM BIOPH RES CO, V347, P988, DOI 10.1016/j.bbrc.2006.06.193; Ron D, 2008, INT J BIOCHEM CELL B, V40, P2040, DOI 10.1016/j.biocel.2008.03.013; Rong ZL, 2009, CELL RES, V19, P208, DOI 10.1038/cr.2008.320; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Soulez M, 2019, MOL CELL BIOL, V39, DOI 10.1128/MCB.00527-18; Stidham RW, 2018, CLIN COLON RECT SURG, V31, P168, DOI 10.1055/s-0037-1602237; Su Y, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aau9657; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142; Taniguchi K, 2014, SEMIN IMMUNOL, V26, P54, DOI 10.1016/j.smim.2014.01.001; Torii S, 2004, DEV CELL, V7, P33, DOI 10.1016/j.devcel.2004.05.019; Tsang M, 2002, NAT CELL BIOL, V4, P165, DOI 10.1038/ncb749; Wang KP, 2014, IMMUNITY, V41, P1052, DOI 10.1016/j.immuni.2014.11.009; West NR, 2015, NAT REV IMMUNOL, V15, P615, DOI 10.1038/nri3896; Wu SG, 2009, NAT MED, V15, P1016, DOI 10.1038/nm.2015; Zisman-Rozen S, 2007, ONCOGENE, V26, P6093, DOI 10.1038/sj.onc.1210424	43	14	14	1	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					452	464		10.1038/s41388-020-01540-4	http://dx.doi.org/10.1038/s41388-020-01540-4		NOV 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33177649				2022-12-17	WOS:000588591500001
J	Gamaev, L; Mizrahi, L; Friehmann, T; Rosenberg, N; Pappo, O; Olam, D; Zeira, E; Halpern, KB; Caruso, S; Zucman-Rossi, J; Axelrod, JH; Galun, E; Goldenberg, DS				Gamaev, Lika; Mizrahi, Lina; Friehmann, Tomer; Rosenberg, Nofar; Pappo, Orit; Olam, Devorah; Zeira, Evelyne; Bahar Halpern, Keren; Caruso, Stefano; Zucman-Rossi, Jessica; Axelrod, Jonathan H.; Galun, Eithan; Goldenberg, Daniel S.			The pro-oncogenic effect of the lncRNA H19 in the development of chronic inflammation-mediated hepatocellular carcinoma	ONCOGENE			English	Article							NONCODING RNA H19; LIVER CARCINOGENESIS; MOLECULAR-MECHANISMS; MURINE; GENE; EXPRESSION; POLYPLOIDIZATION; CLASSIFICATION; PROLIFERATION; CONTRIBUTES	The oncofetal long noncoding RNA (lncRNA) H19 is postnatally repressed in most tissues, and re-expressed in many cancers, including hepatocellular carcinoma (HCC). The role of H19 in carcinogenesis is a subject of controversy. We aimed to examine the role of H19 in chronic inflammation-mediated hepatocarcinogenesis using the Mdr2/Abcb4 knockout (Mdr2-KO) mouse, a well-established HCC model. For this goal, we have generated Mdr2-KO/H19-KO double knockout (dKO) mice and followed spontaneous tumor development in the dKO and control Mdr2-KO mice. Cellular localization of H19 and effects of H19 loss in the liver were determined in young and old Mdr2-KO mice. Tumor incidence and tumor load were both significantly decreased in the liver of dKO versus Mdr2-KO females. The expression levels of H19 and Igf2 were variable in nontumor liver tissues of Mdr2-KO females and were significantly downregulated in most matched tumors. In nontumor liver tissue of aged Mdr2-KO females, H19 was expressed mainly in hepatocytes, and hepatocyte proliferation was increased compared to dKO females. At an early age, dKO females displayed lower levels of liver injury and B-cell infiltration, with higher percentage of binuclear hepatocytes. In human samples, H19 expression was higher in females, positively correlated with cirrhosis (in nontumor liver samples) and negatively correlated with CTNNB1 (beta-catenin) mutations and patients' survival (in tumors). Our data demonstrate that the lncRNA H19 is pro-oncogenic during the development of chronic inflammation-mediated HCC in the Mdr2-KO mouse model, mainly by increasing liver injury and decreasing hepatocyte polyploidy in young mice.	[Gamaev, Lika; Mizrahi, Lina; Friehmann, Tomer; Rosenberg, Nofar; Olam, Devorah; Zeira, Evelyne; Axelrod, Jonathan H.; Galun, Eithan; Goldenberg, Daniel S.] Hadassah Hebrew Univ, Med Ctr, Goldyne Savad Inst Gene & Cell Therapy, Jerusalem, Israel; [Pappo, Orit] Hadassah Hebrew Univ, Med Ctr, Dept Pathol, Jerusalem, Israel; [Bahar Halpern, Keren] Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel; [Caruso, Stefano; Zucman-Rossi, Jessica] Univ Paris, Sorbonne Univ, INSERM, Ctr Rech Cordeliers,Funct Genom Solid Tumors Lab, F-75006 Paris, France; [Zucman-Rossi, Jessica] Hop Europeen Georges Pompidou, AP HP, F-75015 Paris, France	Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center; Weizmann Institute of Science; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Goldenberg, DS (corresponding author), Hadassah Hebrew Univ, Med Ctr, Goldyne Savad Inst Gene & Cell Therapy, Jerusalem, Israel.	goldenberg@hadassah.org.il	Caruso, Stefano/AAA-9564-2020; zucman-rossi, Jessica/B-5098-2009; Galun, Eithan/AAD-9117-2022; j, zucman-rossi/AAV-3594-2021	Caruso, Stefano/0000-0002-6319-3642; zucman-rossi, Jessica/0000-0002-5687-0334; Galun, Eithan/0000-0002-6243-6702; j, zucman-rossi/0000-0002-5687-0334; Goldenberg, Daniel/0000-0002-1618-4145	Robert H. Benson Living Trust; Selma Kron Foundation; Kamea Scientific Foundation of the Israeli Government; ISF [923/14, 486/2017]; Labex OncoImunology; CARPEM; INSERM; Ligue Nationale contre le Cancer (Equipe Labellisee); Labex OncoImmunology (investissement d'avenir); grant IREB; Coup d'Elan de la Fondation Bettencourt-Schueller; SIRIC CARPEM; Raymond Rosen Award from the Fondation pour le Recherche Medicale; Prix Rene and Andree Duquesne-Comite de Paris Ligue Contre le Cancer; Fondation Merieux; ERC [786575-RxmiRcanceR]; Deutsche Forschungsgemeinschaft (DFG) [SFB841]; NIH [CA197081-02]; MOST; ISF collaboration with Canada [2473/2017]; ICORE-ISF [41/2011]; DKFZ-MOST	Robert H. Benson Living Trust; Selma Kron Foundation; Kamea Scientific Foundation of the Israeli Government; ISF(Israel Science Foundation); Labex OncoImunology; CARPEM; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Ligue Nationale contre le Cancer (Equipe Labellisee)(Ligue nationale contre le cancer); Labex OncoImmunology (investissement d'avenir)(French National Research Agency (ANR)); grant IREB; Coup d'Elan de la Fondation Bettencourt-Schueller; SIRIC CARPEM; Raymond Rosen Award from the Fondation pour le Recherche Medicale; Prix Rene and Andree Duquesne-Comite de Paris Ligue Contre le Cancer; Fondation Merieux; ERC(European Research Council (ERC)European Commission); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MOST; ISF collaboration with Canada; ICORE-ISF; DKFZ-MOST	Robert H. Benson Living Trust and Selma Kron Foundation to student fellowships. DSG is supported by the Kamea Scientific Foundation of the Israeli Government. JHA was supported by ISF 923/14. SC was supported by a funding from Labex OncoImunology and CARPEM. The JZR group was supported by INSERM, Ligue Nationale contre le Cancer (Equipe Labellisee), Labex OncoImmunology (investissement d'avenir), grant IREB, Coup d'Elan de la Fondation Bettencourt-Schueller, the SIRIC CARPEM, Raymond Rosen Award from the Fondation pour le Recherche Medicale, Prix Rene and Andree Duquesne-Comite de Paris Ligue Contre le Cancer and Fondation Merieux. The work of EG was supported by the: ERC advance-GA No. 786575-RxmiRcanceR, Deutsche Forschungsgemeinschaft (DFG) SFB841 project C3, NIH CA197081-02, MOST, ISF collaboration with Canada (2473/2017), personal ISF (486/2017), ICORE-ISF (41/2011), and by DKFZ-MOST.	Adriaenssens E, 1999, ONCOGENE, V18, P4460, DOI 10.1038/sj.onc.1202819; Boyault S, 2007, HEPATOLOGY, V45, P42, DOI 10.1002/hep.21467; Chen X, 2015, CANCER SCI, V106, P972, DOI 10.1111/cas.12700; Chiang DY, 2008, CANCER RES, V68, P6779, DOI 10.1158/0008-5472.CAN-08-0742; Ella E, 2014, ONCOTARGET, V5, P10318, DOI 10.18632/oncotarget.2515; Faggioli F, 2018, HEPATOLOGY, V67, P1970, DOI 10.1002/hep.29636; Goyal N, 2019, J MOL MED, V97, P115, DOI 10.1007/s00109-018-1718-6; Guidotti JE, 2003, J BIOL CHEM, V278, P19095, DOI 10.1074/jbc.M300982200; Hao PP, 2015, J HEPATOL, V62, P1278, DOI 10.1016/j.jhep.2014.12.033; Hoppstadter J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01446; Jiang YC, 2018, HEPATOL COMMUN, V2, P1356, DOI 10.1002/hep4.1252; Jones SA, 2016, ANN RHEUM DIS, V75, P739, DOI 10.1136/annrheumdis-2015-207744; Katzenellenbogen M, 2006, CANCER RES, V66, P4001, DOI 10.1158/0008-5472.CAN-05-2937; Katzenellenbogen M, 2007, MOL CANCER RES, V5, P1159, DOI 10.1158/1541-7786.MCR-07-0172; Lecerf C, 2019, CELL MOL LIFE SCI, V76, P4673, DOI 10.1007/s00018-019-03240-z; Lee JW, 2019, NATURE, V567, P249, DOI 10.1038/s41586-019-1004-y; Li XJY, 2018, HEPATOLOGY, V68, P599, DOI 10.1002/hep.29838; Li XJY, 2017, HEPATOLOGY, V66, P869, DOI 10.1002/hep.29145; Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.18, 10.1038/nrdp.2016.19]; Martinez-Quetglas I, 2016, GASTROENTEROLOGY, V151, P1192, DOI 10.1053/j.gastro.2016.09.001; Matouk IJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000845; MAUAD TH, 1994, AM J PATHOL, V145, P1237; Nemeth J, 2009, HEPATOLOGY, V50, P1251, DOI 10.1002/hep.23099; Pope C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187557; Potikha T, 2013, HEPATOLOGY, V58, P192, DOI 10.1002/hep.26335; Raveh E, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0458-2; Ricci E, 2019, J LEUKOCYTE BIOL, V105, P187, DOI 10.1002/JLB.3AB0718-255R; Robert O, 2016, J HEPATOL, V64, P916, DOI 10.1016/j.jhep.2015.11.023; Schultheiss CS, 2017, CELL STRESS, V1, P37, DOI 10.15698/cst2017.10.105; Shoshani O, 2012, CANCER RES, V72, P6403, DOI 10.1158/0008-5472.CAN-12-1155; Stoyanov E, 2015, ONCOTARGET, V6, P11047, DOI 10.18632/oncotarget.3567; Uehara T, 2013, TOXICOL SCI, V132, P53, DOI 10.1093/toxsci/kfs342; Wilkinson PD, 2019, HEPATOLOGY, V69, P1242, DOI 10.1002/hep.30286; Xu GQ, 2015, ONCOTARGET, V6, P33636, DOI 10.18632/oncotarget.5602; Yamamoto Y, 2004, J HEPATOL, V40, P808, DOI 10.1016/j.jhep.2004.01.022; Yang F, 2012, FEBS J, V279, P3159, DOI 10.1111/j.1742-4658.2012.08694.x; Yang JB, 2018, ONCOGENE, V37, P1192, DOI 10.1038/s41388-017-0048-4; Yang NM, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0756-7; Yang XW, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-909; Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267; Yoshimizu T, 2008, P NATL ACAD SCI USA, V105, P12417, DOI 10.1073/pnas.0801540105; Zhang JQ, 2019, HEPATOLOGY, V69, P1549, DOI 10.1002/hep.30153; Zhang L, 2013, CARCINOGENESIS, V34, P577, DOI 10.1093/carcin/bgs381; Zhang SY, 2018, DEV CELL, V44, P447, DOI 10.1016/j.devcel.2018.01.010; Zhang YX, 2016, SCI REP-UK, V6, DOI 10.1038/srep20559; Zhao RZ, 2020, NATURE, V577, P416, DOI 10.1038/s41586-019-1873-0; Zhu PP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8122	47	14	14	1	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					127	139		10.1038/s41388-020-01513-7	http://dx.doi.org/10.1038/s41388-020-01513-7		OCT 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33093654	Green Published			2022-12-17	WOS:000581554300001
J	He, Q; Lin, ZY; Wang, ZH; Huang, WJ; Tian, D; Liu, M; Xia, LM				He, Qin; Lin, Zhuoying; Wang, Zhihui; Huang, Wenjie; Tian, Dean; Liu, Mei; Xia, Limin			SIX4 promotes hepatocellular carcinoma metastasis through upregulating YAP1 and c-MET	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; THERAPEUTIC TARGET; CANCER; INHIBITOR; YAP/TAZ; THERAPIES; PROTEIN; EGFR; SIZE; AXIS	Metastasis is the main reason for high mortality in hepatocellular carcinoma (HCC) patients and the molecular mechanism remains unclear. Therefore, it is important to elucidate the mechanism underlying HCC metastasis. Here, we report a novel role of SIX homeobox 4 (SIX4), one of the SIX gene family, in promoting HCC metastasis. The elevated expression of SIX4 was positively correlated with loss of tumor encapsulation, microvascular invasion, higher TNM stage, and poor prognosis in human HCC. SIX4 expression was an independent and significant risk factor for the recurrence and survival in HCC patients. Upregulation of SIX4 promoted HCC invasion and metastasis, whereas downregulation of SIX4 decreased HCC invasion and metastasis. SIX4 transactivated Yes1 associated transcriptional regulator (YAP1) and MET proto-oncogene, receptor tyrosine kinase (MET) expression through directly binding to their promoters. Knockdown of YAP1 and c-MET inhibited SIX4-medicated HCC metastasis, while the stable overexpression of YAP1 and c-MET reversed the decreased metastasis induced by SIX4 knockdown. Hepatocyte growth factor (HGF), the specific ligand of c-MET, upregulated SIX4 expression through ERK/NF-kappa B pathway. Knockdown of SIX4 significantly decreased HGF-enhanced HCC metastasis. In human HCC tissues, SIX4 expression was positively correlated with nuclear YAP1, c-MET and HGF expression. Patients with positive coexpression of SIX4/ nuclear YAP1, SIX4/c-MET or HGF/SIX4 had the poorest prognosis. Moreover, the combination treatment of YAP1 inhibitor Verteporfin and c-MET inhibitor Capmatinib significantly suppressed SIX4-mediated HCC metastasis. In conclusion, SIX4 is a prognostic biomarker in HCC patients and targeting the HGF-SIX4-c-MET positive feedback loop may provide a promising strategy for the treatment of SIX4-driven HCC metastasis.	[He, Qin; Lin, Zhuoying; Wang, Zhihui; Tian, Dean; Liu, Mei; Xia, Limin] Huazhong Univ Sci & Technol, Dept Gastroenterol, Inst Liver & Gastrointestinal Dis, Tongji Hosp,Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China; [Huang, Wenjie] Huazhong Univ Sci & Technol, Hepat Surg Ctr, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China; [Huang, Wenjie] Clin Med Res Ctr Hepat Surg Hubei Prov, Wuhan 430030, Hubei, Peoples R China; [Huang, Wenjie] Minist Educ, Key Lab Organ Transplantat, Wuhan 430030, Hubei, Peoples R China; [Huang, Wenjie] Minist Publ Hlth, Wuhan 430030, Hubei, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology	Liu, M; Xia, LM (corresponding author), Huazhong Univ Sci & Technol, Dept Gastroenterol, Inst Liver & Gastrointestinal Dis, Tongji Hosp,Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China.	fliumei@126.com; xialimin@tjh.tjmu.edu.cn		Xia, Limin/0000-0002-6327-6034; He, Qin/0000-0002-9887-9388	National Key Research and Development Program of China [2018YFC1312103]; National Natural Science Foundation of China [81871911, 81972237, 81772623]	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Research was supported by grants from the National Key Research and Development Program of China 2018YFC1312103 (LX), National Natural Science Foundation of China No. 81871911 (WH), No. 81972237 (LX), and No. 81772623 (LX).	Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558; Bisso A, 2020, HEPATOLOGY, V72, P1430, DOI 10.1002/hep.31120; Bladt F, 2014, CANCERS, V6, P1736, DOI 10.3390/cancers6031736; Bouattour M, 2018, HEPATOLOGY, V67, P1132, DOI 10.1002/hep.29496; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chen J, 2020, HEPATOLOGY, V71, P1712, DOI 10.1002/hep.30951; Chen RC, 2018, HEPATOLOGY, V67, P1823, DOI 10.1002/hep.29663; Christensen KL, 2008, ADV CANCER RES, V101, P93, DOI 10.1016/S0065-230X(08)00405-3; Coletta RD, 2004, P NATL ACAD SCI USA, V101, P6478, DOI 10.1073/pnas.0401139101; Comoglio PM, 2018, NAT REV CANCER, V18, P341, DOI 10.1038/s41568-018-0002-y; Craig AJ, 2020, NAT REV GASTRO HEPAT, V17, P139, DOI 10.1038/s41575-019-0229-4; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Dong QZ, 2019, CANCER RES, V79, P819, DOI 10.1158/0008-5472.CAN-18-1273; Faivre S, 2020, J HEPATOL, V72, P342, DOI 10.1016/j.jhep.2019.09.010; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Forner A, 2018, LANCET, V391, P1301, DOI 10.1016/S0140-6736(18)30010-2; Garcia-Vilas JA, 2018, WORLD J GASTROENTERO, V24, P3695, DOI 10.3748/wjg.v24.i33.3695; Gavini J, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1989-z; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Gibault F, 2017, CHEMMEDCHEM, V12, P954, DOI 10.1002/cmdc.201700063; Giordano S, 2014, J HEPATOL, V60, P442, DOI 10.1016/j.jhep.2013.09.009; Hu CT, 2017, CANCERS, V9, DOI 10.3390/cancers9060058; Lau EYT, 2016, CELL REP, V15, P1175, DOI 10.1016/j.celrep.2016.04.019; Li GD, 2017, PEERJ, V5, DOI 10.7717/peerj.3394; Li H, 2019, GASTROENTEROLOGY, V156, P1849, DOI 10.1053/j.gastro.2019.01.252; Li L, 2018, CANCER CELL, V33, P368, DOI 10.1016/j.ccell.2018.01.010; Liu XD, 2011, CLIN CANCER RES, V17, P7127, DOI 10.1158/1078-0432.CCR-11-1157; Liu Z, 2019, J DENT RES, V98, P572, DOI 10.1177/0022034519835204; McCoy EL, 2009, J CLIN INVEST, V119, P2663, DOI 10.1172/JCI37691; Mizuguchi T, 2009, J GASTROINTEST SURG, V13, P325, DOI 10.1007/s11605-008-0711-8; Oliphant MUJ, 2019, CANCER RES, V79, P720, DOI 10.1158/0008-5472.CAN-18-1791; Ono H, 2012, ONCOGENE, V31, P4923, DOI 10.1038/onc.2011.646; Ou SHI, 2017, J THORAC ONCOL, V12, P145, DOI 10.1016/j.jtho.2016.09.131; Papaccio F, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113595; Patel SH, 2017, GASTROENTEROLOGY, V152, P533, DOI 10.1053/j.gastro.2016.10.047; Shah AM, 2020, DIS MODEL MECH, V13, DOI 10.1242/dmm.043489; Shi C, 2018, REDOX BIOL, V14, P59, DOI 10.1016/j.redox.2017.08.013; Sun XL, 2020, AM J CANCER RES, V10, P224; Tang XP, 2019, BIOCHEM BIOPH RES CO, V516, P851, DOI 10.1016/j.bbrc.2019.06.114; Vejchapipat P, 2004, J GASTROENTEROL, V39, P1182, DOI 10.1007/s00535-004-1469-8; Wang CA, 2012, J CLIN INVEST, V122, P1895, DOI 10.1172/JCI59858; Wang HY, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00055; Xiang CA, 2017, CANCERS, V9, DOI 10.3390/cancers9050044; Xu MZ, 2009, CANCER-AM CANCER SOC, V115, P4576, DOI 10.1002/cncr.24495; Yang JD, 2019, NAT REV GASTRO HEPAT, V16, P589, DOI 10.1038/s41575-019-0186-y; Yang X, 2014, HEPATOLOGY, V59, P1874, DOI 10.1002/hep.26941; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966; Yu ZB, 2020, ONCOGENE, V39, P3163, DOI 10.1038/s41388-020-1206-7; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhang SH, 2019, CURR OPIN CELL BIOL, V61, P64, DOI 10.1016/j.ceb.2019.07.006; Zhang XD, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0892-2; Zhang YZ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0796-y; Zheng Y, 2018, THERANOSTICS, V8, P972, DOI 10.7150/thno.22328	54	14	14	1	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2020	39	50					7279	7295		10.1038/s41388-020-01500-y	http://dx.doi.org/10.1038/s41388-020-01500-y		OCT 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PD4HE	33046796				2022-12-17	WOS:000578784100001
J	Ukai, S; Honma, R; Sakamoto, N; Yamamoto, Y; Pham, QT; Harada, K; Takashima, T; Taniyama, D; Asai, R; Fukada, K; Naka, K; Tanabe, K; Ohdan, H; Yasui, W				Ukai, Shoichi; Honma, Ririno; Sakamoto, Naoya; Yamamoto, Yusuke; Pham, Quoc Thang; Harada, Kenji; Takashima, Tsuyoshi; Taniyama, Daiki; Asai, Ryuichi; Fukada, Kaho; Naka, Kazuhito; Tanabe, Kazuaki; Ohdan, Hideki; Yasui, Wataru			Molecular biological analysis of 5-FU-resistant gastric cancer organoids; KHDRBS3 contributes to the attainment of features of cancer stem cell	ONCOGENE			English	Article							DRUG-RESISTANCE; EXPRESSION; LEUCOVORIN; INTERACTS; TISSUE	5-FU is one of the key drugs in the treatment of gastric cancer (GC). Much evidence has shown that cancer stem cells (CSCs) play a key role in the acquisition of drug resistance. The organoid is a novel 3D cell culture system technology that sustains stem-cell-driven formation of near-physiological, self-renewing tissues using specific niche factors in a dish. In this study, we established GC organoids (GCOs) and gradually treated them with higher concentrations of 5-FU. We successfully harvested four 5-FU-resistant GCOs, which were supported by significant changes in the expression of molecules related to 5-FU metabolism. We then performed microarray analysis using three normal gastric organoids and three pairs of 5-FU-resistant and parental GCOs. Through the comparison of expression profiles and further validation, we chose KHDRBS3 as a target gene. We found KHDRBS3 to be an independent prognostic factor in GC patients, especially in GC patients treated with 5-FU chemotherapy. We also determined that KHDRBS3 might play an important role in the acquisition of stem cell-like features, such as multi-drug resistance and organoid formation, by regulating CD44 variant expression. We found KHDRBS3, which is thought to play an important role in the acquisition of characteristics of CSCs in GC, to be a promising candidate marker for predicting therapeutic effect and prognosis in GC patients.	[Ukai, Shoichi; Honma, Ririno; Sakamoto, Naoya; Pham, Quoc Thang; Harada, Kenji; Takashima, Tsuyoshi; Taniyama, Daiki; Asai, Ryuichi; Fukada, Kaho; Yasui, Wataru] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Mol Pathol, Hiroshima, Japan; [Yamamoto, Yusuke] Natl Canc Ctr, Div Mol & Cellular Med, Tokyo, Japan; [Naka, Kazuhito] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Stem Cell Biol, Hiroshima, Japan; [Tanabe, Kazuaki] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Hlth Care Adults, Hiroshima, Japan; [Ohdan, Hideki] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Gastroenterol & Transplant Surg, Hiroshima, Japan	Hiroshima University; National Cancer Center - Japan; Hiroshima University; Hiroshima University; Hiroshima University	Yasui, W (corresponding author), Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Mol Pathol, Hiroshima, Japan.	wyasui@hiroshima-u.ac.jp	tanabe, kazuaki/S-6282-2019; Ohdan, Hideki/G-4719-2019; Pham, Quoc Thang/AAP-5919-2021	Ohdan, Hideki/0000-0002-9066-1288; Pham, Quoc Thang/0000-0001-8787-367X; Ukai, Shoichi/0000-0001-8491-1183; Harada, Kenji/0000-0002-8995-2846; TSUYOSHI, TAKASHIMA/0000-0003-1362-3883	Japan Society for the Promotion of Science [JP15H04713, JP16K08691, JP16H06999, 26670175, JP16K15247]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	The present study was supported by Grants in Aid for Scientific Research (JP15H04713, JP16K08691, JP16H06999) and for Challenging Exploratory Research (26670175, JP16K15247) from the Japan Society for the Promotion of Science.	Al-Batran SE, 2016, LANCET ONCOL, V17, P1697, DOI 10.1016/S1470-2045(16)30531-9; Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Gao YY, 2019, INT J CLIN EXP PATHO, V12, P1095; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Honma R, 2017, GASTRIC CANCER, V20, P960, DOI 10.1007/s10120-017-0714-9; Ishikawa A, 2020, ONCOL REP, V43, P581, DOI 10.3892/or.2019.7422; Lancaster MA, 2014, SCIENCE, V345, DOI 10.1126/science.1247125; Lei KF, 2011, ONCOL REP, V26, P1115, DOI 10.3892/or.2011.1369; Matsumoto Y, 2018, CANCER MED-US, V7, P454, DOI 10.1002/cam4.1296; Mazzoldi EL, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020368; Nakamura A, 2014, GASTRIC CANCER, V17, P188, DOI 10.1007/s10120-013-0249-7; Okuyama K, 2019, PATHOL ONCOL RES, V25, P603, DOI 10.1007/s12253-018-0529-y; Pacifico MD, 2006, INT J CANCER, V118, P1460, DOI 10.1002/ijc.21504; Sakamoto N, 2014, CANCER SCI, V105, P236, DOI 10.1111/cas.12330; Sato T, 2013, SCIENCE, V340, P1190, DOI 10.1126/science.1234852; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Seidlitz T, 2019, GUT, V68, P207, DOI 10.1136/gutjnl-2017-314549; Shen XM, 2015, CELL BIOCHEM BIOPHYS, V71, P1653, DOI 10.1007/s12013-014-0387-5; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Steele NG, 2019, CELL MOL GASTROENTER, V7, P161, DOI 10.1016/j.jcmgh.2018.09.008; van de Wetering M, 2015, CELL, V161, P933, DOI 10.1016/j.cell.2015.03.053; Venables JP, 1999, HUM MOL GENET, V8, P959, DOI 10.1093/hmg/8.6.959; Wang WG, 2004, CANCER RES, V64, P8167, DOI 10.1158/0008-5472.CAN-04-0970; Yang HHN, 2018, CELL STEM CELL, V23, P882, DOI 10.1016/j.stem.2018.09.016	25	14	16	5	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2020	39	50					7265	7278		10.1038/s41388-020-01492-9	http://dx.doi.org/10.1038/s41388-020-01492-9		OCT 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PD4HE	33046798	Green Submitted			2022-12-17	WOS:000578784100002
J	Zhang, JL; Wong, CC; Leung, KT; Wu, F; Zhou, YH; Tong, JHM; Chan, RCK; Li, H; Wang, YF; Yan, H; Liu, LP; Wu, WKK; Chan, MWY; Cheng, ASL; Yu, J; Wong, NA; Lo, KW; To, KF; Kang, W				Zhang, Jinglin; Wong, Chi Chun; Leung, Kam Tong; Wu, Feng; Zhou, Yuhang; Tong, Joanna H. M.; Chan, Ronald C. K.; Li, Hui; Wang, Yifei; Yan, Huan; Liu, Liping; Wu, William K. K.; Chan, Michael W. Y.; Cheng, Alfred S. L.; Yu, Jun; Wong, Nathalie; Lo, Kwok Wai; To, Ka Fai; Kang, Wei			FGF18-FGFR2 signaling triggers the activation of c-Jun-YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; GENE AMPLIFICATION; FGFR2 GENE; CROSS-TALK; PATHWAYS; AZD4547; OVEREXPRESSION; EFFICACY; HEDGEHOG; WNT	Fibroblast growth factor receptor type 2 (FGFR2) has emerged as a key oncogenic factor that regulates gastric cancer (GC) progression, but the underlying mechanism of FGF-FGFR2 signaling pathway remains largely unknown. To identify the potential molecular mechanisms of the oncogenic FGFR2 in gastric carcinogenesis and convey a novel therapeutic strategy, we profiled the FGFR alterations and analyzed their clinical associations in TCGA and Hong Kong GC cohorts. We found that FGFR2 overexpression in GC cell lines and primary tumors predicted poor survival and was associated with advanced stages of GC. Functionally, growth abilities and cell cycle progression of GC were inhibited by inactivation of ERK-MAPK signal transduction after FGFR2 knockdown, while apoptosis was promoted. Meanwhile, the first-line anti-cancer drug sensitivity was enhanced. RNA-seq analysis further revealed that YAP1 signaling serves as a significant downstream modulator and mediates the oncogenic signaling of FGFR2. When stimulating FGFR2 by rhFGF18, we observed intensified F-actin, nuclear accumulation of YAP1, and overexpression of YAP1 targets, but these effects were attenuated by either FGFR2 depletion or AZD4547 administration. Additionally, the FGF18-FGFR2 signaling upregulated YAP1 expression through activating c-Jun, an effector of MAPK signaling. In our cohort, 28.94% of GC cases were characterized as FGFR2, c-Jun, and YAP1 co-positive and demonstrated worse clinical outcomes. Remarkably, we also found that co-targeting FGFR2 and YAP1 by AZD4547 and Verteporfin synergistically enhanced the antitumor effects in vitro and in vivo. In conclusion, we have identified the oncogenic FGF-FGFR2 regulates YAP1 signaling in GC. The findings also highlight the translational potential of FGFR2-c-Jun-YAP1 axis, which may serve as a prognostic biomarker and therapeutic target for GC.	[Zhang, Jinglin; Wu, Feng; Zhou, Yuhang; Tong, Joanna H. M.; Chan, Ronald C. K.; Li, Hui; Wang, Yifei; Yan, Huan; Lo, Kwok Wai; To, Ka Fai; Kang, Wei] Chinese Univ Hong Kong, Prince Wales Hosp, State Key Lab Translat Oncol, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; [Zhang, Jinglin; Wong, Chi Chun; Zhou, Yuhang; Tong, Joanna H. M.; Li, Hui; Wang, Yifei; Yan, Huan; Yu, Jun; To, Ka Fai; Kang, Wei] Chinese Univ Hong Kong, State Key Lab Digest Dis, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Zhang, Jinglin; Zhou, Yuhang; Tong, Joanna H. M.; Li, Hui; Wang, Yifei; Yan, Huan; Wong, Nathalie; Lo, Kwok Wai; To, Ka Fai; Kang, Wei] Chinese Univ Hong Kong, Sir YK Pao Canc Ctr, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; [Leung, Kam Tong] Chinese Univ Hong Kong, Dept Pediat, Hong Kong, Peoples R China; [Liu, Liping] Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Hepatobiliary & Pancreat Surg, Shenzhen, Guangdong, Peoples R China; [Wu, William K. K.] Chinese Univ Hong Kong, Dept Anaesthesia & Intens Care, Hong Kong, Hong Kong, Peoples R China; [Chan, Michael W. Y.] Natl Chung Cheng Univ, Dept Life Sci, Chiayi, Taiwan; [Cheng, Alfred S. L.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Yu, Jun] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; [Wong, Nathalie] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Jinan University; Chinese University of Hong Kong; National Chung Cheng University; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	To, KF; Kang, W (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, State Key Lab Translat Oncol, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China.; To, KF; Kang, W (corresponding author), Chinese Univ Hong Kong, State Key Lab Digest Dis, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China.; To, KF; Kang, W (corresponding author), Chinese Univ Hong Kong, Sir YK Pao Canc Ctr, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China.	kfto@cuhk.edu.hk; weikang@cuhk.edu.hk	KANG, Wei/C-5451-2016; Wu, William K.K./A-3277-2009; Leung, Kam Tong/I-8569-2017	KANG, Wei/0000-0002-4651-677X; Wu, William K.K./0000-0002-5662-5240; Leung, Kam Tong/0000-0002-7695-2513; Wong, Chi Chun/0000-0003-1362-3541; , Huan/0000-0003-3370-0479; Chan, Michael/0000-0003-0314-2437	Research Grants Council of the Hong Kong Special Administrative Region, China [CUHK 14100019, 14118518]; CUHK Direct Grant for Research from The Chinese University of Hong Kong [2019.001]	Research Grants Council of the Hong Kong Special Administrative Region, China(Hong Kong Research Grants Council); CUHK Direct Grant for Research from The Chinese University of Hong Kong	We thank the TCGA Research Network (http://ca ncergenome.nih.gov/), The UCSC Cancer Genomics Browser (https:// genome-cancer.ucsc.edu/), NCI Center for Cancer Genomics Office (http://gdc.nci.nih.gov/), and JASPAR 2020 database (http://jaspar.genereg.net/) for the gastric cancer dataset and analysis. We also appreciate the technical support from Core Utilities of Cancer Genomics and Pathobiology of Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong. The manuscript is under the support of Research Grants Council of the Hong Kong Special Administrative Region, China [Project No.: CUHK 14100019 and 14118518 (for GRF projects)], and CUHK Direct Grant for Research (2019.001) from The Chinese University of Hong Kong.	Ahn S, 2016, MODERN PATHOL, V29, P1095, DOI 10.1038/modpathol.2016.96; Babina IS, 2017, NAT REV CANCER, V17, P318, DOI 10.1038/nrc.2017.8; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Bosetti C, 2008, ANN ONCOL, V19, P631, DOI 10.1093/annonc/mdm597; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brooks AN, 2012, CLIN CANCER RES, V18, P1855, DOI 10.1158/1078-0432.CCR-11-0699; Chang JJ, 2015, ONCOTARGET, V6, P2009, DOI 10.18632/oncotarget.2987; Dey JH, 2010, CANCER RES, V70, P4151, DOI 10.1158/0008-5472.CAN-09-4479; Dienstmann R, 2014, ANN ONCOL, V25, P552, DOI 10.1093/annonc/mdt419; Dudka AA, 2010, CANCER RES, V70, P3391, DOI 10.1158/0008-5472.CAN-09-3033; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Farre D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605; Fornes O, 2020, NUCLEIC ACIDS RES, V48, pD87, DOI 10.1093/nar/gkz1001; Haugsten EM, 2010, MOL CANCER RES, V8, P1439, DOI 10.1158/1541-7786.MCR-10-0168; Helsten T, 2016, CLIN CANCER RES, V22, P259, DOI 10.1158/1078-0432.CCR-14-3212; Hu B, 2012, J GASTROINTEST ONCOL, V3, P251, DOI 10.3978/j.issn.2078-6891.2012.021; Huang TT, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0493-7; Jang J, 2017, TRANSL ONCOL, V10, P469, DOI 10.1016/j.tranon.2017.03.001; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kang W, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0134-0; Kang W, 2011, CLIN CANCER RES, V17, P2130, DOI 10.1158/1078-0432.CCR-10-2467; Karolchik D, 2004, NUCLEIC ACIDS RES, V32, pD493, DOI 10.1093/nar/gkh103; Katoh M, 2006, INT J ONCOL, V29, P163; Katoh M, 2006, CANCER BIOL THER, V5, P1059, DOI 10.4161/cbt.5.9.3151; Kim HS, 2019, J CANCER, V10, P20, DOI 10.7150/jca.28204; Lau WM, 2018, MOL CANCER THER, V17, P232, DOI 10.1158/1535-7163.MCT-17-0367; Leung WK, 2018, GASTROENTEROLOGY, V155, P67, DOI 10.1053/j.gastro.2018.03.028; Liao RG, 2013, CANCER RES, V73, P5195, DOI 10.1158/0008-5472.CAN-12-3950; Matsuda Y, 2012, MOL CANCER THER, V11, P2010, DOI 10.1158/1535-7163.MCT-12-0243; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Mi HY, 2019, NUCLEIC ACIDS RES, V47, pD419, DOI 10.1093/nar/gky1038; Mitsuno Y, 2001, GUT, V49, P18, DOI 10.1136/gut.49.1.18; Ohta H, 2009, BRIT J CANCER, V100, P389, DOI 10.1038/sj.bjc.6604846; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; Shoji H, 2015, ANTICANCER RES, V35, P5055; Su X, 2014, BRIT J CANCER, V110, P967, DOI 10.1038/bjc.2013.802; Sun D, 2016, ONCOTARGET, V7, P81062, DOI 10.18632/oncotarget.13188; Thisse B, 2005, DEV BIOL, V287, P390, DOI 10.1016/j.ydbio.2005.09.011; Tsang Michael, 2004, Sci STKE, V2004, ppe17, DOI 10.1126/stke.2282004pe17; Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Van Cutsem E, 2017, ANN ONCOL, V28, P1316, DOI 10.1093/annonc/mdx107; Xie L, 2013, CLIN CANCER RES, V19, P2572, DOI 10.1158/1078-0432.CCR-12-3898; Yanai K, 2008, CANCER LETT, V263, P145, DOI 10.1016/j.canlet.2007.12.030; Zhang CY, 2009, CLIN CANCER RES, V15, P4017, DOI 10.1158/1078-0432.CCR-08-2824; Zhang JL, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060637; Zhang JL, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071576; Zhang JL, 2019, ONCOGENE, V38, P33, DOI 10.1038/s41388-018-0430-x	48	14	16	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2020	39	43					6647	6663		10.1038/s41388-020-01458-x	http://dx.doi.org/10.1038/s41388-020-01458-x		SEP 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OF2UT	32934314	Green Published, hybrid			2022-12-17	WOS:000571179500001
J	Shah, K; Gagliano, T; Garland, L; O'Hanlon, T; Bortolotti, D; Gentili, V; Rizzo, R; Giamas, G; Dean, M				Shah, Kalpit; Gagliano, Teresa; Garland, Lisa; O'Hanlon, Timothy; Bortolotti, Daria; Gentili, Valentina; Rizzo, Roberta; Giamas, Georgios; Dean, Michael			Androgen receptor signaling regulates the transcriptome of prostate cancer cells by modulating global alternative splicing	ONCOGENE			English	Article							INTRON RETENTION; DNA-BINDING; ANTIANDROGEN; MECHANISM; EXPRESSION; REPRESSION; RESISTANCE; THERAPY; NETWORK	Androgen receptor (AR), is a transcription factor and a member of a hormone receptor superfamily. AR plays a vital role in the progression of prostate cancer and is a crucial target for therapeutic interventions. While the majority of advanced-stage prostate cancer patients will initially respond to the androgen deprivation, the disease often progresses to castrate-resistant prostate cancer (CRPC). Interestingly, CRPC tumors continue to depend on hyperactive AR signaling and will respond to potent second-line antiandrogen therapies, including bicalutamide (CASODEX(R)) and enzalutamide (XTANDI(R)). However, the progression-free survival rate for the CRPC patients on antiandrogen therapies is only 8-19 months. Hence, there is a need to understand the mechanisms underlying CRPC progression and eventual treatment resistance. Here, we have leveraged next-generation sequencing and newly developed analytical methodologies to evaluate the role of AR signaling in regulating the transcriptome of prostate cancer cells. The genomic and pharmacologic stimulation and inhibition of AR activity demonstrates that AR regulates alternative splicing within cancer-relevant genes. Furthermore, by integrating transcriptomic data from in vitro experiments and in prostate cancer patients, we found that a significant number of AR-regulated splicing events are associated with tumor progression. For example, we found evidence for an inadvertent AR-antagonist-mediated switch inIDH1andPL2G2Aisoform expression, which is associated with a decrease in overall survival of patients. Mechanistically, we discovered that the epithelial-specific splicing regulators (ESRP1 and ESRP2), flank many AR-regulated alternatively spliced exons. And, using 2D invasion assays, we show that the inhibition of ESRPs can suppress AR-antagonist-driven tumor invasion. Our work provides evidence for a new mechanism by which AR alters the transcriptome of prostate cancer cells by modulating alternative splicing. As such, our work has important implications for CRPC progression and development of resistance to treatment with bicalutamide and enzalutamide.	[Shah, Kalpit; Garland, Lisa; Dean, Michael] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA; [Gagliano, Teresa] Univ Udine, Dept Med Sci, Udine, Italy; [O'Hanlon, Timothy] Frederick Natl Lab Canc Res, Canc Genom Res Lab, Bethesda, MD 20892 USA; [Bortolotti, Daria; Gentili, Valentina; Rizzo, Roberta] Univ Ferrara, Dept Chem & Pharmaceut Sci, Ferrara, Italy; [Giamas, Georgios] Univ Sussex, Sch Life Sci, Dept Biochem & Biomed, Brighton BN1 9QG, E Sussex, England; [Shah, Kalpit] Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Udine; University of Ferrara; University of Sussex; Roche Holding; Genentech	Shah, K; Dean, M (corresponding author), NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.; Shah, K (corresponding author), Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.	kalpit.shah2016@gmail.com; michael.dean@nih.gov	Bortolotti, Daria/K-5125-2016; Giamas, Georgios/AAP-3487-2021; Dean, Michael C/G-8172-2012; Gagliano, Teresa/G-1645-2015; Gentili, Valentina/AAC-1028-2022	Bortolotti, Daria/0000-0003-4496-9561; Dean, Michael C/0000-0003-2234-0631; Gagliano, Teresa/0000-0002-4877-6292; Gentili, Valentina/0000-0003-4572-5497; O'Hanlon, Timothy/0000-0003-2759-733X	intramural research program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health	intramural research program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health	This work was supported by grants from the intramural research program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health. This work utilized the computational resources of the NIH HPC Biowulf cluster and DCEG CCAD cluster (http://hpc.nih.gov).	Auboeuf D, 2002, SCIENCE, V298, P416, DOI 10.1126/science.1073734; Azad AA, 2015, NAT REV UROL, V12, P26, DOI 10.1038/nrurol.2014.320; Baniwal SK, 2009, MOL ENDOCRINOL, V23, P1203, DOI 10.1210/me.2008-0470; Braunschweig U, 2014, GENOME RES, V24, P1774, DOI 10.1101/gr.177790.114; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen SY, 2006, P NATL ACAD SCI USA, V103, P15969, DOI 10.1073/pnas.0604193103; David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010; Di CX, 2019, CELL DEATH DIFFER, V26, P1181, DOI 10.1038/s41418-018-0231-3; Dutertre M, 2010, CANCER RES, V70, P3760, DOI 10.1158/0008-5472.CAN-09-3988; Dvinge H, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0168-9; Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470-2045(12)70379-0; FURR BJA, 1987, J ENDOCRINOL, V113, pR7, DOI 10.1677/joe.0.113R007; Ganesan K, 2008, CANCER RES, V68, P4277, DOI 10.1158/0008-5472.CAN-07-6517; Georget V, 1997, MOL CELL ENDOCRINOL, V129, P17, DOI 10.1016/S0303-7207(97)04034-3; Georget V, 2002, BIOCHEMISTRY-US, V41, P11824, DOI 10.1021/bi0259150; Gregory CW, 2005, CLIN CANCER RES, V11, P1704, DOI 10.1158/1078-0432.CCR-04-1158; Gregory CW, 2004, J BIOL CHEM, V279, P7119, DOI 10.1074/jbc.M307649200; Grosse A, 2012, MOL CELL ENDOCRINOL, V352, P46, DOI 10.1016/j.mce.2011.06.032; Hammes A, 2005, CELL, V122, P751, DOI 10.1016/j.cell.2005.06.032; Huang H, 2002, CRIT REV EUKAR GENE, V12, P193, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i3.30; HUGGINS C, 1946, JAMA-J AM MED ASSOC, V131, P576, DOI 10.1001/jama.1946.02870240008003; Iwasaki K, 2018, CANCER SCI, V109, P3159, DOI 10.1111/cas.13754; Jung- H, 2015, NAT GENET, V47, P1242, DOI 10.1038/ng.3414; Kahles A, 2018, CANCER CELL, V34, P211, DOI 10.1016/j.ccell.2018.07.001; Lee Y, 2015, ANNU REV BIOCHEM, V84, P291, DOI 10.1146/annurev-biochem-060614-034316; Lin TH, 2013, J BIOL CHEM, V288, P19359, DOI 10.1074/jbc.M113.477216; Liu WW, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0743-1; Liu YN, 2008, MOL CELL BIOL, V28, P7096, DOI 10.1128/MCB.00449-08; Lu-Yao GL, 2014, JAMA INTERN MED, V174, P1460, DOI 10.1001/jamainternmed.2014.3028; Mellinghoff IK, 2004, CANCER CELL, V6, P517, DOI 10.1016/j.ccr.2004.09.031; Miao L, 2017, CANCER RES, V77, P3101, DOI 10.1158/0008-5472.CAN-16-2169; Molenaar RJ, 2018, ONCOGENE, V37, P1949, DOI 10.1038/s41388-017-0077-z; Munkley J, 2019, ELIFE, V8, DOI 10.7554/eLife.47678; Nilsen TW, 2010, NATURE, V463, P457, DOI 10.1038/nature08909; OLIVIER JL, 1994, BIOCHEMISTRY-US, V33, P7134, DOI 10.1021/bi00189a017; Paradon M, 1998, EUR J BIOCHEM, V258, P113, DOI 10.1046/j.1432-1327.1998.2580113.x; Park JW, 2016, NUCLEIC ACIDS RES, V44, pW333, DOI 10.1093/nar/gkw410; Penson DF, 2016, J CLIN ONCOL, V34, P2098, DOI 10.1200/JCO.2015.64.9285; Prescott J, 2007, PROSTATE, V67, P1371, DOI 10.1002/pros.20623; Rasmussen KD, 2016, GENE DEV, V30, P733, DOI 10.1101/gad.276568.115; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Sirotnak FM, 2004, MOL CARCINOGEN, V41, P150, DOI 10.1002/mc.20051; Smart AC, 2018, NAT BIOTECHNOL, V36, P1056, DOI 10.1038/nbt.4239; Stebbing J, 2018, ONCOGENE, V37, P3113, DOI 10.1038/s41388-018-0197-0; Stylianou N, 2019, ONCOGENE, V38, P913, DOI 10.1038/s41388-018-0488-5; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Verras M, 2007, CANCER RES, V67, P967, DOI 10.1158/0008-5472.CAN-06-3552; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Warzecha CC, 2010, EMBO J, V29, P3286, DOI 10.1038/emboj.2010.195; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Weber MJ, 2004, J CELL BIOCHEM, V91, P13, DOI 10.1002/jcb.10683; WONG CI, 1993, J BIOL CHEM, V268, P19004; Wong YNS, 2014, NAT REV CLIN ONCOL, V11, P365, DOI 10.1038/nrclinonc.2014.72; Yang YQ, 2016, MOL CELL BIOL, V36, P1704, DOI 10.1128/MCB.00019-16; Yun SJ, 2017, ONCOTARGET, V8, P114845, DOI 10.18632/oncotarget.22296; Zhang YJ, 2018, NAT GENET, V50, P814, DOI 10.1038/s41588-018-0120-1	56	14	14	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2020	39	39					6172	6189		10.1038/s41388-020-01429-2	http://dx.doi.org/10.1038/s41388-020-01429-2		AUG 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NS8XO	32820253	Green Published, hybrid, Green Accepted, Green Submitted			2022-12-17	WOS:000561253800004
J	Chi, HC; Tsai, CY; Wang, CS; Yang, HY; Lo, CH; Wang, WJ; Lee, KF; Lai, LY; Hong, JH; Chang, YF; Tsai, MM; Yeh, CT; Wu, CH; Hsieh, CC; Wang, LH; Chen, WJ; Lin, KH				Chi, Hsiang-Cheng; Tsai, Chung-Ying; Wang, Chia-Siu; Yang, Huang-Yu; Lo, Chien-Hui; Wang, Won-Jing; Lee, Kam-Fai; Lai, Li-Yin; Hong, Ji-Hong; Chang, Yen-Fang; Tsai, Ming-Ming; Yeh, Chau-Ting; Wu, Cheng Heng; Hsieh, Ching-Chuan; Wang, Lu-Hai; Chen, Wei-Jan; Lin, Kwang-Huei			DOCK6 promotes chemo- and radioresistance of gastric cancer by modulating WNT/beta-catenin signaling and cancer stem cell traits	ONCOGENE			English	Article							BETA-CATENIN; RAC1; EXPRESSION; MIGRATION; CARCINOMA; COMPLEX	Gastric cancer (GC) is the third leading cause of cancer-related mortality worldwide and prognosis after potentially curative gastrectomy remains poor. Administration of GC-targeting molecules in combination with adjuvant chemo- or radiotherapy following surgical resection has been proposed as a potentially effective treatment option. Here, we have identified DOCK6, a guanine nucleotide exchange factor (GEF) for Rac1 and CDC42, as an independent biomarker for GC prognosis. Clinical findings indicate the positive correlation of higher DOCK6 expression with tumor size, depth of invasion, lymph node metastasis, vascular invasion, and pathological stage. Furthermore, elevated DOCK6 expression was significantly associated with shorter cumulative survival in both univariate and multivariate analyses. Gene ontology analysis of three independent clinical GC cohorts revealed significant involvement of DOCK6-correlated genes in the WNT/beta-catenin signaling pathway. Ectopic expression of DOCK6 promoted GC cancer stem cell (CSC) characteristics and chemo- or radioresistance concomitantly through Rac1 activation. Conversely, depletion of DOCK6 suppressed CSC phenotypes and progression of GC, further demonstrating the pivotal role of DOCK6 in GC progression. Our results demonstrate a novel mechanistic link between DOCK6, Rac1, and beta-catenin in GCCSC for the first time, supporting the utility of DOCK6 as an independent marker of GC	[Chi, Hsiang-Cheng] Chang Gung Univ, Chang Gung Mem Hosp, Inst Radiol Res, Radiat Biol Res Ctr, Taoyuan, Taiwan; [Chi, Hsiang-Cheng; Wu, Cheng Heng; Lin, Kwang-Huei] Chang Gung Univ, Dept Biochem, Coll Med, Taoyuan, Taiwan; [Chi, Hsiang-Cheng; Wang, Lu-Hai] China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan; [Tsai, Chung-Ying] Chang Gung Mem Hosp, Dept Nephrol, Kidney Res Ctr, Taoyuan, Taiwan; [Wang, Chia-Siu; Tsai, Ming-Ming; Hsieh, Ching-Chuan] Chang Gung Mem Hosp, Dept Gen Surg, Chiayi, Taiwan; [Yang, Huang-Yu] Chang Gung Univ, Chang Gung Mem Hosp, Coll Med, Kidney Res Inst,Nephrol Dept, Taoyuan, Taiwan; [Yang, Huang-Yu; Chang, Yen-Fang] Chang Gung Univ, Grad Inst Biomed Sci, Coll Med, Taoyuan, Taiwan; [Yang, Huang-Yu] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; [Lo, Chien-Hui; Wang, Won-Jing] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Coll Life Sci, Taipei, Taiwan; [Lo, Chien-Hui; Wang, Won-Jing] Natl Yang Ming Univ, Taiwan Int Grad Program TIGP Mol Med, Taipei, Taiwan; [Lo, Chien-Hui; Wang, Won-Jing] Acad Sinica, Taipei, Taiwan; [Lee, Kam-Fai] Chang Gung Mem Hosp, Dept Pathol, Chiayi, Taiwan; [Lai, Li-Yin] Natl Taiwan Univ, Dept Microbiol & Internal Med, Taipei, Taiwan; [Hong, Ji-Hong] Chang Gung Mem Hosp Linkou, Inst Radiol Res, Dept Radiat Oncol, Taoyuan, Taiwan; [Tsai, Ming-Ming] Chang Gung Univ Sci & Technol, Dept Nursing, Taoyuan, Taiwan; [Tsai, Ming-Ming; Lin, Kwang-Huei] Chang Gung Univ Sci & Technol, Coll Human Ecol, Res Ctr Chinese Herbal Med, Taoyuan, Taiwan; [Yeh, Chau-Ting; Lin, Kwang-Huei] Chang Gung Mem Hosp, Liver Res Ctr, Taoyuan, Taiwan; [Wang, Lu-Hai] Natl Hlth Res Inst, Inst Mol & Genom Med, Zhunan, Miaoli County, Taiwan; [Chen, Wei-Jan] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Div Cardiol, Taoyuan, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; China Medical University Taiwan; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; Chang Gung Memorial Hospital; National Taiwan University; Chang Gung Memorial Hospital; Chang Gung University of Science & Technology; Chang Gung University of Science & Technology; Chang Gung Memorial Hospital; National Health Research Institutes - Taiwan; Chang Gung Memorial Hospital; Chang Gung University	Lin, KH (corresponding author), Chang Gung Univ, Dept Biochem, Coll Med, Taoyuan, Taiwan.; Wang, LH (corresponding author), China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan.; Lin, KH (corresponding author), Chang Gung Univ Sci & Technol, Coll Human Ecol, Res Ctr Chinese Herbal Med, Taoyuan, Taiwan.; Lin, KH (corresponding author), Chang Gung Mem Hosp, Liver Res Ctr, Taoyuan, Taiwan.; Wang, LH (corresponding author), Natl Hlth Res Inst, Inst Mol & Genom Med, Zhunan, Miaoli County, Taiwan.; Chen, WJ (corresponding author), Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Div Cardiol, Taoyuan, Taiwan.	lu-hai.wang@nhri.org.tw; wjchen@adm.cgmh.org.tw; khlin@mail.cgu.edu.tw	Lai, Li-Yin/ABD-8471-2021	Lai, Li-Yin/0000-0003-0244-6834; Wang, Won-Jing/0000-0001-9733-0839; YANG, HUANG-YU/0000-0001-6826-9717; Chi, Hsiang Cheng/0000-0001-5691-2453	Chang Gung Memorial Hospital, Taoyuan, Taiwan [CMRPD1H0631-0632, CMRPD1G0421-0423, CMRPD1J0051, NMRPD1G0942, NMRPD1G0951, CMRPG6F0621-0623, NMRPG6G0051]; Ministry of Science and Technology of the Republic of China [MOST 106-2320-B-182-031-MY3, 106-2320-B-182-032-MY3, 106-2314-B-182A-130, MOST 105-2321-B-182 -002-MY3, 107-2320-B-182-025]	Chang Gung Memorial Hospital, Taoyuan, Taiwan(Chang Gung Memorial Hospital); Ministry of Science and Technology of the Republic of China(Ministry of Science and Technology, Taiwan)	This work was supported by grants from Chang Gung Memorial Hospital, Taoyuan, Taiwan (CMRPD1H0631-0632, CMRPD1G0421-0423, CMRPD1J0051, NMRPD1G0942, and NMRPD1G0951 to K-HL; CMRPG6F0621-0623 and NMRPG6G0051 to C-SW) and the Ministry of Science and Technology of the Republic of China (MOST 106-2320-B-182-031-MY3 and 106-2320-B-182-032-MY3 to K-HL, 106-2314-B-182A-130 to C-SW, and MOST 105-2321-B-182 -002-MY3 and 107-2320-B-182-025 to H-CC).	Al-Hajj M, 2007, CURR OPIN ONCOL, V19, P61; Baniak N, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0969-3; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Bravo-Cordero JJ, 2012, CURR OPIN CELL BIOL, V24, P277, DOI 10.1016/j.ceb.2011.12.004; Buongiorno P, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-73; Chahdi A, 2013, J BIOL CHEM, V288, P34019, DOI 10.1074/jbc.M113.480103; Chen G, 2018, BIO-PROTOCOL, V8, DOI 10.21769/BioProtoc.2994; Chen X, 2003, MOL BIOL CELL, V14, P3208, DOI 10.1091/mbc.E02-12-0833; Chi HC, 2017, ONCOGENE, V36, P5274, DOI 10.1038/onc.2017.136; Chi HC, 2016, AUTOPHAGY, V12, P2271, DOI 10.1080/15548627.2016.1230583; Chi HC, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.227; Cho JY, 2011, CLIN CANCER RES, V17, P1850, DOI 10.1158/1078-0432.CCR-10-2180; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; D'Errico M, 2009, EUR J CANCER, V45, P461, DOI 10.1016/j.ejca.2008.10.032; Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854; Debruyne DN, 2018, ONCOGENE, V37, P241, DOI 10.1038/onc.2017.323; Gadea G, 2014, EUR J CELL BIOL, V93, P466, DOI 10.1016/j.ejcb.2014.06.003; Gilles C, 2003, CANCER RES, V63, P2658; Gotoh K, 2008, BLOOD, V111, P2973, DOI 10.1182/blood-2007-09-112169; Han ME, 2011, CELL MOL LIFE SCI, V68, P3589, DOI 10.1007/s00018-011-0672-z; Hoey T, 2009, CELL STEM CELL, V5, P168, DOI 10.1016/j.stem.2009.05.019; Jamieson C, 2015, J CELL SCI, V128, P3933, DOI 10.1242/jcs.167742; Japanese Gastric Cancer Association, 1998, GASTRIC CANCER, V1, P10, DOI [DOI 10.1007/S101209800016], DOI 10.1007/PL00011681]; Kwon KJ, 2014, GASTRIC CANCER, V17, P43, DOI 10.1007/s10120-013-0234-1; Li XW, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0729-z; Lou H, 2007, ONCOGENE, V26, P1357, DOI 10.1038/sj.onc.1210200; Mao J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.515; McNiven MA, 2004, FRONT BIOSCI-LANDMRK, V9, P1944, DOI 10.2741/1348; Miyamoto Y, 2007, EXP CELL RES, V313, P791, DOI 10.1016/j.yexcr.2006.11.017; Notani D, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000296; O'Dwyer D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027718; Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052; Saegusa M, 2005, LAB INVEST, V85, P768, DOI 10.1038/labinvest.3700273; Schlessinger K, 2009, GENE DEV, V23, P265, DOI 10.1101/gad.1760809; Shaheen R, 2011, AM J HUM GENET, V89, P328, DOI 10.1016/j.ajhg.2011.07.009; Shi Lei, 2013, Commun Integr Biol, V6, pe26839, DOI 10.4161/cib.26839; Stamos JL, 2013, COLD SPRING HARB PER, V5, DOI DOI 10.1101/CSHPERSPECT.A007898; Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30; Tsai CY, 2018, FASEB J, V32, P2601, DOI 10.1096/fj.201700094R; Tsai MM, 2016, EUR J CANCER, V64, P137, DOI 10.1016/j.ejca.2016.05.007; Upadhyay G, 2008, ONCOGENE, V27, P5845, DOI 10.1038/onc.2008.202; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Vojnits K, 2015, SCI REP-UK, V5, DOI 10.1038/srep17355; Wang Q, 2012, MED ONCOL, V29, P77, DOI 10.1007/s12032-010-9766-y; Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052; Yamauchi J, 2008, J CELL BIOL, V181, P351, DOI 10.1083/jcb.200709033; Yoon CH, 2011, FEBS LETT, V585, P2331, DOI 10.1016/j.febslet.2011.05.070	47	14	14	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2020	39	37					5933	5949		10.1038/s41388-020-01390-0	http://dx.doi.org/10.1038/s41388-020-01390-0		AUG 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NM2OY	32753649				2022-12-17	WOS:000555747100002
J	Yi, HY; Li, GP; Long, YK; Liang, WZ; Cui, HN; Zhang, B; Tan, Y; Li, YF; Shen, LC; Deng, DQ; Tang, YS; Mao, CY; Tian, SY; Cai, YT; Zhu, QH; Hu, YH; Chen, W; Fang, L				Yi, Hongyang; Li, Guipeng; Long, Yongkang; Liang, Weizheng; Cui, Huanhuan; Zhang, Bin; Tan, Ying; Li, Yunfei; Shen, Luochen; Deng, Daqi; Tang, Yisen; Mao, Chenyu; Tian, Shuye; Cai, Yunting; Zhu, Qionghua; Hu, Yuhui; Chen, Wei; Fang, Liang			Integrative multi-omics analysis of a colon cancer cell line with heterogeneous Wnt activity revealed RUNX2 as an epigenetic regulator of EMT	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CONSENSUS MOLECULAR SUBTYPES; TRANSCRIPTION FACTOR RUNX2; STEM-CELLS; TGF-BETA; OSTEOBLAST DIFFERENTIATION; INTRATUMOR HETEROGENEITY; EXPRESSION; GENERATION; PLASTICITY	Epithelial-mesenchymal transition (EMT) program, which facilitates tumor metastasis, stemness and therapy resistance, is a reversible biological process that is largely orchestrated at the epigenetic level under the regulation of different cell signaling pathways. EMT state is often heterogeneous within individual tumors, though the epigenetic drivers underlying such heterogeneity remain elusive. In colon cancer, hyperactivation of the Wnt/beta-catenin signaling not only drives tumor initiation, but also promotes metastasis in late stage by promoting EMT program. However, it is unknown whether the intratumorally heterogeneous Wnt activity could directly drive EMT heterogeneity, and, if so, what are the underlying epigenetic driver(s). Here, by analyzing a phenotypically and molecularly heterogeneous colon cancer cell line using single-cell RNA sequencing, we identified two distinct cell populations with positively correlated Wnt activity and EMT state. Integrative multi-omics analysis of these two cell populations revealed RUNX2 as a critical transcription factor epigenetically driving the EMT heterogeneity. Both in vitro and in vivo genetic perturbation assays validated the EMT-enhancing effect of RUNX2, which remodeled chromatin landscape and activated a panel of EMT-associated genes through binding to their promoters and/or potential enhancers. Finally, by exploring the clinical data, we showed that RUNX2 expression is positively correlated with metastasis development and poor survival of colon cancer patients, as well as patients afflicted with other types of cancer. Taken together, our work revealed RUNX2 as a new EMT-promoting epigenetic regulator in colon cancer, which may potentially serve as a prognostic marker for tumor metastasis.	[Yi, Hongyang; Liang, Weizheng] Harbin Inst Technol, Harbin, Peoples R China; [Yi, Hongyang; Li, Guipeng; Long, Yongkang; Liang, Weizheng; Cui, Huanhuan; Tan, Ying; Li, Yunfei; Shen, Luochen; Deng, Daqi; Tang, Yisen; Mao, Chenyu; Tian, Shuye; Cai, Yunting; Zhu, Qionghua; Hu, Yuhui; Chen, Wei; Fang, Liang] Southern Univ Sci & Technol, Dept Biol, Shenzhen, Peoples R China; [Li, Guipeng; Cui, Huanhuan; Hu, Yuhui; Chen, Wei; Fang, Liang] Southern Univ Sci & Technol, Acad Adv Interdisciplinary Studies, Shenzhen, Peoples R China; [Zhang, Bin] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore	Harbin Institute of Technology; Southern University of Science & Technology; Southern University of Science & Technology; National University of Singapore	Hu, YH; Chen, W; Fang, L (corresponding author), Southern Univ Sci & Technol, Dept Biol, Shenzhen, Peoples R China.; Hu, YH; Chen, W; Fang, L (corresponding author), Southern Univ Sci & Technol, Acad Adv Interdisciplinary Studies, Shenzhen, Peoples R China.	huyh@sustech.edu.cn; chenw@sustech.edu.cn; fangl@sustech.edu.cn	chen, wei/AFV-4999-2022; Fang, Liang/V-5019-2018	Cui, Huanhuan/0000-0002-6190-6135; Fang, Liang/0000-0003-4502-1756; Li, Guipeng/0000-0002-3244-5499; Long, Yongkang/0000-0003-0953-7325	National Natural Science Foundation of China [31701237]; Shenzhen Science and Technology Program [JCYJ20170817110925887, KQTD20180411143432337, GJHZ20170310161947503]; Center for Computational Science and Engineering of Southern University of Science and Technology; Laboratory Animal Center of Southern University of Science and Technology	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shenzhen Science and Technology Program; Center for Computational Science and Engineering of Southern University of Science and Technology; Laboratory Animal Center of Southern University of Science and Technology	This work was supported by the National Natural Science Foundation of China (Grant No. 31701237) and the Shenzhen Science and Technology Program (Grant No. JCYJ20170817110925887, KQTD20180411143432337, and GJHZ20170310161947503). Bioinformatic analysis was supported by the Center for Computational Science and Engineering of Southern University of Science and Technology. Animal experiments were supported by the Laboratory Animal Center of Southern University of Science and Technology.	Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Nieto MA, 2009, INT J DEV BIOL, V53, P1541, DOI 10.1387/ijdb.072410mn; Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; Baniwal SK, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-258; Barnes GL, 2004, CANCER RES, V64, P4506, DOI 10.1158/0008-5472.CAN-03-3851; Barnes GL, 2003, CANCER RES, V63, P2631; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bedard PL, 2013, NATURE, V501, P355, DOI 10.1038/nature12627; Bian SH, 2018, SCIENCE, V362, P1060, DOI 10.1126/science.aao3791; Blois SM, 2014, MUCOSAL IMMUNOL, V7, P348, DOI 10.1038/mi.2013.53; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Buenrostro Jason D, 2015, Curr Protoc Mol Biol, V109, DOI 10.1002/0471142727.mb2129s109; Chimge NO, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3073; Melo FDE, 2017, NATURE, V543, P676, DOI 10.1038/nature21713; Derynck R, 2014, CURR OPIN CELL BIOL, V31, P56, DOI 10.1016/j.ceb.2014.09.001; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Driessens G, 2012, NATURE, V488, P527, DOI 10.1038/nature11344; Fang L, 2016, CANCER RES, V76, P891, DOI 10.1158/0008-5472.CAN-15-1519; Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660; Hinohara K, 2018, CANCER CELL, V34, P939, DOI 10.1016/j.ccell.2018.10.014; Hu Y, 2018, GENE CHROMOSOME CANC, V57, P140, DOI 10.1002/gcc.22512; Inman CK, 2003, J BIOL CHEM, V278, P48684, DOI 10.1074/jbc.M308001200; Jagan I, 2013, ONCOGENE, V32, P1305, DOI 10.1038/onc.2012.140; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Komori T, 2008, FRONT BIOSCI-LANDMRK, V13, P898, DOI 10.2741/2730; Krebs AM, 2017, NAT CELL BIOL, V19, P518, DOI 10.1038/ncb3513; Lee JW, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09810-w; Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200; Li HP, 2017, NAT GENET, V49, P708, DOI 10.1038/ng.3818; Ligorio M, 2019, CELL, V178, P160, DOI 10.1016/j.cell.2019.05.012; Lin CW, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13867; Magnani L, 2011, TRENDS GENET, V27, P465, DOI 10.1016/j.tig.2011.07.002; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; McGranahan N, 2015, CANCER CELL, V27, P15, DOI 10.1016/j.ccell.2014.12.001; Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807; Niu DF, 2012, LAB INVEST, V92, P1181, DOI 10.1038/labinvest.2012.84; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Pistore C, 2017, ONCOGENE, V36, P5551, DOI 10.1038/onc.2017.159; Pratap J, 2005, MOL CELL BIOL, V25, P8581, DOI 10.1128/MCB.25.19.8581-8591.2005; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Puram SV, 2017, CELL, V171, P1611, DOI 10.1016/j.cell.2017.10.044; Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Selvamurugan N, 2004, J BIOL CHEM, V279, P27764, DOI 10.1074/jbc.M312870200; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Soares Kevin C, 2014, J Vis Exp, P51677, DOI 10.3791/51677; Stark AL, 2010, AM J HUM GENET, V87, P829, DOI 10.1016/j.ajhg.2010.10.018; Sveen A, 2018, CLIN CANCER RES, V24, P794, DOI 10.1158/1078-0432.CCR-17-1234; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; van Staalduinen J, 2018, ONCOGENE, V37, P6195, DOI 10.1038/s41388-018-0378-x; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9; Yang J, 2001, CANCER RES, V61, P5652; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Yeung F, 2002, J BIOL CHEM, V277, P2468, DOI 10.1074/jbc.M105947200; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304	67	14	14	0	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2020	39	28					5152	5164		10.1038/s41388-020-1351-z	http://dx.doi.org/10.1038/s41388-020-1351-z		JUN 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MH4RK	32535615				2022-12-17	WOS:000539953300003
J	Crawford, LJ; Campbell, DC; Morgan, JJ; Lawson, MA; Down, JM; Chauhan, D; McAvera, RM; Morris, TC; Hamilton, C; Krishnan, A; Rajalingam, K; Chantry, AD; Irvine, AE				Crawford, Lisa J.; Campbell, David C.; Morgan, Jonathan J.; Lawson, Michelle A.; Down, Jennifer M.; Chauhan, Dharminder; McAvera, Roisin M.; Morris, Treen C.; Hamilton, Claudia; Krishnan, Aswini; Rajalingam, Krishnaraj; Chantry, Andrew D.; Irvine, Alexandra E.			The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma	ONCOGENE			English	Article							UBIQUITIN LIGASES; DOWN-REGULATION; BORTEZOMIB; CANCER; CELLS; APOPTOSIS; GROWTH; ARF	Proteasome inhibitors have provided a significant advance in the treatment of multiple myeloma (MM). Consequently, there is increasing interest in developing strategies to target E3 ligases, de-ubiquitinases, and/or ubiquitin receptors within the ubiquitin proteasome pathway, with an aim to achieve more specificity and reduced side-effects. Previous studies have shown a role for the E3 ligase HUWE1 in modulating c-MYC, an oncogene frequently dysregulated in MM. Here we investigated HUWE1 in MM. We identified elevated expression of HUWE1 in MM compared with normal cells. Small molecule-mediated inhibition of HUWE1 resulted in growth arrest of MM cell lines without significantly effecting the growth of normal bone marrow cells, suggesting a favorable therapeutic index. Studies using a HUWE1 knockdown model showed similar growth inhibition. HUWE1 expression positively correlated with MYC expression in MM bone marrow cells and correspondingly, genetic knockdown and biochemical inhibition of HUWE1 reduced MYC expression in MM cell lines. Proteomic identification of HUWE1 substrates revealed a strong association of HUWE1 with metabolic processes in MM cells. Intracellular glutamine levels are decreased in the absence of HUWE1 and may contribute to MYC degradation. Finally, HUWE1 depletion in combination with lenalidomide resulted in synergistic anti-MM activity in both in vitro and in vivo models. Taken together, our data demonstrate an important role of HUWE1 in MM cell growth and provides preclinical rationale for therapeutic strategies targeting HUWE1 in MM.	[Crawford, Lisa J.; Campbell, David C.; Morgan, Jonathan J.; McAvera, Roisin M.; Morris, Treen C.; Hamilton, Claudia; Irvine, Alexandra E.] Queens Univ Belfast, Patrick G Johnston Ctr Canc Res, Belfast, Antrim, North Ireland; [Lawson, Michelle A.; Down, Jennifer M.; Chantry, Andrew D.] Univ Sheffield, Sch Med, Sheffield Myeloma Res Team, Dept Oncol & Metab, Sheffield, S Yorkshire, England; [Chauhan, Dharminder] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA; [Chauhan, Dharminder] Harvard Med Sch, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr, Boston, MA 02115 USA; [Krishnan, Aswini; Rajalingam, Krishnaraj] Univ Med Ctr Mainz, Cell Biol Unit, Mainz, Germany	Queens University Belfast; University of Sheffield; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Johannes Gutenberg University of Mainz	Crawford, LJ (corresponding author), Queens Univ Belfast, Patrick G Johnston Ctr Canc Res, Belfast, Antrim, North Ireland.	lisa.crawford@qub.ac.uk	Lawson, Michelle/M-6095-2019	Lawson, Michelle/0000-0002-5446-923X; Morgan, Jonathan/0000-0002-9062-1542; Crawford, Lisa/0000-0001-5162-1809; McAvera, Roisin/0000-0002-1222-3047	Blood Cancer UK; Leukemia Lymphoma NI	Blood Cancer UK; Leukemia Lymphoma NI	This work was supported by a grant from Blood Cancer UK and funding from Leukemia & Lymphoma NI.	Adhikary S, 2005, CELL, V123, P409, DOI 10.1016/j.cell.2005.08.016; Bankhead P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17204-5; Bosshard M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15380-y; Chang Xiu-Bao, 2011, Int J Biochem Mol Biol, V2, P287; Chauhan D, 2012, CANCER CELL, V22, P345, DOI 10.1016/j.ccr.2012.08.007; Choe KN, 2016, EMBO REP, V17, P874, DOI 10.15252/embr.201541685; Confalonieri S, 2009, ONCOGENE, V28, P2959, DOI 10.1038/onc.2009.156; Crawford LJ, 2016, ONCOTARGET, V7, P70481, DOI 10.18632/oncotarget.12026; Effenberger M, 2017, ONCOTARGET, V8, P85858, DOI 10.18632/oncotarget.20691; El Arfani C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041200; Groen K, 2019, CANCER MANAG RES, V11, P2663, DOI 10.2147/CMAR.S150653; Guerrero-Garcia TA, 2018, EXPERT REV PROTEOMIC, V15, P1033, DOI 10.1080/14789450.2018.1543595; Hao ZY, 2012, J EXP MED, V209, P173, DOI 10.1084/jem.20111363; Horenstein AL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00760; Inoue S, 2013, GENE DEV, V27, P1101, DOI 10.1101/gad.214577.113; Jang ER, 2014, MOL CELL BIOL, V34, P3579, DOI 10.1128/MCB.00811-14; Jovanovic KK, 2018, LEUKEMIA, V32, P1295, DOI 10.1038/s41375-018-0036-x; Kao SH, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0470-0; Krishnan A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15955-w; Lawson MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119546; Lee HJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10374-y; Leleu X, 2019, CL LYMPH MYELOM LEUK, V19, P9, DOI 10.1016/j.clml.2018.08.016; Liu P, 2019, EPIGENET CHROMATIN, V12, DOI 10.1186/s13072-019-0322-5; Nguyen L, 2017, GENES-BASEL, V8, DOI 10.3390/genes8040116; Mansour MA, 2018, INT J BIOCHEM CELL B, V101, P80, DOI 10.1016/j.biocel.2018.06.001; Michel MA, 2017, MOL CELL, V68, P233, DOI 10.1016/j.molcel.2017.08.020; Moortgat S, 2018, EUR J HUM GENET, V26, P64, DOI 10.1038/s41431-017-0038-6; Myant KB, 2017, EMBO MOL MED, V9, P181, DOI 10.15252/emmm.201606684; Ohtake F, 2016, MOL CELL, V64, P251, DOI 10.1016/j.molcel.2016.09.014; Pandya RK, 2010, J BIOL CHEM, V285, P5664, DOI 10.1074/jbc.M109.051805; Peter S, 2014, EMBO MOL MED, V6, P1525, DOI 10.15252/emmm.201403927; Poulsen EG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050548; Qi CF, 2013, LEUKEMIA RES, V37, P1680, DOI 10.1016/j.leukres.2013.09.009; Qi CF, 2012, INT J MOL SCI, V13, P6204, DOI 10.3390/ijms13056204; Rajkumar SV, 2019, HEMATOL ONCOL, V37, P62, DOI 10.1002/hon.2586; Richardson PG, 2018, EXPERT OPIN PHARMACO, V19, P1949, DOI 10.1080/14656566.2018.1528229; Rizzieri D, 2019, J CANC METASTASIS TR, V5, P26, DOI 10.20517/2394-4722.2019.05; Sander B, 2017, ELIFE, V6, DOI 10.7554/eLife.21036; Song Y, 2017, ONCOGENE, V36, P5631, DOI 10.1038/onc.2017.172; Vaughan L, 2015, CELL REP, V10, P88, DOI 10.1016/j.celrep.2014.12.012; Velasco R, 2019, J PERIPHER NERV SYST, V24, pS52, DOI 10.1111/jns.12338; Walker BA, 2018, BLOOD, V132, P587, DOI 10.1182/blood-2018-03-840132; Wallington-Beddoe CT, 2018, BRIT J HAEMATOL, V182, P11, DOI 10.1111/bjh.15210; Wang D, 2017, CANCER METAST REV, V36, P683, DOI 10.1007/s10555-017-9703-z; Wang SSS, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.18; Yang D, 2018, THERANOSTICS, V8, P3517, DOI 10.7150/thno.24401; Yang D, 2017, CANCER RES, V77, P4773, DOI 10.1158/0008-5472.CAN-16-2597; Zaal EA, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00500; Zhang ZB, 2016, BLOOD, V127, P1676, DOI 10.1182/blood-2015-07-658203	49	14	15	3	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 2	2020	39	27					5001	5014		10.1038/s41388-020-1345-x	http://dx.doi.org/10.1038/s41388-020-1345-x		JUN 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ME5NL	32523091	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000539515400001
J	Cassandri, M; Butera, A; Amelio, I; Lena, AM; Montanaro, M; Mauriello, A; Anemona, L; Candi, E; Knight, RA; Agostini, M; Melino, G				Cassandri, Matteo; Butera, Alessio; Amelio, Ivano; Lena, Anna Maria; Montanaro, Manuela; Mauriello, Alessandro; Anemona, Lucia; Candi, Eleonora; Knight, Richard A.; Agostini, Massimiliano; Melino, Gerry			ZNF750 represses breast cancer invasion via epigenetic control of prometastatic genes	ONCOGENE			English	Article							COMPREHENSIVE MOLECULAR PORTRAITS; CELL-MIGRATION; EXPRESSION; P63; CHROMOSOME-17; LAMININ-332; METASTASIS; COMPLEX; HEAD; KLF4	Breast cancer is the second leading cause of cancer-related deaths among women, largely due to the progression of a significant fraction of primary tumours to the metastatic stage. Here, we show that zinc-finger protein 750 (ZNF750) opposes the migration and invasion of breast cancer cells by repressing a prometastatic transcriptional programme, which includes genes involved in focal adhesion and extracellular matrix interactions, such as LAMB3 and CTNNAL1. Mechanistically, ZNF750 recruits the epigenetic modifiers KDM1A and HDAC1 to the promoter regions of LAMB3 and CTNNAL1, influencing histone marks and transactivating these genomic sites. Gene expression analysis in cancer patient datasets indicated that ZNF750 and its targets were negative prognostic factors in breast cancer. Together, our findings shed light on the molecular mechanism by which ZNF750 regulates cell migration and invasion, suggesting a role in breast cancer metastasis.	[Cassandri, Matteo; Butera, Alessio; Amelio, Ivano; Lena, Anna Maria; Montanaro, Manuela; Mauriello, Alessandro; Anemona, Lucia; Candi, Eleonora; Agostini, Massimiliano; Melino, Gerry] Univ Roma Tor Vergata, TOR, Dept Expt Med, I-00133 Rome, Italy; [Amelio, Ivano; Knight, Richard A.; Melino, Gerry] Univ Cambridge, MRC Toxicol Unit, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England; [Candi, Eleonora] IRCCS, IDI, Via Monti Creta 106, I-00166 Rome, Italy; [Cassandri, Matteo] Bambino Gesu Pediat Hosp, Dept Oncohematol, I-00146 Rome, Italy	University of Rome Tor Vergata; University of Cambridge; IRCCS Istituto Dermopatico dell'Immacolata (IDI); IRCCS Bambino Gesu	Agostini, M; Melino, G (corresponding author), Univ Roma Tor Vergata, TOR, Dept Expt Med, I-00133 Rome, Italy.; Melino, G (corresponding author), Univ Cambridge, MRC Toxicol Unit, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.	m.agostini@med.uniroma2.it; gm614@mrc-tox.cam.ac.uk	Anemona, lucia/AAB-3491-2022; Cassandri, Matteo/AAB-3730-2019; Agostini, Massimiliano/G-9579-2014	Anemona, lucia/0000-0002-3711-2714; Cassandri, Matteo/0000-0002-2919-676X; Lena, Anna Maria/0000-0001-6285-9927; Agostini, Massimiliano/0000-0003-3124-2072; Montanaro, Manuela/0000-0001-8441-3731; Butera, Alessio/0000-0001-7196-4235; Amelio, Ivano/0000-0002-9126-5391	Medical Research Council UK; Associazione Italiana per la Ricerca contro il Cancro (AIRC) [20473]; AIRC [22206, 23219]; Ministero Salute, IDI-IRCCS; Italian Ministry of Foreign Affairs and International Cooperation; Regione Lazio through the LazioInnova Progetto Gruppo di Ricerca [85-2017-14986]	Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Associazione Italiana per la Ricerca contro il Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); AIRC(Fondazione AIRC per la ricerca sul cancro); Ministero Salute, IDI-IRCCS; Italian Ministry of Foreign Affairs and International Cooperation(Ministry of Foreign Affairs and International Cooperation (Italy)); Regione Lazio through the LazioInnova Progetto Gruppo di Ricerca	We would like to thank Dr Annalisa Conti for helpful comments and suggestions and K. Dudek and C. Jones for assistance in gene microarray analysis. This work has been supported by the Medical Research Council (to GM) UK, the Associazione Italiana per la Ricerca contro il Cancro (AIRC) (to GM; IG#20473 (2018-2022)), the AIRC (to EC; IG#22206 (2019-2023)), the AIRC (Start-Up to IA; ID 23219), the Ministero Salute, IDI-IRCCS (RC to EC), and the Italian Ministry of Foreign Affairs and International Cooperation (to EC). The work has also been supported by Regione Lazio through the LazioInnova Progetto Gruppo di Ricerca n 85-2017-14986 (to GM).	Aubrey BJ, 2018, CELL DEATH DIFFER, V25, P104, DOI 10.1038/cdd.2017.169; Boxer LD, 2014, GENE DEV, V28, P2013, DOI 10.1101/gad.246579.114; Cassandri M, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.71; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chalcrabarti R, 2014, NAT CELL BIOL, V16, P1004, DOI 10.1038/ncb3040; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Courjal F, 1997, CANCER RES, V57, P4368; Engeland K, 2018, CELL DEATH DIFFER, V25, P114, DOI 10.1038/cdd.2017.172; Fan LC, 2011, ONCOGENE, V30, P2610, DOI 10.1038/onc.2010.637; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Hazawa M, 2017, ONCOGENE, V36, P2243, DOI 10.1038/onc.2016.377; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; Jain N, 2009, INT J BIOCHEM CELL B, V41, P72, DOI 10.1016/j.biocel.2008.10.006; Jia Yuping, 2016, J Carcinog, V15, P3, DOI 10.4103/1477-3163.182809; Jiang P, 2009, CANCER LETT, V284, P122, DOI 10.1016/j.canlet.2009.02.034; Kaiser AM, 2018, CELL DEATH DIFFER, V25, P93, DOI 10.1038/cdd.2017.171; Kinoshita T, 2012, ONCOTARGET, V3, P1386, DOI 10.18632/oncotarget.709; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kreiseder B, 2013, INT J CANCER, V132, P521, DOI 10.1002/ijc.27698; Kwon OH, 2011, BIOCHEM BIOPH RES CO, V406, P539, DOI 10.1016/j.bbrc.2011.02.082; Lin DC, 2014, NAT GENET, V46, P467, DOI 10.1038/ng.2935; Marinkovich MP, 2007, NAT REV CANCER, V7, P370, DOI 10.1038/nrc2089; Maziveyi M, 2017, ONCOTARGET, V8, P48471, DOI 10.18632/oncotarget.17265; Memmi EM, 2015, P NATL ACAD SCI USA, V112, P3499, DOI 10.1073/pnas.1500762112; Millarte V, 2012, SCI WORLD J, DOI 10.1100/2012/498278; Orsetti B, 2004, CANCER RES, V64, P6453, DOI 10.1158/0008-5472.CAN-04-0756; Polyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295; Sen GL, 2012, DEV CELL, V22, P669, DOI 10.1016/j.devcel.2011.12.001; Su X, 2017, ONCOGENE, V36, P2377, DOI 10.1038/onc.2016.388; SUGIMOTO Y, 1987, MOL CELL BIOL, V7, P4549, DOI 10.1128/MCB.7.12.4549; Sullivan KD, 2018, CELL DEATH DIFFER, V25, P133, DOI 10.1038/cdd.2017.174; Sweeney C, 2014, CANCER EPIDEM BIOMAR, V23, P714, DOI 10.1158/1055-9965.EPI-13-1023; Tucci P, 2012, P NATL ACAD SCI USA, V109, P15312, DOI 10.1073/pnas.1110977109; Wang XL, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0053938, 10.1371/journal.pone.0050627]; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Ye X, 2015, TRENDS CELL BIOL, V25, P675, DOI 10.1016/j.tcb.2015.07.012; Yeo SK, 2017, TRENDS CANCER, V3, P753, DOI 10.1016/j.trecan.2017.09.001; Zhang H, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1320-z; Zhang PP, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1224-3; Zhang W, 2011, INT J MOL SCI, V12, P5672, DOI 10.3390/ijms12095672; Zhang Z, 2016, TUMOR BIOL, V37, P1671, DOI 10.1007/s13277-015-3901-5	41	14	15	3	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	22					4331	4343		10.1038/s41388-020-1277-5	http://dx.doi.org/10.1038/s41388-020-1277-5		APR 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LR9IT	32313225				2022-12-17	WOS:000527509300003
J	Tian, Q; Yuan, P; Quan, CT; Li, MY; Xiao, JJ; Zhang, L; Lu, H; Ma, TF; Zou, L; Wang, F; Xue, PP; Ni, XF; Wang, W; Liu, L; Wang, Z; Zhu, F; Duan, QH				Tian, Qin; Yuan, Ping; Quan, Chuntao; Li, Mingyang; Xiao, Juanjuan; Zhang, Lu; Lu, Hui; Ma, Tengfei; Zou, Ling; Wang, Fei; Xue, Peipei; Ni, Xiaofang; Wang, Wei; Liu, Lin; Wang, Zhe; Zhu, Feng; Duan, Qiuhong			Phosphorylation of BCKDK of BCAA catabolism at Y246 by Src promotes metastasis of colorectal cancer	ONCOGENE			English	Article							AMINO-ACID-METABOLISM; HEPATOCELLULAR-CARCINOMA; MESENCHYMAL TRANSITION; CELL-PROLIFERATION; TYROSINE KINASES; FAMILY KINASES; TARGETING SRC; GROWTH; PROGRESSION; ACTIVATION	Branched-chain alpha-keto acid dehydrogenase kinase (BCKDK), the key enzyme of branched-chain amino acids (BCAAs) metabolism, has been reported to promote colorectal cancer (CRC) tumorigenesis by upregulating the MEK-ERK signaling pathway. However, the profile of BCKDK in metastatic colorectal cancer (mCRC) remains unknown. Here, we report a novel role of BCKDK in mCRC. BCKDK is upregulated in CRC tissues. Increased BCKDK expression was associated with metastasis and poor clinical prognosis in CRC patients. Knockdown of BCKDK decreased CRC cell migration and invasion ex vivo, and lung metastasis in vivo. BCKDK promoted the epithelial mesenchymal transition (EMT) program, by decreasing the expression of E-cadherin, epithelial marker, and increasing the expression of N-cadherin and Vimentin, which are mesenchymal markers. Moreover, BCKDK-knockdown experiments in combination with phosphoproteomics analysis revealed the potent role of BCKDK in modulating multiple signal transduction pathways, including EMT and metastasis. Src phosphorylated BCKDK at the tyrosine 246 (Y246) site in vitro and ex vivo. Knockdown and knockout of Src downregulated the phosphorylation of BCKDK. Importantly, phosphorylation of BCKDK by Src enhanced the activity and stability of BCKDK, thereby promoting the migration, invasion, and EMT of CRC cells. In summary, the identification of BCKDK as a novel prometastatic factor in human CRC will be beneficial for further diagnostic biomarker studies and suggests novel targeting opportunities.	[Tian, Qin; Yuan, Ping; Xiao, Juanjuan; Zhang, Lu; Lu, Hui; Ma, Tengfei; Zou, Ling; Wang, Fei; Ni, Xiaofang; Wang, Wei; Liu, Lin; Zhu, Feng; Duan, Qiuhong] Huazhong Univ Sci & Technol, Sch Basic Med, Dept Biochem & Mol Biol, Wuhan 430030, Hubei, Peoples R China; [Quan, Chuntao] Huazhong Univ Sci & Technol, Tongji Sch Pharm, Wuhan 430030, Hubei, Peoples R China; [Li, Mingyang; Wang, Zhe] Fourth Mil Med Univ, Xijing Hosp, Dept Pathol, State Key Lab Canc Biol, Xian 710032, Peoples R China; [Li, Mingyang; Wang, Zhe] Fourth Mil Med Univ, Sch Basic Med, Xian 710032, Peoples R China; [Xiao, Juanjuan; Zhu, Feng] Guilin Med Univ, Affiliated Hosp, Canc Res Inst, Guilin 541000, Guangxi, Peoples R China; [Xue, Peipei] Populat & Family Planning Sci & Technol Res Inst, Key Lab Birth Defects & Reprod Hlth, Natl Hlth & Family Planning Commiss, Chongqing 400020, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Air Force Military Medical University; Air Force Military Medical University; Guilin Medical University	Zhu, F; Duan, QH (corresponding author), Huazhong Univ Sci & Technol, Sch Basic Med, Dept Biochem & Mol Biol, Wuhan 430030, Hubei, Peoples R China.; Wang, Z (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Pathol, State Key Lab Canc Biol, Xian 710032, Peoples R China.; Wang, Z (corresponding author), Fourth Mil Med Univ, Sch Basic Med, Xian 710032, Peoples R China.; Zhu, F (corresponding author), Guilin Med Univ, Affiliated Hosp, Canc Res Inst, Guilin 541000, Guangxi, Peoples R China.	zhwang@fmmu.edu.cn; fengzhu@hust.edu.cn; duanqhwz@hust.edu.cn	Li, Mingyang/C-2324-2018	Li, Mingyang/0000-0003-1766-7867	National Natural Science Foundation of China [81972762, 81672936, 81672739, 81902849, 81503105]; Independent innovation project of Huazhong University of Science and Technology [2018KFYYXJJ084, 2016YXZD034]; Hubei Province Health and Family Planning Scientific Research Project [WJ2019M109]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Independent innovation project of Huazhong University of Science and Technology; Hubei Province Health and Family Planning Scientific Research Project	This study was supported by the National Natural Science Foundation of China (Nos. 81972762, 81672936, 81672739, 81902849, and 81503105). The Independent innovation project of Huazhong University of Science and Technology (Nos. 2018KFYYXJJ084 and 2016YXZD034). Hubei Province Health and Family Planning Scientific Research Project (Nos. WJ2019M109).	Allgayer H, 2002, CANCER, V94, P344, DOI 10.1002/cncr.10221; Ananieva EA, 2018, CURR OPIN CLIN NUTR, V21, P64, DOI 10.1097/MCO.0000000000000430; Antoni S, 2016, B WORLD HEALTH ORGAN, V94, P174, DOI 10.2471/BLT.15.164384; Beaudet AL, 2012, SCIENCE, V338, P342, DOI 10.1126/science.1229178; Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9; Burrage LC, 2014, HUM MOL GENET, V23, pR1, DOI 10.1093/hmg/ddu123; Cao H, 2015, PATHOL RES PRACT, V211, P557, DOI 10.1016/j.prp.2015.05.010; Montero JC, 2011, CLIN CANCER RES, V17, P5546, DOI 10.1158/1078-0432.CCR-10-2616; Cheon S, 2019, P NATL ACAD SCI USA, V116, P3662, DOI 10.1073/pnas.1818751116; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Dey P, 2017, NATURE, V542, P119, DOI 10.1038/nature21052; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harris RA, 2005, J NUTR, V135, p1527S, DOI 10.1093/jn/135.6.1527S; Hattori A, 2017, NATURE, V545, P500, DOI 10.1038/nature22314; Katagiri R, 2018, GASTROENTEROLOGY, V155, P1474, DOI 10.1053/j.gastro.2018.07.033; Kim JY, 2013, P NATL ACAD SCI USA, V110, P12414, DOI 10.1073/pnas.1220674110; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lieu C, 2010, CLIN COLORECTAL CANC, V9, P89, DOI 10.3816/CCC.2010.n.012; Liu KA, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-6; Martinez-Perez J, 2017, HUM PATHOL, V67, P119, DOI 10.1016/j.humpath.2017.05.025; Matysiak M, 2017, ARCH GYNECOL OBSTET, V295, P817, DOI 10.1007/s00404-017-4304-1; Mayers JR, 2017, CANCER RES, V77, P3131, DOI 10.1158/0008-5472.CAN-17-0165; Mayers JR, 2016, SCIENCE, V353, P1161, DOI 10.1126/science.aaf5171; Mochel F, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000647; Nelson ER, 2013, SCIENCE, V342, P1094, DOI 10.1126/science.1241908; Olea-Flores M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101133; Panosyan EH, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3148-1; Patra KC, 2013, CANCER CELL, V24, P213, DOI 10.1016/j.ccr.2013.06.014; Polonio-Vallon T, 2014, CELL CYCLE, V13, P115, DOI 10.4161/cc.26857; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Schwartz D, 2005, NAT BIOTECHNOL, V23, P1391, DOI 10.1038/nbt1146; Seeber A, 2016, ONCOL RES TREAT, V39, P796, DOI 10.1159/000453027; Shiozawa S, 2016, J NIPPON MED SCH, V83, P248, DOI 10.1272/jnms.83.248; Singh V, 2017, PROTEIN J, V36, P1, DOI 10.1007/s10930-017-9696-z; Suryawan A, 1998, AM J CLIN NUTR, V68, P72, DOI 10.1093/ajcn/68.1.72; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Tauriello DVF, 2017, MOL ONCOL, V11, P97, DOI 10.1002/1878-0261.12018; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Tonjes M, 2013, NAT MED, V19, P901, DOI 10.1038/nm.3217; Tso SC, 2014, J BIOL CHEM, V289, P20583, DOI 10.1074/jbc.M114.569251; Varkaris A, 2014, CANCER METAST REV, V33, P595, DOI 10.1007/s10555-013-9481-1; Wang TJ, 2011, NAT MED, V17, P448, DOI 10.1038/nm.2307; Wang ZQ, 2015, ONCOTARGET, V6, P31522, DOI 10.18632/oncotarget.5159; White PJ, 2018, CELL METAB, V27, P1281, DOI 10.1016/j.cmet.2018.04.015; Xue PP, 2017, EBIOMEDICINE, V20, P50, DOI 10.1016/j.ebiom.2017.05.001; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yi TF, 2014, P NATL ACAD SCI USA, V111, P11223, DOI 10.1073/pnas.1411381111; Yoo PS, 2006, CLIN COLORECTAL CANC, V6, P202, DOI 10.3816/CCC.2006.n.036; Zhang L, 2017, BIOCHEM BIOPH RES CO, V486, P224, DOI 10.1016/j.bbrc.2017.02.101; Zhang SY, 2012, TRENDS PHARMACOL SCI, V33, P122, DOI 10.1016/j.tips.2011.11.002; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309; Zheng YH, 2016, LIVER INT, V36, P1836, DOI 10.1111/liv.13178	55	14	14	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	20					3980	3996		10.1038/s41388-020-1262-z	http://dx.doi.org/10.1038/s41388-020-1262-z		APR 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LN3GC	32238881	Green Published, hybrid			2022-12-17	WOS:000522804800001
J	Shibata, N; Ohoka, N; Tsuji, G; Demizu, Y; Miyawaza, K; Ui-Tei, K; Akiyama, T; Naito, M				Shibata, Norihito; Ohoka, Nobumichi; Tsuji, Genichiro; Demizu, Yosuke; Miyawaza, Keiji; Ui-Tei, Kumiko; Akiyama, Tetsu; Naito, Mikihiko			Deubiquitylase USP25 prevents degradation of BCR-ABL protein and ensures proliferation of Ph-positive leukemia cells	ONCOGENE			English	Article							IDENTIFICATION; INHIBITORS; TANKYRASE; FUSIONS; TARGET; GENES; HEAT-SHOCK-PROTEIN-90; BIOTINYLATION; OMACETAXINE; LINE	Fusion genes resulting from chromosomal rearrangements are frequently found in a variety of cancer cells. Some of these are known to be driver oncogenes, such as BCR-ABL in chronic myelogenous leukemia (CML). The products of such fusion genes are abnormal proteins that are ordinarily degraded in cells by a mechanism known as protein quality control. This suggests that the degradation of BCR-ABL protein is suppressed in CML cells to ensure their proliferative activity. Here, we show that ubiquitin-specific protease 25 (USP25) suppresses the degradation of BCR-ABL protein in cells harboring Philadelphia chromosome (Ph). USP25 was found proximal to BCR-ABL protein in cells. Depletion of USP25 using shRNA-mediated gene silencing increased the ubiquitylated BCR-ABL, and reduced the level of BCR-ABL protein. Accordingly, BCR-ABL-mediated signaling and cell proliferation were suppressed in BCR-ABL-positive leukemia cells by the depletion of USP25. We further found that pharmacological inhibition of USP25 induced rapid degradation of BCR-ABL protein in Ph-positive leukemia cells, regardless of their sensitivity to tyrosine kinase inhibitors. These results indicate that USP25 is a novel target for inducing the degradation of oncogenic BCR-ABL protein in Ph-positive leukemia cells. This could be an effective approach to overcome resistance to kinase inhibitors.	[Shibata, Norihito; Ohoka, Nobumichi; Naito, Mikihiko] Natl Inst Hlth Sci, Div Mol Target & Gene Therapy Prod, Kawasaki, Kanagawa 2109501, Japan; [Tsuji, Genichiro; Demizu, Yosuke] Natl Inst Hlth Sci, Div Organ Chem, Kawasaki, Kanagawa 2109501, Japan; [Miyawaza, Keiji] Univ Yamanashi, Grad Sch Med, Dept Biochem, Yamanashi 4093898, Japan; [Ui-Tei, Kumiko] Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 1130033, Japan; [Ui-Tei, Kumiko] Univ Tokyo, Grad Sch Frontier Sci, Dept Computat Biol & Med Sci, Chiba 2778561, Japan; [Akiyama, Tetsu] Univ Tokyo, Inst Quantitat Biosci, Lab Mol & Genet Informat, Tokyo 1130032, Japan	National Institute of Health Sciences - Japan; National Institute of Health Sciences - Japan; University of Yamanashi; University of Tokyo; University of Tokyo; University of Tokyo	Naito, M (corresponding author), Natl Inst Hlth Sci, Div Mol Target & Gene Therapy Prod, Kawasaki, Kanagawa 2109501, Japan.	miki-naito@nihs.go.jp	Demizu, Yosuke/AAE-2839-2022	Demizu, Yosuke/0000-0001-7521-4861; SHIBATA, NORIHITO/0000-0001-5792-8510; Ui-Tei, Kumiko/0000-0001-8695-9025	Japan Society for the Promotion of Science (KAKENHI) [18K07311, 16H05090, 18H05502]; Project for Cancer Research and Therapeutic Evolution (P-CREATE) from the Japan Agency for Medical Research and Development (AMED) [JP17cm0106522j0002]; Takeda Science Foundation	Japan Society for the Promotion of Science (KAKENHI)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Project for Cancer Research and Therapeutic Evolution (P-CREATE) from the Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Takeda Science Foundation(Takeda Science Foundation (TSF))	This study was supported, in part, by the Japan Society for the Promotion of Science (KAKENHI Grant Numbers 18K07311 to NS, 16H05090 and 18H05502 to MN), by the Project for Cancer Research and Therapeutic Evolution (P-CREATE) (JP17cm0106522j0002 to NS) from the Japan Agency for Medical Research and Development (AMED), and by the Takeda Science Foundation (to NS).	Altun M, 2011, CHEM BIOL, V18, P1401, DOI 10.1016/j.chembiol.2011.08.018; Alvandi F, 2014, ONCOLOGIST, V19, P94, DOI 10.1634/theoncologist.2013-0077; Choi-Rhee E, 2004, PROTEIN SCI, V13, P3043, DOI 10.1110/ps.04911804; Cronan JE, 2005, J NUTR BIOCHEM, V16, P416, DOI 10.1016/j.jnutbio.2005.03.017; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; Demizu Y, 2016, BIOORG MED CHEM LETT, V26, P4865, DOI 10.1016/j.bmcl.2016.09.041; Deng SS, 2007, BREAST CANCER RES TR, V104, P21, DOI 10.1007/s10549-006-9393-7; Denuc A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005571; Gandhi V, 2014, CLIN CANCER RES, V20, P1735, DOI 10.1158/1078-0432.CCR-13-1283; Gelmini S, 2004, CANCER LETT, V216, P81, DOI 10.1016/j.canlet.2004.05.010; Gersch M, 2019, MOL CELL, V74, P436, DOI 10.1016/j.molcel.2019.02.030; Harrigan JA, 2018, NAT REV DRUG DISCOV, V17, P57, DOI 10.1038/nrd.2017.152; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; Hjerpe R, 2009, EMBO REP, V10, P1250, DOI 10.1038/embor.2009.192; Hochhaus A, 2017, NEW ENGL J MED, V376, P917, DOI 10.1056/NEJMoa1609324; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Kawaguchi K, 2017, SCI REP-UK, V7, DOI 10.1038/srep45037; KISHI K, 1985, LEUKEMIA RES, V9, P381, DOI 10.1016/0145-2126(85)90060-8; Klejman A, 2002, EMBO J, V21, P5766, DOI 10.1093/emboj/cdf562; Kohno T, 2012, NAT MED, V18, P375, DOI 10.1038/nm.2644; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; Lai AC, 2016, ANGEW CHEM INT EDIT, V55, P807, DOI 10.1002/anie.201507634; Lawson AP, 2015, CANCER RES, V75, P5130, DOI 10.1158/0008-5472.CAN-15-1544; Li J, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-166; Lipson D, 2012, NAT MED, V18, P382, DOI 10.1038/nm.2673; Liu B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07510-5; Massimino M, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0805-1; Okabe S, 2010, EXP HEMATOL, V38, P765, DOI 10.1016/j.exphem.2010.04.017; Pal A, 2014, CANCER RES, V74, P4955, DOI 10.1158/0008-5472.CAN-14-1211; Peng C, 2007, CELL CYCLE, V6, P2227, DOI 10.4161/cc.6.18.4722; Peng C, 2007, BLOOD, V110, P678, DOI 10.1182/blood-2006-10-054098; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Reckel S, 2017, LEUKEMIA, V31, P1502, DOI 10.1038/leu.2017.36; Roux KJ, 2012, J CELL BIOL, V196, P801, DOI 10.1083/jcb.201112098; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; RUDKIN GT, 1964, SCIENCE, V144, P1229, DOI 10.1126/science.144.3623.1229; Sauer F, 2019, MOL CELL, V74, P421, DOI 10.1016/j.molcel.2019.02.029; Shibata N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31913-5; Shibata N, 2017, CANCER SCI, V108, P1657, DOI 10.1111/cas.13284; Shimokawa K, 2017, ACS MED CHEM LETT, V8, P1042, DOI 10.1021/acsmedchemlett.7b00247; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Takeuchi K, 2012, NAT MED, V18, P378, DOI 10.1038/nm.2658; Tanno H, 2014, J BIOL CHEM, V289, P2415, DOI 10.1074/jbc.M113.528372; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tsukahara F, 2010, BLOOD, V116, P3582, DOI 10.1182/blood-2009-10-249623; Ui-Tei K, 2004, NUCLEIC ACIDS RES, V32, P936, DOI 10.1093/nar/gkh247; Wang WQ, 2015, CELL REP, V13, P524, DOI 10.1016/j.celrep.2015.09.014; Wrigley JD, 2017, ACS CHEM BIOL, V12, P3113, DOI 10.1021/acschembio.7b00334; Xu DC, 2017, GENE DEV, V31, P1024, DOI 10.1101/gad.300889.117	50	14	14	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	19					3867	3878		10.1038/s41388-020-1253-0	http://dx.doi.org/10.1038/s41388-020-1253-0		MAR 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LK4OF	32203161				2022-12-17	WOS:000519342000001
J	Khan, A; Valli, E; Lam, H; Scott, DA; Murray, J; Hanssen, KM; Eden, G; Gamble, LD; Pandher, R; Flemming, CL; Allan, S; Osterman, AL; Haber, M; Norris, MD; Fletcher, JI; Yu, DMT				Khan, Aaminah; Valli, Emanuele; Lam, Hayley; Scott, David A.; Murray, Jayne; Hanssen, Kimberley M.; Eden, Georgina; Gamble, Laura D.; Pandher, Rupinder; Flemming, Claudia L.; Allan, Sophie; Osterman, Andrei L.; Haber, Michelle; Norris, Murray D.; Fletcher, Jamie, I; Yu, Denise M. T.			Targeting metabolic activity in high-risk neuroblastoma through Monocarboxylate Transporter 1 (MCT1) inhibition	ONCOGENE			English	Article							CANCER-CELLS; N-MYC; GLYCOLYSIS; HYPOXIA; GROWTH; ACTIVATION; PYRUVATE; GLUTAMINOLYSIS; COMBINATION; METASTASIS	Amplification of the MYCN oncogene occurs in similar to 25% of primary neuroblastomas and is the single most powerful biological marker of poor prognosis in this disease. MYCN transcriptionally regulates a range of biological processes important for cancer, including cell metabolism. The MYCN-regulated metabolic gene SLC16A1, encoding the lactate transporter monocarboxylate transporter 1 (MCT1), is a potential therapeutic target. Treatment of neuroblastoma cells with the MCT1 inhibitor SR13800 increased intracellular lactate levels, disrupted the nicotinamide adenine dinucleotide (NADH/NAD(+)) ratio, and decreased intracellular glutathione levels. Metabolite tracing with 13C-glucose and 13C-glutamine following MCT1 inhibitor treatment revealed increased quantities of tricarboxylic acid (TCA) cycle intermediates and increased oxygen consumption rate. MCT1 inhibition was highly synergistic with vincristine and LDHA inhibition under cell culture conditions, but this combination was ineffective against neuroblastoma xenografts. Posttreatment xenograft tumors had increased synthesis of the MCT1 homolog MCT4/SLC16A, a known resistance factor to MCT1 inhibition. We found that MCT4 was negatively regulated by MYCN in luciferase reporter assays and its synthesis in neuroblastoma cells was increased under hypoxic conditions and following hypoxia-inducible factor (HIF1) induction, suggesting that MCT4 may contribute to resistance to MCT1 inhibitor treatment in hypoxic neuroblastoma tumors. Co-treatment of neuroblastoma cells with inhibitors of MCT1 and LDHA, the enzyme responsible for lactate production, resulted in a large increase in intracellular pyruvate and was highly synergistic in decreasing neuroblastoma cell viability. These results highlight the potential of targeting MCT1 in neuroblastoma in conjunction with strategies that involve disruption of pyruvate homeostasis and indicate possible resistance mechanisms.	[Khan, Aaminah; Valli, Emanuele; Lam, Hayley; Murray, Jayne; Hanssen, Kimberley M.; Eden, Georgina; Gamble, Laura D.; Pandher, Rupinder; Flemming, Claudia L.; Allan, Sophie; Haber, Michelle; Norris, Murray D.; Fletcher, Jamie, I; Yu, Denise M. T.] UNSW Sydney, Childrens Canc Inst, Lowy Canc Res Ctr, Sydney, NSW 2052, Australia; [Khan, Aaminah; Lam, Hayley] UNSW Sydney, Sch Med Sci, Sydney, NSW 2052, Australia; [Valli, Emanuele; Hanssen, Kimberley M.; Fletcher, Jamie, I; Yu, Denise M. T.] UNSW Sydney, Sch Womens & Childrens Hlth, Sydney, NSW 2052, Australia; [Scott, David A.; Osterman, Andrei L.] Sanford Burnham Prebys Med Discovery Inst, Canc Metab Core, La Jolla, CA 92037 USA; [Norris, Murray D.] Univ New South Wales, Ctr Childhood Canc Res, Sydney, NSW, Australia	Children's Cancer Institute; University of New South Wales Sydney; University of New South Wales Sydney; University of New South Wales Sydney; Sanford Burnham Prebys Medical Discovery Institute; University of New South Wales Sydney	Fletcher, JI; Yu, DMT (corresponding author), UNSW Sydney, Childrens Canc Inst, Lowy Canc Res Ctr, Sydney, NSW 2052, Australia.; Fletcher, JI; Yu, DMT (corresponding author), UNSW Sydney, Sch Womens & Childrens Hlth, Sydney, NSW 2052, Australia.	JFletcher@ccia.unsw.edu.au; DYu@ccia.unsw.edu.au	Valli, Emanuele/ABD-7213-2020; Murray, Jayne/AAM-8115-2021	Valli, Emanuele/0000-0002-0928-8624; Haber, Michelle/0000-0003-2036-8817; Gamble, Laura D./0000-0001-8496-9705; Fletcher, Jamie/0000-0003-2949-9469; Scott, David/0000-0002-8668-2449; Hanssen, Kimberley/0000-0002-2919-3104; Murray, Jayne/0000-0002-1861-6570	Balnaves Foundation Young Investigator Grant; National Health and Medical Research Council [APP1016699]; SBP NCI Cancer Center Support Grant [P30 CA030199]	Balnaves Foundation Young Investigator Grant; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); SBP NCI Cancer Center Support Grant	We thank Donna Lai and Sheng Hua from the Bosch Molecular Biology Facility, University of Sydney for support with Seahorse Analyses, and Alan Truong for technical support. This work was supported by a Balnaves Foundation Young Investigator Grant (DMTY), a National Health and Medical Research Council Program Grant APP1016699 (MH, MDN), and a SBP NCI Cancer Center Support Grant P30 CA030199 (DS, AO).	Benjamin D, 2018, CELL REP, V25, P3047, DOI 10.1016/j.celrep.2018.11.043; Birsoy K, 2013, NAT GENET, V45, P104, DOI 10.1038/ng.2471; Bonuccelli G, 2010, CELL CYCLE, V9, P3506, DOI 10.4161/cc.9.17.12731; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; Curtis NJ, 2017, ONCOTARGET, V8, P69219, DOI 10.18632/oncotarget.18215; Doherty JR, 2014, CANCER RES, V74, P908, DOI 10.1158/0008-5472.CAN-13-2034; Fang J, 2006, MOL PHARMACOL, V70, P2108, DOI 10.1124/mol.106.026245; Faubert B, 2017, CELL, V171, P358, DOI 10.1016/j.cell.2017.09.019; Fiaschi T, 2012, CANCER RES, V72, P5130, DOI 10.1158/0008-5472.CAN-12-1949; Fotsis T, 1999, EUR J BIOCHEM, V263, P757, DOI 10.1046/j.1432-1327.1999.00575.x; Galluzzi L, 2013, NAT REV DRUG DISCOV, V12, P829, DOI 10.1038/nrd4145; Gan L, 2016, ONCOGENE, V35, P3037, DOI 10.1038/onc.2015.360; Gherardi S, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00042; Groninger E, 2002, INT J ONCOL, V21, P1339; Halestrap AP, 2012, IUBMB LIFE, V64, P109, DOI 10.1002/iub.572; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Henderson MJ, 2011, J NATL CANCER I, V103, P1236, DOI 10.1093/jnci/djr256; Hong CS, 2016, CELL REP, V14, P1590, DOI 10.1016/j.celrep.2016.01.057; Huang M, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014415; Jin L, 2016, ONCOGENE, V35, P3619, DOI 10.1038/onc.2015.447; Kocak H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.84; Le Floch R, 2011, P NATL ACAD SCI USA, V108, P16663, DOI 10.1073/pnas.1106123108; Levy AG, 2012, INVEST NEW DRUG, V30, P191, DOI 10.1007/s10637-010-9551-y; Lin RY, 1998, J BIOL CHEM, V273, P28959, DOI 10.1074/jbc.273.44.28959; Matthay KK, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.78; Noble RA, 2017, HAEMATOLOGICA, V102, P1247, DOI 10.3324/haematol.2016.163030; Obre E, 2015, INT J BIOCHEM CELL B, V59, P167, DOI 10.1016/j.biocel.2014.12.008; Park JR, 2010, HEMATOL ONCOL CLIN N, V24, P65, DOI 10.1016/j.hoc.2009.11.011; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; Pertega-Gomes N, 2015, ONCOTARGET, V6, P21675, DOI 10.18632/oncotarget.4328; Polanski R, 2014, CLIN CANCER RES, V20, P926, DOI 10.1158/1078-0432.CCR-13-2270; Qing GL, 2012, CANCER CELL, V22, P631, DOI 10.1016/j.ccr.2012.09.021; Qing GL, 2010, CANCER RES, V70, P10351, DOI 10.1158/0008-5472.CAN-10-0740; Quanz M, 2018, MOL CANCER THER, V17, P2285, DOI 10.1158/1535-7163.MCT-17-1253; Ratnikov B, 2015, ONCOTARGET, V6, P7379, DOI 10.18632/oncotarget.3132; Ren P, 2015, J PATHOL, V235, P90, DOI 10.1002/path.4429; Scott DA, 2011, J BIOL CHEM, V286, P42626, DOI 10.1074/jbc.M111.282046; Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843; Sounni NE, 2014, CELL METAB, V20, P280, DOI 10.1016/j.cmet.2014.05.022; Sullivan LB, 2016, NAT REV CANCER, V16, P680, DOI 10.1038/nrc.2016.85; Thangaraju M, 2009, BIOCHEM J, V417, P379, DOI 10.1042/BJ20081132; Tu Y, 2013, INT J MOL MED, V31, P113, DOI 10.3892/ijmm.2012.1167; Ullah MS, 2006, J BIOL CHEM, V281, P9030, DOI 10.1074/jbc.M511397200; Valli E, 2012, BBA-GENE REGUL MECH, V1819, P1173, DOI 10.1016/j.bbagrm.2012.08.001; Wagner W, 2015, CELL COMMUN SIGNAL, V13, DOI 10.1186/s12964-015-0114-x; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Xiao DB, 2015, ONCOTARGET, V6, P40655, DOI 10.18632/oncotarget.5821; Xu RH, 2005, CANCER RES, V65, P613; Zhang XL, 2011, MOL CELL BIOCHEM, V358, P287, DOI 10.1007/s11010-011-0979-y; Zhao L, 2004, CLIN CANCER RES, V10, P7994, DOI 10.1158/1078-0432.CCR-04-1087; Zhao YX, 2011, J CEREBR BLOOD F MET, V31, P1412, DOI 10.1038/jcbfm.2010.230	51	14	14	3	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	17					3555	3570		10.1038/s41388-020-1235-2	http://dx.doi.org/10.1038/s41388-020-1235-2		MAR 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LH1YK	32123312	Green Accepted			2022-12-17	WOS:000517738400001
J	Fang, RP; Xu, FF; Shi, H; Wu, Y; Cao, C; Li, H; Ye, K; Zhang, YY; Liu, Q; Zhang, SQ; Zhang, WY; Ye, LH				Fang, Runping; Xu, Feifei; Shi, Hui; Wu, Yue; Cao, Can; Li, Hang; Ye, Kai; Zhang, Yingyi; Liu, Qian; Zhang, Shuqin; Zhang, Weiying; Ye, Lihong			LAMTOR5 raises abnormal initiation of O-glycosylation in breast cancer metastasis via modulating GALNT1 activity	ONCOGENE			English	Article							ONCOPROTEIN; GROWTH; HBXIP; PHOSPHORYLATION; ACTIVATION; LUNG; IDENTIFICATION; TRANSCRIPTION; EXPRESSION; PROGNOSIS	During malignancy, perturbed O-glycosylation confers global influence on cancer progression. As a hallmark of cancer metastasis, GalNAc-type O-glycosylation initiation is aberrantly raised, but the regulatory mechanism is still mysterious. Here, we show that LAMTOR5 raises abnormal initiation of O-glycosylation in breast cancer metastasis. LAMTOR5 was highly expressed in adenocarcinoma and correlated with Tn antigen, a product of O-glycosylation initiation, in both clinical metastatic breast cancer specimens and secondary metastasis mouse model. LAMTOR5-modulated O-glycosylation initiating enzyme GALNT1 conferred Tn accumulation and predicted poor survival. Mechanistically, LAMTOR5 stimulated transcriptions of GALNT1 through coactivating c-Jun, and triggered dislocation of GALNT1 in the endoplasmic reticulum (ER) via LAMTOR5 dependent-activation of c-Src. This unusual initiation of O-glycosylation resulted in the abundance of Tn modified glycoproteins, such as MUC1 and OPN. Collectively, our findings indicate that LAMTOR5/c-Jun/c-Src axis serves as the upstream regulator of abnormal O-glycosylation initiation and potential therapeutic targets in breast cancer metastasis.	[Fang, Runping; Xu, Feifei; Shi, Hui; Wu, Yue; Cao, Can; Li, Hang; Ye, Kai; Zhang, Yingyi; Liu, Qian; Zhang, Shuqin; Zhang, Weiying; Ye, Lihong] Nankai Univ, State Key Lab Med Chem Biol, Tianjin Key Lab Prot Sci, Dept Biochem,Coll Life Sci, Tianjin 300071, Peoples R China	Nankai University	Ye, LH (corresponding author), Nankai Univ, State Key Lab Med Chem Biol, Tianjin Key Lab Prot Sci, Dept Biochem,Coll Life Sci, Tianjin 300071, Peoples R China.	yelihong@nankai.edu.cn	Fang, Runping/AAF-6835-2020					Nguyen AT, 2017, CANCER CELL, V32, P639, DOI 10.1016/j.ccell.2017.10.001; Bar-Peled L, 2012, CELL, V150, P1196, DOI 10.1016/j.cell.2012.07.032; Baum LG, 1996, J BIOL CHEM, V271, P10793, DOI 10.1074/jbc.271.18.10793; Berger T, 2010, P NATL ACAD SCI USA, V107, P2995, DOI 10.1073/pnas.1000101107; Cummings R.D., 2015, ESSENTIALS GLYCOBIOL, P611; Desai PR, 2000, TRANSFUS MED REV, V14, P312, DOI 10.1053/tmrv.2000.16229; Farre D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605; Finlin BS, 2003, P NATL ACAD SCI USA, V100, P14469, DOI 10.1073/pnas.2437756100; Gill DJ, 2013, P NATL ACAD SCI USA, V110, pE3152, DOI 10.1073/pnas.1305269110; Gill DJ, 2011, TRENDS CELL BIOL, V21, P149, DOI 10.1016/j.tcb.2010.11.004; Gill DJ, 2010, J CELL BIOL, V189, P843, DOI 10.1083/jcb.201003055; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hofmann BT, 2014, CLIN CANCER RES, V20, P6117, DOI 10.1158/1078-0432.CCR-14-0716; Hu N, 2011, J BIOL CHEM, V286, P13714, DOI 10.1074/jbc.M110.204131; Ju TZ, 2011, ANGEW CHEM INT EDIT, V50, P1770, DOI 10.1002/anie.201002313; Kariya Y, 2014, BIOCHEM J, V463, P93, DOI 10.1042/BJ20140060; Korourian S, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-136; Laack E, 2002, AM J PATHOL, V160, P1001, DOI 10.1016/S0002-9440(10)64921-8; Lee TH, 2012, KOREAN J RADIOL S1, V13, pS12; Li C, 2016, CANCER RES, V76, P1273, DOI 10.1158/0008-5472.CAN-15-2309; Li C, 2014, CLIN CANCER RES, V20, P4001, DOI 10.1158/1078-0432.CCR-13-3397; Li H, 2015, J BIOL CHEM, V290, P22649, DOI 10.1074/jbc.M115.658468; Li YH, 2016, CANCER RES, V76, P293, DOI 10.1158/0008-5472.CAN-14-3607; Lu G, 2014, CANCER CELL, V26, P222, DOI 10.1016/j.ccr.2014.06.026; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Milde-Langosch K, 2015, BREAST CANCER RES TR, V151, P515, DOI 10.1007/s10549-015-3425-0; Minai-Tehrani A, 2013, INT J MOL MED, V32, P1137, DOI 10.3892/ijmm.2013.1483; Miwa HE, 2010, J BIOL CHEM, V285, P1208, DOI 10.1074/jbc.M109.035436; Nath S, 2014, TRENDS MOL MED, V20, P332, DOI 10.1016/j.molmed.2014.02.007; Ooms LM, 2015, CANCER CELL, V28, P155, DOI 10.1016/j.ccell.2015.07.003; Pangeni RP, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0089-x; Park JH, 2010, CANCER RES, V70, P2759, DOI 10.1158/0008-5472.CAN-09-3911; Pinho SS, 2015, NAT REV CANCER, V15, P540, DOI 10.1038/nrc3982; Qiu YH, 2008, J PROTEOME RES, V7, P1693, DOI 10.1021/pr700706s; Remmers N, 2013, CLIN CANCER RES, V19, P1981, DOI 10.1158/1078-0432.CCR-12-2662; Ritchie S, 2000, J BIOL CHEM, V275, P847, DOI 10.1074/jbc.275.2.847; Rottger S, 1998, J CELL SCI, V111, P45; Singh R, 2007, CANCER BIOL THER, V6, P481, DOI 10.4161/cbt.6.4.4201; Song KH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13796; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Yue L, 2013, CARCINOGENESIS, V34, P927, DOI 10.1093/carcin/bgs399; Zhang YY, 2013, J BIOL CHEM, V288, P18961, DOI 10.1074/jbc.M113.458638; Zhao Y, 2016, CANCER RES, V76, P4696, DOI 10.1158/0008-5472.CAN-15-1734	45	14	14	5	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2290	2304		10.1038/s41388-019-1146-2	http://dx.doi.org/10.1038/s41388-019-1146-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31836847				2022-12-17	WOS:000519440400005
J	Yoe, J; Kim, D; Kim, S; Lee, Y				Yoe, Jeehyun; Kim, Donghyo; Kim, Sanguk; Lee, Yoontae			Capicua restricts cancer stem cell-like properties in breast cancer cells	ONCOGENE			English	Article							TRANSCRIPTION FACTORS; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; MICE; ASSOCIATION; RESISTANCE; MUTATIONS; FUSION; FAMILY; LINKS	Cancer stem cells (CSCs) play a central role in cancer initiation, progression, therapeutic resistance, and recurrence in patients. Here we present Capicua (CIC), a developmental transcriptional repressor, as a suppressor of CSC properties in breast cancer cells. CIC deficiency critically enhances CSC self-renewal and multiple CSC subpopulations of breast cancer cells without altering their growth rate or invasiveness. Loss of CIC relieves repression of ETV4 and ETV5 expression, consequently promoting self-renewal capability, EpCAM(+)/CD44(+)/CD24(low/-) expression, and ALDH activity. In xenograft models, CIC deficiency significantly increases CSC frequency and drives tumor initiation through derepression of ETV4. Consistent with the experimental data, the CD44(high)/CD24(low) CSC-like feature is inversely correlated with CIC levels in breast cancer patients. We also identify SOX2 as a downstream target gene of CIC that partly promotes CSC properties. Taken together, our study demonstrates that CIC suppresses breast cancer formation via restricting cancer stemness and proposes CIC as a potential regulator of stem cell maintenance.	[Yoe, Jeehyun; Kim, Donghyo; Kim, Sanguk; Lee, Yoontae] Pohang Univ Sci & Technol POSTECH, Dept Life Sci, Pohang 37673, Gyeongbuk, South Korea; [Kim, Sanguk; Lee, Yoontae] Pohang Univ Sci & Technol POSTECH, Div Integrat Biosci & Biotechnol, Pohang 37673, Gyeongbuk, South Korea	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH)	Lee, Y (corresponding author), Pohang Univ Sci & Technol POSTECH, Dept Life Sci, Pohang 37673, Gyeongbuk, South Korea.; Lee, Y (corresponding author), Pohang Univ Sci & Technol POSTECH, Div Integrat Biosci & Biotechnol, Pohang 37673, Gyeongbuk, South Korea.	yoontael@postech.ac.kr		Kim, Sanguk/0000-0002-3449-3814	National Research Foundation (NRF) of Korea [2017R1A5A1015366, 2018R1A2B2004416]; BK21 Plus Program (Program of Bio-Molecular Function, POSTECH)	National Research Foundation (NRF) of Korea(National Research Foundation of Korea); BK21 Plus Program (Program of Bio-Molecular Function, POSTECH)	We thank the Lee lab members for helpful discussions on this study as well as helping to conduct the experiments. This work was supported by grants from the National Research Foundation (NRF) of Korea (2017R1A5A1015366 and 2018R1A2B2004416 to YL). JY and DK were supported by the BK21 Plus Program (Program of Bio-Molecular Function, POSTECH).	Ahmad ST, 2018, REGULATION NEURAL ST, DOI [10.1101/335984, DOI 10.1101/335984]; Akagi T, 2015, J BIOL CHEM, V290, P22460, DOI 10.1074/jbc.M115.675595; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bieche I, 2004, CARCINOGENESIS, V25, P405, DOI 10.1093/carcin/bgh024; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Charafe-Jauffret E, 2010, CLIN CANCER RES, V16, P45, DOI 10.1158/1078-0432.CCR-09-1630; Choi N, 2015, ONCOTARGET, V6, P23533, DOI 10.18632/oncotarget.4372; Chotteau-Lelievre A, 2004, CLIN CANCER RES, V10, P7297, DOI 10.1158/1078-0432.CCR-04-0593; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Colacino JA, 2018, STEM CELL REP, V10, P1596, DOI 10.1016/j.stemcr.2018.03.001; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Eleveld TF, 2018, CANCER RES, V78, P6297, DOI 10.1158/0008-5472.CAN-18-1045; Firlej V, 2008, J CELL SCI, V121, P3393, DOI 10.1242/jcs.027201; Fores M, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006622; Gattazzo F, 2014, BBA-GEN SUBJECTS, V1840, P2506, DOI 10.1016/j.bbagen.2014.01.010; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Graham C, 2012, HUM PATHOL, V43, P180, DOI 10.1016/j.humpath.2011.04.023; Han SK, 2016, ONCOTARGET, V7, P56147, DOI 10.18632/oncotarget.11269; Hess DA, 2006, BLOOD, V107, P2162, DOI 10.1182/blood-2005-06-2284; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Hyun KA, 2016, ONCOTARGET, V7, P24677, DOI 10.18632/oncotarget.8250; Jimenez G, 2012, J CELL SCI, V125, P1383, DOI 10.1242/jcs.092965; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; Kawamura-Saito M, 2006, HUM MOL GENET, V15, P2125, DOI 10.1093/hmg/ddl136; Kim E, 2018, HEPATOLOGY, V67, P2287, DOI 10.1002/hep.29738; Kim E, 2015, SCI REP-UK, V5, DOI 10.1038/srep08272; Kurpios NA, 2003, J MAMMARY GLAND BIOL, V8, P177, DOI 10.1023/A:1025948823955; LeBlanc VG, 2017, J PATHOL, V242, P206, DOI 10.1002/path.4894; Lee JS, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1111-8; Lee Y, 2011, DEV CELL, V21, P746, DOI 10.1016/j.devcel.2011.08.017; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009; Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154; Lu HC, 2017, NAT GENET, V49, P527, DOI 10.1038/ng.3808; Masui S, 2007, NAT CELL BIOL, V9, P625, DOI 10.1038/ncb1589; Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676; Oh S, 2012, BBA-REV CANCER, V1826, P1, DOI 10.1016/j.bbcan.2012.02.002; Okimoto RA, 2017, NAT GENET, V49, P87, DOI 10.1038/ng.3728; Park S, 2019, HEPATOLOGY, V70, P358, DOI 10.1002/hep.30594; Park S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16037; Patel M, 2008, LUNG CANCER, V59, P340, DOI 10.1016/j.lungcan.2007.08.033; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Simon-Carrasco L, 2017, GENE DEV, V31, P1456, DOI 10.1101/gad.300244.117; Tan QM, 2018, P NATL ACAD SCI USA, V115, pE1511, DOI 10.1073/pnas.1716452115; Tanei T, 2009, CLIN CANCER RES, V15, P4234, DOI 10.1158/1078-0432.CCR-08-1479; Wong D, 2019, ONCOGENE, V38, P273, DOI 10.1038/s41388-018-0427-5; Yip S, 2012, J PATHOL, V226, P7, DOI 10.1002/path.2995; Yuan ZY, 2014, ONCOTARGETS THER, V7, P1733, DOI 10.2147/OTT.S66692	53	14	15	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	17					3489	3506		10.1038/s41388-020-1230-7	http://dx.doi.org/10.1038/s41388-020-1230-7		FEB 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LH1YK	32108163				2022-12-17	WOS:000516891300001
J	Tian, LT; Yao, K; Liu, K; Han, B; Dong, HG; Zhao, W; Jiang, WB; Qiu, FB; Qu, LL; Wu, ZH; Zhou, B; Zhong, MY; Zhao, JB; Qiu, XF; Zhong, LF; Guo, XF; Shi, TL; Hong, XH; Lu, SC				Tian, Lantian; Yao, Ke; Liu, Kun; Han, Bing; Dong, Hanguang; Zhao, Wei; Jiang, Weibo; Qiu, Fabo; Qu, Linlin; Wu, Zehua; Zhou, Bin; Zhong, Mengya; Zhao, Jiabao; Qiu, Xingfeng; Zhong, Lifeng; Guo, Xiaofeng; Shi, Tianlu; Hong, Xuehui; Lu, Shichun			PLK1/NF-kappa B feedforward circuit antagonizes the mono-ADP-ribosyltransferase activity of PARP10 and facilitates HCC progression	ONCOGENE			English	Article							POLO-LIKE KINASE; HEPATOCELLULAR-CARCINOMA; PLK1; PHOSPHORYLATION; PROLIFERATION; RIBOSYLATION; REPLICATION; ACTIVATION; RESISTANCE	Dysregulation of PARP10 has been implicated in various tumor types and plays a vital role in delaying hepatocellular carcinoma (HCC) progression. However, the mechanisms controlling the expression and activity of PARP10 in HCC remain mostly unknown. The crosstalk between PLK1, PARP10, and NF-kappa B pathway in HCC was determined by performing different in vitro and in vivo assays, including mass spectrometry, kinase, MARylation, chromatin immunoprecipitation, and luciferase reporter measurements. Functional examination was performed by using small chemical drug, cell culture, and mice HCC models. Correlation between PLK1, NF-kappa B, and PARP10 expression was determined by analyzing clinical samples of HCC patients with using immunohistochemistry. PLK1, an important regulator for cell mitosis, directly interacts with and phosphorylates PARP10 at T601. PARP10 phosphorylation at T601 significantly decreases its binding to NEMO and disrupts its inhibition to NEMO ubiquitination, thereby enhancing the transcription activity of NF-kappa B toward multiple target genes and promoting HCC development. In turn, NF-kappa B transcriptionally inhibits the PARP10 promoter activity and leads to its downregulation in HCC. Interestingly, PLK1 is mono-ADP-ribosylated by PARP10 and the MARylation of PLK1 significantly inhibits its kinase activity and oncogenic function in HCC. Clinically, the expression levels of PLK1 and phosphor-p65 show an inverse correlation with PARP10 expression in human HCC tissues. These findings are the first to uncover a PLK1/PARP10/NF-kappa B signaling circuit that underlies tumorigenesis and validate PLK1 inhibitors, alone or with NF-kappa B antagonists, as potential effective therapeutics for PARP10-expressing HCC.	[Tian, Lantian; Han, Bing; Zhao, Wei; Jiang, Weibo; Qiu, Fabo; Qu, Linlin; Wu, Zehua; Zhou, Bin] Qingdao Univ, Affiliated Hosp, Dept Hepatopancreatobiliary Surg, Qingdao, Shandong, Peoples R China; [Tian, Lantian; Lu, Shichun] Chinese Peoples Liberat Army Gen Hosp, Clin Med Ctr 1, Dept Hepatobiliary Surg, Beijing, Peoples R China; [Yao, Ke] Qingdao Univ, Affiliated Hosp, Dept Obstet & Gynaecol, Qingdao, Shandong, Peoples R China; [Liu, Kun] PLA Navy, Hosp 971, Dept Gen Surg, Qingdao, Shandong, Peoples R China; [Dong, Hanguang] Shandong Univ, Dept Gen Surg, Qilu Hosp, Qingdao, Shandong, Peoples R China; [Zhong, Mengya; Zhao, Jiabao; Qiu, Xingfeng; Zhong, Lifeng; Hong, Xuehui] Xiamen Univ, Dept Gastrointestinal Surg, Zhongshan Hosp, Xiamen, Fujian, Peoples R China; [Zhong, Mengya; Zhao, Jiabao; Qiu, Xingfeng; Zhong, Lifeng; Hong, Xuehui] Xiamen Univ, Inst Gastrointestinal Oncol, Sch Med, Xiamen, Fujian, Peoples R China; [Guo, Xiaofeng] Zhongshan Univ, Affiliated Hosp, Dept Hepatopancreatobiliary Surg, Guangzhou, Guangdong, Peoples R China; [Shi, Tianlu] Univ Sci & Technol China, Affiliated Hosp 1, Div Life Sci & Med, Dept Pharm, Hefei, Anhui, Peoples R China	Qingdao University; Chinese People's Liberation Army General Hospital; Qingdao University; Sixth Medical Center of Chinese PLA General Hospital; Shandong University; Xiamen University; Xiamen University; Sun Yat Sen University; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Lu, SC (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Clin Med Ctr 1, Dept Hepatobiliary Surg, Beijing, Peoples R China.; Hong, XH (corresponding author), Xiamen Univ, Dept Gastrointestinal Surg, Zhongshan Hosp, Xiamen, Fujian, Peoples R China.; Hong, XH (corresponding author), Xiamen Univ, Inst Gastrointestinal Oncol, Sch Med, Xiamen, Fujian, Peoples R China.; Shi, TL (corresponding author), Univ Sci & Technol China, Affiliated Hosp 1, Div Life Sci & Med, Dept Pharm, Hefei, Anhui, Peoples R China.	tianlu828@163.com; hongxu@xmu.edu.cn; lushichun889@126.com	Zhong, Mengya/AAA-6082-2021		National Natural Science Foundation of China [81602149]; Natural Science Foundation of Fujian Province [2016J01619]; Training Program for Young Talents of Fujian Health System [2016-ZQN-85]; Fujian Provincial Funds for Distinguished Young Scientists [2018D0016]; Affiliated Hospital of Qingdao University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Fujian Province(Natural Science Foundation of Fujian Province); Training Program for Young Talents of Fujian Health System; Fujian Provincial Funds for Distinguished Young Scientists; Affiliated Hospital of Qingdao University	The authors would like to thank the Affiliated Hospital of Qingdao University for providing clinical samples and the contributions and supports of the entire research team. This study was supported by National Natural Science Foundation of China (Grant No. 81602149), Natural Science Foundation of Fujian Province (Grant No. 2016J01619), Training Program for Young Talents of Fujian Health System (Grant No. 2016-ZQN-85), Fujian Provincial Funds for Distinguished Young Scientists (No. 2018D0016).	Almeida LO, 2014, FEBS OPEN BIO, V4, P96, DOI 10.1016/j.fob.2013.12.003; Chen YC, 2010, J BIOL CHEM, V285, P41244, DOI 10.1074/jbc.M110.155242; Chou HYE, 2006, J BIOL CHEM, V281, P15201, DOI 10.1074/jbc.M506745200; de Carcer G, 2011, CELL CYCLE, V10, P2255, DOI 10.4161/cc.10.14.16494; Dietrich P, 2018, ONCOTARGET, V9, P3605, DOI 10.18632/oncotarget.23188; Feijs KLH, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-5; Fu Z, 2017, CANCERS, V9, DOI 10.3390/cancers9100131; Gutteridge REA, 2016, MOL CANCER THER, V15, P1427, DOI 10.1158/1535-7163.MCT-15-0897; Hong XH, 2018, ELIFE, V7, DOI 10.7554/eLife.29511; Hong XH, 2014, GUT, V63, P1635, DOI 10.1136/gutjnl-2013-305302; Huang GL, 2010, WORLD J GASTROENTERO, V16, P2046, DOI 10.3748/wjg.v16.i16.2046; Kachaner D, 2012, MOL CELL, V45, P553, DOI 10.1016/j.molcel.2011.12.030; Lasek AL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150225; Li XY, 2017, CELL CYCLE, V16, P1933, DOI 10.1080/15384101.2017.1363942; Ling F, 2017, ONCOTARGET, V8, P72773, DOI 10.18632/oncotarget.20347; Liu XQ, 2015, TRANSL ONCOL, V8, P185, DOI 10.1016/j.tranon.2015.03.010; Lo J, 2015, HEPATOLOGY, V62, P534, DOI 10.1002/hep.27859; de Lima CDM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041772; Marton J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0187789; Paone G, 2006, J BIOL CHEM, V281, P17054, DOI 10.1074/jbc.M603042200; Qu C, 2016, J HEPATOL, V64, P1076, DOI 10.1016/j.jhep.2016.01.005; Schleicher EM, 2018, NUCLEIC ACIDS RES, V46, P8908, DOI 10.1093/nar/gky658; Sokolova O, 2017, TOXINS, V9, DOI 10.3390/toxins9040119; Song RP, 2014, HEPATOLOGY, V60, P1659, DOI 10.1002/hep.27312; Studach LL, 2009, HEPATOLOGY, V50, P414, DOI 10.1002/hep.22996; Teloni F, 2016, NUCLEIC ACIDS RES, V44, P993, DOI 10.1093/nar/gkv1383; Varol B, 2014, TUMOR BIOL, V35, P5575, DOI 10.1007/s13277-014-1735-1; Verheugd P, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2672; Wang G, 2013, J CELL SCI, V126, P1355, DOI 10.1242/jcs.114918; Wright G, 2017, ACS CHEM BIOL, V12, P1883, DOI 10.1021/acschembio.7b00147; Yau L, 2003, EUR J BIOCHEM, V270, P101, DOI 10.1046/j.1432-1033.2003.03366.x; Zhao YH, 2018, ONCOGENE, V37, P2921, DOI 10.1038/s41388-018-0168-5; Zhu Y., 2018, IEEE J SEL TOP QUANT, V24, P1	33	14	15	6	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	15					3145	3162		10.1038/s41388-020-1205-8	http://dx.doi.org/10.1038/s41388-020-1205-8		FEB 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LB8NS	32060423				2022-12-17	WOS:000513384600002
J	Zhang, Q; Fan, H; Liu, HD; Jin, JJ; Zhu, SH; Zhou, L; Liu, HB; Zhang, F; Zhan, P; Lv, TF; Song, Y				Zhang, Qun; Fan, Hang; Liu, Hongda; Jin, Jiajia; Zhu, Suhua; Zhou, Li; Liu, Hongbin; Zhang, Fang; Zhan, Ping; Lv, Tangfeng; Song, Yong			WNT5B exerts oncogenic effects and is negatively regulated by miR-5587-3p in lung adenocarcinoma progression	ONCOGENE			English	Article							WNT/BETA-CATENIN PATHWAY; CANCER; IDENTIFICATION; PROLIFERATION; DISEASE; FAMILY; WNT-5B; CELLS; RISK	WNT5B glycoprotein belongs to the Wnt protein family. Limited investigations revealed a possible role of WNT5B in malignancies, such as triple-negative breast cancer and oral squamous cell carcinoma. However, whether WNT5B contributes to the progression of lung adenocarcinoma (LAD) remains unclear. Here, we initially determine that WNT5B is highly expressed in LAD and is positively correlated with lymph node metastasis and TNM stage. Consistently, clinical analysis reveals WNT5B as an independent prognostic biomarker in LAD. Silencing WNT5B suppresses the proliferation of LAD both in vitro and in vivo by interfering G1/S cell-cycle progression and modulating amino acid metabolism, revealing its remarkable oncogenic role in LAD. Of note, we also identified miR-5587-3p as a negative upstream regulator of WNT5B in LAD, which may help develop therapies targeting LAD patients with high WNT5B expression. Taken together, our results revealed an oncogenic role of WNT5B in LAD, which could be a prognostic biomarker and promising therapeutic target for LAD patients.	[Zhang, Qun; Fan, Hang; Zhu, Suhua; Zhou, Li; Liu, Hongbin; Zhang, Fang; Zhan, Ping; Lv, Tangfeng; Song, Yong] Nanjing Univ, Jinling Hosp, Dept Resp Med, Sch Med, Nanjing 210002, Jiangsu, Peoples R China; [Zhang, Qun] Nanjing Med Univ, Dept Resp Med, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China; [Liu, Hongda] Nanjing Med Univ, Dept Gen Surg, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China; [Jin, Jiajia] Southern Med Univ, Jinling Hosp, Dept Resp Med, Nanjing 210002, Jiangsu, Peoples R China	Nanjing University; Nanjing Medical University; Nanjing Medical University; Southern Medical University - China	Zhan, P; Lv, TF; Song, Y (corresponding author), Nanjing Univ, Jinling Hosp, Dept Resp Med, Sch Med, Nanjing 210002, Jiangsu, Peoples R China.	zhanping207@163.com; bairoushui@163.com; yong_song6310@yahoo.com		Liu, Hongda/0000-0002-5977-9130	National Natural Science Foundation of China [81572937, 81572273, 81772500]; 16th batch "Summit of the Six Top Talents" Program of Jiangsu Province [WSN-154]; China Postdoctoral Science Foundation 12th batch Special fund [45786]; China Postdoctoral Science Foundation [45786]; Jiangsu Provincial Postdoctoral Science Foundation [2018K049A]; Natural Science Foundation of Jiangsu province [BK20180139, BK20161386]; Jiangsu Provincial Medical Youth Talent [QNRC2016125]; Nanjing Medical Science and Technology Development Project [ZKX17044]; Jiangsu Provincial Key Research and Development Program [BE2016721]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 16th batch "Summit of the Six Top Talents" Program of Jiangsu Province; China Postdoctoral Science Foundation 12th batch Special fund; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Jiangsu Provincial Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Natural Science Foundation of Jiangsu province(Natural Science Foundation of Jiangsu Province); Jiangsu Provincial Medical Youth Talent; Nanjing Medical Science and Technology Development Project; Jiangsu Provincial Key Research and Development Program	This work was supported by grants from the National Natural Science Foundation of China (grant numbers 81572937, 81572273, and 81772500); the16th batch "Summit of the Six Top Talents" Program of Jiangsu Province (grant number WSN-154); China Postdoctoral Science Foundation 12th batch Special fund (Postdoctoral number: 45786); China Postdoctoral Science Foundation 64th batch (Postdoctoral number: 45786); Jiangsu Provincial Postdoctoral Science Foundation (grant number 2018K049A); the Natural Science Foundation of Jiangsu province (grant numbers BK20180139 and BK20161386); Jiangsu Provincial Medical Youth Talent (grant number QNRC2016125), and the Nanjing Medical Science and Technology Development Project (No. ZKX17044), the Jiangsu Provincial Key Research and Development Program (No. BE2016721).	Behari J, 2014, AM J PATHOL, V184, P3284, DOI 10.1016/j.ajpath.2014.08.022; Bergethon K, 2012, J CLIN ONCOL, V30, P863, DOI 10.1200/JCO.2011.35.6345; Chen WQ, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2014.04.05; Cormerais Y, 2018, J BIOL CHEM, V293, P2877, DOI 10.1074/jbc.RA117.001342; Cormerais Y, 2016, CANCER RES, V76, P4481, DOI 10.1158/0008-5472.CAN-15-3376; Dato S, 2019, BIOGERONTOLOGY, V20, P17, DOI 10.1007/s10522-018-9770-8; Dissanayake SK, 2007, J BIOL CHEM, V282, P17259, DOI 10.1074/jbc.M700075200; Ghosh S, 2008, DEV GROWTH DIFFER, V50, P289, DOI [10.1111/j.1440-169x.2008.01000.x, 10.1111/j.1440-169X.2008.01000.x]; Giroux-Leprieur E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092835; Grant SFA, 2006, NAT GENET, V38, P320, DOI 10.1038/ng1732; HABAS R, 2005, J BIOL LONDON, V4; Hou J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010312; Kanazawa A, 2004, AM J HUM GENET, V75, P832, DOI 10.1086/425340; Komiya Yuko, 2008, Organogenesis, V4, P68; Krishnamurthy N, 2018, CANCER TREAT REV, V62, P50, DOI 10.1016/j.ctrv.2017.11.002; Lu TP, 2010, CANCER EPIDEM BIOMAR, V19, P2590, DOI 10.1158/1055-9965.EPI-10-0332; Mani A, 2007, SCIENCE, V315, P1278, DOI 10.1126/science.1136370; Niu XC, 2015, CELL PHYSIOL BIOCHEM, V37, P1527, DOI 10.1159/000438520; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Ozeki N, 2014, EXP CELL RES, V328, P69, DOI 10.1016/j.yexcr.2014.05.006; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Rapp J, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0650-6; Rydell-Tormanen K, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.12727; Sherwood V, 2015, MOL CELL BIOL, V35, P2, DOI 10.1128/MCB.00992-14; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Skronska-Wasek W, 2018, PHARMACOL THERAPEUT, V187, P150, DOI 10.1016/j.pharmthera.2018.02.009; Spanjer AIR, 2016, FASEB J, V30, P1823, DOI 10.1096/fj.201500129; Stewart DJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt356; Tian J, 2014, TUMOR BIOL, V35, P9439, DOI 10.1007/s13277-014-2433-8; van Dijk EM, 2016, AM J PHYSIOL-LUNG C, V310, pL1166, DOI 10.1152/ajplung.00226.2015; Wang QY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015479; Wang SH, 2017, ONCOGENE, V36, P1503, DOI 10.1038/onc.2016.317; Watanabe K, 2011, P NATL ACAD SCI USA, V108, P5929, DOI 10.1073/pnas.1103102108; Weyandt Jamie D, 2017, Am Soc Clin Oncol Educ Book, V37, P825, DOI 10.14694/EDBK_175561; Xi SC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013764; Xu XD, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-373; Yuan X, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0087-z; Zhan P, 2017, J CELL MOL MED, V21, P665, DOI 10.1111/jcmm.13010; Zhang Q, 2018, BIOMED PHARMACOTHER, V105, P204, DOI 10.1016/j.biopha.2018.05.074; Zhang Q, 2018, J CELL MOL MED, V22, P3560, DOI 10.1111/jcmm.13634; Zhang Q, 2014, PHARMACOL RES, V84, P32, DOI 10.1016/j.phrs.2014.04.009	42	14	13	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1484	1497		10.1038/s41388-019-1071-4	http://dx.doi.org/10.1038/s41388-019-1071-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31666682				2022-12-17	WOS:000513289600007
J	Ji, JX; Ding, KK; Luo, T; Xu, R; Zhang, X; Huang, B; Chen, AJ; Zhang, D; Miletic, H; Bjerkvig, R; Thorsen, F; Wang, J; Li, XG				Ji, Jianxiong; Ding, Kaikai; Luo, Tao; Xu, Ran; Zhang, Xin; Huang, Bin; Chen, Anjing; Zhang, Di; Miletic, Hrvoje; Bjerkvig, Rolf; Thorsen, Frits; Wang, Jian; Li, Xingang			PMEPA1 isoform a drives progression of glioblastoma by promoting protein degradation of the Hippo pathway kinase LATS1	ONCOGENE			English	Article							NEDD4-BINDING PROTEIN; DECREASED EXPRESSION; TGF-BETA; INVASION; GENE; YAP; PHOSPHORYLATION; HOMEOSTASIS; SUPPRESSES; CELLS	The Hippo signaling pathway controls organ development and is also known, in cancer, to have a tumor suppressing role. Within the Hippo pathway, we here demonstrate, in human gliomas, a functional interaction of a transmembrane protein, prostate transmembrane protein, androgen induced 1 (PMEPA1) with large tumor suppressor kinase 1 (LATS1). We show that PMEPA1 is upregulated in primary human gliomas. The PMEPA1 isoform PMEPA1a was predominantly expressed in glioma specimens and cell lines, and ectopic expression of the protein promoted glioma growth and invasion in vitro and in an orthotopic xenograft model in nude mice. In co-immunoprecipitation experiments, PMEPA1a associated with the Hippo tumor suppressor kinase LATS1. This interaction led to a proteasomal degradation of LATS1 through recruitment of the ubiquitin ligase, neural precursor cell expressed, developmentally downregulated 4 (NEDD4), which led to silencing of Hippo signaling. Alanine substitution in PMEPA1a at PY motifs resulted in failed LATS1 degradation. Targeting of a downstream component in the Hippo signaling pathway, YAP, with shRNA, interfered with the growth promoting activities of PMEPA1a in vitro and in vivo. In conclusion, the presented work shows that PMEPA1a contributes to glioma progression by a dysregulation of the Hippo signaling pathway and thus represents a promising target for the treatment of gliomas.	[Ji, Jianxiong; Ding, Kaikai; Luo, Tao; Xu, Ran; Zhang, Xin; Huang, Bin; Chen, Anjing; Zhang, Di; Thorsen, Frits; Wang, Jian; Li, Xingang] Shandong Univ, Qilu Hosp, Dept Neurosurg, Jinan, Peoples R China; [Ji, Jianxiong; Ding, Kaikai; Luo, Tao; Xu, Ran; Zhang, Xin; Huang, Bin; Chen, Anjing; Zhang, Di; Thorsen, Frits; Wang, Jian; Li, Xingang] Shandong Univ, Inst Brain & Brain Inspired Sci, Jinan, Peoples R China; [Ji, Jianxiong; Ding, Kaikai; Luo, Tao; Xu, Ran; Zhang, Xin; Huang, Bin; Chen, Anjing; Zhang, Di; Thorsen, Frits; Wang, Jian; Li, Xingang] Shandong Key Lab Brain Funct Remodeling, Jinan, Peoples R China; [Chen, Anjing] Shandong Univ, Sch Med, Jinan, Peoples R China; [Miletic, Hrvoje; Bjerkvig, Rolf; Thorsen, Frits; Wang, Jian] Univ Bergen, Dept Biomed, Jonas Lies Vei 91, N-5009 Bergen, Norway; [Miletic, Hrvoje] Haukeland Hosp, Dept Pathol, Jonas Lies Vei 65, N-5021 Bergen, Norway; [Bjerkvig, Rolf] Luxembourg Inst Hlth, Dept Oncol, 84 Val Fleuri, L-1526 Luxembourg, Luxembourg; [Thorsen, Frits] Univ Bergen, Mol Imaging Ctr, Dept Biomed, Jonas Lies Vei 91, N-5009 Bergen, Norway	Shandong University; Shandong University; Shandong University; University of Bergen; University of Bergen; Haukeland University Hospital; Luxembourg Institute of Health; University of Bergen	Wang, J; Li, XG (corresponding author), Shandong Univ, Qilu Hosp, Dept Neurosurg, Jinan, Peoples R China.; Wang, J; Li, XG (corresponding author), Shandong Univ, Inst Brain & Brain Inspired Sci, Jinan, Peoples R China.; Wang, J; Li, XG (corresponding author), Shandong Key Lab Brain Funct Remodeling, Jinan, Peoples R China.; Wang, J (corresponding author), Univ Bergen, Dept Biomed, Jonas Lies Vei 91, N-5009 Bergen, Norway.	jian.wang@uib.no; lixg@sdu.edu.cn	Chen, Anjing/GYE-2355-2022; Huang, Bin/AAT-4514-2021	Thorsen, Frits/0000-0002-7762-3703	National Natural Science Foundation of China [81701329, 81702474]; Department of Science & Technology of Shandong Province [2017CXGC1502, 2017CXGC1504, 2018GSF118082]; Special Foundation for Taishan Scholars [ts20110814, tshw201502056, tsqn20161067]; Shandong Provincial Natural Science Foundation [ZR2017MH116, ZR2017MH015]; China Postdoctoral Science Foundation [2018M642666]; Jinan Science and Technology Bureau of Shandong Province [201704096]; Norwegian Research Council; Nowegian Cancer Society; Helse-Vest, Haukeland University Hospital	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Department of Science & Technology of Shandong Province; Special Foundation for Taishan Scholars; Shandong Provincial Natural Science Foundation(Natural Science Foundation of Shandong Province); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Jinan Science and Technology Bureau of Shandong Province; Norwegian Research Council(Research Council of NorwayEuropean Commission); Nowegian Cancer Society; Helse-Vest, Haukeland University Hospital	We thank Dr Mengmeng Jin for helping edit the paper. This work was supported by the National Natural Science Foundation of China (81701329 and 81702474), the Department of Science & Technology of Shandong Province (2017CXGC1502, 2017CXGC1504 and 2018GSF118082), the Special Foundation for Taishan Scholars (ts20110814, tshw201502056 and tsqn20161067), the Shandong Provincial Natural Science Foundation (ZR2017MH116 and ZR2017MH015), the China Postdoctoral Science Foundation (2018M642666), the Jinan Science and Technology Bureau of Shandong Province (201704096), and the Norwegian Research Council, The Nowegian Cancer Society and Helse-Vest, Haukeland University Hospital.	Anazawa Y, 2004, ONCOGENE, V23, P7621, DOI 10.1038/sj.onc.1207270; Arif T, 2017, NEURO-ONCOLOGY, V19, P951, DOI 10.1093/neuonc/now297; Bae SJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7314; Brunschwig EB, 2003, CANCER RES, V63, P1568; Cheng CY, 2014, J NEURO-ONCOL, V120, P273, DOI 10.1007/s11060-014-1558-3; Du YY, 2018, J BIOL CHEM, V293, P5847, DOI 10.1074/jbc.RA117.000972; Fournier PGJ, 2015, CANCER CELL, V27, P809, DOI 10.1016/j.ccell.2015.04.009; Giannini G, 2003, MOL CARCINOGEN, V38, P188, DOI 10.1002/mc.10162; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Ho KC, 2016, P NATL ACAD SCI USA, V113, pE5776, DOI 10.1073/pnas.1613909113; Hu Y, 2013, CARCINOGENESIS, V34, P1764, DOI 10.1093/carcin/bgt132; Ji JX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0548-3; Ji TH, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-67; Jiang Z, 2006, NEUROSCI RES, V56, P450, DOI 10.1016/j.neures.2006.09.006; Keunen O, 2011, P NATL ACAD SCI USA, V108, P3749, DOI 10.1073/pnas.1014480108; Koido M, 2016, BIOCHEM BIOPH RES CO, V479, P615, DOI 10.1016/j.bbrc.2016.09.166; Li HY, 2008, J BIOL CHEM, V283, P28988, DOI 10.1074/jbc.M710528200; Liu CY, 2010, J BIOL CHEM, V285, P37159, DOI 10.1074/jbc.M110.152942; Ma B, 2015, NAT CELL BIOL, V17, P95, DOI 10.1038/ncb3073; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; Oh H, 2009, ONCOGENE, V28, P1916, DOI 10.1038/onc.2009.43; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Persaud A, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005290; Rae FK, 2001, MOL CARCINOGEN, V32, P44, DOI 10.1002/mc.1063; Salah Z, 2013, CELL CYCLE, V12, P3817, DOI 10.4161/cc.26672; Singha Prajjal K, 2014, Genes Cancer, V5, P320; Varelas X, 2014, DEVELOPMENT, V141, P1614, DOI 10.1242/dev.102376; Wang CJ, 2012, BIOCHEM J, V444, P279, DOI 10.1042/BJ20111983; Xu LL, 2003, CANCER RES, V63, P4299; Xu LL, 2000, GENOMICS, V70, P407, DOI 10.1006/geno.2000.6458; Xu R, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0665-3; Yeung B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061027; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhang H, 2016, TUMOR BIOL, V37, P11321, DOI 10.1007/s13277-016-4995-0; Zhang X, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1451-5; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810	37	14	15	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					1125	1139		10.1038/s41388-019-1050-9	http://dx.doi.org/10.1038/s41388-019-1050-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31605013	Green Published, hybrid			2022-12-17	WOS:000511209700013
J	Shi, HC; Sun, Y; He, M; Yang, X; Hamada, M; Fukunaga, T; Zhang, XP; Chang, CS				Shi, Hangchuan; Sun, Yin; He, Miao; Yang, Xiong; Hamada, Michiaki; Fukunaga, Tsukasa; Zhang, Xiaoping; Chang, Chawnshang			Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression	ONCOGENE			English	Article							RENAL-CELL CARCINOMA; TRANS-RETINOIC ACID; ACUTE PROMYELOCYTIC LEUKEMIA; IN-VITRO; GENE-EXPRESSION; TUMOR-CELLS; CANCER; METFORMIN; THERAPY; RESISTANCE	Renal cell carcinoma (RCC) is one of the most lethal urological tumors. Using sunitinib to improve the survival has become the first-line therapy for metastatic RCC patients. However, the occurrence of sunitinib resistance in the clinical application has curtailed its efficacy. Here we found TR4 nuclear receptor might alter the sunitinib resistance to RCC via altering the TR4/lncTASR/AXL signaling. Mechanism dissection revealed that TR4 could modulate lncTASR (ENST00000600671.1) expression via transcriptional regulation, which might then increase AXL protein expression via enhancing the stability of AXL mRNA to increase the sunitinib resistance in RCC. Human clinical surveys also linked the expression of TR4, lncTASR, and AXL to the RCC survival, and results from multiple RCC cell lines revealed that targeting this newly identified TR4-mediated signaling with small molecules, including tretinoin, metformin, or TR4-shRNAs, all led to increase the sunitinib sensitivity to better suppress the RCC progression, and our preclinical study using the in vivo mouse model further proved tretinoin had a better synergistic effect to increase sunitinib sensitivity to suppress RCC progression. Future successful clinical trials may help in the development of a novel therapy to better suppress the RCC progression.	[Shi, Hangchuan; Yang, Xiong; Zhang, Xiaoping] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Urol, Wuhan 430022, Peoples R China; [Shi, Hangchuan; Sun, Yin; He, Miao; Yang, Xiong; Chang, Chawnshang] Univ Rochester, Wilmot Canc Inst, Radiat Oncol, Med Ctr, Rochester, NY 14642 USA; [Hamada, Michiaki; Fukunaga, Tsukasa] Waseda Univ, Fac Sci & Engn, Tokyo 1698555, Japan; [Chang, Chawnshang] China Med Univ Hosp, Sex Hormone Res Ctr, Taichung 404, Taiwan; [Chang, Chawnshang] China Med Univ Hosp, Dept Urol, Taichung 404, Taiwan; [Hamada, Michiaki] Natl Inst Adv Ind Sci & Technol, Computat Bio Big Data Open Innovat Lab CBBD OIL, Tokyo 1698555, Japan	Huazhong University of Science & Technology; University of Rochester; Waseda University; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; National Institute of Advanced Industrial Science & Technology (AIST)	Zhang, XP (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Urol, Wuhan 430022, Peoples R China.; Chang, CS (corresponding author), Univ Rochester, Wilmot Canc Inst, Radiat Oncol, Med Ctr, Rochester, NY 14642 USA.; Chang, CS (corresponding author), China Med Univ Hosp, Sex Hormone Res Ctr, Taichung 404, Taiwan.; Chang, CS (corresponding author), China Med Univ Hosp, Dept Urol, Taichung 404, Taiwan.	xzhang@hust.edu.cn; chang@urmc.rochester.edu	Shi, Hangchuan/GWV-5076-2022; Shi, Hangchuan/J-2637-2014; Hamada, Michiaki/L-9371-2018	Shi, Hangchuan/0000-0001-6269-742X; Chang, Chawnshang/0000-0001-8510-3516; Hamada, Michiaki/0000-0001-9466-1034	NIH [CA156700]; George Whipple Professorship Endowment; Taiwan Department of Health Clinical Trial and Research Center of Excellence [MOHW104-TDU-B-212-113002]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); George Whipple Professorship Endowment; Taiwan Department of Health Clinical Trial and Research Center of Excellence	We thank Karen Wolf for help with manuscript preparation. This work was supported by NIH grant (CA156700), George Whipple Professorship Endowment and Taiwan Department of Health Clinical Trial and Research Center of Excellence (MOHW104-TDU-B-212-113002) to China Medical University, Taichung, Taiwan). Computations were partially performed on the NIG supercomputer at ROIS National Institute of Genetics.	Adelaiye-Ogala R, 2018, CANCER RES, V78, P2886, DOI 10.1158/0008-5472.CAN-17-3386; Bai J, 2018, ONCOGENE, V37, P5901, DOI 10.1038/s41388-018-0269-1; Baldewijns MML, 2008, BBA-REV CANCER, V1785, P133, DOI 10.1016/j.bbcan.2007.12.002; Benson MJ, 2007, J EXP MED, V204, P1765, DOI 10.1084/jem.20070719; Busch J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-295; Chae YK, 2016, ONCOTARGET, V7, P40767, DOI 10.18632/oncotarget.8194; Chandel NS, 2016, CELL METAB, V23, P569, DOI 10.1016/j.cmet.2016.03.010; Chen WF, 2016, NATURE, V539, P112, DOI 10.1038/nature19796; Chen XY, 2014, CLIN CANCER RES, V20, P2617, DOI 10.1158/1078-0432.CCR-13-3224; Choueiri TK, 2018, EUR J CANCER, V94, P115, DOI 10.1016/j.ejca.2018.02.012; Coppin C, 2011, BJU INT, V108, P1556, DOI 10.1111/j.1464-410X.2011.10629.x; Ding XF, 2015, MOL CANCER, V14, DOI 10.1186/s12943-014-0281-1; Ellis L, 2012, MOL CANCER THER, V11, P383, DOI 10.1158/1535-7163.MCT-11-0748; Faivre S, 2007, NAT REV DRUG DISCOV, V6, P734, DOI 10.1038/nrd2380; Froushani SMA, 2014, IRAN J BASIC MED SCI, V17, P632; Fukunaga T, 2017, BIOINFORMATICS, V33, P2666, DOI 10.1093/bioinformatics/btx287; Gilkes DM, 2014, NAT REV CANCER, V14, P430, DOI 10.1038/nrc3726; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Huang D, 2010, CANCER RES, V70, P1053, DOI 10.1158/0008-5472.CAN-09-3722; Jin RA, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0287-5; Jing YK, 2001, BLOOD, V97, P264, DOI 10.1182/blood.V97.1.264; Joosten SC, 2015, BBA-REV CANCER, V1855, P1, DOI 10.1016/j.bbcan.2014.11.002; Kasznicki J, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2014.06.01; Kim E, 2011, DIABETES, V60, P1493, DOI 10.2337/db10-0393; Kordes S, 2015, LANCET ONCOL, V16, P839, DOI 10.1016/S1470-2045(15)00027-3; Li B, 2015, EUR J PHARMACOL, V749, P107, DOI 10.1016/j.ejphar.2015.01.009; Liu J, 2013, UROL ONCOL-SEMIN ORI, V31, P264, DOI 10.1016/j.urolonc.2011.01.003; Liu L, 2009, CANCER RES, V69, P6871, DOI 10.1158/0008-5472.CAN-08-4490; Liu QL, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.417; Liu S, 2014, ENDOCR-RELAT CANCER, V21, pR279, DOI 10.1530/ERC-13-0529; Liu XZ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.197; Lorenzen JM, 2016, NAT REV NEPHROL, V12, P360, DOI 10.1038/nrneph.2016.51; Lou N, 2017, UROL ONCOL-SEMIN ORI, V35, DOI 10.1016/j.urolonc.2016.07.012; Mahadevan D, 2007, ONCOGENE, V26, P3909, DOI 10.1038/sj.onc.1210173; Mei D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182835; Motzer RJ, 2009, J CLIN ONCOL, V27, P3584, DOI 10.1200/JCO.2008.20.1293; Pawlyk AC, 2014, DIABETES, V63, P2590, DOI 10.2337/db13-1367; Qu L, 2016, CANCER CELL, V29, P653, DOI 10.1016/j.ccell.2016.03.004; Rho JK, 2014, CANCER RES, V74, P253, DOI 10.1158/0008-5472.CAN-13-1103; Rini BI, 2009, LANCET ONCOL, V10, P992, DOI 10.1016/S1470-2045(09)70240-2; Schodel J, 2016, EUR UROL, V69, P646, DOI 10.1016/j.eururo.2015.08.007; Seo GY, 2017, CELL IMMUNOL, V322, P49, DOI 10.1016/j.cellimm.2017.10.001; Shalita A, 1996, J AM ACAD DERMATOL, V34, P482, DOI 10.1016/S0190-9622(96)90443-0; Shen JL, 2016, ONCOTARGET, V7, P32088, DOI 10.18632/oncotarget.8525; Shojaei F, 2010, CANCER RES, V70, P10090, DOI 10.1158/0008-5472.CAN-10-0489; Staehler M, 2005, CURR DRUG TARGETS, V6, P835, DOI 10.2174/138945005774574498; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tannir NM, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912-017-0566-9; Terai G, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-015-2307-5; van der Mijn JC, 2016, INT J CANCER, V138, P3002, DOI 10.1002/ijc.30022; Wang MC, 2018, INT J CANCER, V143, P100, DOI 10.1002/ijc.31289; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; Weiss RH, 2018, SEMIN NEPHROL, V38, P175, DOI 10.1016/j.semnephrol.2018.01.006; Wheaton WW, 2014, ELIFE, V3, DOI 10.7554/eLife.02242; Yoon JH, 2012, MOL CELL, V47, P648, DOI 10.1016/j.molcel.2012.06.027; Yu SC, 2015, PROSTATE, V75, P1632, DOI 10.1002/pros.23044; Zhai W, 2017, CELL DEATH DIFFER, V24, P1502, DOI 10.1038/cdd.2017.74; Zhou L, 2016, ONCOGENE, V35, P2687, DOI 10.1038/onc.2015.343; Zhou XE, 2011, J BIOL CHEM, V286, P2877, DOI 10.1074/jbc.M110.168740	59	14	14	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					530	545		10.1038/s41388-019-0962-8	http://dx.doi.org/10.1038/s41388-019-0962-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31501521	Green Published, hybrid			2022-12-17	WOS:000509718300004
J	Tung, CH; Kuo, LW; Huang, MF; Wu, YY; Tsai, YT; Wu, JE; Hsu, KF; Chen, YL; Hong, TM				Tung, Chia-Hao; Kuo, Li-Wei; Huang, Meng-Fan; Wu, Yi-Ying; Tsai, Yao-Tsung; Wu, Jia-En; Hsu, Keng-Fu; Chen, Yuh-Ling; Hong, Tse-Ming			MicroRNA-150-5p promotes cell motility by inhibiting c-Myb-mediated Slug suppression and is a prognostic biomarker for recurrent ovarian cancer	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; MONOCLONAL-ANTIBODY; COLORECTAL-CANCER; EARLY RELAPSE; MIR-150; EXPRESSION; METASTASIS; INVASION; ACTIVATION; SIGNATURES	Treatment of ovarian cancer (OvCa) remains challenging owing to its high recurrence rates. Detachment of cancer cells into the peritoneal fluid plays a key role in OvCa relapse, but how this occurs remains incompletely understood. Here we examined global miRNA expression profiles of paired primary/recurrent OvCa specimens and identified a novel biomarker, microRNA-150-5p (miR-150-5p), that was significantly upregulated in 16 recurrent OvCa tissues compared with their matched primary specimens. Analyses of cohorts from two other groups confirmed that expression of miR-150-5p was associated with early relapse and poor survival of OvCa patients. Inhibition of miR-150-5p significantly inhibited the migration and invasion of OvCa cells and induced a mesenchymal-epithelial transition (MET) phenotype. We demonstrated that the proto-oncogene, MYB, is an miR-150-5p target in OvCa cells and that the miR-150-5p/c-Myb/Slug axis plays important roles in regulating epithelial-mesenchymal transition (EMT) in OvCa cells. Expression of MYB was significantly correlated with good clinical outcome in OvCa and was negatively correlated with Slug expression in late-stage clinical specimens. These results suggest that miR-150-5p upregulation mediates the progression of recurrent OvCa by targeting the c-Myb/Slug pathway. Inhibition of miR-150-5p may serve as a new therapeutic strategy for preventing recurrence of OvCa.	[Tung, Chia-Hao; Tsai, Yao-Tsung; Wu, Jia-En] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan, Taiwan; [Kuo, Li-Wei; Huang, Meng-Fan; Hsu, Keng-Fu; Hong, Tse-Ming] Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan, Taiwan; [Wu, Yi-Ying; Hong, Tse-Ming] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Clin Med Res Ctr, Tainan, Taiwan; [Hsu, Keng-Fu] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Obstet & Gynecol, Tainan, Taiwan; [Chen, Yuh-Ling] Natl Cheng Kung Univ, Coll Med, Inst Oral Med, Tainan, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University	Hong, TM (corresponding author), Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan, Taiwan.; Hong, TM (corresponding author), Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Clin Med Res Ctr, Tainan, Taiwan.; Chen, YL (corresponding author), Natl Cheng Kung Univ, Coll Med, Inst Oral Med, Tainan, Taiwan.	yuhling@mail.ncku.edu.tw; tmhong@mail.ncku.edu.tw	Tung, Chia-Hao/AAI-7923-2020; Chen, Yuh-Ling/AAS-7957-2021	Huang, Meng-Fan/0000-0001-5113-1746; Tung, Chia-Hao/0000-0001-5638-4216; Kuo, Li-Wei/0000-0002-1135-8740	Ministry of Science and Technology, Taiwan [MOST 107-2314-B-006-068-MY3, MOST 108-2314-B-006-004, MOST 108-2321-B-006-010, MOST 106-2314-B-006-015-MY2]	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, TaiwanMinistry of Science, ICT & Future Planning, Republic of Korea)	We are grateful for providing the services from the RNAi Core Lab, Research Center of Clinical Medicine, National Cheng Kung University Hospital, Taiwan. RNAi reagents were obtained from the National RNAi Core Facility located at the Institute of Molecular Biology/Genomic Research Center, Academia Sinica, Taiwan. This study was supported by grants MOST 107-2314-B-006-068-MY3, MOST 108-2314-B-006-004, MOST 108-2321-B-006-010, and MOST 106-2314-B-006-015-MY2 from the Ministry of Science and Technology, Taiwan.	Bagnoli M, 2016, LANCET ONCOL, V17, P1137, DOI 10.1016/S1470-2045(16)30108-5; Bagnoli M, 2011, ONCOTARGET, V2, P1265, DOI 10.18632/oncotarget.401; BAST RC, 1983, NEW ENGL J MED, V309, P883, DOI 10.1056/NEJM198310133091503; BENARD J, 1985, CANCER RES, V45, P4970; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bureau of Health Promotion DoH, 2018, CANC REG ANN REP 201; CAMP RL, 2004, CLIN CANCER RES, V10, P7252, DOI [10.1158/1078-0432.CCR-04-0713, DOI 10.1158/1078-0432.CCR-04-0713]; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Chan CK, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.160275; Cordero Alexis B, 2010, J Vis Exp, DOI 10.3791/2125; Cormio G, 2003, INT J GYNECOL CANCER, V13, P125, DOI 10.1046/j.1525-1438.2003.13054.x; Davidson B, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00033; Dong Peixin, 2018, Oncotarget, V9, P23253, DOI 10.18632/oncotarget.25298; Feng JL, 2014, J CELL MOL MED, V18, P2125, DOI 10.1111/jcmm.12398; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; Goonewardene TI, 2007, LANCET ONCOL, V8, P813, DOI 10.1016/S1470-2045(07)70273-5; Gunaje JJ, 2011, AM J PHYSIOL-CELL PH, V301, pC478, DOI 10.1152/ajpcell.00348.2010; Guo YH, 2016, ONCOTARGET, V7, P42513, DOI 10.18632/oncotarget.9893; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hsu IL, 2016, ONCOTARGET, V7, P62925, DOI 10.18632/oncotarget.7497; Huntzinger E, 2011, NAT REV GENET, V12, P99, DOI 10.1038/nrg2936; Jayson GC, 2014, LANCET, V384, P1376, DOI 10.1016/S0140-6736(13)62146-7; Jia LY, 2016, ONCOTARGET, V7, P36743, DOI 10.18632/oncotarget.9163; Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626; Karlan BY, 2014, GYNECOL ONCOL, V132, P334, DOI 10.1016/j.ygyno.2013.12.021; Konecny GE, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju249; Kurrey NK, 2005, GYNECOL ONCOL, V97, P155, DOI 10.1016/j.ygyno.2004.12.043; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Li GM, 2008, CELL RES, V18, P1, DOI 10.1038/cr.2008.9; Li H, 2016, SCI REP-UK, V6, DOI 10.1038/srep39001; Lin YC, 2008, MOL BIOL EVOL, V25, P2189, DOI 10.1093/molbev/msn165; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888; MAINGUENE C, 1986, J NUCL MED ALLIED S, V30, P19; Mateescu B, 2011, NAT MED, V17, P1627, DOI 10.1038/nm.2512; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611; Narod S, 2016, NAT REV CLIN ONCOL, V13, P255, DOI 10.1038/nrclinonc.2015.224; NOSEDA A, 1987, LIPIDS, V22, P878, DOI 10.1007/BF02535548; Peng Y, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2015.4; Pradeep S, 2014, CANCER CELL, V26, P77, DOI 10.1016/j.ccr.2014.05.002; Shih KK, 2011, GYNECOL ONCOL, V121, P444, DOI 10.1016/j.ygyno.2011.01.025; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smith BN, 2016, J CLIN MED, V5, DOI 10.3390/jcm5020017; Smolle E, 2014, ANTICANCER RES, V34, P1553; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun Y, 2015, J PATHOL, V235, P25, DOI 10.1002/path.4443; Theriault BL, 2007, CARCINOGENESIS, V28, P1153, DOI 10.1093/carcin/bgm015; Torre LA, 2018, CA-CANCER J CLIN, V68, P284, DOI 10.3322/caac.21456; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Vang S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058226; Vergara D, 2010, CANCER LETT, V291, P59, DOI 10.1016/j.canlet.2009.09.017; Verhaak RGW, 2013, J CLIN INVEST, V123, P517, DOI 10.1172/JCI65833; Wang F, 2015, ONCOL LETT, V10, P11, DOI 10.3892/ol.2015.3170; Wang F, 2018, PEERJ, V6, DOI 10.7717/peerj.5912; Wang WH, 2014, ASIAN PAC J CANCER P, V15, P6269, DOI 10.7314/APJCP.2014.15.15.6269; Wang Y, 2012, ONCOGENE, V31, P2512, DOI 10.1038/onc.2011.435; Xiao CC, 2007, CELL, V131, P146, DOI 10.1016/j.cell.2007.07.021; Xu L, 2017, NEOPLASIA, V19, P374, DOI 10.1016/j.neo.2017.01.011; Yang D, 2013, CANCER CELL, V23, P186, DOI 10.1016/j.ccr.2012.12.020; Zhang HY, 2017, GENE, V633, P61, DOI 10.1016/j.gene.2017.08.009; Zhang J, 2012, INT J ONCOL, V40, P747, DOI 10.3892/ijo.2011.1242; Zhang YJ, 2010, MOL CELL, V39, P133, DOI 10.1016/j.molcel.2010.06.010; Zhao LJ, 2019, ONCOGENE, V38, P2305, DOI 10.1038/s41388-018-0577-5	66	14	15	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					862	876		10.1038/s41388-019-1025-x	http://dx.doi.org/10.1038/s41388-019-1025-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31570789				2022-12-17	WOS:000509197200009
J	Sheng, YH; Wong, KY; Seim, I; Wang, R; He, YW; Wu, A; Patrick, M; Lourie, R; Schreiber, V; Giri, R; Ng, CP; Popat, A; Hooper, J; Kijanka, G; Florin, TH; Begun, J; Radford, KJ; Hasnain, S; McGuckin, MA				Sheng, Yong Hua; Wong, Kuan Yau; Seim, Inge; Wang, Ran; He, Yaowu; Wu, Andy; Patrick, Maya; Lourie, Rohan; Schreiber, Veronika; Giri, Rabina; Ng, Choa Ping; Popat, Amirali; Hooper, John; Kijanka, Gregor; Florin, Timothy H.; Begun, Jakob; Radford, Kristen J.; Hasnain, Sumaira; McGuckin, Michael A.			MUC13 promotes the development of colitis-associated colorectal tumors via beta-catenin activity	ONCOGENE			English	Article							CELL-SURFACE MUCIN; SUPPRESSOR-CELLS; DENDRITIC CELLS; MUCOSAL BARRIER; STEM-CELLS; COLON; INFLAMMATION; RESPONSES; PATHWAY; OVEREXPRESSION	Many adenocarcinomas, including colorectal cancer (CRC), overexpress the MUC13 cell surface mucin, but the functional significance and mechanisms are unknown. Here, we report the roles of MUC13 in colonic tumorigenesis and tumor progression. High-MUC13 expression is associated with poor survival in two independent patient cohorts. In a comprehensive series of in vivo experiments, we identified a critical role for MUC13 in the development of this malignancy, by promoting survival and proliferation of tumor-initiating cells and driving an immunosuppressive environment that protects tumors from checkpoint inhibitor immunotherapy. In Muc13-deficient mice, fewer tumors are generated after exposure to carcinogens and inflammation, they have markedly reduced beta-catenin signaling, have more tumor-infiltrating CD103(+) dendritic cells and CD8(+) T lymphocytes, fewer myeloid-derived suppressor cells, and are rendered sensitive to checkpoint inhibitor immunotherapy (anti-PD-L1). Mechanistically, we show that MUC13 protects beta-catenin from degradation, by interacting with GSK-3 beta, which increases beta-catenin nuclear translocation and promotes its signaling, thereby driving cancer initiation, progression, invasion, and immune suppression. Therefore, MUC13 is a potential marker of poor prognosis in colorectal cancer, and inhibiting MUC13 may be useful in the treatment of colitis-associated cancer and sensitizing tumors to immunotherapy.	[Sheng, Yong Hua; Wong, Kuan Yau; Seim, Inge; Wang, Ran; Patrick, Maya; Lourie, Rohan; Ng, Choa Ping; Popat, Amirali; Hasnain, Sumaira; McGuckin, Michael A.] Univ Queensland, Translat Res Inst, Mater Res Inst, Inflammatory Dis Biol & Therapeut Grp, Brisbane, Qld 4102, Australia; [Seim, Inge] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Translat Res Inst, Comparat & Endocrine Biol Lab, Brisbane, Qld 4012, Australia; [Seim, Inge] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Translat Res Inst, Ghrelin Res Grp, Brisbane, Qld 4102, Australia; [Seim, Inge] Nanjing Normal Univ, Coll Life Sci, Integrat Biol Lab, Nanjing 210023, Jiangsu, Peoples R China; [He, Yaowu; Hooper, John] Univ Queensland, Mater Res Inst, Canc Biol Grp, Brisbane, Qld 4101, Australia; [Wu, Andy] Univ Queensland, Translat Res Inst, Mater Res Inst, Bones & Immunol Grp, Brisbane, Qld 4102, Australia; [Lourie, Rohan; Schreiber, Veronika; Giri, Rabina; Florin, Timothy H.; Begun, Jakob] Univ Queensland, Translat Res Inst, Mater Res Inst, Inflammatory Bowel Dis Grp, Brisbane, Qld 4102, Australia; [Popat, Amirali] Univ Queensland, Sch Pharm, Brisbane, Qld 4072, Australia; [Kijanka, Gregor] Univ Queensland, Translat Res Inst, Mater Res Inst, Immune Profiling & Canc Grp, Brisbane, Qld 4102, Australia; [Radford, Kristen J.] Univ Queensland, Translat Res Inst, Mater Res Inst, Canc Immunotherapies Grp, Brisbane, Qld 4101, Australia; [McGuckin, Michael A.] Univ Melbourne, Fac Med Dent & Hlth Sci, Melbourne, Vic 3010, Australia	Mater Research; University of Queensland; Queensland University of Technology (QUT); Queensland University of Technology (QUT); Nanjing Normal University; Mater Research; University of Queensland; Mater Research; University of Queensland; Mater Research; University of Queensland; University of Queensland; Mater Research; University of Queensland; Mater Research; University of Queensland; University of Melbourne	Hasnain, S; McGuckin, MA (corresponding author), Univ Queensland, Translat Res Inst, Mater Res Inst, Inflammatory Dis Biol & Therapeut Grp, Brisbane, Qld 4102, Australia.; McGuckin, MA (corresponding author), Univ Melbourne, Fac Med Dent & Hlth Sci, Melbourne, Vic 3010, Australia.	sumaira.hasnain@mater.uq.edu.au; michael.mcguckin@unimelb.edu.au	Wang, Ran/AAP-1920-2020; Radford, Kristen J/B-5550-2011; Begun, Jakob/J-6793-2014; sheng, yong H/C-5052-2013; Hooper, John/C-1481-2016; Hasnain, Sumaira/N-3412-2014	Wang, Ran/0000-0002-1741-6446; Radford, Kristen J/0000-0001-6512-6323; Begun, Jakob/0000-0001-5256-7672; sheng, yong H/0000-0002-4623-9098; Giri, Rabina/0000-0002-6712-6076; Wu, Andy C/0000-0002-0864-4447; McGuckin, Michael/0000-0002-8375-2675; HE, Yaowu/0000-0002-7828-263X; Hooper, John/0000-0003-1054-8486; Hasnain, Sumaira/0000-0001-8577-8628; Schreiber, Veronika/0000-0001-6088-7828	NHMRC [1060698]; Mater Foundation; NHMRC; Betty McGrath/Mater Practitioner Research Fellowship; QUT Vice-Chancellor's Senior Research Fellowship; Australian Government	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Mater Foundation; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Betty McGrath/Mater Practitioner Research Fellowship; QUT Vice-Chancellor's Senior Research Fellowship; Australian Government(Australian GovernmentCGIAR)	Supported by NHMRC project grant 1060698 and funding by the Mater Foundation, MAM was supported by an NHMRC Principal Research Fellowship. RL was partly supported by a Betty McGrath/Mater Practitioner Research Fellowship. IS is supported by a QUT Vice-Chancellor's Senior Research Fellowship. The Translational Research Institute (TRI) is supported by a grant from the Australian Government.	Augustin I, 2016, STEM CELL RES, V17, P607, DOI 10.1016/j.scr.2016.10.010; Bedoui S, 2009, NAT IMMUNOL, V10, P488, DOI 10.1038/ni.1724; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Brabletz S, 2009, J PATHOL, V217, P307, DOI 10.1002/path.2475; Chauhan SC, 2012, MOL CANCER THER, V11, P24, DOI 10.1158/1535-7163.MCT-11-0598; Chauhan SC, 2009, CANCER RES, V69, P765, DOI 10.1158/0008-5472.CAN-08-0587; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Day FL, 2013, CLIN CANCER RES, V19, P3285, DOI 10.1158/1078-0432.CCR-12-3614; De Robertis Mariangela, 2011, J Carcinog, V10, P9, DOI 10.4103/1477-3163.78279; Fuertes MB, 2011, J EXP MED, V208, P2005, DOI 10.1084/jem.20101159; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gavert N, 2007, J CELL BIOCHEM, V102, P820, DOI 10.1002/jcb.21505; Goldman M, 2015, NUCLEIC ACIDS RES, V43, pD812, DOI 10.1093/nar/gku1073; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Gupta BK, 2014, J GASTROENTEROL, V49, P1378, DOI 10.1007/s00535-013-0885-z; Gupta BK, 2012, J HISTOCHEM CYTOCHEM, V60, P822, DOI 10.1369/0022155412460678; Hildner K, 2008, SCIENCE, V322, P1097, DOI 10.1126/science.1164206; Hong Y, 2015, CANCER RES, V75, P656, DOI 10.1158/0008-5472.CAN-14-2377; Jensen MA, 2017, BLOOD, V130, P453, DOI 10.1182/blood-2017-03-735654; Jonckheere N, 2014, BBA-REV CANCER, V1846, P142, DOI 10.1016/j.bbcan.2014.04.008; Katoh H, 2013, CANCER CELL, V24, P631, DOI 10.1016/j.ccr.2013.10.009; Khan S, 2017, ONCOGENE, V36, P491, DOI 10.1038/onc.2016.218; Khan S, 2014, ONCOTARGET, V5, P7599, DOI 10.18632/oncotarget.2281; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Linden SK, 2008, MUCOSAL IMMUNOL, V1, P183, DOI 10.1038/mi.2008.5; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; McAuley JL, 2007, J CLIN INVEST, V117, P2313, DOI 10.1172/JCI26705; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Najdi Rani, 2011, J Carcinog, V10, P5, DOI 10.4103/1477-3163.78111; Nath S, 2014, TRENDS MOL MED, V20, P332, DOI 10.1016/j.molmed.2014.02.007; Pai P, 2016, CARCINOGENESIS, V37, P223, DOI 10.1093/carcin/bgw005; Said AH, 2014, CANCERS, V6, P366, DOI 10.3390/cancers6010366; Salmon H, 2016, IMMUNITY, V44, P924, DOI 10.1016/j.immuni.2016.03.012; Schmierer B, 2007, NAT REV MOL CELL BIO, V8, P970, DOI 10.1038/nrm2297; Schneikert J, 2007, GUT, V56, P417, DOI 10.1136/gut.2006.093310; Sheng YH, 2017, ONCOGENE, V36, P700, DOI 10.1038/onc.2016.241; Sheng YH, 2013, MUCOSAL IMMUNOL, V6, P557, DOI 10.1038/mi.2012.98; Sheng YH, 2012, J GASTROEN HEPATOL, V27, P28, DOI 10.1111/j.1440-1746.2011.06909.x; Sheng YH, 2011, GUT, V60, P1661, DOI 10.1136/gut.2011.239194; Sheng YH, 2017, INT J CANCER, V140, P2351, DOI 10.1002/ijc.30651; Shimamura T, 2005, CANCER SCI, V96, P265, DOI 10.1111/j.1349-7006.2005.00043.x; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Spranger S, 2017, CANCER CELL, V31, P711, DOI 10.1016/j.ccell.2017.04.003; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Vilar E, 2010, NAT REV CLIN ONCOL, V7, P153, DOI 10.1038/nrclinonc.2009.237; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Walsh MD, 2007, HUM PATHOL, V38, P883, DOI 10.1016/j.humpath.2006.11.020; Williams SJ, 2001, J BIOL CHEM, V276, P18327, DOI 10.1074/jbc.M008850200; WITTY JP, 1994, CANCER RES, V54, P4805; Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791; Zauber AG, 2012, NEW ENGL J MED, V366, P687, DOI 10.1056/NEJMoa1100370; Zhi XF, 2014, CANCER LETT, V346, P104, DOI 10.1016/j.canlet.2013.12.021	54	14	14	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2019	38	48					7294	7310		10.1038/s41388-019-0951-y	http://dx.doi.org/10.1038/s41388-019-0951-y			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JR4XX	31427737	Green Submitted			2022-12-17	WOS:000499631000002
J	Li, Y; Li, WG; Zeng, XM; Tang, XM; Zhang, S; Zhong, FY; Peng, XN; Zhong, Y; Rosol, TJ; Deng, XY; Liu, ZH; Peng, SH; Peng, XN				Li, Yue; Li, Weiguo; Zeng, Xiaomin; Tang, Xuemei; Zhang, Shan; Zhong, Feiya; Peng, Xiangni; Zhong, Yang; Rosol, Thomas J.; Deng, Xiyun; Liu, Zhonghua; Peng, Sihua; Peng, Xiaoning			The role of microRNA-148a and downstream DLGAP1 on the molecular regulation and tumor progression on human glioblastoma	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CELL INVASION; PROTEIN; MIR-148A; POLARITY; MIGRATION; SURVIVAL; GROWTH; PROLIFERATION; TUMORIGENESIS	Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Currently, the prognosis of the patients with GBM is very poor and new molecular targets and treatment strategies are urgently needed to combat it. MicroRNA-148a (miR-148a) has been shown to be dysregulated in certain tumor types. However, the role of miR-148a in the pathogenesis of GBM is not fully understood. Here we comprehensively analyzed the roles of miR-148a, downstream DLGAP1, and their molecular pathways in GBM. We showed that miR-148a promote the proliferation and growth of GBM cells both in vitro and in vivo, and also induced the migration, invasion, and EMT (epithelial-mesenchymal transition) program of GBM cells by directly targeting DLGAP1. Furthermore, we identified 31 new miR-148a targets and found that miR-148a function was mainly involved in the cell adhesion signaling pathway and was associated with nervous system diseases. Our findings provide a new mechanism for miR-148a-mediated GBM cell invasion and reveal previously unreported targets of miR-148a as well as novel miR-148 a-mediated regulatory networks in GBM. These results increase the understanding of the role of miR-148a in GBM and may lead to novel therapeutic strategies for GBM.	[Li, Yue; Tang, Xuemei; Zhang, Shan; Deng, Xiyun; Peng, Xiaoning] Hunan Normal Univ, Dept Pathol & Pathophysiol, Sch Med, Changsha 410013, Hunan, Peoples R China; [Li, Yue] Xiangtan Cent Hosp, Dept Pathol, Xiangtan 411100, Peoples R China; [Li, Weiguo] Hunan Normal Univ, Coll Math & Comp Sci, Dept Stat, Changsha 410081, Hunan, Peoples R China; [Zeng, Xiaomin] Cent S Univ, Publ Hlth Sch, Dept Epidemiol & Hlth Stat, Changsha 410078, Hunan, Peoples R China; [Zhong, Feiya] Wuhan Univ, Coll Life Sci, Dept Genet, Wuhan 430072, Hubei, Peoples R China; [Peng, Xiangni; Zhong, Yang] Xiangtan Univ, Sch Math & Computat Sci, Dept Informat & Comp Sci, Xiangtan 411105, Peoples R China; [Rosol, Thomas J.] Ohio Univ, Heritage Coll Osteopath Med, Dept Biomed Sci, Athens, OH 45701 USA; [Liu, Zhonghua] Hunan Normal Univ, Coll Life Sci, Dept Biochem & Mol Biol, Changsha 410081, Hunan, Peoples R China; [Peng, Sihua] Shanghai Ocean Univ, Minist Educ, Key Lab Explorat & Utilizat Aquat Genet Resources, Shanghai 201306, Peoples R China; [Peng, Sihua] Minist Agr, Natl Pathogen Collect Ctr Aquat Anim, Shanghai 201306, Peoples R China; [Peng, Sihua] Shanghai Ocean Univ, Minist Sci & Technol, Int Res Ctr Marine Biosci, Shanghai 201306, Peoples R China; [Peng, Xiaoning] Jishou Univ, Dept Pathophysiol, Sch Med, Jishou 416000, Peoples R China	Hunan Normal University; Hunan Normal University; Central South University; Wuhan University; Xiangtan University; University System of Ohio; Ohio University; Hunan Normal University; Shanghai Ocean University; Ministry of Agriculture & Rural Affairs; Shanghai Ocean University; Jishou University	Peng, XN (corresponding author), Hunan Normal Univ, Dept Pathol & Pathophysiol, Sch Med, Changsha 410013, Hunan, Peoples R China.; Liu, ZH (corresponding author), Hunan Normal Univ, Coll Life Sci, Dept Biochem & Mol Biol, Changsha 410081, Hunan, Peoples R China.; Peng, SH (corresponding author), Shanghai Ocean Univ, Minist Educ, Key Lab Explorat & Utilizat Aquat Genet Resources, Shanghai 201306, Peoples R China.; Peng, SH (corresponding author), Minist Agr, Natl Pathogen Collect Ctr Aquat Anim, Shanghai 201306, Peoples R China.; Peng, SH (corresponding author), Shanghai Ocean Univ, Minist Sci & Technol, Int Res Ctr Marine Biosci, Shanghai 201306, Peoples R China.; Peng, XN (corresponding author), Jishou Univ, Dept Pathophysiol, Sch Med, Jishou 416000, Peoples R China.	liuzh@hunnu.edu.cn; shpeng@shou.edu.cn; pxiaoning@hunnu.edu.cn		weiguo, li/0000-0002-9345-580X; Rosol, Thomas/0000-0003-3737-1190	National Natural Science Foundation of China [81472860]; Construct Program of the Key Discipline of Basic Medicine in Hunan Normal University; Hunan Province	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Construct Program of the Key Discipline of Basic Medicine in Hunan Normal University; Hunan Province	This study was jointly supported by the National Natural Science Foundation of China (Grant Number 81472860) and the Construct Program of the Key Discipline of Basic Medicine in Hunan Normal University and Hunan Province.	Bethke L, 2008, CANCER EPIDEM BIOMAR, V17, P987, DOI 10.1158/1055-9965.EPI-07-2807; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Chen YL, 2017, ANTICANCER RES, V37, P781, DOI 10.21873/anticanres.11377; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cui DM, 2017, ONCOTARGET, V8, P25345, DOI 10.18632/oncotarget.15867; Elias MC, 2005, NEOPLASIA, V7, P824, DOI 10.1593/neo.04352; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; Han CL, 2008, MOL CELL PROTEOMICS, V7, P1983, DOI 10.1074/mcp.M800068-MCP200; Hatanpaa KJ, 2010, NEOPLASIA, V12, P675, DOI 10.1593/neo.10688; Hsu CW, 2008, PROTEOMICS, V8, P1975, DOI 10.1002/pmic.200701004; Hu CW, 2013, J PROTEOME RES, V12, P3993, DOI 10.1021/pr400302w; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang JR, 2017, ONCOL LETT, V14, P5386, DOI 10.3892/ol.2017.6844; Jin SG, 2016, AM J TRANSL RES, V8, P1826; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Karagkouni D, 2018, NUCLEIC ACIDS RES, V46, pD239, DOI 10.1093/nar/gkx1141; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim J, 2014, CANCER RES, V74, P1541, DOI 10.1158/0008-5472.CAN-13-1449; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Lee HK, 2008, NEURO-ONCOLOGY, V10, P236, DOI 10.1215/15228517-2008-006; Lee JK, 2014, ONCOTARGETS THER, V7, P1933, DOI 10.2147/OTT.S36582; Li Y, 2016, J CANCER, V7, P1233, DOI 10.7150/jca.14616; Liffers ST, 2011, LAB INVEST, V91, P1472, DOI 10.1038/labinvest.2011.99; Manneville JB, 2010, J CELL BIOL, V191, P585, DOI 10.1083/jcb.201002151; McCaffrey LM, 2012, CANCER CELL, V22, P601, DOI 10.1016/j.ccr.2012.10.003; Mittal V, 2018, ANNU REV PATHOL-MECH, V13, P395, DOI 10.1146/annurev-pathol-020117-043854; Ohgaki H, 2005, J NEUROPATH EXP NEUR, V64, P479, DOI 10.1093/jnen/64.6.479; Ohgaki Hiroko, 2009, V472, P323, DOI 10.1007/978-1-60327-492-0_14; Pearson HB, 2011, J CLIN INVEST, V121, P4257, DOI 10.1172/JCI58509; Piva R, 2002, MOL CELL BIOL, V22, P8375, DOI 10.1128/MCB.22.23.8375-8387.2002; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892; Qin Y, 2005, J CELL BIOL, V171, P1061, DOI 10.1083/jcb.200506094; Rennie W, 2016, RNA BIOL, V13, P554, DOI 10.1080/15476286.2016.1182279; Roth P, 2011, J NEUROCHEM, V118, P449, DOI 10.1111/j.1471-4159.2011.07307.x; Sanchez-Valle J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04400-6; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Sims JN, 2014, INT J ENV RES PUB HE, V11, P5006, DOI 10.3390/ijerph110505006; Skiriute D, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-218; Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Tso CL, 2006, MOL CANCER RES, V4, P607, DOI 10.1158/1541-7786.MCR-06-0005; Wang H, 2015, MOL CANCER, V14, DOI 10.1186/1476-4598-14-2; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Xiong JQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107272; Yu J, 2011, J BIOMED RES, V25, P170, DOI 10.1016/S1674-8301(11)60022-5; Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045; Zhang JP, 2014, ONCOGENE, V33, P4069, DOI 10.1038/onc.2013.369; Zheng BQ, 2011, CLIN CANCER RES, V17, P7574, DOI 10.1158/1078-0432.CCR-11-1714	51	14	14	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2019	38	47					7234	7248		10.1038/s41388-019-0922-3	http://dx.doi.org/10.1038/s41388-019-0922-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP0UL	31477833	hybrid			2022-12-17	WOS:000497989400004
J	Liao, SY; Kuo, IY; Chen, YT; Liao, PC; Liu, YF; Wu, HY; Lai, WW; Wang, YC				Liao, Sheng-You; Kuo, I-Ying; Chen, Yu-Ting; Liao, Pao-Chi; Liu, Ya-Fen; Wu, Hsin-Yi; Lai, Wu-Wei; Wang, Yi-Ching			AKT-mediated phosphorylation enhances protein stability and transcription activity of ZNF322A to promote lung cancer progression	ONCOGENE			English	Article							ZINC-FINGER PROTEIN; INHIBITOR; GROWTH; RECOGNITION; DEGRADATION; ACTIVATION; EXPRESSION; EFFICACY; PATHWAY; MK-2206	ZNF322A is an oncogenic zinc-finger transcription factor. Our published results show that ZNF322A positively regulates transcription of alpha-adducin (ADD1) and cyclin D1 (CCND1) to promote tumorgenicity of lung cancer. However, the upstream regulatory mechanisms of ZNF322A protein function remain elusive. Here, we demonstrate that AKT could phosphorylate ZNF322A by in vitro kinase assay and cell-based mass spectrometry analysis. Overexpression of AKT promoted ZNF322A protein stability and transcriptional activity, whereas these effects were inhibited by knockdown of AKT or treating with AKT inhibitor. We studied AKT-mediated phosphorylation sites, viz. Thr-150, Ser-224, Thr-234, and Thr-262. ZNF322A phosphorylation at Thr-262 by AKT promoted ZNF322A protein stability thus increased ADD1 promoter activity. Interestingly, phosphorylation at Thr-150, Ser-224, and Thr-234 enhanced transcription activity without affecting protein stability of ZNF322A. Chromatin immunoprecipitation and DNA affinity precipitation assays showed that ZNF322A phosphorylation defective mutants Thr-150A, Ser-224A, and Thr-234A attenuated chromatin binding and DNA binding affinity to ADD1 and CCNDI promoters compared with wild-type ZNF322A. Furthermore, AKT-mediated Thr-150, Ser-224, Thr-234, and Thr-262 phosphorylation promoted lung cancer cell growth and metastasis in vitro and in vivo. Clinically, expression of phosphorylated ZNF322A (p-ZNF) correlated with actively phosphorylated AKT (p-AKT) in tumor specimens from 150 lung cancer patients. Multivariate Cox regression analysis indicated that combined p-AKT and p-ZNF expression profile was an independent factor to predict the clinical outcome in lung cancer patients. Our results reveal a new mechanism of AKT signaling in promoting ZNF322A protein stability and transcriptional activity in lung cancer cell, xenograft, and clinical models.	[Liao, Sheng-You; Wang, Yi-Ching] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 70101, Taiwan; [Kuo, I-Ying; Chen, Yu-Ting; Liu, Ya-Fen; Wang, Yi-Ching] Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan; [Liao, Pao-Chi] Natl Cheng Kung Univ, Coll Med, Dept Environm & Occupat Hlth, Tainan 704, Taiwan; [Wu, Hsin-Yi] Natl Taiwan Univ, Instrumentat Ctr, Tainan 10617, Taiwan; [Lai, Wu-Wei] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Surg, Tainan 70101, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Taiwan University; National Cheng Kung University; National Cheng Kung University Hospital	Wang, YC (corresponding author), Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 70101, Taiwan.; Wang, YC (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan.	ycw5798@mail.ncku.edu.tw	Wang, Yi-Ching/J-8702-2019; , 賴吾為/T-8615-2019; Kuo, I-Ying/AAE-4741-2020	Wang, Yi-Ching/0000-0002-7694-2067; , 賴吾為/0000-0001-9174-8310; 	Human Biobank, Research Center of Clinical Medicine, National Cheng Kung University Hospital; Taiwan Ministry of Science and Technology [MOST106-2320-B-006-071-MY3]	Human Biobank, Research Center of Clinical Medicine, National Cheng Kung University Hospital; Taiwan Ministry of Science and Technology	We are grateful for the support from the Human Biobank, Research Center of Clinical Medicine, National Cheng Kung University Hospital. We thank Mass Spectrometry Facilities of National Cheng Kung University for MS analysis. This work is supported by the Taiwan Ministry of Science and Technology Grant MOST106-2320-B-006-071-MY3.	Agarwal NK, 2016, BLOOD, V127, P605, DOI 10.1182/blood-2015-07-658781; Carpenter RL, 2015, ONCOGENE, V34, P546, DOI 10.1038/onc.2013.582; Chuang CW, 2013, J CELL PHYSIOL, V228, P341, DOI 10.1002/jcp.24136; Faber AC, 2009, P NATL ACAD SCI USA, V106, P19503, DOI 10.1073/pnas.0905056106; Fang L, 2014, MOL CELL, V55, P537, DOI 10.1016/j.molcel.2014.06.018; Filtz TM, 2014, TRENDS PHARMACOL SCI, V35, P76, DOI 10.1016/j.tips.2013.11.005; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138; Gamsjaeger R, 2007, TRENDS BIOCHEM SCI, V32, P63, DOI 10.1016/j.tibs.2006.12.007; Harper J, 2007, CANCER RES, V67, P8736, DOI 10.1158/0008-5472.CAN-07-1617; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; Hong J, 2011, CANCER RES, V71, P3980, DOI 10.1158/0008-5472.CAN-10-2914; Ichihara E, 2017, CANCER RES, V77, P2990, DOI 10.1158/0008-5472.CAN-16-2300; Jacobsen K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00450-6; Jen J, 2016, ONCOGENE, V35, P2357, DOI 10.1038/onc.2015.296; Jen JY, 2019, CELL DEATH DIFFER, V26, P1283, DOI 10.1038/s41418-018-0204-6; Laity JH, 2001, CURR OPIN STRUC BIOL, V11, P39, DOI 10.1016/S0959-440X(00)00167-6; Lehmann W, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10498; Li YQ, 2004, BIOCHEM BIOPH RES CO, V325, P1383, DOI 10.1016/j.bbrc.2004.10.183; Liao SY, 2017, ONCOGENE, V36, P5722, DOI 10.1038/onc.2017.168; Lo FY, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-235; McCarty AS, 2003, MOL CELL, V11, P459, DOI 10.1016/S1097-2765(03)00043-1; Ono M, 2004, MOL CANCER THER, V3, P465; Persikov AV, 2015, NUCLEIC ACIDS RES, V43, P1965, DOI 10.1093/nar/gku1395; Phuchareon J, 2015, P NATL ACAD SCI USA, V112, pE3855, DOI 10.1073/pnas.1510733112; Po A, 2017, ONCOGENE, V36, P4641, DOI 10.1038/onc.2017.91; Ramos A, 2018, FASEB J, V32, P6982, DOI 10.1096/fj.201801167RR; Razin SV, 2012, BIOCHEMISTRY-MOSCOW+, V77, P217, DOI 10.1134/S0006297912030017; Riverso M, 2017, ONCOGENE, V36, P3322, DOI 10.1038/onc.2016.481; Singh AR, 2016, MOL CANCER THER, V15, P2553, DOI 10.1158/1535-7163.MCT-15-0976; Tasian SK, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00108; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; Wolin EM, 2013, CANCER LETT, V335, P1, DOI 10.1016/j.canlet.2013.02.016; Yap TA, 2011, J CLIN ONCOL, V29, P4688, DOI 10.1200/JCO.2011.35.5263; Zheng HQ, 2014, CANCER CELL, V26, P358, DOI 10.1016/j.ccr.2014.07.022	35	14	14	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2019	38	41					6723	6736		10.1038/s41388-019-0928-x	http://dx.doi.org/10.1038/s41388-019-0928-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JC8UZ	31399647				2022-12-17	WOS:000489552900001
J	Zhu, YF; Xie, MX; Meng, ZY; Leung, LK; Chan, FL; Hu, X; Chi, KW; Liu, CL; Yao, XQ				Zhu, Yifei; Xie, Mingxu; Meng, Zhaoyue; Leung, Lai-Kwok; Chan, Franky Leung; Hu, Xin; Chi, Kaiwen; Liu, Cuiling; Yao, Xiaoqiang			Knockdown of TM9SF4 boosts ER stress to trigger cell death of chemoresistant breast cancer cells	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; MULTIDRUG-RESISTANCE; PROTEIN; ADHESION; PROLIFERATION	Drug resistance is one of the major obstacles to breast cancer therapy. However, the mechanisms of how cancer cells develop chemoresistance are still not fully understood. In the present study, we found that expression of TM9SF4 proteins was much higher in adriamycin (ADM)-resistant breast cancer cells MCF-7/ADM than in its parental line wild-type breast cancer cells MCF-7/WT. shRNA-mediated knockdown of TM9SF4 preferentially reduced cell growth and triggered cell death in chemoresistant MCF-7/ADM cells compared with MCF-7/WT cells. Knockdown of TM9SF4 also reduced cell growth and triggered cell death in chemoresistant MDA-MB-231/GEM cells. Mechanistic studies showed that TM9SF4 knockdown increased protein misfolding and elevated endoplasmic reticulum (ER) stress level in MCF-7/ADM cells, as indicated by aggresome formation and upregulated expression of ER stress markers, the effect of which was reversed by a small molecule chaperone 4-phenybutyric acid. In an athymic nude mouse model of ADM-resistant human breast xenograft tumor, knockdown of TM9SF4 decreased the growth of tumor xenografts. In chemoresistant breast cancer patients, chemotherapy increased the expression of TM9SF4 proteins in breast tumor samples. Taken together, these results uncovered a novel role of TM9SF4 proteins in alleviating ER stress and protecting chemoresistant breast cancer cells from apoptotic/necrotic cell death. These results highlight a possible strategy of targeting TM9SF4 to overcome breast cancer chemoresistance.	[Zhu, Yifei; Xie, Mingxu; Meng, Zhaoyue; Chan, Franky Leung; Yao, Xiaoqiang] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China; [Zhu, Yifei; Xie, Mingxu; Meng, Zhaoyue; Chan, Franky Leung; Yao, Xiaoqiang] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China; [Zhu, Yifei] Jiangnan Univ, Wuxi Sch Med, Wuxi, Jiangsu, Peoples R China; [Leung, Lai-Kwok] Chinese Univ Hong Kong, Sch Life Sci, Hong Kong, Peoples R China; [Hu, Xin] Fudan Univ, Dept Breast Surg, Key Lab Breast Canc Shanghai, Shanghai Canc Ctr, Shanghai, Peoples R China; [Chi, Kaiwen; Liu, Cuiling] Peking Univ, Dept Pathol, Hlth Sci Ctr, Beijing, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Jiangnan University; Chinese University of Hong Kong; Fudan University; Peking University	Yao, XQ (corresponding author), Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China.; Yao, XQ (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China.	yao2068@cuhk.edu.hk	Leung, Lai K/E-6314-2011; Yao, Xiaoqiang/I-5413-2016	Leung, Lai K/0000-0002-7781-3099; Yao, Xiaoqiang/0000-0002-0687-8186	Hong Kong Research Grant Committee [AoE/M-05/12, GRF/14118516, RIF/R4005-18F]; Hong Kong Innovation and Technology Fund [ITF/096/18, PiH/230/18, PiH/049/19]	Hong Kong Research Grant Committee(Hong Kong Research Grants Council); Hong Kong Innovation and Technology Fund	This work was supported by grants from Hong Kong Research Grant Committee [AoE/M-05/12, GRF/14118516, RIF/R4005-18F] and Hong Kong Innovation and Technology Fund [ITF/096/18, PiH/230/18 and PiH/049/19].	Benghezal M, 2003, MOL BIOL CELL, V14, P2890, DOI 10.1091/mbc.E02-11-0724; Bergeret E, 2008, J CELL SCI, V121, P3325, DOI 10.1242/jcs.030163; Borst P, 2012, OPEN BIOL, V2, DOI 10.1098/rsob.120066; Chang HY, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.504; Chen JA, 2011, CANCER LETT, V300, P48, DOI 10.1016/j.canlet.2010.09.005; Corboy Michael J., 2005, V301, P305; Cornillon S, 2000, J BIOL CHEM, V275, P34287, DOI 10.1074/jbc.M006725200; Daniel C, 2013, BBA-MOL BASIS DIS, V1832, P606, DOI 10.1016/j.bbadis.2013.01.020; Fais S, 2012, TRENDS MOL MED, V18, P4, DOI 10.1016/j.molmed.2011.09.001; Goda K, 2009, CURR CANCER DRUG TAR, V9, P281, DOI 10.2174/156800909788166493; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Harbeck N, 2017, LANCET, V389, P1134, DOI [10.1016/S0140-6736(16)31891-8, 10.1016/s0140-6736(16)31891-8]; Iannitti T, 2011, DRUGS R&D, V11, P227, DOI 10.2165/11591280-000000000-00000; Iliopoulos D, 2007, CLIN CANCER RES, V13, P268, DOI 10.1158/1078-0432.CCR-06-2038; Jones LJ, 2001, J IMMUNOL METHODS, V254, P85, DOI 10.1016/S0022-1759(01)00404-5; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Lebeau P, 2017, J BIOL CHEM, V292, P1510, DOI 10.1074/jbc.M116.744235; Lozupone F, 2015, ONCOGENE, V34, P5163, DOI 10.1038/onc.2014.437; Lozupone F, 2009, EMBO REP, V10, P1348, DOI 10.1038/embor.2009.236; Ma X, 2012, P NATL ACAD SCI USA, V109, P16282, DOI 10.1073/pnas.1202989109; Mekahli D, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004317; Nishitoh H, 2012, J BIOCHEM, V151, P217, DOI 10.1093/jb/mvr143; Ogston KN, 2003, BREAST, V12, P320, DOI 10.1016/S0960-9776(03)00106-1; Paolillo R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126968; Park J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15730; Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003; Ralevic V, 1998, PHARMACOL REV, V50, P413; Ranganathan AC, 2006, CANCER RES, V66, P1702, DOI 10.1158/0008-5472.CAN-05-3092; Salaroglio IC, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0657-0; Salic A, 2008, P NATL ACAD SCI USA, V105, P2415, DOI 10.1073/pnas.0712168105; Sun L, 2018, CELL DEATH DIFFER, V25, P368, DOI 10.1038/cdd.2017.166; Tavera-Mendoza LE, 2017, LAB ANIM-UK, V51, P85, DOI 10.1177/0023677216640706; Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800; Welch WJ, 1996, CELL STRESS CHAPERON, V1, P109, DOI 10.1379/1466-1268(1996)001<0109:IOMACC>2.3.CO;2; Ye FG, 2015, CANCER RES, V75, P1504, DOI 10.1158/0008-5472.CAN-14-2341	35	14	16	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2019	38	29					5778	5791		10.1038/s41388-019-0846-y	http://dx.doi.org/10.1038/s41388-019-0846-y			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IQ4WS	31249383				2022-12-17	WOS:000480752800003
J	Duan, L; Perez, RE; Chastain, PD; Mathew, MT; Bijukumar, DR; Maki, CG				Duan, Lei; Perez, Ricardo E.; Chastain, Paul D., II; Mathew, Mathew T.; Bijukumar, Divya Rani; Maki, Carl G.			JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells	ONCOGENE			English	Article							MOLECULAR-MECHANISMS; ERCC1 EXPRESSION; CANCER CELLS; DNA-REPAIR; S-PHASE; REPLICATION; ATR; DEMETHYLASES; CHROMATIN; CHK1	Platinum-based drugs such as cisplatin (CP) are the first-line chemotherapy for non-small-cell lung carcinoma (NSCLC). Unfortunately, NSCLC has a low response rate to CP and acquired resistance always occurs. Histone methylation regulates chromatin structure and is implicated in DNA repair. We hypothesize histone methylation regulators are involved in CP resistance. We therefore screened gene expression of known histone methyltransferases and demethylases in three NSCLC cell lines with or without acquired resistance to CP. JMJD2s are a family of histone demethylases that remove tri-methyl groups from H3K9 and H3K36. We found expression of several JMJD2 family genes upregulated in CP-resistant cells, with JMJD2B expression being upregulated in all three CP-resistant NSCLC cell lines. Further analysis showed increased JMJD2 protein expression coincided with decreased H3K9me3 and H3K36me3. Chemical inhibitors of JMJD2-family proteins increased H3K9me3 and H3K36me3 levels and sensitized resistant cells to CP. Mechanistic studies showed that JMJD2 inhibition decreased chromatin association of ATR and Chk1 and inhibited the ATR-Chk1 replication checkpoint. Our results reveal that JMJD2 demethylases are potential therapeutic targets to overcome CP resistance in NSCLC.	[Duan, Lei; Perez, Ricardo E.; Maki, Carl G.] Rush Univ, Dept Cell & Mol Med, Med Ctr, Chicago, IL 60612 USA; [Chastain, Paul D., II] Univ Illinois, Dept Hlth Sci Educ, Coll Med Rockford, Rockford, IL 61107 USA; [Mathew, Mathew T.; Bijukumar, Divya Rani] Univ Illinois, Dept Biomed Sci, Coll Med Rockford, Rockford, IL 61107 USA	Rush University; University of Illinois System; University of Illinois Chicago; University of Illinois Rockford; University of Illinois System; University of Illinois Chicago; University of Illinois Rockford	Maki, CG (corresponding author), Rush Univ, Dept Cell & Mol Med, Med Ctr, Chicago, IL 60612 USA.	Carl_Maki@rush.edu	Chastain, Paul/AAN-2692-2020	Chastain, Paul/0000-0001-6782-6788	Swim Across America	Swim Across America	This work was supported in part by a grant from Swim Across America (to CGM). We would like to thank the flow cytometry core at the University of Illinois at Chicago for their assistance in helping us run the replication start assay.	Aggarwal C, 2017, ONCOLOGIST, V22, P700, DOI 10.1634/theoncologist.2016-0345; Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145; Agger K, 2016, GENE DEV, V30, P1278, DOI 10.1101/gad.280495.116; Andrade-Lima LC, 2015, J CELL SCI, V128, P150, DOI 10.1242/jcs.161596; Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22; Basu A, 2010, J NUCLEIC ACIDS, V2010, DOI 10.4061/2010/201367; Berry WL, 2013, CANCER RES, V73, P2936, DOI 10.1158/0008-5472.CAN-12-4300; Bhagwat N, 2009, MOL CELL BIOL, V29, P6427, DOI 10.1128/MCB.00086-09; Britten RA, 2000, INT J CANCER, V89, P453, DOI 10.1002/1097-0215(20000920)89:5<453::AID-IJC9>3.3.CO;2-5; Chang A, 2011, LUNG CANCER, V71, P3, DOI 10.1016/j.lungcan.2010.08.022; Chastain PD, 2015, PHOTOCHEM PHOTOBIOL, V91, P109, DOI 10.1111/php.12361; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; D'Oto A, 2016, J MED ONCOL THER, V1, P34; Dasari S, 2014, EUR J PHARMACOL, V740, P364, DOI 10.1016/j.ejphar.2014.07.025; Dinant C, 2008, EPIGENET CHROMATIN, V1, DOI 10.1186/1756-8935-1-9; EASTMAN A, 1988, BIOCHEMISTRY-US, V27, P4730, DOI 10.1021/bi00413a022; Enoiu M, 2012, NUCLEIC ACIDS RES, V40, P8953, DOI 10.1093/nar/gks670; Ezponda T, 2017, CELL REP, V21, P628, DOI 10.1016/j.celrep.2017.09.078; Ferry KV, 2000, BIOCHEM PHARMACOL, V60, P1305, DOI 10.1016/S0006-2952(00)00441-X; Gadhikar MA, 2013, MOL CANCER THER, V12, P1860, DOI 10.1158/1535-7163.MCT-13-0157; Gagou ME, 2010, MOL BIOL CELL, V21, P739, DOI 10.1091/mbc.E09-07-0618; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Gong F, 2017, J CELL BIOL, V216, P1959, DOI 10.1083/jcb.201611135; Gursoy-Yuzugullu O, 2016, J MOL BIOL, V428, P1846, DOI 10.1016/j.jmb.2015.11.021; Hartlerode AJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049211; Hromas R, 2012, ONCOGENE, V31, P4245, DOI 10.1038/onc.2011.586; Hsiao KY, 2013, J MOL CELL BIOL, V5, P157, DOI 10.1093/jmcb/mjs066; Hyun K, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.11; Johnson DH, 2014, J CLIN ONCOL, V32, P973, DOI 10.1200/JCO.2013.53.1228; KELLAND LR, 1995, J MED CHEM, V38, P3016, DOI 10.1021/jm00016a004; Kooistra SM, 2012, NAT REV MOL CELL BIO, V13, P297, DOI 10.1038/nrm3327; Kumagai A, 2006, CELL CYCLE, V5, P1265, DOI 10.4161/cc.5.12.2834; Kuo LJ, 2008, IN VIVO, V22, P305; Li CC, 2016, ONCOTARGET, V7, P1947, DOI 10.18632/oncotarget.6482; Lord RVN, 2002, CLIN CANCER RES, V8, P2286; Mallette FA, 2012, EMBO J, V31, P1865, DOI 10.1038/emboj.2012.47; Mendoza J, 2013, BRIT J CANCER, V109, P68, DOI 10.1038/bjc.2013.303; Mutreja K, 2018, CELL REP, V24, P2629, DOI 10.1016/j.celrep.2018.08.019; Nam EA, 2011, BIOCHEM J, V436, P527, DOI 10.1042/BJ20102162; Northcott PA, 2009, NAT GENET, V41, P465, DOI 10.1038/ng.336; Petermann E, 2010, P NATL ACAD SCI USA, V107, P16090, DOI 10.1073/pnas.1005031107; Price BD, 2013, CELL, V152, P1344, DOI 10.1016/j.cell.2013.02.011; Saksouk N, 2015, EPIGENET CHROMATIN, V8, DOI 10.1186/1756-8935-8-3; Sangster-Guity N, 2011, ONCOGENE, V30, P2526, DOI 10.1038/onc.2010.624; Sanjiv K, 2016, CELL REP, V14, P298, DOI 10.1016/j.celrep.2015.12.032; Seiler JA, 2007, MOL CELL BIOL, V27, P5806, DOI 10.1128/MCB.02278-06; Steuer CE, 2017, JAMA ONCOL, V3, P1120, DOI 10.1001/jamaoncol.2016.4280; Steward O, 2012, EXP NEUROL, V233, P597, DOI 10.1016/j.expneurol.2011.06.017; Sun YL, 2009, NAT CELL BIOL, V11, P1376, DOI 10.1038/ncb1982; Toledo LI, 2013, CELL, V155, P1088, DOI 10.1016/j.cell.2013.10.043; Toyokawa G, 2016, ANTICANCER RES, V36, P4841, DOI 10.21873/anticanres.11046; Turinetto V, 2015, NUCLEIC ACIDS RES, V43, P2489, DOI 10.1093/nar/gkv061; Usanova S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-248; Vendetti FP, 2015, ONCOTARGET, V6, P44289, DOI 10.18632/oncotarget.6247; Wakeman TP, 2012, EMBO J, V31, P2169, DOI 10.1038/emboj.2012.50; Zhang YW, 2005, MOL CELL, V19, P607, DOI 10.1016/j.molcel.2005.07.019; Zheng H, 2014, ONCOGENE, V33, P734, DOI 10.1038/onc.2013.6; Zhou WD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083978	58	14	17	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5643	5657		10.1038/s41388-019-0814-6	http://dx.doi.org/10.1038/s41388-019-0814-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	30967636				2022-12-17	WOS:000474845100007
J	He, H; Song, DD; Sinha, I; Hessling, B; Li, XD; Haldosen, LA; Zhao, CY				He, Huan; Song, Dandan; Sinha, Indranil; Hessling, Bernd; Li, Xidan; Haldosen, Lars-Arne; Zhao, Chunyan			Endogenous interaction profiling identifies DDX5 as an oncogenic coactivator of transcription factor Fra-1	ONCOGENE			English	Article							RNA HELICASES P68; ESTROGEN-RECEPTOR; MASS-SPECTROMETRY; BINDING-PROTEIN; REVEALS; PROLIFERATION; ALPHA; AP-1; INVASIVENESS; EXPRESSION	Fra-1, a member of the activator protein 1 (AP-1) family, is overexpressed in triple-negative breast cancer (TNBC) and plays crucial roles in tumor growth. Here we report the identification of 118 proteins interacting with endogenous chromatinbound Fra-1 in TNBC cells, highlighting DDX5 as the most enriched Fra-1-interacting protein. DDX5, a previously unrecognized protein in the Fra-1 transcriptional network, shows extensive overlap with Fra-1 cistrome and transcriptome that are highly associated with the TNBC cell growth. We provide evidence that DDX5 expression enhances Fra-1 transcriptional activity and potentiates Fra-1-driven cell proliferation. Furthermore, we show that the DDX5 target gene signature predicts poor clinical outcome in breast cancer patients. DDX5 protein level was higher in triple-negative basallike tumors than in non-basal-like tumors, including luminal A, luminal B, and HER2-enriched subtypes. Collectively, by combining proteomic and genomic approaches we reveal a role for DDX5 as a regulatory protein of Fra-1 signaling and suggest DDX5 as a potential therapeutic target for TNBC.	[He, Huan; Song, Dandan; Sinha, Indranil; Haldosen, Lars-Arne; Zhao, Chunyan] Karolinska Inst, Dept Biosci & Nutr, S-14183 Huddinge, Sweden; [Hessling, Bernd] Heidelberg Univ, Ctr Mol Biol ZMBH, D-69120 Heidelberg, Germany; [Hessling, Bernd] German Canc Res Ctr, D-69120 Heidelberg, Germany; [Li, Xidan] Karolinska Inst, Integrated Cardio Metab Ctr, Dept Med, S-14183 Huddinge, Sweden	Karolinska Institutet; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Karolinska Institutet	Zhao, CY (corresponding author), Karolinska Inst, Dept Biosci & Nutr, S-14183 Huddinge, Sweden.	chunyan.zhao@ki.se	He, Huan/AAF-9644-2019	He, Huan/0000-0001-8123-5765; Sinha, Indranil/0000-0002-2513-5927	China Scholarship Council; Karolinska Institutet; Swedish Cancer Society (Cancerfonden); Swedish Research Council	China Scholarship Council(China Scholarship Council); Karolinska Institutet(Karolinska Institutet); Swedish Cancer Society (Cancerfonden)(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission)	This work was supported by scholarship from the China Scholarship Council, a Ph.D. student grant (KID) from the Karolinska Institutet and grants from the Swedish Cancer Society (Cancerfonden) and the Swedish Research Council. We thank SciLifeLab, Stockholm, for their RNA-seq technical support and the Karolinska Institute/Astra Zeneca Integrated Cardio Metabolic Center (ICMC) for their consultative support. We are grateful to Karin Dahlman-Wright for critically reading the first version of the manuscript.	Andersson R, 2014, NATURE, V507, P455, DOI 10.1038/nature12787; Bates GJ, 2005, EMBO J, V24, P543, DOI 10.1038/sj.emboj.7600550; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Browne AL, 2018, ONCOGENE, V37, P2008, DOI 10.1038/s41388-017-0042-x; Caretti G, 2006, DEV CELL, V11, P547, DOI 10.1016/j.devcel.2006.08.003; Chiappetta G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-17; Christmann M, 2013, NUCLEIC ACIDS RES, V41, P8403, DOI 10.1093/nar/gkt635; Clark ES, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057832; Clark EL, 2008, CANCER RES, V68, P7938, DOI 10.1158/0008-5472.CAN-08-0932; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Dahlman-Wright K, 2012, CARCINOGENESIS, V33, P1684, DOI 10.1093/carcin/bgs223; Dardenne E, 2014, CELL REP, V7, P1900, DOI 10.1016/j.celrep.2014.05.010; Das M, 2018, RNA BIOL, V15, P214, DOI 10.1080/15476286.2017.1397261; Desmet CJ, 2013, P NATL ACAD SCI USA, V110, P5139, DOI 10.1073/pnas.1222085110; Dhillon AS, 2015, ONCOGENE, V34, P4421, DOI 10.1038/onc.2014.374; Diefenbacher ME, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097549; Diesch J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088950; Engstrom K, 2017, ARCH TOXICOL, V91, P2067, DOI 10.1007/s00204-016-1879-4; Fuller-Pace FV, 2013, BBA-GENE REGUL MECH, V1829, P756, DOI 10.1016/j.bbagrm.2013.03.004; Fuller-Pace FV, 2013, RNA BIOL, V10, P121, DOI 10.4161/rna.23312; Fuller-Pace FV, 2011, FUTURE ONCOL, V7, P239, DOI 10.2217/FON.11.1; Guturi KKN, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0496-5; He H, 2018, ONCOGENE, V37, P2586, DOI 10.1038/s41388-018-0165-8; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hendrickson DG, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0878-3; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Iskit S, 2015, ONCOTARGET, V6, P43146, DOI 10.18632/oncotarget.6454; Ji X, 2015, P NATL ACAD SCI USA, V112, P3841, DOI 10.1073/pnas.1502971112; Kim TY, 2012, MOL CELL PROTEOMICS, V11, P1586, DOI 10.1074/mcp.M112.021162; Mazurek A, 2012, CANCER DISCOV, V2, P812, DOI 10.1158/2159-8290.CD-12-0116; Mohammed H, 2016, NAT PROTOC, V11, P316, DOI 10.1038/nprot.2016.020; Ogilvie VC, 2003, NUCLEIC ACIDS RES, V31, P1470, DOI 10.1093/nar/gkg236; Peng YW, 2002, BLOOD, V99, P2408, DOI 10.1182/blood.V99.7.2408; Qiao YC, 2015, ONCOTARGET, V6, P7804, DOI 10.18632/oncotarget.3158; Ross-Innes CS, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-593; Sayan AE, 2012, ONCOGENE, V31, P1493, DOI 10.1038/onc.2011.336; Schreiber M, 2000, DEVELOPMENT, V127, P4937; Searle BC, 2010, PROTEOMICS, V10, P1265, DOI 10.1002/pmic.200900437; Shao AW, 2016, CELL DEATH DIFFER, V23, P865, DOI 10.1038/cdd.2015.150; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2010, CELL SIGNAL, V22, P894, DOI 10.1016/j.cellsig.2009.12.008; Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468; Shin S, 2007, CANCER RES, V67, P7572, DOI 10.1158/0008-5472.CAN-06-4652; Stelloo S, 2018, ONCOGENE, V37, P313, DOI 10.1038/onc.2017.330; Tyanova S, 2016, NAT PROTOC, V11, P2301, DOI 10.1038/nprot.2016.136; Villanueva CJ, 2011, CELL METAB, V13, P413, DOI 10.1016/j.cmet.2011.02.014; Warner DR, 2004, BIOCHEM BIOPH RES CO, V324, P70, DOI 10.1016/j.bbrc.2004.09.017; Yao HJ, 2010, GENE DEV, V24, P2543, DOI 10.1101/gad.1967810; Zhao CY, 2007, CANCER RES, V67, P3955, DOI 10.1158/0008-5472.CAN-06-3505; Zhao CY, 2014, CANCER RES, V74, P3983, DOI 10.1158/0008-5472.CAN-13-3396	50	14	14	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5725	5738		10.1038/s41388-019-0824-4	http://dx.doi.org/10.1038/s41388-019-0824-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	31015574				2022-12-17	WOS:000474845100012
J	Rohwer, N; Jumpertz, S; Erdem, M; Egners, A; Warzecha, KT; Fragoulis, A; Kuhl, AA; Kramann, R; Neuss, S; Rudolph, I; Endermann, T; Zasada, C; Apostolova, I; Gerling, M; Kempa, S; Hughes, R; Lewis, CE; Brenner, W; Malinowski, MB; Stockmann, M; Schomburg, L; Faller, W; Sansom, OJ; Tacke, F; Morkel, M; Cramer, T				Rohwer, Nadine; Jumpertz, Sandra; Erdem, Merve; Egners, Antje; Warzecha, Klaudia T.; Fragoulis, Athanassios; Kuehl, Anja A.; Kramann, Rafael; Neuss, Sabine; Rudolph, Ines; Endermann, Tobias; Zasada, Christin; Apostolova, Ivayla; Gerling, Marco; Kempa, Stefan; Hughes, Russell; Lewis, Claire E.; Brenner, Winfried; Malinowski, Maciej B.; Stockmann, Martin; Schomburg, Lutz; Faller, William; Sansom, Owen J.; Tacke, Frank; Morkel, Markus; Cramer, Thorsten			Non-canonical HIF-1 stabilization contributes to intestinal tumorigenesis	ONCOGENE			English	Article							HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; CARCINOMA-ASSOCIATED FIBROBLASTS; TUMOR-ASSOCIATED MACROPHAGES; TARGETED CANCER-THERAPY; DENDRITIC CELLS; POOR-PROGNOSIS; MURINE MODEL; MOUSE MODEL; STEM-CELLS; FACTOR-I	The hypoxia-inducible transcription factor HIF-1 is appreciated as a promising target for cancer therapy. However, conditional deletion of HIF-1 and HIF-1 target genes in cells of the tumor microenvironment can result in accelerated tumor growth, calling for a detailed characterization of the cellular context to fully comprehend HIF-1's role in tumorigenesis. We dissected cell type-specific functions of HIF-1 for intestinal tumorigenesis by lineage-restricted deletion of the Hif1a locus. Intestinal epithelial cell-specific Hif1a loss reduced activation of Wnt/beta-catenin, tumor-specific metabolism and inflammation, significantly inhibiting tumor growth. Deletion of Hif1a in myeloid cells reduced the expression of fibroblast-activating factors in tumor-associated macrophages resulting in decreased abundance of tumor-associated fibroblasts (TAF) and robustly reduced tumor formation. Interestingly, hypoxia was detectable only sparsely and without spatial association with HIF-1 alpha, arguing for an importance of hypoxia-independent, i.e., non-canonical, HIF-1 stabilization for intestinal tumorigenesis that has not been previously appreciated. This adds a further layer of complexity to the regulation of HIF-1 and suggests that hypoxia and HIF-1 alpha stabilization can be uncoupled in cancer. Collectively, our data show that HIF-1 is a pivotal pro-tumorigenic factor for intestinal tumor formation, controlling key oncogenic programs in both the epithelial tumor compartment and the tumor microenvironment.	[Rohwer, Nadine; Rudolph, Ines] Charite Univ Med Berlin, Hepatol & Gastroenterol, Augustenburger Pl 1, D-13353 Berlin, Germany; [Jumpertz, Sandra; Erdem, Merve; Egners, Antje; Fragoulis, Athanassios; Cramer, Thorsten] RWTH Univ Hosp, Mol Tumor Biol, Dept Gen Visceral & Transplantat Surg, Pauwelsstr 30, D-52074 Aachen, Germany; [Warzecha, Klaudia T.; Tacke, Frank] RWTH Univ Hosp, Med 3, Pauwelsstr 30, D-52074 Aachen, Germany; [Kuehl, Anja A.] Charite Univ Med Berlin, Res Ctr Immunosci, Hindenburgdamm 30, D-12200 Berlin, Germany; [Kramann, Rafael] RWTH Univ Hosp, Med 2, Pauwelsstr 30, D-52074 Aachen, Germany; [Neuss, Sabine] RWTH Univ Hosp, Pathol, Pauwelsstr 30, D-52074 Aachen, Germany; [Endermann, Tobias; Schomburg, Lutz] Charite Univ Med Berlin, Expt Endocrinol, Augustenburger Pl 1, D-13353 Berlin, Germany; [Zasada, Christin; Kempa, Stefan] Max Delbruck Ctr, Robert Rossle Str 10, D-13125 Berlin, Germany; [Apostolova, Ivayla; Brenner, Winfried] Charite Univ Med Berlin, Nucl Med, Augustenburger Pl 1, D-13353 Berlin, Germany; [Gerling, Marco] Karolinska Inst, Biosci & Nutr, Alfred Nobels Alle 8, S-17177 Stockholm, Sweden; [Hughes, Russell; Lewis, Claire E.] Univ Sheffield, Med Sch, Oncol & Metab, Sheffield S10 2RX, S Yorkshire, England; [Malinowski, Maciej B.; Stockmann, Martin] Charite Univ Med Berlin, Surg, Augustenburger Pl 1, D-13353 Berlin, Germany; [Faller, William; Sansom, Owen J.] Canc Res UK Beatson Inst, Glasgow G61 1BD, Lanark, Scotland; [Morkel, Markus] Charite Univ Med Berlin, Inst Pathol, Charitepl 1, D-10117 Berlin, Germany; [Cramer, Thorsten] Maastricht Univ, NUTRIM Sch Nutr & Translat Res Metab, Maastricht, Netherlands; [Cramer, Thorsten] ESCAM, Aachen, Germany; [Cramer, Thorsten] ESCAM, Maastricht, Netherlands; [Malinowski, Maciej B.] Saarland Univ Hosp, Dept Gen Visceral Vasc & Pediat Surg, Homburg, Germany; [Faller, William] Netherlands Canc Inst, Amsterdam, Netherlands	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Karolinska Institutet; University of Sheffield; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Beatson Institute; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Maastricht University; Maastricht University Medical Centre (MUMC); Universitatsklinikum des Saarlandes; Netherlands Cancer Institute	Cramer, T (corresponding author), RWTH Univ Hosp, Mol Tumor Biol, Dept Gen Visceral & Transplantat Surg, Pauwelsstr 30, D-52074 Aachen, Germany.; Cramer, T (corresponding author), Maastricht Univ, NUTRIM Sch Nutr & Translat Res Metab, Maastricht, Netherlands.; Cramer, T (corresponding author), ESCAM, Aachen, Germany.; Cramer, T (corresponding author), ESCAM, Maastricht, Netherlands.	tcramer@ukaachen.de	Tacke, Frank/ABF-2212-2020; Erdem, Merve/H-1563-2015; Cramer, Thorsten/S-2479-2016; Erdem, Merve/HGB-3063-2022; Schomburg, Lutz/D-8096-2013; Kramann, Rafael/K-7995-2013	Cramer, Thorsten/0000-0002-6462-239X; Schomburg, Lutz/0000-0001-9445-1555; Fragoulis, Athanassios/0000-0002-6973-3080; Rohwer, Nadine/0000-0001-6170-1327; Morkel, Markus/0000-0002-2553-9999; Kuhl, Anja/0000-0003-2293-5387; Sansom, Owen J./0000-0001-9540-3010; Kramann, Rafael/0000-0003-4048-6351; Faller, William James/0000-0002-0738-2254; Brenner, Winfried/0000-0003-2478-6004	Deutsche Krebshilfe [109160]; Deutsche Forschungsgemeinschaft [CR 133/2-1, CR 133/2-2, CR 133/2-3, CR 133/2-4]; BMBF (MAPTor-NET) [031A426A]	Deutsche Krebshilfe(Deutsche Krebshilfe); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); BMBF (MAPTor-NET)(Federal Ministry of Education & Research (BMBF))	Research in the Cramer lab was supported by grants from Deutsche Krebshilfe (109160) and Deutsche Forschungsgemeinschaft (CR 133/2-1 until 2-4). NR was supported by a grant from the BMBF (MAPTor-NET (031A426A)). We are indebted to Ralf Weiskirchen (University Hospital Aachen) for help regarding the MLEC assay. We are grateful to Christine Sers (Charite, Berlin) and Florian R. Greten (Georg-Speyer-Haus, Frankfurt) for helpful discussions and to Ilia N. Buhtoiarov (Children's Hospital of New Jersey, USA), Glenn S. Belinsky, Daniel W. Rosenberg (University of Connecticut Health Center, Farmington, USA), and Takuji Tanaka (Gifu Municipal Hospital, Japan) for providing control reagents. We are grateful to Deborah Gumucio (University of Michigan, USA) for providing Villin-Cre mice. The excellent technical assistance of Birgit Bogdanoff and Simone Spiekermann is highly appreciated. Parts of this work were granted the "Best Poster Award" at the 2015 CELL symposium "Cancer, Inflammation and Immunity" in Sitges, Spain.	Baba Y, 2010, AM J PATHOL, V176, P2292, DOI 10.2353/ajpath.2010.090972; Backer V, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0190074; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Biswas SK, 2013, SEMIN IMMUNOPATHOL, V35, P585, DOI 10.1007/s00281-013-0367-7; BUCALA R, 1994, MOL MED, V1, P71, DOI 10.1007/bf03403533; Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225; COOPER HS, 1993, LAB INVEST, V69, P238; Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; Crawford JR, 2010, J IMMUNOL METHODS, V363, P9, DOI 10.1016/j.jim.2010.09.025; Cummins EP, 2008, GASTROENTEROLOGY, V134, P156, DOI 10.1053/j.gastro.2007.10.012; Dilly AK, 2016, TRANSL RES, V169, P19, DOI 10.1016/j.trsl.2015.10.006; Doedens AL, 2010, CANCER RES, V70, P7465, DOI 10.1158/0008-5472.CAN-10-1439; Eichele DD, 2017, WORLD J GASTROENTERO, V23, P6016, DOI 10.3748/wjg.v23.i33.6016; Farrall AL, 2012, INT J CANCER, V131, P2242, DOI 10.1002/ijc.27500; Fluck K, 2016, MUCOSAL IMMUNOL, V9, P379, DOI 10.1038/mi.2015.67; Gascard P, 2016, GENE DEV, V30, P1002, DOI 10.1101/gad.279737.116; Hammerich L, 2015, HEPATOLOGY, V61, P990, DOI 10.1002/hep.27571; Heijmans J, 2012, BBA-MOL BASIS DIS, V1822, P9, DOI 10.1016/j.bbadis.2010.12.001; Hoebler C, 2006, DIGEST DIS SCI, V51, P381, DOI 10.1007/s10620-006-3142-y; Hu J, 1998, BIOCHEM BIOPH RES CO, V245, P894, DOI 10.1006/bbrc.1998.8543; Huang M, 2014, TRENDS PHARMACOL SCI, V35, P41, DOI 10.1016/j.tips.2013.11.004; Hung SP, 2013, CELL TRANSPLANT, V22, P1869, DOI 10.3727/096368912X657954; Imamura T, 2009, INT J CANCER, V124, P763, DOI 10.1002/ijc.24032; Isella C, 2015, NAT GENET, V47, P312, DOI 10.1038/ng.3224; Janakiram NB, 2014, ADV EXP MED BIOL, V816, P25, DOI 10.1007/978-3-0348-0837-8_2; Kaidi A, 2006, CANCER RES, V66, P6683, DOI 10.1158/0008-5472.CAN-06-0425; Karhausen J, 2004, J CLIN INVEST, V114, P1098, DOI 10.1172/JCI200421086; Kim JW, 2012, CANCER RES, V72, P3187, DOI 10.1158/0008-5472.CAN-12-0534; Kim YE, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.033241; Kohne CH, 2014, PROG TUMOR RES, V41, P36, DOI 10.1159/000356436; Kramann R, 2015, CELL STEM CELL, V16, P51, DOI 10.1016/j.stem.2014.11.004; Krishnamachary B, 2003, CANCER RES, V63, P1138; LaGory EL, 2016, NAT CELL BIOL, V18, P356, DOI 10.1038/ncb3330; Louis NA, 2006, J CELL BIOCHEM, V99, P1616, DOI 10.1002/jcb.20947; Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200; Mahler M, 1998, AM J PHYSIOL-GASTR L, V274, pG544, DOI 10.1152/ajpgi.1998.274.3.G544; Mantovani A, 2010, CURR OPIN IMMUNOL, V22, P231, DOI 10.1016/j.coi.2010.01.009; Mazumdar J, 2010, NAT CELL BIOL, V12, P1007, DOI 10.1038/ncb2102; Mikami Y, 2009, BIOCHEM BIOPH RES CO, V379, P1060, DOI 10.1016/j.bbrc.2009.01.002; Mitchem JB, 2013, CANCER RES, V73, P1128, DOI 10.1158/0008-5472.CAN-12-2731; Mizukami Y, 2005, NAT MED, V11, P992, DOI 10.1038/nm1294; Mladenova DN, 2015, DIS MODEL MECH, V8, P1093, DOI 10.1242/dmm.019000; Neufert C, 2013, J CLIN INVEST, V123, P1428, DOI 10.1172/JCI63748; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Okayasu I, 1996, GUT, V39, P87, DOI 10.1136/gut.39.1.87; Palazon A, 2017, CANCER CELL, V32, P669, DOI 10.1016/j.ccell.2017.10.003; Palazon A, 2014, IMMUNITY, V41, P518, DOI 10.1016/j.immuni.2014.09.008; Peterson LW, 2014, NAT REV IMMUNOL, V14, P141, DOI 10.1038/nri3608; Pradere JP, 2013, HEPATOLOGY, V58, P1461, DOI 10.1002/hep.26429; Raffaghello L, 2015, IMMUNOL LETT, V168, P175, DOI 10.1016/j.imlet.2015.06.016; Ragusa S, 2014, CELL REP, V8, P1957, DOI 10.1016/j.celrep.2014.08.041; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Riemer P, 2017, J CELL BIOL, V216, P1567, DOI 10.1083/jcb.201610058; Robinson A, 2008, GASTROENTEROLOGY, V134, P145, DOI 10.1053/j.gastro.2007.09.033; ROSS R, 1961, J BIOPHYS BIOCHEM CY, V11, P677, DOI 10.1083/jcb.11.3.677; Ryan HE, 2000, CANCER RES, V60, P4010; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Shah YM, 2008, GASTROENTEROLOGY, V134, P2036, DOI 10.1053/j.gastro.2008.03.009; Shay JES, 2014, CARCINOGENESIS, V35, P1067, DOI 10.1093/carcin/bgu004; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Stockmann C, 2008, NATURE, V456, P814, DOI 10.1038/nature07445; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Travis MA, 2014, ANNU REV IMMUNOL, V32, P51, DOI 10.1146/annurev-immunol-032713-120257; Trottier MD, 2012, P NATL ACAD SCI USA, V109, P16594, DOI 10.1073/pnas.1213854109; Tymoszuk P, 2014, EUR J IMMUNOL, V44, P2247, DOI 10.1002/eji.201344304; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Waldner MJ, 2012, INT J BIOL SCI, V8, P1248, DOI 10.7150/ijbs.4614; Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015; Wynn TA, 2010, SEMIN LIVER DIS, V30, P245, DOI 10.1055/s-0030-1255354; Xue J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8158; Xue X, 2014, AM J PHYSIOL-GASTR L, V307, pG187, DOI 10.1152/ajpgi.00112.2014; Xue X, 2013, GASTROENTEROLOGY, V145, P831, DOI 10.1053/j.gastro.2013.07.010; Yoshimura H, 2004, CLIN CANCER RES, V10, P8554, DOI 10.1158/1078-0432.CCR-0946-03; Zhong H, 1999, CANCER RES, V59, P5830	79	14	14	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5670	5685		10.1038/s41388-019-0816-4	http://dx.doi.org/10.1038/s41388-019-0816-4			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	31043706	Green Submitted, Green Accepted			2022-12-17	WOS:000474845100009
J	Wu, MQ; Sheng, L; Cheng, MS; Zhang, HJ; Jiang, YZ; Lin, SB; Liang, Y; Zhu, FY; Liu, ZQ; Zhang, YY; Zhang, XH; Gao, Q; Chen, DM; Li, J; Li, Y				Wu, Mingqing; Sheng, Lu; Cheng, Maosheng; Zhang, Haojie; Jiang, Yizhou; Lin, Shuibin; Liang, Yu; Zhu, Fengyu; Liu, Zhenqing; Zhang, Yingyin; Zhang, Xiuhong; Gao, Qian; Chen, Demeng; Li, Jiong; Li, Yang			Low doses of decitabine improve the chemotherapy efficacy against basal-like bladder cancer by targeting cancer stem cells	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; DNA METHYLATION; UROTHELIAL CARCINOMA; MOLECULAR CHARACTERIZATION; AGENT DECITABINE; INITIATING CELLS; PROGRESSION; DIFFERENTIATION; IDENTIFICATION; COMBINATION	Low dose treatment with the DNA methylation inhibitor decitabine has been shown to be applicable for the management of certain types of cancer. However, its antitumor effect and mechanisms are context dependent and its activity has never been systematically studied in bladder cancer treatment. We used mouse models, cultured cell lines and patient-derived xenografts to demonstrate that low dose decitabine treatment remarkably enhanced the effects of cisplatin and gemcitabine on basal-like bladder cancer both in vivo and in vitro. Genetic lineage tracing revealed that the stemness of a bladder cancer stem cell population was inhibited by decitabine treatment in mice. These effects were accompanied by decreases in genome-wide DNA methylation, gene re-expression, and changes in key cellular regulatory pathways such as STAT3 signaling. These results indicate that this DNA-demethylating reagent is a promising therapeutic approach for basal-like bladder cancer treatment.	[Wu, Mingqing; Cheng, Maosheng; Liang, Yu; Zhu, Fengyu; Zhang, Yingyin; Zhang, Xiuhong; Gao, Qian; Li, Yang] Anhui Med Univ, Sch Life Sci, Dept Genet, Hefei 230031, Anhui, Peoples R China; [Sheng, Lu; Zhang, Haojie] Fudan Univ, Huadong Hosp, Dept Urol, Shanghai 200040, Peoples R China; [Jiang, Yizhou] Shenzhen Univ, Inst Adv Study, Shenzhen 518060, Guangdong, Peoples R China; [Lin, Shuibin; Chen, Demeng] Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Translat Med, Guangzhou 510080, Guangdong, Peoples R China; [Liu, Zhenqing; Li, Jiong] Univ Calif Los Angeles, Lab Mol Signaling, Div Oral Biol & Med, Sch Dent, Los Angeles, CA 90095 USA; [Liu, Zhenqing; Li, Jiong] Univ Calif Los Angeles, Broad Stem Cell Res Ctr, Los Angeles, CA 90095 USA; [Li, Jiong] Virginia Commonwealth Univ, Inst Struct Biol Drug Discovery & Dev, Dept Med Chem, Sch Pharm, 800 E Leigh St, Richmond, VA 23284 USA	Anhui Medical University; Fudan University; Shenzhen University; Sun Yat Sen University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Virginia Commonwealth University	Li, Y (corresponding author), Anhui Med Univ, Sch Life Sci, Dept Genet, Hefei 230031, Anhui, Peoples R China.; Chen, DM (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Translat Med, Guangzhou 510080, Guangdong, Peoples R China.; Li, J (corresponding author), Univ Calif Los Angeles, Lab Mol Signaling, Div Oral Biol & Med, Sch Dent, Los Angeles, CA 90095 USA.; Li, J (corresponding author), Univ Calif Los Angeles, Broad Stem Cell Res Ctr, Los Angeles, CA 90095 USA.; Li, J (corresponding author), Virginia Commonwealth Univ, Inst Struct Biol Drug Discovery & Dev, Dept Med Chem, Sch Pharm, 800 E Leigh St, Richmond, VA 23284 USA.	chendm29@mail.sysu.edu.cn; jli29@vcu.edu; liyang@ahmu.edu.cn			National Natural Science Foundation of China [81872313, 81672776, 31501838]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (81872313 and 81672776 to YL, 31501838 to XHZ).	Alcazar O, 2012, INT J CANCER, V131, P18, DOI 10.1002/ijc.26320; Anastasiadis A, 2012, THER ADV UROL, V4, P13, DOI 10.1177/1756287211431976; Babjuk M, 2013, EUR UROL, V64, P639, DOI 10.1016/j.eururo.2013.06.003; BECCI PJ, 1978, CANCER RES, V38, P4463; Beck B, 2013, NAT REV CANCER, V13, P727, DOI 10.1038/nrc3597; Blum W, 2007, J CLIN ONCOL, V25, P3884, DOI 10.1200/JCO.2006.09.4169; Cashen AF, 2010, J CLIN ONCOL, V28, P556, DOI 10.1200/JCO.2009.23.9178; Chan KS, 2009, P NATL ACAD SCI USA, V106, P14016, DOI 10.1073/pnas.0906549106; Chen MX, 2018, INT J CANCER, V143, P1530, DOI 10.1002/ijc.31531; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Deng WK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111988; Felsenstein KM, 2018, NAT REV UROL, V15, P92, DOI 10.1038/nrurol.2017.179; Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260; Flotho C, 2009, LEUKEMIA, V23, P1019, DOI 10.1038/leu.2008.397; Fu XY, 2015, CURR PROTEIN PEPT SC, V16, P329, DOI 10.2174/138920371604150429155740; Ghoshal K, 2005, MOL CELL BIOL, V25, P4727, DOI 10.1128/MCB.25.11.4727-4741.2005; Hagemann S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017388; Ho PL, 2012, NAT REV UROL, V9, P583, DOI 10.1038/nrurol.2012.142; Ho PL, 2012, CANCER RES, V72, P3135, DOI 10.1158/0008-5472.CAN-11-3195; Huang HY, 2007, HUM PATHOL, V38, P1703, DOI 10.1016/j.humpath.2007.04.003; Issa JPJ, 2004, BLOOD, V103, P1635, DOI 10.1182/blood-2003-03-0687; Juergens RA, 2011, CANCER DISCOV, V1, P598, DOI 10.1158/2159-8290.CD-11-0214; Kahn SL, 2008, CANCER CYTOPATHOL, V114, P57, DOI 10.1002/cncr.23258; Kandimalla R, 2013, NAT REV UROL, V10, P327, DOI 10.1038/nrurol.2013.89; Khandelwal M, 2018, MOL CELL BIOCHEM, V446, P105, DOI 10.1007/s11010-018-3278-z; Kurtova AV, 2015, NATURE, V517, P209, DOI 10.1038/nature14034; Li LM, 2018, ONCOTARGETS THER, V11, P6863, DOI 10.2147/OTT.S161919; Li X, 2017, CLIN CANCER RES, V23, P6031, DOI 10.1158/1078-0432.CCR-17-1201; Li Y, 2015, ONCOTARGET, V6, P10195, DOI 10.18632/oncotarget.3555; Li Y, 2011, CANCER SCI, V102, P2043, DOI 10.1111/j.1349-7006.2011.02061.x; Liang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep29479; Licht JD, 2015, CELL, V162, P938, DOI 10.1016/j.cell.2015.08.005; Lv L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.367; Malik P, 2014, CANCER MANAG RES, V6, P53, DOI 10.2147/CMAR.S40600; Momparler RL, 2005, SEMIN HEMATOL, V42, pS9, DOI 10.1053/j.seminhematol.2005.05.002; O'Flaherty JD, 2012, J THORAC ONCOL, V7, P1880, DOI 10.1097/JTO.0b013e31826bfbc6; Oz S, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku775; Oing C, 2016, J UROLOGY, V195, P254, DOI 10.1016/j.juro.2015.06.115; Paner GP, 2014, HUM PATHOL, V45, P1473, DOI 10.1016/j.humpath.2014.02.024; Papafotiou G, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11914; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pei M, 2009, DIFFERENTIATION, V78, P260, DOI 10.1016/j.diff.2009.08.001; Peng D, 2018, EPIGENOMICS-UK, V10, P1189, DOI 10.2217/epi-2018-0017; Rebouissou S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008970; Ribas A, 2014, CLIN CANCER RES, V20, P4982, DOI 10.1158/1078-0432.CCR-14-0933; Saito R, 2018, CANCER RES, V78, P3954, DOI 10.1158/0008-5472.CAN-18-0173; Schulz WA, 2016, EPIGENOMICS-UK, V8, P1415, DOI 10.2217/epi-2016-0064; Shah JB, 2011, CLIN CANCER RES, V17, P2608, DOI 10.1158/1078-0432.CCR-10-2770; Shang DH, 2008, UROLOGY, V71, P1220, DOI 10.1016/j.urology.2007.11.029; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sonpavde G, 2016, J CLIN ONCOL, V34, P780, DOI 10.1200/JCO.2015.65.4442; Su Y, 2010, CANCER EPIDEM BIOMAR, V19, P327, DOI 10.1158/1055-9965.EPI-09-0865; Timp W, 2013, NAT REV CANCER, V13, P497, DOI 10.1038/nrc3486; Triozzi PL, 2012, CANCER IMMUNOL IMMUN, V61, P1441, DOI 10.1007/s00262-012-1204-x; Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029; Van Batavia J, 2014, NAT CELL BIOL, V16, P982, DOI 10.1038/ncb3038; Volkmer JP, 2012, P NATL ACAD SCI USA, V109, P2078, DOI 10.1073/pnas.1120605109; von der Maase H, 2005, J CLIN ONCOL, V23, P4602, DOI 10.1200/JCO.2005.07.757; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Williams PD, 2008, NEOPLASIA, V10, P838, DOI 10.1593/neo.08432; Xylinas E, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6030037; Yan P, 2012, BLOOD, V120, P2466, DOI 10.1182/blood-2012-05-429175; Yang YM, 2008, CANCER INVEST, V26, P725, DOI 10.1080/07357900801941845; Yu GJ, 2019, CELL MOL IMMUNOL, V16, P401, DOI 10.1038/s41423-018-0026-y; Zhao D, 2015, ONCOGENE, V34, P3107, DOI 10.1038/onc.2014.257; Zhu FY, 2017, STEM CELL REP, V9, P429, DOI 10.1016/j.stemcr.2017.07.004	66	14	15	3	26	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5425	5439		10.1038/s41388-019-0799-1	http://dx.doi.org/10.1038/s41388-019-0799-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	30918330				2022-12-17	WOS:000473842500007
J	Aydin, E; Hallner, A; Wiktorin, HG; Staffas, A; Hellstrand, K; Martner, A				Aydin, Ebru; Hallner, Alexander; Wiktorin, Hanna Grauers; Staffas, Anna; Hellstrand, Kristoffer; Martner, Anna			NOX2 inhibition reduces oxidative stress and prolongs survival in murine KRAS-induced myeloproliferative disease	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; DNA-DAMAGE; GENOMIC INSTABILITY; HYDROGEN-PEROXIDE; NADPH OXIDASES; NK CELLS; ROS; HISTAMINE; MELANOMA; METASTASIS	Mutations leading to constitutive RAS activation contribute in myeloid leukemogenesis. RAS mutations in myeloid cells are accompanied by excessive formation of reactive oxygen species (ROS), but the source of ROS and their role for the initiation and progression of leukemia have not been clearly defined. To determine the role of NOX2-derived ROS in RAS-driven leukemia, double transgenic LSL-Kras(G12D) x Mx1-Cre mice expressing oncogenic KRAS in hematopoietic cells (M-Kras(G12D)) were treated with N-alpha-methyl-histamine (NMH) that targeted the production of NOX2-derived ROS in leukemic cells by agonist activity at histamine H-2 receptors. M-Kras(G12D) mice developed myeloid leukemia comprising mature CD11b(+)Gr1(+) myeloid cells that produced NOX2-derived ROS. Treatment of M-Kras(G12D) mice with NMH delayed the development of myeloproliferative disease and prolonged survival. In addition, NMH-treated M-Kras(G12D) mice showed reduction of intracellular ROS along with reduced DNA oxidation and reduced occurence of double-stranded DNA breaks in myeloid cells. The in vivo expansion of leukemia was markedly reduced in triple transgenic mice where KRAS was expressed in hematopoietic cells of animals with genetic NOX2 deficiency (Nox2(-/-) x LSL-Kras(G12D) x Mx1-Cre). Treatment with NMH did not alter in vivo expansion of leukemia in these NOX2-deficient transgenic mice. We propose that NOX2-derived ROS may contribute to the progression of KRAS-induced leukemia and that strategies to target NOX2 merit further evaluation in RAS-mutated hematopoietic cancer.	[Aydin, Ebru; Hallner, Alexander; Wiktorin, Hanna Grauers; Staffas, Anna; Hellstrand, Kristoffer; Martner, Anna] Univ Gothenburg, Sahlgrenska Canc Ctr, TIMM Lab, S-41390 Gothenburg, Sweden; [Staffas, Anna] Univ Gothenburg, Sahlgrenska Acad, Dept Clin Chem & Transfus Med, S-41345 Gothenburg, Sweden	University of Gothenburg; University of Gothenburg	Martner, A (corresponding author), Univ Gothenburg, Sahlgrenska Canc Ctr, TIMM Lab, S-41390 Gothenburg, Sweden.	anna.martner@gu.se		Hellstrand, Kristoffer/0000-0002-6617-5976; Hallner, Alexander/0000-0002-4973-5097; Martner, Anna/0000-0002-6598-5221; Aydin, Ebru/0000-0003-2395-7529				Aurelius J, 2017, J LEUKOCYTE BIOL, V102, P459, DOI 10.1189/jlb.5VMA1116-454R; Aurelius J, 2012, HAEMATOL-HEMATOL J, V97, P1904, DOI 10.3324/haematol.2012.066399; Aurelius J, 2012, BLOOD, V119, P5832, DOI 10.1182/blood-2011-11-391722; Aydin E, 2017, CANCER IMMUNOL RES, V5, P804, DOI 10.1158/2326-6066.CIR-16-0382; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Betten A, 2003, SCAND J IMMUNOL, V58, P321, DOI 10.1046/j.1365-3083.2003.01301.x; Bowen DT, 2005, BLOOD, V106, P2113, DOI 10.1182/blood-2005-03-0867; Braun BS, 2004, P NATL ACAD SCI USA, V101, P597, DOI 10.1073/pnas.0307203101; BRITTAIN RT, 1981, SCAND J GASTROENTERO, V16, P1; Dahlgren C, 1999, J IMMUNOL METHODS, V232, P3, DOI 10.1016/S0022-1759(99)00146-5; DeFlora S, 1996, INT J CANCER, V67, P842, DOI 10.1002/(SICI)1097-0215(19960917)67:6<842::AID-IJC14>3.0.CO;2-3; Dikalov S, 2011, FREE RADICAL BIO MED, V51, P1289, DOI 10.1016/j.freeradbiomed.2011.06.033; Galadari S, 2017, FREE RADICAL BIO MED, V104, P144, DOI 10.1016/j.freeradbiomed.2017.01.004; Govindarajan B, 2007, J CLIN INVEST, V117, P719, DOI 10.1172/JCI30102; Gritsman K, 2014, J CLIN INVEST, V124, P1794, DOI 10.1172/JCI69927; Gysin Stephan, 2011, Genes Cancer, V2, P359, DOI 10.1177/1947601911412376; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Hansson M, 1996, J IMMUNOL, V156, P42; HELLSTRAND K, 1994, J IMMUNOL, V153, P4940; Hordijk PL, 2006, CIRC RES, V98, P453, DOI 10.1161/01.RES.0000204727.46710.5e; Hoyal CR, 2003, P NATL ACAD SCI USA, V100, P5130, DOI 10.1073/pnas.1031526100; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Kelkka T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084148; Kiffin R, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00218; Kuo LJ, 2008, IN VIVO, V22, P305; Le Gal K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad3740; Ligtenberg MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129786; Loh ML, 2011, BRIT J HAEMATOL, V152, P677, DOI 10.1111/j.1365-2141.2010.08525.x; Lyubynska N, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001069; Marlein CR, 2017, BLOOD, V130, P1649, DOI 10.1182/blood-2017-03-772939; Martner A, 2015, J IMMUNOL, V194, P5014, DOI 10.4049/jimmunol.1402991; Mitsushita J, 2004, CANCER RES, V64, P3580, DOI 10.1158/0008-5472.CAN-03-3909; Moiseeva O, 2009, MOL CELL BIOL, V29, P4495, DOI 10.1128/MCB.01868-08; Panieri E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.105; Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Quinlan MP, 2009, FUTURE ONCOL, V5, P105, DOI 10.2217/14796694.5.1.105; Rada Balazs, 2008, V15, P164, DOI 10.1159/000136357; Rassool FV, 2007, CANCER RES, V67, P8762, DOI 10.1158/0008-5472.CAN-06-4807; Saitoh T, 2002, GUT, V50, P786, DOI 10.1136/gut.50.6.786; Sallmyr A, 2008, CANCER LETT, V270, P1, DOI 10.1016/j.canlet.2008.03.036; Sallmyr A, 2008, BLOOD, V111, P3173, DOI 10.1182/blood-2007-05-092510; Sattler M, 2000, J BIOL CHEM, V275, P24273, DOI 10.1074/jbc.M002094200; Sayin VI, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007653; Scott AJ, 2016, CANCER J, V22, P165, DOI 10.1097/PPO.0000000000000187; Stanicka J, 2015, J BIOL CHEM, V290, P9348, DOI 10.1074/jbc.M113.510495; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Vachhani P, 2014, PHYSIOL GENOMICS, V46, P448, DOI 10.1152/physiolgenomics.00173.2013; Valavanidis A, 2009, J ENVIRON SCI HEAL C, V27, P120, DOI 10.1080/10590500902885684; Van Etten RA, 2004, CANCER CELL, V6, P547, DOI 10.1016/j.ccr.2004.12.004; Ward AF, 2012, BLOOD, V120, P3397, DOI 10.1182/blood-2012-05-378596; Weyemi U, 2012, ONCOGENE, V31, P1117, DOI 10.1038/onc.2011.327; Wiktorin HG, 2018, BRIT J HAEMATOL, V182, P290, DOI 10.1111/bjh.14772; Will M, 2014, CANCER DISCOV, V4, P334, DOI 10.1158/2159-8290.CD-13-0611; Wu RF, 2009, FREE RADICAL BIO MED, V47, P1276, DOI 10.1016/j.freeradbiomed.2009.05.037; Zeng M, 2017, CELL CHEM BIOL, V24, P1005, DOI 10.1016/j.chembiol.2017.06.017	56	14	15	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1534	1543		10.1038/s41388-018-0528-1	http://dx.doi.org/10.1038/s41388-018-0528-1			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30323311	Green Published, hybrid			2022-12-17	WOS:000459945800012
J	Chong, PSY; Zhou, JB; Chooi, JY; Chan, ZL; Toh, SHM; Tan, TZ; Wee, S; Gunaratne, J; Zeng, Q; Chng, WJ				Chong, Phyllis S. Y.; Zhou, Jianbiao; Chooi, Jing-Yuan; Chan, Zit-Liang; Toh, Sabrina Hui Min; Tan, Tuan Zea; Wee, Sheena; Gunaratne, Jayantha; Zeng, Qi; Chng, Wee-Joo			Non-canonical activation of beta-catenin by PRL-3 phosphatase in acute myeloid leukemia	ONCOGENE			English	Article							SIGNALING PATHWAY; ASSOCIATION	Aberrant activation of Wnt/beta-catenin signaling pathway is essential for the development of AML; however, the mechanistic basis for this dysregulation is unclear. PRL-3 is an oncogenic phosphatase implicated in the development of LSCs. Here, we identified Leo1 as a direct and specific substrate of PRL-3. Serine-dephosphorylated form of Leo1 binds directly to beta-catenin, promoting the nuclear accumulation of beta-catenin and transactivation of TCF/LEF downstream target genes such as cyclin D1 and c-myc. Importantly, overexpression of PRL-3 in AML cells displayed enhanced sensitivity towards beta-catenin inhibition in vitro and in vivo, suggesting that these cells are addicted to beta-catenin signaling. Altogether, our study revealed a novel regulatory role of PRL-3 in the sustenance of aberrant beta-catenin signaling in AML. PRL-3 may serve as a biomarker to select for the subset of AML patients who are likely to benefit from treatment with beta-catenin inhibitors. Our study presents a new avenue of cancer inhibition driven by PRL-3 overexpression or beta-catenin hyperactivation.	[Chong, Phyllis S. Y.; Zhou, Jianbiao; Chan, Zit-Liang; Toh, Sabrina Hui Min; Tan, Tuan Zea; Chng, Wee-Joo] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore; [Zhou, Jianbiao; Chooi, Jing-Yuan; Chng, Wee-Joo] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore; [Wee, Sheena; Gunaratne, Jayantha; Zeng, Qi] ASTAR, Inst Mol & Cell Biol, Singapore, Singapore; [Gunaratne, Jayantha] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore, Singapore; [Chng, Wee-Joo] Natl Univ Hlth Syst, Dept Haematol Oncol, Natl Univ Canc Inst, Singapore, Singapore	National University of Singapore; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore	Chng, WJ (corresponding author), Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore.; Chng, WJ (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore.; Chng, WJ (corresponding author), Natl Univ Hlth Syst, Dept Haematol Oncol, Natl Univ Canc Inst, Singapore, Singapore.	mdccwj@nus.edu.sg	Tan, Tuan Zea/I-9227-2019	Tan, Tuan Zea/0000-0001-6624-1593	Singapore National Research Foundation; Ministry of Education under the Research Center of Excellence Program; NMRC Clinician-Scientist IRG [CNIG11nov38]; NMRC Singapore Translational Research (STaR) Investigatorship; National Research Foundation Singapore; Singapore Ministry of Education under the Research Centers of Excellence initiative; RNA Biology Center at the Cancer Science Institute of Singapore, NUS under the Singapore Ministry of Education's Tier 3 grants [MOE2014-T3-1-006]	Singapore National Research Foundation(National Research Foundation, Singapore); Ministry of Education under the Research Center of Excellence Program; NMRC Clinician-Scientist IRG(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NMRC Singapore Translational Research (STaR) Investigatorship(National Medical Research Council, Singapore); National Research Foundation Singapore(National Research Foundation, Singapore); Singapore Ministry of Education under the Research Centers of Excellence initiative(Ministry of Education, Singapore); RNA Biology Center at the Cancer Science Institute of Singapore, NUS under the Singapore Ministry of Education's Tier 3 grants(Ministry of Education, SingaporeNational University of Singapore)	This work was supported by the Singapore National Research Foundation and the Ministry of Education under the Research Center of Excellence Program to WJ Chng and NMRC Clinician-Scientist IRG Grant CNIG11nov38 to Zhou J. WJ Chng is supported by NMRC Singapore Translational Research (STaR) Investigatorship. This research is partly supported by the National Research Foundation Singapore and the Singapore Ministry of Education under the Research Centers of Excellence initiative as well as the RNA Biology Center at the Cancer Science Institute of Singapore, NUS, as part of funding under the Singapore Ministry of Education's Tier 3 grants, grant number MOE2014-T3-1-006. No potential conflicts of interest were disclosed. We would also like to thank Prof Phil Koeffler, Prof Dan Tenen, Prof Toshio Suda, and Dr Motomi Osato for helpful discussions and critical reading of the manuscript.	Al-Aidaroos AQO, 2010, J CELL BIOCHEM, V111, P1087, DOI 10.1002/jcb.22913; Beekman R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026537; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Chaudhary K, 2007, ONCOGENE, V26, P7499, DOI 10.1038/sj.onc.1210582; Chong PSY, 2014, CANCER RES, V74, P3043, DOI 10.1158/0008-5472.CAN-13-2321; Chung EJ, 2002, BLOOD, V100, P982, DOI 10.1182/blood.V100.3.982; Gandillet A, 2011, LEUKEMIA, V25, P770, DOI 10.1038/leu.2011.17; Gilliland DG, 2002, SEMIN HEMATOL, V39, P6, DOI 10.1053/shem.2002.36921; Krieghoff E, 2006, J CELL SCI, V119, P1453, DOI 10.1242/jcs.02864; Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535-6108(03)00334-9; Luu HH, 2004, CURR CANCER DRUG TAR, V4, P653, DOI 10.2174/1568009043332709; McParland V, 2011, BIOCHEMISTRY-US, V50, P7579, DOI 10.1021/bi201095z; Mikesch JH, 2007, LEUKEMIA, V21, P1638, DOI 10.1038/sj.leu.2404732; Mosimann C, 2006, CELL, V125, P327, DOI 10.1016/j.cell.2006.01.053; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004; Park JE, 2013, EMBO MOL MED, V5, P1351, DOI 10.1002/emmm.201202183; Patterson KI, 2009, BIOCHEM J, V418, P475, DOI 10.1042/BJ20082234; Reindl C, 2006, BLOOD, V107, P3700, DOI 10.1182/blood-2005-06-2596; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Saito Y, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000349; Simon M, 2005, ONCOGENE, V24, P2410, DOI 10.1038/sj.onc.1208431; Wang HH, 2010, CANCER CELL, V18, P52, DOI 10.1016/j.ccr.2010.04.028; Ysebaert L, 2006, LEUKEMIA, V20, P1211, DOI 10.1038/sj.leu.2404239; Zeng Q, 2000, J BIOL CHEM, V275, P21444, DOI 10.1074/jbc.M000453200; Zeng Q, 2003, CANCER RES, V63, P2716; Zhou JX, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0014752, 10.1371/journal.pone.0024340, 10.1371/journal.pone.0019798]	26	14	16	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1508	1519		10.1038/s41388-018-0526-3	http://dx.doi.org/10.1038/s41388-018-0526-3			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30305722				2022-12-17	WOS:000459945800010
J	Neubauer, HA; Tea, MN; Zebol, JR; Gliddon, BL; Stefanidis, C; Moretti, PAB; Pitman, MR; Costabile, M; Kular, J; Stringer, BW; Day, BW; Samuel, MS; Bonder, CS; Powell, JA; Pitson, SM				Neubauer, Heidi A.; Tea, Melinda N.; Zebol, Julia R.; Gliddon, Briony L.; Stefanidis, Cassandra; Moretti, Paul A. B.; Pitman, Melissa R.; Costabile, Maurizio; Kular, Jasreen; Stringer, Brett W.; Day, Bryan W.; Samuel, Michael S.; Bonder, Claudine S.; Powell, Jason A.; Pitson, Stuart M.			Cytoplasmic dynein regulates the subcellular localization of sphingosine kinase 2 to elicit tumor-suppressive functions in glioblastoma	ONCOGENE			English	Article							INTERMEDIATE CHAIN; CELL-MIGRATION; SPHINGOSINE-1-PHOSPHATE; RECEPTORS; CANCER; EXPRESSION; GROWTH; ROLES; TRANSLOCATION; 1-PHOSPHATE	While the two mammalian sphingosine kinases, SK1 and SK2, both catalyze the generation of pro-survival sphingosine 1-phosphate (S1P), their roles vary dependent on their different subcellular localization. SK1 is generally found in the cytoplasm or at the plasma membrane where it can promote cell proliferation and survival. SK2 can be present at the plasma membrane where it appears to have a similar function to SK1, but can also be localized to the nucleus, endoplasmic reticulum or mitochondria where it mediates cell death. Although SK2 has been implicated in cancer initiation and progression, the mechanisms regulating SK2 subcellular localization are undefined. Here, we report that SK2 interacts with the intermediate chain subunits of the retrograde-directed transport motor complex, cytoplasmic dynein 1 (DYNC1I1 and -2), and we show that this interaction, particularly with DYNC1I1, facilitates the transport of SK2 away from the plasma membrane. DYNC1I1 is dramatically downregulated in patient samples of glioblastoma (GBM), where lower expression of DYNC1I1 correlates with poorer patient survival. Notably, low DYNC1I1 expression in GBM cells coincided with more SK2 localized to the plasma membrane, where it has been recently implicated in oncogenesis. Re-expression of DYNC1I1 reduced plasma membrane-localized SK2 and extracellular S1P formation, and decreased GBM tumor growth and tumor-associated angiogenesis in vivo. Consistent with this, chemical inhibition of SK2 reduced the viability of patient-derived GBM cells in vitro and decreased GBM tumor growth in vivo. Thus, these findings demonstrate a tumor-suppressive function of DYNC1I1, and uncover new mechanistic insights into SK2 regulation which may have implications in targeting this enzyme as a therapeutic strategy in GBM.	[Neubauer, Heidi A.; Tea, Melinda N.; Zebol, Julia R.; Gliddon, Briony L.; Stefanidis, Cassandra; Moretti, Paul A. B.; Pitman, Melissa R.; Costabile, Maurizio; Kular, Jasreen; Samuel, Michael S.; Bonder, Claudine S.; Powell, Jason A.; Pitson, Stuart M.] Univ South Australia, Ctr Canc Biol, Adelaide, SA, Australia; [Neubauer, Heidi A.; Tea, Melinda N.; Zebol, Julia R.; Gliddon, Briony L.; Stefanidis, Cassandra; Moretti, Paul A. B.; Pitman, Melissa R.; Costabile, Maurizio; Kular, Jasreen; Samuel, Michael S.; Bonder, Claudine S.; Powell, Jason A.; Pitson, Stuart M.] SA Pathol, Adelaide, SA, Australia; [Neubauer, Heidi A.; Pitson, Stuart M.] Univ Adelaide, Sch Biol Sci, Adelaide, SA, Australia; [Stefanidis, Cassandra; Costabile, Maurizio] Univ South Australia, Sch Pharm & Med Sci, Adelaide, SA, Australia; [Stringer, Brett W.; Day, Bryan W.] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia; [Samuel, Michael S.; Bonder, Claudine S.; Powell, Jason A.; Pitson, Stuart M.] Univ Adelaide, Adelaide Med Sch, Adelaide, SA, Australia	Centre for Cancer Biology; University of South Australia; SA Pathology; University of Adelaide; University of South Australia; QIMR Berghofer Medical Research Institute; University of Adelaide	Pitson, SM (corresponding author), Univ South Australia, Ctr Canc Biol, Adelaide, SA, Australia.; Pitson, SM (corresponding author), SA Pathol, Adelaide, SA, Australia.; Pitson, SM (corresponding author), Univ Adelaide, Sch Biol Sci, Adelaide, SA, Australia.; Pitson, SM (corresponding author), Univ Adelaide, Adelaide Med Sch, Adelaide, SA, Australia.	stuart.pitson@unisa.edu.au	Day, Bryan/AAV-6170-2020; Neubauer, Heidi A./AAD-8727-2019; Pitson, Stuart/B-9342-2009; Samuel, Michael/D-2706-2011; costabile, maurizio/AEN-4356-2022; Stringer, Brett/GZB-1390-2022	Pitson, Stuart/0000-0002-9527-2740; Samuel, Michael/0000-0001-7880-6379; costabile, maurizio/0000-0002-2162-6497; Dobbins, Julia/0000-0001-5833-2655; Moretti, Paul/0000-0002-3523-1496; Pitman, Melissa/0000-0002-9587-3837; Day, Bryan/0000-0002-8948-9089; Stringer, Brett/0000-0003-4552-9736; Bonder, Claudine S./0000-0001-9875-967X; Gliddon, Briony/0000-0003-3928-7478; Powell, jason/0000-0001-8493-9178; Tea, Melinda/0000-0001-7045-1198; Neubauer, Heidi/0000-0001-7372-7786	Neurosurgical Research Foundation; Fay Fuller Foundation; National Health and Medical Research Council of Australia (NHMRC) [GNT626936]; NHMRC [508098, 1042589]; Australian Postgraduate Award; Royal Adelaide Hospital (RAH) Dawes Scholarship; RAH Research Fund Early Career Fellowship	Neurosurgical Research Foundation; Fay Fuller Foundation; National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Australian Postgraduate Award(Australian Government); Royal Adelaide Hospital (RAH) Dawes Scholarship; RAH Research Fund Early Career Fellowship	This work was supported by the Neurosurgical Research Foundation, the Fay Fuller Foundation, a National Health and Medical Research Council of Australia (NHMRC) Project Grant (GNT626936), NHMRC Senior Research Fellowships (508098 and 1042589) to SMP, an Australian Postgraduate Award and a Royal Adelaide Hospital (RAH) Dawes Scholarship to HAN, and a RAH Research Fund Early Career Fellowship to MRP.	Abuhusain HJ, 2013, J BIOL CHEM, V288, P37355, DOI 10.1074/jbc.M113.494740; Bien-Moller S, 2016, ONCOTARGET, V7, P13031, DOI 10.18632/oncotarget.7366; Blondeau N, 2007, J NEUROCHEM, V103, P509, DOI 10.1111/j.1471-4159.2007.04755.x; Carpinteiro A, 2008, CANCER LETT, V264, P1, DOI 10.1016/j.canlet.2008.02.020; Chipuk JE, 2012, CELL, V148, P988, DOI 10.1016/j.cell.2012.01.038; French KJ, 2010, J PHARMACOL EXP THER, V333, P129, DOI 10.1124/jpet.109.163444; Ha JH, 2008, J CELL BIOL, V181, P1027, DOI 10.1083/jcb.200803150; Hait NC, 2009, SCIENCE, V325, P1254, DOI 10.1126/science.1176709; Horikawa I, 2001, J CELL BIOCHEM, V82, P415, DOI 10.1002/jcb.1169; Ibbetson SJ, 2013, AM J PATHOL, V183, P930, DOI 10.1016/j.ajpath.2013.05.014; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Jarman KE, 2010, J BIOL CHEM, V285, P483, DOI 10.1074/jbc.M109.068395; Kapitonov D, 2009, CANCER RES, V69, P6915, DOI 10.1158/0008-5472.CAN-09-0664; Kardon JR, 2009, NAT REV MOL CELL BIO, V10, P854, DOI 10.1038/nrm2804; Kular J, 2015, DEV CELL, V35, P759, DOI 10.1016/j.devcel.2015.11.026; Kuta A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011682; Ligon LA, 2001, NAT CELL BIOL, V3, P913, DOI 10.1038/ncb1001-913; LIN SXH, 1992, J CELL SCI, V101, P125; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056471; Maceyka M, 2005, J BIOL CHEM, V280, P37118, DOI 10.1074/jbc.M502207200; Neubauer HA, 2017, F1000 RES, V5, P2825; Neubauer HA, 2016, ONCOTARGET, V7, P64886, DOI 10.18632/oncotarget.11714; Neubauer HA, 2013, FEBS J, V280, P5317, DOI 10.1111/febs.12314; Newton J, 2015, EXP CELL RES, V333, P195, DOI 10.1016/j.yexcr.2015.02.025; Olivera A, 2006, J BIOL CHEM, V281, P2515, DOI 10.1074/jbc.M508931200; Palmer KJ, 2009, MOL BIOL CELL, V20, P2885, DOI 10.1091/mbc.E08-12-1160; Pitman MR, 2015, ONCOTARGET, V6, P7065, DOI 10.18632/oncotarget.3178; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559; Pitson SM, 2011, TRENDS BIOCHEM SCI, V36, P97, DOI 10.1016/j.tibs.2010.08.001; Quint K, 2014, TUMOR BIOL, V35, P8979, DOI 10.1007/s13277-014-2172-x; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Roberts JL, 2004, ANAL BIOCHEM, V331, P122, DOI 10.1016/j.ab.2004.03.030; Schroer TA, 2004, ANNU REV CELL DEV BI, V20, P759, DOI 10.1146/annurev.cellbio.20.012103.094623; Siow D, 2011, CRIT REV BIOCHEM MOL, V46, P365, DOI 10.3109/10409238.2011.580097; Sordillo LA, 2016, ANTICANCER RES, V36, P2085; Stringer BW, 2016, ONCOTARGET, V7, P29306, DOI 10.18632/oncotarget.8720; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Sun WY, 2016, J IMMUNOL, V196, P3854, DOI 10.4049/jimmunol.1501510; Takabe K, 2014, J LIPID RES, V55, P1839, DOI 10.1194/jlr.R046656; Van Brocklyn JR, 2005, J NEUROPATH EXP NEUR, V64, P695, DOI 10.1097/01.jnen.0000175329.59092.2c; Van Brocklyn JR, 2003, CANCER LETT, V199, P53, DOI 10.1016/S0304-3835(03)00334-3; Van Brocklyn JR, 2002, CANCER LETT, V181, P195, DOI 10.1016/S0304-3835(02)00050-2; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang QH, 2017, CANCER CELL, V32, P42, DOI 10.1016/j.ccell.2017.06.003; Weigert A, 2009, INT J CANCER, V125, P2114, DOI 10.1002/ijc.24594; Young N, 2007, EXP CELL RES, V313, P1615, DOI 10.1016/j.yexcr.2007.02.009; Zebol JR, 2009, INT J BIOCHEM CELL B, V41, P822, DOI 10.1016/j.biocel.2008.08.012; Zhang J, 2002, MOL MICROBIOL, V44, P381, DOI 10.1046/j.1365-2958.2002.02900.x; Zhu W, 2017, ONCOGENE, V36, P2619, DOI 10.1038/onc.2016.428; Zhu WY, 2017, CANCER RES, V77, P4823, DOI 10.1158/0008-5472.CAN-17-0025	52	14	15	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1151	1165		10.1038/s41388-018-0504-9	http://dx.doi.org/10.1038/s41388-018-0504-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30250299	Green Published, hybrid			2022-12-17	WOS:000459249800001
J	Ohno, Y; Shingyoku, S; Miyake, S; Tanaka, A; Fudesaka, S; Shimizu, Y; Yoshifuji, A; Yamawaki, Y; Yoshida, S; Tanaka, S; Sakura, K; Tanaka, T				Ohno, Yoshiya; Shingyoku, Serina; Miyake, Sakina; Tanaka, Aya; Fudesaka, Sena; Shimizu, Yuta; Yoshifuji, Ai; Yamawaki, Yuki; Yoshida, Sachiyo; Tanaka, Saya; Sakura, Kazuma; Tanaka, Toshiyuki			Differential regulation of the sphere formation and maintenance of cancer-initiating cells of malignant mesothelioma via CD44 and ALK4 signaling pathways	ONCOGENE			English	Article							STEM-CELLS; ACTIVIN-A; PLEURAL MESOTHELIOMA; HYALURONAN; RECEPTOR; TUMORIGENICITY; PATHOGENESIS; INSIGHTS; MARKER; GROWTH	Malignant mesothelioma (MM) has a poor prognosis and is largely resistant to standard treatments, so it is important to seek novel therapeutic strategies for this disease. Cancer-initiating cells (CICs) were previously identified in MM using stem cell-associated markers in combination with spheroid cultures. However, the mechanisms underlying the induction and maintenance of CICs in MM remain to be fully explored. Here we showed that the CICs, which had high aldehyde dehydrogenase levels (ALDH(bri)(g)(ht)) and stem cell-associated genes, were expanded in MM cells cultured under sphere-forming conditions. The MM spheroids also initiated tumors in immunodeficient mice more efficiently than did conventional adherent MM cells. In the MM spheroids, the expression of hyaluronan (HA) synthases was upregulated. Inhibiting the HA synthesis or CD44 functions by gene knockdown or neutralizing antibody abolished the formation of large-sized spheroids and the expansion of ALDH(bri)(g)(ht) CICs. The expression of activin-A was also increased in the spheroids, and type I activin-A receptor subunit (ALK4) was upregulated in the ALDH(bright) CICs. The neutralization of activin-A or functional inactivation of ALK4 diminished the ALDH(bri)(g)(ht) CICs without affecting spheroid formation. The knockdown of CD44 or ALK4 strongly suppressed the tumor growth in immunodeficient mice. These results together suggest that the HA-CD44 and activin-A-ALK4 pathways differentially regulate the spheroid formation and maintenance of ALDH(bri)(g)(ht) CICs in MM cells, and that both pathways play critical roles in tumor growth in immunodeficient hosts. Our findings provide a novel therapeutic option for MM that targets signaling pathways that promote the CIC compartment through CD44 and ALK4.	[Ohno, Yoshiya; Shingyoku, Serina; Miyake, Sakina; Tanaka, Aya; Fudesaka, Sena; Shimizu, Yuta; Yoshifuji, Ai; Yamawaki, Yuki; Yoshida, Sachiyo; Tanaka, Saya; Tanaka, Toshiyuki] Hyogo Univ Hlth Sci, Sch Pharm, Lab Immunobiol, Kobe, Hyogo, Japan; [Sakura, Kazuma] Osaka Univ Hosp, Ctr Med Innovat & Translat Res, Osaka, Japan; [Sakura, Kazuma] Osaka Univ, Dept Surg, Grad Sch Med, Osaka, Japan	Osaka University; Osaka University	Tanaka, T (corresponding author), Hyogo Univ Hlth Sci, Sch Pharm, Lab Immunobiol, Kobe, Hyogo, Japan.	tanaka@huhs.ac.jp			JSPS KAKENHI [JP22700889]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported in part by JSPS KAKENHI Grant Number JP22700889.	Abdullah LN, 2013, CLIN TRANSL MED, V2, DOI 10.1186/2001-1326-2-3; Bueno R, 2016, NAT GENET, V48, P407, DOI 10.1038/ng.3520; Canino C, 2012, ONCOGENE, V31, P3148, DOI 10.1038/onc.2011.485; Cortes-Dericks L, 2014, BMC CANCER, V14, P2818; Cortes-Dericks L, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0546-5; Ghani FI, 2011, BIOCHEM BIOPH RES CO, V404, P735, DOI 10.1016/j.bbrc.2010.12.054; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Hanagiri T, 2012, TUMOR BIOL, V33, P2135, DOI 10.1007/s13277-012-0473-5; Hiraga T, 2013, CANCER RES, V73, P4112, DOI 10.1158/0008-5472.CAN-12-3801; Hoda MA, 2012, BRIT J CANCER, V107, P1978, DOI 10.1038/bjc.2012.519; Hoda MA, 2016, EUR J CANCER, V63, P64, DOI 10.1016/j.ejca.2016.04.018; Husain AN, 2018, ARCH PATHOL LAB MED, V142, P89, DOI 10.5858/arpa.2017-0124-RA; Kultti A, 2009, EXP CELL RES, V315, P1914, DOI 10.1016/j.yexcr.2009.03.002; Lin KC, 2017, NAT CELL BIOL, V19, P996, DOI 10.1038/ncb3581; Liu R, 2016, BIOCHEM BIOPH RES CO, V479, P715, DOI 10.1016/j.bbrc.2016.09.146; Liu SL, 2017, CANCER RES, V77, P3791, DOI 10.1158/0008-5472.CAN-16-2545; Lonardo E, 2011, CELL STEM CELL, V9, P433, DOI 10.1016/j.stem.2011.10.001; Loomans HA, 2016, AM J CANCER RES, V6, P2431; Loomans HA, 2015, CANCERS, V7, P70, DOI 10.3390/cancers7010070; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mossman BT, 2013, AM J PATHOL, V182, P1065, DOI 10.1016/j.ajpath.2012.12.028; Nasreen N, 2001, ONCOL RES, V13, P71; Pasdar EA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119549; Pastrana E, 2011, CELL STEM CELL, V8, P486, DOI 10.1016/j.stem.2011.04.007; Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253; Preca BT, 2017, ONCOTARGET, V8, P11530, DOI 10.18632/oncotarget.14563; Robinson BWS, 2005, LANCET, V366, P397, DOI 10.1016/S0140-6736(05)67025-0; Sekido Y, 2013, CARCINOGENESIS, V34, P1413, DOI 10.1093/carcin/bgt166; Shapiro IM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008639; Tajima K, 2010, ONCOGENE, V29, P1941, DOI 10.1038/onc.2009.478; Tamminen JA, 2015, EXP CELL RES, V332, P102, DOI 10.1016/j.yexcr.2014.12.010; Tanaka K, 2017, CANCER LETT, V385, P215, DOI 10.1016/j.canlet.2016.10.020; TANAKA T, 1993, J EXP MED, V178, P1103, DOI 10.1084/jem.178.3.1103; Turley EA, 2016, CANCER RES, V76, P2507, DOI 10.1158/0008-5472.CAN-15-3114; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Xiang X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027946; Yap TA, 2017, NAT REV CANCER, V17, P475, DOI 10.1038/nrc.2017.42; Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023	38	14	14	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2018	37	49					6357	6367		10.1038/s41388-018-0405-y	http://dx.doi.org/10.1038/s41388-018-0405-y			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HD3AP	30061637	hybrid, Green Published			2022-12-17	WOS:000452384400006
J	Li, TF; Deng, Y; Shi, Y; Tian, RJ; Chen, YL; Zou, L; Kazi, JU; Ronnstrand, L; Feng, B; Chan, SO; Chan, WY; Sun, JM; Zhao, H				Li, Tianfeng; Deng, Yi; Shi, Yu; Tian, Ruijun; Chen, Yonglong; Zou, Lin; Kazi, Julhash U.; Ronnstrand, Lars; Feng, Bo; Chan, Sun On; Chan, Wai Yee; Sun, Jianmin; Zhao, Hui			Bruton's tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma	ONCOGENE			English	Article							POSITIVE NSCLC; CELL LYMPHOMA; IBRUTINIB; BTK; INHIBITOR; ACTIVATION; RESISTANCE; IDENTIFICATION; CRIZOTINIB; MUTATIONS	Aberrant activation of anaplastic lymphoma kinase (ALK) can cause sporadic and familial neuroblastoma. Using a proteomics approach, we identified Bruton's tyrosine kinase (BTK) as a novel ALK interaction partner, and the physical interaction was confirmed by co-immunoprecipitation. BTK is expressed in neuroblastoma cell lines and tumor tissues. Its high expression correlates with poor relapse-free survival probability of neuroblastoma patients. Mechanistically, we demonstrated that BTK potentiates ALK-mediated signaling in neuroblastoma, and increases ALK stability by reducing ALK ubiquitination. Both ALKWT and ALKF1174L can induce BTK phosphorylation and higher capacity of ALKF1174L is observed. Furthermore, the BTK inhibitor ibrutinib can effectively inhibit the growth of neuroblastoma xenograft in nude mice, and the combination of ibrutinib and the ALK inhibitor crizotinib further enhances the inhibition. Our study provides strong rationale for clinical trial of ALK-positive neuroblastoma using ibrutinib or the combination of ibrutinib and ALK inhibitors.	[Li, Tianfeng; Feng, Bo; Chan, Sun On; Chan, Wai Yee; Zhao, Hui] Chinese Univ Hong Kong, Sch Biomed Sci, Key Lab Regenerat Med, Minist Educ,Fac Med, Hong Kong, Hong Kong, Peoples R China; [Sun, Jianmin] Ningxia Med Univ, Dept Pathogen Biol & Immunol, Sch Basic Med Sci, 1160 Shengli St, Yinchuan 750004, Peoples R China; [Deng, Yi; Chen, Yonglong] Southern Univ Sci & Technol, Guangdong Prov Key Lab Cell Microenvironm & Dis R, Dept Biol, Shenzhen 51805, Guangdong, Peoples R China; [Deng, Yi; Chen, Yonglong] Southern Univ Sci & Technol, Shenzhen Key Lab Cell Microenvironm, Shenzhen 51805, Guangdong, Peoples R China; [Shi, Yu] Chongqing Med Univ, Key Lab Child Dev & Disorders, Chongqing Key Lab Translat Med Res Cognit Dev & L, Dept Clin Lab,Minist Educ,Childrens Hosp,Chongqin, Chongqing 400014, Peoples R China; [Tian, Ruijun] South Univ Sci & Technol China, Dept Chem, Guangdong Prov Key Lab Cell Microenvironm & Dis R, Shenzhen 518055, Guangdong, Peoples R China; [Tian, Ruijun] South Univ Sci & Technol China, Shenzhen Key Lab Cell Microenvironm, Shenzhen 518055, Guangdong, Peoples R China; [Zou, Lin] Chongqing Med Univ, Chongqing Int Sci & Technol Cooperat Ctr Child De, Key Lab Pediat Chongqing, Ctr Clin Mol Med,Childrens Hosp,Minist Educ,Key L, Chongqing 400014, Peoples R China; [Kazi, Julhash U.; Ronnstrand, Lars; Sun, Jianmin] Lund Univ, Div Translat Canc Res, Dept Lab Med, Lund, Sweden; [Chan, Wai Yee; Zhao, Hui] Chinese Univ Hong Kong, Kunming Inst Zool, Chinese Acad Sci, Joint Lab Bioresources & Mol Res Common Dis, Hong Kong, Hong Kong, Peoples R China; [Ronnstrand, Lars] Lund Univ, Dept Lab Med, Lund Stem Cell Ctr, Lund, Sweden; [Ronnstrand, Lars] Skane Univ Hosp, Div Oncol, Lund, Sweden	Chinese University of Hong Kong; Ningxia Medical University; Southern University of Science & Technology; Southern University of Science & Technology; Chongqing Medical University; Southern University of Science & Technology; Southern University of Science & Technology; Chongqing Medical University; Lund University; Chinese Academy of Sciences; Kunming Institute of Zoology; Chinese University of Hong Kong; Lund University; Lund University; Skane University Hospital	Zhao, H (corresponding author), Chinese Univ Hong Kong, Sch Biomed Sci, Key Lab Regenerat Med, Minist Educ,Fac Med, Hong Kong, Hong Kong, Peoples R China.; Sun, JM (corresponding author), Ningxia Med Univ, Dept Pathogen Biol & Immunol, Sch Basic Med Sci, 1160 Shengli St, Yinchuan 750004, Peoples R China.; Sun, JM (corresponding author), Lund Univ, Div Translat Canc Res, Dept Lab Med, Lund, Sweden.; Zhao, H (corresponding author), Chinese Univ Hong Kong, Kunming Inst Zool, Chinese Acad Sci, Joint Lab Bioresources & Mol Res Common Dis, Hong Kong, Hong Kong, Peoples R China.	jianmin.sun@nxmu.edu.cn; zhaohui@cuhk.edu.hk	Zhao, Hui/B-8429-2016; Tian, Ruijun/J-3019-2014; Kazi, Julhash U./D-9190-2011; Feng, Bo/D-7831-2014; Chan, Wai Yee/R-7442-2018; Chan, Sun-On/R-6547-2018	Zhao, Hui/0000-0001-8160-6415; Kazi, Julhash U./0000-0002-0719-5336; Feng, Bo/0000-0002-4018-3257; Chan, Wai Yee/0000-0002-9714-0936; Chan, Sun-On/0000-0002-3221-3786; Sun, Jianmin/0000-0003-2327-4285; Tian, Ruijun/0000-0001-9521-5124; Deng, Yi/0000-0003-1378-015X; Ronnstrand, Lars/0000-0003-1275-5809	Research Grants Council of Hong Kong [CUHK24100414, CUHK14167017]; Guangdong Natural Science of Foundation [2017A030313209]; Guangdong Provincial Key Laboratory of Cell Microenvironment and Disease Research [2017B030301018]; Shenzhen Key Laboratory of Cell Microenvironment [ZDSYS20140509142721429]; West China Top Class Discipline Project in Basic Medical Sciences of Ningxia Medical University [NXYLXK2017B07]; CUHK; National Natural Science Foundation of China [31471367, 31671519, 81660473]	Research Grants Council of Hong Kong(Hong Kong Research Grants Council); Guangdong Natural Science of Foundation; Guangdong Provincial Key Laboratory of Cell Microenvironment and Disease Research; Shenzhen Key Laboratory of Cell Microenvironment; West China Top Class Discipline Project in Basic Medical Sciences of Ningxia Medical University; CUHK(Chinese University of Hong Kong); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Dr. Marc Vigny for kindly providing the ALK<SUP>WT</SUP> and ALK<SUP>F1174L</SUP> constructs. This work is supported by the Research Grants Council of Hong Kong (CUHK24100414, CUHK14167017) to HZ, the grants from Guangdong Natural Science of Foundation (2017A030313209) and Guangdong Provincial Key Laboratory of Cell Microenvironment and Disease Research (2017B030301018) and Shenzhen Key Laboratory of Cell Microenvironment (ZDSYS20140509142721429) to YD, the National Natural Science Foundation of China (81660473) and West China Top Class Discipline Project (NXYLXK2017B07) in Basic Medical Sciences of Ningxia Medical University to JS, One-off Funding for KIZ-CUHK Joint Lab/Research Collaboration from CUHK to WYC, the National Natural Science Foundation of China (31471367, 31671519) to YC, and TL is supported by the Graduate Studentships from CUHK. We thank colleagues in our laboratories for the helpful discussion.	Asati V, 2016, EUR J MED CHEM, V109, P314, DOI 10.1016/j.ejmech.2016.01.012; Braun F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125552; Buggy JJ, 2012, INT REV IMMUNOL, V31, P119, DOI 10.3109/08830185.2012.664797; Chakraborty R, 2015, EXPERT REV HEMATOL, V8, P569, DOI 10.1586/17474086.2015.1061427; Cheung NKV, 2013, NAT REV CANCER, V13, P397, DOI 10.1038/nrc3526; de Claro RA, 2015, CLIN CANCER RES, V21, P3586, DOI 10.1158/1078-0432.CCR-14-2225; Ding N, 2015, ONCOTARGET, V6, P15122, DOI 10.18632/oncotarget.3824; Geoerger B, 2015, J CLIN ONCOL, V33; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; Grassilli E, 2016, ONCOGENE, V35, P4368, DOI 10.1038/onc.2015.504; Guo W, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.343; Herman SEM, 2014, BLOOD, V123, P3286, DOI 10.1182/blood-2014-02-548610; Holla VR, 2017, CSH MOL CASE STUD, V3, DOI 10.1101/mcs.a001115; Honigberg LA, 2010, P NATL ACAD SCI USA, V107, P13075, DOI 10.1073/pnas.1004594107; Isozaki H, 2016, CANCER RES, V76, P1506, DOI 10.1158/0008-5472.CAN-15-1010; Jin J, 2004, CURR BIOL, V14, P1436, DOI 10.1016/j.cub.2004.07.051; Khozin S, 2015, CLIN CANCER RES, V21, P2436, DOI 10.1158/1078-0432.CCR-14-3157; Kodityal S, 2016, LUNG CANCER, V92, P19, DOI 10.1016/j.lungcan.2015.11.023; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Larkins E, 2016, CLIN CANCER RES, V22, P5171, DOI 10.1158/1078-0432.CCR-16-1293; Li Y, 2016, ONCOGENE, V35, P6223, DOI 10.1038/onc.2016.155; Louis CU, 2015, ANNU REV MED, V66, P49, DOI 10.1146/annurev-med-011514-023121; MacGurn JA, 2012, ANNU REV BIOCHEM, V81, P231, DOI 10.1146/annurev-biochem-060210-093619; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006; Metro G, 2017, LUNG CANCER, V106, P58, DOI 10.1016/j.lungcan.2017.02.003; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Mosse YP, 2013, LANCET ONCOL, V14, P472, DOI 10.1016/S1470-2045(13)70095-0; Motegi A, 2004, J CELL SCI, V117, P3319, DOI 10.1242/jcs.01183; Park JR, 2010, HEMATOL ONCOL CLIN N, V24, P65, DOI 10.1016/j.hoc.2009.11.011; Roskoski R, 2016, PHARMACOL RES, V113, P395, DOI 10.1016/j.phrs.2016.09.011; Sasaki T, 2010, CANCER RES, V70, P10038, DOI 10.1158/0008-5472.CAN-10-2956; Smith CIE, 2017, ONCOGENE, V36, P2045, DOI 10.1038/onc.2016.343; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Souttou B, 2001, J BIOL CHEM, V276, P9526, DOI 10.1074/jbc.M007333200; Sun J, 2014, ONCOGENE, V33, P5360, DOI 10.1038/onc.2013.479; Tabbo F, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00041; Tan SL, 2013, PHARMACOL THERAPEUT, V138, P294, DOI 10.1016/j.pharmthera.2013.02.001; Tucker DL, 2016, FUTURE ONCOL, V12, P477, DOI 10.2217/fon.15.342; Vela CM, 2016, AM J HEALTH-SYST PH, V73, P367, DOI 10.2146/ajhp140760; Wang CD, 2015, J BIOL CHEM, V290, P21925, DOI 10.1074/jbc.M115.644864; Wang HQ, 2017, ELIFE, V6, DOI 10.7554/eLife.17137; Yau NKM, 2015, CURR CANCER DRUG TAR, V15, P327	43	14	14	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2018	37	47					6180	6194		10.1038/s41388-018-0397-7	http://dx.doi.org/10.1038/s41388-018-0397-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HB2PG	30013190				2022-12-17	WOS:000450883000006
J	Mutvei, AP; Landor, SKJ; Fox, R; Braune, EB; Tsoi, YL; Phoon, YP; Sahlgren, C; Hartman, J; Bergh, J; Jin, SB; Lendahl, U				Mutvei, Anders P.; Landor, Sebastian K-J; Fox, Rhys; Braune, Eike-Benjamin; Tsoi, Yat Long; Phoon, Yee Peng; Sahlgren, Cecilia; Hartman, Johan; Bergh, Jonas; Jin, Shaobo; Lendahl, Urban			Notch signaling promotes a HIF2 alpha-driven hypoxic response in multiple tumor cell types	ONCOGENE			English	Article							INDUCIBLE FACTOR (HIF)-1-ALPHA; HIF2A MUTATIONS; HIF-2-ALPHA; INHIBITION; FACTOR-2; HIF-2; PHEOCHROMOCYTOMAS; DIFFERENTIATION; PARAGANGLIOMA; EXPRESSION	Hyperactivation of Notch signaling and the cellular hypoxic response are frequently observed in cancers, with increasing reports of connections to tumor initiation and progression. The two signaling mechanisms are known to intersect, but while it is well established that hypoxia regulates Notch signaling, less is known about whether Notch can regulate the cellular hypoxic response. We now report that Notch signaling specifically controls expression of HIF2 alpha, a key mediator of the cellular hypoxic response. Transcriptional upregulation of HIF2 alpha by Notch under normoxic conditions leads to elevated HIF2 alpha protein levels in primary breast cancer cells as well as in human breast cancer, medulloblastoma, and renal cell carcinoma cell lines. The elevated level of HIF2 alpha protein was in certain tumor cell types accompanied by downregulation of HIF1 alpha protein levels, indicating that high Notch signaling may drive a HIF1 alpha-to-HIF2 alpha switch. At the transcriptome level, the presence of HIF2 alpha was required for approximately 21% of all Notch-induced genes: among the 1062 genes that were upregulated by Notch in medulloblastoma cells during normoxia, upregulation was abrogated in 227 genes when HIF2 alpha expression was knocked down by HIF2 alpha siRNA. In conclusion, our data show that Notch signaling affects the hypoxic response via regulation of HIF2 alpha, which may be important for future cancer therapies.	[Mutvei, Anders P.; Landor, Sebastian K-J; Fox, Rhys; Braune, Eike-Benjamin; Tsoi, Yat Long; Phoon, Yee Peng; Jin, Shaobo; Lendahl, Urban] Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden; [Landor, Sebastian K-J; Sahlgren, Cecilia] Univ Turku, Turku Ctr Biotechnol, Turku 20520, Finland; [Landor, Sebastian K-J; Sahlgren, Cecilia] Abo Akad Univ, Turku 20520, Finland; [Hartman, Johan] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden; [Bergh, Jonas] Karolinska Univ Hosp, Karolinska Inst, Dept Oncol Pathol, Radiumhemmet,Breast Canc,Canc Theme, Stockholm, Sweden; [Bergh, Jonas] Univ Oxford, Dept Publ Hlth, Oxford OX1 2JD, England	Karolinska Institutet; University of Turku; Abo Akademi University; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; University of Oxford	Jin, SB; Lendahl, U (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden.	Shaobo.Jin@ki.se; Urban.Lendahl@ki.se	Braune, Eike-Benjamin/AAI-5820-2020; Hartman, Johan/N-1406-2015	Hartman, Johan/0000-0002-6500-8527; Fox, Rhys/0000-0002-7433-0331; Bergh, Jonas/0000-0001-5526-1847; MUTVEI, ANDERS/0000-0002-2498-5225	Swedish Cancer Society; Swedish Research Council; BRECT Consortium at Karolinska Institutet; ICMC (AstraZeneca); Albin K. Johanssons Foundation; Jane & Aatos Erkko Foundation	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); BRECT Consortium at Karolinska Institutet; ICMC (AstraZeneca)(AstraZeneca); Albin K. Johanssons Foundation; Jane & Aatos Erkko Foundation	The financial support from the Swedish Cancer Society, the Swedish Research Council, the BRECT Consortium at Karolinska Institutet, and ICMC (AstraZeneca) (UL) is gratefully acknowledged. SKJL was supported by the Jane & Aatos Erkko and Albin K. Johanssons Foundations. This work is dedicated to the memory of the late friend and colleague Lorenz Poellinger.	Toledo RA, 2017, ENDOCR-RELAT CANCER, V24, pC9, DOI 10.1530/ERC-16-0479; Andersson ER, 2014, NAT REV DRUG DISCOV, V13, P359, DOI 10.1038/nrd4252; Andersson ER, 2011, DEVELOPMENT, V138, P3593, DOI 10.1242/dev.063610; Aster JC, 2017, ANNU REV PATHOL-MECH, V12, P245, DOI 10.1146/annurev-pathol-052016-100127; Ayaz F, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00345; Benita Y, 2009, NUCLEIC ACIDS RES, V37, P4587, DOI 10.1093/nar/gkp425; Bertout JA, 2009, CANCER RES, V69, P3213, DOI 10.1158/0008-5472.CAN-08-4223; Braune EB, 2016, STEM CELL REP, V6, P643, DOI 10.1016/j.stemcr.2016.03.004; Bray SJ, 2016, NAT REV MOL CELL BIO, V17, P722, DOI 10.1038/nrm.2016.94; Brogi E, 1996, J CLIN INVEST, V97, P469, DOI 10.1172/JCI118437; Burroughs SK, 2013, FUTURE MED CHEM, V5, P553, DOI [10.4155/FMC.13.17, 10.4155/fmc.13.17]; Chapman G, 2006, J CELL BIOL, V175, P535, DOI 10.1083/jcb.200602009; Chen WF, 2016, NATURE, V539, P112, DOI 10.1038/nature19796; Cho H, 2016, NATURE, V539, P107, DOI 10.1038/nature19795; Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906; Danza G, 2012, MOL CANCER RES, V10, P230, DOI 10.1158/1541-7786.MCR-11-0296; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Favier J, 2012, NEW ENGL J MED, V367, P2161, DOI 10.1056/NEJMc1211953; Gao W, 2012, ARTHRITIS RHEUM-US, V64, P2104, DOI 10.1002/art.34397; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Herranz D, 2014, NAT MED, V20, P1130, DOI 10.1038/nm.3665; Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Jin S, 2013, ONCOGENE, V32, P4892, DOI 10.1038/onc.2012.517; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kilpinen S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r139; Koh MY, 2015, CANCER RES, V75, P316, DOI 10.1158/0008-5472.CAN-13-2190; Koh MY, 2011, CANCER RES, V71, P4015, DOI 10.1158/0008-5472.CAN-10-4142; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Landor SKJ', 2017, EXP CELL RES, V356, P146, DOI 10.1016/j.yexcr.2017.04.030; Lanner F, 2013, STEM CELLS DEV, V22, P1360, DOI 10.1089/scd.2012.0259; Lim KJ, 2015, ONCOTARGET, V6, P1666, DOI 10.18632/oncotarget.2762; Luo WB, 2010, J BIOL CHEM, V285, P3651, DOI 10.1074/jbc.M109.068577; Maillard I, 2004, BLOOD, V104, P1696, DOI 10.1182/blood-2004-02-0514; Main H, 2010, EXP CELL RES, V316, P1610, DOI 10.1016/j.yexcr.2009.12.012; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; Martini S, 2013, STEM CELLS, V31, P741, DOI 10.1002/stem.1320; Meunier A, 2016, HELIYON, V2, DOI 10.1016/j.heliyon.2016.e00104; O'Reilly SM, 2006, AM J PHYSIOL-CELL PH, V290, pC592, DOI 10.1152/ajpcell.00278.2005; Palomero T, 2006, P NATL ACAD SCI USA, V103, P18261, DOI 10.1073/pnas.0606108103; Petrella BL, 2005, ONCOGENE, V24, P1043, DOI 10.1038/sj.onc.1208305; Pietras A, 2011, MOL CANCER RES, V9, P626, DOI 10.1158/1541-7786.MCR-10-0508; Pietras A, 2009, P NATL ACAD SCI USA, V106, P16805, DOI 10.1073/pnas.0904606106; Pirot P, 2004, BIOCHEM BIOPH RES CO, V322, P526, DOI 10.1016/j.bbrc.2004.07.157; Pistollato F, 2010, STEM CELLS, V28, P1918, DOI 10.1002/stem.518; Qiang L, 2012, CELL DEATH DIFFER, V19, P284, DOI 10.1038/cdd.2011.95; Rankin EB, 2007, J CLIN INVEST, V117, P1068, DOI 10.1172/JCI30117; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Sahlgren C, 2008, P NATL ACAD SCI USA, V105, P6392, DOI 10.1073/pnas.0802047105; Scheuermann TH, 2013, NAT CHEM BIOL, V9, P271, DOI [10.1038/NCHEMBIO.1185, 10.1038/nchembio.1185]; Scheuerrnann TH, 2015, J MED CHEM, V58, P5930, DOI 10.1021/acs.jmedchem.5b00529; Schroeder T, 2000, EMBO J, V19, P2558, DOI 10.1093/emboj/19.11.2558; Semenza GL, 2011, NEW ENGL J MED, V365, P537, DOI [10.1056/NEJMra1011165, 10.1056/NEJMc1110602]; Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022; Siebel C, 2017, PHYSIOL REV, V97, P1235, DOI 10.1152/physrev.00005.2017; Toledo RA, 2013, ENDOCR-RELAT CANCER, V20, P349, DOI 10.1530/ERC-13-0101; Uchida T, 2004, J BIOL CHEM, V279, P14871, DOI 10.1074/jbc.M400461200; Wang V, 2005, CANCER RES, V65, P3299, DOI 10.1158/0008-5472.CAN-04-4130; Wettersten HI, 2017, NAT REV NEPHROL, V13, P410, DOI 10.1038/nrneph.2017.59; Xing F, 2011, ONCOGENE, V30, P4075, DOI 10.1038/onc.2011.122; Zhao JD, 2015, CANCER TREAT REV, V41, P623, DOI 10.1016/j.ctrv.2015.05.004; Zhuang ZP, 2012, NEW ENGL J MED, V367, P922, DOI 10.1056/NEJMoa1205119	62	14	15	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2018	37	46					6083	6095		10.1038/s41388-018-0400-3	http://dx.doi.org/10.1038/s41388-018-0400-3			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HA3SQ	29993038	hybrid, Green Published			2022-12-17	WOS:000450175900006
J	Boboila, S; Lopez, G; Yu, JY; Banerjee, D; Kadenhe-Chiweshe, A; Connolly, EP; Kandel, JJ; Rajbhandari, P; Silva, JM; Califano, A; Yamashiro, DJ				Boboila, Shuobo; Lopez, Gonzalo; Yu, Jiyang; Banerjee, Debarshi; Kadenhe-Chiweshe, Angela; Connolly, Eileen P.; Kandel, Jessica J.; Rajbhandari, Presha; Silva, Jose M.; Califano, Andrea; Yamashiro, Darrell J.			Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; THERAPEUTIC TARGETS; EXPRESSION; AP4; METASTASIS; NETWORK; GENES; IDENTIFICATION; PROGRESSION; ASSOCIATION	Despite the identification of MYCN amplification as an adverse prognostic marker in neuroblastoma, MYCN inhibitors have yet to be developed. Here, by integrating evidence from a whole-genome shRNA library screen and the computational inference of master regulator proteins, we identify transcription factor activating protein 4 (TFAP4) as a critical effector of MYCN amplification in neuroblastoma, providing a novel synthetic lethal target. We demonstrate that TFAP4 is a direct target of MYCN in neuroblastoma cells, and that its expression and activity strongly negatively correlate with neuroblastoma patient survival. Silencing TFAP4 selectively inhibits MYCN-amplified neuroblastoma cell growth both in vitro and in vivo, in xenograft mouse models. Mechanistically, silencing TFAP4 induces neuroblastoma differentiation, as evidenced by increased neurite outgrowth and upregulation of neuronal markers. Taken together, our results demonstrate that TFAP4 is a key regulator of MYCN-amplified neuroblastoma and may represent a valuable novel therapeutic target.	[Boboila, Shuobo; Banerjee, Debarshi; Yamashiro, Darrell J.] Columbia Univ, Dept Pediat, Med Ctr, New York, NY 10032 USA; [Boboila, Shuobo; Yamashiro, Darrell J.] Columbia Univ, Dept Pathol & Cell Biol, Med Ctr, New York, NY 10032 USA; [Boboila, Shuobo; Connolly, Eileen P.] Columbia Univ, Dept Radiat Oncol, Med Ctr, New York, NY 10032 USA; [Lopez, Gonzalo; Yu, Jiyang; Rajbhandari, Presha; Califano, Andrea] Columbia Univ, Dept Syst Biol, Med Ctr, New York, NY 10032 USA; [Lopez, Gonzalo] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Banerjee, Debarshi; Kadenhe-Chiweshe, Angela; Yamashiro, Darrell J.] Columbia Univ, Dept Surg, Med Ctr, New York, NY 10032 USA; [Kandel, Jessica J.] Univ Chicago Med & Biol Sci, Dept Surg, Sect Pediat Surg, Chicago, IL 60637 USA; [Rajbhandari, Presha] Columbia Univ, Dept Biol Sci, New York, NY 10025 USA; [Silva, Jose M.] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA; [Lopez, Gonzalo] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; [Lopez, Gonzalo] Childrens Hosp Philadelphia, Ctr Childhood Canc Res, Philadelphia, PA 19104 USA; [Yu, Jiyang] St Jude Childrens Res Hosp, Dept Computat Biol, Kay Res & Care Ctr, IA6053,262 Danny Thomas Pl,Mail Stop 1135, Memphis, TN 38105 USA	Columbia University; Columbia University; Columbia University; Columbia University; University of Pennsylvania; Pennsylvania Medicine; Columbia University; Columbia University; Icahn School of Medicine at Mount Sinai; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; St Jude Children's Research Hospital	Yamashiro, DJ (corresponding author), Columbia Univ, Dept Pediat, Med Ctr, New York, NY 10032 USA.; Yamashiro, DJ (corresponding author), Columbia Univ, Dept Pathol & Cell Biol, Med Ctr, New York, NY 10032 USA.; Califano, A (corresponding author), Columbia Univ, Dept Syst Biol, Med Ctr, New York, NY 10032 USA.; Yamashiro, DJ (corresponding author), Columbia Univ, Dept Surg, Med Ctr, New York, NY 10032 USA.	ac2248@cumc.columbia.edu; dy39@cumc.columbia.edu	Connolly, Eileen/AAX-9112-2021; banerjee, debarshi/AAF-5704-2020	Lopez, Gonzalo/0000-0002-5092-1284; Yamashiro, Darrell/0000-0002-1250-0235; Connolly, Eileen/0000-0001-6558-1932; Califano, Andrea/0000-0003-4742-3679	Alex's Lemonade Stand Foundation; Hyundai Hope on Wheels; Cancer Target Discovery and Development Consortium; National Cancer Institute (NCI) Outstanding Investigator Award [R35CA197745-02];  [NIH-1S10OD021764];  [NIH-1S10OD012351]; NATIONAL CANCER INSTITUTE [U01CA217858, R35CA197745] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [S10OD012351, S10OD021764] Funding Source: NIH RePORTER	Alex's Lemonade Stand Foundation; Hyundai Hope on Wheels; Cancer Target Discovery and Development Consortium; National Cancer Institute (NCI) Outstanding Investigator Award; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by grants from Alex's Lemonade Stand Foundation (DJY), Hyundai Hope on Wheels (DJY), The Cancer Target Discovery and Development Consortium (AC, GL, JS), the National Cancer Institute (NCI) Outstanding Investigator Award (R35CA197745-02) (AC). The computational analyses were supported by instrumentation grants NIH-1S10OD021764 and NIH-1S10OD012351. The results published here are, in part, based upon data generated by the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiative managed by the NCI. We thank Dr. Jose Silva, Icahn School of Medicine at Mount Sinai, for the generous gift of whole-genome shRNA library. We thank Dr. Garrett Brodeur, Children's Hospital of Philadelphia, for the SHEP21N engineered neuroblastoma cell line. We thank Dr. C. Patrick Reynolds, Texas Tech University, for the CHLA-255 neuroblastoma cell line.	Alvarez MJ, 2016, NAT GENET, V48, P838, DOI 10.1038/ng.3593; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Aytes A, 2014, CANCER CELL, V25, P638, DOI 10.1016/j.ccr.2014.03.017; Bhadury J, 2014, P NATL ACAD SCI USA, V111, pE2721, DOI 10.1073/pnas.1406722111; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Califano A, 2017, NAT REV CANCER, V17, P116, DOI 10.1038/nrc.2016.124; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Chong CM, 2016, MOL BIOSYST, V12, P2713, DOI 10.1039/c6mb00343e; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; D'Annibale S, 2014, J BIOL CHEM, V289, P7730, DOI 10.1074/jbc.M114.549535; Dart AE, 2013, EUR J CELL BIOL, V92, P129, DOI 10.1016/j.ejcb.2013.03.002; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Egawa T, 2011, P NATL ACAD SCI USA, V108, P14873, DOI 10.1073/pnas.1112293108; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hong SJ, 2008, NEUROCHEM RES, V33, P1821, DOI 10.1007/s11064-008-9639-3; Hsu CL, 2016, ONCOTARGET, V7, P36293, DOI 10.18632/oncotarget.9202; Huang JZ, 2003, P NATL ACAD SCI USA, V100, P7785, DOI 10.1073/pnas.1432908100; Jackstadt R, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.282; Jackstadt R, 2013, J EXP MED, V210, P1331, DOI 10.1084/jem.20120812; Jung P, 2008, P NATL ACAD SCI USA, V105, P15046, DOI 10.1073/pnas.0801773105; Kamai T, 2003, CLIN CANCER RES, V9, P2632; Kesanakurti D, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.182; Keshelava N, 2005, METH MOLEC MED, V110, P139; Kessler JD, 2012, SCIENCE, V335, P348, DOI 10.1126/science.1212728; Kim MY, 2006, P NATL ACAD SCI USA, V103, P13074, DOI 10.1073/pnas.0601915103; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; LAVENIUS E, 1994, GROWTH FACTORS, V10, P29, DOI 10.3109/08977199409019601; Lefebvre C, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.31; Liu LD, 2012, NATURE, V483, P608, DOI 10.1038/nature10927; Loh SHY, 2008, CELL DEATH DIFFER, V15, P283, DOI 10.1038/sj.cdd.4402258; Lutz W, 1996, ONCOGENE, V13, P803; Margolin AA, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-S1-S7; Matthay KK, 2012, CLIN CANCER RES, V18, P2740, DOI 10.1158/1078-0432.CCR-11-1939; Piovan E, 2013, CANCER CELL, V24, P766, DOI 10.1016/j.ccr.2013.10.022; Rajbhandari P, 2018, CANCER DISCOV, V8, P582, DOI 10.1158/2159-8290.CD-16-0861; Rodriguez-Barrueco R, 2015, GENE DEV, V29, P1631, DOI 10.1101/gad.262642.115; Schofield AV, 2013, CRIT REV BIOCHEM MOL, V48, P301, DOI 10.3109/10409238.2013.786671; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; Shi L, 2014, CANCER RES, V74, P532, DOI 10.1158/0008-5472.CAN-13-2203; Silva JM, 2005, NAT GENET, V37, P1281, DOI 10.1038/ng1650; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tian YM, 2011, DEV BIOL, V353, P206, DOI 10.1016/j.ydbio.2011.02.026; Toyoshima M, 2012, P NATL ACAD SCI USA, V109, P9545, DOI 10.1073/pnas.1121119109; Wyce A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072967; Xue CY, 2016, ONCOTARGET, V7, P54937, DOI 10.18632/oncotarget.10709; Yu Jiyang, 2013, Methods Mol Biol, V980, P371, DOI 10.1007/978-1-62703-287-2_22; Zhou J, 2003, WORLD J GASTROENTERO, V9, P9, DOI 10.3748/wjg.v9.i1.9; Zhou ZX, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-944	50	14	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2018	37	40					5451	5465		10.1038/s41388-018-0326-9	http://dx.doi.org/10.1038/s41388-018-0326-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV7MY	29880876	hybrid, Green Published			2022-12-17	WOS:000446312900006
J	Saponaro, C; Sergio, S; Coluccia, A; De Luca, M; La Regina, G; Mologni, L; Famiglini, V; Naccarato, V; Bonetti, D; Gautier, C; Gianni, S; Vergara, D; Salzet, M; Fournier, I; Bucci, C; Silvestri, R; Passerini, CG; Maffia, M; Coluccia, AML				Saponaro, Concetta; Sergio, Sara; Coluccia, Antonio; De Luca, Maria; La Regina, Giuseppe; Mologni, Luca; Famiglini, Valeria; Naccarato, Valentina; Bonetti, Daniela; Gautier, Candice; Gianni, Stefano; Vergara, Daniele; Salzet, Michel; Fournier, Isabelle; Bucci, Cecilia; Silvestri, Romano; Passerini, Carlo Gambacorti; Maffia, Michele; Coluccia, Addolorata Maria Luce			beta-catenin knockdown promotes NHERF1-mediated survival of colorectal cancer cells: implications for a double-targeted therapy	ONCOGENE			English	Article							SMALL-MOLECULE INHIBITION; REGULATORY FACTOR-1; NUCLEAR NHERF1; PROTEIN; GROWTH; COLON; PTEN; PHOSPHORYLATION; ASSOCIATION; ACTIVATION	Nuclear activated beta-catenin plays a causative role in colorectal cancers (CRC) but remains an elusive therapeutic target. Using human CRC cells harboring different Wnt/beta-catenin pathway mutations in APC/KRAS or beta-catenin/KRAS genes, and both genetic and pharmacological knockdown approaches, we show that oncogenic beta-catenin signaling negatively regulates the expression of NHERF1 (Na+/H+ exchanger 3 regulating factor 1), a PDZ-adaptor protein that is usually lost or downregulated in early dysplastic adenomas to exacerbate nuclear beta-catenin activity. Chromatin immunoprecipitation (ChIP) assays demonstrated that beta-catenin represses NHERF1 via TCF4 directly, while the association between TCF1 and the Nherf1 promoter increased upon beta-catenin knockdown. To note, the occurrence of a cytostatic survival response in settings of single beta-catenin-depleted CRC cells was abrogated by combining NHERF1 inhibition via small hairpin RNA (shRNA) or RS5517, a novel PDZ1-domain ligand of NHERF1 that prevented its ectopic nuclear entry. Mechanistically, dual NHERF1/beta-catenin targeting promoted an autophagy-to-apoptosis switch consistent with the activation of Caspase-3, the cleavage of PARP and reduced levels of phospho-ERK1/2, Beclin-1, and Rab7 autophagic proteins compared with beta-catenin knockdown alone. Collectively, our data unveil novel beta-catenin/TCF-dependent mechanisms of CRC carcinogenesis, also offering preclinical proof of concept for combining beta-catenin and NHERF1 pharmacological inhibitors as a mechanism-based strategy to augment apoptotic death of CRC cells refractory to current Wnt/beta-catenin-targeted therapeutics.	[Saponaro, Concetta; Sergio, Sara; Vergara, Daniele; Maffia, Michele; Coluccia, Addolorata Maria Luce] Giovanni Paolo II Oncol Hosp, Lab Clin Prote, I-73100 Lecce, Italy; [Saponaro, Concetta] IRCCS Ist Tumori Giovanni Paolo II, Funct Biomorphol Lab, Bari, Italy; [Sergio, Sara; De Luca, Maria; Vergara, Daniele; Bucci, Cecilia; Maffia, Michele; Coluccia, Addolorata Maria Luce] Univ Salento, Dept Biol & Environm Sci & Technol, I-73100 Lecce, Italy; [Coluccia, Antonio; La Regina, Giuseppe; Famiglini, Valeria; Naccarato, Valentina; Silvestri, Romano] Sapienza Univ Rome, Ist Pasteur Italia, Fdn Cenci Bolognetti, Dept Drug Chem & Technol, Piazzale Aldo Moro 5, I-00185 Rome, Italy; [Mologni, Luca; Passerini, Carlo Gambacorti] Univ Milano Bicocca, San Gerardo Hosp, Dept Clin Med, I-20052 Monza, Italy; [Bonetti, Daniela; Gautier, Candice; Gianni, Stefano] Sapienza Univ Rome, Ist Pasteur Italia, Fdn Cenci Bolognetti, Dept Biochem, Piazzale Aldo Moro 5, I-00185 Rome, Italy; [Salzet, Michel; Fournier, Isabelle] U1192 Lab Prote Reponse Inflammatoire & Spectrome, F-59000 Lille, France	IRCCS Istituto Tumori Bari Giovanni Paolo II; University of Salento; Fondazione Cenci Bolognetti; Sapienza University Rome; San Gerardo Hospital; University of Milano-Bicocca; Fondazione Cenci Bolognetti; Sapienza University Rome; Universite de Lille - ISITE; Universite de Lille	Coluccia, AML (corresponding author), Giovanni Paolo II Oncol Hosp, Lab Clin Prote, I-73100 Lecce, Italy.; Coluccia, AML (corresponding author), Univ Salento, Dept Biol & Environm Sci & Technol, I-73100 Lecce, Italy.	michele.maffia@unisalento.it; malu.coluccia@unisalento.it	MAFFIA, MICHELE/AAC-2943-2020; Vergara, Daniele/K-3831-2014; La Regina, Giuseppe/I-2161-2012; Mologni, Luca/AAC-1065-2022; Bucci, Cecilia/F-6699-2012; Saponaro, Concetta/K-7886-2018; Coluccia, Antonio/K-3114-2018; SERGIO, SARA/AAL-4019-2021; Salzet, Michel/A-7675-2011; sergio, sara/AAC-3849-2019; FOURNIER, Isabelle/H-9195-2015	Vergara, Daniele/0000-0002-2396-7674; La Regina, Giuseppe/0000-0003-3252-1161; Mologni, Luca/0000-0002-6365-5149; Bucci, Cecilia/0000-0002-6232-6183; Coluccia, Antonio/0000-0002-7940-8206; Salzet, Michel/0000-0003-4318-0817; FOURNIER, Isabelle/0000-0003-1096-5044; Saponaro, Concetta/0000-0002-8196-3583; Sergio, Sara/0000-0002-4490-4189	Italian Association for Cancer Research (AIRC)-Investigator Grant (IG) [14236]; Italian Grant PRIN 2015 [2015FCHJ8E]; European Union's Horizon 2020 Research and Innovation program under the Marie Sklodowska-Curie grant [675341]; AIRC IG 2016 [19068]; Apulia Regione Cluster Project SISTEMA [T7WGSJ3]; Veronesi Foundation fellowship	Italian Association for Cancer Research (AIRC)-Investigator Grant (IG); Italian Grant PRIN 2015; European Union's Horizon 2020 Research and Innovation program under the Marie Sklodowska-Curie grant; AIRC IG 2016; Apulia Regione Cluster Project SISTEMA; Veronesi Foundation fellowship	We thank Dr. Hans Clevers (Hubrecht Laboratory, Utrecht, The Netherlands) for providing the pcDNA<INF>6</INF>TR and pTER vectors. We gratefully acknowledge funding from Italian Association for Cancer Research (AIRC)-Investigator Grant (IG) 2014 No. 14236 (AMLC). This work was partially supported by Italian Grant PRIN 2015 (2015FCHJ8E) (RS), European Union's Horizon 2020 Research and Innovation program under the Marie Sklodowska-Curie grant agreement No. 675341 (SG), AIRC IG 2016 No. 19068 (CB) and Apulia Regione Cluster Project SISTEMA No. T7WGSJ3 (MM). MDL was recipient of a Veronesi Foundation fellowship. We warmly thank Dr. Antonio Danieli for his technical assistance.	Bellizzi A, 2011, HISTOPATHOLOGY, V58, P1086, DOI 10.1111/j.1365-2559.2011.03844.x; Blauwkamp TA, 2008, EMBO J, V27, P1436, DOI 10.1038/emboj.2008.80; Cantalupo G, 2001, EMBO J, V20, P683, DOI 10.1093/emboj/20.4.683; Cardone RA, 2007, MOL BIOL CELL, V18, P1768, DOI 10.1091/mbc.E06-07-0617; Case D. A., 2014, AMBER, V14; Coluccia AML, 2006, CANCER RES, V66, P2279, DOI 10.1158/0008-5472.CAN-05-2057; Cox J, 2014, MOL CELL PROTEOMICS, V13, P2513, DOI 10.1074/mcp.M113.031591; Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j; De Luca M, 2014, J CELL SCI, V127, P2697, DOI 10.1242/jcs.142604; Dixon SL, 2006, CHEM BIOL DRUG DES, V67, P370, DOI 10.1111/j.1747-0285.2006.00384.x; Du GF, 2016, ONCOTARGET, V7, P29440, DOI 10.18632/oncotarget.8751; Ediger TR, 1999, ENDOCRINOLOGY, V140, P2976, DOI 10.1210/en.140.7.2976; Fitzpatrick JM, 2014, BIOCHEMISTRY-US, V53, P5916, DOI 10.1021/bi500368k; Frattini M, 2004, CLIN CANCER RES, V10, P4015, DOI 10.1158/1078-0432.CCR-04-0031; Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611; Georgescu MM, 2008, CURR MOL MED, V8, P459, DOI 10.2174/156652408785748031; Georgescu MM, 2016, NEOPLASIA, V18, P512, DOI 10.1016/j.neo.2016.07.003; Georgescu MM, 2014, NEOPLASIA, V16, P365, DOI 10.1016/j.neo.2014.04.004; Handeli S, 2008, MOL CANCER THER, V7, P521, DOI 10.1158/1535-7163.MCT-07-2063; Hayashi Y, 2010, NEOPLASIA, V12, P1013, DOI 10.1593/neo.10780; Ho-Bouldoires THN, 2015, FREE RADICAL BIO MED, V89, P34, DOI 10.1016/j.freeradbiomed.2015.07.011; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Ivarsson Y, 2007, J BIOL CHEM, V282, P8568, DOI 10.1074/jbc.M611026200; Janssen KP, 2006, GASTROENTEROLOGY, V131, P1096, DOI 10.1053/j.gastro.2006.08.011; Kaidi A, 2007, NAT CELL BIOL, V9, P210, DOI 10.1038/ncb1534; Karn T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028403; Korb Oliver, 2007, Swarm Intelligence, V1, P115, DOI 10.1007/s11721-007-0006-9; Lazar CS, 2004, MOL BIOL CELL, V15, P5470, DOI 10.1091/mbc.E04-03-0239; Liu H, 2015, AUTOPHAGY, V11, P2323, DOI 10.1080/15548627.2015.1074372; Malfettone A, 2012, EXP MOL PATHOL, V92, P296, DOI 10.1016/j.yexmp.2012.03.004; Mamonova T, 2012, BIOCHEMISTRY-US, V51, P3110, DOI 10.1021/bi201213w; Mangia A, 2012, ONCOL REP, V28, P889, DOI 10.3892/or.2012.1895; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; Mayasundari A, 2008, BIOORG MED CHEM LETT, V18, P942, DOI 10.1016/j.bmcl.2007.12.038; Molina JR, 2012, ONCOGENE, V31, P1264, DOI 10.1038/onc.2011.324; Mologni L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051449; Pan Y, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1616; Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p; Saponaro C, 2014, CANCER BIOMARK, V14, P177, DOI 10.3233/CBM-130329; Schroeder TM, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-362; Song GJ, 2015, J BIOL CHEM, V290, P2879, DOI 10.1074/jbc.M114.609768; Song LL, 2015, CLIN COLORECTAL CANC, V14, P133, DOI 10.1016/j.clcc.2015.02.001; Stemmer-Rachamimov AO, 2001, AM J PATHOL, V158, P57, DOI 10.1016/S0002-9440(10)63944-2; Takahashi Y, 2006, EMBO J, V25, P910, DOI 10.1038/sj.emboj.7600979; Thorne CA, 2010, NAT CHEM BIOL, V6, P829, DOI 10.1038/NCHEMBIO.453; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Vaquero J, 2017, ONCOGENE, V36, P3067, DOI 10.1038/onc.2016.462; Verma UN, 2003, CLIN CANCER RES, V9, P1291; Wheeler DS, 2011, ONCOGENE, V30, P32, DOI 10.1038/onc.2010.389; Yang M, 2005, P NATL ACAD SCI USA, V102, P6027, DOI 10.1073/pnas.0501535102	50	14	14	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2018	37	24					3301	3316		10.1038/s41388-018-0170-y	http://dx.doi.org/10.1038/s41388-018-0170-y			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GJ6XB	29551770	Green Published, hybrid			2022-12-17	WOS:000435526600009
J	Abdul-Aziz, AM; Shafat, MS; Sun, Y; Marlein, CR; Piddock, RE; Robinson, SD; Edwards, DR; Zhou, ZG; Collins, A; Bowles, KM; Rushworth, SA				Abdul-Aziz, Amina M.; Shafat, Manar S.; Sun, Yu; Marlein, Christopher R.; Piddock, Rachel E.; Robinson, Stephen D.; Edwards, Dylan R.; Zhou, Zhigang; Collins, Angela; Bowles, Kristian M.; Rushworth, Stuart A.			HIF1 alpha drives chemokine factor pro-tumoral signaling pathways in acute myeloid leukemia	ONCOGENE			English	Article							MIGRATION INHIBITORY FACTOR; HYPOXIA-INDUCIBLE FACTORS; HEMATOPOIETIC STEM-CELLS; TARGET GENES; HIF-1-ALPHA; EXPRESSION; CANCER; AML; CHEMORESISTANCE; MAINTENANCE	Approximately 80% of patients diagnosed with acute myeloid leukemia (AML) die as a consequence of failure to eradicate the tumor from the bone marrow microenvironment. We have recently shown that stroma-derived interleukin-8 (IL-8) promotes AML growth and survival in the bone marrow in response to AML-derived macrophage migration inhibitory factor (MIF). In the present study we show that high constitutive expression of MIF in AML blasts in the bone marrow is hypoxia-driven and, through knockdown of MIF, HIF1 alpha and HIF2 alpha, establish that hypoxia supports AML tumor proliferation through HIF1 alpha signaling. In vivo targeting of leukemic cell HIF1 alpha inhibits AML proliferation in the tumor microenvironment through transcriptional regulation of MIF, but inhibition of HIF2 alpha had no measurable effect on AML blast survival. Functionally, targeted inhibition of MIF in vivo improves survival in models of AML. Here we present a mechanism linking HIF1 alpha to a pro-tumoral chemokine factor signaling pathway and in doing so, we establish a potential strategy to target AML.	[Abdul-Aziz, Amina M.; Shafat, Manar S.; Sun, Yu; Marlein, Christopher R.; Piddock, Rachel E.; Edwards, Dylan R.; Zhou, Zhigang; Bowles, Kristian M.; Rushworth, Stuart A.] Univ East Anglia, Norwich Med Sch, Norwich Res Pk, Norwich NR4 7UQ, Norfolk, England; [Robinson, Stephen D.] Univ East Anglia, Sch Biol Sci, Norwich Res Pk, Norwich NR4 7TJ, Norfolk, England; [Collins, Angela; Bowles, Kristian M.] Norfolk & Norwich Univ Hosp NHS Trust, Dept Haematol, Colney Lane, Norwich NR4 7UY, Norfolk, England	University of East Anglia; University of East Anglia; Norfolk & Norwich University Hospitals NHS Foundation Trust	Rushworth, SA (corresponding author), Univ East Anglia, Norwich Med Sch, Norwich Res Pk, Norwich NR4 7UQ, Norfolk, England.	s.rushworth@uea.ac.uk	Edwards, Dylan R/B-4734-2009	Edwards, Dylan R/0000-0002-3292-2064; Piddock, Rachel E./0000-0002-5831-004X; Robinson, Stephen/0000-0002-6606-7588; Bowles, Kristian/0000-0003-1334-4526; Shafat, Manar/0000-0002-3493-9089; Rushworth, Stuart/0000-0002-3711-7558	Ministry of Higher Education and Scientific Research of the State of Libya; Big C cancer charity (Norfolk, UK); National Institute for Health Research (UK); Rosetrees Trust [M499] Funding Source: researchfish	Ministry of Higher Education and Scientific Research of the State of Libya; Big C cancer charity (Norfolk, UK); National Institute for Health Research (UK)(National Institute for Health Research (NIHR)); Rosetrees Trust(Rosetrees Trust)	The authors wish to thank the Ministry of Higher Education and Scientific Research of the State of Libya, The Big C cancer charity (Norfolk, UK) and the National Institute for Health Research (UK) for funding and Professor Richard Ball, Dr Mark Wilkinson and Mr Iain Sheriffs, Norwich Biorepository (UK), for help with sample collection and storage. pCDH-luciferase-T2A-mCherry was kindly gifted from Prof. Dr. med. Irmela Jeremias, (Helmholtz Zentrum Munchen, Munich, Germany).	Abdul-Aziz AM, 2017, CANCER RES, V77, P303, DOI 10.1158/0008-5472.CAN-16-1095; Ammirante M, 2014, P NATL ACAD SCI USA, V111, P14776, DOI 10.1073/pnas.1416498111; Baugh JA, 2006, BIOCHEM BIOPH RES CO, V347, P895, DOI 10.1016/j.bbrc.2006.06.148; Chow DC, 2001, BIOPHYS J, V81, P685, DOI 10.1016/S0006-3495(01)75733-5; CIPOLLESCHI MG, 1993, BLOOD, V82, P2031; Deeb G, 2011, LEUKEMIA RES, V35, P579, DOI 10.1016/j.leukres.2010.10.020; Dohner H, 2015, NEW ENGL J MED, V373, P1136, DOI 10.1056/NEJMra1406184; Eliasson P, 2010, J CELL PHYSIOL, V222, P17, DOI 10.1002/jcp.21908; Fiegl M, 2009, BLOOD, V113, P1504, DOI 10.1182/blood-2008-06-161539; Forristal CE, 2015, LEUKEMIA, V29, P2075, DOI 10.1038/leu.2015.102; Fu H, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-66; Gaber T, 2011, J IMMUNOL, V186, P764, DOI 10.4049/jimmunol.0903421; Gilkes DM, 2013, FUTURE ONCOL, V9, P1623, DOI [10.2217/fon.13.92, 10.2217/FON.13.92]; GRANT WC, 1947, FED PROC, V6, P114; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Koh MY, 2012, TRENDS BIOCHEM SCI, V37, P364, DOI 10.1016/j.tibs.2012.06.004; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Liu X, 2015, DEV PHASE 1B 2A PROO; Luo JC, 2001, ONCOGENE, V20, P1435, DOI 10.1038/sj.onc.1204228; MacRae T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072884; Mahalingam D, 2016, 1 IN HUMAN PHASE 1 S; Miharada K, 2012, ANN NY ACAD SCI, V1266, P55, DOI 10.1111/j.1749-6632.2012.06564.x; Ortiz-Barahona A, 2010, NUCLEIC ACIDS RES, V38, P2332, DOI 10.1093/nar/gkp1205; Pillinger G, 2015, SCI REP-UK, V5, DOI 10.1038/srep12949; Piya S, 2017, AUTOPHAGY, V13, P214, DOI 10.1080/15548627.2016.1245263; Rapin N, 2014, BLOOD, V123, P894, DOI 10.1182/blood-2013-02-485771; Rouault-Pierre K, 2013, CELL STEM CELL, V13, P549, DOI 10.1016/j.stem.2013.08.011; Rowe JM, 2010, BLOOD, V116, P3147, DOI 10.1182/blood-2010-05-260117; Rushworth SA, 2012, BLOOD, V120, P5188, DOI 10.1182/blood-2012-04-422121; Schepers K, 2015, CELL STEM CELL, V16, P254, DOI 10.1016/j.stem.2015.02.014; Selvendiran K, 2009, INT J CANCER, V125, P2198, DOI 10.1002/ijc.24601; Shachar I, 2012, FEBS LETT, V586, P2906, DOI 10.1016/j.febslet.2012.07.016; Shafat MS, 2017, BLOOD, V129, P1320, DOI 10.1182/blood-2016-08-734798; Simons D, 2011, J CELL MOL MED, V15, P668, DOI 10.1111/j.1582-4934.2010.01041.x; Takubo K, 2010, CELL STEM CELL, V7, P391, DOI 10.1016/j.stem.2010.06.020; Velasco-Hernandez T, 2015, LEUKEMIA, V29, P2366, DOI 10.1038/leu.2015.156; Velasco-Hernandez T, 2014, BLOOD, V124, P3597, DOI 10.1182/blood-2014-04-567065; Vick B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120925; Vukovic M, 2015, J EXP MED, V212, P2223, DOI 10.1084/jem.20150452; Vyas P, 2014, BLOOD, V124, P3510, DOI 10.1182/blood-2014-10-605055; Wang Y, 2011, CELL STEM CELL, V8, P399, DOI 10.1016/j.stem.2011.02.006; Wierenga ATJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093494; Yonekura S, 2013, ANTICANCER RES, V33, P3099; Zaitseva L, 2014, ONCOTARGET, V5, P9930, DOI 10.18632/oncotarget.2479	44	14	14	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	20					2676	2686		10.1038/s41388-018-0151-1	http://dx.doi.org/10.1038/s41388-018-0151-1			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG2TH	29487418	Green Accepted			2022-12-17	WOS:000432545100005
J	Yu, YL; Dai, M; Lu, A; Yu, E; Merlino, G				Yu, Yanlin; Dai, Meng; Lu, Andrew; Yu, Ellen; Merlino, Glenn			PHLPP1 mediates melanoma metastasis suppression through repressing AKT2 activation	ONCOGENE			English	Article							PROTEIN-KINASE-B; CANCER CELL MOTILITY; TUMOR-SUPPRESSOR; TYROSINE PHOSPHATASES; PROMOTES DEVELOPMENT; PROSTATE-CANCER; PTEN; PROGRESSION; EXPRESSION; SURVIVAL	PI3K/AKT pathway activation is thought to be a driving force in metastatic melanomas. Members of the pleckstrin homology (PH) domain leucine-rich repeat protein Ser/Thr specific phosphatase family (PHLPP1 and PHLPP2) can regulate AKT activation. By dephosphorylating specific serine residues in the hydrophobic motif, PHLPP1 and PHLPP2 restrain AKT signalings, thereby regulating cell proliferation and survival. We here show that PHLPP1 expression was significantly downregulated or lost and correlated with metastatic potential in melanoma. Forcing expression of either PHLPP1 or PHLPP2 in melanoma cells inhibited cell proliferation, migration, and colony formation in soft agar; but PHLPP1 had the most profound inhibitory effect on metastasis. Moreover, expression of PH mutant forms of PHLPP1 continued to inhibit metastasis, whereas a phosphatase-dead C-terminal mutant did not. The introduction of activated PHLPP1-specific targets AKT2 or AKT3 also promoted melanoma metastasis, while the non-PHLPP1 target AKT1 did not. AKT2 and AKT3 could even rescue the PHLPP1-mediated inhibition of metastasis. An AKT inhibitor blocked the activity of AKT2 and inhibited AKT2-mediated tumor growth and metastasis in a preclinical mouse model. Our data demonstrate that PHLPP1 functions as a metastasis suppressor through its phosphatase activity, and suggest that PHLPP1 represents a novel diagnostic and therapeutic marker for metastatic melanoma.	[Yu, Yanlin; Lu, Andrew; Yu, Ellen; Merlino, Glenn] NCI, Lab Canc Biol & Genet, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Dai, Meng] Southern Med Univ, Nanfang Hosp, Guangzhou 510515, Guangdong, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Southern Medical University - China	Yu, YL (corresponding author), NCI, Lab Canc Biol & Genet, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.	YuY@mail.nih.gov			NIH intramural research program; NATIONAL CANCER INSTITUTE [ZIABC008756] Funding Source: NIH RePORTER	NIH intramural research program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the funding from the NIH intramural research program. We thank Drs. Miriam Anver, Julia Zhang and Hong Sheng for assistance with tissue microarray and immunohistochemistry.	Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Arboleda MJ, 2003, CANCER RES, V63, P196; Bellacosa A, 2004, CANCER BIOL THER, V3, P268, DOI 10.4161/cbt.3.3.703; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brognard J, 2008, TRENDS ENDOCRIN MET, V19, P223, DOI 10.1016/j.tem.2008.04.001; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Cao J, 2016, ONCOTARGET, V7, P82170, DOI 10.18632/oncotarget.10320; Chen MH, 2011, CANCER CELL, V20, P173, DOI 10.1016/j.ccr.2011.07.013; Cho JH, 2015, CELL REP, V13, P898, DOI 10.1016/j.celrep.2015.09.057; Dai DL, 2005, J CLIN ONCOL, V23, P1473, DOI 10.1200/JCO.2005.07.168; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davies MA, 2009, CLIN CANCER RES, V15, P7538, DOI 10.1158/1078-0432.CCR-09-1985; Dillon RL, 2009, CANCER RES, V69, P5057, DOI 10.1158/0008-5472.CAN-08-4287; Dong L, 2014, ONCOGENE, V33, P4756, DOI 10.1038/onc.2013.420; Durban VM, 2013, J CLIN INVEST, V123, P5104, DOI 10.1172/JCI69619; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gao T, 2008, J BIOL CHEM, V283, P6300, DOI 10.1074/jbc.M707319200; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; Hunter T, 2009, CURR OPIN CELL BIOL, V21, P140, DOI 10.1016/j.ceb.2009.01.028; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Julien SG, 2011, NAT REV CANCER, V11, P35, DOI 10.1038/nrc2980; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li X, 2014, GASTROENTEROLOGY, V146, P1301, DOI 10.1053/j.gastro.2014.02.003; Liu J, 2009, ONCOGENE, V28, P994, DOI 10.1038/onc.2008.450; Mann MB, 2015, NAT GENET, V47, P486, DOI 10.1038/ng.3275; Molina JR, 2012, ONCOGENE, V31, P1264, DOI 10.1038/onc.2011.324; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nitsche C, 2012, GASTROENTEROLOGY, V142, P377, DOI 10.1053/j.gastro.2011.10.026; O'Hayre M, 2012, LEUKEMIA, V26, P1689, DOI 10.1038/leu.2012.6; O'Neill AK, 2013, FEBS J, V280, P572, DOI 10.1111/j.1742-4658.2012.08537.x; Ostman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837; Qiao JB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056382; Qiao M, 2010, MOL CELL, V38, P512, DOI 10.1016/j.molcel.2010.03.017; Rychahou PG, 2008, P NATL ACAD SCI USA, V105, P20315, DOI 10.1073/pnas.0810715105; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Shin SS, 2010, PIGM CELL MELANOMA R, V23, P103, DOI 10.1111/j.1755-148X.2009.00648.x; Silva JM, 2014, MOL CANCER RES, V12, P447, DOI 10.1158/1541-7786.MCR-13-0224-T; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Stambolic V, 2006, TRENDS CELL BIOL, V16, P461, DOI 10.1016/j.tcb.2006.07.001; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Wang ZX, 2013, J SURG ONCOL, V108, P427, DOI 10.1002/jso.23419; Woodgett JR, 2005, CURR OPIN CELL BIOL, V17, P150, DOI 10.1016/j.ceb.2005.02.010; Yan J, 2004, ONCOGENE, V23, P1939, DOI 10.1038/sj.onc.1207306; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033; Yu YL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009072; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966; Yu YL, 2002, CANCER RES, V62, P2951	50	14	14	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	17					2225	2236		10.1038/s41388-017-0061-7	http://dx.doi.org/10.1038/s41388-017-0061-7			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE3FW	29391600	Green Accepted			2022-12-17	WOS:000431100200002
J	Boulianne, B; Feldhahn, N				Boulianne, B.; Feldhahn, N.			Transcribing malignancy: transcription-associated genomic instability in cancer	ONCOGENE			English	Review							ACUTE LYMPHOBLASTIC-LEUKEMIA; B-CELL LYMPHOMA; INDUCED CYTIDINE DEAMINASE; DOUBLE-STRAND BREAKS; NUCLEOTIDE EXCISION-REPAIR; TOPOISOMERASE-II-BETA; R-LOOP FORMATION; DAMAGE-INDUCED DIFFERENTIATION; REPLICATION FORK PROGRESSION; LINEAGE-SURVIVAL ONCOGENE	Transcription is an essential process in all living cells. However, transcription also sensitises genomic DNA to damage from a number of endogenous sources. Although various mechanisms protect the integrity of DNA during transcription, transcription-associated genomic instability occurs in normal and malignant cells and, if unrepaired, can result in genomic alterations. Numerous studies have implicated genomic alterations found in cancer genomes to transcription. Hence, transcription-associated genomic instability can be considered as a major driver of cancer development. In this review, we summarise the body of knowledge on transcription-associated genomic instability and highlight recent discoveries in the field on both healthy and malignant cells. We also discuss how transcription-associated DNA damage might promote transforming lesions at cell type-and lineage-specific genes.	[Boulianne, B.; Feldhahn, N.] Imperial Coll London, Dept Med, Ctr Haematol, London, England	Imperial College London	Boulianne, B; Feldhahn, N (corresponding author), Imperial Coll London, Hammersmith Hosp, Dept Med, Ctr Haematol, Du Cane Rd, London W12 0NN, England.	bboulianne@gmail.com; n.feldhahn@imperial.ac.uk						Adelman K, 2012, NAT REV GENET, V13, P720, DOI 10.1038/nrg3293; Alzu A, 2012, CELL, V151, P835, DOI 10.1016/j.cell.2012.09.041; Ashour ME, 2015, NAT REV CANCER, V15, P137, DOI 10.1038/nrc3892; Barlow JH, 2013, CELL, V152, P620, DOI 10.1016/j.cell.2013.01.006; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Basso K, 2012, IMMUNOL REV, V247, P172, DOI 10.1111/j.1600-065X.2012.01112.x; Beletskii A, 1996, P NATL ACAD SCI USA, V93, P13919, DOI 10.1073/pnas.93.24.13919; Bermejo R, 2012, MOL CELL, V45, P710, DOI 10.1016/j.molcel.2012.03.001; Bhatia V, 2014, NATURE, V511, P362, DOI 10.1038/nature13374; BOGUSLAWSKI SJ, 1986, J IMMUNOL METHODS, V89, P123, DOI 10.1016/0022-1759(86)90040-2; Bonnet A, 2017, MOL CELL, V67, P608, DOI 10.1016/j.molcel.2017.07.002; Boulianne B, 2017, CELL REP, V18, P1687, DOI 10.1016/j.celrep.2017.01.057; Buchanan Justin, 2016, Journal of the Association of Genetic Technologists, V42, P24; Bunch H, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10191; Bunch H, 2014, NAT STRUCT MOL BIOL, V21, P876, DOI 10.1038/nsmb.2878; Burns MB, 2013, NAT GENET, V45, P977, DOI 10.1038/ng.2701; Burns MB, 2013, NATURE, V494, P366, DOI 10.1038/nature11881; Calderwood SK, 2016, TRANSCR-AUSTIN, V7, P75, DOI 10.1080/21541264.2016.1181142; Canela A, 2017, CELL, V170, P507, DOI 10.1016/j.cell.2017.06.034; Cardenas MG, 2016, J CLIN INVEST, V126, P3351, DOI 10.1172/JCI85795; Cerchietti LC, 2010, CANCER CELL, V17, P400, DOI 10.1016/j.ccr.2009.12.050; Chan K, 2015, NAT GENET, V47, P1067, DOI 10.1038/ng.3378; Chan LN, 2017, NATURE, V542, P479, DOI 10.1038/nature21076; Chan YJA, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004288; Chang EYC, 2017, GENES-BASEL, V8, DOI 10.3390/genes8010033; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; Cheung HW, 2011, P NATL ACAD SCI USA, V108, P12372, DOI 10.1073/pnas.1109363108; Chiarle R, 2011, CELL, V147, P107, DOI 10.1016/j.cell.2011.07.049; Coombs CC, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.25; Cortez D, 2015, DNA REPAIR, V32, P149, DOI 10.1016/j.dnarep.2015.04.026; Costantino L, 2015, CURR OPIN CELL BIOL, V34, P39, DOI 10.1016/j.ceb.2015.04.008; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; DATTA A, 1995, SCIENCE, V268, P1616, DOI 10.1126/science.7777859; De Keersmaecker K, 2010, NAT MED, V16, P1321, DOI 10.1038/nm.2246; De Silva NS, 2015, NAT REV IMMUNOL, V15, P137, DOI 10.1038/nri3804; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Di Palma T, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-292; Dominguez-Sanchez MS, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002386; Dominguez-Sola D, 2007, NATURE, V448, P445, DOI 10.1038/nature05953; Drolet M, 2006, MOL MICROBIOL, V59, P723, DOI 10.1111/j.1365-2958.2005.05006.x; El Hage A, 2010, GENE DEV, V24, P1546, DOI 10.1101/gad.573310; Feldhahn N, 2005, J EXP MED, V201, P1837, DOI 10.1084/jem.20042101; Feldhahn N, 2007, J EXP MED, V204, P1157, DOI 10.1084/jem.20062662; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Fleenor CJ, 2015, STEM CELLS, V33, P1345, DOI 10.1002/stem.1936; Gaillard H, 2016, ANNU REV BIOCHEM, V85, P291, DOI 10.1146/annurev-biochem-060815-014908; Gan WJ, 2011, GENE DEV, V25, P2041, DOI 10.1101/gad.17010011; Garcia-Muse T, 2016, NAT REV MOL CELL BIO, V17, P553, DOI 10.1038/nrm.2016.88; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002; Ginno PA, 2013, GENOME RES, V23, P1590, DOI 10.1101/gr.158436.113; Ginno PA, 2012, MOL CELL, V45, P814, DOI 10.1016/j.molcel.2012.01.017; Gomez-Gonzalez B, 2011, EMBO J, V30, P3106, DOI 10.1038/emboj.2011.206; Gomez-Herreros F, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00307-y; Gomez-Herreros F, 2014, NAT GENET, V46, P516, DOI 10.1038/ng.2929; Gontan C, 2008, DEV BIOL, V317, P296, DOI 10.1016/j.ydbio.2008.02.035; Gordon MS, 2003, P NATL ACAD SCI USA, V100, P4126, DOI 10.1073/pnas.0735266100; Green P, 2003, NAT GENET, V33, P514, DOI 10.1038/ng1103; Gutierrez A, 2011, BLOOD, V118, P4169, DOI 10.1182/blood-2010-11-318873; Gutierrez A, 2010, BLOOD, V115, P2845, DOI 10.1182/blood-2009-07-234377; Ha VL, 2017, LEUKEMIA, V31, P2503, DOI 10.1038/leu.2017.70; Haffner MC, 2010, NAT GENET, V42, P668, DOI 10.1038/ng.613; Hamperl S, 2017, CELL, V170, P774, DOI 10.1016/j.cell.2017.07.043; Hamperl S, 2014, DNA REPAIR, V19, P84, DOI 10.1016/j.dnarep.2014.03.023; Hartono SR, 2015, NUCLEIC ACIDS RES, V43, P9729, DOI 10.1093/nar/gkv811; Hatchi E, 2015, MOL CELL, V57, P636, DOI 10.1016/j.molcel.2015.01.011; Havelange V, 2011, BLOOD, V118, P2827, DOI 10.1182/blood-2011-04-350579; Healy S, 2013, PHARMACOL THERAPEUT, V137, P64, DOI 10.1016/j.pharmthera.2012.09.001; Heinaniemi M, 2016, ELIFE, V5, DOI 10.7554/eLife.13087; Helmrich A, 2011, MOL CELL, V44, P966, DOI 10.1016/j.molcel.2011.10.013; Heltemes-Harris LM, 2011, J EXP MED, V208, P1135, DOI 10.1084/jem.20101947; HERMAN RK, 1971, J BACTERIOL, V106, P543, DOI 10.1128/JB.106.2.543-550.1971; Hill SJ, 2016, P NATL ACAD SCI USA, V113, pE7701, DOI 10.1073/pnas.1611673113; Hobson DJ, 2012, MOL CELL, V48, P365, DOI 10.1016/j.molcel.2012.08.027; Hoopes JI, 2016, CELL REP, V14, P1273, DOI 10.1016/j.celrep.2016.01.021; Hraiky C, 2000, J BIOL CHEM, V275, P11257, DOI 10.1074/jbc.275.15.11257; Hsieh HJ, 2017, DNA REPAIR, V49, P9, DOI 10.1016/j.dnarep.2016.11.002; Huertas P, 2003, MOL CELL, V12, P711, DOI 10.1016/j.molcel.2003.08.010; IKEDA H, 1979, P NATL ACAD SCI USA, V76, P4571, DOI 10.1073/pnas.76.9.4571; Imielinski M, 2017, CELL, V168, P460, DOI 10.1016/j.cell.2016.12.025; Iqbal J, 2007, LEUKEMIA, V21, P2332, DOI 10.1038/sj.leu.2404856; Jenjaroenpun P, 2015, NUCLEIC ACIDS RES, V43, pW527, DOI 10.1093/nar/gkv344; Johnson SAS, 2000, MOL CELL BIOL, V20, P5000, DOI 10.1128/MCB.20.14.5000-5009.2000; Jones RM, 2013, ONCOGENE, V32, P3744, DOI 10.1038/onc.2012.387; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Ju BG, 2006, CELL CYCLE, V5, P2557, DOI 10.4161/cc.5.22.3497; Kazanov MD, 2015, CELL REP, V13, P1103, DOI 10.1016/j.celrep.2015.09.077; Klein IA, 2011, CELL, V147, P95, DOI 10.1016/j.cell.2011.07.048; Kotsantis P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13087; Kuppers R, 2005, NAT REV CANCER, V5, P251, DOI 10.1038/nrc1589; Lada AG, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005217; Lang KS, 2017, CELL, V170, P787, DOI 10.1016/j.cell.2017.07.044; Lensing SV, 2016, NAT METHODS, V13, P855, DOI 10.1038/nmeth.3960; Leroy H, 2005, LEUKEMIA, V19, P329, DOI 10.1038/sj.leu.2403614; LESNIK EA, 1995, BIOCHEMISTRY-US, V34, P10807, DOI 10.1021/bi00034a013; Leung-Hagesteijn C, 2013, CANCER CELL, V24, P289, DOI 10.1016/j.ccr.2013.08.009; Li M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7720; Li XL, 2005, CELL, V122, P365, DOI 10.1016/j.cell.2005.06.008; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Lin YF, 2007, MOL CELL BIOL, V27, P6209, DOI 10.1128/MCB.00739-07; Lippert MJ, 2011, P NATL ACAD SCI USA, V108, P698, DOI 10.1073/pnas.1012363108; Lippert MJ, 2004, MOL CELL BIOL, V24, P4801, DOI 10.1128/MCB.24.11.4801-4809.2004; Liu GJ, 2014, GENE DEV, V28, P1337, DOI 10.1101/gad.240416.114; Liu M, 2008, NATURE, V451, P841, DOI 10.1038/nature06547; Lohr JG, 2014, CANCER CELL, V25, P91, DOI 10.1016/j.ccr.2013.12.015; Luna R, 2008, CHROMOSOMA, V117, P319, DOI 10.1007/s00412-008-0158-4; Lyu YL, 2006, MOL CELL BIOL, V26, P7929, DOI 10.1128/MCB.00617-06; Macheret M, 2015, ANNU REV PATHOL-MECH, V10, P425, DOI 10.1146/annurev-pathol-012414-040424; Madabhushi R, 2015, CELL, V161, P1592, DOI 10.1016/j.cell.2015.05.032; Mandal PK, 2012, CELL, V148, P847, DOI 10.1016/j.cell.2012.02.011; Mandelbaum J, 2010, CANCER CELL, V18, P568, DOI 10.1016/j.ccr.2010.10.030; Marteijn JA, 2014, NAT REV MOL CELL BIO, V15, P465, DOI 10.1038/nrm3822; McCormack MP, 2010, SCIENCE, V327, P879, DOI 10.1126/science.1182378; Meng FL, 2014, CELL, V159, P1538, DOI 10.1016/j.cell.2014.11.014; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; Mischo HE, 2011, MOL CELL, V41, P21, DOI 10.1016/j.molcel.2010.12.007; Morales JC, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006107; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Mullighan CG, 2008, NATURE, V453, P110, DOI 10.1038/nature06866; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Mullighan CG, 2009, NEW ENGL J MED, V360, P470, DOI 10.1056/NEJMoa0808253; Muschen M, 2000, J EXP MED, V192, P1833, DOI 10.1084/jem.192.12.1833; Mussil B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073641; Naughton C, 2013, NAT STRUCT MOL BIOL, V20, P387, DOI 10.1038/nsmb.2509; NICKOLOFF JA, 1992, MOL CELL BIOL, V12, P5311, DOI 10.1128/MCB.12.12.5311; Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033; Nonaka T, 2016, J CLIN INVEST, V126, P1367, DOI 10.1172/JCI81522; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; Nutt SL, 2015, NAT REV IMMUNOL, V15, P160, DOI 10.1038/nri3795; Orlovetskie N, 2017, BBA-REV CANCER, V1867, P42, DOI 10.1016/j.bbcan.2016.11.004; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Papaemmanuil E, 2014, NAT GENET, V46, P116, DOI 10.1038/ng.2874; Parsa JY, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002518; Pasqualucci L, 2006, J EXP MED, V203, P311, DOI 10.1084/jem.20052204; Pasqualucci L, 2003, BLOOD, V101, P2914, DOI 10.1182/blood-2002-11-3387; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Paulsen RD, 2009, MOL CELL, V35, P228, DOI 10.1016/j.molcel.2009.06.021; Pavri R, 2017, GENES-BASEL, V8, DOI 10.3390/genes8060154; Pavri R, 2010, CELL, V143, P122, DOI 10.1016/j.cell.2010.09.017; Peng HZ, 1999, BLOOD, V93, P2167, DOI 10.1182/blood.V93.7.2167.407a35_2167_2172; Phan RT, 2004, NATURE, V432, P635, DOI 10.1038/nature03147; Phan RT, 2005, NAT IMMUNOL, V6, P1054, DOI 10.1038/ni1245; Polak P, 2008, GENOME RES, V18, P1216, DOI 10.1101/gr.076570.108; Pommier Y, 2016, NAT REV MOL CELL BIO, V17, P703, DOI 10.1038/nrm.2016.111; Puigvert JC, 2016, FEBS J, V283, P232, DOI 10.1111/febs.13574; Qian J, 2014, CELL, V159, P1524, DOI 10.1016/j.cell.2014.11.013; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; Ramiro AR, 2004, CELL, V118, P431, DOI 10.1016/j.cell.2004.08.006; Ranuncolo SM, 2007, NAT IMMUNOL, V8, P705, DOI 10.1038/ni1478; Robbiani DF, 2009, MOL CELL, V36, P631, DOI 10.1016/j.molcel.2009.11.007; Robbiani DF, 2008, CELL, V135, P1028, DOI 10.1016/j.cell.2008.09.062; Roberts KG, 2012, CANCER CELL, V22, P153, DOI 10.1016/j.ccr.2012.06.005; Roberts SA, 2013, NAT GENET, V45, P970, DOI 10.1038/ng.2702; Rosenbauer F, 2007, NAT REV IMMUNOL, V7, P105, DOI 10.1038/nri2024; Roy D, 2009, MOL CELL BIOL, V29, P3124, DOI 10.1128/MCB.00139-09; Rui LX, 2011, NAT IMMUNOL, V12, P933, DOI 10.1038/ni.2094; Santos MA, 2014, NATURE, V514, P107, DOI 10.1038/nature13483; Santos-Pereira JM, 2015, NAT REV GENET, V16, P583, DOI 10.1038/nrg3961; Sanz LA, 2016, MOL CELL, V63, P167, DOI 10.1016/j.molcel.2016.05.032; Schuetz JM, 2012, LEUKEMIA, V26, P1383, DOI 10.1038/leu.2011.378; Schwieger M, 2004, BLOOD, V103, P2744, DOI 10.1182/blood-2003-07-2280; Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064; Shing DC, 2003, CANCER RES, V63, P4568; Shochat C, 2011, J EXP MED, V208, P901, DOI 10.1084/jem.20110580; Skourti-Stathaki K, 2011, MOL CELL, V42, P794, DOI 10.1016/j.molcel.2011.04.026; Sollier J, 2015, TRENDS CELL BIOL, V25, P514, DOI 10.1016/j.tcb.2015.05.003; Sollier J, 2014, MOL CELL, V56, P777, DOI 10.1016/j.molcel.2014.10.020; Sridhara SC, 2017, CELL REP, V18, P334, DOI 10.1016/j.celrep.2016.12.050; Stirling PC, 2012, GENE DEV, V26, P163, DOI 10.1101/gad.179721.111; Stork CT, 2016, ELIFE, V5, DOI 10.7554/eLife.17548; Swaminathan S, 2015, NAT IMMUNOL, V16, P766, DOI 10.1038/ni.3160; Takahashi T, 2011, P NATL ACAD SCI USA, V108, P692, DOI 10.1073/pnas.1012582108; Tam W, 2006, BLOOD, V107, P4090, DOI 10.1182/blood-2005-09-3778; Taylor BJM, 2014, ELIFE, V3, DOI 10.7554/eLife.03553; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Tous C, 2007, BIOCHEM BIOPH RES CO, V360, P428, DOI 10.1016/j.bbrc.2007.06.098; Trotter KW, 2015, MOL CELL BIOL, V35, P2799, DOI 10.1128/MCB.00230-15; Tsai AG, 2008, CELL, V135, P1130, DOI 10.1016/j.cell.2008.10.035; Tuduri S, 2009, NAT CELL BIOL, V11, P1315, DOI 10.1038/ncb1984; Urban V, 2016, J CELL BIOL, V214, P401, DOI 10.1083/jcb.201507099; Van Vlierberghe P, 2012, J CLIN INVEST, V122, P3398, DOI 10.1172/JCI61269; Vijayraghavan S, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006277; VOELKELMEIMAN K, 1987, CELL, V48, P1071, DOI 10.1016/0092-8674(87)90714-8; Wahba L, 2011, MOL CELL, V44, P978, DOI 10.1016/j.molcel.2011.10.017; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang JW, 2012, CELL, V148, P1001, DOI 10.1016/j.cell.2012.01.040; Wang Q, 2014, P NATL ACAD SCI USA, V111, P18667, DOI 10.1073/pnas.1420575111; Wang X, 2002, P NATL ACAD SCI USA, V99, P15018, DOI 10.1073/pnas.232581199; Wei PC, 2016, CELL, V164, P644, DOI 10.1016/j.cell.2015.12.039; Wellinger RE, 2006, MOL CELL BIOL, V26, P3327, DOI 10.1128/MCB.26.8.3327-3334.2006; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wiedemann EM, 2016, CELL REP, V17, P2927, DOI 10.1016/j.celrep.2016.11.041; Williamson LM, 2011, CARCINOGENESIS, V32, P279, DOI 10.1093/carcin/bgq255; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776; Yamane A, 2011, NAT IMMUNOL, V12, P62, DOI 10.1038/ni.1964; Yang X, 2000, SCIENCE, V287, P131, DOI 10.1126/science.287.5450.131; Yang YZ, 2014, MOL CELL, V53, P484, DOI 10.1016/j.molcel.2014.01.011; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; Yip KW, 2008, ONCOGENE, V27, P6398, DOI 10.1038/onc.2008.307; Yu KF, 2003, NAT IMMUNOL, V4, P442, DOI 10.1038/ni919; Zenatti PP, 2011, NAT GENET, V43, P932, DOI 10.1038/ng.924; Zhang JH, 2011, BLOOD, V118, P3080, DOI 10.1182/blood-2011-03-341412	205	14	14	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2018	37	8					971	981		10.1038/onc.2017.402	http://dx.doi.org/10.1038/onc.2017.402			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FX2QD	29106394	Green Submitted			2022-12-17	WOS:000425905700001
J	Benthani, FA; Herrmann, D; Tran, PN; Pangon, L; Lucas, MC; Allam, AH; Currey, N; Al-Sohaily, S; Giry-Laterriere, M; Warusavitarne, J; Timpson, P; Kohonen-Corish, MRJ				Benthani, F. A.; Herrmann, D.; Tran, P. N.; Pangon, L.; Lucas, M. C.; Allam, A. H.; Currey, N.; Al-Sohaily, S.; Giry-Laterriere, M.; Warusavitarne, J.; Timpson, P.; Kohonen-Corish, M. R. J.			'MCC' protein interacts with E-cadherin and beta-catenin strengthening cell-cell adhesion of HCT116 colon cancer cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; COLORECTAL-CANCER; PROMOTER METHYLATION; IN-VIVO; TRANSCRIPTIONAL ACTIVITY; CYTOPLASMIC DOMAIN; SIGNALING PATHWAY; RECTAL-CANCER; K+ CHANNELS; CARCINOMA	E-cadherin and beta-catenin are key proteins that are essential in the formation of the epithelial cell layer in the colon but their regulatory pathways that are disrupted in cancer metastasis are not completely understood. Mutated in colorectal cancer (MCC) is a tumour suppressor gene that is silenced by promoter methylation in colorectal cancer and particularly in patients with increased lymph node metastasis. Here, we show that MCC methylation is found in 45% of colon and 24% of rectal cancers and is associated with proximal colon, poorly differentiated, circumferential and mucinous tumours as well as increasing T stage and larger tumour size. Knockdown of MCC in HCT116 colon cancer cells caused a reduction in E-cadherin protein level, which is a hallmark of epithelial-mesenchymal transition in cancer, and consequently diminished the E-cadherin/beta-catenin complex. MCC knockdown disrupted cell-cell adhesive strength and integrity in the dispase and transepithelial electrical resistance assays, enhanced hepatocyte growth factor-induced cell scatter and increased tumour cell invasiveness in an organotypic assay. The Src/Abl inhibitor dasatinib, a candidate anti-invasive drug, abrogated the invasive properties induced by MCC deficiency. Mechanistically, we establish that MCC interacts with the E-cadherin/beta-catenin complex. These data provide a significant advance in the current understanding of cell-cell adhesion in colon cancer cells.	[Benthani, F. A.; Herrmann, D.; Tran, P. N.; Pangon, L.; Lucas, M. C.; Allam, A. H.; Currey, N.; Al-Sohaily, S.; Giry-Laterriere, M.; Warusavitarne, J.; Timpson, P.; Kohonen-Corish, M. R. J.] Garvan Inst Med Res, Kinghorn Canc Ctr, Darlinghurst, NSW, Australia; [Benthani, F. A.; Herrmann, D.; Tran, P. N.; Pangon, L.; Timpson, P.; Kohonen-Corish, M. R. J.] UNSW Sydney, St Vincents Clin Sch, Sydney, NSW, Australia; [Kohonen-Corish, M. R. J.] Univ Western Sydney, Sch Med, Sydney, NSW, Australia	Garvan Institute of Medical Research; University of New South Wales Sydney; Western Sydney University	Timpson, P; Kohonen-Corish, MRJ (corresponding author), Garvan Inst Med Res, 370 Victoria St, Darlinghurst, NSW 2010, Australia.	p.timpson@garvan.org.au; m.corish@garvan.org.au	Lucas, Morghan/S-4982-2018; Lucas, Morghan C/Y-6452-2019; Kohonen-Corish, Maija/Q-9763-2019; Timpson, Paul/A-9429-2016	Lucas, Morghan/0000-0001-7654-9137; Lucas, Morghan C/0000-0001-7654-9137; Kohonen-Corish, Maija/0000-0002-4073-1479; Benthani, Fahad/0000-0002-3283-307X; Dyson, Nicola/0000-0002-4173-1913; Timpson, Paul/0000-0002-5514-7080; Herrmann, David/0000-0002-9514-7501	Cancer Council NSW [RG14-08, RG17-05]; NHMRC [1020406, 1043501, 1089497, 1105640, 1129401]; Cancer Institute NSW [10CDF232, 12CDF234]; Australian Research Council Future Fellowship [FT120100880]; Len Ainsworth Pancreatic Cancer Fellowship; Cancer Australia [1049846]; Cure Cancer Australia [1049846]; Gastroenterological Society of Australia; Sydney Catalyst; Tour de Cure	Cancer Council NSW(Cancer Council New South Wales); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute NSW; Australian Research Council Future Fellowship(Australian Research Council); Len Ainsworth Pancreatic Cancer Fellowship; Cancer Australia; Cure Cancer Australia; Gastroenterological Society of Australia; Sydney Catalyst; Tour de Cure	We thank Irvin Ng, Melissa Abas, Sabine Meessen, Monica Killen and Sean Warren for advice and technical assistance. The work was supported by Cancer Council NSW (RG14-08, RG17-05), NHMRC (1020406, 1043501, 1089497, 1105640, 1129401), Cancer Institute NSW (10CDF232, 12CDF234), the Australian Research Council Future Fellowship (FT120100880), the Len Ainsworth Pancreatic Cancer Fellowship, Cancer Australia and Cure Cancer Australia (1049846), Gastroenterological Society of Australia, Sydney Catalyst and Tour de Cure. The contents of the published material are solely the responsibility of the administering institution, a participating institution or individual authors and do not reflect the views of the NHMRC. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Al-Sohaily S, 2014, HISTOPATHOLOGY, V65, P155, DOI 10.1111/his.12295; Antoni D, 2015, INT J MOL SCI, V16, P5517, DOI 10.3390/ijms16035517; Arnaud C, 2009, FEBS LETT, V583, P2326, DOI 10.1016/j.febslet.2009.06.034; Bard-Chapeau EA, 2014, NAT GENET, V46, P24, DOI 10.1038/ng.2847; BEHRENS J, 1985, J CELL BIOL, V101, P1307, DOI 10.1083/jcb.101.4.1307; Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449; Canel M, 2010, CANCER RES, V70, P9413, DOI 10.1158/0008-5472.CAN-10-1454; Chen CL, 2009, J CELL SCI, V122, P513, DOI 10.1242/jcs.035469; Compton CC, 2003, MODERN PATHOL, V16, P376, DOI 10.1097/01.MP.0000062859.46942.93; David JM, 2012, CANCER RES, V72, P2917, DOI 10.1158/0008-5472.CAN-11-3498; Erami Z, 2016, CELL REP, V14, P152, DOI 10.1016/j.celrep.2015.12.020; Fleming M, 2012, J GASTROINTEST ONCOL, V3, P153, DOI 10.3978/j.issn.2078-6891.2012.030; Fu XS, 2012, J CLIN PATHOL, V65, P675, DOI 10.1136/jclinpath-2011-200602; Fukuyama R, 2008, ONCOGENE, V27, P6044, DOI 10.1038/onc.2008.204; Gamazon ER, 2013, BLOOD, V121, P4366, DOI 10.1182/blood-2012-10-464149; Gargalionis AN, 2014, INT J CANCER, V134, P2019, DOI 10.1002/ijc.28299; Giry-Laterriere M, 2011, HUM GENE THER, V22, P1255, DOI 10.1089/hum.2010.179; GRIFFIN MJ, 1976, IN VITRO CELL DEV B, V12, P393, DOI 10.1007/BF02796317; Howard S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023899; Huang RYJ, 2012, J CELL SCI, V125, P4417, DOI 10.1242/jcs.099697; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim K, 2002, CELL BIOL INT, V26, P463, DOI 10.1006/cbir.2002.0901; Kohonen-Corish MRJ, 2007, ONCOGENE, V26, P4435, DOI 10.1038/sj.onc.1210210; Kohonen-Corish MRJ, 2014, INT J CANCER, V134, P2820, DOI 10.1002/ijc.28619; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lim L, 2014, HEPATOLOGY, V59, P202, DOI 10.1002/hep.26662; Matsumine A, 1996, J BIOL CHEM, V271, P10341, DOI 10.1074/jbc.271.17.10341; Mizuno S, 2013, INT J MOL SCI, V14, P888, DOI 10.3390/ijms14010888; Morton JP, 2010, GASTROENTEROLOGY, V139, P292, DOI 10.1053/j.gastro.2010.03.034; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Nobis M, 2013, CANCER RES, V73, P4674, DOI 10.1158/0008-5472.CAN-12-4545; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Pangon L, 2016, ONCOGENE, V35, P2834, DOI 10.1038/onc.2015.347; Pangon L, 2015, INT J CANCER, V136, P55, DOI 10.1002/ijc.28967; Pangon L, 2012, BBA-MOL CELL RES, V1823, P1058, DOI 10.1016/j.bbamcr.2012.03.011; Pangon Laurent, 2010, Genes Cancer, V1, P917, DOI 10.1177/1947601910388937; Poursoltan P, 2012, LUNG CANCER, V77, P272, DOI 10.1016/j.lungcan.2012.04.001; Serrels A, 2009, CANCER RES, V69, P2714, DOI 10.1158/0008-5472.CAN-08-4308; Shamir ER, 2014, J CELL BIOL, V204, P839, DOI 10.1083/jcb.201306088; Shook D, 2003, MECH DEVELOP, V120, P1351, DOI 10.1016/j.mod.2003.06.005; Shukla R, 2013, CELL, V153, P101, DOI 10.1016/j.cell.2013.02.032; Sigglekow ND, 2012, ANTICANCER RES, V32, P73; Spina A, 2015, BIOMEDICINES, V3, P71, DOI 10.3390/biomedicines3010071; Starr TK, 2009, SCIENCE, V323, P1747, DOI 10.1126/science.1163040; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tian XR, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/567305; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; VONBONSDORFF CH, 1985, EMBO J, V4, P2781, DOI 10.1002/j.1460-2075.1985.tb04004.x	53	14	15	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2018	37	5					663	672		10.1038/onc.2017.362	http://dx.doi.org/10.1038/onc.2017.362			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FU4GT	29035389				2022-12-17	WOS:000423812200011
J	Anjanappa, M; Hao, Y; Simpson, ER; Bhat-Nakshatri, P; Nelson, JB; Tersey, SA; Mirmira, RG; Cohen-Gadol, AA; Saadatzadeh, MR; Li, L; Fang, F; Nephew, KP; Miller, KD; Liu, Y; Nakshatri, H				Anjanappa, M.; Hao, Y.; Simpson, E. R.; Bhat-Nakshatri, P.; Nelson, J. B.; Tersey, S. A.; Mirmira, R. G.; Cohen-Gadol, A. A.; Saadatzadeh, M. R.; Li, L.; Fang, F.; Nephew, K. P.; Miller, K. D.; Liu, Y.; Nakshatri, H.			A system for detecting high impact-low frequency mutations in primary tumors and metastases	ONCOGENE			English	Article							BREAST-CANCER CELLS; H3K4 MONOMETHYLATION; THERAPEUTIC TARGETS; EARLY DISSEMINATION; BRANCHED EVOLUTION; BRAIN METASTASES; STEM-CELLS; IDENTIFICATION; METABOLISM; REVEALS	Tumor complexity and intratumor heterogeneity contribute to subclonal diversity. Despite advances in next-generation sequencing (NGS) and bioinformatics, detecting rare mutations in primary tumors and metastases contributing to subclonal diversity is a challenge for precision genomics. Here, in order to identify rare mutations, we adapted a recently described epithelial reprograming assay for short-term propagation of epithelial cells from primary and metastatic tumors. Using this approach, we expanded minor clones and obtained epithelial cell-specific DNA/RNA for quantitative NGS analysis. Comparative Ampliseq Comprehensive Cancer Panel sequence analyses were performed on DNA from unprocessed breast tumor and tumor cells propagated from the same tumor. We identified previously uncharacterized mutations present only in the cultured tumor cells, a subset of which has been reported in brain metastatic but not primary breast tumors. In addition, whole-genome sequencing identified mutations enriched in liver metastases of various cancers, including Notch pathway mutations/chromosomal inversions in 5/5 liver metastases, irrespective of cancer types. Mutations/rearrangements in FHIT, involved in purine metabolism, were detected in 4/5 liver metastases, and the same four liver metastases shared mutations in 32 genes, including mutations of different HLA-DR family members affecting OX40 signaling pathway, which could impact the immune response to metastatic cells. Pathway analyses of all mutated genes in liver metastases showed aberrant tumor necrosis factor and transforming growth factor signaling in metastatic cells. Epigenetic regulators including KMT2C/MLL3 and ARID1B, which are mutated in >50% of hepatocellular carcinomas, were also mutated in liver metastases. Thus, irrespective of cancer types, organ-specific metastases may share common genomic aberrations. Since recent studies show independent evolution of primary tumors and metastases and in most cases mutation burden is higher in metastases than primary tumors, the method described here may allow early detection of subclonal somatic alterations associated with metastatic progression and potentially identify therapeutically actionable, metastasis-specific genomic aberrations.	[Anjanappa, M.; Bhat-Nakshatri, P.; Nakshatri, H.] Indiana Univ Sch Med, Dept Surg, Indianapolis, IN 46202 USA; [Hao, Y.; Simpson, E. R.; Li, L.; Liu, Y.] Indiana Univ Sch Med, Ctr Computat Biol & Bioinformat, Indianapolis, IN 46202 USA; [Nelson, J. B.; Tersey, S. A.; Mirmira, R. G.; Saadatzadeh, M. R.] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; [Cohen-Gadol, A. A.] Indiana Univ Sch Med, Dept Neurosurg, Indianapolis, IN 46202 USA; [Li, L.; Liu, Y.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; [Fang, F.; Nephew, K. P.] Indiana Univ, Med Sci Program, Bloomington, IN USA; [Miller, K. D.] Indiana Univ Sch Med, Dept Med, Div Hematol Oncol, Indianapolis, IN 46202 USA; [Nakshatri, H.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; [Nakshatri, H.] Roudebush VA Med Ctr, Indianapolis, IN USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	Liu, Y; Nakshatri, H (corresponding author), Indiana Univ Sch Med, Surg Biochem Mol Biol, C218C,980 West Walnut St, Indianapolis, IN 46202 USA.	Yunliu@iu.edu; hnakshat@iupui.edu	Simpson, Edward/G-1912-2015; Mirmira, Raghavendra G/AAD-7592-2020	Simpson, Edward/0000-0001-9015-9864; Mirmira, Raghavendra G/0000-0002-5013-6075; Tersey, Sarah/0000-0003-0667-2361; Cohen-Gadol, Aaron/0000-0002-4946-1524; Nakshatri, Harikrishna/0000-0001-8876-0052	IUPUI Signature Center for the Cure of Glioblastoma; Susan G Komen for the Cure [SAC110025]; Indiana CTSI Project development pilot grant; IU Simon Cancer Center Breast Cancer Program Pilot grant; National Institutes of Health [P30 DK097512]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK097512] Funding Source: NIH RePORTER	IUPUI Signature Center for the Cure of Glioblastoma; Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation); Indiana CTSI Project development pilot grant; IU Simon Cancer Center Breast Cancer Program Pilot grant; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank tissue collection team at the IU Simon Cancer Center, Clinical Research Office and Neurooncology Center at IU School of Medicine for collection of fresh tissues for the study. We also thank the flow cytometry core at the IU Simon Cancer Center. Excellent support from New York Genome Center, particularly Mr Benjamin Hubert, is highly appreciated. IUPUI Signature Center for the Cure of Glioblastoma supported brain metastases tissue collection. Susan G Komen for the Cure (SAC110025 to HN), Indiana CTSI Project development pilot grant (to HN, LL and KNP) and IU Simon Cancer Center Breast Cancer Program Pilot grant (to YL and HN) supported this study. This study utilized core services by National Institutes of Health Grant P30 DK097512 to the Indiana University School of Medicine.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Arun B, 2005, CANCER EPIDEM BIOMAR, V14, P1681, DOI 10.1158/1055-9965.EPI-04-0278; Bafna S, 2010, ONCOGENE, V29, P2893, DOI 10.1038/onc.2010.87; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Brastianos PK, 2015, CANCER DISCOV, V5, P1164, DOI 10.1158/2159-8290.CD-15-0369; Brodt P, 2016, CLIN CANCER RES, V22, P5971, DOI 10.1158/1078-0432.CCR-16-0460; Burnett RM, 2015, ONCOTARGET, V6, P12682, DOI 10.18632/oncotarget.3707; Buxton ILO, 2010, CANCER LETT, V291, P131, DOI 10.1016/j.canlet.2009.09.021; Cejalvo JM, 2017, CANCER RES, V77, P2213, DOI 10.1158/0008-5472.CAN-16-2717; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen DW, 2015, ONCOTARGET, V6, P40815, DOI 10.18632/oncotarget.5886; Chen LX, 2017, SCIENCE, V355, P752, DOI 10.1126/science.aai8690; Cheng J, 2014, MOL CELL, V53, P979, DOI 10.1016/j.molcel.2014.02.032; Cheung LWT, 2014, CANCER CELL, V26, P479, DOI 10.1016/j.ccell.2014.08.017; Chmielecki J, 2013, NAT GENET, V45, P131, DOI 10.1038/ng.2522; Collins DC, 2017, TRENDS PHARMACOL SCI, V38, P25, DOI 10.1016/j.tips.2016.10.012; Cormier S, 2004, GENE EXPR PATTERNS, V4, P713, DOI 10.1016/j.modgep.2004.04.003; de Brachene AC, 2016, CELL MOL LIFE SCI, V73, P1159, DOI 10.1007/s00018-015-2112-y; Eirew P, 2015, NATURE, V518, P422, DOI 10.1038/nature13952; Fisher MM, 2015, DIABETES, V64, P3867, DOI 10.2337/db15-0430; Flowers M, 2017, CANCER RES, V77, P3386, DOI 10.1158/0008-5472.CAN-17-0232; Fujimoto A, 2012, NAT GENET, V44, P760, DOI 10.1038/ng.2291; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Giampieri R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072843; Gruber TA, 2015, BLOOD, V126, P943, DOI 10.1182/blood-2015-05-567859; Hao YY, 2017, J COMPUT BIOL, V24, P637, DOI 10.1089/cmb.2017.0057; Hao YY, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2905-x; Harper KL, 2016, NATURE, V540, P588, DOI 10.1038/nature20609; Hosseini H, 2016, NATURE, V540, P552, DOI 10.1038/nature20785; Hu X, 2015, INT J MOL MED, V35, P1219, DOI 10.3892/ijmm.2015.2132; Jozwik KM, 2016, CELL REP, V17, P2715, DOI 10.1016/j.celrep.2016.11.028; Kim J, 2012, P NATL ACAD SCI USA, V109, P6124, DOI 10.1073/pnas.1203203109; Kishi N, 2001, INT J DEV NEUROSCI, V19, P21, DOI 10.1016/S0736-5748(00)00071-X; Kloosterman WP, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-10-r103; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kostadinov R, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004413; Kumar R, 2006, MOL CANCER RES, V4, P655, DOI 10.1158/1541-7786.MCR-05-0249; Linch SN, 2016, P NATL ACAD SCI USA, V113, pE319, DOI 10.1073/pnas.1510518113; Liu XF, 2012, AM J PATHOL, V180, P599, DOI 10.1016/j.ajpath.2011.10.036; McCreery MQ, 2015, NAT MED, V21, P1514, DOI 10.1038/nm.3979; McDonald OG, 2017, NAT GENET, V49, P367, DOI 10.1038/ng.3753; Miller CA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12498; Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100; Nakshatri H, 2015, SCI REP-UK, V5, DOI 10.1038/srep13526; Odore E, 2016, CLIN PHARMACOKINET, V55, P397, DOI 10.1007/s40262-015-0327-6; Park JT, 2015, ONCOGENE, V34, P2801, DOI 10.1038/onc.2014.223; Pepe C, 2007, BREAST CANCER RES TR, V103, P29, DOI 10.1007/s10549-006-9349-y; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Petit FM, 2013, HUM REPROD, V28, P852, DOI 10.1093/humrep/des452; Prasad V, 2016, LANCET ONCOL, V17, pE81, DOI 10.1016/S1470-2045(15)00620-8; Robinson DR, 2013, NAT GENET, V45, P180, DOI 10.1038/ng.2509; Sebestyen E, 2015, NUCLEIC ACIDS RES, V43, P1345, DOI 10.1093/nar/gku1392; Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610; Sholl LM, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87062; Sinha R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060142; Steeg PS, 2011, NAT REV CANCER, V11, P352, DOI 10.1038/nrc3053; Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017; Vainchenker W, 2017, BLOOD, V129, P667, DOI 10.1182/blood-2016-10-695940; van Bon BWM, 2013, HUM MOL GENET, V22, P3138, DOI 10.1093/hmg/ddt170; Vaque JP, 2013, MOL CELL, V49, P94, DOI 10.1016/j.molcel.2012.10.018; Visvader JE, 2014, GENE DEV, V28, P1143, DOI 10.1101/gad.242511.114; Yan W, 2016, SCI REP-UK, V6, DOI 10.1038/srep19303; Yates LR, 2015, NAT MED, V21, P751, DOI 10.1038/nm.3886; Zhang Z, 2016, CELL REP, V16, P3146, DOI 10.1016/j.celrep.2016.08.048	65	14	15	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2018	37	2					185	196		10.1038/onc.2017.322	http://dx.doi.org/10.1038/onc.2017.322			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS8AN	28892047	Green Accepted, Green Submitted			2022-12-17	WOS:000422631700005
J	Chi, XZ; Lee, JW; Lee, YS; Park, IY; Ito, Y; Bae, SC				Chi, X-Z; Lee, J-W; Lee, Y-S; Park, I. Y.; Ito, Y.; Bae, S-C			Runx3 plays a critical role in restriction-point and defense against cellular transformation	ONCOGENE			English	Article							K-RAS ONCOGENE; GENE-EXPRESSION; LUNG-CANCER; P53; FAMILY; PROLIFERATION; SUPPRESSION; ACTIVATION; INDUCTION; CYCLE	The restriction (R)-point decision is fundamental to normal differentiation and the G(1)-S transition, and the decision-making machinery is perturbed in nearly all cancer cells. The mechanisms underlying the cellular context-dependent R-point decision remain poorly understood. We found that the R-point was dysregulated in Runx3(-/-) mouse embryonic fibroblasts (MEFs), which formed tumors in nude mice. Ectopic expression of Runx3 restored the R-point and abolished the tumorigenicity of Runx3-/-MEFs and K-Ras-activated Runx3(-/-) MEFs (Runx3(-/-); K-Ras(G12D/+)). During the R-point, Runx3 transiently formed a complex with pRb and Brd2 and induced Cdkn1a (p21(Waf1/Cip1/Sdi1); p21), a key regulator of the R-point transition. Cyclin D-CDK4/6 promoted dissociation of the pRb-Runx3-Brd2 complex, thus turning off p21 expression. However, cells harboring oncogenic K-Ras maintained the pRb-Runx3-Brd2 complex and p21 expression even after introduction of Cyclin D1. Thus, Runx3 plays a critical role in R-point regulation and defense against cellular transformation.	[Chi, X-Z; Lee, J-W; Lee, Y-S; Bae, S-C] Chungbuk Natl Univ, Dept Biochem, Sch Med, Cheongju 361763, South Korea; [Chi, X-Z; Lee, J-W; Lee, Y-S; Bae, S-C] Chungbuk Natl Univ, Inst Tumor Res, Cheongju 361763, South Korea; [Park, I. Y.] Chungbuk Natl Univ, Coll Pharm, Cheongju, South Korea; [Ito, Y.] Natl Univ Singapore, Canc Sci Inst Singapore, Ctr Translat Med, Singapore, Singapore	Chungbuk National University; Chungbuk National University; Chungbuk National University; National University of Singapore	Bae, SC (corresponding author), Chungbuk Natl Univ, Dept Biochem, Sch Med, Cheongju 361763, South Korea.; Bae, SC (corresponding author), Chungbuk Natl Univ, Inst Tumor Res, Cheongju 361763, South Korea.	scbae@chungbuk.ac.kr			National Research Foundation (NRF) of Korea [2014R1A3A2030690]; Basic Science Research Program [2014R1A1A2007204]; NRF - Ministry of Education of Korea [2013R1A1A2057659]; Rural Development Administration, Republic of Korea [PJ01226101]	National Research Foundation (NRF) of Korea(National Research Foundation of Korea); Basic Science Research Program; NRF - Ministry of Education of Korea; Rural Development Administration, Republic of Korea(Rural Development Administration (RDA), Republic of Korea)	S-C Bae is supported by a Creative Research Grant (2014R1A3A2030690) through the National Research Foundation (NRF) of Korea. J-W Lee is supported by the Basic Science Research Program (2014R1A1A2007204) Y-S Lee is supported by Basic Science Research Program (2013R1A1A2057659) through the NRF funded by the Ministry of Education of Korea. IY Park was supported by "Cooperative Research Program for Agriculture Science and Technology Development (PJ01226101)" Rural Development Administration, Republic of Korea.	Balmain A, 2002, NATURE, V417, P235, DOI 10.1038/417235a; Berns A, 2010, NATURE, V468, P519, DOI 10.1038/468519a; Blagosklonny MV, 2002, CELL CYCLE, V1, P100, DOI 10.4161/cc.1.2.107; Calo E, 2010, NATURE, V466, P1110, DOI 10.1038/nature09264; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Denis GV, 2006, J PROTEOME RES, V5, P502, DOI 10.1021/pr050430u; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Drosten M, 2016, J MOL MED, V94, P121, DOI 10.1007/s00109-015-1360-5; Feldser DM, 2010, NATURE, V468, P572, DOI 10.1038/nature09535; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; HARPER JW, 1993, CELL, V75, P805; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Ito Y, 2008, ADV CANCER RES, V99, P33, DOI 10.1016/S0065-230X(07)99002-8; Ito Y, 2015, NAT REV CANCER, V15, P81, DOI 10.1038/nrc3877; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Junttila MR, 2010, NATURE, V468, P567, DOI 10.1038/nature09526; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lee KS, 2010, ONCOGENE, V29, P3349, DOI 10.1038/onc.2010.79; Lee YS, 2013, CANCER CELL, V24, P603, DOI 10.1016/j.ccr.2013.10.003; Lund AH, 2002, CANCER CELL, V1, P213, DOI 10.1016/S1535-6108(02)00049-1; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Martin M, 2011, EMBNET J, V17, P1, DOI [10.14806/ej.17.1.200, DOI 10.14806/EJ.17.1.200]; Martinsson HS, 2005, EXP CELL RES, V305, P383, DOI 10.1016/j.yexcr.2005.01.023; MICHIELI P, 1994, CANCER RES, V54, P3391; Muzumdar MD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12685; Naoe Y, 2007, J EXP MED, V204, P1749, DOI 10.1084/jem.20062456; Odell A, 2010, AGING-US, V2, P160, DOI 10.18632/aging.100129; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Weinberg Reditor, 2007, BIOL CANC; Whittle MC, 2015, CELL, V161, P1345, DOI 10.1016/j.cell.2015.04.048; ZETTERBERG A, 1991, COLD SH Q B, V56, P137; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365	43	14	14	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2017	36	50					6884	6894		10.1038/onc.2017.290	http://dx.doi.org/10.1038/onc.2017.290			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FQ0JM	28846108	Green Published, hybrid			2022-12-17	WOS:000418041800005
J	Yadav, A; Kumar, B; Lang, JC; Teknos, TN; Kumar, P				Yadav, A.; Kumar, B.; Lang, J. C.; Teknos, T. N.; Kumar, P.			A muscle-specific protein 'myoferlin' modulates IL-6/STAT3 signaling by chaperoning activated STAT3 to nucleus	ONCOGENE			English	Article							GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; PHOSPHOLIPID-BINDING; TUMOR-METASTASIS; EXPRESSION; GENE; INTERLEUKIN-6; HEAD; EHD2; IDENTIFICATION	Myoferlin, a member of ferlin family of proteins, was first discovered as a candidate gene for muscular dystrophy and cardiomyopathy. Recently, myoferlin was shown to be also expressed in endothelial and cancer cells where it was shown to modulate vascular endothelial growth factor (VEGFR)-2 and epidermal growth factor receptor (EGFR) signaling by enhancing their stability and recycling. Based on these reports, we hypothesized that myoferlin might be regulating IL-6 signaling by modulating IL-6R stabilization and recycling. However, in our immunoprecipitation (IP) experiments, we did not observe myoferlin binding with IL-6R. Instead, we made a novel discovery that in resting cells myoferlin was bound to EHD2 protein and when cells were treated with IL-6, myoferlin dissociated from EHD2 and binds to activated STAT3. Interestingly, myoferlin depletion did not affect STAT3 phosphorylation, but completely blocked STAT3 translocation to nucleus. In addition, inhibition of STAT3 phosphorylation by phosphorylation-defective STAT3 mutants or JAK inhibitor blocked STAT3 binding to myoferlin and nuclear translocation. Myoferlin knockdown significantly decreased IL-6-mediated tumor cell migration, tumorsphere formation and ALDH-positive cancer stem cell population, in vitro. Furthermore, myoferlin knockdown significantly decreased IL-6-meditated tumor growth and tumor metastasis. Based on these results, we have proposed a novel model for the role of myoferlin in chaperoning phosphorylated STAT3 to the nucleus.	[Yadav, A.; Kumar, B.; Lang, J. C.; Teknos, T. N.; Kumar, P.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Kumar, B.; Lang, J. C.; Teknos, T. N.; Kumar, P.] Ohio State Univ, Dept Otolaryngol Head & Neck Surg, 420W 12th Ave,Room 464, Columbus, OH 43210 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Kumar, P (corresponding author), Ohio State Univ, Dept Otolaryngol Head & Neck Surg, 420W 12th Ave,Room 464, Columbus, OH 43210 USA.	Pawan.Kumar@osumc.edu			NIH/NCI [CA178649]; Ohio State University Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE [R21CA178649] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ohio State University Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by funding from NIH/NCI (CA178649 to PK) and The Ohio State University Comprehensive Cancer Center (PK and TNT). NIH/NCI-CA178649 (P Kumar) and The Ohio State University Comprehensive Cancer Center.	Abba MC, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-37; Adam PJ, 2003, J BIOL CHEM, V278, P6482, DOI 10.1074/jbc.M210184200; Al Moustafa AE, 2004, ONCOGENE, V23, P350, DOI 10.1038/sj.onc.1207148; Amatschek S, 2004, CANCER RES, V64, P844, DOI 10.1158/0008-5472.CAN-03-2361; Bernatchez PN, 2007, J BIOL CHEM, V282, P30745, DOI 10.1074/jbc.M704798200; Bernatchez PN, 2009, AM J PHYSIOL-CELL PH, V297, pC484, DOI 10.1152/ajpcell.00498.2008; Bourguignon LYW, 2012, ONCOGENE, V31, P149, DOI 10.1038/onc.2011.222; Brenner JC, 2010, HEAD NECK-J SCI SPEC, V32, P417, DOI 10.1002/hed.21198; Davis DB, 2000, HUM MOL GENET, V9, P217, DOI 10.1093/hmg/9.2.217; Davis DB, 2002, J BIOL CHEM, V277, P22883, DOI 10.1074/jbc.M201858200; DeFranco DB, 2000, KIDNEY INT, V57, P1241, DOI 10.1046/j.1523-1755.2000.00957.x; Demonbreun AR, 2010, J CELL SCI, V123, P2413, DOI 10.1242/jcs.065375; Dethlefsen C, 2013, BREAST CANCER RES TR, V138, P657, DOI 10.1007/s10549-013-2488-z; Difilippantonio S, 2003, EUR J CANCER, V39, P1936, DOI 10.1016/S0959-8049(03)00419-2; Doherty KR, 2008, J BIOL CHEM, V283, P20252, DOI 10.1074/jbc.M802306200; Doherty KR, 2005, DEVELOPMENT, V132, P5565, DOI 10.1242/dev.02155; Duffy SA, 2008, CANCER-AM CANCER SOC, V113, P750, DOI 10.1002/cncr.23615; Eisenberg MC, 2011, P NATL ACAD SCI USA, V108, P20078, DOI 10.1073/pnas.1116327108; Harrell MI, 2008, J IMMUNOL METHODS, V332, P170, DOI 10.1016/j.jim.2007.11.012; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Jimenez JL, 2007, J NEUROL SCI, V260, P114, DOI 10.1016/j.jns.2007.04.016; Kishimoto T, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1916; Kumar B, 2016, ONCOTARGET, V7, P18665, DOI 10.18632/oncotarget.7625; Kumar Bhavna, 2015, Genes Cancer, V6, P169; Kumar P, 2005, LAB INVEST, V85, P756, DOI 10.1038/labinvest.3700272; Kumar P, 2008, LAB INVEST, V88, P740, DOI 10.1038/labinvest.2008.46; Lederle W, 2011, INT J CANCER, V128, P2803, DOI 10.1002/ijc.25621; Lesina M, 2011, CANCER CELL, V19, P456, DOI 10.1016/j.ccr.2011.03.009; Li M, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0396-4; Li RW, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0051897, 10.1371/journal.pone.0037127, 10.1371/journal.pone.0029392]; Liu J, 1998, NAT GENET, V20, P31, DOI 10.1038/1682; Liu L, 2005, P NATL ACAD SCI USA, V102, P8150, DOI 10.1073/pnas.0501643102; Liu YP, 2008, INT J MOL MED, V21, P153; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lv JJ, 2015, CANCER INVEST, V33, P420, DOI 10.3109/07357907.2015.1055757; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Nakashima J, 2000, CLIN CANCER RES, V6, P2702; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Real PJ, 2002, ONCOGENE, V21, P7611, DOI 10.1038/sj.onc.1206004; Riedel F, 2005, ANTICANCER RES, V25, P2761; Roux I, 2006, CELL, V127, P277, DOI 10.1016/j.cell.2006.08.040; Schreiner SJ, 2002, J BIOL CHEM, V277, P45680, DOI 10.1074/jbc.M204255200; Shi YH, 2015, J MOL HISTOL, V46, P221, DOI 10.1007/s10735-015-9614-7; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TIAN SS, 1994, BLOOD, V84, P1760; Turtoi A, 2013, CANCER RES, V73, P5438, DOI 10.1158/0008-5472.CAN-13-1142; Turtoi A, 2011, J PROTEOME RES, V10, P4302, DOI 10.1021/pr200527z; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Villalva C, 2011, INT J CANCER, V128, P826, DOI 10.1002/ijc.25416; Wente SR, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000562; Yadav A, 2011, MOL CANCER RES, V9, P1658, DOI 10.1158/1541-7786.MCR-11-0271; Yahata Y, 2003, J BIOL CHEM, V278, P40026, DOI 10.1074/jbc.M301866200; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; Yang XJ, 2015, TUMOR BIOL, V36, P3717, DOI 10.1007/s13277-014-3011-9; Yu C, 2011, VASC PHARMACOL, V55, P26, DOI 10.1016/j.vph.2011.04.001; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	57	14	14	3	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2017	36	46					6374	6382		10.1038/onc.2017.245	http://dx.doi.org/10.1038/onc.2017.245			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM9WN	28745314	Green Accepted			2022-12-17	WOS:000415622900002
J	Ye, J; Wei, X; Shang, Y; Pan, Q; Yang, M; Tian, Y; He, Y; Peng, Z; Chen, L; Chen, W; Wang, R				Ye, J.; Wei, X.; Shang, Y.; Pan, Q.; Yang, M.; Tian, Y.; He, Y.; Peng, Z.; Chen, L.; Chen, W.; Wang, R.			Core 3 mucin-type O-glycan restoration in colorectal cancer cells promotes MUC1/p53/miR-200c-dependent epithelial identity	ONCOGENE			English	Article							MESENCHYMAL-TRANSITION; SPONTANEOUS COLITIS; PANCREATIC-CANCER; TUMOR-GROWTH; GLYCOSYLATION; METASTASIS; SUPPRESSES; SYNTHASE; TRANSCRIPTION; FIBRONECTIN	The attachment of cell-surface carbohydrates to proteins mediated by the amino acids serine or threonine (O-glycan) is involved in tumor metastasis; the roles of O-glycans vary depending on their structure, but the detailed mechanisms by which O-glycans trigger signaling to control tumor metastasis are largely unknown. In this study, we found that the reduced expression of core 3 synthase correlated with metastasis to lymph nodes and distant organs, resulting in poor prognosis for colorectal cancer (CRC) patients. Mechanically, we revealed that mucin-type core 3 O-glycan was synthesized at the membrane-tethered MUC1 N terminus because of core 3 synthase expression in colon cancer cells. This further inhibited the translocation of MUC1-C to the nucleus, initiated p53 gene transcription that was dependent on the inhibition of MUC1-C nucleus translocation, activated p53-mediated miR-200c expression and resulted in mesenchymal-epithelial transition (MET). Inhibition of MUC1 via small interfering RNA (siRNA) in re-expressed core 3 synthase colon cancer cells further inhibited MUC1-C nucleus translocation, increased p53 and miR-200c expression, and enhanced MET. However, inhibition of p53 via siRNA or miR-200c via miR-200c inhibitor in re-expressed core 3 synthase colon cancer cells promoted the epithelial-mesenchymal transition (EMT) in a reversible manner. Core 3 synthase mRNA levels and the p53 mRNA levels or miR-200c levels in the colon cancerous samples were positively correlated. Our findings suggest a novel mechanism linking mucin-type core 3 O-glycan to the EMT-MET plasticity of CRC cells via MUC1/p53/miR-200c-dependent signaling cascade and shed light on therapeutic strategies to treat this malignancy.	[Ye, J.; Wei, X.; Shang, Y.; Pan, Q.; Yang, M.; Tian, Y.; He, Y.; Peng, Z.; Chen, L.; Chen, W.; Wang, R.] Third Mil Med Univ, Inst Gastroenterol PLA, Southwest Hosp, Dept Gastroenterol, Gaotanyan Main St 30, Chongqing 400038, Peoples R China	Army Medical University	Wang, R (corresponding author), Third Mil Med Univ, Inst Gastroenterol PLA, Southwest Hosp, Dept Gastroenterol, Gaotanyan Main St 30, Chongqing 400038, Peoples R China.	rongquanw@hotmail.com		ye, jun/0000-0002-0631-556X; shang, yangyang/0000-0003-0764-0572; Wang, Rongquan/0000-0001-5307-0086	National Natural Science Foundation of China [81500410, 81170340, 81372557]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the following awards: 81500410 (to YT), 81170340 and 81372557 (to RW) from the National Natural Science Foundation of China.	Bergstrom K, 2017, MUCOSAL IMMUNOL, V10, P91, DOI 10.1038/mi.2016.45; Bergstrom K, 2016, GASTROENTEROLOGY, V151, P152, DOI 10.1053/j.gastro.2016.03.039; Byrd JC, 2004, CANCER METAST REV, V23, P77, DOI 10.1023/A:1025815113599; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Chou CH, 2015, ONCOTARGET, V6, P6123, DOI 10.18632/oncotarget.3045; Dimitroff CJ, 2015, CANCER RES, V75, P3195, DOI 10.1158/0008-5472.CAN-15-0834; Du J, 2015, J BIOL CHEM, V290, P12000, DOI 10.1074/jbc.M115.636969; Freire-De-Lima L, 2011, P NATL ACAD SCI USA, V108, P17690, DOI 10.1073/pnas.1115191108; Gabriel M, 2005, CLIN ORAL INVEST, V9, P284, DOI 10.1007/s00784-005-0007-2; Gao N, 2016, AM J PHYSIOL-GASTR L, V311, pG74, DOI 10.1152/ajpgi.00060.2016; Hur K, 2013, GUT, V62, P1315, DOI 10.1136/gutjnl-2011-301846; Iwai T, 2005, P NATL ACAD SCI USA, V102, P4572, DOI 10.1073/pnas.0407983102; Iwai T, 2002, J BIOL CHEM, V277, P12802, DOI 10.1074/jbc.M112457200; KUAN SF, 1989, J BIOL CHEM, V264, P19271; Kufe D, 2010, ONCOGENE, V29, P5663, DOI 10.1038/onc.2010.334; Lee SH, 2009, J BIOL CHEM, V284, P17157, DOI 10.1074/jbc.M109.010934; Levin B, 2008, CA-CANCER J CLIN, V58, P130, DOI 10.3322/CA.2007.0018; Lillehoj EP, 2004, AM J PHYSIOL-LUNG C, V287, pL809, DOI 10.1152/ajplung.00385.2003; Lu JS, 2014, J BIOL CHEM, V289, P34627, DOI 10.1074/jbc.M114.593392; Macao B, 2006, NAT STRUCT MOL BIOL, V13, P71, DOI 10.1038/nsmb1035; Moran AP, 2011, GUT, V60, P1412, DOI 10.1136/gut.2010.212704; Pan Q, 2013, J BIOL CHEM, V288, P5407, DOI 10.1074/jbc.M112.408245; Park JH, 2011, NEOPLASIA, V13, P320, DOI 10.1593/neo.101440; Pinho SS, 2015, NAT REV CANCER, V15, P540, DOI 10.1038/nrc3982; Ponnusamy MP, 2010, ONCOGENE, V29, P5741, DOI 10.1038/onc.2010.309; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Radhakrishnan P, 2014, P NATL ACAD SCI USA, V111, pE4066, DOI 10.1073/pnas.1406619111; Radhakrishnan P, 2013, INT J CANCER, V133, P2824, DOI 10.1002/ijc.28322; Rao XJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9468; Roy LD, 2011, ONCOGENE, V30, P1449, DOI 10.1038/onc.2010.526; Shamir ER, 2014, J CELL BIOL, V204, P839, DOI 10.1083/jcb.201306088; Singh PK, 2006, TRENDS CELL BIOL, V16, P467, DOI 10.1016/j.tcb.2006.07.006; Spaderna S, 2006, GASTROENTEROLOGY, V131, P830, DOI 10.1053/j.gastro.2006.06.016; Springer SA, 2016, J PROTEOMICS, V135, P90, DOI 10.1016/j.jprot.2015.11.022; Tagde A, 2016, BLOOD, V127, P2587, DOI 10.1182/blood-2015-07-659151; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tian Y, 2014, J BIOL CHEM, V289, P36101, DOI 10.1074/jbc.M114.598383; Tran DT, 2013, J BIOL CHEM, V288, P6921, DOI 10.1074/jbc.R112.418558; Tsuboi S, 2012, TRENDS MOL MED, V18, P224, DOI 10.1016/j.molmed.2012.02.001; Wei XL, 2007, CANCER RES, V67, P1853, DOI 10.1158/0008-5472.CAN-06-3063; Yang YN, 2011, J CLIN INVEST, V121, P1373, DOI 10.1172/JCI42579; Ye J, 2015, GUT PATHOG, V7, DOI 10.1186/s13099-015-0078-9; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	44	14	17	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2017	36	46					6391	6407		10.1038/onc.2017.241	http://dx.doi.org/10.1038/onc.2017.241			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM9WN	28745318				2022-12-17	WOS:000415622900004
J	Trinidad, AG; Whalley, N; Rowlinson, R; Delpuech, O; Dudley, P; Rooney, C; Critchlow, SE				Trinidad, A. G.; Whalley, N.; Rowlinson, R.; Delpuech, O.; Dudley, P.; Rooney, C.; Critchlow, S. E.			Pyruvate dehydrogenase kinase 4 exhibits a novel role in the activation of mutant KRAS, regulating cell growth in lung and colorectal tumour cells	ONCOGENE			English	Article							CANCER-CELLS; DICHLOROACETATE DCA; METABOLIC SWITCH; BREAST-CANCER; FATTY-ACIDS; IN-VITRO; RAS; EXPRESSION; PROTEIN; PDK4	RAS signalling is involved in the control of several metabolic pathways including glycolysis, mitochondrial respiration and glutamine metabolism. Importantly, we have found here that loss of PDHK4, a key regulator of the pyruvate dehydrogenase complex, caused a profound cell growth inhibition in tumour cells harbouring KRAS mutations. Using isogenic cells and a panel of colorectal and lung cell lines we demonstrated that KRAS mutant cells showed a dependency on PDHK4 whereas KRAS wild-type cells were significantly resistant to PDHK4 knockdown. We have found that PDHK4 plays a role in the post-translational regulation of mutant KRAS activity. Depletion of PDHK4 causes disruption of KRAS cellular localization, a reduction in KRAS activity which, in turn, results in reduced MAPK signalling. Interestingly, PDHK4 and KRAS depletion resulted in a similar metabolic phenotype consisting of a reduction of glucose and fatty acid oxidation. Moreover, stable expression of PDHK4 increased localization of activated KRAS at the plasma membrane and induced tumour cell growth in vitro and in vivo. Taken together these data support a model where PDHK4 regulates KRAS signalling and its tumorigenic properties and suggest that inhibition of PDHK4 could represent a novel therapeutic strategy to target KRAS mutant colorectal and lung cancers.	[Trinidad, A. G.; Rowlinson, R.; Dudley, P.; Rooney, C.] AstraZeneca iMED Oncol, Alderley Pk, Macclesfield, Cheshire, England; [Trinidad, A. G.; Whalley, N.; Delpuech, O.; Critchlow, S. E.] AstraZeneca iMED Oncol, Cambridge CB10 1XL, England		Trinidad, AG (corresponding author), AstraZeneca iMED Oncol, Cambridge CB10 1XL, England.	antonio.garcia-trinidad@astrazeneca.com			AstraZeneca	AstraZeneca(AstraZeneca)	We would like to thank Dr Oliver Maddocks for helpful discussions, Mike Dymond for fluidigm data analysis support and the AZ laboratory animal sciences group for in vivo support. AZD7545 was discovered by AstraZeneca and the study was funded by the AstraZeneca post-doctoral program.	Ahearn IM, 2012, NAT REV MOL CELL BIO, V13, P39, DOI 10.1038/nrm3255; Cadoudal T, 2008, DIABETES, V57, P2272, DOI 10.2337/db08-0477; Cao WG, 2008, PROSTATE, V68, P1223, DOI 10.1002/pros.20788; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; Dry JR, 2010, CANCER RES, V70, P2264, DOI 10.1158/0008-5472.CAN-09-1577; Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007; Grassian AR, 2011, GENE DEV, V25, P1716, DOI 10.1101/gad.16771811; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015; Houten SM, 2009, CELL MOL LIFE SCI, V66, P1283, DOI 10.1007/s00018-009-9066-x; Huang BL, 2002, DIABETES, V51, P276, DOI 10.2337/diabetes.51.2.276; Hwang B, 2009, BIOCHEM J, V423, P243, DOI 10.1042/BJ20090390; James G, 1996, P NATL ACAD SCI USA, V93, P4454, DOI 10.1073/pnas.93.9.4454; Kamphorst JJ, 2013, P NATL ACAD SCI USA, V110, P8882, DOI 10.1073/pnas.1307237110; Kaplon J, 2013, NATURE, V498, P109, DOI 10.1038/nature12154; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Kim YI, 2006, DIABETES, V55, P2311, DOI 10.2337/db05-1606; Kolobova E, 2001, BIOCHEM J, V358, P69, DOI 10.1042/0264-6021:3580069; KOROTCHKINA LG, 1995, J BIOL CHEM, V270, P14297, DOI 10.1074/jbc.270.24.14297; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Leclerc D, 2017, BRIT J CANCER, V116, P930, DOI 10.1038/bjc.2017.38; Li G, 2017, ONCOGENE, V36, P989, DOI 10.1038/onc.2016.265; Liu ZB, 2014, J BIOL CHEM, V289, P29739, DOI 10.1074/jbc.M114.584821; Mazar J, 2016, MOL CELL BIOL, V36, P1090, DOI 10.1128/MCB.00762-15; Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554; Morrell JA, 2003, BIOCHEM SOC T, V31, P1168; Munoz-Pinedo C, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.123; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Puthanveetil P, 2010, ENDOCRINOLOGY, V151, P2306, DOI 10.1210/en.2009-1072; Salloum D, 2014, MOL CANCER THER, V13, P733, DOI 10.1158/1535-7163.MCT-13-0762; Samatar AA, 2014, NAT REV DRUG DISCOV, V13, P928, DOI 10.1038/nrd4281; Sanchez-Arago M, 2010, CARCINOGENESIS, V31, P567, DOI 10.1093/carcin/bgq012; Savkur RS, 2005, BIOCHEM BIOPH RES CO, V329, P391, DOI 10.1016/j.bbrc.2005.01.141; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Srivastava N, 2014, CELL METAB, V20, P650, DOI 10.1016/j.cmet.2014.08.003; Stephen AG, 2014, CANCER CELL, V25, P272, DOI 10.1016/j.ccr.2014.02.017; Sugden Mary C., 2006, Archives of Physiology and Biochemistry, V112, P139, DOI 10.1080/13813450600935263; Sun RC, 2010, BREAST CANCER RES TR, V120, P253, DOI 10.1007/s10549-009-0435-9; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Wynn RM, 2008, J BIOL CHEM, V283, P25305, DOI 10.1074/jbc.M802249200; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; Zhang Y, 2016, J BIOL CHEM, V291, P17405, DOI 10.1074/jbc.M116.713735; Zimmermann G, 2013, NATURE, V497, P638, DOI 10.1038/nature12205	50	14	14	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2017	36	44					6164	6176		10.1038/onc.2017.224	http://dx.doi.org/10.1038/onc.2017.224			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FL5CU	28692044	Green Published, hybrid			2022-12-17	WOS:000414249800010
J	Read, ML; Fong, JC; Modasia, B; Fletcher, A; Imruetaicharoenchoke, W; Thompson, RJ; Nieto, H; Reynolds, JJ; Bacon, A; Mallick, U; Hackshaw, A; Watkinson, JC; Boelaert, K; Turnell, AS; Smith, VE; McCabe, CJ				Read, M. L.; Fong, J. C.; Modasia, B.; Fletcher, A.; Imruetaicharoenchoke, W.; Thompson, R. J.; Nieto, H.; Reynolds, J. J.; Bacon, A.; Mallick, U.; Hackshaw, A.; Watkinson, J. C.; Boelaert, K.; Turnell, A. S.; Smith, V. E.; McCabe, C. J.			Elevated PTTG and PBF predicts poor patient outcome and modulates DNA damage response genes in thyroid cancer	ONCOGENE			English	Article							TUMOR-TRANSFORMING-GENE; HUMAN BREAST-CANCER; BINDING-FACTOR; MICROSATELLITE INSTABILITY; GENOMIC INSTABILITY; COLORECTAL-CANCER; CELLS; EXPRESSION; TUMORIGENESIS; GROWTH	The proto-oncogene PTTG and its binding partner PBF have been widely studied in multiple cancer types, particularly thyroid and colorectal, but their combined role in tumourigenesis is uncharacterised. Here, we show for the first time that together PTTG and PBF significantly modulate DNA damage response (DDR) genes, including p53 target genes, required to maintain genomic integrity in thyroid cells. Critically, DDR genes were extensively repressed in primary thyrocytes from a bitransgenic murine model (Bi-Tg) of thyroid-specific PBF and PTTG overexpression. Irradiation exposure to amplify p53 levels further induced significant repression of DDR genes in Bi-Tg thyrocytes (P = 2.4 x 10(-4)) compared with either PBF-(P = 1.5 x 10(-3)) or PTTG-expressing thyrocytes (P = NS). Consistent with this, genetic instability was greatest in Bi-Tg thyrocytes with a mean genetic instability (GI) index of 35.8 +/- 2.6%, as well as significant induction of gross chromosomal aberrations in thyroidal TPC-1 cells following overexpression of PBF and PTTG. We extended our findings to human thyroid cancer using TCGA data sets (n = 322) and found striking correlations with PBF and PTTG expression in well-characterised DDR gene panel RNA-seq data. In addition, genetic associations and transient transfection identified PBF as a downstream target of the receptor tyrosine kinase-BRAF signalling pathway, emphasising a role for PBF as a novel component in a pathway well described to drive neoplastic growth. We also showed that overall survival (P = 1.91 x 10(-5)) and disease-free survival (P = 4.9 x 10(-5)) was poorer for TCGA patients with elevated tumoural PBF/PTTG expression and mutationally activated BRAF. Together our findings indicate that PBF and PTTG have a critical role in promoting thyroid cancer that is predictive of poorer patient outcome.	[Read, M. L.; Fong, J. C.; Modasia, B.; Fletcher, A.; Imruetaicharoenchoke, W.; Thompson, R. J.; Nieto, H.; Bacon, A.; Boelaert, K.; Smith, V. E.; McCabe, C. J.] Univ Birmingham, Inst Metab & Syst Res, Birmingham, W Midlands, England; [Reynolds, J. J.; Turnell, A. S.] Univ Birmingham, Inst Canc & Genom Sci, Birmingham, W Midlands, England; [Mallick, U.] Freeman Rd Hosp, Northern Ctr Canc Care, Newcastle Upon Tyne, Tyne & Wear, England; [Hackshaw, A.] UCL, Canc Res UK, London, England; [Hackshaw, A.] UCL, UCL Canc Trials Ctr, London, England; [Watkinson, J. C.] Univ Hosp Birmingham NHS Fdn Trust, Dept Otolaryngol Head & Neck Surg, Birmingham, W Midlands, England	University of Birmingham; University of Birmingham; Newcastle Freeman Hospital; Newcastle University - UK; Cancer Research UK; University of London; University College London; University of London; University College London; University of Birmingham	McCabe, CJ (corresponding author), Univ Birmingham, Coll Med & Dent Sci, Inst Metab & Syst Res, Birmingham B15 2TH, W Midlands, England.	mccabcjz@bham.ac.uk	Read, Martin/A-3505-2012; Smith, Vicki E/F-6972-2010	Read, Martin/0000-0001-8918-4333; Smith, Vicki E/0000-0003-0757-7198; Fletcher, Anne/0000-0003-1534-1142; Reynolds, John Joseph/0000-0001-8690-5828	Medical Research Council [MR/J001414/1]; Wellcome Trust; Cancer Research UK; Get Ahead Charitable Trust; AMEND; Medical Research Council [MR/P000509/1, 1367609, G0601811] Funding Source: researchfish; MRC [G0601811, MR/P000509/1, MR/J001414/1] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Cancer Research UK(Cancer Research UK); Get Ahead Charitable Trust; AMEND; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the Medical Research Council (MR/J001414/1), Wellcome Trust, Cancer Research UK, Get Ahead Charitable Trust and AMEND. Results are in part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/.	Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Basik M, 1997, GENE CHROMOSOME CANC, V18, P19, DOI 10.1002/(SICI)1098-2264(199701)18:1<19::AID-GCC3>3.0.CO;2-4; Bernal JA, 2002, NAT GENET, V32, P306, DOI 10.1038/ng997; Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711; Boelaert K, 2003, J CLIN ENDOCR METAB, V88, P2341, DOI 10.1210/jc.2002-021113; Byrne M, 2014, ANN NY ACAD SCI, V1310, P89, DOI 10.1111/nyas.12370; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chesnokova V, 2009, ENDOCRINOLOGY, V150, P2603, DOI 10.1210/en.2008-0972; Chien WW, 2000, J BIOL CHEM, V275, P19422, DOI 10.1074/jbc.M910105199; Fong MY, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-532; Gao H, 2016, AM J CANCER RES, V6, P425; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Grogan RH, 2013, SURGERY, V154, P1436, DOI 10.1016/j.surg.2013.07.008; Gurvits N, 2016, CELL ONCOL, V39, P319, DOI 10.1007/s13402-016-0277-5; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hamid T, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-18; Haymart MR, 2009, ONCOLOGIST, V14, P216, DOI 10.1634/theoncologist.2008-0194; Heaney AP, 2001, J CLIN ENDOCR METAB, V86, P5025, DOI 10.1210/jc.86.10.5025; Higgs MR, 2015, MOL CELL, V59, P462, DOI 10.1016/j.molcel.2015.06.007; Hsu YH, 2010, J BIOL CHEM, V285, P22630, DOI 10.1074/jbc.M109.096255; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Kim D, 2005, ONCOGENE, V24, P4861, DOI 10.1038/sj.onc.1208659; Kim DS, 2007, CARCINOGENESIS, V28, P749, DOI 10.1093/carcin/bgl202; Knauf JA, 2005, CANCER RES, V65, P4238, DOI 10.1158/0008-5472.CAN-05-0047; La Vecchia C, 2015, INT J CANCER, V136, P2187, DOI 10.1002/ijc.29251; Lancia I, 2016, J CLIN INVEST, V126, P1052, DOI 10.1172/JCI85271; Leeman-Neill RJ, 2014, CANCER-AM CANCER SOC, V120, P799, DOI 10.1002/cncr.28484; Lewy GD, 2013, ENDOCRINOLOGY, V154, P4408, DOI 10.1210/en.2012-2156; Liang HQ, 2015, ONCOTARGET; McCabe CJ, 2003, CLIN ENDOCRINOL, V58, P141, DOI 10.1046/j.1365-2265.2003.01598.x; Melloni GEM, 2014, GENOME MED, V6, DOI 10.1186/gm563; Mitmaker E, 2008, J SURG RES, V150, P40, DOI 10.1016/j.jss.2007.12.760; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Pellegriti G, 2013, J CANCER EPIDEMIOL, V2013, DOI 10.1155/2013/965212; Read ML, 2016, MOL CARCINOGEN, V55, P15, DOI 10.1002/mc.22254; Read ML, 2014, ENDOCRINOLOGY, V155, P1222, DOI 10.1210/en.2013-1646; Read ML, 2011, CANCER RES, V71, P6153, DOI 10.1158/0008-5472.CAN-11-0720; Ruan JW, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3226; Rubinek T, 2007, AM J PHYSIOL-CELL PH, V293, pC1082, DOI 10.1152/ajpcell.00145.2007; Salehi F, 2008, ENDOCR-RELAT CANCER, V15, P721, DOI 10.1677/ERC-08-0012; Santos JC, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-79; Smith VE, 2009, J CELL SCI, V122, P3393, DOI 10.1242/jcs.045427; Stratford AL, 2005, J CLIN ENDOCR METAB, V90, P4341, DOI 10.1210/jc.2005-0523; Vaish M, 2004, EXP MOL MED, V36, P122, DOI 10.1038/emm.2004.18; Wang H, 2016, MOL CELL, V63, P277, DOI 10.1016/j.molcel.2016.05.038; Wang X, 2015, ONCOTARGET, V6, P40959, DOI 10.18632/oncotarget.5726; Watkins RJ, 2010, CANCER RES, V70, P3739, DOI 10.1158/0008-5472.CAN-09-3531; Yoon CH, 2012, J BIOL CHEM, V287, P19516, DOI 10.1074/jbc.M111.337428; Zheng Y, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0126-9; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	53	14	15	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2017	36	37					5296	5308		10.1038/onc.2017.154	http://dx.doi.org/10.1038/onc.2017.154			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FG8HT	28504713	Green Accepted, Green Submitted			2022-12-17	WOS:000410671700008
J	Hernandez-Perez, S; Cabrera, E; Salido, E; Lim, M; Reid, L; Lakhani, SR; Khanna, KK; Saunus, JM; Freire, R				Hernandez-Perez, S.; Cabrera, E.; Salido, E.; Lim, M.; Reid, L.; Lakhani, S. R.; Khanna, K. K.; Saunus, J. M.; Freire, R.			DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer (vol 36, pg 4802, 2017)	ONCOGENE			English	Correction													Cabrera, Elisa/GPX-3455-2022; Freire, Raimundo/Q-7660-2019	Freire, Raimundo/0000-0003-4473-8894				Cabrera E, 2017, ONCOGENE, V36, P678, DOI 10.1038/onc.2016.239	1	14	15	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4817	4817		10.1038/onc.2017.220	http://dx.doi.org/10.1038/onc.2017.220			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28650472	Bronze			2022-12-17	WOS:000407702400014
J	Colleoni, B; Paternot, S; Pita, JM; Bisteau, X; Coulonval, K; Davis, RJ; Raspe, E; Roger, PP				Colleoni, B.; Paternot, S.; Pita, J. M.; Bisteau, X.; Coulonval, K.; Davis, R. J.; Raspe, E.; Roger, P. P.			JNKs function as CDK4-activating kinases by phosphorylating CDK4 and p21	ONCOGENE			English	Article							N-TERMINAL KINASE; THYROID EPITHELIAL-CELLS; CYCLIN-DEPENDENT KINASES; JUN NH2-TERMINAL KINASE; SIGNAL-TRANSDUCTION; ACTIVATING KINASE; MAMMALIAN TARGET; UBIQUITIN LIGASE; PROTEIN-KINASES; CANCER	Cyclin D-CDK4/6 are the first cyclin-dependent kinase (CDK) complexes to be activated by mitogenic/oncogenic pathways. They have a central role in the cell multiplication decision and in its deregulation in cancer cells. We identified T172 phosphorylation of CDK4 rather than cyclin D accumulation as the distinctly regulated step determining CDK4 activation. This finding challenges the view that the only identified metazoan CDK-activating kinase, cyclin H-CDK7-Mat1 (CAK), which is constitutively active, is responsible for the activating phosphorylation of all cell cycle CDKs. We previously showed that T172 phosphorylation of CDK4 is conditioned by an adjacent proline (P173), which is not present in CDK6 and CDK1/2. Although CDK7 activity was recently shown to be required for CDK4 activation, we proposed that proline-directed kinases might specifically initiate the activation of CDK4. Here, we report that JNKs, but not ERK1/2 or CAK, can be direct CDK4-activating kinases for cyclin D-CDK4 complexes that are inactivated by p21-mediated stabilization. JNKs and ERK1/2 also phosphorylated p21 at S130 and T57, which might facilitate CDK7-dependent activation of p21-bound CDK4, however, mutation of these sites did not impair the phosphorylation of CDK4 by JNKs. In two selected tumor cells, two different JNK inhibitors inhibited the phosphorylation and activation of cyclin D1-CDK4-p21 but not the activation of cyclin D3-CDK4 that is mainly associated to p27. Specific inhibition by chemical genetics in MEFs confirmed the involvement of JNK2 in cyclin D1-CDK4 activation. Therefore, JNKs could be activating kinases for cyclin D1-CDK4 bound to p21, by independently phosphorylating both CDK4 and p21.	[Colleoni, B.; Paternot, S.; Pita, J. M.; Bisteau, X.; Coulonval, K.; Raspe, E.; Roger, P. P.] Univ Libre Bruxelles, Inst Interdisciplinary Res IRIBHM, WELBIO, Brussels, Belgium; [Colleoni, B.; Paternot, S.; Pita, J. M.; Bisteau, X.; Coulonval, K.; Raspe, E.; Roger, P. P.] Univ Libre Bruxelles, U CRC, Brussels, Belgium; [Davis, R. J.] Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA USA; [Davis, R. J.] Howard Hughes Med Inst, Worcester, MA USA	Universite Libre de Bruxelles; WELBIO; Universite Libre de Bruxelles; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute	Roger, PP (corresponding author), Univ Libre Bruxelles, IRIBHM, Campus Erasme,808 Route Lennik, B-1070 Brussels, Belgium.; Roger, PP (corresponding author), ASTAR, IMCB, 61 Biopolis Dr,Proteos 3-09, Singapore 138673, Singapore.	proger@ulb.ac.be	Bisteau, Xavier/AAH-6744-2021; Bisteau, Xavier/Q-7239-2018	Bisteau, Xavier/0000-0002-8896-5098; Davis, Roger/0000-0002-0130-1652	WELBIO (Walloon Excellence in Lifesciences and Biotechnology); Belgian Foundation against Cancer [2014-130]; FRS-FNRS [T003813F, J.0002.16]; Docteur JP Naets Fund; Fondation Rose et Jean Hoguet; Fonds David et Alice Van Buuren; Fondation Jaumotte-Demoulin; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK107220] Funding Source: NIH RePORTER	WELBIO (Walloon Excellence in Lifesciences and Biotechnology)(WELBIO); Belgian Foundation against Cancer; FRS-FNRS(Fonds de la Recherche Scientifique - FNRS); Docteur JP Naets Fund; Fondation Rose et Jean Hoguet; Fonds David et Alice Van Buuren; Fondation Jaumotte-Demoulin; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The p21 expression plasmids and MCF-7 cells were provided by Ludger Hengst (Innsbruck University) and Geert Berx (Ghent University), respectively. Amin Bredan edited the English text. We thank Professor Jacques E. Dumont (Universite Libre de Bruxelles) for continued interest and support. This study was supported by WELBIO (Walloon Excellence in Lifesciences and Biotechnology), the Belgian Foundation against Cancer (Grant 2014-130), the FRS-FNRS Grants T003813F and J.0002.16 and the Docteur JP Naets Fund (managed by the King Baudouin Foundation). BC was a fellow of the FRIA and is supported by the Fondation Rose et Jean Hoguet, the Fonds David et Alice Van Buuren and the Fondation Jaumotte-Demoulin, JMP is a fellow of the Televie and PPR is a Senior Research Associate of the FRS-FNRS.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Asghar U, 2015, NAT REV DRUG DISCOV, V14, P130, DOI 10.1038/nrd4504; Bach S, 2005, J BIOL CHEM, V280, P31208, DOI 10.1074/jbc.M500806200; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bisteau X, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003546; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Blancquaert S, 2010, MOL ENDOCRINOL, V24, P1453, DOI 10.1210/me.2010-0087; Bockstaele L, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-25; Bockstaele L, 2006, MOL CELL BIOL, V26, P5070, DOI 10.1128/MCB.02006-05; Bockstaele L, 2009, MOL CELL BIOL, V29, P4188, DOI 10.1128/MCB.01823-08; Bode AM, 2007, MOL CARCINOGEN, V46, P591, DOI 10.1002/mc.20348; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Bubici C, 2014, BRIT J PHARMACOL, V171, P24, DOI 10.1111/bph.12432; Cellurale C, 2011, MOL CELL BIOL, V31, P1565, DOI 10.1128/MCB.01122-10; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Choi YJ, 2012, CANCER CELL, V22, P438, DOI 10.1016/j.ccr.2012.09.015; Coulonval K, 2003, EXP CELL RES, V291, P135, DOI 10.1016/S0014-4827(03)00392-6; Coulonval K, 2011, MOL BIOL CELL, V22, P3971, DOI 10.1091/mbc.E11-02-0136; Cui J, 2005, J BIOL CHEM, V280, P9913, DOI 10.1074/jbc.M412165200; Cui J, 2006, CANCER RES, V66, P10024, DOI 10.1158/0008-5472.CAN-06-0136; Cui J, 2009, MOL CANCER THER, V8, P3214, DOI 10.1158/1535-7163.MCT-09-0408; Das M, 2011, GENE DEV, V25, P634, DOI 10.1101/gad.1989311; Das M, 2007, P NATL ACAD SCI USA, V104, P15759, DOI 10.1073/pnas.0707782104; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Fallahi-Sichani M, 2015, MOL SYST BIOL, V11, DOI 10.15252/msb.20145877; Finegan KG, 2010, CANCER RES, V70, P5797, DOI 10.1158/0008-5472.CAN-09-3669; Fisher RP, 2005, J CELL SCI, V118, P5171, DOI 10.1242/jcs.02718; Ganuza M, 2012, EMBO J, V31, P2498, DOI 10.1038/emboj.2012.94; Grimmler M, 2007, CELL, V128, P269, DOI 10.1016/j.cell.2006.11.047; Hamilton E, 2016, CANCER TREAT REV, V45, P129, DOI 10.1016/j.ctrv.2016.03.002; Hui LJ, 2008, J CLIN INVEST, V118, P3943, DOI 10.1172/JCI37156; Hwang CY, 2009, MOL CELL BIOL, V29, P3379, DOI 10.1128/MCB.01758-08; Jakel H, 2012, CELL CYCLE, V11, P1910, DOI 10.4161/cc.19957; Jaeschke A, 2006, MOL CELL, V23, P899, DOI 10.1016/j.molcel.2006.07.028; Jarviluoma A, 2006, MOL CELL BIOL, V26, P2430, DOI 10.1128/MCB.26.6.2430-2440.2006; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; Kaldis P, 1998, MOL BIOL CELL, V9, P2545, DOI 10.1091/mbc.9.9.2545; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; Khatlani TS, 2007, ONCOGENE, V26, P2658, DOI 10.1038/sj.onc.1210050; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Larochelle S, 2006, NAT STRUCT MOL BIOL, V13, P55, DOI 10.1038/nsmb1028; Larochelle S, 2007, MOL CELL, V25, P839, DOI 10.1016/j.molcel.2007.02.003; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Liu Y, 2004, J BIOL CHEM, V279, P4507, DOI 10.1074/jbc.M309995200; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; Nitta RT, 2011, ONCOGENE, V30, P234, DOI 10.1038/onc.2010.414; Nitta RT, 2008, J BIOL CHEM, V283, P34935, DOI 10.1074/jbc.M804970200; Parra E, 2010, ONCOL REP, V24, P1339, DOI 10.3892/or_00000991; Patel R, 1998, J CELL SCI, V111, P2247; Paternot S, 2006, CELL CYCLE, V5, P61, DOI 10.4161/cc.5.1.2265; Paternot S, 2003, J BIOL CHEM, V278, P26533, DOI 10.1074/jbc.M302492200; Paternot S, 2006, MOL ENDOCRINOL, V20, P3279, DOI 10.1210/me.2005-0515; Paternot S, 2014, CELL CYCLE, V13, P2879, DOI 10.4161/15384101.2014.946841; Paternot S, 2010, CELL CYCLE, V9, P689, DOI 10.4161/cc.9.4.10611; Paternot S, 2009, CANCER RES, V69, P4577, DOI 10.1158/0008-5472.CAN-08-3260; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Puyol M, 2010, CANCER CELL, V18, P63, DOI 10.1016/j.ccr.2010.05.025; Ray A, 2009, MOL CELL BIOL, V29, P986, DOI 10.1128/MCB.00898-08; Rocha AS, 2008, MOL BIOL CELL, V19, P4814, DOI 10.1091/mbc.E08-06-0617; ROGER PP, 1992, J CELL BIOL, V117, P383, DOI 10.1083/jcb.117.2.383; Sakurai T, 2006, P NATL ACAD SCI USA, V103, P10544, DOI 10.1073/pnas.0603499103; Satyanarayana A, 2009, ONCOGENE, V28, P2925, DOI 10.1038/onc.2009.170; Schachter MM, 2013, MOL CELL, V50, P250, DOI 10.1016/j.molcel.2013.04.003; Schwabe RF, 2003, HEPATOLOGY, V37, P824, DOI 10.1053/jhep.2003.50135; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 2016, CANCER DISCOV, V6, P353, DOI 10.1158/2159-8290.CD-15-0894; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SOLOMON MJ, 1994, TRENDS BIOCHEM SCI, V19, P496, DOI 10.1016/0968-0004(94)90137-6; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tournier Cathy, 2013, Genes Cancer, V4, P397, DOI 10.1177/1947601913486349; Tsuiki H, 2003, CANCER RES, V63, P250; Turner NC, 2015, NEW ENGL J MED, V373, P209, DOI 10.1056/NEJMoa1505270; Ubersax JA, 2007, NAT REV MOL CELL BIO, V8, P530, DOI 10.1038/nrm2203; Ventura JJ, 2006, MOL CELL, V21, P701, DOI 10.1016/j.molcel.2006.01.018; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wang L, 2004, ONCOGENE, V23, P5978, DOI 10.1038/sj.onc.1207802; Welcker M, 1998, CANCER RES, V58, P5053; Wesierska-Gadek J, 2009, ACTA BIOCHIM POL, V56, P495; Wohlbold L, 2006, CELL CYCLE, V5, P546, DOI 10.4161/cc.5.5.2541; Xue Y, 2003, MOL CARCINOGEN, V36, P38, DOI 10.1002/mc.10096; Yang YM, 2003, CLIN CANCER RES, V9, P391; Yao G, 2008, NAT CELL BIOL, V10, P476, DOI 10.1038/ncb1711; Zhan J, 2007, MOL CELL BIOL, V27, P3530, DOI 10.1128/MCB.00086-06; Zhang T, 2012, CHEM BIOL, V19, P140, DOI 10.1016/j.chembiol.2011.11.010; Zhu HY, 2005, J BIOL CHEM, V280, P29282, DOI 10.1074/jbc.M407352200	95	14	15	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4349	4361		10.1038/onc.2017.7	http://dx.doi.org/10.1038/onc.2017.7			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	28368408	Green Published, hybrid			2022-12-17	WOS:000406360600011
J	Tang, X; Ding, CK; Wu, J; Sjol, J; Wardell, S; Spasojevic, I; George, D; McDonnell, DP; Hsu, DS; Chang, JT; Chi, JT				Tang, X.; Ding, C-K; Wu, J.; Sjol, J.; Wardell, S.; Spasojevic, I.; George, D.; McDonnell, D. P.; Hsu, D. S.; Chang, J. T.; Chi, J-T			Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling (vol 36, pg 4235, 2017)	ONCOGENE			English	Correction																		Tang X, 2017, ONCOGENE, V36, P4235, DOI 10.1038/onc.2016.394	1	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4379	4379		10.1038/onc.2017.192	http://dx.doi.org/10.1038/onc.2017.192			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	28604749	Bronze			2022-12-17	WOS:000406360600014
J	Li, Y; Zhou, T; Wang, Y; Ning, C; Lv, Z; Han, G; Morris, JC; Taylor, EN; Wang, R; Xiao, H; Hou, C; Ma, Y; Shen, B; Feng, J; Guo, R; Li, Y; Chen, G				Li, Y.; Zhou, T.; Wang, Y.; Ning, C.; Lv, Z.; Han, G.; Morris, J. C.; Taylor, E. N.; Wang, R.; Xiao, H.; Hou, C.; Ma, Y.; Shen, B.; Feng, J.; Guo, R.; Li, Y.; Chen, G.			The protumorigenic potential of FTY720 by promoting extramedullary hematopoiesis and MDSC accumulation	ONCOGENE			English	Article							TUMOR-BEARING MICE; SUPPRESSOR-CELLS; MULTIPLE-SCLEROSIS; HEPATOCELLULAR-CARCINOMA; LYMPHOCYTE EGRESS; GM-CSF; FINGOLIMOD; RECEPTOR; CANCER; ACTIVATION	FTY720 (also called fingolimod) is recognized as an immunosuppressant and has been approved by the Food and Drug Administration to treat refractory multiple sclerosis. However, long-term administration of FTY720 potentially increases the risk for cancer in recipients. The underlying mechanisms remain poorly understood. Herein, we provided evidence that FTY720 administration potentiated tumor growth. Mechanistically, FTY720 enhanced extramedullary hematopoiesis and massive accumulation of myeloid-derived suppressor cells (MDSCs), which actively suppressed antitumor immune responses. Granulocyte-macrophage colony-stimulating factor (GM-CSF), mainly produced by MDSCs, was identified as a key factor to mediate these effects of FTY720 in tumor microenvironment. Furthermore, we showed that FTY720 triggers MDSCs to release GM-CSF via S1P receptor 3 (S1pr3) through Rho kinase and extracellular signal-regulated kinase-dependent pathway. Thus, our findings provide mechanistic explanation for the protumorigenic potentials of FTY720 and suggest that targeting S1pr3 simultaneously may be beneficial for the patients receiving FTY720 treatment.	[Li, Y.; Zhou, T.; Wang, Y.; Ning, C.; Lv, Z.; Han, G.; Wang, R.; Xiao, H.; Hou, C.; Shen, B.; Feng, J.; Li, Y.; Chen, G.] Inst Basic Med Sci, Dept Immunol, Taiping Rd 27, Beijing 100850, Peoples R China; [Li, Y.; Ma, Y.] Henan Univ, Med Sch, Lab Cellular & Mol Immunol, Kaifeng, Peoples R China; [Li, Y.] Peoples Hosp Luanchuan Cty, Dept Internal Med, Luoyang, Peoples R China; [Li, Y.; Zhou, T.; Han, G.; Wang, R.; Xiao, H.; Hou, C.; Shen, B.; Feng, J.; Li, Y.; Chen, G.] State Key Lab Toxicol & Med Countermeasures, Beijing, Peoples R China; [Wang, Y.] Acad Mil Med Sci, Affiliated Hosp, Dept Hematol & Transplantat, Beijing, Peoples R China; [Ning, C.] 161st Hosp PLA, Dept Oncol, Wuhan, Peoples R China; [Morris, J. C.; Taylor, E. N.] Univ New South Wales, Sch Chem, Sydney, NSW, Australia; [Guo, R.] Univ Michigan, Dept Pathol, Ann Arbor, MI USA	Henan University; Academy of Military Medical Sciences - China; University of New South Wales Sydney; University of Michigan System; University of Michigan	Han, G; Chen, G (corresponding author), Inst Basic Med Sci, Dept Immunol, Taiping Rd 27, Beijing 100850, Peoples R China.	genchenghan@163.com; guogangch@yahoo.com	Wang, Renxi/AAM-1326-2020; Morris, Jonathan C/A-9923-2008	Morris, Jonathan C/0000-0002-5109-9069; Wang, Renxi/0000-0003-4130-3334	National Key Basic Research Program of China [2015CB553704, 2013CB530506]; National Natural Science Foundation of China [81672803, 81472647, 81272320]; Beijing Natural Science Foundation [7132151]; Service Industry Scientific Research of National Health and Family Planning Commission of China [2015SQ00192]	National Key Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation); Service Industry Scientific Research of National Health and Family Planning Commission of China	This work was supported by grants from the National Key Basic Research Program of China (2015CB553704, 2013CB530506), the National Natural Science Foundation of China (81672803, 81472647, 81272320), Beijing Natural Science Foundation (7132151), Service Industry Scientific Research of National Health and Family Planning Commission of China (2015SQ00192).	Bayne LJ, 2012, CANCER CELL, V21, P822, DOI 10.1016/j.ccr.2012.04.025; Bronte V, 2003, J IMMUNOL, V170, P270, DOI 10.4049/jimmunol.170.1.270; Calabresi PA, 2014, LANCET NEUROL, V13, P545, DOI 10.1016/S1474-4422(14)70049-3; Cohen JA, 2011, ANN NEUROL, V69, P759, DOI 10.1002/ana.22426; Cohen JA, 2010, NEW ENGL J MED, V362, P402, DOI 10.1056/NEJMoa0907839; Collison A, 2013, NAT MED, V19, P232, DOI 10.1038/nm.3049; Condamine T, 2011, TRENDS IMMUNOL, V32, P19, DOI 10.1016/j.it.2010.10.002; Conzett KB, 2011, ARCH DERMATOL, V147, P991, DOI 10.1001/archdermatol.2011.212; Cortez-Retamozo V, 2012, P NATL ACAD SCI USA, V109, P2491, DOI 10.1073/pnas.1113744109; Cyster JG, 2012, ANNU REV IMMUNOL, V30, P69, DOI 10.1146/annurev-immunol-020711-075011; Elkabets M, 2010, EUR J IMMUNOL, V40, P3347, DOI 10.1002/eji.201041037; Euvrard S, 2003, NEW ENGL J MED, V348, P1681, DOI 10.1056/NEJMra022137; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Greten TF, 2011, INT IMMUNOPHARMACOL, V11, P802, DOI 10.1016/j.intimp.2011.01.003; Griseri T, 2012, IMMUNITY, V37, P1116, DOI 10.1016/j.immuni.2012.08.025; Hait NC, 2014, NAT NEUROSCI, V17, P971, DOI 10.1038/nn.3728; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; Hoechst B, 2009, HEPATOLOGY, V50, P799, DOI 10.1002/hep.23054; Hung JH, 2008, CANCER RES, V68, P1204, DOI 10.1158/0008-5472.CAN-07-2621; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Katoh H, 2013, CANCER CELL, V24, P631, DOI 10.1016/j.ccr.2013.10.009; Kim EK, 2014, CANCER RES, V74, P6705, DOI 10.1158/0008-5472.CAN-14-1482; Kusmartsev S, 2004, J IMMUNOL, V172, P989, DOI 10.4049/jimmunol.172.2.989; Lee H, 2010, NAT MED, V16, P1421, DOI 10.1038/nm.2250; Lee TK, 2005, CLIN CANCER RES, V11, P8458, DOI 10.1158/1078-0432.CCR-05-0447; Liu GW, 2014, J IMMUNOL, V192, P3068, DOI 10.4049/jimmunol.1301193; Liu Q, 2010, CLIN CANCER RES, V16, P3182, DOI 10.1158/1078-0432.CCR-09-2484; Lorvik KB, 2012, BLOOD, V119, P2176, DOI 10.1182/blood-2011-10-388892; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Martinez-Moczygemba M, 2003, J ALLERGY CLIN IMMUN, V112, P653, DOI 10.1067/mai.2003.1796; Marvel D, 2015, J CLIN INVEST, V125, P3356, DOI 10.1172/JCI80005; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Mendelson K, 2014, DEVELOPMENT, V141, P5, DOI 10.1242/dev.094805; Mullershausen F, 2009, NAT CHEM BIOL, V5, P428, DOI 10.1038/nchembio.173; Oo ML, 2007, J BIOL CHEM, V282, P9082, DOI 10.1074/jbc.M610318200; Ostrand-Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740; Peranzoni E, 2010, CURR OPIN IMMUNOL, V22, P238, DOI 10.1016/j.coi.2010.01.021; Pham THM, 2008, IMMUNITY, V28, P122, DOI 10.1016/j.immuni.2007.11.017; Pitman MR, 2012, CURR MOL MED, V12, P1207, DOI 10.2174/156652412803833599; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Quatromoni JG, 2015, J LEUKOCYTE BIOL, V97, P201, DOI 10.1189/jlb.5TA0814-373; Saddoughi SA, 2013, EMBO MOL MED, V5, P105, DOI 10.1002/emmm.201201283; Schwab SR, 2007, NAT IMMUNOL, V8, P1295, DOI 10.1038/ni1545; Sevko A, 2013, J CANCER, V4, P3, DOI 10.7150/jca.5047; Sio A, 2013, CANCER RES, V73, P5892, DOI 10.1158/0008-5472.CAN-13-0842; Swirski FK, 2009, SCIENCE, V325, P612, DOI 10.1126/science.1175202; Ueha S, 2011, INT IMMUNOPHARMACOL, V11, P783, DOI 10.1016/j.intimp.2011.03.003; Wu WC, 2014, P NATL ACAD SCI USA, V111, P4221, DOI 10.1073/pnas.1320753111; Yasui H, 2005, CANCER RES, V65, P7478, DOI 10.1158/0008-5472.CAN-05-0850; Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791	50	14	14	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3760	3771		10.1038/onc.2017.2	http://dx.doi.org/10.1038/onc.2017.2			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28218904				2022-12-17	WOS:000404349700011
J	Dermit, M; Casado, P; Rajeeve, V; Wilkes, EH; Foxler, DE; Campbell, H; Critchlow, S; Sharp, TV; Gribben, JG; Unwin, R; Cutillas, PR				Dermit, M.; Casado, P.; Rajeeve, V.; Wilkes, E. H.; Foxler, D. E.; Campbell, H.; Critchlow, S.; Sharp, T. V.; Gribben, J. G.; Unwin, R.; Cutillas, P. R.			Oxidative stress downstream of mTORC1 but not AKT causes a proliferative defect in cancer cells resistant to PI3K inhibition	ONCOGENE			English	Article							IN-VITRO; MYC; EXPRESSION; THERAPY; REVEALS; PATHWAY; APOPTOSIS; HYPOXIA; SGK1	Compounds targeting phosphatidylinositol-3-kinase/mammalian target of rapamycin (PI3K/mTOR) signaling are being investigated in multiple clinical settings, but drug resistance may reduce their benefit. Compound rechallenge after drug holidays can overcome such resistance, yet little is known about the impact of drug holidays on cell biochemistry. We found that PI3K inhibitor (PI3Ki)-resistant cells cultured in the absence of PI3Ki developed a proliferative defect, increased oxygen consumption and accumulated reactive oxygen species (ROS), leading to lactate production through hypoxia-inducible factor-1 alpha. This metabolic imbalance was reversed by mammalian target of rapamycin complex 1 (mTORC1) inhibitors. Interestingly, neither AKT nor c-MYC was involved in mediating the metabolic phenotype, despite the latter contributing to resistant cells' proliferation. These data suggest that an AKT-independent PI3K/mTORC1 axis operates in these cells. The excessive ROS hampered cell division, and the metabolic phenotype made resistant cells more sensitive to hydrogen peroxide and nutrient starvation. Thus, the proliferative defect of PI3Ki-resistant cells during drug holidays is caused by defective metabolic adaptation to chronic PI3K/ mTOR pathway inhibition. This metabolic imbalance may open the therapeutic window for challenge with metabolic drugs during drug holidays.	[Dermit, M.; Casado, P.; Rajeeve, V.; Wilkes, E. H.; Cutillas, P. R.] Queen Mary Univ London, Barts Canc Inst, Ctr Haematooncol, Cell Signalling Prote, London, England; [Foxler, D. E.; Sharp, T. V.] Queen Mary Univ London, Barts Canc Inst, Ctr Mol Oncol, London, England; [Campbell, H.; Critchlow, S.] AstraZeneca, Oncol iMED, Macclesfield, Cheshire, England; [Gribben, J. G.] Queen Mary Univ London, Barts Canc Inst, Canc Immunol Grp, Ctr Haematooncol, London, England; [Unwin, R.] UCL, UCL Ctr Nephrol, Royal Free Campus & Hosp, London, England	University of London; Queen Mary University London; University of London; Queen Mary University London; AstraZeneca; University of London; Queen Mary University London; University of London; University College London	Cutillas, PR (corresponding author), Queen Mary Univ London, Barts Canc Inst, John Vane Sci Ctr, Charterhouse Sq, London EC1M 6BQ, England.	p.cutillas@qmul.ac.uk	Izquierdo, Pedro Casado/AAD-9960-2021; Sharp, Tyson/AAD-6190-2020; Dermit, Maria/AAH-9618-2019	Izquierdo, Pedro Casado/0000-0002-4207-9349; Sharp, Tyson/0000-0003-1861-7984; Foxler, Daniel/0000-0003-3753-0278; Dermit, Maria/0000-0002-6287-8367	St Peters Trust; Barts and The London Charity [BLT 297/2249]; BBSRC [BB/M006174/1]; Biotechnology and Biological Sciences Research Council [BB/G015023/1, BB/L027755/1, BB/M006174/1] Funding Source: researchfish; Cancer Research UK [12733] Funding Source: researchfish; Medical Research Council [MR/N009185/1] Funding Source: researchfish; BBSRC [BB/L027755/1, BB/G015023/1] Funding Source: UKRI; MRC [MR/N009185/1] Funding Source: UKRI	St Peters Trust; Barts and The London Charity; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Gemma Bridge for advice with Seahorse experiments and Dr Soong and Dr Baselga for kindly providing LB771-HNC, CAL33, KYSE70 and KYSE180 parental/resistant pairs of cells. This work was supported by St Peters Trust and Barts and The London Charity (BLT 297/2249). PRC was supported by BBSRC Grant BB/M006174/1	Anacker C, 2013, P NATL ACAD SCI USA, V110, P8708, DOI 10.1073/pnas.1300886110; Bey EA, 2007, P NATL ACAD SCI USA, V104, P11832, DOI 10.1073/pnas.0702176104; Birsoy K, 2014, NATURE, V508, P108, DOI 10.1038/nature13110; Carracedo A, 2008, CELL CYCLE, V7, P3805, DOI 10.4161/cc.7.24.7244; Chmielecki J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002356; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Das Thakur M, 2013, CANCER RES, V73, P6106, DOI 10.1158/0008-5472.CAN-13-1633; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; De Saedeleer CJ, 2014, ONCOGENE, V33, P4060, DOI 10.1038/onc.2013.454; Elkabets M, 2015, CANCER CELL, V27, P533, DOI 10.1016/j.ccell.2015.03.010; Follis AV, 2008, CHEM BIOL, V15, P1149, DOI 10.1016/j.chembiol.2008.09.011; Foxler DE, 2012, NAT CELL BIOL, V14, P201, DOI 10.1038/ncb2424; Friedman AA, 2015, NAT REV CANCER, V15, P747, DOI 10.1038/nrc4015; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Garcia-Martinez JM, 2009, BIOCHEM J, V421, P29, DOI 10.1042/BJ20090489; Gilmartin AG, 2011, CLIN CANCER RES, V17, P989, DOI 10.1158/1078-0432.CCR-10-2200; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hanfstein B, 2011, HAEMATOL-HEMATOL J, V96, P360, DOI 10.3324/haematol.2010.030999; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; Huang MJ, 2006, EXP HEMATOL, V34, P1480, DOI 10.1016/j.exphem.2006.06.019; Ilic N, 2011, P NATL ACAD SCI USA, V108, pE699, DOI 10.1073/pnas.1108237108; Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kessler J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-605; Kim SY, 2006, EXP MOL MED, V38, P535, DOI 10.1038/emm.2006.63; Lindsley CW, 2005, BIOORG MED CHEM LETT, V15, P761, DOI 10.1016/j.bmcl.2004.11.011; Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392; Liu PX, 2011, NAT MED, V17, P1116, DOI 10.1038/nm.2402; Mahalingaiah PKS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087371; Marin-Hernandez A, 2009, MINI-REV MED CHEM, V9, P1084, DOI 10.2174/138955709788922610; Miskimins WK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085576; Muellner MK, 2011, NAT CHEM BIOL, V7, P787, DOI 10.1038/nchembio.695; Murtaza M, 2013, NATURE, V497, P108, DOI 10.1038/nature12065; OMURA S, 1976, BACTERIOL REV, V40, P681, DOI 10.1128/MMBR.40.3.681-697.1976; Park HS, 2004, MOL CELL BIOL, V24, P4384, DOI 10.1128/MCB.24.10.4384-4394.2004; Park JH, 2013, BIOCHEM BIOPH RES CO, V433, P420, DOI 10.1016/j.bbrc.2013.02.108; Piguet AC, 2014, CLIN SCI, V126, P775, DOI 10.1042/CS20130081; Raj L, 2011, NATURE, V475, P231, DOI 10.1038/nature10167; Rehan M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109705; Sceneay J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066388; Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230; Sommer EM, 2013, BIOCHEM J, V452, P499, DOI 10.1042/BJ20130342; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; Tagami M, 1998, LAB INVEST, V78, P1415; Tormos KV, 2011, CELL METAB, V14, P537, DOI 10.1016/j.cmet.2011.08.007; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Widlansky ME, 2011, ANTIOXID REDOX SIGN, V15, P1517, DOI 10.1089/ars.2010.3642; Wilkes EH, 2015, P NATL ACAD SCI USA, V112, P7719, DOI 10.1073/pnas.1423344112; Zhu CP, 2014, SCI REP-UK, V4, DOI 10.1038/srep05029	50	14	14	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2017	36	19					2762	2774		10.1038/onc.2016.435	http://dx.doi.org/10.1038/onc.2016.435			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EU6CF	27991931	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000401120900013
J	Puccetti, MV; Fischer, MA; Arrate, MP; Boyd, KL; Duszynski, RJ; Betous, R; Cortez, D; Eischen, CM				Puccetti, M. V.; Fischer, M. A.; Arrate, M. P.; Boyd, K. L.; Duszynski, R. J.; Betous, R.; Cortez, D.; Eischen, C. M.			Defective replication stress response inhibits lymphomagenesis and impairs lymphocyte reconstitution	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; IMMUNO-OSSEOUS DYSPLASIA; HEMATOPOIETIC STEM-CELLS; DNA-DAMAGE RESPONSE; SMARCAL1; APOPTOSIS; EXPRESSION; MUTATIONS; HALLMARK; REPAIR	DNA replication stress promotes genome instability in cancer. However, the contribution of the replication stress response to the development of malignancies remains unresolved. The DNA replication stress response protein SMARCAL1 stabilizes DNA replication forks and prevents replication fork collapse, a cause of DNA breaks and apoptosis. While the fork regression/remodeling functions of SMARCAL1 have been investigated, its in vivo functions in replication stress and cancer are unclear. Using a gamma radiation (IR)-induced replication stress T-cell lymphoma mouse model, we observed a significant inhibition of lymphomagenesis in mice lacking one or both alleles of Smarcal1. Notably, a quarter of the Smarcal1-deficient mice did not develop tumors. Moreover, hematopoietic stem/progenitor cells (HSPCs) and developing thymocytes in Smarcal1-deficient mice showed increased DNA damage and apoptosis during the proliferation burst following IR and an impaired ability to repopulate the thymus after IR. Additionally, mice lacking Smarcal1 showed significant HSPC defects when challenged to respond to other replication stress stimuli. Thus, our data reveal the critical function of the DNA replication stress response and, specifically, Smarcal1 in hematopoietic cell survival and tumor development. Our results also provide important insight into the immunodeficiency observed in individuals with mutations in SMARCAL1 by suggesting that it is an HSPC defect.	[Puccetti, M. V.; Fischer, M. A.; Arrate, M. P.; Boyd, K. L.; Duszynski, R. J.; Eischen, C. M.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA; [Puccetti, M. V.; Eischen, C. M.] Thomas Jefferson Univ, Dept Canc Biol, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Betous, R.; Cortez, D.] Vanderbilt Univ, Dept Biochem, Med Ctr, Nashville, TN 37232 USA	Vanderbilt University; Jefferson University; Vanderbilt University	Eischen, CM (corresponding author), Thomas Jefferson Univ, Dept Canc Biol, 233S 10th St Bluemle Life Sci Bldg, Philadelphia, PA 19107 USA.	christine.eischen@jefferson.edu	Bétous, Rémy/ABF-4789-2020; Bétous, Rémy/P-2355-2014	Bétous, Rémy/0000-0003-0518-1763; 	Ann Melly Scholarship [F30CA189433, T32GM007347, R01CA160432]; NCI Cancer Center Support Grants [P30CA068485, P30CA056036]; NATIONAL CANCER INSTITUTE [P30CA056036, R01CA160432, F30CA189433, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER	Ann Melly Scholarship; NCI Cancer Center Support Grants; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors would like to thank Dr Cornelius Boerkoel for providing the Smarcal1<SUP>+/triangle</SUP> mice, Carol Bansbach for technical assistance with Figure 1b, Catherine Alford for technical assistance with flow cytometry, the Bioimaging Shared Resource of the Sidney Kimmel Cancer Center, and Dr Sandy Zinkel, Dr Scott Hiebert, and members of the Eischen lab for helpful discussions. This work was supported by F30CA189433 (MVP), T32GM007347 (MVP), Ann Melly Scholarship (MVP), R01CA160432 (CME and DC), and NCI Cancer Center Support Grants P30CA068485 and P30CA056036.	Adams PD, 2015, CELL STEM CELL, V16, P601, DOI 10.1016/j.stem.2015.05.002; Alt JR, 2005, J BIOL CHEM, V280, P18771, DOI 10.1074/jbc.M413387200; Alvarez S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9548; Baldridge MT, 2010, NATURE, V465, P793, DOI 10.1038/nature09135; Bansbach CE, 2009, GENE DEV, V23, P2405, DOI 10.1101/gad.1839909; Baradaran-Heravi A, 2012, HUM MOL GENET, V21, P2572, DOI 10.1093/hmg/dds083; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Betous R, 2013, CELL REP, V3, P1958, DOI 10.1016/j.celrep.2013.05.002; Betous R, 2012, GENE DEV, V26, P151, DOI 10.1101/gad.178459.111; Boerkoel CF, 2002, NAT GENET, V30, P215, DOI 10.1038/ng821; Bouska A, 2008, MOL CELL BIOL, V28, P4862, DOI 10.1128/MCB.01584-07; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cheshier SH, 2007, STEM CELLS DEV, V16, P707, DOI 10.1089/scd.2007.0017; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Ciccia A, 2009, GENE DEV, V23, P2415, DOI 10.1101/gad.1832309; Couch FB, 2013, GENE DEV, V27, P1610, DOI 10.1101/gad.214080.113; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Flach J, 2014, NATURE, V512, P198, DOI 10.1038/nature13619; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; KAPLAN HS, 1952, J NATL CANCER I, V13, P185; Keka IS, 2015, NUCLEIC ACIDS RES, V43, P6359, DOI 10.1093/nar/gkv621; Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026; Kominami R, 2006, CANCER SCI, V97, P575, DOI 10.1111/j.1349-7006.2006.00218.x; Labi V, 2010, GENE DEV, V24, P1602, DOI 10.1101/gad.1940210; Macheret M, 2015, ANNU REV PATHOL-MECH, V10, P425, DOI 10.1146/annurev-pathol-012414-040424; Michalak EM, 2010, GENE DEV, V24, P1608, DOI 10.1101/gad.1940110; Nam EA, 2011, BIOCHEM J, V436, P527, DOI 10.1042/BJ20102162; Nombela-Arrieta C, 2011, NAT REV MOL CELL BIO, V12, P126, DOI 10.1038/nrm3049; Postow L, 2009, J BIOL CHEM, V284, P35951, DOI 10.1074/jbc.M109.048330; Sanyal M, 2015, CLIN IMMUNOL, V161, P355, DOI 10.1016/j.clim.2015.10.005; SPRANGER J, 1991, J PEDIATR-US, V119, P64, DOI 10.1016/S0022-3476(05)81040-6; Walter D, 2015, NATURE, V520, P549, DOI 10.1038/nature14131; Yilmaz OH, 2006, BLOOD, V107, P924, DOI 10.1182/blood-2005-05-2140; Yuan JS, 2009, GENE DEV, V23, P2394, DOI 10.1101/gad.1836409; Yusufzai T, 2008, SCIENCE, V322, P748, DOI 10.1126/science.1161233; Yusufzai T, 2009, GENE DEV, V23, P2400, DOI 10.1101/gad.1831509; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	39	14	14	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2017	36	18					2553	2564		10.1038/onc.2016.408	http://dx.doi.org/10.1038/onc.2016.408			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET9AN	27797382	Green Accepted			2022-12-17	WOS:000400597300006
J	Sochalska, M; Schuler, F; Weiss, JG; Prchal-Murphy, M; Sexl, V; Villunger, A				Sochalska, M.; Schuler, F.; Weiss, J. G.; Prchal-Murphy, M.; Sexl, V.; Villunger, A.			MYC selects against reduced BCL2A1/A1 protein expression during B cell lymphomagenesis	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; BCL-X-L; LEUKOCYTE DEVELOPMENT; MYELOID-LEUKEMIA; IN-VIVO; FAMILY; A1/BFL-1; MICE; RESISTANCE; APOPTOSIS	Rearrangements of MYC or ABL proto-oncogenes lead to deregulated expression of key-regulators of cell cycle and cell survival, thereby constituting important drivers of blood cancer. Members of the BCL-2 family of apoptosis regulators contribute to oncogenic transformation downstream of these oncogenes, but the role of anti-apoptotic BCL2A1/A1 in transformation and drug resistance caused by deregulation of these oncogenes remains enigmatic. Here we analyzed the role of A1 in MYC as well as ABL kinase-driven blood cancer in mice, employing in vivo RNAi. We report that overexpression of either oncogene leads to a significant increase in A1 protein levels in otherwise A1-negative B cell progenitors, indicating a key role downstream of these oncogenes to secure survival during transformation. Knockdown of A1 by RNAi, however, did not impact on tumor latency in v-Abl-driven pre-B-ALL. In contrast, A1 knockdown in premalignant E mu-MYC mice caused a significant reduction of transgenic pre-B cells without impacting on tumor latency as the emerging lymphomas escaped silencing of A1 expression. These findings identify A1 as a MYC target that can be induced prematurely during B cell development to aid expansion of otherwise cell-death-prone MYC transgenic pre-B cells. Hence, A1 should be considered as a putative drug target in MYC-driven blood cancer.	[Sochalska, M.; Schuler, F.; Weiss, J. G.; Villunger, A.] Med Univ Innsbruck, Div Dev Immunol, Bioctr, Innrain 80, A-6020 Innsbruck, Austria; [Prchal-Murphy, M.; Sexl, V.] Univ Vet Med, Inst Pharmacol & Toxicol, Dept Biomed Sci, Vienna, Austria; [Villunger, A.] Tyrolean Canc Res Inst, Innsbruck, Austria	Medical University of Innsbruck; University of Veterinary Medicine Vienna	Villunger, A (corresponding author), Med Univ Innsbruck, Div Dev Immunol, Bioctr, Innrain 80, A-6020 Innsbruck, Austria.	andreas.villunger@i-med.ac.at	Sexl, Veronika/B-8657-2016	Sexl, Veronika/0000-0001-9363-0412; Sochalska, Maja/0000-0002-6665-3309	Austrian Science Fund (FWF) [I1298 (FOR-2036)]; MCBO Doctoral College 'Molecular Cell Biology and Oncology' [W1101]; 'Osterreichische Krebshilfe Tirol'; Doc-fellowship from the Austrian Academy of Science (OAW);  [SFB-F47]; Austrian Science Fund (FWF) [I 1298] Funding Source: researchfish	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); MCBO Doctoral College 'Molecular Cell Biology and Oncology'; 'Osterreichische Krebshilfe Tirol'; Doc-fellowship from the Austrian Academy of Science (OAW); ; Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	We are grateful to K Rossi, C Soratroi and I Gaggl for excellent technical assistance and animal care as well as to S Tuzlak for western analysis of Vav-BFL-1 mice and S Herzog for MYC expression constructs and discussion. We also thank J Borst (NKI) and M Herold (WEHI) for anti-BFL-1 antiserum and anti-A1 antibodies, respectively, and M Hartl for MYC inhibitors. This work was supported by grants from the Austrian Science Fund (FWF), grant I1298 (FOR-2036) and the MCBO Doctoral College 'Molecular Cell Biology and Oncology' (W1101) and the 'Osterreichische Krebshilfe Tirol' to AV and the SFB-F47 to VS. FS is supported by a Doc-fellowship from the Austrian Academy of Science (OAW).	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Anderson MA, 2014, SEMIN HEMATOL, V51, P219, DOI 10.1053/j.seminhematol.2014.05.008; Beverly LJ, 2009, ONCOGENE, V28, P1274, DOI 10.1038/onc.2008.466; Carter MJ, 2016, CELL DEATH DIFFER, V23, P303, DOI 10.1038/cdd.2015.97; Delbridge ARD, 2015, CELL DEATH DIFFER, V22, P1071, DOI 10.1038/cdd.2015.50; Deng J, 2007, CANCER CELL, V12, P171, DOI 10.1016/j.ccr.2007.07.001; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Glaser SP, 2012, GENE DEV, V26, P120, DOI 10.1101/gad.182980.111; Haq R, 2013, P NATL ACAD SCI USA, V110, P4321, DOI 10.1073/pnas.1205575110; Hatakeyama S, 1998, INT IMMUNOL, V10, P631, DOI 10.1093/intimm/10.5.631; Hoelbl A, 2010, EMBO MOL MED, V2, P98, DOI 10.1002/emmm.201000062; Kelly GL, 2014, GENE DEV, V28, P58, DOI 10.1101/gad.232009.113; Kelly PN, 2007, BLOOD, V109, P4907, DOI 10.1182/blood-2006-10-051847; Kelly PN, 2011, BLOOD, V118, P6380, DOI 10.1182/blood-2011-07-367672; Kuroda J, 2006, P NATL ACAD SCI USA, V103, P14907, DOI 10.1073/pnas.0606176103; Lang MJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.519; Morales AA, 2005, INT J CANCER, V113, P730, DOI 10.1002/ijc.20614; Muthalagu N, 2014, CELL REP, V8, P1347, DOI 10.1016/j.celrep.2014.07.057; Ogilvy S, 1999, BLOOD, V94, P1855; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Ottina E, 2015, J IMMUNOL, V194, P1316, DOI 10.4049/jimmunol.1400637; Ottina E, 2012, BLOOD, V119, P6032, DOI 10.1182/blood-2011-12-399089; Ottina E, 2012, EXP CELL RES, V318, P1291, DOI 10.1016/j.yexcr.2012.01.021; Pegman PM, 2006, J VIROL, V80, P8133, DOI 10.1128/JVI.00278-06; Shen Y, 2011, BLOOD, V118, P5593, DOI 10.1182/blood-2011-03-343988; Sochalska M, 2016, CELL DEATH DIFFER, V23, P628, DOI 10.1038/cdd.2015.130; Sochalska M, 2015, FEBS J, V282, P834, DOI 10.1111/febs.13188; Vier J, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.23; Vogler M, 2012, CELL DEATH DIFFER, V19, P67, DOI 10.1038/cdd.2011.158; Vogler M, 2009, BLOOD, V113, P4403, DOI 10.1182/blood-2008-08-173310; Warsch W, 2013, BLOOD, V122, P2167, DOI 10.1182/blood-2013-02-485573; Yecies D, 2010, BLOOD, V115, P3304, DOI 10.1182/blood-2009-07-233304; Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103	33	14	14	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2017	36	15					2066	2073		10.1038/onc.2016.362	http://dx.doi.org/10.1038/onc.2016.362			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DK	27694901	Green Published, hybrid			2022-12-17	WOS:000399782500003
J	Liu, H; Qiu, H; Song, Y; Liu, Y; Wang, H; Lu, M; Deng, M; Gu, Y; Yin, J; Luo, K; Zhang, Z; Jia, X; Zheng, G; He, Z				Liu, H.; Qiu, H.; Song, Y.; Liu, Y.; Wang, H.; Lu, M.; Deng, M.; Gu, Y.; Yin, J.; Luo, K.; Zhang, Z.; Jia, X.; Zheng, G.; He, Z.			Cip2a promotes cell cycle progression in triple-negative breast cancer cells by regulating the expression and nuclear export of p27Kip1	ONCOGENE			English	Article							PROTEIN PHOSPHATASE 2A; EPITHELIAL-MESENCHYMAL TRANSITION; KINASE INHIBITOR P27; C-MYC; CLINICAL-IMPLICATIONS; PHOSPHORYLATES P27; CYTOPLASMIC P27; PARP INHIBITION; POOR-PROGNOSIS; LUNG-CANCER	Triple-negative breast cancer (TNBC) is very aggressive and currently has no specific therapeutic targets; as a consequence, TNBC exhibits poor clinical outcome. In this study, we showed that cancerous inhibitor of protein phosphatase 2A (Cip2a) represents a promising target in TNBC because Cip2a was highly expressed in TNBC cells and tumor tissues, and its expression showed an inverse correlation with overall survival in patients with TNBC. We found that inhibition of Cip2a in TNBC cells induced cell cycle arrest at the G2/M phase, inhibited cell proliferation and delayed tumor growth in the xenograft model. Moreover, Cip2a markedly decreased the expression and nuclear localization of p27Kip1 and this is critical for the ability of Cip2a to promote TNBC progression. Mechanistically, our studies showed that Cip2a promoted p27Kip1 phosphoration at Ser10 via inhibiting Akt-associated PP2A activity, which seems to relocalize p27Kip1 to the cytoplasm in TNBC cells. On the other hand, Cip2a also recruited c-myc to mediate the transcriptional inhibition of p27Kip1. Notably, we observed negative correlation between Cip2a and p27Kip1 expression in TNBC specimens. In addition, our data showed that Cip2a depletion could sensitize TNBC to PARP inhibition. Collectively, these data suggested that Cip2a effectively promotes TNBC cell cycle progression and tumor growth via regulation of PP2A/c-myc/p27Kip1 signaling, which could serve as a potential therapeutic target for TNBC patients.	[Liu, H.; Qiu, H.; Song, Y.; Lu, M.; Deng, M.; Gu, Y.; Yin, J.; Luo, K.; Zhang, Z.; Jia, X.; Zheng, G.; He, Z.] Guangzhou Med Univ, Canc Hosp, 78 Hengzhigang Rd, Guangzhou 510095, Guangdong, Peoples R China; [Liu, H.; Qiu, H.; Song, Y.; Lu, M.; Deng, M.; Gu, Y.; Yin, J.; Luo, K.; Zhang, Z.; Jia, X.; Zheng, G.; He, Z.] Guangzhou Med Univ, Canc Res Inst, 78 Hengzhigang Rd, Guangzhou 510095, Guangdong, Peoples R China; [Liu, Y.] Guangdong Inst Microbiol, Guangdong Prov Key Lab Microbial Culture Collect, Guangzhou, Guangdong, Peoples R China; [Wang, H.] Sun Yat Sen Univ, Sch Pharmaceut Sci, Dept Microbial & Biochem Pharm, Guangzhou, Guangdong, Peoples R China	Guangzhou Medical University; Guangzhou Medical University; Guangdong Academy of Sciences; Institute of Microbiology, Guangdong Academy of Sciences; Sun Yat Sen University	He, Z (corresponding author), Guangzhou Med Univ, Canc Hosp, 78 Hengzhigang Rd, Guangzhou 510095, Guangdong, Peoples R China.; He, Z (corresponding author), Guangzhou Med Univ, Canc Res Inst, 78 Hengzhigang Rd, Guangzhou 510095, Guangdong, Peoples R China.	hezhimin2005@yahoo.com		Liu, Hao/0000-0001-6338-4003	National Natural Science Foundation of China [81472184, 81402497]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by grants from the National Natural Science Foundation of China (Grant No. 81472184, No. 81402497).	Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; Baldacchino S, 2014, EPMA J, V5, DOI 10.1186/1878-5085-5-3; Bockelman C, 2012, CANCER BIOL THER, V13, P289, DOI [10.4161/cbt.18922, 10.4161/cbt.13.5.18922]; Bosch A, 2010, CANCER TREAT REV, V36, P206, DOI 10.1016/j.ctrv.2009.12.002; Chen KF, 2010, ONCOGENE, V29, P6257, DOI 10.1038/onc.2010.357; Chibazakura T, 2004, P NATL ACAD SCI USA, V101, P4465, DOI 10.1073/pnas.0400655101; Choi YA, 2011, FEBS LETT, V585, P755, DOI 10.1016/j.febslet.2011.01.018; Come C, 2009, CLIN CANCER RES, V15, P5092, DOI 10.1158/1078-0432.CCR-08-3283; Cuadrado M, 2009, CANCER RES, V69, P8726, DOI 10.1158/0008-5472.CAN-09-0729; De P, 2015, AM J CANCER RES, V5, P2872; Denicourt C, 2007, CANCER RES, V67, P9238, DOI 10.1158/0008-5472.CAN-07-1375; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dong QZ, 2011, ANN SURG ONCOL, V18, P857, DOI 10.1245/s10434-010-1313-8; Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005; Gysin S, 2005, CANCER RES, V65, P4870, DOI 10.1158/0008-5472.CAN-04-2848; Hnit SST, 2015, INT J BIOCHEM CELL B, V68, P9, DOI 10.1016/j.biocel.2015.08.005; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Iwase H, 2010, BREAST CANCER-TOKYO, V17, P118, DOI 10.1007/s12282-009-0113-0; Janghorban M, 2014, P NATL ACAD SCI USA, V111, P9157, DOI 10.1073/pnas.1317630111; Johnson N, 2011, NAT MED, V17, P875, DOI 10.1038/nm.2377; Johnson N, 2009, MOL CELL, V35, P327, DOI 10.1016/j.molcel.2009.06.036; Junttila MR, 2007, CELL, V130, P51, DOI 10.1016/j.cell.2007.04.044; Khanna A, 2015, ONCOTARGET, V6, P19661, DOI 10.18632/oncotarget.3875; Khanna A, 2013, CANCER RES, V73, P6548, DOI 10.1158/0008-5472.CAN-13-1994; Kim JS, 2013, CANCER RES, V73, P6667, DOI 10.1158/0008-5472.CAN-13-0888; Kossatz U, 2004, GENE DEV, V18, P2602, DOI 10.1101/gad.321004; Laine A, 2013, CANCER DISCOV, V3, P182, DOI 10.1158/2159-8290.CD-12-0292; Lee TY, 2010, J BIOL CHEM, V285, P21567, DOI 10.1074/jbc.M109.094953; Li WJ, 2008, CLIN CANCER RES, V14, P3722, DOI 10.1158/1078-0432.CCR-07-4137; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liu H, 2015, ONCOTARGET, V6, P14913, DOI 10.18632/oncotarget.3818; Lucas CM, 2011, BLOOD, V117, P6660, DOI 10.1182/blood-2010-08-304477; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Nacusi LP, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-11; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nasi S, 2001, FEBS LETT, V490, P153, DOI 10.1016/S0014-5793(01)02118-4; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Niemela M, 2012, ONCOGENE, V31, P4266, DOI 10.1038/onc.2011.599; O'Shaughnessy J, 2011, NEW ENGL J MED, V364, P205, DOI 10.1056/NEJMoa1011418; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pagano M, 2004, MOL CELL, V14, P414, DOI 10.1016/S1097-2765(04)00268-0; Payne SR, 2008, MOL CELL BIOL, V28, P258, DOI 10.1128/MCB.01536-07; Perrotti D, 2013, LANCET ONCOL, V14, pE229, DOI 10.1016/S1470-2045(12)70558-2; Puustinen P, 2014, J CELL BIOL, V204, P713, DOI 10.1083/jcb.201304012; Qu W, 2012, MED ONCOL, V29, P113, DOI 10.1007/s12032-010-9768-9; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812; See WL, 2010, ONCOGENE, V29, P1720, DOI 10.1038/onc.2009.465; Serres MP, 2011, ONCOGENE, V30, P2846, DOI 10.1038/onc.2011.9; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tseng LM, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3175; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wang CG, 2005, J BIOL CHEM, V280, P12339, DOI 10.1074/jbc.C400536200; Wu Y, 2015, CANCER LETT, V356, P646, DOI 10.1016/j.canlet.2014.10.013; Yanagi T, 2014, CANCER RES, V74, P5795, DOI 10.1158/0008-5472.CAN-14-0872; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; Yu GZ, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0524-9; Zhao D, 2015, ONCOGENE, V34, P5447, DOI 10.1038/onc.2014.473	58	14	15	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2017	36	14					1952	1964		10.1038/onc.2016.355	http://dx.doi.org/10.1038/onc.2016.355			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ER6EQ	27694903				2022-12-17	WOS:000398898500006
J	Lone, MUD; Baghel, KS; Kanchan, RK; Shrivastava, R; Malik, SA; Tewari, BN; Tripathi, C; Negi, MPS; Garg, VK; Sharma, M; Bhatt, MLB; Bhadauria, S				Lone, M-U-D; Baghel, K. S.; Kanchan, R. K.; Shrivastava, R.; Malik, S. A.; Tewari, B. N.; Tripathi, C.; Negi, M. P. S.; Garg, V. K.; Sharma, M.; Bhatt, M. L. B.; Bhadauria, S.			Physical interaction of estrogen receptor with MnSOD: implication in mitochondrial O-2(center dot-) upregulation and mTORC2 potentiation in estrogen-responsive breast cancer cells	ONCOGENE			English	Article							MANGANESE SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; LYSINE ACETYLATION; GENE-EXPRESSION; DNA-DAMAGE; ALPHA; SIRT3; BETA; OVEREXPRESSION; CARCINOGENESIS	Augmented reactive oxygen species levels consequential to functional alteration of key mitochondrial attributes contribute to carcinogenesis, either directly via oxidative DNA damage infliction or indirectly via activation of oncogenic signaling cascades. We previously reported activation of a key oncogenic signaling cascade via mammalian target of rapamycin (mTOR) signaling complex-2 (mTORC2) owing to estrogen receptor (ER-alpha)-dependent augmentation of O-2(-) within the mitochondria of 17-beta-estradiol (E2)-stimulated breast cancer cells. Manganese superoxide dismutase (MnSOD) is the principal mitochondrial attribute governing mitochondrial O-2(-) homeostasis, raising the possibility that its functional alteration could be instrumental in augmenting mitochondrial O-2(-) levels in breast cancer cells. Here we show ER-dependent transient inhibition of MnSOD catalytic function in breast cancer cells. Catalytic function of MnSOD is tightly regulated at the post-translational level. Post-translational modifications such as phosphorylation, nitration and acetylation represent key regulatory means governing the catalytic function of MnSOD. Acetylation at lysine-68 (K68) inhibits MnSOD catalytic activity and thus represents an important post-translational regulatory mechanism in human cells. Using reciprocal immunoprecipitation and proximity ligation assay, we demonstrate the occurrence of direct physical interaction between ER-alpha and MnSOD in human breast cancer cells, which in turn was associated with potentiated acetylation of MnSOD at K68. In addition, we also observed diminished interaction of MnSOD with sirtuin-3, the key mitochondrial deacetylase that deacetylates MnSOD at critical K68 and thereby activates it for scavenging O-2(-). Consequently, compromised deacetylation of MnSOD at K68 leading to its inhibition and a resultant buildup of O-2(-) within the mitochondria culminated in the activation of mTORC2. In agreement with this, human breast cancer tissue specimen exhibited a positive correlation between acetyl-MnSODK68 levels and phospho-Ser(2481) mTOR levels. In addition to exposing the crosstalk of ER-alpha with MnSOD posttranslational regulatory mechanisms, these data also unravel a regulatory role of ER/MnSOD interaction as an important control switch for redox regulation of ER-alpha-responsive oncogenic signaling cascades. Furthermore, our study provides a mechanistic link for ER-alpha-dependent O-2(-) potentiation and resultant mTORC2 activation in breast cancer cells.	[Lone, M-U-D; Baghel, K. S.; Kanchan, R. K.; Shrivastava, R.; Malik, S. A.; Tripathi, C.; Bhadauria, S.] CSIR, Div Toxicol, Cent Drug Res Inst, Jankipuram Ext Sect 10, Lucknow 226031, Uttar Pradesh, India; [Tewari, B. N.] KGMU, Dept Surg Oncol, Lucknow, Uttar Pradesh, India; [Negi, M. P. S.] CSIR, CDRI, Dept Clin & Expt Med, Lucknow, Uttar Pradesh, India; [Garg, V. K.] Lucknow Canc Inst, Dept Oncosurg, Lucknow, Uttar Pradesh, India; [Sharma, M.] Lucknow Canc Inst, Dept Pathol, Lucknow, Uttar Pradesh, India; [Bhatt, M. L. B.] KGMU, Dept Radiotherapy, Lucknow, Uttar Pradesh, India; [Bhadauria, S.] Acad Sci & Innovat Res AcSIR, New Delhi, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI); King George's Medical University; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI); King George's Medical University; Academy of Scientific & Innovative Research (AcSIR)	Bhadauria, S (corresponding author), CSIR, Div Toxicol, Cent Drug Res Inst, Jankipuram Ext Sect 10, Lucknow 226031, Uttar Pradesh, India.	smraticdri@gmail.com	tripathi, chakrapani/K-5220-2019; Kanchan, Ranjana Kumari/AAD-6218-2022; Lone, Mehraju Din/GQA-5070-2022	tripathi, chakrapani/0000-0002-0370-5829; Kanchan, Ranjana Kumari/0000-0002-9649-9488; Lone, Mehraju Din/0000-0001-8511-4207; Tewari, Brij Nath/0000-0002-1025-7411	DST [SR/FT/LS-169/2012]; CSIR India [BSC0103]; Indian Council of Medical Research, New Delhi [3/1/3/JRF-2011/HRD-69(12035)]	DST(Department of Science & Technology (India)); CSIR India(Council of Scientific & Industrial Research (CSIR) - India); Indian Council of Medical Research, New Delhi(Indian Council of Medical Research (ICMR))	We thank the Director of CDRI for providing the facility and infrastructure. We also thank Dr Kalyan Mitra and Dr Kavita Singh (SAIF) for providing microscopy facilities and Dr AL Vishwakarma (SAIF) for providing flow cytometry facilities. The financial grants received for this study were SR/FT/LS-169/2012 from DST and No. BSC0103 from CSIR India. Mehraj u din alone received fellowship from the Indian Council of Medical Research, New Delhi under ICMR-JRF scheme vide award letter no. 3/1/3/JRF-2011/HRD-69(12035). The institutional manuscript no. for this article is 9324.	Aykin-Burns N, 2009, BIOCHEM J, V418, P29, DOI 10.1042/BJ20081258; BORGSTAHL GEO, 1992, CELL, V71, P107, DOI 10.1016/0092-8674(92)90270-M; BORRELLO S, 1993, MOL ASPECTS MED, V14, P253, DOI 10.1016/0098-2997(93)90012-3; Buetler TM, 2004, NEWS PHYSIOL SCI, V19, P120, DOI 10.1152/nips.01514.2003; Butterfield DA, 2013, ANTIOXID REDOX SIGN, V19, P823, DOI 10.1089/ars.2012.5027; Chen BH, 2009, INVEST OPHTH VIS SCI, V50, P5587, DOI 10.1167/iovs.09-3633; Chen JQ, 2004, J CELL BIOCHEM, V93, P358, DOI 10.1002/jcb.20178; Chen YH, 2011, EMBO REP, V12, P534, DOI 10.1038/embor.2011.65; Copp J, 2009, CANCER RES, V69, P1821, DOI 10.1158/0008-5472.CAN-08-3014; Dhar SK, 2012, FREE RADICAL BIO MED, V52, P2209, DOI 10.1016/j.freeradbiomed.2012.03.009; Domej W, 2014, INT J CHRONIC OBSTR, V9, P1207, DOI 10.2147/COPD.S51226; Dwivedi SKD, 2011, MOL ENDOCRINOL, V25, P922, DOI 10.1210/me.2010-0512; Felty Q, 2005, BIOCHEMISTRY-US, V44, P6900, DOI 10.1021/bi047629p; Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197; Griendling KK, 2000, ARTERIOSCL THROM VAS, V20, P2175, DOI 10.1161/01.ATV.20.10.2175; Hayashi SI, 2003, ENDOCR-RELAT CANCER, V10, P193, DOI 10.1677/erc.0.0100193; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Kanchan RK, 2012, FREE RADICAL BIO MED, V53, P1929, DOI 10.1016/j.freeradbiomed.2012.08.595; Kawanishi S, 2001, MUTAT RES-REV MUTAT, V488, P65, DOI 10.1016/S1383-5742(00)00059-4; Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026; Klaunig JE, 2004, ANNU REV PHARMACOL, V44, P239, DOI 10.1146/annurev.pharmtox.44.101802.121851; Lombard DB, 2007, MOL CELL BIOL, V27, P8807, DOI 10.1128/MCB.01636-07; MISRA HP, 1972, J BIOL CHEM, V247, P6960; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Oberley LW, 2005, BIOMED PHARMACOTHER, V59, P143, DOI 10.1016/j.biopha.2005.03.006; OBERLEY LW, 1979, CANCER RES, V39, P1141; Ogrunc M, 2014, CELL DEATH DIFFER, V21, P998, DOI 10.1038/cdd.2014.16; Pedram A, 2006, MOL BIOL CELL, V17, P2125, DOI 10.1091/mbc.E05-11-1013; Quintela-Fandino M, 2010, CLIN TRANSL ONCOL, V12, P662, DOI 10.1007/s12094-010-0575-8; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Scher MB, 2007, GENE DEV, V21, P920, DOI 10.1101/gad.1527307; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; Stoica GE, 2003, MOL ENDOCRINOL, V17, P818, DOI 10.1210/me.2002-0330; Yan MH, 2013, FREE RADICAL BIO MED, V62, P90, DOI 10.1016/j.freeradbiomed.2012.11.014; Yan T, 1996, CANCER RES, V56, P2864	35	14	14	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2017	36	13					1829	1839		10.1038/onc.2016.346	http://dx.doi.org/10.1038/onc.2016.346			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EQ5NF	27721400				2022-12-17	WOS:000398128900008
J	Yim, H; Shin, SB; Woo, SU; Lee, PCW; Erikson, RL				Yim, H.; Shin, S-B; Woo, S. U.; Lee, P. C-W; Erikson, R. L.			Plk1-mediated stabilization of 53BP1 through USP7 regulates centrosome positioning to maintain bipolarity	ONCOGENE			English	Article							POLO-LIKE KINASE; DNA-DAMAGE RESPONSE; STRAND BREAK REPAIR; CENP-F; CHECKPOINT ACTIVATION; SPINDLE-CHECKPOINT; TUMOR-SUPPRESSOR; HISTONE H2AX; P53; MITOSIS	Although 53BP1 has been established well as a mediator in DNA damage response, its function in mitosis is not clearly understood. We found that 53BP1 is a mitotic-binding partner of the kinases Plk1 and AuroraA, and that the binding with Plk1 increases the stability of 53BP1 by accelerating its interaction with the deubiquitinase USP7. Depletion of 53BP1 induces mitotic defects such as chromosomal missegregation, misorientation of spindle poles and the generation of extra centrosomes, which is similar phenotype to USP7-knockdown cells. In addition, 53BP1 depletion reduces the levels of p53 and centromere protein F ( CENPF), interacting proteins of 53BP1. These phenotypes induced by 53BP1 depletion were rescued by expression of wild-type or phosphomimic mutant 53BP1 but not by expression of a dephosphomimic mutant. We propose that phosphorylation of 53BP1 at S380 accelerates complex formation with USP7 and CENPF to regulate their stability, thus having a crucial role in proper centrosome positioning, chromosomal alignment, and centrosome number.	[Yim, H.; Shin, S-B; Woo, S. U.] Hanyang Univ, Coll Pharm, Inst Pharmaceut Sci & Technol, Dept Pharm, Ansan 15588, Gyeonggi Do, South Korea; [Yim, H.; Erikson, R. L.] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; [Lee, P. C-W] Univ Ulsan, Coll Med, CDRC, Dept Biomed Sci, Seoul, South Korea	Hanyang University; Harvard University; University of Ulsan	Yim, H (corresponding author), Hanyang Univ, Coll Pharm, Inst Pharmaceut Sci & Technol, Dept Pharm, Ansan 15588, Gyeonggi Do, South Korea.	hsyim@hanyang.ac.kr	Shin, Sol-bi/N-7443-2019	Shin, Sol-bi/0000-0002-2519-9605	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [NRF-2012R1A2A2A06044458, NRF-2014R1A2A1 A11049701]	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology	We thank Dr Phillip B Carpenter (University of Texas Health Sciences Center, TX, USA), Dr Stephen J Elledge (Harvard University, MA, USA), Dr Daniel Durocher (University of Toronto, Canada) and Dr Anindya Dutta (University of Virginia School of Medicine, VA, USA) for generously providing plasmids for HA-53BP1, GFP-53BP1 and USP7, respectively. We thank Dr Jeong-Ho Hong (Korea University, Korea), Dr Mi-Ran Byun, Mi Kyung Sung and Hay Ran Jang (Hanyang University, Korea) for technical assistance. This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (NRF-2012R1A2A2A06044458; NRF-2014R1A2A1 A11049701) to HY.	Ahonen LJ, 2005, CURR BIOL, V15, P1078, DOI 10.1016/j.cub.2005.05.026; Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Basto R, 2008, CELL, V133, P1032, DOI 10.1016/j.cell.2008.05.039; Benada J, 2015, CELL CYCLE, V14, P219, DOI 10.4161/15384101.2014.977067; Bolhy S, 2011, J CELL BIOL, V192, P855, DOI 10.1083/jcb.201007118; Bomont P, 2005, EMBO J, V24, P3927, DOI 10.1038/sj.emboj.7600848; Brennan IM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000409; Dietzmann K, 2001, J NEURO-ONCOL, V53, P1, DOI 10.1023/A:1011808200978; Eletr ZM, 2014, BBA-MOL CELL RES, V1843, P114, DOI 10.1016/j.bbamcr.2013.06.027; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Eliezer Y, 2009, J BIOL CHEM, V284, P426, DOI 10.1074/jbc.M807375200; Elowe S, 2007, GENE DEV, V21, P2205, DOI 10.1101/gad.436007; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Fradet-Turcotte A, 2013, NATURE, V499, P50, DOI 10.1038/nature12318; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Giunta S, 2010, J CELL BIOL, V190, P197, DOI 10.1083/jcb.200911156; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; Gurden MDJ, 2010, J CELL SCI, V123, P321, DOI 10.1242/jcs.062075; Habedanck R, 2005, NAT CELL BIOL, V7, P1140, DOI 10.1038/ncb1320; Holt SV, 2005, J CELL SCI, V118, P4889, DOI 10.1242/jcs.02614; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwabuchi K, 1998, J BIOL CHEM, V273, P26061, DOI 10.1074/jbc.273.40.26061; Izumi H, 2009, ONCOGENE, V28, P2806, DOI 10.1038/onc.2009.141; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; Jullien D, 2002, J CELL SCI, V115, P71; Kang YH, 2011, J BIOL CHEM, V286, P19744, DOI 10.1074/jbc.M111.224105; Kishi K, 2009, MOL CELL BIOL, V29, P3134, DOI 10.1128/MCB.01663-08; Kwak HJ, 2005, J CANCER RES CLIN, V131, P789, DOI 10.1007/s00432-005-0035-y; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Li J, 2005, NEOPLASIA, V7, P312, DOI 10.1593/neo.04325; Liu J, 2006, STRUCTURE, V14, P1811, DOI 10.1016/j.str.2006.10.009; Liu XQ, 2006, MOL CELL BIOL, V26, P2093, DOI 10.1128/MCB.26.6.2093-2108.2006; Morales JC, 2006, P NATL ACAD SCI USA, V103, P3310, DOI 10.1073/pnas.0511259103; Morales JC, 2003, J BIOL CHEM, V278, P14971, DOI 10.1074/jbc.M212484200; Moynihan KL, 2009, MOL BIOL CELL, V20, P4790, DOI 10.1091/mbc.E09-07-0560; Nakamura T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2752; Nelson G, 2009, CELL CYCLE, V8, P3379, DOI 10.4161/cc.8.20.9857; Nigg EA, 2007, TRENDS CELL BIOL, V17, P215, DOI 10.1016/j.tcb.2007.03.003; Nigg EA, 2009, CELL, V139, P663, DOI 10.1016/j.cell.2009.10.036; Orthwein A, 2014, SCIENCE, V344, P189, DOI 10.1126/science.1248024; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Sankaran S, 2005, MOL CELL BIOL, V25, P8656, DOI 10.1128/MCB.25.19.8656-8668.2005; Scully R, 2013, MUTAT RES-FUND MOL M, V750, P5, DOI 10.1016/j.mrfmmm.2013.07.007; Sumara I, 2004, CURR BIOL, V14, P1712, DOI 10.1016/j.cub.2004.09.049; van Vugt MATM, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000287; Varis A, 2006, CHROMOSOMA, V115, P288, DOI 10.1007/s00412-005-0046-0; Vergnolle MAS, 2007, CURR BIOL, V17, P1173, DOI 10.1016/j.cub.2007.05.077; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Ward IM, 2005, MOL CELL BIOL, V25, P10079, DOI 10.1128/MCB.25.22.10079-10086.2005; Yang ZY, 2005, MOL CELL BIOL, V25, P4062, DOI 10.1128/MCB.25.10.4062-4074.2005; Yim H, 2014, MUTAT RES-REV MUTAT, V761, P31, DOI 10.1016/j.mrrev.2014.02.005; Yim HS, 2009, MOL CELL BIOL, V29, P2609, DOI 10.1128/MCB.01277-08; Yoo E, 2005, ONCOGENE, V24, P5423, DOI 10.1038/sj.onc.1208710; Zhang D, 2006, CELL, V126, P529, DOI 10.1016/j.cell.2006.06.039	57	14	14	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	2017	36	7					966	978		10.1038/onc.2016.263	http://dx.doi.org/10.1038/onc.2016.263			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8JG	27477698				2022-12-17	WOS:000394169100009
J	Marom, A; Barak, AF; Kramer, MP; Lewinsky, H; Binsky-Ehrenreich, I; Cohen, S; Tsitsou-Kampeli, A; Kalchenko, V; Kuznetsov, Y; Mirkin, V; Dezorella, N; Shapiro, M; Schwartzberg, PL; Cohen, Y; Shvidel, L; Haran, M; Becker-Herman, S; Herishanu, Y; Shachar, I				Marom, A.; Barak, A. F.; Kramer, M. P.; Lewinsky, H.; Binsky-Ehrenreich, I.; Cohen, S.; Tsitsou-Kampeli, A.; Kalchenko, V.; Kuznetsov, Y.; Mirkin, V.; Dezorella, N.; Shapiro, M.; Schwartzberg, P. L.; Cohen, Y.; Shvidel, L.; Haran, M.; Becker-Herman, S.; Herishanu, Y.; Shachar, I.			CD84 mediates CLL-microenvironment interactions	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; B-CELLS; BONE-MARROW; CD74-DEPENDENT MANNER; EXPRESSION; APOPTOSIS; SURVIVAL; CHEMOKINES; MIGRATION; RECEPTOR	Chronic lymphocytic leukemia (CLL) is a malignant disease of small mature lymphocytes. Signals from the CLL microenvironment promote progression of the disease and induce drug resistance. This phenomenon is largely dependent on direct contact between the malignant B cells and stromal cells. CD84 belongs to the signaling lymphocyte activation molecule family of immunoreceptors, which self-associates, forming an orthogonal homophilic dimer. We therefore hypothesized that CD84 may bridge between CLL cells and their microenvironment, promoting cell survival. Our in vitro results show that CD84 expressed on CLL cells interact with CD84 expressed on cells in their microenvironment, inducing cell survival in both sides. Blocking CD84 in vitro and in vivo disrupt the interaction of CLL cells with their microenvironment, resulting in induced cell death. Thus, our findings suggest novel therapeutic strategies based on the blockade of this CD84- dependent survival pathway.	[Marom, A.; Barak, A. F.; Kramer, M. P.; Lewinsky, H.; Binsky-Ehrenreich, I.; Cohen, S.; Tsitsou-Kampeli, A.; Becker-Herman, S.; Shachar, I.] Weizmann Inst Sci, Dept Immunol, 234 Herzel St, IL-76100 Rehovot, Israel; [Kalchenko, V.; Kuznetsov, Y.] Weizmann Inst Sci, Dept Vet Resources, Rehovot, Israel; [Mirkin, V.; Shvidel, L.; Haran, M.] Kaplan Med Ctr, Hematol Inst, Rehovot, Israel; [Dezorella, N.; Shapiro, M.; Herishanu, Y.] Tel Aviv Sourasky Med Ctr, Dept Hematol, Tel Aviv, Israel; [Schwartzberg, P. L.] NHGRI, NIH, Bethesda, MA USA; [Cohen, Y.] Laniado Med Ctr, Sanz Med Ctr, Dept Hematol, Netanya, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Hebrew University of Jerusalem; Kaplan Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Shachar, I (corresponding author), Weizmann Inst Sci, Dept Immunol, 234 Herzel St, IL-76100 Rehovot, Israel.	idit.shachar@weizmann.ac.il	Kramer, Matthias/L-1782-2016; Kalchenko, Vyacheslav/F-2924-2012; Kramer, Matthias P/A-6224-2009	Kramer, Matthias/0000-0002-0289-5261; Dezorella, Nili/0000-0003-4376-3131; Kalchenko, Vyacheslav/0000-0002-3166-7049	Israel Science Foundation; Israel Cancer association; Israel Cancer Research Fund (ICRF); DKFZ-MOST cooperation in cancer research; Quinquin foundation; Rubenstein charitable foundation; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG000123] Funding Source: NIH RePORTER	Israel Science Foundation(Israel Science Foundation); Israel Cancer association; Israel Cancer Research Fund (ICRF); DKFZ-MOST cooperation in cancer research; Quinquin foundation; Rubenstein charitable foundation; NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	We thank members of the Shachar laboratory for fruitful discussion and support. IS is the incumbent of the Dr Morton and Ann Kleiman Professorial Chair. This research was supported by the Israel Science Foundation, Israel Cancer association, Israel Cancer Research Fund (ICRF), DKFZ-MOST cooperation in cancer research, Quinquin foundation and Rubenstein charitable foundation.	Bichi R, 2002, P NATL ACAD SCI USA, V99, P6955, DOI 10.1073/pnas.102181599; Binder M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015992; BINET JL, 1977, CANCER-AM CANCER SOC, V40, P855, DOI 10.1002/1097-0142(197708)40:2<855::AID-CNCR2820400239>3.0.CO;2-1; Binsky I, 2007, P NATL ACAD SCI USA, V104, P13408, DOI 10.1073/pnas.0701553104; Binsky I, 2010, J IMMUNOL, V184, P4761, DOI 10.4049/jimmunol.0904149; Binsky-Ehrenreich I, 2014, ONCOGENE, V33, P1006, DOI 10.1038/onc.2013.31; Bojarska-Junak A, 2008, LEUKEMIA RES, V32, P225, DOI 10.1016/j.leukres.2007.06.007; Burger JA, 2000, BLOOD, V96, P2655; Burger JA, 2007, LEUKEMIA RES, V31, P887, DOI 10.1016/j.leukres.2006.12.004; Burger JA, 2009, BLOOD, V114, P3367, DOI 10.1182/blood-2009-06-225326; Burger JA, 2009, BLOOD, V113, P3050, DOI 10.1182/blood-2008-07-170415; Calpe S, 2008, ADV IMMUNOL, V97, P177, DOI 10.1016/S0065-2776(08)00004-7; Cannons JL, 2010, IMMUNITY, V32, P253, DOI 10.1016/j.immuni.2010.01.010; Cohen Y, 2014, ACTA HAEMATOL-BASEL, V132, P129, DOI 10.1159/000357101; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Gordin M, 2010, J IMMUNOL, V185, P2020, DOI 10.4049/jimmunol.0902566; Guan E, 2002, J BIOL CHEM, V277, P32348, DOI 10.1074/jbc.M203077200; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; Hallek M, 2015, AM J HEMATOL, V90, P446, DOI 10.1002/ajh.23979; Haran M, 2004, LEUKEMIA, V18, P1948, DOI 10.1038/sj.leu.2403512; Hofbauer JP, 2011, LEUKEMIA, V25, P1452, DOI 10.1038/leu.2011.111; Kalchenko V, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2364903; Kay NE, 2007, LEUKEMIA RES, V31, P899, DOI 10.1016/j.leukres.2006.11.024; Kurtova AV, 2009, BLOOD, V114, P4441, DOI 10.1182/blood-2009-07-233718; Lagneaux L, 1998, BLOOD, V91, P2387, DOI 10.1182/blood.V91.7.2387.2387_2387_2396; Martin M, 2001, J IMMUNOL, V167, P3668, DOI 10.4049/jimmunol.167.7.3668; Messmer BT, 2005, J CLIN INVEST, V115, P755, DOI 10.1172/JCI23409; Moreno A, 2001, BLOOD, V97, P242, DOI 10.1182/blood.V97.1.242; Nicholas NS, 2016, BBA-MOL CELL RES, V1863, P471, DOI 10.1016/j.bbamcr.2015.11.003; Plander M, 2011, ANN HEMATOL, V90, P1381, DOI 10.1007/s00277-011-1218-z; Ramsay AD, 2013, BRIT J HAEMATOL, V162, P15, DOI 10.1111/bjh.12344; Ray Avijit, 2010, J Vis Exp, DOI 10.3791/1488; Reittie JE, 1996, LEUKEMIA LYMPHOMA, V22, P83, DOI 10.3109/10428199609051732; Romero X, 2005, J IMMUNOL, V174, P7033, DOI 10.4049/jimmunol.174.11.7033; ROZMAN C, 1995, NEW ENGL J MED, V333, P1052, DOI 10.1056/NEJM199510193331606; Sivina M, 2011, BLOOD, V117, P1662, DOI 10.1182/blood-2010-09-307249; ten Hacken E, 2014, PHARMACOL THERAPEUT, V144, P338, DOI 10.1016/j.pharmthera.2014.07.003; Witowski J, 2001, AM J PATHOL, V158, P1441, DOI 10.1016/S0002-9440(10)64095-3; Witowski J, 2006, PERITON DIALYSIS INT, V26, P292; Yan QR, 2007, P NATL ACAD SCI USA, V104, P10583, DOI 10.1073/pnas.0703893104; Zucchetto A, 2009, CANCER RES, V69, P4001, DOI 10.1158/0008-5472.CAN-08-4173	41	14	14	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	2017	36	5					628	638		10.1038/onc.2016.238	http://dx.doi.org/10.1038/onc.2016.238			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IS	27452524				2022-12-17	WOS:000394167700005
J	Metheetrairut, C; Adams, BD; Nallur, S; Weidhaas, JB; Slack, FJ				Metheetrairut, C.; Adams, B. D.; Nallur, S.; Weidhaas, J. B.; Slack, F. J.			cel-mir-237 and its homologue, hsa-miR-125b, modulate the cellular response to ionizing radiation	ONCOGENE			English	Article							NEGATIVE BREAST-CANCER; DNA-DAMAGE RESPONSE; LOCOREGIONAL RECURRENCE; ELEGANS MICRORNAS; MESSENGER-RNAS; C. ELEGANS; EXPRESSION; TARGETS; MIR-125B; MIRNAS	Elucidating the mechanisms involved in sensitizing radioresistant tumors to ionizing radiation (IR) treatments while minimizing injury to surrounding normal tissue is an important clinical goal. Due to their sequence-derived specificity and properties as gene regulators in IR-affected pathways, microRNAs (miRNAs) could serve as adjuvant therapeutic agents that alter cellular sensitivity to radiation treatment. To identify radiosensitizing miRNAs, we initially utilized the Caenorhabditis elegans vulval cell model, an in vivo system developed to study IR-dependent radiosensitivity as a measure of clonogenic cell death. We tested several candidate miRNA-deletion mutants post gamma-irradiation and identified cel-mir-237 as a miRNA which when deleted caused animals to be more resistant to IR, whereas cel-mir-237 overexpressing strains were IR sensitive. In addition, wild-type animals downregulated cel-mir-237 levels post IR in a time-dependent manner. We identified jun-1 (JUN transcription factor homolog) as a novel target of cel-mir-237. Specifically, jun-1 transcript levels increased in wild-type animals post gamma-irradiation, and loss of cel-mir-237 also resulted in higher jun-1 expression. As expected, loss of jun-1 resulted in IR sensitivity, similar to the phenotype of cel-mir-237 overexpressors. As miR-237 is the homolog of human miR-125, we validated our findings in MCF-7 and MDA-MB-231 breast cancer cell lines, which harbor lower hsa-miR-125b levels than normal human mammary epithelial cells (HMECs). Forced expression of hsa-miR-125b in these cells resulted in radiosensitivity, as seen by reduced clonogenic survival, enhanced apoptotic activity and enhanced senescence post IR. Finally, re-expression of c-JUN in MDA-MB-231 cells promoted radioresistance and abrogated miR-125-mediated radiosensitization. Our findings suggest that overexpression of cel-mir-237 and its homolog, hsa-miR-125b, functions as sensitizers to gamma-irradiation in both a nematode in vivo model and breast cancer cells, and could potentially be utilized as an adjuvant therapeutic to enhance radiation sensitivity.	[Metheetrairut, C.; Adams, B. D.; Slack, F. J.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT USA; [Adams, B. D.; Slack, F. J.] Harvard Med Sch, BIDMC Canc Ctr, Dept Pathol, Inst RNA Med, 3 Blackfan Circle, Boston, MA 02115 USA; [Nallur, S.; Weidhaas, J. B.] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06510 USA; [Metheetrairut, C.] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Biochem, Bangkok 10700, Thailand; [Weidhaas, J. B.] UCLA, Sch Med, Div Mol & Cellular Oncol, Los Angeles, CA 90095 USA	Yale University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Yale University; Mahidol University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Slack, FJ (corresponding author), Harvard Med Sch, BIDMC Canc Ctr, Dept Pathol, Inst RNA Med, 3 Blackfan Circle, Boston, MA 02115 USA.	fslack@bidmc.harvard.edu	Adams, Brian D./D-9476-2017	Adams, Brian D./0000-0001-8372-2970; Metheetrairut, Chanatip/0000-0002-4394-5085	National Institutes of Health National Center; NIH [R01 CA157749, R01 CA131301];  [5T32 HG003198-10]; NATIONAL CANCER INSTITUTE [R01CA131301, R01CA157749] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG003198] Funding Source: NIH RePORTER	National Institutes of Health National Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	We thank Geoffrey Lyon, Yale Cell Sorter Core Facility, for assistance with fluorescence- activated cell sorting and analysis, the Yale Cesium Irradiator Shared Resource for use of gamma-irradiator, Valerie Horsley for use of imaging equipment, and to Shirin Bahmanyar for providing space and making equipment available for these studies. We thank Alan Jiao and Catherine O. Adams for critical reading of this manuscript. Nematode strains used in this work were provided by the C. elegans Genetics Center, which is funded by the National Institutes of Health National Center for Research Resources. This work was supported by grants to FJS and JBW from the NIH (R01 CA157749 and R01 CA131301). BDA was supported by a training grant (5T32 HG003198-10).	Adams BD, 2016, CANCER RES, V76, P927, DOI 10.1158/0008-5472.CAN-15-2321; Adams BD, 2014, CURR BIOL, V24, pR762, DOI 10.1016/j.cub.2014.06.043; Ambros V, 2003, CURR BIOL, V13, P807, DOI 10.1016/S0960-9822(03)00287-2; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Babar IA, 2011, CANCER BIOL THER, V12, P908, DOI 10.4161/cbt.12.10.17681; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; BERNHARD EJ, 1995, RADIAT ENVIRON BIOPH, V34, P79, DOI 10.1007/BF01275210; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; Betel D, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r90; BRENNER S, 1974, GENETICS, V77, P71; Brown JM, CANC BIOL THER, V2, P477; Cheng CJ, 2015, NATURE, V518, P107, DOI 10.1038/nature13905; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Emmrich S, 2014, GENE DEV, V28, P858, DOI 10.1101/gad.233791.113; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Esquela-Kerscher A, 2005, DEV DYNAM, V234, P868, DOI 10.1002/dvdy.20572; Farazi TA, 2011, J PATHOL, V223, P102, DOI 10.1002/path.2806; Feliciano A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076247; Feng HY, 2012, METHODS MOL BIOL, V786, P21, DOI 10.1007/978-1-61779-292-2_2; Ferracin M, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-130; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Garofalo M, 2013, DRUG RESIST UPDATE, V16, P47, DOI 10.1016/j.drup.2013.05.001; Gefen N, 2010, LEUKEMIA, V24, P89, DOI 10.1038/leu.2009.208; Girard LR, 2007, NUCLEIC ACIDS RES, V35, pD472, DOI 10.1093/nar/gkl894; Hammell M, 2008, NAT METHODS, V5, P813, DOI 10.1038/NMETH.1247; Hoogewijs D, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-9; Huang L, 2011, INT J CANCER, V128, P1758, DOI 10.1002/ijc.25509; Iliakis G, 1997, SEMIN ONCOL, V24, P602; Isik Meltem, 2013, Methods Mol Biol, V940, P77, DOI 10.1007/978-1-62703-110-3_7; Jan CH, 2011, NATURE, V469, P97, DOI 10.1038/nature09616; Kai ZS, 2010, NAT STRUCT MOL BIOL, V17, P5, DOI 10.1038/nsmb.1762; Kappelmann M, 2013, ONCOGENE, V32, P2984, DOI 10.1038/onc.2012.307; Kato M, 2009, ONCOGENE, V28, P2419, DOI 10.1038/onc.2009.106; Krejci L, 2012, NUCLEIC ACIDS RES, V40, P5795, DOI 10.1093/nar/gks270; Le MTN, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002242; Le MTN, 2009, GENE DEV, V23, P862, DOI 10.1101/gad.1767609; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lieber MR, 2010, ANNU REV BIOCHEM, V79, P181, DOI 10.1146/annurev.biochem.052308.093131; Lim LP, 2003, GENE DEV, V17, P991, DOI 10.1101/gad.1074403; Lin KY, 2016, ONCOGENE, V35, P3376, DOI 10.1038/onc.2015.396; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lowery AJ, 2012, BREAST CANCER RES TR, V133, P831, DOI 10.1007/s10549-011-1891-6; MacFarlane LA, 2010, CURR GENOMICS, V11, P537, DOI 10.2174/138920210793175895; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Metheetrairut C, 2013, CURR OPIN GENET DEV, V23, P12, DOI 10.1016/j.gde.2013.01.002; Miska EA, 2007, PLOS GENET, V3, P2395, DOI 10.1371/journal.pgen.0030215; Misso G, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2014.47; Nyholm AM, 2014, BMC DERMATOL, V14, DOI 10.1186/1471-5945-14-8; Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5; Peter ME, 2010, ONCOGENE, V29, P2161, DOI 10.1038/onc.2010.59; Praitis V, 2001, GENETICS, V157, P1217; Puissegur MP, 2012, LEUKEMIA, V26, P2224, DOI 10.1038/leu.2012.95; Rajabi Hasan, 2010, Genes Cancer, V1, P62; Scott GK, 2007, J BIOL CHEM, V282, P1479, DOI 10.1074/jbc.M609383200; Shi XB, 2011, PROSTATE, V71, P538, DOI 10.1002/pros.21270; Shiiba M, 2013, BRIT J CANCER, V108, P1817, DOI 10.1038/bjc.2013.175; Shrivastav M, 2008, CELL RES, V18, P134, DOI 10.1038/cr.2007.111; Song R, 2014, NATURE, V510, P115, DOI 10.1038/nature13413; Stiernagle T., 2006, MAINTENANCE C ELEGAN; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; Surdziel E, 2011, BLOOD, V117, P4338, DOI 10.1182/blood-2010-06-289058; Tan GY, 2012, J BIOL CHEM, V287, P33036, DOI 10.1074/jbc.M112.383273; Tang J, 2012, INT J MOL SCI, V13, P13414, DOI 10.3390/ijms131013414; The C, 2006, WORMBOOK, DOI 10.1895/wormbook.1.54.1; van Haaften G, 2006, CURR BIOL, V16, P1344, DOI 10.1016/j.cub.2006.05.047; Weidhaas JB, 2006, P NATL ACAD SCI USA, V103, P9946, DOI 10.1073/pnas.0603791103; Weidhaas JB, 2007, CANCER RES, V67, P11111, DOI 10.1158/0008-5472.CAN-07-2858; Welker NC, 2007, RNA, V13, P1090, DOI 10.1261/rna.542107; Wu DY, 2013, ONCOL LETT, V5, P829, DOI 10.3892/ol.2013.1123; Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103; Zaky SS, 2011, ANN SURG ONCOL, V18, P2858, DOI 10.1245/s10434-011-1669-4; Zhang C, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1116-2; Zhang L, 2014, GENE DEV, V28, P2532, DOI 10.1101/gad.248377.114; Zhang LA, 2011, CELL STEM CELL, V8, P294, DOI 10.1016/j.stem.2011.01.014; Zhang Y, 2011, CANCER RES, V71, P1; Zhao ZY, 2010, GENETICS, V184, P853, DOI 10.1534/genetics.109.110270	79	14	16	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 26	2017	36	4					512	524		10.1038/onc.2016.222	http://dx.doi.org/10.1038/onc.2016.222			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8II	27321180	Green Accepted, Green Submitted			2022-12-17	WOS:000394166700008
J	Liu, T; Zhao, M; Liu, J; He, Z; Zhang, Y; You, H; Huang, J; Lin, X; Feng, XH				Liu, T.; Zhao, M.; Liu, J.; He, Z.; Zhang, Y.; You, H.; Huang, J.; Lin, X.; Feng, X-H			Tumor suppressor bromodomain-containing protein 7 cooperates with Smads to promote transforming growth factor-beta responses	ONCOGENE			English	Article							NASOPHARYNGEAL CARCINOMA-CELLS; BRD7 EXPRESSION; TRANSCRIPTIONAL REGULATION; GENE; COACTIVATOR; ACTIVATION; INTERACTS; PATHWAYS; SUBUNIT; BINDS	Smad proteins are central mediators in the canonical transforming growth factor-beta (TGF-beta) signaling pathway in mammalian cells. We report here that bromodomain-ontaining protein 7 (BRD7) functions as a novel transcription coactivator for Smads in TGF-beta signaling. BRD7 forms a TGF-beta inducible complex with Smad3/ 4 through its N-terminal Smad-binding domain. BRD7 simultaneously binds to acetylated histones to promote Smad-chromatin association, and associates with histone acetyltransferase p300 to enhance Smad transcriptional activity. Ectopic expression of BRD7, but not its mutants defective in Smad binding, enhances TGF-beta transcriptional, tumor-suppressing and epithelial-mesenchymal transition responses. Conversely, depletion of BRD7 inhibits TGF-beta responses. Thus, our study provides compelling evidence for a new function of BRD7 in fine-tuning TGF-beta physiological responses.	[Liu, T.; Zhao, M.; Liu, J.; He, Z.; Zhang, Y.; Huang, J.; Feng, X-H] Zhejiang Univ, Life Sci Inst, Hangzhou, Zhejiang, Peoples R China; [Liu, T.; Zhao, M.; Liu, J.; He, Z.; Zhang, Y.; Huang, J.; Feng, X-H] Zhejiang Univ, Innovat Ctr Cell Signaling Network, Hangzhou, Zhejiang, Peoples R China; [Liu, T.] Zhejiang Univ, Sch Med, Dept Cell Biol, Hangzhou, Zhejiang, Peoples R China; [Liu, T.] Zhejiang Univ, Sch Med, Program Mol Cell Biol, Hangzhou, Zhejiang, Peoples R China; [You, H.] Coll Life Sci, State Key Lab Cellular Stress Biol, Xiamen, Fujian, Peoples R China; [You, H.] Coll Life Sci, State Key Lab Cellular Stress Biol, Xiamen, Fujian, Peoples R China; [Lin, X.; Feng, X-H] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA; [Lin, X.; Feng, X-H] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University; Baylor College of Medicine; Baylor College of Medicine	Liu, T; Feng, XH (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	liuting518@zju.edu.cn; xfeng@bcm.edu		Liu, Jinquan/0000-0002-5180-5613	NSFC [91540205, 31571447, 31171347]; MOST [2012CB966600, 2015CB553800, 2013CB945303]; NIH [R01GM63773, R01AR053591, R01CA108454, R01DK073932]; Project 111; PhD Programs Foundation of Ministry of Education of China [20110101120152]; Fundamental Research Funds for the Central Universities; NATIONAL CANCER INSTITUTE [R21CA112939, R01CA108454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053591] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063773] Funding Source: NIH RePORTER	NSFC(National Natural Science Foundation of China (NSFC)); MOST; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Project 111(Ministry of Education, China - 111 Project); PhD Programs Foundation of Ministry of Education of China(Ministry of Education, China); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank David Luskutoff for p800 (PAI-1)-luc, Bert Vogelstein for WWP1 (p21)-luc and SBE-luc. We are grateful to the laboratory members for helpful discussion and technical assistance. This research was partly supported by grants from NSFC (91540205, 31571447, 31171347) and MOST (2012CB966600, 2015CB553800, 2013CB945303), NIH (R01GM63773, R01AR053591, R01CA108454, and R01DK073932), Project 111, PhD Programs Foundation of Ministry of Education of China (20110101120152), and the Fundamental Research Funds for the Central Universities.	Bai RY, 2002, NAT CELL BIOL, V4, P181, DOI 10.1038/ncb753; Balasubramanian Anandh, 2015, Asian Pac J Cancer Prev, V16, P1615; Burrows AE, 2010, P NATL ACAD SCI USA, V107, P14280, DOI 10.1073/pnas.1009559107; Chan HM, 2001, J CELL SCI, V114, P2363; Chiu YH, 2014, MOL CELL, V54, P193, DOI 10.1016/j.molcel.2014.02.016; Dai FY, 2009, DEV CELL, V16, P345, DOI 10.1016/j.devcel.2009.01.022; Derynck R, 2007, TGF BETA FAMILY CELL; Drost J, 2010, NAT CELL BIOL, V12, P380, DOI 10.1038/ncb2038; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Harte MT, 2010, CANCER RES, V70, P2538, DOI 10.1158/0008-5472.CAN-09-2089; Itoh S, 2000, NUCLEIC ACIDS RES, V28, P4291, DOI 10.1093/nar/28.21.4291; Kaeser MD, 2008, J BIOL CHEM, V283, P32254, DOI 10.1074/jbc.M806061200; Kikuchi M, 2009, BBA-MOL CELL RES, V1793, P1828, DOI 10.1016/j.bbamcr.2009.11.001; Kim ES, 2004, INT J ONCOL, V25, P1375; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Liu HY, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-111; Liu HY, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-253; Mantovani F, 2010, CELL CYCLE, V9, P2777; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Park YA, 2014, CLIN CANCER RES, V20, P565, DOI 10.1158/1078-0432.CCR-13-1271; Park YA, 2012, GYNECOL ONCOL, V124, P125, DOI 10.1016/j.ygyno.2011.09.026; Peng C, 2006, J CELL BIOCHEM, V97, P882, DOI 10.1002/jcb.20645; Peng C, 2007, MOL CELL BIOCHEM, V303, P141, DOI 10.1007/s11010-007-9466-x; Ross S, 2008, INT J BIOCHEM CELL B, V40, P383, DOI 10.1016/j.biocel.2007.09.006; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Wang DG, 2008, CANCER RES, V68, P783, DOI 10.1158/0008-5472.CAN-07-0008; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wu MY, 2009, DEV CELL, V16, P329, DOI 10.1016/j.devcel.2009.02.012; Wu WJ, 2013, EUR J CLIN INVEST, V43, P131, DOI 10.1111/eci.12024; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Xu Y, 2015, BEHAV BRAIN RES, V286, P1, DOI 10.1016/j.bbr.2015.02.031; Zhou J, 2004, J CELL PHYSIOL, V200, P89, DOI 10.1002/jcp.20013	39	14	14	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	2017	36	3					362	372		10.1038/onc.2016.204	http://dx.doi.org/10.1038/onc.2016.204			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IB	27270427	Green Accepted			2022-12-17	WOS:000394166000006
J	Cui, Y; Sun, Y; Hu, S; Luo, J; Li, L; Li, X; Yeh, S; Jin, J; Chang, C				Cui, Y.; Sun, Y.; Hu, S.; Luo, J.; Li, L.; Li, X.; Yeh, S.; Jin, J.; Chang, C.			Neuroendocrine prostate cancer (NEPCa) increased the neighboring PCa chemoresistance via altering the PTHrP/p38/Hsp27/androgen receptor (AR)/p21 signals	ONCOGENE			English	Article							SHOCK-PROTEIN 27; ACQUIRED DOCETAXEL RESISTANCE; MITOXANTRONE PLUS PREDNISONE; ANDROGEN RECEPTOR; P38 MAPK; CELL-SURVIVAL; GROWTH; EXPRESSION; ACTIVATION; KINASE	Prostatic neuroendocrine cells (NE) are an integral part of prostate cancer (PCa) and are associated with PCa progression. As the current androgen deprivation therapy with anti-androgens may promote the neuroendocrine PCa (NEPCa) development, and few therapies can effectively suppress NEPCa, understanding the impact of NEPCa on PCa progression may help us to develop better therapies to battle PCa. Here, we found NEPCa cells could increase the docetaxel resistance of their neighboring PCa cells. Mechanism dissection revealed that through secretion of PTHrP, NEPCa cells could alter the p38/MAPK/Hsp27 signals in their neighboring PCa cells that resulted in increased androgen receptor (AR) activity via promoting AR nuclear translocation. The consequences of increased AR function might then increase docetaxel resistance via increasing p21 expression. In vivo xenograft mice experiments also confirmed that NEPCa could increase the docetaxel resistance of neighboring PCa, and targeting this newly identified PTHrP/p38/Hsp27/AR/p21 signaling pathway with either p38 inhibitor (SB203580) or shPTHrP may result in improving/restoring the docetaxel sensitivity to better suppress PCa.	[Cui, Y.; Hu, S.; Li, X.; Jin, J.] Peking Univ, Dept Urol, Hosp 1, Beijing, Peoples R China; [Cui, Y.; Sun, Y.; Hu, S.; Luo, J.; Li, L.; Yeh, S.; Chang, C.] Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA; [Cui, Y.; Sun, Y.; Hu, S.; Luo, J.; Li, L.; Yeh, S.; Chang, C.] Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Urol, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA; [Cui, Y.; Sun, Y.; Hu, S.; Luo, J.; Li, L.; Yeh, S.; Chang, C.] Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Radiat Oncol, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA; [Cui, Y.; Sun, Y.; Hu, S.; Luo, J.; Li, L.; Yeh, S.; Chang, C.] Univ Rochester, Med Ctr, Wilmot Canc Ctr, Rochester, NY USA; [Chang, C.] China Med Univ Hosp, Sex Hormone Res Ctr, Taichung, Taiwan	Peking University; University of Rochester; University of Rochester; University of Rochester; University of Rochester; China Medical University Taiwan; China Medical University Hospital - Taiwan	Chang, C (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.; Chang, C (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Urol, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.; Chang, C (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Radiat Oncol, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.; Chang, C (corresponding author), Univ Rochester, Med Ctr, Wilmot Canc Ctr, Rochester, NY USA.; Jin, J (corresponding author), Peking Univ, Hosp 1, Dept Urol, Natl Urol Canc Ctr, Xishiku St 8, Beijing 100034, Peoples R China.	jinjie@vip.163.com; chang@urmc.rochester.edu	Luo, Jie/AAG-3091-2019	Chang, Chawnshang/0000-0001-8510-3516	NIH [CA155477, CA156700]; Taiwan Department of Health Clinical Trial, Research Center of Excellence [DOH99-TD-B-111-004]; China 973 Program [2012CB518305]; George Whipple Professorship Endowment; NATIONAL CANCER INSTITUTE [R01CA155477, R01CA156700] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Taiwan Department of Health Clinical Trial, Research Center of Excellence; China 973 Program(National Basic Research Program of China); George Whipple Professorship Endowment; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH grants (CA155477 and CA156700), George Whipple Professorship Endowment and Taiwan Department of Health Clinical Trial, Research Center of Excellence (DOH99-TD-B-111-004 to China Medical University, Taichung, Taiwan) and China 973 Program (2012CB518305). We thank Karen Wolf for help in preparing the manuscript.	Abrahamsson PA, 1999, ENDOCR-RELAT CANCER, V6, P503, DOI 10.1677/erc.0.0060503; BERCHEM GJ, 1995, CANCER RES, V55, P735; Berthold DR, 2008, J CLIN ONCOL, V26, P242, DOI 10.1200/JCO.2007.12.4008; Bhardwaj A, 2014, ONCOTARGET, V5, P11490, DOI 10.18632/oncotarget.2571; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Cerasuolo M, 2015, CANCER RES, V75, P2975, DOI 10.1158/0008-5472.CAN-14-3830; Chung LY, 2012, CLIN CANCER RES, V18, P4037, DOI 10.1158/1078-0432.CCR-11-3348; Conn EM, 2009, AM J PATHOL, V175, P1638, DOI 10.2353/ajpath.2009.090384; Corcelle E, 2007, AUTOPHAGY, V3, P57, DOI 10.4161/auto.3424; Dang Q, 2015, MOL ONCOL, V9, P1241, DOI 10.1016/j.molonc.2015.02.010; DaSilva J, 2009, CANCER RES, V69, P7402, DOI 10.1158/0008-5472.CAN-08-4687; DaSilva JO, 2013, PROSTATE, V73, P801, DOI 10.1002/pros.22624; Dizeyi N, 2004, PROSTATE, V59, P328, DOI 10.1002/pros.10374; Dizeyi N, 2011, UROL ONCOL-SEMIN ORI, V29, P436, DOI 10.1016/j.urolonc.2009.09.013; Domingo-Domenech J, 2012, CANCER CELL, V22, P373, DOI 10.1016/j.ccr.2012.07.016; Fan WQ, 2007, J BIOL CHEM, V282, P7329, DOI 10.1074/jbc.M610447200; Fizazi K, 2015, LANCET ONCOL, V16, P787, DOI 10.1016/S1470-2045(15)00011-X; Geng H, 2010, CANCER RES, V70, P3239, DOI 10.1158/0008-5472.CAN-09-3186; Guo YS, 2001, J BIOL CHEM, V276, P22941, DOI 10.1074/jbc.M101801200; Hadchity E, 2009, MOL THER, V17, P1387, DOI 10.1038/mt.2009.90; Harper ME, 1996, BRIT J CANCER, V74, P910, DOI 10.1038/bjc.1996.456; Heron-Milhavet L, 2002, J BIOL CHEM, V277, P15600, DOI 10.1074/jbc.M111142200; Hirano D, 2004, EUR UROL, V45, P586, DOI 10.1016/j.eururo.2003.11.032; Hobisch A, 1998, CANCER RES, V58, P4640; Hsu HS, 2011, CANCER-AM CANCER SOC, V117, P1516, DOI 10.1002/cncr.25599; Hu S, 2015, MOL ONCOL, V9, P44, DOI 10.1016/j.molonc.2014.07.013; Jazirehi AR, 2004, CANCER RES, V64, P7117, DOI 10.1158/0008-5472.CAN-03-3500; Jia YF, 2001, J BIOL CHEM, V276, P39911, DOI 10.1074/jbc.M103510200; Jin RJ, 2008, CANCER RES, V68, P6762, DOI 10.1158/0008-5472.CAN-08-0107; Jin RJ, 2004, CANCER RES, V64, P5489, DOI 10.1158/0008-5472.CAN-03-3117; Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206; Kim JY, 2008, ENDOCRINOLOGY, V149, P3085, DOI 10.1210/en.2007-1367; Lamoureux F, 2014, EUR UROL, V66, P145, DOI 10.1016/j.eururo.2013.12.019; Leotoing L, 2007, J MOL ENDOCRINOL, V39, P151, DOI 10.1677/JME-07-0021; Levine L, 2003, CANCER RES, V63, P3495; Liao JH, 2008, INT J CANCER, V123, P2267, DOI 10.1002/ijc.23602; Lin JQ, 1999, CANCER RES, V59, P2891; Lu S, 2000, MOL ENDOCRINOL, V14, P753, DOI 10.1210/me.14.5.753; Marengo B, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.118; Marin-Aguilera M, 2014, MOL CANCER THER, V13, P1270, DOI 10.1158/1535-7163.MCT-13-0775; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; O'Shaughnessy RFL, 2007, J BIOL CHEM, V282, P17297, DOI 10.1074/jbc.M610386200; Ongkeko WM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085803; Park SI, 2013, CANCER RES, V73, P6574, DOI 10.1158/0008-5472.CAN-12-4692; Pienta KJ, 2005, CA-CANCER J CLIN, V55, P300, DOI 10.3322/canjclin.55.5.300; Qi JF, 2010, CANCER CELL, V18, P23, DOI 10.1016/j.ccr.2010.05.024; Razandi M, 2010, MOL CELL BIOL, V30, P3249, DOI 10.1128/MCB.01354-09; Salido M, 2004, CELL BIOL INT, V28, P397, DOI 10.1016/j.cellbi.2004.03.008; Shah GV, 2008, ENDOCR-RELAT CANCER, V15, P953, DOI 10.1677/ERC-08-0136; Small GW, 2007, CANCER RES, V67, P4459, DOI 10.1158/0008-5472.CAN-06-2644; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Terry S, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00060; Thadani-Mulero M, 2014, CANCER RES, V74, P2270, DOI 10.1158/0008-5472.CAN-13-2876; Thadani-Mulero M, 2012, CANCER RES, V72, P4611, DOI 10.1158/0008-5472.CAN-12-0783; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Vilches J, 2004, HISTOL HISTOPATHOL, V19, P951, DOI 10.14670/HH-19.951; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiao DM, 2002, REGUL PEPTIDES, V109, P141, DOI 10.1016/S0167-0115(02)00197-0; Xu L, 2006, ONCOGENE, V25, P2987, DOI 10.1038/sj.onc.1209337; Yuan J, 2008, J CELL BIOCHEM, V103, P648, DOI 10.1002/jcb.21439; Yuan TC, 2006, ENDOCR-RELAT CANCER, V13, P151, DOI 10.1677/erc.1.01043; Zelivianski S, 2003, INT J CANCER, V107, P478, DOI 10.1002/ijc.11413; Zhang XQ, 2003, ONCOGENE, V22, P6704, DOI 10.1038/sj.onc.1206764; Zhao YP, 2006, J SURG RES, V136, P325, DOI 10.1016/j.jss.2006.06.031; Zhu YZ, 2013, MOL CANCER THER, V12, P1829, DOI 10.1158/1535-7163.MCT-13-0208; Zoubeidi A, 2007, CANCER RES, V67, P10455, DOI 10.1158/0008-5472.CAN-07-2057	69	14	15	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2016	35	47					6065	6076		10.1038/onc.2016.135	http://dx.doi.org/10.1038/onc.2016.135			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CE	27375022	Green Accepted			2022-12-17	WOS:000388509800003
J	Wen, J; Lee, J; Malhotra, A; Nahta, R; Arnold, AR; Buss, MC; Brown, BD; Maier, C; Kenney, AM; Remke, M; Ramaswamy, V; Taylor, MD; Castellino, RC				Wen, J.; Lee, J.; Malhotra, A.; Nahta, R.; Arnold, A. R.; Buss, M. C.; Brown, B. D.; Maier, C.; Kenney, A. M.; Remke, M.; Ramaswamy, V.; Taylor, M. D.; Castellino, R. C.			WIP1 modulates responsiveness to Sonic Hedgehog signaling in neuronal precursor cells and medulloblastoma	ONCOGENE			English	Article							PHOSPHATASE; PATHWAY; PPM1D; SUPPRESSOR; CHILDREN; TUMORS; GROWTH; MODEL; MDM2; MICE	High-level amplification of the protein phosphatase PPM1D (WIP1) is present in a subset of medulloblastomas (MBs) that have an expression profile consistent with active Sonic Hedgehog (SHH) signaling. We found that WIP1 overexpression increased expression of Shh target genes and cell proliferation in response to Shh stimulation in NIH3T3 and cerebellar granule neuron precursor cells in a p53-independent manner. Thus, we developed a mouse in which WIP1 is expressed in the developing brain under control of the Neurod2 promoter (ND2:WIP1). The external granule layer (EGL) in early postnatal ND2:WIP1 mice exhibited increased proliferation and expression of Shh downstream targets. MB incidence increased and survival decreased when ND2:WIP1 mice were crossed with an Shh-activated MB mouse model. Conversely, Wip1 knockout significantly suppressed MB formation in two independent mouse models of Shh-activated MB. Furthermore, Wip1 knockdown or treatment with a WIP1 inhibitor suppressed the effects of Shh stimulation and potentiated the growth inhibitory effects of SHH pathway-inhibiting drugs in Shh-activated MB cells in vitro. This suggests an important cross-talk between SHH and WIP1 pathways that accelerates tumorigenesis and supports WIP1 inhibition as a potential treatment strategy for MB.	[Wen, J.; Lee, J.; Malhotra, A.; Arnold, A. R.; Buss, M. C.; Brown, B. D.; Maier, C.; Kenney, A. M.; Castellino, R. C.] Aflac Canc & Blood Disorders Ctr, Dept Pediat, Atlanta, GA USA; [Nahta, R.; Kenney, A. M.; Castellino, R. C.] Winship Canc Ctr, Atlanta, GA USA; [Nahta, R.; Kenney, A. M.; Castellino, R. C.] Emory Univ, Sch Med, Atlanta, GA USA; [Nahta, R.] Dept Pharmacol, Atlanta, GA USA; [Remke, M.; Taylor, M. D.] Arthur & Sonia Labatt Brain Tumour Res Ctr, Div Neurosurg, Toronto, ON, Canada; [Remke, M.; Taylor, M. D.] Program Dev & Stem Cell Biol, Toronto, ON, Canada; [Ramaswamy, V.] Univ Toronto, Hosp Sick Children, Div Haematol Oncol, Toronto, ON, Canada; [Castellino, R. C.] Childrens Healthcare Atlanta, Atlanta, GA USA	Emory University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Children's Healthcare of Atlanta (CHOA)	Castellino, RC (corresponding author), 1760 Haygood Dr,NE,Room E394, Atlanta, GA 30322 USA.	rccaste@emory.edu	Arnold, Amanda/AAH-6678-2020; Castellino, Robert/GRF-7847-2022	Ramaswamy, Vijay/0000-0002-6557-895X; Taylor, Michael/0000-0001-7009-3466; Malhotra, Anshu/0000-0002-0255-2680; Roe, Caroline/0000-0003-4680-9553; Remke, Marc/0000-0002-9404-9993	NIH [1R01CA172392, CA159859]; St Baldrick's Foundation; CURE Childhood Cancer Foundation; Dr Mildred-Scheel Foundation; NATIONAL CANCER INSTITUTE [R01CA148699, R01CA159859, R01CA172392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS061070] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); St Baldrick's Foundation; CURE Childhood Cancer Foundation; Dr Mildred-Scheel Foundation(Deutsche Krebshilfe); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We acknowledge Drs James Olson and Xiongbin Lu for providing mice and expression constructs, and Dr Oskar Laur in the Emory University CCCF for plasmid construction. This work was supported by the NIH (1R01CA172392, RCC; CA159859, MDT), St Baldrick's Foundation (RCC), CURE Childhood Cancer Foundation (RCC) and the Dr Mildred-Scheel Foundation (MR).	Abe Y, 2008, P NATL ACAD SCI USA, V105, P4838, DOI 10.1073/pnas.0712216105; Bhatia B, 2010, CELL CYCLE, V9, P4307, DOI 10.4161/cc.9.21.13441; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Burnett ME, 1997, CANCER GENET CYTOGEN, V97, P25, DOI 10.1016/S0165-4608(96)00319-6; Buss MC, 2015, ONCOGENE, V34, P1126, DOI 10.1038/onc.2014.37; Buss MC, 2012, NEURO-ONCOLOGY, V14, P440, DOI 10.1093/neuonc/nos001; Castellino RC, 2008, J NEURO-ONCOL, V86, P245, DOI 10.1007/s11060-007-9470-8; Castellino RC, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-127; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Choi J, 2002, MOL CELL BIOL, V22, P1094, DOI 10.1128/MCB.22.4.1094-1105.2002; Demidov ON, 2007, ONCOGENE, V26, P2502, DOI 10.1038/sj.onc.1210032; Doucette TA, 2012, NEUROSURGERY, V70, P1003, DOI 10.1227/NEU.0b013e31823e5332; Ellison D, 2002, NEUROPATH APPL NEURO, V28, P257, DOI 10.1046/j.1365-2990.2002.00419.x; Ellison DW, 2011, ACTA NEUROPATHOL, V121, P381, DOI 10.1007/s00401-011-0800-8; Emelyanov A, 2015, ONCOGENE, V34, P4429, DOI 10.1038/onc.2014.375; Frank AJ, 2004, MOL BRAIN RES, V121, P137, DOI 10.1016/j.molbrainres.2003.11.016; Gilmartin AG, 2014, NAT CHEM BIOL, V10, P181, DOI [10.1038/NCHEMBIO.1427, 10.1038/nchembio.1427]; Hallahan AR, 2004, CANCER RES, V64, P7794, DOI 10.1158/0008-5472.CAN-04-1813; Hatton BA, 2008, CANCER RES, V68, P1768, DOI 10.1158/0008-5472.CAN-07-5092; Hyman JM, 2009, P NATL ACAD SCI USA, V106, P14132, DOI 10.1073/pnas.0907134106; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Lamprecht MR, 2007, BIOTECHNIQUES, V42, P71, DOI 10.2144/000112257; Lu XB, 2008, CELL CYCLE, V7, P164, DOI 10.4161/cc.7.2.5299; Marino S, 2000, GENE DEV, V14, P994; Nannenga B, 2006, MOL CARCINOGEN, V45, P594, DOI 10.1002/mc.20195; Northcott PA, 2012, NATURE, V488, P49, DOI 10.1038/nature11327; Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324; Oliver TG, 2005, DEVELOPMENT, V132, P2425, DOI 10.1242/dev.01793; Pandolfi S, 2013, ONCOGENE, V32, P4737, DOI 10.1038/onc.2012.502; Parathath SR, 2008, DEVELOPMENT, V135, P3291, DOI 10.1242/dev.022871; Rayter S, 2008, ONCOGENE, V27, P1036, DOI 10.1038/sj.onc.1210729; Rodon J, 2014, CLIN CANCER RES, V20, P1900, DOI 10.1158/1078-0432.CCR-13-1710; Saito-Ohara F, 2003, CANCER RES, V63, P1876; Samkari A, 2015, EXPERT REV NEUROTHER, V15, P763, DOI 10.1586/14737175.2015.1052796; Schuller U, 2008, CANCER CELL, V14, P123, DOI 10.1016/j.ccr.2008.07.005; Stecca B, 2009, EMBO J, V28, P663, DOI 10.1038/emboj.2009.16; Suresh Kp, 2011, J Hum Reprod Sci, V4, P8, DOI 10.4103/0974-1208.82352; Tabori U, 2010, J CLIN ONCOL, V28, P1345, DOI 10.1200/JCO.2009.23.5952; TORRES CF, 1994, NEW ENGL J MED, V330, P892, DOI 10.1056/NEJM199403313301303; Vanner RJ, 2014, CANCER CELL, V26, P33, DOI 10.1016/j.ccr.2014.05.005; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; von Hoff K, 2009, EUR J CANCER, V45, P1209, DOI 10.1016/j.ejca.2009.01.015; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; Yoda A, 2008, J BIOL CHEM, V283, P18969, DOI 10.1074/jbc.M800560200	46	14	14	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2016	35	42					5552	5564		10.1038/onc.2016.96	http://dx.doi.org/10.1038/onc.2016.96			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XO	27086929	Green Accepted			2022-12-17	WOS:000386998200009
J	Griveau, A; Devailly, G; Eberst, L; Navaratnam, N; Le Calve, B; Ferrand, M; Faull, P; Augert, A; Dante, R; Vanacker, JM; Vindrieux, D; Bernard, D				Griveau, A.; Devailly, G.; Eberst, L.; Navaratnam, N.; Le Calve, B.; Ferrand, M.; Faull, P.; Augert, A.; Dante, R.; Vanacker, J. M.; Vindrieux, D.; Bernard, D.			The PLA2R1-JAK2 pathway upregulates ERR alpha and its mitochondrial program to exert tumor-suppressive action	ONCOGENE			English	Article							ESTROGEN-RELATED RECEPTOR; BREAST-CANCER; CELLS; PGC-1-ALPHA; METABOLISM; PGC-1-BETA; MIGRATION; STRESS; GROWTH; VEGF	Little is known about the biological role of the phospholipase A2 receptor (PLA2R1) transmembrane protein. In recent years, PLA2R1 has been shown to have an important role in regulating tumor-suppressive responses via JAK2 activation, but the underlying mechanisms are largely undeciphered. In this study, we observed that PLA2R1 increases the mitochondrial content, judged by increased levels of numerous mitochondrial proteins, of the mitochondrial structural component cardiolipin, of the mitochondrial DNA content, and of the mitochondrial DNA replication and transcription factor TFAM. This effect of PLA2R1 relies on a transcriptional program controlled by the estrogen-related receptor alpha1 (ERR alpha) mitochondrial master regulator. Expression of ERR alpha and of its nucleus-encoded mitochondrial targets is upregulated upon PLA2R1 ectopic expression, and this effect is mediated by JAK2. Conversely, downregulation of PLA2R1 decreases the level of ERR alpha and of its nucleus-encoded mitochondrial targets. Finally, blocking the ERR alpha-controlled mitochondrial program largely inhibits the PLA2R1-induced tumor-suppressive response. Together, our data document ERR alpha and its mitochondrial program as downstream effectors of the PLA2R1-JAK2 pathway leading to oncosuppression.	[Griveau, A.; Devailly, G.; Eberst, L.; Le Calve, B.; Ferrand, M.; Augert, A.; Dante, R.; Vindrieux, D.; Bernard, D.] Ctr Rech Cancerol Lyon, INSERM, U1052, Lyon, France; [Griveau, A.; Devailly, G.; Eberst, L.; Le Calve, B.; Ferrand, M.; Augert, A.; Dante, R.; Vindrieux, D.; Bernard, D.] CNRS, UMR 5286, Lyon, France; [Griveau, A.; Devailly, G.; Eberst, L.; Le Calve, B.; Ferrand, M.; Augert, A.; Dante, R.; Vindrieux, D.; Bernard, D.] Ctr Leon Berard, Lyon, France; [Griveau, A.; Devailly, G.; Eberst, L.; Le Calve, B.; Ferrand, M.; Augert, A.; Dante, R.; Vindrieux, D.; Bernard, D.] Univ Lyon, Lyon, France; [Navaratnam, N.] Imperial Coll, Fac Med, MRC Clin Sci Ctr, Cellular Stress Grp, Hammersmith Campus, London, England; [Faull, P.] Imperial Coll London, MRC Clin Sci Ctr, Biol Mass Spectrometry & Prote Lab, London, England; [Vanacker, J. M.] Univ Lyon 1, CNRS, UMR5242, Inst Genom Fonctionnelle Lyon,Ecole Normale Super, Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UNICANCER; Centre Leon Berard; Imperial College London; Imperial College London; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Ecole Normale Superieure de Lyon (ENS de LYON)	Bernard, D (corresponding author), Ctr Rech Cancerol Lyon, CNRS, INSERM, U1052, F-69373 Lyon 08, France.	david.bernard@lyon.unicancer.fr	Devailly, Guillaume/S-3998-2019; Bernard, David/D-6265-2018	Devailly, Guillaume/0000-0001-8878-9357; GRIVEAU, Audrey/0000-0002-5928-6328; Bernard, David/0000-0002-1557-2074; Faull, Peter/0000-0001-8491-8086; Vindrieux, David/0000-0002-4713-5768	Association for International Cancer Research [AICR-11-0722]; ANR [ANR-14-CE12-0003]; Groupe Pasteur Mutualite; Ligue contre le cancer, comite du Puy de Dome et de la Drome	Association for International Cancer Research; ANR(French National Research Agency (ANR)); Groupe Pasteur Mutualite; Ligue contre le cancer, comite du Puy de Dome et de la Drome	We thank the laboratory members for helpful discussions. This work was carried out with the support of the Association for International Cancer Research (AICR-11-0722) and the ANR (ANR-14-CE12-0003) for DB, the Groupe Pasteur Mutualite for LE and the Ligue contre le cancer, comite du Puy de Dome et de la Drome for JMV.	Ao A, 2008, P NATL ACAD SCI USA, V105, P7821, DOI 10.1073/pnas.0711677105; Arany Z, 2008, NATURE, V451, P1008, DOI 10.1038/nature06613; Augert A, 2013, FREE RADICAL BIO MED, V65, P969, DOI 10.1016/j.freeradbiomed.2013.08.177; Augert A, 2009, EMBO REP, V10, P271, DOI 10.1038/embor.2008.255; Bernard D, 2014, BBA-REV CANCER, V1846, P40, DOI 10.1016/j.bbcan.2014.03.003; Bianco S, 2012, J STEROID BIOCHEM, V130, P180, DOI 10.1016/j.jsbmb.2011.03.014; Deblois G, 2013, NAT REV CANCER, V13, P27, DOI 10.1038/nrc3396; Deblois G, 2010, CANCER RES, V70, P10277, DOI 10.1158/0008-5472.CAN-10-2840; Devailly G, 2015, NUCLEIC ACIDS RES, V43, P5838, DOI 10.1093/nar/gkv508; Ferbeyre G, 2011, BBA-REV CANCER, V1815, P104, DOI 10.1016/j.bbcan.2010.10.004; Fradet A, 2011, CANCER RES, V71, P5728, DOI 10.1158/0008-5472.CAN-11-1431; Gallet M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054837; Hong EJ, 2013, P NATL ACAD SCI USA, V110, P17975, DOI 10.1073/pnas.1315319110; Li Y, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003230; Manna S, 2015, CLIN CANC RES; Menschikowski M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-576; Miwa S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4837; Sailland J, 2014, P NATL ACAD SCI USA, V111, P15108, DOI 10.1073/pnas.1402094111; Sasaki A, 2003, J BIOL CHEM, V278, P2432, DOI 10.1074/jbc.C200608200; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schindler C, 2007, J BIOL CHEM, V282, P20059, DOI 10.1074/jbc.R700016200; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Sonoda J, 2007, GENE DEV, V21, P1909, DOI 10.1101/gad.1553007; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Villena JA, 2007, P NATL ACAD SCI USA, V104, P1418, DOI 10.1073/pnas.0607696104; Vindrieux D, 2014, ONCOTARGET, V5, P1004, DOI 10.18632/oncotarget.1681; Vindrieux D, 2013, CANCER RES, V73, P6334, DOI 10.1158/0008-5472.CAN-13-0318; Willy PJ, 2004, P NATL ACAD SCI USA, V101, P8912, DOI 10.1073/pnas.0401420101; Zou C, 2014, J PATHOL, V233, P61, DOI 10.1002/path.4329	29	14	15	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2016	35	38					5033	5042		10.1038/onc.2016.43	http://dx.doi.org/10.1038/onc.2016.43			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW9GT	27041564				2022-12-17	WOS:000383965300007
J	Kim, DY; Helfman, DM				Kim, D. Y.; Helfman, D. M.			Loss of MLCK leads to dleisruption of cell-cell adhesion and invasive behavior of breast epithelial cells via increased expression of EGFR and ERK/JNK signaling	ONCOGENE			English	Article							LIGHT-CHAIN KINASE; E-CADHERIN; CANCER-CELLS; SPHEROID FORMATION; DISTINCT ROLES; MIGRATION; PHOSPHORYLATION; PAXILLIN; RECEPTOR; GROWTH	Myosin light chain kinase (MLCK) expression is downregulated in breast cancer, including invasive ductal carcinoma compared with ductal breast carcinoma in situ and metastatic breast tumors. However, little is known about how loss of MLCK expression contributes to tumor progression. MLCK is a component of the actin cytoskeleton and its known role is the phosphorylation of the regulatory light chain of myosin II. To gain insights into the role of MLCK in breast cancer, we perturbed its function using small interfering RNA (siRNA) or pharmacological inhibition in untransformed breast epithelial cells (MCF10A). Loss of MLCK by siRNAs led to increased cell migration and invasion, disruption of cell-cell adhesions and enhanced formation of focal adhesions at the leading edge of migratory cells. In addition, downregulation of MLCK cooperated with HER2 in MCF10A cells to promote cell migration and invasion and low levels of MLCK is associated with a poor prognosis in HER2-positive breast cancer patients. Associated with these altered migratory behaviors were increased expression of epidermal growth factor receptor and activation of extracellular signal-regulated kinase and c-Jun N-terminal kinase signaling pathways in MLCK downregulated MCF10A cells. By contrast, inhibition of the kinase function of MLCK using pharmacological agents inhibited cell migration and invasion, and did not affect cellular adhesions. Our results show that loss of MLCK contributes to the migratory properties of epithelial cells resulting from changes in cell-cell and cell-matrix adhesions, and increased epidermal growth factor receptor signaling. These findings suggest that decreased expression of MLCK may have a critical role during tumor progression by facilitating the metastatic potential of tumor cells.	[Kim, D. Y.; Helfman, D. M.] Korea Adv Inst Sci & Technol, Dept Biol Sci, 291 Daehak Ro, Daejeon 34141, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Helfman, DM (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, 291 Daehak Ro, Daejeon 34141, South Korea.	dhelfman@kaist.ac.kr			National Research Foundation of Korea - Ministry of Education Science and Technology [R1A2A2A01003372]	National Research Foundation of Korea - Ministry of Education Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of KoreaNational Research Foundation of Korea)	DMH is supported by the National Research Foundation of Korea funded by the Ministry of Education Science and Technology (#R1A2A2A01003372).	Bill HM, 2004, MOL CELL BIOL, V24, P8586, DOI 10.1128/MCB.24.19.8586-8599.2004; Birukov KG, 2001, J BIOL CHEM, V276, P8567, DOI 10.1074/jbc.M005270200; Cabodi S, 2004, BIOCHEM SOC T, V32, P438, DOI 10.1042/BST0320438; Chen C, 2014, J BIOL CHEM, V289, P28478, DOI 10.1074/jbc.M114.567446; Chen J, 2012, CANCER RES, V72, P4130, DOI 10.1158/0008-5472.CAN-12-0655; Choi C, 2014, ONCOGENE, V33, P3668, DOI 10.1038/onc.2013.341; Connell LE, 2006, J CELL SCI, V119, P2269, DOI 10.1242/jcs.02926; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Duan L, 2011, J BIOL CHEM, V286, P620, DOI 10.1074/jbc.M110.188086; Dudek SM, 2002, BIOCHEM BIOPH RES CO, V298, P511, DOI 10.1016/S0006-291X(02)02492-0; Dudek SM, 2010, MOL BIOL CELL, V21, P4042, DOI 10.1091/mbc.E09-10-0876; Dulyaninova NG, 2004, J CELL SCI, V117, P1481, DOI 10.1242/jcs.00993; Fazal F, 2005, MOL CELL BIOL, V25, P6259, DOI 10.1128/MCB.25.14.6259-6266.2005; Garcia JGN, 1999, AM J PHYSIOL-LUNG C, V276, pL989, DOI 10.1152/ajplung.1999.276.6.L989; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Glinsky VV, 2003, CANCER RES, V63, P3805; Gu LZ, 2006, EUR J CANCER, V42, P948, DOI 10.1016/j.ejca.2005.12.017; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; Hidalgo-Carcedo C, 2011, NAT CELL BIOL, V13, P49, DOI 10.1038/ncb2133; Huang C, 2004, CELL CYCLE, V3, P4, DOI 10.4161/cc.3.1.601; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Ivascu A, 2007, INT J ONCOL, V31, P1403; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kimura K, 2008, INVEST OPHTH VIS SCI, V49, P125, DOI 10.1167/iovs.07-0725; Laprise P, 2004, J CELL PHYSIOL, V199, P32, DOI 10.1002/jcp.10432; Li QW, 2008, NEOPLASIA, V10, P1444, DOI 10.1593/neo.08968; Lin RZ, 2006, CELL TISSUE RES, V324, P411, DOI 10.1007/s00441-005-0148-2; Mukherjee M, 2012, EMBO J, V31, P1308, DOI 10.1038/emboj.2011.496; Olson MF, 2009, CLIN EXP METASTAS, V26, P273, DOI 10.1007/s10585-008-9174-2; Ren G, 2009, J BIOL CHEM, V284, P18913, DOI 10.1074/jbc.M109.000307; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Simpson KJ, 2008, NAT CELL BIOL, V10, P1027, DOI 10.1038/ncb1762; Sodek KL, 2009, INT J CANCER, V124, P2060, DOI 10.1002/ijc.24188; Streuli CH, 2009, BIOCHEM J, V418, P491, DOI 10.1042/BJ20081948; Totsukawa G, 2004, J CELL BIOL, V164, P427, DOI 10.1083/jcb.200306172; Totsukawa G, 2000, J CELL BIOL, V150, P797, DOI 10.1083/jcb.150.4.797; Usatyuk PV, 2012, J BIOL CHEM, V287, P9360, DOI 10.1074/jbc.M111.294546; Verin AD, 1998, AM J RESP CELL MOL, V19, P767, DOI 10.1165/ajrcmb.19.5.3126; Wadgaonkar R, 2003, J CELL BIOCHEM, V88, P623, DOI 10.1002/jcb.10370; Wang HH, 2009, AM J PHYSIOL-HEART C, V296, pH1683, DOI 10.1152/ajpheart.00965.2008; WATTERSON DM, 1995, FEBS LETT, V373, P217; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wu Q, 2010, ONCOGENE, V29, P4183, DOI 10.1038/onc.2010.165; Yilmaz M, 2010, MOL CANCER RES, V8, P629, DOI 10.1158/1541-7786.MCR-10-0139; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Yu HJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079776; Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786	49	14	14	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	34					4495	4508		10.1038/onc.2015.508	http://dx.doi.org/10.1038/onc.2015.508			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU4AC	26876209				2022-12-17	WOS:000382153100007
J	Min, B; Park, H; Lee, S; Li, Y; Choi, JM; Lee, JY; Kim, J; Choi, YD; Kwon, YG; Lee, HW; Bae, SC; Yun, CO; Chung, KC				Min, B.; Park, H.; Lee, S.; Li, Y.; Choi, J-M; Lee, J. Y.; Kim, J.; Choi, Y. D.; Kwon, Y-G; Lee, H-W; Bae, S-C; Yun, C-O; Chung, K. C.			CHIP-mediated degradation of transglutaminase 2 negatively regulates tumor growth and angiogenesis in renal cancer	ONCOGENE			English	Article							TISSUE TRANSGLUTAMINASE; E3 LIGASE; PROGNOSTIC-SIGNIFICANCE; PROTEIN; EXPRESSION; SUPPRESSOR; ADENOCARCINOMA; CALCIFICATION; SENSITIVITY; METASTASIS	The multifunctional enzyme transglutaminase 2 (TG2) primarily catalyzes cross-linking reactions of proteins via (gamma-glutamyl) lysine bonds. Several recent findings indicate that altered regulation of intracellular TG2 levels affects renal cancer. Elevated TG2 expression is observed in renal cancer. However, the molecular mechanism underlying TG2 degradation is not completely understood. Carboxyl-terminus of Hsp70-interacting protein (CHIP) functions as an ubiquitin E3 ligase. Previous studies reveal that CHIP deficiency mice displayed a reduced life span with accelerated aging in kidney tissues. Here we show that CHIP promotes polyubiquitination of TG2 and its subsequent proteasomal degradation. In addition, TG2 upregulation contributes to enhanced kidney tumorigenesis. Furthermore, CHIP-mediated TG2 downregulation is critical for the suppression of kidney tumor growth and angiogenesis. Notably, our findings are further supported by decreased CHIP expression in human renal cancer tissues and renal cancer cells. The present work reveals that CHIP-mediated TG2 ubiquitination and proteasomal degradation represent a novel regulatory mechanism that controls intracellular TG2 levels. Alterations in this pathway result in TG2 hyperexpression and consequently contribute to renal cancer.	[Min, B.; Chung, K. C.] Yonsei Univ, Dept Syst Biol, Coll Life Sci & Biotechnol, Yonsei Ro 50, Seoul 03722, South Korea; [Park, H.; Lee, S.; Choi, J-M; Kwon, Y-G; Lee, H-W] Yonsei Univ, Dept Biochem, Coll Life Sci & Biotechnol, Seoul, South Korea; [Li, Y.; Yun, C-O] Hanyang Univ, Dept Bioengn, Coll Engn, Seoul, South Korea; [Lee, J. Y.; Choi, Y. D.] Yonsei Univ, Dept Urol, Coll Med, Seoul, South Korea; [Kim, J.] Catholic Univ Korea, Sch Med, Dept Anat, Seoul, South Korea; [Bae, S-C] Chungbuk Natl Univ, Dept Biochem, Coll Med, Cheongju, South Korea	Yonsei University; Yonsei University; Hanyang University; Yonsei University; Yonsei University Health System; Catholic University of Korea; Chungbuk National University	Chung, KC (corresponding author), Yonsei Univ, Dept Syst Biol, Coll Life Sci & Biotechnol, Yonsei Ro 50, Seoul 03722, South Korea.	kchung@yonsei.ac.kr		Yun, Chae-Ok/0000-0002-9466-4531; Choi, Young Deuk/0000-0002-8545-5797	National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning (MSIP), Republic of Korea [2014M3C7A1064545]; Korea Healthcare Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI14C0093]; NRF [2015R1A2A2A01003080, 2007-0056092]	National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning (MSIP), Republic of Korea; Korea Healthcare Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea; NRF	We thank SY Kim and DH Lee for providing plasmids and JJ Hwang for providing renal cancer cell line lysates. We also thank KH Chun, IK Chung and J Song for their technical assistances, critical comments and helpful discussions. This research was supported by grants from the National Research Foundation of Korea (NRF; 2014M3C7A1064545 to KCC) funded by the Ministry of Science, ICT & Future Planning (MSIP), Republic of Korea, and from the Korea Healthcare Technology R&D Project (HI14C0093 to KCC) through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea. This work was supported in part by NRF grants (2015R1A2A2A01003080 and 2007-0056092 to KCC).	Ahmed SF, 2012, J BIOL CHEM, V287, P15996, DOI 10.1074/jbc.M111.321083; Ai LB, 2008, CARCINOGENESIS, V29, P510, DOI 10.1093/carcin/bgm280; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bento CF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015062; Boroughs LK, 2011, J BIOL CHEM, V286, P37094, DOI 10.1074/jbc.M111.242438; Chen NX, 2013, AM J NEPHROL, V37, P191, DOI 10.1159/000347031; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Dyer LM, 2011, J NEURO-ONCOL, V101, P429, DOI 10.1007/s11060-010-0277-7; ELSASSER HP, 1993, EUR J CELL BIOL, V61, P321; Erdem S, 2015, WORLD J UROL, V33, P1553, DOI 10.1007/s00345-014-1462-7; Filiano AJ, 2008, FASEB J, V22, P2662, DOI 10.1096/fj.07-097709; Fok JY, 2006, MOL CANCER THER, V5, P1493, DOI 10.1158/1535-7163.MCT-06-0083; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Hidaka H, 2012, ONCOTARGET, V3, P44; Hwang JY, 2008, CANCER RES, V68, P5849, DOI 10.1158/0008-5472.CAN-07-6130; Jan CI, 2011, J PATHOL, V225, P424, DOI 10.1002/path.2921; Jang KW, 2011, J CELL BIOCHEM, V112, P3612, DOI 10.1002/jcb.23292; Johnson TS, 2007, J AM SOC NEPHROL, V18, P3078, DOI 10.1681/ASN.2006070690; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kim DS, 2011, ONCOGENE, V30, P4780, DOI 10.1038/onc.2011.183; Koleganova N, 2009, NEPHROL DIAL TRANSPL, V24, P2488, DOI 10.1093/ndt/gfp137; Ku BM, 2014, J CANCER RES CLIN, V140, P757, DOI 10.1007/s00432-014-1623-5; Ku BM, 2013, FASEB J, V27, P3487, DOI 10.1096/fj.12-224220; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Mehta K, 2004, CLIN CANCER RES, V10, P8068, DOI 10.1158/1078-0432.CCR-04-1107; Min JN, 2008, MOL CELL BIOL, V28, P4018, DOI 10.1128/MCB.00296-08; Muller P, 2008, ONCOGENE, V27, P3371, DOI 10.1038/sj.onc.1211010; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Park D, 2010, AMINO ACIDS, V39, P619, DOI 10.1007/s00726-010-0500-z; Paul I, 2013, ONCOGENE, V32, P1284, DOI 10.1038/onc.2012.144; Pavlovich CP, 2004, NAT REV CANCER, V4, P381, DOI 10.1038/nrc1364; Sarkar S, 2014, ONCOGENE, V33, P26, DOI 10.1038/onc.2012.561; Su CH, 2011, CELL SIGNAL, V23, P1824, DOI 10.1016/j.cellsig.2011.06.018; Verma A, 2008, CLIN CANCER RES, V14, P1997, DOI 10.1158/1078-0432.CCR-07-1533; Verma A, 2006, CANCER RES, V66, P10525, DOI 10.1158/0008-5472.CAN-06-2387; Wang SY, 2013, GUT, V62, P496, DOI 10.1136/gutjnl-2011-301522; Wang YM, 2014, CARCINOGENESIS, V35, P983, DOI 10.1093/carcin/bgt393; Wiesener MS, 2001, CANCER RES, V61, P5215; Xin H, 2005, J BIOL CHEM, V280, P20842, DOI 10.1074/jbc.M412275200; Xu T, 2011, CANCER SCI, V102, P959, DOI 10.1111/j.1349-7006.2011.01888.x; Yakubov B, 2013, NEOPLASIA, V15, P609, DOI 10.1593/neo.121878; Yan S, 2010, EMBO J, V29, P3773, DOI 10.1038/emboj.2010.245; Yang MJ, 2011, J EXP MED, V208, P2099, DOI 10.1084/jem.20102667; Yuan L, 2007, ONCOGENE, V26, P2563, DOI 10.1038/sj.onc.1210048; Zemskov EA, 2007, J CELL SCI, V120, P3188, DOI 10.1242/jcs.010397	45	14	14	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2016	35	28					3718	3728		10.1038/onc.2015.439	http://dx.doi.org/10.1038/onc.2015.439			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UQ	26568304				2022-12-17	WOS:000379622800010
J	Wang, Z; Kim, J; Teng, Y; Ding, HF; Zhang, J; Hai, T; Cowell, JK; Yan, C				Wang, Z.; Kim, J.; Teng, Y.; Ding, H-F; Zhang, J.; Hai, T.; Cowell, J. K.; Yan, C.			Loss of ATF3 promotes hormone-induced prostate carcinogenesis and the emergence of CK5(+)CK8(+) epithelial cells	ONCOGENE			English	Article							ACTIVATING TRANSCRIPTION FACTOR-3; TO-LUMINAL DIFFERENTIATION; ADAPTIVE-RESPONSE; CANCER; ESTROGEN; BASAL; PTEN; GROWTH; BETA; INFLAMMATION	Steroid sex hormones can induce prostate carcinogenesis, and are thought to contribute to the development of prostate cancer during aging. However, the mechanism for hormone-induced prostate carcinogenesis remains elusive. Here, we report that activating transcription factor 3 (ATF3)-a broad stress sensor-suppressed hormone-induced prostate carcinogenesis in mice. Although implantation of testosterone and estradiol (T+E-2) pellets for 2 months in wild-type mice rarely induced prostatic intraepithelial neoplasia (PIN) in dorsal prostates (one out of eight mice), the loss of ATF3 led to the appearance of not only PIN but also invasive lesions in almost all examined animals. The enhanced carcinogenic effects of hormones on ATF3-deficient prostates did not appear to be caused by a change in estrogen signaling, but were more likely a consequence of elevated androgen signaling that stimulated differentiation of prostatic basal cells into transformation-preferable luminal cells. Indeed, we found that hormone-induced lesions in ATF3-knockout mice often contained cells with both basal and luminal characteristics, such as p63(+) cells (a basal-cell marker) showing luminal-like morphology, or cells double-stained with basal (CK5(+)) and luminal (CK8(+)) markers. Consistent with these findings, low ATF3 expression was found to be a poor prognostic marker for prostate cancer in a cohort of 245 patients. Our results thus support that ATF3 is a tumor suppressor in prostate cancer.	[Wang, Z.; Teng, Y.; Ding, H-F; Cowell, J. K.; Yan, C.] Georgia Regents Univ, GRU Canc Ctr, 1410 Laney Walker Blvd,CN2134, Augusta, GA 30912 USA; [Wang, Z.; Yan, C.] Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; [Kim, J.] Sungkyunkwan Univ, Dept Stat, Seoul, South Korea; [Ding, H-F] Georgia Regents Univ, Med Coll Georgia, Dept Pathol, Augusta, GA USA; [Zhang, J.] Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, Cleveland, OH 44106 USA; [Hai, T.] Ohio State Univ, Dept Biol Chem & Pharmacol, Columbus, OH 43210 USA; [Yan, C.] Georgia Regents Univ, Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA USA	University System of Georgia; Augusta University; Albany Medical College; Sungkyunkwan University (SKKU); University System of Georgia; Augusta University; Case Western Reserve University; University System of Ohio; Ohio State University; University System of Georgia; Augusta University	Yan, C (corresponding author), Georgia Regents Univ, GRU Canc Ctr, 1410 Laney Walker Blvd,CN2134, Augusta, GA 30912 USA.	cyan@gru.edu	Hai, Tsonwin/E-3185-2011; Teng, Yong/AAK-4160-2020	Hai, Tsonwin/0000-0003-4510-0315; Teng, Yong/0000-0002-1856-7289; Ding, Han-Fei/0000-0001-5702-3439; Yan, Chunhong/0000-0002-3974-7991	NIH [R01CA139107, R01CA164006]; Department of Defense award [W81XWH-15-1-0049]; NATIONAL CANCER INSTITUTE [R01CA139107, R01CA164006, P30CA016058] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense award(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH grants R01CA139107 and R01CA164006, and a Department of Defense award W81XWH-15-1-0049 to CY. We thank Dr Ahmed Chadli for providing the PR antibody.	Bennett NC, 2010, INT J BIOCHEM CELL B, V42, P813, DOI 10.1016/j.biocel.2009.11.013; Berger R, 2004, CANCER RES, V64, P8867, DOI 10.1158/0008-5472.CAN-04-2938; Bonkhoff H, 1996, PROSTATE, V28, P98; Bosland Maarten C, 2005, Rev Urol, V7 Suppl 3, pS4; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Choi N, 2012, CANCER CELL, V21, P253, DOI 10.1016/j.ccr.2012.01.005; Culig ZR, 2003, J UROLOGY, V170, P1363, DOI 10.1097/01.ju.0000075099.20662.7f; Ding ZH, 2011, NATURE, V470, P269, DOI 10.1038/nature09677; Gilchrist M, 2006, NATURE, V441, P173, DOI 10.1038/nature04768; Gnanapragasam VJ, 2000, BJU INT, V86, P1001, DOI 10.1046/j.1464-410x.2000.00943.x; Goldstein AS, 2013, GENE DEV, V27, P1539, DOI 10.1101/gad.222380.113; Hai T, 1999, GENE EXPRESSION, V7, P321; Hai T, 2010, GENE EXPRESSION, V15, P1, DOI 10.3727/105221610X12819686555015; Hartman MG, 2004, MOL CELL BIOL, V24, P5721, DOI 10.1128/MCB.24.13.5721-5732.2004; Heemers HW, 2005, ENDOCR REV, V28, P778; Hoetzenecker W, 2012, NAT MED, V18, P128, DOI 10.1038/nm.2557; Huang XW, 2008, J BIOL CHEM, V283, P29795, DOI 10.1074/jbc.M802515200; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Kwon OJ, 2014, P NATL ACAD SCI USA, V111, pE592, DOI 10.1073/pnas.1318157111; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lau KM, 2000, CANCER RES, V60, P3175; Liu YQ, 2013, CANCER LETT, V337, P66, DOI 10.1016/j.canlet.2013.05.022; Lu TL, 2013, AM J PATHOL, V182, P975, DOI 10.1016/j.ajpath.2012.11.025; Mulholland DJ, 2011, CANCER CELL, V19, P792, DOI 10.1016/j.ccr.2011.05.006; NOBLE RL, 1977, CANCER RES, V37, P1929; Okamoto A, 2006, MOL CELL BIOL, V26, P1087, DOI 10.1128/MCB.26.3.1087-1097.2006; Prins GS, 2008, STEROIDS, V73, P233, DOI 10.1016/j.steroids.2007.10.013; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Ricke WA, 2008, FASEB J, V22, P1512, DOI 10.1096/fj.07-9526com; Ricke WA, 2007, DIFFERENTIATION, V75, P871, DOI 10.1111/j.1432-0436.2007.00224.x; Risbridger G, 2001, DEV BIOL, V229, P432, DOI 10.1006/dbio.2000.9994; Risbridger GP, 2001, ENDOCRINOLOGY, V142, P2443, DOI 10.1210/en.142.6.2443; Thompson MR, 2009, J MOL MED, V87, P1053, DOI 10.1007/s00109-009-0520-x; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Wang HB, 2012, MOL CELL BIOL, V32, P3190, DOI 10.1128/MCB.00159-12; Wang JJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4415; Wang L, 2005, PROSTATE, V63, P117, DOI 10.1002/pros.20170; Wang Z, 2015, ONCOGENE, V34, P4975, DOI 10.1038/onc.2014.426; Wang Z, MOL CELL ON IN PRESS; Wang ZA, 2014, CELL REP, V8, P1339, DOI 10.1016/j.celrep.2014.08.002; Wolford CC, 2013, J CLIN INVEST, V123, P2893, DOI 10.1172/JCI64410; Yan CH, 2005, EMBO J, V24, P2425, DOI 10.1038/sj.emboj.7600712; Yan CH, 2006, CELL CYCLE, V5, P926, DOI 10.4161/cc.5.9.2714	43	14	14	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 7	2016	35	27					3555	3564		10.1038/onc.2015.417	http://dx.doi.org/10.1038/onc.2015.417			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UD	26522727	Green Accepted			2022-12-17	WOS:000379621500008
J	Berscheminski, J; Brun, J; Speiseder, T; Wimmer, P; Ip, WH; Terzic, M; Dobner, T; Schreiner, S				Berscheminski, J.; Brun, J.; Speiseder, T.; Wimmer, P.; Ip, W. H.; Terzic, M.; Dobner, T.; Schreiner, S.			Sp100A is a tumor suppressor that activates p53-dependent transcription and counteracts E1A/E1B-55K-mediated transformation	ONCOGENE			English	Article							EARLY REGION 4; CELL-TRANSFORMATION; 55-KILODALTON PROTEIN; SUMO-1 MODIFICATION; NUCLEAR EXPORT; REPRESSES P53; ADENOVIRUS; ONCOPROTEIN; LOCALIZATION; EXPRESSION	Human adenoviruses (HAdV) are used as a model system to investigate tumorigenic processes in mammalian cells where the viral oncoproteins E1A and E1B-55K are absolutely required for oncogenic transformation, because they simultaneously accelerate cell cycle progression and inhibit tumor suppressor proteins such as p53, although the underlying mechanism is still not understood in detail. In our present study, we provide evidence that E1B-55K binding to the PML-NB component Sp100A apparently has an essential role in regulating adenovirus-mediated transformation processes. Specifically, when this E1B-55K/Sp100A complex recruits p53, Sp100A-induced activation of p53 transcriptional activity is effectively abolished. Hence, Sp100A exhibits tumor-suppressive activity, not only by stabilizing p53 transactivation but also by depressing E1A/E1B-55K-mediated transformation. E1B-55K counteracts this suppressive activity, inducing Sp100A SUMOylation and sequestering the modified cellular factor into the insoluble matrix of the nucleus or into cytoplasmic inclusions. These observations provide novel insights into how E1B-55K modulates cellular determinants to maintain growth-promoting activity during oncogenic processes and lytic infection.	[Berscheminski, J.; Brun, J.; Speiseder, T.; Wimmer, P.; Ip, W. H.; Dobner, T.; Schreiner, S.] Leibniz Inst Expt Virol, Heinrich Pette Inst, Dept Viral Transformat, D-20251 Hamburg, Germany; [Terzic, M.; Schreiner, S.] Tech Univ Munich, Helmholtz Zentrum Munchen, Inst Virol, D-80290 Munich, Germany	Heinrich Pette Institute; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich	Dobner, T (corresponding author), Leibniz Inst Expt Virol, Heinrich Pette Inst, Dept Viral Transformat, D-20251 Hamburg, Germany.; Schreiner, S (corresponding author), Tech Univ Munich, Helmholtz Zentrum Munchen, Inst Virol, D-80290 Munich, Germany.	thomas.dobner@hpi.uni-hamburg.de; sabrina.schreiner@tum.de		Brun, Juliane/0000-0002-0964-3681; Schreiner, Sabrina/0000-0002-5744-7159; Ip, Wing Hang/0000-0002-5367-1401	Freie und Hansestadt Hamburg; Bundesministerium fur Gesundheit (BMG); Deutsche Forschungsgemeinschaft (DFG) [DO 343/7-1]; Drager Stiftung; DFG; Wilhelm Sander-Stiftung; Else Kroner-Fresenius-Stiftung; Deutsche Krebshilfe e. V.; B. Braun Stiftung; Fonds der Chemischen Industrie	Freie und Hansestadt Hamburg; Bundesministerium fur Gesundheit (BMG); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Drager Stiftung; DFG(German Research Foundation (DFG)); Wilhelm Sander-Stiftung; Else Kroner-Fresenius-Stiftung; Deutsche Krebshilfe e. V.(Deutsche Krebshilfe); B. Braun Stiftung; Fonds der Chemischen Industrie(Fonds der Chemischen IndustrieEuropean Commission)	We thank Ron Hay, Ellis Jaffray, Roger Everett, Hans Will, Thomas Sternsdorf and Nicole Fischer for providing reagents and scientific discussion. The Heinrich Pette Institute, Leibniz Institute for Experimental Virology is supported by the Freie und Hansestadt Hamburg and the Bundesministerium fur Gesundheit (BMG). JB was supported by grant from the Deutsche Forschungsgemeinschaft (DFG) to TD (DO 343/7-1). MT was supported by the Drager Stiftung. TD is supported by the DFG and the Wilhelm Sander-Stiftung. SS was supported by the Else Kroner-Fresenius-Stiftung and the Deutsche Krebshilfe e. V. Part of this work was supported by the B. Braun Stiftung and the Fonds der Chemischen Industrie.	Adler M, 2011, J GEN VIROL, V92, P1532, DOI 10.1099/vir.0.030981-0; Berscheminski J, 2014, J VIROL, V88, P6076, DOI 10.1128/JVI.00469-14; Berscheminski J, 2013, J VIROL, V87, P965, DOI 10.1128/JVI.02023-12; Endter C, 2005, ONCOGENE, V24, P55, DOI 10.1038/sj.onc.1208170; Endter C, 2004, CURR TOP MICROBIOL, V273, P163; Endter C, 2001, P NATL ACAD SCI USA, V98, P11312, DOI 10.1073/pnas.191361798; Goodrum FD, 1996, J VIROL, V70, P6323, DOI 10.1128/JVI.70.9.6323-6335.1996; Gripon P, 2002, P NATL ACAD SCI USA, V99, P15655, DOI 10.1073/pnas.232137699; Grotzinger T, 1996, EUR J BIOCHEM, V238, P554, DOI 10.1111/j.1432-1033.1996.0554z.x; Gunther T, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004274; GULDNER HH, 1992, J IMMUNOL, V149, P4067; Guldner HH, 1999, J CELL SCI, V112, P733; Hartl B, 2008, ONCOGENE, V27, P3673, DOI 10.1038/sj.onc.1211039; Kim YE, 2011, J VIROL, V85, P11928, DOI 10.1128/JVI.00758-11; LEPPARD KN, 1989, EMBO J, V8, P2329, DOI 10.1002/j.1460-2075.1989.tb08360.x; Lethbridge KJ, 2003, J GEN VIROL, V84, P259, DOI 10.1099/vir.0.18820-0; Li W, 2010, MED SCI MONITOR, V16, pBR174; Ling PD, 2005, EMBO J, V24, P3565, DOI 10.1038/sj.emboj.7600820; Logan J, 1984, CANCER CELL, V2, P527; Martin MED, 1998, J VIROL, V72, P3146, DOI 10.1128/JVI.72.4.3146-3154.1998; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; Mitsudomi T, 1992, Nihon Geka Gakkai Zasshi, V93, P944; Moller A, 2003, ONCOGENE, V22, P8731, DOI 10.1038/sj.onc.1207079; Muller D, 2012, J VIROL, V86, P8296, DOI 10.1128/JVI.00222-12; Muller S, 2008, CELL CYCLE, V7, P754, DOI 10.4161/cc.7.6.5495; Negorev D, 2001, J CELL SCI, V114, P59; Nevels M, 1999, ONCOGENE, V18, P9, DOI 10.1038/sj.onc.1202284; Nevels M, 2006, ADENOVIRUS METHODS P, P187; Newhart A, 2013, MOL BIOL CELL, V24, P1454, DOI 10.1091/mbc.E12-09-0669; ORNELLES DA, 1991, J VIROL, V65, P424, DOI 10.1128/JVI.65.1.424-429.1991; Pennella MA, 2010, J VIROL, V84, P12210, DOI 10.1128/JVI.01442-10; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; Schreiner S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002549; Schreiner S, 2011, J VIROL, V85, P8752, DOI 10.1128/JVI.00440-11; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Seeler JS, 2001, MOL CELL BIOL, V21, P3314, DOI 10.1128/MCB.21.10.3314-3324.2001; Sieber T, 2007, J VIROL, V81, P95, DOI 10.1128/JVI.01608-06; Stepp WH, 2013, MBIO, V4, DOI 10.1128/mBio.00845-13; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Tatham MH, 2009, NAT PROTOC, V4, P1363, DOI 10.1038/nprot.2009.128; Teodoro JG, 1997, J VIROL, V71, P3620, DOI 10.1128/JVI.71.5.3620-3627.1997; Wimmer P, 2013, ONCOGENE, V32, P1626, DOI 10.1038/onc.2012.187; Wimmer P, 2010, ONCOGENE, V29, P5511, DOI 10.1038/onc.2010.284; Wimmer P, 2015, ONCOGENE, P53; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	46	14	14	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2016	35	24					3178	3189		10.1038/onc.2015.378	http://dx.doi.org/10.1038/onc.2015.378			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO9GI	26477309				2022-12-17	WOS:000378092700009
J	Gordon, DJ; Motwani, M; Pellman, D				Gordon, D. J.; Motwani, M.; Pellman, D.			Modeling the initiation of Ewing sarcoma tumorigenesis in differentiating human embryonic stem cells	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; ENRICHMENT ANALYSIS; GENOMIC LANDSCAPE; GENE; EXPRESSION; CANCER; GROWTH; FAMILY; EWS/FLI; PHENOTYPE	Oncogenic transformation in Ewing sarcoma tumors is driven by the fusion oncogene EWS-FLI1. However, despite the well-established role of EWS-FLI1 in tumor initiation, the development of models of Ewing sarcoma in human cells with defined genetic elements has been challenging. Here, we report a novel approach to model the initiation of Ewing sarcoma tumorigenesis that exploits the developmental and pluripotent potential of human embryonic stem cells. The inducible expression of EWS-FLI1 in embryoid bodies, or collections of differentiating stem cells, generates cells with properties of Ewing sarcoma tumors, including characteristics of transformation. These cell lines exhibit anchorage-independent growth, a lack of contact inhibition and a strong Ewing sarcoma gene expression signature. Furthermore, these cells also demonstrate a requirement for the persistent expression of EWS-FLI1 for cell survival and growth, which is a hallmark of Ewing sarcoma tumors.	[Gordon, D. J.; Motwani, M.; Pellman, D.] Dana Farber Canc Inst, Dept Pediat Oncol, 450 Brookline Ave, Boston, MA 02115 USA; [Pellman, D.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; [Pellman, D.] Howard Hughes Med Inst, Boston, MA 02115 USA; [Gordon, D. J.] Univ Iowa, Div Pediat Hematol Oncol, Dept Pediat, 25S Grand Ave, Iowa City, IA 52242 USA; [Motwani, M.] Univ Massachusetts, Sch Med, Grad Sch Biomed Sci, Worcester, MA 01655 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of Iowa; University of Massachusetts System; University of Massachusetts Worcester	Pellman, D (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, 450 Brookline Ave, Boston, MA 02115 USA.; Gordon, DJ (corresponding author), Univ Iowa, Div Pediat Hematol Oncol, Dept Pediat, 25S Grand Ave, Iowa City, IA 52242 USA.	david-j-gordon@uiowa.edu; david_pellman@dfci.harvard.edu	Motwani, Mona/AAV-8162-2020	Motwani, Mona/0000-0003-0912-5478; Gordon, David/0000-0003-1830-4371	NCI K08 award [5K08 CA160346-03]; CureSearch Award; Sarcoma Foundation of America Award; NIH [GM083299]; NATIONAL CANCER INSTITUTE [K08CA160346] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM083299] Funding Source: NIH RePORTER	NCI K08 award; CureSearch Award; Sarcoma Foundation of America Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Hubo Li for helpful discussions and Kelli Goss for assistance with the drug dose-response experiments. DJG is supported by a NCI K08 award (5K08 CA160346-03), a CureSearch Award and a Sarcoma Foundation of America Award. DP is a HHMI investigator and supported by NIH grant GM083299.	Amaral AR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083645; Balamuth NJ, 2010, LANCET ONCOL, V11, P184, DOI 10.1016/S1470-2045(09)70286-4; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Benini S, 2004, INT J CANCER, V108, P358, DOI 10.1002/ijc.11576; Brenner JC, 2012, CANCER RES, V72, P1608, DOI 10.1158/0008-5472.CAN-11-3648; Brohl AS, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004475; Chansky HA, 2004, J ORTHOPAED RES, V22, P910, DOI 10.1016/j.orthres.2003.12.008; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; Crompton BD, 2014, CANCER DISCOV, V4, P1326, DOI 10.1158/2159-8290.CD-13-1037; De Vito C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023592; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Erkizan HV, 2009, NAT MED, V15, P750, DOI 10.1038/nm.1983; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; Ganem NJ, 2014, CELL, V158, P833, DOI 10.1016/j.cell.2014.06.029; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Grohar PJ, 2011, JNCI-J NATL CANCER I, V103, P962, DOI 10.1093/jnci/djr156; Grunewald TGP, 2012, MOL CANCER RES, V10, P52, DOI 10.1158/1541-7786.MCR-11-0524; Hancock JD, 2008, CELL CYCLE, V7, P250, DOI 10.4161/cc.7.2.5229; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hulsen T, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-488; Kauer M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005415; Kinsey M, 2006, MOL CANCER RES, V4, P851, DOI 10.1158/1541-7786.MCR-06-0090; Kobayashi E, 2010, MOL CANCER THER, V9, P535, DOI 10.1158/1535-7163.MCT-09-0774; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Kowalewski Ashley A., 2011, Sarcoma, V2011, P598704, DOI 10.1155/2011/598704; KOWALVERN A, 1992, MODERN PATHOL, V5, P56; Ladanyi M, 2002, CANCER BIOL THER, V1, P330; Lawlor ER, 1998, CANCER RES, V58, P2469; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Leacock SW, 2012, DIS MODEL MECH, V5, P95, DOI 10.1242/dmm.007401; Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535-6108(02)00056-9; Lessnick SL, 2012, ANNU REV PATHOL-MECH, V7, P145, DOI 10.1146/annurev-pathol-011110-130237; Maire G, 2008, CANCER GENET CYTOGEN, V181, P81, DOI 10.1016/j.cancergencyto.2007.11.002; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Miyagawa Y, 2008, MOL CELL BIOL, V28, P2125, DOI 10.1128/MCB.00740-07; Navarro S, 2007, ANTICANCER RES, V27, P2457; Owen LA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001965; Postel-Vinay S, 2012, NAT GENET, V44, P323, DOI 10.1038/ng.1085; Potikyan G, 2008, LAB INVEST, V88, P1291, DOI 10.1038/labinvest.2008.99; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Richter GHS, 2009, P NATL ACAD SCI USA, V106, P5324, DOI 10.1073/pnas.0810759106; Riggi N, 2014, CANCER CELL, V26, P1; Riggi N, 2008, CANCER RES, V68, P2176, DOI 10.1158/0008-5472.CAN-07-1761; Riggi N, 2010, GENE DEV, V24, P916, DOI 10.1101/gad.1899710; Roberts P, 2008, GENE CHROMOSOME CANC, V47, P207, DOI 10.1002/gcc.20523; Rocchi A, 2010, J CLIN INVEST, V120, P668, DOI 10.1172/JCI36667; Sanchez G, 2008, P NATL ACAD SCI USA, V105, P6004, DOI 10.1073/pnas.0710748105; Scotlandi K, 2003, J CLIN ONCOL, V21, P1952, DOI 10.1200/JCO.2003.11.111; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Solomon DA, 2011, SCIENCE, V333, P1039, DOI 10.1126/science.1203619; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tilan JU, 2013, ONCOTARGET, V4, P2487, DOI 10.18632/oncotarget.1604; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Tirode F, 2014, CANCER DISCOV, V4, P1342, DOI 10.1158/2159-8290.CD-14-0622; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; von Levetzow C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019305; Wiles ET, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059369; Williams SA, 2013, LAB INVEST, V93, P970, DOI 10.1038/labinvest.2013.92; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760	59	14	15	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2016	35	24					3092	3102		10.1038/onc.2015.368	http://dx.doi.org/10.1038/onc.2015.368			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO9GI	26455317	Green Submitted, Green Accepted			2022-12-17	WOS:000378092700002
J	de la Cruz-Herrera, CF; Baz-Martinez, M; Lang, V; El Motiam, A; Barbazan, J; Couceiro, R; Abal, M; Vidal, A; Esteban, M; Munoz-Fontela, C; Nieto, A; Rodriguez, MS; Collado, M; Rivas, C				de la Cruz-Herrera, C. F.; Baz-Martinez, M.; Lang, V.; El Motiam, A.; Barbazan, J.; Couceiro, R.; Abal, M.; Vidal, A.; Esteban, M.; Munoz-Fontela, C.; Nieto, A.; Rodriguez, M. S.; Collado, M.; Rivas, C.			Conjugation of SUMO to p85 leads to a novel mechanism of PI3K regulation	ONCOGENE			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; CATALYTIC SUBUNIT; TARGET PROTEINS; PTEN; SUMOYLATION; ACTIVATION; P85-BETA; PROLIFERATION; TUMORIGENESIS	Class IA phosphatidylinositol 3-kinases (PI3Ks) are composed of p110 catalytic and p85 regulatory subunits. How regulatory subunits modulate PI3K activity remains only partially understood. Here we identified SUMO (small ubiquitin-related modifier) as a new player modulating this regulation. We demonstrate that both p85 beta and p85 alpha are conjugated to SUMO1 and SUMO2. We identified two lysine residues located at the inter-SH2 domain on p85 beta, a critical region required for inhibition of p110, as being required for SUMO conjugation. A SUMOylation-defective mutant p85 beta shows higher activation of the PI3K pathway, and increased cell migration and transformation. Moreover, the cancer-related KS459del mutant in p85 alpha was less efficiently SUMOylated compared with the wild-type protein. Finally, our results show that SUMO modulates p85 tyrosine phosphorylation, a modification correlating with PI3K pathway activation. Thus, SUMO reduces the levels of tyrosine-phosphorylated-p85 while loss of SUMOylation results in increased tyrosine phosphorylation of p85. In summary, we identify SUMO as a new important player in the regulation of the PI3K pathway through modulation of p85.	[de la Cruz-Herrera, C. F.; Esteban, M.; Nieto, A.; Rivas, C.] CSIC, Ctr Nacl Biotecnol, Dept Biol Mol & Celular, Darwin 3, Madrid, Spain; [Baz-Martinez, M.; El Motiam, A.; Vidal, A.; Rivas, C.] Univ Santiago de Compostela, Inst Invest Sanitarias IDIS, Ctr Invest Med Mol & Enfermedades Cron CIMUS, Santiago De Compostela, Spain; [Lang, V.; Rodriguez, M. S.] Inbiomed, Ubiquitylat & Canc Mol Biol Lab, San Sebastian, Gipuzkoa, Spain; [Barbazan, J.; Couceiro, R.; Abal, M.; Collado, M.] Complexo Hosp Univ Santiago de Compostela CHUS, Inst Invest Sanitaria Santiago de Compostela IDIS, Santiago De Compostela, Spain; [Munoz-Fontela, C.] Leibniz Inst Expt Virol, Heinrich Pette Inst, Hamburg, Germany; [Nieto, A.] CIBER Enfermedades Resp CIBERES, Mallorca, Illes Balears, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Universidade de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela; Heinrich Pette Institute; CIBER - Centro de Investigacion Biomedica en Red; CIBERES	Rivas, C (corresponding author), Campus Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Mol & Cellular Biol, Darwin 3, Madrid 28049, Spain.	crivas@cnb.csic.es	elmotiam, ahmed/AAB-6287-2019; Baz-Martínez, Maite/L-4626-2017; Rivas, Carmen/L-3162-2017; Vidal, Anxo/B-5010-2015; Barbazán, Jorge/AAM-3263-2020; RODRIGUEZ, Manuel S./D-5439-2018; Collado, Manuel/K-8140-2014; Rivas, Carmen/AAB-6278-2019	elmotiam, ahmed/0000-0003-2855-1368; Baz-Martínez, Maite/0000-0001-9160-7833; Rivas, Carmen/0000-0002-0518-7199; Vidal, Anxo/0000-0002-0866-4202; Barbazán, Jorge/0000-0002-7165-8497; Collado, Manuel/0000-0002-0330-0880; Rivas, Carmen/0000-0002-0518-7199; de la Cruz-Herrera, Carlos/0000-0002-7493-5154; Abal Posada, Miguel/0000-0003-3533-7781; Munoz-Fontela, Cesar/0000-0002-7725-2586; ESTEBAN, MARIANO/0000-0003-0846-2827	La Caixa fellowship; CONACYT; ISCIII [PI14/00554];  [BFU2014-58530]	La Caixa fellowship(La Caixa Foundation); CONACYT(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); ISCIII(Instituto de Salud Carlos III); 	We thank Drs Lewis Cantley and Lynda Chin who deposited p85 plasmids at Addgene. Funding at the laboratory of CR is provided by BFU2014-58530. CFC-H is supported by La Caixa fellowship and CONACYT. Work in the laboratory of MC is funded by ISCIII (PI14/00554). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Bassi C, 2013, SCIENCE, V341, P395, DOI 10.1126/science.1236188; Campagna M, 2011, CELL DEATH DIFFER, V18, P72, DOI 10.1038/cdd.2010.77; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cariaga-Martinez AE, 2014, BIOL OPEN, V3, P924, DOI 10.1242/bio.20148185; Cheung LWT, 2011, CANCER DISCOV, V1, P170, DOI 10.1158/2159-8290.CD-11-0039; Cortes I, 2012, P NATL ACAD SCI USA, V109, P11318, DOI 10.1073/pnas.1118138109; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; de la Cruz-Herrera CF, 2015, ONCOGENE, V34, P1442, DOI 10.1038/onc.2014.48; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Gonzalez-Santamaria J, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.135; Hale BG, 2006, P NATL ACAD SCI USA, V103, P14194, DOI 10.1073/pnas.0606109103; Huang J, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1919; Ito Y, 2014, P NATL ACAD SCI USA, V111, P16826, DOI 10.1073/pnas.1420281111; Li R, 2013, CANCER RES, V73, P5742, DOI 10.1158/0008-5472.CAN-13-0538; Marcos-Villar L, 2009, J VIROL, V83, P8849, DOI 10.1128/JVI.00339-09; Martinez-Lorenzo MJ, 2000, INT J BIOCHEM CELL B, V32, P435, DOI 10.1016/S1357-2725(99)00142-9; Philp AJ, 2001, CANCER RES, V61, P7426; Quayle SN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049466; Risso G, 2013, CELL CYCLE, V12, P3165, DOI 10.4161/cc.26183; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; Shekar SC, 2005, J BIOL CHEM, V280, P27850, DOI 10.1074/jbc.M506005200; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Street A, 2004, J BIOL CHEM, V279, P12232, DOI 10.1074/jbc.M312245200; Sun MH, 2010, P NATL ACAD SCI USA, V107, P15547, DOI 10.1073/pnas.1009652107; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vertegaal ACO, 2006, MOL CELL PROTEOMICS, V5, P2298, DOI 10.1074/mcp.M600212-MCP200; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379	29	14	14	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2873	2880		10.1038/onc.2015.356	http://dx.doi.org/10.1038/onc.2015.356			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	26411363				2022-12-17	WOS:000377473700007
J	Pangon, L; Ng, I; Giry-Laterriere, M; Currey, N; Morgan, A; Benthani, F; Tran, PN; Al-Sohaily, S; Segelov, E; Parker, BL; Cowley, MJ; Wright, DC; St Heaps, L; Carey, L; Rooman, I; Kohonen-Corish, MRJ				Pangon, L.; Ng, I.; Giry-Laterriere, M.; Currey, N.; Morgan, A.; Benthani, F.; Tran, P. N.; Al-Sohaily, S.; Segelov, E.; Parker, B. L.; Cowley, M. J.; Wright, D. C.; St Heaps, L.; Carey, L.; Rooman, I.; Kohonen-Corish, M. R. J.			JRK is a positive regulator of beta-catenin transcriptional activity commonly overexpressed in colon, breast and ovarian cancer	ONCOGENE			English	Article							INHIBITION; JERKY; BCL9	The loss of beta-catenin inhibitory components is a well-established mechanism of carcinogenesis but beta-catenin hyperactivity can also be enhanced through its coactivators. Here we first interrogated a highly validated genomic screen and the largest repository of cancer genomics data and identified JRK as a potential new oncogene and therapeutic target of the beta-catenin pathway. We proceeded to validate the oncogenic role of JRK in colon cancer cells and primary tumors. Consistent with a beta-catenin activator function, depletion of JRK in several cancer cell lines repressed beta-catenin transcriptional activity and reduced cell proliferation. Importantly, JRK expression was aberrantly elevated in 21% of colorectal cancers, 15% of breast and ovarian cancers and was associated with increased expression of beta-catenin target genes and increased cell proliferation. This study shows that JRK is required for beta-catenin hyperactivity regardless of the adenomatous polyposis coli/beta-catenin mutation status and targeting JRK presents new opportunities for therapeutic intervention in cancer.	[Pangon, L.; Ng, I.; Giry-Laterriere, M.; Currey, N.; Morgan, A.; Benthani, F.; Tran, P. N.; Al-Sohaily, S.; Cowley, M. J.; Rooman, I.; Kohonen-Corish, M. R. J.] Garvan Inst Med Res, Kinghorn Canc Ctr, Sydney, NSW 2010, Australia; [Pangon, L.; Benthani, F.; Segelov, E.; Cowley, M. J.; Rooman, I.; Kohonen-Corish, M. R. J.] UNSW Australia, UNSW Med, St Vincents Clin Sch, Sydney, NSW, Australia; [Parker, B. L.] Garvan Inst Med Res, Biol Mass Spectrometry Unit, Sydney, NSW 2010, Australia; [Parker, B. L.] Univ Sydney, Sch Mol Biosci, Charles Perkins Ctr, Sydney, NSW 2006, Australia; [Cowley, M. J.] Garvan Inst Med Res, Kinghorn Ctr Clin Genom, Sydney, NSW 2010, Australia; [Wright, D. C.; St Heaps, L.; Carey, L.] Childrens Hosp Westmead, Cytogenet, Westmead, NSW, Australia	Garvan Institute of Medical Research; University of New South Wales Sydney; Garvan Institute of Medical Research; University of Sydney; Garvan Institute of Medical Research; University of Sydney	Pangon, L (corresponding author), Garvan Inst Med Res, Canc Div, 384 Victoria St, Sydney, NSW 2010, Australia.	l.pangon@garvan.org.au	Segelov, Eva/Q-7611-2019; Kohonen-Corish, Maija/Q-9763-2019; Cowley, Mark/K-8731-2019; Parker, Beth L/E-6013-2019	Segelov, Eva/0000-0002-4410-6144; Kohonen-Corish, Maija/0000-0002-4073-1479; Cowley, Mark/0000-0002-9519-5714; Parker, Beth L/0000-0002-5513-7333; Rooman, Ilse/0000-0001-7264-2246; Dyson, Nicola/0000-0002-4173-1913; Benthani, Fahad/0000-0002-3283-307X	National Health and Medical Research Council of Australia [GNT1020406]; Cure Cancer Australia/Cancer Australia [1049846]; Cancer Institute NSW [13ECF1-46, 10CDF232]	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cure Cancer Australia/Cancer Australia; Cancer Institute NSW	We thank the South Western Sydney Colorectal Tissue Bank for the colorectal cancer patient specimens and Dr Christopher Henderson (Liverpool Hospital, Sydney, Australia) for helping with immunohistochemistry scoring. beta-Catenin constructs were a gift from A/Prof Beric Henderson (Westmead Institute for Cancer Research, Westmead Millennium Institute, Sydney, Australia). JRK-FLAG and TCf7L2 constructs were a gift from Dr Benchabane (Department of Genetics and the Norris Cotton Cancer Center, Dartmouth Medical School, Hanover, NH, USA). The M50 Super 8x TOPFlash and M51 Super 8x FOPFlash reporter constructs were obtained from Addgene and originally provided by Prof Randall Moon (University of Washington, Seattle, Washington). This work was supported by grants from the National Health and Medical Research Council of Australia (GNT1020406), Cure Cancer Australia/Cancer Australia (1049846), Cancer Institute NSW (13ECF1-46) and Cancer Institute NSW (10CDF232). The contents of the published material are solely the responsibility of the administering institution, participating institutions or individual authors and do not reflect the views of NHMRC.	Al-Sohaily S, 2014, HISTOPATHOLOGY, V65, P155, DOI 10.1111/his.12295; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Benchabane H, 2011, EMBO J, V30, P1444, DOI 10.1038/emboj.2011.67; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; de la Roche M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1680; de la Roche M, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-199; Donovan GP, 1997, J NEUROSCI, V17, P4562; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Hatzis P, 2008, MOL CELL BIOL, V28, P2732, DOI 10.1128/MCB.02175-07; Kawamoto SA, 2012, J MED CHEM, V55, P1137, DOI 10.1021/jm201125d; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092-8674(02)00679-7; Major MB, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.2000037; Mani M, 2009, CANCER RES, V69, P7577, DOI 10.1158/0008-5472.CAN-09-0773; Moore T, 2001, EPILEPSY RES, V46, P157, DOI 10.1016/S0920-1211(01)00275-3; Morris JR, 2006, HUM MOL GENET, V15, P599, DOI 10.1093/hmg/ddi476; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Pangon L, 2015, INT J CANCER, V136, P55, DOI 10.1002/ijc.28967; Pangon L, 2012, BBA-MOL CELL RES, V1823, P1058, DOI 10.1016/j.bbamcr.2012.03.011; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2012, EMBO J, V31, P2737, DOI 10.1038/emboj.2012.126; Takada K, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003808; Trosset JY, 2006, PROTEINS, V64, P60, DOI 10.1002/prot.20955; Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960-9822(03)00240-9; Waldron R, 2004, BIOCHEM SOC T, V32, P920, DOI 10.1042/BST0320920	28	14	14	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2834	2841		10.1038/onc.2015.347	http://dx.doi.org/10.1038/onc.2015.347			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	26455321				2022-12-17	WOS:000377473700003
J	Pinato, DJ; Chowdhury, S; Stebbing, J				Pinato, D. J.; Chowdhury, S.; Stebbing, J.			TAMing resistance to multi-targeted kinase inhibitors through Axl and Met inhibition	ONCOGENE			English	Editorial Material							RECEPTOR TYROSINE KINASES; CELL LUNG-CANCER; MYELOID-LEUKEMIA; HETEROGENEITY; ACTIVATION; CARCINOMA; THERAPY; TARGETS; TUMORS	TAM (Tyro3-Axl-Mer) receptor tyrosine kinases and Met are implicated in several hallmarks of cancer progression including sustained angiogenesis, enhanced motility, tissue invasion and acquisition of metastatic potential through the upregulation of epithelial-to-mesenchymal transition. Increasing evidence has confirmed Axl and Met as emerging central drivers of adaptive resistance to targeted therapies across a wide variety of cancers. In this issue of Oncogene, Zhou et al. describe the mechanisms linking Axl and Met activation to acquired resistance to sunitinib in renal cell carcinoma (RCC), providing a pre-clinical rationale for the development of Axl and Met inhibitors including cabozantinib in anti-angiogenic resistant RCC.	[Pinato, D. J.; Stebbing, J.] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Hammersmith Hosp Campus,Du Cane Rd, London W12 0HS, England; [Chowdhury, S.] Guys & St Thomas NHS Fdn Trust, Guys Hosp, Dept Med Oncol, London, England	Imperial College London; Guy's & St Thomas' NHS Foundation Trust	Pinato, DJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Hammersmith Hosp Campus,Du Cane Rd, London W12 0HS, England.	david.pinato@imperial.ac.uk	Pinato, David James/ABB-3719-2020	Stebbing, Justin/0000-0002-1117-6947; Pinato, David James/0000-0002-3529-0103	Medical Research Council [MR/L000172/1] Funding Source: Medline; Department of Health [NIHR-RP-011-053] Funding Source: Medline; MRC [MR/L000172/1] Funding Source: UKRI; Academy of Medical Sciences (AMS) [AMS-SGCL13-Pinato] Funding Source: researchfish; Cancer Research UK [14549] Funding Source: researchfish; National Institute for Health Research [NIHR-RP-011-053, CL-2015-21-010] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Academy of Medical Sciences (AMS)(Academy of Medical Sciences (AMS)); Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR))		Brand TM, 2014, CANCER RES, V74, P5152, DOI 10.1158/0008-5472.CAN-14-0294; Burchert A, 1998, ONCOGENE, V16, P3177, DOI 10.1038/sj.onc.1201865; Choueiri TK, 2014, ANN ONCOL, V25, P1603, DOI 10.1093/annonc/mdu184; Ciccarese C, 2015, CANCER TREAT REV, V41, P614, DOI 10.1016/j.ctrv.2015.05.006; Dufies M, 2011, ONCOTARGET, V2, P874, DOI 10.18632/oncotarget.360; Faivre S, 2007, NAT REV DRUG DISCOV, V6, P734, DOI 10.1038/nrd2380; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Graham DK, 2014, NAT REV CANCER, V14, P769, DOI 10.1038/nrc3847; Grunwald V, 2013, EUR J CANCER, V49, P2504, DOI 10.1016/j.ejca.2013.03.022; Kim MS, 2014, MOL CELL PROTEOMICS, V13, P2803, DOI 10.1074/mcp.M114.038547; Kirane A, 2015, CANC RES; Linger RM, 2010, EXPERT OPIN THER TAR, V14, P1073, DOI 10.1517/14728222.2010.515980; Liu L, 2009, CANCER RES, V69, P6871, DOI 10.1158/0008-5472.CAN-08-4490; Nickerson ML, 2008, CLIN CANCER RES, V14, P4726, DOI 10.1158/1078-0432.CCR-07-4921; Park IK, 2015, LEUKEMIA, V29, P2382, DOI 10.1038/leu.2015.147; Rankin EB, 2014, P NATL ACAD SCI USA, V111, P13373, DOI 10.1073/pnas.1404848111; Santoro A, 2013, LANCET ONCOL, V14, P55, DOI 10.1016/S1470-2045(12)70490-4; Scagliotti GV, 2013, CANCER TREAT REV, V39, P793, DOI 10.1016/j.ctrv.2013.02.001; Seo JS, 2012, GENOME RES, V22, P2109, DOI 10.1101/gr.145144.112; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509; Watermann I, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0362-5; Yoshida T, 2014, CLIN CANCER RES, V20, P4059, DOI 10.1158/1078-0432.CCR-13-1559	24	14	15	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2016	35	21					2684	2686		10.1038/onc.2015.374	http://dx.doi.org/10.1038/onc.2015.374			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MJ	26434595				2022-12-17	WOS:000377472700002
J	Yang, W; Mok, MTS; Li, MSM; Kang, W; Wang, H; Chan, AW; Chou, JL; Chen, J; Ng, EKW; To, KF; Yu, J; Chan, MWY; Chan, FKL; Sung, JJY; Cheng, ASL				Yang, W.; Mok, M. T. S.; Li, M. S. M.; Kang, W.; Wang, H.; Chan, A. W.; Chou, J-L; Chen, J.; Ng, E. K. W.; To, K-F; Yu, J.; Chan, M. W. Y.; Chan, F. K. L.; Sung, J. J. Y.; Cheng, A. S. L.			Epigenetic silencing of GDF1 disrupts SMAD signaling to reinforce gastric cancer development	ONCOGENE			English	Article							DIFFERENTIATION FACTOR-I; INTESTINAL METAPLASIA; SOMATIC MUTATIONS; TUMOR-SUPPRESSOR; GENE; EXPRESSION; RISK; RECEPTOR; CELLS; FOXD3	Accumulating evidence reveals the effectiveness of epigenetic therapy in gastric cancer. However, the molecular mechanisms and targets underlying such therapeutic responses remain elusive. Herein, we report an aberrant yet therapeutically rectifiable epigenetic signaling in gastric carcinogenesis. Administration of DNA-demethylating drug 5-aza-2'-deoxycytidine (5-aza-dC) reduced gastric cancer incidence by similar to 74% (P<0.05) in N-nitroso-N-methylurea-treated mice. Through genome-wide methylation scanning, novel promoter hypermethylation-silenced and drug-targeted genes were identified in the resected murine stomach tumors and tissues. We uncovered that growth/differentiation factor 1 (Gdf1), a member of the transforming growth factor-beta superfamily, was silenced by promoter hypermethylation in control tumor-bearing mice, but became reactivated in 5-aza-dCtreated mice (P<0.05). In parallel, the downregulated SMAD2/3 phosphorylation in gastric cancer was revived by 5-aza-dC in vivo. Such hypermethylation-dependent silencing and 5-aza-dC-mediated reactivation of GDF1-SMAD2/3 activity was conserved in human gastric cancer cells (Po0.05). Subsequent functional characterization further revealed the antiproliferative activity of GDF1, which was exerted through activation of SMAD2/3/4-mediated signaling, transcriptional controls on p15, p21 and c-Myc cell-cycle regulators and phosphorylation of retinoblastoma protein. Clinically, hypermethylation and loss of GDF1 was significantly associated with reduced phosphorylated-SMAD2/3 and poor survival in stomach cancer patients (Po0.05). Taken together, we demonstrated a causal relationship between DNA methylation and a tumor-suppressive pathway in gastric cancer. Epigenetic silencing of GDF1 abrogates the growth-inhibitory SMAD signaling and renders proliferation advantage to gastric epithelial cells during carcinogenesis. This study lends support to epigenetic therapy for gastric cancer chemoprevention and identifies a potential biomarker for prognosis.	[Yang, W.; Yu, J.; Chan, F. K. L.; Sung, J. J. Y.; Cheng, A. S. L.] Chinese Univ Hong Kong, State Key Lab Digest Dis, Shatin, Hong Kong, Peoples R China; [Yang, W.; Yu, J.; Chan, F. K. L.; Sung, J. J. Y.] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; [Mok, M. T. S.; Li, M. S. M.; Cheng, A. S. L.] Chinese Univ Hong Kong, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China; [Mok, M. T. S.; Cheng, A. S. L.] Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China; [Kang, W.; Chan, A. W.; To, K-F] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; [Wang, H.] Chinese Univ Hong Kong, Jockey Club Sch Publ Hlth & Primary Care, Hong Kong, Hong Kong, Peoples R China; [Chou, J-L; Chan, M. W. Y.] Natl Chung Cheng Univ, Dept Life Sci, Chiayi 621, Taiwan; [Chen, J.] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastroenterol, Guangzhou 510275, Guangdong, Peoples R China; [Ng, E. K. W.] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong, Shenzhen; Chinese University of Hong Kong; Chinese University of Hong Kong; National Chung Cheng University; Sun Yat Sen University; Chinese University of Hong Kong	Cheng, ASL (corresponding author), Chinese Univ Hong Kong, State Key Lab Digest Dis, Shatin, Hong Kong, Peoples R China.; Cheng, ASL (corresponding author), Chinese Univ Hong Kong, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China.	alfredcheng@cuhk.edu.hk	KANG, Wei/C-5451-2016; Wang, Maggie Haitian/F-5954-2017; Mok, Myth/M-2958-2013; Chan, Michael/F-9615-2018; Sung, Joseph J. Y./R-3203-2018; Cheng, Alfred SL/C-3327-2014; Yu, Jun/D-8569-2015; Chan, Anthony/U-7768-2019; Chan, Anthony W.H./N-6719-2016; Chan, Francis K. L./F-4851-2010; Chan, Anthony Wing Hung/HGB-4311-2022; Ng, Enders Kwok-wai/E-8276-2016	KANG, Wei/0000-0002-4651-677X; Wang, Maggie Haitian/0000-0003-1223-4595; Mok, Myth/0000-0003-3156-4944; Chan, Michael/0000-0003-1431-322X; Sung, Joseph J. Y./0000-0003-3125-5199; Cheng, Alfred SL/0000-0003-2345-6951; Yu, Jun/0000-0001-5008-2153; Chan, Anthony/0000-0002-1771-163X; Chan, Anthony W.H./0000-0002-1771-163X; Chan, Francis K. L./0000-0001-7388-2436; Chan, Anthony Wing Hung/0000-0002-1771-163X; Chan, Michael/0000-0003-0314-2437; Ng, Enders Kwok-wai/0000-0001-7219-5810	Health and Medical Research Fund [08070172]; National Natural Science Foundation of China [373492, 81302167]; Chinese University of Hong Kong;  [1907301]	Health and Medical Research Fund; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese University of Hong Kong(Chinese University of Hong Kong); 	This study was supported by the Health and Medical Research Fund (08070172), National Natural Science Foundation of China (373492, 81302167), Focused Investment Scheme - Scheme B (1907301) and the Direct Grant from the Chinese University of Hong Kong.	Andersson O, 2006, DEV BIOL, V293, P370, DOI 10.1016/j.ydbio.2006.02.002; Asada K, 2015, GUT, V64, P388, DOI 10.1136/gutjnl-2014-307094; Azad N, 2013, NAT REV CLIN ONCOL, V10, P256, DOI 10.1038/nrclinonc.2013.42; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Blaser MJ, 2004, J CLIN INVEST, V113, P321, DOI [10.1172/JCI200420925, 10.1172/JCI20925]; Burt David W., 1994, Progress in Growth Factor Research, V5, P99; Cheng ASL, 2013, GASTROENTEROLOGY, V144, P122, DOI 10.1053/j.gastro.2012.10.002; Cheng SK, 2003, GENE DEV, V17, P31, DOI 10.1101/gad.1041203; Cheung KF, 2012, CANCER-AM CANCER SOC, V118, P947, DOI 10.1002/cncr.26189; Crew KD, 2006, WORLD J GASTROENTERO, V12, P354, DOI 10.3748/wjg.v12.i3.354; Drabsch Y, 2012, CANCER METAST REV, V31, P553, DOI 10.1007/s10555-012-9375-7; Ehata S, 2011, ONCOGENE, V30, P1693, DOI 10.1038/onc.2010.546; Feng H, 2011, J CLIN INVEST, V121, P3159, DOI 10.1172/JCI45967; Fuerer C, 2014, J BIOL CHEM, V289, P17854, DOI 10.1074/jbc.M114.550301; Geutjes EJ, 2012, ONCOGENE, V31, P3827, DOI 10.1038/onc.2011.552; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Holbrook JD, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-119; Ivanova T, 2013, GUT, V62, P22, DOI 10.1136/gutjnl-2011-301113; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kaasinen E, 2010, HUM MOL GENET, V19, P2747, DOI 10.1093/hmg/ddq164; Kaminskas E, 2005, ONCOLOGIST, V10, P176, DOI 10.1634/theoncologist.10-3-176; Kang W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033919; Karkera JD, 2007, AM J HUM GENET, V81, P987, DOI 10.1086/522890; Katsuno Y, 2012, J PATHOL, V228, P391, DOI 10.1002/path.4020; LEE SJ, 1991, P NATL ACAD SCI USA, V88, P4250, DOI 10.1073/pnas.88.10.4250; LEE SJ, 1990, MOL ENDOCRINOL, V4, P1034, DOI 10.1210/mend-4-7-1034; Leung WK, 2008, CARCINOGENESIS, V29, P1648, DOI 10.1093/carcin/bgn156; Leung WK, 2004, GUT, V53, P1244, DOI 10.1136/gut.2003.034629; Li X, 2012, ONCOGENE, V31, P3419, DOI 10.1038/onc.2011.511; Liu J, 2012, ONCOL REP, V28, P545, DOI 10.3892/or.2012.1838; Liu X, 2010, ONCOGENE, V29, P442, DOI 10.1038/onc.2009.332; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Nagarajan N, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-12-r115; Niwa T, 2013, CANCER PREV RES, V6, P263, DOI 10.1158/1940-6207.CAPR-12-0369; Qiu H, 2009, CANCER SCI, V100, P181, DOI 10.1111/j.1349-7006.2008.01004.x; Rankin CT, 2000, NAT GENET, V24, P262, DOI 10.1038/73472; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Schmid CA, 2013, GASTROENTEROLOGY, V144, P22, DOI 10.1053/j.gastro.2012.11.014; Shin VY, 2011, CARCINOGENESIS, V32, P240, DOI 10.1093/carcin/bgq240; Sun XW, 2013, MOL BIOL REP, V40, P1291, DOI 10.1007/s11033-012-2172-0; Sung JJY, 2000, GASTROENTEROLOGY, V119, P7, DOI 10.1053/gast.2000.8550; Wall NA, 2000, DEV BIOL, V227, P495, DOI 10.1006/dbio.2000.9926; Wang K, 2014, NAT GENET, V46, P573, DOI 10.1038/ng.2983; Wang K, 2011, NAT GENET, V43, P1219, DOI 10.1038/ng.982; Wong BCY, 2004, JAMA-J AM MED ASSOC, V291, P187, DOI 10.1001/jama.291.2.187; Yoda Y, 2015, GASTRIC CANCER, V18, P65, DOI 10.1007/s10120-014-0348-0; Zang ZJ, 2012, NAT GENET, V44, P570, DOI 10.1038/ng.2246; Zhang L, 2013, TRENDS BIOCHEM SCI, V38, P612, DOI 10.1016/j.tibs.2013.10.001; Zhang Y, 2014, BBA-MOL BASIS DIS, V1842, P232, DOI 10.1016/j.bbadis.2013.11.018; Zouridis H, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004504	50	14	14	1	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2016	35	16					2133	2144		10.1038/onc.2015.276	http://dx.doi.org/10.1038/onc.2015.276			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ9AH	26212015				2022-12-17	WOS:000374505600012
J	Chen, X; Gohain, N; Zhan, C; Lu, WY; Pazgier, M; Lu, W				Chen, X.; Gohain, N.; Zhan, C.; Lu, W-Y; Pazgier, M.; Lu, W.			Structural basis of how stress-induced MDMX phosphorylation activates p53	ONCOGENE			English	Article							SITE-SPECIFIC INCORPORATION; EXPRESSED PROTEIN LIGATION; NATIVE CHEMICAL LIGATION; DNA-DAMAGE; TYROSINE PHOSPHORYLATION; EMBRYONIC LETHALITY; GENERAL-METHOD; ATM; DOMAIN; DEGRADATION	The tumor-suppressor protein p53 is tightly controlled in normal cells by its two negative regulators-the E3 ubiquitin ligase MDM2 and its homolog MDMX. Under stressed conditions such as DNA damage, p53 escapes MDM2- and MDMX-mediated functional inhibition and degradation, acting to prevent damaged cells from proliferating through induction of cell cycle arrest, DNA repair, senescence or apoptosis. Ample evidence suggests that stress signals induce phosphorylation of MDM2 and MDMX, leading to p53 activation. However, the structural basis of stress-induced p53 activation remains poorly understood because of the paucity of technical means to produce site-specifically phosphorylated MDM2 and MDMX proteins for biochemical and biophysical studies. Herein, we report total chemical synthesis, via native chemical ligation, and functional characterization of (24-108) MDMX and its Tyr99-phosphorylated analog with respect to their ability to interact with a panel of p53-derived peptide ligands and PMI, a p53-mimicking but more potent peptide antagonist of MDMX, using FP and surface plasmon resonance techniques. Phosphorylation of MDMX at Tyr99 weakens peptide binding by approximately two orders of magnitude. Comparative X-ray crystallographic analyses of MDMX and of pTyr99 MDMX in complex with PMI as well as modeling studies reveal that the phosphate group of pTyr99 imposes extensive steric clashes with the C-terminus of PMI or p53 peptide and induces a significant lateral shift of the peptide ligand, contributing to the dramatic decrease in the binding affinity of MDMX for p53. Because DNA damage activates c-Abl tyrosine kinase that phosphorylates MDMX at Tyr99, our findings afford a rare glimpse at the structural level of how stress-induced MDMX phosphorylation dislodges p53 from the inhibitory complex and activates it in response to DNA damage.	[Chen, X.; Gohain, N.; Zhan, C.; Pazgier, M.; Lu, W.] Univ Maryland, Sch Med, Inst Human Virol, 725 West Lombard St, Baltimore, MD 21201 USA; [Chen, X.; Gohain, N.; Zhan, C.; Pazgier, M.; Lu, W.] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; [Chen, X.; Lu, W-Y] Fudan Univ, Sch Pharm, Key Lab Smart Drug Delivery MOE, Shanghai 200433, Peoples R China; [Chen, X.; Lu, W-Y] Fudan Univ, Sch Pharm, PLA, Shanghai 200433, Peoples R China; [Lu, W.] Xi An Jiao Tong Univ, Ctr Translat Med, Sch Life Sci & Technol, Xian, Shaanxi, Peoples R China	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Fudan University; Fudan University; Xi'an Jiaotong University	Pazgier, M; Lu, W (corresponding author), Univ Maryland, Sch Med, Inst Human Virol, 725 West Lombard St, Baltimore, MD 21201 USA.	mpazgier@ihv.umaryland.edu; wlu@ihv.umaryland.edu	Gohain, Neelakshi/P-7493-2015; Lu, Weiyue/E-7938-2010; Lu, Wuyuan/J-8452-2017; Lu, Wuyuan/B-2268-2010	Lu, Wuyuan/0000-0003-1318-9968; Gohain, Neelakshi/0000-0003-1370-312X	US National Institutes of Health [CA167296]; National Natural Science Foundation of China [81128015]; National Basic Research Program of China (973 Program) [2013CB932500]; China Scholarship Council; DOE Office of Biological and Environmental Research; National Institutes of Health, National Center for Research Resources, Biomedical Technology Program [P41RR001209]; National Institute of General Medical Sciences; NATIONAL CANCER INSTITUTE [R21CA167296] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001209] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China (973 Program)(National Basic Research Program of China); China Scholarship Council(China Scholarship Council); DOE Office of Biological and Environmental Research(United States Department of Energy (DOE)); National Institutes of Health, National Center for Research Resources, Biomedical Technology Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was partially supported by the US National Institutes of Health grant CA167296 and the Overseas Scholars Collaborative Research grant 81128015 from the National Natural Science Foundation of China (WL), and by the National Basic Research Program of China (973 Program, 2013CB932500) (W-YL). XC was the recipient of a scholarship from the China Scholarship Council. Portions of this research were carried out at the University of Maryland X-ray Crystallography Shared Service and the Stanford Synchrotron Radiation Lightsource, a Directorate of SLAC National Accelerator Laboratory and an Office of Science User Facility operated for the U.S. Department of Energy Office of Science by Stanford University. The SSRL Structural Molecular Biology Program is supported by the DOE Office of Biological and Environmental Research and by the National Institutes of Health, National Center for Research Resources, Biomedical Technology Program (P41RR001209), and the National Institute of General Medical Sciences.	Brown CJ, 2009, NAT REV CANCER, V9, P862, DOI 10.1038/nrc2763; Chen LH, 2005, EMBO J, V24, P3411, DOI 10.1038/sj.emboj.7600812; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; Cheng Q, 2009, EMBO J, V28, P3857, DOI 10.1038/emboj.2009.294; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; Dawson PE, 2000, ANNU REV BIOCHEM, V69, P923, DOI 10.1146/annurev.biochem.69.1.923; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Hoe KK, 2014, NAT REV DRUG DISCOV, V13, P217, DOI 10.1038/nrd4236; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kallen J, 2009, J BIOL CHEM, V284, P8803, DOI 10.1074/jbc.M809096200; Kent SBH, 2009, CHEM SOC REV, V38, P338, DOI 10.1039/b700141j; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Li C, 2010, 2010 INTERNATIONAL FORUM ON BIOMEDICAL TEXTILE MATERIALS, PROCEEDINGS, P398; Lu W, 2003, BIOCHEMISTRY-US, V42, P5461, DOI 10.1021/bi0340144; Lu W, 2001, MOL CELL, V8, P759, DOI 10.1016/S1097-2765(01)00369-0; LUNA RMD, 1995, NATURE, V378, P203; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Mayo LD, 1997, CANCER RES, V57, P5013; McCoy MA, 2003, P NATL ACAD SCI USA, V100, P1645, DOI 10.1073/pnas.0334477100; Meek DW, 2009, NAT REV CANCER, V9, P714, DOI 10.1038/nrc2716; Muir TW, 1998, P NATL ACAD SCI USA, V95, P6705, DOI 10.1073/pnas.95.12.6705; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; Okamoto K, 2005, MOL CELL BIOL, V25, P9608, DOI 10.1128/MCB.25.21.9608-9620.2005; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Pazgiera M, 2009, P NATL ACAD SCI USA, V106, P4665, DOI 10.1073/pnas.0900947106; Pereg Y, 2005, P NATL ACAD SCI USA, V102, P5056, DOI 10.1073/pnas.0408595102; Popowicz GM, 2008, CELL CYCLE, V7, P2441, DOI 10.4161/cc.6365; Popowicz GM, 2011, ANGEW CHEM INT EDIT, V50, P2680, DOI 10.1002/anie.201003863; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Schwarzer D, 2005, CURR OPIN CHEM BIOL, V9, P561, DOI 10.1016/j.cbpa.2005.09.018; Showalter SA, 2008, J AM CHEM SOC, V130, P6472, DOI 10.1021/ja800201j; Tarrant MK, 2009, ANNU REV BIOCHEM, V78, P797, DOI 10.1146/annurev.biochem.78.070907.103047; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; Waning DL, 2011, J BIOL CHEM, V286, P216, DOI 10.1074/jbc.M110.183012; Worralll EG, 2010, J MOL BIOL, V398, P414, DOI 10.1016/j.jmb.2010.03.023; Zhan CY, 2012, J MED CHEM, V55, P6237, DOI 10.1021/jm3005465; Zhan CY, 2012, J AM CHEM SOC, V134, P6855, DOI 10.1021/ja301255n; Zuckerman V, 2009, J BIOL CHEM, V284, P4031, DOI 10.1074/jbc.M809211200	44	14	15	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2016	35	15					1919	1925		10.1038/onc.2015.255	http://dx.doi.org/10.1038/onc.2015.255			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ2CC	26148237	Green Accepted			2022-12-17	WOS:000374010300005
J	Tsai, WB; Long, Y; Park, JR; Chang, JT; Liu, H; Rodriguez-Canales, J; Savaraj, N; Feun, LG; Davies, MA; Wistuba, II; Kuo, MT				Tsai, W-B; Long, Y.; Park, J-R; Chang, J. T.; Liu, H.; Rodriguez-Canales, J.; Savaraj, N.; Feun, L. G.; Davies, M. A.; Wistuba, I. I.; Kuo, M. T.			Gas6/Axl is the sensor of arginine-auxotrophic response in targeted chemotherapy with arginine-depleting agents	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASES; CHRONIC MYELOID-LEUKEMIA; QUALITY-OF-LIFE; AXL KINASE; ARGININOSUCCINATE SYNTHETASE; BREAST-CANCER; PROTEIN-S; TRANSLATION INITIATION; DEIMINASE RESISTANCE; DEGRADING ENZYMES	Many human malignancies lack de novo biosynthesis of arginine (Arg) as the key enzyme argininosuccinate synthetase 1 (ASS1) is silenced. These tumors acquire ectopic Arg for survival, and depleting this source by Arg-depleting recombinant enzyme ADI-PEG20 results in cell death. Mechanisms underlying Arg auxotrophy in these tumors and how they respond to Arg-auxotrophic stress are poorly understood. Here, we report that an immediate-early event of Arg-auxotrophic response involves reactive oxygen species-mediated secretion of Gas6, which interacts with its receptor Axl and activates the downstream Ras/PI3K/Akt growth signal leading to accumulation of c-Myc by protein stabilization. Arg-auxotrophic challenge also transcriptionally upregulates c-Myc expression, which provides a feedback mechanism to enhance Axl expression. c-Myc is a positive regulator of ASS1, but elevated ASS1 provides a feedback mechanism to suppress c-Myc and Axl. Our results revealed multiple inter-regulatory pathways in Arg-auxotrophic response, consisting of Axl, c-Myc and ASS1, which regulate Arg homeostasis and ADI-PEG20 sensitivity. These pathways provide potential targets for improving the efficacy of treating Arg-auxotrophic tumors using Arg-deprivation strategies.	[Tsai, W-B; Long, Y.; Liu, H.; Rodriguez-Canales, J.; Wistuba, I. I.; Kuo, M. T.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, 2130 West Holcombe Blvd,Life Sci Plaza LSP9,4206, Houston, TX 77030 USA; [Park, J-R] Kangwon Natl Univ, Dept Thorac & Cardiovasc Surg, Gangwon, South Korea; [Chang, J. T.] Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; [Savaraj, N.] Univ Miami, Sylvester Comprehens Canc Ctr, VA Med Ctr, Miami, FL USA; [Feun, L. G.] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA; [Davies, M. A.] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Kangwon National University; University of Texas System; University of Texas Health Science Center Houston; University of Miami; University of Miami; University of Texas System; UTMD Anderson Cancer Center	Kuo, MT (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, 2130 West Holcombe Blvd,Life Sci Plaza LSP9,4206, Houston, TX 77030 USA.	tkuo@mdanderson.org	Liu, Hui/AAJ-4339-2020	Liu, Hui/0000-0002-7669-9386	NIH/NCI Grant [R01 CA149260, P30CA16672]; NATIONAL CANCER INSTITUTE [R01CA152197, P30CA016672, R01CA149260] Funding Source: NIH RePORTER; Veterans Affairs [I01BX003328] Funding Source: NIH RePORTER	NIH/NCI Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	We thank Drs Bor-Wen Wu and John S Bomalaski (Polaris Pharmacologies) for ADI-PEG20 and anti-ASS1 antibody, Drs RM Melillo, S Jakob and WB Ou for recombinant DNAs. This research was supported in part by the NIH/NCI Grants R01 CA149260 (to MTK) and P30CA16672 (MD Anderson Core).	AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; BEAUDET AL, 1986, ADV HUM GENET, V15, P291; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; Cirone P, 2014, CANCER CHEMOTH PHARM, V73, P525, DOI 10.1007/s00280-014-2376-1; Conacci-Sorrell Maralice, 2014, Cold Spring Harb Perspect Med, V4, pa014357, DOI 10.1101/cshperspect.a014357; Ekman C, 2010, J THROMB HAEMOST, V8, P838, DOI 10.1111/j.1538-7836.2010.03752.x; Erez A, 2013, GENET MED, V15, P251, DOI 10.1038/gim.2012.166; Erez A, 2011, NAT MED, V17, P1619, DOI 10.1038/nm.2544; Feneyrolles C, 2014, MOL CANCER THER, V13, P2141, DOI 10.1158/1535-7163.MCT-13-1083; Feun LG, 2012, BRIT J CANCER, V106, P1481, DOI 10.1038/bjc.2012.106; Feun Lynn, 2006, Expert Opin Investig Drugs, V15, P815, DOI 10.1517/13543784.15.7.815; Giles KM, 2013, MOL CANCER THER, V12, P2541, DOI 10.1158/1535-7163.MCT-13-0170; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Goodwin BL, 2008, BIOCHEM BIOPH RES CO, V370, P254, DOI 10.1016/j.bbrc.2008.03.089; Graham DK, 2014, NAT REV CANCER, V14, P769, DOI 10.1038/nrc3847; GRIFFIN JH, 1992, BLOOD, V79, P3203; Haines RJ, 2012, J BIOL CHEM, V287, P26168, DOI 10.1074/jbc.M112.378794; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Holbrook AM, 2005, ARCH INTERN MED, V165, P1095, DOI 10.1001/archinte.165.10.1095; Holland SJ, 2010, CANCER RES, V70, P1544, DOI 10.1158/0008-5472.CAN-09-2997; Huang Z, 2014, MOL CELL ENDOCRINOL, V388, P20, DOI 10.1016/j.mce.2014.02.005; Jackson RJ, 2010, NAT REV MOL CELL BIO, V11, P113, DOI 10.1038/nrm2838; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Khoury HJ, 2012, BLOOD, V119, P3403, DOI 10.1182/blood-2011-11-390120; Kilberg MS, 2012, ADV NUTR, V3, P295, DOI 10.3945/an.112.001891; Kimball SR, 2010, J BIOL CHEM, V285, P29027, DOI 10.1074/jbc.R110.137208; Kimball SR, 1998, J BIOL CHEM, V273, P30945, DOI 10.1074/jbc.273.47.30945; Kodigepalli KM, 2015, FEBS LETT, V589, P3, DOI 10.1016/j.febslet.2014.11.036; Konishi A, 2004, J BIOL CHEM, V279, P28766, DOI 10.1074/jbc.M401977200; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Kuo MT, 2010, ONCOTARGET, V1, P246, DOI 10.18632/oncotarget.135; Laurance S, 2012, ADV NUTR, V3, P196, DOI 10.3945/an.111.001826; Lemke G, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009076; Long Y, 2013, MOL CANCER THER, V12, P2581, DOI 10.1158/1535-7163.MCT-13-0302; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Nickel W, 2010, CURR OPIN BIOTECH, V21, P621, DOI 10.1016/j.copbio.2010.06.004; Paccez JD, 2014, INT J CANCER, V134, P1024, DOI 10.1002/ijc.28246; Phillips MM, 2013, CANCER RES TREAT, V45, P251, DOI 10.4143/crt.2013.45.4.251; Qiu FM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004761; Rahl PB, 2010, CELL, V141, P432, DOI 10.1016/j.cell.2010.03.030; Rochlitz C, 1999, LEUKEMIA, V13, P1352, DOI 10.1038/sj.leu.2401484; Saenz JB, 2009, NAT CHEM BIOL, V5, P157, DOI 10.1038/nchembio.144; Sasaki T, 2006, EMBO J, V25, P80, DOI 10.1038/sj.emboj.7600912; Sasaki T, 2002, J BIOL CHEM, V277, P44164, DOI 10.1074/jbc.M207340200; Segawa K, 2014, CELL CYCLE, V13, P2990, DOI 10.4161/15384101.2014.962865; Shan JX, 2012, J BIOL CHEM, V287, P36393, DOI 10.1074/jbc.M112.399600; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; Suh CH, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3088; Suzuki J, 2014, METHOD ENZYMOL, V544, P381, DOI 10.1016/B978-0-12-417158-9.00015-7; Syed N, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.197; Trask PC, 2013, LEUKEMIA RES, V37, P9, DOI 10.1016/j.leukres.2012.09.013; Trask PC, 2012, LEUKEMIA RES, V36, P438, DOI 10.1016/j.leukres.2011.10.011; Tsai WB, 2012, CANCER RES, V72, P2622, DOI 10.1158/0008-5472.CAN-11-3605; Tsai WB, 2009, MOL CANCER THER, V8, P3223, DOI 10.1158/1535-7163.MCT-09-0794; Verma A, 2011, MOL CANCER THER, V10, P1763, DOI 10.1158/1535-7163.MCT-11-0116; Walz S, 2014, NATURE, V511, P483, DOI 10.1038/nature13473; Wiese KE, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014290; Wu XL, 2014, ONCOTARGET, V5, P9546, DOI 10.18632/oncotarget.2542; Ye X, 2010, ONCOGENE, V29, P5254, DOI 10.1038/onc.2010.268; Zhang YX, 2008, CANCER RES, V68, P1905, DOI 10.1158/0008-5472.CAN-07-2661; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330	63	14	15	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2016	35	13					1632	1642		10.1038/onc.2015.237	http://dx.doi.org/10.1038/onc.2015.237			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RP	26096933	Green Accepted			2022-12-17	WOS:000373064200003
J	Li, H; Zhao, X; Yan, X; Jessen, WJ; Kim, MO; Dombi, E; Liu, PP; Huang, G; Wu, J				Li, H.; Zhao, X.; Yan, X.; Jessen, W. J.; Kim, M-O; Dombi, E.; Liu, P. P.; Huang, G.; Wu, J.			Runx1 contributes to neurofibromatosis type 1 neurofibroma formation	ONCOGENE			English	Article							SCHWANN-CELLS; NF1; DIFFERENTIATION; PROLIFERATION; MICROENVIRONMENT; EXPRESSION; MATURATION; PROGENITOR; INHIBITOR; ORIGIN	Neurofibromatosis type 1 (NF1) patients are predisposed to neurofibromas but the driver(s) that contribute to neurofibroma formation are not fully understood. By cross comparison of microarray gene lists on human neurofibroma-initiating cells and developed neurofibroma Schwann cells (SCs) we identified RUNX1 overexpression in human neurofibroma initiation cells, suggesting RUNX1 might relate to neurofibroma formation. Immunostaining confirmed RUNX1 protein overexpression in human plexiform neurofibromas. Runx1 overexpression was confirmed in mouse Schwann cell progenitors (SCPs) and mouse neurofibromas at the messenger RNA and protein levels. Genetic inhibition of Runx1 expression by small hairpin RNA or pharmacological inhibition of Runx1 function by a Runx1/Cbf beta interaction inhibitor, Ro5-3335, decreased mouse neurofibroma sphere number in vitro. Targeted genetic deletion of Runx1 in SCs and SCPs delayed mouse neurofibroma formation in vivo. Mechanistically, loss of Nf1 increased embryonic day 12.5 Runx1(+)/Blbp(+) progenitors that enable tumor formation. These results suggest that Runx1 has an important role in Nf1 neurofibroma initiation, and inhibition of RUNX1 function might provide a novel potential therapeutic treatment strategy for neurofibroma patients.	[Li, H.; Zhao, X.; Yan, X.; Jessen, W. J.; Huang, G.; Wu, J.] Univ Cincinnati, Cincinnati Childrens Hosp, Cincinnati Childrens Hosp Res Fdn, Div Expt Hematol & Canc Biol,Canc & Blood Dis Ins, Cincinnati, OH 45229 USA; [Kim, M-O] Univ Cincinnati, Cincinnati Childrens Hosp, Cincinnati Childrens Hosp Res Fdn, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA; [Dombi, E.] NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA; [Liu, P. P.] NHGRI, NIH, Bethesda, MD 20892 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Wu, J (corresponding author), Univ Cincinnati, Cincinnati Childrens Hosp, Cincinnati Childrens Hosp Res Fdn, Div Expt Hematol & Canc Biol,Canc & Blood Dis Ins, Cincinnati, OH 45229 USA.	Jianqiang.wu@cchmc.org		Jessen, Walter/0000-0003-3840-4337; Kim, Mi-Ok/0000-0002-7712-3653	Cincinnati Children's Hospital Trustee Grant;  [NS28840]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG000030, ZIAHG000102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028840] Funding Source: NIH RePORTER	Cincinnati Children's Hospital Trustee Grant; ; NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dr Nancy Ratner for providing the microarray data (supported by NS28840 to NR) and critical review and helpful discussions of the manuscript. This work was supported by a Cincinnati Children's Hospital Trustee Grant to JW.	Aldskogius H, 2009, STEM CELLS, V27, P1592, DOI 10.1002/stem.77; BLATT J, 1986, CANCER, V57, P1225, DOI 10.1002/1097-0142(19860315)57:6<1225::AID-CNCR2820570627>3.0.CO;2-P; Bushweller JH, 2000, SEMIN CELL DEV BIOL, V11, P377, DOI 10.1006/scdb.2000.0182; Chimge NO, 2013, ONCOGENE, V32, P2121, DOI 10.1038/onc.2012.328; Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; Cunningham L, 2012, P NATL ACAD SCI USA, V109, P14592, DOI 10.1073/pnas.1200037109; Friedman JM, 1999, AM J MED GENET, V89, P1; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Inoue KI, 2008, NEURAL DEV, V3, DOI 10.1186/1749-8104-3-20; Jaegle M, 2003, GENE DEV, V17, P1380, DOI 10.1101/gad.258203; Jouhilahti EM, 2011, AM J PATHOL, V178, P500, DOI 10.1016/j.ajpath.2010.10.041; Kim HA, 1997, MOL CELL BIOL, V17, P862, DOI 10.1128/MCB.17.2.862; Le LQ, 2007, ONCOGENE, V26, P4609, DOI 10.1038/sj.onc.1210261; Le LQ, 2009, CELL STEM CELL, V4, P453, DOI 10.1016/j.stem.2009.03.017; Logan TT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059250; Mayes DA, 2011, CANCER RES, V71, P4675, DOI 10.1158/0008-5472.CAN-10-4558; MCCORMICK F, 1995, CURR OPIN GENET DEV, V5, P51, DOI 10.1016/S0959-437X(95)90053-5; Miller SJ, 2009, EMBO MOL MED, V1, P236, DOI 10.1002/emmm.200900027; Motoda L, 2007, STEM CELLS, V25, P2976, DOI 10.1634/stemcells.2007-0061; Murthy M, 2014, GENE, V540, P191, DOI 10.1016/j.gene.2014.02.038; Nagamachi A, 2010, DEV BIOL, V345, P226, DOI 10.1016/j.ydbio.2010.07.015; Planaguma J, 2004, CANCER RES, V64, P8846, DOI 10.1158/0008-5472.CAN-04-2066; Scheitz CJF, 2013, J CELL BIOCHEM, V114, P985, DOI 10.1002/jcb.24453; Scheitz CJF, 2012, EMBO J, V31, P4124, DOI 10.1038/emboj.2012.270; SIMEONE A, 1995, DEV DYNAM, V203, P61, DOI 10.1002/aja.1002030107; Theriault FM, 2005, J NEUROSCI, V25, P2050, DOI 10.1523/JNEUROSCI.5108-04.2005; Williams JP, 2008, CELL STEM CELL, V3, P658, DOI 10.1016/j.stem.2008.10.003; Wu JQ, 2008, CANCER CELL, V13, P105, DOI 10.1016/j.ccr.2007.12.027; Zheng H, 2008, CANCER CELL, V13, P117, DOI 10.1016/j.ccr.2008.01.002; Zhu Y, 2002, SCIENCE, V296, P920, DOI 10.1126/science.1068452	30	14	14	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2016	35	11					1468	1474		10.1038/onc.2015.207	http://dx.doi.org/10.1038/onc.2015.207			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG6LQ	26073082	Green Accepted			2022-12-17	WOS:000372196400013
J	Marques, E; Englund, JI; Tervonen, TA; Virkunen, E; Laakso, M; Myllynen, M; Makela, A; Ahvenainen, M; Lepikhova, T; Monni, O; Hautaniemi, S; Klefstrom, J				Marques, E.; Englund, J. I.; Tervonen, T. A.; Virkunen, E.; Laakso, M.; Myllynen, M.; Makela, A.; Ahvenainen, M.; Lepikhova, T.; Monni, O.; Hautaniemi, S.; Klefstrom, J.			Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers	ONCOGENE			English	Article							TIGHT JUNCTION FORMATION; MYC-INDUCED APOPTOSIS; C-MYC; POLARITY; LOCALIZATION; DROSOPHILA; GENES; AKT; TUMORIGENESIS; MORPHOGENESIS	Differentiated epithelial structure communicates with individual constituent epithelial cells to suppress their proliferation activity. However, the pathways linking epithelial structure to cessation of the cell proliferation machinery or to unscheduled proliferation in the context of tumorigenesis are not well defined. Here we demonstrate the strong impact of compromised epithelial integrity on normal and oncogenic Myc-driven proliferation in three-dimensional mammary epithelial organoid culture. Systematic silencing of 34 human homologs of Drosophila genes, with previously established functions in control of epithelial integrity, demonstrates a role for human genes of apico-basal polarity, Wnt and Hippo pathways and actin dynamics in regulation of the size, integrity and cell proliferation in organoids. Perturbation of these pathways leads to diverse functional interactions with Myc: manifested as a RhoA-dependent synthetic lethality and Par6-dependent effects on the cell cycle. Furthermore, we show a role for Par6G as a negative regulator of the phosphatidylinositol 3'-kinase/phosphoinositide-dependent protein kinase 1/Akt pathway and epithelial cell proliferation and evidence for frequent inactivation of Par6G gene in epithelial cancers. The findings demonstrate that determinants of epithelial structure regulate the cell proliferation activity via conserved and cancer-relevant regulatory circuitries, which are important for epithelial cell cycle restriction and may provide new targets for therapeutic intervention.	[Marques, E.; Englund, J. I.; Tervonen, T. A.; Virkunen, E.; Myllynen, M.; Makela, A.; Ahvenainen, M.; Klefstrom, J.] Univ Helsinki, Translat Canc Biol, Res Programs Unit, Canc Cell Circuitry Lab, FIN-00014 Helsinki, Finland; [Marques, E.; Englund, J. I.; Tervonen, T. A.; Virkunen, E.; Myllynen, M.; Makela, A.; Ahvenainen, M.; Klefstrom, J.] Univ Helsinki, Inst Biomed, FIN-00014 Helsinki, Finland; [Laakso, M.; Hautaniemi, S.] Univ Helsinki, Genome Scale Biol Program, Syst Biol Lab, FIN-00014 Helsinki, Finland; [Laakso, M.; Lepikhova, T.; Monni, O.; Hautaniemi, S.] Univ Helsinki, Inst Biomed, Biomedicum Helsinki, FIN-00014 Helsinki, Finland; [Lepikhova, T.; Monni, O.] Univ Helsinki, Genome Scale Biol Program, FIN-00014 Helsinki, Finland; [Lepikhova, T.] Univ Helsinki, Mol Oncol Lab, FIN-00014 Helsinki, Finland; [Lepikhova, T.] Univ Helsinki, Mol Canc Biol Program, Inst Clin Med, Biomedicum Helsinki, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki	Klefstrom, J (corresponding author), Univ Helsinki, Translat Canc Biol Res Program, Canc Cell Circuitry Lab, Haartmaninkatu 8,Room B507,POB 63, FIN-00014 Helsinki, Finland.	Juha.Klefstrom@helsinki.fi	Englund, Johanna/GYJ-7086-2022; Englund, Johanna/ABG-6420-2021; Hautaniemi, Sampsa/A-3122-2009; Hautaniemi, Sampsa/CAG-0362-2022	Englund, Johanna/0000-0001-9637-6843; Hautaniemi, Sampsa/0000-0002-7749-2694; Hautaniemi, Sampsa/0000-0002-7749-2694	Academy of Finland; Center of Excellence in Cancer Genetics Research; TEKES; Sigrid Juselius Foundation; Finnish Cancer Organizations; Helsinki Graduate Program in Biotechnology and Molecular Biology; Innovative Medicines Initiative Joint Undertaking [115188]	Academy of Finland(Academy of Finland); Center of Excellence in Cancer Genetics Research; TEKES(Finnish Funding Agency for Technology & Innovation (TEKES)); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Finnish Cancer Organizations; Helsinki Graduate Program in Biotechnology and Molecular Biology; Innovative Medicines Initiative Joint Undertaking	We thank all the members of Klefstrom laboratory for discussions and critical comments. We thank Tiina Raatikainen and Tarja Valimaki for technical assistance and Biomedicum Imaging Unit and Biomedicum Functional Genomics Unit for core services and technical support. This study was funded by the Academy of Finland (to JK and SH), Center of Excellence in Cancer Genetics Research (to SH and ML), TEKES, Sigrid Juselius Foundation, Finnish Cancer Organizations (to JK), Helsinki Graduate Program in Biotechnology and Molecular Biology (to EM) and Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115188 (to JK).	Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Assemat E, 2008, BBA-BIOMEMBRANES, V1778, P614, DOI 10.1016/j.bbamem.2007.08.029; Avruch J, 2012, SEMIN CELL DEV BIOL, V23, P770, DOI 10.1016/j.semcdb.2012.07.002; Banks L, 2012, NAT REV CANCER, V12, P876, DOI 10.1038/nrc3400; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Bouchard C, 2004, EMBO J, V23, P2830, DOI 10.1038/sj.emboj.7600279; Brody T, 1999, TRENDS GENET, V15, P333, DOI 10.1016/S0168-9525(99)01775-8; Brumby AM, 2005, NAT REV CANCER, V5, P626, DOI 10.1038/nrc1671; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Bryant DM, 2008, NAT REV MOL CELL BIO, V9, P887, DOI 10.1038/nrm2523; Cameron ER, 2004, ONCOGENE, V23, P4308, DOI 10.1038/sj.onc.1207130; Chan JC, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001754; Chatterjee S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034343; Chen A, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-552; Cheng TL, 2004, EXP CELL RES, V295, P497, DOI 10.1016/j.yexcr.2004.02.002; Clegg NJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017449; Cunliffe HE, 2012, AM J CANCER RES, V2, P478; Curto M, 2008, BRIT J CANCER, V98, P256, DOI 10.1038/sj.bjc.6604002; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Fogg VC, 2005, J CELL SCI, V118, P2859, DOI 10.1242/jcs.02412; Gonzalez-Mariscal L, 2012, ANN NY ACAD SCI, V1257, P133, DOI 10.1111/j.1749-6632.2012.06537.x; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hariharan IK, 2006, ANNU REV GENET, V40, P335, DOI 10.1146/annurev.genet.39.073003.100738; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hemmings BA, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011189; Huang L, 2010, CURR OPIN GENET DEV, V20, P41, DOI 10.1016/j.gde.2009.12.001; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Lee MH, 2008, J CELL SCI, V121, P1141, DOI 10.1242/jcs.016634; Leung CT, 2012, NATURE, V482, P410, DOI 10.1038/nature10826; Link W, 2005, J CELL BIOCHEM, V95, P979, DOI 10.1002/jcb.20479; Ma Z, 2007, J CELL BIOL, V179, P23, DOI 10.1083/jcb.200706097; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169; McCaffrey LM, 2012, CANCER CELL, V22, P601, DOI 10.1016/j.ccr.2012.10.003; McCrea PD, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a002923; Niggli V, 2008, INT J BIOCHEM CELL B, V40, P344, DOI 10.1016/j.biocel.2007.02.012; Nolan ME, 2008, CANCER RES, V68, P8201, DOI 10.1158/0008-5472.CAN-07-6567; Oka T, 2010, BIOCHEM J, V432, P461, DOI 10.1042/BJ20100870; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Partanen JI, 2007, P NATL ACAD SCI USA, V104, P14694, DOI 10.1073/pnas.0704677104; Partanen JI, 2012, P NATL ACAD SCI USA, V109, pE388, DOI 10.1073/pnas.1120421109; Partanen JI, 2009, CELL CYCLE, V8, P716, DOI 10.4161/cc.8.5.7786; Royer C, 2011, CELL DEATH DIFFER, V18, P1470, DOI 10.1038/cdd.2011.60; Sourisseau T, 2006, MOL CELL BIOL, V26, P2387, DOI 10.1128/MCB.26.6.2387-2398.2006; Tervonen TA, 2011, ADV CANCER RES, V111, P97, DOI 10.1016/B978-0-12-385524-4.00003-9; Vleugel M, 2012, DEV CELL, V23, P239, DOI 10.1016/j.devcel.2012.06.013; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; Weber KL, 2007, J CELL SCI, V120, P3625, DOI 10.1242/jcs.011445; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Weyrich P, 2007, MOL CELL ENDOCRINOL, V268, P30, DOI 10.1016/j.mce.2007.01.011; Whyte J, 2010, J CELL SCI, V123, P3316, DOI 10.1242/jcs.065243; Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045	54	14	14	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2016	35	11					1386	1398		10.1038/onc.2015.196	http://dx.doi.org/10.1038/onc.2015.196			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG6LQ	26073086	Green Published, hybrid			2022-12-17	WOS:000372196400005
J	Ho, JCS; Nadeem, A; Rydstrom, A; Puthia, M; Svanborg, C				Ho, J. C. S.; Nadeem, A.; Rydstrom, A.; Puthia, M.; Svanborg, C.			Targeting of nucleotide-binding proteins by HAMLET-a conserved tumor cell death mechanism	ONCOGENE			English	Article							HUMAN ALPHA-LACTALBUMIN; TYROSINE KINASES; INHIBITION; CANCER; IDENTIFICATION; FEATURES; LETHAL	HAMLET (Human Alpha-lactalbumin Made LEthal to Tumor cells) kills tumor cells broadly suggesting that conserved survival pathways are perturbed. We now identify nucleotide-binding proteins as HAMLET binding partners, accounting for about 35% of all HAMLET targets in a protein microarray comprising 8000 human proteins. Target kinases were present in all branches of the Kinome tree, including 26 tyrosine kinases, 10 tyrosine kinase-like kinases, 13 homologs of yeast sterile kinases, 4 casein kinase 1 kinases, 15 containing PKA, PKG, PKC family kinases, 15 calcium/calmodulin-dependent protein kinase kinases and 13 kinases from CDK, MAPK, GSK3, CLK families. HAMLET acted as a broad kinase inhibitor in vitro, as defined in a screen of 347 wild-type, 93 mutant, 19 atypical and 17 lipid kinases. Inhibition of phosphorylation was also detected in extracts from HAMLET-treated lung carcinoma cells. In addition, HAMLET recognized 24 Ras family proteins and bound to Ras, RasL11B and Rap1B on the cytoplasmic face of the plasma membrane. Direct cellular interactions between HAMLET and activated Ras family members including Braf were confirmed by co-immunoprecipitation. As a consequence, oncogenic Ras and Braf activity was inhibited and HAMLET and Braf inhibitors synergistically increased tumor cell death in response to HAMLET. Unlike most small molecule kinase inhibitors, HAMLET showed selectivity for tumor cells in vitro and in vivo. The results identify nucleotide-binding proteins as HAMLET targets and suggest that dysregulation of the ATPase/kinase/GTPase machinery contributes to cell death, following the initial, selective recognition of HAMLET by tumor cells. The findings thus provide a molecular basis for the conserved tumoricidal effect of HAMLET, through dysregulation of kinases and oncogenic GTPases, to which tumor cells are addicted.	[Ho, J. C. S.; Nadeem, A.; Rydstrom, A.; Puthia, M.; Svanborg, C.] Lund Univ, Inst Lab Med, Dept Microbiol Immunol & Glycobiol MIG, Solvegatan 23, S-22362 Lund, Sweden	Lund University	Svanborg, C (corresponding author), Lund Univ, Inst Lab Med, Dept Microbiol Immunol & Glycobiol MIG, Solvegatan 23, S-22362 Lund, Sweden.	catharina.svanborg@med.lu.se	Ho, James CS/AAF-8197-2022; Ho, James CS/ADQ-2735-2022; Nadeem, Aftab/GRJ-0009-2022	Ho, James CS/0000-0002-6131-1297; Ho, James CS/0000-0002-6131-1297; Nadeem, Aftab/0000-0002-1439-6216; Rydstrom, Anna/0000-0002-3404-7195; Puthia, Manoj/0000-0001-6048-7234	Sharon D Lund foundation grant; Swedish Cancer Society; Medical Faculty (Lund University); Soderberg Foundation; Segerfalk Foundation; Maggie Stephens Foundation; Gunnar Nilsson Cancer Foundation; Inga-Britt and Arne Lundberg Foundation; HJ Forssman Foundation for Medical Research; Royal Physiographic Society	Sharon D Lund foundation grant; Swedish Cancer Society(Swedish Cancer Society); Medical Faculty (Lund University); Soderberg Foundation; Segerfalk Foundation; Maggie Stephens Foundation; Gunnar Nilsson Cancer Foundation; Inga-Britt and Arne Lundberg Foundation; HJ Forssman Foundation for Medical Research; Royal Physiographic Society	This study was supported by the Sharon D Lund foundation grant, the Swedish Cancer Society, the Medical Faculty (Lund University), the Soderberg Foundation, the Segerfalk Foundation, the Maggie Stephens Foundation, the Gunnar Nilsson Cancer Foundation, the Inga-Britt and Arne Lundberg Foundation, the HJ Forssman Foundation for Medical Research and the Royal Physiographic Society. We thank Petter Storm for conducting the Biacore and Braf activity experiments.	Anastassiadis T, 2011, NAT BIOTECHNOL, V29, P1039, DOI 10.1038/nbt.2017; Baselga J, 2006, SCIENCE, V312, P1175, DOI 10.1126/science.1125951; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Chene P, 2002, NAT REV DRUG DISCOV, V1, P665, DOI 10.1038/nrd894; Druker BJ, 2008, BLOOD, V112, P4808, DOI 10.1182/blood-2008-07-077958; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Duringer C, 2003, J BIOL CHEM, V278, P42131, DOI 10.1074/jbc.M306462200; Egorov VV, 2007, DOKL BIOCHEM BIOPHYS, V414, P152, DOI 10.1134/S1607672907030167; Fischer W, 2004, CANCER RES, V64, P2105, DOI 10.1158/0008-5472.CAN-03-2661; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108; Garuti L, 2010, CURR MED CHEM, V17, P2804, DOI 10.2174/092986710791859333; Gustafsson L, 2004, NEW ENGL J MED, V350, P2663, DOI 10.1056/NEJMoa032454; Gustafsson L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005229; HAKANSSON A, 1995, P NATL ACAD SCI USA, V92, P8064, DOI 10.1073/pnas.92.17.8064; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; HARVEY JJ, 1964, NATURE, V204, P1104, DOI 10.1038/2041104b0; Ho J, 2015, J MOL BIOL, V427, P1866, DOI 10.1016/j.jmb.2015.01.024; Hojjat-Farsangi M, 2014, INT J MOL SCI, V15, P13768, DOI 10.3390/ijms150813768; Hu YG, 2006, P NATL ACAD SCI USA, V103, P16870, DOI 10.1073/pnas.0606509103; KIRSTEN WH, 1970, BIBL HAEMATOL, V1969, P246; MacBeath G, 2000, SCIENCE, V289, P1760; Manning Brendan D, 2002, Sci STKE, V2002, ppe49, DOI 10.1126/stke.2002.162.pe49; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; MEGGIO F, 1995, EUR J BIOCHEM, V234, P317, DOI 10.1111/j.1432-1033.1995.317_c.x; Mor A, 2006, ANNU REV IMMUNOL, V24, P771, DOI 10.1146/annurev.immunol.24.021605.090723; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Mossberg AK, 2007, INT J CANCER, V121, P1352, DOI 10.1002/ijc.22810; Mossberg AK, 2010, J UROLOGY, V183, P1590, DOI 10.1016/j.juro.2009.12.008; Nakano H, 2009, J ANTIBIOT, V62, P17, DOI 10.1038/ja.2008.4; Newman RH, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.12; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Puthia M, 2014, GUT, V63, P131, DOI 10.1136/gutjnl-2012-303715; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; Rodrik-Outmezguine VS, 2011, CANCER DISCOV, V1, P248, DOI 10.1158/2159-8290.CD-11-0085; Satoh J, 2006, J NEUROSCI METH, V152, P278, DOI 10.1016/j.jneumeth.2005.09.015; Sekiguchi T, 2004, J BIOL CHEM, V279, P8343, DOI 10.1074/jbc.M305935200; Spang A, 2010, FEBS LETT, V584, P2646, DOI 10.1016/j.febslet.2010.04.005; Stolle K, 2007, BBA-GENE STRUCT EXPR, V1769, P514, DOI 10.1016/j.bbaexp.2007.05.005; Storm P, 2011, ONCOGENE, V30, P4765, DOI 10.1038/onc.2011.196; Storm P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058578; Svensson M, 2000, P NATL ACAD SCI USA, V97, P4221, DOI 10.1073/pnas.97.8.4221; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; Tee AR, 2005, FEBS LETT, V579, P4763, DOI 10.1016/j.febslet.2005.07.054; Trulsson M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017179; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Yan JL, 2008, MOL CELL BIOL, V28, P5803, DOI 10.1128/MCB.00393-08; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	49	14	14	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2016	35	7					897	907		10.1038/onc.2015.144	http://dx.doi.org/10.1038/onc.2015.144			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RO	26028028				2022-12-17	WOS:000370332200010
J	Chua, JS; Liew, HP; Guo, L; Lane, DP				Chua, J. S.; Liew, H. P.; Guo, L.; Lane, D. P.			Tumor-specific signaling to p53 is mimicked by Mdm2 inactivation in zebrafish: insights from mdm2 and mdm4 mutant zebrafish	ONCOGENE			English	Article							ZINC-FINGER NUCLEASES; LI-FRAUMENI-SYNDROME; ACTIVITY IN-VIVO; EMBRYONIC LETHALITY; MDM4-NULL MICE; CELL-DEATH; PROTEIN; RESCUE; UBIQUITINATION; ONCOPROTEIN	In mice, the deletion of either Mdm2 or Mdm4 results in a p53-dependent embryonic lethality. We used zinc-finger nucleases to construct mutations in the mdm2 and mdm4 genes of zebrafish. Although the loss of mdm2 results in a p53-dependent early embryonic lethality, mdm4 mutant fish are viable and grow to adulthood. We also found that an in-frame five-amino acid deletion in mdm2 creates a novel hypomorphic allele. The lethal phenotype observed in the mdm2 mutant fish could be partially rescued by injecting mRNA encoding functional Mdm2, and this required the E3 ligase activity of the protein. Complete rescue was obtained by crossing the mdm2 mutant fish onto a p53M214K mutant background. Although p53 mutant fish on a wild-type mdm2 background were shown to accumulate high levels of p53 protein specifically in tumor tissues, we detected extensive staining of p53 in many normal tissues of the mdm2-p53M214K double-mutant fish. Our results are suggestive of the hypothesis that p53 protein accumulates during tumor formation as a result of tumor-specific inactivation of the Mdm2 pathway.	[Chua, J. S.; Liew, H. P.; Lane, D. P.] ASTAR, Inst Biomed Sci, Lab p53, Singapore 138648, Singapore; [Guo, L.] Aegis Biotech, Singapore, Singapore	Agency for Science Technology & Research (A*STAR)	Lane, DP (corresponding author), ASTAR, Inst Biomed Sci, Lab p53, 06-04-05 Immunos, Singapore 138648, Singapore.	dplane@p53lab.a-star.edu.sg		Lane, David/0000-0003-0551-3545	Biomedical Research Council of Singapore	Biomedical Research Council of Singapore(Agency for Science Technology & Research (A*STAR))	This work was supported by the Biomedical Research Council of Singapore. We thank Dr Verma Chandra, Bioinformatics Institute, Singapore, for the homology modeling of Mdm4 and p53; Dr Venkatesh Byrappa, Institute of Molecular and Cell Biology, Singapore, for scouring the databases for zebrafish Mdm4 homologs; Dr Julin Wong for growing the hybridomas for the p53-5.1 and p53-9.1 antibodies; and our students who helped with genotyping of the zebrafish. The zebrafish p53M214K mutant line was provided by Professor A. Thomas Look (Dana Farber Cancer Institute, Boston, MA, USA). Adult zebrafish were processed and paraffin embedded at the Advanced Molecular Pathology Laboratory, IMCB, A*STAR, Singapore. All the adult zebrafish were maintained by the Zebrafish Facility at the Institute of Molecular and Cell Biology.	Berghmans S, 2005, P NATL ACAD SCI USA, V102, P407, DOI 10.1073/pnas.0406252102; Chavez-Reyes A, 2003, CANCER RES, V63, P8664; Doumont G, 2005, EMBO J, V24, P3093, DOI 10.1038/sj.emboj.7600769; Doyon Y, 2008, NAT BIOTECHNOL, V26, P702, DOI 10.1038/nbt1409; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Finch RA, 2002, CANCER RES, V62, P3221; Francoz S, 2006, P NATL ACAD SCI USA, V103, P3232, DOI 10.1073/pnas.0508476103; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Guo L, 2013, ONCOGENE, V32, P4009, DOI 10.1038/onc.2012.409; HALL PA, 1994, J PATHOL, V172, P1, DOI 10.1002/path.1711720103; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huang L, 2011, P NATL ACAD SCI USA, V108, P12001, DOI 10.1073/pnas.1102309108; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Lane David P, 2012, Genes Cancer, V3, P320, DOI 10.1177/1947601912458285; Lane DP, 2010, CELL CYCLE, V9, P540, DOI 10.4161/cc.9.3.10516; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Langheinrich U, 2002, CURR BIOL, V12, P2023, DOI 10.1016/S0960-9822(02)01319-2; Lee KC, 2008, ONCOGENE, V27, P629, DOI 10.1038/sj.onc.1210695; Linares LK, 2003, P NATL ACAD SCI USA, V100, P12009, DOI 10.1073/pnas.2030930100; LUNA RMD, 1995, NATURE, V378, P203; MacInnes AW, 2008, P NATL ACAD SCI USA, V105, P10408, DOI 10.1073/pnas.0805036105; Marine JC, 2006, CELL DEATH DIFFER, V13, P927, DOI 10.1038/sj.cdd.4401912; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Meng XD, 2008, NAT BIOTECHNOL, V26, P695, DOI 10.1038/nbt1398; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Pant V, 2014, GENE DEV, V28, P1739, DOI 10.1101/gad.247452.114; Pant V, 2011, P NATL ACAD SCI USA, V108, P11995, DOI 10.1073/pnas.1102241108; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Peller S, 1998, SEMIN CANCER BIOL, V8, P379, DOI 10.1006/scbi.1998.0100; Robu ME, 2007, PLOS GENET, V3, P787, DOI 10.1371/journal.pgen.0030078; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Steinman HA, 2005, ONCOGENE, V24, P7935, DOI 10.1038/sj.onc.1208930; Taylor JS, 2003, GENOME RES, V13, P382, DOI 10.1101/gr.640303; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yang YL, 2004, ONCOGENE, V23, P2096, DOI 10.1038/sj.onc.1207411; Zhang Y, 2014, J PATHOL, V233, P380, DOI 10.1002/path.4368	42	14	14	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2015	34	48					5933	5941		10.1038/onc.2015.57	http://dx.doi.org/10.1038/onc.2015.57			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CX1CO	25746004	Green Published, hybrid			2022-12-17	WOS:000365434000008
J	Kale, S; Raja, R; Thorat, D; Soundararajan, G; Patil, TV; Kundu, GC				Kale, S.; Raja, R.; Thorat, D.; Soundararajan, G.; Patil, T. V.; Kundu, G. C.			Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via alpha 9 beta 1 integrin (vol 33, pg 2295, 2014)	ONCOGENE			English	Correction													Kundu, Gopal C./ABA-9897-2020; Raja, Remya/GXM-8598-2022	Raja, Remya/0000-0002-7576-6778				Kale S, 2014, ONCOGENE, V33, P2295, DOI 10.1038/onc.2013.184	1	14	16	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2015	34	42					5408	5410		10.1038/onc.2015.315	http://dx.doi.org/10.1038/onc.2015.315			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EI	26473949	Bronze			2022-12-17	WOS:000363479200012
J	Meniel, V; Megges, M; Young, MA; Cole, A; Sansom, OJ; Clarke, AR				Meniel, V.; Megges, M.; Young, M. A.; Cole, A.; Sansom, O. J.; Clarke, A. R.			Apc and p53 interaction in DNA damage and genomic instability in hepatocytes	ONCOGENE			English	Article							POLYPOSIS-COLI PROTEIN; HEPATOCELLULAR-CARCINOMA; CHROMOSOMAL INSTABILITY; MUTATIONS; PREDISPOSES; DEFICIENCY; ANEUPLOIDY; APOPTOSIS; PATHWAYS; GENETICS	Disruption of Apc (adenomatous polyposis coli) within hepatocytes activates Wnt signalling, perturbs differentiation and ultimately leads to neoplasia. Apc negatively regulates Wnt signalling but is also involved in organizing the cytoskeleton and may have a role in chromosome segregation. In vitro studies have implicated Apc in the control of genomic stability. However, the relevance of this data has been questioned in vivo as Apc is lost earlier than the onset of genomic instability. Here we analyse the relationship between immediate loss of Apc and the acquisition of genomic instability in hepatocytes. We used Cre-lox technology to inactivate Apc and in combination with p53 in vivo, to define the consequences of gene loss on cell cycle regulation, proliferation, death and aneuploidy. We show that, although Apc loss leads to increased proliferation, it also leads to increased apoptosis, the accumulation of p53, p21 and markers of double-strand breaks and DNA repair. Flow cytometry revealed an increased 4N DNA content, consistent with a G2 arrest. Levels of anaphase bridges were also elevated, implicating failed chromosome segregation. This was accompanied by an increase in centrosome number, which demonstrates a role for Apc in maintaining euploidy. To address the role of p53 in these processes, we analysed combined loss of Apc and p53, which led to a further increase in proliferation, cell death, DNA damages and repair and a bypass of G2 arrest than was observed with Apc loss. However, we observed only a marginal effect on anaphase bridges and centrosome number, which could be due to increased cell death. Our data therefore establishes, in an in vivo setting, that APC loss leads to a DNA damage signature and genomic instability in the liver and that additional loss of p53 leads to an increase in the DNA damage signal but not to an immediate increase in the genomic instability phenotype.	[Meniel, V.; Young, M. A.; Clarke, A. R.] Cardiff Univ, European Canc Stem Cell Res Inst, Cardiff CF24 4HQ, S Glam, Wales; [Megges, M.] Max Planck Inst Mol Genet, Dept Vertebrate Genom, D-14195 Berlin, Germany; [Cole, A.; Sansom, O. J.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Cardiff University; Max Planck Society; Beatson Institute	Meniel, V (corresponding author), Cardiff Univ, European Canc Stem Cell Res Inst, Hadyn Ellis Bldg,Maindy Rd, Cardiff CF24 4HQ, S Glam, Wales.	Menielvs@cf.ac.uk		Sansom, Owen J./0000-0001-9540-3010; Clarke, Alan/0000-0002-4281-426X; Young, Maddy/0000-0002-1487-0694	Cancer research UK [RCBMA7613]; Cancer Research UK [12481, 15937] Funding Source: researchfish	Cancer research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK)	We thank Mark Bishop (genotyping) and Derek Scarborough (histology). This work was financially supported by Cancer research UK RCBMA7613.	Guerrero AA, 2010, P NATL ACAD SCI USA, V107, P4159, DOI 10.1073/pnas.0912143106; Aoki K, 2007, ONCOGENE, V26, P3511, DOI 10.1038/sj.onc.1210141; Bree RT, 2004, DNA REPAIR, V3, P989, DOI 10.1016/j.dnarep.2004.03.016; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Caldwell CM, 2007, J CELL BIOL, V178, P1109, DOI 10.1083/jcb.200703186; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; CLARKE AR, 1995, ONCOGENE, V11, P1913; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Dikovskaya D, 2004, MOL BIOL CELL, V15, P2978, DOI 10.1091/mbc.E03-08-0613; Dikovskaya D, 2007, J CELL BIOL, V176, P183, DOI 10.1083/jcb.200610099; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Feng GJ, 2012, GASTROENTEROLOGY, V143, P1650, DOI 10.1053/j.gastro.2012.08.047; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798; Godinho SA, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0467; Gougelet A, 2012, INT J HEPATOL, V2012, DOI 10.1155/2012/816125; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Hadjihannas MV, 2006, CELL CYCLE, V5, P2077, DOI 10.4161/cc.5.18.3282; Hans F, 2001, ONCOGENE, V20, P3021, DOI 10.1038/sj.onc.1204326; Hanson CA, 2005, GENE, V361, P1, DOI 10.1016/j.gene.2005.07.024; Hoffelder DR, 2004, CHROMOSOMA, V112, P389, DOI 10.1007/s00412-004-0284-6; Hussain SP, 2007, ONCOGENE, V26, P2166, DOI 10.1038/sj.onc.1210279; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Jain S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026799; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Laurent-Puig P, 2006, ONCOGENE, V25, P3778, DOI 10.1038/sj.onc.1209547; Nasser M, 2008, J CELL BIOL, V181, P719; Pineau P, 2008, MUTAT RES-GEN TOX EN, V653, P6, DOI 10.1016/j.mrgentox.2008.01.012; Prost S, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.16.e80; Reed KR, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-162; Reed KR, 2008, P NATL ACAD SCI USA, V105, P18919, DOI 10.1073/pnas.0805778105; Sansom OJ, 2005, ONCOGENE, V24, P8205, DOI 10.1038/sj.onc.1208956; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Shih IM, 2001, CANCER RES, V61, P818; Torre C, 2011, INT J BIOCHEM CELL B, V43, P271, DOI 10.1016/j.biocel.2009.11.004; Vaziri C, 1997, J BIOL CHEM, V272, P2762, DOI 10.1074/jbc.272.5.2762; Vitre BD, 2012, CURR OPIN CELL BIOL, V24, P809, DOI 10.1016/j.ceb.2012.10.006; Weaver BAA, 2006, CURR OPIN CELL BIOL, V18, P658, DOI 10.1016/j.ceb.2006.10.002	42	14	14	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	31					4118	4129		10.1038/onc.2014.342	http://dx.doi.org/10.1038/onc.2014.342			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN9PE	25347740	Green Accepted			2022-12-17	WOS:000358780500010
J	Wu, DW; Lee, MC; Hsu, NY; Wu, TC; Wu, JY; Wang, YC; Cheng, YW; Chen, CY; Lee, H				Wu, D-W; Lee, M-C; Hsu, N-Y; Wu, T-C; Wu, J-Y; Wang, Y-C; Cheng, Y-W; Chen, C-Y; Lee, H.			FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-kappa B/Slug-mediated PUMA reduction (vol 34, pg 2505, 2015)	ONCOGENE			English	Correction																		Wu DW, 2015, ONCOGENE, V34, P2505, DOI 10.1038/onc.2014.184	1	14	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	29					3882	3883		10.1038/onc.2015.203	http://dx.doi.org/10.1038/onc.2015.203			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM9BV	26179457	Bronze			2022-12-17	WOS:000358001600014
J	Czarnecka, M; Trinh, E; Lu, C; Kuan-Celarier, A; Galli, S; Hong, SH; Tilan, JU; Talisman, N; Izycka-Swieszewska, E; Tsuei, J; Yang, C; Martin, S; Horton, M; Christian, D; Everhart, L; Maheswaran, I; Kitlinska, J				Czarnecka, M.; Trinh, E.; Lu, C.; Kuan-Celarier, A.; Galli, S.; Hong, S-H; Tilan, J. U.; Talisman, N.; Izycka-Swieszewska, E.; Tsuei, J.; Yang, C.; Martin, S.; Horton, M.; Christian, D.; Everhart, L.; Maheswaran, I.; Kitlinska, J.			Neuropeptide Y receptor Y5 as an inducible pro-survival factor in neuroblastoma: implications for tumor chemoresistance	ONCOGENE			English	Article							NEUROTROPHIC FACTOR ACTIVATION; G-PROTEIN; MEDIATED NEUROPROTECTION; TYROSINE KINASES; EWING SARCOMA; IN-VIVO; BRAIN; EXPRESSION; CELLS; TRKB	Neuroblastoma (NB) is a pediatric tumor of neural crest origin with heterogeneous phenotypes. Although low-stage tumors carry a favorable prognosis, >50% of high-risk NB relapses after treatment with a fatal outcome. Thus developing therapies targeting refractory NB remains an unsolved clinical problem. Brain-derived neurotrophic factor (BDNF) and its TrkB receptor are known to protect NB cells from chemotherapy-induced cell death, while neuropeptide Y (NPY), acting via its Y2 receptor (Y2R), is an autocrine proliferative and angiogenic factor crucial for maintaining NB tumor growth. Here we show that in NB cells, BDNF stimulates the synthesis of NPY and induces expression of another one of its receptors, Y5R. In human NB tissues, the expression of NPY and Y5R positively correlated with the expression of BDNF and TrkB. Functionally, BDNF triggered Y5R internalization in NB cells, whereas Y5R antagonist inhibited BDNF-induced p44/42 mitogen-activated protein kinase activation and its pro-survival activity. These observations suggested TrkB-Y5R transactivation that resulted in cross-talk between their signaling pathways. Additionally, NPY and Y5R were upregulated in a BDNF-independent manner in NB cells under pro-apoptotic conditions, such as serum deprivation and chemotherapy, as well as in cell lines and tissues derived from posttreatment NB tumors. Blocking Y5R in chemoresistant NB cells rich in this receptor sensitized them to chemotherapy-induced apoptosis and inhibited their growth in vivo by augmenting cell death. In summary, the NPY/Y5R axis is an inducible survival pathway activated in NB by BDNF or cellular stress. Upon such activation, Y5R augments the pro-survival effect of BDNF via its interactions with TrkB receptor and exerts an additional BDNF-independent anti-apoptotic effect, both of which contribute to NB chemoresistance. Therefore, the NPY/Y5R pathway may become a novel therapeutic target for patients with refractory NB, thus far an incurable form of this disease.	[Czarnecka, M.; Trinh, E.; Kuan-Celarier, A.; Galli, S.; Talisman, N.; Tsuei, J.; Yang, C.; Everhart, L.; Maheswaran, I.; Kitlinska, J.] Georgetown Univ, Med Ctr, Dept Biochem & Mol & Cellular Biol, Washington, DC 20057 USA; [Lu, C.] MIT, McGovern Inst, Boston, MA USA; [Hong, S-H] Georgetown Univ, Med Ctr, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA; [Tilan, J. U.] Georgetown Univ, Dept Nursing, Sch Nursing & Hlth Studies, Washington, DC 20057 USA; [Tilan, J. U.; Martin, S.; Horton, M.; Christian, D.] Georgetown Univ, Dept Human Sci, Sch Nursing & Hlth Studies, Washington, DC 20057 USA; [Izycka-Swieszewska, E.] Med Univ Gdansk, Dept Pathol & Neuropathol, Gdansk, Poland	Georgetown University; Massachusetts Institute of Technology (MIT); Georgetown University; Georgetown University; Georgetown University; Fahrenheit Universities; Medical University Gdansk	Kitlinska, J (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol & Cellular Biol, 3900 Reservoir,Basic Sci Bldg,Room 231A, Washington, DC 20057 USA.	jbk4@georgetown.edu	Izycka-Swieszewska, Ewa/AAX-5191-2020	izycka-swieszewska, ewa/0000-0001-7550-1326	National Institutes of Health grants from National Center for Advancing Translational Sciences (NCATS) through the Clinical and Translational Science Awards Program (CTSA) [UL1RR031975, 1R01CA123211, 1R03CA178809, UL1TR000101]; Children's Cancer Foundation (Baltimore, MD, USA); NIH/NCI grant [P30-CA051008]; Georgetown Undergraduate Research Opportunities Program; NATIONAL CANCER INSTITUTE [P30CA051008, R01CA123211, R03CA178809] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000101] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR031975] Funding Source: NIH RePORTER	National Institutes of Health grants from National Center for Advancing Translational Sciences (NCATS) through the Clinical and Translational Science Awards Program (CTSA); Children's Cancer Foundation (Baltimore, MD, USA); NIH/NCI grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Georgetown Undergraduate Research Opportunities Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Human NB samples at diagnosis were provided by the Children's Oncology Group. We thank Dr Garret Brodeur for providing SY5Y/TrkB transfectants. This work was supported by the National Institutes of Health grants: UL1TR000101 (previously UL1RR031975) from the National Center for Advancing Translational Sciences (NCATS), through the Clinical and Translational Science Awards Program (CTSA), 1R01CA123211 and 1R03CA178809 to JK, as well as funding from Children's Cancer Foundation (Baltimore, MD, USA) to JK, and Georgetown Undergraduate Research Opportunities Program to MH and DC. Experiments were performed with use of the Lombardi Comprehensive Cancer Center Shared Resources (Histopathology and Tissue, Biostatistics and Bioinformatics, Microscopy and Imaging, Animal Model and Tissue Culture) partially supported by the NIH/NCI grant P30-CA051008. We thank Dr Aykut Oren, Dr Ruijun Han and Dr Kristi Graves for their critical reading of the manuscript.	Garcia-Sainz JA, 2010, EUR J PHARMACOL, V648, P1, DOI 10.1016/j.ejphar.2010.08.049; Barnea A, 2001, BRAIN RES, V919, P57, DOI 10.1016/S0006-8993(01)02999-7; Borroto-Escuela DO, 2011, IUBMB LIFE, V63, P463, DOI 10.1002/iub.473; Brodeur GM, 2009, CLIN CANCER RES, V15, P3244, DOI 10.1158/1078-0432.CCR-08-1815; Brodeur GM, 1997, J NEURO-ONCOL, V31, P49, DOI 10.1023/A:1005729329526; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; COHEN PS, 1990, CANCER RES, V50, P6055; Decressac M, 2012, NEUROBIOL AGING, V33, P2125, DOI 10.1016/j.neurobiolaging.2011.06.018; Delcourt N, 2007, TRENDS PHARMACOL SCI, V28, P602, DOI 10.1016/j.tips.2007.09.007; Dotsch J, 1998, REGUL PEPTIDES, V75-6, P185, DOI 10.1016/S0167-0115(98)00067-6; Dudas J, 2011, ORAL ONCOL, V47, P98, DOI 10.1016/j.oraloncology.2010.11.002; Erondu N, 2006, CELL METAB, V4, P275, DOI 10.1016/j.cmet.2006.08.002; Erondu N, 2007, OBESITY, V15, P895, DOI 10.1038/oby.2007.620; Flajolet M, 2008, NAT NEUROSCI, V11, P1402, DOI 10.1038/nn.2216; Gehlert DR, 2007, BIOCHEM PHARMACOL, V74, P1652, DOI 10.1016/j.bcp.2007.08.017; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; Hansel DE, 2001, NATURE, V410, P940, DOI 10.1038/35073601; Ho R, 2002, CANCER RES, V62, P6462; Jaboin J, 2003, CANCER LETT, V193, P109, DOI 10.1016/S0304-3835(02)00723-1; Jaboin J, 2002, CANCER RES, V62, P6756; Keshelava N, 1998, CANCER RES, V58, P5396; Kitlinska J, 2005, CANCER RES, V65, P1719, DOI 10.1158/0008-5472.CAN-04-2192; Klocker N, 2000, J NEUROSCI, V20, P6962, DOI 10.1523/JNEUROSCI.20-18-06962.2000; KOGNER P, 1994, ACTA PAEDIATR, V83, P423, DOI 10.1111/j.1651-2227.1994.tb18134.x; Lee EW, 2003, J CLIN INVEST, V111, P1853, DOI 10.1172/JCI200316929; Lee FS, 2002, CYTOKINE GROWTH F R, V13, P11, DOI 10.1016/S1359-6101(01)00024-7; Li Z, 2007, CELL DEATH DIFFER, V14, P318, DOI 10.1038/sj.cdd.4401983; Lou XJ, 2001, MOL BIOL CELL, V12, P615, DOI 10.1091/mbc.12.3.615; Lu C, 2010, ONCOGENE, V29, P5630, DOI 10.1038/onc.2010.301; Lu CY, 2011, J BIOL CHEM, V286, P27494, DOI 10.1074/jbc.M111.224089; Malva JO, 2012, NEUROPEPTIDES, V46, P299, DOI 10.1016/j.npep.2012.09.001; Maris JM, 2005, CURR OPIN PEDIATR, V17, P7, DOI 10.1097/01.mop.0000150631.60571.89; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; Movafagh S, 2006, FASEB J, V20, P1924, DOI 10.1096/fj.05-4770fje; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; Nakagawara A, 2001, CANCER LETT, V169, P107, DOI 10.1016/S0304-3835(01)00530-4; Nakagawara A, 1997, EUR J CANCER, V33, P2050, DOI 10.1016/S0959-8049(97)00280-3; Pandey SC, 2003, TRENDS PHARMACOL SCI, V24, P456, DOI 10.1016/S0165-6147(03)00226-8; Pedrazzini T, 2003, CELL MOL LIFE SCI, V60, P350, DOI 10.1007/s000180300029; Pellieux C, 2000, P NATL ACAD SCI USA, V97, P1595, DOI 10.1073/pnas.030533197; Pfeiffer M, 2001, J BIOL CHEM, V276, P14027, DOI 10.1074/jbc.M006084200; Pons J, 2003, CAN J PHYSIOL PHARM, V81, P177, DOI 10.1139/Y02-166; Pons J, 2008, CAN J PHYSIOL PHARM, V86, P438, DOI [10.1139/Y08-054, 10.1139/y08-054]; Pyne NJ, 2003, BIOCHEM SOC T, V31, P1220; Rajagopal R, 2004, J NEUROSCI, V24, P6650, DOI 10.1523/JNEUROSCI.0010-04.2004; Rakhit S, 2001, MOL PHARMACOL, V60, P63, DOI 10.1124/mol.60.1.63; Reibel S, 2000, EUR J NEUROSCI, V12, P595, DOI 10.1046/j.1460-9568.2000.00941.x; Schramm A, 2005, CANCER LETT, V228, P143, DOI 10.1016/j.canlet.2005.02.051; Sheriff' S, 1998, REGUL PEPTIDES, V75-6, P309, DOI 10.1016/S0167-0115(98)00083-4; Sheriff S, 2010, MOL CANCER RES, V8, P604, DOI 10.1158/1541-7786.MCR-09-0301; Skaper SD, 1998, J NEUROCHEM, V70, P1859, DOI 10.1046/j.1471-4159.1998.70051859.x; Takei N, 1996, MOL BRAIN RES, V37, P283; Thiele CJ, 2009, CLIN CANCER RES, V15, P5962, DOI 10.1158/1078-0432.CCR-08-0651; Tilan JU, 2013, ONCOTARGET, V4, P2487, DOI 10.18632/oncotarget.1604; Tilan JU, 2013, FASEB J, V27, P2244, DOI 10.1096/fj.12-213546; Waters CM, 2005, CELL SIGNAL, V17, P263, DOI 10.1016/j.cellsig.2004.07.011; Wilhelm JC, 2012, J NEUROSCI, V32, P5002, DOI 10.1523/JNEUROSCI.1411-11.2012; Williams AG, 1998, BIOCHEM J, V333, P505, DOI 10.1042/bj3330505; Wirth MJ, 2005, P NATL ACAD SCI USA, V102, P3064, DOI 10.1073/pnas.0404712102; Xapelli S, 2008, EUR J NEUROSCI, V27, P2089, DOI 10.1111/j.1460-9568.2008.06172.x; Yoshimura R, 2009, NEUROSCI LETT, V450, P262, DOI 10.1016/j.neulet.2008.12.010; Zeine R, 2009, MODERN PATHOL, V22, P950, DOI 10.1038/modpathol.2009.52	64	14	15	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2015	34	24					3131	3143		10.1038/onc.2014.253	http://dx.doi.org/10.1038/onc.2014.253			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3FD	25132261	Green Accepted			2022-12-17	WOS:000356101100005
J	Lei, ZJ; Wang, J; Xiao, HL; Guo, Y; Wang, T; Li, Q; Liu, L; Luo, X; Fan, LL; Lin, L; Mao, CY; Wang, SN; Wei, YL; Lan, CH; Jiang, J; Yang, XJ; Liu, PD; Chen, DF; Wang, B				Lei, Z-J; Wang, J.; Xiao, H-L; Guo, Y.; Wang, T.; Li, Q.; Liu, L.; Luo, X.; Fan, L-L; Lin, L.; Mao, C-Y; Wang, S-N; Wei, Y-L; Lan, C-H; Jiang, J.; Yang, X-J; Liu, P-D; Chen, D-F; Wang, B.			Lysine-specific demethylase 1 promotes the stemness and chemoresistance of Lgr5+ liver cancer initiating cells by suppressing negative regulators of beta-catenin signaling (vol 34, pg 3188, 2015)	ONCOGENE			English	Correction													Li, Qunqing/O-2254-2014	Li, Qunqing/0000-0001-9565-0855				Lei ZJ, 2015, ONCOGENE, V34, P3188, DOI 10.1038/onc.2015.129	1	14	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2015	34	24					3214	3214		10.1038/onc.2015.182	http://dx.doi.org/10.1038/onc.2015.182			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3FD	26062983	Bronze			2022-12-17	WOS:000356101100013
J	Najib, S; Kowalski-Chauvel, A; Do, C; Roche, S; Cohen-Jonathan-Moyal, E; Seva, C				Najib, S.; Kowalski-Chauvel, A.; Do, C.; Roche, S.; Cohen-Jonathan-Moyal, E.; Seva, C.			Progastrin a new pro-angiogenic factor in colorectal cancer	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; INTESTINAL EPITHELIAL-CELLS; GLYCINE-EXTENDED GASTRIN; TYROSINE PHOSPHORYLATION; VEGF EXPRESSION; MICE; PROLIFERATION; PRECURSOR; CADHERIN; PERMEABILITY	Angiogenesis is essential in tumor progression and metastatic process, and increased angiogenesis has been associated with poor prognosis and relapse of colorectal cancer (CRC). VEGF has become the main target of anti-angiogenic therapy. However, most patients relapse after an initial response or present a resistance to the treatment. Identification of new pro-angiogenic factors may help to improve anti-angiogenic therapy. In this study, we demonstrated that the pro-hormone progastrin (PG), over-expressed in CRC, recognized as a growth factor, is a potent pro-angiogenic factor. In transgenic mice and human colorectal HPs producing high levels of PG, we correlated PG overexpression with an increased vascularization. In vitro, exogenous PG and conditioned media (CM) from CRC cells producing PG increased endothelial cell proliferation and migration. We also showed that treatment with exogenous PG can increase the ability of endothelial cells to form capillary-like structures. Moreover, we demonstrated that PG enhanced endothelial permeability. The finding that PG stimulated the phosphorylation of vascular endothelial (VE)-cadherin, p125-FAK, paxillin and induced actin remodelling was consistent with a role of these components in PG-stimulated endothelial cell migration and permeability. The pro-angiogenic effects observed with CM were significantly inhibited when CRC cells expressed a PG shRNA. In vivo, we found an important decrease in tumor growth and neovascularization when the CRC cells expressing the PG shRNA were xenografted in mice or in the chick chorioallantoic membrane model. We also observed an increase in the coverage of blood vessels by pericytes and a decrease in endothelial permeability when PG expression was blocked. Our results demonstrate that PG is a new pro-angiogenic factor in CRC and an attractive therapeutic target.	[Najib, S.; Kowalski-Chauvel, A.; Do, C.; Cohen-Jonathan-Moyal, E.; Seva, C.] Univ Toulouse 3, CRCT, INSERM, UMR 1037, F-31062 Toulouse, France; [Roche, S.] Univ Montpellier I & II, CRBM, CNRS, UMR5237, Montpellier, France; [Cohen-Jonathan-Moyal, E.] Inst Claudius Regaud, F-31052 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; UNICANCER; Institut Claudius Regaud	Seva, C (corresponding author), Inst Claudius Regaud, CRCT, INSERM, UMR 1037, 20-24 Rue Pont St Pierre, F-31052 Toulouse, France.	cathy.seva@inserm.fr	Kowalski-Chauvel, Aline/O-9212-2014; SEVA, Catherine/O-9166-2014; Moyal, Elizabeth/A-9802-2015	SEVA, Catherine/0000-0002-4265-7372; Moyal, Elizabeth/0000-0002-6593-9276; do, catherine/0000-0002-9796-4345; Najib, Souad/0000-0001-5509-1411; roche, serge/0000-0003-3413-3859	INSERM; ANR	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); ANR(French National Research Agency (ANR))	We thank Prof Shulkes, Melbourne University (Australia) for the specific antibody against Progastrin. This work was supported by: grants from INSERM and ANR.	Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Baldwin GS, 2001, J BIOL CHEM, V276, P7791, DOI 10.1074/jbc.M009985200; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Bertrand C, 2010, INT J CANCER, V126, P2847, DOI 10.1002/ijc.25001; Brown D, 2003, ENDOCRINOLOGY, V144, P201, DOI 10.1210/en.2002-220501; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Chen XL, 2012, DEV CELL, V22, P146, DOI 10.1016/j.devcel.2011.11.002; CICCOTOSTO GD, 1995, GASTROENTEROLOGY, V109, P1142, DOI 10.1016/0016-5085(95)90572-3; Clarke JM, 2013, J GASTROINTEST ONCOL, V4, P253, DOI 10.3978/j.issn.2078-6891.2013.036; Clarke PA, 2006, CANCER RES, V66, P3504, DOI 10.1158/0008-5472.CAN-05-0280; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; Des Guetz G, 2006, BRIT J CANCER, V94, P1823, DOI 10.1038/sj.bjc.6603176; Dimaline R, 2014, J PHYSIOL-LONDON, V592, P2951, DOI 10.1113/jphysiol.2014.272435; Do C, 2012, CANCER PREV RES, V5, P675, DOI 10.1158/1940-6207.CAPR-11-0408; Duckworth CA, 2013, GASTROENTEROLOGY, V145, P197, DOI 10.1053/j.gastro.2013.03.012; Esser S, 1998, J CELL SCI, V111, P1853; Ferrand A, 2005, CANCER RES, V65, P2770, DOI 10.1158/0008-5472.CAN-04-0978; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; Hollande F, 1997, GASTROENTEROLOGY, V113, P1576, DOI 10.1053/gast.1997.v113.pm9352860; Hollande F, 2003, J CELL SCI, V116, P1187, DOI 10.1242/jcs.00321; Jin GC, 2013, GASTROENTEROLOGY, V145, P820, DOI 10.1053/j.gastro.2013.07.034; Kowalski-Chauvel A, 2012, J BIOL CHEM, V287, P41458, DOI 10.1074/jbc.M112.382465; Monaghan-Benson E, 2009, J BIOL CHEM, V284, P25602, DOI 10.1074/jbc.M109.009894; NEMETH J, 1993, GUT, V34, P90, DOI 10.1136/gut.34.1.90; Ribatti D, 2006, NAT PROTOC, V1, P85, DOI 10.1038/nprot.2006.13; Rmali KA, 2007, COLORECTAL DIS, V9, P3, DOI 10.1111/j.1463-1318.2006.01089.x; Shojaei F, 2012, CANCER LETT, V320, P130, DOI 10.1016/j.canlet.2012.03.008; Siddheshwar RK, 2001, GUT, V48, P47, DOI 10.1136/gut.48.1.47; Singh P, 2000, GASTROENTEROLOGY, V119, P162, DOI 10.1053/gast.2000.8527; Singh P, 2003, AM J PHYSIOL-GASTR L, V284, pG328, DOI 10.1152/ajpgi.00351.2002; Sirvent A, 2010, ONCOGENE, V29, P1303, DOI 10.1038/onc.2009.450; Smith AM, 2000, GUT, V47, P820, DOI 10.1136/gut.47.6.820; TAKAHASHI Y, 1995, CANCER RES, V55, P3964; Tokunaga T, 1998, BRIT J CANCER, V77, P998, DOI 10.1038/bjc.1998.164; Umar S, 2008, ONCOGENE, V27, P5599, DOI 10.1038/onc.2008.169; VANSOLINGE WW, 1993, GASTROENTEROLOGY, V104, P1099, DOI 10.1016/0016-5085(93)90279-L; Wang TC, 1996, J CLIN INVEST, V98, P1918, DOI 10.1172/JCI118993; Wu H, 2003, AM J PHYSIOL-GASTR L, V285, pG1097, DOI 10.1152/ajpgi.00216.2003	40	14	15	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2015	34	24					3120	3130		10.1038/onc.2014.255	http://dx.doi.org/10.1038/onc.2014.255			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3FD	25109333				2022-12-17	WOS:000356101100004
J	Yeom, E; Hong, ST; Choi, KW				Yeom, E.; Hong, S-T; Choi, K-W			Crumbs interacts with Xpd for nuclear division control in Drosophila	ONCOGENE			English	Article							TRANSMEMBRANE PROTEIN CRUMBS; EPITHELIAL-CELLS; DNA METABOLISM; MUTATIONS; POLARITY; MELANOGASTER; COMPLEX; MORPHOGENESIS; ORGANIZATION; EXPRESSION	Crumbs (Crb) family proteins are crucial for cell polarity. Recent studies indicate that they are also involved in growth regulation and cancer. However, it is not well-understood how Crb participates in mitotic processes. Here, we report that Drosophila Crb is critically involved in nuclear division by interacting with Xeroderma pigmentosum D (XPD). A novel gene named galla-1 was identified from a genetic screen for crb modifiers. Galla-1 protein shows homology to MIP18, a subunit of the mitotic spindle-associated MMS19-XPD complex. Loss-of-function galla-1 mutants show abnormal chromosome segregation, defective centrosome positions and branched spindles during nuclear division in early embryos. Embryos with loss-of-function or overexpression of crb show similar mitotic defects and genetic interaction with galla-1. Both Galla-1 and Crb proteins show overlapping localization with spindle microtubules during nuclear division. Galla-1 physically interacts with the intracellular domain of Crb. Interestingly, Galla-1 shows little binding to the Drosophila homolog of XPD, but a related protein Galla-2 binds both Crb and Xpd. Loss-of-function galla-2 mutants show similar mitotic defects as galla-1 and strong genetic interaction with crb. Xpd can form a physical complex with Crb. In imaginal disc, Crb overexpression causes tissue overgrowth as well as DNA damages marked by H2Av phosphorylation. These phenotypes are suppressed by reduction of Xpd. Taken together, this study identifies a novel Crb-Galla-Xpd complex and its function for proper chromosome segregation during nuclear division, implicating a potential link between Crb and Xpd-related genome instability.	[Yeom, E.; Hong, S-T; Choi, K-W] Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; [Choi, K-W] Korea Adv Inst Sci & Technol, Grad Sch Nanosci & Technol, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST)	Choi, KW (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, 291 Daehak Ro, Taejon 305701, South Korea.	kchoi100@kaist.ac.kr	Choi, Kwang-Wook/C-1707-2011	Choi, Kwang-Wook/0000-0002-8997-3065; Hong, Sung-Tae/0000-0001-5981-4859	World Class University Program [R31-2008-000-10071-0]; National President Fellowship [35B-2011-1-C00033]; National Research Laboratory grant through the National Research Foundation of Korea - Ministry of Education, Science Technology [NRF-2011-0028326]	World Class University Program; National President Fellowship; National Research Laboratory grant through the National Research Foundation of Korea - Ministry of Education, Science Technology	We are grateful to Kyung-Ok Cho, Sang-Chul Nam and Walton Jones for critical comments on the manuscript. We thank Beat Suter and Tom Kaufmann for xpd mutant and anti-centrosomin antibody, respectively. We also thank Yang Hong for Crb::GFP and crb mutant alleles. We acknowledge the Bloomington Drosophila Stock Center, the National Institute of Genetics stock center and the Developmental Studies Hybridoma Bank for fly stocks and antibodies. This research was supported by grants from the World Class University Program (R31-2008-000-10071-0), the National President Fellowship (35B-2011-1-C00033) and the National Research Laboratory grant (NRF-2011-0028326) through the National Research Foundation of Korea funded by the Ministry of Education, Science & Technology.	Bachmann A, 2001, NATURE, V414, P638, DOI 10.1038/414638a; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brust-Mascher I, 2007, INT REV CYTOL, V259, P139, DOI 10.1016/S0074-7696(06)59004-7; Cameroni E, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-24; Capalbo L, 2011, P NATL ACAD SCI USA, V108, P17343, DOI 10.1073/pnas.1103720108; Chen CL, 2010, P NATL ACAD SCI USA, V107, P15810, DOI 10.1073/pnas.1004060107; Chen J, 2003, NATURE, V424, P228, DOI 10.1038/nature01746; den Hollander AI, 1999, NAT GENET, V23, P217, DOI 10.1038/13848; den Hollander AI, 2001, HUM MOL GENET, V10, P2767, DOI 10.1093/hmg/10.24.2767; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gao GJ, 2009, P NATL ACAD SCI USA, V106, P10728, DOI 10.1073/pnas.0902707106; Gari K, 2012, SCIENCE, V337, P243, DOI 10.1126/science.1219664; Grzeschik NA, 2010, CURR BIOL, V20, P573, DOI 10.1016/j.cub.2010.01.055; Hehnly H, 2014, DEV CELL, V28, P497, DOI 10.1016/j.devcel.2014.01.014; Herranz H, 2006, EMBO REP, V7, P297, DOI 10.1038/sj.embor.7400617; Hong Y, 2001, NATURE, V414, P634, DOI 10.1038/414634a; Huang J, 2009, P NATL ACAD SCI USA, V106, P8284, DOI 10.1073/pnas.0900641106; Ito S, 2010, MOL CELL, V39, P632, DOI 10.1016/j.molcel.2010.07.029; Izaddoost S, 2002, NATURE, V416, P178, DOI 10.1038/nature720; Klebes A, 2000, CURR BIOL, V10, P76, DOI 10.1016/S0960-9822(99)00277-8; KNUST E, 1987, EMBO J, V6, P761, DOI 10.1002/j.1460-2075.1987.tb04818.x; Li KJ, 1996, CELL, V85, P585, DOI 10.1016/S0092-8674(00)81258-1; Li XM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000876; Ling C, 2010, P NATL ACAD SCI USA, V107, P10532, DOI 10.1073/pnas.1004279107; Madigan JP, 2002, NUCLEIC ACIDS RES, V30, P3698, DOI 10.1093/nar/gkf496; Medina E, 2002, J CELL BIOL, V158, P941, DOI 10.1083/jcb.200203080; Parsons LM, 2010, FLY, V4, P288, DOI 10.4161/fly.4.4.13116; Pellikka M, 2002, NATURE, V416, P143, DOI 10.1038/nature721; PERRIMON N, 1984, GENETICS, V108, P927; Robinson BS, 2010, CURR BIOL, V20, P582, DOI 10.1016/j.cub.2010.03.019; Rorth P, 1998, MECH DEVELOP, V78, P113, DOI 10.1016/S0925-4773(98)00157-9; Stehling O, 2012, SCIENCE, V337, P195, DOI 10.1126/science.1219723; Su TT, 2001, CURR BIOL, V11, P8, DOI 10.1016/S0960-9822(00)00042-7; Tanentzapf G, 2000, J CELL BIOL, V151, P891, DOI 10.1083/jcb.151.4.891; TEPASS U, 1990, ROUX ARCH DEV BIOL, V199, P189, DOI 10.1007/BF01682078; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; Tepass U, 2012, ANNU REV CELL DEV BI, V28, P655, DOI 10.1146/annurev-cellbio-092910-154033; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5; WODARZ A, 1993, MECH DEVELOP, V44, P175, DOI 10.1016/0925-4773(93)90066-7; WOLFF T, 1993, DEV DROSOPHILA MELAN, V2, P1277; Zurita M, 2003, TRENDS GENET, V19, P578, DOI 10.1016/j.tig.2003.08.005	42	14	17	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2015	34	21					2777	2789		10.1038/onc.2014.202	http://dx.doi.org/10.1038/onc.2014.202			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI7XN	25065591	Bronze			2022-12-17	WOS:000354979500010
J	Hsu, FF; Yeh, CT; Sun, YJ; Chiang, MT; Lan, WM; Li, FA; Lee, WH; Chau, LY				Hsu, F-F; Yeh, C-T; Sun, Y-J; Chiang, M-T; Lan, W-M; Li, F-A; Lee, W-H; Chau, L-Y			Signal peptide peptidase-mediated nuclear localization of heme oxygenase-1 promotes cancer cell proliferation and invasion independent of its enzymatic activity (vol 34, pg 2360, 2015)	ONCOGENE			English	Correction													Chau, Lee-Young/N-7659-2018	Chau, Lee-Young/0000-0002-6316-2328				Hsu FF, 2015, ONCOGENE, V34, P2360, DOI 10.1038/onc.2014.166	1	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2015	34	18					2410	2411		10.1038/onc.2014.464	http://dx.doi.org/10.1038/onc.2014.464			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH2AH	25924715	Bronze			2022-12-17	WOS:000353824800014
J	Gilan, O; Diesch, J; Amalia, M; Jastrzebski, K; Chueh, AC; Verrills, NM; Pearson, RB; Mariadason, J; Tulchinsky, E; Hannan, RD; Dhillon, AS				Gilan, O.; Diesch, J.; Amalia, M.; Jastrzebski, K.; Chueh, A. C.; Verrills, N. M.; Pearson, R. B.; Mariadason, J. M.; Tulchinsky, E.; Hannan, R. D.; Dhillon, A. S.			PR55 alpha-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; FACTOR C-JUN; BETA-CATENIN; COLORECTAL-CANCER; TUMOR-SUPPRESSOR; UP-REGULATION; DNA-BINDING; PP2A; FRA-1; PHOSPHORYLATION	The proto-oncogene c-Jun is a component of activator protein-1 (AP-1) transcription factor complexes that regulates processes essential for embryonic development, tissue homeostasis and malignant transformation. Induction of gene expression by c-Jun involves stimulation of its transactivation ability and upregulation of DNA binding capacity. While it is well established that the former requires JNK-mediated phosphorylation of S63/S73, the mechanism(s) through which binding of c-Jun to its endogenous target genes is regulated remains poorly characterized. Here we show that interaction of c-Jun with chromatin is positively regulated by protein phosphatase 2A (PP2A) complexes targeted to c-Jun by the PR55 alpha regulatory subunit. PR55 alpha-PP2A specifically dephosphorylates T239 of c-Jun, promoting its binding to genes regulating tumour cell migration and invasion. PR55 alpha-PP2A also enhanced transcription of these genes, without affecting phosphorylation of c-Jun on S63. These findings suggest a critical role for interplay between JNK and PP2A pathways determining the functional activity of c-Jun/AP-1 in tumour cells.	[Gilan, O.; Diesch, J.; Amalia, M.; Pearson, R. B.; Hannan, R. D.; Dhillon, A. S.] Peter MacCallum Canc Ctr, Div Res, East Melbourne, Vic, Australia; [Gilan, O.; Diesch, J.; Pearson, R. B.; Hannan, R. D.] Univ Melbourne, Inst Bio21, Biochem & Mol Biol, Parkville, Vic 3052, Australia; [Chueh, A. C.; Mariadason, J. M.] Ludwig Inst Canc Res, Heidelberg, Vic, Australia; [Verrills, N. M.] Univ Newcastle, Fac Hlth, Sch Biomed Sci & Pharm, Callaghan, NSW 2308, Australia; [Verrills, N. M.] Hunter Med Res Inst, New Lambton, NSW, Australia; [Pearson, R. B.; Hannan, R. D.; Dhillon, A. S.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, East Melbourne, Vic, Australia; [Pearson, R. B.; Hannan, R. D.] Monash Univ, Biochem & Mol Biol, Clayton, Vic, Australia; [Tulchinsky, E.] Univ Leicester, Canc Studies & Mol Med, Leicester, Leics, England; [Hannan, R. D.] Univ Queensland, SchBiomed Sci, St Lucia, Qld, Australia; [Dhillon, A. S.] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia	Peter Maccallum Cancer Center; University of Melbourne; Ludwig Institute for Cancer Research; University of Newcastle; Hunter Medical Research Institute; University of Newcastle; Peter Maccallum Cancer Center; University of Melbourne; Monash University; University of Leicester; University of Queensland; University of Melbourne	Dhillon, AS (corresponding author), Peter MacCallum Canc Ctr, Div Res, St Andrews Pl, Melbourne, Vic 3002, Australia.	Amardeep.Dhillon@petermac.org	Pearson, Richard Bruce/I-1451-2013; Chüeh, Anderly C/AFC-2076-2022; Chueh, Anderly/AAF-9375-2022; Diesch, Jeannine/J-8558-2017; Chueh, Anderly C./D-8615-2015; Tulchinsky, Eugene/ABD-7070-2021	Pearson, Richard Bruce/0000-0001-5919-5090; Chüeh, Anderly C/0000-0003-1140-5516; Diesch, Jeannine/0000-0002-4667-3468; Chueh, Anderly C./0000-0003-1140-5516; Mariadason, John/0000-0001-9123-7684; Dhillon, Amardeep/0000-0002-6065-663X; Jastrzesbki, Katarzyna/0000-0002-3062-9016; Verrills, Nicole/0000-0002-7894-0137; Hannan, Ross/0000-0002-2166-4493	National Health and Medical Research Council of Australia; Cancer Institute NSW	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute NSW	We thank Drs David Gillespie, Eisuke Nishida, Chunming Liu, Kanaga Sabapathy and William Kaelin for providing reagents used in this study. This work was supported by project grants (to ASD and RDH) and Research Fellowships (to RDH, RBP and JMM) from the National Health and Medical Research Council of Australia and the Cancer Institute NSW (to NMV).	Adams DG, 2005, J BIOL CHEM, V280, P42644, DOI 10.1074/jbc.M502464200; Adiseshaiah P, 2007, CANCER RES, V67, P6204, DOI 10.1158/0008-5472.CAN-06-4687; Aguilera C, 2011, NATURE, V469, P231, DOI 10.1038/nature09607; Al-Murrani SWK, 1999, BIOCHEM J, V341, P293, DOI 10.1042/0264-6021:3410293; ALBERTS AS, 1993, MOL CELL BIOL, V13, P2104, DOI 10.1128/MCB.13.4.2104; Andreolas C, 2008, INT J CANCER, V122, P1745, DOI 10.1002/ijc.23309; Batut J, 2008, DEVELOPMENT, V135, P2927, DOI 10.1242/dev.020842; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Brabletz T, 2005, CELLS TISSUES ORGANS, V179, P56, DOI 10.1159/000084509; Bryant JC, 1999, BIOCHEM J, V339, P241, DOI 10.1042/0264-6021:3390241; Chen BK, 2007, MOL BIOL CELL, V18, P1118, DOI 10.1091/mbc.E06-09-0797; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen W, 2005, CANCER RES, V65, P8183, DOI 10.1158/0008-5472.CAN-05-1103; CHOU SY, 1992, MOL BIOL CELL, V3, P1117, DOI 10.1091/mbc.3.10.1117; Desmet CJ, 2013, P NATL ACAD SCI USA, V110, P5139, DOI 10.1073/pnas.1222085110; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; Francia G, 1999, INT J CANCER, V82, P709, DOI 10.1002/(SICI)1097-0215(19990827)82:5<709::AID-IJC14>3.3.CO;2-I; Fuchs SY, 1996, ONCOGENE, V13, P1531; Hartl M, 2003, CURR CANCER DRUG TAR, V3, P41, DOI 10.2174/1568009033333781; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; Huang CC, 2008, ONCOGENE, V27, P2422, DOI 10.1038/sj.onc.1210888; Ito A, 2000, EMBO J, V19, P562, DOI 10.1093/emboj/19.4.562; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; Morton S, 2003, EMBO J, V22, P3876, DOI 10.1093/emboj/cdg388; Mumby M, 2007, CELL, V130, P21, DOI 10.1016/j.cell.2007.06.034; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; Raivich G, 2006, PROG NEUROBIOL, V78, P347, DOI 10.1016/j.pneurobio.2006.03.006; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Sayan AE, 2012, ONCOGENE, V31, P1493, DOI 10.1038/onc.2011.336; Schonthaler HB, 2011, ANN RHEUM DIS, V70, pI109, DOI 10.1136/ard.2010.140533; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Tan J, 2010, CANCER CELL, V18, P459, DOI 10.1016/j.ccr.2010.10.021; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Virshup DM, 2009, MOL CELL, V33, P537, DOI 10.1016/j.molcel.2009.02.015; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Young MR, 2006, GENE, V379, P1, DOI 10.1016/j.gene.2006.05.001; Zenz R, 2006, INT J BIOCHEM CELL B, V38, P1043, DOI 10.1016/j.biocel.2005.11.011; Zhang W, 2009, J BIOL CHEM, V284, P22649, DOI 10.1074/jbc.M109.013698	45	14	15	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2015	34	10					1333	1339		10.1038/onc.2014.26	http://dx.doi.org/10.1038/onc.2014.26			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC9JX	24632621				2022-12-17	WOS:000350687100013
J	Essers, PB; Klasson, TD; Pereboom, TC; Mans, DA; Nicastro, M; Boldt, K; Giles, RH; MacInnes, AW				Essers, P. B.; Klasson, T. D.; Pereboom, T. C.; Mans, D. A.; Nicastro, M.; Boldt, K.; Giles, R. H.; MacInnes, A. W.			The von Hippel-Lindau tumor suppressor regulates programmed cell death 5-mediated degradation of Mdm2	ONCOGENE			English	Article						renal cell carcinoma; von Hippel-Lindau tumor suppressor; programmed cell death 5	ZEBRAFISH MODEL; P53 PATHWAY; PROTEIN; GENE; VHL; APOPTOSIS; EXPRESSION; CHECKPOINT; INHIBITION; CARCINOMA	Functional loss of the von Hippel-Lindau (VHL) tumor suppressor protein (pVHL), which is part of an E3-ubiquitin ligase complex, initiates most inherited and sporadic clear-cell renal cell carcinomas (ccRCC). Genetic inactivation of the TP53 gene in ccRCC is rare, suggesting that an alternate mechanism alleviates the selective pressure for TP53 mutations in ccRCC. Here we use a zebrafish model to describe the functional consequences of pVHL loss on the p53/Mdm2 pathway. We show that p53 is stabilized in the absence of pVHL and becomes hyperstabilized upon DNA damage, which we propose is because of a novel in vivo interaction revealed between human pVHL and a negative regulator of Mdm2, the programmed cell death 5 (PDCD5) protein. PDCD5 is normally localized at the plasma membrane and in the cytoplasm. However, upon hypoxia or loss of pVHL, PDCD5 relocalizes to the nucleus, an event that is coupled to the degradation of Mdm2. Despite the subsequent hyperstabilization and normal transcriptional activity of p53, we find that zebrafish vhl(-/-) cells are still as highly resistant to DNA damage-induced cell cycle arrest and apoptosis as human ccRCC cells. We suggest this is because of a marked increase in expression of birc5a, the zebrafish homolog of Survivin. Accordingly, when we knock down Survivin in human ccRCC cells we are able to restore caspase activity in response to DNA damage. Taken together, our study describes a new mechanism for p53 stabilization through PDCD5 upon hypoxia or pVHL loss, and reveals new clinical potential for the treatment of pathobiological disorders linked to hypoxic stress.	[Essers, P. B.; Pereboom, T. C.; MacInnes, A. W.] KNAW, Hubrecht Inst Dev Biol & Stem Cell Res, NL-3584 CT Utrecht, Netherlands; [Essers, P. B.; Pereboom, T. C.; MacInnes, A. W.] Univ Med Ctr Utrecht, NL-3584 CT Utrecht, Netherlands; [Klasson, T. D.; Nicastro, M.; Giles, R. H.] Univ Med Ctr Utrecht, Dept Hypertens & Nephrol, Utrecht, Netherlands; [Mans, D. A.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands; [Mans, D. A.] Radboud Univ Nijmegen, Nijmegen Ctr Mol Life Sci, NL-6525 ED Nijmegen, Netherlands; [Boldt, K.] Univ Tubingen, Med Proteome Ctr, Ctr Ophthalm Res, Tubingen, Germany	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Radboud University Nijmegen; Radboud University Nijmegen; Eberhard Karls University of Tubingen	MacInnes, AW (corresponding author), KNAW, Hubrecht Inst Dev Biol & Stem Cell Res, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	a.macinnes@hubrecht.eu		Giles, Rachel/0000-0001-9133-2008	European Community [241955, 305608]	European Community(European Commission)	This research was supported by grants from the European Community's Seventh Framework Programme FP7/2009 under grant agreement 241955, SYSCILIA and 305608, EURenOmics (RHG). We would like to thank Susanne Lens for the kind gift of siRNA against Survivin, the animal caretakers of the Hubrecht Institute, and www. art-4-science.com for the creation of the graphic illustration.	Alarcon R, 1999, CANCER RES, V59, P6046; Albers J, 2013, EMBO MOL MED, V5, P949, DOI 10.1002/emmm.201202231; Boldt K, 2011, J CLIN INVEST, V121, P2169, DOI 10.1172/JCI45627; Chen LN, 2006, APOPTOSIS, V11, P101, DOI 10.1007/s10495-005-3134-y; Chen YY, 2001, FEBS LETT, V509, P191, DOI 10.1016/S0014-5793(01)03062-9; Coene KLM, 2011, HUM MOL GENET, V20, P3592, DOI 10.1093/hmg/ddr280; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Cui D, 2014, ONCOGENE, V33, P2225, DOI 10.1038/onc.2013.170; Dong Z, 2003, AM J PATHOL, V163, P663, DOI 10.1016/S0002-9440(10)63693-0; Dong Z, 2002, BIOCHEM J, V364, P413, DOI 10.1042/BJ20011431; Esteban MA, 2006, CANCER RES, V66, P3567, DOI 10.1158/0008-5472.CAN-05-2670; Frew IJ, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.124pe30; Fu LP, 2011, CANCER RES, V71, P6848, DOI 10.1158/0008-5472.CAN-11-1745; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583; Horn HF, 2007, ONCOGENE, V26, P1306, DOI 10.1038/sj.onc.1210263; Hsu T, 2012, ONCOGENE, V31, P2247, DOI 10.1038/onc.2011.442; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kim EL, 2010, NEURO-ONCOLOGY, V12, P389, DOI 10.1093/neuonc/nop046; Kleymenova E, 2004, CARCINOGENESIS, V25, P309, DOI 10.1093/carcin/bgh017; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lai YL, 2011, J PROTEOME RES, V10, P5175, DOI 10.1021/pr200642c; Lane DP, 2005, COLD SH Q B, V70, P489, DOI 10.1101/sqb.2005.70.049; MacInnes AW, 2008, P NATL ACAD SCI USA, V105, P10408, DOI 10.1073/pnas.0805036105; Mack FA, 2003, CANCER CELL, V3, P75, DOI 10.1016/S1535-6108(02)00240-4; Mans DA, 2013, J PATHOL, V231, P117, DOI 10.1002/path.4219; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Pereboom TC, 2011, BLOOD, V118, P5458, DOI 10.1182/blood-2011-04-351460; Qi H, 2003, CANCER RES, V63, P7076; Rankin EB, 2006, CANCER RES, V66, P2576, DOI 10.1158/0008-5472.CAN-05-3241; Roe JS, 2006, MOL CELL, V22, P395, DOI 10.1016/j.molcel.2006.04.006; Roe JS, 2011, CELL CYCLE, V10, P3920, DOI 10.4161/cc.10.22.18096; Sansam CL, 2010, GENE DEV, V24, P183, DOI 10.1101/gad.1860310; Sato Y, 2013, NAT GENET, V45, P860, DOI 10.1038/ng.2699; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sermeus A, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.48; Shepard JL, 2004, METHOD CELL BIOL, V76, P109; Spinola M, 2006, J CLIN ONCOL, V24, P1672, DOI 10.1200/JCO.2005.04.4339; Szymanska K, 2010, CANCER LETT, V293, P92, DOI 10.1016/j.canlet.2009.11.024; Tan Wan-long, 2006, Nan Fang Yi Ke Da Xue Xue Bao, V26, P1316; Tsuchiya H, 1996, CANCER RES, V56, P2881; van Rooijen E, 2011, METHOD CELL BIOL, V105, P163, DOI 10.1016/B978-0-12-381320-6.00007-2; van Rooijen E, 2009, BLOOD, V113, P6449, DOI 10.1182/blood-2008-07-167890; Westerfield M., 2000, ZEBRAFISH BOOK GUIDE; Xiong Lin, 2006, Nan Fang Yi Ke Da Xue Xue Bao, V26, P805; Xu LJ, 2012, APOPTOSIS, V17, P1235, DOI 10.1007/s10495-012-0754-x; Xu LJ, 2009, NEOPLASIA, V11, P345, DOI 10.1593/neo.81524; Yang YH, 2006, APOPTOSIS, V11, P993, DOI 10.1007/s10495-006-6714-6; Yuen JSP, 2011, BRIT J CANCER, V104, P941, DOI 10.1038/bjc.2011.55; Zucchi I, 2004, P NATL ACAD SCI USA, V101, P18147, DOI 10.1073/pnas.0408260101	56	14	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2015	34	6					771	779		10.1038/onc.2013.598	http://dx.doi.org/10.1038/onc.2013.598			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DG	24469044				2022-12-17	WOS:000348853800010
J	Kim, Y; Kim, J; Jang, SW; Ko, J				Kim, Y.; Kim, J.; Jang, S-W; Ko, J.			The role of sLZIP in cyclin D3-mediated negative regulation of androgen receptor transactivation and its involvement in prostate cancer	ONCOGENE			English	Article						prostate cancer; androgen receptor; sLZIP; cyclin D3	CELLS; MECHANISMS; GROWTH; GENE; D3; PROGRESSION; EXPRESSION; RAPAMYCIN; INVASION; COMPLEX	Androgen and the androgen receptor (AR) have important roles in prostate cancer (PCa) development, and androgen ablation has been the main therapeutic option for the treatment of PCa. However, the transition mechanism from androgen-dependent to -independent PCa after androgen depletion remains unclear. We investigated the distinct roles of small leucine zipper protein (sLZIP) in proliferation of androgen-dependent and -independent PCa cells. Cyclin D3 is known to interact with AR and attenuates the ligand-dependent function of AR in PCa cells. sLZIP regulates the transcription of cyclin D3 by binding directly to the AP-1 region in the cyclin D3 promoter. sLZIP represses AR transcriptional activity by interaction with AR that is phosphorylated by cyclin D3/cyclin-dependent kinase11(p58), leading to the suppression of androgen-dependent proliferation of PCa cells. The expression level of sLZIP is elevated in androgen-independent PCa cells and advanced human prostate tumors. Knockdown of endogenous sLZIP suppresses proliferation of androgen-independent PCa cells. LNCaP cells transformed to androgen-independent PCa cells exhibit increased expressions of sLZIP and cyclin D3. Tumor formation is inhibited in nude mouse xenografts from two androgen-independent PCa cells that are stably transfected with sh-sLZIP. Our findings indicate that sLZIP negatively regulates AR transactivation in androgen-dependent PCa cells and functions as a positive regulator in tumor progression of androgen-independent PCa. sLZIP contributes to the malignant phenotype of PCa and constitutes a novel therapeutic target for human PCa.	[Kim, Y.; Kim, J.; Ko, J.] Korea Univ, Div Life Sci, Seoul 136701, South Korea; [Jang, S-W] Univ Ulsan, Grad Sch, Dept Med, Seoul, South Korea	Korea University; University of Ulsan	Ko, J (corresponding author), Korea Univ, Div Life Sci, 5-1 Anam Dong, Seoul 136701, South Korea.	jesangko@korea.ac.kr			Korea University; Basic Research Laboratory Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [2009-0087099]	Korea University; Basic Research Laboratory Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology	This work was supported by a Korea University Grant and the Basic Research Laboratory Program (2009-0087099) through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology.	Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Compagno D, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001006; Cui JJ, 2011, CELL MOL LIFE SCI, V68, P1091, DOI 10.1007/s00018-010-0511-7; Galderisi U, 2003, ONCOGENE, V22, P5208, DOI 10.1038/sj.onc.1206558; Garcia-Morales P, 2006, MOL CANCER THER, V5, P2172, DOI 10.1158/1535-7163.MCT-05-0363; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Heemers HV, 2007, ENDOCR REV, V28, P778, DOI 10.1210/er.2007-0019; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Henzinger T, 1998, J BIOL CHEM, V273, P14958, DOI 10.1074/jbc.273.24.14958; Hleb M, 2004, J BIOL CHEM, V279, P31948, DOI 10.1074/jbc.M400638200; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; Jang SY, 2012, CANCER LETT, V314, P185, DOI 10.1016/j.canlet.2011.09.028; Kang H, 2011, J BIOL CHEM, V286, P42072, DOI 10.1074/jbc.M111.272302; Kang H, 2009, MOL ENDOCRINOL, V23, P1746, DOI 10.1210/me.2009-0009; Li YR, 2009, CANCER RES, V69, P3332, DOI 10.1158/0008-5472.CAN-08-3380; Lin DY, 2004, MOL CELL BIOL, V24, P10529, DOI 10.1128/MCB.24.24.10529-10541.2004; Lu S, 1999, ENDOCRINOLOGY, V140, P5054, DOI 10.1210/en.140.11.5054; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Olshavsky NA, 2008, ONCOGENE, V27, P3111, DOI 10.1038/sj.onc.1210981; Pienta KJ, 2006, CLIN CANCER RES, V12, P1665, DOI 10.1158/1078-0432.CCR-06-0067; REISMAN D, 1995, MOL ENDOCRINOL, V9, P1500, DOI 10.1210/me.9.11.1500; Tilley WD, 1996, CLIN CANCER RES, V2, P277; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Zong HL, 2007, MOL CELL BIOL, V27, P7125, DOI 10.1128/MCB.01753-06	25	14	14	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2015	34	2					226	236		10.1038/onc.2013.538	http://dx.doi.org/10.1038/onc.2013.538			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AY8FS	24441043				2022-12-17	WOS:000347790500010
J	Hall, WA; Petrova, AV; Colbert, LE; Hardy, CW; Fisher, SB; Saka, B; Shelton, JW; Warren, MD; Pantazides, BG; Gandhi, K; Kowalski, J; Kooby, DA; El-Rayes, BF; Staley, CA; Adsay, NV; Curran, WJ; Landry, JC; Maithel, SK; Yu, DS				Hall, W. A.; Petrova, A. V.; Colbert, L. E.; Hardy, C. W.; Fisher, S. B.; Saka, B.; Shelton, J. W.; Warren, M. D.; Pantazides, B. G.; Gandhi, K.; Kowalski, J.; Kooby, D. A.; El-Rayes, B. F.; Staley, C. A., III; Adsay, N. Volkan; Curran, W. J.; Landry, J. C.; Maithel, S. K.; Yu, D. S.			Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer	ONCOGENE			English	Article						CHD5; DNA damage response; biomarker; pancreatic cancer; tumor suppressor	REMODELING FACTOR CHD5; TUMOR-SUPPRESSOR; ANALYSIS REVEALS; DOWN-REGULATION; CHEMOTHERAPY; GENE; HYPERMETHYLATION; GEMCITABINE; FLUOROURACIL; PROGNOSIS	The DNA damage response (DDR) promotes genome integrity and serves as a cancer barrier in precancerous lesions but paradoxically may promote cancer survival. Genes that activate the DDR when dysregulated could function as useful biomarkers for outcome in cancer patients. Using a siRNA screen in human pancreatic cancer cells, we identified the CHD5 tumor suppressor as a gene, which, when silenced, activates the DDR. We evaluated the relationship of CHD5 expression with DDR activation in human pancreatic cancer cells and the association of CHD5 expression in 80 patients with resected pancreatic adenocarcinoma (PAC) by immunohistochemical analysis with clinical outcome. CHD5 depletion and low CHD5 expression in human pancreatic cancer cells lead to increased H2AX-Ser139 and CHK2-Thr68 phosphorylation and accumulation into nuclear foci. On Kaplan-Meier log-rank survival analysis, patients with low CHD5 expression had a median recurrence-free survival (RFS) of 5.3 vs 15.4 months for patients with high CHD5 expression (P = 0.03). In 59 patients receiving adjuvant chemotherapy, low CHD5 expression was associated with decreased RFS (4.5 vs 16.3 months; P = 0.001) and overall survival (OS) (7.2 vs 21.6 months; P = 0.003). On multivariate Cox regression analysis, low CHD5 expression remained associated with worse OS (HR: 3.187 (95% CI: 1.49-6.81); P = 0.003) in patients undergoing adjuvant chemotherapy. Thus, low CHD5 expression activates the DDR and predicts for worse OS in patients with resected PAC receiving adjuvant chemotherapy. Our findings support a model in which dysregulated expression of tumor suppressor genes that induce DDR activation can be utilized as biomarkers for poor outcome.	[Hall, W. A.; Petrova, A. V.; Colbert, L. E.; Hardy, C. W.; Shelton, J. W.; Warren, M. D.; Pantazides, B. G.; Curran, W. J.; Landry, J. C.; Yu, D. S.] Emory Univ, Winship Canc Inst, Dept Radiat Oncol, Atlanta, GA 30322 USA; [Fisher, S. B.; Kooby, D. A.; Staley, C. A., III; Maithel, S. K.] Emory Univ, Winship Canc Inst, Dept Surg, Div Surg Oncol, Atlanta, GA 30322 USA; [Saka, B.; Adsay, N. Volkan] Emory Univ, Winship Canc Inst, Dept Pathol, Atlanta, GA 30322 USA; [Gandhi, K.; Kowalski, J.] Winship Canc Inst, Atlanta, GA USA; [Kooby, D. A.] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA; [El-Rayes, B. F.] Emory Univ, Winship Canc Inst, Dept Med Oncol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Emory University	Yu, DS (corresponding author), Emory Univ, Sch Med, Dept Radiat Oncol, 1365 Clifton Rd NE,C3008, Atlanta, GA 30322 USA.	dsyu@emory.edu	Shelton, Joseph/AAH-1851-2020; Saka, Burcu/R-3487-2016; Adsay, Volkan/N-7130-2017; el-rayes, bassel/ABD-2901-2021; Colbert, Lauren/G-5860-2016	Adsay, Volkan/0000-0002-1308-3701; el-rayes, bassel/0000-0002-2661-5746; Colbert, Lauren/0000-0001-5806-4339; Kowalski, Jeanne/0000-0003-3458-3024; Fisher, Sarah/0000-0002-6881-2633	National Center for Advancing Translational Sciences of the National Institutes of Health [ULl TR000454, TLlTR000456]; PanCAN/AACR [16982]; DOD/PRCRP [CA110535]; Georgia Cancer Coalition [11072]; NATIONAL CANCER INSTITUTE [R44CA110535, R43CA110535] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000454] Funding Source: NIH RePORTER	National Center for Advancing Translational Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); PanCAN/AACR; DOD/PRCRP; Georgia Cancer Coalition; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We thank members of the Yu lab for helpful discussion. This work is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Numbers ULl TR000454 to LEC and SBF and TLlTR000456 to LEC, PanCAN/AACR 16982 to DSY, DOD/PRCRP CA110535 to DSY and Georgia Cancer Coalition 11072 to DSY.	Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Colbert LE, 2013, CANCER-AM CANCER SOC, V119, P3148, DOI 10.1002/cncr.28144; Du XL, 2013, CLIN TRANSL ONCOL, V15, P198, DOI 10.1007/s12094-012-0903-2; Fisher SL, 2012, TRANSFORMING PLACES: LESSONS FROM APPALACHIA, P1; Forbes S, 2006, BRIT J CANCER, V94, P318, DOI 10.1038/sj.bjc.6602928; Fujita T, 2008, JNCI-J NATL CANCER I, V100, P940, DOI 10.1093/jnci/djn176; Garcia I, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-277; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gorringe KL, 2008, NEOPLASIA, V10, P1253, DOI 10.1593/neo.08718; Iacobuzio-Donahue CA, 2009, J CLIN ONCOL, V27, P1806, DOI 10.1200/JCO.2008.17.7188; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Koyama H, 2012, CLIN CANCER RES, V18, P1588, DOI 10.1158/1078-0432.CCR-11-2644; Law ME, 2005, CANCER GENET CYTOGEN, V160, P1, DOI 10.1016/j.cancergencyto.2004.11.012; Maithel SK, 2011, ANN SURG ONCOL, V18, P2699, DOI 10.1245/s10434-011-1610-x; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Maupin KA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013002; Mokarram P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007012; Mulero-Navarro S, 2008, EPIGENETICS-US, V3, P210, DOI 10.4161/epi.3.4.6610; Neoptolemos JP, 2010, JAMA-J AM MED ASSOC, V304, P1073, DOI 10.1001/jama.2010.1275; Ng David, 2008, BMC Res Notes, V1, P86, DOI 10.1186/1756-0500-1-86; Oettle H, 2007, JAMA-J AM MED ASSOC, V297, P267, DOI 10.1001/jama.297.3.267; Okawa ER, 2008, ONCOGENE, V27, P803, DOI 10.1038/sj.onc.1210675; Paul S, 2013, CELL REP, V3, P92, DOI 10.1016/j.celrep.2012.12.009; Pei HD, 2009, CANCER CELL, V16, P259, DOI 10.1016/j.ccr.2009.07.016; Regine WF, 2008, JAMA-J AM MED ASSOC, V299, P1019, DOI 10.1001/jama.299.9.1019; Robbins CM, 2011, GENOME RES, V21, P47, DOI 10.1101/gr.107961.110; Wang J, 2011, ORAL ONCOL, V47, P601, DOI 10.1016/j.oraloncology.2011.05.003; Wang L, 2013, J CLIN NEUROSCI, V20, P958, DOI 10.1016/j.jocn.2012.07.021; Wang X, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-95; Wong RRY, 2011, GYNECOL OBSTET INVES, V72, P203, DOI 10.1159/000323883; Wu X, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3182; Zhao R, 2012, LUNG CANCER, V76, P324, DOI 10.1016/j.lungcan.2011.11.019	33	14	15	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2014	33	47					5450	5456		10.1038/onc.2013.488	http://dx.doi.org/10.1038/onc.2013.488			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MG	24276239				2022-12-17	WOS:000345120700007
J	Wu, MH; Chen, YA; Chen, HH; Chang, KW; Chang, IS; Wang, LH; Hsu, HL				Wu, M-H; Chen, Y-A; Chen, H-H; Chang, K-W; Chang, I-S; Wang, L-H; Hsu, H-L			MCT-1 expression and PTEN deficiency synergistically promote neoplastic multinucleation through the Src/p190B signaling activation	ONCOGENE			English	Article							TUMOR-SUPPRESSOR PTEN; BREAST-CANCER; CHROMOSOME SEGREGATION; TRASTUZUMAB RESISTANCE; CELL-SURVIVAL; AKT PATHWAY; ONCOGENE; 3-KINASE; CYTOKINESIS; INSTABILITY	Multinucleation is associated with malignant neoplasms; however, the molecular mechanism underlying the nuclear abnormality remains unclear. Loss or mutation of PTEN promotes the development of malignant tumors. We now demonstrate that increased expression of the oncogene MCT-1 (multiple copies in T-cell malignancy 1) antagonizes PTEN gene presentation, PTEN protein stability and PTEN functional activity, thereby further promoting phosphoinositide 3 kinase/AKT signaling, survival rate and malignancies of the PTEN-deficient cells. In the PTEN-null cancer cells, MCT-1 interacts with p190B and Src in vivo, supporting that they are in proximity of the signaling complexes. MCT-1 overexpression and PTEN loss synergistically augments the Src/p190B signaling function that leads to inhibition of RhoA activity. Under such a condition, the incidence of mitotic catastrophes including spindle multipolarity and cytokinesis failure is enhanced, driving an Src/p190B/RhoA-dependent neoplastic multinucleation. Targeting MCT-1 by the short hairpin RNA markedly represses the Src/p190B function, improves nuclear structures and suppresses xenograft tumorigenicity of the PTEN-null breast cancer cells. Consistent with the oncogenic effects in vitro, clinical evidence has confirmed that MCT-1 gene stimulation is correlated with p190B gene promotion and PTEN gene suppression in human breast cancer. Accordingly, MCT-1 gene induction is recognized as a potential biomarker of breast tumor development. Abrogating MCT-1 function may be a promising stratagem for management of breast cancer involving Src hyperactivation and/or PTEN dysfunction.	[Wu, M-H; Chen, Y-A; Chen, H-H; Wang, L-H; Hsu, H-L] Natl Hlth Res Inst, Inst Mol & Genom Med, Zhunan 35053, Miaoli County, Taiwan; [Chang, K-W] Natl Hlth Res Inst, Inst Populat Hlth Sci, Zhunan 35053, Miaoli County, Taiwan; [Chang, I-S] Natl Hlth Res Inst, Natl Inst Canc Res, Zhunan 35053, Miaoli County, Taiwan; [Chang, I-S] Natl Hlth Res Inst, Div Biostat & Bioinformat, Zhunan 35053, Miaoli County, Taiwan	National Health Research Institutes - Taiwan; National Health Research Institutes - Taiwan; National Health Research Institutes - Taiwan; National Health Research Institutes - Taiwan	Hsu, HL (corresponding author), Natl Hlth Res Inst, Inst Mol & Genom Med, 35 Keyan Rd, Zhunan 35053, Miaoli County, Taiwan.	hsinling88@nhri.org.tw	Chang, I-Shou/D-2084-2010; Wang, Lu-Hai/E-3986-2010; Hsu, Hsin-Ling/E-3672-2010		NSC [99-3112-B-400-002, 100-2320-B-400-013, 101-2320-B-400-014-MY3, NSC102-2319-B-400-001, DOH103-TD-C-111-004]	NSC(Ministry of Science and Technology, Taiwan)	This work was funded by NSC 99-3112-B-400-002 (to HLH), NSC 100-2320-B-400-013 (to HLH), NSC 101-2320-B-400-014-MY3 (to HLH), NSC102-2319-B-400-001 (to ISC) and DOH103-TD-C-111-004 (to LHW). We would like to acknowledge technical support from Cell Sorter Core (Chao-Yang Hsiao), Live Cell Image Core (Kang-Lin Chu) and Optical Biology Core (Shu-Fen Hu) facilities of National Health Research Institutes.	Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Alimonti A, 2010, NAT GENET, V42, P454, DOI 10.1038/ng.556; Blanco-Aparicio C, 2007, CARCINOGENESIS, V28, P1379, DOI 10.1093/carcin/bgm052; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chang CJ, 2008, MOL CELL BIOL, V28, P3281, DOI 10.1128/MCB.00310-08; Chung JH, 2005, CANCER RES, V65, P8096, DOI 10.1158/0008-5472.CAN-05-1888; Dillon RL, 2007, ONCOGENE, V26, P1338, DOI 10.1038/sj.onc.1210202; Draviam VM, 2004, CURR OPIN GENET DEV, V14, P120, DOI 10.1016/j.gde.2004.02.007; Duijf PHG, 2013, ONCOGENE, V32, P4727, DOI 10.1038/onc.2012.616; Gollin SM, 2005, SEMIN CANCER BIOL, V15, P33, DOI 10.1016/j.semcancer.2004.09.004; Guigon CJ, 2009, ONCOGENE, V28, P509, DOI 10.1038/onc.2008.407; Haskell MD, 2001, J CELL SCI, V114, P1699; Hsu HL, 2007, DNA REPAIR, V6, P1319, DOI 10.1016/j.dnarep.2007.02.028; Hwang Melissa, 2012, Cancers (Basel), V4, P475, DOI 10.3390/cancers4020475; Janetopoulos C, 2005, DEV CELL, V8, P467, DOI 10.1016/j.devcel.2005.02.010; Kasiappan R, 2009, MOL CANCER RES, V7, P536, DOI 10.1158/1541-7786.MCR-08-0422; Kim J, 2012, ONCOGENE, V31, P322, DOI 10.1038/onc.2011.236; Lan KH, 2005, ANN NY ACAD SCI, V1059, P70, DOI 10.1196/annals.1339.026; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; Lynch ED, 1997, AM J HUM GENET, V61, P1254, DOI 10.1086/301639; Manchinelly SAS, 2010, J BIOL CHEM, V285, P26923, DOI 10.1074/jbc.M110.103804; Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Papakonstanti EA, 2007, EMBO J, V26, P3050, DOI 10.1038/sj.emboj.7601763; Planchon SM, 2008, J CELL SCI, V121, P249, DOI 10.1242/jcs.022459; Radke J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056691; Regnier V, 2005, MOL CELL BIOL, V25, P3967, DOI 10.1128/MCB.25.10.3967-3981.2005; Ruggeri BA, 1998, MOL CARCINOGEN, V21, P81, DOI 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R; Sachdev P, 2002, J BIOL CHEM, V277, P17638, DOI 10.1074/jbc.M111575200; Salmena L, 2007, NAT REV CANCER, V7, P409, DOI 10.1038/nrc2145; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Shi B, 2003, BLOOD, V102, P297, DOI 10.1182/blood-2002-11-3486; Shih HJ, 2012, ONCOTARGET, V3, P1401; Shih HJ, 2012, CELL CYCLE, V11, P934, DOI 10.4161/cc.11.5.19452; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Su L, 2003, J CELL BIOL, V163, P571, DOI 10.1083/jcb.200308007; Su L, 2009, EXP CELL RES, V315, P1347, DOI 10.1016/j.yexcr.2009.02.014; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tokunaga Eriko, 2006, Breast Cancer, V13, P137, DOI 10.2325/jbcs.13.137; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vicente-Duenas C, 2013, EMBO J, V32, P1502, DOI 10.1038/emboj.2013.97; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(00)00088-5; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; Yin Y, 2008, ONCOGENE, V27, P5443, DOI 10.1038/onc.2008.241; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309; Zheng HW, 2008, NATURE, V455, P1129, DOI 10.1038/nature07443	50	14	14	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2014	33	43					5109	5120		10.1038/onc.2014.125	http://dx.doi.org/10.1038/onc.2014.125			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OF	24858043	Green Published, hybrid			2022-12-17	WOS:000343768400006
J	Hug, E; Hobeika, E; Reth, M; Jumaa, H				Hug, E.; Hobeika, E.; Reth, M.; Jumaa, H.			Inducible expression of hyperactive Syk in B cells activates Blimp-1-dependent terminal differentiation	ONCOGENE			English	Article						B-cell transformation; Bcl-2; Blimp-1; hyperactive Syk; terminal differentiation	LYMPHOCYTES DEPENDS; TYROSINE KINASES; BLIMP-1; GENE; BCL-2; SURVIVAL; APOPTOSIS; 3-KINASE; TARGETS; MCL-1	The non-receptor protein tyrosine kinase Syk (spleen tyrosine kinase) is an important mediator of signal transduction in B cells. By acting downstream of the B-cell antigen receptor, Syk promotes signaling pathways involved in proliferation, differentiation and survival of B cells. To study the oncogenic potential of Syk, we generated a mouse model for the inducible expression of the leukemia-derived TEL-Syk fusion protein exhibiting constitutive kinase activity. To achieve B-cell-specific expression of TEL-Syk in adult mice, we used a tamoxifen-inducible Cre mouse line. This study shows that inducible expression of TEL-Syk in B cells leads to transient proliferation and subsequent plasma cell differentiation. However, it does not lead to B-cell transformation. Instead, Syk activation induces the tumor suppressor B-lymphocyte-induced maturation protein-1 (Blimp-1), which interferes with the expression of the antiapoptotic protein Bcl-2. Combined induction of TEL-Syk with transgenic expression of Bcl-2 results in a severe phenotype and plasma cell expansion. Our results suggest that deregulated Syk activity by itself is not sufficient for the transformation of B cells, as downstream effectors, such as Blimp-1, limit the survival and expansion of the activated B cell.	[Hug, E.; Reth, M.; Jumaa, H.] Univ Freiburg, BIOSS Ctr Biol Signalling Studies, D-79106 Freiburg, Germany; [Hug, E.; Hobeika, E.; Reth, M.; Jumaa, H.] Univ Freiburg, Fac Biol, Dept Mol Immunol, D-79106 Freiburg, Germany; [Hug, E.; Hobeika, E.; Reth, M.; Jumaa, H.] Max Planck Inst Immunbiol & Epigenet, D-79108 Freiburg, Germany	University of Freiburg; University of Freiburg; Max Planck Society	Jumaa, H (corresponding author), Max Planck Inst Immunbiol & Epigenet, Stuebeweg 51, D-79108 Freiburg, Germany.	jumaa@ie-freiburg.mpg.de	hobeika, elias/AAV-6663-2021		Deutsche Krebshilfe [108935]	Deutsche Krebshilfe(Deutsche Krebshilfe)	We thank A Nil for critical discussion and help with mouse analyses. We thank M Bach, C Eschbach, I Fiedler, C Sainz Rueda for technical assistance; U Zimber-Strobl for providing Rosa26-targeting construct; Benoit Kanzler and the transgenic mouse unit for ES cell injection; A Wuerch and S Hobitz for cell sorting; F Koehler and M Bach for proofreading the manuscript; S Srinivas for the Rosa26-YFP mice, A Strasser for the Bcl-2 tg mice, A Tarakhovsky for the Syk<SUP>fl</SUP>/<SUP>fl</SUP> mice and K Rajewsky for the CD21-Cre mice. This work was supported by the Deutsche Krebshilfe (project no. 108935), the Deutsche Forschungsgemeinschaft (SFB620) and the Excellence Initiative of the German Federal and State Governments (EXC294).	Adachi T, 1996, EMBO J, V15, P1534, DOI 10.1002/j.1460-2075.1996.tb00497.x; Beitz LO, 1999, J BIOL CHEM, V274, P32662, DOI 10.1074/jbc.274.46.32662; Calado DP, 2010, CANCER CELL, V18, P580, DOI 10.1016/j.ccr.2010.11.024; Carrington EM, 2010, P NATL ACAD SCI USA, V107, P10967, DOI 10.1073/pnas.1005256107; Chen LF, 2008, BLOOD, V111, P2230, DOI 10.1182/blood-2007-07-100115; Cretney E, 2011, NAT IMMUNOL, V12, P304, DOI 10.1038/ni.2006; De Vos J, 2006, IMMUNOL REV, V210, P86, DOI 10.1111/j.0105-2896.2006.00362.x; Feil R, 1997, BIOCHEM BIOPH RES CO, V237, P752, DOI 10.1006/bbrc.1997.7124; Gobessi S, 2009, LEUKEMIA, V23, P686, DOI 10.1038/leu.2008.346; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; Herzog S, 2008, NAT IMMUNOL, V9, P623, DOI 10.1038/ni.1616; Homig-Holzel C, 2008, J EXP MED, V205, P1317, DOI 10.1084/jem.20080238; Holmes ML, 2008, IMMUNOL CELL BIOL, V86, P47, DOI 10.1038/sj.icb.7100134; Kallies A, 2006, NAT IMMUNOL, V7, P466, DOI 10.1038/ni1321; Kallies A, 2007, CURR OPIN IMMUNOL, V19, P156, DOI 10.1016/j.coi.2007.01.003; Kanie T, 2004, LEUKEMIA, V18, P548, DOI 10.1038/sj.leu.2403266; Knodel M, 1999, EUR J IMMUNOL, V29, P2988; Kraus M, 2004, CELL, V117, P787, DOI 10.1016/j.cell.2004.05.014; Kulathu Y, 2008, EMBO J, V27, P1333, DOI 10.1038/emboj.2008.62; Kuno Y, 2001, BLOOD, V97, P1050, DOI 10.1182/blood.V97.4.1050; Leseux L, 2006, BLOOD, V108, P4156, DOI 10.1182/blood-2006-05-026203; Mandelbaum J, 2010, CANCER CELL, V18, P568, DOI 10.1016/j.ccr.2010.10.030; Marshall AJ, 2000, IMMUNOL REV, V176, P30; Martins G, 2008, ANNU REV IMMUNOL, V26, P133, DOI 10.1146/annurev.immunol.26.021607.090241; Merino D, 2012, BLOOD, V119, P5807, DOI 10.1182/blood-2011-12-400929; Peperzak V, 2013, NAT IMMUNOL, V14, P290, DOI 10.1038/ni.2527; Riccaboni M, 2010, DRUG DISCOV TODAY, V15, P517, DOI 10.1016/j.drudis.2010.05.001; Rinaldi A, 2006, BRIT J HAEMATOL, V132, P303, DOI 10.1111/j.1365-2141.2005.05883.x; Saijo K, 2003, NAT IMMUNOL, V4, P274, DOI 10.1038/ni893; Shaffer AL, 2004, IMMUNITY, V21, P81, DOI 10.1016/j.immuni.2004.06.010; Shaffer AL, 2002, IMMUNITY, V17, P51, DOI 10.1016/S1074-7613(02)00335-7; Shapiro-Shelef M, 2003, IMMUNITY, V19, P607, DOI 10.1016/S1074-7613(03)00267-X; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; Visan I, 2003, EUR J IMMUNOL, V33, P1163, DOI 10.1002/eji.200323747; Werner M, 2010, IMMUNOL REV, V237, P55, DOI 10.1111/j.1600-065X.2010.00934.x; Wossning T, 2006, J EXP MED, V203, P2829, DOI 10.1084/jem.20060967; Young RM, 2009, BLOOD, V113, P2508, DOI 10.1182/blood-2008-05-158618	39	14	14	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2014	33	28					3730	3741		10.1038/onc.2013.326	http://dx.doi.org/10.1038/onc.2013.326			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2GC	23955076				2022-12-17	WOS:000338942900012
J	Martin, D; Nguyen, Q; Molinolo, A; Gutkind, JS				Martin, D.; Nguyen, Q.; Molinolo, A.; Gutkind, J. S.			Accumulation of dephosphorylated 4EBP after mTOR inhibition with rapamycin is sufficient to disrupt paracrine transformation by the KSHV vGPCR oncogene	ONCOGENE			English	Article						Kaposi's sarcoma; mTOR; PI3K; 4EBP; rapamycin; cancer	KAPOSIS-SARCOMA; MAMMALIAN TARGET; PROTEIN; CELL; INFECTION; GROWTH; PATHOGENESIS; EXPRESSION; SIROLIMUS; CYTOKINES	Dysregulation of the PI3K/Akt/mTOR pathway is one of the most frequent events in human cancer. However, the clinical benefits of PI3K/Akt/mTOR inhibitors have not yet achieved their predicted potential in many of the most prevalent human cancers. Of interest, treatment of Kaposi's sarcoma (KS) patients with rapamycin provided the first evidence of the antineoplastic activity of mTOR inhibitors in humans, becoming the standard of care for KS arising in renal transplant patients. Thus, the study of KS may provide a unique opportunity to dissect the contribution of specific mTOR downstream targets to cancer development. The KS associated herpesvirus (KSHV) is the etiological agent for KS, and the KSHV-encoded oncogene viral-G protein-coupled receptor (vGPCR) promotes the potent activation of the PI3K-Akt-mTOR pathway by both direct and paracrine mechanisms. We focused on a direct target of mTOR, EIF4EBP1/2/3 (4EBP), which inhibits the translation of eukaryotic initiation factor 4E (eiF4E)-bound mRNAs. 4EBP phosphorylation by mTOR relieves its inhibitory activity, hence resulting in increased eiF4E-dependent mRNA translation. We developed a paracrine transformation model, recapitulating the cellular composition of KS lesions, in which vGPCR-expressing cells promote the rapid proliferation of endothelial cells, thus expressing KSHV-latent genes by the release of growth factors. Using this model, we show here that the accumulation of dephosphorylated 4EBP in response to rapamycin or by the expression of an mTOR-insensitive mutant of 4EBP1 is sufficient to disrupt the eiF4E function downstream of mTOR to a similar extent than the mTOR catalytic inhibitor Torin2 and to halt KS development. We also provide evidence that eiF4E contributes to paracrine neoplastic, signaling through the release of pro-angiogenic factors that are acting on endothelial cells, expressing KSHV-latent genes. These findings may provide a preclinical platform and the rationale for the development of novel mTOR, inhibiting agents that may selectively disrupt the mTOR-4EBP interaction for the treatment of KS and other tumor lesions, exhibiting hyperactive mTOR pathway function.	[Martin, D.; Nguyen, Q.; Molinolo, A.; Gutkind, J. S.] Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bldg 30 Room 320,30 Convent Dr MSC 4340, Bethesda, MD 20892 USA.	sg39v@nih.gov	Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482; Martin Izquierdo, Daniel/0000-0002-8880-9087	National Institutes of Health Intramural AIDS-Targeted Antiviral Program; National Institute of Dental and Craniofacial Research; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER	National Institutes of Health Intramural AIDS-Targeted Antiviral Program; National Institute of Dental and Craniofacial Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This research was supported by the National Institutes of Health Intramural AIDS-Targeted Antiviral Program and the National Institute of Dental and Craniofacial Research. We apologize to colleagues whose primary research papers may not have been cited due to space constraints.	Alain T, 2012, CANCER RES, V72, P6468, DOI 10.1158/0008-5472.CAN-12-2395; Atkins MB, 2004, J CLIN ONCOL, V22, P909, DOI 10.1200/JCO.2004.08.185; Benjamin D, 2011, NAT REV DRUG DISCOV, V10, P868, DOI 10.1038/nrd3531; Bieleski L, 2001, J VIROL, V75, P1864, DOI 10.1128/JVI.75.4.1864-1869.2001; Cesarman E, 2000, J EXP MED, V191, P417, DOI 10.1084/jem.191.3.417; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Dancey J, 2010, NAT REV CLIN ONCOL, V7, P209, DOI 10.1038/nrclinonc.2010.21; Dann SG, 2007, TRENDS MOL MED, V13, P252, DOI 10.1016/j.molmed.2007.04.002; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Ganem D, 2006, ANNU REV PATHOL-MECH, V1, P273, DOI 10.1146/annurev.pathol.1.110304.100133; Gasperini P, 2009, LEUKEMIA, V23, P1867, DOI 10.1038/leu.2009.117; Gasperini P, 2008, J LEUKOCYTE BIOL, V84, P994, DOI 10.1189/jlb.1107777; Hosseini-Moghaddam SM, 2012, TRANSPL INFECT DIS, V14, P338, DOI 10.1111/j.1399-3062.2011.00714.x; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Liu QS, 2012, METHODS MOL BIOL, V821, P447, DOI 10.1007/978-1-61779-430-8_29; Martin D, 2008, ONCOGENE, V27, P1844, DOI [10.1038/sj.onc.1210817, 10.1038/onc.2009.351]; Mesri EA, 2010, NAT REV CANCER, V10, P707, DOI 10.1038/nrc2888; Minchinton AI, 2006, NAT REV CANCER, V6, P583, DOI 10.1038/nrc1893; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; Mutlu AD, 2007, CANCER CELL, V11, P245, DOI 10.1016/j.ccr.2007.01.015; Sodhi A, 2004, P NATL ACAD SCI USA, V101, P4821, DOI 10.1073/pnas.0400835101; Sodhi A, 2006, CANCER CELL, V10, P133, DOI 10.1016/j.ccr.2006.05.026; Stallone G, 2005, NEW ENGL J MED, V352, P1317, DOI 10.1056/NEJMoa042831; Stallone G, 2008, TRANSPL INT, V21, P825, DOI 10.1111/j.1432-2277.2008.00697.x; Vilar E, 2011, MOL CANCER THER, V10, P395, DOI 10.1158/1535-7163.MCT-10-0905; Vitale-Cross L, 2012, CANCER PREV RES, V5, P562, DOI 10.1158/1940-6207.CAPR-11-0502; Vuiblet V, 2012, NEPHROL DIAL TRANSPL, V27, P411, DOI 10.1093/ndt/gfr261; Yanagiya A, 2012, MOL CELL, V46, P847, DOI 10.1016/j.molcel.2012.04.004	28	14	15	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2014	33	18					2405	2412		10.1038/onc.2013.193	http://dx.doi.org/10.1038/onc.2013.193			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AG5ID	23708663	Bronze			2022-12-17	WOS:000335451800013
J	Stone, HR; Morris, JR				Stone, H. R.; Morris, J. R.			DNA damage emergency: cellular garbage disposal to the rescue?	ONCOGENE			English	Review						ubiquitin; DNA repair; proteasome; POH1; 53BP1	DOUBLE-STRAND BREAKS; UBIQUITIN E3 LIGASE; DEUBIQUITINATING ENZYME; AAA-ATPASE; 53BP1 RECRUITMENT; HOMOLOGOUS RECOMBINATION; PROTEIN-DEGRADATION; 26S PROTEASOME; RAP80 PROTEIN; KU80 REMOVAL	The proteasome is a cellular machine found in the cytosol, nucleus and on chromatin that performs much of the proteolysis in eukaryotic cells. Recent reports show it is enriched at sites of double-stranded DNA breaks (DSBs) in mammalian cells. What is it doing there? This review will address three possibilities suggested by recent reports: in degrading proteins after their ubiquitination at and eviction from chromatin; as a deubiquitinase, specific to the antagonism of ubiquitin conjugates generated as part of the signalling of a DSB; and as a functional component of DNA repair mechanism itself. These findings add complexity to the proteasome as a potential therapeutic target in cancer treatment.	[Stone, H. R.; Morris, J. R.] Univ Birmingham, Coll Med & Dent Sci, Sch Canc Sci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Morris, JR (corresponding author), Univ Birmingham, Coll Med & Dent Sci, Sch Canc Sci, Birmingham B15 2TT, W Midlands, England.	j.morris.3@bham.ac.uk	Morris, Joanna/AAK-3388-2021	Morris, Joanna/0000-0001-9762-8133	Breast Cancer Campaign [2010NovPhD02]	Breast Cancer Campaign	HRS is supported by the Breast Cancer Campaign Grant 2010NovPhD02.	Acs K, 2011, NAT STRUCT MOL BIOL, V18, P1345, DOI 10.1038/nsmb.2188; Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Beaven AW, 2012, LEUKEMIA LYMPHOMA, V53, P254, DOI 10.3109/10428194.2011.608445; Ben-Aroya S, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000852; Ben-Saadon R, 2006, MOL CELL, V24, P701, DOI 10.1016/j.molcel.2006.10.022; Bin W, 2007, P NATL ACAD SCI USA, V104, P20759, DOI 10.1073/pnas.0710061104; Blickwedehl J, 2008, P NATL ACAD SCI USA, V105, P16165, DOI 10.1073/pnas.0803145105; Blickwedehl J, 2007, RADIAT RES, V167, P663, DOI 10.1667/RR0690.1; Bothmer A, 2011, MOL CELL, V42, P319, DOI 10.1016/j.molcel.2011.03.019; Bouwman P, 2010, NAT STRUCT MOL BIOL, V17, P688, DOI 10.1038/nsmb.1831; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Burnett B, 2003, HUM MOL GENET, V12, P3195, DOI 10.1093/hmg/ddg344; Butler LR, 2012, EMBO J, V31, P3918, DOI 10.1038/emboj.2012.232; Cao L, 2009, MOL CELL, V35, P534, DOI 10.1016/j.molcel.2009.06.037; Chapman JR, 2012, J CELL SCI, V125, P3529, DOI 10.1242/jcs.105353; Chen Q, 2005, BLOOD, V106, P698, DOI 10.1182/blood-2004-11-4286; CIECHANOVER A, 1981, P NATL ACAD SCI-BIOL, V78, P761, DOI 10.1073/pnas.78.2.761; Cooper EM, 2009, EMBO J, V28, P621, DOI 10.1038/emboj.2009.27; Cvek B, 2011, CURR CANCER DRUG TAR, V11, P332, DOI 10.2174/156800911794519806; Cvek B, 2012, PROG MOL BIOL TRANSL, V109, P161, DOI 10.1016/B978-0-12-397863-9.00005-5; D'Arcy P, 2012, INT J BIOCHEM CELL B, V44, P1729, DOI 10.1016/j.biocel.2012.07.011; Dalla Via L, 2012, FUTURE MED CHEM, V4, P525, DOI [10.4155/FMC.11.187, 10.4155/fmc.11.187]; Dantuma NP, 2006, J CELL BIOL, V173, P19, DOI 10.1083/jcb.200510071; Dimitrova N, 2008, NATURE, V456, P524, DOI 10.1038/nature07433; Doil C, 2009, CELL, V136, P435, DOI 10.1016/j.cell.2008.12.041; Dou H, 2010, MOL CELL, V39, P333, DOI 10.1016/j.molcel.2010.07.021; Ernst R, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000605; Feng L, 2012, NAT STRUCT MOL BIOL, V19, P201, DOI 10.1038/nsmb.2211; Feng L, 2010, J BIOL CHEM, V285, P30982, DOI 10.1074/jbc.M110.135392; Franz A, 2011, MOL CELL, V44, P85, DOI 10.1016/j.molcel.2011.08.028; Fushman D, 2010, J MOL BIOL, V395, P803, DOI 10.1016/j.jmb.2009.10.039; Galanty Y, 2012, GENE DEV, V26, P1179, DOI 10.1101/gad.188284.112; Gallery M, 2007, MOL CANCER THER, V6, P262, DOI 10.1158/1535-7163.MCT-06-0542; GOLDKNOPF IL, 1977, P NATL ACAD SCI USA, V74, P864, DOI 10.1073/pnas.74.3.864; GOLDSTEIN G, 1975, P NATL ACAD SCI USA, V72, P11, DOI 10.1073/pnas.72.1.11; Gudjonsson T, 2012, CELL, V150, P697, DOI 10.1016/j.cell.2012.06.039; Gudmundsdottir K, 2007, ONCOGENE, V26, P7601, DOI 10.1038/sj.onc.1210579; Guzzo CM, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003485; Hanna J, 2003, MOL CELL BIOL, V23, P9251, DOI 10.1128/MCB.23.24.9251-9261.2003; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hu X, 2012, J BIOL CHEM, V287, P25510, DOI 10.1074/jbc.M112.374116; Huang J, 2009, NAT CELL BIOL, V11, P592, DOI 10.1038/ncb1865; Huen MSY, 2007, CELL, V131, P901, DOI 10.1016/j.cell.2007.09.041; Indig FE, 2004, J STRUCT BIOL, V146, P251, DOI 10.1016/j.jsb.2003.11.009; Jacobson AD, 2009, J BIOL CHEM, V284, P35485, DOI 10.1074/jbc.M109.052928; Jacquemont C, 2007, CANCER RES, V67, P7395, DOI 10.1158/0008-5472.CAN-07-1015; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Joo HY, 2007, NATURE, V449, P1068, DOI 10.1038/nature06256; Juang YC, 2012, MOL CELL, V45, P384, DOI 10.1016/j.molcel.2012.01.011; Kim HT, 2007, J BIOL CHEM, V282, P17375, DOI 10.1074/jbc.M609659200; Kim HT, 2012, METHODS MOL BIOL, V832, P653, DOI 10.1007/978-1-61779-474-2_46; Kim HT, 2009, EMBO J, V28, P1867, DOI 10.1038/emboj.2009.115; Kirisako T, 2006, EMBO J, V25, P4877, DOI 10.1038/sj.emboj.7601360; Kojic M, 2005, MOL CELL BIOL, V25, P2547, DOI 10.1128/MCB.25.7.2547-2557.2005; Kolas NK, 2007, SCIENCE, V318, P1637, DOI 10.1126/science.1150034; Komander D, 2009, NAT REV MOL CELL BIO, V10, P550, DOI 10.1038/nrm2731; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Kristensen CN, 2010, MUTAT RES-FUND MOL M, V694, P60, DOI 10.1016/j.mrfmmm.2010.08.007; Krogan NJ, 2004, MOL CELL, V16, P1027, DOI 10.1016/j.molcel.2004.11.033; Kuehn L, 1997, MOL BIOL REP, V24, P89, DOI 10.1023/A:1006897801858; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Lander GC, 2012, NATURE, V482, P186, DOI 10.1038/nature10774; Lasker K, 2012, P NATL ACAD SCI USA, V109, P1380, DOI 10.1073/pnas.1120559109; Levy-Barda A, 2011, CELL CYCLE, V10, P4300, DOI 10.4161/cc.10.24.18642; Liu H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005544; Liu J, 2010, NAT STRUCT MOL BIOL, V17, P1260, DOI 10.1038/nsmb.1904; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; Livingstone M, 2005, CANCER RES, V65, P7533, DOI 10.1158/0008-5472.CAN-04-3729; Lok GTM, 2012, NUCLEIC ACIDS RES, V40, P196, DOI 10.1093/nar/gkr655; Lou ZK, 2003, J BIOL CHEM, V278, P13599, DOI 10.1074/jbc.C300060200; Luo KT, 2012, EMBO J, V31, P3008, DOI 10.1038/emboj.2012.158; Mailand N, 2007, CELL, V131, P887, DOI 10.1016/j.cell.2007.09.040; Mallette FA, 2012, CELL RES, V22, P1221, DOI 10.1038/cr.2012.58; Mallette FA, 2012, EMBO J, V31, P1865, DOI 10.1038/emboj.2012.47; Marteijn JA, 2009, J CELL BIOL, V186, P835, DOI 10.1083/jcb.200902150; Matilla A, 2001, HUM MOL GENET, V10, P2821, DOI 10.1093/hmg/10.24.2821; Mattiroli F, 2012, CELL, V150, P1182, DOI 10.1016/j.cell.2012.08.005; Meerang M, 2011, NAT CELL BIOL, V13, P1376, DOI 10.1038/ncb2367; Meyer H, 2012, NAT CELL BIOL, V14, P117, DOI 10.1038/ncb2407; Min JR, 2007, NAT STRUCT MOL BIOL, V14, P1229, DOI 10.1038/nsmb1340; Mochan TA, 2003, CANCER RES, V63, P8586; Mok MTS, 2010, CELL SIGNAL, V22, P47, DOI 10.1016/j.cellsig.2009.09.007; Moreau P, 2012, BLOOD, V120, P947, DOI 10.1182/blood-2012-04-403733; Mott C, 2011, DNA REPAIR, V10, P408, DOI 10.1016/j.dnarep.2011.01.007; Murakawa Y, 2007, CANCER RES, V67, P8536, DOI 10.1158/0008-5472.CAN-07-1166; Nabhan JF, 2006, J BIOL CHEM, V281, P16099, DOI 10.1074/jbc.M512086200; Nakada S, 2012, CANCER RES, V72, P4974, DOI 10.1158/0008-5472.CAN-12-1057; Nakada S, 2010, NATURE, V466, P941, DOI 10.1038/nature09297; Neri P, 2011, BLOOD, V118, P6368, DOI 10.1182/blood-2011-06-363911; Nicassio F, 2007, CURR BIOL, V17, P1972, DOI 10.1016/j.cub.2007.10.034; Nijman SMB, 2005, MOL CELL, V17, P331, DOI 10.1016/j.molcel.2005.01.008; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Nishikawa H, 2004, J BIOL CHEM, V279, P3916, DOI 10.1074/jbc.M308540200; Nishio K, 2009, BIOCHEM BIOPH RES CO, V390, P855, DOI 10.1016/j.bbrc.2009.10.062; Patterson-Fortin J, 2010, J BIOL CHEM, V285, P30971, DOI 10.1074/jbc.M110.135319; Pegoraro G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031684; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Peth A, 2010, MOL CELL, V40, P671, DOI 10.1016/j.molcel.2010.11.002; Peth A, 2009, MOL CELL, V36, P794, DOI 10.1016/j.molcel.2009.11.015; Popov N, 2007, CELL CYCLE, V6, P2327, DOI 10.4161/cc.6.19.4804; Postow L, 2008, J CELL BIOL, V182, P467, DOI 10.1083/jcb.200802146; Raman M, 2011, MOL CELL, V44, P72, DOI 10.1016/j.molcel.2011.06.036; Ramchandren R, 2012, ONCOLOGIST, V17, P367, DOI 10.1634/theoncologist.2011-0258; Richly H, 2005, CELL, V120, P73, DOI 10.1016/j.cell.2004.11.013; Rumpf S, 2006, MOL CELL, V21, P261, DOI 10.1016/j.molcel.2005.12.014; Russell NS, 2004, BIOCHEMISTRY-US, V43, P4844, DOI 10.1021/bi035626r; San Miguel JF, 2008, NEW ENGL J MED, V359, P906, DOI 10.1056/NEJMoa0801479; Sato Y, 2012, J BIOL CHEM, V287, P25860, DOI 10.1074/jbc.M112.364752; Sauer RT, 2004, CELL, V119, P9, DOI 10.1016/j.cell.2004.09.020; Scheel H, 2003, HUM MOL GENET, V12, P2845, DOI 10.1093/hmg/ddg297; Schoenfeld AR, 2004, MOL CELL BIOL, V24, P7444, DOI 10.1128/MCB.24.17.7444-7455.2004; Shao G, 2009, P NATL ACAD SCI USA, V106, P3166, DOI 10.1073/pnas.0807485106; Shi W, 2008, J BIOL CHEM, V283, P31608, DOI 10.1074/jbc.M801082200; Sigurdsson S, 2001, GENE DEV, V15, P3308, DOI 10.1101/gad.935501; Sobhian B, 2007, SCIENCE, V316, P1198, DOI 10.1126/science.1139516; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Stewart GS, 2009, CELL, V136, P420, DOI 10.1016/j.cell.2008.12.042; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Takeshita T, 2009, CANCER CHEMOTH PHARM, V64, P1039, DOI 10.1007/s00280-009-0961-5; Tan MKM, 2011, MOL CELL BIOL, V31, P3687, DOI 10.1128/MCB.05746-11; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Ustrell V, 2002, EMBO J, V21, P3516, DOI 10.1093/emboj/cdf333; Varadan R, 2002, J MOL BIOL, V324, P637, DOI 10.1016/S0022-2836(02)01198-1; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Verma R, 2011, MOL CELL, V41, P82, DOI 10.1016/j.molcel.2010.12.017; Virdee S, 2010, NAT CHEM BIOL, V6, P750, DOI [10.1038/NCHEMBIO.426, 10.1038/nchembio.426]; Vyas R, 2013, CELL DEATH DIFFER, V20, P490, DOI 10.1038/cdd.2012.145; Wang B, 2007, SCIENCE, V316, P1194, DOI 10.1126/science.1139476; Wang B, 2009, GENE DEV, V23, P729, DOI 10.1101/gad.1770309; Wang CY, 2001, NAT STRUCT BIOL, V8, P47; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Wiener R, 2012, NATURE, V483, P618, DOI 10.1038/nature10911; Wilcox AJ, 2009, NAT CELL BIOL, V11, P1481, DOI 10.1038/ncb1997; Wu JX, 2012, J BIOL CHEM, V287, P22919, DOI 10.1074/jbc.M112.351007; Xu P, 2009, CELL, V137, P133, DOI 10.1016/j.cell.2009.01.041; Yamada T, 2000, FEBS LETT, V466, P287, DOI 10.1016/S0014-5793(99)01673-7; Yan J, 2008, CANCER LETT, V271, P179, DOI 10.1016/j.canlet.2008.04.046; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071; Yin YL, 2012, GENE DEV, V26, P1196, DOI 10.1101/gad.189274.112; Zhang D, 2006, CELL, V126, P529, DOI 10.1016/j.cell.2006.06.039; Zhang HT, 2000, DNA CELL BIOL, V19, P253, DOI 10.1089/10445490050021168; Zhou QW, 2007, MOL CELL BIOL, V27, P2512, DOI 10.1128/MCB.01907-06	145	14	14	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					805	813		10.1038/onc.2013.60	http://dx.doi.org/10.1038/onc.2013.60			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23503465				2022-12-17	WOS:000331626900001
J	Vaites, LP; Lian, Z; Lee, EK; Yin, B; DeMicco, A; Bassing, CH; Diehl, JA				Vaites, L. P.; Lian, Z.; Lee, E. K.; Yin, B.; DeMicco, A.; Bassing, C. H.; Diehl, J. A.			ATM deficiency augments constitutively nuclear cyclin D1-driven genomic instability and lymphomagenesis	ONCOGENE			English	Article						cyclin D1T286A; ATM; genomic instability; lymphoma; c-Myc	C-MYC; D1 PHOSPHORYLATION; DNA; REPLICATION; P53; ACTIVATION; EXPRESSION; OVEREXPRESSION; PROTEOLYSIS; DELETION	Cyclin D1 deregulation is implicated in the genesis of multiple human cancers. Importantly, nuclear cyclin D1 retention during S-phase promotes DNA re-replication and subsequent genomic instability, providing a direct correlation between aberrant cyclin D1/CDK4 activity, transcriptional regulation and double strand DNA break (DSB) induction. Together, these molecular events catalyze the genomic instability necessary for neoplastic transformation. Given that replication-associated DNA damage is central to cyclin D1-driven neoplasia, inactivation of critical checkpoint mediators should augment cyclin D1-dependent tumorigenesis in vivo. To interrogate potential synergy between constitutively nuclear cyclin D1 expression and impaired DSB-induced checkpoint integrity, Ataxia Telangiectasia Mutated (ATM)-deficient mice harboring the Em-D1T286A transgene were generated and evaluated for tumor onset. Em-D1T286A/ATM -/- mice exhibit dramatically accelerated incidence of both B-and T-cell lymphomas relative to Em-D1T286A or ATM -/- control cohorts. Lymphomas exhibit clonal chromosomal alterations distinct from ATM -/- mice, which typically acquire translocations involving the Tcra/d locus during V(D)J recombination, and instead harbor alterations at the c-Myc locus. Collectively, these findings reveal an intricate relationship wherein nuclear cyclin D1/CDK4 drives genomic instability in the absence of ATM function and clonal selection of cells harboring alterations within the murine c-Myc locus, ultimately facilitating transformation and tumor formation.	[Vaites, L. P.; Lian, Z.; Lee, E. K.; Diehl, J. A.] Univ Penn, Leonard & Madlyn Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [Vaites, L. P.; Lian, Z.; Lee, E. K.; Diehl, J. A.] Univ Penn, Dept Canc Biol, Philadelphia, PA 19104 USA; [Yin, B.; DeMicco, A.; Bassing, C. H.] Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Diehl, JA (corresponding author), Univ Penn, Leonard & Madlyn Abramson Family Canc Res Inst, 438 BRB 2 3,421 Curie Blvd, Philadelphia, PA 19104 USA.	adiehl@mail.med.upenn.edu	Lian, Zhaorui/AAW-2379-2020		NIH [CA93237]; NATIONAL CANCER INSTITUTE [R01CA093237] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors wish to thank Margarita Romero for excellent technical assistance and maintenance of the mouse colony, Dr Eric Brown for providing ATM+/- mice for colony generation and insightful comments on the work, the AFCRI histology core for assistance with tissue paraffin embedding and sectioning, and Dr Priya Aggarwal for assistance with flow cytometry and cytogenetic techniques. This work was supported by a grant from the NIH (CA93237) (JAD).	Aggarwal P, 2007, GENE DEV, V21, P2908, DOI 10.1101/gad.1586007; Aggarwal P, 2010, CANCER CELL, V18, P329, DOI 10.1016/j.ccr.2010.08.012; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Ghosh M, 2006, MOL CELL BIOL, V26, P5270, DOI 10.1128/MCB.02137-05; Girard-Reydet C, 2004, GENE, V332, P129, DOI 10.1016/j.gene.2004.02.031; Gladden AB, 2006, ONCOGENE, V25, P998, DOI 10.1038/sj.onc.1209147; Gostissa M, 2009, NATURE, V462, P803, DOI 10.1038/nature08633; Greiner TC, 2006, P NATL ACAD SCI USA, V103, P2352, DOI 10.1073/pnas.0510441103; Hakim O, 2012, NATURE, V484, P69, DOI 10.1038/nature10909; Hemmer S, 2001, AM J PATHOL, V158, P1355, DOI 10.1016/S0002-9440(10)64086-2; Jares P, 2008, BRIT J HAEMATOL, V142, P149, DOI 10.1111/j.1365-2141.2008.07124.x; Jin JP, 2006, MOL CELL, V23, P709, DOI 10.1016/j.molcel.2006.08.010; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lin DI, 2008, ONCOGENE, V27, P1231, DOI 10.1038/sj.onc.1210738; Liyanage M, 2000, BLOOD, V96, P1940, DOI 10.1182/blood.V96.5.1940.h8001940_1940_1946; Lowndes NF, 2005, CURR BIOL, V15, pR99, DOI 10.1016/j.cub.2005.01.029; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Monni O, 1999, BRIT J HAEMATOL, V104, P665, DOI 10.1046/j.1365-2141.1999.01257.x; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nagy B, 2003, BRIT J HAEMATOL, V120, P434, DOI 10.1046/j.1365-2141.2003.04121.x; Nishitani H, 2006, EMBO J, V25, P1126, DOI 10.1038/sj.emboj.7601002; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Norio P, 2005, MOL CELL, V20, P575, DOI 10.1016/j.molcel.2005.10.029; Pontano LL, 2008, MOL CELL BIOL, V28, P7245, DOI 10.1128/MCB.01085-08; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Ramiro AR, 2006, NATURE, V440, P105, DOI 10.1038/nature04495; Robbiani DF, 2008, CELL, V135, P1028, DOI 10.1016/j.cell.2008.09.062; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Slotta-Huspenina J, 2012, HAEMATOL-HEMATOL J, V97, P1422, DOI 10.3324/haematol.2011.055715; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Zha S, 2010, J EXP MED, V207, P1369, DOI 10.1084/jem.20100285; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou J, 2002, P NATL ACAD SCI USA, V99, P13693, DOI 10.1073/pnas.212392399	38	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2014	33	1					129	133		10.1038/onc.2012.577	http://dx.doi.org/10.1038/onc.2012.577			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	282YU	23318439	Green Accepted			2022-12-17	WOS:000329212000014
J	Yan, HX; Wu, HP; Zhang, HL; Ashton, C; Tong, C; Wu, J; Qian, QJ; Wang, HY; Ying, QL				Yan, H-X; Wu, H-P; Zhang, H-L; Ashton, C.; Tong, C.; Wu, J.; Qian, Q-J; Wang, H-Y; Ying, Q-L			DNA damage-induced sustained p53 activation contributes to inflammation-associated hepatocarcinogenesis in rats	ONCOGENE			English	Article						DNA damage; p53; inflammation; cirrhosis; hepatocellular carcinoma	LIVER; EXPRESSION; HEPATOCYTES; PATHOGENESIS; SENESCENCE; PROMOTION; MODELS; MOUSE	The tumor suppressor p53 has an important role in inducing cell-intrinsic responses to DNA damage, including cellular senescence or apoptosis, which act to thwart tumor development. It has been shown, however, that senescent or dying cells are capable of eliciting inflammatory responses, which can have pro-tumorigenic effects. Whether DNA damage-induced p53 activity can contribute to senescence-or apoptosis-associated pro-tumorigenic inflammation is unknown. Recently, we generated a p53 knock-out rat via homologous recombination in rat embryonic stem cells. Here we show that in a rat model of inflammation-associated hepatocarcinogenesis, heterozygous deficiency of p53 resulted in attenuated inflammatory responses and ameliorated hepatic cirrhosis and tumorigenesis. Chronic administration of hepatocarcinogenic compound, diethylnitrosamine, led to persistent DNA damage and sustained induction of p53 protein in the wild-type livers, and much less induction in p53 heterozygous livers. Sustained p53 activation subsequent to DNA damage was accompanied by apoptotic rather than senescent hepatic injury, which gave rise to the hepatic inflammatory responses. In contrast, the non-hepatocarcinogenic agent, carbon tetrachloride, failed to induce p53, and caused a similar degree of chronic hepatic inflammation and cirrhosis in wild type and p53 heterozygous rats. These results suggest that although p53 is usually regarded as a tumor suppressor, its constant activation can promote pro-tumorigenic inflammation, especially in livers exposed to agents that inflict lasting mutagenic DNA damage.	[Yan, H-X; Wu, H-P; Ashton, C.; Tong, C.; Wu, J.; Ying, Q-L] Univ So Calif, Keck Sch Med, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Dept Cell & Neurobiol, Los Angeles, CA 90033 USA; [Yan, H-X; Wu, H-P; Zhang, H-L; Qian, Q-J; Wang, H-Y] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Shanghai 200438, Peoples R China	University of Southern California; Naval Medical University	Yan, HX (corresponding author), Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, 225 Changhai Rd, Shanghai 200438, Peoples R China.	hexiny@yahoo.com; qying@usc.edu	Wu, Jun/AAF-1830-2019	Wu, Jun/0000-0001-9863-1668	NIH [R01OD010926]; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012885, R24AA012885] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [R01OD010926] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Jiaohong Wang, Shoudong Ye and Zhengmao Lu for technical assistance. This work was supported by a NIH grant to QLY (R01OD010926).	Abbott A, 2004, NATURE, V428, P464, DOI 10.1038/428464a; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Fausto N, 1999, SEMIN LIVER DIS, V19, P243, DOI 10.1055/s-2007-1007114; Greenblatt MS, 1997, CANCER RES, V57, P426; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KEMP CJ, 1995, MOL CARCINOGEN, V12, P132, DOI 10.1002/mc.2940120304; Kodama T, 2011, J CLIN INVEST, V121, P3343, DOI 10.1172/JCI44957; Krizhanovsky V, 2008, CELL, V134, P657, DOI 10.1016/j.cell.2008.06.049; Kuraishy A, 2011, IMMUNITY, V35, P467, DOI 10.1016/j.immuni.2011.09.006; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; LIVNI N, 1995, CANCER, V75, P2420, DOI 10.1002/1097-0142(19950515)75:10<2420::AID-CNCR2820751006>3.0.CO;2-6; Newell P, 2008, J HEPATOL, V48, P858, DOI 10.1016/j.jhep.2008.01.008; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RAJEWSKY MF, 1966, SCIENCE, V152, P83, DOI 10.1126/science.152.3718.83; Sarfraz S, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-133; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Tong C, 2010, NATURE, V467, P211, DOI 10.1038/nature09368; vanGijssel HE, 1997, CARCINOGENESIS, V18, P1027, DOI 10.1093/carcin/18.5.1027; Verna L, 1996, PHARMACOL THERAPEUT, V71, P57, DOI 10.1016/0163-7258(96)00062-9	21	14	15	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2013	32	38					4565	4571		10.1038/onc.2012.451	http://dx.doi.org/10.1038/onc.2012.451			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223SW		Green Accepted			2022-12-17	WOS:000324831300012
